Rank,NCT Number,Title,Conditions,Interventions,Sponsor/Collaborators,Phases,Enrollment,Funded Bys,Start Date,Primary Completion Date,Completion Date
1,NCT05869201,"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","Influenza|Influenza, Human|Influenza Viral Infections|Vaccine Reaction|Vaccination; Infection",Biological: Influenza vaccine [inactivated],St. Petersburg Research Institute of Vaccines and Sera,Phase 2|Phase 3,450,Other,"October 6, 2020","December 8, 2020","December 8, 2020"
2,NCT05862441,A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts,Cutaneous Warts,Drug: AV2-SA2|Drug: SA,Universiteit Antwerpen,Phase 2|Phase 3,260,Other,"January 1, 2018","December 31, 2019","December 31, 2019"
3,NCT05736081,Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema,Diabetic Macular Edema,Procedure: Intravitreal dexamethasone implant,Asociación para Evitar la Ceguera en México,Phase 2|Phase 3,15,Other,"February 15, 2018","June 30, 2019","June 30, 2019"
4,NCT05702957,Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome|Infertility,Drug: letrozole 2.5mg-7.5mg|Drug: Clomiphene Citrate 50mg-150mg,"Services Institute of Medical Sciences, Pakistan",Phase 2|Phase 3,220,Other,Sep-16,Oct-19,Dec-19
5,NCT05665985,Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Drug: Moringa Oleifera,Universitas Sebelas Maret,Phase 1|Phase 2,30,Other,"May 1, 2020","July 30, 2020","September 30, 2020"
6,NCT05651256,Efficacy of Botulinum Toxin in Temporomandibular Disorders,Temporomandibular Joint Disorder Bilateral,Drug: Botulinum toxin type A injection,University of Salamanca,Phase 2|Phase 3,20,Other,"March 1, 2021","March 30, 2021","July 30, 2021"
7,NCT05631444,Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia,Chronic Limb-threatening Ischemia|Diabetes Mellitus,Biological: Cell-based therapy,Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle,Phase 1|Phase 2,24,Other,"January 1, 2019","September 30, 2020","October 28, 2022"
8,NCT05600673,Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata,Alopecia Areata,Drug: Bimatoprost 0.03% solution|Device: CO2 fractional laser,Ahmed Hassan Nouh MD|Al-Azhar University,Phase 1|Phase 2,30,Other,"January 1, 2019","January 30, 2021","May 1, 2021"
9,NCT05573425,Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars,Acne Scar,Drug: Tazarotene gel 0.1%|Device: Microneedling,Jinnah Postgraduate Medical Centre,Phase 2|Phase 3,202,Other,"August 22, 2020","February 21, 2021","February 21, 2021"
10,NCT05547659,Multimodal and Unimodal Analgesia in Cholecystectomy,Compare Unimodal and Multimodal Analgesics,Drug: Pregabalin 150mg|Drug: Acetaminophen 1 G Oral Tablet|Drug: Celecoxib 400Mg Oral Capsule,October 6 University|Beni-Suef University,Phase 1|Phase 2,95,Other,"January 1, 2019","April 1, 2020","December 1, 2020"
11,NCT05484856,Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA),"Osteoarthritis, Knee",Biological: Autologous adipose tissue derived stromal cells,Dr. Himanshu Bansal Foundation,Phase 1|Phase 2,140,Other,"May 16, 2016","June 27, 2020","February 25, 2021"
12,NCT05445089,Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients,COVID-19|COVID-19 Pneumonia|COVID-19 Respiratory Infection|COVID-19 Acute Respiratory Distress Syndrome|COVID-19 Lower Respiratory Infection,Drug: Carvacrol|Other: Control group,Instituto Venezolano de Investigaciones Cientificas,Phase 2|Phase 3,600,Other,"August 1, 2020","November 1, 2020","December 15, 2020"
13,NCT05359484,Delta Q Value to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction,Urinary Obstruction|Detrusor Underactivity,Diagnostic Test: Uroflowmetry,Ain Shams University,Phase 2|Phase 3,238,Other,"January 1, 2019","January 1, 2021","May 1, 2021"
14,NCT05299242,"The Anti-Freaze-F Study- ""Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study""",Frozen Shoulder,Drug: Adalimumab Injection|Drug: Placebo,"University of Oxford|National Institute for Health Research, United Kingdom|180 Life Sciences",Phase 2|Phase 3,9,Other,"February 17, 2017","January 20, 2020","July 20, 2020"
15,NCT05283317,Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock,Sepsis|Septic Shock,Biological: Mesenchymal stem cells,TC Erciyes University,Phase 1|Phase 2,30,Other,"March 11, 2018","August 25, 2019","November 13, 2019"
16,NCT05241145,Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients,Keratoconus|Corneal Ectasia,Drug: IVMED-80|Other: Placebo,"iVeena Delivery Systems, Inc.|Codet Vision Institute",Phase 1|Phase 2,38,Industry|Other,"February 8, 2019","July 8, 2020","July 8, 2020"
17,NCT05192265,Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine,Malaria Fever|Plasmodium Falciparum Malaria|Uncomplicated Malaria,"Drug: Antimalarials, pyronaridine-artesunate|Drug: Antimalarials, Artemether + Lumefantrine","University of Ibadan|Shin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea|Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan",Phase 2|Phase 3,172,Other,"May 20, 2019","December 23, 2020","December 23, 2020"
18,NCT05154591,CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells,Chronic Renal Failure of Unknown Cause,Genetic: Adipose-derived stromal vascular fraction cells,Samuel Vilchez|Ministerio de Salud de Nicaragua|GID BIO|National Autonomous University of Nicaragua,Phase 1|Phase 2,18,Other,"January 1, 2018","February 28, 2021","February 28, 2021"
19,NCT05149339,Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia,Acute Myeloid Leukemia|Vitamin D Deficiency|ADAMTS13|Interleukin 6,Drug: Cholecalciferol 2800 I.U. ml oral drops,Zagazig University,Phase 1|Phase 2,38,Other,"March 1, 2019","February 1, 2020","March 15, 2021"
20,NCT05149248,Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study,Cancer of Cervix,"Biological: Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|Biological: Two dose|Other: Control group|Biological: 2 dose vaccination over 6 month","Instituto Nacional de Salud Publica, Mexico|Universidad Nacional Autonoma de Mexico|National Council of Science and Technology, Mexico",Phase 2|Phase 3,6000,Other,"May 30, 2018","October 30, 2019","November 28, 2019"
21,NCT05145686,The Role of Matrix Metalloproteinases on the Primary Teeth Pulpotomy Treatments,Reversible Pulpitis,"Diagnostic Test: Matris metalloproteinase -2, -8, -9 expressions",Ege University,Phase 1|Phase 2,57,Other,"January 1, 2018","July 1, 2019","December 1, 2019"
22,NCT05145530,Selective Nerve Root Block With Ultrasound Guidance Improves Surgical Outcome of Selective Discectomy in Patients With Multilevel Cervical Disc Disease,Selective Nerve Root Block|Selective Discectomy,Procedure: selective anterior cervical discectomy and fusion (ACDF)|Procedure: SNRB+ selective anterior cervical discectomy and fusion (ACDF),Assiut University,Phase 2|Phase 3,60,Other,"August 10, 2017","March 30, 2020","April 30, 2020"
23,NCT05132270,Clinical Experience of Thalidomide in Thalassemic Patients,"Thalassemia, Beta",Drug: hydroxyurea and thalidomide,Children's Hospital Karachi,Phase 2|Phase 3,135,Other,"January 1, 2020","December 31, 2020","January 31, 2021"
24,NCT05127018,Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile,"Smiling|Botulinum Toxins, Type A",Drug: injection of Botulinum type A,Peking University,Phase 1|Phase 2,33,Other,"November 20, 2019","August 20, 2020","October 20, 2021"
25,NCT05091775,The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure,Fissure in Ano|Diarrhea,Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease,Shiraz University of Medical Sciences,Phase 1|Phase 2,140,Other,"June 1, 2020","August 2, 2020","January 10, 2021"
26,NCT05082662,"Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium), in Healthy Subjects Under Fasting Condition",Non-steroidal Anti-inflammatory (NSAID)|Analgesic|Antipyretic,Drug: Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|Drug: Cataflam® 50 coated tablet,Pharmactive Ilac Sanayi ve Tic A.S.,Phase 1|Phase 2,36,Industry,"August 25, 2020","September 16, 2020","September 16, 2020"
27,NCT05067608,Study on the Safety and Efficacy of Cryopreserved Platelets in Hypoproliferative Thrombocytopenic Patients,Hypoproliferative Thrombocytopenia,Biological: Control arm receiving normal (never before frozen) platelets as per current clinical practice|Biological: Treatment arm receiving cryopreserved platelets,"Singapore General Hospital|DSO National Laboratories|Health Sciences Authority, Singapore",Phase 1|Phase 2,17,Other,"October 25, 2019","March 24, 2021","March 24, 2021"
28,NCT05050071,"Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth",Drug Effect,Drug: Allium Sativum|Device: Polymerase chain reaction,Suez Canal University,Phase 2|Phase 3,48,Other,"October 8, 2019","October 8, 2020","July 17, 2021"
29,NCT05046548,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19",Coronavirus Infections|Vaccine,Biological: Vaccine for intramuscular injection|Other: Placebo comparator (without active ingredient) for intramuscular injection,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,Phase 1|Phase 2,400,Other,"October 3, 2020","October 15, 2020","October 1, 2021"
30,NCT05031143,Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment,Vogt Koyanagi Harada Disease,Drug: Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease,Benha University,Phase 2|Phase 3,6,Other,"April 1, 2020","February 20, 2021","August 24, 2021"
31,NCT05017844,"[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome",Dry Eye Syndromes,Drug: KSR-001-04|Drug: KSR-001-02|Drug: KSR-001-03,"Kukje Pharma|Samil Pharmaceutical Co., Ltd.",Phase 2|Phase 3,222,Other|Industry,"February 18, 2020","February 8, 2021","June 22, 2021"
32,NCT05017493,"Treatment of Covid-19 With a Herbal Compound, Xagrotin",Covid19,Combination Product: Xagrotin,"Biomad AS|Directorate of health of Sulaimani, Iraq -KRG",Phase 1|Phase 2,661,Industry|Other,"July 1, 2020","December 7, 2020","February 8, 2021"
33,NCT04996810,The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines,Glabellar Frown Lines,Biological: PROTOXIN|Biological: Botox®,Protox Inc.,Phase 1|Phase 2,60,Industry,"December 10, 2020","April 2, 2021","May 26, 2021"
34,NCT04990830,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,COVID-19 Acute Respiratory Distress Syndrome|Hypoxemia,Drug: Inhaled Low molecular weight heparin|Drug: Standard Treatment,Istanbul University,Phase 2|Phase 3,80,Other,"February 3, 2021","April 21, 2021","May 21, 2021"
35,NCT04988776,PECS II Versus ICBN Block Plus SCNB for AV Fistula Creation in CRF Patients,Intraoperative Analgesia|Postoperative Pain,Other: ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|Other: ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block,Menoufia University|Mamdoh Elsayed Lotfy|amany aly sultan|reem gaber abdel-mageed,Phase 1|Phase 2,40,Other,"February 1, 2020","February 28, 2021","February 28, 2021"
36,NCT04973488,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,COVID-19 Pneumonia|COVID-19 Respiratory Infection|Acute Respiratory Failure|Acute Respiratory Distress Syndrome,Other: Therapeutic plasma exchange,"Novacescu Alexandru|University of Medicine and Pharmacy ""Victor Babes"" Timisoara",Phase 2|Phase 3,38,Other,"July 25, 2020","January 10, 2021","January 10, 2021"
37,NCT04971759,Dexmedetomidine to Levobupivacaine for Transversus Abdominis Plane Block in Elderly Patients Undergoing Inguinal Hernia Repair Surgery,Dexmedetomidine|Fentanyl,Drug: Levobupivacaine|Drug: Dexmedetomidine Hydrochloride|Drug: Fentanyl,Assiut University,Phase 2|Phase 3,90,Other,"December 1, 2019","December 30, 2020","February 1, 2021"
38,NCT04968392,Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty,Adductor Canal Block|Levobupivacaine|Dexmedetomidine,Drug: Dexmedetomidine Hydrochloride|Drug: Levobupivacaine,Assiut University,Phase 2|Phase 3,60,Other,"March 1, 2019","February 1, 2020","May 1, 2020"
39,NCT04931719,Comparing Efficacy of PRP Combined With Different Hyaluronan for the Treatment of Knee Osteoarthritis,Knee Osteoarthritis,Combination Product: PRP+Artz group|Combination Product: PRP+ HYAJOINT Plus group,Kaohsiung Veterans General Hospital.,Phase 2|Phase 3,95,Other,"July 1, 2019","June 30, 2020","June 30, 2020"
40,NCT04919473,Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa,Retinitis Pigmentosa|Retinal Diseases|Retinal Degeneration,Biological: Gene Therapy product:vMCO-I,Nanoscope Therapeutics Inc.,Phase 1|Phase 2,11,Industry,"October 23, 2019","February 25, 2020","October 31, 2020"
41,NCT04916756,A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients,Sjogren's Syndrome,Drug: Baricitinib 2 MG,Peking Union Medical College Hospital,Phase 1|Phase 2,11,Other,"January 16, 2020","December 24, 2020","March 25, 2021"
42,NCT04907942,Feasibility and Acceptability of Click's EMA and Text Message Intervention for STRESS Management,"Stress, Psychological|Loneliness|Covid19|Stress",Device: EMA + Automated Text Message Intervention|Behavioral: EMA Alone,"Click Therapeutics, Inc.",Phase 1|Phase 2,82,Industry,"October 29, 2020","December 18, 2020","June 20, 2021"
43,NCT04906538,Objective Results of Anterior Cruciate Ligament Reconstruction With and Without Internal Suture Augmentation Technique,Anterior Cruciate Ligament Injuries,Procedure: all- inside anterior cruciate ligament reconstruction,Ain Shams University,Phase 2|Phase 3,38,Other,"September 1, 2018","April 1, 2021","April 1, 2021"
44,NCT04893941,Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD),Moderate-to-severe Atopic Dermatitis,Drug: CM310|Drug: Placebo,Keymed Biosciences Co.Ltd,Phase 1|Phase 2,39,Industry,"July 21, 2020","January 22, 2021","January 22, 2021"
45,NCT04879511,Effect of Metformin in Children With Type 1 Diabetes,Effect of Change in T1DM Glycemic Control,Drug: metformin|Drug: Basal/bolus insulin,Ain Shams University,Phase 2|Phase 3,80,Other,"February 10, 2018","January 1, 2021","January 29, 2021"
46,NCT04879030,Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD,COPD Exacerbation Acute,Drug: Beta-Lactams|Drug: Fluoroquinolone,Haiphong University of Medicine and Pharmacy,Phase 2|Phase 3,170,Other,"January 1, 2020","August 30, 2020","December 30, 2020"
47,NCT04876976,Isoamyl 2-Cyanoacrylate in the Urethro-cutaneous Fistula Repair,Hypospadias,"Drug: Cyanoacrylate, Isobutyl|Procedure: Classic surgical repair",Ain Shams University,Phase 2|Phase 3,40,Other,"January 1, 2017","January 1, 2020","January 1, 2020"
48,NCT04870502,Effect of Ubiquinol Supplementation on Ovulation Induction in Clomiphene Citrate Resistance,Polycystic Ovarian Syndrome,Drug: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG,Saudi German Hospital - Madinah,Phase 2|Phase 3,161,Other,"April 1, 2019","July 31, 2020","July 31, 2020"
49,NCT04869969,Supine Percutaneous Nephrolithotomy,Renal Stone,Procedure: percutaneous nephrolithotomy (supine position)|Procedure: percutaneous nephrolithotomy ( prone position),Ain Shams University,Phase 2|Phase 3,70,Other,"June 1, 2019","January 1, 2021","September 30, 2021"
50,NCT04857346,Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus,Type 2 Diabetes Mellitus|Prediabetic State|Chronic Periodontitis,Drug: Indocyanine green,King Saud University,Phase 2|Phase 3,80,Other,"June 1, 2020","December 12, 2020","February 1, 2021"
51,NCT04852510,Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin,Polycystic Ovary Syndrome (PCOS),Drug: Metformin Versus a combination of Metformin and Thymoquinone (TQ),Saudi German Hospital - Madinah,Phase 2|Phase 3,253,Other,"February 1, 2019","August 31, 2020","August 31, 2020"
52,NCT04830371,Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants,Typhoid Fever,Biological: EuTCV (Vi-CRM Typhoid conjugate vaccine)|Biological: Typbar-TCV,"EuBiologics Co.,Ltd",Phase 2|Phase 3,444,Industry,"September 7, 2020","March 18, 2021","August 1, 2021"
53,NCT04821804,Local Application of Hyaluronic Acid (HYADENT BG) With Free Soft Tissue Grafing Improves Treatment Outcomes.,"Gingival Recession, Plastic Surgery",Drug: Hyaluronic Acid (HYADENT BG),Jordan University of Science and Technology,Phase 2|Phase 3,24,Other,"January 2, 2020","September 1, 2020","September 5, 2020"
54,NCT04821479,Repeated Mesenchymal Stem Cell Injections in ALS,Amyotrophic Lateral Sclerosis,Biological: Mesenchymal stem cells (MSC),Hadassah Medical Organization,Phase 1|Phase 2,20,Other,"January 1, 2016","June 30, 2020","December 31, 2020"
55,NCT04817800,"To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray",Seasonal Allergic Rhinitis,Drug: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate),Pharmactive Ilac Sanayi ve Tic A.S.,Phase 1|Phase 2,48,Industry,"March 25, 2021","April 10, 2021","April 10, 2021"
56,NCT04804423,Fluoride Therapies on Hypersensitive Carious Lesions in Primary Teeth,Dentin Hypersensitivity|Active Dental Caries,Drug: 38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|Drug: Sodium fluoride varnish (generic name; Duraphat®),University Medicine Greifswald|SDI Limited,Phase 2|Phase 3,30,Other,"January 13, 2020","March 31, 2021","April 1, 2021"
57,NCT04799041,Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study,Back Pain|Acute Pain,Drug: GTX 2/3|Drug: Placebo,Algenis SpA,Phase 1|Phase 2,30,Industry,"October 11, 2019","March 19, 2020","March 19, 2020"
58,NCT04784481,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Covid19|SARS (Severe Acute Respiratory Syndrome),Drug: Ivermectin,"Ministry of Public Health, Argentina",Phase 1|Phase 2,254,Other,"September 20, 2020","December 20, 2020","January 18, 2021"
59,NCT04779606,"Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers",Healthy Subjects,Drug: Ocular gel,Sintetica SA,Phase 1|Phase 2,105,Industry,"June 16, 2020","October 13, 2020","October 20, 2020"
60,NCT04767321,A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus,Nasal Decolonization of Staphylococcus Aureus,"Drug: LTX-109 gel, 3% w/w|Drug: Placebo",Pharma Holdings AS|CTC Clinical Trial Consultants AB,Phase 1|Phase 2,15,Industry,"February 22, 2021","March 23, 2021","June 1, 2021"
61,NCT04767269,Efficacy of Cuminum Cyminum Herbal =Preparation in Inhibition of Plaque and Gingivitis.,Chronic Gingivitis,Drug: Cuminum Cyminum|Drug: herbal Mouthwash,Maharishi Markendeswar University (Deemed to be University),Phase 2|Phase 3,30,Other,"January 1, 2019","January 15, 2021","January 31, 2021"
62,NCT04756206,Role of Dutasteride in Treatment of Chronic Prostatitis,Dutasteride|Category IIIB Chronic Prostatitis,Drug: Dutasteride 0.5 mg|Drug: Placebo,Ain Shams University,Phase 2|Phase 3,50,Other,"January 1, 2019","January 1, 2020","September 1, 2020"
63,NCT04753710,"Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers",Healthy Volunteers,Drug: Ocular gel,Sintetica SA,Phase 2|Phase 3,96,Industry,"June 29, 2020","November 6, 2020","December 9, 2020"
64,NCT04747158,COVID-19 Convalescent Plasma Therapy,SARS-CoV-2 Infection|COVID-19 Infection,Biological: Convalescent plasma,"Universidad Nacional de Asunción|Consejo Nacional de Ciencias y Tecnología, Paraguay|Ministerio de Salud Pública y Bienestar Social, Paraguay|Centro de información y recursos para el desarrollo, Paraguay",Phase 2|Phase 3,350,Other,"August 10, 2020","December 10, 2020","January 10, 2021"
65,NCT04729491,EAT-DUTA AndroCoV Trial,Covid19,Drug: Dutasteride 0.5 mg|Drug: Azithromycin|Drug: Nitazoxanide|Drug: Placebo,Corpometria Institute,Phase 2|Phase 3,138,Other,"June 30, 2020","September 15, 2020","October 7, 2020"
66,NCT04724538,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,"Covid19|Pneumonia, Viral",Radiation: 99mTc-pertechnetate aerosol|Drug: 99mTc-pertechnetate aerosol,National Medical Research Radiological Centre of the Ministry of Health of Russia,Phase 1|Phase 2,25,Other,"October 15, 2020","February 10, 2021","March 15, 2021"
67,NCT04705753,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Covid19|Viral Infection|Respiratory Viral Infection,Dietary Supplement: Cretan IAMA,University of Crete|Galenica SA|Olvos Science SA,Phase 2|Phase 3,20,Other,"April 1, 2020","October 15, 2020","October 15, 2020"
68,NCT04704622,"Comparison Between Dexmeditomidine, Midazolam and Ketamine as a Sedative to Help Cannula Insertion in Pediatric Patient",Cannula Site Pain,Drug: Ketamine|Drug: Midazolam|Drug: Dexmedetomidine,Ain Shams University,Phase 2|Phase 3,150,Other,"January 1, 2021","February 15, 2021","February 15, 2021"
69,NCT04701710,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Covid19|SARS (Severe Acute Respiratory Syndrome),Drug: Ivermectin / Iota-Carrageenan,"Maria de los Angeles Peral de Bruno|Ministry of Public Health, Argentina",Phase 1|Phase 2,300,Other,"October 15, 2020","December 18, 2020","December 31, 2020"
70,NCT04693312,"Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?","Pain, Chronic",Drug: Depo medrol,Assiut University,Phase 2|Phase 3,60,Other,"January 1, 2020","March 1, 2020","July 1, 2020"
71,NCT04688346,Cardiovascular Effects of Racemic Epinephrine Pellets,Epinephrine Causing Adverse Effects in Therapeutic Use,Drug: HemeRX epinephrine pellets,University of Washington,Phase 2|Phase 3,13,Other,"June 10, 2019","November 30, 2019","November 30, 2019"
72,NCT04685512,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Covid19,Drug: tenofovir disoproxil and emtricitabine,"University Hospital, Caen",Phase 2|Phase 3,60,Other,"November 18, 2020","April 1, 2021","May 1, 2021"
73,NCT04680143,Systemic Erythropoietin Injection in Patients Having Optic Atrophy,Optic Atrophy,Drug: Systemic erythropoietin injection,Alexandria University,Phase 1|Phase 2,10,Other,"September 1, 2020","March 1, 2021","March 30, 2021"
74,NCT04675177,Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease,Hemorrhoids,Drug: Polidocanol foam sclerotherapy|Procedure: Doppler-guided hemorrhoidal artery ligation,Universidade do Porto,Phase 2|Phase 3,45,Other,"September 1, 2019","February 1, 2020","March 25, 2020"
75,NCT04674332,Long Acting Insulin Versus Multiple Dose Regimen for Control of Gestational Diabetes Mellitus,Long Acting Insulin in Control of Gestational Diabetes Mellitus,Drug: Long acting insulin|Drug: multiple dose regimen,Ain Shams University,Phase 2|Phase 3,148,Other,"September 1, 2019","December 14, 2020","December 14, 2020"
76,NCT04671017,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects",SARS-CoV-2 Virus Infection,Biological: VLA2001,"Valneva Austria GmbH|National Institute for Health Research, United Kingdom",Phase 1|Phase 2,153,Industry|Other,"December 16, 2020","February 26, 2021","April 6, 2022"
77,NCT04670107,The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy,NSCLC|Angiogenesis|Immunotherapy,Drug: Anlotinib in combination with Immune checkpoint inhibitors,The Affiliated Hospital of Qingdao University,Phase 1|Phase 2,30,Other,"June 1, 2018","October 1, 2020","November 1, 2020"
78,NCT04656067,Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate,"Blood Loss, Surgical|Blood Loss, Postoperative","Drug: Oxytocin ,Tranexamic acid and Ethamsylate",Egymedicalpedia,Phase 1|Phase 2,230,Industry,"April 1, 2020","October 1, 2020","November 10, 2020"
79,NCT04655937,Wellbeing After Stroke (WAterS),Stroke|Psychological Distress|Cognitive Dysfunction|Communication Disorders|Psychological Adjustment,Other: Acceptance and Commitment Therapy,University of Manchester|Stroke Association,Phase 1|Phase 2,20,Other,"January 5, 2021","March 15, 2021","May 1, 2023"
80,NCT04655625,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),COVID-19,Biological: Group A (AG0302-COVID19)|Biological: Group A (Placebo)|Biological: Group B (AG0302-COVID19)|Biological: Group B (Placebo),"AnGes, Inc.|Japan Agency for Medical Research and Development",Phase 2|Phase 3,500,Industry|Other,"November 23, 2020","April 2, 2021","February 1, 2022"
81,NCT04654624,Child Discomfort and Parental Acceptability of Silver Diamine Fluoride and Alternative Restorative Treatment,Dental Caries|Child Discomfort,Drug: SDF|Drug: ART,Nourhan M.Aly|Alexandria University|Princess Nourah Bint Abdulrahman University|University of Alexandria,Phase 2|Phase 3,80,Other,"October 12, 2018","October 1, 2019","October 30, 2019"
82,NCT04644926,The Effect of Remote Ischemic Conditioning on the Microcirculation in Sepsis,Septic Shock|Sepsis,Procedure: Remote ischemic conditioning,Lithuanian University of Health Sciences,Phase 1|Phase 2,26,Other,"February 1, 2018","September 1, 2020","September 1, 2020"
83,NCT04643678,Anakinra in the Management of COVID-19 Infection,Covid19|Pneumonia|Cytokine Release Syndrome|Corona Virus Infection|Viral Infection,Drug: Anakinra|Other: Standard of Care,Hamad Medical Corporation,Phase 2|Phase 3,80,Industry,"October 30, 2020","March 1, 2021","April 30, 2021"
84,NCT04637633,Topical Cyclosporine-A for Management of Epiphora,Epiphora,"Drug: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,",Farwaniya Hospital,Phase 2|Phase 3,12,Other,"August 15, 2020","October 30, 2020","November 1, 2020"
85,NCT04623242,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"Alzheimers Disease|Dementia|Alzheimers Disease, Familial",Drug: Gantenerumab|Drug: Solanezumab|Drug: Matching Placebo (Gantenerumab)|Drug: Matching Placebo (Solanezumab),Washington University School of Medicine|Eli Lilly and Company|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Avid Radiopharmaceuticals|Accelerating Medicines Partnership (AMP),Phase 2|Phase 3,194,Other|Industry|NIH,Dec-12,"November 22, 2019","March 6, 2020"
86,NCT04620447,Intelligent Virtual Reality Therapy System and Testing Its Clinical Efficacy,Phobias|Acrophobia|Anxiety,Other: Intelligent Virtual Reality Therapy System (IVRTS),"University College of Medical Sciences, India|Norwegian University of Science and Technology|Indraprastha Institute of Information Technology Delhi",Phase 1|Phase 2,500,Other,"February 5, 2018","March 1, 2020","March 1, 2020"
87,NCT04608838,"A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)",Acute Ischemic Stroke,Biological: JTR-161|Biological: Placebo,Teijin Pharma Limited,Phase 1|Phase 2,79,Industry,"January 30, 2019","February 15, 2021","November 24, 2021"
88,NCT04605289,Levels of Matrix Metalloproteinase-8 After Intrapocket Treatment in Moderate Periodontitis Patients.,Periodontitis,Drug: lemongrass essential oil gel|Drug: Placebo|Procedure: Scaling and root planing,Alexandria University,Phase 1|Phase 2,40,Other,"January 13, 2020","August 31, 2020","October 14, 2020"
89,NCT04591600,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Covid19,Drug: Ivermectin and Doxycyline|Drug: Standard of care,Alkarkh Health Directorate-Baghdad,Phase 1|Phase 2,140,Other,"July 1, 2020","September 30, 2020","October 14, 2020"
90,NCT04573322,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,SARS-CoV-2 (Covid19),Drug: Trans Sodium Crocetinate|Drug: Normal saline,Diffusion Pharmaceuticals Inc,Phase 1|Phase 2,25,Industry,"September 10, 2020","March 17, 2021","April 29, 2021"
91,NCT04553705,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Covid19|Immunodeficiency,Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator,"Beni-Suef University|Maternity and Children Hospital, Makkah|University of Arizona",Phase 2|Phase 3,150,Other,"September 20, 2020","November 4, 2020","December 4, 2021"
92,NCT04550325,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","Covid19|Pneumonia, Viral",Biological: Kamada Anti-SARS-CoV-2,"Kamada, Ltd.",Phase 1|Phase 2,12,Industry,"August 5, 2020","November 26, 2020","November 26, 2020"
93,NCT04546607,Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia,Asthenia|Cancer,Other: Nuvastatic TM (C5OSEW5050ESA) 1000 mg,Natureceuticals Sdn Bhd,Phase 2|Phase 3,110,Industry,"September 2, 2017","October 28, 2019","October 31, 2019"
94,NCT04545307,Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis,Pulp Necroses|Apical Periodontitis,Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis,Universidad Central de Venezuela|Instituto Venezolano de Investigaciones Cientificas,Phase 2|Phase 3,5,Other,"November 27, 2019","December 27, 2019","January 27, 2020"
95,NCT04545060,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,Covid19,Biological: VIR-7831 (sotrovimab)|Drug: Placebo,"Vir Biotechnology, Inc.|GlaxoSmithKline",Phase 2|Phase 3,1057,Industry,"August 27, 2020","April 8, 2021","September 2, 2021"
96,NCT04539262,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",COVID-19,Drug: Remdesivir (RDV)|Drug: Placebo,Gilead Sciences,Phase 1|Phase 2,156,Industry,"September 14, 2020","February 26, 2021","March 22, 2021"
97,NCT04537949,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,Covid-19|Protection Against COVID-19,Biological: BNT162b3,BioNTech SE,Phase 1|Phase 2,96,Industry,"September 9, 2020","March 12, 2021","February 7, 2022"
98,NCT04530357,"Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine",Covid19|SARS-CoV Infection|Vaccine Adverse Reaction,Biological: QazCovid-in® - COVID-19 inactivated vaccine|Other: Placebo,Research Institute for Biological Safety Problems|National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan,Phase 1|Phase 2,244,Other,"September 19, 2020","November 25, 2020","April 25, 2021"
99,NCT04529525,Ivermectin to Prevent Hospitalizations in COVID-19,Covid19,Drug: Ivermectin|Drug: Placebo,Instituto de Cardiología de Corrientes,Phase 2|Phase 3,501,Other,"August 19, 2020","February 22, 2021","February 22, 2021"
100,NCT04527081,Study of COVID-19 DNA Vaccine (AG0302-COVID19),COVID-19,Biological: AG0302-COVID19,"AnGes, Inc.",Phase 1|Phase 2,30,Industry,"August 31, 2020","November 9, 2020","September 24, 2021"
101,NCT04521309,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,COVID-19,Biological: SARS-CoV-2 antibody based IVIG therapy,Dow University of Health Sciences|Higher Education Commission (Pakistan),Phase 1|Phase 2,50,Other,"June 19, 2020","January 26, 2021","February 8, 2021"
102,NCT04520321,A Phase 1/ Phase 2 Study of TTHX1114(NM141),Corneal Endothelial Dystrophy|Fuchs Endothelial Corneal Dystrophy|Pseudophakic Bullous Keratopathy|Endothelial Dysfunction,Drug: TTHX1114(NM141)|Other: Vehicle (placebo),"Trefoil Therapeutics, Inc.",Phase 1|Phase 2,22,Industry,"August 19, 2020","April 23, 2021","May 18, 2021"
103,NCT04520022,Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB,Recessive Dystrophic Epidermolysis Bullosa,Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells,Gangnam Severance Hospital|Daewoong Pharmaceutical Co. LTD.,Phase 1|Phase 2,5,Other|Industry,"October 13, 2016","January 10, 2020","January 10, 2020"
104,NCT04505683,A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP),Complicated Urinary Tract Infection Including Acute Pyelonephritis,Drug: Benapenem|Drug: Ertapenem,Sihuan Pharmaceutical Holdings Group Ltd.,Phase 2|Phase 3,112,Industry,"December 13, 2018","May 8, 2020","May 8, 2020"
105,NCT04504877,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Covid19|Burn Out|Post Traumatic Stress Disorder,Drug: Cannabidiol,University of Sao Paulo,Phase 2|Phase 3,120,Other,"June 16, 2020","November 16, 2020","December 16, 2020"
106,NCT04502251,LDN and tDCS in Fibromyalgia,Fibromyalgia,Drug: Low-Dose Naltrexone|Device: Transcranial Direct Current Stimulation|Drug: Placebo|Device: Sham Transcranial Direct Current Stimulation,Centro Universitario La Salle|Hospital de Clinicas de Porto Alegre,Phase 2|Phase 3,92,Other,"August 1, 2018","August 1, 2019","July 1, 2020"
107,NCT04495569,A Bridging Study of the SYN023 on Healthy Adult Subjects,Communicable Disease Transmission|Zoonotic Disease|Rabies Human|Vaccine Reaction|Immunisation Reaction,Biological: recombinant anti-rabies human monoclonal antibody injection (SYN023)|Biological: Rabies Vaccine,"Synermore Biologics (Suzhou) Co., Ltd.",Phase 1|Phase 2,33,Industry,"February 26, 2019","June 20, 2019","February 20, 2020"
108,NCT04494984,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",Covid19,Drug: INM005|Drug: Placebo,Inmunova S.A.,Phase 2|Phase 3,242,Other,"July 27, 2020","November 23, 2020","December 30, 2020"
109,NCT04494204,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Treatment of Covid-19 Virus Infection,Combination Product: Immunofree tablets and Reginmune capsule,PUNEET MITTAL|Nutrin GmbH,Phase 2|Phase 3,100,Other,"August 7, 2020","December 1, 2020","December 20, 2020"
110,NCT04491240,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Covid19|SARS-CoV-2 PNEUMONIA|COVID-19,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin",Phase 1|Phase 2,30,Other,"July 20, 2020","October 1, 2020","October 20, 2020"
111,NCT04489446,Sildenafil in COVID-19,Covid19|SARS-COV2 Infection,Drug: Sildenafil|Drug: Placebo,"Universidad Nacional Andres Bello|Hospital Naval Almirante Nef, Viña del Mar, Chile",Phase 1|Phase 2,40,Other,"August 19, 2020","April 30, 2021","June 30, 2021"
112,NCT04485962,Treatment of Patients With Skin Burns Using Keratinocytes and Skin Fibroblasts,Burns,Biological: Fibroblasts and keratinocytes,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,Phase 1|Phase 2,12,Other,"January 1, 2017","December 31, 2019","December 31, 2019"
113,NCT04484402,Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells,Corneal Ulcer|Corneal Disease|Corneal Dystrophy,Biological: mesenchymal stem cells|Biological: limbal stem cells|Other: standard treatment,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,Phase 1|Phase 2,25,Other,"October 3, 2016","December 30, 2019","December 30, 2019"
114,NCT04483830,Suloexide in the Treatment of Early Stages of COVID-19,Covid19,Drug: Sulodexide|Drug: Placebo,Clinedem|Alfasigma S.p.A.,Phase 2|Phase 3,243,Other|Industry,"June 5, 2020","August 6, 2020","September 7, 2020"
115,NCT04480957,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,SARS-CoV-2,Biological: ARCT-021 Dose 1|Biological: ARCT-021 Dose 2|Biological: ARCT-021 Dose 3|Biological: ARCT-021 Dose 4|Biological: ARCT-021 Dose Regimen 1|Biological: ARCT-021 Dose Regimen 2|Other: Placebo,"Arcturus Therapeutics, Inc.",Phase 1|Phase 2,106,Industry,"August 4, 2020","January 29, 2021","January 29, 2021"
116,NCT04480775,Triamcinolone Versus Methylprednisolone in Transversus Abdominis Plane Block,Major Abdominal Surgery,Drug: Triamcinolone|Drug: Methylprednisolone|Drug: bupivacaine,ghada fouad|Mansoura University,Phase 2|Phase 3,84,Other,"July 15, 2020","December 15, 2020","December 15, 2020"
117,NCT04480593,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Covid19,Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care,D'Or Institute for Research and Education|Hospital Sao Rafael,Phase 2|Phase 3,120,Other,"June 2, 2020","August 30, 2020","August 30, 2020"
118,NCT04477811,Comparative Study Evaluating the Effect of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients,End Stage Renal Disease on Dialysis,Drug: Vitamin K1|Drug: Vitamin k2|Other: placebo,Ain Shams University,Phase 2|Phase 3,40,Other,"July 25, 2020","November 1, 2020","January 1, 2021"
119,NCT04475120,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Covid19,Drug: liposomal lactoferrin|Drug: SOC therapy,University of Rome Tor Vergata,Phase 2|Phase 3,92,Other,"April 15, 2020","July 2, 2020","July 2, 2020"
120,NCT04473170,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Coronavirus Disease 2019 (COVID-19),Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,Abu Dhabi Stem Cells Center,Phase 1|Phase 2,146,Other,"April 4, 2020","May 20, 2020","July 14, 2020"
121,NCT04471519,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,COVID-19|SARS-CoV-2 Infection,Biological: BBV152A - Phase I|Biological: BBV152B - Phase I|Biological: BBV152C - Phase I|Biological: Placebo - Phase I|Biological: BBV152A - Phase II|Biological: BBV152B - Phase II,Bharat Biotech International Limited|Indian Council of Medical Research,Phase 1|Phase 2,755,Industry|Other,"July 15, 2020","July 31, 2020","June 30, 2021"
122,NCT04469777,Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy,Optic Neuropathy,Drug: erythropoietin,Alexandria University,Phase 1|Phase 2,20,Other,"April 1, 2019","December 15, 2020","December 30, 2020"
123,NCT04469673,"A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..",Hyperlipemia,Biological: Biological：JS002|Biological: Placebo,"Shanghai Junshi Bioscience Co., Ltd.",Phase 1|Phase 2,90,Other,"May 23, 2019","May 3, 2020","June 28, 2020"
124,NCT04467541,Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months,Hand Foot & Mouth Disease,Biological: Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell),"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 1|Phase 2,430,Other,"December 24, 2019","January 31, 2020","January 31, 2020"
125,NCT04467476,Effects of tDCS on Anaerobic Power of Lower Limb Muscles,Healthy Volunteers,Device: Transcranial direct current stimulation,Universidade Federal do Piauí,Phase 2|Phase 3,50,Other,"January 1, 2021","February 28, 2021","April 29, 2021"
126,NCT04465279,Trifocal Diffractive Intraocular Lens After Cataract Extraction With Phacoemulsification,Refractive Errors,Device: Trifocal diffractive intraocular lens,Alexandria University,Phase 2|Phase 3,36,Other,"October 15, 2018","May 15, 2020","June 15, 2020"
127,NCT04463472,Study of COVID-19 DNA Vaccine (AG0301-COVID19),COVID-19,Biological: AG0301-COVID19,"AnGes, Inc.|Japan Agency for Medical Research and Development",Phase 1|Phase 2,30,Industry|Other,"June 29, 2020","September 28, 2020","August 12, 2021"
128,NCT04460183,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,COVID-19,"Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care",Thirty Respiratory Limited,Phase 2|Phase 3,19,Industry,"July 29, 2020","April 24, 2021","May 21, 2021"
129,NCT04457063,Endothelial Cell Loss After Penetrating Keratoplasty,Keratoconus,Procedure: PKP,Alexandria University,Phase 2|Phase 3,8,Other,"July 1, 2018","June 1, 2020","June 15, 2020"
130,NCT04453241,Immunogenicity and Safety Study of NBP615 in Healthy Female,Cervical Cancer,Biological: NBP615|Biological: Gardasil,"SK Bioscience Co., Ltd.",Phase 1|Phase 2,200,Industry,"December 22, 2018","December 30, 2019","December 30, 2019"
131,NCT04452448,Analysis of I-Trace High Order Aberrations Induced by Wavefront Optimized Ablation Profiles,Myopia,Device: LASIK,Alexandria University,Phase 2|Phase 3,10,Other,"January 10, 2018","May 30, 2020","June 10, 2020"
132,NCT04446897,Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction,"Periodontitis, Chronic",Biological: mesenchymal stem cells|Other: standard treatment,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,Phase 1|Phase 2,10,Other,"August 3, 2020","December 31, 2020","December 31, 2020"
133,NCT04446884,Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells,Stress Urinary Incontinence,Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Phase 1|Phase 2,10,Other,"March 1, 2018","December 31, 2019","December 31, 2019"
134,NCT04446871,Methylene Blue in Early Septic Shock,Septic Shock,Drug: 0.9% sodium chloride|Drug: Methylene Blue,Hospital Civil de Guadalajara,Phase 2|Phase 3,91,Other,"March 17, 2017","December 10, 2020","January 25, 2021"
135,NCT04443881,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),COVID-19 Pnemonia,Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret],Fundacion Miguel Servet,Phase 2|Phase 3,179,Other,"May 8, 2020","March 31, 2021","March 31, 2021"
136,NCT04441112,Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial,Arthritis Knee|Arthritis of Hip,Drug: Ketorolac Intraarticular Injection|Drug: Triamcinolone Intraarticular Injection,Saint Alphonsus Regional Medical Center,Phase 2|Phase 3,120,Other,"May 20, 2018","August 20, 2019","August 20, 2019"
137,NCT04437875,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Preventive Immunization COVID-19,Biological: Gam-COVID-Vac Lyo,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development",Phase 1|Phase 2,38,Other,"June 17, 2020","August 3, 2020","August 10, 2020"
138,NCT04436471,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Preventive Immunization COVID-19,Biological: Gam-COVID-Vac,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development",Phase 1|Phase 2,38,Other,"June 17, 2020","August 3, 2020","August 10, 2020"
139,NCT04434794,Treatment of Gingival Recession Using Mesenchymal Stem Cells,Gingival Recession,Biological: mesenchymal stem cells|Other: standard treatment,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education,Phase 1|Phase 2,27,Other,"January 1, 2018","December 31, 2019","December 31, 2019"
140,NCT04434443,Effects of Trunk Exercise on Trunk Control and Balance in Persons With Stroke,Cerebrovascular Accident|Balance Impairment,Other: trunk exercise on unstable exercise|Other: Upper limb range of motion exercise,"National Cheng Kung University|Tainan Hospital, Ministry of Health and Welfare",Phase 1|Phase 2,35,Other,"August 9, 2018","October 6, 2019","October 6, 2019"
141,NCT04434430,Preemptive Oral Gabapentin 600 mg in Reducing Morphine Requirement After Non Obstetric Lower Abdominal Surgery,Non-obstetric Lower Abdominal Surgery,Drug: Gabapentin|Other: Placebo,Indonesia University,Phase 1|Phase 2,72,Other,"November 11, 2019","February 29, 2020","February 29, 2020"
142,NCT04430777,Use of Tranexamic Acid in Liposculpture,"Blood Loss, Surgical",Drug: Tranexamic acid,Total Definer Research Group,Phase 2|Phase 3,141,Other,"January 17, 2019","February 22, 2020","February 22, 2020"
143,NCT04426643,Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells,Urinary Incontinence,Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The state institution N. N. Alexandrov National Cancer Centre of Belarus,Phase 1|Phase 2,10,Other,"August 1, 2020","February 20, 2021","March 31, 2021"
144,NCT04425252,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,COVID-19,Drug: Brequinar|Other: Standard of Care,"Clear Creek Bio, Inc.",Phase 1|Phase 2,25,Industry,"August 19, 2020","December 29, 2020","January 12, 2021"
145,NCT04423341,Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm,"Blepharospasm|Blepharospasm, Benign Essential|CBD",Drug: Cannabidiol Oral Solution [Epidiolex],Silkiss Eye Surgery|Benign Essential Blepharospasm Research Foundation|Jazz Pharmaceuticals|Smith-Kettlewell Eye Research Institute,Phase 2|Phase 3,12,Other|Industry,"May 20, 2020","March 22, 2021","October 1, 2021"
146,NCT04422561,Prophylactic Ivermectin in COVID-19 Contacts,COVID,Drug: Ivermectin Tablets,Zagazig University,Phase 2|Phase 3,340,Other,"May 31, 2020","July 14, 2020","July 27, 2020"
147,NCT04422509,Lanadelumab for Treatment of COVID-19 Disease,COVID-19,Biological: lanadelumab|Other: regular care,Radboud University Medical Center|Takeda,Phase 1|Phase 2,43,Other|Industry,"October 30, 2020","February 25, 2021","April 30, 2021"
148,NCT04414995,Effect of Paracetamol and Ibuprofen Reducing Morphine Requirements After Total Knee Arthroplasty,Analgesia,Drug: Paracetamol injection and Ibuprofen injection|Drug: Paracetamol injection and normal saline|Drug: Ibuprofen Injection and normal saline,Indonesia University,Phase 2|Phase 3,36,Other,"June 5, 2020","November 30, 2020","December 15, 2020"
149,NCT04409132,Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.,End Stage Renal Disease,Drug: Triferic,"Rockwell Medical Technologies, Inc.",Phase 1|Phase 2,23,Industry,"June 25, 2020","April 2, 2021","April 2, 2021"
150,NCT04405843,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),COVID-19,Drug: Ivermectin Oral Product|Drug: Placebo,Centro de Estudios en Infectogía Pediatrica,Phase 2|Phase 3,476,Other,"July 14, 2020","December 21, 2020","December 21, 2020"
151,NCT04405193,The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms,Methamphetamine Dependence in Remission,Drug: N-acetyl cysteine|Drug: Placebo,Melva Louisa|Indonesia University,Phase 2|Phase 3,66,Other,"October 1, 2019","July 30, 2020","December 30, 2020"
152,NCT04403555,Ivermectin as a Novel Therapy in COVID-19 Treatment,COVID,Drug: Ivermectin,Tanta University,Phase 2|Phase 3,164,Other,"June 1, 2020","October 31, 2020","December 1, 2020"
153,NCT04402762,Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®,Enoxaparin,Drug: Ovine Enoxaparin|Drug: Enoxaparin Prefilled Syringe [Lovenox],Indonesia University|PT Metiska Farma,Phase 1|Phase 2,20,Other,"December 20, 2019","April 17, 2020","May 3, 2020"
154,NCT04402060,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,COVID|Covid-19|Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Ards|Acute Respiratory Distress Syndrome,Drug: APL-9|Other: Vehicle Control,"Apellis Pharmaceuticals, Inc.",Phase 1|Phase 2,72,Industry,"May 28, 2020","February 13, 2021","February 13, 2021"
155,NCT04400032,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome|Covid19,Biological: Mesenchymal Stromal Cells,Ottawa Hospital Research Institute|Stem Cell Network|Ontario Research Fund,Phase 1|Phase 2,15,Other,"May 15, 2020","April 22, 2021","April 22, 2021"
156,NCT04397367,Low Dose Ruxolitinib in Combination With Methylprednisolone,aGVHD|Stem Cell Transplant Complications,Drug: Ruxolitinib 10 mg twice a day combined with Corticosteroids|Drug: Ruxolitinib 5 mg twice a day combined with Corticosteroids|Drug: Ruxolitinib 5 mg once a day combined with Corticosteroids|Drug: Ruxolitinib 2.5 mg once a day combined with Corticosteroids,Chinese PLA General Hospital,Phase 1|Phase 2,38,Other,"January 1, 2019","July 1, 2020","December 31, 2020"
157,NCT04397289,Anticoagulation Therapy After Splenectomy in Cirrhosis Patient,Liver Cirrhosis|Portal Hypertension|Anticoagulant-induced Bleeding|Thrombosis,Drug: Heparin and Rivaroxaban,First Affiliated Hospital Xi'an Jiaotong University,Phase 1|Phase 2,70,Other,"February 12, 2018","March 31, 2021","March 31, 2021"
158,NCT04392778,Clinical Use of Stem Cells for the Treatment of Covid-19,Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection,Biological: MSC Treatment|Biological: Saline Control,SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus),Phase 1|Phase 2,30,Other,"April 1, 2020","November 1, 2020","November 30, 2020"
159,NCT04392141,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,COVID-19,Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,Kermanshah University of Medical Sciences,Phase 1|Phase 2,120,Other,"April 1, 2020","November 1, 2020","November 1, 2020"
160,NCT04390178,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),COVID-19,Biological: SARS-CoV-2 convalescent plasma,Joakim Dillner|Danderyd Hospital|Karolinska Institutet|Karolinska University Hospital,Phase 1|Phase 2,10,Other,"April 10, 2020","June 30, 2020","December 31, 2020"
161,NCT04384497,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,COVID-19,Biological: SARS-CoV-2 convalescent plasma,Joakim Dillner|Danderyd Hospital|Karolinska University Hospital|Karolinska Institutet,Phase 1|Phase 2,10,Other,"May 7, 2020","June 1, 2020","December 1, 2020"
162,NCT04382924,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,COVID,Drug: NP-120 (Ifenprodil),Algernon Pharmaceuticals|Novotech (Australia),Phase 2|Phase 3,168,Industry|Other,"August 5, 2020","December 24, 2020","January 26, 2021"
163,NCT04380519,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),COVID-19,Drug: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"R-Pharm International, LLC|Data Management 365|K-Research, LLC|R-Pharm",Phase 2|Phase 3,372,Industry|Other,"April 23, 2020","July 10, 2020","July 24, 2020"
164,NCT04380259,Mindfulness-Based Trauma Recovery for Refugees (MBTR-R),"Stress Disorders, Post-Traumatic|Stress Related Disorder",Behavioral: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R),University of Haifa,Phase 1|Phase 2,158,Other,"May 10, 2018","May 18, 2019","May 18, 2019"
165,NCT04379271,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",COVID-19,Drug: IMU-838|Other: Placebo,Immunic AG|FGK Clinical Research GmbH,Phase 2|Phase 3,223,Industry,"June 11, 2020","January 12, 2021","February 23, 2021"
166,NCT04378569,Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema,Chronic Hand Eczema,Drug: ARQ-252 cream 0.3%|Drug: ARQ-252 cream 0.1%|Drug: ARQ-252 Vehicle Cream,"Arcutis Biotherapeutics, Inc.",Phase 1|Phase 2,230,Industry,"April 20, 2020","February 24, 2021","February 24, 2021"
167,NCT04374032,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,COVID-19 Infection,Drug: metenkefalin + tridecactide|Drug: The standard of care,Bosnalijek D.D,Phase 2|Phase 3,120,Industry,"May 1, 2020","October 7, 2020","November 3, 2020"
168,NCT04366245,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,Andalusian Network for Design and Translation of Advanced Therapies,Phase 1|Phase 2,72,Other,"April 23, 2020","December 30, 2020","December 30, 2020"
169,NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,COVID-19,Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment,Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Colsanitas-Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia (HUN)|Fundación Cardioinfantil Instituto de Cardiología|Clínica Infantil Santa María del Lago,Phase 2|Phase 3,650,Other,"August 18, 2020","March 20, 2021","June 30, 2021"
170,NCT04358731,Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age,Vaccine for Meningococcal Disease,Biological: NmCV-5|Biological: Menactra,Serum Institute of India Pvt. Ltd.,Phase 2|Phase 3,1640,Industry,"December 27, 2019","March 24, 2021","March 24, 2021"
171,NCT04358614,Baricitinib Therapy in COVID-19,COVID|Pneumonia,Drug: Baricitinib 4 MG Oral Tablet,Fabrizio Cantini|Hospital of Prato,Phase 2|Phase 3,12,Other,"March 16, 2020","April 5, 2020","April 7, 2020"
172,NCT04357782,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,COVID-19|Hypoxia,Drug: L-ascorbic acid,Hunter Holmes Mcguire Veteran Affairs Medical Center|McGuire Research Institute,Phase 1|Phase 2,20,U.S. Fed|Other,"April 16, 2020","October 13, 2020","October 13, 2020"
173,NCT04355728,Use of UC-MSCs for COVID-19 Patients,"Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19",Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,Camillo Ricordi|University of Miami,Phase 1|Phase 2,24,Other,"April 25, 2020","October 31, 2020","October 31, 2020"
174,NCT04353336,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,COVID-19|Coronavirus Infection,Drug: Chloroquine or Hydroxychloroquine,Tanta University,Phase 2|Phase 3,194,Other,"March 23, 2020","June 1, 2020","July 1, 2020"
175,NCT04353128,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Covid19|SARS-CoV 2|Coronavirus Infection,Drug: Melatonin 2mg|Drug: Placebo oral tablet,Instituto de Investigación Hospital Universitario La Paz,Phase 2|Phase 3,450,Other,"April 20, 2020","October 1, 2020","December 1, 2020"
176,NCT04352608,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),COVID-19,Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule|Biological: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Three doses of placebo at the emergency vaccination schedule|Biological: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Three doses of placebo at the routine vaccination schedule,"Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd",Phase 1|Phase 2,744,Industry,"April 16, 2020","July 10, 2020","July 24, 2021"
177,NCT04352075,Intra Articular Injection of Microfat and PRP in Knee Osteoarthritis,Knee Osteoarthritis,Drug: Autologous biologic drug of innovative therapy /cell therapy drug,Clinique Juge,Phase 1|Phase 2,30,Other,"November 15, 2018","August 1, 2019","March 1, 2020"
178,NCT04351295,Efficacy of Faviprevir in COVID-19 Treatment,COVID,Drug: Favipiravir|Drug: Chloroquine,Tanta University,Phase 2|Phase 3,92,Other,"April 20, 2020","September 28, 2020","September 28, 2020"
179,NCT04349410,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",The Camelot Foundation,Phase 2|Phase 3,1800,Other,"April 11, 2020","September 14, 2020","September 14, 2020"
180,NCT04347954,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),COVID-19,Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%,Stanford University,Phase 1|Phase 2,47,Other,"August 15, 2020","December 13, 2020","December 13, 2020"
181,NCT04347031,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,Burnasyan Federal Medical Biophysical Center,Phase 2|Phase 3,320,Other,"April 8, 2020","November 1, 2020","November 20, 2020"
182,NCT04345419,Remdesivir Efficacy in Coronavirus Disease,COVID,Drug: Remdesivir|Other: Standard of care treatment,Tanta University,Phase 2|Phase 3,200,Other,"June 16, 2020","December 1, 2020","December 1, 2020"
183,NCT04343287,Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment,Dry Eye Syndrome,Drug: BRM421|Drug: Placebo,"BRIM Biotechnology Inc.|ORA, Inc.",Phase 2|Phase 3,220,Industry,"January 15, 2020","June 23, 2020","June 23, 2020"
184,NCT04342065,Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Spine Fixation Surgery,Post-Operative Pain,Drug: Celecoxib capsules|Drug: Pregabalin 150mg,South Egypt Cancer Institute,Phase 2|Phase 3,200,Other,"January 1, 2019","January 30, 2020","February 1, 2020"
185,NCT04340609,Stem Cell in Acute Myocardial Infarction,Acute Myocardial Infarction,Biological: Mesenchymal Stem Cells,PT. Prodia Stem Cell Indonesia,Phase 1|Phase 2,4,Industry,"March 11, 2019","April 8, 2021","April 8, 2022"
186,NCT04340284,Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion,Nonunion of Fracture,Biological: autologous adipose tissue derived stromal vascular fraction (SVF),Dr. Himanshu Bansal Foundation,Phase 1|Phase 2,11,Other,"November 10, 2019","February 14, 2020","February 14, 2020"
187,NCT04336709,Comparison of Anti-microbial Efficacy of Calcipex and Metapex in Endodontic Treatment of Chronic Apical Periodontitis,Chronic Apical Periodontitis,Drug: Calcipex II|Drug: Metapex,Aga Khan University,Phase 2|Phase 3,60,Other,"April 6, 2020","April 30, 2021","April 30, 2021"
188,NCT04334044,Treatment of SARS Caused by COVID-19 With Ruxolitinib,COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Ruxolitinib Oral Tablet,Grupo Cooperativo de Hemopatías Malignas,Phase 1|Phase 2,77,Other,"September 1, 2020","April 12, 2021","April 30, 2021"
189,NCT04332835,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Coronavirus|Coronavirus Infection,Drug: Plasma|Drug: Standard Therapy,Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud,Phase 2|Phase 3,92,Other,"August 8, 2020","October 31, 2020","November 15, 2020"
190,NCT04330534,First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH,Paroxysmal Nocturnal Hemoglobinuria,Drug: BCX9930|Drug: Placebo,BioCryst Pharmaceuticals,Phase 1|Phase 2,168,Industry,"March 3, 2020","November 11, 2020","January 25, 2021"
191,NCT04328961,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2,Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid,University of Washington|Bill and Melinda Gates Foundation,Phase 2|Phase 3,943,Other,"March 31, 2020","September 24, 2020","October 8, 2020"
192,NCT04328636,Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn,Persistent Fetal Circulation|Persistent Pulmonary Hypertension of the Newborn|PPHN,Drug: Nebulized Magnesium Sulfate|Drug: Intravenous Magnesium Sulfate,Sohag University,Phase 1|Phase 2,28,Other,"November 1, 2017","July 1, 2020","August 1, 2020"
193,NCT04318639,The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder,Alcohol Use Disorder|Mild Cognitive Impairment,Combination Product: Donepazil,VA Connecticut Healthcare System,Phase 2|Phase 3,15,U.S. Fed,"August 17, 2018","December 31, 2019","December 31, 2019"
194,NCT04317508,Using Anesthetic Gel Patches to Reduce Pain of Palatal Injection,"Anesthesia, Dental",Drug: Topicale GelPatch (Benzocaine 18%)|Drug: Benzocaine oral gel 20%,Dina Youssef Attia|Alexandria University,Phase 1|Phase 2,50,Other,"November 1, 2019","February 13, 2020","February 19, 2020"
195,NCT04315298,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,COVID-19,Drug: Sarilumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 2|Phase 3,1912,Industry,"March 18, 2020","July 24, 2020","September 2, 2020"
196,NCT04315025,Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa,Retinitis Pigmentosa,Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Biological: Conditioned Medium (CM),PT. Prodia Stem Cell Indonesia,Phase 1|Phase 2,18,Industry,"October 7, 2018","June 20, 2019","September 20, 2019"
197,NCT04314362,Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD),Meibomian Gland Dysfunction,Drug: AZR-MD-001 ointment/semi-solid drug,Azura Ophthalmics|The University of New South Wales,Phase 2|Phase 3,32,Industry|Other,"July 14, 2020","January 6, 2021","January 6, 2021"
198,NCT04311697,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Critical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection|Acute Lung Injury,Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care,"NeuroRx, Inc.|Lavin Consulting, LLC",Phase 2|Phase 3,196,Industry|Other,"May 15, 2020","February 22, 2021","February 22, 2021"
199,NCT04303416,Plasma Exchange With Albumin in AMN Patients,Adrenomyeloneuropathy|Adrenoleukodystrophy,Drug: Albumin solution,"Onofre, Aurora Pujol, M.D.",Phase 2|Phase 3,5,Other,"March 9, 2020","February 24, 2021","September 13, 2021"
200,NCT04301336,Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia,Vaso-occlusive Crisis|Sickle Cell Disease|Sickle Cell Anemia in Children,Drug: Omega 3|Drug: Vit D|Drug: Zinc sulfate|Drug: Statins (Cardiovascular Agents)|Drug: Hydroxy Urea|Drug: Folic Acid Supplementation|Drug: Morphine Sulfate|Procedure: blood transfusion session,"Beni-Suef University|Benisuef university hospital|University of Arizona|Maternity and Children Hospital, Makkah",Phase 2|Phase 3,350,Other,"November 1, 2019","November 1, 2020","December 10, 2020"
201,NCT04293679,"Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC",Bowen's Disease|Cutaneous Squamous Cell Carcinoma in Situ,Drug: STP705,Sirnaomics|Amarex Clinical Research,Phase 1|Phase 2,25,Industry|Other,"March 21, 2019","October 21, 2020","October 21, 2020"
202,NCT04292314,"Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia",Iron Overload|Oxidative Stress|Thalassemia Major,Drug: Omega 3|Drug: Nigella Sativa Oil|Drug: Hydroxyurea|Drug: Honey|Drug: Deferoxamine|Procedure: blood transfusion session,"Beni-Suef University|Maternity and Children Hospital, Makkah|Beni-Suef Health insurance hospital|University of Arizona",Phase 2|Phase 3,350,Other,"November 1, 2019","December 20, 2020","January 20, 2021"
203,NCT04290195,Use of Ziv Aflibercept in Different Retinal Diseases,Central Retinal Vein Occlusion With Macular Edema,Drug: Ziv-Aflibercept 25 MG/ML [Zaltrap],Amin El Sayed Nawar|Tanta University,Phase 1|Phase 2,55,Other,"June 1, 2019","December 1, 2019","January 1, 2020"
204,NCT04281095,A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines,Glabellar Frown Lines,Drug: Botulinum toxin type A,"ATGC Co., Ltd.",Phase 1|Phase 2,60,Industry,"November 1, 2019","April 30, 2020","April 30, 2020"
205,NCT04275245,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Coronavirus Disease 2019 (COVID-19),Drug: Meplazumab for Injection,Tang-Du Hospital,Phase 1|Phase 2,17,Other,"February 3, 2020","March 9, 2020","March 9, 2020"
206,NCT04274257,A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis,"Scleroderma, Systemic|Skin Sclerosis|Lung Fibrosis|Autoimmune Diseases|Collagen Diseases",Drug: Double-Blind Placebo|Drug: Double-Blind Rituximab,"Tokyo University|Japan Agency for Medical Research and Development|Zenyaku Kogyo Co., Ltd.",Phase 2|Phase 3,56,Other|Industry,"December 4, 2017","May 9, 2019","November 5, 2019"
207,NCT04270994,Misoprostol as a Treatment for Endometrial Polyps in Infertile Patients,Endometrial Polyps in Infertile Patients,Drug: Misoprostol,"Henry Aristoteles Mate-Sánez|Mateo-Sánez, Henry A.",Phase 2|Phase 3,54,Other,Sep-16,Aug-19,Nov-19
208,NCT04254939,A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor,Gastrointestinal Stromal Tumors,Drug: CS3007 (BLU-285),CStone Pharmaceuticals|Blueprint Medicines Corporation,Phase 1|Phase 2,65,Industry,"August 15, 2019","April 30, 2020","April 11, 2023"
209,NCT04254679,Pilot Trial: Postoperative Opioid-free Analgesia,Outpatient Surgery|Abdominal Surgery|Breast Surgery,Drug: Opioid analgesics|Drug: Non-opioid analgesics,McGill University Health Centre/Research Institute of the McGill University Health Centre|Society of American Gastrointestinal and Endoscopic Surgeons,Phase 2|Phase 3,81,Other,"January 29, 2020","September 20, 2020","December 3, 2020"
210,NCT04251689,"The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial",Cis-Platinum Nephropathy|Mannitol Adverse Reaction,Drug: Mannitol|Drug: Placebo,Phramongkutklao College of Medicine and Hospital,Phase 2|Phase 3,48,Other,"December 1, 2018","July 1, 2020","February 14, 2021"
211,NCT04244591,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,COVID-19 Infections,Drug: methylprednisolone therapy|Other: Standard care,Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University,Phase 2|Phase 3,80,Other,"January 26, 2020","April 13, 2020","April 13, 2020"
212,NCT04237532,Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment,Anti-anxiety Agents|Moderate Sedation,Drug: Intranasal Dexmedetomidine|Drug: Sublingual Dexmedetomidine,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2|Phase 3,42,Other,"August 27, 2019","August 1, 2020","August 10, 2020"
213,NCT04236830,Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars,Tertiary Dentine|Indirect Pulp Capping,Drug: Silver diamine fluoride/ potassium iodide|Drug: Silver diamine fluoride|Drug: Resin modified glass ionomer cement,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2|Phase 3,108,Other,"November 1, 2019","March 1, 2021","March 25, 2021"
214,NCT04225533,SP16 Inflammatory Response Inhibition Trial,Myocardial Infarction|Inflammation,Drug: SP16,"Serpin Pharma, LLC|Virginia Commonwealth University",Phase 1|Phase 2,10,Other,"February 24, 2020","January 4, 2021","December 21, 2021"
215,NCT04222725,A Study of TRS01 in Participants With Post-surgical Ocular Inflammation,Post Surgical Ocular Inflammation,Drug: TRS01 eye drops|Drug: Placebo eye drops,Tarsier Pharma,Phase 1|Phase 2,37,Industry,"February 1, 2020","July 17, 2020","July 17, 2020"
216,NCT04222712,A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis,Non-infectious Anterior Uveitis,Drug: TRS01 eye drops,Tarsier Pharma,Phase 1|Phase 2,16,Industry,"February 1, 2020","August 24, 2020","August 24, 2020"
217,NCT04218058,Reduction of Zygomatic Arch in Zygomaticomaxillary Fractures,Zygomatic Arch Reduction,Procedure: reduction of zygomatic arch in zygomaticomaxillary complex fracture,Alexandria University,Phase 1|Phase 2,20,Other,"May 15, 2018","September 25, 2019","November 23, 2019"
218,NCT04216888,Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine,"Depressive Disorder, Treatment-Resistant",Drug: Ketamine Hydrochloride,Dan Iosifescu|Nathan Kline Institute for Psychiatric Research,Phase 2|Phase 3,9,Other,"June 26, 2019","December 28, 2020","December 28, 2020"
219,NCT04210193,Is Intralymphatic Allergen Immunotherapy Effective and Safe?,Allergic Rhinitis Due to Grass Pollen,Drug: ALK Alutard 5-grasses|Drug: ALK Diluent,Lars Olaf Cardell|Karolinska Institutet,Phase 2|Phase 3,15,Other,"April 25, 2014","December 1, 2019","December 1, 2019"
220,NCT04210180,Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction,Smoking Cessation|Harm Reduction,Drug: Varenicline|Other: e-cigarette,"Rose Research Center, LLC|Foundation for a Smoke Free World INC",Phase 2|Phase 3,25,Industry|Other,"November 19, 2019","October 14, 2020","March 22, 2021"
221,NCT04208087,PK and Safety of SI-722 in IC/BPS,Interstitial Cystitis|Bladder Pain Syndrome,Drug: SI-722|Drug: Placebo,Seikagaku Corporation,Phase 1|Phase 2,33,Industry,"March 30, 2020","January 12, 2021","January 12, 2021"
222,NCT04206176,The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease,Platelet Dysfunction Due to Drugs,Drug: Ticagrelor,The University of The West Indies,Phase 1|Phase 2,25,Other,"October 1, 2019","March 31, 2020","March 31, 2020"
223,NCT04204954,Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery,Demodex Infestation|Demodicosis|Cataract,Other: Tea Tree Oil Shampoo|Drug: Ciprofloxacin Ophthalmic Ointment 0.3%|Other: Baby shampoo|Other: Blephaclean,"Hospital de La Luz|Claudia Palacio Pastrana, M.D., M.Sc.|Samuel J. Avalos Lara, M.D.|Hector Perez Cano, Ph.D.|Bani Antonio-Aguirre, M.D., M.P.H.c.|Cristina Mendoza-Velasquez, M.D., M.Sc.|Azyadeh Camacho-Ordóñez, M.D., M.Sc.c.|Andric C. Perez-Ortiz, M.D., M.P.H.",Phase 2|Phase 3,160,Other,"May 6, 2019","November 14, 2019","December 13, 2019"
224,NCT04203537,"Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)",Postsurgical Pain,Drug: CA-008|Drug: Placebo,Concentric Analgesics,Phase 1|Phase 2,193,Industry,"December 4, 2019","October 26, 2020","October 26, 2020"
225,NCT04202952,"The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects",Chronic Hepatitis C,Drug: HEC110114 Tablet|Drug: Sofosbuvir Tablet,"Sunshine Lake Pharma Co., Ltd.",Phase 1|Phase 2,24,Industry,"July 6, 2020","August 27, 2020","August 27, 2020"
226,NCT04201574,Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease,Dry Eye Disease,Drug: ALY688,Allysta Pharmaceutical,Phase 1|Phase 2,138,Industry,"December 16, 2019","September 15, 2020","September 15, 2020"
227,NCT04189666,Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium,Delirium,Drug: Rivastigmine Transdermal System [Exelon]|Drug: Melatonin,Ain Shams University,Phase 1|Phase 2,180,Other,"November 18, 2019","April 10, 2020","May 1, 2020"
228,NCT04185246,A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography,Cardiac Disease,Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension|Diagnostic Test: Echocardiogram,"Trust Bio-sonics, Inc.|StatPlus,Inc.",Phase 1|Phase 2,36,Industry|Other,"November 4, 2019","July 1, 2020","July 1, 2020"
229,NCT04184258,Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells,Systemic Lupus Erythematosus,Biological: Pooled mesenchymal stem cell|Other: Standard treatment according to the Clinical protocols,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,Phase 1|Phase 2,7,Other,"July 1, 2019","December 31, 2020","December 31, 2020"
230,NCT04183114,Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study),Congenital Rubella Infection|Measles,Biological: Measles-Rubella vaccine Bio Farma|Biological: MR Vaccine SII,PT Bio Farma,Phase 2|Phase 3,540,Industry,"September 3, 2019","November 11, 2019","November 11, 2019"
231,NCT04179266,Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache,Cluster Headache,Drug: Ketamine,CCH Pharmaceuticals|Danish Headache Center,Phase 1|Phase 2,23,Industry|Other,"November 20, 2019","May 12, 2020","May 25, 2020"
232,NCT04172233,A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Biological: AK101|Biological: placebo,"Akeso|Akeso Tiancheng, Inc",Phase 1|Phase 2,96,Industry|Other,"January 9, 2018","May 31, 2019","October 31, 2019"
233,NCT04170088,Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma,Effect of Drugs|Adverse Effects of Medical Drugs,Drug: Tranexamic Acid|Drug: 0.9% Normal Saline,Jinnah Postgraduate Medical Centre,Phase 2|Phase 3,30,Other,"September 1, 2018","May 1, 2019","June 30, 2019"
234,NCT04158219,Healthy Heart Habits,Acute Coronary Syndrome|Depression,Behavioral: Behavioral activation for health and depression (BA-HD),Hennepin Healthcare Research Institute,Phase 1|Phase 2,8,Other,"November 15, 2019","February 24, 2021","February 24, 2021"
235,NCT04149899,Safety and IOP-Lowering Effects of WB007,"Glaucoma, Primary Open Angle|Ocular Hypertension",Drug: WB007 0.05%|Drug: WB007 0.15%|Drug: WB007 0.4%|Drug: Timolol 0.5%,"Whitecap Biosciences, LLC",Phase 1|Phase 2,77,Industry,"November 14, 2019","January 31, 2021","December 14, 2022"
236,NCT04147650,Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome,Dry Eye Syndrome|Keratoconjunctivitis Sicca,Drug: 0.05% Voclosporin Ophthalmic Solution (VOS)|Drug: 0.10% VOS|Drug: 0.20% VOS|Drug: Vehicle Ophthalmic Solution,Aurinia Pharmaceuticals Inc.,Phase 2|Phase 3,508,Industry,"October 14, 2019","September 17, 2020","October 8, 2020"
237,NCT04141969,A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome,Post-Lyme Disease Syndrome (PLDS),Dietary Supplement: RLP|Other: Placebo,Optimal Health Research,Phase 2|Phase 3,100,Other,"November 29, 2019","December 31, 2020","March 28, 2021"
238,NCT04139122,"Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease",Dry Eye Disease|Dry Eye Syndrome,Drug: SJP-0132|Drug: Placebo,"Senju Pharmaceutical Co., Ltd.",Phase 1|Phase 2,89,Industry,"October 5, 2019","March 3, 2020","March 3, 2020"
239,NCT04138498,CTx-1301 Comparative Bioavailability Study,ADHD,"Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Drug: Dexmethylphenidate 6.25 mg Tablet|Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Drug: Dexmethylphenidate 50 mg Tablet",Cingulate Therapeutics,Phase 1|Phase 2,45,Industry,"December 6, 2019","March 6, 2020","March 6, 2020"
240,NCT04137185,"Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",Differentiated Thyroid Cancer,Drug: Recombinant Human Thyroid Stimulating Hormone for Injection,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Phase 1|Phase 2,64,Industry,"June 10, 2019","December 29, 2020","December 29, 2020"
241,NCT04136548,Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Fentanyl,Healthy,Drug: Fentanyl|Other: Placebo,University of Texas Southwestern Medical Center|United States Department of Defense,Phase 1|Phase 2,41,Other|U.S. Fed,"June 1, 2019","November 18, 2020","November 18, 2020"
242,NCT04124822,Effectiveness if Premedication With Single Dose Piroxicam and Prednisolone After a Single Visit Root Canal Treatment .,Post-operative Endodontic Pain,Drug: Piroxicam 20 mg|Drug: prednisolone 20 mg,Dow University of Health Sciences,Phase 2|Phase 3,60,Other,"May 30, 2018","July 15, 2019","July 15, 2019"
243,NCT04123743,Efficacy of Extract of Trigonella Foenum-graceum as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women,Skin Aging,Drug: Trigonella foenum-graceum extract topical cream|Other: Facial Wash|Other: Sunscreen Cream|Other: Placebo,Indonesia University,Phase 1|Phase 2,21,Other,"August 10, 2019","November 3, 2019","November 10, 2019"
244,NCT04119011,Probiotics in Women With Primary Dysmenorrhoea,Primary Dysmenorrhea,Biological: Probiotic|Other: Placebo,National University of Malaysia|B-Crobes Marketing(M) Sdn Bhd,Phase 1|Phase 2,72,Other,"October 1, 2019","March 31, 2020","March 31, 2020"
245,NCT04118296,Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream,Acne Vulgaris,Drug: Anti-Acne Preparations for Topical Use,Sukma Skin Treatment,Phase 1|Phase 2,150,Other,"October 8, 2019","November 6, 2019","November 30, 2019"
246,NCT04118101,Erector Spinae Plane Block,Post Operative Pain,Drug: ESPB block|Other: control,Theodor Bilharz Research Institute,Phase 2|Phase 3,46,Other,"October 25, 2019","December 10, 2020","February 15, 2021"
247,NCT04116138,Antisecretory Factor in Primary Glioblastoma 1,Glioblastoma|Cerebral Edema|Chemotherapy Effect,Dietary Supplement: Salovum,Peter Siesjö|Region Skane|Lund University|Skane University Hospital|Lantmannen Medical AB,Phase 1|Phase 2,8,Other,"September 1, 2019","March 31, 2021","March 31, 2021"
248,NCT04115072,Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study,Schistosomiasis,Drug: Praziquantel 600Mg Oral Tablet x 5|Drug: Praziquantel 600Mg Oral Tablet x 1,"Vendsyssel Hospital|Charite University, Berlin, Germany|Leiden University Medical Center|Nagasaki University|Umeå University|Merck Serono International SA|Ministry of Health, Madagascar",Phase 2|Phase 3,116,Other|Industry,"September 3, 2019","February 21, 2020","February 21, 2020"
249,NCT04114864,A Primary Prevention Intervention for the Promotion of Psycho-social Wellbeing in Adolescent Young Carers:,Adolescent - Emotional Problem|Mental Health Wellness 1|Caregivers|Primary Prevention|Cognitive Therapy,Behavioral: Psycho-educational sessions,"Valentina Hlebec|LINNEUNIVERSITETET (LNU), Sweden (leading the consortium)|EUROCARERS-ASSOCIATION EUROPEENNE TRAVAILLANT AVEC ET POUR LES|THE UNIVERSITY OF SUSSEX (UoS), UK|CARERS TRUST (Carers Trust), UK|STIFTUNG KALAIDOS FACHHOCHSCHULE (Kalaidos FH), SW|MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT (NLNA), NL|STICHTING VILANS (VILANS), NL|ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI INRCA (INRCA), IT|ANZIANI E NON SOLO SOCIETA COOPERATIVA SOCIALE (ANZIANI E), IT|UNIVERZA V LJUBLJANI (UL), SI|Nationellt kompetenscentrum anhöriga (Nka), (Swedish Family Care Competence Centre), Kalmar, Sweden|University of Ljubljana",Phase 1|Phase 2,295,Other,"October 20, 2019","March 20, 2021","June 30, 2021"
250,NCT04113720,Levobupivacaine vs Levobupivacaine + Dexmedetomidine Infiltration for Post-tonsillectomy Analgesia and Laryngospasm in Pediatric Patients,Post-tonsillectomy Analgesia|Levobupivacaine,Drug: Levobupivacaine hydrochloride|Drug: Levobupivacaine Hydrochloride + Dexmedetomidine,Assiut University,Phase 1|Phase 2,90,Other,"November 15, 2019","October 30, 2020","November 30, 2020"
251,NCT04100759,A Comparative Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Adult Smokers and Non Smokers,Erectile Dysfunction|Smoking|Pharmacokinetics|Pharmacodynamics,Drug: Sildenafil 50 mg Oral Tablet,"Ain Shams University|Drug Research Centre, Cairo, Egypt",Phase 1|Phase 2,36,Other,"June 11, 2019","June 25, 2019","July 8, 2019"
252,NCT04091139,Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong,Depressive Disorder|Anxiety Disorders,Behavioral: Unified protocol for adolescents (UP-A)|Behavioral: Treatment as usual (TAU),Chinese University of Hong Kong|Castle Peak Hospital,Phase 2|Phase 3,27,Other,"September 24, 2019","May 22, 2020","May 22, 2020"
253,NCT04088721,Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis,Allergic Rhinitis,Biological: AD17002|Other: Formulation Buffer,Advagene Biopharma Co. Ltd.|Clinipace Worldwide|Taipei Medical University,Phase 1|Phase 2,48,Industry|Other,"March 26, 2019","July 30, 2020","December 11, 2020"
254,NCT04088448,The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients,Major Depressive Disorder,Drug: Placebo oral tablet|Drug: Metformin,Sadat City University,Phase 1|Phase 2,80,Other,"January 1, 2017","June 1, 2020","June 1, 2020"
255,NCT04083157,Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients,Inflammatory Bowel Diseases|Hepatitis B,Biological: Intradermal hepatitis B vaccine with imiquimod|Biological: Intramuscular hepatitis B vaccine with aqueous cream,The University of Hong Kong,Phase 2|Phase 3,104,Other,"August 12, 2019","December 30, 2020","December 30, 2021"
256,NCT04080921,Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis,Encephalitis|Meningitis,Combination Product: Stem cell transplantation,Vinmec Research Institute of Stem Cell and Gene Technology,Phase 1|Phase 2,22,Other,"June 16, 2014","June 30, 2019","August 30, 2019"
257,NCT04078841,Treating Post-Lyme Disease Syndrome With Acetogenins,Post-Lyme Disease Syndrome (PLDS),Dietary Supplement: ReaLife+ (RLP)|Other: Inert Brown powder,Optimal Health Research,Phase 1|Phase 2,30,Other,"July 1, 2019","November 14, 2019","January 30, 2020"
258,NCT04077671,CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer,Diabetic Neuropathic Foot Ulcers,Biological: CHF6467 active,Chiesi Farmaceutici S.p.A.|Comac Medical,Phase 1|Phase 2,93,Industry,"October 17, 2018","January 7, 2021","January 7, 2021"
259,NCT04075396,A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC),"Carcinoma, Non-Small-Cell Lung",Drug: Lazertinib,"Janssen Research & Development, LLC|Yuhan Corporation",Phase 1|Phase 2,30,Industry,"October 16, 2019","January 8, 2021","November 3, 2022"
260,NCT04072341,Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients.,Chronic Kidney Disease Requiring Chronic Dialysis,Drug: Propolis Period (Green Propolis 250mg/day)|Other: Control Period,"University of Sao Paulo General Hospital|Hospital Sao Rafael|Alagoas State University of Health Science , Maceió , Brazil.",Phase 1|Phase 2,40,Other,"August 1, 2019","December 15, 2019","January 30, 2020"
261,NCT04071574,Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility,Female Infertility|Female Infertility Due to Ovulatory Disorder|Premature Ovarian Failure|Polycystic Ovary Syndrome|Female Infertility of Tubal Origin|Ectopic Pregnancy|Salpingitis|Female Infertility Due to Tubal Block|Female Infertility Due to Tubal Occlusion|Hydrosalpinx|Female Infertility - Cervical/Vaginal|Female Infertility Endocrine|Endometriosis|Fibroids|Congenital Uterine Anomaly|Infections Uterine|Female Infertility of Other Origin,Drug: Human Chorionic Gonadotropin (hCG)|Drug: Gonadotropins|Drug: GNRH-A Triptorelin|Drug: GnRH antagonist,Lebanese University,Phase 1|Phase 2,200,Other,"February 1, 2018","August 22, 2019","May 5, 2023"
262,NCT04068519,"Study Investigating Safety, Tolerability, Pharmacokinetics（PK） and Antitumor Activities of Anti-PD-1(Programmed Death-1) Monoclonal Antibody",Advanced Solid Tumors,Drug: Tislelizumab,BeiGene,Phase 1|Phase 2,300,Industry,"December 28, 2016","May 31, 2020","October 13, 2020"
263,NCT04068246,The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients,Rheumatoid Arthritis,Drug: Metformin|Drug: Placebo,Sadat City University,Phase 1|Phase 2,120,Other,"August 1, 2019","December 31, 2020","February 28, 2021"
264,NCT04066023,Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches,Cluster Headache,Drug: C213 Microneedle System|Drug: Placebo,Zosano Pharma Corporation,Phase 2|Phase 3,42,Industry,"October 3, 2019","April 14, 2021","April 14, 2021"
265,NCT04061265,Articaine Efficacy and Safety for Children Below Age of 4-years,Behaviour Assessment|Pain,Drug: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Drug: lidocaine hydrochloride 2% and epinephrine 1:100000,Minia University,Phase 1|Phase 2,184,Other,"August 25, 2019","January 15, 2020","January 15, 2020"
266,NCT04051463,Rhopressa for Corneal Edema Associated With Fuchs Dystrophy,Fuchs Endothelial Dystrophy,Drug: Netarsudil Ophthalmic Solution|Drug: Placebo,Price Vision Group,Phase 2|Phase 3,29,Industry,"August 5, 2019","July 1, 2020","July 1, 2020"
267,NCT04050020,Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function,Erectile Dysfunction Due to Arterial Insufficiency,Biological: Platelet-Rich Plasma (PRP)|Biological: Normal saline injection,"Institute for the Study of Urological Diseases, Greece|European Society for Sexual Medicine",Phase 2|Phase 3,60,Other,"September 2, 2019","March 26, 2020","September 24, 2020"
268,NCT04049916,Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission,"Malaria,Falciparum",Drug: Pyronaridine Tetraphosphate/Artesunate|Drug: Dihydroartemisinin/Piperaquine|Drug: Primaquine Diphosphate,"London School of Hygiene and Tropical Medicine|Malaria Research and Training Center, Bamako, Mali|Radboud University Medical Center",Phase 2|Phase 3,100,Other,"September 12, 2019","January 7, 2020","January 7, 2020"
269,NCT04048135,A Multiple Ascending Dose Study of BIO89-100 in Subjects With Biopsy Confirmed NASH or NAFLD and at High Risk of NASH,NASH,Drug: BIO89-100|Other: Placebo,"89bio, Inc.|ProSciento, Inc.",Phase 1|Phase 2,101,Industry,"July 29, 2019","August 28, 2020","January 19, 2022"
270,NCT04042324,A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients,End Stage Renal Disease,Drug: Triferic|Drug: Heparin,"Rockwell Medical Technologies, Inc.",Phase 1|Phase 2,12,Industry,"September 30, 2019","January 16, 2020","January 16, 2020"
271,NCT04030754,Comparison of Effectiveness of Amniotic Membrane and Duoderm Dressings in Pediatric Burns,Burns,Combination Product: amniotic membrane|Combination Product: duoderm dressing,King Edward Medical University,Phase 2|Phase 3,172,Other,"November 1, 2018","February 14, 2020","February 14, 2020"
272,NCT04030741,Non-operative Treatment of Acute Non-perforated Appendicitis,Acute Appendicitis,Drug: Meronem and flagyl|Procedure: Appendectomy,King Edward Medical University,Phase 2|Phase 3,180,Other,"September 1, 2018","December 1, 2019","December 1, 2020"
273,NCT04030143,A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder,Schizophrenia|Bipolar I Disorder,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|PRA Health Sciences",Phase 1|Phase 2,266,Industry,"July 31, 2019","July 1, 2020","July 1, 2020"
274,NCT04026945,Sustained Release Lidocaine for Treatment of Scrotal Pain,Chronic Pain,Drug: Lidocaine,University of British Columbia,Phase 1|Phase 2,12,Other,"October 31, 2019","March 24, 2021","March 24, 2021"
275,NCT04022629,ASSET 2 Study: Long-Term Follow-up of a Randomised Control Trial,Shoulder Dislocation,Procedure: Arthroscopic Washout Only|Procedure: Arthroscopic Bankart Repair,Royal Infirmary of Edinburgh,Phase 2|Phase 3,88,Other,"May 1, 2019","July 30, 2019","January 1, 2020"
276,NCT04018885,A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris,Acne Vulgaris,Drug: ALA 2.5%|Drug: ALA 5%|Drug: ALA 10%,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",Phase 1|Phase 2,72,Industry,"July 11, 2019","January 20, 2020","January 20, 2020"
277,NCT03997851,Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects,Pruritus,Drug: Acetaminophen|Drug: Carbomer 980,University of Miami,Phase 1|Phase 2,17,Other,"July 22, 2019","March 18, 2020","March 18, 2020"
278,NCT03994913,Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma,Refractory B-Cell Non-Hodgkin Lymphoma|Relapsed B-cell Non-Hodgkin Lymphoma,Biological: CAR-CD19 T Cells,"CARsgen Therapeutics Co., Ltd.|First Affiliated Hospital of Zhejiang University|RenJi Hospital",Phase 1|Phase 2,20,Industry|Other,"August 14, 2019","January 20, 2021","May 27, 2021"
279,NCT03992482,IVIG-eye Drops Treatment for Dry Eye Disease,Dry Eye,Drug: Intravenous Immune Globulin (IVIG)|Drug: Placebo,"Sandeep Jain, MD|University of Illinois at Chicago",Phase 1|Phase 2,27,Other,"May 1, 2019","August 2, 2019","August 2, 2019"
280,NCT03989531,Adrecizumab in Cardiogenic Shock,Cardiogenic Shock|Endothelial Dysfunction,Biological: Adrecizumab|Drug: Placebo,Dr. med. Mahir Karakas|Universitätsklinikum Hamburg-Eppendorf,Phase 2|Phase 3,150,Other,"April 4, 2019","April 26, 2021","April 26, 2021"
281,NCT03987854,The University of Michigan PCOS Intervention Using Nutritional Ketosis,Polycystic Ovary Syndrome,Behavioral: diet and lifestyle program,University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1|Phase 2,29,Other|NIH,"July 5, 2019","March 1, 2020","March 1, 2020"
282,NCT03981627,A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Drug: ADO09 formulation|Drug: NovoRapid®,Adocia,Phase 1|Phase 2,44,Industry,"June 6, 2019","June 27, 2020","June 27, 2020"
283,NCT03978091,A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam,Bacterial Infection,Drug: AZACTAM|Drug: Ceftazidime-Avibactam,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,48,NIH,"July 9, 2019","November 23, 2020","November 23, 2020"
284,NCT03973151,Study of HL-085 in NRAS Mutant Advanced Melanoma,Melanoma,Drug: HL-085,"Shanghai Kechow Pharma, Inc.",Phase 1|Phase 2,42,Industry,"September 1, 2017","January 18, 2021","January 18, 2021"
285,NCT03970876,Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects,Moderate to Severe Glabellar Lines,Biological: ATGC-100|Biological: Botox®,"EuBiologics Co.,Ltd",Phase 1|Phase 2,60,Industry,"April 19, 2019","September 11, 2019","December 23, 2019"
286,NCT03967197,Lidocaine Before Esophageal Manometry and Ambulatory pH Monitoring,"Pain, Acute",Drug: Saline spray|Drug: Lidocaine Hydrochloride,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2|Phase 3,304,Other,"August 6, 2019","August 5, 2020","August 5, 2020"
287,NCT03963921,Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients,NASH - Nonalcoholic Steatohepatitis,Drug: HepaStem,Promethera Therapeutics,Phase 1|Phase 2,23,Industry,"April 9, 2019","May 28, 2020","August 31, 2020"
288,NCT03963115,Can Epinephrine Coated Syringe for Subcutaneous Immunotherapy (SCIT) Reduce Large Local Reaction?,Injection Reactions Site|Systemic Reactions,Drug: Epinephrine or normal saline,Mahidol University,Phase 1|Phase 2,17,Other,"October 24, 2018","August 25, 2019","September 1, 2019"
289,NCT03960658,Ketamine and Prolonged Exposure in PTSD,Post-traumatic Stress Disorder,Drug: ketamine-enhanced prolonged exposure,Minneapolis Veterans Affairs Medical Center,Phase 1|Phase 2,12,U.S. Fed,"April 3, 2019","November 18, 2019","December 4, 2019"
290,NCT03957694,Study of AMG531(Romiplostim) in Patients With Aplastic Anemia,Aplastic Anemia,Drug: Romiplostim,"Kyowa Kirin Co., Ltd.",Phase 2|Phase 3,17,Industry,"April 25, 2019","November 5, 2020","May 26, 2021"
291,NCT03953820,Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study,Epilepsy,Drug: Diazepam Buccal Film|Drug: Diastat® Rectal Gel (Valeant Pharmaceuticals USA),Aquestive Therapeutics,Phase 1|Phase 2,31,Industry,"April 13, 2019","July 31, 2019","July 31, 2019"
292,NCT03952650,Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...,Malaria,Drug: Chloroquine Phosphate|Biological: PfSPZ Challenge|Drug: Pyrimethamine|Drug: Coartem|Drug: ibuprofen,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,252,NIH,"May 23, 2019","February 10, 2021","February 10, 2021"
293,NCT03947554,Ginseng HRG80 in Stress and Fatigue,Psychological Stress,Dietary Supplement: HRG80 Panax ginseng|Dietary Supplement: Panax ginseng|Dietary Supplement: Placebo,"EuroPharma, Inc.|Botalys SA",Phase 1|Phase 2,50,Industry|Other,"April 1, 2019","June 15, 2019","July 1, 2019"
294,NCT03945864,Antimicrobial Synthetic Bone Grafts,Bone Infection|Bone Graft Infection,Device: antimicrobial synthetic bone graft|Device: parentaral antimicrobials and pure bone grafts,Eskisehir Osmangazi University,Phase 1|Phase 2,12,Other,"June 1, 2019","September 1, 2020","August 15, 2021"
295,NCT03945110,Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury,Spinal Cord Injuries,Device: iAluRil® intravesical instillations,The University of Western Australia|Royal Perth Hospital|Fiona Stanley Hospital|Perth Urology Clinic,Phase 1|Phase 2,10,Other,"September 18, 2019","September 22, 2020","March 18, 2021"
296,NCT03944109,"The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia",Hyperlipidemia,Drug: SHR-1209|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1|Phase 2,110,Industry,"June 20, 2019","December 22, 2020","December 22, 2020"
297,NCT03937206,"Evaluation of the Pharmacokinetics, Safety and Effects of NutriterraTM in Healthy Adults",Healthy,Dietary Supplement: NutriterraTM|Dietary Supplement: Placebo,"Nuseed Americas Inc.|Nutrasource Pharmaceutical and Nutraceutical Services, Inc.",Phase 1|Phase 2,132,Industry|Other,"May 1, 2019","December 13, 2019","December 13, 2019"
298,NCT03936426,Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™,Meningioma,Drug: Cu-64 SARTATE and Cu-67 SARTATE,Clarity Pharmaceuticals Ltd,Phase 1|Phase 2,5,Industry,"July 9, 2018","September 19, 2019","September 19, 2019"
299,NCT03926754,Beta 3 Agonist Treatment in Heart Failure-2,Heart Failure With Reduced Ejection Fraction NYHA Class III-IV,Drug: Mirabegron,"Henning Bundgaard|Bispebjerg-Frederiksberg Hospital, Denmark|Hillerød hospital, Denmark|Herlev Hospital|Hvidovre University Hospital|Bornholm Hospital, Denmark|Royal North Shore Hospital|Rigshospitalet, Denmark",Phase 2|Phase 3,56,Other,"January 23, 2017","January 21, 2021","January 21, 2021"
300,NCT03920215,Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease,Long Term Follow up Dry Eye Disease,"Drug: OC-01 Low Dose, 0.12 mg/mL|Drug: OC-01 Mid Dose, 0.6 mg/mL|Drug: OC-01 High Dose, 1.2 mg/mL|Drug: Placebo (vehicle) nasal spray","Oyster Point Pharma, Inc.",Phase 2|Phase 3,101,Industry,"August 15, 2018","September 20, 2019","September 20, 2019"
301,NCT03919578,Protectivity and Safety Following Recombinant Hepatitis B Vaccine,Immunogenicity,Biological: Recombinant Hepatitis B vaccine|Biological: Recombinant Hepatitis B (Bio Farma),PT Bio Farma,Phase 2|Phase 3,536,Industry,"September 11, 2019","January 30, 2020","February 28, 2020"
302,NCT03918109,OTO-313 in Subjects With Subjective Tinnitus,"Tinnitus, Subjective",Drug: OTO-313|Drug: Placebo,"Otonomy, Inc.",Phase 1|Phase 2,43,Industry,"April 4, 2019","May 29, 2020","May 29, 2020"
303,NCT03913806,FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW,Soft Tissue Sarcoma,Drug: Bevacizumab-IRDye800CW,University Medical Center Groningen,Phase 1|Phase 2,16,Other,"May 1, 2018","December 22, 2019","January 1, 2020"
304,NCT03913741,A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies,Solid Tumor,Drug: tisotumab vedotin,Genmab|Seagen Inc.,Phase 1|Phase 2,23,Industry,"February 27, 2019","August 14, 2020","October 30, 2021"
305,NCT03907267,Taurine in Peripartum Cardiomyopathy,Peripartum Cardiomyopathy,Drug: Taurine Solution|Dietary Supplement: Normal Saline,Ain Shams University,Phase 2|Phase 3,40,Other,"January 1, 2015","December 1, 2019","January 1, 2020"
306,NCT03905811,A Pilot Study of Terazosin for Parkinson's Disease,Parkinson Disease,Drug: Terazosin 5 MG|Drug: Placebo oral capsule,Jordan Schultz|University of Iowa,Phase 1|Phase 2,13,Other,"September 24, 2019","June 5, 2020","November 18, 2020"
307,NCT03902925,Pain During Pars Plana Vitrectomy With Sub-tenon Anesthesia,Retinal Disease|Diabetic Retinopathy|Maculopathy,Procedure: Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Procedure: Peribulbar injection,University of Sao Paulo,Phase 1|Phase 2,56,Other,"January 1, 2019","August 31, 2019","October 31, 2019"
308,NCT03894449,Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects,Iron-deficiency,Combination Product: Prebiotic + Iron Forificant,"University of Veterinary and Animal Sciences, Lahore - Pakistan",Phase 1|Phase 2,75,Other,"April 6, 2019","July 6, 2019","July 6, 2019"
309,NCT03892421,Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma,Drug: Rituximab|Drug: Carboplatin|Drug: Cytarabine Injection|Drug: Dexamethasone|Drug: Filgrastim 0.3 MG/ML,La Raza Medical Center,Phase 1|Phase 2,22,Other,"April 5, 2018","January 30, 2021","April 30, 2021"
310,NCT03891407,Acceptability and Feasibility of Unsupervised HIV Self-Testing Among Networks of Men,HIV Infections|HIV/AIDS|Hiv,Diagnostic Test: Self-Testing Education and Promotion,University of South Carolina,Phase 1|Phase 2,500,Other,"June 1, 2019","July 30, 2019","September 1, 2019"
311,NCT03887208,Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells,Skin|Scar|Cutis Laxa|Keloid|Cicatrix,Procedure: Laser therapy|Biological: Autologous ADSC injection|Procedure: Normal saline injection,Medical University of Warsaw|Timeless Chirurgia Plastyczna-Janusz Jaworowski|Melitus sp. z o.o.|Polish Stem Cells Bank S.A.,Phase 1|Phase 2,100,Other,"January 31, 2018","January 18, 2020","January 18, 2020"
312,NCT03887169,Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.,Pulmonary Alveolar Proteinosis|Mutation Ala393Thr of the MARS Gene|mutationSer567Leu of the MARS Gene,"Drug: Methionine|Drug: Vitamin B12, B9, B6, C supplementation|Diagnostic Test: Methionine/homocysteine Dosage|Diagnostic Test: Thoracic CT scan|Diagnostic Test: Abdominal and liver ultrasound.|Diagnostic Test: Brain MRI",Assistance Publique - Hôpitaux de Paris,Phase 1|Phase 2,3,Other,"September 16, 2019","June 1, 2020","June 1, 2020"
313,NCT03886597,Nutritional Intervention With Table Olives in Healthy Volunteers,Healthy|Biological Availability|Nutritional Intervention|Functional Food|Nutrition Physiology,Other: Table Olives,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Ministerio de Economía y Competitividad (Spain) AGL 2013-41188R|University of Barcelona,Phase 1|Phase 2,58,Other,"March 25, 2019","May 25, 2019","June 15, 2019"
314,NCT03876327,Fecal Microbiota Transplantation As a Potential Treatment for Parkinson's Disease,Parkinson Disease,Procedure: fecal microbial transplantation,Soroka University Medical Center,Phase 2|Phase 3,10,Other,"August 19, 2015","December 30, 2019","June 30, 2020"
315,NCT03875937,The Trauma INtramuscular Tranexamic Acid Clinical Trial,Traumatic Haemorrhage,Drug: Tranexamic 1 gram,London School of Hygiene and Tropical Medicine|Barts & The London NHS Trust|St George's University Hospitals NHS Foundation Trust|University of Versailles|JP Moulton Charitable Foundation,Phase 1|Phase 2,31,Other,"September 17, 2019","February 12, 2020","February 12, 2020"
316,NCT03874585,Text Messaging-Based Smoking Cessation Program for Homeless Youth,Cigarette Smoking,"Behavioral: Group counseling and nicotine replacement|Behavioral: Group counseling, nicotine replacement, and text messaging support",RAND,Phase 1|Phase 2,77,Other,"May 30, 2019","May 21, 2020","May 21, 2020"
317,NCT03872453,Acute Treatment Trial in Adult Subjects With Migraines,Migraine,Drug: Zavegepant|Drug: Zavegepant matching placebo|Device: Intranasal Aptar Pharma Unit Dose System,"Biohaven Pharmaceuticals, Inc.",Phase 2|Phase 3,2154,Industry,"March 25, 2019","October 31, 2019","November 11, 2019"
318,NCT03871972,Umbilical Cord Blood Transfusion in Progeria Syndrome,Hutchinson-Gilford Progeria Syndrome,Drug: Umbilical Cord Blood Unit,Bundang CHA Hospital,Phase 1|Phase 2,2,Other,"March 5, 2019","June 1, 2020","June 1, 2020"
319,NCT03871725,Sonodynamic Therapy in the Treatment of Carotid Atherosclerosis,Carotid Atherosclerosis,Combination Product: Sonodynamic therapy (SDT),First Affiliated Hospital of Harbin Medical University,Phase 1|Phase 2,15,Other,"January 5, 2019","January 30, 2020","January 30, 2020"
320,NCT03870178,Effects of tDCS on Maximal Isometric Strength and Endurance Test of Trunk Extensors.,Healthy,Device: Transcranial direct current stimulation (tDCS),Universidade Federal do Piauí,Phase 2|Phase 3,20,Other,"January 2, 2019","November 30, 2019","April 30, 2021"
321,NCT03868241,Coated Devices to Decrease Infection in the Intensive Care Unit,Critically Ill,Device: Coated devices|Device: Control,Hospital do Coracao|Bactiguard AB,Phase 1|Phase 2,103,Other|Industry,"April 6, 2019","February 13, 2020","February 28, 2020"
322,NCT03867734,Aztreonam for Pharyngeal Gonorrhea,Gonorrhea of Pharynx|Gonorrhea,Drug: Aztreonam,University of Washington,Phase 2|Phase 3,32,Other,"April 5, 2019","September 30, 2019","September 30, 2019"
323,NCT03865394,Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells,Diabetic Foot Ulcer,Biological: Application of allogeneic ADSC stem cells in fibrin gel|Procedure: Standard care in diabetic foot ulcer,Medical University of Warsaw|Polish Stem Cells Bank S.A.,Phase 1|Phase 2,46,Other,"July 1, 2019","March 31, 2021","September 30, 2021"
324,NCT03863977,Post-operative Analgesic Effects of Dexamethasone Added to Bupivacaine in Transversusabdominis Plane (TAP) Block,Postoperative Analgesia,Drug: Dexamethasone|Drug: Bupivacaine,Assiut University,Phase 2|Phase 3,90,Other,"March 15, 2019","December 1, 2019","January 1, 2020"
325,NCT03861338,An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder,Opioid-use Disorder,Drug: Sublocade,New York State Psychiatric Institute,Phase 1|Phase 2,11,Other,"March 1, 2019","February 28, 2020","February 28, 2020"
326,NCT03861000,Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D),Depression,Drug: [C-11]T-1650|Drug: BPN14770,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,3,NIH,"March 12, 2019","February 11, 2020","February 11, 2020"
327,NCT03856164,Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,Post Partum Hemorrhage|Fibrinolysis; Hemorrhage|Blood Loss,Drug: Tranexamic Acid|Drug: Placebo,University of Texas Southwestern Medical Center,Phase 2|Phase 3,110,Other,"June 17, 2019","January 10, 2020","August 31, 2020"
328,NCT03840278,The Bihormonal iLet Bionic Pancreas Feasibility Study,Type 1 Diabetes Mellitus,Device: Bihormonal iLet Bionic Pancreas|Device: Insulin-only Bionic Pancreas|Drug: Dasiglucagon,"Massachusetts General Hospital|Beta Bionics, Inc.|Zealand Pharma",Phase 2|Phase 3,12,Other|Industry,"May 15, 2019","July 3, 2019","July 3, 2019"
329,NCT03838874,Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty,Knee Osteoarthritis|Hip Osteoarthritis,Drug: Low-Dose Bupivacaine|Drug: Mepivacaine,Mayo Clinic,Phase 2|Phase 3,154,Other,"February 25, 2019","October 29, 2019","October 29, 2019"
330,NCT03836781,Teh Effect of Subgingival Irrigation Wif Ketorolac and Chlorhexidine in Patients Wif Chronic Periodontist,Chronic Periodontitis,Drug: Ketorolac|Drug: Chlorhexidine 2%,"Amirhossein Farahmand|Islamic Azad University, Tehran",Phase 2|Phase 3,2,Other,"April 10, 2018","June 8, 2019","June 15, 2019"
331,NCT03833895,The Phenylephrine vs. Norepinephrine Infusion Undergoing Cesarean Section,Cesarean Section Complications,Drug: Norepinephrine|Drug: Phenylephrine|Drug: Ringer's Solution,China International Neuroscience Institution,Phase 2|Phase 3,238,Other,"February 20, 2019","September 1, 2019","September 2, 2019"
332,NCT03833388,Study of TOP1630 for Dry Eye Syndrome,Dry Eye Syndrome,Drug: TOP1630 0.1% Ophthalmic Solution TID OU|Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU,Topivert Pharma Ltd,Phase 2|Phase 3,202,Industry,"February 13, 2019","May 14, 2019","May 14, 2019"
333,NCT03829917,Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis,"Cutaneous Leishmaniasis, American",Drug: Miltefosine and Paromomycin|Drug: miltefosine|Drug: paromomycin,"Fundacion Nacional de Dermatologia|Hospital Dermatológico de Jorochito|Ministerio de Salud de Bolivia, Programa Nacional de Leishmaniasis|Alfred Berman Foundation",Phase 2|Phase 3,120,Other,"February 1, 2019","December 1, 2020","December 31, 2020"
334,NCT03829904,The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Drug: VGH-BPH1|Drug: Placebo (Corn starch pill manufactured to mimic VGH-BPH1),"Taipei Veterans General Hospital, Taiwan",Phase 1|Phase 2,23,Other,"March 6, 2019","January 2, 2020","January 2, 2020"
335,NCT03829007,PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC,Head and Neck Cancer,Diagnostic Test: PD-L1 imaging|Drug: Durvalumab,Radboud University Medical Center|AstraZeneca,Phase 1|Phase 2,33,Other|Industry,"April 15, 2019","December 17, 2020","December 9, 2021"
336,NCT03828838,Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer,Prostate Neoplasm,Drug: Lu-177 PSMA-617,Radboud University Medical Center,Phase 1|Phase 2,10,Other,"July 1, 2018","November 1, 2019","November 1, 2019"
337,NCT03824587,Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy,Hyperphosphatemia,Drug: Tenapanor|Drug: Placebo|Drug: Phosphate Binder Agents,Ardelyx,Phase 2|Phase 3,236,Industry,"February 28, 2019","July 17, 2019","July 17, 2019"
338,NCT03820596,Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL,Safety and Efficacy,Drug: Sintilimab|Drug: Chidamide,Huiqiang Huang|Sun Yat-sen University,Phase 1|Phase 2,40,Other,"March 29, 2019","May 20, 2020","November 30, 2021"
339,NCT03818932,Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction,Anterior Cruciate Ligament Injury,Drug: Celecoxib|Drug: Hydrocodone-Acetaminophen|Drug: Ketorolac|Drug: Gabapentin|Drug: Acetaminophen|Drug: Diazepam,Henry Ford Health System,Phase 2|Phase 3,62,Other,"January 22, 2019","January 20, 2020","May 20, 2020"
340,NCT03814590,"A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",Respiratory Syncytial Virus Infections,Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose|Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose|Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Drug: Placebo (Saline solution),GlaxoSmithKline,Phase 1|Phase 2,1053,Industry,"January 21, 2019","December 12, 2019","November 30, 2020"
341,NCT03813602,Detection of Cannabis Impairment With an Eye Tracker,Cannabis Intoxication,Drug: Cannabis Sativa,Centre for Addiction and Mental Health,Phase 1|Phase 2,10,Other,"August 15, 2019","November 15, 2019","November 15, 2019"
342,NCT03812900,Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections,Respiratory Tract Infections,Drug: Echinacea purpurea alcoholic extract,A. Vogel AG|Cantonal Hospital of St. Gallen|Labormedizinisches Zentrum Dr. Risch,Phase 2|Phase 3,246,Industry|Other,"November 27, 2018","June 5, 2019","June 7, 2019"
343,NCT03811028,"A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients",Sanfilippo Syndrome Type A (MPS IIIA),Drug: SOBI003,Swedish Orphan Biovitrum,Phase 1|Phase 2,6,Industry,"January 19, 2019","April 30, 2021","May 7, 2021"
344,NCT03805750,Trial of Cannabis for Essential Tremor,Essential Tremor,Drug: CBD/THC|Drug: Placebo oral capsule,"University of California, San Diego|International Essential Tremor Foundation|Tilray|Center for Medicinal Cannabis Research",Phase 1|Phase 2,7,Other|Industry,"January 22, 2019","September 1, 2020","November 30, 2020"
345,NCT03805386,Patient-Directed Postoperative Opioid Prescribing for Gynecologic Surgery,Gynecology|Surgery|Opioid Use,Drug: Physician directed opioid prescribing|Drug: Patient directed opioid prescribing,Mayo Clinic,Phase 2|Phase 3,65,Other,"January 15, 2019","April 15, 2020","April 15, 2020"
346,NCT03805347,The Therapeutic Effect of Dau-Di-Wu-Gong in Patient With Ankle Fracture,Ankle Fractures,Drug: Helminthostachys zeylanica(L.)Hook|Drug: Starch,Changhua Christian Hospital,Phase 1|Phase 2,45,Other,"December 12, 2020","January 11, 2021","January 11, 2021"
347,NCT03803202,"A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine",Healthy Volunteers|Pneumococcal Disease,Biological: ASP3772|Biological: PCV13|Biological: PPSV23,"Affinivax, Inc.",Phase 1|Phase 2,630,Industry,"January 24, 2019","September 28, 2020","September 28, 2020"
348,NCT03801707,Utilization of Hepatitis C Positive Kidneys in Negative Recipients,Kidney Transplant|Hepatitis C|HCV,Drug: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|Drug: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET],Ohio State University,Phase 2|Phase 3,30,Other,"March 22, 2019","April 28, 2021","April 30, 2021"
349,NCT03792750,A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors,Advanced Cancer,Drug: BMS-986205|Biological: Nivolumab,Bristol-Myers Squibb,Phase 1|Phase 2,12,Industry,"December 31, 2018","December 18, 2020","December 18, 2020"
350,NCT03790033,"Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial",Cold Hypersensitivity,Drug: Ucha-Shinki-Hwan|Drug: Placebo,Gachon University Gil Oriental Medical Hospital|Kyunghee University Medical Center|Kyung Hee University Hospital at Gangdong|Semyung University Affiliated Oriental Medical Hospital|Sangji University Oriental Medical Hospital,Phase 2|Phase 3,164,Other,"December 11, 2018","August 14, 2019","September 14, 2019"
351,NCT03789175,Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome,Cancer|Skin Fibroblasts|Muscle Weakness,Dietary Supplement: Nicotinamide Riboside (NR),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 1|Phase 2,1,NIH,"March 25, 2019","November 1, 2019","November 1, 2019"
352,NCT03786744,Allogenic Cord Blood Transfusion in Patients With Autism,Autism Spectrum Disorder|Autism,Biological: ASD CB-MNC injection.|Other: Standard therapy.,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Phase 1|Phase 2,20,Other,"October 12, 2018","October 12, 2019","December 12, 2019"
353,NCT03786029,Pre-emptive Analgesic Administration in Primary Tooth Extraction,Local Anesthesia|Tooth Extraction,Drug: Acetaminophen|Drug: Placebo|Drug: Ibuprofen,Tishreen University,Phase 2|Phase 3,66,Other,"April 1, 2019","June 1, 2019","June 10, 2019"
354,NCT03778671,Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block,Transversus Abdominis Block,Drug: Levobupivacaine|Drug: Dexmedetomidine Injection [Precedex]|Drug: fentanyl,Assiut University,Phase 1|Phase 2,90,Other,"January 1, 2019","November 1, 2019","December 1, 2019"
355,NCT03777683,Evaluation the Effects of French Maritime Pine Bark Extract on the Clinical Status in Traumatic Brain Injury Patients,Traumatic Brain Injury,Dietary Supplement: Dietary Supplement (OLIGOPIN)|Other: Placebo,Mashhad University of Medical Sciences,Phase 1|Phase 2,67,Other,"April 14, 2019","December 22, 2019","February 20, 2020"
356,NCT03775538,Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study,Parkinson Disease|Movement Disorders|Neuro-Degenerative Disease|Nervous System Diseases|Brain Diseases,Drug: Cerebral Dopamine Neurotrophic Factor|Device: Renishaw Drug Delivery System,Herantis Pharma Plc.|Renishaw plc.,Phase 1|Phase 2,15,Industry|Other,"July 5, 2018","July 8, 2020","July 8, 2020"
357,NCT03774407,Vaginal Estriol in Multiple Sclerosis,Multiple Sclerosis|Neurogenic Bladder,Drug: vaginal estriol,Texas Tech University Health Sciences Center,Phase 2|Phase 3,21,Other,"June 20, 2019","November 10, 2020","November 29, 2020"
358,NCT03773276,Norepinephrine Boluses in Liver Transplantation,Living Donor Liver Transplantation|Norepinephrine Bolus|Postperfusion Syndrome,Drug: Norepinephrine boluses,Mansoura University,Phase 1|Phase 2,40,Other,"December 17, 2018","April 18, 2020","August 28, 2020"
359,NCT03772964,Effects of Metformin in a Non-Diabetic Patient Population,Inflammatory Response,Drug: MetFORMIN Hydrochloride ER|Drug: Placebo,Brian Zuckerbraun|University of Pittsburgh,Phase 1|Phase 2,32,Other,"January 22, 2019","March 31, 2020","March 31, 2020"
360,NCT03770325,A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine,Cardiovascular Risk Factor,Drug: Berberine|Drug: Placebo,"The University of Hong Kong|Food and Health Bureau, Hong Kong",Phase 2|Phase 3,84,Other,"April 1, 2019","November 1, 2020","November 1, 2020"
361,NCT03768089,Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis,Cystic Fibrosis,Drug: Placebo (matched to VX-121 suspension)|Drug: VX-121 (Suspension)|Drug: TEZ/IVA|Drug: IVA|Drug: Placebo (matched to TEZ/IVA)|Drug: Placebo (matched to IVA)|Drug: VX-121 (Tablet)|Drug: Placebo (matched to VX-121 tablet),Vertex Pharmaceuticals Incorporated,Phase 1|Phase 2,115,Industry,"March 20, 2018","May 3, 2019","May 3, 2019"
362,NCT03759132,Effects of Transcranial Direct Current Stimulation on Postural Control,Parkinson Disease,Procedure: Transcranial direct current stimulation,Universidade Federal do Piauí,Phase 2|Phase 3,18,Other,"December 1, 2018","June 30, 2020","October 30, 2020"
363,NCT03752905,A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB),Recessive Dystrophic Epidermolysis Bullosa,Drug: PTR-01|Drug: Normal saline,"Phoenix Tissue Repair, Inc.",Phase 1|Phase 2,12,Industry,"January 9, 2019","November 30, 2020","November 30, 2020"
364,NCT03748199,"Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF",Cystic Fibrosis,Drug: POL6014|Drug: Placebo,Santhera Pharmaceuticals,Phase 1|Phase 2,32,Industry,"November 8, 2018","December 30, 2020","December 30, 2020"
365,NCT03746951,Comparative Evaluation of Lumbar Plexus and Suprainguinal Fascia Iliaca Compartment Blocks,Orthopedic Disorder,Drug: Ropivacaine Hcl 0.5% Inj Vil 20Ml,Nationwide Children's Hospital,Phase 2|Phase 3,15,Other,"April 24, 2019","January 31, 2020","January 31, 2020"
366,NCT03745586,Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab,Giant Cell Arteritis,Drug: Tocilizumab|Drug: Glucocorticoids,"University Hospital Inselspital, Berne",Phase 1|Phase 2,18,Other,"December 1, 2018","November 30, 2020","March 1, 2021"
367,NCT03742518,A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia,Androgenetic Alopecia,Drug: Topical SM04554 solution|Drug: Topical vehicle solution,"Biosplice Therapeutics, Inc.",Phase 2|Phase 3,675,Industry,"November 1, 2018","December 31, 2020","December 31, 2020"
368,NCT03732807,PF-06651600 for the Treatment of Alopecia Areata,Alopecia Areata,Drug: PF-06651600 Induction Dose|Drug: PF-06651600 Maintenance Dose #1|Drug: PF-06651600 Maintenance Dose #2|Drug: PF-06651600 Maintenance Dose #3|Drug: Placebo,Pfizer,Phase 2|Phase 3,718,Industry,"December 3, 2018","December 31, 2020","June 24, 2021"
369,NCT03732638,Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults,Migraine,Drug: Rimegepant|Drug: Placebo,Pfizer,Phase 2|Phase 3,1590,Industry,"November 14, 2018","December 10, 2019","February 2, 2021"
370,NCT03730714,Surgicel and Analgesic Reservoir,Postoperative Pain,"Drug: ""Local Anesthetic"", ""Epinephrine"" and ""Morphine""|Drug: ""Local Anesthetic"", ""Epinephrine"", ""Morphine"" and ""Surgicel""|Drug: ""Normal Saline""",Assiut University,Phase 2|Phase 3,90,Other,"November 15, 2018","August 12, 2020","August 12, 2020"
371,NCT03730129,Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig,Secondary Immune Deficiency Disorder,Drug: Hizentra,Rochester General Hospital,Phase 2|Phase 3,20,Other,"November 5, 2018","July 3, 2020","July 3, 2020"
372,NCT03729479,"The MHERO Study (Michigan's Hypertension, Diabetes, and Obesity Education Research Online)",Type2 Diabetes Mellitus|Hypertension|PreDiabetes|Overweight and Obesity,"Behavioral: DASH diet|Behavioral: Very low carbohydrate, ketogenic diet|Behavioral: Extras",University of Michigan,Phase 1|Phase 2,94,Other,"November 1, 2018","August 9, 2020","August 9, 2020"
373,NCT03729128,Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder,Stimulants Use Disorder,Drug: dextromethorphan and memantine (DM+MM)|Drug: Placebos,"Tzu-Yun Wang|Ministry of Science and Technology, Taiwan|National Cheng-Kung University Hospital",Phase 1|Phase 2,85,Other,"July 24, 2018","August 31, 2020","August 31, 2020"
374,NCT03728634,"Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).",Healthy Volunteers|hATTR Amyloidosis,Drug: ION-682884|Drug: Placebo|Dietary Supplement: Vitamin A,"Ionis Pharmaceuticals, Inc.",Phase 1|Phase 2,47,Industry,"December 21, 2018","February 20, 2020","February 20, 2020"
375,NCT03726658,AGN-241751 in the Treatment of Major Depressive Disorder,Major Depressive Disorder,Drug: AGN-241751|Drug: Placebo,"Gate Neurosciences, Inc",Phase 1|Phase 2,223,Industry,"November 8, 2018","October 23, 2019","October 23, 2019"
376,NCT03721718,"Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers",Healthy,Biological: GLS-5300|Device: Cellectra 2000 Electroporation,"GeneOne Life Science, Inc.|Inovio Pharmaceuticals|International Vaccine Institute",Phase 1|Phase 2,60,Industry|Other,"August 28, 2018","May 30, 2019","April 22, 2020"
377,NCT03720899,Comparing NicoBloc to Nicotine Lozenges,Smoking Cessation|Nicotine Dependence,Drug: NicoBloc|Drug: Nicotine Lozenge,University of Alabama at Birmingham,Phase 2|Phase 3,45,Other,"March 21, 2019","January 3, 2021","March 3, 2021"
378,NCT03720353,Pharmacological Intervention for Symptomatic Snoring,Snoring,Drug: SAS2094AH and SAS2094BH|Drug: SAS2094AL and SAS2094BL|Drug: Placebo,Brigham and Women's Hospital,Phase 1|Phase 2,27,Other,"December 17, 2018","December 10, 2019","December 10, 2019"
379,NCT03719586,Investigational Therapeutics for the Treatment of People With Ebola Virus Disease,Ebola Virus,Drug: ZMapp|Drug: Remdesivir|Drug: MAb114|Drug: REGN-EB3,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 2|Phase 3,681,NIH,"November 21, 2018","September 9, 2019","August 18, 2020"
380,NCT03711500,D-serine Augmentation of Neuroplasticity,Schizophrenia|Schizo Affective Disorder,Drug: D-serine|Drug: Placebo,New York State Psychiatric Institute|Nathan Kline Institute for Psychiatric Research,Phase 1|Phase 2,45,Other,"March 13, 2019","April 30, 2021","April 30, 2021"
381,NCT03707353,An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP,Malaria,Biological: ChAd63 ME-TRAP and MVA ME-TRAP vaccination,University of Oxford,Phase 1|Phase 2,43,Other,"October 30, 2018","June 10, 2019","June 10, 2019"
382,NCT03701295,"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement",Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL|Leukemia Cutis|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia,Drug: Azacitidine|Drug: Pinometostat,National Cancer Institute (NCI),Phase 1|Phase 2,1,NIH,"January 16, 2019","December 8, 2020","January 12, 2021"
383,NCT03699839,Reducing the Burden of Influenza After Solid-Organ Transplantation,Influenza|Organ Transplantation,Biological: High-dose influenza vaccine|Biological: MF59-adjuvanted influenza vaccine|Biological: Standard intramuscular influenza vaccine,"Oriol Manuel|University Hospital, Basel, Switzerland|University of Bern|University Hospital, Geneva|University of Zurich|Cantonal Hospital of St. Gallen|Fondazione Epatocentro Ticino|Cantonal Hospital Chur|Hospitales Universitarios Virgen del Rocío|University of Lausanne Hospitals",Phase 2|Phase 3,619,Other,"October 26, 2018","August 15, 2020","August 15, 2020"
384,NCT03695757,Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG,Immunotherapy,Biological: Part A) Healthy subjects|Biological: Part B) Advanced solid tumor,Ajou University School of Medicine,Phase 1|Phase 2,24,Other,"November 6, 2018","January 26, 2021","March 24, 2021"
385,NCT03694444,A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis,Gingivitis,Drug: AMY-101|Other: Water for injection,Amyndas Pharmaceuticals S.A.,Phase 1|Phase 2,39,Industry,"July 22, 2019","August 30, 2020","October 30, 2020"
386,NCT03691909,Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: HB-adMSCs,Hope Biosciences,Phase 1|Phase 2,15,Industry,"September 25, 2018","August 17, 2020","September 28, 2020"
387,NCT03691844,AMZ001 for the Treatment of Knee Osteoarthritis Symptoms,"Osteoarthritis, Knee",Drug: AMZ001|Drug: Placebo|Drug: Comparator,Amzell,Phase 2|Phase 3,444,Industry,"October 4, 2018","July 9, 2019","July 9, 2019"
388,NCT03691727,Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM),"Subarachnoid Hemorrhage, Aneurysmal",Drug: tirofiban hydrochloride (AGGRASTAT®)|Diagnostic Test: MRI|Diagnostic Test: Neurological Exam|Behavioral: Questionnaires|Diagnostic Test: Vital Signs|Other: Standard of Care Treatment,David Hasan|University of Iowa,Phase 1|Phase 2,30,Other,"January 24, 2019","July 1, 2020","July 1, 2021"
389,NCT03684993,Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients,High Caries Risk Patients|Caries|Antimicrobial Effect|Side Effect,"Drug: Arabic, Gum|Drug: Licorice Root|Drug: Chlorhexidine",Cairo University,Phase 2|Phase 3,63,Other,"December 10, 2019","January 15, 2020","January 15, 2020"
390,NCT03683667,Protein Plus: Improving Infant Growth Through Diet and Enteric Health,Stunting|Malnutrition; Protein|Enteric Pathogens|Campylobacter Infections,Drug: Azithromycin Oral Product|Drug: Placebos|Dietary Supplement: Protein Supplement|Dietary Supplement: Isocaloric Supplement|Dietary Supplement: Egg|Behavioral: Nutrition Education,"Johns Hopkins Bloomberg School of Public Health|International Centre for Diarrhoeal Disease Research, Bangladesh|Bill and Melinda Gates Foundation",Phase 2|Phase 3,5283,Other,"September 23, 2018","March 19, 2020","March 24, 2020"
391,NCT03681067,A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease,Crohn Disease,Drug: GSK1070806|Drug: Placebo- sodium chloride,University of Birmingham|GlaxoSmithKline|University Hospital Birmingham,Phase 1|Phase 2,5,Other|Industry,"February 20, 2019","June 2, 2020","June 2, 2020"
392,NCT03674970,Effects of Random Nicotine Delivery on Smoking Cessation,Smoking Cessation|Cigarette Smoking|Smoking (Tobacco) Addiction,Drug: Nicotine Film,Milton S. Hershey Medical Center|National Institute on Drug Abuse (NIDA),Phase 1|Phase 2,45,Other|NIH,"March 12, 2019","November 25, 2019","November 25, 2019"
393,NCT03673956,Topical Antibiotics in Chronic Rhinosinusitis,Chronic Rhinosinusitis (Diagnosis),Drug: Mupirocin|Drug: Tobramycin|Drug: Levofloxacin|Drug: Vancomycin,Mayo Clinic,Phase 1|Phase 2,19,Other,"September 26, 2018","February 1, 2021","February 1, 2021"
394,NCT03672240,Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment,Non-Muscle Invasive Bladder Cancer (NMIBC),Drug: APL-1202,"Asieris Pharmaceutical Technologies Co., Ltd.|AsierisPharma",Phase 1|Phase 2,6,Industry,"November 30, 2018","October 30, 2019","June 30, 2020"
395,NCT03672188,Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B,Chronic Hepatitis B,Drug: VIR-2218|Drug: Placebo,"Vir Biotechnology, Inc.|Alnylam Pharmaceuticals",Phase 1|Phase 2,82,Industry,"November 14, 2018","September 3, 2020","September 3, 2020"
396,NCT03665155,"First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody",Multiple Myeloma,Drug: 89Zr-daratumumab|Device: PET/CT scans|Other: Blood draws,Memorial Sloan Kettering Cancer Center,Phase 1|Phase 2,11,Other,"September 5, 2018","April 20, 2020","April 20, 2020"
397,NCT03662789,Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients,Heart Transplant Recipients,"Drug: Iron Isomaltoside 1000|Other: Placebo: NaCl 0,9%",Oslo University Hospital|Pharmacosmos A/S,Phase 2|Phase 3,102,Other|Industry,"April 25, 2018","February 27, 2020","February 27, 2020"
398,NCT03660878,A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis,Allergic Conjunctivitis,Drug: Reproxalap Ophthalmic Solution (0.25%)|Drug: Reproxalap Ophthalmic Solution (0.5%)|Drug: Vehicle Ophthalmic Solution,"Aldeyra Therapeutics, Inc.",Phase 1|Phase 2,52,Industry,"September 8, 2018","November 19, 2019","November 19, 2019"
399,NCT03652948,Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults,Depression|Depressive Symptoms,Behavioral: Meru Health Ascend Program,"Palo Alto Veterans Institute for Research|Meru Health, Inc.|Stanford University",Phase 2|Phase 3,70,Other|Industry,"July 12, 2018","January 15, 2021","January 15, 2021"
400,NCT03640949,Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest,Heart Arrest,"Drug: Vasopressin, Arginine|Drug: Methylprednisolone|Drug: NaCl",Lars Wiuff Andersen|University of Aarhus|Aarhus University Hospital,Phase 2|Phase 3,501,Other,"September 17, 2018","January 21, 2021","January 21, 2022"
401,NCT03640507,Vaginal Preparation With Chlorhexidine-alcohol vs. Povidine-iodine vs. Saline,Cesarean Section; Infection|Surgical Site Infection,Drug: Chlorhexidine-alcohol|Drug: Povidine-iodine|Drug: Sterile saline,Columbia University,Phase 2|Phase 3,30,Other,"October 1, 2018","May 8, 2019","June 14, 2019"
402,NCT03640052,Pharmacological Activation of HMN for OSA,Obstructive Sleep Apnea,Drug: Placebo oral capsule|Drug: LTM1201L|Drug: LTM1201LN|Drug: LTM1201LB|Drug: LTM1201LD,Brigham and Women's Hospital,Phase 1|Phase 2,6,Other,"October 30, 2018","September 30, 2019","December 31, 2019"
403,NCT03639883,A Safety and Efficacy Study to Evaluate Wound Healing,Wound Heal,Drug: AIV001,"AiViva BioPharma, Inc.",Phase 1|Phase 2,16,Industry,"November 5, 2018","December 4, 2019","December 19, 2019"
404,NCT03638622,Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.,Oral Cancer,Combination Product: Photodynamic Therapy,Massachusetts General Hospital|Jawaharlal Nehru Medical College|National Cancer Institute (NCI),Phase 1|Phase 2,30,Other|NIH,"March 10, 2017","October 12, 2020","October 12, 2020"
405,NCT03636906,Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV,Respiratory Syncytial Virus Infections,"Biological: RSV (GSK3389245A) lower dose formulation vaccine|Biological: RSV (GSK3389245A) higher dose formulation vaccine|Biological: GSK's multicomponent meningococcal B vaccine|Biological: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|Biological: GSK's pneumococcal polysaccharide conjugate vaccine|Biological: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|Drug: Placebo",GlaxoSmithKline,Phase 1|Phase 2,201,Industry,"April 8, 2019","January 16, 2020","July 22, 2021"
406,NCT03633084,RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration,Age-related Macular Degeneration,Drug: RBM-007 Injectable Solution,Ribomic USA Inc,Phase 1|Phase 2,9,Industry,"August 29, 2018","June 26, 2019","June 26, 2019"
407,NCT03631004,Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients,Postoperative Nausea|Postoperative Nausea and Vomiting,Drug: Olanzapine,Instituto do Cancer do Estado de São Paulo,Phase 2|Phase 3,100,Other,"October 1, 2018","February 10, 2021","February 10, 2021"
408,NCT03630939,"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis",Psoriatic Plaque,Drug: ESR-114|Other: Placebo,Escalier Biosciences B.V.|Innovaderm Research Inc.,Phase 1|Phase 2,104,Industry|Other,"August 9, 2018","June 5, 2019","June 12, 2019"
409,NCT03627507,Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.,Hepatitis B Infection,Biological: Hepa-B|Biological: Engerix B,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2|Phase 3,158,Other,"July 29, 2018","May 27, 2019","June 3, 2019"
410,NCT03623750,E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C,"Carcinoma, Non-Small-Cell Lung",Drug: EGFR-TK Inhibitor|Biological: EGF-PTI|Drug: Cyclophosphamide,Instituto Oncológico Dr Rosell|Bioven Europe|MFAR,Phase 1|Phase 2,23,Other|Industry,"July 6, 2018","March 26, 2020","December 14, 2021"
411,NCT03618420,Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function,"Diabetes Mellitus, Type 1|Nephropathy|Diabetic Nephropathies|Juvenile Diabetes|Diabetes Mellitus Complication|Autoimmune Diabetes|Type 1 Diabetes Mellitus",Drug: Aminohippurate Sodium Inj 20%|Drug: Iohexol Inj 300 mg/mL,"University of Colorado, Denver",Phase 1|Phase 2,50,Other,"October 1, 2018","October 19, 2019","August 1, 2021"
412,NCT03617900,"Efficacy of Ginger Extract (Compare Between the Ginger Preparation of Ancient Concept of Thai Traditional Practitioner, Standard Drug and Placebo) by Using Pain Score to Evaluate After Pain of Three Groups of First Normal Postpartum Women.",Postpartum Disorder,Drug: Ginger|Drug: Placebo oral capsule|Drug: Paracetamol,Thammasat University,Phase 1|Phase 2,99,Other,"August 29, 2018","May 25, 2019","May 25, 2019"
413,NCT03617861,Effect of Secretin in Functional Dyspepsia and Healthy Subjects,Dyspepsia|Healthy,Drug: Human Secretin|Drug: Placebo,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1|Phase 2,20,Other|NIH,"November 7, 2018","July 1, 2019","August 1, 2019"
414,NCT03614663,Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX),Fragile X Syndrome,Drug: ZYN002 - Cannabidiol Transdermal Gel|Other: Placebo Transdermal Gel,"Zynerba Pharmaceuticals, Inc.",Phase 2|Phase 3,212,Industry,"June 12, 2018","June 14, 2020","June 14, 2020"
415,NCT03608696,Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure,Neonatal Abstinence Syndrome|Neonatal Opiate Withdrawal Syndrome,Drug: Buprenorphine,Thomas Jefferson University|Chiesi Farmaceutici S.p.A.,Phase 1|Phase 2,10,Other|Industry,"August 29, 2018","July 11, 2019","July 11, 2019"
416,NCT03606928,mFLOT Chemotherapy as First-line Treatment in GC,Gastric Cancer,"Drug: docetaxel, oxaliplatin, 5-FU, leucovorin",Ruijin Hospital,Phase 1|Phase 2,18,Other,"July 1, 2018","November 9, 2019","January 1, 2020"
417,NCT03602053,Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia,Diarrhea|Diarrhea Rotavirus,Biological: ROTAVAC®|Biological: ROTAVAC 5D|Biological: Rotarix®,"Centre for Infectious Disease Research in Zambia|PATH|Christian Medical College, Vellore, India|Children's Hospital Medical Center, Cincinnati|Bharat Biotech International Limited",Phase 2|Phase 3,450,Other|Industry,"January 22, 2019","October 4, 2019","October 4, 2019"
418,NCT03593187,A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma,HIV-1 Infection,Drug: Cal-1 (LVsh5/C46) drug product,Assistance Publique - Hôpitaux de Paris|CSL Behring,Phase 1|Phase 2,2,Other|Industry,"January 15, 2019","July 28, 2020","July 28, 2020"
419,NCT03592537,Fentanyl Versus Midazolam as an Adjunct to Intrathecal Bupivacaine In Children,Postoperative Analgesia,Drug: Fentanyl|Drug: Midazolam|Drug: Bupivacaine Hydrochloride,Assiut University,Phase 2|Phase 3,90,Other,"August 15, 2018","April 20, 2021","May 14, 2021"
420,NCT03589287,Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis,Knee Osteoarthritis,Biological: Chondrochymal®,"Taipei Veterans General Hospital, Taiwan|Virginia Contract Research Organization Co., Ltd.",Phase 1|Phase 2,18,Other,"May 2, 2018","May 3, 2019","April 30, 2020"
421,NCT03583554,Electrophysiological Biomarkers of AV-101,Healthy,Drug: Placebo|Drug: AV-101 720 mg|Drug: AV-101 1440 mg,"Marijn Lijffijt, PhD|Michael E. DeBakey VA Medical Center|VistaGen Therapeutics, Inc.|Baylor College of Medicine",Phase 1|Phase 2,18,Other|U.S. Fed|Industry,"September 1, 2018","October 19, 2019","October 19, 2019"
422,NCT03580148,BMA vs Cortisone for Glenohumeral Osteoarthritis,Osteo Arthritis Shoulders,Drug: Cortisone|Biological: Bone Marrow Aspirate,Women's College Hospital|University of Toronto,Phase 2|Phase 3,34,Other,"October 8, 2015","July 30, 2020","November 23, 2021"
423,NCT03568175,A Study of JR-141 in Patients With Mucopolysaccharidosis II,Mucopolysaccharidosis II,Drug: JR-141,"JCR Pharmaceuticals Co., Ltd.",Phase 2|Phase 3,28,Industry,"August 1, 2018","February 20, 2020","February 20, 2020"
424,NCT03566199,MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma,Diffuse Intrinsic Pontine Glioma,Drug: Panobinostat Nanoparticle Formulation MTX110|Drug: Convection-Enhanced Delivery (CED),"Sabine Mueller, MD, PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California, San Francisco",Phase 1|Phase 2,7,Other|Industry,"May 22, 2018","March 31, 2021","March 31, 2021"
425,NCT03564106,Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis,Pain Management,Drug: intraarticular radiofrequency + intraarticular methylprednisolone|Drug: intraarticular methylprednisolone,Assiut University,Phase 2|Phase 3,40,Other,"March 1, 2019","January 1, 2021","January 15, 2021"
426,NCT03562871,"IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC",NSCLC,Biological: IO102|Biological: pembrolizumab (Keytruda)|Drug: Carboplatin (Carboplatin Kabi)|Drug: Pemetrexed (Pemetrexed Alvogen),IO Biotech|Merck Sharp & Dohme LLC,Phase 1|Phase 2,109,Industry,"August 22, 2018","February 6, 2021","April 12, 2022"
427,NCT03560258,HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study,HIV Infections,Biological: p24CE1/2 pDNA vaccine|Biological: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|Biological: Full-length p55^gag pDNA vaccine|Biological: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,45,NIH,"March 26, 2019","February 10, 2021","February 10, 2021"
428,NCT03557099,A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient,Severe Aplastic Anemia,Drug: Hetrombopag Olamine,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1|Phase 2,55,Industry,"June 20, 2018","October 31, 2019","July 23, 2020"
429,NCT03556956,Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Drug: Masitinib,AB Science,Phase 2|Phase 3,219,Industry,Jul-15,Dec-20,Dec-20
430,NCT03541252,Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study,"Carcinoma, Basal Cell",Drug: AFL-assisted cisplatin+5-FU,Merete Haedersdal|Bispebjerg Hospital,Phase 1|Phase 2,20,Other,"March 9, 2018","September 2, 2019","September 2, 2019"
431,NCT03536143,"A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients",Dystrophic Epidermolysis Bullosa,Biological: Topical beremagene geperpavec|Biological: Placebo gel,"Krystal Biotech, Inc.",Phase 1|Phase 2,12,Industry,"May 6, 2018","November 1, 2019","November 1, 2019"
432,NCT03535168,Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients,Cough,Drug: BAY1902607|Drug: Matching placebo|Drug: Midazolam,Bayer,Phase 1|Phase 2,59,Industry,"May 29, 2018","September 25, 2019","October 11, 2019"
433,NCT03533101,Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation,Cytokine Release Syndrome|Stem Cell Transplant Complications,Drug: Tocilizumab,Hospital Universitario Dr. Jose E. Gonzalez,Phase 1|Phase 2,30,Other,"May 25, 2018","May 15, 2019","June 15, 2019"
434,NCT03532789,Herbal Patch for Overactive Bladder,Overactive Bladder Syndrome,Drug: herbal patch|Drug: placebo patch,En Chu Kong Hospital,Phase 2|Phase 3,66,Other,"May 14, 2018","October 23, 2019","October 23, 2019"
435,NCT03531632,MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer,Colorectal Cancer Metastatic,Biological: MGD007 + MGA012,MacroGenics,Phase 1|Phase 2,38,Industry,"June 4, 2018","February 8, 2020","February 8, 2020"
436,NCT03527732,Efficacy and Safety of IVM/ALB Co-administration,Trichuriasis,Drug: Albendazole|Drug: Albendazole and Ivermectin,"Jennifer Keiser|Centre Suisse de Recherches Scientifiques en Cote d'Ivoire|Lao Tropical and Public Health Institute|Public Health Laboratory of Pemba, Tanzania|Swiss Tropical & Public Health Institute",Phase 2|Phase 3,1673,Other,"September 9, 2018","May 15, 2020","July 15, 2020"
437,NCT03525730,LRAs United as a Novel Anti-HIV Strategy.,HIV-1-infection,Drug: Valproic Acid|Drug: Pyrimethamine,Erasmus Medical Center,Phase 1|Phase 2,28,Other,"April 18, 2018","July 25, 2019","October 1, 2020"
438,NCT03524339,Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery,Urinary Retention|Lower Urinary Tract Symptoms|Stress Urinary Incontinence|Pelvic Organ Prolapse,Drug: Placebo oral capsule|Drug: Tamsulosin,University Hospitals Cleveland Medical Center,Phase 2|Phase 3,132,Other,"August 1, 2018","June 9, 2020","June 9, 2020"
439,NCT03520439,Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis,Adenomyosis,Drug: Mifepristone|Drug: Placebo,"xinmei zhang|Anhui Province Cancer Hospital|Huzhou Maternity and Child Care Hospital|Jiaxing Maternity and Child Health Care Hospital|Jinhua Municipal Central Hospital|The Central Hospital of Lishui City|The Affiliated Hospital of Medical School of Ningbo University|Ningbo Maternity and Child Care Hospital|The People's Hospital of Quzhou|Shaoxing Women and Children's Hospital|First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sir Run Run Shaw Hospital|Taizhou First People's Hospital|Zhoushan Maternity and Infant Hospital|Shaoxing People's Hospital|Women's Hospital School Of Medicine Zhejiang University",Phase 2|Phase 3,134,Other,"May 19, 2018","July 31, 2019","October 1, 2019"
440,NCT03519711,A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia,BH4 Deficiency|Hyperphenylalaninemia,Drug: CNSA-001,PTC Therapeutics,Phase 1|Phase 2,6,Industry,"June 24, 2018","January 9, 2021","January 9, 2021"
441,NCT03516487,Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria,Phenylketonuria|Healthy,Drug: SYNB1618|Drug: Placebo,Synlogic,Phase 1|Phase 2,70,Industry,"April 17, 2018","June 21, 2019","June 21, 2019"
442,NCT03508687,Study of Gemcabene in Adults With FPLD,Familial Partial Lipodystrophy|Hypertriglyceridemia|Fatty Liver|NASH - Nonalcoholic Steatohepatitis,Drug: 300mg Gemcabene|Drug: 600mg Gemcabene,Elif Oral|University of Michigan,Phase 1|Phase 2,5,Other,"March 13, 2018","July 31, 2019","July 31, 2019"
443,NCT03503422,Optimizing Chronic Low Back Pain Exercise Therapies With Cerebral Electrical Stimulation,"Low Back Pain, Recurrent|Chronic Low Back Pain",Procedure: Real transcranial direct current stimulation + therapeutic exercises for back pain|Procedure: Sham transcranial direct current stimulation + therapeutic exercises for back pain,Universidade Federal do Piauí|Foundation for Research Support of the State of Piauí,Phase 2|Phase 3,60,Other,"April 10, 2018","February 10, 2020","January 15, 2021"
444,NCT03502148,Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma,Oral Squamous Cell Carcinoma,Drug: PRV111 (Cisplatin Transmucosal System),Privo Technologies|National Cancer Institute (NCI),Phase 1|Phase 2,10,Industry|NIH,"June 19, 2018","October 27, 2019","May 6, 2020"
445,NCT03500289,Ketamine for Treatment of MS Fatigue,Multiple Sclerosis|Fatigue,Drug: Ketamine|Drug: Midazolam,Johns Hopkins University|National Multiple Sclerosis Society,Phase 1|Phase 2,18,Other,"August 10, 2018","August 30, 2019","August 30, 2019"
446,NCT03496545,Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury,Subarachnoid Hemorrhage|Subdural Hematoma|Traumatic Brain Injury|Ischemic Stroke|Fever|Intracerebral Hemorrhage,Drug: Bromocriptine 5 MG|Drug: Acetaminophen 650 MG,"University of California, San Francisco",Phase 1|Phase 2,47,Other,"November 30, 2018","November 2, 2019","November 2, 2019"
447,NCT03493282,Effect of CT1812 Treatment on Brain Synaptic Density,Alzheimer Disease,Drug: Active Treatment- CT1812 100 mg|Drug: Active Treatment- CT1812 300 mg|Drug: Placebo,Cognition Therapeutics|National Institute on Aging (NIA),Phase 1|Phase 2,23,Industry|NIH,"March 28, 2018","October 16, 2020","October 16, 2020"
448,NCT03491215,"Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease",Acute Graft Versus Host Disease,Drug: Ruxolitinib,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,45,Industry,"February 21, 2019","March 11, 2021","February 2, 2023"
449,NCT03490032,68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa),Prostate Cancer Metastatic,Drug: [68Ga]-PSMA-R2,Advanced Accelerator Applications,Phase 1|Phase 2,30,Industry,"May 23, 2018","August 20, 2019","September 13, 2019"
450,NCT03487211,Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia,Fibromyalgia,Drug: Duloxetine|Drug: Escitalopram,Shaheed Zulfiqar Ali Bhutto Medical University,Phase 2|Phase 3,200,Other,"April 9, 2018","February 26, 2020","February 26, 2020"
451,NCT03483194,Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH),Hematologic Neoplasms,Device: Virtual Reality|Drug: Kalinox,Weprom|L'effet Papillon,Phase 2|Phase 3,126,Other,"September 6, 2018","April 20, 2020","June 19, 2020"
452,NCT03482635,BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis,"Colitis, Ulcerative",Drug: Spesolimab|Drug: Placebo,Boehringer Ingelheim,Phase 2|Phase 3,98,Industry,"March 27, 2018","May 18, 2020","May 18, 2020"
453,NCT03482050,"A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)",ALS (Amyotrophic Lateral Sclerosis),Biological: AstroRx,Kadimastem,Phase 1|Phase 2,16,Industry,"April 12, 2018","June 22, 2020","June 22, 2020"
454,NCT03481348,Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis,Device: Pharyngeal Electrical Stimulation,University of Ulm,Phase 1|Phase 2,20,Other,"February 1, 2018","July 21, 2020","July 21, 2020"
455,NCT03479372,"Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD",Neovascular Age-related Macular Degeneration,Drug: PAN-90806 Ophthalmic Suspension,"PanOptica, Inc.",Phase 1|Phase 2,51,Industry,"April 26, 2018","May 27, 2019","June 27, 2019"
456,NCT03476044,Effect of Selenium on Succinylcholine-Induced POM,Postoperative Myalgia,Drug: Placebo|Drug: Selenium,Assiut University,Phase 2|Phase 3,80,Other,"June 1, 2018","March 31, 2020","March 31, 2020"
457,NCT03473977,Benralizumab for Eosinophilic Gastritis (BEGS),Eosinophilic Gastritis or Gastroenteritis,Biological: Benralizumab|Biological: Placebo,"Children's Hospital Medical Center, Cincinnati|AstraZeneca",Phase 2|Phase 3,26,Other|Industry,"April 23, 2018","June 22, 2020","January 12, 2022"
458,NCT03473522,Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.,Parkinson Disease,Device: tDCS|Behavioral: Exercise Therapy,Alessandra Tanuri Magalhães|Foundation for Research Support of the State of Piauí|Universidade Federal do Piauí,Phase 2|Phase 3,30,Other,"February 1, 2018","December 1, 2019","January 15, 2021"
459,NCT03473301,A Study of UCB and MSCs in Children With CP: ACCeNT-CP,Cerebral Palsy,Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",Phase 1|Phase 2,91,Other,"April 10, 2018","February 26, 2020","May 31, 2021"
460,NCT03466320,DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2,AML|MDS,Biological: NKR-2,Celyad Oncology SA|IQVIA Biotech,Phase 1|Phase 2,21,Industry,"September 18, 2018","February 1, 2021","February 1, 2021"
461,NCT03459781,Compassion Meditation for Cancer Survivor-Caregiver Dyads,Cancer Survivors|Informal Cancer Caregivers (Family and Friends of Cancer Survivors),Behavioral: Cognitively-Based Compassion Training|Behavioral: CHE (Cancer Health Education),Thaddeus Pace|University of Arizona,Phase 1|Phase 2,82,Other,"March 14, 2018","January 11, 2020","January 11, 2020"
462,NCT03453424,Analgesic Efficacy of Dexmedetomidine Added to Fentanyl in PCEA,Abdominal Pain|Abdominal Cancer,Procedure: TEA+DEX|Procedure: TEA,South Egypt Cancer Institute,Phase 2|Phase 3,90,Other,"June 30, 2017","May 10, 2019","May 30, 2019"
463,NCT03453151,Abdominal Nerve Blockade in Chronic Heart Failure.,Heart Failure,Drug: splanchnic nerve anesthesia with a local anesthetic,Duke University,Phase 1|Phase 2,19,Other,"May 1, 2018","June 27, 2019","December 27, 2019"
464,NCT03452943,Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents,Tourette Syndrome,Drug: TEV-50717|Drug: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.|Nuvelution TS Pharma, Inc.",Phase 2|Phase 3,119,Industry,"February 5, 2018","November 12, 2019","November 12, 2019"
465,NCT03452917,Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest,Out-Of-Hospital Cardiac Arrest,Drug: Placebo|Drug: sodium nitrite 45 mg|Drug: sodium nitrite 60 mg,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2|Phase 3,1502,Other|NIH,"February 8, 2018","December 31, 2019","April 30, 2020"
466,NCT03452072,Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds,Wound of Skin|Wound Heal|Wound Open|Surgical Wound,Drug: 0.25% Timolol gel with paraffin gauze dressings|Other: Vaseline dressing,Brigham and Women's Hospital,Phase 2|Phase 3,88,Other,"August 20, 2018","December 29, 2020","June 30, 2021"
467,NCT03450330,"Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer",Nonsmall Cell Lung Cancer,Drug: AZD4205,Dizal Pharmaceuticals,Phase 1|Phase 2,10,Industry,"April 16, 2018","September 3, 2019","January 10, 2020"
468,NCT03447990,"v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491",Heart Failure With Reduced Ejection Fraction|Dilated Cardiomyopathy,Drug: MYK-491|Drug: Placebo,Bristol-Myers Squibb,Phase 1|Phase 2,52,Industry,"February 6, 2018","October 24, 2019","October 24, 2019"
469,NCT03447782,Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children,New Daily Persistent Headache (NDPH),Drug: Naltrexone HCl (Bulk) Powder,Boston Children's Hospital,Phase 1|Phase 2,45,Other,"July 23, 2018","November 20, 2020","November 20, 2020"
470,NCT03443635,Cooking for Health Optimization With Patients,Cardiovascular Diseases|Cardiovascular Risk Factor|Nutrition Disorders|Diabetes|Hypertension|Cancer|Depression|Obesity|Physical Activity,Behavioral: Treatment,Tulane University,Phase 1|Phase 2,7192,Other,"February 1, 2018","December 18, 2020","December 18, 2020"
471,NCT03439982,Fecal Transplant for Hepatic Encephalopathy,Hepatic Encephalopathy,Biological: FMT,University of Alberta|Rebiotix Inc.,Phase 1|Phase 2,3,Other|Industry,"April 12, 2016","August 7, 2019","March 18, 2021"
472,NCT03437577,Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients,Kidney Transplant Failure and Rejection,Drug: immediate-release tacrolimus|Drug: extended release tacrolimus,University of Minnesota,Phase 1|Phase 2,18,Other,"May 8, 2018","March 31, 2020","March 31, 2020"
473,NCT03426631,DAW1033B2 in Obstructive Sleep Apnea,Obstructive Sleep Apnea (OSA),Drug: Placebo oral capsule|Drug: DAW1033B2 oral capsule,Brigham and Women's Hospital,Phase 1|Phase 2,13,Other,"September 15, 2017","October 1, 2019","January 20, 2020"
474,NCT03425552,A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment,Schizophrenia,Drug: Paliperidone,Pharmathen S.A.,Phase 1|Phase 2,70,Industry,"March 11, 2018","May 2, 2019","May 2, 2019"
475,NCT03423186,A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients,Sanfilippo Syndrome Type A (MPS IIIA),Drug: SOBI003,Swedish Orphan Biovitrum,Phase 1|Phase 2,6,Industry,"June 19, 2018","October 25, 2019","October 25, 2019"
476,NCT03420144,Growth Hormone Therapy in Liver Cirrhosis,"Cirrhosis, Liver",Drug: Standard Medical Therapy|Drug: Growth Hormone,Postgraduate Institute of Medical Education and Research,Phase 2|Phase 3,76,Other,"January 15, 2018","June 30, 2020","June 30, 2020"
477,NCT03418714,Effects of Salvinorin A on Brain Function,Drug Effect,Drug: Salvinorin A,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 1|Phase 2,13,Other|NIH,"December 14, 2017","March 2, 2020","March 2, 2020"
478,NCT03418233,Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF),Heart Failure,Drug: CardioCell|Drug: Placebos,"John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland",Phase 2|Phase 3,115,Other,"April 19, 2018","January 27, 2021","March 31, 2021"
479,NCT03415594,"Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support",Short Bowel Syndrome,Drug: FE203799 GLP-2 analogue|Drug: FE203799 Placebo GLP-2 analogue,GlyPharma Therapeutics|VectivBio AG,Phase 1|Phase 2,8,Industry,"May 8, 2018","November 21, 2019","November 21, 2019"
480,NCT03414983,An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread,Colorectal Cancer,Biological: Nivolumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Bevacizumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 2|Phase 3,196,Industry,"February 20, 2018","February 1, 2021","December 28, 2022"
481,NCT03414645,Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease,Dry Eye|Graft-versus-host-disease|Ocular Discomfort,Biological: CAM-101 10%|Biological: Vehicle Control|Biological: CAM-101 30%,Cambium Medical Technologies LLC|Massachusetts Eye and Ear Infirmary|Oregon Health and Science University|University of Michigan|Duke University|Stanford University|University of Minnesota,Phase 1|Phase 2,64,Industry|Other,"May 1, 2018","December 12, 2019","February 20, 2020"
482,NCT03411161,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,Metastatic Breast Cancer|Metastatic Triple Negative Breast Cancer,Drug: Combination therapy (S81694 + paclitaxel) phase I|Drug: Paclitaxel|Drug: Combination therapy (S81694 + paclitaxel) phase II,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 1|Phase 2,22,Other|Industry,"January 4, 2018","June 8, 2020","June 8, 2020"
483,NCT03410693,Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma,"Carcinoma, Transitional Cell",Drug: Rogaratinib (BAY1163877)|Drug: Chemotherapy,Bayer,Phase 2|Phase 3,175,Industry,"May 31, 2018","October 27, 2020","October 27, 2020"
484,NCT03408483,Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty,Total Hip Arthroplasty,Drug: Quadratus Lumborum Block (QLB)|Drug: Standard of Care,University of Alabama at Birmingham,Phase 2|Phase 3,80,Other,"April 1, 2018","May 10, 2019","August 22, 2020"
485,NCT03408132,Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency,SBS - Short Bowel Syndrome,Drug: FE203799,GlyPharma Therapeutics|VectivBio AG,Phase 1|Phase 2,8,Industry,"May 2, 2018","October 28, 2019","October 28, 2019"
486,NCT03407378,A Study to Investigate a New Treatment in Patients With Parkinson's Disease,Parkinson Disease,Drug: IPT803|Genetic: Optional pharmacogenetic assessment|Other: Questionnaires|Other: Optional Blood-Oxygen-level Dependent functionalMRI|Other: Motor Assessments before taking regular PD treatment|Other: Motor Assessments on regular PD treatment,Tools4Patient,Phase 1|Phase 2,110,Other,"June 26, 2018","February 7, 2020","March 31, 2020"
487,NCT03406871,Regorafenib and Nivolumab Simultaneous Combination Therapy,Advanced and Metastatic Solid Tumor,Drug: Regorafenib|Drug: Nivolumab,"Kohei Shitara|Ono Pharmaceutical Co. Ltd|Bayer Yakuhin, Ltd.|National Cancer Center Hospital East",Phase 1|Phase 2,50,Other|Industry,"January 25, 2018","October 23, 2019","November 26, 2020"
488,NCT03406585,Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes,Type1 Diabetes Mellitus,Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos,NextCell Pharma Ab,Phase 1|Phase 2,24,Industry,"November 28, 2017","July 1, 2020","September 4, 2020"
489,NCT03404063,Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI),Myocardial Infarction,Drug: Cardiac Drug|Drug: Placebos,"John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland",Phase 2|Phase 3,105,Other,"October 20, 2017","July 2, 2020","March 31, 2021"
490,NCT03402152,NRX101 Glx Biomarker Validation Study,Bipolar Depression|Suicidal Ideation,Drug: NRX-101|Drug: Lurasidone HCl|Drug: Placebo,"NeuroRx, Inc.|Target Health Inc.",Phase 2|Phase 3,8,Industry,"November 1, 2018","January 1, 2021","June 1, 2021"
491,NCT03397771,"DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence",Urinary Incontinence,Drug: Litoxetine|Drug: placebo,Ixaltis SA,Phase 1|Phase 2,84,Industry,"April 3, 2018","May 30, 2019","May 30, 2019"
492,NCT03397264,A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema,Diabetic Macular Edema,Biological: Aflibercept|Biological: OPT-302|Other: Sham intravitreal injection,Opthea Limited,Phase 1|Phase 2,153,Industry,"January 16, 2018","March 26, 2020","June 11, 2020"
493,NCT03394885,Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer,Ovarian Cancer|Ovarian Neoplasms,Drug: Atezolizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Bevacizumab,"Duke University|Johns Hopkins University|Genentech, Inc.",Phase 1|Phase 2,18,Other|Industry,"June 19, 2018","July 20, 2020","July 20, 2020"
494,NCT03394729,Effect of a Propolis Tablet on the Saliva and the Amount of Adolescent Dental Plaque Microbes,Dental Plaque,Drug: Propolis tablet to limit dental biofilm|Drug: Xilytol tablet to limit dental biofilm,Universidade Federal do Rio de Janeiro|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Phase 2|Phase 3,30,Other,"September 29, 2017","October 21, 2020","October 21, 2020"
495,NCT03391232,PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO),Colorectal Cancer,Biological: PolyPEPI1018 CRC Vaccine,Treos Bio Zrt|Mayo Clinic|University of Pisa|Laboratory Corporation of America|PPD|ImmunXperts SA,Phase 1|Phase 2,11,Industry|Other,"May 3, 2018","July 17, 2019","July 17, 2019"
496,NCT03389555,"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",Sepsis|Septic Shock|Metabolic Disturbance,"Drug: vitamin C, vitamin B1, hydrocortisone|Drug: Normal saline",Beth Israel Deaconess Medical Center|Open Philanthropy,Phase 2|Phase 3,205,Other,"February 9, 2018","November 26, 2019","February 28, 2020"
497,NCT03389035,Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT,"Acute Lymphoblastic Leukemia, in Relapse",Biological: CARCIK-CD19,Fondazione Matilde Tettamanti Menotti De Marchi Onlus,Phase 1|Phase 2,21,Other,"December 20, 2017","March 31, 2021","December 30, 2022"
498,NCT03387787,Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2,Type 2 Diabetes Mellitus,Device: GlucoTab|Drug: Insulin Degludec,"University Hospital Inselspital, Berne",Phase 2|Phase 3,15,Other,"January 30, 2018","January 30, 2020","January 30, 2020"
499,NCT03387215,"Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure","Heart Failure, Systolic",Drug: ITI-214|Other: Placebo,"Intra-Cellular Therapies, Inc.",Phase 1|Phase 2,36,Industry,"July 10, 2018","March 16, 2020","March 16, 2020"
500,NCT03384420,A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome,Mitochondrial Diseases|Pearson Syndrome,Biological: CD34+ cells enriched with MNV-BLD,Minovia Therapeutics Ltd.,Phase 1|Phase 2,7,Industry,"February 13, 2019","March 9, 2021","March 9, 2021"
501,NCT03383887,DAW1033D in Obstructive Sleep Apnea,Obstructive Sleep Apnea (OSA),Drug: Placebo oral capsule|Drug: DAW1033D oral capsule,Brigham and Women's Hospital,Phase 1|Phase 2,11,Other,"December 13, 2017","January 20, 2020","January 20, 2020"
502,NCT03376555,Cheese Consumption and Human Microvascular Function,Microvascular Dysfunction,Drug: Acetylcholine (ACh) Dose Response|Drug: Local Heating (LH)|Drug: Flow Mediated Dilation with nitroglycerin,Lacy M. Alexander|National Dairy Council|Penn State University,Phase 1|Phase 2,15,Other,Mar-16,"March 1, 2021","March 1, 2021"
503,NCT03374345,Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT),Cold Hypersensitivity,Drug: Sipjeondaebo-tang Granule|Drug: Placebo,Gachon University Gil Oriental Medical Hospital|Kyunghee University Medical Center|Kyung Hee University Hospital at Gangdong|Semyung University Affiliated Oriental Medical Hospital|Sangji University Oriental Medical Hospital,Phase 2|Phase 3,60,Other,"January 31, 2018","December 30, 2019","December 30, 2019"
504,NCT03371979,Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer,Small-cell Lung Cancer,Drug: Pegzilarginase|Drug: Pembrolizumab,Aeglea Biotherapeutics|Merck Sharp & Dohme LLC,Phase 1|Phase 2,68,Industry,"December 21, 2017","January 1, 2021","January 1, 2021"
505,NCT03371251,Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care,Systemic Lupus Erythematosus,Drug: BOS161721|Drug: Placebo,Boston Pharmaceuticals,Phase 1|Phase 2,143,Industry,"January 10, 2018","November 26, 2020","November 26, 2020"
506,NCT03366480,A Study to Assess the Efficacy and Safety of ABTL0812,Endometrial Cancer|Squamous Non-Small Cell Lung Cancer,Drug: ABTL0812 in combination with paclitaxel and carboplatin,"Ability Pharmaceuticals SL|Hospital Vall d'Hebron|Institut Català d'Oncologia|Hospital Clínico Universitario de Valencia|Hospitales Universitarios Virgen del Rocío|Centre Leon Berard|Institut Paoli-Calmettes|Gustave Roussy, Cancer Campus, Grand Paris",Phase 1|Phase 2,103,Industry|Other,"December 1, 2016","June 1, 2020","November 15, 2020"
507,NCT03365947,Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV),Hepatitis B,Drug: ARO-HBV Injection|Other: Sterile Normal Saline (0.9% NaCl),Arrowhead Pharmaceuticals,Phase 1|Phase 2,114,Industry,"March 27, 2018","April 23, 2020","April 23, 2020"
508,NCT03365180,Starter Kit Study in Insulin naïve Patients,"Diabetes Mellitus, Type 2",Device: Starter Kit Algorithm,Signe Schmidt|Technical University of Denmark|Novo Nordisk A/S|Hvidovre University Hospital,Phase 2|Phase 3,8,Other|Industry,"January 3, 2018","November 1, 2019","January 15, 2020"
509,NCT03362359,Ga-68-PSMA-11 in High-risk Prostate Cancer,High-risk Prostate Cancer|Prostate Cancer|Prostate Cancer Metastatic|Lymphnode Metastasis,Drug: Ga-68-PSMA-11,German Cancer Research Center|ABX CRO|Friedrich-Alexander-Universität Erlangen-Nürnberg|University Hospital Freiburg,Phase 1|Phase 2,173,Other,"October 9, 2017","July 6, 2020","July 6, 2020"
510,NCT03360929,"Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759",Non Small Cell Lung Cancer,Drug: AZD3759,"LYZZ Alpha Holding Ltd|Tigermed Consulting Co., Ltd",Phase 1|Phase 2,15,Industry,"October 30, 2017","November 13, 2020","November 13, 2020"
511,NCT03358147,Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma,Asthma,Drug: GP MDI 28.8 μg|Drug: GP MDI 14.4 μg|Drug: GP MDI 7.2 μg|Drug: Placebo MDI|Drug: Spiriva Respimat 2.5 μg,"Pearl Therapeutics, Inc.",Phase 2|Phase 3,1077,Industry,"December 13, 2017","September 12, 2019","September 12, 2019"
512,NCT03350633,Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders,Neuromyelitis Optica Spectrum Disorders|Neuromyelitis Optica,Drug: Tocilizumab Injection|Drug: Azathioprine,Tianjin Medical University General Hospital,Phase 2|Phase 3,118,Other,"November 1, 2017","September 1, 2019","September 1, 2019"
513,NCT03348930,Tolcapone in Obsessive Compulsive Disorder,Obsessive-Compulsive Disorder,Drug: Tolcapone 200 MG,University of Chicago,Phase 2|Phase 3,20,Other,"March 20, 2018","December 14, 2020","December 14, 2020"
514,NCT03343782,Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes,Type 2 Diabetes Mellitus,Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell,Vinmec Research Institute of Stem Cell and Gene Technology,Phase 1|Phase 2,30,Other,"November 1, 2017","August 1, 2019","August 1, 2019"
515,NCT03343665,Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma,Hodgkin Lymphoma,Drug: Nivolumab 40 mg in 4 ml Injection,St. Petersburg State Pavlov Medical University,Phase 1|Phase 2,30,Other,"August 1, 2017","December 20, 2019","December 20, 2019"
516,NCT03343366,Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy,Chronic Periodontitis|Type 2 Diabetes Mellitus,Drug: Metronidazole|Procedure: Scaling Root Planing|Behavioral: Oral Hygiene Instructions,Dow University of Health Sciences|Higher Education Commission (Pakistan),Phase 2|Phase 3,150,Other,"January 1, 2018","June 30, 2020","July 30, 2020"
517,NCT03341403,"Effect of a Synbiotic ""Probiotical® "" in Asthma",Asthma,Dietary Supplement: Probiotical®|Other: Placebo,University of Liege|European Union,Phase 2|Phase 3,55,Other,"January 17, 2017","September 30, 2020","September 30, 2020"
518,NCT03340974,Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer,Pancreatic Cancer|Stereotactic Body Radiation Therapy,Drug: Avasopasem (GC4419)|Drug: Placebo|Radiation: Stereotactic Radiation Therapy (SBRT),"Galera Therapeutics, Inc.|M.D. Anderson Cancer Center",Phase 1|Phase 2,47,Industry|Other,"February 12, 2018","August 21, 2020","May 26, 2021"
519,NCT03338569,Vitamin C and Septic Shock,Septic Shock|Sepsis,Drug: Vitamin C|Drug: Placebo,University of Minnesota,Phase 2|Phase 3,125,Other,"December 20, 2017","June 30, 2020","August 10, 2020"
520,NCT03336866,Study of Antibody for Methamphetamine Outpatient Therapy,Methamphetamine-dependence|Methamphetamine Abuse,Drug: Placebo|Drug: IXT-m200,"InterveXion Therapeutics, LLC|National Institute on Drug Abuse (NIDA)",Phase 1|Phase 2,77,Industry|NIH,"May 3, 2018","November 23, 2020","March 9, 2021"
521,NCT03335371,Evaluation of TTP399 in Patients With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug: TTP399|Drug: Placebo Oral Tablet,vTv Therapeutics|Juvenile Diabetes Research Foundation,Phase 1|Phase 2,115,Industry|Other,"October 25, 2017","December 20, 2019","January 6, 2020"
522,NCT03334175,Walnuts to Achieve Lasting NUTrition to Prevent Diabetes,PreDiabetes|Overweight and Obesity,Drug: Walnuts,"University of California, San Francisco",Phase 1|Phase 2,18,Other,"May 21, 2018","August 5, 2019","August 5, 2019"
523,NCT03333265,Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride,Colorectal Adenomas,Drug: 100mg Berberine hydrochloride|Drug: 300mg Berberine hydrochloride|Drug: Placebo Oral Tablet,Xijing Hospital of Digestive Diseases,Phase 2|Phase 3,100,Other,"September 1, 2017","August 31, 2020","June 1, 2021"
524,NCT03332498,"Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease,Drug: Pembrolizumab|Drug: Ibrutinib,"H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC|Merck Sharp & Dohme LLC",Phase 1|Phase 2,40,Other|Industry,"January 24, 2018","December 5, 2019","September 9, 2021"
525,NCT03332095,"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents",HIV Infections,Drug: Doravirine (DOR)|Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|Drug: Antiretroviral (ARV) medications,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,55,NIH,"July 2, 2018","August 19, 2020","May 25, 2022"
526,NCT03326505,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,Multiple Sclerosis,Biological: Umbilical cord derived Mesenchymal Stem Cells|Other: Supervised physical therapy,University of Jordan,Phase 1|Phase 2,60,Other,"September 25, 2017","January 25, 2020","February 20, 2020"
527,NCT03324607,Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI,COPD,Drug: hyperpolarized 129Xe gas MRI|Drug: Bevespi Aerosphere,Bastiaan Driehuys|Duke University,Phase 2|Phase 3,20,Other,"April 20, 2018","November 12, 2019","November 12, 2019"
528,NCT03322384,"UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",Advanced Solid Tumors|Lymphoma,Drug: epacadostat|Drug: SD-101|Radiation: Radiotherapy,"University of California, Davis",Phase 1|Phase 2,20,Other,"January 17, 2018","February 24, 2020","April 8, 2020"
529,NCT03315039,Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML),"Leukemia, Myeloid, Acute",Drug: Liposomal Annamycin,"Moleculin Biotech, Inc.",Phase 1|Phase 2,7,Industry,"March 28, 2018","January 14, 2020","June 20, 2020"
530,NCT03310645,Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients,Cough,Drug: BAY1817080|Drug: Matching Placebo,Bayer,Phase 1|Phase 2,87,Industry,"December 7, 2017","May 28, 2019","June 19, 2019"
531,NCT03309657,Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid,Pharmacokinetics,Drug: Ceftolozane/tazobactam,Royal Brisbane and Women's Hospital|The University of Queensland,Phase 1|Phase 2,10,Other,"February 1, 2018","May 1, 2020","June 1, 2020"
532,NCT03303625,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age",Respiratory Syncytial Viruses|Respiratory Tract Infections,Biological: Ad26.RSV.preF (1*10^11 vp)|Biological: Ad26.RSV.preF (5*10^10 vp)|Drug: Placebo,Janssen Vaccines & Prevention B.V.,Phase 1|Phase 2,48,Industry,"November 29, 2017","April 21, 2020","April 21, 2020"
533,NCT03303092,Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine,Migraine,Drug: TEV-48125|Drug: TEV-48125 or placebo|Drug: Placebo,"Otsuka Pharmaceutical Co., Ltd.",Phase 2|Phase 3,357,Industry,"December 19, 2017","November 22, 2019","November 22, 2019"
534,NCT03303079,Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine,Migraine,Drug: TEV-48125|Drug: TEV-48125 or placebo|Drug: Placebo,"Otsuka Pharmaceutical Co., Ltd.",Phase 2|Phase 3,571,Industry,"December 19, 2017","November 30, 2019","November 30, 2019"
535,NCT03300453,Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome,Sanfilippo Syndrome B,Drug: rAAV2/5-hNAGLU,UniQure Biopharma B.V.|Venn Life Sciences|Institut Pasteur,Phase 1|Phase 2,4,Industry|Other,"September 17, 2013","November 27, 2019","November 27, 2019"
536,NCT03298893,Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months,Cervical Cancer|Locally Advanced Cervical Cancer,Drug: Nivolumab Injection|Drug: Cisplatin|Radiation: radiotherapy,Institut Curie|Bristol-Myers Squibb,Phase 1|Phase 2,21,Other|Industry,"November 27, 2017","October 30, 2020","March 7, 2022"
537,NCT03295786,Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease,Parkinson Disease|Movement Disorders|Neurodegenerative Diseases|Nervous System Diseases|Brain Diseases,Drug: Cerebral Dopamine Neurotrophic Factor|Device: Renishaw Drug Delivery System,Herantis Pharma Plc.|Renishaw plc.,Phase 1|Phase 2,17,Industry|Other,"September 26, 2017","December 19, 2019","December 19, 2019"
538,NCT03295565,Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel,Prostate Cancer Metastatic|Metastasis,Drug: Cabazitaxel|Drug: Abiraterone|Drug: Enzalutamide,The Netherlands Cancer Institute,Phase 2|Phase 3,100,Other,"May 7, 2017","December 16, 2020","March 2, 2022"
539,NCT03295487,ToT and Estrogen in Postmenopausal Females,Stress Urinary Incontinence|Postmenopausal Disorder,Procedure: TVT-O,Kasr El Aini Hospital,Phase 2|Phase 3,210,Other,"March 1, 2017","November 30, 2020","November 30, 2020"
540,NCT03291080,Oral Liquid 13-cis-retinoic Acid (13-CRA),Neuroblastoma,Drug: Liquid 13-Cis Retinoic Acid|Drug: Extracted capsules 13-CRA,Nova Laboratories Limited,Phase 1|Phase 2,20,Industry,"April 17, 2018","September 12, 2019","September 12, 2019"
541,NCT03290846,Secretin Activates Human Brown Fat and Induces Satiation.,Obesity,Drug: Secretin Human|Drug: Saline Solution|Other: Cold exposure,Turku University Hospital|Technical University of Munich,Phase 2|Phase 3,23,Other,"August 2, 2016","October 30, 2019","November 30, 2019"
542,NCT03289455,CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL),B Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia|B-cell Acute Lymphoblastic Leukemia,Biological: AUTO3 (CD19/22 CAR T cells,Autolus Limited,Phase 1|Phase 2,23,Industry,"June 26, 2017","May 18, 2020","May 18, 2020"
543,NCT03287674,TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer,Metastatic Ovarian Cancer,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2|Drug: Ipilimumab|Drug: Nivolumab,Inge Marie Svane|Herlev Hospital,Phase 1|Phase 2,7,Other,"October 9, 2017","June 1, 2020","June 1, 2020"
544,NCT03284710,Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine,HIV Infections,Biological: ALVAC-HIV (vCP2438)|Biological: Bivalent Subtype C gp120/MF59|Biological: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Biological: Bivalent Subtype C gp120,"National Institute of Allergy and Infectious Diseases (NIAID)|HIV Vaccine Trials Network|Sanofi Pasteur, a Sanofi Company|GlaxoSmithKline",Phase 1|Phase 2,132,NIH|Other|Industry,"June 19, 2017","December 12, 2019","December 12, 2019"
545,NCT03281096,A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer,Colorectal Adenomas,Drug: Berberine hydrochloride|Drug: Placebo,Xijing Hospital of Digestive Diseases,Phase 2|Phase 3,1000,Other,"August 29, 2017","October 12, 2020","March 1, 2021"
546,NCT03278405,Avelumab in G3 NEC,Neuroendocrine Carcinoma,Drug: Avelumab,"Sunnybrook Health Sciences Centre|Merck KGaA, Darmstadt, Germany",Phase 1|Phase 2,10,Other|Industry,"November 15, 2017","August 9, 2019","March 12, 2020"
547,NCT03276988,"Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients",Total Thyroidectomy|Near-total Thyroidectomy,"Drug: Period 1 GX-30, Period 2 THYROGEN®|Drug: Period 1 THYROGEN®, Period 2 GX-30","Genexine, Inc.|Symyoo",Phase 1|Phase 2,8,Industry,"September 7, 2017","January 20, 2020","January 20, 2020"
548,NCT03275870,Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa,Hidradenitis Suppurativa|Hidradenitis|Acne Inversa|Boils|Follicular Occlusion Triad|Follicular Occlusion Tetrad,Drug: Hydroxychloroquine,"Elena Gonzalez Brant, MD|University of Pittsburgh",Phase 1|Phase 2,17,Other,"September 28, 2017","June 30, 2019","June 30, 2019"
549,NCT03275350,Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up,Opioid-use Disorder|Hiv,Drug: Naltrexone Injectable Suspension|Other: Treatment as usual,Oregon Health and Science University|National Institute on Drug Abuse (NIDA)|Johns Hopkins University|University of Kentucky|Jackson Health System|Tarzana Treatment Centers|Ruth M. Rothstein CORE Center,Phase 2|Phase 3,114,Other|NIH,"February 5, 2018","November 8, 2019","November 8, 2019"
550,NCT03268902,Early Life Interventions for Childhood Growth and Development In Tanzania,Malnutrition|Stunting|Cognitive Development|Enteric Pathogens,Drug: Azithromycin Oral Liquid Product|Drug: Nitazoxanide Oral Suspension|Dietary Supplement: Nicotinamide|Drug: Placebos,Haydom Lutheran Hospital|University of Virginia|Bill and Melinda Gates Foundation,Phase 2|Phase 3,1188,Other,"September 5, 2017","February 28, 2020","March 26, 2020"
551,NCT03268057,VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,"Carcinoma, Non-Small-Cell Lung",Drug: VX15/2503 + avelumab,"Vaccinex Inc.|Merck KGaA, Darmstadt, Germany",Phase 1|Phase 2,62,Industry,"October 5, 2017","September 9, 2020","September 10, 2020"
552,NCT03267784,"Allogeneic ABCB5-positive Stem Cells for Treatment of DFU ""Malum Perforans""",Diabetic Neuropathic Ulcer,Biological: allo-APZ2-DFU,RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services,Phase 1|Phase 2,23,Industry|Other,"November 21, 2017","June 29, 2020","June 29, 2020"
553,NCT03266588,Open Label Safety Study in Acute Treatment of Migraine,"Migraine, With or Without Aura",Drug: Rimegepant,Pfizer,Phase 2|Phase 3,3019,Industry,"August 30, 2017","July 15, 2019","July 15, 2019"
554,NCT03259529,"Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL",Diffuse Large B Cell Lymphoma,Drug: Bendamustine hydrochloride|Drug: Gemcitabine 500 mg|Drug: Gemcitabine 700 mg|Drug: Gemcitabine 1000 mg|Drug: Nivolumab|Drug: Rituximab,St. Petersburg State Pavlov Medical University,Phase 1|Phase 2,30,Other,"March 27, 2017","January 27, 2020","January 27, 2020"
555,NCT03257098,Allogeneic ABCB5-positive Stem Cells for Treatment of CVU,Skin Ulcer Venous Stasis Chronic,Biological: allo-APZ2-CVU,RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services,Phase 1|Phase 2,31,Industry|Other,"November 16, 2017","June 25, 2020","June 25, 2020"
556,NCT03254394,Lidocaine for Oxaliplatin-induced Neuropathy,"Neuropathy, Painful|Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer",Drug: Lidocaine Hydrochloride|Drug: Placebo|Drug: FOLFOX regimen,Washington University School of Medicine,Phase 1|Phase 2,26,Other,"September 15, 2017","September 28, 2020","April 1, 2021"
557,NCT03254173,Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia,Advanced Cancer|Cancer Associated Anorexia - Cachexia,Drug: Mirtazapine 30 mg oral tablets|Drug: Placebo oral tablets,Catherine Naseef Hunter|Kasr El Aini Hospital,Phase 2|Phase 3,120,Other,"March 26, 2018","October 17, 2019","October 17, 2019"
558,NCT03252522,Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study,Attention Deficit Hyperactivity Disorder,"Combination Product: Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Dietary Supplement: Placebo",Oregon Health and Science University|Ohio State University|University of Lethbridge|National University of Natural Medicine|Foundation for Excellence in Mental Health Care|Waterloo Foundation,Phase 1|Phase 2,135,Other,"April 23, 2018","July 10, 2020","May 31, 2021"
559,NCT03251092,"Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis",Healthy Volunteer - Complete|Cystic Fibrosis - Complete,Drug: PTI-808|Drug: Placebo|Drug: PTI-428|Drug: PTI-801,"Proteostasis Therapeutics, Inc.",Phase 1|Phase 2,179,Industry,"July 17, 2017","December 23, 2019","December 23, 2019"
560,NCT03245190,Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma,Hepatocellular Carcinoma,Drug: Chiauranib,"Chipscreen Biosciences, Ltd.",Phase 1|Phase 2,27,Industry,"April 28, 2018","November 1, 2019","November 1, 2019"
561,NCT03245008,Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain,"Osteoarthritis, Knee / Osteoarthritis, Hip",Drug: MT-5547|Drug: MT-5547-matching placebo,Mitsubishi Tanabe Pharma Corporation,Phase 2|Phase 3,626,Industry,"September 8, 2017","December 14, 2019","March 9, 2021"
562,NCT03241914,Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer,Endometrial Neoplasm Malignant Stage I,Drug: Megestrol Acetate|Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS),Fudan University,Phase 2|Phase 3,64,Other,"July 4, 2017","June 18, 2020","June 18, 2020"
563,NCT03241888,Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia,Atypical Endometrial Hyperplasia,Drug: Megestrol Acetate|Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS),Fudan University|Shanghai 6th People's Hospital|Zhejiang Cancer Hospital|Shanghai Changning Maternity & Infant Health Hospital,Phase 2|Phase 3,180,Other,"July 4, 2017","June 18, 2020","June 18, 2020"
564,NCT03241173,A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,Advanced Malignancies,Drug: INCAGN01949|Drug: Nivolumab|Drug: Ipilimumab,Incyte Biosciences International Sàrl|Incyte Corporation,Phase 1|Phase 2,52,Industry,"October 9, 2017","September 17, 2019","September 17, 2019"
565,NCT03239392,A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL,LGL Leukemia|CTCL,Drug: BNZ132-1-40,Bioniz Therapeutics,Phase 1|Phase 2,50,Industry,"April 1, 2018","June 30, 2020","June 30, 2020"
566,NCT03238430,Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia .,"Pain, Postoperative",Drug: intrathecal morphine|Drug: Morphine PCA|Drug: Ropivacaine infiltration,"University Hospital, Lille",Phase 2|Phase 3,186,Other,"May 20, 2015","May 25, 2019","May 25, 2019"
567,NCT03232619,CD19-CART Treatment for ALL,Acute Leukemia,Biological: CD19 CART,Bioray Laboratories|Second Xiangya Hospital of Central South University,Phase 1|Phase 2,4,Industry|Other,"August 1, 2018","May 6, 2020","September 15, 2020"
568,NCT03229668,Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations,Pregabalin on Catheter Related Bladder Discomfort,Drug: Placebo oral capsule|Drug: Pregabalin Oral Capsule [Lyrica] 75mg|Drug: Pregabalin Oral Capsule [Lyrica] 150 mg,Saint Savvas Anticancer Hospital|University of Thessaly,Phase 2|Phase 3,78,Other,"July 28, 2017","December 31, 2019","February 20, 2020"
569,NCT03226522,Addressing Dementia Via Agitation-Centered Evaluation,"Agitation in Patients With Dementia of the Alzheimer's Type|Alzheimer Disease|Agitation,Psychomotor",Drug: AXS-05|Drug: Bupropion|Drug: Placebo,"Axsome Therapeutics, Inc.",Phase 2|Phase 3,366,Industry,"July 13, 2017","April 17, 2020","April 17, 2020"
570,NCT03226444,Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome,Primary Sjögren Syndrome|Dry Eye,Drug: 0.005% Lacripep|Drug: 0.01% Lacripep|Drug: Placebo,"TearSolutions, Inc.",Phase 1|Phase 2,204,Industry,"June 30, 2017","December 27, 2019","December 27, 2019"
571,NCT03216538,Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD),Neovascular Age-related Macular Degeneration,Drug: AS101 1% oral solution|Drug: Placebo,Feramda,Phase 1|Phase 2,20,Industry,"October 8, 2018","May 1, 2020","July 1, 2020"
572,NCT03215264,"Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",Colorectal Cancer,Drug: hydroxychloroquine|Drug: entinostat|Drug: regorafenib,Abramson Cancer Center at Penn Medicine,Phase 1|Phase 2,27,Other,"October 2, 2017","June 1, 2020","June 1, 2020"
573,NCT03214250,Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,Metastatic Pancreatic Adenocarcinoma,Drug: APX005M|Drug: Nivolumab|Drug: Nab-Paclitaxel|Drug: Gemcitabine,"Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Apexigen America, Inc.|Cancer Research Institute, New York City",Phase 1|Phase 2,129,Other|Industry,"July 21, 2017","February 11, 2021","February 25, 2022"
574,NCT03213639,Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial),Preeclampsia,Drug: Esomeprazole 40 mg Oral Tablet|Drug: Placebo Oral Tablet,Assiut University,Phase 2|Phase 3,205,Other,"March 15, 2018","July 1, 2020","October 15, 2020"
575,NCT03211065,Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig,Secondary Immune Deficiency,Drug: 20% subcutaneous immunoglobulin,Rochester General Hospital,Phase 2|Phase 3,16,Other,"July 21, 2017","November 1, 2019","November 1, 2019"
576,NCT03208270,Antithrombin Supplementation in ECMO,Extracorporeal Membrane Oxygenation,Drug: Antithrombin supplementation|Drug: No antithrombin supplementation,Policlinico Hospital|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies,Phase 2|Phase 3,49,Other,"July 28, 2017","May 15, 2019","May 15, 2019"
577,NCT03208231,Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy,HIV Infections,Biological: VRC01|Drug: Combination Antiretroviral Therapy (cART),National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,61,NIH,"August 6, 2018","June 16, 2020","February 11, 2021"
578,NCT03203005,"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients",Hepatocellular Carcinoma,Drug: IMA970A plus CV8102 and Cyclophosphamide,"National Cancer Institute, Naples|Immatics Biotechnologies GmbH|CureVac|European Commission -FP7-Health-2013-Innovation-1",Phase 1|Phase 2,22,Other|Industry,"September 18, 2017","December 20, 2019","December 20, 2019"
579,NCT03194529,FMT in Pediatric Crohn's Disease,Crohn Disease|Pediatric Crohns Disease,Biological: FMT,Children's Hospital Los Angeles,Phase 1|Phase 2,9,Other,"October 9, 2017","June 30, 2019","July 31, 2019"
580,NCT03192202,AFM13 in Relapsed/Refractory Cutaneous Lymphomas,"Lymphoma, T-Cell, Cutaneous",Drug: AFM13,Ahmed Sawas|Columbia University,Phase 1|Phase 2,18,Other,"July 17, 2017","April 1, 2020","April 1, 2020"
581,NCT03189953,68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH,Insulinoma,Radiation: 68Ga-NODAGA-exendin 4 PET/CT,"Radboud University Medical Center|University Medical Center Groningen|Charite University, Berlin, Germany|University Hospital, Basel, Switzerland|University Hospital Inselspital, Berne|University College, London|University of Helsinki|University of Turku",Phase 1|Phase 2,56,Other,Apr-15,Jan-21,May-21
582,NCT03189914,RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug: RX-3117,"Rexahn Pharmaceuticals, Inc.",Phase 1|Phase 2,46,Industry,"October 2, 2017","October 1, 2019","November 21, 2019"
583,NCT03188627,Autologous Bronchial Basal Cell Transplantation for Treatment of COPD,Chronic Obstructive Pulmonary Disease,Biological: Bronchial basal cells,"Regend Therapeutics|Southwest Hospital, China|Tongji University",Phase 1|Phase 2,24,Industry|Other,"June 12, 2018","December 26, 2019","December 26, 2019"
584,NCT03187626,Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis,Base-of-thumb Osteoarthritis,Drug: botulinum toxin A|Drug: saline,Assistance Publique - Hôpitaux de Paris|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne,Phase 2|Phase 3,60,Other,"November 29, 2018","February 16, 2021","April 23, 2021"
585,NCT03186040,Open-label Clinical Trial of Lacosamide in ALS,Amyotrophic Lateral Sclerosis,Drug: Lacosamide,Chiba University,Phase 1|Phase 2,7,Other,"July 13, 2017","April 30, 2020","May 31, 2020"
586,NCT03178708,Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients,Spinal Curvatures,Drug: Group A amantadine sulfate|Other: Group B ringer lactate,Assiut University,Phase 2|Phase 3,60,Other,"August 1, 2017","December 30, 2019","December 30, 2019"
587,NCT03177668,Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma,Malignant Pleural Mesothelioma,Drug: YS110,"Kissei Pharmaceutical Co., Ltd.",Phase 1|Phase 2,40,Industry,"August 8, 2017","February 5, 2020","February 5, 2020"
588,NCT03176771,Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia,Tardive Dyskinesia,Drug: MT-5199|Drug: Placebo,Mitsubishi Tanabe Pharma Corporation,Phase 2|Phase 3,256,Industry,"June 21, 2017","September 29, 2020","September 29, 2020"
589,NCT03173417,Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T),Leukemia,Biological: IM19 CAR-T|Drug: fludarabine and cyclophosphamide,"Beijing Immunochina Medical Science & Technology Co., Ltd.",Phase 1|Phase 2,177,Industry,"May 23, 2017","May 1, 2019","May 1, 2019"
590,NCT03169816,Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder,Opioid-use Disorder,Drug: Lorcaserin|Drug: Placebo,New York State Psychiatric Institute,Phase 2|Phase 3,60,Other,"May 25, 2017","August 30, 2019","August 30, 2019"
591,NCT03168139,Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer,Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer,Drug: Olaptesed pegol - Monotherapy|Drug: Olaptesed pegol + Pembrolizumab - Combination Therapy,TME Pharma AG|Merck Sharp & Dohme LLC,Phase 1|Phase 2,20,Industry,"April 18, 2017","March 25, 2020","March 25, 2020"
592,NCT03167398,Fecal Microbiota Transplantation for Eradication of CRE,Antibiotic Resistant Strain|Microbial Colonization,Biological: Fecal Microbiota Transplantation,Rambam Health Care Campus|Tel-Aviv Sourasky Medical Center,Phase 1|Phase 2,15,Other,"February 1, 2018","December 30, 2019","December 30, 2019"
593,NCT03166306,Angiogenic Imaging in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension|Exercise Associated Pulmonary Arterial Hypertension,Diagnostic Test: PET-CT Imaging with [89Zr]-bevacizumab,Brigham and Women's Hospital,Phase 1|Phase 2,5,Other,"May 1, 2018","October 31, 2019","March 31, 2020"
594,NCT03165149,"Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding",Breast Cancer,Drug: group (A)|Drug: group (B)|Drug: group (c),Assiut University,Phase 2|Phase 3,90,Other,"June 1, 2017","August 1, 2019","March 1, 2020"
595,NCT03162224,Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer,Head and Neck Cancer|Human Papilloma Virus,Drug: MEDI0457|Device: CELLECTRA®5P device|Drug: Durvalumab,MedImmune LLC,Phase 1|Phase 2,35,Industry,"June 26, 2017","March 19, 2021","March 19, 2021"
596,NCT03158727,Cx611-0204 SEPCELL Study,Bacterial Pneumonia,Biological: Cx611|Other: Placebo,"Tigenix S.A.U.|European Commission|Centre Hospital Regional Universitaire de Limoges|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Hospital San Carlos, Madrid|Takeda",Phase 1|Phase 2,84,Industry|Other,"January 30, 2017","July 7, 2020","July 7, 2020"
597,NCT03155646,Dexmedetomidine Versus Clonidine in TAP Block,Transversus Abdominis Plane Block,Drug: Dexmedetomidine|Drug: Clonidine|Drug: Levobupivacaine,Assiut University,Phase 2|Phase 3,90,Other,"June 10, 2017","August 1, 2019","August 1, 2019"
598,NCT03152565,Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients,Colorectal Carcinoma,Drug: Avelumab,Grupo Espanol Multidisciplinario del Cancer Digestivo,Phase 1|Phase 2,28,Other,"March 12, 2018","June 30, 2019","October 5, 2020"
599,NCT03151681,The Trauma of Betrayal: Treating Adjustment Disorder With Reconsolidation Blockade Under Propranolol,Adjustment Disorders|Posttraumatic Stress Disorder|Trauma and Stressor Related Disorders,Drug: Propranolol Pill,Douglas Mental Health University Institute,Phase 2|Phase 3,84,Other,"November 1, 2015","September 30, 2020","June 6, 2022"
600,NCT03151148,Targeted Microbiome Transplant in Atopic Dermatitis,Atopic Dermatitis (AD),Biological: TMT Lotion|Drug: Placebo Lotion,National Institute of Allergy and Infectious Diseases (NIAID)|Atopic Dermatitis Research Network,Phase 1|Phase 2,54,NIH|Other,"September 28, 2017","May 14, 2019","June 7, 2019"
601,NCT03150862,A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma,Brain and Central Nervous System Tumors,Drug: Pamiparib|Drug: TMZ|Radiation: Radiation,"BeiGene USA, Inc.|BeiGene",Phase 1|Phase 2,116,Industry,"July 24, 2017","March 17, 2021","March 17, 2021"
602,NCT03149549,PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors,"Solid Tumor, Adult|Breast Cancer|Non Small Cell Lung Cancer|Head and Neck Cancer|Ovarian Cancer",Drug: CX-2009,CytomX Therapeutics,Phase 1|Phase 2,99,Industry,"June 1, 2017","September 10, 2020","September 10, 2020"
603,NCT03148990,"Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella",Rubella|Measles,"Biological: Measles and Rubella vaccine|Biological: Measles, Mumps and Rubella vaccine",The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Oswaldo Cruz Institute,Phase 2|Phase 3,432,Other,"November 20, 2018","August 12, 2020","August 12, 2020"
604,NCT03146806,Intranasal (NAS) Ketamine for Cancer Pain,Cancer|Pain,Drug: Intranasal ketamine,Emory University,Phase 1|Phase 2,10,Other,"July 25, 2017","April 22, 2020","April 22, 2020"
605,NCT03146741,Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV),Heart Failure,Drug: Zepatier,University of Pennsylvania|Merck Sharp & Dohme LLC,Phase 1|Phase 2,20,Other|Industry,"May 16, 2017","September 10, 2019","November 30, 2019"
606,NCT03143634,The Modular Protocol for Mental Health (MPMH),Major Depressive Disorder|Generalized Anxiety Disorder|Posttraumatic Stress Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder|Illness Anxiety Disorder,Behavioral: The Modular Protocol for Mental Health|Behavioral: Treatment-as-usual,Medical Research Council Cognition and Brain Sciences Unit|Cambridgeshire and Peterborough NHS Foundation Trust,Phase 1|Phase 2,43,Other,"July 18, 2017","July 31, 2020","July 31, 2020"
607,NCT03143192,Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser,Diabetic Macular Edema,Combination Product: Micropulse Laser|Device: Sham Laser,Keyvan Koushan|Toronto Retina Institute,Phase 2|Phase 3,31,Other,"March 8, 2017","May 9, 2019","May 9, 2019"
608,NCT03141203,Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients,Peripheral T Cell Lymphoma,Drug: Romidepsin|Drug: Carfilzomib,University of Birmingham|Bloodwise|Celgene|Amgen,Phase 1|Phase 2,50,Other|Industry,"July 13, 2015",Aug-20,"September 23, 2021"
609,NCT03140969,Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene,Leber's Congenital Amaurosis,Drug: QR-110,ProQR Therapeutics,Phase 1|Phase 2,11,Industry,"October 16, 2017","October 2, 2019","October 2, 2019"
610,NCT03137121,Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients,Advanced Cancer,Drug: Olanzapine|Other: Placebo,University of Alabama at Birmingham|Mayo Clinic,Phase 2|Phase 3,30,Other,"July 12, 2017","July 12, 2019","September 15, 2020"
611,NCT03136653,A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma,Multiple Myeloma in Relapse,Biological: MP0250 plus BOR+DEX,Molecular Partners AG,Phase 1|Phase 2,33,Industry,"May 23, 2017","October 12, 2020","January 13, 2021"
612,NCT03130816,Mechanism of Allogeneic UCB Therapy in Cerebral Palsy,Cerebral Palsy|Child Development,Biological: allogeneic cord blood transplantation,Bundang CHA Hospital,Phase 1|Phase 2,90,Other,"July 29, 2015","May 21, 2019","May 21, 2019"
613,NCT03129113,Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV,Hepatic Steatosis|HIV-1-infection,Drug: Maraviroc|Drug: Metformin,"University College, London|Medical Research Council|ViiV Healthcare|Royal Free Hospital NHS Foundation Trust",Phase 2|Phase 3,90,Other|Industry,"March 1, 2017","November 5, 2020","November 6, 2020"
614,NCT03123783,CD40 Agonistic Antibody APX005M in Combination With Nivolumab,Cancer|Non Small Cell Lung Cancer Metastatic|Metastatic Melanoma|Neoplasm of Lung|Melanoma,Drug: APX005M|Drug: Nivolumab,"Apexigen America, Inc.|Bristol-Myers Squibb",Phase 1|Phase 2,140,Industry,"July 10, 2017","November 16, 2020","November 16, 2020"
615,NCT03122223,"Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants",HIV Infections,Biological: ALVAC-HIV (vCP2438)|Biological: Bivalent subtype C gp120/MF59|Biological: Bivalent subtype C gp120/AS01(B)|Biological: Placebo,"National Institute of Allergy and Infectious Diseases (NIAID)|GlaxoSmithKline|Sanofi Pasteur, a Sanofi Company",Phase 1|Phase 2,160,NIH|Industry,"January 16, 2018","July 30, 2020","July 30, 2020"
616,NCT03120533,Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study,"Scleroderma, Systemic",Drug: Iontophoresis of treprostinil|Drug: Iontophoresis of placebo,"University Hospital, Grenoble|Linksium|University Grenoble Alps",Phase 1|Phase 2,18,Other,"June 20, 2017","June 3, 2019","June 3, 2019"
617,NCT03120247,Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.,Sedation,Drug: OTM Dexmedetomidine 1µg/ kg.|Drug: OTM Dexmedetomidine 0.75µg/ kg.|Drug: OTM Dexmedetomidine 0.5µg/ kg.,Assiut University,Phase 2|Phase 3,36,Other,"April 5, 2017","June 1, 2019","July 1, 2019"
618,NCT03119961,Blood Brain Barrier Opening in Alzheimer' Disease,Alzheimer Disease,Device: SONOCLOUD®,Assistance Publique - Hôpitaux de Paris|CarThera|BPIfrance,Phase 1|Phase 2,10,Other|Industry,"June 26, 2017","October 2, 2020","October 7, 2020"
619,NCT03117738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,Alzheimer Disease,Drug: AstroStem|Other: Placebo-Control,Nature Cell Co. Ltd.,Phase 1|Phase 2,21,Industry,"May 9, 2017","June 26, 2019","August 31, 2019"
620,NCT03116113,A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112,X-Linked Retinitis Pigmentosa,Biological: BIIB112,"NightstaRx Ltd, a Biogen Company|Biogen",Phase 1|Phase 2,50,Other,"March 16, 2017","November 18, 2020","November 18, 2020"
621,NCT03114631,Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer,Dendritic Cells|Pancreatic Neoplasms,Biological: Dendritic cells pulsed with tumor lysate|Biological: Dendritic cells pulsed with MUC-1/WT-1 peptides,The Republican Research and Practical Center for Epidemiology and Microbiology|Belarusian State Medical University,Phase 1|Phase 2,30,Other,"January 9, 2017","May 3, 2019","May 23, 2019"
622,NCT03112590,Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,"Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer",Biological: Interferon-gamma (IFN-γ)|Drug: Paclitaxel|Drug: Trastuzumab|Other: Pertuzumab|Procedure: Post Therapy Surgery,"H. Lee Moffitt Cancer Center and Research Institute|Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 1|Phase 2,51,Other|Industry,"June 23, 2017","March 31, 2021","February 20, 2023"
623,NCT03107377,Phase 2B/3 Double-blinded Placebo-controlled,Chlamydia Trachomatis Infection,Drug: EVO100|Drug: Placebo,"Evofem Inc.|Clinical Research Management, Inc.",Phase 2|Phase 3,860,Industry,"November 3, 2017","August 22, 2019","August 22, 2019"
624,NCT03106844,The ICON Study: Outcomes After FMT for Patients With IBD and CDI,Inflammatory Bowel Diseases|Clostridium Difficile Infection,Drug: Fecal Microbiota Transplantation,Brigham and Women's Hospital|Indiana University|Icahn School of Medicine at Mount Sinai|The Miriam Hospital,Phase 1|Phase 2,50,Other,"August 1, 2017","April 7, 2020","December 31, 2020"
625,NCT03103152,A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression,Prostate Cancer,"Drug: High dose Aspirin & Vitamin D|Drug: High dose Aspirin, Vitamin D placebo|Drug: Low dose Aspirin , Vitamin D|Drug: Low dose Aspirin, Vitamin D placebo|Drug: Aspirin Placebo, Vitamin D|Drug: Aspirin placebo, Vitamin D placebo",Queen Mary University of London|Barts and the London School of Medicine and Dentistry|Cancer Research UK,Phase 2|Phase 3,104,Other,Dec-16,"March 31, 2020","March 31, 2020"
626,NCT03101358,Study of Topical SOR007 Ointment for Cutaneous Metastases,Cutaneous Metastasis,Drug: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment,"NanOlogy, LLC|US Biotest, Inc.",Phase 1|Phase 2,23,Industry,"January 31, 2018","April 29, 2020","April 29, 2020"
627,NCT03101085,S-Equol in Alzheimer's Disease 2 Trial,Alzheimer Disease,Drug: S-equol|Other: Placebo,"Russell Swerdlow|Ausio Pharmaceuticals, LLC|University of Kansas Medical Center",Phase 1|Phase 2,40,Other|Industry,"May 5, 2017","March 1, 2021","March 1, 2021"
628,NCT03100032,Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis,Spondylolisthesis,Biological: NVD-001|Procedure: Standard of Care,Novadip Biosciences,Phase 1|Phase 2,48,Industry,Jan-17,Jan-21,Jun-21
629,NCT03098550,"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",Advanced Cancer,Biological: Nivolumab|Biological: Daratumumab,"Bristol-Myers Squibb|Janssen Biotech, Inc.",Phase 1|Phase 2,105,Industry,"June 15, 2017","July 6, 2020","July 6, 2020"
630,NCT03098433,Effects of Liothyronine on Energy Expenditure and Cardiovascular Function,Healthy,Drug: Liothyronine|Drug: Levothyroxine|Drug: Placebos,Virginia Commonwealth University,Phase 1|Phase 2,22,Other,"October 20, 2017","June 24, 2019","June 24, 2019"
631,NCT03098030,Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer,Small Cell Lung Cancer,Biological: Dinutuximab|Drug: Irinotecan|Drug: Topotecan,United Therapeutics,Phase 2|Phase 3,483,Industry,"June 1, 2017","January 27, 2020","March 26, 2020"
632,NCT03097770,Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,Biological: anti-CD19/20-CAR vector-transduced T cells,Chinese PLA General Hospital,Phase 1|Phase 2,100,Other,"April 1, 2017","May 10, 2019","January 31, 2020"
633,NCT03093870,Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine|Drug: Placebo (for Varlitinib),"ASLAN Pharmaceuticals|bioRASI, LLC|CMIC Co, Ltd. Japan|Syneos Health",Phase 2|Phase 3,151,Other|Industry,"July 4, 2017","November 12, 2019","April 17, 2020"
634,NCT03092934,A Study of AK-01 (LY3295668) in Solid Tumors,"Neoplasms|Neoplasm Metastasis|Triple Negative Breast Neoplasms|Head and Neck Neoplasms|Breast Neoplasms|Solid Tumor, Adult|Small Cell Lung Carcinoma",Drug: LY3295668,Eli Lilly and Company|AurKa Pharma Inc.,Phase 1|Phase 2,13,Industry|Other,"May 29, 2017","April 20, 2020","April 20, 2020"
635,NCT03087955,Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense,"Trypanosomiasis, African|Gambiense Trypanosomiasis|Sleeping Sickness",Drug: Acoziborole (SCYX-7158),Drugs for Neglected Diseases,Phase 2|Phase 3,260,Other,"October 11, 2016","August 28, 2020","August 28, 2020"
636,NCT03086564,A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT),Hepatocellular Carcinoma,Biological: ADCC & TACE|Procedure: TACE,"Yuehua Huang|Third Affiliated Hospital, Sun Yat-Sen University",Phase 1|Phase 2,70,Other,"May 1, 2017","May 1, 2020","October 29, 2020"
637,NCT03086369,A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug: Olaratumab|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Placebo,Eli Lilly and Company,Phase 1|Phase 2,184,Industry,"June 22, 2017","January 5, 2021","June 17, 2021"
638,NCT03085680,Curcumin and Function in Older Adults,Older Adults|Physical Function|Cognitive Function,Drug: Curcumin|Drug: microcrystalline cellulose,University of Florida|National Institute on Aging (NIA)|National Institutes of Health (NIH),Phase 2|Phase 3,17,Other|NIH,"August 11, 2017","October 18, 2019","October 18, 2019"
639,NCT03081858,"Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer",Bladder Cancer Cell Transitional|Non-Muscle Invasive Bladder Cancer|Bladder Cancer|Urinary Bladder|Transitional Cell Carcinoma of the Bladder|Urinary Bladder Neoplasms|Urologic Neoplasms|Urogenital Neoplasms|Urinary Bladder Diseases|Urologic Diseases,Drug: TSD-001,"Lipac Oncology LLC|TesoRx Pharma, LLC",Phase 1|Phase 2,15,Industry,"May 17, 2018","August 27, 2020","August 5, 2021"
640,NCT03081702,"A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",Platinum-resistant Epithelial Ovarian Cancer,Drug: Hydroxychloroquine|Drug: Itraconazole,"University Health Network, Toronto",Phase 1|Phase 2,13,Other,"July 25, 2017","August 27, 2019","August 27, 2019"
641,NCT03076437,Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies,Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma,Combination Product: Drugs and Anti-CD19-CAR transduced T cells,Shenzhen Institute for Innovation and Translational Medicine|Dongguan People's Hospital,Phase 1|Phase 2,28,Other,"January 15, 2016","May 26, 2019","December 31, 2019"
642,NCT03076164,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,Lung Adenocarcinoma|Lung Cancer|Lung Cancer Metastatic|Lung Cancer Stage IV|Recurrent Lung Adenocarcinoma|Recurrent Lung Cancer,Drug: Trametinib|Drug: Erlotinib,Memorial Sloan Kettering Cancer Center|GlaxoSmithKline,Phase 1|Phase 2,24,Other|Industry,"March 1, 2017","December 18, 2020","December 18, 2020"
643,NCT03072043,Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,Myelodysplastic Syndrome|Acute Myeloid Leukemia|Myeloproliferative Neoplasm|Chronic Myelomonocytic Leukemia,Drug: APR-246|Drug: Azacitidine,H. Lee Moffitt Cancer Center and Research Institute|Aprea Therapeutics,Phase 1|Phase 2,55,Other|Industry,"May 18, 2017","November 15, 2019","December 8, 2021"
644,NCT03069014,Study of LM11A-31-BHS in Mild-moderate AD Patients,Mild to Moderate Alzheimer's Disease,Drug: 400mg LM11A-31-BHS|Drug: 800mg LM11A-31-BHS|Drug: Placebos,PharmatrophiX Inc.|National Institute on Aging (NIA),Phase 1|Phase 2,242,Industry|NIH,"February 15, 2017","June 8, 2020","June 8, 2020"
645,NCT03067129,"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection",Hepatitis C Virus (HCV),Drug: Glecaprevir/Pibrentasvir Adult Formulation|Drug: Glecaprevir + Pibrentasvir Pediatric Formulation,AbbVie,Phase 2|Phase 3,129,Industry,"March 20, 2017","May 21, 2020","September 12, 2022"
646,NCT03066635,Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues,Cluster Headache,Drug: Botulinum Toxin Type A 25 IU|Drug: Botulinum Toxin Type A 12.5 IU,Norwegian University of Science and Technology|St. Olavs Hospital,Phase 1|Phase 2,10,Other,"April 18, 2017","September 13, 2019","September 13, 2019"
647,NCT03066258,Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial,Neovascular Age-related Macular Degeneration|Wet Age-related Macular Degeneration,Genetic: RGX-314,REGENXBIO Inc.,Phase 1|Phase 2,42,Industry,"March 29, 2017","November 24, 2019","June 17, 2021"
648,NCT03052127,Study in Subjects With Small Primary Choroidal Melanoma,Uveal Melanoma|Ocular Melanoma|Choroidal Melanoma,Drug: Light-activated AU-011|Device: Laser Activation,Aura Biosciences,Phase 1|Phase 2,57,Industry,"February 27, 2017","January 26, 2021","January 26, 2021"
649,NCT03050801,Functional Connectivity as a Biomarker of rTMS,Traumatic Brain Injury,Device: rTMS,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,68,NIH,"March 24, 2017","March 10, 2020","August 7, 2020"
650,NCT03047980,Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome,Sturge-Weber Syndrome,Drug: Sirolimus,"Anne Comi, MD|Children's Hospital Medical Center, Cincinnati|Pfizer|National Institutes of Health (NIH)|Faneca 66 Foundation|National Institute of Neurological Disorders and Stroke (NINDS)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 2|Phase 3,10,Other|Industry|NIH,Jan-17,"June 4, 2019","October 27, 2020"
651,NCT03047109,Ephedrine and Phenylephrine for Spinal Hypotension,Spinal Hypotension,Drug: Phenylephrine|Drug: Ephedrine,Assiut University,Phase 2|Phase 3,60,Other,"February 7, 2017","March 30, 2020","March 30, 2020"
652,NCT03046927,Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes,Type 1 Diabetes,Drug: Ergocalciferol|Other: Placebo,"Benjamin U. Nwosu, MD|University of Massachusetts, Worcester|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",Phase 2|Phase 3,48,Other|NIH,"October 19, 2017","April 12, 2021","April 20, 2021"
653,NCT03039686,"Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy",Duchenne Muscular Dystrophy,Drug: RO7239361|Drug: Placebo for RO7239361,Hoffmann-La Roche,Phase 2|Phase 3,166,Industry,"July 6, 2017","April 28, 2020","April 28, 2020"
654,NCT03038308,Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole,Hyperprolactinemia|Prolactinoma,Drug: Ropinirole,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1|Phase 2,16,Other|NIH,"September 16, 2016","November 5, 2020","November 5, 2020"
655,NCT03037073,Duloxetine for Succinylcholine-induced Postoperative Myalgia,Postoperative Myalgia,Drug: Duloxetine|Drug: Placebo oral capsule,Assiut University,Phase 2|Phase 3,70,Other,"April 15, 2017","November 30, 2019","November 30, 2019"
656,NCT03035591,ODM-207 in Patients With Advance Solid Tumours,Solid Tumors,Drug: ODM-207,"Orion Corporation, Orion Pharma",Phase 1|Phase 2,36,Industry,"December 22, 2016","May 10, 2019","May 10, 2019"
657,NCT03033680,Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA,MSA,Drug: [F-18]PBR06,Brigham and Women's Hospital,Phase 1|Phase 2,17,Other,"March 24, 2017","January 15, 2021","January 15, 2021"
658,NCT03031444,Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis,Colorectal Cancer Stage IV|Metastasis,Drug: Cetuximab plus FOLFIRI/FOLFOX|Drug: FOLFIRI/FOLFOX/CapeOX,Peking University Cancer Hospital & Institute|Beijing Municipal Administration of Hospitals|West China Hospital|Zhejiang Cancer Hospital|First Affiliated Hospital of Kunming Medical University,Phase 2|Phase 3,135,Other,Jan-16,"December 30, 2020","December 30, 2020"
659,NCT03029598,"Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,University of Washington|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC,Phase 1|Phase 2,29,Other|NIH|Industry,"March 14, 2017","April 20, 2021","December 31, 2021"
660,NCT03019185,A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL,Alport Syndrome,Drug: Placebo Oral Capsule|Drug: Bardoxolone Methyl,"Reata Pharmaceuticals, Inc.",Phase 2|Phase 3,187,Industry,"March 2, 2017","October 6, 2020","October 30, 2020"
661,NCT03018275,Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis,Atopic Dermatitis,Biological: Roseomonas mucosa,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,31,NIH,"April 20, 2017","October 11, 2019","October 11, 2019"
662,NCT03017508,Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder,Social Anxiety Disorder|Performance Anxiety,Drug: BHV-0223|Drug: Placebo,"Yale University|Biohaven Pharmaceuticals, Inc.",Phase 2|Phase 3,22,Other|Industry,Jan-17,Dec-19,"January 29, 2021"
663,NCT03015272,Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD),Autism,Behavioral: Auditory-Motor Mapping Training|Behavioral: Speech-Repetition Therapy,Beth Israel Deaconess Medical Center|Boston University,Phase 2|Phase 3,14,Other,Nov-14,Sep-19,Dec-19
664,NCT03015246,Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence,Heroin Dependence|Opioid Use Disorder,Drug: Extended release morphine|Drug: Buprenorphine/Naloxone low dose|Drug: Buprenorphine/Naloxone moderate dose|Drug: Buprenorphine/Naloxone high dose|Drug: Active stressor|Drug: Placebo stressor,Wayne State University,Phase 1|Phase 2,26,Other,Dec-16,Jun-20,Aug-20
665,NCT03010358,"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",Anemia|B-Cell Prolymphocytic Leukemia|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Hairy Cell Leukemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Richter Syndrome,Drug: Entospletinib|Other: Laboratory Biomarker Analysis|Biological: Obinutuzumab|Other: Pharmacological Study,"Alexey Danilov, MD|Gilead Sciences|Oregon Health and Science University|OHSU Knight Cancer Institute",Phase 1|Phase 2,24,Other|Industry,"July 17, 2017","April 29, 2021","April 29, 2021"
666,NCT03005353,Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.,"Infection, Fungal",Drug: Cumin seed extract|Drug: clotrimazole,Assiut University,Phase 2|Phase 3,100,Other,"March 1, 2018","October 31, 2019","January 31, 2020"
667,NCT03003637,ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma,Immunotherapy|Head and Neck Neoplasms,Drug: Nivolumab|Drug: Ipilimumab,The Netherlands Cancer Institute,Phase 1|Phase 2,33,Other,"February 28, 2017","October 12, 2019","February 12, 2021"
668,NCT03003364,Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury,"Spinal Cord Injury, Chronic",Drug: XCEL-UMC-BETA|Drug: Placebo,"Banc de Sang i Teixits|Hospital de Neurorehabilitació Institut Guttmann|Recerca Clínica S.L.|Syntax for Science, S.L",Phase 1|Phase 2,10,Other|Industry,"December 27, 2016","July 25, 2019","February 11, 2020"
669,NCT03001310,Gene Therapy for Achromatopsia (CNGB3),Achromatopsia,Biological: AAV - CNGB3,"MeiraGTx UK II Ltd|Janssen Research & Development, LLC",Phase 1|Phase 2,23,Industry,"January 16, 2017","October 25, 2019","October 25, 2019"
670,NCT02999815,Intrathecal Tetanus Immunoglobulin to Treat Tetanus,Tetanus,Procedure: Human tetanus immunoglobulin|Procedure: Intramuscular antitoxin,"Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Phase 1|Phase 2,272,Other,"February 13, 2017","December 31, 2019","May 1, 2020"
671,NCT02991807,RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome,PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome,Drug: RAD001|Drug: Placebo,Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1|Phase 2,46,Other|NIH|Industry,"June 12, 2017","February 18, 2021","December 22, 2021"
672,NCT02991209,Study of Testosterone vs Placebo in Testicular Cancer Survivors,Metabolic Syndrome|Testicular Cancer|Leydig Cell Failure in Adult,Drug: Testosterone|Drug: Placebos,"Mikkel Bandak|Rigshospitalet, Denmark",Phase 2|Phase 3,69,Other,Nov-16,Jun-19,Jun-19
673,NCT02990468,"A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer",Head and Neck Cancer,Drug: BMX-001|Radiation: Radiation Therapy|Drug: Cisplatin,"BioMimetix JV, LLC|Duke University|University of California, San Francisco",Phase 1|Phase 2,29,Industry|Other,"April 19, 2017","February 21, 2020","March 31, 2022"
674,NCT02987829,"Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients","Metastatic Castrate-resistant Prostate Cancer|Adenocarcinoma, Prostate",Drug: TRC253,"Tracon Pharmaceuticals Inc.|Janssen Pharmaceutica N.V., Belgium",Phase 1|Phase 2,72,Industry,"May 23, 2017","October 6, 2019","November 9, 2020"
675,NCT02987426,Can Brief-mindfulness Interventions Improve Psychiatric Symptoms?,Psychiatric Disorders,Behavioral: Mindfulness-oriented intervention,Lady Davis Institute,Phase 2|Phase 3,20,Other,"May 19, 2017","February 1, 2020","February 1, 2020"
676,NCT02983188,Berberine as Adjuvant Treatment for Schizophrenia Patients,Schizophrenia|Schizophrenia Spectrum and Other Psychotic Disorders|Metabolic Syndrome x,Drug: Berberine|Drug: Placebos|Drug: Antipsychotic Agents,"The University of Hong Kong|Queen Mary Hospital, Hong Kong|Kowloon Hospital, Hong Kong|Castle Peak Hospital|Zhejiang Provincial Tongde Hospital",Phase 2|Phase 3,113,Other,"April 25, 2018","December 30, 2020","January 4, 2021"
677,NCT02979691,Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01,Esophagus Cancer|Esophagogastric Junction Cancer|Radiotherapy; Complications|Chemoradiation,Radiation: SIB-IMRT|Drug: S-1,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Hebei Medical University Fourth Hospital|Tianjin Medical University Cancer Institute and Hospital|Anyang Tumor Hospital|The First Affiliated Hospital with Nanjing Medical University|Affiliated Hospital of Hebei University|Fujian Cancer Hospital|Tengzhou Central People's Hospital|The First Affiliated Hospital of Zhengzhou University|The Affiliated Hospital of Inner Mongolia Medical University|Sichuan Cancer Hospital and Research Institute",Phase 2|Phase 3,350,Other,Oct-16,Apr-20,Apr-20
678,NCT02979522,"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma",Hodgkin Disease,Drug: Brentuximab vedotin|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine,Takeda,Phase 1|Phase 2,59,Industry,"September 6, 2017","May 5, 2020","September 24, 2021"
679,NCT02975297,Exenatide Once Weekly for Smoking Cessation,Smoking Cessation,Drug: Exenatide|Drug: NRT|Behavioral: Counseling|Drug: Placebo,"The University of Texas Health Science Center, Houston",Phase 1|Phase 2,84,Other,Jul-16,"January 3, 2020","January 3, 2020"
680,NCT02967874,Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment,"Osteoarthritis|Joint Disease|Osteoarthritis,Knee|Arthritis, Degenerative|Osteoarthrosis|Osteoarthrosis Deformans",Procedure: Intra-articular auto-SVFs injection|Drug: Hyaluronic Acid,Russian Academy of Medical Sciences,Phase 1|Phase 2,27,Other,Mar-16,Jun-19,Sep-19
681,NCT02963818,Smartphone Technology: Young Adult Drinking,Alcohol Use|Alcohol Drinking|Drinking Behavior,Other: Smartphone breathalyzer device/app use|Other: BAC estimator app use|Other: Text messaging procedure,University of Florida|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1|Phase 2,110,Other|NIH,Nov-16,"June 20, 2019","June 20, 2019"
682,NCT02958709,Optimizing Treatment to Improve TBM Outcomes in Children,"Tuberculosis, Meningeal","Drug: High-dose: RIF, INH, PZA, EMB|Drug: High dose: RIF, INH, PZA, LEVO|Drug: Standard of care: RIF, INH, PZA, EMB","Johns Hopkins University|National Institute for Research in Tuberculosis, Chennai, India|University of North Carolina|B. J. Medical College, Pune|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Phase 1|Phase 2,38,Other|NIH,"February 22, 2017","November 15, 2020","November 15, 2020"
683,NCT02957123,Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome,"Organic Brain Syndrome, Nonpsychotic|Neurocognitive Disorders|Mental Disorder, Organic|Delirium, Dementia, Amnestic, Cognitive Disorders|Nonpsychotic Organic Brain Syndrome|Organic Mental Disorder|Encephalopathy, Post-Traumatic, Chronic|Encephalopathy, Ischemic|Brain Ischemia",Drug: Intranasal auto-M2-BFs,Russian Academy of Medical Sciences,Phase 1|Phase 2,30,Other,Mar-16,Sep-20,Sep-20
684,NCT02953782,Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer,Solid Tumor|Colorectal Cancer,Drug: Magrolimab|Drug: Cetuximab,Gilead Sciences|California Institute for Regenerative Medicine (CIRM),Phase 1|Phase 2,78,Industry|Other,"November 2, 2016","February 10, 2020","February 10, 2020"
685,NCT02950883,Saline Hypertonic in Preschoolers + CT,Cystic Fibrosis,Drug: Active Treatment Group 7% Hypertonic Saline|Drug: Control Group 0.9% Isotonic Saline,"University of Washington, the Collaborative Health Studies Coordinating Center|Cystic Fibrosis Foundation",Phase 2|Phase 3,116,Other,"March 24, 2015","December 15, 2020","June 25, 2021"
686,NCT02946047,The Effect of Ixazomib on the Latent HIV Reservoir,Human Immunodeficiency Virus (HIV),Drug: Ixazomib 1 MG|Drug: Ixazomib 2 MG|Drug: Ixazomib 3 MG|Drug: Ixazomib 4 MG,Mayo Clinic|Takeda,Phase 1|Phase 2,17,Other|Industry,"March 20, 2017","August 19, 2019","August 19, 2019"
687,NCT02945553,Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery,Anterior Cruciate Ligament Reconstruction,Device: Neuromuscular electrical stimulation|Device: Microstimulation,University of Vermont,Phase 1|Phase 2,25,Other,Oct-16,Sep-19,Sep-19
688,NCT02942264,Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma,Drug: Zotiraciclib (TG02)|Drug: Temozolomide (TMZ),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,53,NIH,"December 14, 2016","August 26, 2020","August 26, 2020"
689,NCT02942173,CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT,Leukemia|Lymphoma|Myelodysplastic Syndromes|GvHD|Opportunistic Infections|Graft-versus-Host Disease,Biological: CD45RA-depleted peripheral blood mononuclear cells,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",Phase 2|Phase 3,150,Other,Oct-16,"August 21, 2019","August 21, 2020"
690,NCT02936323,PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,"Neuroendocrine Tumors|Carcinoma, Small Cell Lung|Neuroendocrine Carcinoma",Drug: PEN-221,Tarveda Therapeutics,Phase 1|Phase 2,89,Industry,"December 8, 2016","July 31, 2020","February 25, 2021"
691,NCT02933320,BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia,B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinemia,Biological: BI-1206 single agent dose escalation phase|Biological: Combination of BI-1206 with rituximab escalation phase|Biological: BI-1206 single agent expansion phase|Biological: Combination of BI-1206 with rituximab expansion phase,Cancer Research UK|BioInvent International AB|Bloodwise,Phase 1|Phase 2,14,Other|Industry,"October 27, 2016","March 19, 2020","March 19, 2020"
692,NCT02931097,DBS of the MLR for Gait and Balance Disorders in PD Patients,Parkinson's Disease,Device: Deep brain stimulation|Device: Sham stimulation,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1|Phase 2,6,Other,Oct-16,Oct-19,Oct-20
693,NCT02929862,Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer,Cancer,Drug: LYC-55716,Lycera Corp.,Phase 1|Phase 2,119,Industry,Dec-16,"May 31, 2019","May 31, 2019"
694,NCT02927145,"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate",Malaria,Biological: RH5.1/ ASO1,University of Oxford,Phase 1|Phase 2,88,Other,"October 17, 2016","June 27, 2019","June 27, 2019"
695,NCT02926352,Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training,Phobias|Claustrophobia|Social Phobia,Behavioral: Extinction Training|Device: Low-Level Laser Therapy|Device: Sham Low-Level Laser Therapy,University of Texas at Austin,Phase 1|Phase 2,112,Other,"August 1, 2015","May 4, 2020","May 4, 2020"
696,NCT02925000,Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy,Cancer,Drug: TLC178,Taiwan Liposome Company,Phase 1|Phase 2,46,Industry,"June 19, 2017","October 6, 2020","October 6, 2020"
697,NCT02923115,"Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism",Pulmonary Embolism|Thrombotic Disease,Drug: DS-1040b|Drug: Placebo|Drug: Enoxaparin,"Daiichi Sankyo, Inc.",Phase 1|Phase 2,134,Industry,"June 23, 2016","August 5, 2019","August 5, 2019"
698,NCT02919111,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"University of California, San Francisco",Phase 2|Phase 3,299,Other,"September 23, 2016","December 31, 2019","December 31, 2019"
699,NCT02916693,Mirabegron For Erectile Dysfunction,Erectile Dysfunction|Overactive Bladder|Urinary Incontinence,Drug: Mirabegron,"Johns Hopkins University|Astellas Pharma US, Inc.",Phase 1|Phase 2,20,Other|Industry,"August 1, 2017","January 1, 2020","January 1, 2020"
700,NCT02915016,"Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults",HIV Infections,Biological: DNA-HIV-PT123 vaccine|Biological: Bivalent Subtype C gp120/MF59 vaccine|Biological: Bivalent Subtype C gp120/AS01B vaccine|Biological: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,334,NIH,"December 7, 2016","August 7, 2019","February 12, 2020"
701,NCT02912793,Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients,"Niemann-Pick Disease, Type C1",Drug: Hydroxypropyl-beta-cyclodextrin,"Cyclo Therapeutics, Inc.",Phase 1|Phase 2,12,Industry,"March 20, 2017","March 3, 2021","March 3, 2021"
702,NCT02912676,Thiopurine EnhAnced Maintenance Therapy,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,Drug: Thioguanine (oral),"Kjeld Schmiegelow|Danish Child Cancer Foundation|Nordic Society for Pediatric Hematology and Oncology|Rigshospitalet, Denmark",Phase 1|Phase 2,30,Other,Oct-16,Mar-20,Apr-20
703,NCT02911935,Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II,"Respiratory Syncytial Virus, Bronchiolitis",Drug: Oral azithromycin|Drug: Placebo,Washington University School of Medicine,Phase 2|Phase 3,200,Other,Nov-16,Apr-21,Apr-21
704,NCT02910063,Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL,B-Cell Non Hodgkin Lymphoma,Drug: Blinatumomab,Amgen,Phase 2|Phase 3,41,Industry,"January 23, 2017","March 12, 2020","March 12, 2020"
705,NCT02904226,JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors,Cancer,Drug: JTX-2011|Drug: Nivolumab|Drug: Ipilimumab|Drug: Pembrolizumab,"Jounce Therapeutics, Inc.",Phase 1|Phase 2,242,Industry,Aug-16,"July 1, 2020","July 1, 2020"
706,NCT02903914,Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors,Metastatic Cancer|Solid Tumors|Colorectal Cancer (CRC)|Gastric Cancer|Head and Neck Cancer|Lung Cancer|Renal Cell Carcinoma (RCC)|Bladder Cancer|UC (Urothelial Cancer)|Mesothelioma,Drug: INCB001158|Drug: Pembrolizumab,Incyte Corporation,Phase 1|Phase 2,260,Industry,"September 14, 2016","August 31, 2020","August 15, 2022"
707,NCT02902042,Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,Malignant Melanoma,Drug: Encorafenib|Drug: Binimetinib|Drug: Pembrolizumab|Drug: Pembrolizumab alone,"Prof. Dr. med. Dirk Schadendorf|University Hospital, Essen",Phase 1|Phase 2,16,Other,"April 24, 2018","November 30, 2020","November 30, 2020"
708,NCT02899078,Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,Metastatic Renal Cell Cancer|Stage IV Renal Cell Cancer,Drug: Ibrutinib|Drug: Nivolumab,"University of California, Davis|Pharmacyclics LLC.",Phase 1|Phase 2,31,Other|Industry,"November 15, 2016","August 5, 2020","February 24, 2021"
709,NCT02896192,Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity,Pro-opiomelanocortin (POMC) Deficiency Obesity,Drug: Setmelanotide|Drug: Placebo,"Rhythm Pharmaceuticals, Inc.",Phase 2|Phase 3,15,Industry,"February 14, 2017","July 16, 2020","July 16, 2020"
710,NCT02895360,Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma,Neoplasms,Drug: BAL101553|Drug: BAL101553 at MTD,Basilea Pharmaceutica,Phase 1|Phase 2,43,Industry,"August 24, 2016","August 7, 2020","August 7, 2020"
711,NCT02889562,Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation,Coronary Artery Bypass Grafting|Postoperative Atrial Fibrilation|Stroke|Systemic Embolism|Deep Venous Thrombosis,Drug: Apixaban|Drug: Warfarin,Sanford Health|Bristol-Myers Squibb,Phase 2|Phase 3,56,Other|Industry,Sep-16,"May 11, 2019","May 11, 2019"
712,NCT02888665,Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,Sarcoma,Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,37,Other|NIH,"December 5, 2016","March 17, 2020","October 9, 2020"
713,NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,"Diabetes Mellitus, Type 2",Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",Phase 1|Phase 2,16,Other|NIH,"October 20, 2017","August 26, 2019","September 3, 2020"
714,NCT02879760,Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients,Non-Small Cell Lung Cancer,Biological: Ad-MAGEA3|Biological: MG1-MAGEA3|Biological: Pembrolizumab,"Turnstone Biologics, Corp.",Phase 1|Phase 2,16,Industry,"March 8, 2017","February 15, 2020","May 24, 2020"
715,NCT02878785,Decitabine and Talazoparib in Untreated AML and R/R AML,Acute Myeloid Leukemia,Drug: Decitabine|Drug: talazoparib,"University of Maryland, Baltimore|Pfizer|Van Andel Research Institute",Phase 1|Phase 2,25,Other|Industry,Aug-16,"January 5, 2020","November 19, 2020"
716,NCT02872857,Subarachnoid Hemorrhage Recovery And Galantamine,Subarachnoid Hemorrhage,Drug: Placebo|Drug: 8mg galantamine twice daily|Drug: 12mg galantamine twice daily,"The University of Texas Health Science Center, Houston",Phase 1|Phase 2,60,Other,Sep-16,"July 20, 2019","July 20, 2019"
717,NCT02871791,Palbociclib With Everolimus + Exemestane In BC,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor (HR)-Positive Breast Cancer,Drug: Palbociclib|Drug: Everolimus|Drug: Exemestane,Dana-Farber Cancer Institute|Pfizer,Phase 1|Phase 2,41,Other|Industry,"August 24, 2016","December 3, 2020",Sep-21
718,NCT02870777,MRD-directed Therapy for Low-risk and Intermediate-risk AML.,Acute Myeloid Leukemia|Minimal Residual Disease,Combination Product: MRD-directed therapy,"Nanfang Hospital of Southern Medical University|Guangzhou First People's Hospital|Zhujiang Hospital|Peking University People's Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University",Phase 2|Phase 3,743,Other,Aug-16,"August 31, 2019","December 31, 2019"
719,NCT02870348,Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE),Alpha1-Antitrypsin Deficiency,Biological: Alpha-1 MP,Grifols Therapeutics LLC|Grifols Japan K.K.,Phase 1|Phase 2,4,Industry|Other,"July 29, 2016","February 16, 2021","February 16, 2021"
720,NCT02859441,A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab,Von Hippel-Lindau Syndrome,Drug: Ranibizumab|Drug: E10030,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,3,NIH,"January 23, 2017","July 9, 2019","July 9, 2019"
721,NCT02859324,A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),"Carcinoma, Hepatocellular",Drug: CC-122|Drug: Nivolumab,Celgene,Phase 1|Phase 2,21,Industry,"September 20, 2016","March 27, 2020","March 27, 2020"
722,NCT02858076,Anti-VEGF vs. Prompt Vitrectomy for VH From PDR,Proliferative Diabetic Retinopathy|Vitreous Hemorrhage,Drug: 2-mg Intravitreous Aflibercept Injection|Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation,Jaeb Center for Health Research|National Institutes of Health (NIH)|Regeneron Pharmaceuticals|National Eye Institute (NEI),Phase 2|Phase 3,205,Other|NIH|Industry,Nov-16,Jan-20,Jan-20
723,NCT02857569,A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma,Stage III/IV Melanoma,Drug: Ipilimumab IT|Drug: Ipilimumab IV|Drug: Nivolumab IV,"Gustave Roussy, Cancer Campus, Grand Paris",Phase 1|Phase 2,90,Other,"December 5, 2016",Jan-21,"May 20, 2022"
724,NCT02855203,Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours,Renal Cell Carcinoma,Radiation: Stereotactic Ablative Body Radiosurgery (SABR)|Drug: Pembrolizumab,"Peter MacCallum Cancer Centre, Australia",Phase 1|Phase 2,30,Other,"October 20, 2016","May 22, 2020","May 22, 2020"
725,NCT02851784,Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma,Hepatocellular Carcinoma,Biological: adoptive immunotherapy|Procedure: MWA,Chinese PLA General Hospital,Phase 2|Phase 3,40,Other,Dec-09,"July 30, 2020","March 1, 2021"
726,NCT02849587,The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking,Cannabis Intoxication,Drug: Cannabis,"University of California, San Diego",Phase 1|Phase 2,199,Other,"February 24, 2017","June 17, 2019","June 17, 2019"
727,NCT02848079,TAS-OX for Refractory Metastatic Colon Cancer,Colorectal Neoplasms,Drug: combined TAS-102 and TAS-OX,Yale University,Phase 1|Phase 2,41,Other,"October 31, 2016","June 2, 2020","June 2, 2020"
728,NCT02845843,MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b,Middle East Respiratory Syndrome Coronavirus (MERS-CoV),Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b|Drug: Placebo,King Abdullah International Medical Research Center,Phase 2|Phase 3,95,Other,Jul-16,May-20,May-20
729,NCT02841033,Daratumumab for the Treatment of Patients With AL Amyloidosis,AL Amyloidosis,Drug: daratumumab,Boston Medical Center|Janssen Pharmaceuticals,Phase 1|Phase 2,22,Other|Industry,"March 20, 2017","May 28, 2020","July 17, 2020"
730,NCT02834403,L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,Metastatic Triple Negative Breast Cancer,Drug: L-NMMA|Drug: Docetaxel|Drug: Amlodipine|Drug: Pegfilgrastim|Drug: Enteric-coated aspirin,The Methodist Hospital Research Institute,Phase 1|Phase 2,48,Other,Nov-16,Jan-21,Jan-21
731,NCT02829957,RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding,Venous Thromboembolism|Menstruation,Drug: Apixaban|Drug: Rivaroxaban,Indiana University,Phase 2|Phase 3,19,Other,Sep-16,"February 13, 2020","February 13, 2020"
732,NCT02825212,Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia,Hepatitis C|Cryoglobulinemia,Drug: Harvoni|Drug: Epclusa,Icahn School of Medicine at Mount Sinai|Gilead Sciences,Phase 2|Phase 3,10,Other|Industry,Feb-16,"July 19, 2019","July 19, 2019"
733,NCT02821026,Omental Islet Transplant,Type 1 Diabetes,Procedure: Omental Islet transplant|Drug: Anti-Thymocyte Globulin|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Drug: Etanercept|Drug: Sirolimus,University of Alberta,Phase 1|Phase 2,4,Other,May-16,"November 13, 2019","November 13, 2019"
734,NCT02807844,Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,Triple Negative Breast Cancer|Pancreatic Carcinoma|Melanoma|Endometrial Carcinoma,Drug: MCS110|Drug: PDR001,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,141,Industry,"June 29, 2016","June 4, 2020","June 4, 2020"
735,NCT02806414,Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.,Rosacea,Drug: Ivermectin,"University of California, San Diego|Galderma R&D",Phase 1|Phase 2,25,Other|Industry,Jul-16,Jul-19,May-21
736,NCT02805725,Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide,Soft-tissue Sarcomas,Drug: Phase 1: Trabectedin|Drug: Phase 2: Trabectedin|Drug: Phase 1: Cyclophosphamide|Drug: Phase 2: Cyclophosphamide,Institut Bergonié|PharmaMar,Phase 1|Phase 2,50,Other|Industry,Dec-15,Apr-20,Dec-21
737,NCT02803229,Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder,Cannabis Use Disorder|Attention-deficit/Hyperactivity Disorder,Drug: Adderall-XR|Drug: Matched placebo,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),Phase 2|Phase 3,33,Other|NIH,Jul-16,Jun-20,Jun-20
738,NCT02801695,Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE),Pre-eclampsia|Pregnancy,Drug: Citrulline|Drug: Placebo,Nantes University Hospital,Phase 2|Phase 3,116,Other,"February 20, 2017","December 1, 2020","December 1, 2020"
739,NCT02799147,GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia,"Leukemia, Acute Lymphoblastic|Acute Myeloid Leukemia|Mixed-Lineage Acute Leukemias",Procedure: Allogeneic stem cell transplantation|Drug: Fludarabine monophosphate|Drug: Busulfan|Drug: Bendamustine,St. Petersburg State Pavlov Medical University,Phase 1|Phase 2,27,Other,Jun-16,Nov-20,Nov-20
740,NCT02797977,A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer,Advanced Solid Tumors,"Drug: SRA737, gemcitabine, cisplatin|Drug: SRA737, gemcitabine","Sierra Oncology, Inc.",Phase 1|Phase 2,153,Industry,Jul-16,"April 8, 2020","April 8, 2020"
741,NCT02797964,A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer,Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL),Drug: SRA737,"Sierra Oncology, Inc.",Phase 1|Phase 2,107,Industry,Jul-16,"October 28, 2019","October 28, 2019"
742,NCT02797587,Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV),HIV Infection|Alcohol Use|Smoking,Drug: Varenicline|Drug: Cytisine|Drug: Nicotine Replacement Therapy|Drug: Varenicline Placebo|Drug: Cytisine Placebo|Drug: Nicotine Replacement Therapy Placebo,Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2|Phase 3,400,Other|NIH,"July 19, 2017","April 30, 2020","December 15, 2020"
743,NCT02796898,"Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",Prostate Cancer|Rising Prostate Specific Antigen (PSA),Drug: SM88 (Cohort 1)|Drug: SM88 (Cohort 2),"Tyme, Inc",Phase 1|Phase 2,23,Industry,Jun-16,"May 30, 2019","May 30, 2019"
744,NCT02796001,Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans,Healthy Volunteers,Biological: human rhinovirus|Other: no intervention,University of Virginia,Phase 1|Phase 2,46,Other,"September 25, 2017","May 1, 2020","May 1, 2020"
745,NCT02786992,Misoprostol+Oxytocin vs. Carbetocin in CS,Cesarean Section,Drug: Misoprostol|Drug: Oxytocin|Drug: Carbetocin|Drug: Placebo,Ain Shams University,Phase 2|Phase 3,600,Other,May-16,Jan-20,Jan-20
746,NCT02786836,13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF,Acute Liver Failure,Drug: 13C-Methacetin,"University of Texas Southwestern Medical Center|Medical University of South Carolina|University of Michigan|Meridian Bioscience, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",Phase 2|Phase 3,76,Other|Industry|NIH,"June 10, 2016","September 18, 2019","September 18, 2019"
747,NCT02780609,Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,Multiple Myeloma,Drug: Selinexor|Drug: Melphalan|Drug: Dexamethasone|Procedure: Autologous Hematopoietic Cell Transplantation (HCT)|Drug: Fosaprepitant,H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics Inc,Phase 1|Phase 2,22,Other|Industry,"July 20, 2017","February 20, 2021","February 23, 2021"
748,NCT02762981,Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors,Solid Tumors,Drug: Relacorilant with nab-paclitaxel,Corcept Therapeutics,Phase 1|Phase 2,85,Industry,"May 23, 2016","May 12, 2020","September 12, 2020"
749,NCT02757651,KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,Breast Cancer,Drug: Hydrogen Peroxide,"Institute of Cancer Research, United Kingdom|Kortuc, Inc.",Phase 1|Phase 2,12,Other|Industry,"January 19, 2017","November 12, 2020","November 12, 2020"
750,NCT02755714,Atrovent in Exercise Induced Laryngeal Obstruction (EILO),Exercise Induced Laryngeal Obstruction (EILO),Drug: Ipratropium bromide spray,Haukeland University Hospital,Phase 1|Phase 2,20,Other,"June 22, 2016","October 31, 2020","October 31, 2020"
751,NCT02755298,Chronic Clinical Effect of Acetazolamide,"Hypertension, Pulmonary",Drug: Acetazolamide|Drug: Placebo,University of Zurich,Phase 2|Phase 3,24,Other,Oct-16,Nov-20,Nov-20
752,NCT02754076,A Treatment Study of Mucopolysaccharidosis Type IIIB,MPS III B|Mucopolysaccharidosis Type IIIB,Drug: AX 250,Allievex Corporation,Phase 1|Phase 2,23,Industry,Apr-16,"June 24, 2020","July 31, 2020"
753,NCT02750891,A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas,Glioblastoma|Diffuse Intrinsic Pontine Glioma,Drug: DSP-7888,"Sumitomo Pharma Co., Ltd.",Phase 1|Phase 2,18,Industry,Apr-16,Jan-20,Jan-20
754,NCT02744742,"G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT",Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning,Drug: Decitabine|Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Drug: Granulocyte Colony-Stimulating Factor(G-CSF),Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Institute of Hematology & Blood Diseases Hospital|Peking University People's Hospital|First People's Hospital of Chenzhou|Liuzhou Workers Hospital,Phase 2|Phase 3,202,Other,"April 18, 2016","September 30, 2019","September 30, 2021"
755,NCT02743377,PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome,Nervous System Disease,Other: Brain PET Imaging with 11C Rolipram|Drug: Whole Body PET Baseline with 11C Rolipram|Drug: Whole Body PET Blocked with Roflumilast,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,16,NIH,"April 4, 2018","October 23, 2019","May 19, 2020"
756,NCT02743351,Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies,Hematologic Malignancies|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Acute Graft-versus-host Disease,Biological: ProTmune|Biological: Control Arm,Fate Therapeutics,Phase 1|Phase 2,96,Industry,"December 20, 2016","December 4, 2020","November 5, 2021"
757,NCT02737475,An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread,Advanced Cancer,Drug: BMS-986178|Drug: Nivolumab|Drug: Ipilimumab|Biological: Tetanus vaccine|Biological: DPV-001 vaccine|Drug: Cyclophosphamide,Bristol-Myers Squibb,Phase 1|Phase 2,166,Industry,"June 17, 2016","November 2, 2020","November 2, 2020"
758,NCT02733094,Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum,Pyoderma Gangrenosum,Drug: Secukinumab,Technical University of Munich|Novartis,Phase 1|Phase 2,8,Other|Industry,Apr-16,"September 10, 2019","September 19, 2019"
759,NCT02732119,Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.,Breast Cancer,Drug: Ribociclib|Drug: Everolimus|Drug: Exemestane,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,104,Industry,"June 14, 2016","February 25, 2020","February 25, 2020"
760,NCT02728687,Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy,Diabetic Peripheral Neuropathy,Drug: Mannitol|Drug: Menthol,University of British Columbia,Phase 1|Phase 2,72,Other,"March 15, 2017","March 30, 2020","December 18, 2020"
761,NCT02718144,Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,Breast Neoplasms,Drug: Estetrol,Pantarhei Oncology B.V.,Phase 1|Phase 2,12,Other,"June 1, 2017","December 31, 2019","December 31, 2019"
762,NCT02714959,IL-2 in Refractory Autoimmune Encephalitis,Encephalitis,Drug: Proleukin,Seoul National University Hospital,Phase 1|Phase 2,10,Other,Mar-16,"June 12, 2019","June 12, 2019"
763,NCT02714036,A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),Amyotrophic Lateral Sclerosis,Drug: ibudilast,MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates,Phase 1|Phase 2,35,Industry|Other,"May 6, 2016","December 31, 2019","June 30, 2020"
764,NCT02713373,Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,Biological: Cetuximab|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC,Phase 1|Phase 2,45,Other|NIH|Industry,"August 5, 2016","July 28, 2020","July 20, 2021"
765,NCT02711956,A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,Metastatic Castration-Resistant Prostate Cancer,Drug: ZEN003694|Drug: Enzalutamide,Zenith Epigenetics,Phase 1|Phase 2,75,Industry,Dec-16,Nov-19,Nov-19
766,NCT02710890,Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.,Epilepsy,Drug: Lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 2|Phase 3,103,Industry,"May 30, 2017","June 28, 2019","June 28, 2019"
767,NCT02710240,Indocyanine Green for Central Nervous System Tumors,Suspected Central Nervous System Tumors,Drug: Indocyanine Green (ICG)|Radiation: Intraoperative near-infrared (NIR),Abramson Cancer Center at Penn Medicine,Phase 1|Phase 2,336,Other,"June 10, 2015","February 4, 2020","April 2, 2020"
768,NCT02708680,Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,Breast Cancer,Drug: entinostat|Drug: atezolizumab|Drug: Placebo,Syndax Pharmaceuticals|Roche Pharma AG,Phase 1|Phase 2,81,Industry,May-16,"March 10, 2021","March 10, 2021"
769,NCT02707393,Allogeneic Stem Cell Transplantation for Children With CML,Chronic Myeloid Leukemia,Drug: Fludarabine|Drug: Thiotepa|Drug: Melphalan|Drug: ATG|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Biological: bone marrow or peripheral blood stem cells,St. Anna Kinderkrebsforschung,Phase 2|Phase 3,13,Other,"April 30, 2009","December 1, 2020","December 1, 2020"
770,NCT02701140,Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease,Myocardial Ischemia,Procedure: Coronary stenting|Procedure: intracoronary ECG recording|Procedure: Coronary Flow reserve|Procedure: Index of Microcirculatory Resistance|Procedure: Fractional Flow Reserve,Italo Porto|AstraZeneca|Catholic University of the Sacred Heart,Phase 2|Phase 3,58,Other|Industry,Jun-16,Nov-20,Nov-20
771,NCT02697591,A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors,Advanced Malignancies|Metastatic Cancer,Drug: INCAGN01876,Incyte Biosciences International Sàrl|Incyte Corporation,Phase 1|Phase 2,100,Industry,"June 20, 2016","December 16, 2019","December 16, 2019"
772,NCT02692755,Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer,Hormone Receptor Positive HER-2 Negative Breast Cancer,Drug: Palbociclib + Letrozole or Fulvestrant,Georgetown University|University of Chicago|Thomas Jefferson University,Phase 2|Phase 3,35,Other,Sep-16,"December 16, 2019","March 23, 2021"
773,NCT02689284,"Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",Gastric Cancer|Stomach Cancer|Esophageal Cancer,Biological: Margetuximab 10 mg/kg|Biological: Margetuximab 15 mg|Biological: Pembrolizumab,MacroGenics|Merck Sharp & Dohme LLC,Phase 1|Phase 2,95,Industry,Jan-16,Jan-21,Jan-21
774,NCT02686658,Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration,Geographic Atrophy|Macular Degeneration,Drug: Zimura|Other: Sham,"IVERIC bio, Inc.",Phase 2|Phase 3,286,Industry,"January 20, 2016","September 26, 2019","April 23, 2020"
775,NCT02685748,Aspirin in Young Psychotic Patients,Psychosis|Acute Psychosis|Schizophrenia,Drug: Aspirin|Drug: Placebo|Drug: Pantoprazole,"Clinic for Psychiatric Disorders, Dr Laza Lazarevic|Stanley Medical Research Institute",Phase 2|Phase 3,60,Other,"July 20, 2017","December 31, 2019","December 31, 2019"
776,NCT02684812,Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.,Subarachnoid Hemorrhage,Drug: Tranexamic Acid,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Stichting Nuts Ohra,Phase 2|Phase 3,955,Other,"July 16, 2012","July 29, 2019","November 1, 2020"
777,NCT02678975,Disulfiram in Recurrent Glioblastoma,Glioma|Glioblastoma,Drug: Disulfiram|Dietary Supplement: Copper|Drug: Alkylating Agents,"Sahlgrenska University Hospital, Sweden|St. Olavs Hospital|Lund University Hospital|Karolinska University Hospital|University Hospital, Linkoeping|Region Örebro County|Ryhov County Hospital|Uppsala University Hospital",Phase 2|Phase 3,88,Other,Jan-17,"January 15, 2021","January 15, 2021"
778,NCT02678741,Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.,Metastatic Melanoma,Drug: TLPLDC Vaccine,"Cancer Insight, LLC|Elios Therapeutics, LLC",Phase 1|Phase 2,45,Industry,Feb-16,"October 30, 2019","November 13, 2019"
779,NCT02678351,68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery,Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma,Drug: 68Ga-PSMA-11|Procedure: Magnetic resonance imaging (MRI)|Procedure: Positron Emission Tomography (PET),Andrei Iagaru|National Cancer Institute (NCI)|Stanford University,Phase 2|Phase 3,74,Other|NIH,"April 18, 2016","December 13, 2020",Dec-21
780,NCT02667483,Study of DS-5141b in Patients With Duchenne Muscular Dystrophy,Duchenne Muscular Dystrophy,Drug: DS-5141b,"Daiichi Sankyo Co., Ltd.|Orphan Disease Treatment Institute Co., Ltd.|Daiichi Sankyo, Inc.",Phase 1|Phase 2,7,Industry|Other,Oct-15,"October 20, 2020","October 20, 2020"
781,NCT02661542,Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas,Solid Tumors|Lymphomas,Drug: FF-10502-01,"Fujifilm Pharmaceuticals U.S.A., Inc.",Phase 1|Phase 2,99,Industry,Jan-16,"November 5, 2020","November 5, 2020"
782,NCT02659085,Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder,"Depressive Disorder, Major",Drug: Ketamine IV Infusion|Procedure: ECT,Pouya Movahed Rad|Region Skane,Phase 2|Phase 3,198,Other,Feb-15,Aug-19,Aug-19
783,NCT02659020,A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,Soft Tissue Sarcoma,Drug: Olaratumab|Drug: Gemcitabine|Drug: Docetaxel|Drug: Placebo,Eli Lilly and Company,Phase 1|Phase 2,310,Industry,"March 1, 2016","July 28, 2020","April 27, 2021"
784,NCT02657473,Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis,Non-CF Bronchiectasis,Drug: tobramycin inhalation solution|Drug: Saline 0.9% inhalation solution,Medical Center Alkmaar,Phase 2|Phase 3,58,Other,"August 13, 2016","December 13, 2019","December 13, 2019"
785,NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",Breast Cancer,Drug: Ribociclib|Drug: T-DM1|Drug: Trastuzumab|Drug: Fulvestrant,Dana-Farber Cancer Institute|Novartis,Phase 1|Phase 2,25,Other|Industry,"March 9, 2016","August 27, 2020","June 30, 2022"
786,NCT02651675,A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH),Homozygous Familial Hypercholesterolemia (HoFH),Biological: AAV directed hLDLR gene therapy,"REGENXBIO Inc.|National Heart, Lung, and Blood Institute (NHLBI)",Phase 1|Phase 2,9,Industry|NIH,Mar-16,"November 27, 2020","November 27, 2020"
787,NCT02651350,Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI,"Drug-induced Liver Injury,Chronic",Drug: Methylprednisolone|Drug: Standard Treatment,Beijing 302 Hospital,Phase 1|Phase 2,80,Other,Dec-15,Jul-19,Jul-19
788,NCT02648724,Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,Oncology|MET Gene Amplification|NSCLC|MET Gene Mutation|Non Small Cell Lung Cancer,Drug: Sym015,Symphogen A/S,Phase 1|Phase 2,57,Industry,Mar-16,Dec-20,Dec-20
789,NCT02645981,Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma,HCC,Drug: Donafenib|Drug: Sorafenib,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Tigermed Consulting Co., Ltd",Phase 2|Phase 3,668,Industry,Mar-16,"November 27, 2019","December 17, 2019"
790,NCT02635464,Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy,Chronic Ischemic Cardiomyopathy,Biological: hUC-MSCs+Injectable collagen scaffold+CABG|Biological: hUC-MSCs+CABG|Procedure: CABG,Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Phase 1|Phase 2,50,Other,Oct-15,Aug-19,Aug-19
791,NCT02630316,Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE,Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema,Drug: Inhaled Treprostinil|Drug: Placebo,United Therapeutics,Phase 2|Phase 3,326,Industry,"February 3, 2017","December 26, 2019","December 26, 2019"
792,NCT02628132,Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients,Breast Cancer,Drug: Paclitaxel|Drug: Durvalumab,King Faisal Specialist Hospital & Research Center|AstraZeneca,Phase 1|Phase 2,22,Other|Industry,Nov-16,"December 31, 2019","March 24, 2020"
793,NCT02615730,"PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma",Advanced Gastric Adenocarcinoma,Drug: GSK2636771|Drug: Paclitaxel,Yonsei University,Phase 1|Phase 2,42,Other,Feb-16,"March 31, 2021","March 31, 2021"
794,NCT02608203,[68 Ga]-DOTANOC PET/CT in GEP-NETs,Gastroenteropancreatic Neuroendocrine Tumors,Drug: [68Ga]-DOTANOC PET/CT,Assistance Publique Hopitaux De Marseille,Phase 2|Phase 3,18,Other,"May 26, 2016","June 24, 2019","June 30, 2020"
795,NCT02606461,Selinexor in Advanced Liposarcoma,Dedifferentiated Liposarcoma,Drug: Selinexor|Drug: Placebo,Karyopharm Therapeutics Inc,Phase 2|Phase 3,342,Industry,"January 4, 2016","October 28, 2020","October 26, 2021"
796,NCT02606305,"Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer",Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,Drug: Mirvetuximab soravtansine|Drug: Bevacizumab|Drug: Carboplatin|Drug: Pegylated Liposomal Doxorubicin|Drug: Pembrolizumab,"ImmunoGen, Inc.",Phase 1|Phase 2,264,Industry,Dec-15,"March 12, 2021","March 12, 2021"
797,NCT02604784,"Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors",Peritoneal Carcinomatosis,Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose,Fondazione del Piemonte per l'Oncologia,Phase 1|Phase 2,105,Other,Oct-15,"May 31, 2020","May 31, 2020"
798,NCT02601586,"Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease",Parkinson Disease,Drug: PR Oxycodone|Drug: Levodopa|Drug: Oxycodone Placebo|Drug: Levodopa placebo,"University Hospital, Toulouse",Phase 2|Phase 3,67,Other,Sep-16,Nov-20,Nov-20
799,NCT02598960,"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.",Solid Tumors,Drug: BMS-986156|Drug: Nivolumab,Bristol-Myers Squibb,Phase 1|Phase 2,295,Industry,"October 14, 2015","December 16, 2019","December 16, 2019"
800,NCT02590263,Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma,Malignant Glioma|Glioblastoma Multiforme,Radiation: Whole Brain Radiation|Drug: Temozolomide|Drug: ABT-414,AbbVie,Phase 1|Phase 2,53,Industry,"August 24, 2015","August 27, 2020","August 27, 2020"
801,NCT02586233,"Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke",Acute Ischemic Stroke|Thrombotic Disease,Drug: DS-1040b|Drug: Placebo,"Daiichi Sankyo, Inc.",Phase 1|Phase 2,106,Industry,Sep-15,"August 13, 2019","August 13, 2019"
802,NCT02581631,An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas,Non-Hodgkin's Disease,Biological: Nivolumab|Drug: Brentuximab Vedotin,Bristol-Myers Squibb|Seagen Inc.,Phase 1|Phase 2,145,Industry,"February 11, 2016","January 16, 2020","February 7, 2022"
803,NCT02581462,FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer,Stomach Cancer|Gastroesophageal Junction Cancer,Drug: FLOT alone|Biological: FLOT + Herceptin/Pertuzumab,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Trium Analysis Online GmbH,Phase 2|Phase 3,81,Other|Industry,Jun-16,"July 17, 2020","July 17, 2020"
804,NCT02574078,A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Drug: Nivolumab|Drug: Bevacizumab|Drug: Pemetrexed|Other: Best Supportive Care|Drug: nab-Paclitaxel|Drug: Paclitaxel|Drug: Docetaxel|Drug: Gemcitabine|Drug: Erlotinib|Drug: Crizotinib|Drug: Carboplatin,Bristol-Myers Squibb,Phase 1|Phase 2,341,Industry,"November 23, 2015","April 15, 2020","April 15, 2020"
805,NCT02570308,A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,Uveal Melanoma,Drug: IMCgp100,Immunocore Ltd,Phase 1|Phase 2,146,Industry,"February 29, 2016","March 20, 2020","October 17, 2022"
806,NCT02562898,Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug: Ibrutinib|Drug: Paclitaxel|Drug: Gemcitabine,"Margaret Tempero|Stand Up To Cancer|Lustgarten Foundation|University of California, San Francisco",Phase 1|Phase 2,18,Other,"October 12, 2015","November 15, 2019","September 1, 2020"
807,NCT02561455,Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,Advanced Solid Tumors|Acute Myeloid Leukemia,Drug: Gilteritinib,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1|Phase 2,9,Industry,"May 3, 2016","July 28, 2020","July 28, 2020"
808,NCT02561273,Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma,"Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma",Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Prednisone|Drug: Vincristine Sulfate,University of Nebraska|National Cancer Institute (NCI),Phase 1|Phase 2,54,Other|NIH,Oct-15,Nov-19,Nov-20
809,NCT02561234,"A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors",Advanced Cancers,Drug: Co-ArgI-PEG,Aeglea Biotherapeutics,Phase 1|Phase 2,98,Industry,Oct-15,May-19,May-19
810,NCT02560779,Trial of TRC105 and Sorafenib in Patients With HCC,Hepatocellular Carcinoma,Drug: Carotuximab (TRC105)|Drug: Sorafenib,Tracon Pharmaceuticals Inc.,Phase 1|Phase 2,27,Industry,Nov-16,Aug-19,Aug-19
811,NCT02545907,A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis,Amyloidosis,Drug: Carfilzomib|Drug: Thalidomide|Drug: Dexamethasone,"University College, London",Phase 1|Phase 2,10,Other,"September 14, 2017","September 26, 2019","October 21, 2019"
812,NCT02541370,Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133,Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid Leukemias,Biological: anti-CD133-CAR vector-transduced T cells,Chinese PLA General Hospital,Phase 1|Phase 2,20,Other,Jun-15,Jun-19,Jun-19
813,NCT02535572,Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment,Depression,Device: FEAST|Device: RUL UB,Medical University of South Carolina|Augusta University,Phase 2|Phase 3,48,Other,Aug-15,"June 10, 2019","June 10, 2019"
814,NCT02528682,MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT,Hematological Malignancies,Biological: MiHA-loaded PD-L-silenced DC Vaccination,Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Cancer Society,Phase 1|Phase 2,10,Other,Jan-16,"March 31, 2021","March 31, 2021"
815,NCT02520076,Aralast NP in Islet Transplant,Type 1 Diabetes Mellitus,Drug: Alpha-1 Antitrypsin,University of Alberta|Shire,Phase 1|Phase 2,5,Other|Industry,Aug-15,"September 30, 2019","September 30, 2019"
816,NCT02517593,Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake,Breast Cancer,Genetic: Polygenic Risk Score,Mayo Clinic|CancerCare Manitoba,Phase 1|Phase 2,151,Other,Mar-16,"December 1, 2019","December 1, 2019"
817,NCT02515227,Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab,Melanoma,Biological: 6MHP|Drug: Pembrolizumab,"Craig L Slingluff, Jr|National Cancer Institute (NCI)|University of Virginia",Phase 1|Phase 2,22,Other|NIH,Nov-15,"March 14, 2020","March 14, 2020"
818,NCT02513472,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC),Breast Neoplasm,Drug: Eribulin Mesylate|Drug: Pembrolizumab,Eisai Inc.|Merck Sharp & Dohme LLC,Phase 1|Phase 2,258,Industry,"August 28, 2015","July 31, 2019","April 6, 2021"
819,NCT02504333,Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma,Metastatic Pancreatic Adenocarcinoma,Drug: nab-paclitaxel|Drug: gemcitabine|Drug: m-FOLFOX,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Phase 1|Phase 2,168,Other,Jul-15,Apr-21,Apr-21
820,NCT02501096,A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors,Tumors,Drug: Lenvatinib|Drug: Pembrolizumab,Eisai Inc.|Merck Sharp & Dohme LLC,Phase 1|Phase 2,357,Industry,"July 22, 2015","August 18, 2020","July 11, 2022"
821,NCT02496741,Metformin And Chloroquine in IDH1/2-mutated Solid Tumors,Glioma|Cholangiocarcinoma|Chondrosarcoma,Drug: Metformin and chloroquine combination,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 1|Phase 2,15,Other,Nov-15,"November 18, 2019","November 18, 2019"
822,NCT02496676,Magnesium Supplementation in People With XMEN Syndrome,XMEN,Dietary Supplement: Magnesium L-threonate|Other: Placebo|Drug: Intravenous (IV) magnesium sulfate (MgSO4),National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,8,NIH,"May 17, 2016","April 23, 2020","April 23, 2020"
823,NCT02490488,Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients,Ovarian Cancer,Drug: Masitinib|Drug: Gemcitabine|Drug: Placebo,AB Science,Phase 2|Phase 3,248,Industry,Apr-14,Dec-20,Dec-20
824,NCT02488759,"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",Various Advanced Cancer,Drug: Nivolumab|Drug: Ipilimumab|Drug: Relatlimab|Drug: Daratumumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 1|Phase 2,578,Industry,"October 13, 2015","March 19, 2021","October 24, 2022"
825,NCT02486406,A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects,Chronic Hepatitis C Infection,Drug: Ombitasvir/paritaprevir/ritonavir|Drug: Dasabuvir|Drug: Ribavirin|Drug: Ombitasvir mini tablet|Drug: Paritaprevir mini tablet|Drug: Ritonavir mini tablet|Drug: Dasabuvir mini tablet|Drug: Ribavirin solution,AbbVie,Phase 2|Phase 3,64,Industry,"October 28, 2015","November 19, 2020","November 19, 2020"
826,NCT02485899,An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease,Jansky-Bielschowsky Disease|Batten Disease|Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2|CLN2 Disease|CLN2 Disorder,Biological: BMN 190|Device: Intracerebroventricular (ICV) access device,BioMarin Pharmaceutical,Phase 1|Phase 2,23,Industry,Feb-15,"December 10, 2020","December 10, 2020"
827,NCT02483468,The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain,"Chronic Low Back Pain|Opioid Use, Unspecified",Behavioral: Cognitive Behavioral Therapy for Pain|Device: Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation,Medical University of South Carolina,Phase 2|Phase 3,160,Other,Aug-15,"April 28, 2021","April 28, 2021"
828,NCT02481440,Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI,Spinal Cord Injuries,Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs),"Limin Rong|Third Affiliated Hospital, Sun Yat-Sen University",Phase 1|Phase 2,102,Other,"March 30, 2018","March 31, 2020","March 31, 2020"
829,NCT02474199,Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction,Liver Transplant Recipient|Living Donor (of the Respective Liver Transplant Recipient),Biological: darTregs|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Immunosuppression (IS) Withdrawal|Procedure: Study Mandated Procedures,"National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation in Children|Rho Federal Systems Division, Inc.",Phase 1|Phase 2,15,NIH|Other|Industry,"June 6, 2016","December 16, 2019","December 16, 2019"
830,NCT02472054,Treatment of Familiar Lymphohistiocytosis,Hemophagocytic Lymphohistiocytosis (HLH),Drug: Alemtuzumab|Drug: Methyl Prednisolone (MP)|Drug: Cyclosporin A (CSA),Assistance Publique - Hôpitaux de Paris,Phase 1|Phase 2,29,Other,"June 29, 2015","September 12, 2019","May 20, 2020"
831,NCT02471716,Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor,Pigmented Villonodular Synovitis|Tenosynovial Giant Cell Tumor,Biological: FPA008,"Five Prime Therapeutics, Inc.",Phase 1|Phase 2,66,Industry,Jun-15,"April 30, 2020","April 30, 2020"
832,NCT02464657,"Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Nivolumab|Drug: Idarubicin|Drug: Cytarabine|Drug: Solu-medrol|Drug: Dexamethasone,M.D. Anderson Cancer Center|Bristol-Myers Squibb,Phase 1|Phase 2,44,Other|Industry,Jul-15,"May 7, 2020","May 7, 2020"
833,NCT02460224,Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,Advanced Solid Tumors,Drug: LAG525|Drug: PDR001,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,490,Industry,"June 17, 2015","December 31, 2020","December 31, 2020"
834,NCT02454205,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis,Tuberculosis|Multidrug Resistant Tuberculosis|Extensively-drug Resistant Tuberculosis,Drug: Linezolid|Drug: Bedaquiline|Drug: Levofloxacin|Drug: Pyrazinamide|Drug: Isoniazid|Drug: Ethionamide|Drug: Terizidone|Drug: Moxifloxacin|Drug: Kanamycin,University of Cape Town|University of Limpopo|Walter Sisulu University|University of Stellenbosch|University of Cape Town Lung Institute,Phase 2|Phase 3,154,Other,"November 12, 2015","December 31, 2020","August 30, 2021"
835,NCT02453516,The Effect of the Serratus Block on Pain Control After Breast Surgery,Anesthesia,Procedure: Serratus Block|Procedure: Placebo Block|Drug: ropivacaine|Drug: epinephrine|Other: sterile saline,Women's College Hospital,Phase 2|Phase 3,40,Other,"October 29, 2014","September 11, 2019","December 11, 2019"
836,NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,Breast Cancer Stage IV|Unresectable Locally Advanced Invasive Breast Cancer|Metastatic Invasive Breast Cancer,Drug: Palbociclib|Drug: Bazedoxifene,Dana-Farber Cancer Institute|Pfizer,Phase 1|Phase 2,36,Other|Industry,"July 9, 2015","August 12, 2019","March 3, 2021"
837,NCT02447991,Rizatriptan for Episodic Dizziness in Vestibular Migraine,Vestibular Migraine|Migrainous Vertigo,Drug: Rizatriptan|Drug: Placebo,"Robert W. Baloh|University of California, Los Angeles",Phase 2|Phase 3,223,Other,Dec-14,"July 31, 2020","July 31, 2020"
838,NCT02447406,"Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment",Advanced Gastric Adenocarcinoma,Drug: AZD6094|Drug: docetaxel,Samsung Medical Center,Phase 1|Phase 2,7,Other,"April 30, 2015","June 30, 2020","September 20, 2020"
839,NCT02442440,Anisodamine Critically Ill SeptIc Shock,Septic Shock,Drug: anisodamine,Jinhua Central Hospital,Phase 1|Phase 2,355,Other,Apr-15,Oct-20,"October 1, 2020"
840,NCT02441283,A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530,Hepatitis C,Drug: ABT-493|Drug: ABT-530,AbbVie,Phase 2|Phase 3,384,Industry,"June 22, 2015","October 15, 2019","October 15, 2019"
841,NCT02436252,Study of DSP-7888 in Patients With Myelodysplastic Syndrome,Myelodysplastic Syndrome,Drug: DSP-7888,"Sumitomo Pharma Co., Ltd.",Phase 1|Phase 2,48,Industry,May-15,Mar-20,Mar-20
842,NCT02432274,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC),Drug: Lenvatinib|Drug: Ifosfamide|Drug: Etoposide,Eisai Limited|Merck Sharp & Dohme LLC|Eisai Inc.,Phase 1|Phase 2,117,Industry,"December 29, 2014","July 18, 2019","July 20, 2022"
843,NCT02429375,Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,Hodgkin Lymphoma,Drug: Mocetinostat Plus Brentuximab Vedotin,Memorial Sloan Kettering Cancer Center|MethylGene Inc.,Phase 1|Phase 2,7,Other|Industry,"April 22, 2015","February 17, 2021","February 17, 2021"
844,NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,Metastatic Melanoma,Biological: Melanoma antigens-specific CD8+ T lymphocytes,Nantes University Hospital|UMR892,Phase 1|Phase 2,7,Other,"May 26, 2015","May 6, 2019","May 6, 2019"
845,NCT02421185,"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","Carcinoma, Hepatocellular",Drug: JNJ-42756493 (erdafitinib),"Janssen Research & Development, LLC",Phase 1|Phase 2,53,Industry,"May 25, 2015","May 13, 2019","May 16, 2019"
846,NCT02419417,Study of BMS-986158 in Subjects With Select Advanced Cancers,Advanced Tumors,Drug: BMS-986158|Biological: Nivolumab,Bristol-Myers Squibb,Phase 1|Phase 2,83,Industry,"June 19, 2015","March 17, 2021","March 17, 2021"
847,NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: Selinexor|Drug: Cladribine|Drug: G-CSF|Drug: Cytarabine|Procedure: Bone marrow biopsy,Washington University School of Medicine|Karyopharm Therapeutics Inc,Phase 1|Phase 2,40,Other|Industry,"June 16, 2015","June 21, 2019","June 21, 2019"
848,NCT02414945,TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients,Pleural Mesothelioma,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Autologous tumor infiltrating lymphocytes (TILs)|Biological: Interleukin-2,"University Health Network, Toronto",Phase 1|Phase 2,9,Other,"May 15, 2015",Oct-20,Oct-20
849,NCT02414607,Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment,Mild Cognitive Impairment,Biological: Elderberry Juice|Other: Placebo,University of Missouri-Columbia,Phase 1|Phase 2,24,Other,Sep-16,Dec-19,Dec-19
850,NCT02409810,Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes,Anxiety|Burns,Drug: Dexmedetomidine,Ohio State University,Phase 1|Phase 2,20,Other,Apr-15,"March 20, 2020","March 20, 2020"
851,NCT02406742,"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","Leukemia, Lymphocytic, Chronic, B-Cell",Drug: CC-122|Drug: Ibrutinib|Drug: Obinutuzumab,Celgene,Phase 1|Phase 2,47,Industry,"July 27, 2015","July 7, 2020","July 7, 2020"
852,NCT02406170,Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma,Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis,Drug: Regorafenib|Drug: Paclitaxel,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 1|Phase 2,47,Other,Apr-15,Oct-19,Oct-19
853,NCT02405338,DC Vaccination for Post-remission Therapy in AML,Acute Myeloid Leukemia,Biological: WT1/PRAME vaccination,Medigene AG,Phase 1|Phase 2,20,Industry,Mar-15,Nov-19,Nov-19
854,NCT02404441,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,Melanoma|Non-small Sell Lung Cancer (NSCLC)|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors,Biological: PDR001,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,319,Industry,"April 27, 2015","July 21, 2020","July 21, 2020"
855,NCT02401815,CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors,Gastrointestinal Stromal Tumors,Drug: PLX9486|Drug: Pexidartinib|Drug: Sunitinib,"Cogent Biosciences, Inc.|Plexxikon",Phase 1|Phase 2,51,Industry,"March 6, 2015","May 11, 2020","May 11, 2020"
856,NCT02400281,Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,Acute Myeloid Leukemia,Drug: Crenolanib besylate|Drug: Idarubicin|Drug: Cytarabine|Drug: Azacytidine|Drug: Mitoxantrone|Drug: Etoposide|Drug: Fludarabine|Drug: G-CSF,"Arog Pharmaceuticals, Inc.",Phase 1|Phase 2,28,Industry,Sep-15,"July 15, 2020","July 15, 2020"
857,NCT02397889,Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD),Posttraumatic Stress Disorder (PTSD),Drug: Ketamine|Drug: Midazolam,Icahn School of Medicine at Mount Sinai,Phase 2|Phase 3,30,Other,"May 18, 2015","January 27, 2020","January 27, 2020"
858,NCT02396342,Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B,Hemophilia B,Genetic: AAV5-hFIX,CSL Behring,Phase 1|Phase 2,10,Industry,"June 10, 2015","April 15, 2021","April 15, 2021"
859,NCT02392871,Radiotherapy & Combi in Metastatic Melanoma,Metastatic Melanoma,Radiation: Palliative radiotherapy|Drug: Dabrafenib and trametinib (combination),Melanoma and Skin Cancer Trials Limited|Melanoma Institute Australia,Phase 1|Phase 2,10,Other,May-15,"September 23, 2019","April 17, 2020"
860,NCT02386397,Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer,Digestive Cancer,Drug: Regorafenib|Drug: GEMOX,Institut du Cancer de Montpellier - Val d'Aurelle,Phase 1|Phase 2,66,Other,Sep-14,Dec-19,Dec-19
861,NCT02383108,Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children,HIV Infection,Drug: DTG +DRV/r|Drug: SOC,"PENTA Foundation|Institut National de la Santé Et de la Recherche Médicale, France|MRC CTU at UCL|PHPT",Phase 2|Phase 3,318,Other,Jun-16,Aug-20,Oct-20
862,NCT02372006,Trial of Afatinib in Pediatric Tumours,Neuroectodermal Tumors|Rhabdomyosarcoma,Drug: afatinib,Boehringer Ingelheim,Phase 1|Phase 2,56,Industry,"April 29, 2015","August 5, 2020","August 5, 2020"
863,NCT02371447,VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer,Bladder Cancer,Drug: VPM1002BC,Swiss Group for Clinical Cancer Research,Phase 1|Phase 2,39,Other,"September 8, 2015","October 22, 2019","March 7, 2023"
864,NCT02364206,Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma,Adult Glioblastoma,Drug: LY2228820|Drug: Temozolomide|Radiation: radiotherapy,"Centre Jean Perrin|National Cancer Institute, France|ARC Foundation for Cancer Research",Phase 1|Phase 2,18,Other,"June 8, 2015",Aug-19,Aug-19
865,NCT02351180,Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients,Lung Transplant Infection,Drug: Inhaled beclomethasone|Drug: Placebo,Washington University School of Medicine,Phase 1|Phase 2,16,Other,"February 1, 2017","January 31, 2021","January 31, 2021"
866,NCT02351102,Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy,Congenital Cytomegalovirus Infection,Drug: Valacyclovir|Drug: Placebo,Rabin Medical Center,Phase 2|Phase 3,100,Other,Nov-15,Jul-19,Jul-19
867,NCT02348008,Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:,Clear Cell Renal Carcinoma,Drug: MK-3475|Drug: Bevacizumab,"Arkadiusz Z. Dudek, MD|Merck Sharp & Dohme LLC|Big Ten Cancer Research Consortium",Phase 1|Phase 2,61,Other|Industry,Mar-15,"December 5, 2019","December 5, 2019"
868,NCT02343120,Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,B-cell Malignancies,Drug: Zanubrutinib,BeiGene,Phase 1|Phase 2,385,Industry,"September 4, 2014","March 31, 2021","March 31, 2021"
869,NCT02338999,Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE),Systemic Lupus Erythematosus,Radiation: PET/CT|Drug: Pioglitazone|Drug: Placebo,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,88,NIH,"June 18, 2015","July 14, 2020","July 14, 2020"
870,NCT02335905,Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children,Hematogenously Acquired Staphylococcus Aureus Osteomyelitis|Bone Infection|Osteomyelitis,Drug: Ceftaroline Fosamil,Baylor College of Medicine|Allergan,Phase 1|Phase 2,11,Other|Industry,"June 3, 2015","June 16, 2020","June 16, 2020"
871,NCT02335099,Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis,End Stage Renal Disease|Vascular Access Patency,Drug: ticagrelor|Drug: Placebo,University of Virginia|AstraZeneca,Phase 1|Phase 2,54,Other|Industry,Dec-14,Jun-19,Jun-19
872,NCT02329457,VZV Vaccine for Hematopoietic Stem Cell Transplantation,Varicella Zoster Infection,Biological: Zostavax|Biological: Normal Saline,The University of Hong Kong,Phase 2|Phase 3,100,Other,Dec-14,Sep-19,Oct-19
873,NCT02327078,"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma,Drug: Nivolumab|Drug: Epacadostat|Drug: Chemotherapy,Incyte Corporation|Bristol-Myers Squibb,Phase 1|Phase 2,307,Industry,"November 26, 2014","June 16, 2020","June 16, 2020"
874,NCT02325739,FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression,Hepatocellular Carcinoma (HCC)|Solid Malignancies,Drug: FGF401|Biological: PDR001,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,172,Industry,"December 29, 2014","May 30, 2019","May 30, 2019"
875,NCT02324543,Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug: Gemcitabine|Drug: Taxotere|Drug: Xeloda|Drug: Cisplatin|Drug: Irinotecan,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Swim Across America Laboratory,Phase 1|Phase 2,47,Other,Feb-15,Jun-19,Feb-20
876,NCT02323698,Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury,Spinal Cord Injuries,Drug: Caffeine|Other: AIH|Other: Placebo|Other: SHAM,Spaulding Rehabilitation Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1|Phase 2,36,Other|NIH,"January 1, 2019","March 19, 2021","February 19, 2022"
877,NCT02318277,A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203),Solid Tumors|Head and Neck Cancer|Lung Cancer|UC (Urothelial Cancer),Drug: MEDI4736|Drug: INCB024360,Incyte Corporation|AstraZeneca,Phase 1|Phase 2,176,Industry,"January 5, 2015","August 28, 2019","October 16, 2020"
878,NCT02311361,Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,Pancreatic Neoplasms|Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer,Biological: Durvalumab|Biological: Tremelimumab|Radiation: Sterostatic body radiation therapy (SBRT),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,65,NIH,"March 25, 2015","October 23, 2019","December 31, 2020"
879,NCT02308553,Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma,Cutaneous Malignant Melanoma,Drug: Nintedanib|Drug: Nintedanib-Placebo|Drug: Paclitaxel,"Prof. Dr. med. Dirk Schadendorf|Boehringer Ingelheim|medac GmbH|Alcedis GmbH|University Hospital, Essen",Phase 1|Phase 2,33,Other|Industry,"March 17, 2015","October 17, 2019",Nov-19
880,NCT02294630,Aerosolized Surfactant in Neonatal RDS,"Respiratory Distress Syndrome, Newborn",Drug: Surfactant,"Sood, Beena G., MD, MS",Phase 1|Phase 2,159,Other,Dec-14,Jul-19,Jul-20
881,NCT02292654,"Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency",Sphingomyelin Lipidosis,Drug: Olipudase alfa,"Genzyme, a Sanofi Company|Sanofi",Phase 1|Phase 2,20,Industry,"May 1, 2015","December 9, 2019","December 9, 2019"
882,NCT02291432,Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery,Urinary Incontinence|Stress|Urination Disorders|Urologic Diseases|Lower Urinary Tract Symptoms|Urological Manifestations,Biological: autologous muscle-derived cells (AMDC),Cook MyoSite,Phase 1|Phase 2,25,Industry,"February 19, 2015","June 28, 2019","June 28, 2019"
883,NCT02291133,Treatment of Primary Liver Tumors With Electrochemotherapy (ECT),Liver Cancer,Procedure: Electrochemotherapy|Device: Cliniporator Vitae®|Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP),Masa Bosnjak|Institute of Oncology Ljubljana|University of Ljubljana|University Medical Centre Ljubljana,Phase 1|Phase 2,25,Other,Jun-14,Sep-19,Jan-20
884,NCT02290041,Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response,Discordant Immunological Response in HIV Infected Subjects,Drug: Infusion of MSC|Drug: Infusion of placebo,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,Phase 1|Phase 2,5,Other,"February 8, 2017","July 30, 2019","July 30, 2019"
885,NCT02281500,"Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia",Congenital Afibrinogenemia,Biological: Human Plasma-Derived Fibrinogen Concentrate,"Grifols Therapeutics LLC|Instituto Grifols, S.A.",Phase 1|Phase 2,24,Industry,"July 22, 2016","November 11, 2019","November 11, 2019"
886,NCT02281409,"Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors",Advanced Solid Tumors|Metastatic Solid Tumors,Biological: Mogamulizumab (KW-0761),"Memorial Sloan Kettering Cancer Center|Kyowa Hakko Kirin Pharma, Inc.",Phase 1|Phase 2,17,Other|Industry,Oct-14,Feb-20,Feb-20
887,NCT02280317,Dose Finding Safety Study of VAL201 in Cancer Patients,Stage III Prostate Carcinoma|Stage IV Prostate Carcinoma,Drug: VAL201,ValiRx Plc,Phase 1|Phase 2,12,Industry,Oct-14,"January 27, 2020","January 27, 2020"
888,NCT02279719,"A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",Hepatocellular Carcinoma,Drug: BBI608|Drug: BBI503|Drug: Sorafenib,"Sumitomo Pharma Oncology, Inc.",Phase 1|Phase 2,97,Industry,Dec-14,Jul-19,Oct-19
889,NCT02265731,Study Evaluating Venetoclax in Subjects With Hematological Malignancies,Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Acute Myeloid Leukemia (AML),Drug: azacitadine|Drug: venetoclax|Drug: rituximab / IDEC-C2B8,"AbbVie|Genentech, Inc.",Phase 1|Phase 2,38,Industry,"September 22, 2014","March 12, 2021","March 12, 2021"
890,NCT02264613,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,Solid Tumor|Lymphoma|Peripheral T-Cell Lymphoma,Drug: ALRN-6924,"Aileron Therapeutics, Inc.",Phase 1|Phase 2,149,Industry,Oct-14,Mar-20,Apr-20
891,NCT02262299,"European Trial of Pirfenidone in BOS, A European Multi-center Study","Disorder Related to Lung Transplantation|CLAD, Bronchiolitis Obliterans",Drug: Pirfenidone|Drug: Placebo,"Rigshospitalet, Denmark",Phase 2|Phase 3,90,Other,May-15,Dec-19,Dec-19
892,NCT02261714,Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer,"Pancreatic Cancer, Resected",Biological: TG01,Targovax ASA,Phase 1|Phase 2,32,Industry,Dec-12,May-19,May-19
893,NCT02257138,Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia,Blasts More Than 20 Percent of Bone Marrow Nucleated Cells|Blasts More Than 20 Percent of Peripheral Blood White Cells|Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia,Drug: Decitabine|Other: Laboratory Biomarker Analysis|Drug: Ruxolitinib Phosphate,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,30,Other|NIH,"February 12, 2015","March 19, 2021","March 19, 2021"
894,NCT02255617,Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study,Hepatic Encephalopathy,Biological: Fecal Microbiota Transplant,University of Alberta,Phase 1|Phase 2,4,Other,"July 23, 2014","July 25, 2019","September 23, 2019"
895,NCT02250664,"Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers",Tobacco Use Disorder,Other: Very low nicotine content cigarettes,University of Vermont|Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 1|Phase 2,775,Other|NIH,Oct-16,Oct-19,Oct-19
896,NCT02250534,"Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women",Tobacco Use Disorder,Other: Very low nicotine content cigarettes,University of Vermont|Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 1|Phase 2,775,Other|NIH,Oct-16,Oct-19,Oct-19
897,NCT02250300,MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation,Allogeneic Hematopoietic Stem Cell Transplantation,Drug: MLN9708 (2.3 mg)|Drug: MLN9708 (4.0 mg)|Drug: MLN9708 (3.0 mg),Mehdi Hamadani|Medical College of Wisconsin,Phase 1|Phase 2,68,Other,"November 19, 2014","October 6, 2020","October 6, 2020"
898,NCT02248636,Cholinesterase Inhibitor Discontinuation,Dementia,Drug: Cholinesterase inhibitor|Drug: Sham discontinuation,VA Office of Research and Development,Phase 2|Phase 3,72,U.S. Fed,"January 22, 2015","October 1, 2019","October 1, 2019"
899,NCT02247193,Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair,Cleft Lip|Scarring|Cleft Palate,Drug: Botulinum Toxin Type A|Drug: Normal Saline Injection,"The University of Texas Health Science Center, Houston",Phase 1|Phase 2,30,Other,Dec-15,"January 13, 2020","January 13, 2020"
900,NCT02244632,Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer,Colorectal Neoplasm,Drug: Modufolin (arfolitixorin)|Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Bevacizumab,Isofol Medical AB,Phase 1|Phase 2,105,Industry,Sep-14,"January 30, 2020","January 30, 2020"
901,NCT02240238,"Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",Solid Tumors,Drug: NC-6004|Drug: Gemcitabine,"NanoCarrier Co., Ltd.",Phase 1|Phase 2,209,Industry,May-14,"May 6, 2019","May 6, 2019"
902,NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,Breast Cancer,Drug: Neratinib|Drug: T-DM1,"NSABP Foundation Inc|Puma Biotechnology, Inc.",Phase 1|Phase 2,49,Other|Industry,Aug-14,Dec-20,Aug-21
903,NCT02231879,Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome,Myelokathexis|Infections|Neutropenia|Warts|Hypogammaglobulinemia,Drug: Plerixafor|Drug: G-CSF,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 2|Phase 3,20,NIH,"October 14, 2014","October 8, 2020","February 24, 2021"
904,NCT02225366,Intratumoral Injections of LL37 for Melanoma,Melanoma,Biological: LL37|Other: Photographs,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,4,Other|NIH,"July 8, 2015","November 24, 2020","November 24, 2020"
905,NCT02221219,Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury,Intraventricular Hemorrhage|Periventricular Leukomalacia|Brain Injury|Renal Injury,Drug: Indomethacin|Procedure: delay in umbilical cord clamp at birth|Drug: placebo infusion|Procedure: immediate cord clamp at birth,Hong Huang|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Kentucky,Phase 1|Phase 2,256,Other|NIH,Aug-14,"October 27, 2019","August 28, 2021"
906,NCT02213705,Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells,SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT,Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS,Assistance Publique - Hôpitaux de Paris,Phase 1|Phase 2,20,Other,"May 6, 2014","February 9, 2020","June 16, 2022"
907,NCT02199496,"Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency",Gastrointestinal Inflammation Associated With CVID|CVID Enteropathy,Biological: Stelara (ustekinumab),National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,5,NIH,"October 19, 2015","August 16, 2019","July 10, 2020"
908,NCT02193958,Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies,AML|CMML|MDS,Drug: FF-10501-01,"Fujifilm Pharmaceuticals U.S.A., Inc.",Phase 1|Phase 2,41,Industry,Jul-14,"August 9, 2019","October 15, 2019"
909,NCT02172976,Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma,Resectable Prancreas Carcinoma,Drug: Gemcitabine|Drug: Oxaliplatin|Drug: 5-Fluorouracil|Drug: Irinotecan|Drug: Natriumfolinate,Krankenhaus Nordwest,Phase 2|Phase 3,40,Other,Nov-14,Jan-20,May-20
910,NCT02168686,Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency,Alpha 1-Antitrypsin Deficiency,Genetic: ADVM-043,"Adverum Biotechnologies, Inc.",Phase 1|Phase 2,6,Industry,"November 28, 2017","August 29, 2019","August 29, 2019"
911,NCT02166944,Tamoxifen Treatment in Patients With Motor Neuron Disease,Amyotrophic Lateral Sclerosis|ALS Functional Ration Scale|TAR-DNA-binding Protein-43|Tamoxifen|mTOR,Drug: tamoxifen 40 mg daily for one year,Taipei Medical University Shuang Ho Hospital,Phase 1|Phase 2,20,Other,Apr-14,"September 17, 2019","September 18, 2019"
912,NCT02166905,"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Carcinoma,Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Drug: Epacadostat|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Poly ICLC,Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celldex Therapeutics|Incyte Corporation,Phase 1|Phase 2,40,Other|NIH|Industry,"October 10, 2014","August 20, 2020","August 20, 2020"
913,NCT02163226,A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms,Bone Metastases,Radiation: Hypofractionated Radiation Treatment|Radiation: One Radiation Treatment|Behavioral: Questionnaire,M.D. Anderson Cancer Center,Phase 2|Phase 3,167,Other,"August 6, 2014","September 2, 2020","September 2, 2020"
914,NCT02160808,Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection,Injury of Body of Pancreas,Drug: Secretin|Drug: Placebo,Dartmouth-Hitchcock Medical Center,Phase 2|Phase 3,170,Other,May-14,"September 21, 2019","September 21, 2019"
915,NCT02160470,Enhancing Exposure Therapy for Snake and Spider Phobias,Specific Phobia,Behavioral: Exposure Therapy with Retrieval|Behavioral: Exposure Therapy with Compound Extinction|Behavioral: Exposure Therapy with Retrieval and Compound Extinction|Behavioral: Therapist-guided Exposure Therapy,University of Texas at Austin|National Institute of Mental Health (NIMH),Phase 1|Phase 2,120,Other|NIH,Aug-12,Dec-19,Dec-19
916,NCT02150993,First-Line Treatment for HIV-2,HIV-2 Infection,Drug: Tenofovir + Emtricitabine or Lamivudine + Zidovudine|Drug: Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|Drug: Tenofovir + Emtricitabine or Lamivudine + Raltegravir,"ANRS, Emerging Infectious Diseases",Phase 2|Phase 3,210,Other,"January 26, 2016","May 15, 2019","May 15, 2019"
917,NCT02140151,Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration,Age-related Macular Degeneration,Drug: Ranibizumab 0.5mg,"Southern California Desert Retina Consultants, MC",Phase 1|Phase 2,108,Other,"September 17, 2014","July 9, 2020","July 9, 2020"
918,NCT02132130,"Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss",Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss,Drug: CGF166,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,22,Industry,"June 23, 2014","December 9, 2019","December 9, 2019"
919,NCT02131467,Safety and Tolerability of Perampanel in Cervical Dystonia,Cervical Dystonia,Drug: Perampanel,"University Health Network, Toronto|Dystonia Study Group",Phase 1|Phase 2,25,Other,"September 1, 2017","February 28, 2020","February 28, 2020"
920,NCT02128282,Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,Cholangiocarcinoma,Drug: CX-4945|Drug: Cisplatin|Drug: Gemcitabine,"Senhwa Biosciences, Inc.",Phase 1|Phase 2,127,Industry,Jun-14,"November 6, 2020","August 5, 2021"
921,NCT02124772,"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",Cancer,Drug: Trametinib|Drug: Dabrafenib,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,139,Industry,"January 15, 2015","December 29, 2020","December 29, 2020"
922,NCT02121639,"Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy",Prostate Cancer,Drug: Placebo|Drug: AZD5363,University Hospital Southampton NHS Foundation Trust|AstraZeneca|Cancer Research UK,Phase 1|Phase 2,160,Other|Industry,"January 29, 2014","October 8, 2020","September 13, 2021"
923,NCT02118337,"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",Select Advanced Malignancies|Kidney Cancer|Clear Cell Renal Cell Carcinoma,Biological: MEDI0680|Biological: Durvalumab|Biological: Nivolumab,MedImmune LLC,Phase 1|Phase 2,97,Industry,"May 19, 2014","March 17, 2020","March 17, 2020"
924,NCT02113982,SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Acute Myeloid Leukemia,Drug: SL-401,"Stemline Therapeutics, Inc.|The Leukemia and Lymphoma Society",Phase 1|Phase 2,138,Other,Sep-14,"February 1, 2020","March 12, 2020"
925,NCT02111850,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive,Cervical Cancer|Renal Cancer|Urothelial Cancer|Melanoma|Breast Cancer,Biological: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,21,NIH,"February 7, 2014","March 24, 2021","March 24, 2021"
926,NCT02111798,Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence,Substance Abuse|Cocaine Dependence,Drug: Placebo|Drug: Bupropion XL|Behavioral: Abstinence Initiation|Behavioral: Relapse Prevention,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 2|Phase 3,83,Other|NIH,Jul-14,May-20,Jan-21
927,NCT02094118,Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications,Blood Transfusion Complications,Biological: Point-of-care washed red blood cell transfusion.|Biological: Standard of care red blood cell transfusion.,Mayo Clinic|Duke University|Blood Systems Research Institute,Phase 1|Phase 2,171,Other,Jan-16,"May 30, 2019","May 30, 2019"
928,NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),Renal Cell Carcinoma|Melanoma,Biological: Pembrolizumab|Biological: PegIFN-2b|Biological: Ipilimumab,Merck Sharp & Dohme LLC,Phase 1|Phase 2,295,Industry,"March 17, 2014","April 1, 2021","April 1, 2021"
929,NCT02087631,Safety and Tolerability of Quetiapine in Multiple Sclerosis,Multiple Sclerosis,Drug: Extended-release quetiapine fumarate,University of Calgary|Multiple Sclerosis Society of Canada,Phase 1|Phase 2,14,Other,Dec-14,Jul-19,Jul-19
930,NCT02077166,Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Ibrutinib|Drug: Lenalidomide|Drug: Rituximab,"Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation",Phase 1|Phase 2,138,Industry,"March 13, 2014","December 17, 2020","December 17, 2020"
931,NCT02071459,Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA,Multiple System Atrophy,Drug: L-Threo DOPS|Drug: placebo,"University Hospital, Toulouse",Phase 2|Phase 3,107,Other,"January 21, 2014","October 28, 2019","October 28, 2019"
932,NCT02067975,Tryptophan MRI in People With Schizophrenia and Healthy Controls,Schizophrenia,Drug: Tryptophan|Drug: Placebo,"University of Maryland, Baltimore|Mitsubishi Tanabe Pharma Corporation|National Institute of Mental Health (NIMH)",Phase 2|Phase 3,93,Other|Industry|NIH,Sep-14,Dec-19,Dec-19
933,NCT02066532,Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,Metastatic Breast Cancer|Breast Carcinoma|HER-2 Positive Breast Cancer,Drug: Ruxolitinib|Drug: Trastuzumab,Dawn L. Hershman|Incyte Corporation|National Cancer Institute (NCI)|Columbia University,Phase 1|Phase 2,28,Other|Industry|NIH,Jun-14,"October 14, 2020","October 14, 2020"
934,NCT02065245,AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery,Frailty,Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo|Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs),"Longeveron Inc.|The Emmes Company, LLC",Phase 1|Phase 2,65,Industry,"March 3, 2014","October 2, 2019","October 2, 2020"
935,NCT02064569,Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients,Leber Hereditary Optic Neuropathy,Genetic: GS010,GenSight Biologics,Phase 1|Phase 2,19,Industry,"February 13, 2014","June 25, 2020","June 25, 2020"
936,NCT02061397,Safety of Simvastatin in LAM and TSC,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,Drug: Simvastatin|Drug: Sirolimus Oral Product|Drug: Everolimus Oral Product,University of Pennsylvania|The LAM Foundation,Phase 1|Phase 2,10,Other,Mar-14,"December 13, 2019","December 13, 2019"
937,NCT02059239,Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma,Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Carmustine|Drug: Etoposide|Drug: Melphalan|Drug: Cytarabine|Drug: Alemtuzumab|Biological: Autologous Stem Cell Transplantation|Biological: Allogeneic Stem Cell Transplantation|Drug: Rituximab,Weill Medical College of Cornell University,Phase 1|Phase 2,34,Other,"June 4, 2014","December 16, 2019","June 15, 2020"
938,NCT02058095,Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3),Cardiomyopathy|Renal Impairment,Drug: Tadalafil|Drug: Placebo,Mayo Clinic,Phase 1|Phase 2,22,Other,Mar-14,Jun-19,Dec-19
939,NCT02054208,Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease,Alzheimer's Disease,Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL,Medipost Co Ltd.,Phase 1|Phase 2,46,Industry,Mar-14,Dec-19,Dec-19
940,NCT02053363,Tranexamic Acid Dosing in Adult Spinal Deformity Surgery,Adult Spinal Deformity,Drug: Tranexamic Acid (Cyklokapron),Washington University School of Medicine|AOSpine North America,Phase 2|Phase 3,64,Other|Industry,Mar-14,"June 26, 2020","June 26, 2020"
941,NCT02043899,A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma,Metastatic Neuroblastoma,Drug: [124I]meta-Iodobenzylguanidine,Cancer Research UK,Phase 1|Phase 2,36,Other,Feb-14,"October 15, 2020","October 15, 2020"
942,NCT02034409,A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis,"Osteoarthritis, Degenerative",Device: Pulsed Low Intensity Ultrasound|Device: Sham Comparator,VA Office of Research and Development,Phase 1|Phase 2,140,U.S. Fed,"May 22, 2015","June 1, 2020","September 30, 2020"
943,NCT02030067,Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies,Solid Tumor|Metastatic Bladder Cancer,Drug: RX-3117,"Rexahn Pharmaceuticals, Inc.",Phase 1|Phase 2,124,Industry,Dec-13,Jul-19,Dec-19
944,NCT02018861,"A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)",B-Cell Malignancies,Drug: Parsaclisib|Drug: Itacitinib|Drug: Rituximab|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide,Incyte Corporation,Phase 1|Phase 2,88,Industry,"September 22, 2016","April 12, 2021","April 12, 2021"
945,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,Breast Cancer,Biological: LA TNBC: DC vaccine+Preop chemo|Biological: ER+/HER2-BC:DC vaccine+Preop chemo,Baylor Research Institute,Phase 1|Phase 2,10,Other,May-14,"September 18, 2019","September 18, 2019"
946,NCT02012296,Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer,Drug: enzalutamide|Drug: mifepristone|Other: laboratory biomarker analysis|Other: pharmacological study,University of Chicago|National Cancer Institute (NCI),Phase 1|Phase 2,88,Other|NIH,"December 13, 2013","June 10, 2019","August 1, 2020"
947,NCT02009332,Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer,Non-muscle Invasive Bladder Cancer (NMIBC),Drug: ABI-009|Drug: Gemcitabine,"Aadi Bioscience, Inc.|National Cancer Institute (NCI)",Phase 1|Phase 2,21,Industry|NIH,"April 9, 2014","December 1, 2019","December 1, 2019"
948,NCT02006147,Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO,Central Retinal Vein Occlusion With Macular Edema|Branch Retinal Vein Occlusion With Macular Edema,Drug: TLC399,Taiwan Liposome Company,Phase 1|Phase 2,14,Industry,Nov-14,"July 15, 2020","July 15, 2020"
949,NCT02004418,A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland,Prostatic Neoplasms,Radiation: 11C-Choline,AHS Cancer Control Alberta,Phase 1|Phase 2,21,Other,Mar-14,Nov-19,Sep-20
950,NCT02001623,Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors,Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer(NSCLC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN),Drug: Tisotumab Vedotin (HuMax-TF-ADC),Seagen Inc.|Genmab,Phase 1|Phase 2,195,Industry,"November 30, 2013","May 2, 2019","May 2, 2019"
951,NCT01994382,"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL",Follicular Lymphoma (FL/Indolent NHL)|Aggressive NHL (a NHL)|Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|T-cell Lymphoma (PTCL and CTCL)|B-cell Non Hodgkin Lymphoma (NHL),Drug: Cerdulatinib|Biological: Rituximab,Alexion|Portola Pharmaceuticals,Phase 1|Phase 2,260,Industry,"August 30, 2013","December 15, 2020","December 15, 2020"
952,NCT01989546,"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",Advanced Ovarian Cancer|Primary Peritoneal Cancer|Advanced Breast Cancer|Advanced Solid Tumors,Drug: BMN 673,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,9,NIH,"February 4, 2014","March 26, 2020","March 26, 2020"
953,NCT01986075,A Sequenced Behavioral and Medication Intervention for Cocaine Dependence,Cocaine Dependence,Behavioral: Computer-assisted behavior therapy|Drug: Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Drug: Placebo,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),Phase 1|Phase 2,145,Other|NIH,Jan-14,Jan-21,Jan-21
954,NCT01981720,Extension Study of PRX-102 for up to 60 Months,Fabry Disease,Biological: PRX-102 (pegunigalsidase alfa),Protalix,Phase 1|Phase 2,15,Industry,"January 16, 2014","August 26, 2020","November 9, 2021"
955,NCT01976585,In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,Low-Grade B-cell Lymphoma,Drug: rhuFlt3L/CDX-301|Drug: Poly-ICLC,Joshua Brody|Celldex Therapeutics|Icahn School of Medicine at Mount Sinai,Phase 1|Phase 2,21,Other|Industry,"January 3, 2014","November 20, 2020","November 20, 2020"
956,NCT01970176,Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2),Cardiomyopathy|Renal Impairment,Drug: Tadalafil|Drug: Placebo,Mayo Clinic,Phase 1|Phase 2,20,Other,"January 9, 2014",Sep-19,Sep-19
957,NCT01962246,Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction,Gastroesophageal Junction Adenocarcinoma,Drug: Oxaliplatin; Capecitabine|Other: Oxaliplatin; Capecitabine; concurrent radiotherapy,Hebei Medical University,Phase 2|Phase 3,169,Other,Feb-12,Feb-20,Aug-21
958,NCT01946711,Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi,Rhinosinusitis|Chronic Polyposis,Drug: Budesonide,Pari Pharma GmbH,Phase 1|Phase 2,14,Industry,"August 28, 2013","February 3, 2020","June 21, 2021"
959,NCT01942122,DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis,Endometrioma|Visual Analogue Pain Scale: Moderate or Severe Pain,Drug: DLBS1442 100|Drug: Mefenamic acid|Drug: DLBS1442 200,Dexa Medica Group,Phase 2|Phase 3,60,Industry,Oct-15,Feb-21,Apr-21
960,NCT01937247,Redesigned Process in the Operating Room,"Non-operative Time|General Surgery, Above 18 Years of Age",Procedure: Patients will be inducted in the induction room|Procedure: Redesigned process|Drug: patient will be reversed with sugammadex 4mg/kg IV|Procedure: STANDARD PROCESS,American University of Beirut Medical Center|Merck Sharp & Dohme LLC,Phase 2|Phase 3,120,Other|Industry,"May 18, 2018","October 30, 2020","October 30, 2020"
961,NCT01935635,A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB,Chronic Hepatitis B,Biological: HPDCs-T immune therapy,"Third Affiliated Hospital, Sun Yat-Sen University|Ruijin Hospital|Second People's Hospital of Yunnan Province",Phase 1|Phase 2,400,Other,Jan-15,Dec-19,Dec-19
962,NCT01926587,Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine,Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia,Drug: oral rigosertib|Drug: Azacitidine,"Onconova Therapeutics, Inc.",Phase 1|Phase 2,45,Industry,Aug-13,"December 8, 2020","February 16, 2021"
963,NCT01922921,Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy,HER2/Neu Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer,Biological: HER-2/neu Intracellular Domain Protein|Other: Laboratory Biomarker Analysis|Biological: Pertuzumab|Other: Placebo|Biological: Polysaccharide-K|Biological: Trastuzumab,University of Washington|National Cancer Institute (NCI)|National Center for Complementary and Integrative Health (NCCIH),Phase 1|Phase 2,31,Other|NIH,"February 5, 2014","October 31, 2019","September 1, 2021"
964,NCT01898221,Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation,Ventricular Tachycardia|Atrial Fibrillation,Drug: Ethanol|Procedure: Ablation,"Miguel X. Valderrabano, MD|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|The Methodist Hospital Research Institute",Phase 2|Phase 3,423,Other|NIH,Oct-13,Dec-19,Dec-19
965,NCT01896856,Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer,Previously Treated Metastatic Colorectal Cancer,Drug: SGI-110 Dose Escalation|Drug: Regorafenib|Drug: TAS-102|Drug: SGI-110|Drug: Irinotecan,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Van Andel Research Institute|Astex Pharmaceuticals, Inc.",Phase 1|Phase 2,118,Other|Industry,"October 23, 2013","August 26, 2019","August 26, 2019"
966,NCT01896102,A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD),Cerebral Adrenoleukodystrophy (CALD),Genetic: Lenti-D Drug Product (eli-cel),bluebird bio,Phase 2|Phase 3,32,Industry,"August 21, 2013","March 26, 2021","March 26, 2021"
967,NCT01893320,Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,Leukemia,Drug: Vosaroxin|Drug: Decitabine,M.D. Anderson Cancer Center|Sunesis Pharmaceuticals,Phase 1|Phase 2,66,Other|Industry,"July 18, 2013","January 11, 2021","January 11, 2021"
968,NCT01885897,IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndromes (MDS)|Lymphoma|Myeloma|Chronic Lymphocytic Leukemia (CLL)|Chronic Myelogenous Leukemia (CML),Biological: ALT-803,"Masonic Cancer Center, University of Minnesota",Phase 1|Phase 2,33,Other,"November 11, 2013",Jul-19,Jul-20
969,NCT01882361,Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone,Opiate Dependence|Human Immunodeficiency Virus,Drug: injectable naltrexone|Drug: placebo comparator,University of Pennsylvania|National Institute on Drug Abuse (NIDA),Phase 2|Phase 3,77,Other|NIH,Jun-13,"July 31, 2020","July 31, 2020"
970,NCT01879085,Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,Sarcoma,Drug: Docetaxel|Drug: Gemcitabine|Drug: Vorinostat|Drug: Pegfilgrastim,"Melissa Burgess, MD|Merck Sharp & Dohme LLC|University of Pittsburgh",Phase 1|Phase 2,37,Other|Industry,"September 24, 2013","April 15, 2021","April 15, 2021"
971,NCT01869413,Tranexamic Acid During Cystectomy Trial (TACT),Bladder Cancer,Drug: Tranexamic Acid|Drug: Placebo,"Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Dalhousie University|McGill University Health Centre/Research Institute of the McGill University Health Centre|Centre hospitalier de l'Université de Montréal (CHUM)|Laval University|University of Western Ontario, Canada|University Health Network, Toronto",Phase 2|Phase 3,354,Other,Jun-13,Jan-21,Jun-21
972,NCT01868386,Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate,Prostate Cancer,Radiation: Hypofractionated therapy,"Timothy Showalter, MD|University of Virginia",Phase 1|Phase 2,32,Other,Apr-13,Dec-20,Dec-20
973,NCT01865617,"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",CD19-Positive Neoplastic Cells Present|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma,Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,204,Other|NIH,"May 22, 2013","March 26, 2021","March 26, 2021"
974,NCT01862926,Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD,Interstitial Lung Disease|Scleroderma|Idiopathic Inflammatory Myositis|Mixed Connective Tissue Disease,Drug: Rituximab|Drug: Cyclophosphamide,Royal Brompton & Harefield NHS Foundation Trust|Imperial College London|University of East Anglia|University College London Hospitals,Phase 2|Phase 3,104,Other,Nov-14,Jan-21,Jan-21
975,NCT01847755,Hyperbaric Treatment of Traumatic Brain Injury (TBI),Traumatic Brain Injury,Drug: Oxygen at 1.5 ATA (atmospheres absolute).,"Barry Miskin, MD|Jupiter Medical Center",Phase 1|Phase 2,18,Other,Apr-13,Dec-20,Dec-20
976,NCT01835067,Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD,Exudative Macular Degeneration|Retinal Hemorrhage,Drug: Ranibizumab|Drug: C3F8 Gas|Drug: tPA,King's College Hospital NHS Trust,Phase 2|Phase 3,55,Other,Sep-14,Nov-19,Dec-19
977,NCT01833520,Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma,Sarcoma,Drug: Ra-223 Dichloride,M.D. Anderson Cancer Center|Bayer,Phase 1|Phase 2,18,Other|Industry,"October 16, 2013","April 8, 2020","April 8, 2020"
978,NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",Advanced Biliary Tract Carcinoma,Drug: Gemcitabine|Drug: Cisplatin|Drug: MEK162,Memorial Sloan Kettering Cancer Center|Array BioPharma,Phase 1|Phase 2,42,Other|Industry,Apr-13,"May 30, 2019","May 30, 2019"
979,NCT01827579,Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT),Haematological Malignancies,Biological: CD25/71 allodepleted donor T-cells,"University College, London|Medical Research Council",Phase 1|Phase 2,37,Other,Jul-14,Jan-20,Jan-20
980,NCT01813539,A Study of ARGX-110 in Participants With Advanced Malignancies,Neoplasms,Drug: ARGX-110,"Janssen Research & Development, LLC|argenx",Phase 1|Phase 2,99,Industry,"February 27, 2013","July 10, 2020","July 10, 2020"
981,NCT01800526,A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease,Sickle Cell Disease|Sickle Cell Anemia,Drug: N-Acetylcysteine,Bloodworks|University of Washington,Phase 1|Phase 2,21,Other,Mar-13,"January 24, 2020","June 30, 2020"
982,NCT01788189,"Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas",B-cell Lymphoma,Drug: Lenalidomide,"University Hospital, Essen|Celgene",Phase 1|Phase 2,37,Other|Industry,Jan-13,"February 20, 2020","February 20, 2020"
983,NCT01783756,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",Central Nervous System Metastases|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer,Drug: lapatinib ditosylate|Drug: everolimus|Drug: capecitabine|Other: laboratory biomarker analysis,Jonsson Comprehensive Cancer Center,Phase 1|Phase 2,9,Other,"June 26, 2013","May 10, 2019","May 10, 2019"
984,NCT01783041,Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants,Prematurity|Neurodevelopmental Disorder|Carnitine Deficiency,Drug: L-carnitine|Drug: 5% Dextrose,Montefiore Medical Center|The Gerber Foundation,Phase 2|Phase 3,144,Other,Jan-13,Dec-20,"December 28, 2021"
985,NCT01782989,Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA),Geographic Atrophy,Drug: ORACEA®|Drug: Placebo,"Paul Yates, MD, PhD|MEDARVA Foundation|University of Virginia",Phase 2|Phase 3,286,Other,Feb-13,Nov-20,Nov-20
986,NCT01778946,Nicotine Treatment of Cognitive Decline in Down Syndrome,Down Syndrome|Mild Cognitive Impairment,Drug: Low Dose Nicotine (7mg)|Drug: Moderate Dose Nicotine (14mg),Vanderbilt University Medical Center,Phase 1|Phase 2,7,Other,Apr-13,Feb-21,Feb-21
987,NCT01765244,"Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment",Severe Trophic Corneal Ulcers Refractory to Conventional Treatment|Sequelae of Previous Trophic Corneal Ulcers,Drug: Anterior lamellar nanostructured artificial human cornea.|Other: Amniotic membrane transplantation,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,Phase 1|Phase 2,16,Other,"January 17, 2014","January 14, 2021","January 14, 2021"
988,NCT01757288,"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC",STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER,Drug: NAB-PACLITAXEL|Drug: PACLITAXEL,University of Texas Southwestern Medical Center|Celgene,Phase 1|Phase 2,98,Other|Industry,"March 25, 2013","June 3, 2019","June 3, 2019"
989,NCT01751568,"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB",HIV Infections|Tuberculosis,Drug: Raltegravir,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1|Phase 2,40,NIH,"November 12, 2014","November 27, 2019","November 27, 2019"
990,NCT01750918,BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),Cancer,Drug: Dabrafenib|Drug: Trametinib|Drug: Panitumumab|Device: 5-fluorouracil,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,166,Industry,"December 19, 2012","June 18, 2020","June 18, 2020"
991,NCT01745783,"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",Multiple Sclerosis,Other: Bone marrow mesenchymal stem cells autologous|Other: Placebo comparator,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies,Phase 1|Phase 2,26,Other,Jan-13,"June 30, 2020","June 30, 2020"
992,NCT01730547,Mesenchymal Stem Cells for Multiple Sclerosis,Multiple Sclerosis,Biological: Autologous mesenchymal stem cells,Karolinska Institutet,Phase 1|Phase 2,2,Other,Feb-13,"May 9, 2019","November 20, 2021"
993,NCT01714739,A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors,"CANCER,NOS",Drug: Lirilumab|Drug: Nivolumab|Drug: Ipilimumab,Bristol-Myers Squibb,Phase 1|Phase 2,337,Industry,"October 7, 2012","December 13, 2019","December 13, 2019"
994,NCT01693562,A Phase 1/2 Study to Evaluate MEDI4736,Advanced Solid Tumors,Drug: MEDI4736,MedImmune LLC,Phase 1|Phase 2,1022,Industry,"September 5, 2012","February 28, 2020","February 28, 2020"
995,NCT01680965,Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease,Chronic Graft Versus Host Disease,Drug: Ofatumumab,H. Lee Moffitt Cancer Center and Research Institute,Phase 1|Phase 2,44,Other,"November 14, 2012",Aug-20,"August 30, 2020"
996,NCT01677741,"A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects","Neoplasms, Brain",Drug: Dabrafenib,Novartis Pharmaceuticals|Novartis,Phase 1|Phase 2,85,Industry,"May 23, 2013","December 4, 2020","December 4, 2020"
997,NCT01657331,Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL),Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,Drug: Brentuximab Vedotin|Drug: Bendamustine|Drug: Neulasta,Columbia University,Phase 1|Phase 2,71,Other,Jul-12,Apr-20,Apr-20
998,NCT01644994,Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma,Malignant Pleural Mesothelioma,Combination Product: intracavitary cisplatin-fibrin,University of Zurich|Swiss National Science Foundation|Swiss Accident Insurance Fund SUVA,Phase 1|Phase 2,47,Other,Nov-12,Dec-19,Aug-21
999,NCT01642056,EPI-743 for Metabolism or Mitochondrial Disorders,Mitochondrial Disease|Neurology|Myopathy,Drug: EPI-743|Drug: Placebo,National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,20,NIH,"September 1, 2012","September 24, 2019","September 24, 2019"
1000,NCT01626833,Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone,Anorexia Nervosa|Interruption of Growth|Delayed Puberty|Osteopenia With Failure of Acquisition of Bone Mass,Drug: SOMATROPINE* : Norditropine® simplexx®|Biological: Placebo,Assistance Publique - Hôpitaux de Paris|Novo Nordisk A/S,Phase 2|Phase 3,15,Other|Industry,Mar-13,Mar-21,Mar-21
1001,NCT01625234,"Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer",Advanced Solid Tumors|Non-small Cell Lung Cancer,Drug: Phase I: X-396 (ensartinib)|Drug: Phase II: X-396 (ensartinib),"Xcovery Holding Company, LLC",Phase 1|Phase 2,131,Industry,Jun-12,"September 17, 2020","September 17, 2020"
1002,NCT01606215,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,Multiple Sclerosis,Drug: Mesenchymal stem cells|Drug: Placebo,Imperial College London,Phase 1|Phase 2,21,Other,Jan-13,Aug-19,Aug-19
1003,NCT01590160,"Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma",Lung Cancer - Malignant Pleural Mesothelioma,Drug: Ganetespib,"University College, London|Cancer Research UK",Phase 1|Phase 2,27,Other,Aug-13,"November 5, 2019","November 5, 2019"
1004,NCT01566123,Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS),Retroperitoneal Soft Tissue Sarcoma,Radiation: Neoadjuvant intensity-modulated radiation therapy (IMRT)|Radiation: intraoperative radiation therapy (IORT),University Hospital Heidelberg|German Cancer Research Center,Phase 1|Phase 2,37,Other,Mar-07,Jan-20,Feb-20
1005,NCT01555697,Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia,Schizophrenia,Drug: Memantine|Drug: Placebo,"University of California, San Diego",Phase 1|Phase 2,80,Other,Jul-14,"June 1, 2019","June 1, 2019"
1006,NCT01554371,Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies,Malignant Solid Tumour|Breast Cancer Nos Metastatic Recurrent|Neuropathy,Drug: Eribulin|Drug: Cyclophosphamide,"University of California, San Francisco|Eisai Inc.",Phase 1|Phase 2,44,Other|Industry,"March 27, 2012","December 31, 2019","December 31, 2019"
1007,NCT01548729,Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis,Cystic Fibrosis|Diabetes Related Cystic Fibrosis|Insulin-dependent Diabetes,Procedure: Combined pancreatic islet and lung transplantation,"University Hospital, Strasbourg, France",Phase 1|Phase 2,14,Other,"February 25, 2012","December 20, 2019","December 20, 2019"
1008,NCT01539096,Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery,Stroke,Procedure: tDCS: noninvasive brain stimulation|Behavioral: Constraint induced movement therapy (CIMT)|Procedure: Sham tDCS: placebo noninvasive brain stimulation,The Cleveland Clinic|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1|Phase 2,67,Other|NIH,Jul-11,Dec-19,Dec-19
1009,NCT01506856,Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,Drug: Paclitaxel(intravenous) + Carboplatin(intravenous)|Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal),Gynecologic Oncology Trial & Investigation Consortium|Japanese Gynecologic Oncology Group,Phase 2|Phase 3,655,Other,May-10,"February 28, 2021","February 28, 2021"
1010,NCT01505868,Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Lymphadenopathy|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Carcinoma Metastatic in the Bone|Prostate Small Cell Carcinoma,Drug: Cabazitaxel|Drug: Carboplatin|Other: Laboratory Biomarker Analysis,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,170,Other|NIH,"July 11, 2012","December 9, 2019","December 9, 2019"
1011,NCT01496118,Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma,Multiple Myeloma,Drug: panobinostat|Drug: carfilzomib,"SCRI Development Innovations, LLC|Onyx Therapeutics, Inc.|Novartis",Phase 1|Phase 2,80,Other|Industry,Dec-11,Dec-20,Dec-20
1012,NCT01468831,Minocycline to Treat Branch Retinal Vein Occlusion,Retinal Vein Occlusion,Drug: Minocycline|Other: Placebo|Drug: Bevacizumab,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,9,NIH,"March 28, 2012","February 25, 2020","March 18, 2021"
1013,NCT01434602,Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,Brain Tumor|Glioblastoma|Anaplastic Glioma,Drug: everolimus|Drug: sorafenib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,86,NIH,"October 2, 2012","October 19, 2020","July 13, 2021"
1014,NCT01423851,"Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF",Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis,Drug: NS-018,"NS Pharma, Inc.",Phase 1|Phase 2,77,Industry,Jun-11,"April 22, 2020","April 22, 2020"
1015,NCT01421186,A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma,Multiple Myeloma,Drug: MOR03087 phase 1 dose escalation|Drug: MOR03087|Drug: Dexamethasone|Drug: Pomalidomide|Drug: Lenalidomide,MorphoSys AG,Phase 1|Phase 2,91,Industry,Jul-11,Aug-20,Aug-20
1016,NCT01402271,"Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer,Drug: carboplatin|Drug: paclitaxel|Drug: pazopanib hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study,European Organisation for Research and Treatment of Cancer - EORTC,Phase 1|Phase 2,88,Other,Jul-12,"May 15, 2019","July 13, 2020"
1017,NCT01395641,A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC,Aromatic L-amino Acid Decarboxylase (AADC) Deficiency,Drug: gene therapy,National Taiwan University Hospital|PTC Therapeutics,Phase 1|Phase 2,10,Other|Industry,"October 22, 2014","December 18, 2020","March 7, 2022"
1018,NCT01380990,Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency,Adenosine Deaminase Deficiency|Severe Combined Immunodeficiencies (SCID),Genetic: Infusion of autologous EFS-ADA LV CD34+ cells|Other: Haematopoietic Stem Cell Transplantation (HSCT)|Drug: Busulfan|Drug: Peg-Ada,Great Ormond Street Hospital for Children NHS Foundation Trust|Orchard Therapeutics,Phase 1|Phase 2,36,Other|Industry,"November 15, 2012","December 23, 2019","December 23, 2019"
1019,NCT01347242,Gene Therapy for Wiskott-Aldrich Syndrome (WAS),Wiskott-Aldrich Syndrome,Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene,Genethon|Great Ormond Street Hospital for Children NHS Foundation Trust|Institute of Child Health,Phase 1|Phase 2,6,Other,Mar-11,"November 13, 2019","November 13, 2019"
1020,NCT01294670,Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors,Solid Tumors|Relapsed/Refractory Sarcomas,Drug: Vorinostat and Etoposide,Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme LLC|Phoenix Children's Hospital|Milton S. Hershey Medical Center|Johns Hopkins University|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Children's Hospital Colorado|University of Florida|Alberta Children's Hospital|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|Children's Mercy Hospital & Clinics|Johns Hopkins All Children's Hospital|Arnold Palmer Hospital for Children,Phase 1|Phase 2,27,Other|Industry,"February 9, 2011","December 8, 2020","December 8, 2020"
1021,NCT01289353,Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer,Breast Cancer,Drug: Carboplatin|Radiation: 3D-RT or IMRT,NYU Langone Health,Phase 1|Phase 2,92,Other,"March 6, 2009","July 8, 2019","July 8, 2019"
1022,NCT01240057,Tracheal Occlusion To Accelerate Lung Growth (TOTAL) Trial for Severe Pulmonary Hypoplasia,Congenital Diseases|Diaphragmatic Hernia|Pulmonary Hypoplasia,Procedure: fetal endoluminal tracheal occlusion|Other: watchful waiting during pregnancy,"University Hospital, Gasthuisberg|King's College Hospital NHS Trust (UK)|Hospital Clinic of Barcelona|Hopital Antoine Beclere|University Hospital, Bonn|Mater Mothers' Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Ospedale Pediatrico Bambino Gesù, Rome (IT)|Mount Sinai Hospital, Canada|National Center for Child Health and Development, Tokyo (JP)|The University of Texas Health Science Center, Houston|Medical University of Warsaw",Phase 2|Phase 3,93,Other,Nov-11,Mar-20,Dec-20
1023,NCT01217060,Trimodality Management of T1b Esophageal Cancers,Esophageal Cancer,Drug: Docetaxel|Drug: 5-FU|Radiation: Radiotherapy|Procedure: Esophagectomy|Drug: Dexamethasone,M.D. Anderson Cancer Center,Phase 1|Phase 2,4,Other,Oct-10,"June 14, 2020","June 14, 2020"
1024,NCT01208051,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,Drug: Cediranib|Drug: Cediranib Maleate|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide,National Cancer Institute (NCI),Phase 1|Phase 2,127,NIH,"September 9, 2010","February 1, 2020","February 1, 2020"
1025,NCT01128218,A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors,Brain Neoplasms,Drug: Tumor fluorescence,"Southern Illinois University|DUSA Pharmaceuticals, Inc.",Phase 1|Phase 2,35,Other|Industry,Mar-11,Feb-21,Feb-21
1026,NCT01091636,Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer,Epithelial Ovarian Cancer,Procedure: Hyperthermic Intraperitoneal Chemotherapy,"National Cancer Center, Korea|Ajou University",Phase 2|Phase 3,184,Other,Mar-10,"January 10, 2020","January 10, 2020"
1027,NCT01051193,Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures,Partial Onset Seizures,Drug: Oxcarbazepine,Nobelpharma,Phase 2|Phase 3,88,Industry,"January 5, 2010","September 30, 2019","September 30, 2019"
1028,NCT01007994,Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients,Hypertension Secondary to Kidney Transplant,"Drug: New Medication: Enalapril, Isradipine, Propranolol",Northwell Health|Children's Hospital of Philadelphia,Phase 2|Phase 3,33,Other,Nov-09,Jan-20,Aug-20
1029,NCT00972569,Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction,Heart Failure|Renal Dysfunction,Drug: BNP and PDE-V|Drug: BNP,Mayo Clinic|National Institutes of Health (NIH),Phase 1|Phase 2,60,Other|NIH,Oct-09,Jun-19,Dec-19
1030,NCT00892424,Sorafenib-RT Treatment for Liver Metastasis (SLIM),Liver Metastasis|Cancer,Drug: Sorafenib,"University Health Network, Toronto",Phase 1|Phase 2,54,Other,Nov-08,"September 8, 2020","September 8, 2020"
1031,NCT00769483,MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer,Pancreatic Cancer|Pancreatic Adenocarcinoma,Drug: MK-0646|Drug: Gemcitabine|Drug: Erlotinib,M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC,Phase 1|Phase 2,81,Other|Industry,"November 13, 2008","September 1, 2020","September 1, 2020"
1032,NCT00685919,Peripheral Dopamine in Postural Tachycardia Syndrome,Postural Tachycardia Syndrome|Orthostatic Intolerance,Drug: Carbidopa|Drug: Placebo,Vanderbilt University|Vanderbilt University Medical Center,Phase 2|Phase 3,32,Other,May-08,Jul-20,Dec-21
1033,NCT00630253,"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia",Fanconi Anemia,Biological: Anti-Thymocyte Globulin|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Hematopoietic Stem Cell Transplantation|Drug: Methylprednisolone|Drug: Filgrastim|Drug: Cyclosporine|Drug: Mycophenolate Mofetil,"Masonic Cancer Center, University of Minnesota",Phase 1|Phase 2,31,Other,"February 17, 2000","October 10, 2020","October 10, 2020"
1034,NCT00566618,Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis,Breast Cancer|Bone Metastases,Drug: Dasatinib|Drug: Zoledronic Acid,M.D. Anderson Cancer Center|Bristol-Myers Squibb,Phase 1|Phase 2,31,Other|Industry,"November 1, 2007","November 17, 2020","November 17, 2020"
1035,NCT00543777,Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease,Liver Cancer,Diagnostic Test: Magnetic Resonance Elastogram|Diagnostic Test: 2-Point Dixon Magnetic Resonance Imaging,M.D. Anderson Cancer Center,Phase 1|Phase 2,44,Other,Sep-07,"January 13, 2020","January 13, 2020"
1036,NCT00514046,Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B,Drug: Vandetanib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,17,NIH,"July 20, 2007","December 10, 2019","November 1, 2020"
1037,NCT00507728,"Pharmacogenetics, Emotional Reactivity and Smoking",Tobacco Use Disorder|Smoking Cessation,Drug: Bupropion|Drug: Varenicline|Drug: Placebo|Behavioral: Smoking Cessation Counseling,M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),Phase 2|Phase 3,646,Other|NIH,"December 8, 2005","December 18, 2019","December 18, 2019"
1038,NCT00477412,"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma",Mantle Cell Lymphoma,Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Methotrexate|Biological: Rituximab|Drug: Vincristine,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,107,Other|NIH,"April 3, 2007","October 28, 2020","October 28, 2020"
1039,NCT00416351,Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment,Leukemia|Lymphoma|Small Intestine Cancer,Drug: clofarabine,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|University of Rochester|The Cleveland Clinic,Phase 1|Phase 2,29,Other|NIH,"June 27, 2006","March 1, 2021","March 1, 2021"
1040,NCT00352976,TBI Dose De-escalation for Fanconi Anemia,Fanconi Anemia,Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Total Body Irradiation|Procedure: Bone Marrow Transplantation|Drug: Mycophenolate Mofetil|Drug: Sirolimus,"Masonic Cancer Center, University of Minnesota",Phase 2|Phase 3,83,Other,"May 18, 2006","October 9, 2020","October 9, 2020"
1041,NCT00317772,"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer",Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Cancer,Drug: Topotecan|Drug: Gefitinib,M.D. Anderson Cancer Center|AstraZeneca|GlaxoSmithKline,Phase 1|Phase 2,19,Other|Industry,"September 2, 2004","November 4, 2020","November 4, 2020"
1042,NCT00303849,"Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors",Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma|Oligoastrocytoma,Drug: Carboplatin|Drug: Etoposide|Drug: Etoposide Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mannitol|Drug: Melphalan|Other: Quality-of-Life Assessment|Drug: Sodium Thiosulfate,OHSU Knight Cancer Institute|Oregon Health and Science University,Phase 1|Phase 2,33,Other,"September 15, 2005","March 12, 2021","March 12, 2021"
1043,NCT00194714,Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab,HER2/Neu Positive|HLA-A2 Positive Cells Present|Stage IV Breast Cancer|Stage IV Ovarian Cancer,Biological: HER-2/neu Peptide Vaccine|Other: Laboratory Biomarker Analysis,University of Washington|National Cancer Institute (NCI),Phase 1|Phase 2,22,Other|NIH,May-16,"March 31, 2021","May 22, 2023"
1044,NCT00177047,Autologous Transplant for Multiple Myeloma,Multiple Myeloma,Procedure: Stem Cell Transplant|Drug: Cyclophosphamide + Mesna|Drug: Melphalan|Biological: Granulocyte-colony stimulating factor,"Masonic Cancer Center, University of Minnesota",Phase 2|Phase 3,363,Other,"April 20, 2004","August 1, 2020","August 1, 2020"
1045,NCT00123669,Primary Progesterone Therapy for Operable Breast Cancer,Breast Neoplasms,Drug: 500 mg of depot hydroxy-progesterone,"Tata Memorial Hospital|Ministry of Science and Technology, India",Phase 2|Phase 3,1000,Other,Oct-97,"May 29, 2020","May 29, 2020"
1046,NCT00003816,Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",Biological: anti-thymocyte globulin|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: thiotepa|Radiation: total-body irradiation,Roswell Park Cancer Institute,Phase 2|Phase 3,361,Other,"October 19, 1998","July 12, 2019","July 12, 2019"
1047,NCT00002663,"Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",EBV-induced Lymphomas|EBV-associated Malignancies|Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma,Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs),Atara Biotherapeutics|Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),Phase 1|Phase 2,58,Industry|Other|NIH,Mar-95,Jul-19,Jul-19
1048,NCT00001322,The Effects of Reproductive Hormones on Mood and Behavior,Healthy Volunteers,Drug: Leuprolide Acetate 3.75|Drug: Estradiol|Drug: Progesterone|Drug: Placebo suppository|Drug: Placebo patch,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),Phase 1|Phase 2,100,NIH,"June 9, 1994","March 3, 2020","March 3, 2020"
1049,NCT05874336,"An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol",NASH,Drug: Aramchol,Galmed Pharmaceuticals Ltd|Quotient Sciences,Phase 1,6,Industry,"June 17, 2020","August 11, 2020","August 11, 2020"
1050,NCT05850637,Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer,Breast Cancer Female,Radiation: adjuvant ultra-hypofractionated radiotherapy,Prevent Senior Institute,Phase 2,60,Other,"January 30, 2019","February 11, 2021","April 1, 2023"
1051,NCT05847023,Proof-of-concept Study of LUNA Intervention in Aphasia,Aphasia|Stroke,Behavioral: LUNA,"City, University of London",Phase 1,28,Other,"June 14, 2020","April 1, 2021","April 28, 2021"
1052,NCT05845996,"Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects",Healthy Volunteers,Drug: SAR441344|Drug: placebo|Biological: Keyhole limpet hemocyanin,Sanofi,Phase 1,56,Industry,"February 26, 2019","April 10, 2020","April 10, 2020"
1053,NCT05841446,Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects,Healthy,Drug: test apixaban tablets|Drug: reference apixaban tablets,The Affiliated Hospital of Qingdao University,Phase 1,54,Other,"March 2, 2021","March 17, 2021","April 7, 2021"
1054,NCT05840640,Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis,Alcoholic Hepatitis,Drug: Standard Medical Therapy|Drug: G-CSF|Drug: G-CSF and NAC,Postgraduate Institute of Medical Education and Research,Phase 4,66,Other,"October 1, 2017","February 28, 2021","February 28, 2021"
1055,NCT05840445,Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles,Face|Skin Fold|Rejuvenation,Drug: Onabotulinum toxin A|Drug: Prabotulinumtoxin A,Instituto de Oftalmología Fundación Conde de Valenciana,Phase 4,26,Other,"June 15, 2020","January 15, 2021","January 15, 2021"
1056,NCT05824793,The Efficacy of A-PRF+ on Postoperative Outcomes Following Surgical Removal of Impacted Mandibular Third Molars (A-PRF+: Advanced Platelet Rich Fibrin),PRF,Combination Product: A-PRF+,University of Medicine and Pharmacy at Ho Chi Minh City,Phase 4,76,Other,"October 1, 2019","April 23, 2021","April 30, 2021"
1057,NCT05815264,Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above,Pneumonia,Biological: 23-valent pneumococcal polysaccharide vaccine|Biological: pneumococcal vaccine polyvalent,"Ab&b Biotechnology Co., Ltd.JS",Phase 1,144,Other,"September 7, 2020","March 26, 2021","March 26, 2021"
1058,NCT05810389,EVALUATION OF AN ALTERNATIVE TECHNIQUE FOR THE APPLICATION OF SODIUM FLUOROPHOSPHATE: A 2-YEARS DOUBLE-BLIND RCT,"Caries,Dental",Combination Product: Fluoride,University of Buenos Aires,Phase 4,300,Other,"April 1, 2017","November 30, 2019","November 30, 2019"
1059,NCT05806177,"Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects",Alzheimer Disease,Drug: AD16 30mg、40mg|Drug: AD16 Placebo 30mg、40mg,Xiangya Hospital of Central South University,Phase 1,20,Other,"May 26, 2020","July 31, 2020","July 31, 2020"
1060,NCT05802290,NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN,Squamous Cell Carcinoma of Head and Neck,Drug: Nivolumab 240 MG in 24 ML Injection,Gruppo Oncologico del Nord-Ovest,Phase 3,124,Other,"November 27, 2017","March 26, 2020","March 26, 2020"
1061,NCT05800418,Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers,Gastric Cancer|Non-small Cell Lung Cancer|Colo-rectal Cancer,Drug: Ramucirumab Injection|Drug: Ramucirumab Injection [Cyramza],"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Phase 1,88,Industry,"November 4, 2019","February 18, 2020","February 18, 2020"
1062,NCT05787041,The Effect of High Fat Diet on the Pharmacokinetics of AD16 Tablets in Healthy Chinese Adult Subjects,Alzheimer Disease,Other: high-fat diet group（AD16 20mg）|Other: fasted group（AD16 20mg）,Xiangya Hospital of Central South University,Phase 1,16,Other,"June 14, 2019","December 14, 2019","December 14, 2019"
1063,NCT05787028,"Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration",Alzheimer's Disease,Drug: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Drug: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg,Xiangya Hospital of Central South University,Phase 1,70,Other,"January 30, 2019","May 31, 2020","May 31, 2020"
1064,NCT05780268,LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial),COVID-19,Biological: LY3819253|Biological: Placebo|Biological: Remdesivir,"National Institute of Allergy and Infectious Diseases (NIAID)|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)|University of Copenhagen|Medical Research Council|Kirby Institute|Washington D.C. Veterans Affairs Medical Center|AIDS Clinical Trials Group|National Heart, Lung, and Blood Institute (NHLBI)|US Department of Veterans Affairs|Prevention and Early Treatment of Acute Lung Injury|Cardiothoracic Surgical Trials Network|Eli Lilly and Company|University of Minnesota",Phase 3,314,NIH|Other|U.S. Fed|Industry,"August 5, 2020","February 1, 2021","February 1, 2021"
1065,NCT05770960,Colonic Motor Patterns in Healthy Volunteers,Opioid-Induced Constipation,Drug: Naloxegol|Drug: codeine phosphate|Other: Placebo,Universitaire Ziekenhuizen KU Leuven,Phase 4,15,Other,"June 27, 2018","May 9, 2019","May 9, 2019"
1066,NCT05762523,Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years,Smallpox|Monkeypox|Cowpox|Vaccinia Virus Infection,Biological: VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|Biological: VAC∆6 vaccine - once at a dose of 10⁷ PFU|Biological: VAC∆6 vaccine - twice at a dose of 10⁶ PFU|Biological: Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",Phase 1,60,Other,"May 18, 2019","July 22, 2019","January 27, 2020"
1067,NCT05759416,Evaluation Efficacy of Melatonin Gel as Adjunctive Therapy in Chronic Periodontitis,Chronic Periodontitis,Drug: Melatonin2%gel|Drug: PLACEBO,Al-Azhar University,Phase 4,40,Other,"April 1, 2020","December 1, 2020","March 1, 2021"
1068,NCT05748249,Evaluation of the Efficacy of Vertistop® D and Vertistop® L in the Prevention of BPPV Recurrence,Benign Paroxysmal Positional Vertigo|Vitamin D|Antioxidants,Drug: Vertistop® D,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Phase 1,126,Other,"November 1, 2018","September 30, 2019","September 30, 2019"
1069,NCT05737927,Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects,Obese,Drug: Glucose 8 g coated beads (47% w/w)|Drug: Glucose 12 g coated beads (47% w/w)|Drug: Glucose 16 g coated beads (47% w/w)|Drug: Glucose 12 g uncoated beads|Drug: Glucose 12 g coated beads (60% w/w),"Aphaia Pharma US LLC|NovaClin Medical Research Center S.R.L|ACC GmbH Analytical Clinical Concepts|SC Bioclinica SA|Galephar Pharmaceutical Research (PR), Inc.",Phase 1,20,Industry|Other,"September 16, 2020","September 16, 2020","November 9, 2020"
1070,NCT05734235,UVB-Induced MVP Release in Human Skin,Ultraviolet B Radiation|Microvesicle Particles,Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin E,Wright State University,Phase 1,8,Other,"July 16, 2018","March 5, 2020","October 26, 2022"
1071,NCT05731778,Clinical Study to Assess Therapeutic Delay and Resolution of Induced Gingivitis,Gingivitis,Drug: Stannous Fluoride Toothpaste|Drug: Colgate fluoride toothpaste,Colgate Palmolive,Phase 4,26,Industry,"December 22, 2018","December 22, 2020","December 22, 2020"
1072,NCT05718453,"Assessment of Trace Elements, Systemic Inflammation and Electrolytes",Copd,Combination Product: Laboratory Tests,Egymedicalpedia,Phase 1,140,Industry,"June 1, 2019","December 1, 2019","December 15, 2019"
1073,NCT05716126,Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers,Healthy,Drug: [14C]Iruplinalkib (WX-0593),"Qilu Pharmaceutical Co., Ltd.",Phase 1,6,Industry,"April 15, 2020","December 15, 2020","January 13, 2021"
1074,NCT05713773,Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects,Metabolic Syndrome|Obesity,Drug: coated beads glucose (8 g) and caffeine anhydrous|Drug: coated beads glucose (8 g)|Drug: uncoated beads glucose (8 g) and caffeine anhydrous,"Aphaia Pharma US LLC|ACC GmbH Analytical Clinical Concepts, Germany|Nova-Clin Medical Research Center S.R.L., Romania|BioClinica, Inc.|Galephar Pharmaceutical Research (PR), Inc, Puerto Rico",Phase 1,20,Industry|Other,"October 25, 2019","December 3, 2019","December 3, 2019"
1075,NCT05712642,A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity,Retinopathy of Prematurity,Drug: Intravitreal Bevacizumab,Cairo University,Phase 3,19,Other,"February 1, 2020","December 30, 2020","January 28, 2021"
1076,NCT05709938,Comparison of Insulin Glargine and Regular Insulin Versus NPH and Regular Insulin in the Treatment of T1DM,To Assess the Glycemic Control of Insulin Glargine in Combination With Regular Insulin in Type 1 Diabetes in Children,Drug: Glargine and regular insulin versus NPH and regular insulin,King Edward Medical University,Phase 4,68,Other,"November 1, 2019","January 5, 2021","April 20, 2021"
1077,NCT05694728,A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine,Human Papilloma Virus Infection,"Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)","Beijing Health Guard Biotechnology, Inc|Jiangsu Province Centers for Disease Control and Prevention|National Institutes for Food and Drug Control, China|Nanjing Sangruisi pharmtech Ltd.|Shanghai Canming pharmtech Ltd.",Phase 2,780,Industry|Other,"May 23, 2020","December 11, 2020","January 27, 2021"
1078,NCT05680454,A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine,Human Papillomavirus Infection,"Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|Biological: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine","Beijing Health Guard Biotechnology, Inc|Jiangsu Province Centers for Disease Control and Prevention|National Institutes for Food and Drug Control, China|Nanjing Sangruisi Pharmaceutical Technology Co., Ltd|School of Public Health of Southeastern University",Phase 1,160,Industry|Other,"September 1, 2019","April 6, 2020","May 10, 2022"
1079,NCT05669781,The Effects of Combined Gum-chewing and Parenteral Metoclopramide on Post-operative Ileus,Ileus Postoperative,Drug: Metoclopramide 10mg|Combination Product: Gum and metoclopramide|Other: Gum|Other: Control,"Ikechukwu Bartholomew Ulasi|University College Hospital, Ibadan",Phase 4,105,Other,"October 1, 2018","September 30, 2019","September 30, 2019"
1080,NCT05663827,Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease,Steroid Refractory GVHD,Drug: Ruxolitinib,Yi-Lun Wang|Chang Gung Memorial Hospital,Phase 3,6,Other,"January 1, 2019","January 1, 2020","November 30, 2022"
1081,NCT05641311,Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants,Wilson Disease,Drug: ALXN1840,Alexion,Phase 1,24,Industry,"February 20, 2019","May 2, 2019","May 2, 2019"
1082,NCT05639803,A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults,Herpes Zoster,Drug: PEGIFNα1b|Drug: Placebo,Shanghai Institute Of Biological Products,Phase 1,50,Industry,"July 7, 2020","October 22, 2020","October 22, 2020"
1083,NCT05632445,Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA),Left Atrial Appendage Occlusion,Drug: Apixaban vs. DAPT,DR. XAVIER FREIXA|Hospital Clinic of Barcelona,Phase 4,160,Other,"May 1, 2019","June 12, 2019","October 30, 2022"
1084,NCT05630274,A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants,Healthy,Drug: Selpercatinib|Drug: Moxifloxacin|Drug: Placebo,"Eli Lilly and Company|Loxo Oncology, Inc.",Phase 1,32,Industry,"April 16, 2019","June 21, 2019","June 21, 2019"
1085,NCT05622357,Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer,Locally Advanced Rectal Carcinoma,Radiation: short course radiation therapy followed by 6 cycles of CAPOX then surgery,"National Cancer Institute, Egypt",Phase 2,51,Other,"March 18, 2018","December 20, 2020","September 1, 2021"
1086,NCT05614362,Channa Striatus Extract on Albumin and Hs-CRP ESRD,End-Stage Renal Disease|Inflammation,Dietary Supplement: Channa Striatus extract|Dietary Supplement: Maltodextrin,Universitas Sebelas Maret,Phase 4,40,Other,"January 1, 2021","March 1, 2021","March 1, 2021"
1087,NCT05606055,The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection,HIV-1-infection,Drug: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Phase 4,100,Other,"December 1, 2020","February 1, 2021","March 3, 2022"
1088,NCT05599997,"A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function",Congestive Heart Failure|Renal Impairment,Drug: Pecavaptan (BAY1753011),Bayer,Phase 1,32,Industry,"November 25, 2019","January 22, 2021","May 18, 2021"
1089,NCT05599828,A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,Healthy Participants,Drug: AMG 510|Drug: Omeprazole|Drug: Famotidine,Amgen,Phase 1,14,Industry,"July 17, 2020","September 13, 2020","September 13, 2020"
1090,NCT05598281,Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants,Healthy Participants,Drug: AMG 510|Drug: Digoxin,Amgen,Phase 1,14,Industry,"November 5, 2019","November 19, 2019","November 19, 2019"
1091,NCT05598242,Amniotic Membrane Treatment for Hyposecretory Dry Eye,Dry Eye Syndromes|Sjogren Syndrome With Keratoconjunctivitis,Biological: Amniotic membrane extract eye drops (AMEED),Hospital Nacional Profesor Alejandro Posadas,Phase 3,37,Other,"February 1, 2019","September 1, 2019","December 15, 2019"
1092,NCT05591456,Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients,Breast Cancer Radiotherapy,Radiation: adjuvant radiotherapy,Zagazig University,Phase 3,100,Other,"January 1, 2018","June 30, 2019","June 30, 2019"
1093,NCT05590650,A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients,Head and Neck Neoplasm|Chemoradiotherapy,Drug: SZKJT(San-Zhong-Kui-Jian-Tang),China Medical University Hospital,Phase 1,21,Other,"July 7, 2018","June 14, 2020","December 25, 2020"
1094,NCT05581992,Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,Healthy Participants,Drug: AMG 510|Drug: Omeprazole,Amgen,Phase 1,14,Industry,"January 6, 2020","January 26, 2020","January 26, 2020"
1095,NCT05581758,A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,Healthy Participants,Drug: AMG 510,Amgen,Phase 1,14,Industry,"November 14, 2019","November 25, 2019","December 9, 2019"
1096,NCT05578859,"A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects",Healthy Subjects,Drug: AMG 510,Amgen,Phase 1,8,Industry,"March 11, 2020","March 24, 2020","March 24, 2020"
1097,NCT05578391,Passive Immunotherapy In Patients With SARS CoV-2,COVID-19,Biological: Convalescent plasma,Fundacin Biomedica Galicia Sur|Health Knowledge Agency,Phase 2,61,Other,"January 1, 2020","December 31, 2020","March 31, 2021"
1098,NCT05577624,A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants,Healthy Participants,Drug: AMG 510|Drug: Rifampin,Amgen,Phase 1,14,Industry,"November 5, 2019","December 1, 2019","December 1, 2019"
1099,NCT05571163,A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants,Healthy Participants,Drug: AMG 510,Amgen,Phase 1,13,Industry,"March 6, 2020","June 14, 2020","June 14, 2020"
1100,NCT05568082,A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,Healthy Participants,Drug: AMG 510|Drug: Itraconazole,Amgen,Phase 1,14,Industry,"December 3, 2019","December 17, 2019","December 17, 2019"
1101,NCT05567393,A Study of TAK-951 in Healthy Adults,Healthy Volunteers,Drug: TAK-951 Placebo|Drug: TAK-951,Takeda,Phase 1,128,Industry,"March 7, 2019","November 2, 2020","November 2, 2020"
1102,NCT05567367,"A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234",Healthy Volunteer,Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|Drug: Vardenafil Oral Tablet,"Respira Therapeutics, Inc.",Phase 1,31,Industry,"July 31, 2018","December 4, 2019","December 4, 2019"
1103,NCT05562362,Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension,Healthy Subjects,"Drug: RE-021, sparsentan","Travere Therapeutics, Inc.",Phase 1,47,Industry,"June 18, 2020","November 12, 2020","November 12, 2020"
1104,NCT05550129,Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants,Healthy Volunteers,Drug: AMG 510|Drug: Metformin,Amgen,Phase 1,13,Industry,"November 13, 2019","November 25, 2019","November 25, 2019"
1105,NCT05547815,Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine,Rabies|Antibody,Biological: 5 doses program,"Changchun Zhuoyi Biological Co., Ltd",Phase 4,149,Other,"November 11, 2019","December 17, 2020","November 8, 2021"
1106,NCT05533788,ABSK091 Food Effect Study in Healthy Subjects,"Health, Subjective|Food-drug Interaction",Drug: ABSK091 tablet,"Abbisko Therapeutics Co, Ltd",Phase 1,13,Industry,"September 8, 2020","April 30, 2021","April 30, 2021"
1107,NCT05533073,"Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination",Healthy,Drug: A1: Etoricoxib / Tramadol Fixed dose combination|Drug: A2: Etoricoxib|Drug: A3: Tramadol,Laboratorios Silanes S.A. de C.V.,Phase 1,42,Industry,"August 3, 2020","September 7, 2020","November 30, 2020"
1108,NCT05533008,CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients,Hemodialysis,Drug: CR845 0.5 mcg/kg|Other: Placebo,"Cara Therapeutics, Inc.",Phase 1,35,Industry,"December 31, 2019","June 11, 2020","June 11, 2020"
1109,NCT05532332,Bioequivalence Study of Fluoxetine in Healthy Adult Subjects Under Fasting Condition,Healthy Subjects,Drug: Fluoxetine 10 mg capsules|Drug: Prozac® 10 mg capsules,Future University in Egypt,Phase 1,34,Other,"January 18, 2021","February 11, 2021","February 11, 2021"
1110,NCT05532306,Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition,Healthy Subjects,Drug: Ribavirin 400 mg film coated tablet (1*400mg)|Drug: Copegus® 200 mg film coated tablet (2*200mg),Future University in Egypt,Phase 1,36,Other,"October 11, 2020","November 23, 2020","November 23, 2020"
1111,NCT05532280,Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition,Healthy Subjects,Drug: Etoricoxib 90 mg film coated tablet|Drug: Arcoxia 90 mg film coated tablet,Future University in Egypt,Phase 1,30,Other,"December 28, 2020","January 14, 2021","January 14, 2021"
1112,NCT05532267,Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition,Healthy Subjects,Drug: Ciprofloxacin 750 mg|Drug: Ciproxin 750 mg,Future University in Egypt,Phase 1,30,Other,"November 4, 2020","November 13, 2020","November 13, 2020"
1113,NCT05532254,Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition,Healthy Subjects,Drug: Aripiprazole 10 mg tablet|Drug: Abilify® 10 mg tablet,Future University in Egypt,Phase 1,31,Other,"February 14, 2021","March 11, 2021","March 11, 2021"
1114,NCT05526820,A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine,Varicella,Biological: The live attenuated varicella vaccine and the inactivated hepatitis A vaccine,"Sinovac (Dalian) Vaccine Technology Co., Ltd.",Phase 4,450,Industry,"April 8, 2021","April 8, 2021","February 27, 2022"
1115,NCT05526690,"Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects",Hypertension,Drug: Metformin|Drug: CIN-107,"CinCor Pharma, Inc.",Phase 1,27,Industry,"October 28, 2020","December 12, 2020","December 12, 2020"
1116,NCT05522816,KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis,Psoriasis,"Drug: KX01 0.01% (0.1 mg/g)|Drug: Placebo|Drug: KX01 0.1% (1.0 mg/g)|Drug: KX01 1% (10 mg/g) for 5 days|Drug: KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles","PharmaEssentia|Athenex, Inc.",Phase 1,28,Industry,"October 27, 2015","March 10, 2021","March 10, 2021"
1117,NCT05521633,Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver,NAFLD,Drug: Metformin and Pioglitazone,King Edward Medical University,Phase 3,96,Other,"June 6, 2019","January 19, 2021","May 24, 2022"
1118,NCT05517746,"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",Endometriosis,Drug: BAY2395840 tablet|Drug: BAY2395840 oral solution|Drug: Placebo oral solution|Drug: Placebo tablet,Bayer,Phase 1,63,Industry,"December 18, 2019","December 17, 2020","March 11, 2021"
1119,NCT05517239,Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment,"Hepatocellular Carcinoma, Unresectable, Advanced","Drug: Gemcitabine, Oxaliplatin",Yonsei University,Phase 2,32,Other,"May 1, 2015","September 30, 2019","September 30, 2020"
1120,NCT05513625,Phase I Trial to Evaluate the Potential Influence of Pantoprazole on the Pharmacokinetics of Pritelivir,HSV Infection,Drug: Pritelivir|Drug: ESO and pritelivir,AiCuris Anti-infective Cures AG,Phase 1,16,Industry,"July 13, 2020","October 13, 2020","October 13, 2020"
1121,NCT05507047,Emdogain Implementation With Transcrestal Sinus Lifting and Dental Implant Placement,Osseointegration Failure of Dental Implant|Bone Density Increased,Drug: Enamel Matrix Protein,T.C. Dumlupınar Üniversitesi,Phase 4,24,Other,Jan-17,Jan-20,Dec-20
1122,NCT05504317,A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis,Psoriasis,Drug: AK111|Drug: Placebo,Akeso,Phase 1,48,Industry,"May 19, 2020","March 9, 2021","March 9, 2021"
1123,NCT05500820,Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects,Hypertension,Drug: CIN-107|Drug: Matching Placebo,"CinCor Pharma, Inc.",Phase 1,56,Industry,"December 19, 2019","April 3, 2020","April 3, 2020"
1124,NCT05486195,A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect,Cognitive Disorders,Drug: SDI-118|Drug: Placebo,AbbVie|Syndesi Therapeutics|KU Leuven,Phase 1,32,Industry|Other,"March 14, 2019","July 29, 2019","March 11, 2020"
1125,NCT05473104,"PEERS® for Italy, a Study on Social Skills Intervention for Adolescents With Autism Spectrum Disorder (ASD).",Autism Spectrum Disorder,Behavioral: Program for the Education and Enrichment of Relational Skills,Istituto Superiore di Sanità|University of Roma La Sapienza,Phase 2,37,Other,"January 14, 2021","April 14, 2021","November 14, 2021"
1126,NCT05472428,Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida,Stem Cell Infusion,Combination Product: Autologous bone marrow mononuclear cell transplantation,Vinmec Research Institute of Stem Cell and Gene Technology|Vinmec Health Care System (Vingroup Joint Stock Company),Phase 1,11,Other,"July 1, 2016","December 25, 2020","August 31, 2021"
1127,NCT05470725,Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function,Hypertension,Drug: CIN-107,"CinCor Pharma, Inc.",Phase 1,33,Industry,"January 12, 2021","April 30, 2021","April 30, 2021"
1128,NCT05469100,A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function,Healthy|Renal Insufficiency,Drug: Selpercatinib,"Eli Lilly and Company|Loxo Oncology, Inc.",Phase 1,37,Industry,"December 19, 2018","August 7, 2019","August 7, 2019"
1129,NCT05468060,"Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects",Chronic HBV Infection,Drug: PA1010,"Zhejiang Palo Alto Pharmaceuticals, Inc.",Phase 1,80,Industry,"June 28, 2020","December 12, 2020","December 12, 2020"
1130,NCT05465889,Efficacy and Safety of Oral Sulfate Solution on Bowel Preparation for Colonoscopy,Bowel Preparation for Colonoscopy,Drug: Oral sulfate solution (OSS)|Drug: Polyethylene Glycol Electrolyte,"Changhai Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Hospital of Integrated Traditional Chinese and Western Medicine|China-japan Friendship Hospital, Jilin University|Beijing Hospital|First affiliated hospital of Nanchang University|Zhongshan Hospital Xiamen University|Henan Provincial People's Hospital|Hebei Provincial People's Hospital|Shandong University Qilu Hospital",Phase 3,348,Other,"May 15, 2019","January 9, 2020","March 15, 2020"
1131,NCT05457894,"Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women","Influenza, Human|Vaccination; Infection|Vaccines","Biological: Flu-M, Inactivated split influenza vaccine|Biological: Ultrix®, Inactivated Split Influenza Vaccine",St. Petersburg Research Institute of Vaccines and Sera,Phase 3,207,Other,"January 23, 2020","March 11, 2021","July 26, 2021"
1132,NCT05457296,Salivary Cortisol Measurement in Corticotrope Deficiency Substitution With Hydrocortisone.,Adrenal Insufficiency,Drug: Hydrocortisone (capsule),University Tunis El Manar,Phase 4,40,Other,"January 1, 2021","April 30, 2021","April 30, 2021"
1133,NCT05455151,Hysteroscopic Injections of Autologous Endometrial Cells and Platelet-rich Plasma in Patients With Thin Endometrium,Thin Endometrium,Procedure: Conservative therapy|Biological: PRP injection|Biological: Injection of PRP after conservative therapy|Biological: Injection of PRP with endometrial cells,"Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare|Sechenov University",Phase 1,115,Other,"October 1, 2018","January 11, 2021","March 1, 2021"
1134,NCT05447026,The Effect of Adjunctive Therapies in Regenerative Treatment of Stage III Grade C Periodontitis,Periodontitis|Lasers|Ozone|Wound Healing|Regeneration,Device: Control group|Device: Antimicrobial photodynamic therapy (aPDT) group|Device: LED photobiomodulation group|Device: Topical ozone group,Gazi University,Phase 3,40,Other,"January 1, 2018","February 10, 2021","September 15, 2021"
1135,NCT05446493,Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction,Erectile Dysfunction|Erectile Dysfunction With Diabetes Mellitus,Drug: Tadalafil 5mg,Aswan University,Phase 4,60,Other,"April 1, 2019","March 15, 2021","January 5, 2022"
1136,NCT05444036,Caudal Ketamine-bupivacaine More Effective Than Bupivacaine-saline,Surgery|Pediatric Surgery,Drug: Ketamine,Egymedicalpedia,Phase 1,60,Industry,"September 1, 2018","May 15, 2019","June 1, 2019"
1137,NCT05441904,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.",NASH - Nonalcoholic Steatohepatitis,Drug: PXL770,Poxel SA,Phase 1,16,Industry,"March 8, 2021","March 29, 2021","March 29, 2021"
1138,NCT05441631,Can Intensive Insulin Therapy Improve Outcomes of COVID-19 Patients,COVID-19|Dysglycemia,Drug: Insulin|Drug: Subcutaneous Insulin,Benha University,Phase 1,436,Other,"April 1, 2020","July 15, 2020","December 1, 2021"
1139,NCT05436912,A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants,Healthy|Hepatic Impairment,Drug: Selpercatinib,"Eli Lilly and Company|Loxo Oncology, Inc.",Phase 1,25,Industry,"December 10, 2018","October 4, 2019","October 30, 2019"
1140,NCT05433896,Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions,Pharmacokinetics|Drug Interactions,Drug: Dasatinib ASD|Drug: Omeprazole 40 MG,Xspray Pharma AB|Axis Clinicals Limited,Phase 1,17,Industry,"November 1, 2020","December 19, 2020","December 19, 2020"
1141,NCT05430685,"The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students",Stress|Sleep|Craving|Well Being,Dietary Supplement: Ashwagandha|Other: Placebo,"University of Colorado, Colorado Springs",Phase 2,60,Other,"May 29, 2019","April 10, 2020","April 10, 2020"
1142,NCT05427305,TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer,Efficacy,Drug: TAB008|Drug: Bevacizumab,"TOT Biopharm Co., Ltd.",Phase 3,549,Industry,"October 20, 2017","March 24, 2020","March 24, 2020"
1143,NCT05426148,Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female,Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection,"Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®","Xiamen Innovax Biotech Co., Ltd|Jiangsu Province Centers for Disease Control and Prevention|Dongtai City Centers for Disease Control and Prevention",Phase 4,540,Industry|Other,"May 1, 2020","August 1, 2020","April 30, 2021"
1144,NCT05418803,BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects,Healthy Volunteer,Drug: YHP1807 Tab. 2.5mg|Drug: YHR1901 Tab. 2.5mg,Yuhan Corporation,Phase 1,34,Industry,"January 28, 2020","February 14, 2020","February 14, 2020"
1145,NCT05418426,"A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women",Vulvovaginal Atrophy|Vasomotor Symptoms,Device: IVR Dose 1|Device: IVR Dose 2|Drug: Oral Reference,"Daré Bioscience, Inc.",Phase 1,31,Industry,"August 18, 2020","April 27, 2021","January 27, 2022"
1146,NCT05414669,"Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL",Kidney Calculi,Drug: Allopurinol Tablet 300 mg|Drug: Control Group,Sanglah General Hospital,Phase 4,35,Other,"August 6, 2020","March 1, 2021","April 20, 2021"
1147,NCT05412472,"Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419",Renal Impairment,Drug: GC4419,"Galera Therapeutics, Inc.",Phase 1,26,Industry,"April 4, 2019","January 30, 2021","April 6, 2021"
1148,NCT05406050,Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects,Healthy,Drug: reference eldecalcitol soft capsule|Drug: test eldecalcitol soft capsule,"The Affiliated Hospital of Qingdao University|Wenzhou Haihe Pharmaceutical Co., Ltd.",Phase 1,58,Other,"October 20, 2020","December 31, 2020","July 15, 2021"
1149,NCT05405244,Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM,Overweight and Obesity|Eating Behavior,Drug: Placebo|Drug: Bromocriptine-QR,"University of North Carolina, Chapel Hill|American Diabetes Association",Phase 3,55,Other,"September 19, 2017","September 19, 2019","September 19, 2019"
1150,NCT05401305,Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b,Haemophilus Influenzae Infection|Vaccines,Biological: Vaccine for the prevention of infections caused by Haemophilus influenza type b|Biological: Placebo,St. Petersburg Research Institute of Vaccines and Sera,Phase 1,60,Other,"January 14, 2020","March 30, 2020","June 17, 2020"
1151,NCT05398965,Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19),COVID-19,Drug: Eucalyptus Oil|Drug: Standard COVID medication,"Hasanuddin University|Ministry of Agriculture, Republic of Indonesia",Phase 2,54,Other,"November 18, 2020","January 28, 2021","March 1, 2022"
1152,NCT05398562,Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers,Tuberculosis|Skin Tests,Diagnostic Test: Mycobacterial recombinant allergens 0.1 μg|Diagnostic Test: Mycobacterial recombinant allergens 0.2 μg|Diagnostic Test: Placebo,St. Petersburg Research Institute of Vaccines and Sera,Phase 1,75,Other,"February 13, 2020","June 17, 2020","June 26, 2020"
1153,NCT05396742,Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers,Healthy,Drug: Ravulizumab|Drug: rHuPH20,Alexion,Phase 1,49,Industry,"August 9, 2018","May 21, 2019","May 21, 2019"
1154,NCT05393856,CG-549 Tablet Pharmacokinetics Study,Healthy,Drug: CG-549,"CrystalGenomics, Inc.",Phase 1,24,Industry,"September 23, 2019","January 20, 2020","June 30, 2020"
1155,NCT05386069,Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use,Opioid Use,Drug: NOMO Protocol,Prisma Health-Upstate,Phase 3,11,Other,"November 15, 2019","December 1, 2020","June 1, 2021"
1156,NCT05370716,"Drug-Drug Interaction Study of ""CG-651"" in Healthy Volunteer",Healthy,Drug: Polmacoxib|Drug: Pregabalin,"CrystalGenomics, Inc.",Phase 1,47,Industry,"November 11, 2019","April 30, 2020","May 19, 2020"
1157,NCT05367479,"Antibiotics, Gastric Bypass, and the Microbiome","Obesity, Morbid|Hypertension|Bariatric Surgery Candidate",Drug: Antibiotic,Medical College of Wisconsin,Phase 1,23,Other,"July 18, 2018","January 9, 2020","January 9, 2020"
1158,NCT05361005,Tolerability and Safety of BDB-001 Injection in Healthy Subjects,Healthy,Drug: BDB-001 injection|Drug: Placebo,"Staidson (Beijing) Biopharmaceuticals Co., Ltd|Beijing Defengrei Biotechnology Co.,Ltd",Phase 1,33,Industry|Other,"March 12, 2020","May 8, 2020","May 8, 2020"
1159,NCT05360927,Safety and Tolerability of BDB-001 Injection in Healthy Subjects,Healthy,Drug: BDB-001 injection|Drug: Placebo,"Staidson (Beijing) Biopharmaceuticals Co., Ltd|Beijing Defengrei Biotechnology Co.,Ltd",Phase 1,28,Industry|Other,"September 25, 2019","December 25, 2020","December 25, 2020"
1160,NCT05360147,Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,"Drug: Liraglutide|Drug: Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides",Third Military Medical University,Phase 3,30,Other,"January 20, 2021","April 20, 2021","May 10, 2021"
1161,NCT05354336,A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers,Healthy Volunteers,Drug: SHR6390(100mg)|Drug: SHR6390(125mg)|Drug: SHR6390(150mg),The Affiliated Hospital of Qingdao University,Phase 1,36,Other,"June 13, 2019","August 24, 2019","August 24, 2019"
1162,NCT05354050,Pharmacokinetic Study of DARE-BV1,Bacterial Vaginosis,Drug: DARE-BV1,"Daré Bioscience, Inc.",Phase 1,21,Industry,"November 3, 2020","November 18, 2020","December 2, 2020"
1163,NCT05353686,A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes,"Efficacy|Safety|Pharmacokinetics|Diabetes Mellitus, Type 2",Drug: Placebo|Drug: XEN-D0501,Pila Pharma|Biomapas,Phase 2,54,Industry|Other,"February 25, 2019","December 19, 2019","December 19, 2019"
1164,NCT05351840,To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers,Healthy,Drug: LivaloV|Drug: A|Drug: LivaloVA,JW Pharmaceutical,Phase 1,31,Industry,"November 2, 2020","December 19, 2020","January 15, 2021"
1165,NCT05350683,Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR,Aortic Aneurysm|Ischemic Preconditioning,Procedure: Remote ischemic preconditioning,Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery|Hospital Clínico Universitario de Valladolid,Phase 2,120,Other,"January 1, 2017","September 17, 2019","May 20, 2020"
1166,NCT05348980,Intramuscular Phenylephrine HCL for Prevention of Spinal Anesthesia Induced Hypotension,Hypotension|Anesthesia,Drug: Phenylephrine Hydrochloride 4 mg|Drug: Phenylephrine Hydrochloride 8 mg,Rehman Medical Institute - RMI,Phase 4,60,Other,"January 1, 2020","July 31, 2020","July 31, 2020"
1167,NCT05345912,Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male Adults,Healthy,Drug: CG-745 IV Solution|Drug: CG-750 125mg capsule|Other: PO Placebo|Other: IV Placebo: 0.9 % normal saline,"CrystalGenomics, Inc.",Phase 1,24,Industry,"December 16, 2019","September 18, 2020","May 19, 2021"
1168,NCT05344638,"A Clinical Trial to Evaluate the Safety and Efficacy of ""AG1904"" in Acute Bronchitis",Acute Bronchitis,Drug: AGS (Experimental)|Drug: AGU (Active Comparator),"Ahn-Gook Pharmaceuticals Co.,Ltd",Phase 3,220,Industry,"October 17, 2019","July 29, 2020","July 29, 2020"
1169,NCT05343637,A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI),"Respira Therapeutics, Inc.",Phase 2,14,Industry,"July 30, 2019","January 17, 2020","January 17, 2020"
1170,NCT05342597,Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study),Healthy Adult Subjects,Drug: MT-1186,Mitsubishi Tanabe Pharma Corporation,Phase 1,16,Industry,"June 10, 2019","July 24, 2019","July 24, 2019"
1171,NCT05342558,Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.,COPD,Drug: Fluticasone Furoate/Vilanterol 100/25 mcgs|Drug: Umeclidinium/Vilanterol 62.5/25 mcgs,"National Institute of Respiratory Diseases, Mexico",Phase 4,133,Other,"September 19, 2017","November 19, 2020","February 1, 2021"
1172,NCT05340192,Effect of Octreotide on Saliva,Healthy,Drug: Octreotide 1 MG/ML,Duke University,Phase 1,4,Other,"September 24, 2019","February 26, 2020","February 26, 2020"
1173,NCT05338502,Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants,Healthy,Drug: Selpercatinib|Drug: Ranitidine|Drug: Omeprazole,"Eli Lilly and Company|Loxo Oncology, Inc.",Phase 1,20,Industry,"July 8, 2019","September 3, 2019","September 3, 2019"
1174,NCT05337878,"A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants",Healthy Participants,Drug: Placebo|Drug: Pelacarsen,"Ionis Pharmaceuticals, Inc.",Phase 1,29,Industry,"October 15, 2018","December 18, 2019","December 18, 2019"
1175,NCT05332028,Ultrasound-guided Paravertebral Block Versus Mid-point Transverse Process Pleura Block in Mastectomy Surgery,"Mastectomy; Lymphedema|Anesthesia, Local|Surgery",Drug: bupivacaine|Device: 22 gauge 100 mm needle|Drug: Propofol|Drug: fentanyl,Ataturk University,Phase 4,64,Other,"March 26, 2020","April 20, 2021","April 20, 2021"
1176,NCT05330000,Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects,Healthy Adults,Drug: 4 mg/kg Voriconazole|Drug: 6 mg/kg Voriconazole,The Affiliated Hospital of Qingdao University,Phase 1,48,Other,"May 22, 2020","July 8, 2020","September 16, 2020"
1177,NCT05329454,To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Modified-Release Tablets 800 mg,Chronic Pain,Drug: Ibuprofen Tablets,"Overseas Pharmaceuticals, Ltd.",Phase 1,30,Industry,"December 24, 2020","February 6, 2021","July 18, 2021"
1178,NCT05320991,Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers,Ketamine-Induced Psychotic Disorder|Social Cognition|Theory of Mind,Drug: Ketamine|Drug: Nacl 0.9%,"University Hospital, Bonn",Phase 4,70,Other,"June 15, 2019","September 27, 2020","September 27, 2020"
1179,NCT05317767,"The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.",Influenza,Biological: Flu-M [Inactivated split influenza vaccine]|Biological: Inactivated Split Influenza Vaccine,St. Petersburg Research Institute of Vaccines and Sera,Phase 3,600,Other,"February 10, 2020","July 5, 2020","September 14, 2020"
1180,NCT05316818,Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma,Metastatic Colorectal Cancer,Drug: FOLFOXIRI Protocol,Kasr El Aini Hospital,Phase 2,64,Other,"January 16, 2018","December 1, 2020","April 10, 2021"
1181,NCT05314673,Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients,Pterygium,Drug: Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|Procedure: pterygium surgery without adjunctive therapy,University Hospital Fattouma Bourguiba,Phase 4,60,Other,"January 1, 2019","January 1, 2021","January 1, 2021"
1182,NCT05313646,Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults,COVID-19,Biological: batch 1 of Ad5-nCoV|Biological: batch 2 of Ad5-nCoV|Biological: batch 3 of Ad5-nCoV,Jiangsu Province Centers for Disease Control and Prevention,Phase 4,1050,Other,"March 8, 2021","April 8, 2021","September 8, 2021"
1183,NCT05303324,Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults,Healthy,Drug: ALXN1840,Alexion,Phase 1,48,Industry,"July 4, 2019","October 9, 2019","October 9, 2019"
1184,NCT05301530,Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.,Breast Cancer Metastatic|Breast Cancer Female|Breast Cancer Recurrent,Drug: Faceptor|Drug: Herceptin|Drug: Docetaxel,Nanogen Pharmaceutical Biotechnology Joint Stock Company|Vietstar Biomedical Research|MedProve Inc,Phase 1,50,Industry|Other,"May 27, 2019","August 31, 2020","February 19, 2021"
1185,NCT05301010,Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients,Breast Cancer Metastatic|Breast Cancer Recurrent|Breast Cancer Female,Drug: Faceptor|Drug: Herceptin|Drug: Docetaxel,Nanogen Pharmaceutical Biotechnology Joint Stock Company|Vietstar Biomedical Research|MedProve Inc,Phase 3,128,Industry|Other,"February 2, 2018","February 19, 2021","February 19, 2021"
1186,NCT05294536,A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects,Type 2 Diabetes,"Drug: Liraglutide injection,RD12014|Drug: Liraglutide injection,Victoza","Sunshine Lake Pharma Co., Ltd.",Phase 1,50,Industry,"June 22, 2020","July 20, 2020","November 27, 2020"
1187,NCT05290506,Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus,PreDiabetes|Type 2 Diabetes,Drug: Dipeptidyl-Peptidase IV Inhibitors,National University of Malaysia,Phase 3,50,Other,"August 1, 2020","March 1, 2021","March 1, 2021"
1188,NCT05288738,Comparing Post-Operative Analgesic Effects of PCAM With Dexmedetomidine 1 mcg/ml vs PCAM With Dexmedetomidine 2 mcg/ml,"Post-Operative Analgesia|Opioid Use, Unspecified|Laparotomy Surgery",Drug: Dexmedetomidine 1 mcg/ml|Drug: Dexmedetomidine 2 mcg/ml,Universiti Kebangsaan Malaysia Medical Centre,Phase 4,68,Other,"December 9, 2019","December 8, 2020","January 10, 2021"
1189,NCT05286346,Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B,Chronic Hepatitis b,Drug: Tenofovir disoproxil 245mg|Drug: Tenofovir disoproxil fumarate 300mg,"Samjin Pharmaceutical Co., Ltd.",Phase 4,113,Industry,"October 12, 2018","August 10, 2020","August 10, 2020"
1190,NCT05285787,A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD),End-Stage Renal Disease (ESRD),Drug: EPN-701 (Oral),"Epizon Pharma, Inc.",Phase 2,20,Other,"March 1, 2019","April 30, 2021","April 30, 2021"
1191,NCT05283681,A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants,Healthy Volunteers,Drug: Risankizumab,AbbVie,Phase 1,226,Industry,"April 2, 2019","November 11, 2019","November 11, 2019"
1192,NCT05283616,Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer,Neutropenia,Drug: Pegfilgrastim,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 3,122,Other,"May 15, 2017","October 10, 2019","October 15, 2021"
1193,NCT05283499,Opioid Analgesic Reduction Study (OARS) - Pilot,Post Operative Pain,Drug: OPIOID|Drug: NON-OPIOID,"Rutgers, The State University of New Jersey|University of Illinois at Chicago|University of Maryland, Baltimore|University of Michigan|University of Rochester",Phase 3,53,Other,"July 6, 2020","March 12, 2021","March 26, 2021"
1194,NCT05283278,Effect of Administration of Combined Enteral Lactoferrin and Probiotic On Invasive Fungal Infections In Preterm Neonates,Fungal Infection,Drug: Lactoferrin Bovine|Combination Product: Lactoferrin Bovine and probiotics|Other: Placebo,Ain Shams University,Phase 1,80,Other,"February 10, 2020","March 27, 2021","April 27, 2021"
1195,NCT05282914,"A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects",GERD,Drug: administration of UI058|Drug: administration of UIC202004,Korea United Pharm. Inc.,Phase 1,41,Industry,"February 3, 2021","April 14, 2021","September 1, 2021"
1196,NCT05276336,The Effect of Early Radiofrequency Turbinate Reduction on Persistent Allergic Rhinitis,Allergic Rhinitis,Procedure: Radiofrequency turbinate reduction|Drug: Pharmacology treatment,Indonesia University,Phase 3,32,Other,"July 1, 2018","February 1, 2020","February 1, 2020"
1197,NCT05276323,Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study,Atopic Dermatitis,Drug: Medihoney Derma Cream|Drug: Hydrocortisone 1% cream,Soroka University Medical Center,Phase 2,30,Other,"October 1, 2020","February 28, 2021","December 31, 2021"
1198,NCT05274087,Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers,Healthy Volunteers,Drug: Risankizumab,AbbVie,Phase 1,30,Industry,"September 15, 2020","April 7, 2021","April 7, 2021"
1199,NCT05271058,Effect of Intracameral Steroids During Phacoemulsification on the Cornea,Corneal Edema,Other: Control group|Drug: Dexamethasone group|Drug: Triamcinolone (TA) group,Cairo University|Beni-Suef University,Phase 3,69,Other,"June 16, 2019","June 16, 2020","August 15, 2020"
1200,NCT05268068,A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China,Healthy Volunteers,Drug: Risankizumab,AbbVie,Phase 1,30,Industry,"June 27, 2019","April 26, 2020","April 26, 2020"
1201,NCT05267938,Microneedle Pretreatment as a Strategy to Improve the Effectiveness of Topical Anesthetics Formulations,Oral Cavity Disease,Drug: Topical Anesthetic|Drug: Local anesthetic,"University of Campinas, Brazil|Texas Tech University",Phase 1,30,Other,"August 1, 2019","October 30, 2019","January 30, 2020"
1202,NCT05265676,Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects,Healthy,Drug: Enoxaparin Sodium (Venus Remedies Limited)|Drug: Enoxaparin Sodium (Sanofi),Venus Remedies Limited,Phase 1,24,Industry,"February 26, 2021","March 7, 2021","March 11, 2021"
1203,NCT05264493,Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector,Healthy Volunteers,"Drug: NaxRedy ™|Drug: Naloxone Hydrochloride Injection, USP",Pfizer,Phase 1,13,Industry,"October 6, 2020","January 8, 2021","January 8, 2021"
1204,NCT05259098,Morphine vs Sufentanil PCA: Same Same or Different?,Analgesia|Post Operative Pain|Patient Satisfaction|Chronic Pain,Drug: Sufentanil Sublingual Tablet System|Drug: Intravenous Patient-Controlled Analgesia with morfine,Hospital Central do Funchal,Phase 4,54,Other,"October 1, 2019","June 30, 2020","October 31, 2020"
1205,NCT05258955,Title: Comparison of Anti-plaque Efficacy of Natural Honey With Chlorhexidine Mouthwash: A Randomized Controlled Trial,Dental Plaque,Other: Natural honey|Drug: Chlorhexidine mouthwash,Liaquat National Hospital & Medical College|Liaquat College of Medicine and Dentostry,Phase 1,60,Other,"June 3, 2020","December 30, 2020","January 21, 2021"
1206,NCT05253456,Modified Second Layer Repair for Distal Penile Hypospadias,Hypospadias,Procedure: Derma -Dartos Flap for second layer closure,Ain Shams University,Phase 2,102,Other,"March 1, 2018","September 1, 2020","September 2, 2020"
1207,NCT05247385,Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel,Coronary Artery Disease,Drug: Prasugrel|Drug: Ticagrelor,University of Sao Paulo,Phase 4,87,Other,"March 20, 2017","February 26, 2021","December 20, 2021"
1208,NCT05246631,Haloperidol and Dexamethasone Towards Postoperative Nausea and Pain in Adult After Laparoscopy,Laparoscopy|Postoperative Nausea and Vomiting,Drug: Dexamethasone injection|Drug: Haloperidol Injection,Indonesia University,Phase 4,80,Other,"January 1, 2020","March 30, 2020","July 30, 2020"
1209,NCT05244759,"Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937",Healthy,Drug: [14C]-BLU-5937,Bellus Health Inc,Phase 1,6,Industry,"August 25, 2020","September 23, 2020","March 2, 2021"
1210,NCT05241509,Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis,Periodontitis Chronic Generalized Moderate,Drug: Cymbopogon citratus (lemongrass) oil gel,Souzy Kamal|Alexandria University,Phase 4,40,Other,"July 6, 2019","December 14, 2020","December 4, 2021"
1211,NCT05240872,Effects of Autologous Blood Injection Versus Platelet Rich Plasma on Chronic Plantar Fasciitis,Plantar Fascitis,Biological: PRP injection|Biological: ABI injection,Istanbul Training and Research Hospital,Phase 3,60,Other,"March 1, 2020","October 30, 2020","January 15, 2022"
1212,NCT05238714,"Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects",Disorders of Sphingolipid Metabolism (Healthy Volunteers),Drug: venglustat,"Genzyme, a Sanofi Company|Sanofi",Phase 1,6,Industry,"May 26, 2020","June 26, 2020","June 26, 2020"
1213,NCT05237115,Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy,Gastritis|Peptic Ulcer|Dyspepsia,Drug: Clostridium butyricum capsule|Drug: esomeprazole|Drug: amoxicillin|Drug: clarithromycin|Drug: Bacillus clotting|Drug: Bismuth,Xijing Hospital of Digestive Diseases,Phase 4,600,Other,"May 5, 2020","December 5, 2020","December 5, 2020"
1214,NCT05229536,Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months,"Meningitis, Meningococcal",Biological: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 2,720,Industry,"December 21, 2018","November 21, 2019","November 21, 2019"
1215,NCT05226728,Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer,Non-small Cell Lung Cancer,Drug: pembrolizumab,Sun Yat-sen University,Phase 1,33,Other,"October 10, 2018","February 1, 2021","February 1, 2021"
1216,NCT05226000,Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults,Overweight/Obese Adults,Drug: Benaglutide Injection,The Affiliated Hospital of Qingdao University,Phase 1,16,Other,"July 7, 2020","December 1, 2020","May 20, 2021"
1217,NCT05223361,Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery,Heart Valve Diseases,Drug: Six percent hydroxy ethyl starch 130/0.4|Drug: Ringer lactate,Rajaie Cardiovascular Medical and Research Center|Heart Valve Disease Research Center,Phase 3,120,Other,Apr-16,"April 30, 2021","November 30, 2021"
1218,NCT05222243,DPC in Primary Molars.,Direct Pulp Capping in Primary Teeth,Drug: Direct pulp capping with calcium hydroxide|Drug: Direct pulp capping with MTA|Drug: Direct pulp capping with Formocresol,Mansoura University,Phase 4,60,Other,"January 1, 2019","August 3, 2020","December 1, 2020"
1219,NCT05219461,"Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects",Dry Eye Syndromes,Drug: Single dose of rhEGF 10mcg/ml or placebo|Drug: Single dose of rhEGF 50mcg/ml or placebo|Drug: Single dose of rhEGF 100mcg/ml or placebo|Drug: Multiple dose of rhEGF 10mcg/ml or placebo|Drug: Multiple dose of rhEGF 50mcg/ml or placebo|Drug: Multiple dose of rhEGF 100mcg/ml or placebo,Daewoong Bio Inc.,Phase 1,48,Industry,"March 29, 2019","November 13, 2019","November 13, 2019"
1220,NCT05216289,The Efficacy of an Oral Probiotic Associated With a Fixed Combination of Benzoyl Peroxide and Adapalene in the Treatment of Acne,Acne Vulgaris,Dietary Supplement: Probiac|Other: Placebo,Federal University of São Paulo|Medcin Instituto da Pele Ltda,Phase 4,400,Other,"April 1, 2018","April 1, 2021","April 1, 2021"
1221,NCT05214690,A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2,Osteoarthritis|Rheumatoid Arthritis|Back Pain|Acute Upper Respiratory Tract Infection,Drug: DW1809-T2|Drug: DW1809-1,"Daewon Pharmaceutical Co., Ltd.",Phase 1,37,Industry,"August 13, 2020","September 8, 2020","September 8, 2020"
1222,NCT05214677,A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809,Osteoarthritis|Rheumatoid Arthritis|Back Pain|Acute Upper Respiratory Tract Infection,Drug: DW1809|Drug: DW1809-1,"Daewon Pharmaceutical Co., Ltd.",Phase 1,38,Industry,"August 15, 2020","September 7, 2020","September 7, 2020"
1223,NCT05213182,Peer Support Intervention to Mitigate Social Isolation and Stigma of Adolescent Motherhood in Zimbabwe,"Mental Health Disorder|Social Isolation|Stigma, Social",Behavioral: Young Women of Today,West Chester University of Pennsylvania|Bill and Melinda Gates Foundation|University of South Carolina|Organization for Public Health Interventions and Development|University of Zimbabwe|SpeakUp! Pennsylvania,Phase 2,183,Other,"October 1, 2018","September 30, 2019","September 30, 2019"
1224,NCT05208996,The siCoV/KK46 Drug Open-safety Study,COVID-19,Drug: siCoV/KK46,National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia|St. Petersburg Research Institute of Vaccines and Sera,Phase 1,10,Other,"January 22, 2021","March 26, 2021","March 26, 2021"
1225,NCT05197517,Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition,Bioequivalence,Drug: Rosuvastatin 10 mg,Rania Mahmoud Mohamed|Future University in Egypt,Phase 1,38,Other,"September 21, 2020","October 1, 2020","October 1, 2020"
1226,NCT05197374,Effect of Estradiol Pretreatment on Antagonist ICSI Cycles,Female Infertility,Drug: Estradiol Valerate 4mg,Alexandria University,Phase 4,114,Other,"June 1, 2020","February 20, 2021","November 15, 2021"
1227,NCT05194046,"Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers",Helicobacter Pylori Associated Gastrointestinal Disease,Drug: JP-1366 20mg 1capsule|Drug: Amoxicillin 500Mg Cap|Drug: Clarithromycin 500Mg Tab,Onconic Therapeutics Inc.,Phase 1,29,Industry,"November 18, 2020","January 16, 2021","January 19, 2021"
1228,NCT05192902,Pain Perception Following Computer-Controlled vs. Conventional Dental Anesthesia,Pain Perception,Device: Computer-controlled Local Anaesthesia (CCLA)|Device: Conventional Local Anaesthesia,University of Giessen,Phase 4,60,Other,"September 1, 2019","June 30, 2020","December 31, 2020"
1229,NCT05181124,Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian,Anti-Ulcer Agents,Drug: coadministration of JP-1366 and aceclofenac|Drug: coadministration of JP-1366 and meloxicam|Drug: coadministration of JP-1366 and naproxen|Drug: single-dosing of JP-1366 in Korean and Caucasian,Onconic Therapeutics Inc.,Phase 1,88,Industry,"March 5, 2021","March 15, 2021","March 23, 2021"
1230,NCT05178823,Short- and Long Term Antibacterial Effects of a Single Rinse With Different Mouthwashes: a Randomized Clinical Trial,Gingival Diseases|Caries,Drug: Chlorhexidine mouthwash,Semmelweis University,Phase 4,171,Other,"June 1, 2017","September 1, 2019","September 1, 2020"
1231,NCT05178355,"A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers",Hereditary Angioedema,Drug: KVD824|Drug: Placebo to KVD824,"KalVista Pharmaceuticals, Ltd.",Phase 1,108,Industry,"February 12, 2019","June 21, 2019","June 21, 2019"
1232,NCT05175833,Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19,COVID-19 Lower Respiratory Infection|Microbial Colonization|Severe COVID-19|Secondary Bacterial Pneumonia,Combination Product: Oral probiotics|Other: Oral placebo,Universidade de Passo Fundo,Phase 2,70,Other,"September 11, 2020","January 25, 2021","February 7, 2021"
1233,NCT05174598,A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis,Mild to Moderate Plaque Psoriasis,"Drug: Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Drug: Calcipotriol Ointment 50 micrograms/g|Other: Placebo","Cadila Pharnmaceuticals|Lipidor AB, Svärdvägen 13 SE-182 33 Danderyd, Sweden",Phase 3,278,Industry|Other,"October 3, 2018","November 6, 2019","December 3, 2020"
1234,NCT05173545,Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects,Recurrent/Refractory Lymphoma,Drug: Mitoxantrone Hydrochloride Liposome Injection,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1,24,Industry,"July 29, 2019","October 28, 2020","October 28, 2020"
1235,NCT05169801,To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC,Non-small Cell Lung Cancer(NSCLC),"Drug: BP102, paclitaxel, carboplatin|Drug: Avastin®, paclitaxel, carboplatin","Jiangsu HengRui Medicine Co., Ltd.",Phase 3,520,Industry,"January 25, 2018","October 21, 2019","June 17, 2021"
1236,NCT05163756,To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient,Gastritis Acute|Gastritis Chronic,Drug: DW1903|Drug: DW1903-R1,"Daewon Pharmaceutical Co., Ltd.",Phase 3,332,Industry,"November 25, 2020","April 27, 2021","May 10, 2021"
1237,NCT05160090,Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg,Bioequivalence,Drug: Bupropion HCl MR tablets 300mg,Alembic Pharmaceuticals Ltd.,Phase 1,34,Industry,"January 18, 2020","February 5, 2020","February 5, 2020"
1238,NCT05158647,Adding Magnesium Sulfate to Bupivacaine for Ilioinguinal and Iliohypogastric Nerve Block,Magnesium Sulfate Causing Adverse Effects in Therapeutic Use,Other: normal saline|Drug: MgSo4,"Abdelrady S Ibrahim, MD|Assiut University",Phase 2,90,Other,"August 12, 2018","February 7, 2020","April 21, 2020"
1239,NCT05155540,Direct Mechanical Thrombectomy Versus Bridging Therapy,Thrombectomy|Ischemic Stroke|Large-Artery Atherosclerosis (Embolus/Thrombosis),Device: Trevo and or Merci devices for stent retreival|Device: Penumbra system for stent aspiration|Drug: recombinant tissue plasminogen activator,Alexandria University,Phase 4,51,Other,"July 1, 2019","July 1, 2020","September 1, 2020"
1240,NCT05155072,Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903,Gastritis,Drug: DW1903|Drug: DW1903-R1|Drug: DW1903-R2,"Daewon Pharmaceutical Co., Ltd.",Phase 1,31,Industry,"May 15, 2020","September 7, 2020","September 7, 2020"
1241,NCT05152017,"The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers",Influenza,Biological: Flu-M Quadro [inactivated split influenza vaccine] with preservative|Biological: Flu-M Quadro [inactivated split influenza vaccine] without preservative|Biological: Placebo,St. Petersburg Research Institute of Vaccines and Sera,Phase 1,75,Other,"November 16, 2019","January 22, 2020","January 24, 2020"
1242,NCT05149924,Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment,Infertility,Drug: QL1012|Drug: Gonal-f ®,"Qilu Pharmaceutical Co., Ltd.",Phase 3,354,Industry,"October 31, 2018","October 17, 2019","October 17, 2019"
1243,NCT05147207,SuperPath Versus Posterior Approach for THA,Surgical Approach|Hip Arthropathy,Procedure: Superpath Approach,Queen's University,Phase 4,45,Other,"April 1, 2017","May 1, 2019","June 1, 2021"
1244,NCT05140096,A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants,Healthy Volunteers,Drug: Acalabrutinib|Drug: Fluconazole|Drug: Isavuconazole,Acerta Pharma BV,Phase 1,30,Industry,"January 3, 2020","April 15, 2020","April 15, 2020"
1245,NCT05138367,Effects of UCA-PSCs in Women With POF,Premature Ovarian Failure,Procedure: transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients,Li-jun Ding|Nanjing University,Phase 1,20,Other,"December 1, 2018","December 1, 2019","December 1, 2019"
1246,NCT05136521,Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions,Healthy,Drug: Trazodone HCl - new polymer|Drug: Trazodone HCl - Contramid®,Aziende Chimiche Riunite Angelini Francesco S.p.A|Cross Research S.A.,Phase 1,28,Industry,"February 17, 2020","July 19, 2020","July 19, 2020"
1247,NCT05135793,"Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)",Healthy,Drug: Topoprazan|Drug: Takecab,"Genuine Research Center, Egypt|Hikma Pharma",Phase 1,29,Industry|Other,"January 19, 2021","February 2, 2021","March 1, 2021"
1248,NCT05135143,Role of Antioxidants in the Reduction of Oxidative Stress in Infertile Patients,Infertility|Oligoasthenozoospermia|Male,Combination Product: Antioxidant formula,"University of Tetova|University of Tetova, Faculty of Medical Sciences",Phase 4,211,Other,"September 1, 2017","June 30, 2019","January 31, 2021"
1249,NCT05134350,Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants,Healthy Volunteers,Drug: LOXO-305|Drug: Omeprazole,"Loxo Oncology, Inc.|Eli Lilly and Company",Phase 1,10,Industry,"February 6, 2020","March 23, 2020","March 23, 2020"
1250,NCT05134337,Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants,Healthy Volunteers,Drug: LOXO-305|Drug: Itraconazole|Drug: Rifampin,"Loxo Oncology, Inc.|Eli Lilly and Company",Phase 1,24,Industry,"February 12, 2020","October 30, 2020","October 30, 2020"
1251,NCT05133752,Oral Nemonoxacin in Treating Elderly Patients With CAP,Community-acquired Pneumonia,Drug: Nemonoxacin,"TaiGen Biotechnology Co., Ltd.",Phase 4,100,Industry,"September 11, 2018","March 23, 2020","March 23, 2020"
1252,NCT05126628,The South Proxa-Rescue AndroCoV Trial Against COVID-19,COVID-19,Drug: Proxalutamide|Drug: Placebo,"Corpometria Institute|Hospital da Brigada Militar de Porto Alegre, Porto Alegre, Brazil|Hospital Arcanjo Sao Miguel, Gramado, Brazil|Hospital Unimed Chapeco, Chapeco, Brazil",Phase 3,133,Other,"March 6, 2021","March 16, 2021","April 15, 2021"
1253,NCT05125640,Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects,Pharmacokinetics,"Drug: Progesterone 200 mg Soft Capsule (JSC ""Farmak"", Ukraine)|Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)","Joint Stock Company ""Farmak""",Phase 1,48,Industry,"December 13, 2019","January 7, 2020","January 7, 2020"
1254,NCT05125627,Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route,Pharmacokinetics,"Drug: Progesterone 200 mg Soft Capsule (JSC ""Farmak"", Ukraine)|Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)","Joint Stock Company ""Farmak""",Phase 1,66,Industry,"August 28, 2019","October 21, 2019","October 21, 2019"
1255,NCT05124717,Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers,Pharmacokinetics,"Drug: Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|Drug: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)","Joint Stock Company ""Farmak""",Phase 1,28,Industry,"June 25, 2019","July 3, 2019","July 3, 2019"
1256,NCT05123976,"Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.",Pharmacokinetics,"Drug: Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|Drug: Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)","Joint Stock Company ""Farmak""",Phase 1,32,Industry,"October 21, 2020","November 30, 2020","November 30, 2020"
1257,NCT05123170,Dexmedetomidine in IVRA,Regional Anesthesia Morbidity,Drug: Dexmedetomidine Injectable Solution [Dexdomitor]|Drug: Lidocaine IV,Menoufia University,Phase 4,90,Other,"February 28, 2020","March 25, 2021","June 20, 2021"
1258,NCT05122312,Comparative Study on the Efficacy of OliNano SEAL and Curodont D' Senz in Treatment of Dentin Hypersensitivity,Dentin Hypersensitivity,Drug: Olinanoseal|Drug: Curodont D'senz,Al-Azhar University,Phase 4,70,Other,"April 20, 2020","November 23, 2020","January 12, 2021"
1259,NCT05118958,Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations,Hereditary Angioedema,Drug: KVD824 Prototype 1 modified-release tablet|Drug: KVD824 Prototype 2 modified-release tablet|Drug: KVD824 Immediate-Release Capsule|Drug: Placebo to KVD824 Prototype 1|Drug: KVD824 Prototype 3 modified-release tablet,"KalVista Pharmaceuticals, Ltd.",Phase 1,37,Industry,"May 19, 2020","December 1, 2020","December 1, 2020"
1260,NCT05118542,Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Hyperthyroidism|Graves Disease|Atherosclerosis of Artery|Pathophysiology,Drug: Propylthiouracil|Drug: Methimazole,Indonesia University,Phase 3,36,Other,"January 1, 2019","June 1, 2020","August 1, 2020"
1261,NCT05110118,"Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects",Metastatic Colorectal Cancer|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Recurrent,Drug: LY01008|Drug: Avastin,"Shandong Boan Biotechnology Co., Ltd",Phase 1,112,Industry,"August 4, 2020","January 13, 2021","January 13, 2021"
1262,NCT05109455,Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.,Kidney Transplant Infection,Dietary Supplement: MANOSAR®|Dietary Supplement: Proanthocyanidins,"Arafarma Group, S.A.",Phase 4,60,Industry,"April 16, 2019","March 25, 2021","February 17, 2023"
1263,NCT05108597,Effect of Rectal Misoprostol in Reducing Intra-operative Blood Loss During Myomectomy,"Blood Loss, Surgical|Uterine Myoma",Drug: Misoprostol,Pak Emirates Military Hospital,Phase 3,200,Other,"March 4, 2019","March 4, 2020","March 4, 2020"
1264,NCT05108051,Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir,Drug-drug Interaction,Drug: ZSP1273|Drug: Oseltamivir,"Guangdong Raynovent Biotech Co., Ltd",Phase 1,36,Industry,"November 19, 2020","March 17, 2021","March 17, 2021"
1265,NCT05104931,PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects,Pain,Drug: Nanoformed Piroxicam IR Tablet|Drug: Felden (piroxicam) Tablets|Drug: Brexidol (piroxicam) Tablets,Nanoform Finland Plc,Phase 1,12,Industry,"December 2, 2020","February 1, 2021","February 1, 2021"
1266,NCT05103878,"A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects",Healthy Volunteers,Drug: BT051 100mg|Drug: BT051 300mg|Drug: BT051 700mg|Drug: BT051 1500mg|Drug: BT051 3500mg|Drug: Matching Placebo,"Bacainn Therapeutics, Inc.|Adiso Therapeutics",Phase 1,50,Industry,"June 24, 2020","November 13, 2020","November 13, 2020"
1267,NCT05101811,Vitamin D Levels in Women With Polycystic Ovary Syndrome,Polycystic Ovary Syndrome,Drug: Vitamin D Levels measurement using chemiluminescent assay|Device: Vitamin D level assessment,Ghamra Military Hospital|Al-Azhar University,Phase 4,90,Other,"May 1, 2020","April 1, 2021","May 1, 2021"
1268,NCT05096312,Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients,Acne Vulgaris,Dietary Supplement: Zinc gluconate|Drug: Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Other: Placebo,"East Avenue Medical Center, Philippines",Phase 4,23,Other,"December 21, 2018","July 19, 2019","July 20, 2019"
1269,NCT05095545,Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza,Influenza,Drug: AV5080|Other: Placebo,Viriom,Phase 2,135,Industry,"November 13, 2017","August 7, 2019","August 30, 2019"
1270,NCT05095480,Effect of Red Yeast Rice Beside Statin on Lipid Profile,Hyperlipidemias,Drug: Red Yeast Rice Pill|Drug: Placebo,Shiraz University of Medical Sciences,Phase 4,92,Other,"March 1, 2019","March 1, 2021","April 1, 2021"
1271,NCT05091008,Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children,"Hepatitis C, Chronic",Drug: Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet,Mansoura University Children Hospital,Phase 2,50,Other,"March 1, 2018","August 30, 2019","March 10, 2020"
1272,NCT05090449,"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions",Healthy,Drug: Chlorthalidone (HIGROTON® 50)|Drug: Losartan (COZZAR®)|Drug: A1+ A2 Co-administration of Chlorthalidone and Losartan|Drug: Chlorthalidone + Losartan Fixed-Dose combination,Laboratorios Silanes S.A. de C.V.,Phase 1,36,Industry,"May 1, 2019","April 8, 2020","May 25, 2020"
1273,NCT05089123,"The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old",Influenza,Biological: Flu-M [Inactivated split influenza vaccine]|Biological: Inactivated Split Influenza Vaccine,St. Petersburg Research Institute of Vaccines and Sera,Phase 3,320,Other,"March 3, 2020","May 28, 2020","August 24, 2020"
1274,NCT05088642,A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects,Sever Aplastic Anaemia,Drug: Hetrombopag Olamine Tablet,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"September 28, 2020","December 4, 2020","December 4, 2020"
1275,NCT05088343,Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects,Healthy Subjects,Drug: Rosuvastatin|Drug: Hetrombopag,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,14,Industry,"September 7, 2020","January 16, 2021","January 16, 2021"
1276,NCT05088174,A Trial of Hetrombopag in Healthy Subjects,Sever Aplastic Anaemia,Drug: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,26,Industry,"September 3, 2020","October 22, 2020","October 22, 2020"
1277,NCT05087797,The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion,Coronary Artery Disease,Drug: nicorandil,Peking University Third Hospital,Phase 4,61,Other,"April 8, 2019","July 8, 2020","July 8, 2020"
1278,NCT05082753,"Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions",Anthelmintic Agent,Drug: Ivermectin tablets (3 mg Ivermectin)|Drug: Stromectol ® tablets,Pharmactive Ilac Sanayi ve Tic A.S.,Phase 1,50,Industry,"November 19, 2020","December 21, 2020","December 21, 2020"
1279,NCT05081349,Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia,Sickle Cell Disease,"Drug: Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Drug: Hydroxycarbamide 500 Mg Oral Capsule|Drug: L-Carnitine, 250 Mg Oral Capsule",Assiut University,Phase 4,91,Other,"January 10, 2017","June 10, 2020","July 10, 2021"
1280,NCT05078372,Ropivacaine and Midazolam by Intraarticular vs Epidural Administration in Arthroscopic ACL,Anterior Cruciate Ligament Injuries|Anesthesia Injection Site|Knee Injuries,Drug: ropivacaine and midazolam intraarticular administration|Drug: ropivacaine and midazolam epidural administration,Universidad Autonoma de Nuevo Leon|Universitat Autonoma de Barcelona,Phase 2,108,Other,"January 31, 2019","January 31, 2021","February 5, 2021"
1281,NCT05075304,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients",COVID-19,Drug: BDB-001 injection,"Staidson (Beijing) Biopharmaceuticals Co., Ltd|Beijing Defengrui Biotechnology Co. Ltd",Phase 1,18,Industry|Other,"February 21, 2020","April 14, 2020","April 14, 2020"
1282,NCT05070520,"Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites",MALARIA,Drug: Artemether-lumefantrine,"Programme National de Lutte contre le Paludisme, Niger",Phase 4,259,Other,"September 1, 2020","September 30, 2020","October 28, 2020"
1283,NCT05070468,Effect of Dexamethasone on Labor Induction,Dexamethasone|Pregnancy,Drug: Dexamethasone 0.5mg|Drug: Placebo,Alborz Medical University,Phase 3,84,Other,"November 22, 2020","January 21, 2021","March 21, 2021"
1284,NCT05069246,"The Clinical Assessment of Nigella Sativa Oil vs Chlorohexidine as a Therapeutic Aid for Gingivitis, Effect on Gingival IL-6 and IL-18 and Antimicrobial Efficacy.",Gingivitis,Other: Nigella Sativa oil|Drug: Chlorhexidine mouthwash,Ishrat Rahman|Princess Nourah Bint Abdulrahman University,Phase 2,37,Other,"December 8, 2020","December 24, 2020","February 28, 2021"
1285,NCT05066516,"The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects",Diabetes Mellitus,"Drug: FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin",Korea University Anam Hospital,Phase 1,48,Other,"June 25, 2020","August 18, 2020","October 18, 2020"
1286,NCT05060809,Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients,Vascular Calcification,Drug: oral vitamin k1 (phylloquinone),Assiut University,Phase 4,120,Other,"January 1, 2018","July 30, 2019","January 1, 2020"
1287,NCT05058209,"Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance","Osteoarthritis, Knee",Drug: Triamcinolone acetonide extended-release injectable suspension|Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension,ROC Foundation,Phase 4,20,Other,"November 30, 2020","April 28, 2021","April 28, 2021"
1288,NCT05058118,"Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)",Healthy,Drug: FL058|Drug: Placebo,"Qilu Pharmaceutical Co., Ltd.",Phase 1,54,Industry,"December 8, 2019","June 3, 2020","June 3, 2020"
1289,NCT05058105,"Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)",Healthy,Drug: FL058 500mg and Meropenem 1000mg（ IV 120min）|Drug: FL058 Placebo and Meropenem 1000mg（ IV 120min）|Drug: FL058 1000mg（ IV 120min）|Drug: FL058 Placebo （ IV 120min）|Drug: Meropenem 1000 mg （ IV 120min）|Drug: Meropenem Placebo （ IV 120min）|Drug: FL058 1000mg and Meropenem 1000mg （ IV 120min）|Drug: FL058 Placebo and Meropenem 1000mg （ IV 120min）|Drug: FL058 1000mg and Meropenem 2000mg （ IV 120min）|Drug: FL058 Placebo and Meropenem 2000m（ IV 120min）|Drug: FL058 1000mg and Meropenem 2000mg （ IV 180min）|Drug: FL058 Placebo and Meropenem 2000m（ IV 180min）|Drug: FL058 2000mg and Meropenem 2000mg（ IV 180min）|Drug: FL058 Placebo and Meropenem 2000mg（ IV 180min）,"Qilu Pharmaceutical Co., Ltd.",Phase 1,40,Industry,"October 8, 2020","February 24, 2021","February 24, 2021"
1290,NCT05056935,"Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus",Ileus,Drug: LB1148|Drug: Placebo,"Newsoara Biopharma Co., Ltd.",Phase 2,131,Industry,"July 9, 2019","July 22, 2020","August 8, 2020"
1291,NCT05055752,"Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.",Bioequivalence,Drug: Pharmaceutical-lipid aspirin (PL-ASA),PLx Pharma,Phase 1,24,Industry,"May 7, 2020","June 29, 2020","October 1, 2020"
1292,NCT05055687,"Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)",Healthy,Drug: FL058|Drug: Placebo,"Qilu Pharmaceutical Co., Ltd.",Phase 1,20,Industry,"July 5, 2020","July 27, 2020","July 27, 2020"
1293,NCT05052437,PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer,Advanced and Metastatic Breast Cancer,Drug: Utidelone Injection; capecitabine|Drug: Utidelone,"Beijing Biostar Pharmaceuticals Co., Ltd.|Chengdu Biostar Pharmaceuticals",Phase 1,16,Industry,"October 15, 2020","January 13, 2021","February 19, 2021"
1294,NCT05047484,A Study of Multiple Doses of ALXN2050 in Healthy Adults,Healthy,Drug: ALXN2050|Drug: Placebo,"Alexion|Achillion, a wholly owned subsidiary of Alexion",Phase 1,45,Industry,"January 7, 2019","July 23, 2019","July 23, 2019"
1295,NCT05045248,Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis,Myasthenia Gravis|Ocular Myasthenia Gravis,Drug: Apraclonidine Hcl 0.5% Oph Soln,American University of Beirut Medical Center,Phase 2,10,Other,"June 1, 2020","April 15, 2021","April 15, 2021"
1296,NCT05042297,Combined Ring (APR) Fixation Vs Posterior Ring Fixation in Tile B2 and C1 Pelvic Ring Injuries,Evaluation of PR Fixation in Tile B2 and C1 Injuries,Procedure: Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention,Ain Shams University,Phase 2,40,Other,"March 9, 2019","July 7, 2020","July 15, 2021"
1297,NCT05041985,Clinical Efficacy of Diazepam After Whiplash : A Randomized Controlled Study,Whiplash Injuries|Whiplash Injury of Cervical Spine,Drug: Diazepam Tablets,Edin Mešanović|Cantonal Hospital Dr. Safet Mujic Mostar,Phase 4,89,Other,"January 1, 2020","December 31, 2020","December 31, 2020"
1298,NCT05040828,Early Intervention in Allergic Patients,Allergic Rhinitis Due to Weed Pollen|Montelukast,Behavioral: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Behavioral: Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|Drug: No oral drug therapy throughout the pollen period,Beijing Tongren Hospital,Phase 4,59,Other,"July 1, 2020","September 30, 2020","November 10, 2020"
1299,NCT05038969,"Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)",Healthy,Drug: Stomopral|Drug: Nexium,"Genuine Research Center, Egypt|Future Pharmaceuticals Industries, Egypt",Phase 1,30,Industry|Other,"March 18, 2021","April 1, 2021","May 28, 2021"
1300,NCT05032391,"Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization",Rotavirus Infection,"Biological: The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Drug: Placebo",Limited Liability Company Pharm Aid,Phase 3,100,Other,"February 22, 2019","September 22, 2019","October 25, 2019"
1301,NCT05030116,Clinical Trial for 'Shen Qu Xiao Shi' Oral Liquid in the Treatments of Children's Functional Dyspepsia,Dyspepsia,Drug: Shenqu Xiaoshi oral liquid|Drug: Domperidone suspension,Ruijin Hospital,Phase 4,356,Other,"June 26, 2019","May 10, 2020","May 23, 2020"
1302,NCT05029076,Human Bioequivalence Test of Liraglutide Injection,Type 2 Diabetes,Drug: Liraglutide injection|Drug: Victoza,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Phase 1,28,Industry,"May 21, 2019","June 1, 2019","July 1, 2019"
1303,NCT05027126,"Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen, in Healthy Subjects, Under Fasting Conditions",Healthy,Drug: Dexketoprofen 25 MG|Drug: Fixed dose Dexketoprofen-Vitamin B Complex,Laboratorios Silanes S.A. de C.V.,Phase 1,36,Industry,"February 28, 2019","November 15, 2019","December 2, 2019"
1304,NCT05025306,Healing Effect of Ziziphus Honey on Extracted Tooth Socket in Humans by Evaluating the Levels of BMP-2 and OPN,Healing Wound,Drug: ziziphus honey,"Postgraduate Medical Institute, Lahore",Phase 3,30,Other,"January 1, 2020","March 16, 2020","June 1, 2020"
1305,NCT05022108,Alpha-Bisabolol Gel With Antihistamine Action,Wounds and Injuries,Biological: Alpha bisabolol gel,Universidade do Vale do Sapucai,Phase 1,20,Other,"April 1, 2020","August 1, 2020","December 20, 2020"
1306,NCT05021016,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,Covid19,Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19),"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",Phase 3,150,Other,"November 19, 2020","January 30, 2021","January 30, 2021"
1307,NCT05020067,Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy,Nasopharyngeal Carcinoma|Radiation-induced Xerostomia,Radiation: superficial parotid lobe-sparing intensity-modulated radiotherapy,Sun Yat-sen University,Phase 2,90,Other,"January 12, 2018","November 6, 2019","August 17, 2021"
1308,NCT05017870,"[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001",Dry Eye Syndromes,Drug: KSR-001|Drug: KSR-004|Drug: KSR-001-02|Drug: KSR-001-03,Kukje Pharma,Phase 1,24,Other,"December 2, 2018","June 14, 2019","January 15, 2020"
1309,NCT05015322,Comparison of the Effectiveness of the Ultrasound Guided Injections in Patients With Shoulder Impingement Syndrome,Shoulder Impingement|Ultrasound Guided Injection,Drug: bupivacaine and methylprednisolone,Bursa Yüksek İhtisas Education and Research Hospital,Phase 4,88,Other,"January 1, 2017","January 1, 2021","January 1, 2021"
1310,NCT05014490,Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers,Bioequivalence|Healthy Subjects,Drug: Exib 120 mg etoricoxib film-coated tablets|Drug: Arcoxia® 120 mg etoricoxib film-coated tablets,Darnitsa Pharmaceutical Company|Anapharm Bioanalytics,Phase 1,28,Industry|Other,"February 24, 2021","March 24, 2021","March 24, 2021"
1311,NCT05013164,Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder,Autism Spectrum Disorder,Drug: Folinic Acid,Nishtar Medical University,Phase 2,44,Other,"October 1, 2020","March 30, 2021","March 30, 2021"
1312,NCT05008367,Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty,Postoperative Pain,Drug: Dexamethasone|Drug: Isotonic saline,"Naestved Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4,485,Other,"September 14, 2018","March 11, 2020","June 7, 2020"
1313,NCT05008068,Effect of Local Application of Platelet-rich Fibrin Scaffold Loaded With Simvastatin on Peri-implant Bone Changes,Platelet-rich Fibrin|Simvastatin,Drug: Simvastatin,British University In Egypt,Phase 1,8,Other,"August 12, 2019","September 12, 2020","September 12, 2020"
1314,NCT05006898,Compound to Control Presbyopia Symptoms,Presbyopia,Combination Product: PBO to control presbyopia symptoms,Optall Vision,Phase 1,11,Other,"June 1, 2020","July 1, 2020","July 1, 2020"
1315,NCT05004753,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,Covid19,Dietary Supplement: Artemisinin|Drug: Dexamethasone,Mateon Therapeutics|Windlas Biotech Private Limited,Phase 4,120,Industry|Other,"September 30, 2020","February 28, 2021","April 30, 2021"
1316,NCT05002361,Effect of Dexamethasone Shortly Before Surgery on the Intraoperative Dose of Remifentanil,Perioperative Pain,Drug: Dexamethasone|Drug: Isotonic saline,Naestved Hospital|Bispebjerg Hospital,Phase 4,94,Other,"September 14, 2018","March 11, 2020","June 7, 2020"
1317,NCT05002101,Daily Zinc Supplement Effect on Prevention of Diarrhea and Acute Respiratory Infections in Children Less Than Five Years,Zinc Deficiency|Child Nutrition Disorders,Dietary Supplement: zinc|Drug: Placebo,Ain Shams University,Phase 4,140,Other,"August 1, 2018","August 1, 2019","August 1, 2020"
1318,NCT04997707,The Effect of Balanced Anesthesia Regimen on Intraoperative Trans-cranial Motor Evoked Potential During Spine Surgeries:,Motor Evoked Potential,Drug: Propofol Abbott|Drug: Sevoflurane Inhalation Solution|Diagnostic Test: transcranial motor evoked potential(Tcm,El-Sahel Teaching Hospital,Phase 4,60,Other,"April 6, 2017","March 5, 2020","April 5, 2021"
1319,NCT04993339,Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound,ACL Injury,Drug: OOC,"University of Miami|Arthrex, Inc.",Phase 3,26,Other|Industry,"October 24, 2016","February 20, 2020","February 20, 2020"
1320,NCT04993222,A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects,Bioequivalence,Drug: Amphotericin B liposome for injection|Drug: AmBisome®,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",Phase 1,12,Industry,"June 4, 2020","September 8, 2020","November 16, 2020"
1321,NCT04993040,A PK Study of Oraxol in Breast Cancer Patients,Breastcancer,Drug: Oraxol,"Athenex, Inc.",Phase 1,24,Industry,"April 22, 2019","December 9, 2019","December 9, 2020"
1322,NCT04992442,"Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants",Healthy Volunteers,Drug: TAK-935 Oral Tablet|Drug: [14C]TAK-935 IV Infusion|Drug: [14C]TAK-935 Oral Solution,Takeda,Phase 1,6,Industry,"July 9, 2020","August 18, 2020","August 18, 2020"
1323,NCT04991012,"Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Analysis and Fractal Dimension",Oral Lichen Planus,Device: PDT Therapy|Drug: Triamcinolone (Substance) therapy side,Wroclaw Medical University,Phase 2,30,Other,"February 8, 2020","March 8, 2021","June 10, 2021"
1324,NCT04989400,Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion,Induction of Second Trimester Abortion,Drug: Ulipristal Acetate|Drug: Misoprostol,Ain Shams University,Phase 4,24,Other,"January 1, 2019","October 1, 2019","January 1, 2020"
1325,NCT04982055,Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients,Critical Illness,Drug: Nadroparin (intravenous Infusion)|Drug: Nadroparin (subcutaneous group),Clinique Saint Pierre Ottignies,Phase 4,60,Other,"April 8, 2015","December 31, 2020","December 31, 2020"
1326,NCT04981379,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,Covid19,Drug: Hydroxychloroquine|Drug: Favipiravir|Drug: Favipiravir + Hydroxychloroquine|Drug: Placebo,Health Institutes of Turkey,Phase 3,1120,Other,"November 16, 2020","January 31, 2021","February 16, 2021"
1327,NCT04977661,"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients",Nonalcoholic Steatohepatitis (NASH),Drug: Vitamin E|Drug: Ursodeoxycholic acid|Drug: Pentoxifylline,Kafrelsheikh University,Phase 4,102,Other,"February 1, 2020","May 20, 2020","January 10, 2021"
1328,NCT04976673,Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus,"Lichen Planus, Oral",Drug: Triamcinolone Acetonide|Procedure: Photodynamic Therapy,Wroclaw Medical University,Phase 2,30,Other,"December 10, 2020","January 14, 2021","May 22, 2021"
1329,NCT04975022,A Study Evaluating the Bioavailability of Oral Insulin (N11005),"PK, PD, and Safety",Drug: N11005|Drug: Novolin R,Beijing Hospital,Phase 1,12,Other,"December 10, 2019","August 14, 2020","August 14, 2020"
1330,NCT04972539,Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults,"Diabetes Mellitus, Type 2",Drug: AJU-A51 Tab.|Drug: A51R1 Tab. and A51R2 Tab.,"AJU Pharm Co., Ltd.",Phase 1,48,Industry,"August 1, 2020","November 30, 2020","March 9, 2021"
1331,NCT04972383,Comparing Effect of Autologous Platelet-Rich Plasma Versus Hyaluronic Acid Treatment on Knee Osteoarthritis,Knee Osteoarthritis,Combination Product: Platelet Rich Plasma|Combination Product: Hyaluronic Acid,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 3,116,Other,"November 7, 2017","October 16, 2019","October 16, 2019"
1332,NCT04972045,Bioavailability of Curcumin Capsules in Healthy Adult Subjects,Healthy Adult Subjects,Drug: CuminUP60®|Drug: Curcumin capsules,The Affiliated Hospital of Qingdao University|Chenland Nutritionals Inc.,Phase 1,12,Other|Industry,"April 9, 2021","April 23, 2021","June 22, 2021"
1333,NCT04970940,The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2,T2DM (Type 2 Diabetes Mellitus),Drug: Treatment A|Drug: Treatment B|Drug: Treatment C,"AJU Pharm Co., Ltd.",Phase 1,30,Industry,"July 2, 2020","October 7, 2020","December 31, 2020"
1334,NCT04970667,Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder,Emotional Disorder|Neurologic Disorder,Drug: Flupentixol melitracen tablets,Peking University Third Hospital,Phase 4,100,Other,"January 1, 2018","January 31, 2020","April 30, 2020"
1335,NCT04970589,Enhancing Efficacy of Mango Polyphenols in Lean and Obese,Obesity,Other: Mango|Dietary Supplement: Probiotics|Other: Placebo,Texas A&M University,Phase 1,100,Other,"September 30, 2018","September 30, 2019","December 28, 2019"
1336,NCT04969679,Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.,Ulcerative Colitis,Drug: E. coli Nissle 1917 (Mutaflor®)|Drug: Placebo,Kangbuk Samsung Hospital,Phase 4,134,Other,"March 16, 2018","June 3, 2020","June 3, 2020"
1337,NCT04967859,Evaluation of the Efficacy of Prophylactic Topical Gentamicin in Tunnelled Catheters for Hemodialysis,Hemodialysis Catheter Infection,Drug: 0.1% gentamicin|Drug: Placebo,Universidade Estadual Paulista Júlio de Mesquita Filho,Phase 1,90,Other,"July 1, 2018","November 1, 2019","July 1, 2020"
1338,NCT04966338,Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing-Remitting,"Biological: Ocrelizumab (CinnaGen, Iran)|Biological: Ocrelizumab (Roche, Switzerland)",Cinnagen,Phase 3,170,Industry,"August 19, 2019","November 9, 2020","October 1, 2021"
1339,NCT04965662,The Role of Home Packs of HIV PEPSE in High Risk Individuals,HIV-1-infection,Drug: Maraviroc|Drug: Truvada,Guy's and St Thomas' NHS Foundation Trust|ViiV Healthcare|Gilead Sciences,Phase 4,139,Other|Industry,"January 1, 2018","March 16, 2021","March 16, 2021"
1340,NCT04962451,Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke,"Cerebrovascular Accident|Cerebrovascular Accident, Acute",Drug: ticagrelor + ASA|Drug: Placebo+ASA,"Peking University Third Hospital|AstraZeneca Investment (China) Co., Ltd",Phase 4,13000,Other,"September 1, 2017","September 30, 2019","October 31, 2019"
1341,NCT04957212,Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer,HER2-positive Breast Cancer,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Carboplatin|Drug: Docetaxel,Cinnagen,Phase 3,214,Industry,"August 11, 2018","May 27, 2020","May 27, 2020"
1342,NCT04956367,Efficacy of Fractional Carbon Dioxide Laser Combined With Platelet-rich Plasma,Striae Gravidarum,Procedure: Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Device: CO2 laser with PRP|Device: CO2 laser with placebo,Jose R. Reyes Memorial Medical Center,Phase 3,16,Other,"July 1, 2019","October 31, 2019","November 30, 2019"
1343,NCT04953793,High School SUCCESS: Vocational Soft Skills Program for Transition-Age ASD Youth,Autism Spectrum Disorder,Behavioral: TAY SUCCESS|Other: Usual Care,"Rady Children's Hospital, San Diego",Phase 1,42,Other,"November 6, 2017","January 20, 2020","December 31, 2020"
1344,NCT04952051,Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension,Hypertension,Drug: Enalapril Folic Acid Tablets Combined With amlodipine|Drug: Enalapril Folic Acid Tablets Combined With hydrochlorothiazide,"Second Affiliated Hospital, School of Medicine, Zhejiang University|National Clinical Research Center, Southern Medical University|Ningbo Yinzhou Community Health Service Center",Phase 3,1000,Other,"July 1, 2014","July 31, 2019","July 1, 2020"
1345,NCT04951245,Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy,Breast Cancer,Procedure: UC group: ultrasound-assisted CNSs guided|Procedure: GC group: CNSs plus ICG dual-tracer-guided,Guangdong Provincial People's Hospital,Phase 3,330,Other,"December 1, 2019","April 30, 2021","June 1, 2021"
1346,NCT04948385,Driving Performance After Deep Sedation for Outpatient Endoscopy,Driving Impaired,Drug: Propofol|Procedure: No sedation,University of Liege,Phase 4,60,Other,"February 6, 2019","May 6, 2019","May 6, 2019"
1347,NCT04947566,Comparison of Efficacy of Naproxen Versus Ibuprofen,"Pain, Postoperative",Drug: Comparison of Efficacy of Naproxen versus Ibuprofen,Fatima Memorial Hospital,Phase 4,116,Other,"September 2, 2019","February 25, 2020","February 25, 2020"
1348,NCT04947267,To Compare the Pulpal Oxygen Saturation Level After Administering Mepivacaine With and Without Vasoconstrictor,LOCAL ANESTHESIA,"Drug: 3% Mepivacaine Hydrochloride|Drug: 2% Mepivacaine with 1:100,000 epinephrine",Afshan Amjad Ali|Dow University of Health Sciences,Phase 2,60,Other,"May 30, 2018","September 21, 2019","November 19, 2019"
1349,NCT04942262,Oral Health-related Quality of Life and Masticatory Function After Using Denture Adhesive and Denture Liner,Complete Denture|Complete Edentulism,"Drug: denture adhesive (Polident®, GlaxoSmithKline, Ireland)",Chulalongkorn University,Phase 3,80,Other,"January 31, 2019","January 17, 2020","April 30, 2020"
1350,NCT04941196,Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition,Healthy Individuals,Drug: Anplag (Ticagrelor 90 mg)|Drug: Brilinta (Ticagrelor 90 mg),"University of Karachi|PharmEvo Private Limited., Pakistan",Phase 1,30,Other,"October 16, 2020","October 26, 2020","November 25, 2020"
1351,NCT04940520,Alpha-bisabolol for Onychomycosis Treatment,Onychomycosis,Biological: Drug recommended by the Brazilian Society of Dermatology|Combination Product: Alpha bisabolol product and laser|Biological: Alpha bisabolol product,Universidade do Vale do Sapucai,Phase 1,60,Other,"June 1, 2020","November 30, 2020","May 1, 2021"
1352,NCT04939779,Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches,Healthy,"Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)","LegoChem Biosciences, Inc",Phase 1,25,Industry,"January 14, 2021","January 24, 2021","February 1, 2021"
1353,NCT04938856,Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions,Bioequivalence,Drug: Lamotrigine tablet,"University of Karachi|The Searle Company LTD., Pakistan.",Phase 1,26,Other,"September 4, 2020","September 24, 2020","October 25, 2020"
1354,NCT04937933,Effect of Coolant Spray on Traumatic Rib Pain of Geriatric Patients,"Thorax; Fracture|Pain; Thorax, Thoracic, Spine, With Radicular and Visceral Pain","Drug: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|Drug: Saline solution",Ataturk University,Phase 4,101,Other,"October 1, 2019","October 1, 2020","November 1, 2020"
1355,NCT04936984,Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.,Osteoporosis,Combination Product: abaloparatide-sMTS (Patheon)|Combination Product: abaloparatide-sMTS (Kindeva),"Radius Health, Inc.|Medpace, Inc.",Phase 1,36,Industry,"November 16, 2020","February 9, 2021","August 13, 2021"
1356,NCT04933864,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,SARS-CoV-2,Drug: Methylene Blue and Photodynamic Therapy,I.M. Sechenov First Moscow State Medical University|Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS),Phase 1,60,Other,"April 24, 2020","May 20, 2020","July 30, 2020"
1357,NCT04929093,Novel Dose Adjustment Schedule for Late Injection in SCIT in AR,Allergic Rhinitis|Immunotherapy,Biological: Novel dose adjustment of Alutard SQ|Biological: conventional dose adjustment of Alutard SQ|Biological: Routine continuous cluster of Alutard SQ,Beijing Tongren Hospital,Phase 4,102,Other,"June 11, 2020","April 16, 2021","April 30, 2021"
1358,NCT04921371,Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque,Gingivitis|Plaque,Other: Colgate® Cavity Protection Toothpaste|Other: Listerine® Cool Mint®|Other: Concept Curve Winter Series Toothbrush|Other: 5% Hydroalcohol Mouthrinse|Other: Mouthrinse Prototype 1|Other: Mouthrinse Prototype 2,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Phase 1,157,Industry,"October 8, 2019","December 19, 2019","December 19, 2019"
1359,NCT04919317,Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty,"Pain, Postoperative|Mammaplasty",Drug: Dexamethasone 4mg|Drug: Saline,Temple University,Phase 2,56,Other,"September 29, 2017","November 7, 2020","November 25, 2020"
1360,NCT04916093,Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Vildagliptin 50 MG|Drug: Sitagliptin 100mg|Drug: MetFORMIN 1000 Mg Oral Tablet,Beni-Suef University|Minia University,Phase 4,60,Other,"December 20, 2019","June 10, 2020","December 15, 2020"
1361,NCT04915456,Effect of Postoperative Additive Systemic Steroids in CRSwNP,"Sinusitis, Chronic",Drug: Systemic Steroid (Prednisolone)|Other: Placebo,Friedrich-Alexander-Universität Erlangen-Nürnberg,Phase 4,106,Other,"January 18, 2005",Apr-20,Feb-21
1362,NCT04911413,Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery,Cardiac Surgical Procedures|Blood Transfusion|Tranexamic Acid,Drug: Tranexamic acid,"Chinese Academy of Medical Sciences, Fuwai Hospital",Phase 4,210,Other,"September 1, 2017","March 5, 2021","June 15, 2021"
1363,NCT04905667,Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®,Breast Cancer,Drug: GB221|Drug: Herceptin,"Genor Biopharma Co., Ltd.",Phase 1,87,Industry,"November 13, 2019","September 8, 2020","September 11, 2020"
1364,NCT04900948,Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life,Atopic Dermatitis,Drug: Pimecrolimus cream 1%|Drug: cream 0.1% methylprednisolone aceponate,"National Medical Research Center for Children's Health, Russian Federation",Phase 4,108,Other,"December 10, 2017","April 25, 2020","April 25, 2020"
1365,NCT04900129,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Covid19,"Combination Product: Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%",Sher-E-Bangla Medical College,Phase 1,43,Other,"December 1, 2020","December 30, 2020","December 30, 2020"
1366,NCT04898270,Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients,Schizophrenia; Psychosis|Metabolic Syndrome|Flupentixol|Antipsychotic Agents|Central Nervous System Diseases|Clinical Therapy|Olanzapine|Quetiapine,Drug: Flupentixol|Drug: Multi-acting receptor-targeted antipsychotics (MARTAs),Taichung Veterans General Hospital,Phase 4,30,Other,"December 19, 2019","December 31, 2020","April 20, 2021"
1367,NCT04895657,Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion,Gram-Negative Infections,Drug: Piperacillin/Tazobactam Continuous infusion|Drug: Piperacillin/Tazobactam Intermittent infusion,Ain Shams University,Phase 4,56,Other,"July 27, 2018","January 26, 2020","January 26, 2020"
1368,NCT04889781,Piezo-surgery Technique and Intramuscular Dexamethasone Injection to Reduce Postoperative Pain After Impacted Mandibular Third Molar Surgery,Impacted Mandibular Third Molar Extraction,Drug: Dexamethasone injection|Procedure: Piezosurgery|Procedure: Conventional Rotatory instruments,Central Military Healthcare - Oral and Maxillofacial Surgery Department,Phase 4,80,Other,"February 1, 2019","June 1, 2019","July 1, 2019"
1369,NCT04884503,Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome,Burning Mouth Syndrome|Glossodynia,Drug: Clonazepam tablets|Device: tongue pads,Wroclaw Medical University,Phase 2,58,Other,"January 12, 2019","April 3, 2020","September 6, 2020"
1370,NCT04884191,"Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib",Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post- Essential Thrombocythemia Myelofibrosis,Drug: Pacritinib,CTI BioPharma,Phase 2,165,Industry,"July 31, 2017","September 4, 2019","September 4, 2019"
1371,NCT04883203,The Effect of Vitamin D Supplementation on COVID-19 Recovery,Covid19,Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol]|Drug: Physiological Irrigating Solution,University of Monastir|Loussaief Chawki|Nissaf Ben Alaya|Cyrine Ben Nasrallah|Manel Ben Belgacem|Hela Abroug|Imen Zemni|Manel Ben fredj|Wafa Dhouib,Phase 3,130,Other,"April 22, 2020","September 30, 2020","October 31, 2020"
1372,NCT04883125,Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment,"Chronic Myelogenous Leukemia, BCR-ABL Positive|CML, Chronic Phase",Drug: Pioglitazone 15mg,Mansoura University,Phase 2,90,Other,"January 1, 2018","April 15, 2021","April 15, 2021"
1373,NCT04882761,Socket Shield With Immediate Implant Stability,Dental Implant,Device: Dental implant,Ain Shams University,Phase 4,16,Other,"April 12, 2017","January 20, 2021","February 24, 2021"
1374,NCT04881006,Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions,Healthy Subjects,Drug: Dapagliflozin 10 mg tablets|Drug: Farxiga® 10 mg tablets,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1,30,Industry,"December 10, 2020","December 20, 2020","January 15, 2021"
1375,NCT04880993,Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions,Healthy Subjects,Drug: Dapagliflozin 10 mg tablets|Drug: Farxiga® 10 mg tablets,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1,30,Industry,"December 14, 2020","December 24, 2020","February 4, 2021"
1376,NCT04878835,Effects of Ranibizumab in Primary Pterygium Surgery,Patients With Primary Nasal Pterygium,Biological: intralesional ranibizumab,Universiti Sains Malaysia,Phase 1,52,Other,"May 1, 2018","April 1, 2020","April 30, 2020"
1377,NCT04877067,Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation,Methanol Poisoning|Toxic Optic Neuropathy|Stem Cell Tyrosine Kinase 1 Y842X|Magnetic Field Exposure,Biological: Wharton jelly derived mesenchymal stem cell|Device: Repetitive electromagnetic stimulation,Ankara Universitesi Teknokent|International Olympic Committee,Phase 3,18,Other,"April 1, 2019","April 30, 2021","April 30, 2021"
1378,NCT04875962,"A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)",Parkinson's Disease,Drug: UCB0599|Drug: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,31,Industry,"May 6, 2019","February 19, 2020","February 19, 2020"
1379,NCT04874701,"Effects of Capsimax on Appetite, Energy Intake and Blood Pressure",Obesity|Body Weight|Weight Loss|Overweight,Drug: Capsimax|Other: Energy restriction,Laval University|OmniActive Health Technologies,Phase 4,63,Other|Industry,"January 7, 2018","July 2, 2019","July 2, 2019"
1380,NCT04874142,Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A,Dyslipidemias,Drug: YYC506-T|Drug: YYC506-A|Drug: YYC506-T + YYC506-A|Drug: YYC506-A + YYC506-T,"Yooyoung Pharmaceutical Co., Ltd.",Phase 1,48,Industry,"November 20, 2019","March 23, 2020","March 23, 2020"
1381,NCT04872231,Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects,Healthy,Drug: Voriconazole Inhalation Powder|Drug: Placebo,"TFF Pharmaceuticals, Inc.",Phase 1,65,Industry,"November 22, 2019","July 29, 2020","August 26, 2020"
1382,NCT04871724,Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects,RSV Infection,Drug: EDP-938|Drug: Fluconazole,"Enanta Pharmaceuticals, Inc",Phase 1,24,Industry,"March 12, 2021","March 30, 2021","April 16, 2021"
1383,NCT04870372,Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease,Parkinson Disease,Drug: Selegiline,Second Affiliated Hospital of Soochow University,Phase 4,141,Other,"March 1, 2020","December 31, 2020","April 30, 2021"
1384,NCT04869072,Convalescent Plasma Therapy - Zurich Protocol,COVID-19,Drug: Convalescent plasma,University of Zurich,Phase 1,30,Other,"April 29, 2020","November 30, 2020","March 30, 2021"
1385,NCT04868344,A Study of MRG003 in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: MRG003,Shanghai Miracogen Inc.,Phase 1,61,Industry,"May 9, 2018","March 29, 2021","March 29, 2021"
1386,NCT04865497,Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old,"Dysentery|Dysentery, Bacillary",Biological: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Biological: Haemophilus b Conjugate Vaccine,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",Phase 2,1050,Industry,"January 19, 2019","December 7, 2019","December 31, 2020"
1387,NCT04860531,The Role of Intra-articular Injection of PRP Versus Corticosteriods in Treatment of Lumbar Facet Disease,Lumbar Facet Joint Syndrome,Drug: Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Drug: Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone,Ain Shams University,Phase 3,30,Other,"September 17, 2019","January 22, 2021","January 22, 2021"
1388,NCT04859738,The Effect of Lidocaine and Benzocaine on Pain and Injection Satisfaction in Peripheral Intravenous Catheter Application,Peripheral Intravenous Catheterization Application,Drug: Lidocaine Spray|Drug: Benzokain Sprey|Other: Alcohol,TC Erciyes University,Phase 3,120,Other,"March 4, 2020","July 7, 2020","October 20, 2020"
1389,NCT04857177,A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration,Neovascular(Wet) Age Related Macular Degeneration,Drug: CKD-701|Drug: Lucentis®,Chong Kun Dang Pharmaceutical,Phase 3,312,Industry,"October 19, 2018","March 17, 2021","March 17, 2021"
1390,NCT04854642,A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers,no Condition,Drug: Ladarixin,Dompé Farmaceutici S.p.A,Phase 1,36,Industry,"October 20, 2020","December 9, 2020","December 9, 2020"
1391,NCT04854538,"Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)",Healthy,Drug: Ekmasonid|Drug: Uceris (first dose)|Drug: Uceris (second dose),"Genuine Research Center, Egypt|Hikma Pharmaceuticals LLC",Phase 1,30,Industry,"September 17, 2020","October 1, 2020","December 4, 2020"
1392,NCT04854460,"Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)",Healthy,Drug: Revemact|Drug: Stromectol (first dose)|Drug: Stromectol (second dose),"Genuine Research Center, Egypt|Eva Pharma",Phase 1,30,Industry,"January 28, 2021","February 25, 2021","March 22, 2021"
1393,NCT04853901,Remdesivir Efficacy In Management Of COVID-19 Patients,Covid19,Drug: Remdesivir|Drug: Standard of care_1|Drug: Standard of care_2,Ain Shams University,Phase 3,77,Other,"July 27, 2020","January 1, 2021","March 1, 2021"
1394,NCT04853407,A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD),Major Depressive Disorder (MDD),Drug: LY03005 extended-release tablet|Drug: Placebo,Luye Pharma Group Ltd.,Phase 3,558,Industry,"December 5, 2018","December 24, 2020","December 24, 2020"
1395,NCT04851769,Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography,Randomized Controlled Trials,Drug: PCSK9 inhibitor plus statin|Drug: standard statin therapy|Procedure: Coronary imaging follow-up,Beijing Anzhen Hospital,Phase 4,60,Other,"March 2, 2019","January 28, 2021","March 1, 2021"
1396,NCT04851431,Effects of Peer Mentoring on Caregivers of Patients With Acquired Brain Injury,Acquired Brain Injury|Family Members,Behavioral: one-to-one peer mentoring,"Shepherd Center, Atlanta GA",Phase 2,41,Other,"January 8, 2019","January 30, 2021","January 30, 2021"
1397,NCT04850885,Efficacy of Dexamethasone or Adrenaline in Inferior Alveolar Nerve Block,Oral Surgical Procedure,Drug: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml,"Tribhuvan University, Nepal|National Medical College, Birgunj, Nepal",Phase 3,83,Other,"August 1, 2020","February 2, 2021","February 28, 2021"
1398,NCT04846335,Familiar Fatal Insomnia: Preventive Treatment With Doxycycline in Subject With Disease Risk,Familial Fatal Insomnia,Drug: Doxycycline Hcl|Drug: Placebo,Mario Negri Institute for Pharmacological Research|Fondazione Telethon,Phase 2,29,Other,"April 28, 2011","April 12, 2021","April 12, 2021"
1399,NCT04845971,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,COVID-19 Pneumonia,Dietary Supplement: Saisei Maf capsules,Dr. Spadera Lucrezia|Ospedale del Mare,Phase 2,97,Other,"November 5, 2020","April 30, 2021","June 30, 2021"
1400,NCT04841993,Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation,Cannabis Use|Healthy Subjects,Drug: Cannabis decoction|Drug: Cannabis oil|Drug: Vaporized cannabis,Germans Trias i Pujol Hospital|Fundació Institut Germans Trias i Pujol|Istituto Superiore di Sanità,Phase 1,43,Other,"December 10, 2018","December 18, 2019","February 28, 2021"
1401,NCT04838145,The Diabetes Virus Detection and Intervention Trial,Type1 Diabetes Mellitus|Enterovirus,Drug: Ribavirin + Pleconaril|Drug: Placebos,Oslo University Hospital,Phase 2,96,Other,"August 30, 2018","October 25, 2020","October 25, 2020"
1402,NCT04838054,The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis,Peri-implant Mucositis,Drug: Stabilized chlorine dioxide oral rinse|Other: Placebo,"Rowpar Pharmaceuticals, Inc.|Stony Brook University",Phase 4,57,Industry|Other,"March 15, 2018","January 15, 2020","March 4, 2020"
1403,NCT04835116,Comparison of Post-Operative Analgesia After Percutaneous Nephrolithotomy.,Pain|Postoperative Pain,Drug: Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Drug: paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.,"Armed Forces Institute of Urology, Rawalpindi",Phase 4,68,Other,"April 11, 2019","October 11, 2019","October 11, 2019"
1404,NCT04834791,Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance,Clomiphene Citrate Resistance|Ovulation Induction|Letrozole|Gonadotropins,Drug: Letrozole 2.5mg|Drug: Gonadotropin,Tanta University,Phase 4,70,Other,"March 1, 2019","October 31, 2019","October 31, 2019"
1405,NCT04833569,"ICG-PDT, Periimplantitis, Diabetes Mellitus",Peri-Implantitis,Biological: ICG-PDT|Device: peri-implant mechanical debridement,King Saud University,Phase 1,50,Other,"September 20, 2020","February 15, 2021","March 10, 2021"
1406,NCT04832906,UA Versus UAE in Treatment of Fibroids,Uterine Fibroid,Drug: Ulipristal Oral Tablet|Procedure: Uterine artery embolization,Ain Shams Maternity Hospital,Phase 4,70,Other,"March 13, 2019","March 13, 2021","March 13, 2021"
1407,NCT04830969,Impact of Periodontal Therapy on Patients With Diabetes,"Diabetes Mellitus, Type II|Periodontitis",Drug: Chlorhexidine gluconate oral rinse|Procedure: Scaling & Root Planing|Device: Soft Picks,"State University of New York at Buffalo|Sunstar, Inc.",Phase 2,116,Other|Industry,"November 8, 2016","January 28, 2021","January 28, 2021"
1408,NCT04830358,Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults,Pneumococcal Disease,Biological: EuPCV15|Biological: Prevenar13,"EuBiologics Co.,Ltd",Phase 1,60,Industry,"May 28, 2020","August 14, 2020","February 1, 2021"
1409,NCT04828720,Assessment of Platelet-Rich Fibrin and Topical Ozonated Oil in the Management of Palatal Wound Healing After Free Gingival Graft Harvest,Inadequately Attached Gingiva (Disorder),Drug: ozonated oil,Cairo University|October 6 University,Phase 1,39,Other,"October 1, 2019","April 1, 2020","June 1, 2020"
1410,NCT04824586,Intraoperative Insulin Administration at Cardiac Surgery for Diabetic Patients,Diabetes Mellitus|Cardiac Event,Drug: Fast-acting human insulin,The Hashemite University,Phase 4,70,Other,"June 1, 2019","January 30, 2020","January 30, 2020"
1411,NCT04823390,Anesthetist Controlled Versus Patient-controlled Sedation: Risks and Benefits,Patient Satisfaction,Drug: Midazolam-Fentanyl combination,Cairo University,Phase 1,30,Other,"September 14, 2019","February 20, 2021","February 24, 2021"
1412,NCT04822909,A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum,Erythema Nodosum Leprosum,Drug: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet,Postgraduate Institute of Medical Education and Research,Phase 4,10,Other,"September 15, 2019","March 14, 2020","June 30, 2020"
1413,NCT04820543,Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A,"Smiling|Botulinum Toxins, Type A",Drug: injection of Botulinum type A,Peking University,Phase 4,55,Other,"February 20, 2019","November 20, 2019","June 20, 2020"
1414,NCT04820439,Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection,Healthy Volunteers,Drug: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|Drug: Perjeta ®,The Affiliated Hospital of Qingdao University,Phase 1,88,Other,"October 13, 2020","February 1, 2021","March 13, 2021"
1415,NCT04819581,Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects,Healthy,Drug: SP-103|Drug: ZTlido,"Scilex Pharmaceuticals, Inc.",Phase 1,15,Industry,"August 3, 2019","August 27, 2019","August 27, 2019"
1416,NCT04819438,Riluzole Orodispersible Film Replicate Bioavailability,Bioequivalence,Drug: Riluzole 50 mg Oral Film|Drug: Rilutek 50Mg Tablet,Cross Research S.A.|Zambon SpA,Phase 1,54,Industry,"January 15, 2021","March 14, 2021","March 14, 2021"
1417,NCT04817332,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,Covid19,Drug: Brensocatib|Drug: Placebo,University of Dundee|NHS Tayside|Insmed Incorporated,Phase 3,406,Other|Industry,"June 5, 2020","February 28, 2021","February 28, 2021"
1418,NCT04816942,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Convalescent Plasma|Covid19|Immunoglobulins|Plasma|Egypt,Biological: Convalescent Plasma,"Ministry of Health and Population, Egypt",Phase 3,102,Other,"April 23, 2020","July 21, 2020","October 12, 2020"
1419,NCT04816110,Evaluation of Mineralized Plasmatic Matrix With and Without Collagen Membrane in Peri-implant Bone Regeneration,Horizontal Alveolar Bone Defect|Alveolar Bone Loss,Biological: mineralized plasmatic matrix with collagen membrane|Biological: mineralized plasmatic matrix (MPM) without collagen membrane,Alexandria University,Phase 2,16,Other,"April 10, 2019","September 10, 2020","December 15, 2020"
1420,NCT04812509,Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors,Bone Metastases,Drug: MW032|Drug: Xgeva,"Mabwell (Shanghai) Bioscience Co., Ltd.",Phase 3,708,Industry,"March 20, 2020","April 29, 2021","January 28, 2022"
1421,NCT04810728,Efficacy of Psidii Guava's Extract For COVID-19,Covid19,Drug: Extract Psidii guava|Combination Product: Standard therapy for Covid-19 patient,Faculty of Medicine Baiturrahmah University,Phase 3,90,Other,"June 20, 2020","December 4, 2020","January 30, 2021"
1422,NCT04810533,"The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers",Healthy Male Volunteers,Drug: [14C] SH-1028,"Nanjing Sanhome Pharmaceutical, Co., Ltd.",Phase 1,6,Industry,"May 13, 2020","March 5, 2021","March 5, 2021"
1423,NCT04810507,MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus,Type 2 Diabetes,Drug: Anagliptin BID Treatment,JW Pharmaceutical,Phase 4,89,Industry,"November 9, 2018","September 2, 2020","January 5, 2021"
1424,NCT04808622,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers,Healthy Subjects,Drug: Trans-Sodium Crocetinate|Drug: Placebo,Diffusion Pharmaceuticals Inc,Phase 1,30,Industry,"March 17, 2021","March 21, 2021","March 25, 2021"
1425,NCT04807543,Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes,Preterm Premature Rupture of Membrane,Drug: 17-hydroxyprogesterone caproate|Drug: Castor Oil,Ain Shams University,Phase 2,100,Other,"January 10, 2018","October 10, 2020","December 10, 2020"
1426,NCT04806425,The Cardioprotective Effect of Intralipid in Decreasing the Ischemic Insults During Off-pump Coronary Artery Revascularization,Anesthesia,Drug: Intralipid|Drug: Placebo,Ain Shams University,Phase 4,46,Other,"October 1, 2020","February 20, 2021","March 1, 2021"
1427,NCT04804111,Study of of URC102 to Assess the Efficacy and Safety in Gout Patients,Gout,Drug: arm 0|Drug: arm 1|Drug: arm 2|Drug: arm 3|Drug: arm 4,JW Pharmaceutical,Phase 2,171,Industry,"January 21, 2019","September 4, 2020","November 29, 2020"
1428,NCT04803396,Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A,no Condition,Drug: DF2755A,Dompé Farmaceutici S.p.A,Phase 1,32,Industry,"November 15, 2018","June 29, 2019","March 13, 2020"
1429,NCT04801199,Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus,Uncontrolled Type 2 Diabetes Mellitus,Drug: CPL-2009-0031 140 mg|Drug: Sitagliptin 100mg,"Cadila Pharnmaceuticals|New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India",Phase 3,355,Industry|Other,"January 26, 2020","January 13, 2021","February 11, 2021"
1430,NCT04799782,Role of Mirtazapine in Ameliorating Sleep Disordered Breathing,Spinal Cord Injuries|Sleep Disordered Breathing,Drug: Mirtazapine|Drug: Placebo,Wayne State University,Phase 2,18,Other,Jan-17,"May 18, 2019","May 18, 2019"
1431,NCT04798703,Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID),Bladder Carcinoma in Situ (CIS),Drug: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID),Fidia Farmaceutici s.p.a.,Phase 1,20,Industry,"May 24, 2017","May 4, 2020","November 18, 2020"
1432,NCT04798326,"Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults",Bone Tumor,Drug: MW032|Drug: Xgeva®,"Mabwell (Shanghai) Bioscience Co., Ltd.",Phase 1,120,Industry,"June 25, 2019","January 10, 2020","February 26, 2020"
1433,NCT04798313,"Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults","Osteoporosis, Postmenopausal",Drug: MW031|Drug: Prolia®,"Mabwell (Shanghai) Bioscience Co., Ltd.",Phase 1,120,Industry,"June 2, 2020","December 7, 2020","December 31, 2020"
1434,NCT04797936,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,Covid19|Nasopharyngitis|Anosmia|Fever|Myalgia|Cough|Nasal Congestion,Drug: BNO 1030|Other: Standard care,Ivano-Frankivsk National Medical University,Phase 4,133,Other,"May 1, 2020","December 19, 2020","January 8, 2021"
1435,NCT04794439,Plaque Removal Efficacy of Four Dentifrices Following a Single Brushing,"Plaque, Dental",Drug: Dentifrices,"Church & Dwight Company, Inc.",Phase 2,70,Industry,"November 16, 2020","December 18, 2020","December 18, 2020"
1436,NCT04793074,Transforming Nanoparticle Dressing For Management of Chronic Venous Ulcers,Chronic Venous Hypertension With Ulcer,Combination Product: Transforming nanoparticle dressing|Combination Product: Conventional compression dressing,Egyptian Biomedical Research Network,Phase 4,60,Other,"July 1, 2019","December 31, 2020","December 31, 2020"
1437,NCT04792333,Pharmacokinetics in End Stage Renal Disease Patients,Healthy Volunteers|Renal Failure,Drug: firibastat,Quantum Genomics SA|Eurofins Optimed,Phase 1,28,Industry,"September 17, 2019","July 10, 2020","July 10, 2020"
1438,NCT04790292,Impact of Dexamethasone Added to Intra-articular Morphine and Bupivacaine for Post-operative Analgesia After Knee Arthroscopy,Anesthesia,Drug: group M|Drug: group MD,Ain Shams University,Phase 4,40,Other,"January 1, 2020","July 1, 2020","August 1, 2020"
1439,NCT04790136,Cannabidiol Bioavailability Trial With Oral Multiple Dose Administration,Comparative Bioavailability,"Drug: GLA-015|Drug: DAC C-052 ""Cannabidiol"" / NRF 22.10 ""Oily cannabidiol solution 100 mg/ml""",SocraTec R&D GmbH|Glatt Pharmaceutical Services GmbH & Co. KG|SocraMetrics GmbH,Phase 1,18,Other|Industry,"March 17, 2021","April 16, 2021","May 12, 2021"
1440,NCT04789005,Comparison of Phenylephrine and Norepinephrine for Spinal-induced Hypotension,Spinal Induced-hypotension,Drug: Norepinephrine|Drug: Phenylephrine,"Tribhuvan University Teaching Hospital, Institute Of Medicine.",Phase 3,80,Other,"November 10, 2019","May 5, 2020","May 5, 2020"
1441,NCT04788485,Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance,Gastroesophageal Reflux in Neonates,Drug: Diosmectite,Ain Shams Maternity Hospital,Phase 4,20,Other,"September 1, 2017","February 25, 2021","March 1, 2021"
1442,NCT04788355,Prevention of Complications (SARS-CoV-2): Clinical Study,Complication,Drug: Control group (standard hospital treatment)|Drug: Group Hydroxychloroquine|Drug: Group Hydroxychloroquine and apixaban|Drug: Group Apixaban,Universidade do Vale do Sapucai|Pfizer|Apsen Farmaceutica S.A.|Dermadia|Methodos Laboratory|Biofarma,Phase 3,176,Other|Industry,"July 1, 2020","November 15, 2020","December 23, 2020"
1443,NCT04787887,A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers,Gaucher Disease,Drug: Abcertin|Drug: EU-sourced Cerezyme,"ISU Abxis Co., Ltd.",Phase 1,42,Industry,"January 29, 2020","September 27, 2020","October 26, 2020"
1444,NCT04786327,Minimally Invasive Flap With Platelet Rich Fibrin or Growth Factor Enhanced Matrix in Treatment of Intrabony Defect,Periodontal Regeneration,Procedure: Minimal invasive flap technique|Procedure: Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|Combination Product: minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S,Tanta University,Phase 2,21,Other,"January 1, 2018","October 1, 2019","October 1, 2019"
1445,NCT04785755,Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites,Hepatic Ascites,Drug: Oral standard diuretics therapy|Drug: Hypertonic saline solution|Drug: Etilefrine,Hala Abd EL-Tawab Ibrahim Radwan|Tanta University,Phase 2,90,Other,"November 30, 2017","March 21, 2020","April 30, 2020"
1446,NCT04785612,Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults,Respiratory Syncytial Virus Infections,Biological: RSVPreF|Other: Placebo,Hvivo|Pfizer,Phase 2,62,Industry,"November 10, 2020","April 8, 2021","August 16, 2021"
1447,NCT04784728,Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure,Healthy,Drug: Lidocaine topical system 1.8%,"Scilex Pharmaceuticals, Inc.",Phase 1,24,Industry,"August 21, 2019","August 31, 2019","August 31, 2019"
1448,NCT04784000,Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527,Healthy Volunteer Study,Drug: Period 1: AT-527 550 mg|Drug: Period 2: carbamazepine|Drug: Period 3: AT-527 550 mg + carbamazepine|Drug: Period 3: AT-527 1100 mg + carbamazepine,"Atea Pharmaceuticals, Inc.|Hoffmann-La Roche",Phase 1,20,Industry,"March 1, 2021","April 10, 2021","April 10, 2021"
1449,NCT04782505,Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers,Healthy,Drug: DWJ1248,Daewoong Pharmaceutical Co. LTD.,Phase 1,61,Industry,"March 12, 2021","March 16, 2021","June 28, 2021"
1450,NCT04782388,"Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants",Healthy Study Participants,Drug: Alprazolam|Other: Placebo,UCB Biopharma SRL|UCB Pharma,Phase 1,30,Industry,"March 4, 2021","April 26, 2021","April 26, 2021"
1451,NCT04781075,Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery,"Pain, Postoperative",Other: Pain Scale|Drug: Exparel Injectable Product|Drug: Bupivacaine Injection,Ochsner Health System,Phase 4,76,Other,"December 1, 2017","December 31, 2020","July 31, 2021"
1452,NCT04780984,Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease (COPD),Drug: Tiotropium bromide inhalation solution|Drug: Placebo,"Nephron Pharmaceuticals Corporation|Rho, Inc.",Phase 2,116,Industry,"November 1, 2020","April 20, 2021","April 26, 2021"
1453,NCT04780451,Omega-3 Supplementation Combined With Endurance Training Improve Running Economy in Recreational Runners.,Effect of Omega-3 Supplementation on Exercise Performance and Muscle Tissue Functions,Dietary Supplement: Omega-3 supplementation in recreational runners,Gdansk University of Physical Education and Sport|Medical University of Gdansk|University of Southampton,Phase 3,40,Other,"September 16, 2020","December 20, 2020","March 2, 2021"
1454,NCT04780386,Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2,Healthy,Drug: NVP-1805|Drug: NVP-1805-R1and NVP-1805-R2,NVP Healthcare,Phase 1,58,Industry,"August 29, 2020","November 2, 2020","February 16, 2021"
1455,NCT04779892,The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety,Rheumatoid Arthritis,Drug: Infliximab,"Taizhou Mabtech Pharmaceutical Co.,Ltd",Phase 1,90,Industry,"February 1, 2020","June 15, 2020","June 15, 2020"
1456,NCT04778137,"The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety",Asthma,Drug: Omalizumab,"Taizhou Mabtech Pharmaceutical Co.,Ltd",Phase 1,114,Industry,"December 1, 2020","April 26, 2021","May 25, 2021"
1457,NCT04777968,Evaluation Of Fluoride Uptake By Dentine Following Silver Diamine Fluoride Under Resin Modified Glass Ionomer Restoration In Carious Primary Molars,Dental Caries,Drug: Silver diamine fluoride,Cairo University,Phase 4,20,Other,"August 1, 2020","December 1, 2020","February 1, 2021"
1458,NCT04776889,"The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients",Prostate Cancer Metastatic,Drug: Rosuvastatin 20mg|Procedure: surgical castration,"National Cancer Institute, Egypt",Phase 4,70,Other,"January 15, 2019","December 30, 2020","December 30, 2020"
1459,NCT04776135,Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube,Healthy Adult Subjects,Drug: MT-1186,Mitsubishi Tanabe Pharma Corporation,Phase 1,36,Industry,"February 26, 2021","April 1, 2021","April 16, 2021"
1460,NCT04775732,Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease,Crohn Disease|Ulcerative Colitis,Biological: infliximab therapeutic drug monitoring,Imelda GI Clinical Research Center,Phase 4,187,Other,"June 1, 2018","August 31, 2019","September 30, 2019"
1461,NCT04775225,Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis,Juvenile Idiopathic Arthritis|Hip Arthritis,Drug: Lidocaine|Drug: Placebo|Drug: Steroid,Sohag University,Phase 3,120,Other,"January 6, 2021","April 6, 2021","April 6, 2021"
1462,NCT04774874,A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers,Androgenetic Alopecia,Drug: Topical formulation,"Follicum AB|proDERM GmbH|Hair and Skin Institute, Charité, Berlin, Germany|Centroderm GmbH, Wuppertal, Germany",Phase 2,209,Industry|Other,"June 24, 2020","January 29, 2021","January 29, 2021"
1463,NCT04773977,Clinical Study of IBI362 in Healthy Chinese Male Subjects,Overweight/Obesity,Drug: IBI362 liquid formulation|Drug: IBI362 lyophilized powder,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,24,Industry,"March 3, 2021","March 9, 2021","June 17, 2021"
1464,NCT04773886,Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine. .,Pulpitis - Irreversible,Drug: Mineral trioxide aggregate|Drug: Biodentine|Biological: Platelet rich fibrin,Maharishi Markendeswar University (Deemed to be University),Phase 4,60,Other,"February 1, 2020","March 12, 2021","March 12, 2021"
1465,NCT04773756,Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt,Covid19,Drug: Sofosbuvir 400 MG/ Daclatasvir 60mg,Alexandria University,Phase 4,54,Other,"November 1, 2020","November 30, 2020","December 12, 2020"
1466,NCT04773431,Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency,Limbus Corneae|Limbus Corneae Insufficiency Syndrome,Drug: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation,"CliPS Co., Ltd",Phase 1,6,Industry,"January 31, 2020","January 14, 2021","January 14, 2021"
1467,NCT04770701,Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes,HIV-1-infection|AIDS,Drug: Ahah Drug|Device: Ahah Placebo,"Trieu, Nguyen Thi, M.D.",Phase 4,60,Other,Dec-15,"January 8, 2021","January 10, 2021"
1468,NCT04770194,"Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008",Acute Coronary Syndrome|Stroke,Drug: SP-8008 Prototype Capsule A|Drug: SP-8008 Prototype Capsule B|Drug: Placebo,Shin Poong Pharmaceutical Co. Ltd.,Phase 1,48,Industry,"October 1, 2019","January 23, 2020","January 23, 2020"
1469,NCT04769583,14-day Quadruple Therapy Versus Triple Therapy in HP Eradication,Gastritis H Pylori,Drug: metronidazole based quadriple therapy|Drug: placebo based quadriple therapy,mohamed bouchoucha|Les Laboratoires des Médicaments Stériles,Phase 4,121,Industry,"February 10, 2019","February 17, 2020","March 5, 2020"
1470,NCT04769271,Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis,Periodontitis,Procedure: Scaling and Root Planing|Drug: Scaling and Root Planing with tea tree oil,Alexandria University,Phase 2,30,Other,"November 10, 2019","August 15, 2020","August 25, 2020"
1471,NCT04768673,A Study to Investigate the PK and Safety of CKD-393,Type II Diabetes,"Drug: CKD-393 formulation I|Drug: CKD-393 formulation II|Drug: D501, D759, H053",Chong Kun Dang Pharmaceutical,Phase 1,26,Industry,"March 26, 2021","April 22, 2021","April 27, 2021"
1472,NCT04768530,Nitazoxanide as a New Local Adjunctive to Nonsurgical Treatment of Moderate Periodontitis,Periodontitis,Procedure: Scaling and Root Planing|Drug: Nitazoxanide hydrogel,Maha Talaab|Alexandria University,Phase 2,40,Other,"July 20, 2019","April 1, 2020","April 30, 2020"
1473,NCT04768439,Low and High Doses of Prophylactic Vitamin D in Prevention of Osteopenia of Prematurity,Osteopenia of Prematurity,Drug: Low Dose Vitamin D|Drug: High Dose Vitamin D,Alexandria University,Phase 2,80,Other,"August 10, 2020","April 20, 2021","April 30, 2021"
1474,NCT04767724,Extracorporeal Shock Wave Versus Local Corticosteroid Injection for Carpal Tunnel Syndrome,Carpal Tunnel Syndrome|Shock Wave,Device: Extracorporeal shock wave,Chinese Medical Association,Phase 4,55,Other,"April 10, 2018","August 2, 2019","April 10, 2020"
1475,NCT04767035,"Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine",Procedural Sedation,Drug: midazolam / ketamine sublingual tablet,Melt Pharmaceuticals|Worldwide Clinical Trials,Phase 1,25,Industry|Other,"December 1, 2020","January 14, 2021","January 14, 2021"
1476,NCT04764630,Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone,Healthy Subjects|Opioid Antagonist|Pharmacokinetics,Drug: Four naloxone nasal spray doses (1 every 2.5 min)|Drug: Four naloxone nasal spray doses (2 every 2.5 min)|Drug: Two naloxone nasal spray doses (1 every 2.5 min),Food and Drug Administration (FDA)|Spaulding Clinical Research LLC,Phase 1,21,U.S. Fed|Other,"March 1, 2021","March 20, 2021","March 20, 2021"
1477,NCT04764201,The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers,Atrial Fibrillation,Drug: HIP2001|Drug: HGP2001,Hanmi Pharmaceutical Company Limited,Phase 1,50,Industry,"January 16, 2021","February 26, 2021","March 8, 2021"
1478,NCT04763876,Intramuscular Ketorolac at Two Single-Dose Regimens,Musculoskeletal Pain|Analgesia|Adverse Event,Drug: Ketorolac Injection 15 mg|Drug: Ketorolac Injection 60 mg,William Beaumont Army Medical Center,Phase 4,110,U.S. Fed,"June 27, 2020","November 9, 2020","November 9, 2020"
1479,NCT04763733,Laparoscopic Splenectomy in Children,Laparoscopic Splenectomy|Children|Benign Blood Diseases,Other: laparoscopic splenectomy,Tanta University,Phase 1,137,Other,"January 2, 2012","February 14, 2021","February 16, 2021"
1480,NCT04763265,Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines,Frown Lines,"Biological: Botulinum toxin A ""BoNT/A-DP""|Biological: Botulinum toxin A ""Botox Cosmetics""",Croma-Pharma GmbH|Hugel,Phase 2,200,Industry,"December 18, 2019","October 8, 2020","February 1, 2021"
1481,NCT04763096,Evaluate the Efficacy and Safety of the ADVAGRAF®,Evidence of Liver Transplantation,Drug: Advagraf,Linical Korea|Asan Medical Center,Phase 4,101,Industry|Other,Nov-16,Apr-20,Apr-20
1482,NCT04762407,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903",Healthy,Drug: HGP1910|Drug: HGP1909|Drug: HCP1903,Hanmi Pharmaceutical Company Limited,Phase 1,57,Industry,"November 20, 2020","February 24, 2021","February 24, 2021"
1483,NCT04761341,FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment,Age Related Macular Degeneration,Drug: NUTROF TOTAL,"University Hospital Inselspital, Berne",Phase 4,28,Other,"June 1, 2018","October 22, 2019","October 22, 2019"
1484,NCT04760743,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),COVID-19 (Healthy Volunteers),Biological: NBP2001 adjuvanted with alum (RBD 30μg/dose)|Biological: NBP2001 adjuvanted with alum (RBD 50μg/dose)|Other: Normal Saline,"SK Bioscience Co., Ltd.",Phase 1,50,Industry,"December 17, 2020","April 2, 2021","March 2, 2022"
1485,NCT04759339,"An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920",Healthy,Drug: AG-920,"American Genomics, LLC",Phase 1,14,Industry,"February 24, 2021","February 25, 2021","February 25, 2021"
1486,NCT04757532,Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.,Healthy Volunteers,Drug: Bupropion|Drug: Anastrozole|Drug: Testosterone cyclopentylpropionate|Drug: Danazol|Drug: Chlorthalidone,Parc de Salut Mar,Phase 1,9,Other,"December 3, 2020","March 10, 2021","March 10, 2021"
1487,NCT04756960,Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast),Chronic Obstructive Pulmonary Disease,Drug: CHF6001,Chiesi Farmaceutici S.p.A.,Phase 1,8,Industry,"March 10, 2021","April 19, 2021","April 29, 2021"
1488,NCT04755894,HDDO-1756 Bio Equivalence Study,Hyperlipidemias,Drug: HDDO-1756|Drug: HDDO-17561/HDDO-17562,"Hyundai Pharmaceutical Co., LTD.",Phase 1,56,Industry,"June 12, 2020","June 19, 2020","July 27, 2020"
1489,NCT04751318,Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions,Bioequivalence,Drug: Duloxetine 60mg Test Drug Enteric Coated Granules|Drug: Duloxetine 60mg Reference Product Enteric Coated Granules,Laboratorios Andromaco S.A.,Phase 1,36,Industry,"February 27, 2021","February 27, 2021","March 16, 2021"
1490,NCT04750837,Platelet Rich Plasma and Diabetic Foot Ulcer,Platelet Rich Plasma,Procedure: debridement of the wound|Biological: platelet rich plasma|Procedure: conventional dressing,Zagazig University,Phase 2,72,Other,"January 16, 2020","December 21, 2020","January 20, 2021"
1491,NCT04750603,Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents,Asthma in Children,Drug: Fluticasone furoate (FF)/Vilanterol (VI)|Drug: Salbutamol,Rambam Health Care Campus,Phase 4,92,Other,"December 1, 2018","January 31, 2020","April 15, 2020"
1492,NCT04750317,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,COVID-19,Drug: Tofacitinib,I.M. Sechenov First Moscow State Medical University,Phase 2,414,Other,"May 11, 2020","August 1, 2020","September 1, 2020"
1493,NCT04750005,A Twelve Week Study of Virtually Supervised Mouth Rinse and Flossing,Healthy,Other: Listerine Cool Mint|Other: Colgate Cavity Protection Toothpaste|Other: Reach Unflavored Waxed Dental Floss|Other: American Dental Association (ADA) Ref Toothbrush,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Phase 4,209,Industry,"October 23, 2020","February 1, 2021","February 1, 2021"
1494,NCT04748562,Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies,Twin Pregnancy With Antenatal Problem,Drug: Progesterone,Ain Shams University,Phase 4,100,Other,"January 1, 2020","August 1, 2020","December 1, 2020"
1495,NCT04748536,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,Healthy Volunteer,Drug: IRL201104|Drug: Placebo,Revolo Biotherapeutics,Phase 1,18,Industry,"January 29, 2021","April 5, 2021","April 5, 2021"
1496,NCT04747808,Study of LL-BMT1 in Patients With Elevated Intraocular Pressure,Primary Open Angle Glaucoma|Ocular Hypertension,Drug: LL-BMT1,"MediPrint Ophthalmics, Inc.",Phase 2,5,Industry,"January 8, 2021","February 16, 2021","February 16, 2021"
1497,NCT04747392,Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults,Postmenopausal Osteoporosis,Biological: SAL001|Biological: FORSTEO,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",Phase 1,64,Industry,"August 19, 2020","October 30, 2020","November 11, 2020"
1498,NCT04746365,Ivermectin Role in Covid-19 Clinical Trial,Covid19,Drug: ivermectin|Drug: hydroxychloroquine|Drug: Placebo,Elaraby Hospital|Shebin El-Kom Teaching Hospital,Phase 4,300,Other,"December 6, 2020","January 31, 2021","February 6, 2021"
1499,NCT04745767,A Study of Different Forms of TAK-994 in Healthy Adults,Healthy Participants,Drug: TAK-994,Takeda,Phase 1,54,Industry,"February 16, 2021","March 25, 2021","April 5, 2021"
1500,NCT04745442,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Covid19|Severe Acute Respiratory Syndrome|Distress Respiratory Syndrome,Drug: Antithrombin + best available treatment|Drug: Best available treatment,Maimónides Biomedical Research Institute of Córdoba,Phase 2,48,Other,"April 27, 2020","December 20, 2020","January 15, 2021"
1501,NCT04743986,The Effect of Platelet Rich Plasma on Partial Thickness Rotator Cuff Tears: A Randomized Controlled Trial,Rotator Cuff Injuries,Biological: Platelet Rich Plasma (PRP)|Drug: Corticosteroid (CS),University of Calgary,Phase 4,104,Other,"March 13, 2015","June 6, 2019","June 6, 2019"
1502,NCT04743622,Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost,Glaucoma|Ocular Hypertension,Drug: Monoprost|Drug: Xalatan,"CHA University|Samil Pharmaceutical Co., Ltd.",Phase 4,57,Other|Industry,"April 30, 2019","June 23, 2020","September 13, 2020"
1503,NCT04743414,Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects,Healthy Volunteers,Drug: CTP-543,Concert Pharmaceuticals,Phase 1,22,Industry,"March 2, 2021","March 27, 2021","April 5, 2021"
1504,NCT04742322,Efficacy of Bifidobacterium Lactis CCT 7858 in Adults Using Antibiotics,Surgery|Infection,Dietary Supplement: Bifidobacterium Lactis CCT7858|Dietary Supplement: Maltodextrin,Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude,Phase 2,116,Other,"January 11, 2021","January 11, 2021","December 30, 2021"
1505,NCT04742218,Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers,Healthy,Drug: K-877,"Kowa Research Institute, Inc.",Phase 1,18,Industry,"January 13, 2021","April 11, 2021","April 11, 2021"
1506,NCT04742062,First in Human Clinical Trial of ApTOLL in Healthy Volunteers,Stroke,Drug: ApTOLL|Other: Placebo,aptaTargets S.L.|Science and Innovation Spanish Ministry|Anagram,Phase 1,46,Industry|Other,"July 18, 2019","February 27, 2020","March 20, 2020"
1507,NCT04739774,Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast),Chronic Obstructive Pulmonary Disease,Drug: CHF6001 DPI|Drug: Itraconazole,Chiesi Farmaceutici S.p.A.,Phase 1,24,Industry,"February 22, 2021","April 20, 2021","April 26, 2021"
1508,NCT04739410,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Covid19,Drug: Ivermectin,FMH College of Medicine and Dentistry,Phase 4,50,Other,"May 1, 2020","June 30, 2020","June 30, 2020"
1509,NCT04737980,Liposomal Bupivacaine Plus Bupivacaine Peripheral Nerve Blockade Versus Ropivacaine Plus Dexamethasone Peripheral Nerve Blockade for Arthroscopic Rotator Cuff Repair,Rotator Cuff Tears|Shoulder Pain,Drug: Liposomal bupivacaine|Drug: Bupivacaine Hcl 0.5% Inj|Drug: Ropivacaine 0.5% Injectable Solution|Drug: Dexamethasone,Hospital for Special Surgery Florida,Phase 4,92,Other,"July 18, 2019","February 28, 2020","March 18, 2020"
1510,NCT04737876,"A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults",Healthy Volunteers,Biological: BX002-A|Other: Placebo,"BiomX, Inc.",Phase 1,18,Industry,"October 28, 2020","December 21, 2020","December 21, 2020"
1511,NCT04737486,A First-in-Human Study of AV-001 in Healthy Subjects,Covid19-associated ARDS|Covid19|ARDS,Drug: AV-001|Other: Placebo,"Vasomune Therapeutics, Inc.",Phase 1,48,Industry,"December 16, 2020","March 10, 2021","March 10, 2021"
1512,NCT04736927,Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects,Healthy,Drug: GLPG3667|Drug: Midazolam,Galapagos NV,Phase 1,14,Industry,"January 15, 2021","February 25, 2021","February 25, 2021"
1513,NCT04734275,Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers,Chronic Kidney Disease,Drug: AZD5718,AstraZeneca|Parexel,Phase 1,16,Industry,"February 1, 2021","March 25, 2021","March 25, 2021"
1514,NCT04733001,A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112,Obesity,Drug: HSG4112,Glaceum|Seoul National University Hospital,Phase 1,12,Industry|Other,"July 12, 2020","February 10, 2021","February 10, 2021"
1515,NCT04730323,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Covid19,Drug: Tocilizumab,FMH College of Medicine and Dentistry,Phase 4,93,Other,"May 12, 2020","June 12, 2020","June 12, 2020"
1516,NCT04730297,Comparative Analgesic Effects of Paracetamol/Codeine and Ibuprofen on Pain After Third Molar Surgery,To Control Pain After Third Molar Surgery,Drug: paracetamol 500 mg plus codeine 30 mg preoperative administration|Drug: ibuprofen 400 mg preoperative administration|Drug: Placebo oral tablet preoperative administration,University of Roma La Sapienza,Phase 4,120,Other,"January 1, 2018","September 4, 2020","October 14, 2020"
1517,NCT04730245,Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease,Parkinson's Disease Aggravated,"Drug: sodium phosphate enema, oral rifaximin and polyethylene glycol",Torre Médica Santé,Phase 1,14,Other,"June 1, 2018","March 30, 2020","March 30, 2020"
1518,NCT04729764,Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects,Influenza,Drug: GP681 Tablet,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,Phase 1,56,Industry,"August 27, 2020","December 15, 2020","December 15, 2020"
1519,NCT04728802,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Covid19|SARS (Severe Acute Respiratory Syndrome),Drug: Proxalutamide|Drug: Placebo,"Applied Biology, Inc.",Phase 3,645,Industry,"February 1, 2021","April 15, 2021","April 15, 2021"
1520,NCT04724629,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),Covid19,Biological: Ixekizumab|Biological: Aldesleukin|Drug: Colchicine|Drug: Standard of care (SOC),University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Science Valley Research Institute,Phase 3,60,Other,"January 5, 2021","March 31, 2021","July 30, 2021"
1521,NCT04723238,Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions,Bioequivalence,Drug: Duloxetine 60mg Test Drug Enteric Coated Granules|Drug: Duloxetine 60mg Reference Product Enteric Coated Granules,Laboratorios Andromaco S.A.,Phase 1,36,Industry,"January 23, 2021","February 9, 2021","March 26, 2021"
1522,NCT04722653,A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men,Non-alcoholic Steatohepatitis,Drug: NNC0194-0499|Drug: Placebo (NNC0194-0499 ),Novo Nordisk A/S,Phase 1,42,Industry,"February 2, 2021","April 27, 2021","April 27, 2021"
1523,NCT04721457,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,SARS-CoV-2|COVID-19|Mouthwashes|Viral Load|Polymerase Chain Reaction|Coronavirus|Covid19|Saliva,Drug: Distilled Water|Drug: 1% Povidone Iodine (PVP-I)|Drug: 1.5% Hydrogen Peroxide (H2O2)|Drug: 0.075% Cetylpyridinium Chloride (CPC)|Drug: 0.1% Sodium Hypochlorite|Other: No rinse group,King Abdulaziz University,Phase 4,90,Other,"January 3, 2021","March 28, 2021","December 10, 2021"
1524,NCT04720547,Sleep and Breathing in the General Population - Chemical Stimuli,Sleep-disordered Breathing,Drug: Zolpidem|Other: No Treatment,"Wayne State University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,14,Other|NIH,"July 3, 2018","February 29, 2020","February 29, 2020"
1525,NCT04720287,Ultrasound Guided Quadratus Lumborum Block Compared to Caudal Bupivacaine/ Neostigmine in Pediatric Lower Abdominal Surgeries,Postoperative Analgesia,Drug: bupivacaine/ neostigmine.,Ain Shams University,Phase 4,60,Other,"February 1, 2021","April 30, 2021","April 30, 2021"
1526,NCT04720183,"Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects",Healthy,Drug: Sulfasalazine|Drug: GLPG3970,Galapagos NV,Phase 1,8,Industry,"January 11, 2021","April 21, 2021","April 23, 2021"
1527,NCT04718805,A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions,Healthy,Drug: Darunavir|Drug: Cobicistat|Drug: Darunavir/Cobicistat FDC,"Janssen Research & Development, LLC",Phase 1,22,Industry,"January 26, 2021","March 1, 2021","March 1, 2021"
1528,NCT04718714,Effects of Dexmedetomidine vs Propofol in Patients With Intra-abdominal Sepsis,Septic Peritonitis,Drug: Midazolam|Drug: Propofol|Drug: Dexmedetomidine,Assiut University,Phase 4,60,Other,"January 23, 2021","April 10, 2021","April 10, 2021"
1529,NCT04718324,PREMs on PROMs in Breast Disease (PREMs_PROMs),Breast Disease|Breast Cancer|Breast Neoplasms,Other: e-PROMS|Other: p-PROMS,Uppsala University,Phase 3,230,Other,"September 1, 2019","March 30, 2021","April 30, 2021"
1530,NCT04718233,Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss,Recurrent Pregnancy Loss,Drug: Sildenafil 25Mg Tablet|Drug: Placebo Oral Tablet,Ain Shams University,Phase 2,80,Other,"September 5, 2018","July 1, 2019","July 1, 2019"
1531,NCT04717063,Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria Saliva and Bioaerosol Contamination Phase 2,Healthy,Drug: Peroxyl Oral Product|Drug: Placebo,Colgate Palmolive,Phase 2,100,Industry,"November 16, 2020","December 30, 2020","January 7, 2021"
1532,NCT04716894,A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood,Healthy,Drug: BI 474121|Drug: Itraconazole,Boehringer Ingelheim,Phase 1,14,Industry,"February 1, 2021","April 1, 2021","April 1, 2021"
1533,NCT04714554,"A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men",Healthy,Drug: Relugolix/E2/NETA FDC|Drug: Relugolix|Drug: Erythromycin,Myovant Sciences GmbH,Phase 1,43,Industry,"January 6, 2021","March 29, 2021","March 29, 2021"
1534,NCT04714229,Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old,"Infection, Meningococcal","Biological: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|Biological: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine","EuBiologics Co.,Ltd",Phase 1,60,Industry,"September 1, 2020","November 1, 2020","September 1, 2021"
1535,NCT04714073,A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood,Healthy,Drug: BI 706321|Drug: Itraconazole,Boehringer Ingelheim,Phase 1,14,Industry,"February 11, 2021","April 30, 2021","April 30, 2021"
1536,NCT04713904,Bioavailability of Clormadinone/Ethinyl Estradiol Tablets 2 mg/0.02 mg With Regards to Reference Product,Bioequivalence,Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets,Laboratorios Andromaco S.A.,Phase 1,38,Industry,"January 16, 2021","January 16, 2021","February 2, 2021"
1537,NCT04713709,"A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder",Opioid Overdose,Combination Product: Nasus Pharma FMXIN001|Combination Product: Nasal Naloxone liquid spray,Nasus Pharma,Phase 1,46,Industry,"January 31, 2021","March 30, 2021","October 10, 2021"
1538,NCT04713254,Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men,Healthy,Drug: Lu AG06466|Other: Midazolam|Other: Metoprolol|Other: Bupropion,H. Lundbeck A/S,Phase 1,15,Industry,"December 8, 2020","April 9, 2021","April 9, 2021"
1539,NCT04712838,Study on the Bioavailability of SHR0302 in Healthy Subjects,Healthy Subjects,Drug: SHR0302,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"March 15, 2021","April 13, 2021","April 13, 2021"
1540,NCT04712500,A Food-Effect Study of AND017 in Healthy Participants,Healthy Volunteers,Drug: AND017,Kind Pharmaceuticals LLC,Phase 1,14,Industry,"July 30, 2020","August 16, 2020","August 21, 2020"
1541,NCT04712396,A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body,"Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)",Drug: Capivasertib|Drug: Itraconazole,AstraZeneca|Parexel,Phase 1,11,Industry,"February 1, 2021","March 25, 2021","March 25, 2021"
1542,NCT04711213,A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery,Cataract in Inflammatory Ocular Disorders,Drug: Dexamethasone Dose 1|Drug: Dexamethasone Dose 2|Drug: Placebo Dose 1|Drug: Placebo Dose 2,"iDrop, Inc.",Phase 2,60,Industry,"September 14, 2020","October 31, 2020","November 15, 2020"
1543,NCT04710810,UCB Stem Cells for Autism Spectrum Disorders,Autism Spectrum Disorder,Other: umbilical cord blood mononuclear stem cells,St. Petersburg Bekhterev Research Psychoneurological Institute,Phase 1,30,Other,"November 4, 2019","January 31, 2021","July 31, 2021"
1544,NCT04710407,"Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers",Healthy Volunteers,Drug: TBPM-PI-HBr,Spero Therapeutics|Clinartis,Phase 1,30,Industry,"December 7, 2020","March 10, 2021","March 10, 2021"
1545,NCT04709913,Multiple Ascending Dose Study of HU6 in High BMI Volunteers,NASH - Nonalcoholic Steatohepatitis,Drug: HU6,"Rivus Pharmaceuticals, Inc.",Phase 1,30,Industry,"January 4, 2021","April 30, 2021","July 30, 2021"
1546,NCT04709094,A Drug Interaction Study of Danicopan,Healthy,Drug: Danicopan|Drug: Warfarin|Drug: Bupropion|Drug: Ethinyl Estradiol/Norethindrone,"Alexion|Achillion, a wholly owned subsidiary of Alexion|Celerion",Phase 1,52,Industry,"July 28, 2019","October 14, 2019","April 17, 2020"
1547,NCT04709081,A Drug Interaction Study of ACH-0145228,Healthy,Drug: ACH-0145228|Drug: Midazolam|Drug: Digoxin|Drug: Itraconazole,"Alexion|Achillion, a wholly owned subsidiary of Alexion|Celerion",Phase 1,38,Industry,"December 22, 2019","April 16, 2020","April 16, 2020"
1548,NCT04708795,Clinical Trial on Pharmacokinetic and Tolerability of AP701,Pharmacokinetic|Tolerability|Safety,Drug: AP701,CannaXan GmbH,Phase 1,15,Industry,"January 11, 2020","March 7, 2021","March 7, 2021"
1549,NCT04708184,A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970,Healthy,Drug: GLPG3970 oral solution|Drug: GLPG3970 tablet,Galapagos NV,Phase 1,12,Industry,"January 11, 2021","February 25, 2021","February 25, 2021"
1550,NCT04707547,Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy,Liver Cancer,Biological: immunotherapy with Nivolumab|Procedure: Radiofrequency Ablation,Taipei Medical University WanFang Hospital,Phase 4,5,Other,"October 16, 2019","July 23, 2020","July 23, 2020"
1551,NCT04706494,A Study to Investigate the Efficacy of AlphaWave® L-Theanine on Stress,Stress,Dietary Supplement: AlphaWave® LTheanine|Dietary Supplement: Placebo,"Ethical Naturals, Inc.",Phase 1,16,Other,"February 2, 2020","September 25, 2020","September 25, 2020"
1552,NCT04706416,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Coronavirus|Covid19,Dietary Supplement: N-acetyl glucosamine (NAG)|Other: Control,Quantinosis.ai LLC,Phase 1,150,Industry,"November 14, 2020","January 15, 2021","January 15, 2021"
1553,NCT04705922,Relative Bioavailability Study and Food Effect Study of TT-00420 Capsule and Tablet Formulations in Healthy Volunteers,Healthy,Drug: TT-00420 Capsule|Drug: TT-00420 Tablet,"TransThera Sciences (Nanjing), Inc.",Phase 1,24,Industry,"December 29, 2020","March 7, 2021","July 23, 2021"
1554,NCT04705714,Antibacterial and Anti-biofilm Activity of Frankincense Extract Against Porphyromonas Gingivalis,Periodontal Diseases,Drug: Frankincense Extract,Tanta University,Phase 1,30,Other,"January 15, 2021","March 1, 2021","March 1, 2021"
1555,NCT04705142,Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE),HIE,Drug: MgSo4,"Services Institute of Medical Sciences, Pakistan",Phase 2,200,Other,"May 1, 2019","December 30, 2020","December 30, 2020"
1556,NCT04705077,A Study to Assess the Pharmacokinetics and Food Effect of SR419 in Healthy Subjects,Healthy,Drug: SR419,SIMR (Australia) Biotech Pty Ltd.|SIMRAustraliaBiotech,Phase 1,24,Industry,"February 2, 2021","March 12, 2021","March 12, 2021"
1557,NCT04704739,Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205,Healthy,Drug: GLPG1205 film-coated tablets|Drug: [14C]-GLPG1205 solution for infusion|Drug: GLPG1205 capsules,Galapagos NV,Phase 1,12,Industry,"January 13, 2021","March 2, 2021","March 10, 2021"
1558,NCT04704232,"Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers",Pain,Drug: ACD440|Drug: PLAC,AlzeCure Pharma,Phase 1,24,Industry,"January 12, 2021","March 10, 2021","March 10, 2021"
1559,NCT04703803,Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care,Myofascial Pain Syndromes|Cancer,Combination Product: 1% lidocaine injection in trigger points,University of Sao Paulo,Phase 3,30,Other,"August 17, 2020","March 19, 2021","May 17, 2022"
1560,NCT04702698,Effect of Food on Peposertib PK,Healthy,Drug: Peposertib,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,12,Industry,"January 14, 2021","March 3, 2021","March 3, 2021"
1561,NCT04702503,Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL),Cutaneous T-Cell Lymphoma/Mycosis Fungoides,Drug: WP1220,"Moleculin Biotech, Inc.",Phase 1,5,Industry,"March 8, 2019","November 15, 2019","November 15, 2020"
1562,NCT04701697,Phase Ib of Recombinant Human Albumin Injection,Ascites,Drug: Recombinant Human Albumin Injection|Drug: HumanAlbumin,The First Hospital of Jilin University,Phase 1,36,Other,"March 15, 2020","September 10, 2020","October 25, 2020"
1563,NCT04701502,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Covid19|Respiratory Disease|Immune System|Immunomodulator|Antiseptic|Supportive Care,Dietary Supplement: Viusid|Dietary Supplement: Asbrip|Drug: Standard Care,Catalysis SL,Phase 2,60,Industry,"November 9, 2020","February 15, 2021","February 15, 2021"
1564,NCT04700839,SGLT2 Inhibitors in Patients With PCOS,Polycystic Ovary Syndrome,Drug: SGLT2 inhibitors|Drug: Metformin,Shanghai 10th People's Hospital,Phase 4,68,Other,"May 1, 2020","April 28, 2021","April 30, 2021"
1565,NCT04699669,A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers,Subcutaneous Fat,"Drug: CBL-514, placebo|Drug: CBL-514","Caliway Biopharmaceuticals Co., Ltd.",Phase 1,40,Industry,"November 27, 2018","August 20, 2019","August 20, 2019"
1566,NCT04699656,Plazomicin Study in ESRD Patients Receiving IHD,End Stage Renal Disease,Drug: Plazomicin Injection,Cipla USA Inc.,Phase 1,6,Industry,"January 5, 2021","March 8, 2021","June 9, 2021"
1567,NCT04699110,Adrenaline for the Treatment of No-Reflow in Normotensive Patients,Acute Coronary Syndrome|No-Reflow Phenomenon|Normotensive,Drug: Adrenaline|Drug: Adenosine,"National Institute of Cardiovascular Diseases, Pakistan",Phase 4,201,Other,"January 1, 2021","April 30, 2021","April 30, 2021"
1568,NCT04698642,"A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat",Subcutaneous Fat,Drug: CBL-514,"Caliway Biopharmaceuticals Co., Ltd.",Phase 2,43,Industry,"February 3, 2020","November 12, 2020","November 12, 2020"
1569,NCT04698525,Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.,Migraine Headache,Drug: Valproate Sodium|Drug: Memantine,Universidad Autonoma de San Luis Potosí,Phase 3,33,Other,"February 15, 2019","January 15, 2020","January 15, 2020"
1570,NCT04697537,Ultrasound-guided Regional Anesthesia vs Local Infiltration Anesthesia With Dexmedetomidine and Ropivacaine,"Pain, Postoperative|Anesthesia, Local|Gonarthrosis",Drug: Ultrasound guided regional anesthesia|Drug: Local infiltration analgesia,Medical University of Graz,Phase 3,50,Other,"February 1, 2021","April 9, 2021","April 9, 2021"
1571,NCT04697511,Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants,Healthy,Drug: Midazolam|Drug: M2951,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,16,Industry,"January 11, 2021","February 25, 2021","February 25, 2021"
1572,NCT04697199,The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis,Chronic Periodontitis,Drug: Lactobacillus Reuteri Oral Drops|Procedure: Scaling and root planing,Tanta University,Phase 1,12,Other,"September 1, 2018","September 6, 2019","February 6, 2020"
1573,NCT04696393,A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants,Healthy Volunteers,Drug: Mitapivat tablet,"Agios Pharmaceuticals, Inc.",Phase 1,26,Industry,"January 6, 2021","March 19, 2021","March 19, 2021"
1574,NCT04695951,Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract,"Renal Injury|Kidney Injury|Kidney Calculi|Ureteral Obstruction|Ureteral Calculi|Renal Stone|Ureteral Injury|Renal Disease|Urolithiasis, Calcium Oxalate|Urolithiasis; Lower Urinary Tract|Urolithiasis",Dietary Supplement: Renalof|Other: Placebo,Catalysis SL,Phase 2,155,Industry,"August 1, 2019","July 1, 2020","October 1, 2020"
1575,NCT04695613,Shivering Control After Percutaneous Nephrolithotomy,Shivering Control,Drug: Aminoacid|Drug: Magnesium sulfate,Assiut University,Phase 3,80,Other,"January 3, 2021","March 25, 2021","April 10, 2021"
1576,NCT04694989,A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2),Hypertension and Dyslipidemia,"Drug: CKD-386|Drug: D013, D326, D337",Chong Kun Dang Pharmaceutical,Phase 1,62,Industry,"February 20, 2021","April 7, 2021","May 4, 2021"
1577,NCT04693455,ZD03 Capsule Study,Healthy,Drug: ZD03|Other: Placebo,"Shanxi Zhendong Leading Biotechnology Co., Ltd.|Shanxi Zhendong Pharmacy Co., Ltd",Phase 1,48,Industry,"November 6, 2019","April 27, 2020","April 27, 2020"
1578,NCT04693429,Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+,Safety|Tolerability|Ocular Surface|Ocular Comfort,Drug: Bepotastine Besilate,Laboratorios Sophia S.A de C.V.,Phase 1,22,Industry,"September 24, 2020","November 27, 2020","December 8, 2020"
1579,NCT04692623,EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY,"Blood Glucose, Low|Hypoglycemia",Drug: Moxifloxacin 400mg|Drug: Gemifloxacin 320 MG,Shaheed Benazir Bhutto University Sheringal Dir Upper|Khyber Medical University Peshawar,Phase 1,25,Other,"March 1, 2021","March 15, 2021","April 1, 2021"
1580,NCT04692415,Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors,"Diabetes Mellitus, Type 2",Drug: Degludec|Drug: Glargine U300,"University of Split, School of Medicine|Pavle Vrebalov Cindro|Jonatan Vuković|Darko Modun|Božo Smajić|Gordan Kardum|Tina Tičinović Kurir|Doris Rušić|Ana Šešelja Perišin|Josipa Bukić",Phase 4,25,Other,"December 15, 2018","June 27, 2019","June 27, 2019"
1581,NCT04692285,Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia,Focal Dystonia,Drug: Zolpidem|Drug: Placebo,University Medical Centre Ljubljana|Slovenian Research Agency|Clinical Centre of Serbia,Phase 1,24,Other,"September 30, 2017","April 30, 2021","April 30, 2021"
1582,NCT04692025,Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers,Healthy|NAFLD|Hyperlipidemia,Drug: ASC41 tablet,"Gannex Pharma Co., Ltd.|Hunan Provincial People's Hospital",Phase 1,12,Industry|Other,"December 27, 2020","January 14, 2021","January 21, 2021"
1583,NCT04691908,"Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine",Covid19|SARS-CoV Infection|Vaccine Adverse Reaction,Biological: QazCovid-in®-vaccine against COVID-19|Other: Placebo,Research Institute for Biological Safety Problems|City polyclinic No. 4 of the UZO of Almaty|Clinic of the International Institute of Postgraduate Education|City Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl Region,Phase 3,3000,Other,"December 25, 2020","April 26, 2021","July 11, 2021"
1584,NCT04690387,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",COVID-19,Biological: AV-COVID-19|Other: GM-CSF,"Aivita Biomedical, Inc.|PT AIVITA Biomedika Indonesia|Indonesia Ministry of Health|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",Phase 1,27,Industry|Other,"December 7, 2020","January 13, 2021","January 15, 2021"
1585,NCT04688632,Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects,Symptomatic Neurogenic Orthostatic Hypertension|nOH,Drug: Ampreloxetine <Dose A>|Drug: Ampreloxetine <Dose B>|Drug: Ampreloxetine Placebo|Drug: Moxifloxacin|Drug: Moxifloxacin Placebo,Theravance Biopharma,Phase 1,72,Industry,"January 18, 2021","March 13, 2021","March 26, 2021"
1586,NCT04688008,Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations,Bioavailability Study,Drug: Hetrombopag,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,58,Industry,"September 18, 2020","October 12, 2020","October 30, 2020"
1587,NCT04687930,Genicular Nerve Block in Juvenile Idiopathic Arthritis,Juvenile Idiopathic Arthritis|Persistent Knee Arthritis|no Intra-articular Injection in the Last 3 Months|no Other Cause for Chronic Kneearthritis,Drug: genicular nerve block|Drug: intra-articular steroid injection,Sohag University,Phase 4,104,Other,"December 1, 2020","February 15, 2021","February 15, 2021"
1588,NCT04687813,"Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers",Healthy,Drug: Placebo,"Haisco Pharmaceutical Group Co., Ltd.",Phase 1,31,Industry,"December 23, 2020","February 26, 2021","March 18, 2021"
1589,NCT04686994,Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects,Overweight and Obesity|NAFLD|Hyperlipidemia,Drug: ASC 41|Drug: ASC 41 Placebo,"Gannex Pharma Co., Ltd.|Hunan Provincial People's Hospital",Phase 1,20,Industry|Other,"December 22, 2020","January 19, 2021","February 7, 2021"
1590,NCT04686825,The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects,Healthy,Drug: DA-8010 2.5mg (Fasting)|Drug: DA-8010 2.5mg (Fed)|Drug: DA-8010 5mg (Fasting)|Drug: DA-8010 5mg (Fed),"Dong-A ST Co., Ltd.",Phase 1,29,Industry,"January 13, 2021","February 17, 2021","March 11, 2021"
1591,NCT04686669,A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations,Relative Bioavailability,Drug: FOR-6219 capsule formulation|Drug: FOR-6219 tablet formulation,Forendo Pharma Ltd|Richmond Pharmacology Limited,Phase 1,12,Industry,"December 10, 2020","January 16, 2021","January 16, 2021"
1592,NCT04686591,Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects,Cardiovascular Disease,"Drug: AZD9977 capsule 50 mg|Drug: [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|Drug: [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)",AstraZeneca|Quotient Sciences,Phase 1,8,Industry,"December 21, 2020","February 4, 2021","February 4, 2021"
1593,NCT04685538,Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.,Cataract,Drug: Chloroprocaine 3%|Drug: Tetracaine 0.5%,Sintetica SA,Phase 3,338,Industry,"September 9, 2020","March 1, 2021","March 9, 2021"
1594,NCT04685213,Electrical Stimulation for Critically Ill Covid-19 Patients,Covid19|Muscle Atrophy|Muscle Weakness,Device: Electrical Stimulation|Device: Electrical Stimulation - Sham,"Baylor College of Medicine|Avazzia, Inc",Phase 1,19,Other|Industry,"December 22, 2020","March 18, 2021","March 18, 2021"
1595,NCT04683926,A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects,Pain,Drug: Desmetramadol,"Syntrix Biosystems, Inc.|Celerion|National Institute on Drug Abuse (NIDA)",Phase 1,24,Industry|NIH,"January 8, 2021","January 18, 2021","January 18, 2021"
1596,NCT04682873,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Joint Stock Company ""Farmak""",Phase 3,592,Industry,"May 15, 2020","March 26, 2021","March 26, 2021"
1597,NCT04682119,A Safety Study of LY3526318 in Healthy Participants,Healthy,Drug: LY3526318|Drug: Placebo,Eli Lilly and Company,Phase 1,16,Industry,"December 29, 2020","April 21, 2021","April 21, 2021"
1598,NCT04681547,Ultrasound-guided Genicular Nerve Block for Total Knee Arthroplasty.,Pain,Procedure: Genicular nerve Block|Procedure: Local Infiltration Analgesia,Hospital Clinic of Barcelona,Phase 4,60,Other,"December 15, 2020","April 30, 2021","April 30, 2021"
1599,NCT04680949,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,Covid19,Drug: Anakinra|Drug: Placebo,Hellenic Institute for the Study of Sepsis,Phase 3,606,Other,"December 23, 2020","March 31, 2021","February 6, 2022"
1600,NCT04680273,"Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential",Healthy Volunteers,Drug: [14C]-GDC-9545|Drug: GDC-9545 Solution for Infusion|Drug: GDC-9545/F12 Capsule|Drug: GDC-9545/F18 Capsule,"Genentech, Inc.",Phase 1,16,Industry,"January 7, 2021","April 12, 2021","April 12, 2021"
1601,NCT04679948,"A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood",Healthy,"Drug: Drug Cocktail consisting of caffeine, warfarin, omeprazole and midazolam|Drug: BI 730357",Boehringer Ingelheim,Phase 1,16,Industry,"December 21, 2020","March 17, 2021","March 17, 2021"
1602,NCT04679753,Brainsway DTMS for Treatment of MDD Using iTBS,Major Depressive Disorder,Device: Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Device: Brainsway DTMS with High Frequency (HF) Stimulation,Brainsway,Phase 4,177,Industry,"January 1, 2019","July 1, 2020","July 1, 2020"
1603,NCT04679493,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers",Covid19|Healthy Volunteers,Drug: XC7 100 mg single|Drug: XC7 200 mg single|Drug: Placebo single|Drug: XC7 200 mg multiple|Drug: Placebo multiple,NP Therapeutics,Phase 1,16,Other,"December 17, 2020","April 9, 2021","April 9, 2021"
1604,NCT04679103,"A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC ""GENERIUM"", Russian Federation)",Paroxysmal Nocturnal Hemoglobinuria,"Biological: Eculizumab (JSC GENERIUM, Russia)",AO GENERIUM,Phase 3,50,Industry,"May 3, 2018","April 20, 2020","April 20, 2020"
1605,NCT04678739,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Covid19|Covid-19 ARDS,Drug: Remdesivir|Drug: Tocilizumab,M Abdur Rahim Medical College and Hospital|First Affiliated Hospital Xi'an Jiaotong University|Cox's Bazar 250 Bed District Sadar Hospital|Chattogram General Hospital,Phase 3,205,Other,"August 15, 2020","January 30, 2021","February 10, 2021"
1606,NCT04678531,TTO Swabs Versus Baby Shampoo in Patients With Seborrehic Blepharitis,Seborrheic Blepharitis,Drug: Swabs containing tea tree oil and chamomile oil|Drug: Baby shampoo,Istanbul University - Cerrahpasa (IUC)|Koç University,Phase 4,49,Other,"November 12, 2018","November 15, 2019","November 15, 2019"
1607,NCT04677933,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002",Osteoarthritis,Drug: A: OLP-1002|Drug: B: OLP-1002|Drug: C: Placebo,OliPass Australia Pty Ltd|Novotech (Australia) Pty Limited,Phase 1,30,Industry,"June 3, 2020","December 22, 2020","December 22, 2020"
1608,NCT04676906,A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds,Healthy Volunteers|Type 2 Diabetes,Drug: NNC0113-6861|Drug: NNC0113-6860|Drug: NNC0113-6891,Novo Nordisk A/S,Phase 1,18,Industry,"November 26, 2020","April 28, 2021","April 28, 2021"
1609,NCT04676659,Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE),Acute Ischemic Stroke,Drug: TNK-tPA,"Beijing Tiantan Hospital|Guangzhou Recomgen Biotech Co., Ltd.|The First Hospital Of Qiqihar|Hebei Medical University Third Hospital|Yantai Yuhuangding Hospital|Fudan University|First Affiliated Hospital of Jinan University|The First Hospital of Jilin University|Huashan Hospital|West China Hospital|Inner Mongolia Baogang Hospital|Linyi People's Hospital|The First Affiliated Hospital of Zhengzhou University|Baotou Central Hospital",Phase 2,240,Other|Industry,"May 12, 2018","May 30, 2020","July 10, 2020"
1610,NCT04675619,Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis,Hypersensitivity Pneumonitis,Drug: Oral pirfenidone|Drug: Standard care,Zagazig University,Phase 2,40,Other,"December 1, 2019","June 30, 2020","June 30, 2020"
1611,NCT04675385,Hyaluronic Acid 0.2% Application Enhanced Chronic Periodontitis Treatment in Non-surgical Phase,"Chronic Periodontitis, Hyaluronic Acid",Drug: 0.2% hyaluronic acid gel,University of Medicine and Pharmacy at Ho Chi Minh City,Phase 4,28,Other,"June 21, 2019","September 21, 2019","July 31, 2020"
1612,NCT04675021,Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects,Cancer,"Drug: AZD6094 (Savolitinib) film coated tablets 600 mg|Drug: [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|Drug: [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)",AstraZeneca|Quotient Sciences,Phase 1,8,Industry,"November 13, 2020","January 11, 2021","January 11, 2021"
1613,NCT04673864,A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386,Hypertension and Dyslipidemia,"Drug: CKD-386|Drug: D012, D326, D337",Chong Kun Dang Pharmaceutical,Phase 1,66,Industry,"January 17, 2021","March 4, 2021","March 30, 2021"
1614,NCT04673214,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Covid19,Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Drug: Azithromycin / Ribaroxaban / Paracetamol,"Gilberto Cruz Arteaga|Coordinación de Investigación en Salud, Mexico",Phase 3,114,Other,"December 16, 2020","February 25, 2021","February 25, 2021"
1615,NCT04673162,Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients,Covid19,"Drug: Methylprednisolone, Placebo",Azienda Unità Sanitaria Locale Reggio Emilia,Phase 3,260,Other,"December 17, 2020","April 21, 2021","July 12, 2021"
1616,NCT04672499,Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants,Healthy,Drug: Miricorilant 300 mg tablets|Drug: Miricorilant 150 mg tablets|Drug: Placebo 150 mg tablets,Corcept Therapeutics,Phase 1,36,Industry,"April 27, 2020","September 7, 2020","September 7, 2020"
1617,NCT04672083,A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers,HIV Infections,Drug: CPT31|Drug: Placebo,"Navigen, Inc.|Covance|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,32,Industry|NIH,"November 16, 2020","April 26, 2021","April 29, 2021"
1618,NCT04671953,Effect of BMS-986165 on the Blood Levels of Metformin,Healthy Participants,Drug: BMS-986165|Drug: Metformin,Bristol-Myers Squibb,Phase 1,36,Industry,"December 18, 2020","March 3, 2021","March 30, 2021"
1619,NCT04671563,Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate,Pharmacokinetic of Tenofovir in Healthy Subjects,Drug: Tenofovir Disoproxil Fumarate 300 MG,"Yung Shin Pharm. Ind. Co., Ltd.|Taichung Veterans General Hospital",Phase 4,28,Industry|Other,"April 22, 2019","May 9, 2020","August 31, 2020"
1620,NCT04671316,"Bioequivalence Study Between ""DA-5209 Tab"" and ""Lixiana Tab""",Healthy,Drug: DA-5209 60mg Tab|Drug: Lixiana 60mg Tab,"Dong-A ST Co., Ltd.",Phase 1,121,Industry,"November 23, 2020","February 4, 2021","February 4, 2021"
1621,NCT04671069,Drug Interaction Study of MGL-3196 With Clopidogrel,Healthy,Drug: MGL-3196|Drug: Clopidogrel,"Madrigal Pharmaceuticals, Inc.",Phase 1,20,Industry,"July 26, 2019","August 30, 2019","September 14, 2019"
1622,NCT04669795,Osteogenic Potential of Cissus Quadrangularis Alveolar Ridge Distraction,Distraction of Bone|Dental Implant,Drug: Cissus Quadrangularis,Al-Azhar University,Phase 2,20,Other,"April 15, 2017","May 30, 2019","August 15, 2019"
1623,NCT04669353,Platelet Rich Plasma and Wound Healing After Cesarean Section,Infection,Drug: Platelet rich plasma,Menoufia University,Phase 4,200,Other,"April 1, 2018","July 1, 2020","December 30, 2020"
1624,NCT04668352,A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly,Respiratory Tract Infections,Drug: Dactolisib|Other: Placebo,Restorbio Inc.,Phase 3,1024,Industry,"April 15, 2019","December 2, 2019","December 2, 2019"
1625,NCT04668274,"JOTROL PK, Safety, and Food Effect Assessment",Pharmacokinetics|Safety|Food-drug Interaction,Drug: 200 mg resveratrol as JOTROL|Drug: 500 mg resveratrol as JOTROL|Drug: 700 mg resveratrol as JOTROL|Drug: 500 mg resveratrol as JOTROL administered to assess influence of food,Jupiter Orphan Therapeutics Inc.|National Institute on Aging (NIA),Phase 1,24,Industry|NIH,"January 21, 2021","February 28, 2021","May 31, 2021"
1626,NCT04667624,Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers,Hypertension,Drug: Twynsta|Drug: LodineT,"Hanlim Pharm. Co., Ltd.",Phase 1,32,Industry,"February 29, 2020","April 28, 2020","May 18, 2020"
1627,NCT04667156,Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects,Healthy Volunteers,Drug: SHR6390,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"December 13, 2020","January 29, 2021","January 29, 2021"
1628,NCT04666441,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,COVID-19,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,Regeneron Pharmaceuticals,Phase 2,1149,Industry,"December 15, 2020","March 4, 2021","September 21, 2021"
1629,NCT04665830,PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients,Kideny Transplant Recipients With High Cardiovascular Risk Score,Drug: Evolocumab,Hamid Al-Essa Organ Transplant Center,Phase 3,200,Other,"May 1, 2018","May 1, 2020","May 1, 2020"
1630,NCT04665284,Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus,Type II Diabetes Mellitus,Drug: Empagliflozin|Drug: Usual care group,Getz Pharma,Phase 4,244,Industry,"June 1, 2019","September 15, 2020","September 28, 2020"
1631,NCT04665050,"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Japanese Adults (pPCV-002)",Pneumococcal Infection,Biological: pPCV|Biological: PNEUMOVAX™23,Merck Sharp & Dohme LLC,Phase 1,102,Industry,"February 4, 2021","April 6, 2021","April 6, 2021"
1632,NCT04663464,Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.,Healthy Volunteers,Combination Product: abaloparatide-sMTS|Combination Product: abaloparatide-SC,"Radius Health, Inc.|Medpace, Inc.",Phase 1,52,Industry,"November 16, 2020","March 27, 2021","November 19, 2021"
1633,NCT04662385,The Effect of Toothpaste Containing Aloe Vera on Gingivitis,Generalized Gingivitis,Drug: aloe vera toothpaste|Drug: Colgate Total,Zainab J Abbas|University of Baghdad,Phase 2,24,Other,"March 13, 2020","May 26, 2020","November 19, 2020"
1634,NCT04662177,Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA),Carotid Stenosis,Drug: Dexmedetomidine,"University Hospital Inselspital, Berne",Phase 4,23,Other,"November 21, 2018","October 16, 2020","December 4, 2020"
1635,NCT04660890,A Study of the Cardiac Effects of ALXN2050 in Healthy Adults,Healthy,Drug: ALXN2050|Drug: ALXN2050-matching Placebo|Drug: Moxifloxacin|Drug: Moxifloxacin-matching Placebo,Alexion|Celerion,Phase 1,39,Industry,"December 12, 2020","March 16, 2021","March 16, 2021"
1636,NCT04659551,Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients,Breast Cancer,Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Triptorelin|Drug: Exemestane|Drug: Nivolumab,Istituto Oncologico Veneto IRCCS|University of Padova,Phase 2,43,Other,"October 5, 2017","May 25, 2020","May 25, 2020"
1637,NCT04658927,Dextenza With ILUX for Treatment of MGD,Meibomian Gland Dysfunction|Evaporative Dry Eye,"Drug: Dexamethasone, 0.4mg|Drug: Prednisone acetate|Other: Control",Warrenville Eyecare,Phase 4,30,Other,"January 4, 2021","January 11, 2021","May 30, 2021"
1638,NCT04657809,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,Anosmia,Combination Product: Insulin film|Device: Fast dissolving film,Soad Ali|Minia University|Deraya University,Phase 2,40,Other,"October 1, 2020","February 18, 2021","March 20, 2021"
1639,NCT04657744,"Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).",Healthy,Drug: Sphingomod|Drug: Gilenya,"Genuine Research Center, Egypt|Hikma Pharmaceuticals LLC",Phase 1,34,Industry,"August 10, 2020","September 28, 2020","October 20, 2020"
1640,NCT04657497,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),SARS-CoV-2 Infection (COVID-19),Drug: FOY-305|Drug: Placebo,Ono Pharmaceutical Co. Ltd,Phase 3,155,Industry,"November 9, 2020","March 26, 2021","April 9, 2021"
1641,NCT04657172,Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults,Presbyopia,Drug: Pilocarpine Ophthalmic|Drug: Placebo,Eyenovia Inc.,Phase 3,84,Industry,"December 15, 2020","March 26, 2021","March 26, 2021"
1642,NCT04656288,A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood,Healthy,Drug: BI 764198 - Formula A|Drug: BI 764198 - Formula B|Drug: BI 764198 - Formula C|Drug: BI 764198 - Formula D,Boehringer Ingelheim,Phase 1,28,Industry,"January 15, 2021","March 15, 2021","March 15, 2021"
1643,NCT04656249,Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer,Cholangiocarcinoma|Biliary Tract Cancer|Targeted Therapy,Drug: Lenvatinib,Peking Union Medical College Hospital,Phase 2,46,Other,"January 1, 2018","December 1, 2020","May 1, 2021"
1644,NCT04655898,Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects,Healthy Volunteer,Drug: [14C]CC-90001,Celgene,Phase 1,8,Industry,"December 16, 2020","March 11, 2021","March 11, 2021"
1645,NCT04655872,Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects,Healthy Male Subjects,Drug: [14C]TPN171H,"Vigonvita Life Sciences|Shanghai Institute of Materia Medica, Chinese Academy of Sciences",Phase 1,6,Industry|Other,"November 26, 2020","January 27, 2021","January 27, 2021"
1646,NCT04655040,Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants,Healthy Participants,Drug: Caffeine|Other: Ritlecitinib,Pfizer,Phase 1,12,Industry,"December 18, 2020","March 5, 2021","March 5, 2021"
1647,NCT04654897,Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects,Healthy,Drug: [14C]-NT-814,Bayer|Quotient Sciences,Phase 1,6,Industry,"September 30, 2020","October 29, 2020","October 29, 2020"
1648,NCT04654676,DPP4 Inhibitor on Glycemic Variability,"Diabetes Mellitus, Type 2",Drug: Vildagliptin,University Malaysia Sarawak|Sarawak General Hospital,Phase 4,12,Other,"September 15, 2018","August 31, 2019","August 31, 2019"
1649,NCT04654611,Tafluprost Preservative Free Switch Study,Glaucoma|Primary Open Angle Glaucoma|Ocular Hypertension,Drug: preservative free tafluprost 0.0015%,Tun Hussein Onn National Eye Hospital,Phase 4,28,Other,"February 1, 2019","February 1, 2020","February 1, 2020"
1650,NCT04654182,Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method,Hand Hygiene,Drug: Chlorhexidine Gluconate,"Molnlycke Health Care AB|BioScience Laboratories, Inc.",Phase 4,32,Industry,"November 30, 2020","December 24, 2020","December 24, 2020"
1651,NCT04654078,Study to Evaluate the Pharmacokinetic Characteristics and Safety of IN-C004 in Healthy Volunteers,Healthy,Drug: IN-C004 with water|Drug: IN-C004 without water|Drug: K-CAB tab. with water,HK inno.N Corporation,Phase 1,48,Industry,"January 18, 2021","February 5, 2021","February 15, 2021"
1652,NCT04654065,Study to Evaluate Oral Mucosa Absorption of IN-C004 in Healthy Volunteers,Healthy,Drug: IN-C004,HK inno.N Corporation,Phase 1,6,Industry,"January 4, 2021","January 5, 2021","January 5, 2021"
1653,NCT04653792,Role Of Pregabalin To Decrease Postoperative Pain In Microdiscectomy,"Pain, Nerve|Prolapsed Intervertebral Disc",Drug: Pregabalin 75mg|Device: Placebo,Ziauddin University,Phase 4,84,Other,"June 4, 2018","April 17, 2020","April 17, 2020"
1654,NCT04653766,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects",Healthy,Drug: Ir-CPI - Dose 1|Drug: Ir-CPI - Dose 2|Drug: Ir-CPI - Dose 3|Drug: Ir-CPI - Dose 4|Drug: Placebo,Bioxodes S.A.,Phase 1,32,Industry,"September 12, 2019","July 18, 2020","January 4, 2023"
1655,NCT04653415,Large Doses of Methylprednisolone Combined With Gabapentin in Total Knee Arthroplasty,"Arthroplasty Complications|Knee Osteoarthritis|Pain, Postoperative|Perioperative Complication",Drug: Gabapentin 300mg|Drug: Methylprednisolone 125 mg|Drug: Tablet|Drug: Normal Saline 10 mL Injection,Jagiellonian University,Phase 4,160,Other,"June 1, 2019","January 1, 2020","May 1, 2020"
1656,NCT04652648,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Covid19|Hydroxychloroquine|Coronavirus Infection|Transmission|Prophylaxis,Drug: Hydroxychloroquine,Bryn Mawr Hospital|Sharpe-Strumia Research Foundation|Bryn Mawr Hospital Foundation|Cotswold Foundation,Phase 4,54,Other,"May 27, 2020","October 31, 2020","November 15, 2020"
1657,NCT04652349,Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia,Primary Hypercholesterolemia,Drug: HGP1910|Drug: HCP1903|Drug: HGP1909|Drug: HGP1911,Hanmi Pharmaceutical Company Limited,Phase 3,279,Industry,"July 6, 2020","December 17, 2020","January 14, 2021"
1658,NCT04651556,Intraperitoneal Magnesium Sulphate and Bupivacaine Versus Intravenous Analgesia in Laparoscopic Surgeries in Pediatrics,Intraperitoneal Magnesium Sulphate in Laparoscope in Pediatrics,Drug: Magnesium Sulfate & bupivacaine|Drug: paracetamol & ketorolac,Menoufia University,Phase 4,66,Other,"April 4, 2019","June 15, 2020","November 15, 2020"
1659,NCT04650971,"Study to Assess Safety, Tolerability and Reactogenicity of Vaccine ""UniFluVec"" After Two Intranasal Administrations in Healthy Volunteers",Influenza A,Biological: UniFluVec|Biological: Placebo,Pharmenterprises Biotech LLC,Phase 1,60,Other,"August 29, 2019","March 31, 2020","March 31, 2020"
1660,NCT04649723,Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin),"Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459",Drug: Rifampin|Drug: SHR1459,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,20,Industry,"November 24, 2020","December 14, 2020","December 14, 2020"
1661,NCT04649216,"Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371",Healthy Volunteers,Drug: PCO371|Drug: [14C]PCO371,Chugai Pharmaceutical,Phase 1,11,Industry,"November 25, 2020","December 30, 2020","December 30, 2020"
1662,NCT04649203,Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy,Diabetic Neuropathies,Drug: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Drug: Placebo,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 3,216,Industry,"November 25, 2020","March 29, 2021","June 6, 2021"
1663,NCT04649021,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,SARS-CoV-2,Biological: BNT162b2|Other: Placebo,BioNTech SE|Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,Phase 2,950,Industry,"December 4, 2020","February 7, 2021","January 9, 2022"
1664,NCT04648813,Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses,Allergic Asthma,Drug: tiotropium bromide monohydrate (Spiriva Respimat)|Drug: matching placebo,University of Saskatchewan,Phase 4,15,Other,"November 13, 2020","April 20, 2021","April 20, 2021"
1665,NCT04647604,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,COVID-19,Drug: Omegaven®|Drug: Sodium chloride,Karolinska University Hospital,Phase 2,23,Other,"June 23, 2020","January 5, 2021","July 7, 2021"
1666,NCT04646876,Mgso4 as Neuroprotective in Post Traumatic Brain Injury,Magnesium Sulphate|Traumatic Brain Injury|Brain|Injury,Drug: Magnesium Sulfate|Drug: Placebo,Osama Mohamed Abdelwahab|Cairo University,Phase 3,60,Other,"May 2, 2019","March 12, 2020","June 2, 2020"
1667,NCT04646109,Ivermectin for Severe COVID-19 Management,COVID-19,Drug: Ivermectin,Afyonkarahisar Health Sciences University|NeuTec Pharma,Phase 3,66,Other|Industry,"May 11, 2020","September 2, 2020","September 2, 2020"
1668,NCT04645940,Fruquintinib Food Effect and Proton Pump Inhibitor Study,Drug Interaction|Food-drug Interaction,Drug: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|Drug: fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole,Hutchison Medipharma Limited|Hutchmed,Phase 1,14,Industry,"September 24, 2020","November 18, 2020","November 18, 2020"
1669,NCT04645485,Safety and Tolerability of Autologous Non-hematopoietic Peripheral Blood Stem Cells Therapy in Healthy Adult Volunteers.,Healthy,Biological: Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).,Abu Dhabi Stem Cells Center,Phase 1,18,Other,"May 12, 2020","June 30, 2020","July 30, 2020"
1670,NCT04645407,Effects of Fuzheng Huayu Tablets on COVID-19,Novel Coronavirus Pneumonia,Drug: Fuzheng Huayu tablet,ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People's Hospital,Phase 4,66,Other,"February 1, 2020","April 15, 2020","April 15, 2020"
1671,NCT04643249,Drug-drug Interaction Study of KL1333 in Healthy Subjects,Mitochondrial Disease,Drug: KL1333|Drug: Flurbiprofen|Drug: Dextromethorphan|Drug: Bupropion|Drug: Midazolam injection|Drug: Omeprazole|Drug: Caffeine|Drug: Repaglinide,Abliva AB,Phase 1,14,Industry,"November 10, 2020","December 17, 2020","December 17, 2020"
1672,NCT04642664,Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer,Biliary Tract Cancer|Cholangiocarcinoma|Biomarker|Hepatobiliary Neoplasm,Drug: Apatinib plus Camrelizumab,Peking Union Medical College Hospital,Phase 2,22,Other,"December 1, 2018","December 1, 2020","January 1, 2021"
1673,NCT04642482,Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity,Obesity|Insulin Resistance,Dietary Supplement: Synbiotic (Rillus)|Drug: Placebo,Hasanuddin University,Phase 4,16,Other,"September 24, 2019","December 26, 2019","September 1, 2020"
1674,NCT04641364,Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.,Ascites,Drug: recombinant human albumin injection|Drug: Placebo|Drug: human albumin injection,The First Hospital of Jilin University,Phase 1,80,Other,"June 24, 2019","May 6, 2020","May 6, 2020"
1675,NCT04641260,A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants,Healthy Subjects,Drug: Fezolinetant,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,16,Industry,"November 20, 2020","February 12, 2021","February 21, 2021"
1676,NCT04640831,Safety of GH001 in Healthy Volunteers,Healthy Volunteers,"Drug: 5 Methoxy N,N Dimethyltryptamine",GH Research Ireland Limited,Phase 1,22,Industry,"March 13, 2019","October 4, 2019","October 4, 2019"
1677,NCT04640402,A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),COVID-19,Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: Low-dose placebo (18-59 years) & Two dose regimen|Biological: Low-dose placebo (18-59 years) & Three dose regimen|Biological: High-dose placebo (18-59 years) & Two dose regimen|Biological: High-dose placebo (18-59 years) & Three dose regimen|Biological: Low-dose placebo (60-85 years) & Two dose regimen|Biological: Low-dose placebo (60-85 years) & Three dose regimen|Biological: High-dose placebo (60-85 years) & Two dose regimen|Biological: High-dose placebo (60-85 years) & Three dose regimen,Jiangsu Province Centers for Disease Control and Prevention|West China Hospital,Phase 2,960,Other,"November 17, 2020","February 18, 2021","November 23, 2021"
1678,NCT04640012,"Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects",Hyperlipidemia,Drug: DC371739|Drug: Placebo,"Guangzhou JOYO Pharma Co., Ltd",Phase 1,43,Industry,"September 25, 2020","March 19, 2021","March 15, 2022"
1679,NCT04639869,"Bioequivalence Study of Feniramidol HCl 400 mg Film Tablet (Pharmactive, Turkey) Under Fed Conditions",Bioequivalence,Drug: Phenyramydol HCl 400 mg Film Tablet|Drug: Cabral 400 mg Film Tablet,Pharmactive Ilac Sanayi ve Tic A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,44,Industry|Other,"June 26, 2019","July 26, 2019","August 27, 2019"
1680,NCT04639804,Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers,Healthy,Drug: Tegoprazan|Drug: Naproxen|Drug: Aceclofenac|Drug: Celecoxib,HK inno.N Corporation,Phase 1,60,Industry,"June 6, 2020","July 26, 2020","July 29, 2020"
1681,NCT04637425,Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus Aureus,Allergic Rhinitis,Drug: Ismigen|Drug: Placebo,Medical University of Lublin,Phase 3,70,Other,"April 22, 2018","August 31, 2020","August 31, 2020"
1682,NCT04637308,Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy,Fluid Retention,Drug: Succinylated gelatin,Guangdong Provincial People's Hospital,Phase 2,216,Other,"September 1, 2019","September 30, 2020","September 30, 2020"
1683,NCT04637139,A Study to Evaluate the Mass Balance Absorption and AME of VBR,Chronic Hepatitis B,Drug: Vebicorvir (VBR),Assembly Biosciences,Phase 1,6,Industry,"December 1, 2020","December 22, 2020","December 22, 2020"
1684,NCT04635943,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Covid19|Coronavirus Infection|SARS-CoV Infection,Drug: Ivermectin|Drug: Placebo,Universidad Peruana Cayetano Heredia|Barcelona Institute for Global Health,Phase 2,186,Other,"August 29, 2020","April 30, 2021","April 30, 2021"
1685,NCT04635709,Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis,Bladder Dysfunction on Patients With Multiple Sclerosis,Device: biofeedback training and interferential therapy,Taibah University,Phase 1,50,Other,"February 15, 2019","April 1, 2020","April 1, 2020"
1686,NCT04635696,Ethyl Chloride for NPWT,"Pain, Acute",Drug: Ethyl chloride|Other: Tissue culture grade water,ProMedica Health System,Phase 4,100,Other,"January 7, 2019","December 10, 2020","December 10, 2020"
1687,NCT04634812,Mass Balance Study of KBP-5074 in Healthy Male Subjects,Healthy,Drug: KBP-5074,KBP Biosciences|Covance,Phase 1,7,Industry,"December 3, 2020","December 23, 2020","December 23, 2020"
1688,NCT04634565,PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS,Healthy Participants,Drug: PF-06651600,Pfizer,Phase 1,9,Industry,"October 15, 2020","November 19, 2020","November 19, 2020"
1689,NCT04633564,"MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC",NSCLC Stage IV,Biological: Bevacizumab as MYL-1402O|Biological: Bevacizumab as Avastin,Mylan Pharmaceuticals Inc|Viatris Inc.,Phase 3,671,Industry,"January 21, 2017","June 5, 2019","November 22, 2019"
1690,NCT04632706,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Covid19,Drug: Ivermectin|Drug: Placebo,MedinCell S.A,Phase 1,24,Industry,"September 22, 2020","March 9, 2021","March 9, 2021"
1691,NCT04631874,"A Clinical Trial to Compare Pharmacokinetics of the ""CDFF0318"" and ""Champix Tab. 1mg""",Smoking Cessation|Pharmacokinetics,"Drug: CDFF0318, Champix","CTC Bio, Inc.",Phase 1,32,Industry,"July 24, 2019","May 1, 2020","May 1, 2020"
1692,NCT04631354,Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device,Healthy Volunteer,Drug: Radio-labelled S-770108|Device: S-770108 Inhaler A1,Shionogi|Shionogi Inc.,Phase 1,12,Industry,"November 9, 2020","December 14, 2020","December 21, 2020"
1693,NCT04631315,Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.,Cataract,"Drug: Difluprednate Ophthalmic Emulsion 0.05%|Drug: Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution",Laboratorios Poen,Phase 4,255,Industry,"March 24, 2019","May 24, 2020","July 21, 2020"
1694,NCT04628325,Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF),Heart Failure，Congestive,Drug: Furosemide,University of Palermo,Phase 3,136,Other,"March 1, 2017","June 30, 2019","May 1, 2020"
1695,NCT04628143,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,COVID-19,Drug: Nafamostat Mesilate,Chong Kun Dang Pharmaceutical,Phase 2,13,Industry,"December 21, 2020","April 5, 2021","April 5, 2021"
1696,NCT04627675,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),SARS-CoV-2,Drug: CORVax|Drug: IL-12 plasmid|Device: Cliniporator,Providence Health & Services|OncoSec Medical Incorporated,Phase 1,16,Other|Industry,"December 30, 2020","March 11, 2021","December 28, 2022"
1697,NCT04627532,Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants,Healthy,Drug: PF-07304814|Drug: Placebo,Pfizer,Phase 1,16,Industry,"October 23, 2020","December 17, 2020","December 17, 2020"
1698,NCT04627467,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Covid19,Drug: Chloroquine,Fundacion Clinica Valle del Lili,Phase 2,3217,Other,"March 28, 2020","July 9, 2020","September 30, 2021"
1699,NCT04627129,A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects,Healthy Adult Subjects,Drug: SHR2554 and Itraconazole,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"June 1, 2020","October 1, 2020","October 1, 2020"
1700,NCT04626869,Anterior Suprascapular Nerve Block is an Effective and Diaphragm Protective Approach for Arthroscopic Shoulder Surgery,"Diaphragm Paralysis Due to Local Anesthesia|Anterior Suprascapular Nerve Block|Analgesia, Arthroscopic Shoulder Surgery",Other: Evaluation of Diaphragm Movement,"Alper Tunga Dogan|V.K.V. American Hospital, Istanbul",Phase 4,50,Other,"December 1, 2020","March 15, 2021","April 1, 2021"
1701,NCT04626778,Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination,Healthy,Drug: Peroxyl Mouthwash|Drug: Placebo Mouthwash,Colgate Palmolive,Phase 2,100,Industry,"October 8, 2020","December 15, 2020","December 15, 2020"
1702,NCT04625985,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Metformin Glycinate|Drug: Placebo oral tablet,Laboratorios Silanes S.A. de C.V.,Phase 2,20,Industry,"July 14, 2020","March 8, 2021","March 18, 2021"
1703,NCT04625972,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",COVID-19,Drug: AZD7442|Drug: Placebo,AstraZeneca|Iqvia Pty Ltd,Phase 3,1132,Industry,"December 2, 2020","April 7, 2021","July 25, 2022"
1704,NCT04625855,"Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects",Healthy Volunteers,Drug: TBPM-PI-HBr,Spero Therapeutics|Covance,Phase 1,8,Industry,"September 30, 2020","October 16, 2020","October 16, 2020"
1705,NCT04625062,Comparing Traditional and Biofeedback Telepractice Treatment for Residual Speech Errors,Speech Sound Disorder,Behavioral: Visual-acoustic biofeedback|Behavioral: Motor-based treatment,New York University|Syracuse University|Montclair State University|National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 1,7,Other|NIH,"September 1, 2020","March 18, 2021","March 18, 2021"
1706,NCT04623814,"the Safety, Tolerability, and Pharmacokinetics Study of HEC113995",Major Depressive Disorder,Other: Food|Drug: HEC113995|Drug: placebo,"Sunshine Lake Pharma Co., Ltd.",Phase 1,58,Industry,"March 30, 2020","August 12, 2020","August 12, 2020"
1707,NCT04623684,Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial,Retinopathy of Prematurity,Drug: Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|Drug: Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)],Aristotle University Of Thessaloniki,Phase 4,25,Other,"March 24, 2020","September 22, 2020","September 29, 2020"
1708,NCT04623632,Effect of TAP Block on Time Required for First Analgesic Dose After Cesarean Cection Under Spinal Anesthesia,Postoperative Pain,Drug: Transversus abdominus plane block|Drug: Transversus abdominus plane placebo,Ain Shams Maternity Hospital,Phase 2,60,Other,"September 20, 2020","March 20, 2021","March 20, 2021"
1709,NCT04623164,Complex Phytoadaptogenes in Chronic Periodontitis Treatment.,Chronic Periodontitis,Drug: Cocktail from complex phytoadaptogens (CFA)|Procedure: Standard non-surgical periodontal treatment (NSPT),Vladikavkaz Scientific Center of the Russian Academy of Sciences,Phase 4,30,Other,"February 1, 2019","May 1, 2019","November 1, 2019"
1710,NCT04623021,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,COVID-19,Drug: Nafamostat Mesilate,Chong Kun Dang Pharmaceutical,Phase 2,104,Industry,"September 25, 2020","December 12, 2020","December 12, 2020"
1711,NCT04622358,"A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole",Gastroesophageal Reflux Disease,Drug: AD-214-02|Drug: Rabeprazole,Addpharma Inc.,Phase 1,43,Industry,"December 5, 2020","March 8, 2021","March 8, 2021"
1712,NCT04622111,Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.,Healthy Volunteers,Drug: CPL207280|Drug: Placebo|Drug: Metformin hydrochloride 750 mg,"Celon Pharma SA|National Center for Research and Development, Poland",Phase 1,68,Industry|Other,"May 27, 2020","April 1, 2021","May 5, 2021"
1713,NCT04621461,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,Corona Virus Infection,Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo,"St. Francis Hospital, New York",Phase 4,3,Other,"December 20, 2020","February 8, 2021","February 8, 2021"
1714,NCT04621253,Inhibition Metamizole 2020,Drug-drug Interaction,Drug: Novalgin,"University Hospital, Basel, Switzerland",Phase 1,12,Other,"April 29, 2020","October 2, 2020","October 2, 2020"
1715,NCT04620213,Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis,Mydriasis|Dilation,Drug: Phentolamine Ophthalmic Solution 0.75%|Other: Phentolamine Ophthalmic Solution Vehicle (Placebo),"Ocuphire Pharma, Inc.",Phase 3,185,Industry,"November 18, 2020","December 23, 2020","March 15, 2021"
1716,NCT04619303,Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO,Diabetic Macular Edema|Diabetic Retinopathy,Drug: Dexamethasone intravitreal implant|Drug: Bevacizumab Injectable Product,"Lions Eye Institute, Perth, Western Australia|Lions Outback Vision|Allergan",Phase 4,59,Other|Industry,"February 7, 2017","February 14, 2020","February 14, 2020"
1717,NCT04619264,Impact of Minimally Invasive Restorative Techniques on Pregnant Women Oral Health Related Quality of Life,Quality of Life|Dental Caries,Drug: Papacarie|Procedure: Atraumatic Restorative Treatment,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,162,Other,"January 10, 2019","October 1, 2019","October 20, 2019"
1718,NCT04618952,Effect of Calcium- D Supplement on Hypertension,Hypertension,Drug: Calcium D|Drug: Placebo,Shiraz University of Medical Sciences,Phase 4,98,Other,"January 1, 2019","August 1, 2020","September 1, 2020"
1719,NCT04618497,A Pilot Study on the Use of Methoxyflurane (Penthrox®) for Pain Control in the Emergency Department,Acute Traumatic Pain,Drug: Methoxyflurane|Drug: Ketorolac,"Hospital Authority, Hong Kong",Phase 3,40,Other,"October 28, 2020","November 21, 2020","November 21, 2020"
1720,NCT04618159,Does Helipyl Eradicate,Eradication,Other: lactobacillus reuteri DSMZ 17648,Universitair Ziekenhuis Brussel,Phase 4,10,Other,"February 10, 2019","June 1, 2019","January 25, 2020"
1721,NCT04617782,Crossover Pharmacokinetic (PK) Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers,Healthy Subjects,Combination Product: Donepezil TDS|Drug: Aricept,"Corium, Inc.",Phase 1,60,Industry,"December 8, 2020","April 5, 2021","April 5, 2021"
1722,NCT04617652,Smooth Extubation With Magnesium Sulphate for General Anesthesia With Endotracheal Intubation,Smooth Extubation,Drug: Magnesium sulfate|Drug: Normal saline,Fayoum University Hospital,Phase 4,60,Other,"August 1, 2020","February 1, 2021","April 1, 2021"
1723,NCT04617509,A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248,Pharmacokinetic,Drug: Formulation A GS-248|Drug: Formulation B GS-248,Gesynta Pharma AB|CTC Clinical Trial Consultants AB|RISE Research Institutes of Sweden AB,Phase 1,14,Industry|Other,"March 31, 2020","May 27, 2020","May 27, 2020"
1724,NCT04617483,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Covid19,"Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly","Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd",Phase 3,1040,Industry,"October 31, 2020","November 28, 2020","May 31, 2021"
1725,NCT04616742,Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers,Healthy Adult Male Volunteers,Drug: [14C]SHR6390,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,6,Industry,"November 11, 2020","January 8, 2021","May 1, 2021"
1726,NCT04616716,A Food Effect Study of FMTN on Healthy Chinese Adult Subjects,"Health, Subjective",Drug: FMTN,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"May 6, 2020","September 29, 2020","October 20, 2020"
1727,NCT04613726,The Effect of Intravenous Granisetron and Ondansetron in Patients Undergoing Cesarean Section,"Vomiting, Postoperative|Postoperative Complications|Hypotension",Drug: ondansetron|Drug: Granisetron|Drug: Saline,Ataturk University,Phase 3,120,Other,"December 3, 2018","December 12, 2019","January 1, 2020"
1728,NCT04612972,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru",COVID-19,Biological: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo,"Universidad Peruana Cayetano Heredia|National University of San Marcos, Peru",Phase 3,12000,Other,"September 9, 2020","February 19, 2021","April 3, 2023"
1729,NCT04611789,A Study of LY3832479 (LY-CoV016) in Healthy Participants 1,Healthy,Drug: LY3832479|Drug: Placebo,"Eli Lilly and Company|Shanghai Junshi Bioscience Co., Ltd.",Phase 1,18,Industry|Other,"November 2, 2020","February 10, 2021","February 10, 2021"
1730,NCT04611425,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,Acute Respiratory Failure|COVID-19|Trauma|Stroke|Sepsis|Shock,Drug: Remimazolam,Nantes University Hospital|Paion UK Ltd.,Phase 2,30,Other|Industry,"November 30, 2020","December 2, 2020","October 22, 2021"
1731,NCT04610580,Bioavailability Study of 2 Oral Formulations of ALXN1840,Healthy,Drug: ALXN1840,Alexion,Phase 1,48,Industry,"January 31, 2021","March 24, 2021","April 26, 2021"
1732,NCT04610502,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,Covid19,Biological: Administration of Equine immunoglobulin anti SARS-CoV-2,Caja Costarricense de Seguro Social|Universidad de Costa Rica|Ministry of Health Costa Rica,Phase 2,26,Other,"September 6, 2020","October 6, 2020","December 6, 2020"
1733,NCT04609696,Study of the Metabolism of Danicopan in Healthy Adults,Healthy,Drug: Danicopan: Powder-In-Capsule 1|Drug: Danicopan: Powder-In-Capsule 2|Drug: Danicopan: Tablet,Alexion|Celerion,Phase 1,24,Industry,"October 20, 2020","December 7, 2020","December 7, 2020"
1734,NCT04609254,"Paracetamol, Dexketoprofen and Ibuprofen In Non-Traumatic Acute Low Back Pain","Low Back Pain, Mechanical",Drug: Paracetamol|Drug: Dexketoprofen|Drug: Ibuprofen,Pamukkale University,Phase 4,210,Other,"December 15, 2018","April 15, 2020","September 15, 2020"
1735,NCT04609098,Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2),"Malaria, Falciparum",Drug: Dihydroartemisinin/Piperaquine|Drug: Tafenoquine 100mg [Arakoda],London School of Hygiene and Tropical Medicine,Phase 2,80,Other,"October 29, 2020","December 2, 2020","December 23, 2020"
1736,NCT04608669,Paracetamol Hypothermia Children,Safety Issues,Drug: Paracetamol,Saint George Hospital,Phase 4,60,Other,"July 1, 2019","September 30, 2019","September 30, 2020"
1737,NCT04608344,Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants,Rheumatoid Arthritis,Drug: Atorvastatin|Drug: Pravastatin|Drug: Rosuvastatin|Drug: Filgotinib,Gilead Sciences|Galapagos NV,Phase 1,27,Industry,"November 4, 2020","January 13, 2021","January 13, 2021"
1738,NCT04607525,Dexmedetomidine Infusion Effect on Hemodynamic Variables During Craniotomy,Hemodynamic Instability|Supratentorial Neoplasms,Drug: Dexmedetomidine|Drug: normal saline,Ain Shams University,Phase 4,40,Other,"November 21, 2020","January 20, 2021","January 26, 2021"
1739,NCT04607512,Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects,Cardiac Safety,Drug: telaglenastat|Other: telaglenastat placebo|Other: moxifloxicin,"Calithera Biosciences, Inc",Phase 1,30,Industry,"October 5, 2020","December 30, 2020","December 30, 2020"
1740,NCT04607291,Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening,Colorectal Carcinoma,Other: Community Health Service|Other: Survey Administration,Roswell Park Cancer Institute|National Cancer Institute (NCI),Phase 1,183,Other|NIH,"September 1, 2019","May 14, 2020","May 14, 2021"
1741,NCT04606537,Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects,Healthy|Drug Drug Interaction,Drug: Itraconazole|Drug: Rifampin|Drug: KBP-5074,KBP Biosciences|Covance,Phase 1,24,Industry,"October 24, 2020","November 30, 2020","November 30, 2020"
1742,NCT04606329,To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3),Breast Diseases,Drug: LuminoMark inj.(Conc. for fluorescence)|Drug: Charcotrace Inj.,"Hanlim Pharm. Co., Ltd.",Phase 3,109,Industry,"July 20, 2020","January 28, 2021","January 28, 2021"
1743,NCT04603989,"A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics",Influenza,Drug: HNC042 for Injection|Drug: Placebo Comparator,"Guangzhou Henovcom Bioscience Co. Ltd.|Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.",Phase 1,36,Industry,"August 1, 2020","November 13, 2020","November 13, 2020"
1744,NCT04603729,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Covid 19 Disease,Drug: Dexamethasone 2 MG/ML|Drug: Methylprednisolone Injection,Fatima Memorial Hospital,Phase 3,100,Other,"May 30, 2020","June 30, 2020","July 1, 2020"
1745,NCT04601766,"A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets",Bladder Cancer,Drug: APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Drug: APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2,"Asieris Pharmaceuticals (AUS) Pty Ltd.|Jiangsu Yahong Meditech Co., Ltd aka Asieris",Phase 1,12,Industry,"October 30, 2020","December 18, 2020","February 1, 2021"
1746,NCT04601207,A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population,Healthy|Cannabis,Drug: Cannabis Preparation,New Age Ventures LLC|KGK Science Inc.,Phase 1,32,Industry,"June 19, 2020","November 30, 2020","November 30, 2020"
1747,NCT04600999,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,SARS-CoV-2 Infection,Drug: Favipiravir,University of Pecs|HECRIN Consortium|Hungarian Ministry of Innovation and Technology,Phase 3,14,Other,"October 7, 2020","December 28, 2020","December 28, 2020"
1748,NCT04600284,Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102,Hypertension,Drug: AD-2101|Drug: AD-2102|Drug: AD-2101 + AD-2102,Addpharma Inc.,Phase 1,25,Industry,"November 16, 2020","January 20, 2021","April 30, 2021"
1749,NCT04599894,Reducing Postoperative Side Effect of Pregabalin,"Pain, Postoperative|Arthroplasty, Replacement, Knee|Arthroplasty, Replacement, Hip",Drug: 37.5mg Pregabalin + 75mg Pregabalin|Drug: 75mg Pregabalin,The First Hospital of Jilin University,Phase 4,58,Other,"November 1, 2020","April 30, 2021","May 4, 2021"
1750,NCT04598607,Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects,Major Depressive Disorder,Drug: Hypidone Hydrochloride tablets|Drug: Placebo,"Zhejiang Huahai Pharmaceutical Co., Ltd.",Phase 1,36,Industry,"October 30, 2020","January 11, 2021","January 15, 2021"
1751,NCT04598594,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Covid19|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere,"Drug: Patch, Nicotine|Drug: Patch, Placebo",Assistance Publique - Hôpitaux de Paris,Phase 3,220,Other,"November 6, 2020","April 29, 2021","June 20, 2021"
1752,NCT04598542,Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers,Drug-Drug Interaction,Drug: Lorecivivint (LOR)|Drug: Triamcinolone acetonide (TA),"Biosplice Therapeutics, Inc.",Phase 1,40,Industry,"October 13, 2020","December 22, 2020","December 22, 2020"
1753,NCT04598269,Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis,Atopic Dermatitis,Drug: ATI-1777|Drug: Vehicle,"Aclaris Therapeutics, Inc.",Phase 2,50,Industry,"September 30, 2020","April 8, 2021","April 22, 2021"
1754,NCT04596839,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Covid19,Drug: Remdesivir|Other: Standard of Care,Dr. Md. Alimur Reza|Beximco Pharmaceuticals Ltd.,Phase 2,60,Industry,"September 4, 2020","April 30, 2021","April 30, 2021"
1755,NCT04595916,Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury,Acute Drug Induced Liver Injury,Drug: Polyene phosphatidylcholine injection 930 mg QD|Drug: Magnesium Isoglycyrrhizinate injection 200 mg QD,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 4,73,Industry,"April 4, 2020","October 21, 2020","November 2, 2020"
1756,NCT04594252,Copper Balance in Healthy Participants Administered ALXN1840,Healthy,Drug: ALXN1840,Alexion,Phase 1,17,Industry,"July 1, 2020","November 17, 2020","November 17, 2020"
1757,NCT04594213,"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)",Drug: NT 201|Drug: Placebo,Merz Pharmaceuticals GmbH,Phase 3,362,Industry,"September 23, 2020","April 15, 2021","May 9, 2022"
1758,NCT04593641,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)",SARS-CoV-2 Infection,Biological: CT-P59,Celltrion,Phase 1,18,Industry,"September 4, 2020","October 26, 2020","April 5, 2021"
1759,NCT04592198,Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting,Nausea With Vomiting Chemotherapy-Induced,"Drug: Palonosetron Hydrochloride Buccal Film 0.25 Mg|Drug: Palonosetron Hydrochloride Buccal Film 0.5 Mg|Drug: Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution","Xiamen LP Pharmaceutical Co., Ltd",Phase 2,22,Industry,"October 1, 2020","March 26, 2021","March 26, 2021"
1760,NCT04591444,Fluoride Varnish X Glass Ionomer Sealant on Cervical Dentin Hypersensitivity,Dentin Hypersensitivity|Dentin Sensitivity,Drug: Fluoride Varnish|Drug: Glass Ionomer Sealant|Other: Placebo Group,University of Sao Paulo,Phase 3,121,Other,Jan-17,Oct-19,Mar-20
1761,NCT04591301,"The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects",Major Depressive Disorder,Drug: HEC113995 PA•H2O tablets|Drug: Placebo tablets,"Sunshine Lake Pharma Co., Ltd.",Phase 1,69,Industry,"July 4, 2019","December 6, 2019","December 6, 2019"
1762,NCT04591262,A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants,Healthy,Drug: 14C-PF-06826647-LR 600 mg PO|Drug: PF-06826647 600 mg PO|Drug: 14C-PF-06826647 100 ug IV,Pfizer,Phase 1,6,Industry,"November 10, 2020","January 28, 2021","January 28, 2021"
1763,NCT04590937,"A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body",Healthy,Drug: BI 730357|Drug: CRESTOR®|Drug: Lenoxin®|Drug: MetfoLiquid GeriaSan®|Drug: Lasix®,Boehringer Ingelheim,Phase 1,15,Industry,"October 20, 2020","January 11, 2021","January 11, 2021"
1764,NCT04587713,Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects,"Intestinal Disorder|Bowel Diseases, Inflammatory",Drug: TD-1473 [Tablet A]|Drug: TD-1473 [Tablet B],Theravance Biopharma,Phase 1,58,Industry,"October 16, 2020","December 24, 2020","December 27, 2020"
1765,NCT04587505,Effect of Epidural Anesthesia and Analgesia on Quality of Recovery After Radical Prostatectomy.,Anesthesia|Anesthesia Recovery Period|Radical Prostatectomy|Patient Satisfaction|Postoperative Period|Quality of Life|Analgesia|Epidural|Quality of Recovery,Procedure: Epidural anesthesia with light general anesthesia|Drug: Postoperative epidural analgesia|Procedure: General anesthesia|Drug: Continuous intravenous analgesia,University Hospital of Split,Phase 4,61,Other,"April 1, 2019","April 1, 2021","June 1, 2021"
1766,NCT04587206,A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348,Hypertension and Dyslipidemia,"Drug: CKD-348|Drug: CKD-828, D097, D337",Chong Kun Dang Pharmaceutical,Phase 1,62,Industry,"October 15, 2020","December 30, 2020","January 15, 2021"
1767,NCT04586439,A Study of JNJ-73763989 in Healthy Chinese Adult Participants,Healthy,Drug: JNJ-73763989,"Janssen Research & Development, LLC",Phase 1,18,Industry,"November 24, 2020","February 18, 2021","February 18, 2021"
1768,NCT04585412,Evaluate Bioequivalence of Palonosetron (0.25mg/5mL),"Chemotherapy-induced Nausea and Vomiting, Prophylaxis",Drug: Palonosetron,"Yung Shin Pharm. Ind. Co., Ltd.",Phase 4,16,Industry,"August 17, 2020","October 24, 2020","December 31, 2020"
1769,NCT04584736,To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia,Primary Hypercholesterolemia,"Drug: Livalo, Ezetrol",JW Pharmaceutical,Phase 3,283,Industry,"June 11, 2019","July 16, 2020","October 12, 2020"
1770,NCT04584567,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Covid19,Drug: Doxycyclin,"Hedi Gharsallah|Dacima Consulting|General Administration of Military Health, Tunisia",Phase 3,194,Other,"November 20, 2020","February 1, 2021","November 1, 2021"
1771,NCT04584515,IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers,Solid Tumor,Drug: IMP4297 40 mg|Drug: IMP4297 100 mg,"Impact Therapeutics, Inc.",Phase 1,32,Industry,"November 2, 2020","March 8, 2021","May 27, 2021"
1772,NCT04583592,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),COVID-19,Drug: Camostat Mesilate|Drug: Placebo,Sagent Pharmaceuticals Inc.,Phase 2,295,Industry,"November 9, 2020","March 31, 2021","March 31, 2021"
1773,NCT04582929,Neubotulinum Toxin Injection in Cerivical Dystonia,Cervical Dystonia,Drug: Neuronox ® Injection,Rajavithi Hospital,Phase 3,50,Other,"January 3, 2019","April 30, 2021","May 30, 2021"
1774,NCT04580797,Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations,Healthy Participants,Drug: PF-06700841 IR|Drug: PF-06700841 MR1|Drug: PF-06700841 MR2|Drug: PF-06700841 MR3|Other: Placebo,Pfizer,Phase 1,36,Industry,"October 2, 2020","January 11, 2021","January 11, 2021"
1775,NCT04580745,Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers,Healthy Volunteers,Drug: MORF-057|Drug: Placebo for MORF-057,"Morphic Therapeutic, Inc",Phase 1,67,Industry,"September 23, 2020","March 31, 2021","April 12, 2021"
1776,NCT04579419,Injection Site Pain Botulinum Toxin Reconstituted in NS With and Without Sodium Bicarbonate,Wrinkle,Drug: Sodium Bicarbonate|Drug: Normal Saline,King Abdulaziz Medical City,Phase 3,30,Other,"November 9, 2019","August 9, 2020","August 9, 2020"
1777,NCT04579393,Fostamatinib for Hospitalized Adults With COVID-19,Coronavirus Disease 2019,Drug: Placebo|Drug: fostamatinib,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,59,NIH,"October 8, 2020","March 30, 2021","April 30, 2021"
1778,NCT04578782,Efficacy of OnabotulinumtoxinA in Migraine,Migraine,Drug: OnabotulinumtoxinA,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Phase 2,32,Other,"March 13, 2018","May 31, 2020","May 31, 2020"
1779,NCT04578158,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,COVID-19,Drug: Standard COVID-19 care|Dietary Supplement: Quercetin Phytosome,Liaquat University of Medical & Health Sciences,Phase 3,152,Other,"September 29, 2020","March 28, 2021","April 15, 2021"
1780,NCT04577885,A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects,Healthy,Drug: SHR2554 and Rifampin,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"May 28, 2020","August 30, 2020","September 20, 2020"
1781,NCT04577781,A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug: GLPG3970|Drug: Placebo,Galapagos NV,Phase 2,28,Industry,"October 12, 2020","March 26, 2021","April 7, 2021"
1782,NCT04576702,Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults,Influenza|Human,Biological: Investigational aIIV4c|Biological: IIV4c type 1|Biological: aIIV4|Biological: RIV4 type 2,Seqirus,Phase 2,471,Industry,"October 8, 2020","March 19, 2021","October 6, 2021"
1783,NCT04576312,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,Covid19,Drug: UNI911 inhalation 1% and intranasal spray 1%|Drug: Placebo,UNION therapeutics,Phase 1,64,Industry,"June 29, 2020","December 4, 2020","December 4, 2020"
1784,NCT04575675,Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy,Hypotension|Heart Failure,Drug: Dapagliflozin|Drug: Sacubitril-Valsartan|Drug: Beta blocker|Drug: Mineralocorticoid Receptor Antagonist|Device: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator,Cheng-Hsin General Hospital,Phase 4,78,Other,"May 29, 2020","November 25, 2020","December 30, 2020"
1785,NCT04575116,A Study to Determine the Bioequivalence of Two Doses of Tafamidis,Healthy,Drug: Tafamidis free acid tablet|Drug: Tafamidis meglumine capsule,Pfizer,Phase 1,23,Industry,"September 17, 2020","February 23, 2021","February 23, 2021"
1786,NCT04575038,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,COVID-19 Infection,Drug: Brequinar|Drug: Placebo,"Clear Creek Bio, Inc.",Phase 2,115,Industry,"November 19, 2020","April 28, 2021","April 28, 2021"
1787,NCT04573907,Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg,Healthy,Drug: Drug Levothyroxine 100 mcg|Drug: Drug Eutirox 100 mcg,Tecnoquimicas|DominguezLab,Phase 4,80,Industry|Other,"June 1, 2019","October 1, 2019","May 1, 2020"
1788,NCT04573608,The Impact of Minimally Invasive Restorative Techniques on Dental Pain in Pregnant Women,Dental Pain|Patient Satisfaction,Drug: Papacarie|Drug: Atraumatic Restorative Treatment,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,162,Other,"January 10, 2019","October 1, 2019","October 20, 2019"
1789,NCT04573270,Mesenchymal Stem Cells for the Treatment of COVID-19,Covid19|Prophylaxis,Biological: PrimePro|Other: Placebo,Thomas Advanced Medical LLC|HeartStem Institute,Phase 1,40,Industry|Other,"April 24, 2020","August 20, 2020","September 1, 2020"
1790,NCT04572997,Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS),Palmoplantar Pustulosis,Drug: Apremilast,Kristian Reich|Universitätsklinikum Hamburg-Eppendorf,Phase 2,21,Other,"November 29, 2018","August 29, 2019","August 29, 2019"
1791,NCT04572685,Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients,Schizophrenia Patients,Drug: Paliperidone Palmitate,Luye Pharma Group Ltd.|Alliance for Clinical Trials in Oncology|Evolution Research Group,Phase 1,36,Industry|Other,"January 22, 2020","June 26, 2020","August 20, 2020"
1792,NCT04571996,Blood-Brain Barrier Penetration of Therapeutic Agents in Human,CNS Disease,Drug: ODM-104|Drug: Paracetamol,"Orion Corporation, Orion Pharma",Phase 1,4,Industry,"October 29, 2020","February 23, 2021","February 23, 2021"
1793,NCT04571515,Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain,"Pain|Postoperative Pain|Pain, Acute",Drug: MR-107A-01|Drug: Placebo,Mylan Inc.|Viatris Inc.,Phase 2,114,Industry,"September 29, 2020","December 15, 2020","December 22, 2020"
1794,NCT04571424,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants",Healthy Volunteers,Drug: BIIB133 (Dapirolizumab pegol)|Drug: Placebo,Biogen,Phase 1,33,Industry,"October 14, 2020","April 8, 2021","April 8, 2021"
1795,NCT04570644,Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers,Healthy Volunteers|Alzheimer Disease,Drug: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen),"AZTherapies, Inc.",Phase 1,56,Industry,"August 28, 2020","January 18, 2021","January 18, 2021"
1796,NCT04569279,Rivaroxaban vs. Warfarin in CVT Treatment,Cerebral Vein Thrombosis,Drug: Rivaroxaban|Drug: Warfarin,Damascus University,Phase 3,71,Other,"September 1, 2017","March 1, 2020","March 1, 2020"
1797,NCT04569188,Convalescent Plasma in COVID-19 Elderly Patients,COVID-19,Biological: Convalescent plasma,Azienda Socio Sanitaria Territoriale di Mantova,Phase 2,21,Other,"May 15, 2020","August 15, 2020","September 3, 2020"
1798,NCT04568876,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Covid19,"Dietary Supplement: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Combination Product: Standard Therapy","Epitech Group SpA|Azienda Ospedaliera ""Sant'Andrea""",Phase 4,40,Industry|Other,"October 23, 2020","February 28, 2021","February 28, 2021"
1799,NCT04568863,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,COVID-19|SARS-CoV 2|Coronavirus Infection,Drug: Melatonin intravenous|Drug: Placebo intravenous,Pharmamel S.L.|Hospital Universitario La Paz|Instituto de Investigación Hospital Universitario La Paz,Phase 2,18,Industry|Other,"June 20, 2020","November 30, 2020","November 30, 2020"
1800,NCT04568811,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,Adenovirus Type-5 Vectored COVID-19 Vaccine,Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine,Jiangsu Province Centers for Disease Control and Prevention,Phase 1,89,Other,"September 26, 2020","October 25, 2020","September 11, 2021"
1801,NCT04567810,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Covid19,Drug: anti-SARS-CoV-2 IgY|Drug: Placebo,Stanford University,Phase 1,48,Other,"September 18, 2020","December 14, 2020","December 14, 2020"
1802,NCT04567667,"Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants",Healthy Volunteers,Drug: [14C] BMS-986278|Drug: Kinevac®,Bristol-Myers Squibb,Phase 1,9,Industry,"October 15, 2020","April 11, 2021","April 11, 2021"
1803,NCT04567524,"A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules",Schizophrenia Schizoaffective,Drug: LYN-005,Lyndra Inc.|Worldwide Clinical Trials,Phase 2,34,Industry|Other,"August 13, 2020","December 22, 2020","December 22, 2020"
1804,NCT04567316,A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body,Healthy,Drug: [14C]-radiolabelled BI 1358894|Drug: BI 1358894,Boehringer Ingelheim,Phase 1,15,Industry,"October 19, 2020","January 10, 2021","January 10, 2021"
1805,NCT04567147,Effect of Probiotic on Depression,Depression,Dietary Supplement: Probiotic|Dietary Supplement: Placebo,China Agricultural University,Phase 1,89,Other,"November 20, 2018","June 22, 2019","September 12, 2020"
1806,NCT04566549,The Safety and Efficacy Evaluation of Hair Products Containing Probiotics,Skin Problems,Combination Product: Test group Probiotic Shampoo|Combination Product: Placebo group,GenMont Biotech Incorporation|Chia Nan University of Pharmacy and Science,Phase 2,21,Industry|Other,"July 6, 2020","December 6, 2020","February 6, 2021"
1807,NCT04565678,A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants,Healthy Volunteers,Drug: Mitapivat tablets|Drug: Mitapivat coated granules,"Agios Pharmaceuticals, Inc.",Phase 1,32,Industry,"September 21, 2020","December 3, 2020","December 3, 2020"
1808,NCT04565600,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib,Pain Syndrome,Drug: Etoricoxib,Guangdong Provincial People's Hospital,Phase 2,144,Other,"March 1, 2020","April 22, 2021","June 28, 2021"
1809,NCT04565574,A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants,Healthy Participants,Drug: E7090|Drug: Rabeprazole 20 mg|Drug: Rifampin 600 mg,"Eisai Co., Ltd.|Eisai Inc.",Phase 1,42,Industry,"October 16, 2020","March 31, 2021","March 31, 2021"
1810,NCT04565379,Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients,COVID19 Pneumonia,Drug: NuSepin® 0.1 mg|Drug: NuSepin® 0.2 mg|Drug: Placebo,Shaperon,Phase 2,64,Industry,"September 24, 2020","April 13, 2021","April 13, 2021"
1811,NCT04565184,Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde,"Malaria,Falciparum","Drug: Artesunate-amodiaquine combination|Drug: Artemether, Lumefantrine Drug Combination","University of Yaounde 1|Malaria Research Capacity Development in West and Central Africa Consortium|Developing Excellence in Leadership, Training and Science Africa Initiative|Wellcome Trust United Kingdom|United Kingdom Department for International Development",Phase 4,242,Other,"May 9, 2019","November 30, 2020","November 30, 2020"
1812,NCT04564456,A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers,Bioequivalence,Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|Drug: ADVAIR DISKUS® 500/50,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,34,Industry,"September 22, 2020","October 31, 2020","December 31, 2020"
1813,NCT04564066,A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers,Healthy Volunteers,Biological: efgartigimod IV|Biological: efgartigimod PH20 SC,argenx,Phase 1,54,Industry,"August 18, 2020","December 24, 2020","February 11, 2021"
1814,NCT04564053,"Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants",Osteoarthritis|Knee,Drug: LNA043|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 1,12,Industry,"September 23, 2020","December 10, 2020","December 10, 2020"
1815,NCT04564040,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,Mantle Cell Lymphoma|COVID-19,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D,AstraZeneca|Parexel,Phase 1,20,Industry,"October 12, 2020","December 11, 2020","December 11, 2020"
1816,NCT04563936,Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®,Prostate Cancer,Drug: LY01005 3.6 mg|Drug: ZOLADEX® 3.6 mg,Luye Pharma Group Ltd.,Phase 3,290,Industry,"January 6, 2020","March 9, 2021","March 9, 2021"
1817,NCT04561960,Efficacy of Miswak in Oral Hygiene Maintenance,Dental Plaque,Drug: Fluoride toothpaste|Drug: Toothpaste Product|Device: Toothbrush|Device: Miswak Stick,Riyadh Elm University,Phase 4,30,Other,"September 30, 2020","December 10, 2020","December 30, 2020"
1818,NCT04561752,A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects,Healthy,Drug: ZN-c5,Zeno Alpha Inc.,Phase 1,20,Industry,"November 2, 2020","December 11, 2020","December 16, 2020"
1819,NCT04561219,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Covid19|Corona Virus Infection|Pneumonia, Viral",Drug: Nitazoxanide|Drug: Placebo,"Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|Financiadora de Estudos e Projetos|ATCGen|Hospital Central da Aeronáutica, Rio de Janeiro|Hospital da Força Aérea do Galeão|Hospital Naval Marcilio Dias|Hospital Universitario Pedro Ernesto|Hospital de Força Aérea de São Paulo|Hospital das Clínicas Luzia de Pinho Melo|Complexo Hospitalar Municipal de São Caetano do Sul|Hospital Municipal de Barueri Dr Francisco Moran|Hospital Regional de Sorocaba Dr Adib Domingos Jatene|Hospital Geral de São Mateus Dr Manoel Bifulco|Santa Casa de Misericórdia de Belo Horizonte|Mater Dei Hospital, Brazil|Hospital Eduardo de Menezes|Hospital das Clínicas da Universidade Federal de Pernambuco|Hospital das Forças Armadas, Brazil|Hospital Regional da Asa Norte, Brazil|Complexo Hospitalar do Trabalhador de Curitiba|Hospital Estadual de Doenças Tropicais Dr Anuar Auad|Hospital Geral de Fortaleza",Phase 2,500,Other,"April 19, 2020","October 2, 2020","October 2, 2020"
1820,NCT04560465,Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.,To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy,Drug: Tranexamic acid,Alex Ekwueme Federal University Teaching Hospital,Phase 2,59,Other,"June 1, 2018","May 31, 2019","June 1, 2019"
1821,NCT04560283,HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period,Vagina; Anomaly|Puerperium; Disease|Sexual Dysfunction,Drug: Vaginal gel HYALOGYN®|Behavioral: Expectant management,Ospedale Policlinico San Martino,Phase 4,25,Other,"September 1, 2016","May 1, 2020","September 1, 2020"
1822,NCT04559204,Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4,"Influenza, Human|Pneumonia, Pneumococcal",Biological: IIV4 and PPV23|Biological: IIV4|Biological: PPV23,"China National Biotec Group Company Limited|Center for Disease Control and Prevention, Fujian|Chengdu Institute of Biological Products Co.,Ltd.|Changchun Institute of Biological Products Co., Ltd.|National Institutes for Food and Drug Control, China|Guizhou Center for Disease Control and Prevention|Hunan Provincial Center for Disease Control and Prevention|Peking University",Phase 4,1224,Industry|Other,"September 11, 2020","November 26, 2020","October 9, 2021"
1823,NCT04558697,"Use of Vagitories Based on St. John's Wort, Tea Tree Oil and Shepherd's Purse in the Treatment of Vaginal Inflammation",Non Specific Vaginitis,Drug: Shepherd's Purse extractum oleosum vagitories|Drug: Tea tree oil vagitories|Drug: Hyperici extractum oleosum vagitories|Drug: Vagitories - Probiotic,University of Sarajevo|Institution for Health Protection of Women and Motherhood|University of Tuzla,Phase 4,210,Other,"March 21, 2019","June 21, 2019","September 30, 2019"
1824,NCT04557943,Prolotherapy Intervention Effect in Patient With Knee Osteoarthritis,Knee Osteoarthritis,Drug: Prolotherapy|Drug: Sodium Hyaluronate,Hasanuddin University,Phase 4,36,Other,"September 1, 2019","April 30, 2020","August 1, 2020"
1825,NCT04557800,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers",Healthy Volunteers,Drug: DNL151|Drug: Placebo,Denali Therapeutics Inc.,Phase 1,186,Industry,"November 16, 2017","February 19, 2021","February 19, 2021"
1826,NCT04557397,Fruquintinib CYP3A Inhibitor and Inducer Study,Drug Drug Interaction,Drug: Fruquintinib|Drug: Itraconazole|Drug: Rifampin,Hutchison Medipharma Limited|Covance|Hutchmed,Phase 1,28,Industry,"September 2, 2020","October 18, 2020","October 18, 2020"
1827,NCT04557332,mHealth for ART Adherence by HIV+ African Americans,HIV-1-infection,Behavioral: On the Dot Mobile app,"Environment and Health Group, Inc.|Prisma Health",Phase 2,109,Industry|Other,"April 1, 2019","May 30, 2020","May 30, 2020"
1828,NCT04557319,Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers,Hereditary Angioedema,"Biological: GNR-038, 25 МЕ/kg|Biological: GNR-038, 50 МЕ/kg|Biological: GNR-038, 100 МЕ/kg",AO GENERIUM,Phase 1,36,Industry,"March 10, 2020","August 27, 2020","August 27, 2020"
1829,NCT04557280,A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects,Healthy Subjects,Combination Product: Selatogrel|Drug: Selatogrel,Idorsia Pharmaceuticals Ltd.,Phase 1,24,Industry,"November 6, 2020","December 19, 2020","December 19, 2020"
1830,NCT04557163,Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole),Healthy Subjects,Drug: TS-142|Drug: Itraconazole,"Taisho Pharmaceutical Co., Ltd.",Phase 1,10,Industry,"October 13, 2020","November 14, 2020","November 14, 2020"
1831,NCT04555733,A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants,Healthy Volunteer,Drug: Lemborexant,"Eisai Co., Ltd.|Eisai Inc.",Phase 1,26,Industry,"October 26, 2020","January 13, 2021","January 13, 2021"
1832,NCT04555525,A Pilot Study on the Use of Seysara for Rosacea,Acne Rosacea,Drug: sarecycline|Dietary Supplement: Centrum Adult Multivitamin,"Derm Research, PLLC",Phase 4,100,Other,"April 15, 2019","September 23, 2020","October 1, 2020"
1833,NCT04555148,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Covid19,Biological: GC5131|Other: Placebo,Green Cross Corporation|GC Biopharma Corp,Phase 2,63,Industry,"September 19, 2020","January 22, 2021","April 23, 2021"
1834,NCT04554862,The Analgesic Efficacy of Magnesium and Ketorolac in Ultrasound Supraclavicular Block,Postoperative Pain,Drug: Magnesium sulfate|Drug: Ketorolac Tromethamine|Procedure: supraclavicular block,Fayoum University Hospital,Phase 4,80,Other,"October 1, 2019","September 30, 2020","October 30, 2020"
1835,NCT04553042,A Study of Seltorexant in Healthy Participants,Healthy,Drug: Seltorexant,"Janssen Research & Development, LLC",Phase 1,69,Industry,"September 14, 2020","December 20, 2020","December 30, 2020"
1836,NCT04552483,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Covid19|Coronavirus,Drug: Nitazoxanide|Drug: Placebo,"Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil|National Research Council, Brazil|ATCGen|Complexo Hospitalar Municipal de São Caetano do Sul|Hospital de Transplante Doutor Euryclides de Jesus Zerbini|Secretaria Municipal de Saúde de Bauru|Santa Casa de Misericórdia de Sorocaba|Secretaria Municipal de Saúde de Guarulhos|Hospital e Maternidade Therezinha de Jesus|Secretaria de Estado de Saúde do Distrito Federal",Phase 2,392,Other,"June 8, 2020","August 20, 2020","September 5, 2020"
1837,NCT04552470,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus",Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-06882961,Pfizer,Phase 1,37,Industry,"October 26, 2020","March 25, 2021","March 25, 2021"
1838,NCT04552366,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,COVID-19,Biological: Ad5-nCoV,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China|Zhongnan Hospital",Phase 1,149,Other,"September 29, 2020","December 31, 2020","April 30, 2021"
1839,NCT04552353,Evaluate Bioequivalence of Voriconazole(200mg/Vial) .,Antimycotic for Systematic Use,Drug: Vaway,"Yung Shin Pharm. Ind. Co., Ltd.",Phase 4,14,Industry,"June 13, 2020","June 21, 2020","June 21, 2020"
1840,NCT04552197,A Study of JNJ-64251330 in Healthy Participants,Healthy,Drug: JNJ-64251330|Drug: Tofacitinib,"Janssen Research & Development, LLC",Phase 1,36,Industry,"September 2, 2020","December 29, 2020","December 29, 2020"
1841,NCT04551703,Adrenaline Solution Irrigation and Bleeding During Sinus Surgery,Chronic Rhinosinusitis (Diagnosis),Drug: Adrenaline saline irrigation,Jordan University of Science and Technology,Phase 1,60,Other,"July 1, 2016","August 11, 2020","August 11, 2020"
1842,NCT04551677,"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",Influenza (Healthy Volunteers),"Biological: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|Biological: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 4,90,Industry,"September 16, 2020","December 18, 2020","December 18, 2020"
1843,NCT04551599,A Study of the Effects of Food and Age on Danicopan,Healthy,Drug: Danicopan,Alexion,Phase 1,27,Industry,"February 21, 2020","February 3, 2021","February 3, 2021"
1844,NCT04551586,A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants,Healthy,Drug: ACH-0145228: Immediate Release|Drug: ACH-0145228: Powder-in-capsule,Alexion,Phase 1,28,Industry,"June 26, 2020","October 19, 2020","October 19, 2020"
1845,NCT04551261,GLS4/RTV and TAF Drug-drug Interaction,Chronic Hepatitis B,Drug: GLS4|Drug: RTV|Drug: TAF,"Sunshine Lake Pharma Co., Ltd.",Phase 1,28,Industry,"January 10, 2021","March 12, 2021","March 12, 2021"
1846,NCT04551079,"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants",Healthy Volunteers,Drug: TAK-994|Drug: Placebo,Takeda,Phase 1,19,Industry,"September 23, 2020","December 31, 2020","December 31, 2020"
1847,NCT04550195,"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants",Healthy Volunteers,Drug: BMS-986337|Other: BMS-986337 Placebo|Biological: Famotidine,Bristol-Myers Squibb,Phase 1,26,Industry,"September 17, 2020","March 3, 2021","March 3, 2021"
1848,NCT04549922,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Covid19,Drug: ISIS 721744|Drug: Normal Saline,"Hospital do Coracao|Ionis Pharmaceuticals, Inc.|Hospital Moinhos de Vento",Phase 2,111,Other|Industry,"October 19, 2020","December 9, 2020","December 9, 2021"
1849,NCT04549675,Couple-focused Intervention for Sun Protection,Skin Cancer Prevention,Behavioral: Sun Safe Partners Online|Behavioral: Generic Online Sun Safety Information intervention,"Rutgers, The State University of New Jersey",Phase 3,150,Other,"May 1, 2019","November 30, 2019","November 30, 2020"
1850,NCT04549480,Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition,Healthy Participants,Drug: Bosutinib capsule|Drug: Bosutinib tablet,Pfizer,Phase 1,66,Industry,"September 16, 2020","January 15, 2021","January 15, 2021"
1851,NCT04549376,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,COVID19,Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NS,DR. MALA KHAN|Dhaka Medical College|Bangladesh Reference Institute of Chemical Measurements (BRICM),Phase 2,200,Other,"July 1, 2020","October 20, 2020","October 30, 2020"
1852,NCT04548219,A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants,Healthy,Drug: Mirikizumab,Eli Lilly and Company,Phase 1,60,Industry,"September 15, 2020","January 11, 2021","January 11, 2021"
1853,NCT04547894,A Study of the Pharmacokinetics of ASC09F in Healthy Subjects,Healthy,Drug: ASC09F,"Ascletis Pharmaceuticals Co., Ltd.|Beijing YouAn Hospital",Phase 1,12,Industry|Other,"November 9, 2020","December 7, 2020","December 7, 2020"
1854,NCT04547660,Convalescent Plasma for Severe COVID-19 Patients,Covid19,Biological: Convalescent Plasma|Other: Best Supportive Care,"Hospital de Clinicas de Porto Alegre|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil|Instituto Cultural Floresta",Phase 3,160,Other,"July 16, 2020","January 7, 2021","January 7, 2021"
1855,NCT04547205,A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors,Solid Tumor,Drug: AK109,Akeso,Phase 1,40,Industry,"June 6, 2020","March 24, 2021","October 31, 2022"
1856,NCT04547127,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),COVID-19,Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment,"Instituto Grifols, S.A.|Grifols Therapeutics LLC",Phase 2,200,Industry,"April 29, 2020","February 4, 2021","February 4, 2021"
1857,NCT04546984,"Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects",Nonalcoholic Steatohepatitis (NASH),Drug: HEC96719,"Sunshine Lake Pharma Co., Ltd.",Phase 1,66,Industry,"September 14, 2020","December 29, 2020","December 29, 2020"
1858,NCT04546347,"A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833",Healthy Volunteers,"Radiation: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Drug: AZD9833 film-coated tablet A Dose 1|Drug: AZD9833 Oral Solution|Drug: AZD9833 film-coated tablet B Dose 1|Drug: AZD9833 film-coated tablet A Dose 2|Drug: AZD9833 film-coated tablet B Dose 2",AstraZeneca|Quotient Sciences,Phase 1,32,Industry,"September 17, 2020","January 7, 2021","January 7, 2021"
1859,NCT04546256,A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers,Bioequivalence,Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|Drug: ADVAIR DISKUS® 500/50,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,14,Industry,"September 1, 2020","September 25, 2020","December 31, 2020"
1860,NCT04545944,Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants,Healthy Volunteers,Drug: Vonoprazan|Drug: Midazolam,"Phathom Pharmaceuticals, Inc.",Phase 1,20,Industry,"September 15, 2020","November 13, 2020","November 25, 2020"
1861,NCT04545892,Capsaicin for Cerebral Perfusion Augmentation.,Stroke,Drug: Capsaicin,"Juan Manuel Marquez Romero|Centenario Hospital Miguel Hidalgo|Universidad de Guanajuato|Unidad de Medicina de Alta Especialidad, Torre Medica CMQ",Phase 1,30,Other,"December 1, 2019","July 31, 2020","July 31, 2020"
1862,NCT04545749,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",COVID-19,Biological: UB-612,"United Biomedical Inc., Asia|Vaxxinity, Inc.",Phase 1,60,Industry,"September 25, 2020","January 18, 2021","May 24, 2021"
1863,NCT04543370,Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects,Healthy,Drug: Edasalonexent 2000 mg TID|Drug: Midazolam 2 MG/ML|Drug: Deflazacort 36Mg Tab,Catabasis Pharmaceuticals,Phase 1,26,Industry,"August 8, 2020","September 6, 2020","October 1, 2020"
1864,NCT04543123,Effect of Self-administered tDCS in Patients With MDD,Major Depressive Disorder,Device: tDCS treatment|Drug: Antidepressant Drug(escitalopram),Jeong-Ho Chae|Ybrain Inc.|Seoul St. Mary's Hospital,Phase 4,58,Other|Industry,"November 16, 2017","May 2, 2019","May 2, 2019"
1865,NCT04542967,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Severe COVID-19 Disease,Biological: Biological,Hospital Central Militar,Phase 2,150,Other,"June 23, 2020","September 2, 2020","September 30, 2020"
1866,NCT04542694,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,COVID-19,Drug: Favipiravir|Drug: Standard of care,"Promomed, LLC",Phase 3,200,Other,"May 21, 2020","August 10, 2020","August 20, 2020"
1867,NCT04542252,Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects,Drug Drug Interaction,Drug: SyB V-1901|Drug: Cyclosporine,SymBio Pharmaceuticals,Phase 1,13,Industry,"November 9, 2020","December 22, 2020","January 29, 2021"
1868,NCT04542213,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Hyperglycemia|Covid19,Drug: Linagliptin tablet|Drug: Insulin,Hospital Regional de Alta Especialidad del Bajio,Phase 3,70,Other,"August 1, 2020","February 28, 2021","February 28, 2021"
1869,NCT04541004,Adolescent Mite Allergy Safety Evaluation,Allergic Rhinitis|Allergic Rhinoconjunctivitis,Biological: HDM SLIT-tablet,ALK-Abelló A/S|Syneos Health,Phase 3,254,Industry|Other,"September 23, 2020","April 24, 2021","April 24, 2021"
1870,NCT04540965,Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects,Drug Interaction,Drug: Telaglenastat|Drug: Famotidine|Drug: Placebo for famotidine,"Calithera Biosciences, Inc|Novotech (Australia) Pty Limited",Phase 1,22,Industry,"September 22, 2020","December 8, 2020","December 8, 2020"
1871,NCT04540627,Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV,Healthy Adult Participants,Drug: Palivizumab|Drug: Placebo|Other: RSV-A Memphis 37b virus,mAbxience Research S.L.,Phase 1,56,Industry,"July 6, 2020","October 23, 2020","October 23, 2020"
1872,NCT04540016,Mass Balance and Biotransformation of [14C]HSK7653 in Human,Type II Diabetes,Drug: [14C]HSK7653,"Sichuan Haisco Pharmaceutical Group Co., Ltd|First Affiliated Hospital of Suzhou Medical College|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,6,Industry|Other,"November 15, 2020","January 14, 2021","January 21, 2021"
1873,NCT04539340,"A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers",Mucopolysaccharidosis Type II|Metabolic Diseases,Biological: GNR-055,AO GENERIUM,Phase 1,20,Industry,"February 28, 2020","September 8, 2020","September 8, 2020"
1874,NCT04538599,RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies,Hematologic Malignancies,Drug: RD13-01 cell infusion,He Huang|Zhejiang University,Phase 1,12,Other,"September 10, 2020","February 17, 2021","November 30, 2021"
1875,NCT04538365,Pre-surgical Antisepsis of Hands After Washing With Triclosan 0.5% Compared to Propan-1-ol 60%,Antisepsis,Drug: Triclosan 0.5 % Topical Solution|Drug: propanolol,Centro Ortopedico y Quirurgico del Pie,Phase 4,24,Other,"October 1, 2020","October 20, 2020","October 30, 2020"
1876,NCT04538014,A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain,Healthy,Drug: Lu AF88434|Drug: [11C]-Lu AF88434,H. Lundbeck A/S,Phase 1,8,Industry,"August 24, 2020","October 21, 2020","October 21, 2020"
1877,NCT04537910,A Study of LY3819253 (LY-CoV555) in Healthy Participants,Healthy,Drug: LY3819253|Drug: Placebo,Eli Lilly and Company,Phase 1,25,Industry,"September 2, 2020","December 28, 2020","December 28, 2020"
1878,NCT04537780,Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH),Non Alcoholic Steatohepatitis,Other: Placebo|Drug: Montelukast,Tanta University,Phase 4,44,Other,"August 20, 2019","August 30, 2020","August 30, 2020"
1879,NCT04537234,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older,Influenza (Healthy Volunteers),Biological: High-Dose Quadrivalent Influenza Vaccine|Biological: Standard-Dose Quadrivalent Influenza Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,165,Industry,"November 10, 2020","February 9, 2021","February 9, 2021"
1880,NCT04537078,Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders,"Infertility, Female",Drug: Duphaston|Drug: Gonadotropin|Drug: Cetrotide Injectable Product|Drug: Decapeptyl|Drug: Chorionic Gonadotropin|Drug: Combined Oral Contraceptive|Drug: Cyclo-Progynova|Drug: progesterone,El Shatby University Hospital for Obstetrics and Gynecology,Phase 3,90,Other,"September 1, 2020","March 1, 2021","September 1, 2021"
1881,NCT04536961,A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants,Healthy Volunteers,Drug: Reference Treatment- BMS-986165-01|Drug: Prototype BMS-986165|Drug: Famotidine|Other: Alcohol,Bristol-Myers Squibb,Phase 1,56,Industry,"September 10, 2020","December 25, 2020","December 25, 2020"
1882,NCT04536831,The Association of Vitamin D Supplementation With the Outcome in Critically Ill Children,Critically Ill,Drug: Vitamin D|Drug: Normal saline,Dr Mustahsin Khalil|King Edward Medical University,Phase 4,96,Other,"August 29, 2019","February 25, 2020","February 25, 2020"
1883,NCT04536493,Comparison of 2 Application Techniques for LET Gel Used Prior to Simple Laceration Repair,LET|Laceration of Skin,Drug: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|Drug: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications),Children's Hospital of Orange County,Phase 4,48,Other,"June 19, 2019","November 6, 2019","June 25, 2020"
1884,NCT04536415,Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers,Bioequivalence,Drug: Oseltamivir Phosphate 75 mg capsules|Drug: Tamiflu capsules 75 mg,"Austarpharma, LLC",Phase 4,96,Industry,"August 25, 2020","August 27, 2020","August 27, 2020"
1885,NCT04535947,Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202),Dry Eye,Drug: Vehicle|Drug: SDP-4 Ophthalmic Solution (1.0%),"Silk Technologies, Ltd.",Phase 2,153,Industry,"August 14, 2020","February 10, 2021","February 10, 2021"
1886,NCT04535856,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Covid19|Corona Virus Infection|SAR,Drug: allogeneic mesenchymal stem cell|Other: Placebo,"Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.",Phase 1,9,Other|Industry,"November 14, 2020","January 14, 2021","January 14, 2021"
1887,NCT04535791,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Covid19|Vitamin D,Drug: Cholecalciferol,"Coordinación de Investigación en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez",Phase 3,321,Other,"July 15, 2020","December 30, 2020","July 15, 2021"
1888,NCT04535531,A Phase 3 Molluscum Contagiosum Efficacy and Safety Study,Molluscum Contagiosum,Drug: SB206 10.3% berdazimer|Drug: vehicle gel,"Novan, Inc.|Therapeutics, Inc.|Synteract, Inc.",Phase 3,891,Industry,"September 1, 2020","April 28, 2021","July 28, 2021"
1889,NCT04535063,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Covid19 Pneumonia,Biological: COVID19 convalescent plasma infusion,Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno,Phase 3,200,Other,"April 18, 2020","December 30, 2020","February 25, 2021"
1890,NCT04534699,Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment,Moderate Hepatic Impairment|Healthy,Drug: KBP-5074,KBP Biosciences|Covance,Phase 1,12,Industry,"August 27, 2020","November 19, 2020","November 19, 2020"
1891,NCT04534426,"Topical Arnica and Mucopolysaccharide Polysulfate on Postoperative Pain, Edema and Trismus",Impacted Third Molar Tooth,Drug: : Arnica montana|Drug: Mucopolysaccharide polysulfate|Other: Control group,Abant Izzet Baysal University,Phase 4,60,Other,"December 1, 2018","December 1, 2019","January 30, 2020"
1892,NCT04533841,Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor in Primigravidas,Induction of Labor Affected Fetus / Newborn,Drug: Misoprostol|Drug: Placebo|Drug: Propranolol,Ahmed mohamed fathy ismail|Ain Shams University,Phase 2,128,Other,"February 1, 2020","September 13, 2020","September 15, 2020"
1893,NCT04533048,A Clinical Study to Evaluate MW33 Injection,Covid19,Combination Product: MW33 injection|Combination Product: MW33 injection placebo,"Mabwell (Shanghai) Bioscience Co., Ltd.|Shanghai Public Health Clinical Center",Phase 1,42,Industry|Other,"August 7, 2020","November 16, 2020","December 2, 2020"
1894,NCT04532957,A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects,Healthy,Drug: KBP-7072|Drug: Placebo,KBP Biosciences|Covance,Phase 1,24,Industry,"August 11, 2020","October 8, 2020","October 15, 2020"
1895,NCT04532918,Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers,Chronic Kidney Disease,Drug: Verinurad|Drug: Allopurinol|Drug: Cyclosporine|Drug: Rifampicin,AstraZeneca|Parexel,Phase 1,14,Industry,"September 10, 2020","November 23, 2020","November 23, 2020"
1896,NCT04532684,Comparison of the Efficacy of Duloxetine and Pregabalin in Patients With Knee Osteoarthritis With Mix Type Pain,Knee Osteoarthritis,Drug: Duloxetine|Drug: Pregabalin,Fatih Sultan Mehmet Training and Research Hospital,Phase 4,66,Other,Oct-16,"July 15, 2020","December 15, 2020"
1897,NCT04532567,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects",Healthy,Drug: GLPG1205|Drug: Placebo,Galapagos NV,Phase 1,32,Industry,"August 18, 2020","December 10, 2020","December 10, 2020"
1898,NCT04532294,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Covid19,Drug: BGB DXP593|Drug: Placebo,BeiGene,Phase 1,18,Industry,"September 8, 2020","February 13, 2021","February 13, 2021"
1899,NCT04531150,"Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects",Pharmacokinetic,Drug: INV-101|Drug: Placebo,Inversago Pharma Inc.,Phase 1,40,Industry,"September 8, 2020","January 16, 2021","May 16, 2021"
1900,NCT04531072,Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine,Drug Interaction,Drug: Artemether-lumefantrine|Drug: Atazanavir-ritonavir 300/100 mg,Fogarty International Center of the National Institute of Health|NIH Office of AIDS Research (OAR)|National Institute on Minority Health and Health Disparities (NIMHD)|National Institute of Neurological Disorders and Stroke (NINDS),Phase 4,20,NIH,"September 18, 2018","May 15, 2019","August 15, 2019"
1901,NCT04530656,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),COVID-19,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Biological: Two doses of placebo at the schedule of day 0, 28（high-dose group）|Biological: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）",Jiangsu Province Centers for Disease Control and Prevention|West China Hospital,Phase 1,168,Other,"August 28, 2020","October 28, 2020","November 23, 2021"
1902,NCT04530604,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),COVID|Sars-CoV2|COVID-19|Acute Respiratory Distress Syndrome,Drug: Defibrotide,Gregory Yanik|Jazz Pharmaceuticals|University of Michigan,Phase 1,13,Other|Industry,"October 1, 2020","March 26, 2021","April 9, 2021"
1903,NCT04530422,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Covid19,Drug: Sofosbuvir plus Ledipasvir,Almaza Military Fever Hospital,Phase 3,250,Other,"April 15, 2020","July 8, 2020","July 23, 2020"
1904,NCT04529850,Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer,Head and Neck Cancer|Oral Mucositis,Drug: Drug: GC4419|Radiation: Intensity-modulated radiation therapy (IMRT)|Drug: Cisplatin,"Galera Therapeutics, Inc.",Phase 2,38,Industry,"June 30, 2020","March 10, 2021","March 10, 2021"
1905,NCT04529187,Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.,Cardiac Function|Sedation|Magnetic Resonance Imaging,Drug: Midazolam|Drug: Dexmedetomidine,Masaryk Hospital Krajská zdravotní a.s.,Phase 4,30,Other,"January 1, 2018","December 31, 2019","December 31, 2019"
1906,NCT04527848,Comparison of Two Intraocular Gas Injection Techniques in Macula Hole Surgery,Macular Holes,Drug: small amount of undiluted C3F8,Universidade Federal de Pernambuco,Phase 4,48,Other,"May 10, 2016","July 31, 2020","July 31, 2020"
1907,NCT04527471,Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,Coronavirus Infection|Covid-19|SARS-CoV-2,Drug: Ensifentrine Dose 1|Drug: Placebo pMDI,Verona Pharma Inc|Verona Pharma plc,Phase 2,45,Industry,"September 4, 2020","February 15, 2021","May 1, 2021"
1908,NCT04527354,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,SARS-CoV-2 Infection|Fibrosis Lung,Drug: Treamid|Drug: Placebo,PHARMENTERPRISES LLC,Phase 2,60,Industry,"September 1, 2020","February 10, 2021","February 10, 2021"
1909,NCT04527250,A Study of the Relative Bioavailability of ASC41 in Healthy Subjects,Healthy,Drug: ASC41|Drug: ASC41 placebo,"Ascletis Pharmaceuticals Co., Ltd.|Hunan Provincial People's Hospital",Phase 1,60,Industry|Other,"September 16, 2020","December 18, 2020","December 30, 2020"
1910,NCT04526496,"Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers",Healthy,"Drug: FTP-198, single dose|Drug: Placebo, single dose|Drug: FTP-198, multiple doses|Drug: Placebo, multiple doses","Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,75,Industry,"February 24, 2020","November 5, 2020","November 5, 2020"
1911,NCT04526197,Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.,Wilson Disease,Drug: ALXN1840|Drug: Celecoxib,Alexion,Phase 1,36,Industry,"July 8, 2020","November 3, 2020","November 3, 2020"
1912,NCT04525079,"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",SARS-CoV-2 Infection,Drug: CT-P59|Drug: Placebo,Celltrion,Phase 1,32,Industry,"July 18, 2020","August 7, 2020","November 5, 2020"
1913,NCT04524975,А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder,Anxiety Disorder Generalized,Drug: CD-008-0045|Drug: Placebo,"ChemRar Research and Development Institute, LLC",Phase 2,129,Industry,"October 2, 2018","August 20, 2019","November 1, 2019"
1914,NCT04524507,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,COVID-19,Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2),"University of North Carolina, Chapel Hill",Phase 2,56,Other,"August 27, 2020","January 4, 2021","June 4, 2021"
1915,NCT04524026,RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2,IVF,Drug: Letrozole 5 mg,Nicholas Macklon|Gedeon Richter Ltd.|Igenomix|Zealand University Hospital,Phase 2,25,Other|Industry,"September 18, 2018","November 30, 2020","November 30, 2020"
1916,NCT04523935,Excessive Crying in Children With Cerebral Palsy and Communication Deficits,Cerebral Palsy|Excessive Crying|Pain,"Other: Placebo|Drug: Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.",Sathbhavana Brain Clinic,Phase 4,131,Other,"December 7, 2005","August 4, 2020","August 4, 2020"
1917,NCT04523831,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Covid19,Drug: Ivermectin and Doxycycline|Drug: Standard of care,Dhaka Medical College,Phase 3,400,Other,"June 1, 2020","August 22, 2020","September 10, 2020"
1918,NCT04523571,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,SARS-CoV-2,Biological: BNT162b1|Other: Placebo,BioNTech SE|Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,Phase 1,144,Industry,"July 28, 2020","September 30, 2020","August 10, 2021"
1919,NCT04523324,Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel,Influenza,"Biological: Flublok™ Quadrivalent by Sanofi, Inc.|Biological: VaxigripTetra™ by Sanofi, Inc.",Centers for Disease Control and Prevention|Abt Associates|Clalit Research Institute|Soroka University Medical Center|Rabin Medical Center|University of Michigan,Phase 4,572,U.S. Fed|Industry|Other,"October 31, 2019","January 30, 2020","August 30, 2022"
1920,NCT04522986,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2,Biological: Mesenchymal stem cell,"Rohto Pharmaceutical Co., Ltd.",Phase 1,6,Industry,"August 21, 2020","February 2, 2021","February 2, 2021"
1921,NCT04522830,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,SARS-CoV-2 Infection,Drug: BTL-TML-COVID|Drug: Placebo,"Beech Tree Labs, Inc.|Norwich Clinical Research Associates Ltd.|Curavit Clinical Research",Phase 2,28,Industry|Other,"July 30, 2020","February 28, 2021","February 28, 2021"
1922,NCT04522089,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,COVID-19,Biological: AdimrSC-2f,Adimmune Corporation,Phase 1,68,Industry,"August 24, 2020","November 20, 2020","May 6, 2021"
1923,NCT04521738,First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects,Overweight|Healthy Subjects,Drug: SAR441255|Drug: placebo,Sanofi,Phase 1,48,Industry,"April 25, 2019","September 26, 2019","September 26, 2019"
1924,NCT04521556,Effect of Epidural Anesthesia and Analgesia on Quality of Recovery After Unilateral Nephrectomy.,Anesthesia|Anesthesia Recovery Period|Nephrectomy|Patient Satisfaction|Postoperative Period|Quality of Life|Analgesia|Epidural,Procedure: Epidural anesthesia with light general anesthesia|Procedure: Postoperative epidural analgesia|Procedure: General anesthesia|Drug: Continuous intravenous analgesia,University Hospital of Split,Phase 4,80,Other,"April 1, 2019","April 1, 2021","June 1, 2021"
1925,NCT04521192,Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects,Healthy Adult Subjects,Drug: Fluzoparib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,40,Industry,"May 6, 2019","July 26, 2019","September 5, 2019"
1926,NCT04521049,Tubular Markers in Response to Saxagliptin Therapy,"Diabetes Mellitus, Type 2",Drug: Saxagliptin 5mg,Beni-Suef University,Phase 4,80,Other,"March 1, 2019","March 1, 2020","April 1, 2020"
1927,NCT04521023,A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy,Hypertension,Drug: Cantabell Tab|Drug: Candemore Plus Tab,Chong Kun Dang Pharmaceutical,Phase 4,132,Industry,"September 20, 2017","January 28, 2020","June 3, 2020"
1928,NCT04520230,Three Treatment of Chronic Obstructive Pulmonary Disease Patients,COPD,"Drug: Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|Drug: Tiotropium 18 mcg capsule inhaled once daily + Budesonide|Drug: Formoterol/Tiotropium",Tanta University,Phase 4,45,Other,"October 31, 2014","December 30, 2019","December 31, 2019"
1929,NCT04519788,AT-301 Nasal Spray in Healthy Adults,Healthy,Drug: AT-301B|Drug: AT-301A,"Atossa Therapeutics, Inc.",Phase 1,32,Industry,"August 7, 2020","December 8, 2020","January 12, 2021"
1930,NCT04519567,Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia,Friedreich Ataxia,Biological: CTI-1601|Biological: Placebo,"Larimar Therapeutics, Inc.|Veristat, Inc.|Metrum Research Group, LLC",Phase 1,27,Industry|Other,"July 31, 2020","March 16, 2021","March 16, 2021"
1931,NCT04518462,"Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries",Lower Extremity Surgery|Bunion|Metatarsophalangeal Fushion|Midfoot Fusion|Hindfoot Fushion|Total Ankle Arthroplasty,Drug: Exparel|Drug: Bupivacaine Hydrochloride,"Pacira Pharmaceuticals, Inc",Phase 3,121,Industry,"October 20, 2020","April 5, 2021","April 5, 2021"
1932,NCT04516759,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Covid19,Drug: AZD1656|Other: Placebo,St George Street Capital,Phase 2,170,Other,"August 12, 2020","April 25, 2021","May 12, 2021"
1933,NCT04516746,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",COVID-19|SARS-CoV-2,Biological: AZD1222|Biological: Placebo,AstraZeneca|Iqvia Pty Ltd,Phase 3,32459,Industry,"August 28, 2020","March 5, 2021","February 10, 2023"
1934,NCT04516564,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Coronavirus Disease 2019 (COVID-19),Drug: AK119|Drug: Placebo,Akesobio Australia Pty Ltd|Akeso,Phase 1,29,Industry,"September 29, 2020","March 4, 2021","June 18, 2021"
1935,NCT04516382,Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers,Healthy Volunteers,Drug: PTG-300,"Protagonist Therapeutics, Inc.",Phase 1,12,Industry,"September 14, 2020","January 12, 2021","June 30, 2021"
1936,NCT04516278,A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders,Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration|Wet Macular Degeneration|BRVO - Branch Retinal Vein Occlusion|Diabetic Macular Edema,Biological: bevacizumab,"Outlook Therapeutics, Inc.",Phase 3,195,Industry,"October 1, 2020","February 10, 2021","February 10, 2021"
1937,NCT04516148,"A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting",Burn|Surgery|Infection Wound,Drug: Cefazolin|Drug: Clindamycin,Medstar Health Research Institute,Phase 4,32,Other,"May 29, 2018","October 30, 2020","October 30, 2020"
1938,NCT04515628,Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants,Healthy Participants,Drug: Rosuvastatin|Drug: Branebrutinib,Bristol-Myers Squibb,Phase 1,22,Industry,"August 2, 2020","October 18, 2020","October 26, 2020"
1939,NCT04515576,A Study of LY3493269 in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: LY3493269|Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,Phase 1,56,Industry,"August 25, 2020","March 9, 2021","March 9, 2021"
1940,NCT04515043,EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754),"Solid Tumor, Adult",Drug: INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.,Invectys,Phase 1,6,Industry,"October 16, 2020","December 19, 2020","December 19, 2020"
1941,NCT04514237,"Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects",Healthy Participants,Drug: BOS172767 enantiomer E1 or E2|Drug: Placebo,Boston Pharmaceuticals,Phase 1,12,Industry,"September 12, 2019","January 22, 2020","January 22, 2020"
1942,NCT04513704,A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times,Healthy Volunteers Type 2 Diabetes,Drug: Oral Semaglutide,Novo Nordisk A/S,Phase 1,156,Industry,"August 28, 2020","April 20, 2021","May 26, 2021"
1943,NCT04513652,A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution,"Anesthesia, Local",Drug: AG-920|Drug: Placebo,"American Genomics, LLC",Phase 3,120,Industry,"September 3, 2020","September 30, 2020","December 17, 2020"
1944,NCT04511728,A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia,Induction and Maintenance of General Anesthesia,Drug: HSK3486|Drug: Propofol,"Haisco Pharmaceutical Group Co., Ltd.",Phase 3,129,Industry,"November 24, 2020","December 31, 2020","January 25, 2021"
1945,NCT04511000,Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg,Hypercholesterolemia,Drug: Lipilou®(generic atorvastatin drug) 20 mg|Drug: Lipilou®(generic atorvastatin drug) 10 mg,Chong Kun Dang Pharmaceutical,Phase 4,250,Industry,"October 11, 2017","May 20, 2019","May 20, 2019"
1946,NCT04510922,Lundbeck TOMs Orthostatic Hypotension,Orthostatic Hypotension|Idiopathic Parkinson Disease,Drug: Droxidopa 100 MG [Northera],"Alberto Espay, MD, MSc|Lundbeck LLC|University of Cincinnati",Phase 4,9,Other|Industry,"February 11, 2019","December 31, 2020","December 31, 2020"
1947,NCT04510649,Surufatinib DDI With a PPI and a CYP3A Inducer,Healthy,Drug: Part A|Drug: Part B,Hutchison Medipharma Limited|Hutchmed,Phase 1,28,Industry,"July 9, 2020","September 11, 2020","March 2, 2021"
1948,NCT04510298,"A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia",Schizophrenia,Drug: SP-624|Drug: Placebo,"Sirtsei Pharmaceuticals, Inc.",Phase 1,27,Industry,"October 15, 2020","April 15, 2021","April 15, 2021"
1949,NCT04509947,A Study of Ad26.COV2.S in Adults (COVID-19),Healthy,Biological: Ad26.COV2.S|Biological: Placebo,Janssen Pharmaceutical K.K.,Phase 1,250,Industry,"August 11, 2020","February 22, 2021","November 16, 2021"
1950,NCT04509622,A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia (AML),Drug: Venetoclax|Drug: Cytarabine,AbbVie,Phase 3,14,Industry,"October 5, 2020","April 15, 2021","April 15, 2021"
1951,NCT04508946,Triple Therapy in Septic Shock Patients,Septic Shock|Sepsis|Organ Dysfunction Syndrome Sepsis,Drug: vitamin c - thiamine- hydrocortisone,"Air Force Specialized Hospital, Cairo, Egypt",Phase 3,94,Other,"August 1, 2019","November 9, 2020","November 9, 2020"
1952,NCT04508816,Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy,Nasopharyngeal Carcinoma,Drug: cetuximab (CTX) or nimotuzumab (NTZ),Fudan University,Phase 2,45,Other,"January 1, 2016","October 1, 2020","October 1, 2020"
1953,NCT04508426,Single-dose AME Study With [14C]AR882 in Healthy Male Subjects,Healthy Volunteers,Drug: [14C]AR882,Arthrosi Therapeutics|Celerion,Phase 1,6,Industry,"July 16, 2020","August 12, 2020","August 12, 2020"
1954,NCT04508075,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",SARS-CoV2 Infection,Biological: SARS-CoV-2 vaccine (inactivated)|Biological: Placebo,"PT Bio Farma|Faculty of Medicine Universitas Padjadjaran|National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia|Sinovac Life Sciences Co., Ltd.",Phase 3,1620,Industry|Other,"August 10, 2020","January 9, 2021","August 31, 2021"
1955,NCT04507321,Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254,HIV Infections,Drug: GSK3640254 Oral tablet|Drug: [14C]-GSK3640254 intravenous infusion|Drug: [14C]-GSK3640254 powder,ViiV Healthcare,Phase 1,5,Industry,"September 24, 2020","November 23, 2020","November 23, 2020"
1956,NCT04507022,The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer,"Infertility|Infertility, Female|Infertility, Male",Drug: Estradiol Valerate|Drug: Progesterone|Drug: Aromatase inhibitor,Rahem Fertility Center,Phase 4,112,Other,"August 12, 2020","February 5, 2021","February 5, 2021"
1957,NCT04506827,RCT With 3 Different Biomaterials for Maxillary Sinus Lift,Alveolar Bone Atrophy,Procedure: Maxillary Sinus Augmentation|Device: Maxillary Sinus Graft with ABBM|Device: Maxillary Sinus Graft with TCP|Device: Maxillary Sinus Graft with TCP + HA,University of Pisa,Phase 4,24,Other,"February 23, 2017","June 29, 2019","December 14, 2019"
1958,NCT04505787,S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet,Comparative Bioavailability,Drug: Esflurbiprofen hydrogel patch 165 mg (EFHP)|Drug: Froben 100 mg comprimidos revestidos,"SocraTec R&D GmbH|Teikoku Seiyaku Co., Ltd.|SocraMetrics GmbH",Phase 1,26,Other|Industry,"July 24, 2020","September 9, 2020","September 24, 2020"
1959,NCT04505137,A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers,Pulmonary Arterial Hypertension,Drug: GMA301 Injection|Other: GMA301 Placebo Injection,Gmax Biopharm Australia Pty Ltd.|Metaclinical|Syneos Heath|Gmax Biopharm LLC.,Phase 1,16,Industry|Other,"September 2, 2020","March 19, 2021","March 19, 2021"
1960,NCT04505033,A Study of Injection HB0017 in Adult Healthy Volunteers,Healthy Subjects,Drug: HB0017|Drug: placebo,"Huabo Biopharm Co., Ltd.",Phase 1,40,Industry,"October 2, 2020","January 2, 2021","February 1, 2021"
1961,NCT04504760,"Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects",Healthy Volunteers,Drug: ONO-2910|Drug: Placebo,Ono Pharmaceutical Co. Ltd,Phase 1,80,Industry,"July 10, 2020","March 18, 2021","March 18, 2021"
1962,NCT04504240,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Covid19,Drug: Famotidine 20 MG,Chattogram General Hospital|M Abdur Rahim Medical College and Hospital|First Affiliated Hospital Xi'an Jiaotong University,Phase 3,208,Other,"August 1, 2020","April 15, 2021","April 15, 2021"
1963,NCT04503863,An Additional Study of NPC-22 in Healthy Adult Males,Safety and Pharmacokinetics,Drug: NPC-22|Drug: NPC-22 Placebo,Nobelpharma,Phase 1,32,Industry,"July 20, 2020","November 6, 2020","December 28, 2021"
1964,NCT04503629,A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.,Duodenal Ulcer，DU,Drug: Anaprazole Sodium|Drug: Rabeprazole sodium,Sihuan Pharmaceutical Holdings Group Ltd.,Phase 2,150,Industry,"October 9, 2018","May 17, 2019","May 17, 2019"
1965,NCT04503603,"A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants",Healthy Volunteers,Drug: Lanadelumab|Other: Placebo,"Takeda|Takeda Development Center Americas, Inc.",Phase 1,12,Industry,"August 10, 2020","December 23, 2020","December 23, 2020"
1966,NCT04502901,"the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending",Androgenetic Alopecia,Drug: KX0826|Other: Placebo,"Suzhou Kintor Pharmaceutical Inc,",Phase 1,40,Industry,"January 14, 2020","August 11, 2020","January 15, 2021"
1967,NCT04502667,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,"Covid19|Vitamin D|Children, Only",Drug: Cholecalciferol,"Coordinación de Investigación en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez|Hospital General de México Dr. Eduardo Liceaga",Phase 3,45,Other,"July 15, 2020","March 31, 2021","September 15, 2021"
1968,NCT04501783,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,COVID-19,Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapy,R-Pharm,Phase 3,168,Industry,"May 20, 2020","July 29, 2020","August 4, 2020"
1969,NCT04501640,A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants,Pharmacokinetics of Mirabegron|Food Effect|Healthy Chinese Subjects,Drug: mirabegron,"Astellas Pharma China, Inc.|Astellas Pharma Inc",Phase 4,24,Industry,"September 21, 2020","October 14, 2020","October 27, 2020"
1970,NCT04501107,A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus,Type 1 Diabetes,Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Drug: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Drug: Administration of US-approved Humalog® (IMP3)|Drug: Administration of EU-approved Humalog® (IMP4),Adocia,Phase 1,32,Industry,"August 3, 2020","November 3, 2020","November 3, 2020"
1971,NCT04500808,"A Study of Macitentan, in Healthy Japanese Male Participants",Healthy,Drug: Macitentan Dose 1|Drug: Macitentan Dose 2|Drug: Macitentan Dose 3|Drug: Placebo,Janssen Pharmaceutical K.K.,Phase 1,24,Industry,"July 21, 2020","December 14, 2020","December 14, 2020"
1972,NCT04500210,Comparative Study of Turmeric Extract in Patients With Arthrosis.,"Arthralgia|Stiffness of Unspecified Joint, Not Elsewhere Classified|Disturbance of Activity and Attention|Quality of Life",Dietary Supplement: Placebo|Dietary Supplement: Turmeric,Kaj Winther Hansen|University of Copenhagen,Phase 3,120,Other,"January 1, 2020","September 7, 2020","September 7, 2020"
1973,NCT04500132,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,COVID-19,Drug: EC-18|Drug: Placebo EC-18,Enzychem Lifesciences Corporation,Phase 2,63,Industry,"May 28, 2020","February 4, 2021","February 15, 2021"
1974,NCT04500067,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Covid19|Pneumonia,Drug: IVIG,Biopharma Plasma LLC|Lviv National Medical University|Vinnitsa National Medical University,Phase 3,76,Industry|Other,"May 7, 2020","September 15, 2020","September 15, 2020"
1975,NCT04499235,A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid,"Pemphigoid, Bullous",Drug: Mometasone furoate|Drug: AKST4290|Drug: Placebo,"Alkahest, Inc.",Phase 2,30,Industry,"January 30, 2020","March 29, 2021","April 14, 2021"
1976,NCT04498936,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,COVID,Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide,Assiut University|Helwan University,Phase 4,240,Other,"July 15, 2020","October 30, 2020","October 30, 2020"
1977,NCT04498832,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older,Influenza (Healthy Volunteers),"Biological: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Biological: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,2100,Industry,"October 21, 2020","January 14, 2021","January 14, 2021"
1978,NCT04498390,A Safety Study of LY3493269 in Healthy Participants,Healthy,Drug: LY3493269|Drug: Placebo,Eli Lilly and Company,Phase 1,40,Industry,"September 3, 2020","December 28, 2020","December 28, 2020"
1979,NCT04497987,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,COVID-19|SARS-CoV2,Drug: Bamlanivimab|Drug: Placebo|Drug: Etesevimab,"Eli Lilly and Company|National Institute of Allergy and Infectious Diseases (NIAID)|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.",Phase 3,1180,Industry|NIH|Other,"August 2, 2020","January 16, 2021","May 20, 2021"
1980,NCT04497883,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants",Healthy Volunteers,Drug: Maribavir (400 mg)|Drug: Maribavir (200 mg)|Drug: Maribavir (800 mg),Shire|Takeda,Phase 1,24,Industry,"August 7, 2020","November 12, 2020","November 12, 2020"
1981,NCT04497766,Comparasion of Efficacy of Nebulized With Intravenous Magnesium Sulphate in Children With Asthma,Asthma in Children,Drug: Nebulized Magnesium sulfate|Drug: Intravenous magnesium sulphate,Saima Khatoon|King Edward Medical University,Phase 4,148,Other,"October 1, 2019","September 30, 2020","September 30, 2020"
1982,NCT04497662,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects",Healthy Volunteers,Drug: KPL-404|Other: Matching Placebo,"Kiniksa Pharmaceuticals, Ltd.",Phase 1,52,Industry,"October 22, 2019","January 21, 2021","March 2, 2021"
1983,NCT04497519,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,Covid19,Drug: inhaled hydroxychloroquine,University Medical Center Groningen,Phase 1,12,Other,"September 15, 2020","October 15, 2020","November 1, 2020"
1984,NCT04497324,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,COVID-19,Biological: Convalescent plasma,Universidad Peruana Cayetano Heredia,Phase 2,100,Other,"September 21, 2020","April 17, 2021","April 17, 2021"
1985,NCT04496089,"Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC","Carcinoma, Renal Cell|Clear Cell Renal Cell Carcinoma",Diagnostic Test: 89Zr-girentuximab,Telix International Pty Ltd,Phase 1,6,Industry,"August 1, 2020","October 27, 2020","April 6, 2021"
1986,NCT04495504,Administration of Ropivacaine by Bi-laterosternal Multiperforated Catheters Placed Before a Sternotomy for Cardiac Surgery,Scheduled Cardiac Surgery|Age Under 85 Years,Drug: Ropivacaine,"University Hospital, Clermont-Ferrand",Phase 2,32,Other,"July 22, 2020","January 12, 2021","July 12, 2021"
1987,NCT04495322,"To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.",Healthy Chinese Volunteers,Drug: TG-1000|Drug: Placebo,"TaiGen Biotechnology Co., Ltd.|R&G Pharma Studies Co.,Ltd.",Phase 1,66,Industry,"July 17, 2020","November 26, 2020","December 30, 2020"
1988,NCT04495283,A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy,Postoperative Pain,Drug: Pregabalin|Drug: Acetaminophen|Other: Placebo 1|Other: Placebo 2,"Nevakar, Inc.|Nevakar Injectables, Inc.",Phase 2,87,Industry,"July 28, 2020","November 12, 2020","November 12, 2020"
1989,NCT04495140,"Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961",Healthy Volunteer,"Drug: [14C]PF-06882961, 50 mg|Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug",Pfizer,Phase 1,6,Industry,"July 22, 2020","October 15, 2020","October 15, 2020"
1990,NCT04495101,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,COVID-19,Biological: Prolastin|Drug: Standard Medical Treatment,"Instituto Grifols, S.A.|Grifols Therapeutics LLC",Phase 2,100,Industry,"July 29, 2020","April 26, 2021","June 10, 2021"
1991,NCT04494828,Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor,Central Nervous System Diseases,Drug: Dexmedetomidine|Drug: Normal saline group,Capital Medical University,Phase 4,60,Other,"August 10, 2020","December 12, 2020","December 21, 2020"
1992,NCT04494659,A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib,Healthy Adult Subjects,Drug: Famitinib capsule|Drug: Rifampicin capsule,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,21,Industry,"July 20, 2020","August 13, 2020","August 31, 2020"
1993,NCT04494646,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Covid19,Drug: Bardoxolone Methyl|Drug: Placebo,"NYU Langone Health|Reata Pharmaceuticals, Inc.",Phase 2,40,Other|Industry,"September 8, 2020","January 8, 2021","January 8, 2021"
1994,NCT04494243,"A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole",Gastroesophageal Reflux Disease,Drug: AD-214 10/600mg|Drug: Rabeprazole 10mg,Addpharma Inc.,Phase 1,40,Industry,"August 28, 2020","January 15, 2021","January 15, 2021"
1995,NCT04493931,Drug-drug Interaction Study of Gepotidacin,"Infections, Bacterial",Drug: Gepotidacin|Drug: Cimetidine|Drug: Rifampicin|Drug: Midazolam|Drug: Digoxin|Other: Placebo matching to gepotidacin,GlaxoSmithKline,Phase 1,64,Industry,"August 14, 2020","December 21, 2020","December 21, 2020"
1996,NCT04493463,Effects of Methylprednisolone Plus Ropivacaine Infiltration Before Wound Closure on Laminoplasty or Laminectomy,Postoperative Pain|Neurosurgery,Drug: Methylprednisolone 40 mg + Ropivacaine + Saline|Drug: Ropivacaine + Saline,Beijing Tiantan Hospital,Phase 4,132,Other,"July 31, 2020","April 6, 2021","May 6, 2021"
1997,NCT04493255,A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants,Healthy Volunteers,Drug: [14C]E7090,Eisai Limited|Eisai Inc.,Phase 1,8,Industry,"September 9, 2020","October 21, 2020","October 21, 2020"
1998,NCT04492878,Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment,Dry Eye|Dry Eye Syndromes|Severe Keratitis,Drug: IKERVIS®1mg/mL,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|Santen Oy,Phase 4,25,Other|Industry,"February 4, 2020","January 18, 2021","January 18, 2021"
1999,NCT04492709,A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects,Cardiovascular Disease,Drug: Midazolam|Drug: AZD5718,AstraZeneca|Parexel,Phase 1,14,Industry,"July 30, 2020","October 19, 2020","October 19, 2020"
2000,NCT04492475,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),COVID-19,Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3,969,NIH,"August 5, 2020","December 21, 2020","December 21, 2020"
2001,NCT04492280,Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults,Septic Shock,Drug: Hydrocortisone,Ain Shams University,Phase 4,66,Other,"September 1, 2018","September 1, 2019","September 1, 2019"
2002,NCT04491994,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Covid19|Progression,Drug: HCQ,"UNICEF|Pak Emirates Military Hospital Rawalpindi, Pakistan",Phase 3,540,Other,"April 10, 2020","May 31, 2020","May 31, 2020"
2003,NCT04491838,Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants,Healthy Volunteer,Drug: Pozelimab,Regeneron Pharmaceuticals,Phase 1,40,Industry,"August 3, 2020","March 5, 2021","March 5, 2021"
2004,NCT04491474,Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Methods at Treatment of Acute Migraine Attack in the Emergency Department,Migraine Disorders,Drug: Lidocaine Hydrochloride|Drug: Placebo,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Phase 4,128,Other,"August 15, 2020","March 14, 2021","March 14, 2021"
2005,NCT04490499,A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013),Hepatitis B,Biological: HBVAXPRO™,Merck Sharp & Dohme LLC,Phase 3,207,Industry,"September 2, 2020","December 29, 2020","December 29, 2020"
2006,NCT04489797,A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants,Infectious Disease,Drug: Acalabrutinib|Drug: Rabeprazole,AstraZeneca|Acerta Pharma BV,Phase 1,35,Industry,"July 20, 2020","August 28, 2020","August 28, 2020"
2007,NCT04489511,Study of STG-001 in Subjects With Stargardt Disease,Stargardt Disease-1,Drug: STG-001,"Stargazer Pharmaceuticals, Inc.",Phase 2,10,Industry,"October 1, 2020","April 24, 2021","April 24, 2021"
2008,NCT04488939,Restylane® Skinboosters™ Vital in the décolletage Region,Decolletage Rejuvenation,Device: Restylane® Skinboosters™ Vital (SBV),Erevna Innovations Inc.,Phase 4,33,Other,"March 6, 2020","December 30, 2020","December 31, 2020"
2009,NCT04488029,"PCT for Speech, Language, and Cognitive Intervention in Stroke Patients","Aphasia, Acquired",Other: PCT|Other: Workbooks,The Learning Corp,Phase 2,36,Industry,"March 18, 2019","February 20, 2020","February 20, 2020"
2010,NCT04488016,"A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects",Bioavailability|B-cell Lymphoid Cancer,Drug: Treatment A- Part 1|Drug: Treatment B- Part 1|Drug: Treatment C - Part 1|Drug: Treatment D- Part 1|Drug: Treatment A-Part 2|Drug: Treatment B - Part 2|Drug: Treatment C - Part 2|Drug: Treatment D - Part 2,"AstraZeneca|Acerta Pharma, LLC",Phase 1,54,Industry|Other,"June 24, 2020","January 20, 2021","January 20, 2021"
2011,NCT04487834,Effects of Multilac Baby on Crying Behavior of Colicky Babies,Infantile Colic,Drug: Simethicone Solution|Dietary Supplement: Multilac Baby,The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz,Phase 2,87,Other,"April 16, 2020","June 30, 2020","June 30, 2020"
2012,NCT04487574,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,SARS-CoV-2 Infection,Drug: XC221|Drug: Placebo,RSV Therapeutics LLC,Phase 3,118,Industry,"July 25, 2020","October 29, 2020","October 29, 2020"
2013,NCT04487431,A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B),Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,Drug: BAY1817080|Drug: [14C]BAY1817080,Bayer,Phase 1,14,Industry,"August 5, 2020","September 30, 2020","February 11, 2021"
2014,NCT04486508,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Covid19,Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo,"Rajaie Cardiovascular Medical and Research Center|Brigham and Women's Hospital|Tehran Heart Center|Masih Daneshvari Hospital|Hazrat Rasool Hospital|Modarres Hospital|Firuzgar hospital affiliated to Iran University of Medical Sciences|Imam Khomeini Hospital|Sina Hospital, Iran|Tabriz University of Medical Sciences|Shariati Hospital|Imam Ali Hospital|Labbafinejhad Hospital",Phase 3,600,Other,"July 30, 2020","April 4, 2021","July 5, 2021"
2015,NCT04486430,Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset,Stroke|Cerebral Infarction,Drug: Neu2000KWL|Drug: Placebos,"Beijing Tiantan Hospital|Zhejiang Apeloa Jiayuan Pharmaceutical Co. Ltd.|Subei People's Hospital of Jiangsu Province|The First Hospital of Jilin University|First Hospital of China Medical University|General Hospital of Shenyang Military Region|The First Affiliated Hospital of BaoTou Medical College|Xuanwu Hospital, Beijing|Peking University First Hospital|Peking University Third Hospital|Tianjin First Central Hospital|Tianjin Huanhu Hospital|Hebei Medical University Third Hospital|The Second Hospital of Hebei Medical University|Hebei General Hospital|Second Hospital of Shanxi Medical University|Shandong Provincial Hospital|Qilu Hospital of Shandong University|The First Affiliated Hospital of Soochow University|Nanjing PLA General Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Minhang Central Hospital|First Affiliated Hospital of Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Wenzhou Medical University|Xiangya Hospital of Central South University|Guangzhou First People's Hospital|Second Affiliated Hospital of Guangzhou Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Nanfang Hospital of Southern Medical University|First Affiliated Hospital of Jinan University|Tongji Hospital|The Central Hospital of Lishui City|Shanghai Pudong New Area People's Hospital|Inner Mongolia Baogang Hospital|Daqing Oil Field Hospital",Phase 2,236,Other,"March 2, 2017","June 12, 2019","December 13, 2019"
2016,NCT04486313,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,COVID-19,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,Romark Laboratories L.C.,Phase 3,1092,Industry,"August 13, 2020","February 8, 2021","February 8, 2021"
2017,NCT04486157,Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects,Healthy,Drug: IN-A012|Drug: Akynzeo 300Mg-0.5Mg Capsule,HK inno.N Corporation,Phase 1,44,Industry,"March 18, 2021","April 26, 2021","May 10, 2021"
2018,NCT04485702,Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine,Healthy Volunteers,Drug: Midazolam injection|Drug: Ketamine Injectable Product|Drug: MELT-100,Melt Pharmaceuticals|Worldwide Clinical Trials,Phase 1,17,Industry|Other,"July 20, 2020","August 29, 2020","August 29, 2020"
2019,NCT04485585,A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.,Benign Prostatic Hyperplasia (BPH)|Overactive Bladder,Drug: BR9006-1|Drug: BR9006-2,"Boryung Pharmaceutical Co., Ltd",Phase 1,36,Industry,"July 20, 2020","August 16, 2020","August 26, 2020"
2020,NCT04484792,Green Tea Mouthwash on Generalized Plaque- Induced Gingivitis,Plaque Induced Gingivitis,Other: green tea mouthwash|Other: placebo,Taibah University,Phase 3,45,Other,"November 27, 2018","March 27, 2020","April 20, 2020"
2021,NCT04484493,Corticosteroid Nasal Spray in COVID-19 Anosmia,Covid19|Anosmia,Drug: mometasone furoate nasal spray,Benha University,Phase 3,100,Other,"August 8, 2020","October 25, 2020","November 3, 2020"
2022,NCT04483375,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Coronavirus Disease 2019(COVID-19),Biological: SCTA01|Other: Placebo,Sinocelltech Ltd.,Phase 1,33,Industry,"July 24, 2020","November 17, 2020","November 17, 2020"
2023,NCT04483037,Different Dosing Time of Bowklean for the Bowel Preparation,Bowel Preparation,Drug: Bowklean,Changhua Christian Hospital,Phase 4,297,Other,"January 1, 2019","December 31, 2020","December 31, 2020"
2024,NCT04483024,Effects of Chicken Extract and Collagen on Mobility,Knee Osteoarthritis|Muscle Loss,Dietary Supplement: Collagen hydrolysate and chicken extract,Shan May Yong|Chang Gung Memorial Hospital|Cerebos Pacific Limited,Phase 1,160,Industry|Other,"December 1, 2018","October 31, 2019","December 1, 2019"
2025,NCT04482725,Injection Site Pain Comparison of Excipient Solutions,Obesity,Other: Trial product 1|Other: Trial product 2|Other: Trial product 3|Other: Trial product 4|Other: Trial product 5|Other: Trial product 6|Other: Trial product 7|Other: Trial product 8|Other: Trial product 9|Other: Trial product 10|Other: Trial product 12,Novo Nordisk A/S,Phase 1,108,Industry,"July 20, 2020","September 24, 2020","September 25, 2020"
2026,NCT04482569,"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin",Bacterial Infections,Drug: XNW4107,Evopoint Biosciences Inc.,Phase 1,88,Industry,"July 10, 2020","February 28, 2021","September 30, 2021"
2027,NCT04482270,A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function,Hepatic Impairment|Healthy Volunteers,Drug: fezolinetant,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,26,Industry,"September 2, 2020","March 22, 2021","March 22, 2021"
2028,NCT04482192,Continuous Paravertebral Block by Intraoperative Direct Access Versus Systemic Analgesia for Postthoracotomy Pain Relief,Post Thoracotomy Pain,Combination Product: Thoracic paravertebral block|Drug: Systemic analgesia,Zagazig University,Phase 3,63,Other,"June 15, 2015","January 31, 2020","March 31, 2020"
2029,NCT04481685,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",Covid19,Drug: ATI-450|Drug: Placebo,University of Kansas Medical Center,Phase 2,20,Other,"July 20, 2020","February 25, 2021","June 1, 2021"
2030,NCT04480697,"Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects",Healthy,Drug: HPG1860,"Hepagene (Shanghai) Co., Ltd.",Phase 1,56,Industry,"September 23, 2019","November 25, 2020","August 7, 2021"
2031,NCT04480281,Intravenous Lidocaine in Open Lung Resection Surgery,"Lidocaine|Pain, Postoperative",Drug: Lidocaine Iv|Drug: Normal Saline,Saint-Joseph University,Phase 4,60,Other,"January 10, 2020","May 15, 2020","May 15, 2020"
2032,NCT04479891,Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects,Healthy Subjects,Drug: pyrotinib tablet|Drug: Itraconazole capsule,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"September 18, 2019","October 11, 2019","November 30, 2019"
2033,NCT04479800,Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers,Healthy Volunteer,Drug: ASTX660,"Astex Pharmaceuticals, Inc.",Phase 1,21,Industry,"July 20, 2020","August 25, 2020","August 25, 2020"
2034,NCT04479644,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198",COVID-19,Drug: BRII-198|Drug: Placebo,Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD,Phase 1,17,Industry,"July 13, 2020","February 3, 2021","February 3, 2021"
2035,NCT04479631,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196",COVID-19,Drug: BRII-196|Drug: Placebo,Brii Biosciences Limited|TSB Therapeutics (Beijing) CO.LTD,Phase 1,16,Industry,"July 12, 2020","January 29, 2021","January 29, 2021"
2036,NCT04479449,Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA,Ischemic Stroke,Drug: SP-8203|Drug: Placebo,Shin Poong Pharmaceutical Co. Ltd.,Phase 2,178,Industry,"March 18, 2019","October 19, 2020","December 18, 2020"
2037,NCT04479202,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Berberine|COVID-19,Drug: Berberine|Drug: Montmorrillonite,Chinese Medical Association,Phase 4,76,Other,"February 8, 2020","April 18, 2020","April 23, 2020"
2038,NCT04478513,A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers,Healthy Volunteer/DDI Study,Drug: AZD4635|Drug: Fluvoxamine,AstraZeneca|Parexel,Phase 1,28,Industry,"July 21, 2020","December 23, 2020","December 23, 2020"
2039,NCT04478448,"Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)",Healthy,Drug: Flupirava|Drug: Avigan,"Genuine Research Center, Egypt|European Egyptian Pharmaceutical Industries",Phase 1,26,Industry,"August 13, 2020","August 20, 2020","August 26, 2020"
2040,NCT04478357,"BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG",Neurogenic Detrusor Overactivity,Drug: 4 mg Fesoterodine ER tablet from Zwickau|Drug: 4 mg fesoterodine ER tablet from Freiburg|Drug: 8 mg fesoterodine ER tablet from Zwickau|Drug: 8 mg fesoterodine ER tablet from Freiburg,Pfizer,Phase 1,18,Industry,"November 12, 2019","November 12, 2020","November 12, 2020"
2041,NCT04477096,Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine,Healthy Subjects,Drug: HS-10234|Drug: Emtricitabine,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1,36,Industry,"August 3, 2020","September 24, 2020","September 24, 2020"
2042,NCT04476966,"Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)",Healthy,Drug: Bladogra|Drug: Myrbetriq (first dosing)|Drug: Myrbetriq (second dosing),"Genuine Research Center, Egypt|Multi-Apex Pharma",Phase 1,29,Industry,"January 20, 2020","March 2, 2020","May 11, 2020"
2043,NCT04476407,Pharmacokinetics of Benapenem in Subjects With Renal Impairment,Complicated Urinary Tract Infection; Cuti,Drug: benapenem,Sihuan Pharmaceutical Holdings Group Ltd.,Phase 1,18,Industry,"June 15, 2019","October 21, 2019","October 21, 2019"
2044,NCT04475588,Efficacy and Safety of Itolizumab in COVID-19 Complications,Acute Respiratory Distress Syndrome|Cytokine Release Syndrome|Covid19,Drug: Itolizumab IV infusion|Drug: Best supportive care (BSC),Biocon Limited,Phase 2,32,Industry,"May 1, 2020","July 7, 2020","July 7, 2020"
2045,NCT04475107,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,COVID-19,Drug: Pyronaridine-Artesunate|Drug: Placebo,Shin Poong Pharmaceutical Co. Ltd.,Phase 2,113,Industry,"July 9, 2020","March 25, 2021","April 15, 2021"
2046,NCT04474327,Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants,Neonatal Sepsis,Drug: Montelukast Sodium,Mansoura University Children Hospital,Phase 1,40,Other,"July 24, 2020","February 10, 2021","February 10, 2021"
2047,NCT04473417,Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects,Healthy,Drug: Forxiga|Drug: DA-2811,"Dong-A ST Co., Ltd.",Phase 1,60,Industry,"August 4, 2020","August 26, 2020","October 12, 2020"
2048,NCT04473274,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Coronavirus Infection|Diabetes,Drug: Pioglitazone,Samaritan Health Services,Phase 4,10,Other,"May 21, 2020","November 1, 2020","December 1, 2020"
2049,NCT04472832,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants",Healthy Volunteers,Drug: Placebo for Treatment A|Drug: Mitapivat 100 mg|Drug: Placebo for Treatment B|Drug: Mitapivat 300 mg|Drug: Placebo for Treatment C,"Agios Pharmaceuticals, Inc.",Phase 1,32,Industry,"June 17, 2020","November 23, 2020","November 23, 2020"
2050,NCT04472650,Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults,Tumor,Drug: Sitravatinib,BeiGene,Phase 1,26,Industry,"July 23, 2020","November 9, 2020","November 9, 2020"
2051,NCT04472481,Vitamin D Effect in Rheumatoid Arthritis.,Active Rheumatoid Arthritis,Drug: Ergocalciferol 1.25 mg tablet,Tanta University,Phase 4,20,Other,"September 6, 2019","December 22, 2019","March 22, 2020"
2052,NCT04471337,"Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function",Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,Drug: BAY1817080,Bayer,Phase 1,32,Industry,"August 12, 2020","February 15, 2021","May 6, 2021"
2053,NCT04471298,A Study of Qishenyiqi Dripping Pills in Healthy Participants,Healthy Participants,"Drug: Qishenyiqi dripping pills, 6 bags|Drug: Qishenyiqi dripping pills, 9 bags|Drug: Qishenyiqi dripping pills, 12 bags|Drug: Qishenyiqi dripping pills placebo, 6 bags|Drug: Qishenyiqi dripping pills placebo, 9 bags|Drug: Qishenyiqi dripping pills placebo, 12 bags","Tasly Pharmaceutical Group Co., Ltd",Phase 1,36,Industry,"September 21, 2020","January 11, 2021","January 11, 2021"
2054,NCT04470908,The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males,Healthy|Male,Drug: Zanubrutinib|Drug: Rifabutin,BeiGene,Phase 1,13,Industry,"August 24, 2020","November 11, 2020","November 11, 2020"
2055,NCT04470843,Impact of Acetazolamide in Reducing Referred Postoperative Pain,Prostate Cancer|Men,Drug: Acetazolamide|Other: Placebo,Medical College of Wisconsin,Phase 1,33,Other,"August 22, 2018","March 31, 2021","March 31, 2021"
2056,NCT04470778,Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants,Healthy Participants,Drug: BMS-986256|Drug: Famotidine,Bristol-Myers Squibb,Phase 1,35,Industry,"July 20, 2020","March 21, 2021","March 28, 2021"
2057,NCT04470401,The Treatment of Shoulder Pain in Hemiplegic Spastic Patients With Botulinum Toxin A,Shoulder Pain,Drug: AbobotulinumtoxinA|Drug: Saline,Faculdade de Ciências Médicas da Santa Casa de São Paulo,Phase 4,24,Other,"June 5, 2019","September 5, 2020","March 5, 2021"
2058,NCT04470128,A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Colonoscopy,Analgesia,Drug: Stage I: HSK21542 0.5 μg/kg|Drug: Stage I: HSK21542 1 μg/kg|Drug: HSK21542 0.5 μg/kg|Drug: HSK21542 1 μg/kg|Drug: HSK21542 2 μg/kg|Drug: Placebo,"Haisco Pharmaceutical Group Co., Ltd.",Phase 2,180,Industry,"August 19, 2020","December 28, 2020","January 30, 2021"
2059,NCT04469998,Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction,Posterior Blepharitis|Meibomian Gland Dysfunction,Drug: AXR-270 Low Dose|Drug: AXR-270 High Dose|Drug: AXR-270 Vehicle,"AxeroVision, Inc.",Phase 2,129,Industry,"June 16, 2020","December 1, 2020","December 31, 2020"
2060,NCT04469621,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Corona Virus Infection,Drug: SAR443122|Drug: Placebo,Sanofi,Phase 1,68,Industry,"July 17, 2020","October 23, 2020","October 23, 2020"
2061,NCT04469114,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,Covid19,Drug: Tofacitinib 10 mg|Drug: Placebo,Hospital Israelita Albert Einstein|Pfizer,Phase 3,289,Other|Industry,"September 16, 2020","January 9, 2021","January 9, 2021"
2062,NCT04468958,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",COVID-19|SARS-CoV2,Biological: SAB-185|Other: Normal saline,"SAb Biotherapeutics, Inc.|Department of Health and Human Services|JPEO, Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)",Phase 1,28,Industry|U.S. Fed|Other,"July 1, 2020","December 23, 2020","December 23, 2020"
2063,NCT04468815,"A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)",Healthy Participants,Drug: BMS-986278 Tablet|Drug: Esomeprazole|Drug: BMS-986278 suspension,Bristol-Myers Squibb,Phase 1,24,Industry,"July 10, 2020","October 7, 2020","October 7, 2020"
2064,NCT04468685,Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy,Cholecystitis,Drug: Ondansetron|Drug: Normal saline,National Hepatology & Tropical Medicine Research Institute,Phase 2,50,Other,"July 15, 2020","December 18, 2020","December 18, 2020"
2065,NCT04468425,Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study,Healthy Subjects,Drug: Tofacitinib Citrate,"TWi Biotechnology, Inc.",Phase 1,14,Industry,"October 14, 2020","December 21, 2020","December 21, 2020"
2066,NCT04468009,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,SARS-Associated Coronavirus|Covid19|SARS-CoV Infection,Biological: Convalescent plasma,Hospital de Infecciosas Francisco Javier Muniz,Phase 2,134,Other,"June 25, 2020","January 19, 2021","June 19, 2021"
2067,NCT04467892,Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia,Ventilator Associated Pneumonia,Drug: methylprednisolone|Drug: Methyl Prednisolonate|Device: ventilators,King Abdul Aziz Specialist Hospital,Phase 2,240,Other,"January 2, 2018","February 14, 2020","February 25, 2020"
2068,NCT04467697,Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men,"Hypogonadism, Male",Drug: SOV2012-F1,Marius Pharmaceuticals|Syneos Health,Phase 3,173,Industry|Other,"September 18, 2018","May 1, 2020","May 1, 2020"
2069,NCT04467424,Recovery After Total Intravenous Anesthesia With Ketofol Versus Mixture of Ketofol and Lidocaine for Short Pediatric Surgery,"Surgical Procedure, Unspecified","Drug: ketamine, propofol|Drug: ketamine, propofol, lidocaine",University Hospital of Split,Phase 2,200,Other,"June 20, 2020","November 20, 2020","December 18, 2020"
2070,NCT04467203,Evaluate the Effects of Food on the Pharmacokinetics of Fadanafil in Healthy Subjects,Healthy,Drug: Fadanafil,Sihuan Pharmaceutical Holdings Group Ltd.,Phase 1,14,Industry,"April 28, 2019","May 14, 2019","June 28, 2019"
2071,NCT04466514,A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029,Healthy Volunteers,Drug: ASTX029,"Astex Pharmaceuticals, Inc.",Phase 1,18,Industry,"July 23, 2020","October 1, 2020","October 6, 2020"
2072,NCT04466176,A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers,Bioequivalence,Drug: Test Product|Drug: Reference Product,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,34,Industry,"July 1, 2020","August 4, 2020","December 31, 2020"
2073,NCT04465877,"Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2",Drug: JTT-662|Drug: Placebo,Akros Pharma Inc.,Phase 1,37,Industry,"June 15, 2020","February 17, 2021","February 17, 2021"
2074,NCT04465864,"Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert","Glaucoma, Primary Open Angle|Cataract","Drug: Intracanalicular Dexamethasone, 0.4 mg insert",Wolstan and Goldberg Eye Associates,Phase 4,40,Other,"February 10, 2020","December 31, 2020","January 31, 2021"
2075,NCT04465266,A Phase 1 PK Study of Tolperisone in Healthy Subjects,Healthy,Drug: Tolperisone,"Neurana Pharmaceuticals, Inc.",Phase 1,27,Industry,"July 28, 2020","August 21, 2020","September 1, 2021"
2076,NCT04465162,Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma,Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extranodal Marginal Zone Lymphoma,Other: Radiation Therapy,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,75,Other|NIH,"June 7, 2000","March 15, 2021","March 15, 2021"
2077,NCT04464681,Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects,Healthy Volunteers,Drug: M201-A Injection|Drug: Placebo,Kitasato University|Aetas Pharma Co. Ltd.,Phase 1,18,Other|Industry,"March 30, 2020","November 28, 2020","November 30, 2020"
2078,NCT04464395,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,COVID-19,Drug: CPI-006|Other: Standard of Care,"Corvus Pharmaceuticals, Inc.",Phase 1,30,Industry,"July 1, 2020","March 1, 2021","July 9, 2021"
2079,NCT04464239,"A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants",Healthy Volunteers,Drug: TS-142|Drug: TS-142 Placebo,Taisho Pharmaceutical R&D Inc.,Phase 1,28,Industry,"September 14, 2020","January 21, 2021","January 21, 2021"
2080,NCT04463602,Desidustat in the Management of COVID-19 Patients,COVID-19,Drug: Desidustat|Other: Standard of Care,Zydus Lifesciences Limited,Phase 2,24,Industry,"July 25, 2020","January 25, 2021","March 31, 2021"
2081,NCT04463017,Ascending Dose Study of HU6 in Healthy Volunteers,NASH - Nonalcoholic Steatohepatitis,Drug: HU6,"Rivus Pharmaceuticals, Inc.",Phase 1,64,Industry,"August 12, 2020","March 30, 2021","April 1, 2021"
2082,NCT04463004,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,COVID-19|Sars-CoV2|Pneumonia,Drug: Mavrilimumab|Drug: Placebos,"Virginia Commonwealth University|Kiniksa Pharmaceuticals, Ltd.",Phase 2,2,Other|Industry,"September 2, 2020","November 30, 2020","November 30, 2020"
2083,NCT04462822,A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers,Bioequivalence,Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|Drug: ADVAIR DISKUS® 250/50,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,14,Industry,"August 24, 2020","September 9, 2020","December 31, 2020"
2084,NCT04461483,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants",Healthy Volunteer,Drug: TAK-935|Drug: Placebo,Takeda,Phase 1,33,Industry,"August 13, 2020","November 14, 2020","November 14, 2020"
2085,NCT04461353,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",Severe Acute Respiratory Syndrome Coronavirus 2,Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo,"Pulmoquine Therapeutics, Inc|Rockefeller University",Phase 1,12,Industry|Other,"June 25, 2020","August 17, 2020","August 17, 2020"
2086,NCT04461119,"Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia",Schizophrenia,Drug: Evenamide|Drug: Placebo,Newron Pharmaceuticals SPA,Phase 2,138,Industry,"June 16, 2020","February 20, 2021","March 13, 2021"
2087,NCT04460027,W-SUDs for COVID-19,Substance Use Disorders|Alcohol Use Disorder,Other: Woebot Substance Use Disorder,Woebot Health|Stanford University|National Institute on Drug Abuse (NIDA),Phase 1,180,Industry|Other|NIH,"June 22, 2020","November 30, 2020","November 30, 2020"
2088,NCT04459767,"Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides",Healthy,Drug: Vupanorsen|Drug: Placebo,Pfizer,Phase 1,12,Industry,"August 6, 2020","December 15, 2020","December 15, 2020"
2089,NCT04459598,A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants,Healthy Subjects|Drug-drug Interaction|Pharmacokinetics|Quizartinib,Drug: Efavirenz|Drug: Quizartinib,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.",Phase 1,32,Industry,"August 19, 2020","October 14, 2020","October 14, 2020"
2090,NCT04459325,Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,COVID-19|Coronavirus Disease 2019,Biological: Tigerase® and best available care|Other: Best available care,AO GENERIUM,Phase 3,100,Industry,"June 1, 2020","July 20, 2020","July 20, 2020"
2091,NCT04458805,"Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers",Ulcerative Colitis,Drug: NX-13 250 mg|Drug: Placebo,Landos Biopharma Inc.,Phase 1,56,Industry,"July 10, 2020","October 21, 2020","October 21, 2020"
2092,NCT04458636,Stratified TreAtment to Reduce Risk in COPD,COPD Exacerbation,Drug: Prednisolone,"University of Oxford|National Institute for Health Research, United Kingdom",Phase 4,203,Other,"November 2, 2017","February 28, 2020","April 30, 2020"
2093,NCT04457986,Plane Block vs Intravenous Patient Controlled Analgesia,Lumbar Disc Herniation,Drug: Erector spina plane block (ESP)|Drug: Modified thoracolumbar interfacial plane block (MTI)|Drug: Intravenous patient controlled analgesia (IV-PCA),Diskapi Teaching and Research Hospital,Phase 4,81,Other,"July 1, 2020","September 1, 2020","October 1, 2020"
2094,NCT04457648,Manuka Honey Eye Drops VS Conventional Treatment of Meibomian Gland Dysfunction Related Dry Eye Disease,Meibomian Gland Dysfunction,Device: manuka honey 16% eye drops ( Optimel )|Device: systane eye drops,Chinese University of Hong Kong,Phase 4,59,Other,"June 1, 2018","June 1, 2020","June 1, 2020"
2095,NCT04457050,Effect of Hepatitis C Clearance on Insulin Resistance,Insulin Resistance|Hepatitis C,Drug: Sofosbuvir 400 milligram|Drug: Daclatasvir 60 milligram|Drug: Ribavirin 400 milligram|Drug: Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab,Alexandria University,Phase 4,160,Other,"October 30, 2017","November 1, 2019","December 30, 2019"
2096,NCT04456686,Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis,Osteoarthritis,Drug: LY3016859|Drug: Placebo,Eli Lilly and Company,Phase 2,117,Industry,"July 1, 2020","April 22, 2021","August 26, 2021"
2097,NCT04456634,"Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine",Malaria,Drug: 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Other: 20 mg/120 mg artemether-lumefantrine (AL) + Placebo,Medicines for Malaria Venture|Southern Star Research Pty Ltd.|Nucleus Network Ltd,Phase 1,8,Other|Industry,"September 10, 2020","November 17, 2020","November 17, 2020"
2098,NCT04456452,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,COVID-19,Biological: Ampion|Other: Standard of Care,Ampio Pharmaceuticals. Inc.,Phase 1,10,Industry,"July 27, 2020","September 8, 2020","November 30, 2020"
2099,NCT04456153,Atovaquone for Treatment of COVID-19,COVID-19,Drug: Experimental Group|Drug: Placebo Group,University of Texas Southwestern Medical Center,Phase 2,60,Other,"July 22, 2020","January 31, 2021","January 31, 2021"
2100,NCT04455100,A Phase I Study of SHR1459 in Healthy Subjects,"Health, Subjective",Drug: SHR1459/Itraconazole,"Jiangsu HengRui Medicine Co., Ltd.|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",Phase 1,20,Industry|Other,"July 17, 2020","August 14, 2020","August 14, 2020"
2101,NCT04454918,"Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants",Healthy Volunteers,Drug: TAK-906 Oral Capsule|Drug: [14C]-TAK-906 Intravenous Infusion|Drug: [14C]-TAK-906 Oral Solution,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,6,Industry,"July 30, 2020","September 30, 2020","September 30, 2020"
2102,NCT04454879,Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients,Renal Anemia,Drug: Roxadustat,Peking University First Hospital|Beijing Haidian Hospital|Beijing Hospital of Traditional Chinese Medicine,Phase 4,100,Other,"July 1, 2020","April 3, 2021","August 3, 2021"
2103,NCT04454619,Pre-surgical Antisepsis Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate,Antisepsis,Drug: Hand antisepsis with Clorhexidine and solution,Centro Ortopedico y Quirurgico del Pie,Phase 4,24,Other,"July 12, 2020","July 18, 2020","August 15, 2020"
2104,NCT04454281,Topical Naloxone to Diagnose Ocular Pain,Dry Eye Syndromes|Neuropathic Pain,Drug: Naloxone Hydrochloride 0.4 MG/ML,Seema Capoor|University of Kentucky,Phase 1,1,Other,"October 1, 2020","December 3, 2020","December 3, 2020"
2105,NCT04453852,Monovalent Recombinant COVID19 Vaccine,Coronavirus Infection|COVID,Biological: COVID19 vaccine|Biological: Saline,Vaxine Pty Ltd|Central Adelaide Local Health Network Incorporated,Phase 1,40,Industry|Other,"June 30, 2020","February 1, 2021","April 14, 2021"
2106,NCT04453735,MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study,Statin Adverse Reaction,Drug: Atorvastatin mylan 40 Mg Oral Tablet,Vestre Viken Hospital Trust|The Hospital of Vestfold|Oslo University Hospital,Phase 4,27,Other,"August 19, 2020","December 18, 2020","December 18, 2020"
2107,NCT04453202,A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults,Healthy,Biological: RSV Vaccine|Other: Placebo,Janssen Vaccines & Prevention B.V.,Phase 2,459,Industry,"July 16, 2020","September 24, 2020","April 9, 2021"
2108,NCT04453189,A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants,Healthy Participants,Drug: JNJ-64417184|Drug: Lansoprazole|Drug: Famotidine,"Janssen Research & Development, LLC",Phase 1,14,Industry,"July 20, 2020","September 14, 2020","September 14, 2020"
2109,NCT04453124,An Accessible Low-cost Plant Treatment for Cutaneous Ulcers,Yaws; Cutaneous|Cutaneous Ulcer|Yaws,Biological: Topical antiseptic treatment,"Oriol Mitja|The University of Papua New Guinea|The Royal Botanic Gardens, Kew|Lihir Medical Centre",Phase 2,150,Other,"November 1, 2019","November 22, 2019","November 25, 2019"
2110,NCT04452838,Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer,Neurogenic Detrusor Overactivity,"Drug: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|Drug: Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|Drug: Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|Drug: Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|Drug: Fesoterodine BIC SR4 fed (Treatment E in Part B)",Pfizer,Phase 1,37,Industry,"June 26, 2020","January 4, 2021","January 4, 2021"
2111,NCT04452435,Safety and Efficacy of C21 in Subjects With COVID-19,COVID-19,Drug: C21|Drug: Placebo,Vicore Pharma AB|Orphan Reach,Phase 2,206,Industry|Other,"July 21, 2020","October 13, 2020","October 13, 2020"
2112,NCT04451811,A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers,Healthy,Drug: OPL-002,Oppilan Pharma Ltd|Celerion,Phase 1,12,Industry,"September 7, 2020","February 24, 2021","February 24, 2021"
2113,NCT04451434,Study of Danicopan in Participants of Japanese Descent,Healthy,Drug: Danicopan,Alexion,Phase 1,9,Industry,"August 17, 2020","September 28, 2020","September 28, 2020"
2114,NCT04451330,A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV),Acne Vulgaris,Drug: Trifarotene cream|Drug: Doxycycline hyclate|Drug: Trifarotene Vehicle|Drug: Doxycycline Placebo,Galderma R&D,Phase 4,202,Industry,"July 29, 2020","April 26, 2021","April 26, 2021"
2115,NCT04451083,Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects,Healthy Volunteers,Drug: FOY-305,Ono Pharmaceutical Co. Ltd,Phase 1,14,Industry,"July 1, 2020","August 17, 2020","August 17, 2020"
2116,NCT04450849,Regenerative Potential of a Collagen Membrane Associated or Not to Bovine Bone in Class II Furcation Defects.,Periodontal Diseases|Bone Diseases,Procedure: guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Procedure: guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.,University of Sao Paulo,Phase 4,22,Other,"January 10, 2018","June 15, 2019","January 20, 2020"
2117,NCT04450420,Tunnel Construction Course Pilot Assessment of Simulation-based Training Effectiveness,Cataract,Other: Simulation based curriculum|Other: Standard training,HelpMeSee Inc.,Phase 2,24,Other,"August 28, 2018","August 16, 2019","June 1, 2020"
2118,NCT04450329,A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD),Neovascular Age-related Macular Degeneration,Drug: SB15 (Proposed aflibercept biosimilar)|Drug: Eylea (Aflibercept),"Samsung Bioepis Co., Ltd.",Phase 3,449,Industry,"June 23, 2020","April 15, 2021","March 16, 2022"
2119,NCT04450004,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.",SARS-CoV 2,Biological: Intramuscular Vaccine,Medicago,Phase 1,180,Industry,"July 10, 2020","September 20, 2020","August 30, 2021"
2120,NCT04449952,A Study of Mouth Rinses in Type 1 and Type 2 Diabetic Participants,Gingivits in Diabetics,Other: Listerine Cool Mint|Other: 5% Hydroalcohol Mouth Rinse|Other: Colgate Cavity Protection Toothpaste|Other: Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Device: Concept Curve Winter Series Toothbrush|Device: Listerine Cool Mint Floss,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Phase 4,154,Industry,"December 2, 2019","March 6, 2020","March 6, 2020"
2121,NCT04449939,A Study of Subcutaneous KY1005 in Healthy Volunteers,Immune System Diseases,Drug: KY1005,Kymab Limited,Phase 1,24,Industry,"July 7, 2020","November 30, 2020","November 30, 2020"
2122,NCT04449692,Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes,Type 1 Diabetes|Hypoglycemia,Drug: Dasiglucagon|Other: Carbohydrate (dextrose tablets),Steno Diabetes Center Copenhagen,Phase 2,20,Other,"July 2, 2020","January 4, 2021","January 4, 2021"
2123,NCT04449133,Study of AD128 Versus Placebo in Obstructive Sleep Apnea,Obstructive Sleep Apnea,Drug: AD128|Drug: Placebo,"Istituto Auxologico Italiano|YGHEA, CRO Division of Ecol Studio spa|STM Pharma PRO srl|Apnimed Inc.",Phase 2,20,Other,"July 3, 2020","October 30, 2020","October 31, 2020"
2124,NCT04448964,A Study of JNJ-70033093 in Healthy Participants,Healthy,Drug: JNJ-70033093,"Janssen Research & Development, LLC|Bristol-Myers Squibb",Phase 1,24,Industry,"June 26, 2020","November 14, 2020","November 14, 2020"
2125,NCT04448899,Ivabradine in Patients With Congestive Heart Failure,Congestive Heart Failure,Drug: Ivabradine Oral Tablet|Drug: Blacebo plus standard treatment,Damanhour University,Phase 4,60,Other,"June 1, 2020","February 1, 2021","February 5, 2021"
2126,NCT04448821,A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin,Healthy,Drug: Metformin|Drug: Metformin + Nilotinib,Hyewon Chung|Korea University Guro Hospital,Phase 1,16,Other,"July 23, 2020","September 7, 2020","September 7, 2020"
2127,NCT04448561,"A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",Opioid Use Disorder,Drug: ASP8082|Drug: morphine|Drug: Placebo,"Astellas Pharma Global Development, Inc.|National Institute on Drug Abuse (NIDA)|Astellas Pharma Inc",Phase 1,24,Industry|NIH,"June 30, 2020","September 11, 2020","September 11, 2020"
2128,NCT04447820,Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR,Dyslipidemia,Drug: K-877-ER (Dose A)|Drug: K-877-ER (Dose B)|Drug: K-877-IR,"Kowa Research Institute, Inc.",Phase 2,96,Industry,"June 10, 2020","December 3, 2020","December 3, 2020"
2129,NCT04447534,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,COVID,Drug: Chloroquine or hydroxychloroquine|Drug: zinc,Tanta University,Phase 3,191,Other,"June 23, 2020","July 15, 2020","August 15, 2020"
2130,NCT04447287,"A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder",Opioid Use Disorder,Drug: ASP8062|Drug: Placebo ASP8062|Drug: buprenorphine/naloxone,"Astellas Pharma Global Development, Inc.|National Institute on Drug Abuse (NIDA)|Astellas Pharma Inc",Phase 1,23,Industry|NIH,"June 29, 2020","November 25, 2020","November 25, 2020"
2131,NCT04447261,A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight,Obesity,Drug: BI 1356225|Drug: Placebo,Boehringer Ingelheim,Phase 1,87,Industry,"June 30, 2020","April 25, 2021","April 25, 2021"
2132,NCT04447040,Acetaminophen/Naproxen Sodium Dose Ranging Study,Pain,Drug: Acetaminophen/naproxen sodium Dose A|Drug: Acetaminophen/naproxen sodium Dose B|Drug: Acetaminophen/naproxen sodium Dose C|Drug: Acetaminophen/naproxen sodium Dose D|Drug: Acetaminophen/naproxen sodium Dose E|Drug: Placebo,"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 2,304,Industry,"November 9, 2020","April 9, 2021","May 3, 2021"
2133,NCT04446923,Surgical Hand Antisepsis With Propan-ol-1 60% Per Rubbing and Scrubbing,Skin Diseases|Surgical Site Infection,Drug: Hand antisepsis by scrub,Universidad Complutense de Madrid,Phase 4,24,Other,"June 28, 2020","July 18, 2020","July 20, 2020"
2134,NCT04446572,Application of Lactobacillus Salivarius CECT5713 in Infertility of Unknown Origin,"Abortion, Spontaneous|Abortion in First Trimester|Infertility Unexplained",Biological: Lactobacillus salivarius CECT5713,Universidad Complutense de Madrid|Bisearch Life|Centro de Diagnóstico Médico. Ayuntamiento de Madrid.,Phase 2,58,Other,"October 16, 2018","November 29, 2019","November 29, 2019"
2135,NCT04446377,A Study of LAM-002A for the Prevention of Progression of COVID-19,COVID-19 Disease,Drug: Apilimod Dimesylate Capsule|Other: Placebo,"AI Therapeutics, Inc.|Yale University",Phase 2,142,Industry|Other,"July 15, 2020","March 24, 2021","April 19, 2021"
2136,NCT04446312,Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy,Colonoscopy,Drug: Bowel Prep,Braintree Laboratories,Phase 3,501,Industry,"July 13, 2020","January 7, 2021","February 5, 2021"
2137,NCT04446299,Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy,Colonoscopy,Drug: Bowel Prep,Braintree Laboratories,Phase 3,520,Industry,"July 13, 2020","December 22, 2020","January 22, 2021"
2138,NCT04446104,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Covid-19,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C,"National University Hospital, Singapore",Phase 3,4257,Other,"May 13, 2020","August 31, 2020","August 31, 2020"
2139,NCT04446026,"A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen",Type 2 Diabetes Mellitus,Drug: teneligliptin|Drug: Placebo,Yonsei University,Phase 4,100,Other,"July 8, 2020","December 7, 2020","May 17, 2021"
2140,NCT04445948,Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy,Helicobacter Pylori Infection,Drug: Esomeprazole 40 milligrams Oral Tablet|Drug: Amoxicillin 1000 milligrams tablets|Drug: Clarithromycin 500 milligrams Tablets|Drug: MetroNIDAZOLE 500 milligrams Oral Tablet|Drug: Lactoferrin Bovine sachets 200 milligrams,Alexandria University|University of Alexandria,Phase 4,400,Other,"November 30, 2019","June 21, 2020","June 21, 2020"
2141,NCT04445857,Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine on Spinal Anesthesia in Tramadol-abuse Patients,Analgesia,Drug: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml)|Other: normal saline (NS),Ain Shams University,Phase 4,90,Other,"September 1, 2020","January 31, 2021","January 31, 2021"
2142,NCT04445688,Crossover Trial of AD036 in Obstructive Sleep Apnea,Obstructive Sleep Apnea,Drug: AD036|Drug: Atomoxetine|Drug: Placebo,Apnimed,Phase 2,62,Industry,"July 15, 2020","December 1, 2020","December 1, 2020"
2143,NCT04445272,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,COVID-19,Drug: Tocilizumab,Fundacion SEIMC-GESIDA|Roche Pharma AG|Dynamic Science S.L.,Phase 2,495,Other|Industry,"May 22, 2020","December 23, 2020","December 23, 2020"
2144,NCT04444986,Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions,Bioequivalence,Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT,Kocak Farma|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,30,Industry|Other,"June 5, 2020","June 11, 2020","June 13, 2020"
2145,NCT04443946,Different Anesthesia Maintain Protocol Effect the Outcome of the Patients,Urinary Surgery|General Anesthesia,Drug: Propofol|Drug: 1% Sevoflurane|Drug: 1% Sevoflurane continue|Drug: Sufentanil|Drug: 2% Sevoflurane|Drug: Propofol half,China International Neuroscience Institution,Phase 4,50,Other,"June 25, 2020","August 5, 2020","August 5, 2020"
2146,NCT04443244,Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy,Benign Masseteric Hypertrophy,Drug: Botulinum Toxin Type A Injection (Botulax®) 24Units|Drug: Botulinum Toxin Type A Injection (Botulax®) 48Units|Drug: Botulinum Toxin Type A Injection (Botulax®) 72Units|Drug: Botulinum Toxin Type A Injection (Botulax®) 96Units|Other: Normal Saline,Hugel,Phase 2,80,Industry,"May 27, 2020","November 18, 2020","July 16, 2021"
2147,NCT04442490,A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD),"Depressive Disorder, Major",Drug: SAGE-217|Drug: Placebo,Sage Therapeutics,Phase 3,543,Industry,"May 7, 2020","March 26, 2021","April 21, 2021"
2148,NCT04441996,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,COVID-19,Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care,Emory University,Phase 4,20,Other,"July 17, 2020","March 18, 2021","March 18, 2021"
2149,NCT04441931,A Study of LY3832479 (LY-CoV016) in Healthy Participants,Healthy,Drug: LY3832479|Drug: Placebo,Eli Lilly and Company,Phase 1,26,Industry,"June 19, 2020","October 2, 2020","October 2, 2020"
2150,NCT04441528,Lid Wipes Versus Baby Shampoo in Patients With Seborrehic Blepharitis,Seborrheic Blepharitis,Drug: Lid wipes containing terpinen-4-ol and sodium hyaluronate|Drug: Baby shampoo,Istanbul University - Cerrahpasa (IUC)|Koç University,Phase 4,48,Other,"November 1, 2018","November 1, 2019","November 1, 2019"
2151,NCT04441255,A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants,Healthy Volunteers,Drug: TAK-788,Takeda,Phase 1,14,Industry,"July 1, 2020","August 10, 2020","August 10, 2020"
2152,NCT04440423,Bioavailability of Clotiazepam 5 mg With Regards to Reference Product,Bioequivalence,Drug: Clotiazepam 5 mg Test Product Coated Tablets|Drug: Clotiazepam 5 mg Reference Product Coated Tablets,Laboratorios Andromaco S.A.,Phase 1,26,Industry,"March 11, 2020","March 28, 2020","March 28, 2020"
2153,NCT04439929,"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects",Healthy Participants,Biological: TUR01|Biological: Adalimumab-EU,Turgut İlaçları A.Ş.,Phase 1,168,Industry,"July 17, 2019","January 16, 2020","January 16, 2020"
2154,NCT04439838,A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated,Healthy,Drug: BI 1595043|Drug: Placebo,Boehringer Ingelheim,Phase 1,64,Industry,"August 13, 2020","March 19, 2021","March 19, 2021"
2155,NCT04439825,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Mood,Drug: Botulinum Neurotoxin|Drug: Placebo,DeNova Research,Phase 1,45,Other,"July 20, 2020","September 3, 2020","December 1, 2020"
2156,NCT04439695,Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults,Influenza,Biological: Low dose|Biological: Intermediate dose|Biological: High dose|Biological: Placebo,KBio Inc,Phase 1,120,Industry,"June 25, 2020","February 25, 2021","July 28, 2021"
2157,NCT04439578,Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects,Healthy Subjects,Drug: SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"June 23, 2020","August 17, 2020","January 15, 2021"
2158,NCT04439240,Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W),Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma,Drug: FGFR Inhibitor AZD4547,National Cancer Institute (NCI),Phase 2,52,NIH,"May 31, 2016","June 6, 2019","June 30, 2020"
2159,NCT04438980,Glucocorticoids in COVID-19 (CORTIVID),Covid-19 Pneumonia,Drug: Methylprednisolone|Other: Placebo,Fundacion Miguel Servet|Complejo Hospitalario de Navarra|Hospital Sant Joan Despí Moisès Broggi,Phase 3,72,Other,"May 15, 2020","March 12, 2021","April 9, 2021"
2160,NCT04438057,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,COVID-19,Biological: CCP,Metro Infectious Disease Consultants,Phase 2,103,Other,"August 12, 2020","August 12, 2020","August 12, 2021"
2161,NCT04436562,"Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects",Healthy,Drug: [14C]-Poziotinib,"Spectrum Pharmaceuticals, Inc",Phase 1,8,Industry,"May 29, 2020","July 17, 2020","July 17, 2020"
2162,NCT04435847,Safety and Efficacy of HST 001 in Male Pattern Hair Loss,Male Pattern Hair Loss,Biological: HST 001|Other: Phosphate Buffered Saline,Histogen,Phase 1,36,Industry,"May 26, 2020","November 11, 2020","January 20, 2021"
2163,NCT04435665,NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF),Neurofibromatosis 1|Cutaneous Neurofibroma,Drug: NFX-179 Gel|Drug: Vehicle Gel,"NFlection Therapeutics, Inc.",Phase 2,48,Industry,"August 21, 2020","April 8, 2021","April 14, 2021"
2164,NCT04435522,Maraviroc in Patients With Moderate and Severe COVID-19,COVID,Drug: Maraviroc,Rhode Island Hospital,Phase 1,9,Other,"October 1, 2020","December 31, 2020","December 31, 2020"
2165,NCT04435483,A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers,Pharmacokinetics|Bioavailability,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C,"AstraZeneca|Acerta Pharma, LLC",Phase 1,39,Industry|Other,"May 22, 2020","June 26, 2020","June 26, 2020"
2166,NCT04435184,Crizanlizumab for Treating COVID-19 Vasculopathy,COVID-19,Drug: Crizanlizumab|Other: 0.9% saline,Johns Hopkins University|Novartis|Socar Research SA|Brigham and Women's Hospital,Phase 2,54,Other|Industry,"July 9, 2020","November 28, 2020","January 4, 2021"
2167,NCT04434404,Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy,Breast Cancer,Drug: L-Carnitine 500Mg Oral Tablet,Horus University,Phase 4,83,Other,"September 10, 2018","August 13, 2019","December 10, 2019"
2168,NCT04434300,Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC),Antibiotics|Subcutaneous Injection|Daptomycin,Drug: Daptomycin,"University Hospital, Caen",Phase 1,12,Other,"October 15, 2020","January 15, 2021","November 15, 2021"
2169,NCT04434131,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,COVID-19,Drug: Convalescent Plasma,University of New Mexico,Phase 2,12,Other,"April 28, 2020","July 31, 2020","March 12, 2021"
2170,NCT04433910,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,COVID-19,Drug: Convalesscent Plasma,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,Phase 2,106,Other,"August 30, 2020","January 21, 2021","February 22, 2021"
2171,NCT04432324,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),COVID-19,Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment,"Instituto Grifols, S.A.|Grifols Therapeutics LLC",Phase 2,100,Industry,"June 2, 2020","March 3, 2021","March 3, 2021"
2172,NCT04431687,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)",Type 2 Diabetes Mellitus,"Drug: CKD 501|Drug: D759, D150|Drug: CKD-501, D759, D150",Chong Kun Dang Pharmaceutical,Phase 1,48,Industry,"June 15, 2020","July 24, 2020","October 26, 2020"
2173,NCT04431141,Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin,Type 2 Diabetes Mellitus,Drug: Teneligliptin|Drug: Empagliflozin|Drug: Teneligliptin and Empagliflozin,Handok Inc.,Phase 1,32,Industry,"September 15, 2020","November 16, 2020","January 25, 2021"
2174,NCT04430855,A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms,Hidradenitis Suppurativa (HS),Drug: Upadacitinib|Drug: Placebo,AbbVie,Phase 2,68,Industry,"July 14, 2020","April 22, 2021","January 25, 2022"
2175,NCT04429854,Donated Antibodies Working Against nCoV,COVID-19,Biological: Convalescent Plasma|Drug: Standard of care,Universitaire Ziekenhuizen KU Leuven|Federal Knowledge Centre (KCE),Phase 2,483,Other,"May 2, 2020","April 30, 2021","April 30, 2021"
2176,NCT04429529,"Safety of TY027, a Treatment for COVID-19, in Humans",Coronavirus Disease-2019 (COVID-19),Biological: TY027|Other: 0.9% Saline,Tychan Pte Ltd.,Phase 1,32,Industry,"June 9, 2020","November 19, 2020","January 20, 2021"
2177,NCT04429295,Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand,Pertussis Immunisation|Diphtheria Immunisation|Polio Immunisation|Hepatitis B Immunisation|Haemophilus Influenzae Type B Immunisation|Tetanus Immunisation|Rotavirus Immunisation|Pneumococcal Immunisation,"Biological: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Biological: DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Biological: Inactivated Poliomyelitis Vaccine|Biological: Poliomyelitis Vaccine bivalent types 1 and 3|Biological: Human Rotavirus, live attenuated|Biological: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,460,Industry,"June 28, 2020","February 26, 2021","November 20, 2021"
2178,NCT04428814,Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects,Healthy Subjects,Biological: CT-P43|Biological: EU-approved Stelara|Biological: US-licensed Stelara,Celltrion,Phase 1,271,Industry,"August 3, 2020","February 24, 2021","February 24, 2021"
2179,NCT04428684,COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg,Dysfunctional Uterine Bleeding,Drug: Pepti 3.6 mg,Peptigroupe Inc.,Phase 1,80,Industry,"October 29, 2018","April 1, 2020","June 7, 2020"
2180,NCT04428021,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,COVID-19,Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP),Azienda Ospedaliera Città della Salute e della Scienza di Torino,Phase 2,180,Other,"June 15, 2020","March 31, 2021","October 31, 2021"
2181,NCT04427917,Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants,Healthy,Drug: PF-06835919|Drug: Placebo,Pfizer,Phase 1,8,Industry,"November 24, 2020","March 31, 2021","March 31, 2021"
2182,NCT04426851,A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood,Healthy,Drug: BI 1358894,Boehringer Ingelheim,Phase 1,12,Industry,"July 13, 2020","October 12, 2020","October 12, 2020"
2183,NCT04426708,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers,Type 2 Diabetes Mellitus,Drug: HMS5552,Hua Medicine Limited,Phase 1,25,Industry,"February 18, 2019","July 3, 2020","July 3, 2020"
2184,NCT04426500,Use of Perioperative Pain Blocks In Urological Surgery,"Pain, Postoperative|Nerve Block|Robotic Surgical Procedures",Drug: Bupivacain|Drug: Ultrasound-guided transversus abdominus plane block|Drug: Laparoscopic-guided transversus abdominus plane block,Icahn School of Medicine at Mount Sinai,Phase 3,148,Other,"November 11, 2019","February 13, 2021","February 13, 2021"
2185,NCT04426435,Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer,Breast Cancer,Drug: honey based (HB) syrup,Shiraz University of Medical Sciences|Shahid Beheshti University of Medical Sciences,Phase 2,60,Other,"June 15, 2020","September 25, 2020","October 5, 2020"
2186,NCT04425915,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,COVID,Biological: Convalescent Plasma|Other: Standard of Care,"Institute of Liver and Biliary Sciences, India",Phase 3,400,Other,"June 14, 2020","December 15, 2020","December 15, 2020"
2187,NCT04425902,"Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults",HIV Infections,Drug: GSK3640254 200 mg|Drug: Caffeine 200 mg|Drug: Metoprolol 100 mg|Drug: Montelukast 10 mg|Drug: Flurbiprofen 100 mg|Drug: Omeprazole 40 mg|Drug: Midazolam 5 mg (2.5 mL)|Drug: Digoxin 0.25 mg|Drug: Pravastatin 40 mg,ViiV Healthcare,Phase 1,20,Industry,"December 16, 2020","March 10, 2021","March 10, 2021"
2188,NCT04425538,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,COVID-19,Drug: Infliximab,Tufts Medical Center|National Institutes of Health (NIH),Phase 2,17,Other|NIH,"June 1, 2020","January 22, 2021","January 22, 2021"
2189,NCT04424875,The Effect of Melatonin Application Following Removal of Impacted Third Molar,Impacted Third Molar Tooth,Drug: 3 mg melatonin|Drug: Placebo,Fayoum University,Phase 3,38,Other,"July 1, 2020","March 1, 2021","May 1, 2021"
2190,NCT04424862,Multitarget Therapy for Idiopathic Membranous Nephropathy,Efficacy,"Drug: Prednisone, ciclosporin and mycophenolate mofetil|Drug: Ponticelli Regimen",Beijing Friendship Hospital,Phase 4,82,Other,"June 9, 2020","February 3, 2021","February 3, 2022"
2191,NCT04424381,Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers,Healthy Subjects,Drug: Rivaroxaban 20 MG Oral Tablet [Xarelto]|Drug: Rivaroxaban 20 MG Oral Tablet,The Affiliated Hospital of Qingdao University,Phase 1,72,Other,"June 4, 2019","September 5, 2019","September 20, 2019"
2192,NCT04424264,The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants,HIV-1-infection|Tuberculosis,Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz,"Professor Francois Venter|University of Cape Town|University of Witwatersrand, South Africa",Phase 1,18,Other,"December 5, 2019","October 30, 2020","October 30, 2020"
2193,NCT04424251,Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery,Analgesia,Drug: Experimental: stage I：HSK21542 0.4 μg/kg|Drug: Experimental: stage I：HSK21542 1 μg/kg|Drug: Experimental: stage I：HSK21542 0.5μg/kg|Drug: Experimental: stage I：HSK21542 1μg/kg|Drug: Experimental: stage II：HSK21542 0.5μg/kg|Drug: Experimental: stage II：HSK21542 1μg/kg|Drug: Placebo,"Haisco Pharmaceutical Group Co., Ltd.",Phase 2,120,Industry,"February 2, 2020","January 5, 2021","April 28, 2021"
2194,NCT04423744,Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants,Cough|Endometriosis|Overactive Bladder,Drug: BAY1817080|Drug: Moxifloxacin|Drug: Placebo,Bayer,Phase 1,42,Industry,"June 18, 2020","November 9, 2020","January 21, 2021"
2195,NCT04423666,Findings of a Health-coached Technology Based Walking Program in Unpaid Caregivers of Persons With Dementia,Dementia,Behavioral: Walking using a wireless pedometer,Boston College,Phase 1,32,Other,"April 1, 2018","October 1, 2019","October 1, 2019"
2196,NCT04423601,Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects,Healthy Subjects,Drug: SHR6390 tablet|Drug: Itraconazole capsule,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"June 10, 2020","July 29, 2020","February 2, 2021"
2197,NCT04422496,"The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects",Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis,Drug: HEC96719,"Sunshine Lake Pharma Co., Ltd.",Phase 1,73,Industry,"August 10, 2020","February 23, 2021","February 23, 2021"
2198,NCT04422028,Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product,Bioequivalence,Drug: Desogestrel 0.075 MG,Laboratorios Andromaco S.A.,Phase 1,30,Industry,"January 11, 2020","January 11, 2020","January 28, 2020"
2199,NCT04421911,A Study to Assess Efficacy and Safety of the Ketoprofen vs Diclofenac,Osteoarthritis,Drug: Ketoprofen topical|Drug: Diclofenac Topical,Handok Inc.,Phase 3,236,Industry,"March 20, 2020","September 1, 2020","September 1, 2020"
2200,NCT04421885,Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects,Healthy Volunteers,Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test,Spero Therapeutics,Phase 1,36,Industry,"June 1, 2020","July 11, 2020","July 29, 2020"
2201,NCT04421404,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,COVID-19|Sars-CoV2,Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo,"Priscilla Hsue, MD|Blood Systems Research Institute|San Francisco General Hospital|University of California, San Francisco",Phase 2,34,Other,"June 9, 2020","April 30, 2021","April 30, 2021"
2202,NCT04421027,A Study of Baricitinib (LY3009104) in Participants With COVID-19,COVID-19,Drug: Baricitinib|Drug: Placebo,Eli Lilly and Company,Phase 3,1525,Industry,"June 12, 2020","February 12, 2021","June 10, 2021"
2203,NCT04420741,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,COVID-19|Respiratory Failure,Drug: Iloprost|Drug: Isotonic saline,"Pär Johansson|Rigshospitalet, Denmark",Phase 2,80,Other,"June 15, 2020","February 23, 2021","April 23, 2021"
2204,NCT04420247,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,COVID|COVID-19|SARS-CoV 2|Coronavirus|Corona Virus Infection,Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,Phase 3,142,Other,"April 16, 2020","August 20, 2020","September 3, 2020"
2205,NCT04419636,Binding of Lu AG06466 in the Brain in Healthy Men,Healthy,Drug: Lu AG06466,H. Lundbeck A/S,Phase 1,16,Industry,"May 29, 2020","February 9, 2021","February 16, 2021"
2206,NCT04419623,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood Cancer,Drug: TL-895,"Telios Pharma, Inc.",Phase 1,7,Industry,"July 9, 2020","September 22, 2020","December 15, 2020"
2207,NCT04418986,Incisional Correction of Corneal Astigmatism During Phacoemulsification,Astigmatism,Procedure: opposite clear corneal incisions (OCCI),Al-Rasheed University College|Baghdad Medical City,Phase 4,40,Other,"July 1, 2019","September 30, 2019","September 30, 2019"
2208,NCT04418388,Pharmacokinetics and Safety of PBK-1801 After Single Oral Administration in Healthy Korean Women,Healthy Volunteer,Drug: PBK-1801,"Pharmbio Korea Co., Ltd.",Phase 1,36,Industry,"October 24, 2019","December 3, 2019","December 23, 2019"
2209,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,Indonesia University,Phase 2,60,Other,"January 15, 2018","May 20, 2019","September 5, 2019"
2210,NCT04417543,Effect of Memantine on Cognitive Impairment in Patients With Epilepsy,Epilepsy,Drug: Memantine Hydrochloride|Drug: Placebo,Assiut University,Phase 1,100,Other,"October 1, 2018","October 1, 2019","January 15, 2020"
2211,NCT04416126,"Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects",Ornithine Transcarbamylase Deficiency,Biological: ARCT-810|Other: Placebo,"Arcturus Therapeutics, Inc.",Phase 1,30,Industry,"June 1, 2020","December 9, 2020","December 9, 2020"
2212,NCT04415749,NasoShield in Healthy Adults to Study Safety and Immunogenicity,Healthy Volunteers,Biological: NasoShield|Other: Placebo,"Altimmune, Inc.|Biomedical Advanced Research and Development Authority",Phase 1,42,Industry|U.S. Fed,"June 15, 2020","March 3, 2021","March 3, 2021"
2213,NCT04415645,"Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects",Healthy Adult Male,Drug: [14C]-VVZ-149,"Vivozon, Inc.",Phase 1,6,Industry,"February 24, 2020","March 6, 2020","March 31, 2020"
2214,NCT04414618,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,Coronavirus Infections,Drug: Opaganib|Drug: Placebo,RedHill Biopharma Limited,Phase 2,42,Industry,"July 2, 2020","November 26, 2020","December 23, 2020"
2215,NCT04414267,Bacillus Calmette-guérin Vaccination to Prevent COVID-19,COVID-19|Virus Diseases|Corona Virus Infection|Coronary Heart Disease|Chronic Obstructive Pulmonary Disease,Biological: BCG vaccine|Biological: Placebo,Hellenic Institute for the Study of Sepsis,Phase 4,301,Other,"May 26, 2020","April 28, 2021","May 7, 2021"
2216,NCT04414241,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,SARS-CoV-2,Drug: Hydroxychloroquine,Universidad Peruana Cayetano Heredia,Phase 3,68,Other,"June 25, 2020","November 23, 2020","November 23, 2020"
2217,NCT04413578,CGM - Reimagine Primary Care,"Diabetes Mellitus, Type 2",Device: Dexcom G6|Device: Contour NextOne,"Intermountain Health Care, Inc.",Phase 4,101,Other,"December 1, 2018","November 28, 2019","December 31, 2019"
2218,NCT04413552,INDV-2000 First in Human,Opioid Dependence,Drug: INDV-2000|Drug: Placebo,Indivior Inc.|National Institute on Drug Abuse (NIDA),Phase 1,73,Industry|NIH,"July 6, 2020","April 13, 2021","April 13, 2021"
2219,NCT04412668,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,SARS-CoV-2 (COVID-19) Severe Pneumonia,Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo,"aTyr Pharma, Inc.",Phase 2,32,Industry,"June 12, 2020","December 21, 2020","December 21, 2020"
2220,NCT04412057,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,COVID-19 Pneumonia|Acute Lung Injury|ARDS,Drug: CERC-002|Drug: Placebo,"Aevi Genomic Medicine, LLC, a Cerecor company|Avalo Therapeutics, Inc.",Phase 2,88,Industry,"July 17, 2020","December 14, 2020","January 19, 2021"
2221,NCT04412018,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,COVID-19|Inflammatory Response,Drug: Icosapent ethyl,"Canadian Medical and Surgical Knowledge Translation Research Group|Amarin Corporation|HLS Therapeutics, Inc",Phase 2,100,Other,"June 4, 2020","November 6, 2020","December 12, 2020"
2222,NCT04411953,Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions,Bioequivalence,"Drug: Haloperidol Tablets, Mylan Pharmaceuticals Inc.|Drug: Haloperidol Tablets, Cycle Pharmaceuticals Ltd",Cycle Pharmaceuticals Ltd.|FARMOVS Clinical Research Organisation,Phase 1,32,Industry|Other,"November 15, 2019","December 19, 2019","December 19, 2019"
2223,NCT04411940,Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions,Bioequivalence,"Drug: Haloperidol Tablets, Mylan Pharmaceuticals Inc.|Drug: Haloperidol Tablets, Cycle Pharmaceuticals Ltd",Cycle Pharmaceuticals Ltd.|FARMOVS Clinical Research Organisation,Phase 1,32,Industry|Other,"November 15, 2019","December 18, 2019","December 18, 2019"
2224,NCT04411680,Study of Sargramostim in Patients With COVID-19,COVID-19|SARS-CoV-2,Drug: Sargramostim|Drug: Standard of care,"Partner Therapeutics, Inc.|United States Department of Defense",Phase 2,123,Industry|U.S. Fed,"August 18, 2020","March 2, 2021","May 19, 2021"
2225,NCT04411667,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Sars-CoV2,Drug: Octagam,"George Sakoulas, MD|Octapharma|Sharp HealthCare",Phase 4,34,Other|Industry,"April 28, 2020","June 23, 2020","June 23, 2020"
2226,NCT04411628,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,COVID-19,Drug: LY3819253|Drug: Placebo,Eli Lilly and Company|AbCellera Biologics Inc.,Phase 1,26,Industry,"May 28, 2020","August 26, 2020","August 26, 2020"
2227,NCT04411069,Simplified Algorithm for the Prevention of Postoperative Nausea and Vomiting in an Oncological Hospital,Postoperative Nausea|Postoperative Vomiting,Drug: Droperidol,Instituto do Cancer do Estado de São Paulo,Phase 2,270,Other,"February 20, 2019","March 20, 2020","March 20, 2021"
2228,NCT04411030,A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam,Healthy Volunteer,Drug: ASTX660|Drug: Midazolam|Drug: Itraconazole,"Astex Pharmaceuticals, Inc.",Phase 1,36,Industry,"May 20, 2020","August 23, 2020","August 29, 2020"
2229,NCT04410809,"Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46",Healthy,Biological: TA-46|Other: Placebo,Pfizer,Phase 1,78,Industry,"January 19, 2018","November 27, 2019","November 27, 2019"
2230,NCT04410159,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,COVID-19,Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water,Universiti Sains Islam Malaysia|Universiti Kebangsaan Malaysia Medical Centre,Phase 2,20,Other,"June 22, 2020","June 29, 2020","July 6, 2020"
2231,NCT04410094,A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants,Healthy,Drug: Lazertinib|Drug: Itraconazole|Drug: Rifampin,"Janssen Research & Development, LLC",Phase 1,32,Industry,"September 14, 2020","December 30, 2020","February 2, 2021"
2232,NCT04410081,A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants,Healthy,Drug: 14C-lazertinib,"Janssen Research & Development, LLC",Phase 1,8,Industry,"July 14, 2020","March 2, 2021","March 2, 2021"
2233,NCT04409925,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),COVID-19 Infection,Drug: rhDNase I,McGill University Health Centre/Research Institute of the McGill University Health Centre|Hamilton Health Sciences Corporation|Hoffmann-La Roche|Exactis Innovation,Phase 1,15,Other|Industry,"December 25, 2020","April 1, 2021","August 1, 2021"
2234,NCT04409587,Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump,Type1 Diabetes Mellitus,Drug: Aspart,Mountain Diabetes and Endocrine Center|Novo Nordisk A/S,Phase 4,59,Other|Industry,"April 12, 2018","May 16, 2020","November 1, 2020"
2235,NCT04409509,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Coronavirus Disease 2019 (COVID-19),"Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",CSL Behring,Phase 2,124,Industry,"July 1, 2020","January 12, 2021","January 12, 2021"
2236,NCT04409262,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,Hoffmann-La Roche|Gilead Sciences,Phase 3,649,Industry,"June 16, 2020","February 1, 2021","March 8, 2021"
2237,NCT04409041,Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia,Lichen Planopilaris|Frontal Fibrosing Alopecia,Drug: Low-Dose Naltrexone,Washington University School of Medicine,Phase 2,43,Other,"September 1, 2019","December 31, 2020","December 31, 2020"
2238,NCT04408937,The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.,Liver Disease,Drug: triopifexor|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 1,89,Industry,"May 29, 2020","November 4, 2020","November 4, 2020"
2239,NCT04408456,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,CoVID-19,Drug: HCQ|Other: Standard therapy,Postgraduate Institute of Medical Education and Research,Phase 3,325,Other,"March 1, 2020","July 31, 2020","July 31, 2020"
2240,NCT04407507,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",COVID-19,Drug: Ivermectin|Drug: Placebo,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,Phase 2,66,Other,"July 1, 2020","January 29, 2021","January 29, 2021"
2241,NCT04407377,Effects of Tolperisone on Measures of Drowsiness and Cognitive Function,Healthy,Drug: Tolperisone Hydrochloride|Drug: Cyclobenzaprine Hydrochloride 10 MG|Other: Placebo,"Neurana Pharmaceuticals, Inc.",Phase 1,39,Industry,"June 20, 2020","October 16, 2020","March 31, 2021"
2242,NCT04407286,Vitamin D Testing and Treatment for COVID 19,Covid 19|Vitamin D Deficiency,Dietary Supplement: Vitamin D3,Arizona State University|Southwest College of Naturopathic Medicine,Phase 1,41,Other,"May 19, 2020","August 30, 2020","November 30, 2020"
2243,NCT04407234,A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide,"Overweight|Obesity|Diabetes Mellitus, Type 2",Drug: Tirzepatide|Drug: Acetaminophen,Eli Lilly and Company,Phase 1,36,Industry,"September 15, 2020","January 7, 2021","January 7, 2021"
2244,NCT04407208,Convalescent Plasma Therapy in Patients With COVID-19,Convalescence|Corona Virus Infection|Plaque,Biological: Convalescent plasma,Biofarma|Rumah Sakit Pusat Angkatan Darat Gatot Soebroto|Eijkman Institute for Molecular Biology,Phase 1,10,Other,"May 1, 2020","June 22, 2020","June 22, 2020"
2245,NCT04407182,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Covid-19|Sars-CoV2|Diabete Mellitus|Cardiopathy|Pulmonary Disease|Renal Disease|Liver Diseases,Dietary Supplement: Viusid and Asbrip,Catalysis SL,Phase 2,60,Industry,"May 4, 2020","August 1, 2020","October 1, 2020"
2246,NCT04407130,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,COVID-19 Patients,Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2,72,Other,"June 16, 2020","October 30, 2020","November 20, 2020"
2247,NCT04407091,"A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831",Cardiovascular Disease,Drug: 14C]AZD4831 Oral Solution,AstraZeneca|Quotient Sciences,Phase 1,8,Industry,"June 30, 2020","August 6, 2020","August 6, 2020"
2248,NCT04407000,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions",Bioequivalence,Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan),World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,30,Industry|Other,"June 23, 2020","July 20, 2020","August 8, 2020"
2249,NCT04406896,The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics,Healthy Subjects|Hepatic Impairment,Drug: Selatogrel,Idorsia Pharmaceuticals Ltd.,Phase 1,24,Industry,"July 22, 2020","October 23, 2020","October 23, 2020"
2250,NCT04406883,Effects of Simvastatin in the Prevention of Pain Experienced After Tooth Extraction,Pain,Drug: Extraction + filled with Simvastatin solution impregnated gelatin sponge,"Islamic Azad University, Tehran",Phase 2,40,Other,"April 12, 2019","December 26, 2019","February 29, 2020"
2251,NCT04406415,Oral Nafamostat in Healthy Volunteers,Pharmacokinetics,Drug: Nafamostat Mesilate|Drug: Placebo,Ensysce Biosciences|National Institute on Drug Abuse (NIDA),Phase 1,17,Industry|NIH,"September 21, 2020","November 11, 2020","May 14, 2021"
2252,NCT04406246,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Coronavirus Infection,Drug: Nitazoxanide 500Mg Oral Tablet,Materno-Perinatal Hospital of the State of Mexico|Laboratorios Liomont,Phase 4,150,Other|Industry,"May 21, 2020","December 31, 2020","December 31, 2020"
2253,NCT04406194,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Bioequivalence,Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets,Atabay Kimya Sanayi Ticaret A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,30,Industry|Other,"May 14, 2020","May 22, 2020","June 19, 2020"
2254,NCT04405999,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Increased Risk of SARS-CoV-2 Infection,Drug: Bromhexine Hydrochloride,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Phase 4,50,Other,"May 14, 2020","August 9, 2020","August 31, 2020"
2255,NCT04405791,Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial,Major Depressive Disorder(MDD),Procedure: Active stimulation group Sham stimluation group,Gangnam Severance Hospital,Phase 3,30,Other,"June 12, 2019","March 2, 2021","March 19, 2021"
2256,NCT04405570,"Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","SARS-CoV-2 Infection, COVID-19",Drug: Molnupiravir 200 mg|Drug: Molnupiravir 400 mg|Drug: Molnupiravir 800 mg|Drug: Placebo (PBO),"Ridgeback Biotherapeutics, LP|Merck Sharp & Dohme LLC",Phase 2,204,Industry,"June 19, 2020","February 21, 2021","February 21, 2021"
2257,NCT04405323,Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women,Healthy,Drug: Lu AG06466|Drug: Itraconazole,H. Lundbeck A/S,Phase 1,16,Industry,"May 20, 2020","July 28, 2020","July 28, 2020"
2258,NCT04405310,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,SARS Pneumonia,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),"Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias",Phase 2,42,Other,"May 20, 2020","November 20, 2020","December 10, 2020"
2259,NCT04405245,"Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma",Ocular Hypertension|Primary Open Angle Glaucoma,Drug: Latanoprost ophthalmic solution|Drug: AKB-9778 4%|Drug: Placebo,"EyePoint Pharmaceuticals, Inc.",Phase 2,194,Industry,"June 6, 2020","November 5, 2020","November 5, 2020"
2260,NCT04403724,Sequential and Mixture Injection of Opioids and Hyperbaric Bupivacaine,Bupivacaine Adverse Reaction|Regional Anesthesia Morbidity|Cesarean Section Complications,Drug: Bupivacaine-fentanyl-Morphine.,Assiut University,Phase 4,126,Other,"July 11, 2020","March 17, 2021","March 17, 2021"
2261,NCT04403399,Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]),Parkinson's Disease,Drug: Varenicline|Drug: Placebo,University of Michigan,Phase 2,34,Other,"June 29, 2017","June 26, 2019","June 26, 2019"
2262,NCT04403243,COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19,COVID 19,Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy,Lomonosov Moscow State University Medical Research and Educational Center,Phase 2,70,Other,"May 8, 2020","July 22, 2020","August 23, 2020"
2263,NCT04402970,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),SARS-CoV 2|ARDS,Drug: Dornase Alfa Inhalation Solution,University of Missouri-Columbia,Phase 3,30,Other,"June 19, 2020","December 31, 2020","December 31, 2020"
2264,NCT04402866,TD-0903 for ALI Associated With COVID-19,Acute Lung Injury (ALI) Associated With COVID-19|Lung Inflammation Associated With COVID-19,Drug: TD-0903|Drug: Placebo,Theravance Biopharma,Phase 2,235,Industry,"June 24, 2020","April 21, 2021","April 21, 2021"
2265,NCT04401579,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3,1033,NIH,"May 8, 2020","July 31, 2020","July 31, 2020"
2266,NCT04401345,Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia,Glycopyrrolate|Post-spinal Hypotension|Effect of Drug|Hemodynamic Instability,Drug: Glycopyrrolate 0.2 MG/ML|Drug: Normal saline,Rajesh Deshar|B.P. Koirala Institute of Health Sciences,Phase 4,258,Other,"June 1, 2020","January 31, 2021","January 31, 2021"
2267,NCT04401202,Nigella Sativa in COVID-19,COVID-19|SARS-CoV-2,Dietary Supplement: Nigella sativa oil,King Abdulaziz University,Phase 2,183,Other,"May 21, 2020","December 31, 2020","December 31, 2020"
2268,NCT04401137,The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects,Migraine,Drug: Topiramate,"SK Chemicals Co., Ltd.",Phase 1,42,Industry,"July 1, 2020","October 6, 2020","October 6, 2020"
2269,NCT04400682,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Bioequivalence,Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,Novelfarma Ilaç San. ve Tic. Ltd. Sti.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,30,Industry|Other,"May 28, 2020","June 5, 2020","June 18, 2020"
2270,NCT04400201,A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy,Sedation,Drug: Remimazolam Tosilate|Drug: Propofol,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,330,Industry,"June 15, 2020","October 28, 2020","October 30, 2020"
2271,NCT04400123,A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers,Healthy Adult Subjects,Drug: Famitinib malate,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"May 27, 2020","July 18, 2020","July 18, 2020"
2272,NCT04399980,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,COVID 19|SARS-CoV 2|Pneumonia,Drug: Mavrilimumab|Drug: Placebos,"The Cleveland Clinic|Kiniksa Pharmaceuticals, Ltd.",Phase 2,40,Other|Industry,"May 20, 2020","April 23, 2021","April 23, 2021"
2273,NCT04399356,Niclosamide for Mild to Moderate COVID-19,COVID-19,Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring,Tufts Medical Center,Phase 2,73,Other,"October 1, 2020","April 20, 2021","August 19, 2021"
2274,NCT04399122,Post-operative Pain Control After Photorefractive Keratectomy Comparing Acetaminophen/Codeine vs Acetaminophen/Oxycodone,Post-operative Pain Control,Drug: acetaminophen/codeine vs acetaminophen/oxycodone,59th Medical Wing,Phase 4,200,U.S. Fed,"March 21, 2017","October 28, 2019","October 28, 2019"
2275,NCT04398511,L Brevis for Traumatic Oral Lesions in Orthodontic Patients,Orthodontic Appliance Complication|Oral Mucositis|Bacterium; Agent,Drug: L brevis|Drug: Placebo,Universidade de Passo Fundo|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,Phase 2,20,Other,"January 7, 2019","November 29, 2019","December 13, 2019"
2276,NCT04398225,"A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder",Attention Deficit Hyperactivity Disorder,Drug: Centanafadine,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 1,32,Industry,"June 11, 2020","April 1, 2021","April 1, 2021"
2277,NCT04398108,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,HER2 Positive Metastatic Breast Cancer,Drug: Margetuximab Margetuximab-IV,"Zai Lab (Shanghai) Co., Ltd.|Zai Lab (Hong Kong), Ltd.",Phase 1,16,Industry,"August 25, 2020","April 27, 2021","April 27, 2021"
2278,NCT04398004,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,Hellenic Institute for the Study of Sepsis,Phase 2,90,Other,"May 6, 2020","November 30, 2020","November 30, 2020"
2279,NCT04397757,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,COVID-19,Biological: COVID-19 Convalescent Plasma,University of Pennsylvania,Phase 1,80,Other,"May 13, 2020","February 6, 2021","March 8, 2021"
2280,NCT04397562,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,COVID-19,Drug: Levilimab|Drug: Placebo,Biocad,Phase 3,206,Industry,"April 29, 2020","July 3, 2020","August 3, 2020"
2281,NCT04397445,Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration,Ranitidine Adverse Reaction|Pharmacokinetics|Food-drug Interaction,Drug: Ranitidine|Drug: Placebo|Other: Low nitrite/NDMA meals|Other: High nitrite/NDMA meals,Food and Drug Administration (FDA)|Spaulding Clinical Research LLC,Phase 1,18,U.S. Fed|Other,"June 8, 2020","July 1, 2020","July 1, 2020"
2282,NCT04396639,Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients,Hemophilia A,Biological: Moroctocog-alfa (AF-CC),Pfizer,Phase 4,50,Industry,"January 25, 2020","September 24, 2020","September 24, 2020"
2283,NCT04396561,Evaluation of Unilateral Ultrasound Guided Paravertebral Block as Perioperative Analgesia For Lower Limb-Sparing Surgery In Adult Cancer Patients,Unilateral U/S PVB,Drug: Paravertebral group (group P):,Cairo University,Phase 4,60,Other,"January 20, 2020","June 9, 2020","June 10, 2020"
2284,NCT04396301,Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco,Corneal Endothelial Cell Loss|Mydriasis|Cataract,"Drug: Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).",Cairo University,Phase 3,30,Other,"February 1, 2019","August 30, 2019","September 30, 2019"
2285,NCT04395053,A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers,Healthy Adult Subjects,Drug: SHR1459,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,28,Industry,"June 28, 2020","July 11, 2020","August 1, 2020"
2286,NCT04394845,A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants,Alzheimer Disease,Diagnostic Test: [18F]GTP1,"Genentech, Inc.|Invicro",Phase 1,6,Industry|Other,"August 11, 2020","October 9, 2020","October 9, 2020"
2287,NCT04394377,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Coronavirus Infection,Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d,Brazilian Clinical Research Institute|Hospital Israelita Albert Einstein|Hospital do Coracao|Hospital Sirio-Libanes|Hospital Moinhos de Vento|Hospital Alemão Oswaldo Cruz|Beneficência Portuguesa de São Paulo|Brazilian Research In Intensive Care Network,Phase 4,615,Other,"June 21, 2020","March 26, 2021","May 30, 2021"
2288,NCT04393818,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Mental Health Disorder|Depression|Posttraumatic Stress Disorder|Burnout|Anxiety Disorders,Behavioral: Intervention App,Fundació d'investigació Sanitària de les Illes Balears|Universidad de las Islas Baleares|Hospital Miguel Servet|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Andalusian School of Public Health|Hospital Son Espases,Phase 3,560,Other,"May 5, 2020","August 24, 2020","August 24, 2020"
2289,NCT04393493,The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.,Cardiorenal Syndrome,Drug: Furosemide intravenous solution|Drug: Chlortalidone|Drug: Spironolactone,Hospital Civil de Guadalajara,Phase 2,80,Other,"July 1, 2017","April 1, 2020","April 1, 2020"
2290,NCT04393168,Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function,Lymphedema|Secondary Lymphedema,Combination Product: Lymphatic clearance measurement,"Nicole Lindenblatt|Swiss Federal Institute of Technology|Zurich University of Applied Sciences|University Hospital, Zürich|NanoPass Technologies Ltd|University of Zurich",Phase 1,10,Other|Industry,"May 22, 2020","June 26, 2020","June 26, 2020"
2291,NCT04392830,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers",Healthy,Drug: ALZ002 DS|Drug: Placebo,"AnnJi Pharmaceutical Co., Ltd.",Phase 1,72,Industry,"May 11, 2020","April 28, 2021","June 15, 2021"
2292,NCT04392739,"Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG",Smallpox,Drug: Tpoxx,SIGA Technologies|Biomedical Advanced Research and Development Authority|PPD,Phase 4,34,Industry|U.S. Fed,"July 19, 2019","December 5, 2019","December 5, 2019"
2293,NCT04392531,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,COVID19 Infection,Drug: Cyclosporine|Drug: Standard treatment,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Phase 4,111,Other,"April 16, 2020","March 31, 2021","March 31, 2021"
2294,NCT04392414,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,COVID-19,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",Phase 2,60,Other,"May 1, 2020","July 10, 2020","September 23, 2020"
2295,NCT04392362,A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT),Supra-ventricular Tachycardia,Drug: Adenosine,University of Pretoria,Phase 3,30,Other,"April 1, 2018","December 16, 2020","December 16, 2020"
2296,NCT04392271,A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants,Healthy,Drug: LY3372689|Diagnostic Test: [18F]LSN3316612,Eli Lilly and Company,Phase 1,4,Industry,"August 6, 2020","October 14, 2020","October 14, 2020"
2297,NCT04392219,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Coronavirus,Drug: EIDD-2801|Drug: Placebo,"Ridgeback Biotherapeutics, LP",Phase 1,130,Industry,"April 10, 2020","August 11, 2020","August 11, 2020"
2298,NCT04392102,A Study of Niraparib in Patients With Relapsed Ovarian Cancer,Ovarian Cancer,Drug: ZL-2306(Niraparib）,"Zai Lab (Shanghai) Co., Ltd.|Zai Lab (Hong Kong), Ltd.",Phase 2,15,Industry,"August 4, 2020","April 8, 2021","August 11, 2022"
2299,NCT04391959,Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD),Meibomian Gland Dysfunction,Drug: AZR-MD-001 Active|Drug: AZR-MD-001 Vehicle,Azura Ophthalmics|Avania,Phase 2,31,Industry,"July 17, 2020","January 6, 2021","January 6, 2021"
2300,NCT04391842,Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis,Osteo Arthritis Knee|Arthritis,Combination Product: Sustained Acoustic Device with 1% Diclofenac patch,"ZetrOZ, Inc.",Phase 1,34,Industry,"September 1, 2019","December 31, 2019","December 31, 2019"
2301,NCT04391712,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,COVID-19,Device: MLS Laser|Other: Regular Inpatient Medical Care,Lowell General Hospital,Phase 2,10,Other,"April 30, 2020","May 15, 2020","July 16, 2020"
2302,NCT04391660,"Estimation of the Incidence of Colonization of Peripheral Venous Catheters After Skin Disinfection With 0.5% Sodium Hypochlorite, Preceded or Not by an Application of 70% Ethanol",Skin Disinfection Before Peripheral Venous Catheter Insertion,Drug: 0.5% sodium hypochlorite solution|Drug: 0.5% sodium hypochlorite solution and 70% ethanol,Poitiers University Hospital,Phase 4,240,Other,"June 15, 2020","January 8, 2021","January 8, 2021"
2303,NCT04391179,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection,Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet,University of Michigan,Phase 2,99,Other,"May 31, 2020","February 22, 2021","February 22, 2021"
2304,NCT04391127,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,COVID-19,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,Centenario Hospital Miguel Hidalgo,Phase 3,108,Other,"May 4, 2020","November 6, 2020","November 6, 2020"
2305,NCT04390854,Efficacy of Combined Blood Clot and Platelet Rich Fibrin Scaffolds in Regeneration of Necrotic Immature Permanent Teeth,Pulp Necroses,Biological: Blood clot scaffold|Biological: Blood clot scaffold combined with PRF,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,30,Other,"July 6, 2018","January 20, 2020","August 30, 2020"
2306,NCT04390568,A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body,Healthy,Drug: BI 655130,Boehringer Ingelheim,Phase 1,50,Industry,"May 21, 2020","April 7, 2021","June 4, 2021"
2307,NCT04390334,"A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.",Healthy,Drug: Daridorexant|Drug: Famotidine|Drug: Efavirenz,Idorsia Pharmaceuticals Ltd.,Phase 1,24,Industry,"May 13, 2020","June 26, 2020","June 26, 2020"
2308,NCT04390100,Palatal Wound Healing Evaluation After Application of Platelet Rich Fibrin Versus 0.2% Hyaluronic Acid Dressings,Free Gingival Graft,Drug: hyaluronic acid (Gengiegel 0.2% oral gel )|Other: Platelet rich fibrin|Other: Gel foam,Ain Shams University,Phase 4,30,Other,"February 1, 2019","December 1, 2019","February 1, 2020"
2309,NCT04390022,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Covid-19|Coronavirus Infection|SARS-CoV-2 Infection,Drug: Ivermectin|Drug: Placebo,"Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health",Phase 2,24,Other,"July 31, 2020","September 17, 2020","October 9, 2020"
2310,NCT04389710,Convalescent Plasma for the Treatment of COVID-19,COVID-19,Drug: Convalescent Plasma,Thomas Jefferson University,Phase 2,52,Other,"April 15, 2020","November 3, 2020","December 7, 2020"
2311,NCT04388826,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Respiratory Distress Syndrome, Adult",Drug: Veru-111,Veru Inc.,Phase 2,39,Industry,"June 18, 2020","December 18, 2020","August 13, 2021"
2312,NCT04388527,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,Covid-19,Biological: COVID-19 Convalescent Plasma,University of Pennsylvania,Phase 1,32,Other,"April 30, 2020","January 25, 2021","January 30, 2021"
2313,NCT04388176,Cold Challenge With C21 in RP,Raynaud Phenomenon|Systemic Sclerosis,Drug: C21|Drug: Placebo,"Vicore Pharma AB|SGS Life Sciences, a division of SGS Belgium NV",Phase 2,20,Industry|Other,"January 3, 2020","December 14, 2020","December 14, 2020"
2314,NCT04388111,Intraosseous Morphine in Primary TKA,"Knee Disease|Arthritis Knee|Pain, Acute",Drug: Morphine,The Methodist Hospital Research Institute,Phase 4,48,Other,"May 5, 2020","April 30, 2021","May 31, 2021"
2315,NCT04387981,Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects,Healthy,Drug: [14C]-orvepitant,Nerre Therapeutics Ltd.,Phase 1,6,Industry,"June 1, 2020","June 28, 2020","June 28, 2020"
2316,NCT04387825,Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis,Systemic Sclerosis,Drug: ADSVF application in the right hand,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|National Council of Science and Technology, Mexico",Phase 2,20,Other,"August 13, 2015",May-19,May-20
2317,NCT04387760,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,SARS-CoV 2|COVID-19,Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients,"Royal College of Surgeons in Ireland - Medical University of Bahrain|Ebrahim Khalil Kanoo Community Medical Center|Hereditary blood Disorder Centre - Salmaniya Medical Complex|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali|Jidhafs COVID-19 Centre|Sitra FICU|Salmaniya Medical Complex- 6th Floor|Salmaniya Medical Complex- Helipad",Phase 2,150,Other,"August 11, 2020","March 6, 2021","April 7, 2021"
2318,NCT04387136,Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center,"Pain|Pain, Acute|Anesthesia",Drug: Sublingual Sufentanil,University of Minnesota,Phase 4,53,Other,"October 14, 2020","February 4, 2021","February 4, 2021"
2319,NCT04386876,"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions",Bioequivalence,Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet,World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti,Phase 1,30,Industry|Other,"April 30, 2020","May 22, 2020","June 11, 2020"
2320,NCT04386707,Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine,Poliomyelitis,"Biological: Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Biological: Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Biological: Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Biological: Three doses control wIPV at the schedule of 2,3,4 months of age","Sinovac Biotech Co., Ltd",Phase 3,1300,Industry,"May 11, 2020","May 11, 2020","October 20, 2020"
2321,NCT04386616,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo,"Genentech, Inc.|Biomedical Advanced Research and Development Authority",Phase 2,396,Industry|U.S. Fed,"June 2, 2020","January 8, 2021","February 12, 2021"
2322,NCT04386408,Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections,Immune Response|Respiratory Diseases,Combination Product: Combination of plant extracts (BSL_EP027)|Combination Product: Placebo,Biosearch S.A.,Phase 1,60,Industry,"November 30, 2019","January 31, 2020","January 31, 2020"
2323,NCT04386122,An in Vivo Bioequivalence Study of 2 Loxoprofen Sodium Products in Vietnamese Healthy Male Volunteers,Bioequivalence,Drug: FABALOFEN 60|Drug: JAPROLOX TABLET,"Centre of Clinical Pharmacology, Hanoi Medical University",Phase 1,24,Other,"May 7, 2020","May 17, 2020","May 31, 2020"
2324,NCT04385589,Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure,Heart Failure,Drug: Dapagliflozin|Drug: insulin,Assiut University,Phase 4,100,Other,"May 1, 2020","December 15, 2020","December 20, 2020"
2325,NCT04385420,Phase 1 Study of ATR-002,Influenza,Drug: ATR-002 MEK Inhibitor|Drug: Placebo oral tablet,"Atriva Therapeutics GmbH|SGS Life Sciences, a division of SGS Belgium NV",Phase 1,70,Industry|Other,"April 24, 2019","August 26, 2019","August 26, 2019"
2326,NCT04385199,Convalescent Plasma for Patients With COVID-19,Coronavirus Infection|Coronavirus|COVID,Biological: Convalescent plasma,Henry Ford Health System,Phase 2,30,Other,"May 4, 2020","August 1, 2020","August 1, 2020"
2327,NCT04385095,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,SARS-CoV-2,Drug: SNG001|Drug: Placebo,Synairgen Research Ltd.,Phase 2,221,Industry,"March 16, 2020","February 17, 2021","November 16, 2021"
2328,NCT04384991,HU007 Eye Drops in Patients With Dry Eye Syndrome,Dry Eye Syndromes,Drug: HU007|Drug: Restasis eye drop,"Huons Co., Ltd.",Phase 3,216,Industry,"May 3, 2019","December 5, 2019","December 5, 2019"
2329,NCT04384666,"A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers",Parkinson Disease,Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|Other: Neupro 4 mg / 24 Hr. Transdermal Patch,Luye Pharma Group Ltd.,Phase 1,56,Industry,"June 2, 2020","August 5, 2020","August 10, 2020"
2330,NCT04384523,A Study of OsrHSA in Adult Healthy Male and Female Volunteers,Ascites Hepatic,Drug: OsrHSA 20 mg/kg IV|Drug: OsrHSA 40 mg/kg IV|Drug: OsrHSA 80 mg/kg IV|Drug: OsrHSA 140 mg/kg IV|Drug: OsrHSA 200 mg/kg IV|Other: Placebo,Healthgen Biotechnology Corp.,Phase 1,41,Industry,"November 4, 2019","March 17, 2020","July 13, 2020"
2331,NCT04384081,A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2,Healthy,Drug: BI 456906|Drug: Placebo,Boehringer Ingelheim,Phase 1,37,Industry,"June 1, 2020","November 17, 2020","January 20, 2021"
2332,NCT04382937,Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection,Chronic Hepatitis C Virus Infection,Drug: P1101 + Ribavirin|Drug: PEG-Intron + Ribavirin,PharmaEssentia,Phase 3,222,Industry,"January 12, 2016","July 15, 2020","July 15, 2020"
2333,NCT04382755,Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,COVID-19,Drug: Zilucoplan®|Drug: Placebo,"University Hospital, Ghent|UCB Pharma",Phase 2,81,Other|Industry,"May 22, 2020","December 29, 2020","April 9, 2021"
2334,NCT04382651,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"COVID-19 Pneumonia, Impaired Respiratory Function",Drug: MAS825|Other: Placebo|Drug: Standard of Care (SoC),Novartis Pharmaceuticals|Novartis,Phase 2,140,Industry,"June 11, 2020","January 6, 2021","April 21, 2021"
2335,NCT04382586,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,COVID-19 Pulmonary Complications|COVID-19,Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo,BeiGene,Phase 2,63,Industry,"July 6, 2020","February 1, 2021","February 1, 2021"
2336,NCT04382066,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,COVID-19,Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day,PharmaMar|Apices Soluciones S.L.,Phase 1,46,Industry,"May 12, 2020","November 26, 2020","November 26, 2020"
2337,NCT04382053,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"COVID-19 Pneumonia, Impaired Respiratory Function",Drug: DFV890|Drug: Standard of Care (SoC),Novartis Pharmaceuticals|Novartis,Phase 2,143,Industry,"May 27, 2020","December 10, 2020","December 24, 2020"
2338,NCT04382040,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",COVID-19|Corona Virus Infection|SARS-CoV 2|Coronavirus|Coronavirus Infection,Drug: ArtemiC|Drug: Placebo,MGC Pharmaceuticals d.o.o,Phase 2,50,Industry,"May 8, 2020","November 5, 2020","December 21, 2020"
2339,NCT04381962,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),COVID-19,Drug: Azithromycin Capsule,University of Oxford|Pfizer,Phase 3,298,Other|Industry,"June 3, 2020","January 29, 2021","April 20, 2021"
2340,NCT04381884,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,COVID-19 Drug Treatment,Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes,Phase 2,45,Industry|Other,"May 18, 2020","September 29, 2020","September 29, 2020"
2341,NCT04381858,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin,Centenario Hospital Miguel Hidalgo,Phase 3,196,Other,"May 6, 2020","November 26, 2020","November 26, 2020"
2342,NCT04380961,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Critical Confirmed Coronavirus Disease (COVID)-19,Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC),"Janssen Pharmaceutica N.V., Belgium",Phase 2,212,Industry,"April 24, 2020","April 9, 2021","June 24, 2021"
2343,NCT04380688,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,COVID-19,Drug: Acalabrutinib,AstraZeneca|Acerta Pharma BV,Phase 2,62,Industry,"June 13, 2020","November 16, 2020","November 16, 2020"
2344,NCT04380168,Comparing Effect of Adding Ketamine Versus Dexmedetomidine to Bupivacaine in Pec 11 Modified Block on Postoperative Pain Control in Patients Undergoing Breast Surgery,More Effective Postoperative Analgesia After Modified Radical Mastectomy With Better Drug Combination|More Prolonged Duration of Postoperative Analgesia After Modified Radical Mastectomy With Better Drug Combination,Procedure: Modified pec11 trunk block,Ain Shams University,Phase 3,5,Other,"April 25, 2019","April 1, 2020","April 3, 2020"
2345,NCT04380090,Post-Operative Constipation Following Total Knee Arthroplasty,Constipation,Drug: Propylene Glycol|Drug: Docusate Sodium,The Cleveland Clinic,Phase 2,154,Other,"February 21, 2020","July 15, 2020","July 15, 2020"
2346,NCT04379869,"To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers",Healthy Volunteers,Drug: NNZ-2591|Drug: Placebo,Neuren Pharmaceuticals Limited,Phase 1,28,Industry,"May 29, 2020","February 11, 2021","February 11, 2021"
2347,NCT04377711,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,COVID-19,Drug: Ciclesonide|Drug: Placebo,Covis Pharma S.à.r.l.,Phase 3,400,Industry,"June 8, 2020","January 5, 2021","January 5, 2021"
2348,NCT04377698,PRF and Bone Graft in Endodontic Surgeries,Periapical; Infection,Biological: Platelet Rich Fibrin|Biological: FDBA,Saraswati Dental College,Phase 4,20,Other,"January 24, 2018","November 6, 2019","December 9, 2019"
2349,NCT04377399,High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy,Diabetes Type 2|Diabetic Neuropathies|Vitamin D Deficiency,Drug: Vitamin D,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|Tameside Hospital NHS Foundation Trust",Phase 4,68,Other,"January 10, 2018","June 20, 2019","January 25, 2020"
2350,NCT04377308,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,COVID-19|Cytokine Storm,Drug: Fluoxetine,University of Toledo Health Science Campus|University of Toledo,Phase 4,16,Other,"May 1, 2020","April 30, 2021","April 30, 2021"
2351,NCT04376554,Effect of Tebipenem on Normal Human Intestinal Microbiota,Healthy Volunteers,Drug: TBPM-PI-HBr|Drug: amoxicillin-clavulanate,Spero Therapeutics|Iqvia Pty Ltd,Phase 1,30,Industry,"February 10, 2020","April 6, 2021","April 6, 2021"
2352,NCT04375878,OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis,Exocrine Pancreatic Insufficiency (EPI)|Cystic Fibrosis (CF),Drug: MS1819|Drug: Porcine PERT,"First Wave BioPharma, Inc.",Phase 2,27,Industry,"July 20, 2020","April 8, 2021","April 8, 2021"
2353,NCT04375865,Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112,Pain,Drug: AD-2111|Drug: AD-2112,Addpharma Inc.,Phase 1,30,Industry,"May 30, 2020","July 16, 2020","July 16, 2020"
2354,NCT04375787,Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention,Coronary Disease,Drug: Atorvastatin,Mohamed Abdelfatah|Assiut University,Phase 4,200,Other,"March 15, 2020","June 2, 2020","June 2, 2020"
2355,NCT04375098,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Severe Acute Respiratory Syndrome Coronavirus 2,Biological: COVID-19 convalescent plasma,Pontificia Universidad Catolica de Chile|Fundacion Arturo Lopez Perez,Phase 2,58,Other,"May 4, 2020","August 17, 2020","August 17, 2020"
2356,NCT04374981,Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans,Food-drug Interaction,Drug: Celecoxib 100mg|Drug: Montelukast 10mg,Damanhour University,Phase 2,24,Other,"July 1, 2019","November 1, 2019","December 1, 2019"
2357,NCT04374565,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia,Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,University of Virginia,Phase 2,29,Other,"May 5, 2020","March 5, 2021","March 5, 2021"
2358,NCT04374149,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,Cytokine Release Syndrome|COVID19,Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib,Prisma Health-Upstate,Phase 2,20,Other,"April 30, 2020","September 30, 2020","December 1, 2020"
2359,NCT04373707,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,COVID|Thrombosis|Pulmonary Embolism|Deep Vein Thrombosis,Drug: Enoxaparin,"Central Hospital, Nancy, France|Ministry of Health, France|Grand Est Region|University Hospital of Saint-Etienne",Phase 4,1000,Other,"May 13, 2020","April 29, 2021","September 14, 2021"
2360,NCT04372407,"A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects",Healthy,Drug: Surufatinib|Drug: Itraconazole,Hutchison Medipharma Limited|Hutchmed,Phase 1,13,Industry,"July 9, 2020","September 29, 2020","January 19, 2021"
2361,NCT04372394,A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects,Healthy,Drug: surufatinib,Hutchison Medipharma Limited|Hutchmed,Phase 1,28,Industry,"August 14, 2020","October 31, 2020","March 2, 2021"
2362,NCT04372355,Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients,Diabetic Foot Ulcer (DFU)|Uncontrolled Diabetes With Foot Ulcer,Drug: WF10,"Srinakharinwirot University|Oxo Chemie(Thailand) Co.,Ltd.|Altermed Co.,Ltd.",Phase 2,40,Other,"June 19, 2019","April 30, 2020","June 19, 2020"
2363,NCT04372186,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Genentech, Inc.",Phase 3,377,Industry,"May 14, 2020","August 18, 2020","September 22, 2020"
2364,NCT04371965,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",COVID-19,Drug: Povidone-Iodine,Poitiers University Hospital,Phase 2,24,Other,"September 1, 2020","October 23, 2020","October 23, 2020"
2365,NCT04371367,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",COVID,Biological: avdoralimab|Other: Placebo,Assistance Publique Hopitaux De Marseille|Innate Pharma,Phase 2,208,Other|Industry,"April 27, 2020","March 30, 2021","March 30, 2021"
2366,NCT04371185,Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects,Psoriasis,Drug: BAT2206|Drug: Stelara(US-licensed)|Drug: Stelara(EU-licensed),Bio-Thera Solutions,Phase 1,270,Industry,"August 8, 2020","April 19, 2021","April 19, 2021"
2367,NCT04370782,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,"St. Francis Hospital, New York",Phase 4,18,Other,"April 28, 2020","September 30, 2020","September 30, 2020"
2368,NCT04370548,DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE),Bacterial Vaginosis,"Drug: DARE-BV1clindamycin phosphate vaginal gel, 2%","Daré Bioscience, Inc.",Phase 3,307,Industry,"June 16, 2020","November 30, 2020","December 7, 2020"
2369,NCT04370431,A Study of TTYP01 in Healthy Adult Subjects,Healthy Adult Subjects,"Drug: TTYP01 single ascending doses|Drug: Placebo|Drug: TTYP01, 60 mg|Drug: TTYP01, 120 mg|Drug: Radicut® (ampoule), 30 mg|Drug: Radicut® (bag) , 60 mg|Drug: TTYP01, up to 120 mg",Auzone Biological Technology Pty Ltd|TIGERMED AUSTRALIA PTY LIMITED|CMAX Clinical Research Pty Ltd,Phase 1,72,Industry|Other,"April 24, 2020","December 17, 2020","January 8, 2021"
2370,NCT04370379,Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients,Neovascular Age-related Macular Degeneration,Drug: IBI302 (the first dose level)|Drug: IBI302 (the second dose level)|Drug: Aflibercept,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,18,Industry,"May 28, 2020","April 30, 2021","May 8, 2021"
2371,NCT04370262,Multi-site Adaptive Trials for COVID-19,COVID-19,Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo,Northwell Health,Phase 3,233,Other,"April 7, 2020","September 7, 2020","September 7, 2020"
2372,NCT04369586,A Phase I Clinical Trial of Meplazumab in Healthy Volunteer,Healthy Volunteers,Drug: meplazumab for injection|Drug: Placebo,Xijing Hospital,Phase 1,59,Other,"April 25, 2020","August 18, 2020","November 20, 2020"
2373,NCT04369534,Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction,Acute Coronary Syndrome|STEMI|NSTEMI - Non-ST Segment Elevation MI|PLATELET AGGREGATION|INDIVIDUALIZED THERAPY,Drug: Clopidogrel|Drug: Ticagrelor,University of Zagreb|Croatian Science Foundation|Clinical Hospital Centre Zagreb,Phase 4,120,Other,"December 1, 2015","November 30, 2019","December 1, 2019"
2374,NCT04369430,Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment,Parkinson Disease,Drug: AKST4290|Drug: Placebo,"Alkahest, Inc.",Phase 2,110,Industry,"January 16, 2020","February 11, 2021","March 10, 2021"
2375,NCT04369391,A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.,Schizophrenia,Drug: SEP363856 150 mg|Drug: Placebo|Drug: moxifloxacin 400 mg,Sunovion,Phase 1,150,Industry,"June 18, 2020","November 10, 2020","November 10, 2020"
2376,NCT04368650,RhBMP-2 in Intrabony Defects - A Randomized Controlled Trial,Periodontitis,Drug: BMP-2|Procedure: PRF,SVS Institute of Dental Sciences,Phase 2,40,Other,"December 5, 2017","September 20, 2019","October 11, 2019"
2377,NCT04368585,Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects,Healthy Volunteers,Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Drug: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)|Drug: Omeprazole,Spero Therapeutics,Phase 1,20,Industry,"July 1, 2020","August 8, 2020","August 21, 2020"
2378,NCT04368429,"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age",Meningococcal Infection (Healthy Volunteers),"Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",Sanofi,Phase 3,360,Industry,"May 22, 2020","November 7, 2020","November 7, 2020"
2379,NCT04368377,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,"Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis",Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux,"University of Milan|Fondazione ""Un Cuore per Milano"" - a no profit foundation",Phase 2,5,Other,"April 6, 2020","April 23, 2020","April 23, 2020"
2380,NCT04366726,"Study to Evaluate the PK, PD and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density",Postmenopausal Osteoporosis,Combination Product: abaloparatide-sMTS,"Radius Health, Inc.",Phase 1,22,Industry,"April 9, 2019","May 14, 2019","June 21, 2019"
2381,NCT04366648,"Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor",Solid Tumor,Drug: JK-1201I,"JenKem Technology Co., Ltd.",Phase 1,25,Industry,"May 4, 2018","March 31, 2021","March 31, 2021"
2382,NCT04366427,Enriched Oxygen Mixtures in Athletes,Oxidative Stress|Stem Cell Research,Combination Product: L-HBO|Combination Product: HBO|Combination Product: 30% O2|Combination Product: 50% O2,University of Padova|Performa di Crocicchia Srl,Phase 2,42,Other,"September 15, 2020","November 15, 2020","December 31, 2020"
2383,NCT04366349,"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants",Healthy Volunteers|Asthma,Biological: melrilimab (GSK3772847) 70 milligram (mg)|Biological: melrilimab (GSK3772847) 140 milligram (mg)|Other: Placebo,GlaxoSmithKline,Phase 1,65,Industry,"July 21, 2020","December 21, 2020","December 21, 2020"
2384,NCT04365699,Cardiovascular Effects of COVID-19,COVID-19,Drug: AT-001,NYU Langone Health,Phase 2,81,Other,"April 8, 2020","January 31, 2021","January 31, 2021"
2385,NCT04365686,Smooth Extubation With Ketofol for Induction of General Anesthesia in Laparoscopic Drilling of Polycystic Ovary,Smooth Extubation,Drug: Ketofol as induction agent|Drug: Propofol as induction agent,Fayoum University Hospital,Phase 4,106,Other,"April 1, 2019","April 12, 2020","April 20, 2020"
2386,NCT04365452,The Invia Motion at Cesarean Study,Negative Pressure Wound Therapy|Cesarean Section; Infection,Device: Invia Motion,Indiana University|Medela AG,Phase 4,20,Other|Industry,"March 10, 2020","August 31, 2020","December 31, 2020"
2387,NCT04365270,Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer,"Reversible Pulpitis|Pulpitis|Caries,Dental|Caries Class I|Caries; Dentin|Caries",Drug: Glass Ionomer|Drug: Chitosan Low Molecular Weight (20-200 Mpa.S)|Drug: Chlorhexidine Diacetate|Drug: Titanium Dioxide,Ain Shams University,Phase 3,65,Other,"January 15, 2019","January 5, 2021","January 5, 2021"
2388,NCT04365218,"A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease",Chronic Kidney Disease,Drug: MEDI8367|Drug: Placebo,AstraZeneca|Parexel,Phase 1,12,Industry,"July 22, 2020","January 3, 2021","January 3, 2021"
2389,NCT04365153,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),COVID-19|SARS-CoV 2,Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos,The Cleveland Clinic|Novartis,Phase 2,45,Other|Industry,"April 24, 2020","February 2, 2021","April 1, 2021"
2390,NCT04365127,Progesterone for the Treatment of COVID-19 in Hospitalized Men,COVID-19|Sars-CoV2,Drug: Progesterone 100 MG,Sara Ghandehari|IBSA Institut Biochimique SA|Cedars-Sinai Medical Center,Phase 1,40,Other|Industry,"April 27, 2020","August 20, 2020","August 20, 2020"
2391,NCT04364867,Exparel for Total Shoulder Arthroplasty,Total Shoulder Arthroplasty,Drug: Exparel|Drug: Pain Pump,Norton Healthcare,Phase 4,54,Other,"August 12, 2020","February 8, 2021","February 17, 2021"
2392,NCT04364737,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,COVID-19|Coronavirus|Coronavirus Infection,Biological: Convalescent Plasma|Other: Saline solution,"NYU Langone Health|National Center for Advancing Translational Sciences (NCATS)|Albert Einstein College of Medicine|Yale University|The University of Texas Health Science Center, Houston|The University of Texas Health Science Center at Tyler|University of Miami",Phase 2,941,Other|NIH,"April 17, 2020","March 29, 2021","December 12, 2022"
2393,NCT04364399,Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine,Mumps,"Biological: Mumps vaccine|Biological: measles, mumps and rubella combined vaccine, live","Sinovac (Dalian) Vaccine Technology Co., Ltd.",Phase 4,920,Industry,"November 18, 2020","November 18, 2020","April 7, 2021"
2394,NCT04364022,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Prevention of COVID-19,Drug: Lopinavir/ritonavir,"Calmy Alexandra|University Hospital, Geneva",Phase 3,326,Other,"April 23, 2020","March 24, 2021","March 24, 2021"
2395,NCT04363736,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: Tociliuzumab,Hoffmann-La Roche,Phase 2,97,Industry,"May 5, 2020","August 12, 2020","August 12, 2020"
2396,NCT04363346,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,COVID-19,Drug: FT516,"Masonic Cancer Center, University of Minnesota",Phase 1,5,Other,"May 14, 2020","February 18, 2021","February 18, 2021"
2397,NCT04362813,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia,Drug: Canakinumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,454,Industry,"April 30, 2020","September 16, 2020","December 22, 2020"
2398,NCT04362410,Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects,Healthy Subjects,Biological: Experimental: Tezepelumab|Other: Placebo,AstraZeneca|Amgen,Phase 1,48,Industry,"May 18, 2020","October 9, 2020","October 9, 2020"
2399,NCT04362137,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,Cytokine Storm (Covid-19),Drug: Ruxolitinib|Drug: Placebo,Novartis Pharmaceuticals|Incyte Corporation|Novartis,Phase 3,432,Industry,"May 2, 2020","October 17, 2020","October 17, 2020"
2400,NCT04361513,Genicular Nerve Block in Rheuamtoid Arthritis,Pain|Joint Function Disorder|Inflammation,"Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)",Sohag University,Phase 4,64,Other,"April 15, 2020","July 28, 2020","July 28, 2020"
2401,NCT04361474,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Budesonide|Olfaction Disorders|SARS-CoV-2|Anosmia,Drug: Budesonide Nasal|Other: Physiological serum,Fondation Ophtalmologique Adolphe de Rothschild|Hopital Lariboisière,Phase 3,120,Other,"May 18, 2020","November 24, 2020","June 25, 2021"
2402,NCT04361149,Motor Unit Abnormalities After Experimentally Induced Sensitization,Central Sensitisation|Motor Disorders,"Drug: Capsaicin Topical Cream (0.075%)|Device: Delsys Trigno Galileo System|Device: Excaliber, Natus Medical|Other: Placebo Cream",Toronto Rehabilitation Institute,Phase 4,23,Other,"October 1, 2019","December 20, 2019","March 10, 2020"
2403,NCT04361136,Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream,Healthy Volunteers,Drug: Delgocitinib cream|Drug: Delgocitinib cream vehicle,LEO Pharma,Phase 1,35,Industry,"April 23, 2020","May 30, 2020","May 30, 2020"
2404,NCT04360980,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,COVID-19,Drug: Colchicine Tablets,Shahid Beheshti University of Medical Sciences,Phase 2,80,Other,"March 20, 2020","January 1, 2021","January 30, 2021"
2405,NCT04360915,Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects,Locally Advanced or Metastatic NSCLC,Drug: ASK120067|Dietary Supplement: ASK120067 in fed condition,"Jiangsu Aosaikang Pharmaceutical Co., Ltd.",Phase 1,24,Industry,"December 9, 2019","December 30, 2019","December 30, 2019"
2406,NCT04360824,Covid-19 Associated Coagulopathy,COVID 19 Associated Coagulopathy,Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis,University of Iowa,Phase 4,176,Other,"May 6, 2020","April 16, 2021","April 16, 2021"
2407,NCT04360343,"Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects",Ulcerative Colitis,Drug: Film-coated tablet,LG Chem,Phase 1,18,Industry,"July 1, 2020","October 1, 2020","December 1, 2020"
2408,NCT04359810,Plasma Therapy of COVID-19 in Severely Ill Patients,SARS-CoV-2 Infection,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma),"Max O'Donnell|New York Blood Center|Amazon.com, Inc.|Columbia University",Phase 2,223,Other,"April 21, 2020","December 30, 2020","December 30, 2020"
2409,NCT04359290,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"ARDS, Human|COVID",Drug: Ruxolitinib administration,Philipps University Marburg Medical Center,Phase 2,15,Other,"July 1, 2020","December 31, 2020","July 30, 2021"
2410,NCT04358549,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,COVID-19,Drug: Favipiravir|Other: Standard of Care,"Fujifilm Pharmaceuticals U.S.A., Inc.",Phase 2,50,Industry,"April 17, 2020","September 30, 2020","October 30, 2020"
2411,NCT04358523,A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers,Healthy,Drug: ASC18|Drug: ravidasvir and sofosbuvir,"Ascletis Pharmaceuticals Co., Ltd.",Phase 1,50,Industry,"March 20, 2020","December 15, 2020","December 15, 2020"
2412,NCT04358432,A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia,Hypercholesterolemia,Drug: AK102|Drug: Placebos|Drug: Statins and/or Ezetimibe,"Akeso|AD Pharmaceuticals Co., Ltd.",Phase 2,262,Industry,"May 13, 2020","February 25, 2021","February 25, 2021"
2413,NCT04358367,Intravenous Dexmedetomidine in Cesarean Section Under Spinal Anesthesia,Cesarean Section Complications,Drug: Dexmedetomidine Injectable Product|Drug: Saline,Egyptian Biomedical Research Network,Phase 3,70,Other,"May 19, 2019","October 19, 2019","November 19, 2019"
2414,NCT04358081,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Covid-19,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,20,Industry,"May 1, 2020","July 27, 2020","July 27, 2020"
2415,NCT04358016,Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding,"Cirrhosis, Liver|Upper Gastrointestinal Bleeding",Drug: Terlipressin|Drug: Somatostatin,Changhai Hospital,Phase 4,54,Other,"January 1, 2018","January 1, 2020","March 1, 2020"
2416,NCT04357860,Clinical Trial of Sarilumab in Adults With COVID-19,SARS-CoV 2|SARS,Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment,Maimónides Biomedical Research Institute of Córdoba|Consejería de Salud y Familias - Junta de Andalucía|Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID),Phase 2,120,Other,"April 28, 2020","March 9, 2021","April 6, 2021"
2417,NCT04357808,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Covid-19,Drug: Sarilumab|Other: Standar of care,Maria del Rosario Garcia de Vicuña Pinedo|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Phase 2,30,Other,"April 13, 2020","November 30, 2020","December 4, 2020"
2418,NCT04357730,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome,Drug: Alteplase 50 MG [Activase],"Denver Health and Hospital Authority|Genentech, Inc.|University of Colorado, Denver|National Jewish Health|Beth Israel Deaconess Medical Center|Long Island Jewish Medical Center|Scripps Health|St. Mary's Medical Center|University of Miami|Ben Taub Hospital|Methodist Dallas Medical Center",Phase 2,50,Other|Industry,"May 14, 2020","March 21, 2021","September 30, 2021"
2419,NCT04357444,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,COVID 19,Drug: 1: ILT101|Drug: 2: Placebo Comparator,Assistance Publique - Hôpitaux de Paris|Iltoo Pharma,Phase 2,30,Other|Industry,"October 23, 2020","November 2, 2020","April 5, 2021"
2420,NCT04356937,Efficacy of Tocilizumab on Patients With COVID-19,SARS-CoV 2,Drug: Tocilizumab|Drug: Placebos,"Massachusetts General Hospital|Genentech, Inc.",Phase 3,243,Other|Industry,"April 20, 2020","July 13, 2020","August 27, 2020"
2421,NCT04355936,Telmisartan for Treatment of COVID-19 Patients,COVID-19 Drug Treatment,Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,"Laboratorio Elea Phoenix S.A.|Carlos R. Rojo, MD|Facultad de Medicina, Universidad de Buenos Aires, UBA",Phase 4,400,Industry|Other,"May 19, 2020","November 2, 2020","November 30, 2020"
2422,NCT04355845,A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.,Healthy Volunteers,Drug: Sumatriptan|Drug: PF-06651600,Pfizer,Phase 1,10,Industry,"June 15, 2020","August 10, 2020","August 10, 2020"
2423,NCT04355767,Convalescent Plasma in Outpatients With COVID-19,Covid19,Biological: Convalescent Plasma|Biological: Saline,"Stanford University|National Heart, Lung, and Blood Institute (NHLBI)|Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network|University of Pittsburgh|Medical University of South Carolina",Phase 3,511,Other|NIH,"August 11, 2020","March 29, 2021","March 29, 2021"
2424,NCT04355286,Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study,Absorption; Chemicals|Sunscreening Agents,Drug: Bemotrizinol,"DSM Nutritional Products, Inc.|Spaulding Clinical Research LLC",Phase 1,14,Industry|Other,"November 3, 2020","November 6, 2020","November 17, 2020"
2425,NCT04355117,A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients,Migraine,Drug: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,71,Industry,"June 17, 2020","November 11, 2020","November 11, 2020"
2426,NCT04354987,Compare the Pharmacokinetics and Safety of CKD-391,Hyperlipidemias,"Drug: CKD-391 10/10mg|Drug: D090, D337",Chong Kun Dang Pharmaceutical|Seoul National University Bundang Hospital,Phase 1,44,Industry|Other,"October 30, 2019","January 9, 2020","January 9, 2020"
2427,NCT04354870,COVID-19 PrEP HCW HCQ Study,COVID-19,Drug: Hydroxychloroquine (HCQ),NYU Langone Health,Phase 2,130,Other,"April 3, 2020","September 15, 2020","October 1, 2020"
2428,NCT04354831,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,COVID-19,Biological: anti-SARS-CoV-2 convalescent plasma,Medical College of Wisconsin|Froedtert Hospital,Phase 2,131,Other,"May 11, 2020","February 10, 2021","February 10, 2021"
2429,NCT04354480,A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older,Healthy,Biological: RSV Vaccine|Other: Placebo,Janssen Pharmaceutical K.K.,Phase 1,36,Industry,"May 15, 2020","January 20, 2021","January 20, 2021"
2430,NCT04354337,Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention,Juvenile Idiopathic Arthritis,Behavioral: Sleep Innovations for Preschoolers with Arthritis (SIPA),University of Washington|National Institute of Nursing Research (NINR),Phase 1,12,Other|NIH,"May 1, 2020","March 20, 2021","April 22, 2021"
2431,NCT04353596,Stopping ACE-inhibitors in COVID-19,SARS-CoV-2|COVID-19,"Drug: ACE inhibitor, angiotensin receptor blocker",Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK),Phase 4,216,Other,"April 20, 2020","February 16, 2021","February 24, 2021"
2432,NCT04353362,Alternative Antibiotic Regimen in Periodontitis Treatment,Amoxicillin|Metronidazole|Ofloxacin|Periodontitis|Root Planing,Drug: Ofloxacin|Drug: Amoxicillin|Drug: Metronidazole,Istanbul Medipol University Hospital,Phase 4,74,Other,"April 1, 2017","January 2, 2020","March 10, 2020"
2433,NCT04353284,Camostat Mesylate in COVID-19 Outpatients,COVID-19,Drug: Camostat Mesilate|Other: Placebo,Yale University,Phase 2,70,Other,"June 9, 2020","March 3, 2021","April 22, 2021"
2434,NCT04352361,Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects,Healthy,Drug: TVB-2640|Drug: Placebo,"Ascletis Pharmaceuticals Co., Ltd.",Phase 1,34,Industry,"April 2, 2020","April 29, 2020","April 29, 2020"
2435,NCT04352114,A Study of LY3461767 in Healthy Participants,Healthy,Drug: LY3461767 - SC|Drug: LY3461767 - IV|Drug: Placebo - SC,Eli Lilly and Company,Phase 1,48,Industry,"June 15, 2020","January 13, 2021","January 13, 2021"
2436,NCT04351620,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,COVID-19,Drug: Hydroxychloroquine,University of Chicago,Phase 1,12,Other,"April 20, 2020","June 10, 2020","June 10, 2020"
2437,NCT04351243,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),COVID-19,Drug: Gimsilumab|Drug: Placebo,"Kinevant Sciences GmbH|Roivant Sciences, Inc.",Phase 2,227,Industry,"April 15, 2020","December 1, 2020","April 1, 2021"
2438,NCT04351165,BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects,Solid Tumor,Drug: IMP4297,"Impact Therapeutics, Inc.",Phase 1,18,Industry,"October 29, 2020","February 11, 2021","April 30, 2021"
2439,NCT04351126,Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response,Ovarian Hyperstimulation Syndrome,Drug: Fludrocortisone 0.1 Milligrams (mg)|Drug: Bromocriptine,Ganin Fertility Center,Phase 2,107,Other,"April 1, 2019","February 25, 2020","February 29, 2020"
2440,NCT04350905,Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia,Vector Borne Diseases,Other: Mosquito Feeding,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,42,NIH,"October 27, 2020","April 9, 2021","April 9, 2021"
2441,NCT04350736,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19,Drug: TD-0903|Drug: Placebo,Theravance Biopharma,Phase 1,54,Industry,"April 23, 2020","June 24, 2020","July 1, 2020"
2442,NCT04350606,A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia,Aplastic Anemia,Biological: PF-06462700,Pfizer,Phase 3,3,Industry,"July 25, 2020","January 22, 2021","April 19, 2021"
2443,NCT04350593,Dapagliflozin in Respiratory Failure in Patients With COVID-19,COVID-19,Drug: Dapagliflozin 10 milligram (mg)|Drug: Placebo,Saint Luke's Health System|Saint Luke's Hospital of Kansas City|AstraZeneca|George Clinical Pty Ltd,Phase 3,1250,Other|Industry,"April 22, 2020","March 31, 2021","June 11, 2021"
2444,NCT04350580,Polyvalent Immunoglobulin in COVID-19 Related ARds,Acute Respiratory Distress Syndrome|COVID-19,Drug: Human immunoglobulin|Drug: Placebo,Centre Hospitalier St Anne|Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences|Laboratoire français de Fractionnement et de Biotechnologies,Phase 3,146,Other|Industry,"April 11, 2020","November 20, 2020","February 20, 2021"
2445,NCT04350320,Trial to Study the Benefit of Colchicine in Patients With COVID-19,COVID19,Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,Phase 3,102,Other,"April 30, 2020","October 20, 2020","December 30, 2020"
2446,NCT04350281,Double Therapy With IFN-beta 1b and Hydroxychloroquine,COVID,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,The University of Hong Kong,Phase 2,60,Other,"April 9, 2020","July 1, 2020","July 7, 2020"
2447,NCT04349917,Large-scale Brain Organization During Cognitive Control in ADHD,Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate|Other: Placebo,"University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)",Phase 4,37,Other|NIH,"December 16, 2016","March 14, 2020","March 14, 2020"
2448,NCT04349761,"Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects",Undefined,Drug: MyMD1|Drug: Placebo,"MyMD Pharmaceuticals, Inc.",Phase 1,40,Industry,"June 11, 2019","December 30, 2019","December 30, 2019"
2449,NCT04349722,"The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae",Labor Long,Drug: Hyoscine Butylbromide|Other: Placebo,National University of Malaysia,Phase 4,110,Other,"December 1, 2019","June 30, 2020","June 30, 2020"
2450,NCT04349631,A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19,COVID-19,Biological: HB-adMSCs,Hope Biosciences Stem Cell Research Foundation|Hope Biosciences,Phase 2,56,Other|Industry,"April 22, 2020","November 24, 2020","May 1, 2021"
2451,NCT04349553,"Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine",Enteric Fever,Biological: ZH9PA and ZH9|Biological: Placebo|Biological: ZH9PA,Prokarium Ltd|Simbec Research,Phase 1,46,Industry,"December 16, 2019","September 28, 2020","February 15, 2021"
2452,NCT04349306,Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia,Lymphoma,Drug: RASBURICASE SR29142,Sanofi,Phase 4,50,Industry,"May 14, 2020","March 12, 2021","March 12, 2021"
2453,NCT04349241,Efficacy and Safety of Favipiravir in Management of COVID-19,Coronavirus Disease (COVID-19),Drug: favipiravir|Drug: Standard of care therapy,Ain Shams University,Phase 3,100,Other,"April 18, 2020","June 1, 2020","June 20, 2020"
2454,NCT04349098,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Coronavirus Infection,Drug: Selinexor|Other: Placebo,Karyopharm Therapeutics Inc,Phase 2,190,Industry,"April 17, 2020","October 5, 2020","October 5, 2020"
2455,NCT04348812,"Transcranial Direct Current Stimulation (tDCS) Augments the Effects of Gamified, Mobile Attention Bias Modification",Anxiety|Stress,Behavioral: ABMT|Other: Transcranial direct current stimulation,Hunter College of City University of New York|The City College of New York,Phase 1,38,Other,"February 1, 2019","December 15, 2019","December 15, 2019"
2456,NCT04348786,Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori,Helicobacter Pylori Infection,Drug: Doxycycline|Drug: Levofloxacin 500mg,Damascus Hospital,Phase 4,78,Other,"February 1, 2019","August 30, 2020","September 1, 2020"
2457,NCT04348695,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Coronavirus Infection,Drug: Ruxolitinib plus simvastatin|Other: Standard of Care,Fundación de investigación HM|Apices Soluciones S.L.,Phase 2,94,Other|Industry,"April 12, 2020","January 31, 2021","January 31, 2021"
2458,NCT04348500,Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19),COVID-19,Drug: Clazakizumab,Cedars-Sinai Medical Center,Phase 2,17,Other,"April 28, 2020","September 30, 2020","September 30, 2020"
2459,NCT04348305,Hydrocortisone for COVID-19 and Severe Hypoxia,Covid-19|Hypoxia,Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL,"Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital",Phase 3,30,Other,"April 17, 2020","September 10, 2020","September 8, 2021"
2460,NCT04348175,A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment,Renal Insufficiency,Drug: Setmelanotide,"Rhythm Pharmaceuticals, Inc.",Phase 1,32,Industry,"July 9, 2020","April 17, 2021","April 17, 2021"
2461,NCT04347915,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,COVID-19,Drug: Clevudine|Drug: Placebo,Bukwang Pharmaceutical,Phase 2,64,Industry,"May 26, 2020","February 24, 2021","February 26, 2021"
2462,NCT04347902,Lipid Emulsions and Liver Function - Results After 5 Years.,Liver Failure|Parenteral Nutrition-Related Hepatitis,Drug: Intravenous Lipid Emulsion,Stanley Dudrick's Memorial Hospital,Phase 4,65,Other,Jan-16,Mar-20,Apr-20
2463,NCT04347681,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Convalescent Plasma for COVID 19,Other: convalescent plasma from recovered COVID 19 donor,King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital,Phase 2,575,Other,"April 18, 2020","November 1, 2020","November 16, 2020"
2464,NCT04347382,Honey & Nigella Sativa Trial Against COVID-19,Coronavirus Infection|Sars-CoV2,Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos,Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute,Phase 3,313,Other,"April 30, 2020","August 30, 2020","August 30, 2020"
2465,NCT04347252,Glucagon Regulation of Glucose Metabolism,Insulin Secretion,Drug: Glucagon,"David D'Alessio, M.D.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Duke University",Phase 1,19,Other|NIH,"September 24, 2019","April 16, 2021","April 16, 2021"
2466,NCT04347005,The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males,Healthy Volunteers,Drug: Cohort 1: AR882|Drug: Cohort 2: AR882|Drug: Cohort 3: AR882|Drug: Cohort 4: AR882|Drug: Cohort 5: AR882|Drug: Cohort 6: AR882 Food Effect|Drug: Cohort 7: AR882 Solid Oral Formulation|Drug: Cohort 8: AR882 in combination with allopurinol|Drug: Cohort 9: AR882 in combination with febuxostat,Arthrosi Therapeutics,Phase 1,64,Industry,"January 22, 2019","July 31, 2019","July 31, 2019"
2467,NCT04346901,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Melasma|Hyperthyroidism,Drug: Thiamazol,"Dr.dr.Irma Bernadette, SpKK (K)|Indonesia University",Phase 1,23,Other,"August 1, 2019","January 27, 2020","February 15, 2020"
2468,NCT04346693,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation,Burnasyan Federal Medical Biophysical Center,Phase 3,320,Other,"April 8, 2020","November 1, 2020","November 20, 2020"
2469,NCT04346628,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Sars-CoV2|COVID-19,Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment,Stanford University,Phase 2,149,Other,"July 12, 2020","April 16, 2021","April 16, 2021"
2470,NCT04346446,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,COVID,Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma,"Institute of Liver and Biliary Sciences, India",Phase 2,29,Other,"April 20, 2020","May 30, 2020","May 30, 2020"
2471,NCT04346199,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,COVID-19,Drug: Acalabrutinib,AstraZeneca|Acerta Pharma BV,Phase 2,177,Industry,"June 12, 2020","November 17, 2020","November 17, 2020"
2472,NCT04345926,Dose-response Curves Between Propofol and Intraoperative Electroencephalographic Patterns,Propofol Overdose|EEG,Drug: Propofol|Device: Electroencephalogram recording,University of Chile,Phase 4,15,Other,"August 16, 2018","February 26, 2020","February 26, 2020"
2473,NCT04345653,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,Covid19,Drug: Hydroxychloroquine Sulfate (HCQ),Hackensack Meridian Health,Phase 2,48,Other,"April 14, 2020","June 5, 2020","May 10, 2021"
2474,NCT04345523,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,COVID-19,Other: Blood and derivatives.|Drug: Standard of Care,Cristina Avendaño Solá|Instituto de Salud Carlos III|Puerta de Hierro University Hospital,Phase 2,350,Other,"April 3, 2020","February 5, 2021","April 5, 2021"
2475,NCT04345276,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,COVID-19,Drug: Danoprevir+Ritonavir,"Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.",Phase 4,10,Other|Industry,"March 18, 2020","April 15, 2020","April 15, 2020"
2476,NCT04345107,Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug: SY-009|Drug: SY-009 matching placebo,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",Phase 1,50,Industry,"May 1, 2020","April 29, 2021","September 21, 2021"
2477,NCT04344405,Vitamin D as a Key Player in Rheumatoid Arthritis,the Immunomodulatory Effect,Drug: Vitamin D|Drug: Steroid Drug,Assiut University,Phase 3,40,Other,"June 1, 2019","January 1, 2020","June 1, 2021"
2478,NCT04344379,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,Assistance Publique - Hôpitaux de Paris,Phase 3,122,Other,"April 17, 2020","June 18, 2020","June 18, 2020"
2479,NCT04344041,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Coronavirus,"Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","University Hospital, Angers|Mylan Laboratories",Phase 3,260,Other|Industry,"April 15, 2020","January 14, 2021","January 14, 2021"
2480,NCT04343989,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,COVID-19,Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo,NYU Langone Health,Phase 2,178,Other,"March 31, 2020","February 3, 2021","March 12, 2021"
2481,NCT04343768,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B,Shahid Beheshti University of Medical Sciences,Phase 2,60,Other,"April 9, 2020","April 27, 2020","April 27, 2020"
2482,NCT04343729,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia,Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Phase 2,416,Other,"April 18, 2020","June 16, 2020","October 20, 2020"
2483,NCT04343651,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,Coronavirus Disease 2019,Drug: Placebo|Drug: Leronlimab (700mg),"CytoDyn, Inc.",Phase 2,86,Industry,"April 1, 2020","July 21, 2020","September 20, 2021"
2484,NCT04343261,Convalescent Plasma in the Treatment of COVID 19,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|COVID|Coronavirus,Biological: Convalescent Plasma,Saint Francis Care,Phase 2,48,Other,"April 10, 2020","July 23, 2020","August 13, 2020"
2485,NCT04343222,Control of Pain in Intravitreal Injections Using Topical NSAIDs,Intravitreal Injections|IVI,Drug: Bromfenac|Drug: Artificial tears,"University of Wisconsin, Madison",Phase 4,46,Other,"June 27, 2019","December 19, 2019","December 19, 2019"
2486,NCT04343092,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,COVID 19,Drug: Ivermectin (IVM),University of Baghdad,Phase 1,16,Other,"April 18, 2020","May 31, 2020","June 1, 2020"
2487,NCT04342988,Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery,Dry Eye Syndromes,Drug: Cequa,Research Insight LLC,Phase 4,74,Industry,"April 8, 2020","December 31, 2020","December 31, 2020"
2488,NCT04342676,Lymph Node Ratio and Kras Mutation in R Colon Cancer,Colon Cancer Stage III,Device: k ras|Drug: Panitumumab,Mansoura University,Phase 3,433,Other,"March 10, 2017","August 25, 2019","August 26, 2019"
2489,NCT04342663,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",COVID 19|Coronavirus,Drug: Fluvoxamine|Drug: Placebo,Washington University School of Medicine,Phase 2,152,Other,"April 10, 2020","August 20, 2020","December 12, 2020"
2490,NCT04342650,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial,Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Phase 2,152,Other,"April 8, 2020","May 14, 2020","June 8, 2020"
2491,NCT04342273,A Through QT/QTc Study of KW-6356,Parkinson's Disease,Drug: KW-6356|Drug: Placebo|Drug: Moxifloxacin,"Kyowa Kirin Co., Ltd.",Phase 1,128,Industry,"March 31, 2020","September 5, 2020","September 5, 2020"
2492,NCT04341584,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Corona Virus Infection,Drug: Anakinra,Assistance Publique - Hôpitaux de Paris,Phase 2,161,Other,"April 8, 2020","May 10, 2020","July 25, 2020"
2493,NCT04341389,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),COVID-19,Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China|CanSino Biologics Inc.|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Zhongnan Hospital",Phase 2,508,Other|Industry,"April 12, 2020","November 30, 2020","December 31, 2020"
2494,NCT04341090,A Food Effect Study of Apatinib Mesylate in Healthy Subjects,Healthy Subjects,Drug: Apatinib Mesylate,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,42,Industry,"May 13, 2020","July 6, 2020","July 6, 2020"
2495,NCT04340557,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,SARS-CoV Infection,Drug: Losartan,Sharp HealthCare,Phase 4,31,Other,"March 27, 2020","June 13, 2020","June 13, 2020"
2496,NCT04339985,Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD,Atopic Dermatitis,Drug: ATx201|Drug: ATx201 OINTMENT vehicle,UNION therapeutics,Phase 2,220,Industry,"October 22, 2019","October 22, 2020","March 31, 2021"
2497,NCT04339712,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Hellenic Institute for the Study of Sepsis,Phase 2,102,Other,"April 2, 2020","December 1, 2020","January 8, 2021"
2498,NCT04339348,Comparative Safety and Efficacy of Vaginal Misoprostol Versus Lidocaine-prilocaine Cream in Levonorgestrel IUD Insertion,Contraception,Drug: vaginal misoprostol|Drug: Lidocaine-Prilocaine Topical cream|Drug: placebo,Cairo University,Phase 3,210,Other,"April 30, 2020","February 1, 2021","March 1, 2021"
2499,NCT04338984,Nociception-directed Erector Muscle Spinae Plane Block in Open Heart Surgery,Regional Anesthesia|Heart Surgery,Drug: General anesthetic|Drug: Ropivacaine 0.5% Injectable Solution,Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu,Phase 4,86,Other,"December 1, 2019","April 30, 2021","May 31, 2021"
2500,NCT04338867,Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients,Phase II Clinical Trial|Ninety-six Histologically Confirmed NSCLC Patients With BM|Randomized 1:1 to Received TN Plus WBR or Only WBR|ICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI,Radiation: Whole-brain radiotherapy,Instituto Nacional de Cancerologia de Mexico,Phase 2,96,Other,"March 1, 2020","March 1, 2020","March 1, 2020"
2501,NCT04338724,A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors,Advanced Solid Tumor,Drug: CS1002,CStone Pharmaceuticals,Phase 1,6,Industry,"December 27, 2019","September 21, 2020","September 21, 2020"
2502,NCT04338711,A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations,Healthy,Drug: tofacitinib modified release (MR),Pfizer,Phase 1,23,Industry,"June 17, 2020","September 15, 2020","September 15, 2020"
2503,NCT04338698,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",COVID 19,Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin,Shehnoor Azhar|University of Health Sciences Lahore,Phase 3,550,Other,"April 22, 2020","November 15, 2020","November 22, 2020"
2504,NCT04337918,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Corona Virus Infection,Drug: NORS (Nitric Oxide Releasing Solution),"Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life Science",Phase 2,143,Industry|Other,"May 8, 2020","January 31, 2021","February 2, 2021"
2505,NCT04336917,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,Breast Cancer Surgery|Postoperative Analgesia,Drug: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic,Konya Meram State Hospital,Phase 4,50,Other,"August 31, 2020","February 5, 2021","March 1, 2021"
2506,NCT04336449,Eptinezumab in Healthy Japanese Subjects,Healthy,Drug: Eptinezumab|Drug: Placebo,H. Lundbeck A/S,Phase 1,18,Industry,"April 1, 2020","August 13, 2020","August 13, 2020"
2507,NCT04336124,Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients,Advanced Cancer,Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule),"TaiRx, Inc.",Phase 1,5,Industry,"May 25, 2020","February 8, 2021","April 8, 2022"
2508,NCT04335526,A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles,Human Microbiome,Drug: Cholestyramine Resin,Seoul National University Hospital,Phase 1,15,Other,"May 1, 2020","July 30, 2020","October 21, 2020"
2509,NCT04335266,A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects,Healthy Adult Subjects,Drug: SHR2554,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,20,Industry,"August 6, 2019","September 9, 2019","March 30, 2020"
2510,NCT04335201,Defibrotide in COVID-19 Pneumonia,Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure,Drug: Defibrotide Injection,IRCCS San Raffaele,Phase 2,50,Other,"May 20, 2020","April 7, 2021","May 28, 2021"
2511,NCT04335136,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,COVID-19,Drug: RhACE2 APN01|Drug: Physiological saline solution,Apeiron Biologics,Phase 2,185,Industry,"April 30, 2020","December 26, 2020","December 26, 2020"
2512,NCT04335123,Study of Open Label Losartan in COVID-19,COVID-19,Drug: Losartan,University of Kansas Medical Center,Phase 1,34,Other,"April 4, 2020","June 21, 2020","August 17, 2020"
2513,NCT04334928,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Coronavirus Infection,Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine,Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.,Phase 3,1002,Other|Industry,"April 15, 2020","February 25, 2021","July 11, 2021"
2514,NCT04334460,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Sars-CoV-2|Covid19,Drug: BLD-2660,Blade Therapeutics|Clinipace Worldwide,Phase 2,120,Industry,"May 4, 2020","November 11, 2020","June 21, 2021"
2515,NCT04334213,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150",Type 2 Diabetes,"Drug: CKD-501|Drug: D745, D150|Drug: CKD-501, D745, D150",Chong Kun Dang Pharmaceutical,Phase 1,48,Industry,"May 7, 2020","August 5, 2020","August 5, 2020"
2516,NCT04334148,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,COVID-19,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University,Phase 3,1360,Other,"April 22, 2020","December 10, 2020","January 9, 2021"
2517,NCT04333225,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,COVID-19,Drug: Hydroxychloroquine,Baylor Research Institute,Phase 2,221,Other,"April 3, 2020","June 30, 2020","June 30, 2020"
2518,NCT04333160,Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis,Symptomatic Osteoarthritis of the Knee,Drug: JTA-004|Device: Hylan G-F 20|Other: placebo,Bone Therapeutics S.A|Nordic Bioscience A/S,Phase 3,746,Industry,"March 10, 2020","March 31, 2021","December 9, 2021"
2519,NCT04333134,A Trial of SHR3162 in Healthy Caucasian Volunteers,Healthy Volunteers,Drug: SHR3162,Atridia Pty Ltd.,Phase 1,12,Industry,"April 17, 2020","May 15, 2020","June 30, 2020"
2520,NCT04332991,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Coronavirus|Acute Respiratory Infection|SARS-CoV Infection,Drug: Hydroxychloroquine|Drug: Placebo,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,479,Other|NIH,"April 2, 2020","June 19, 2020","July 23, 2020"
2521,NCT04332978,Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene,Perennial Allergic Rhinitis,Drug: Fluticasone Propionate,Libbs Farmacêutica LTDA,Phase 3,566,Industry,"July 4, 2014","April 1, 2020","April 1, 2020"
2522,NCT04332627,Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine,Neuromuscular Blockade Reversal Agent|Sugammadex|Neostigmine|Quality of Recovery|Laparoscopic Cholecystectomy,Drug: Sugammadex|Drug: Neostigmine,Seoul National University Bundang Hospital,Phase 4,77,Other,"February 24, 2020","May 21, 2020","May 21, 2020"
2523,NCT04332380,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Coronavirus|Coronavirus Infection,Drug: Plasma,Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud,Phase 2,10,Other,"May 1, 2020","July 28, 2020","July 28, 2020"
2524,NCT04331899,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,COVID-19,Drug: Peginterferon Lambda-1a|Other: Placebo,Stanford University,Phase 2,120,Other,"April 25, 2020","August 14, 2020","May 6, 2021"
2525,NCT04331834,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,COVID-19,Drug: Hydroxychloroquine|Drug: Placebos,Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Plató|Hospital de Granollers,Phase 3,275,Other,"April 3, 2020","June 25, 2020","December 31, 2020"
2526,NCT04331795,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",COVID-19,Drug: Tocilizumab,University of Chicago,Phase 2,32,Other,"April 4, 2020","June 5, 2020","June 5, 2020"
2527,NCT04331600,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,COVID-19,Drug: Chloroquine phosphate|Other: Telemedicine,Wroclaw Medical University,Phase 4,16,Other,"April 16, 2020","December 17, 2020","December 17, 2020"
2528,NCT04331145,Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation,Symptomatic Aortic Stenosis,Drug: Ticagrelor 60mg,Andres Iñiguez Romo|Fundacin Biomedica Galicia Sur,Phase 4,40,Other,"June 23, 2020","February 28, 2021","February 28, 2022"
2529,NCT04330872,An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.,"Stroke, Ischemic",Drug: Enteric Coated Aspirin Tablet|Drug: Plain Aspirin,Hamad Medical Corporation,Phase 4,42,Industry,"August 26, 2019","January 4, 2020","March 4, 2020"
2530,NCT04330677,Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin,Oxytocin|Estrogen|Fear Extinction|Emotion Processing|Memory,Drug: Oxytocin nasal spray|Drug: Placebo nasal spray|Drug: Estrogen Gel|Drug: Placebo Gel,"University Hospital, Bonn",Phase 1,487,Other,"September 18, 2016","January 25, 2020","January 25, 2020"
2531,NCT04330638,Treatment of COVID-19 Patients With Anti-interleukin Drugs,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"University Hospital, Ghent|Belgium Health Care Knowledge Centre",Phase 3,342,Other,"April 3, 2020","December 20, 2020","May 21, 2021"
2532,NCT04330586,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,COVID-19,Drug: Ciclesonide Metered Dose Inhaler [Alvesco],Korea University Guro Hospital,Phase 2,68,Other,"April 1, 2020","March 31, 2021","March 31, 2021"
2533,NCT04329832,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,"Intermountain Health Care, Inc.|University of Utah",Phase 2,85,Other,"March 30, 2020","July 1, 2020","January 1, 2021"
2534,NCT04328883,Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin,Platelet Aggregation Inhibitors,Drug: Aspirin,Inova Health Care Services,Phase 1,19,Other,"July 16, 2019","October 3, 2019","October 10, 2019"
2535,NCT04328766,Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers,Drug-drug Interaction,"Drug: DWC202005, alone|Drug: DWP14012 + DWC202005|Drug: DWP14012 + DWC202005, after multiple doses of DWP14012",Daewoong Pharmaceutical Co. LTD.,Phase 1,36,Industry,"September 6, 2020","November 21, 2020","November 21, 2020"
2536,NCT04328506,Bioequivalency Study of CM082 Tablet in Healthy Volunteers,Advanced Malignant Solid Tumors,Drug: CM082 tablet (test product)|Drug: CM082 tablet (reference product),AnewPharma,Phase 1,96,Industry,"June 1, 2020","July 27, 2020","July 27, 2020"
2537,NCT04328493,The Vietnam Chloroquine Treatment on COVID-19,SARS-CoV-2 Infection|COVID-19,Drug: Chloroquine phosphate,"Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city",Phase 2,10,Other,"April 7, 2020","September 10, 2020","September 10, 2020"
2538,NCT04328480,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,COVID-19,Drug: Colchicine|Other: Local standard of care,Estudios Clínicos Latino América|Population Health Research Institute,Phase 3,1279,Other,"April 17, 2020","April 25, 2021","April 26, 2021"
2539,NCT04328467,Pre-exposure Prophylaxis for SARS-Coronavirus-2,COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome,Drug: Hydroxychloroquine|Other: Placebo,University of Minnesota,Phase 3,1483,Other,"April 6, 2020","July 13, 2020","July 13, 2020"
2540,NCT04328441,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,COVID-19,Drug: BCG Vaccine|Drug: Placebo,UMC Utrecht|Radboud University Medical Center,Phase 3,1511,Other,"March 25, 2020","March 31, 2021","March 31, 2021"
2541,NCT04327843,Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY),Schizophrenia|Medication Nonadherence|Schizo Affective Disorder,Behavioral: Customized Adherence Enhancement|Drug: Haloperidol Decanoate,Case Western Reserve University|National Institute of Mental Health (NIMH),Phase 3,22,Other|NIH,"November 5, 2019","July 30, 2020","July 30, 2020"
2542,NCT04327765,Staccato® Granisetron Multiple Dose PK,Healthy,Combination Product: 0.5mg AZ-010|Combination Product: 1mg AZ-010|Combination Product: 3mg AZ-010,"Alexza Pharmaceuticals, Inc.|Celerion",Phase 1,30,Industry,"March 10, 2020","August 4, 2020","August 15, 2020"
2543,NCT04327388,Sarilumab COVID-19,Corona Virus Infection,Drug: Sarilumab SAR153191|Drug: Placebo,Sanofi|Regeneron Pharmaceuticals,Phase 3,420,Industry,"March 28, 2020","July 31, 2020","September 2, 2020"
2544,NCT04327089,Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects,Phase 1,Drug: Setanaxib,Calliditas Therapeutics AB,Phase 1,64,Industry,"June 24, 2020","March 23, 2021","March 23, 2021"
2545,NCT04326920,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),COVID-19,Drug: Sargramostim|Other: Control,"University Hospital, Ghent|Flanders Institute of Biotechnology",Phase 4,87,Other,"March 24, 2020","September 28, 2020","February 26, 2021"
2546,NCT04326868,Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon,Helminths Infection|Drug Resistance,Drug: Benzimidazole Anthelmintic,Centre de Recherche Médicale de Lambaréné,Phase 4,255,Other,"November 11, 2019","December 31, 2020","January 30, 2021"
2547,NCT04325737,"Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia",Schizophrenia,Drug: SEP-363856|Drug: Placebo,"Sumitomo Pharma Co., Ltd.",Phase 1,13,Industry,"March 31, 2020","August 7, 2020","August 7, 2020"
2548,NCT04325620,Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease,Non-erosive Gastroesphageal Reflux Disease,Drug: HIP1601|Drug: HGP1805,Hanmi Pharmaceutical Company Limited,Phase 3,208,Industry,"June 10, 2019","August 3, 2020","August 3, 2020"
2549,NCT04325490,"Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream",Intertrigo,Drug: Liquid powder|Drug: Hydrocortisone cream 1%,Mahidol University|HOE pharmaceuticals Sdn. Bhd.,Phase 4,40,Other,"October 1, 2019","September 30, 2020","September 30, 2020"
2550,NCT04324918,Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis,Perennial Allergic Rhinitis,Drug: HCP1102|Drug: HGP1408,Hanmi Pharmaceutical Company Limited,Phase 3,174,Industry,"October 23, 2018","June 24, 2019","June 24, 2019"
2551,NCT04324697,Radiographic and Histological Evaluation of Regenerated Bone After Grafting Using Allograft Shell and Autogenous Chips,Alveolar Bone Resorption,Procedure: Horizontal alveolar bone augmentation,October 6 University|Ain Shams University,Phase 4,10,Other,"April 8, 2018","July 1, 2019","September 5, 2019"
2552,NCT04324424,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers,Type 2 Diabetes Mellitus,Drug: HMS5552,Hua Medicine Limited,Phase 1,17,Industry,"April 23, 2019","September 30, 2019","September 30, 2019"
2553,NCT04324372,Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors,Advanced Refractory Solid Tumors,Drug: HEC68498,"Sunshine Lake Pharma Co., Ltd.",Phase 1,12,Industry,"February 27, 2019","February 26, 2021","March 26, 2021"
2554,NCT04324359,"Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects",Post-surgical Ocular Inflammation|Post-surgical Ocular Pain,Drug: SURF-201|Drug: Placebo,"Surface Ophthalmics, Inc.",Phase 2,91,Industry,"March 3, 2020","November 3, 2020","November 20, 2020"
2555,NCT04324268,"A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers",Study Conducted in Healthy Volunteers,Drug: lirentelimab (AK002)|Other: Placebo,Allakos Inc.,Phase 1,66,Industry,"March 23, 2020","February 10, 2021","February 10, 2021"
2556,NCT04323800,Convalescent Plasma to Stem Coronavirus (CSSC-001),Coronavirus|Convalescence,Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma,Johns Hopkins University,Phase 2,180,Other,"June 10, 2020","April 22, 2021","June 22, 2021"
2557,NCT04323527,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia,Drug: Chloroquine diphosphate,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça,Phase 2,278,Other,"March 23, 2020","May 7, 2020","June 7, 2020"
2558,NCT04322968,Ketamine Infusion for Comorbid PTSD and Chronic Pain,PTSD|Chronic Pain,Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.,VA Ann Arbor Healthcare System|University of Michigan,Phase 3,41,U.S. Fed|Other,"January 9, 2018","June 4, 2019","June 4, 2019"
2559,NCT04322552,A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects,Advanced Solid Tumor,Drug: Apatinib Mesylate|Drug: Digoxin tablet,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"March 12, 2020","April 3, 2021","May 3, 2021"
2560,NCT04322214,Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat,Pharmacokinetic Interactions|HIV,Drug: Cobicistat 150 MG|Drug: Placebo|Drug: GHB,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Phase 1,12,Other,"January 30, 2020","March 30, 2020","April 30, 2020"
2561,NCT04322123,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,Phase 3,667,Other|Industry,"April 1, 2020","June 2, 2020","June 2, 2020"
2562,NCT04321980,A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers,Healthy,Drug: OP-101,"Orpheris, Inc.",Phase 1,8,Industry,"March 19, 2020","May 22, 2020","May 22, 2020"
2563,NCT04321460,"Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.",Antibiotic-associated Diarrhea,Drug: LRG-002|Drug: Placebo,Sandoz,Phase 3,520,Industry,"October 1, 2020","January 4, 2021","January 4, 2021"
2564,NCT04321278,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,Phase 3,440,Other|Industry,"March 28, 2020","June 14, 2020","June 14, 2020"
2565,NCT04321252,"Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects",Malaria,Drug: KAE609|Drug: Placebo,Novartis Pharmaceuticals|Wellcome Trust|Novartis,Phase 1,57,Industry|Other,"July 22, 2020","November 10, 2020","November 10, 2020"
2566,NCT04321070,Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: Clindamycin Phosphate|Drug: Clindamycin Phosphate RLD|Drug: Placebos,Taro Pharmaceuticals USA,Phase 1,550,Industry,"September 9, 2019","December 14, 2019","March 6, 2020"
2567,NCT04320615,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,Hoffmann-La Roche,Phase 3,452,Industry,"April 3, 2020","June 24, 2020","July 28, 2020"
2568,NCT04320498,Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure,Anal Fissure Chronic|PRP,Biological: prp injection|Drug: Anrecta|Behavioral: sitz bath|Dietary Supplement: nutrition regulation,KTO Karatay University|Istanbul Medipol University Hospital,Phase 4,41,Other,"January 1, 2019","December 14, 2019","January 2, 2021"
2569,NCT04319159,Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK),Actinic Keratoses,Combination Product: BF-200 ALA and red light LED lamp,Biofrontera Bioscience GmbH,Phase 1,48,Industry,"March 5, 2020","September 9, 2020","October 7, 2020"
2570,NCT04318652,OCT Guided Punctal Stenosis Management,Epiphora Due to Insufficient Drainage,Drug: Methylprednisolone eyedrops,Tanta University,Phase 4,80,Other,"September 2, 2018","September 5, 2019","September 20, 2019"
2571,NCT04318535,Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions,Antifungal Agents,Drug: Griseofulvin 500 mg|Drug: Griseofulvin 250 mg|Drug: Reference Griseofulvin 500 mg,GlaxoSmithKline,Phase 1,36,Industry,"January 13, 2020","January 13, 2020","February 6, 2020"
2572,NCT04318015,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),COVID-19|Severe Acute Respiratory Syndrome,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"National Institute of Respiratory Diseases, Mexico",Phase 3,289,Other,"April 14, 2020","December 31, 2020","March 31, 2021"
2573,NCT04317703,Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.,Type 2 Diabetes,Drug: Gemigliptin tartrate sesquihydrate and metformin|Drug: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release,LG Chem,Phase 1,40,Industry,"August 19, 2020","September 5, 2020","September 5, 2020"
2574,NCT04317573,Effect on the Adherence to Glaucoma Eye Drops by Improving Patient Understanding and Using a Tele-reminder System,Glaucoma,Device: Personalised card,"National University Health System, Singapore",Phase 2,59,Other,"October 19, 2018","October 19, 2019","October 19, 2019"
2575,NCT04317040,"Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)",Coronavirus Disease 2019 (COVID-19),Drug: Efprezimod alfa|Drug: Placebo,"OncoImmune, Inc.",Phase 3,234,Industry,"April 24, 2020","October 20, 2020","October 20, 2020"
2576,NCT04316871,Dosage of Epidural Morphine in Elderly Patients,Age Problem|Abdominal Cancer,Drug: 1.5 mg of Morphine Sulfate|Drug: Normal saline|Drug: 3 mg of Morphine Sulfate|Drug: 4.5 mg of Morphine Sulfate,Assiut University,Phase 4,88,Other,"March 20, 2020","December 31, 2020","June 30, 2021"
2577,NCT04316065,Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg,Healthy Volunteers,Drug: YHP1906|Drug: YHR1902,Yuhan Corporation|Metro Hospital,Phase 1,30,Industry|Other,"April 11, 2020","April 20, 2020","April 24, 2020"
2578,NCT04315987,NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,COVID-19 Pneumonia,Biological: NestaCell®|Biological: Placebo,Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz,Phase 2,90,Industry|Other,"June 30, 2020","February 28, 2021","February 28, 2021"
2579,NCT04315896,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),COVID-19|Severe Acute Respiratory Syndrome,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"National Institute of Respiratory Diseases, Mexico",Phase 3,320,Other,"April 14, 2020","July 1, 2020","August 15, 2020"
2580,NCT04315116,A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate,Healthy Participants,Drug: pyrotinib maleate|Drug: Loperamide,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,18,Industry,"April 13, 2020","April 30, 2020","September 1, 2020"
2581,NCT04314986,Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers,Healthy Volunteers,Drug: Cohort 1: AR882 or placebo|Drug: Cohort 2: AR882 or placebo|Drug: Cohort 3: AR882 or placebo|Drug: Cohort 4: AR882 or placebo,Arthrosi Therapeutics,Phase 1,30,Industry,"June 28, 2019","September 18, 2019","September 18, 2019"
2582,NCT04314622,A Study of Supaglutide in Chinese Type 2 Diabetes Patients,"Diabetes Mellitus, Type 2",Drug: Supaglutide|Drug: Placebo,"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.|Shanghai 6th People's Hospital",Phase 2,40,Other,"April 14, 2020","October 25, 2020","March 16, 2021"
2583,NCT04314206,VNRX-5024 Safety and PK in Healthy Adult Volunteers,Healthy Subjects,Drug: VNRX-5024|Drug: Placebo for VNRX-5024,"Venatorx Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,36,Industry|NIH,"July 27, 2020","December 31, 2020","December 31, 2020"
2584,NCT04314037,Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide,Healthy,Drug: Cesol (Test)|Drug: Biltricide (Reference),"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,36,Industry,"June 17, 2020","July 30, 2020","July 30, 2020"
2585,NCT04314024,"Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets",Healthy,Drug: Evobrutinib,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,18,Industry,"May 25, 2020","June 23, 2020","June 23, 2020"
2586,NCT04313647,A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers,Healthy,Biological: 1X level of MSCs-Exo|Biological: 2X level of MSCs-Exo|Biological: 4X level of MSCs-Exo|Biological: 6X level of MSCs-Exo|Biological: 8X level of MSCs-Exo,Ruijin Hospital|Cellular Biomedicine Group Ltd.,Phase 1,24,Other|Industry,"March 12, 2020","April 30, 2020","July 31, 2020"
2587,NCT04313127,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,COVID-19,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital",Phase 1,108,Industry|Other,"March 16, 2020","January 20, 2021","February 20, 2021"
2588,NCT04312048,the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion,IUD Insertion Pain,Drug: Isosorbide mononitrate|Drug: placebo,Cairo University,Phase 3,110,Other,"April 15, 2020","October 25, 2020","November 30, 2020"
2589,NCT04312009,Losartan for Patients With COVID-19 Requiring Hospitalization,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection,Drug: Losartan|Other: Placebo,University of Minnesota|Bill and Melinda Gates Foundation,Phase 2,205,Other,"April 13, 2020","February 1, 2021","February 1, 2021"
2590,NCT04311476,Autologous Cord Blood Cells for Prevention of BPD in Preterm,Safety Issues|BPD - Bronchopulmonary Dysplasia|Neonatal Death,Other: Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Drug: 0.9% Sodiun Chloride,yangjie|Guangdong Women and Children Hospital,Phase 2,62,Other,"July 1, 2018","January 1, 2020","January 1, 2020"
2591,NCT04311463,Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants,Anxiety Disorders,Drug: Paroxetine hydrochloride|Drug: PAXIL (Paroxetine hydrochloride ),GlaxoSmithKline,Phase 1,38,Industry,"December 9, 2020","January 2, 2021","January 2, 2021"
2592,NCT04311424,Study of Tirzepatide in Healthy Participants,Healthy,Drug: 14C Tirzepatide,Eli Lilly and Company,Phase 1,6,Industry,"July 28, 2020","October 2, 2020","October 2, 2020"
2593,NCT04311255,Comparing the Efficacy and Safety of Ultrasound Guided Supraclavicular Block Combined With Either Intercostobrachialor Pec 11for Creation of Surgical Brachio-basilic Fistula in Chronic Renal Failure Patients on Hemodialysis,Best Regional Nerve Block for Creation of Surgical Brachiobasilic Fistula,Procedure: regional anesthesia for the upper limb,Ain Shams University,Phase 3,4,Other,"April 13, 2019","May 3, 2020","May 3, 2020"
2594,NCT04311177,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection,Drug: Losartan|Other: Placebo,University of Minnesota,Phase 2,117,Other,"April 9, 2020","February 1, 2021","February 1, 2021"
2595,NCT04310527,Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults,Healthy Volunteers,Drug: Enasidenib,Celgene,Phase 1,28,Industry,"October 9, 2019","November 27, 2019","December 9, 2019"
2596,NCT04310280,Effects of Local Insulin on Varicose Ulcers for Wound Healing,Chronic Venous Disease|Varicose Ulcer|Wound Healing|Insulin|Angiogenesis,Drug: Insulin Glargine|Drug: Saline,"Hospital Central ""Dr. Ignacio Morones Prieto""",Phase 3,13,Other,"June 1, 2019","December 31, 2019","February 15, 2020"
2597,NCT04310150,Collagen-thrombin Matrix Efficacy During Cardiac Surgery: a Prospective Randomized Controlled Trial,Coronary Artery Disease,Drug: Collastat|Device: Floseal,Yonsei University,Phase 4,80,Other,"February 5, 2018","March 17, 2020","March 31, 2020"
2598,NCT04310085,Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites,"Malaria,Falciparum|Parasitemia|Protozoan Infections|Parasitic Disease",Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Biological: PfSPZ-DVI Challenge,"Medicines for Malaria Venture|SGS Life Sciences, a division of SGS Belgium NV|Institute of Tropical Medicine, Belgium|Swiss BioQuant A.G., Switzerland|PrimeVigilance Ltd., UK|Sanaria Inc.|Iqvia Pty Ltd|FGK Representative Service B.V., The Netherlands",Phase 1,16,Other|Industry,"February 19, 2020","December 17, 2020","December 17, 2020"
2599,NCT04309656,A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid,Multi-drug Resistant Tuberculosis,Drug: Pretomanid,Global Alliance for TB Drug Development,Phase 1,48,Other,"January 14, 2020","February 28, 2020","February 28, 2020"
2600,NCT04309643,Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects,Healthy Volunteers,Drug: CTP-543|Drug: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG),Concert Pharmaceuticals|Celerion,Phase 1,21,Industry,"June 9, 2020","June 25, 2020","July 8, 2020"
2601,NCT04309526,"Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects",Hepatitis B,Drug: NCO-48 Fumarate|Drug: Placebo,"Nucorion Pharmaceuticals, Inc.|Ligand Pharmaceuticals|Medpace, Inc.",Phase 1,48,Industry,"March 18, 2020","August 3, 2020","October 13, 2020"
2602,NCT04308863,Evaluation of Chitosan Scaffold and Mineral Trioxide Aggregate Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis,Pulpitis - Irreversible,Drug: Chitosan scaffold/ MTA pulp dressing material|Drug: MTA pulp dressing material,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,30,Other,"November 15, 2018","October 30, 2020","December 20, 2020"
2603,NCT04308811,Autologous Platelet-Rich Plasma in the Management of Asherman Syndrome,Intrauterine Adhesion,Biological: platelet rich plasma|Combination Product: amniotic membrane graft group|Device: Intrauterine balloon,Ain Shams University,Phase 2,60,Other,"August 10, 2019","February 20, 2020","February 20, 2020"
2604,NCT04308668,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections,Drug: Hydroxychloroquine|Other: Placebo,University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta,Phase 3,1312,Other,"March 17, 2020","May 20, 2020","May 20, 2020"
2605,NCT04308096,A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia,XLH,Drug: KRN23,"Kyowa Kirin Co., Ltd.",Phase 3,27,Industry,"January 9, 2018","December 4, 2020","December 4, 2020"
2606,NCT04307940,Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed,Pain,"Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Hydrocodone/Acetaminophen|Drug: Placebo",Bayer,Phase 4,221,Industry,"March 12, 2020","October 2, 2020","October 5, 2020"
2607,NCT04307290,Dexmedetomidine on Tourniquet Induced -Systemic Effects,Arthropathy of Knee|Spinal Anesthesia|Tourniquet|Ischemia-reperfusion Injury,"Drug: Dexmedetomidine Hydrochloride, or Saline",Wonkwang University Hospital,Phase 4,80,Other,"February 3, 2020","February 10, 2020","March 5, 2020"
2608,NCT04307173,Study of Multiple Ascending Dose of KBL693 in Healthy Participants,Moderate to Severe Asthma,Drug: KBL693,KoBioLabs|Novotech (Australia) Pty Limited,Phase 1,18,Industry,"August 14, 2020","October 30, 2020","November 12, 2020"
2609,NCT04307082,ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects,Fungal Infection,Drug: [14C]-Ibrexafungerp,"Scynexis, Inc.|Inncelerex",Phase 1,6,Industry|Other,"December 5, 2019","May 29, 2020","June 30, 2020"
2610,NCT04306302,A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults,Healthy,Biological: ExPEC10V|Biological: Placebo,Janssen Pharmaceutical K.K.,Phase 1,24,Industry,"March 13, 2020","December 24, 2020","December 24, 2020"
2611,NCT04305899,A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants,Healthy Participants,Drug: BMS-986165 Tablet formulation 1|Drug: BMS-986165 Tablet formulation 2,Bristol-Myers Squibb,Phase 1,40,Industry,"August 31, 2020","November 25, 2020","November 25, 2020"
2612,NCT04305275,"A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor",Essential Tremor,Drug: SAGE-324|Drug: SAGE-324 Placebo,Sage Therapeutics,Phase 2,69,Industry,"June 15, 2020","February 1, 2021","February 15, 2021"
2613,NCT04304807,Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants,Preterm Infant|Feeding Intolerance|Necrotizing Enterocolitis,Drug: Melatonin 20 mg|Drug: Traditional antibiotic treatment,Ain Shams University,Phase 4,90,Other,"December 24, 2018","December 20, 2019","December 31, 2019"
2614,NCT04304547,Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers,Healthy,"Drug: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|Drug: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|Drug: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337",Chong Kun Dang Pharmaceutical,Phase 1,15,Industry,"February 4, 2020","April 2, 2020","April 2, 2020"
2615,NCT04304157,Median Effective Dose of Dexmedetomidine in Elective Upper Limb Lidocaine Intravenous Regional Anesthesia,Intravenous Drug Usage,Drug: Dexmedetomidine,South Valley University|Tanta University,Phase 4,81,Other,"August 1, 2019","February 29, 2020","March 1, 2020"
2616,NCT04304053,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,COVID-19,Drug: Treatment and prophylaxis|Other: Standard Public Health measures,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut",Phase 3,2300,Other,"March 18, 2020","June 15, 2020","June 15, 2020"
2617,NCT04303156,Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026),Human Immunodeficiency Virus (HIV) Infection,Drug: Islatravir,Merck Sharp & Dohme LLC,Phase 1,12,Industry,"June 18, 2020","October 19, 2020","October 19, 2020"
2618,NCT04303039,Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects,Gout|Food-drug Interaction,Drug: ABP-671,"Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.",Phase 1,12,Industry,"May 22, 2020","June 9, 2020","June 19, 2020"
2619,NCT04302532,Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS,Coenzyme q10,Drug: Coenzyme Q10|Drug: clomiphene citrate,Karachi Medical and Dental College,Phase 4,149,Other,"July 1, 2020","September 30, 2020","October 30, 2020"
2620,NCT04302064,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants",Healthy Participants,Drug: Eplontersen|Drug: Placebo,"Ionis Pharmaceuticals, Inc.",Phase 1,24,Industry,"April 23, 2020","September 10, 2020","September 10, 2020"
2621,NCT04301895,"Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression","Opioid; Intoxication, Perception Disturbance (Acute)|Acute Pain|Overdose of Opiate|Respiratory Depression|Safety Issues",Behavioral: Continuous conversational interaction|Drug: Remifentanil infusion,"University of California, San Francisco",Phase 1,20,Other,"April 30, 2019","September 3, 2019","September 3, 2019"
2622,NCT04301804,A Trial of SHR6390 in Healthy Caucasian Volunteers,Healthy Volunteers,Drug: SHR6390,Atridia Pty Ltd.,Phase 1,36,Industry,"March 12, 2020","May 28, 2020","September 28, 2020"
2623,NCT04300621,A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants,Healthy,Drug: OTF 1|Drug: OTF 2|Drug: OTF 3|Drug: OTF 4,"Janssen Research & Development, LLC",Phase 1,16,Industry,"June 19, 2020","August 10, 2020","August 10, 2020"
2624,NCT04300010,Blue Light Therapy of C. Acnes,Acne,Drug: 5% Topical Benzoyl Peroxide Gel|Device: Blue Light Therapy,"University of Wisconsin, Madison",Phase 4,60,Other,"October 5, 2020","January 22, 2021","January 22, 2021"
2625,NCT04299633,Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat,Healthy Volunteers,Drug: Vadadustat|Drug: Sevelamer carbonate|Drug: Calcium acetate|Drug: Auryxia®,Akebia Therapeutics,Phase 1,54,Industry,"June 15, 2020","August 2, 2020","September 28, 2020"
2626,NCT04297631,Intraarticular Antibiotic in TKA,Antibotics in Cementless Knees,Drug: Tobramycin Powder|Device: Vancomyscin,Washington University School of Medicine,Phase 4,20,Other,"February 14, 2020","August 1, 2020","November 1, 2020"
2627,NCT04297241,Nitrate Effect on Exercise Capacitance,Fontan,Drug: Isosorbide Dinitrate,"Children's Hospital Medical Center, Cincinnati",Phase 2,20,Other,"December 12, 2019","June 30, 2020","May 3, 2021"
2628,NCT04295356,To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17,Healthy,Biological: CT-P17,Celltrion,Phase 1,180,Industry,"June 21, 2019","November 15, 2019","November 15, 2019"
2629,NCT04295161,A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone,Pharmacokinetics,Drug: Abiraterone Acetate,"Zentiva, k.s.",Phase 1,33,Industry,"June 25, 2019","November 8, 2019","November 8, 2019"
2630,NCT04295070,Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers,Respiratory Syncytial Virus Infections,Biological: CodaVax-RSV|Biological: Normal saline,"Codagenix, Inc",Phase 1,36,Industry,"July 10, 2020","March 6, 2021","May 26, 2021"
2631,NCT04295044,Effect of High Protein Diet in Stroke Patients With Low Muscle Mass,"Ischemic Stroke|Diet, Healthy|Muscle Loss",Dietary Supplement: high protein diet|Dietary Supplement: normal protein diet,Chang Gung Memorial Hospital,Phase 2,110,Other,"December 15, 2017","December 31, 2020","March 31, 2021"
2632,NCT04294251,Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy,Benign Masseteric Hypertrophy,Drug: DWP450|Drug: Placebo,Daewoong Pharmaceutical Co. LTD.,Phase 3,180,Industry,"March 4, 2020","January 7, 2021","August 10, 2021"
2633,NCT04294147,A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist,Migraine,Drug: Galcanezumab|Drug: Erenumab,Eli Lilly and Company,Phase 4,65,Industry,"October 6, 2020","March 5, 2021","March 5, 2021"
2634,NCT04294056,"A Study to Evaluate the Differences in Pharmadynamics, Pharmacokinetics, and Safety Between Ciprofol and Propofol",Anesthesia,Drug: Ciprofol|Drug: Propofol,"Haisco Pharmaceutical Group Co., Ltd.",Phase 1,18,Industry,"May 26, 2020","June 22, 2020","September 18, 2020"
2635,NCT04293965,Single-dose and Multiple-dose X842 Phase 1 Study,Healthy Volunteers,Drug: Single ascending dose of X842|Drug: Multiple ascending dose of X842|Other: Food Effect,"Jiangsu Sinorda Biomedicine Co., Ltd",Phase 1,80,Industry,"October 23, 2018","September 4, 2019","September 4, 2019"
2636,NCT04293809,Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation,Breast Augmentation,Drug: Exparel Injectable Product|Drug: Bupivacaine Hydrochloride,"Pacira Pharmaceuticals, Inc",Phase 1,30,Industry,"December 19, 2019","January 15, 2020","January 29, 2020"
2637,NCT04293029,Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment,Hepatic Impairment,Drug: SHR0302,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,24,Industry,"May 20, 2020","December 27, 2020","December 30, 2020"
2638,NCT04292899,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),COVID-19,Drug: Remdesivir|Drug: Standard of Care,Gilead Sciences,Phase 3,4891,Industry,"March 6, 2020","April 9, 2020","June 30, 2020"
2639,NCT04292730,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,COVID-19,Drug: Remdesivir|Drug: Standard of Care,Gilead Sciences,Phase 3,1113,Industry,"March 15, 2020","April 29, 2020","June 26, 2020"
2640,NCT04292626,Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose,"Hodgkin Lymphoma, Adult|Non-Hodgkin Lymphoma, Adult",Diagnostic Test: SPECT with 99mTc-1-thio-D-glucose,Tomsk National Research Medical Center of the Russian Academy of Sciences|Uppsala University,Phase 1,16,Other,"January 19, 2020","February 19, 2021","March 19, 2021"
2641,NCT04292535,Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise,Insulin|Exercise,Drug: Placebo into the intranasal mucosa|Drug: 20 IU NovoLog Insulin aspart into the intranasal mucosa|Drug: 40 IU NovoLog Insulin aspart into the intranasal mucosa|Drug: 60 IU NovoLog Insulin aspart into the intranasal mucosa|Drug: 80 IU NovoLog Insulin aspart into the intranasal mucosa|Drug: 100 IU NovoLog Insulin aspart into the intranasal mucosa|Drug: 120 IU NovoLog Insulin aspart into the intranasal mucosa,Michigan State University,Phase 2,116,Other,"June 15, 2018","February 20, 2020","February 20, 2020"
2642,NCT04291846,A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects,Healthy Adult Subjects,"Drug: SHR1459 fasted in P1, high-fat diet in P2|Drug: SHR1459 high-fat diet in P1, fasted in P2","Jiangsu HengRui Medicine Co., Ltd.",Phase 1,28,Industry,"May 24, 2020","June 3, 2020","June 29, 2020"
2643,NCT04291729,Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,COVID-19,Drug: Ganovo+ritonavir+/-Interferon nebulization,"The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.",Phase 4,11,Other|Industry,"February 17, 2020","March 19, 2020","March 19, 2020"
2644,NCT04291066,Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients,Traumatic Brain Injury,Drug: N-Acetyl cysteine,HonorHealth Research Institute,Phase 2,92,Other,"September 1, 2019","April 30, 2020","August 1, 2021"
2645,NCT04290390,Annovera™ Drug-Drug Interaction Study,Women|Contraception,Drug: Segesterone Acetate and Ethinyl Estradiol|Drug: Rifampin|Drug: Itraconazole,TherapeuticsMD,Phase 1,67,Industry,"February 12, 2020","January 6, 2021","January 6, 2021"
2646,NCT04290039,Sublingual vs IV Atropine Bioavailability Study,Toxic Effect of Organophosphate and Carbamate Insecticides,Drug: Atropine Sulfate Ophthalmic Solution|Drug: Atropine Sulphate Injection,"Biomedical Advanced Research and Development Authority|Rho, Inc.",Phase 1,15,U.S. Fed|Industry,"January 4, 2020","February 2, 2020","February 8, 2020"
2647,NCT04289649,K-924 Phase III Confirmatory Study,Hypercholesterolemia,Drug: K-924 LD|Drug: K-924 HD|Drug: K-924 LD Placebo|Drug: K-924 HD Placebo,"Kowa Company, Ltd.",Phase 3,293,Industry,"April 2, 2020","November 21, 2020","November 21, 2020"
2648,NCT04288934,Treatment of Spinal Cord Injuries With (AutoBM-MSCs)vs (WJ-MSCs).,Spinal Cord Injuries,Biological: Collection and expansion of BM-MSC|Diagnostic Test: VI-SCI evaluation and patients' follow up,University of Jordan,Phase 1,20,Other,"August 15, 2017","April 15, 2020","September 20, 2020"
2649,NCT04288518,Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.,Brain|Neoplasms,Diagnostic Test: SPECT with 99mTc-1-thio-D-glucose,Tomsk National Research Medical Center of the Russian Academy of Sciences|Uppsala University,Phase 1,16,Other,"February 15, 2020","February 15, 2021","February 15, 2021"
2650,NCT04288102,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Corona Virus Disease 2019(COVID-19),Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）,"Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|The General Hospital of Central Theater Command|VCANBIO Cell & Gene Engineering Corporation, Ltd",Phase 2,100,Other|Industry,"March 5, 2020","May 12, 2020","July 9, 2020"
2651,NCT04287426,A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 µg/kg in Elderly Patients Over 80 Years,Neuromuscular Blockade|Intubation Complication|Anesthesia,Drug: Rocuronium 0.6 mg/kg|Drug: Remifentanil 2 µg/kg,"Rigshospitalet, Denmark",Phase 4,78,Other,"March 11, 2020","December 10, 2020","December 13, 2020"
2652,NCT04286750,"Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239",Healthy,Drug: ACT-1004-1239|Drug: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,50,Industry,"July 11, 2020","September 25, 2020","September 25, 2020"
2653,NCT04286412,Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B,Hemophilia B,Biological: Nonacog alfa,Pfizer,Phase 4,25,Industry,"February 10, 2020","September 24, 2020","September 24, 2020"
2654,NCT04286035,Two Different Blocks for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Arthroplasty,"Knee Replacement, Total|Pain, Postoperative|Anesthesia, Regional",Drug: Bupivacaine Injection,Sisli Hamidiye Etfal Training and Research Hospital,Phase 4,70,Other,"April 2, 2019","September 29, 2019","October 1, 2019"
2655,NCT04285229,A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis,Spondyloarthritis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Phase 3,147,Industry,"April 10, 2020","March 31, 2021","March 17, 2022"
2656,NCT04284995,A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction,Coronary Disease|Myocardial Infarction|Heart Diseases|Vascular Diseases|STEMI - ST Elevation Myocardial Infarction,Drug: RUC-4 Compound,CeleCor Therapeutics|ST. Antonius hospital Nieuwegein|Diagram B.V.,Phase 2,27,Industry|Other,"June 2, 2020","November 8, 2020","December 14, 2020"
2657,NCT04284514,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution",Ocular Hypertension|Primary Open Angle Glaucoma,Drug: AKB-9778 Ophthalmic Solution|Drug: Placebo Ophthalmic Solution,Aerpio Therapeutics,Phase 1,91,Industry,"May 2, 2019","December 15, 2019","December 15, 2019"
2658,NCT04283474,Phase 1 XG005-03 Topical Study,Pain,Drug: XG005-03|Drug: Placebo,Xgene Pharmaceutical Group,Phase 1,36,Industry,"February 28, 2020","January 28, 2021","January 28, 2021"
2659,NCT04282980,A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST),Gastrointestinal Stromal Tumors,Drug: DCC-2618,"Zai Lab (Shanghai) Co., Ltd.|Zai Lab (Hong Kong), Ltd.",Phase 2,39,Industry,"April 23, 2020","February 26, 2021","August 23, 2022"
2660,NCT04282954,Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease,GERD,Drug: JP-1366|Drug: JP-1366 placebo|Drug: Esomeprazole 40mg|Drug: Esomeprazole placebo,Onconic Therapeutics Inc.,Phase 2,188,Industry,"November 15, 2019","October 20, 2020","December 11, 2020"
2661,NCT04282746,A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants,Healthy,Drug: JNJ-54135419,"Janssen Research & Development, LLC",Phase 1,17,Industry,"February 18, 2020","August 11, 2020","August 17, 2020"
2662,NCT04281758,Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers,Plasma Caffeine Concentration,Other: Beverage,PepsiCo Global R&D,Phase 1,16,Industry,"July 20, 2020","October 1, 2020","October 13, 2020"
2663,NCT04281628,Comparison Between Low-dose Ketamine Infusion and Intravenous Morphine,Ketamine,Drug: Ketamine group:|Drug: Control group,Cairo University,Phase 4,80,Other,"February 21, 2019","May 20, 2020","June 20, 2020"
2664,NCT04280874,Induction of Labor in Term Pregnancies With Unfavourable Cervix,Induction of Labor Affected Fetus / Newborn|Prostaglandins Causing Adverse Effects in Therapeutic Use,Drug: Dinoprostone 0.5 MG|Drug: Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly,Clinical Hospital Merkur,Phase 4,212,Other,"December 10, 2018","July 1, 2020","July 1, 2020"
2665,NCT04280705,Adaptive COVID-19 Treatment Trial (ACTT),COVID-19,Other: Placebo|Drug: Remdesivir,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3,1062,NIH,"February 21, 2020","May 21, 2020","May 21, 2020"
2666,NCT04279197,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Pulmonary Fibrosis Due to COVID-19,Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Drug: Placebo|Other: respiratory function rehabilitation training,ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People's Hospital|Wuhan No.1 Hospital|Wuhan Third Hospital|Huangshi Hospital of Traditional Chinese Medicine,Phase 2,142,Other,"April 23, 2020","March 24, 2021","March 24, 2021"
2667,NCT04279119,Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis,Plaque Psoriasis,Drug: ARQ-151- cream 0.3%,"Arcutis Biotherapeutics, Inc.",Phase 1,26,Industry,"March 10, 2020","March 25, 2021","March 25, 2021"
2668,NCT04278937,Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage,Preterm Birth,Drug: Azithromycin Tablets,Ain Shams Maternity Hospital,Phase 4,50,Other,"April 15, 2019","February 15, 2020","April 15, 2020"
2669,NCT04278391,"Pharmacokinetics and Safety Between ""DWJ1421"" and ""DWC201903"" in Healthy Male Volunteers",Healthy,Drug: DWJ1421|Drug: DWC201903,Daewoong Pharmaceutical Co. LTD.,Phase 1,40,Industry,"July 2, 2019","August 10, 2019","February 19, 2020"
2670,NCT04277910,"A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004",Healthy,Drug: MT2004|Drug: Placebo,Xi'an Biocare Pharma Ltd.,Phase 1,88,Other,"January 9, 2020","April 30, 2021","September 30, 2021"
2671,NCT04277624,A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants,Healthy Volunteers,Drug: fezolinetant - test formulation|Drug: fezolinetant - reference formulation,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,22,Industry,"February 20, 2020","February 21, 2021","February 26, 2021"
2672,NCT04277338,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3,Primary Breast Cancer,Drug: SPECT,"Tomsk National Research Medical Center of the Russian Academy of Sciences|Institute of Bioorganic Chemistry, Russian Academy of Sciences|Uppsala University",Phase 1,30,Other,"February 10, 2020","February 10, 2021","October 4, 2021"
2673,NCT04276987,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Coronavirus,Biological: MSCs-derived exosomes,"Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.",Phase 1,24,Other|Industry,"February 15, 2020","May 31, 2020","July 31, 2020"
2674,NCT04276883,Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder,"Agitation Associated With Bipolar Disorder|Agitation,Psychomotor|Bipolar Disorder",Drug: Sublingual film containing Dexmedetomidine (BXCL501)|Drug: Placebo Film,BioXcel Therapeutics Inc|Cognitive Research Corporation,Phase 3,378,Industry,"February 24, 2020","May 21, 2020","May 21, 2020"
2675,NCT04276688,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Novel Coronavirus Infection,Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B,"The University of Hong Kong|Hospital Authority, Hong Kong",Phase 2,127,Other,"February 10, 2020","March 30, 2020","March 31, 2020"
2676,NCT04276662,Study of Single-dose DS-3201b in Participants With Hepatic Impairment,Hepatic Impairment,Drug: DS-3201b,"Daiichi Sankyo, Inc.",Phase 1,28,Industry,"November 21, 2019","February 23, 2021","February 23, 2021"
2677,NCT04276545,Dexmedetomidine Improves the Surgical Field and Postoperative Recovery of Nasal Endoscopic Surgery,Dexmedetomidine|Bleeding|Surgical Field,Drug: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|Drug: IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery,Eye & ENT Hospital of Fudan University,Phase 3,118,Other,"January 1, 2018","March 10, 2020","March 10, 2020"
2678,NCT04276428,A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug: LY3209590|Drug: Insulin Degludec,Eli Lilly and Company,Phase 1,28,Industry,"February 28, 2020","November 28, 2020","November 28, 2020"
2679,NCT04276207,A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,Phase 1,32,Industry,"February 25, 2020","August 10, 2020","August 10, 2020"
2680,NCT04275960,"Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body",Solid Tumors Harboring NTRK Fusion,Drug: Selitrectinib (BAY2731954),Bayer,Phase 1,24,Industry,"February 28, 2020","October 1, 2020","November 30, 2020"
2681,NCT04275414,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Coronavirus Infections,Drug: Bevacizumab Injection,Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital,Phase 2,27,Other,"February 15, 2020","April 5, 2020","May 2, 2020"
2682,NCT04275115,Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects,Healthy,Drug: Drug Cocktail|Drug: Foliglurax|Drug: midazolam iv,H. Lundbeck A/S,Phase 1,20,Industry,"February 10, 2020","April 3, 2020","April 3, 2020"
2683,NCT04275076,HoLEP Vs BPEP for Large Prostatic Adenoma,Prostate Hyperplasia,Procedure: Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia,Ahmed Maher Gamil Ahmed Higazy|Ain Shams University,Phase 3,100,Other,"February 1, 2018","February 1, 2020","February 1, 2020"
2684,NCT04274075,Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential,Healthy Volunteers,"Drug: GDC-9545 Tablet, Fasted: Treatment A|Drug: GDC-9545 Capsule, Fasted: Treatment B|Drug: GDC-9545 Capsule, Fed: Treatment C","Genentech, Inc.",Phase 1,18,Industry,"March 6, 2020","April 16, 2020","April 16, 2020"
2685,NCT04273984,Efficacy and Safety of Different Doses of Vaginal Misoprostol Prior to Intra Uterine Contraceptive Device Insertion,Intra-uterine Device Complication,Drug: Misoprostol,Ain Shams University,Phase 4,180,Other,"March 1, 2020","June 15, 2020","June 30, 2020"
2686,NCT04273282,A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%,Cataract,Drug: Dexycu intracameral dexamethasone|Drug: Prednisolone Acetate,Research Insight LLC,Phase 4,31,Industry,"December 16, 2019","November 24, 2020","November 24, 2020"
2687,NCT04272502,Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers,Healthy,"Drug: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337",Chong Kun Dang Pharmaceutical|Seoul National University Bundang Hospital,Phase 1,15,Industry|Other,"June 4, 2019","August 26, 2019","August 26, 2019"
2688,NCT04272476,The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy,"Depressive Disorder, Major",Other: acupuncture and moxibustion|Drug: Fluoxetine,Chengdu University of Traditional Chinese Medicine|Massachusetts General Hospital,Phase 2,20,Other,Jan-14,Dec-19,Dec-19
2689,NCT04271592,"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults",Chronic Hepatitis B,Drug: ABI-H3733 Liquid Oral Dosage Form|Drug: ABI-H3733 Solid Oral Dosage Form|Drug: Placebo to ABI-H3733 Liquid Oral Dosage Form|Drug: Placebo to ABI-H3733 Solid Oral Dosage Form,Assembly Biosciences,Phase 1,120,Industry,"May 17, 2020","November 3, 2020","January 14, 2021"
2690,NCT04271514,A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis,Atopic Dermatitis,Drug: RPT193|Drug: Placebo,"RAPT Therapeutics, Inc.",Phase 1,103,Industry,"August 12, 2019","April 26, 2021","April 26, 2021"
2691,NCT04270981,ADME Study of Acoziborole in Healthy Subjects,"Trypanosomiases, African","Drug: [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C",Drugs for Neglected Diseases,Phase 1,6,Other,"February 5, 2020","July 8, 2020","July 8, 2020"
2692,NCT04270487,The DOMINO Trial: Diet Or Medication in Irritable Bowel syNdrOme,Irritable Bowel Syndrome,Other: IBS Diet|Drug: Otilonium Bromide,Universitaire Ziekenhuizen KU Leuven,Phase 4,472,Other,"July 26, 2018","May 4, 2020","July 6, 2020"
2693,NCT04269707,Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044,Iron Deficiency Anemia,Drug: Ferric carboxymaltose,"American Regent, Inc.",Phase 3,7,Industry,"November 19, 2019","December 30, 2020","January 29, 2021"
2694,NCT04269538,"Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants",Healthy,Drug: PF-06480605|Drug: Placebo,Pfizer,Phase 1,16,Industry,"February 19, 2020","November 11, 2020","November 11, 2020"
2695,NCT04269356,"Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants",Healthy Participants,Drug: BMS-986256|Drug: Milk of magnesia,Bristol-Myers Squibb,Phase 1,8,Industry,"February 18, 2020","March 30, 2021","March 30, 2021"
2696,NCT04268953,Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production,Alzheimer Disease,Drug: Tricaprilin,Cerecin,Phase 1,12,Industry,"February 27, 2020","March 26, 2020","May 1, 2020"
2697,NCT04268303,Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia,Agitation|Schizophrenia|Schizo Affective Disorder|Schizoaffective Disorder|Schizophreniform Disorders,Drug: Sublingual film containing dexmedetomidine (BXCL501)|Drug: Placebo Film,BioXcel Therapeutics Inc|Cognitive Research Corporation,Phase 3,381,Industry,"January 24, 2020","May 6, 2020","May 6, 2020"
2698,NCT04268069,Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye,Dry Eye Disease,Drug: PL9643 Ophthalmic Solution|Drug: Placebo Ophthalmic Solution,"ORA, Inc.|Palatin Technologies, Inc",Phase 2,160,Industry,"February 14, 2020","October 5, 2020","October 5, 2020"
2699,NCT04267250,Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids,Healthy Female Volunteers,Drug: PF-06700841|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),Pfizer,Phase 1,18,Industry,"August 24, 2020","November 6, 2020","November 6, 2020"
2700,NCT04266756,A Study of Selexipag in Healthy Male Participant,Healthy,Drug: Selexipag matrix tablet|Drug: Selexipag encapsulated pellets|Drug: Selexipag Immediate-release (IR) tablet,Actelion,Phase 1,24,Industry,"January 23, 2020","August 14, 2020","August 14, 2020"
2701,NCT04266509,Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600,Healthy Volunteers,Drug: PF-06651600|Drug: Rifampin,Pfizer,Phase 1,12,Industry,"June 25, 2020","September 10, 2020","September 10, 2020"
2702,NCT04266288,Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department,Depression|Depression Severe|Depression Acute|Depression and Suicide|Suicidal Ideation,Drug: Ketamine|Drug: Sodium Chloride 0.9%,MercyOne Des Moines Medical Center,Phase 4,29,Other,"October 18, 2019","May 31, 2020","May 31, 2020"
2703,NCT04265911,"Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects",Healthy Volunteers,Biological: ASP3772 (subcutaneous)|Biological: ASP3772 (intramuscular)|Biological: PPSV23 (subcutaneous)|Biological: PPSV23 (intramuscular),"Affinivax, Inc.",Phase 1,126,Industry,"February 19, 2020","November 7, 2020","November 7, 2020"
2704,NCT04265781,Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants,Endometriosis Related Pain|Overactive Bladder|Diabetic Neuropathic Pain|Refractory or Unexplained Chronic Cough,Drug: BAY1817080|Drug: Matching Placebo,Bayer,Phase 1,36,Industry,"February 15, 2020","September 20, 2020","September 20, 2020"
2705,NCT04265456,A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers,Postoperative Pain,Drug: Pregabalin 100mg|Drug: Acetaminophen 1300mg,"Nevakar, Inc.",Phase 1,63,Industry,"January 14, 2020","June 15, 2020","July 22, 2020"
2706,NCT04265001,Topical Hyaluronic Acid and Recurrent Aphthous Stomatitis.,Recurrent Aphthous Stomatitis,Drug: Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash,Cairo University,Phase 3,34,Other,"November 1, 2019","January 20, 2020","January 20, 2020"
2707,NCT04264637,Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis,Allergic Rhinitis,Drug: Azelastine hydrochloride (BAYR9258)|Drug: Placebo,Bayer,Phase 3,110,Industry,"February 3, 2020","March 17, 2021","March 17, 2021"
2708,NCT04264130,Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection,Schistosomiasis Haematobia,Drug: Artesunate-Pyronaridine|Drug: Artemether-Lumefantrine|Drug: Artefenomel-Ferroquine,Centre de Recherche Médicale de Lambaréné,Phase 2,54,Other,"July 31, 2018","December 31, 2019","December 31, 2019"
2709,NCT04263987,"A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial",Benign Prostatic Hyperplasia,Procedure: Moses laser enucleation of prostate,Vanderbilt University Medical Center,Phase 3,60,Other,"January 1, 2020","December 30, 2020","December 30, 2020"
2710,NCT04263844,Intranasal Dexmedetomidine Versus Intranasal Midazolam for Emergence Delirium Prevention,Emergence Delirium,Drug: Intranasal dexmedetomidine|Drug: Intranasal Midazolam,Indonesia University,Phase 4,66,Other,"January 10, 2019","October 10, 2019","October 10, 2019"
2711,NCT04263415,"The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity","PCOS|Semaglutide|Taste, Altered|Tongue Tissue Transcriptome|Gastric Emptying|Central Neural Response",Drug: Semaglutide|Other: Placebo,University Medical Centre Ljubljana,Phase 4,30,Other,"November 2, 2019","May 8, 2020","May 31, 2020"
2712,NCT04263350,A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time,Healthy Participants,Drug: Atazanavir/Cobicistat|Drug: Reyataz Atazanavir|Drug: Cobicistat,Bristol-Myers Squibb,Phase 1,34,Industry,"February 26, 2020","November 12, 2020","November 17, 2020"
2713,NCT04263142,A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants,HIV Infections,Drug: GSK3640254 Tablet|Drug: GSK3640254 Capsule,ViiV Healthcare,Phase 1,39,Industry,"January 27, 2020","March 24, 2020","March 24, 2020"
2714,NCT04262661,A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes,"Healthy Volunteers|Diabetes Mellitus, Type 2",Drug: NNC0472-0147|Drug: insulin glargine|Drug: Placebo (NNC0472-0147),Novo Nordisk A/S,Phase 1,36,Industry,"March 2, 2020","September 25, 2020","September 25, 2020"
2715,NCT04261517,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,"Pneumonia, Pneumocystis|Coronavirus|COVID-19",Drug: Hydroxychloroquine,Shanghai Public Health Clinical Center,Phase 3,30,Other,"February 6, 2020","February 25, 2020","February 25, 2020"
2716,NCT04260685,Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility,Lumbar Disc Herniation,Drug: Lidocaine|Drug: Esmolol,Zagazig University,Phase 2,70,Other,"February 4, 2020","June 15, 2020","June 30, 2020"
2717,NCT04260594,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,2019-nCoV,Drug: Arbidol|Other: basic treatment,Jieming QU|Ruijin Hospital,Phase 4,236,Other,"February 8, 2020","March 12, 2020","December 30, 2020"
2718,NCT04260516,The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major,Thalassemia Major,Drug: N-acetyl cysteine,Beni-Suef University,Phase 1,100,Other,"June 3, 2019","December 3, 2019","December 30, 2019"
2719,NCT04260438,"Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects","Diabetes Mellitus, Type 2","Drug: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|Drug: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|Drug: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T",Chong Kun Dang Pharmaceutical,Phase 1,24,Industry,"April 8, 2020","June 15, 2020","June 24, 2020"
2720,NCT04260373,Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.,Healthy Adult Male Volunteers,Drug: [14C]SHR4640,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,6,Industry,"March 19, 2020","April 3, 2020","April 3, 2020"
2721,NCT04259346,A Study of Two Formulations of Ixekizumab in Healthy Participants,Healthy,Drug: Ixekizumab,Eli Lilly and Company,Phase 1,245,Industry,"February 5, 2020","February 19, 2021","February 19, 2021"
2722,NCT04259086,Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines,"Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)",Drug: DaxibotulinumtoxinA for injection,"Revance Therapeutics, Inc.",Phase 2,48,Industry,"December 6, 2019","November 2, 2020","November 2, 2020"
2723,NCT04258995,"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS",Group B Streptococcal Infections,Biological: Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6),Pfizer,Phase 2,151,Industry,"February 11, 2020","September 15, 2020","September 15, 2020"
2724,NCT04258865,A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348,Hypertension|Dyslipidemias,"Drug: CKD-348 F1|Drug: CKD-348 F2|Drug: CKD-828, D097, D337",Chong Kun Dang Pharmaceutical,Phase 1,30,Industry,"March 25, 2020","April 26, 2020","May 13, 2020"
2725,NCT04258527,Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations,Solid Tumor,Drug: Pemigatinib,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,12,Industry,"March 26, 2020","July 2, 2020","March 8, 2021"
2726,NCT04258189,"A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants",Healthy,Drug: JNJ-64417184,"Janssen Research & Development, LLC",Phase 1,16,Industry,"February 11, 2020","August 5, 2020","August 5, 2020"
2727,NCT04257032,A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood,Healthy,Drug: Rosuvastatin|Drug: Rosuvastatin + BI 1323495|Drug: Dabigatran etexilate|Drug: Dabigatran etexilate + BI 1323495,Boehringer Ingelheim,Phase 1,28,Industry,"February 13, 2020","September 23, 2020","September 23, 2020"
2728,NCT04256629,A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart,Healthy Volunteers (Intended Indication: Chronic Kidney Disease),Drug: Verinurad|Drug: Placebo|Drug: Allopurinol,AstraZeneca|Parexel,Phase 1,24,Industry,"March 3, 2020","August 21, 2020","August 21, 2020"
2729,NCT04256603,Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI,Spinal Cord Injuries|Neuropathic Pain,Drug: Gabapentin|Other: No gabapentin,MetroHealth Medical Center,Phase 4,27,Other,"August 1, 2019","March 30, 2020","April 1, 2020"
2730,NCT04256434,A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.,Health,Drug: Dinalbuphine sebacate|Drug: Nalbuphine HCl,"Lumosa Therapeutics Co., Ltd.",Phase 1,24,Industry,"January 31, 2020","May 29, 2020","May 29, 2020"
2731,NCT04256252,Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE),Neuromyelitis Optica Spectrum Disorder,Drug: Rituximab,Tang-Du Hospital,Phase 4,108,Other,Apr-14,Apr-20,Jun-20
2732,NCT04255992,Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypertensive Blacks Women,Hypertension|Postmenopausal Disorder,Dietary Supplement: Calcium Arm|Dietary Supplement: Vitamin D/Calcium,Yaounde Central Hospital,Phase 4,22,Other,"November 1, 2018","May 15, 2019","May 15, 2019"
2733,NCT04255979,A Study of HY209 in Healthy Male Volunteers for Sepsis,Sepsis,Drug: HY209,Shaperon,Phase 1,40,Industry,"December 5, 2019","June 12, 2020","June 12, 2020"
2734,NCT04255121,Bicarbonate Epidural Injection in Emergency Caesarian,Emergency Caesarean,Drug: 2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|Drug: 2% adrenaline lidocaine,CHU de Reims,Phase 3,400,Other,"June 22, 2020","December 13, 2020","February 26, 2021"
2735,NCT04254913,Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy,Japanese Patients With ALS,Drug: MT-1186,Mitsubishi Tanabe Pharma Corporation,Phase 1,6,Industry,"January 24, 2020","April 16, 2020","April 22, 2020"
2736,NCT04254042,Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.,Hypertension,"Drug: Perindopril Arginine|Drug: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer",Yaounde Central Hospital,Phase 4,24,Other,"October 1, 2018","May 1, 2019","May 1, 2019"
2737,NCT04253353,A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics,Healthy Volunteers,Drug: tafamidis|Drug: rosuvastatin,Pfizer,Phase 1,12,Industry,"February 6, 2020","August 10, 2020","August 10, 2020"
2738,NCT04252885,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Coronavirus Infections,Drug: Lopinavir and Ritonavir Tablets|Drug: Arbidol,Guangzhou 8th People's Hospital,Phase 4,86,Other,"January 28, 2020","April 30, 2020","May 31, 2020"
2739,NCT04252833,"Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers","Pain, Acute|Acute Pain|Surgery|Neuropathy",Drug: CT-044,"Lotus Clinical Research, LLC|CerSci Therapeutics",Phase 1,10,Other,"February 18, 2020","March 16, 2020","March 16, 2020"
2740,NCT04252495,The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics,Hepatic Impairment|Healthy Subjects,Drug: Aprocitentan,Idorsia Pharmaceuticals Ltd.,Phase 1,17,Industry,"June 26, 2020","April 5, 2021","May 6, 2021"
2741,NCT04252300,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",Drug Interactions,Drug: Rosuvastatin|Drug: Rosuvastatin + BAY1817080,Bayer,Phase 1,14,Industry,"March 2, 2020","August 29, 2020","December 7, 2020"
2742,NCT04252131,Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia,Schizophrenia,Drug: cassia seed tablet,Calo Psychiatric Center,Phase 1,92,Other,"May 17, 2018","October 31, 2019","October 31, 2019"
2743,NCT04250792,Efficacy of Low Dose Naltrexone in Psoriasis,Psoriasis,Drug: Naltrexone Pill,Jinnah Postgraduate Medical Centre,Phase 1,42,Other,"January 1, 2019","July 31, 2019","September 30, 2019"
2744,NCT04250506,A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects,Healthy,Drug: Daridorexant|Drug: Placebo|Drug: Moxifloxacin,Idorsia Pharmaceuticals Ltd.,Phase 1,36,Industry,"February 28, 2020","July 22, 2020","July 22, 2020"
2745,NCT04250298,Sucrosomal Iron Supplementation in Blood Donors,Iron-deficiency,Dietary Supplement: sucrosomal iron,"Medical University of Graz|Fresenius Kabi Austria GmbH, Graz|Johannes Kepler University of Linz",Phase 4,50,Other,"November 13, 2019","September 28, 2020","December 20, 2020"
2746,NCT04249804,the Use of Magnesium Sulfate for Prevention of Postspinal Shivering,Prevention of Postspinal Shivering,Drug: Magnesium Sulfate 1000 MG,Cairo University,Phase 4,90,Other,"January 15, 2020","June 1, 2020","June 3, 2020"
2747,NCT04249687,Treatment of Moderate to Severe Lateral Canthal Lines,Lateral Canthal Lines,Biological: botulinum toxin|Biological: Placebo,Galderma R&D,Phase 3,303,Industry,"February 10, 2020","September 25, 2020","February 10, 2021"
2748,NCT04249583,Treatment of Moderate to Severe Glabellar Lines,Glabellar Frown Lines,Biological: botulinum toxin|Biological: Placebo,Galderma R&D,Phase 3,300,Industry,"February 10, 2020","August 7, 2020","January 5, 2021"
2749,NCT04249336,"Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH",Dentin Hypersensitivity,Drug: Fluoro-Calcium-Phospho-Silicate based dentifrices|Drug: 8% Arginine based dentifrices|Drug: 8% Strontium Acetate|Drug: Sodium Fluoride,Dow University of Health Sciences,Phase 3,140,Other,"September 27, 2019","January 16, 2021","January 16, 2021"
2750,NCT04249323,Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants,Healthy Adults,Drug: CORT113176 Lipid Capsule Formulation|Drug: Placebo matching CORT113176 Lipid Capsule Formulation|Drug: Prednisone,Corcept Therapeutics,Phase 1,110,Industry,"January 27, 2020","October 15, 2020","October 15, 2020"
2751,NCT04249284,Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants,Healthy Participants,Drug: BMS-986165|Drug: BMS-986165 prototype 1|Drug: BMS-986165 prototype 2,Bristol-Myers Squibb,Phase 1,18,Industry,"February 6, 2020","March 15, 2020","March 15, 2020"
2752,NCT04249128,"Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)",Hair Loss|Skin Laxity|Cosmetic Acne|Nails; Soft|Skin Aging,Dietary Supplement: Vegetarian Collagen|Dietary Supplement: Keratin|Dietary Supplement: Ceramides|Dietary Supplement: Astaxanthin,ProofPilot|Noho Health,Phase 3,75,Industry|Other,"January 15, 2020","January 28, 2021","February 9, 2021"
2753,NCT04249076,Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2),Cataract,Drug: Clobetasol Propionate|Drug: Vehicle,Salvat,Phase 3,215,Industry,"June 4, 2020","April 14, 2021","April 14, 2021"
2754,NCT04247984,A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Biological: Bevacizumab|Drug: Capecitabine|Drug: Irinotecan|Drug: 5-FU|Drug: CF,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Hospital|Henan Cancer Hospital|Liaoning Tumor Hospital & Institute|Jiangsu Cancer Institute & Hospital",Phase 2,264,Other,"May 1, 2018","April 1, 2021","January 31, 2022"
2755,NCT04247815,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,"Aclaris Therapeutics, Inc.",Phase 2,25,Industry,"March 16, 2020","February 4, 2021","February 4, 2021"
2756,NCT04247074,Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination,Glabellar Frown Lines (GL)|Lateral Canthal Lines (LCL),Biological: botulinum toxin neuromodulator|Biological: Placebo,Galderma R&D,Phase 3,411,Industry,"February 10, 2020","October 2, 2020","February 26, 2021"
2757,NCT04246866,First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration,Dry Age-related Macular Degeneration|Geographic Atrophy|Macular Degeneration|Retinal Disease|Retinal Degeneration,Biological: GEM103,"Gemini Therapeutics, Inc.",Phase 1,12,Industry,"December 19, 2019","October 21, 2020","October 21, 2020"
2758,NCT04246749,Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers,Healthy Volunteers,Drug: [14C]-CRN00808|Drug: CRN00808,Crinetics Pharmaceuticals Inc.,Phase 1,11,Industry,"September 17, 2019","October 25, 2019","October 25, 2019"
2759,NCT04246723,Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1,Chronic Hepatitis c Genotype 1,Drug: Narlaprevir|Drug: Ritonavir|Drug: Sofosbuvir,R-Pharm|Almedis|Scientific Center EFiS|ChromSystemsLab,Phase 2,85,Industry|Other,"May 6, 2019","April 8, 2020","August 12, 2020"
2760,NCT04246554,Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery,ACL Injury|Postoperative Pain,Drug: Ketorolac|Drug: Oxycodone-Acetaminophen,University Hospitals Cleveland Medical Center,Phase 3,49,Other,"May 21, 2019","October 9, 2020","January 1, 2021"
2761,NCT04246255,Pain Relief During Intravenous Cannulation in Pediatric Patients,Cannula Site Pain|Local Anesthesia,"Drug: Xylocaine 10% Oral|Drug: Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul",Yeditepe University,Phase 4,80,Other,"February 3, 2020","August 1, 2020","August 24, 2020"
2762,NCT04245709,Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis,Drug: Clenbuterol,"Dwight Koeberl, M.D., Ph.D.|Duke University",Phase 2,25,Other,"February 10, 2020","March 10, 2021","March 10, 2021"
2763,NCT04244448,Bioequivalence of Solid/Crushed/Dissolved Forms of Biktarvy®,Healthy Volunteers,Drug: receive dissolved form of BIKTARVY®|Drug: receive crushed form of BIKTARVY®|Drug: receive solid form of BIKTARVY®,"University Hospital, Caen",Phase 1,18,Other,"December 2, 2019","April 24, 2021","May 31, 2021"
2764,NCT04244097,The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy,"Pain, Postoperative",Drug: Bupivacaine Hydrochloride|Drug: Neostigmine,Kasr El Aini Hospital,Phase 2,56,Other,"April 10, 2020","July 6, 2020","August 6, 2020"
2765,NCT04244084,Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection,Viral Respiratory Infection,Drug: MMH-407|Drug: Placebo,Materia Medica Holding,Phase 3,240,Industry,"October 8, 2019","April 9, 2020","April 9, 2020"
2766,NCT04243954,Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration,Cancer Pain,Drug: PCA IV Hydromorphone (continuous dose = 0)|Drug: PCA IV Hydromorphone (continuous dose ≠ 0)|Drug: Oral morphine,Fujian Cancer Hospital,Phase 2,95,Other,"April 10, 2020","October 21, 2020","November 21, 2020"
2767,NCT04243863,VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers,Healthy Volunteers,Drug: VNRX-7145|Drug: Placebo,"Venatorx Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,83,Industry|NIH,"January 20, 2020","April 5, 2021","April 5, 2021"
2768,NCT04243681,Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis,"Cirrhosis, Liver",Combination Product: CD 34 and MSC infusion|Drug: Standard of care for Cirrhosis management,"Asian Institute of Gastroenterology, India",Phase 4,5,Other,"July 1, 2019","August 1, 2020","September 1, 2020"
2769,NCT04243486,A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis,Scalp Psoriasis,Drug: UHE-105|Drug: Vehicle,"Therapeutics, Inc.",Phase 2,22,Industry,"January 2, 2020","June 15, 2020","June 15, 2020"
2770,NCT04243083,"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants",Healthy,"Drug: TLL018 tablet, placebo","TLL Pharmaceutical, LLC|Hangzhou Highlightll Pharmaceutical Co., Ltd",Phase 1,100,Industry,"January 26, 2020","December 23, 2020","January 31, 2021"
2771,NCT04242706,VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs,Ventilator-associated Pneumonia,Device: ETTEvac|Device: BIP ETTEvac,Bactiguard AB,Phase 4,323,Industry,"October 31, 2018","May 8, 2020","May 8, 2020"
2772,NCT04241458,A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321,Healthy Volunteers,Drug: BI 703621|Drug: Placebo|Drug: Midazolam,Boehringer Ingelheim,Phase 1,39,Industry,"January 30, 2020","November 25, 2020","November 25, 2020"
2773,NCT04241393,An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects,Healthy Subjects,Drug: Tavapadon tablet|Drug: Tavapadon [14C] suspension,"Cerevel Therapeutics, LLC",Phase 1,12,Industry,"February 4, 2020","November 8, 2020","November 8, 2020"
2774,NCT04240223,A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers,Healthy Volunteers,Drug: Brilacidin|Drug: Placebo|Radiation: 4Mq 99mTc-DTPA,"Innovation Pharmaceuticals, Inc.",Phase 1,9,Industry,"January 6, 2020","February 12, 2020","February 12, 2020"
2775,NCT04239872,Fluoride Retention in the Mouth of Older Adults,Hyposalivation,Drug: Fluoride mouthwash|Drug: Calcium and fluoride mouthwash,University of Michigan,Phase 1,20,Other,"March 11, 2020","April 5, 2021","April 5, 2021"
2776,NCT04239755,Doxycycline in Acute Traumatic Brain Injury,Traumatic Brain Injury,Drug: Doxycycline 100 MG Oral Tablet|Other: placebo,Damanhour University|Tanta University,Phase 4,50,Other,"February 1, 2020","July 30, 2020","October 30, 2020"
2777,NCT04239560,Preventive Effect of Boron-based Gel on Radiation Dermatitis,Radiodermatitis,Drug: Boron-based Gel (Fibore)|Drug: Placebos,Tabriz University of Medical Sciences,Phase 3,257,Other,"February 4, 2019","September 21, 2019","December 21, 2019"
2778,NCT04239313,A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02),Tuberculosis,Biological: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Biological: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",Phase 1,30,Industry,"May 27, 2020","February 24, 2021","June 20, 2022"
2779,NCT04238962,A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens,Overweight|Obesity,Drug: Semaglutide (administered by DV3396 pen-injector)|Drug: Semaglutide (administered by PDS290 pen-injector),Novo Nordisk A/S,Phase 1,111,Industry,"February 3, 2020","October 20, 2020","October 20, 2020"
2780,NCT04238689,"Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F","Malaria,Falciparum",Biological: TB31F,Radboud University Medical Center|The PATH Malaria Vaccine Initiative (MVI),Phase 1,25,Other,"February 14, 2020","March 4, 2021","March 4, 2021"
2781,NCT04238663,Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers,Healthy Volunteers,Drug: MB02 (Bevacizumab Biosimilar)|Drug: EU approved Avastin®|Drug: US licenced Avastin®,mAbxience Research S.L.,Phase 1,115,Industry,"September 24, 2019","March 17, 2020","March 17, 2020"
2782,NCT04238650,A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers,Healthy Volunteers|Male|Japanese,Drug: MB02 (Bevacizumab Biosimilar)|Drug: EU approved Avastin®,mAbxience Research S.L.,Phase 1,49,Industry,"August 2, 2019","December 27, 2019","December 27, 2019"
2783,NCT04238208,The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy,Diabetic Nerve Problems|Diabetic Neuropathy|Diabetic Complications Neurological,"Drug: Lidocaine 5% patch|Drug: Capsaicin 8% Patch, Per 10 Square Centimeters",Corporacion Parc Tauli,Phase 4,290,Other,"January 10, 2019","December 10, 2019","January 2, 2020"
2784,NCT04238195,"A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects",TQT Study,Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Drug: Moxifloxacin 400mg|Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr),Spero Therapeutics|Celerion,Phase 1,24,Industry,"January 19, 2020","February 26, 2020","February 26, 2020"
2785,NCT04237597,Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers,Healthy,Drug: K-877|Drug: CSG452,"Kowa Research Institute, Inc.",Phase 1,20,Industry,"December 17, 2019","January 31, 2020","March 4, 2020"
2786,NCT04237246,Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants,Liver Failure,Drug: Tacrolimus,University of Manitoba,Phase 4,20,Other,Apr-15,"November 27, 2019","November 27, 2019"
2787,NCT04237129,PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males,"Diabetes Mellitus, Type 1",Drug: Gan & Lee Insulin Aspart,"Gan and Lee Pharmaceuticals, USA",Phase 1,36,Industry,"August 27, 2019","December 16, 2019","December 16, 2019"
2788,NCT04237090,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,Breast Cancer|Lung Cancer|Ovarian Cancer|Oesophageal Cancer|Head Cancer Neck|Cervical Cancer|Endometrial Cancer,Drug: Diphenhydramine|Drug: Cetirizine|Drug: Lactose pill|Drug: Sodium chloride 0.9%,Ciusss de L'Est de l'Île de Montréal,Phase 3,27,Other,"February 14, 2020","August 28, 2020","September 4, 2020"
2789,NCT04236960,Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.,Meningococcal Infections,Biological: Meningococcal Group ACYW135 Conjugate Vaccine,"Walvax Biotechnology Co., Ltd.",Phase 1,100,Industry,"July 17, 2018","September 16, 2019","November 28, 2019"
2790,NCT04236921,Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis),Other,Drug: DopaSnap®|Drug: RDL of CD-LD,Riverside Pharmacueticals Corporation,Phase 1,57,Industry,"July 15, 2019","September 11, 2019","December 1, 2019"
2791,NCT04236635,Histopathology Following CCH Injection,Characteristics of Subcutaneous Tissue,Drug: Collagenase Clostridium Histolyticum Single Injection Technique|Drug: Collagenase Clostridium Histolyticum Multiple Injection Technique,Endo Pharmaceuticals,Phase 2,10,Industry,"December 20, 2019","September 23, 2020","October 26, 2020"
2792,NCT04236219,ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers,Hyperuricemia,Drug: ALLN-346|Drug: Placebo,Allena Pharmaceuticals,Phase 1,24,Industry,"September 2, 2020","November 6, 2020","November 6, 2020"
2793,NCT04235985,Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times,General Skin Cleansing,Combination Product: Chlorhexidine Gluconate with HUBS,Molnlycke Health Care AB,Phase 4,26,Industry,"January 23, 2020","April 2, 2020","April 2, 2020"
2794,NCT04235933,A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects,Healthy,Biological: Tai Ai(RC18) 80mg|Biological: Tai Ai(RC18) 160mg|Biological: RC18 240mg,"RemeGen Co., Ltd.",Phase 1,36,Industry,"September 17, 2019","December 20, 2019","December 20, 2019"
2795,NCT04235439,PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males,Diabetes Mellitus,Drug: Gan & Lee Insulin Lispro Injection,"Gan and Lee Pharmaceuticals, USA",Phase 1,36,Industry,"April 23, 2019","July 3, 2019","July 3, 2019"
2796,NCT04235270,A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants,Healthy,Combination Product: FDC of Macitentan and Tadalafil|Drug: Macitentan|Drug: Tadalafil,"Janssen Research & Development, LLC",Phase 1,62,Industry,"January 17, 2020","July 17, 2020","July 17, 2020"
2797,NCT04234672,"A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants",Healthy Volunteers,Drug: TAK-831 Oral Tablet|Drug: [14C]TAK-831 IV Infusion|Drug: [14C]TAK-831 Oral Suspension,Neurocrine Biosciences|Takeda,Phase 1,6,Industry,"February 17, 2020","April 4, 2020","April 4, 2020"
2798,NCT04234464,A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma,Exercise Induced Bronchospasm,Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Combination Product: Placebo metered-dose inhaler,Bond Avillion 2 Development LP,Phase 3,60,Industry,"January 15, 2020","August 28, 2020","August 28, 2020"
2799,NCT04233437,Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects,Stroke,Drug: MLC1501|Drug: CYP Cocktail|Drug: Transporter Cocktail,Moleac Pte Ltd.|Moleac Australia Pty Ltd,Phase 1,27,Industry|Other,"February 10, 2020","May 16, 2020","May 16, 2020"
2800,NCT04233060,A Study of CS3005 in Advanced Solid Tumors,Advanced Solid Tumor,Drug: CS3005,CStone Pharmaceuticals,Phase 1,9,Industry,"January 10, 2020","January 31, 2021","February 17, 2021"
2801,NCT04232943,Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults,Polio,Biological: Inactivated Poliomyelitis Vaccine (IPV)|Biological: E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|Biological: Bivalent Oral Polio Vaccine (bOPV),PATH,Phase 1,87,Other,"January 22, 2020","February 1, 2021","February 1, 2021"
2802,NCT04232826,A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma,Diffuse Non-Hodgkin Lymphoma,Biological: single dose of CNCT19,Juventas Cell Therapy Ltd.,Phase 1,9,Industry,"January 15, 2020","January 1, 2021","November 1, 2022"
2803,NCT04232813,Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream,Vulvovaginal Atrophy,Drug: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|Drug: Promestriene Vaginal,Instituto Palacios|Novo Nordisk A/S,Phase 3,120,Other|Industry,"January 9, 2020","June 30, 2020","November 30, 2020"
2804,NCT04232644,"Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)",ADHD|Narcolepsy,Drug: ADAIR 10mg IR capsules|Drug: Crushed d-amphetamine sulfate IR tablets,"Vallon Pharmaceuticals, Inc.",Phase 1,16,Industry,"May 27, 2019","July 17, 2019","July 17, 2019"
2805,NCT04232514,Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects,Chronic Hepatitis C,Drug: HEC74647|Drug: HEC110114,"Sunshine Lake Pharma Co., Ltd.",Phase 1,28,Industry,"July 15, 2020","August 10, 2020","August 22, 2020"
2806,NCT04232345,A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers,Heart Failure With Preserved Ejection Fraction (HFpEF),Drug: AZD4831|Drug: Placebo,AstraZeneca|Parexel,Phase 1,32,Industry,"January 16, 2020","March 11, 2021","March 11, 2021"
2807,NCT04231994,Therapeutic Plasmaexchange in Early Septic Shock,Septic Shock,Device: TPE,Hannover Medical School,Phase 2,40,Other,"June 1, 2018","July 31, 2020","August 31, 2020"
2808,NCT04231435,"Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin",Healthy Volunteers,Drug: Fedratinib|Drug: Digoxin|Drug: Rosuvastatin|Drug: Metformin,"Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation",Phase 1,24,Industry,"December 18, 2019","February 19, 2020","February 21, 2020"
2809,NCT04231136,"Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers",Healthy,Drug: Tegoprazan 50 mg|Drug: EAPA115|Drug: RAPA115,HK inno.N Corporation,Phase 1,19,Industry,"January 14, 2020","July 29, 2020","August 3, 2020"
2810,NCT04230876,Auditory Training and Hearing Aid Satisfaction,"Hearing Impairment, Sensorineural",Behavioral: Auditory Brian Training Games/Activities,Washington University School of Medicine|National Institute on Aging (NIA),Phase 1,30,Other|NIH,"September 1, 2020","February 28, 2021","February 28, 2021"
2811,NCT04230473,A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia,Relapsed or Refractory Acute Lymphoblastic Leukemia,Biological: single dose of CNCT19,Juventas Cell Therapy Ltd.,Phase 1,10,Industry,"March 13, 2020","December 1, 2020","November 1, 2022"
2812,NCT04230252,A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants,Healthy,Drug: Acetaminophen,"Janssen Korea, Ltd., Korea",Phase 1,30,Industry,"January 7, 2020","February 10, 2020","March 23, 2020"
2813,NCT04230239,Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia,Newly Diagnosed Secondary or High Risk AML,Drug: CPX-351,PETHEMA Foundation,Phase 2,59,Other,"December 26, 2019","April 30, 2021","August 11, 2021"
2814,NCT04230083,Bioavailability of Dienogest 2.0 mg With Regards to Reference Product,Bioequivalence,Drug: Dienogest 2.0 mg Test Drug|Drug: Dienogest 2.0 mg Reference Product,Laboratorios Andromaco S.A.,Phase 1,30,Industry,"December 7, 2019","December 10, 2019","December 24, 2019"
2815,NCT04230070,Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product,Bioequivalence,Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product,Laboratorios Andromaco S.A.,Phase 1,30,Industry,"October 24, 2020","October 31, 2020","November 17, 2020"
2816,NCT04229940,Peritoneal in Laparoscopic Ventral Hernia Repair 2,"Hernia, Ventral|Seroma as Procedural Complication",Procedure: Peritoneal bridging|Procedure: No peritoneal bridging,Karolinska Institutet|Region Örebro County,Phase 2,115,Other,"March 1, 2019","December 31, 2020","December 31, 2021"
2817,NCT04229433,The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects,Thrombus,Drug: SHR2285 tablet|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,36,Industry,"August 11, 2020","November 8, 2020","November 8, 2020"
2818,NCT04229394,2ccPA Study in Patients With Symptomatic Knee Osteoarthritis,Osteoarthritis (OA) of the Knee,Drug: 2ccPA|Drug: placebo,"Orient Europharma Co., Ltd.",Phase 1,40,Industry,"February 13, 2018","March 22, 2021","March 22, 2021"
2819,NCT04229303,"Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects",Allergic Bronchopulmonary Aspergillosis,Drug: Voriconazole inhaled|Drug: oral voriconazole,Zambon SpA,Phase 1,58,Industry,"February 11, 2020","August 31, 2020","August 31, 2020"
2820,NCT04229225,A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee,Knee Osteoarthritis,Drug: UBX0101|Other: Placebo,"Unity Biotechnology, Inc.",Phase 1,35,Industry,"January 23, 2020","September 18, 2020","September 18, 2020"
2821,NCT04229030,RZL-012 for Dercum's Disease Lipomas,Dercum's Disease Lipomas,Drug: RZL-012|Drug: Vehicle,Raziel Therapeutics Ltd.,Phase 2,38,Industry,"July 30, 2020","February 20, 2021","February 20, 2021"
2822,NCT04228354,A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide,Healthy Volunteers|Overweight|Obesity,Drug: Semaglutide,Novo Nordisk A/S,Phase 1,28,Industry,"January 29, 2020","June 1, 2020","June 1, 2020"
2823,NCT04228302,"Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects",Healthy Adults,Drug: EC5026 oral capsule|Other: Placebo oral capsule,EicOsis Human Health Inc.|National Institute of Neurological Disorders and Stroke (NINDS),Phase 1,40,Industry|NIH,"December 9, 2019","July 7, 2020","July 7, 2020"
2824,NCT04227366,Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: BCD-089|Biological: Placebo|Drug: Methotrexat,Biocad,Phase 3,154,Industry,"November 19, 2019","March 15, 2021","March 1, 2022"
2825,NCT04227210,Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults,Respiratory Syncytial Virus Infections,Biological: RSV vaccine MV-012-968 (dosage #1)|Biological: RSV vaccine MV-012-968 (dosage #2),"Meissa Vaccines, Inc.",Phase 1,20,Industry,"January 14, 2020","August 27, 2020","August 27, 2020"
2826,NCT04225364,Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma,Esophageal Squamous Cell Carcinoma|Immunotherapy,Drug: camrelizumab|Drug: Paclitaxel for injection (albumin-bound)|Drug: Cisplatin,"Guangzhou Institute of Respiratory Disease|BGI-Shenzhen|Jiangsu HengRui Medicine Co., Ltd.",Phase 2,56,Other|Industry,"January 17, 2020","January 15, 2021","January 31, 2021"
2827,NCT04225260,Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines,Glabellar Lines|Lateral Canthal Lines,Biological: botulinum toxin neuromodulator,Galderma R&D,Phase 3,902,Industry,"January 27, 2020","April 12, 2021","May 21, 2021"
2828,NCT04225208,Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers,Healthy Volunteers,"Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1",Dizal Pharmaceuticals,Phase 1,8,Industry,"January 6, 2020","March 2, 2020","March 2, 2020"
2829,NCT04225052,Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers,Healthy Volunteer,Drug: YHP1903|Drug: Champix,Yuhan Corporation|Chonbuk National University Hospital,Phase 1,34,Industry|Other,"December 19, 2019","January 8, 2020","January 14, 2020"
2830,NCT04224857,"SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101",Ulcerative Colitis,Drug: AMT-101|Drug: Placebos,Applied Molecular Transport,Phase 1,52,Industry,"April 1, 2019","April 30, 2020","April 30, 2020"
2831,NCT04224818,Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders,Poor Ovarian Reserve,Drug: Dual trigger|Drug: hCG (standard),American University of Beirut Medical Center,Phase 3,140,Other,"July 11, 2018","August 20, 2019","August 30, 2019"
2832,NCT04224207,Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells,Retinitis Pigmentosa|Inherited Retinal Dystrophy,Biological: Wharton's jelly derived mesenchymal stem cell,Ankara Universitesi Teknokent,Phase 3,32,Other,"April 1, 2019","October 30, 2019","January 1, 2020"
2833,NCT04224194,Auto-injector Real Life Handling in Patients,RA,Combination Product: Adalimumab,Alvotech Swiss AG,Phase 3,107,Industry,"November 4, 2019","July 8, 2020","February 26, 2021"
2834,NCT04224116,Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Thoracic Surgery,Bleeding,Drug: Tranexamic acid injection|Drug: SSI,University Tunis El Manar,Phase 4,60,Other,"January 1, 2014","October 2, 2019","October 2, 2019"
2835,NCT04223843,A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium + olodaterol|Drug: Placebo,Boehringer Ingelheim,Phase 4,213,Industry,"January 8, 2020","September 7, 2020","September 29, 2020"
2836,NCT04223583,Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule,Soft Tissue Sarcomas,Drug: Anlotinib Hydrochloride,Henan Cancer Hospital,Phase 4,70,Other,"June 26, 2019","January 31, 2021","April 30, 2021"
2837,NCT04223349,A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants,Healthy,Drug: JNJ-70033093|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,66,Industry,"January 10, 2020","April 8, 2020","April 8, 2020"
2838,NCT04223232,"Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects",Healthy Volunteers,Drug: [14C]-MD1003,MedDay Pharmaceuticals SA|Quotient Sciences,Phase 1,6,Industry,"December 10, 2019","January 22, 2020","January 22, 2020"
2839,NCT04222647,Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA,Vulvovaginal Atrophy,Drug: WO533,Dr. August Wolff GmbH & Co. KG Arzneimittel|proDERM Institut für Angewandte Dermatologische Forschung GmbH|Bremer Pharmacovigilance Service GmbH,Phase 2,43,Industry|Other,"January 27, 2020","August 11, 2020","August 11, 2020"
2840,NCT04221906,Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test,Chronic Plaque Psoriasis,Drug: BOS-475|Drug: Active ingredient-free vehicle cream|Drug: Daivonex cream (calcipotriol 0.005%)|Drug: Betnesol-V cream (betamethasone 0.1%),Boston Pharmaceuticals,Phase 1,15,Industry,"January 6, 2020","March 6, 2020","March 6, 2020"
2841,NCT04221321,Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers,Healthy,Drug: Atorvastatin 40 mg|Drug: Tegoprazan 50 mg|Drug: RAPA114,HK inno.N Corporation,Phase 1,32,Industry,"January 7, 2020","March 12, 2020","April 20, 2020"
2842,NCT04221126,TMFI Enhances Skin Surface and Epidermal PpIX Fluorescence,Normal Skin,Device: TMFI|Drug: ALA cream|Drug: ALA gel,Merete Haedersdal|Bispebjerg Hospital,Phase 4,16,Other,"April 29, 2019","August 8, 2019","December 9, 2019"
2843,NCT04220996,Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD),MDD|Anxiety Disorders,Drug: Vortioxetine,H. Lundbeck A/S,Phase 4,100,Industry,"December 27, 2019","March 9, 2021","March 9, 2021"
2844,NCT04220801,"A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants",Healthy Volunteers,Drug: ZM-H1505R,"Shanghai Zhimeng Biopharma, Inc.",Phase 1,64,Industry,"February 17, 2020","November 18, 2020","November 18, 2020"
2845,NCT04220515,Inactivated Poliomyelitis Vaccine Made From Sabin Strain,Poliomyelitis,Biological: Inactivated Poliomyelitis Vaccine Made From Sabin Strain,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 4,49731,Other,"February 8, 2018","August 8, 2019","October 14, 2019"
2846,NCT04219865,"Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection",Pharmacokinetics,Drug: Group 1: Compound Edaravone/Placebo Injection|Drug: Group 2: Compound Edaravone/Placebo Injection|Drug: Group 3: Compound Edaravone/Placebo Injection|Drug: Group 4: Compound Edaravone/Placebo Injection|Drug: Group 5: Compound Edaravone/Placebo Injection,"Nanjing Yoko Biomedical Co., Ltd.",Phase 1,40,Industry,"June 5, 2019","August 16, 2019","August 16, 2019"
2847,NCT04219657,Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application,Accidental Wound|Heel Injury|Stem Cell Transplant,Biological: mesenchymal stem cell application,King Edward Medical University,Phase 1,110,Other,"October 29, 2016","December 20, 2019","December 22, 2019"
2848,NCT04219124,"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes",Type 2 Diabetes,Drug: IMP oral tablet|Drug: Placebo oral tablet,University of Leicester|Royal Surrey County Hospital NHS Foundation Trust|AstraZeneca,Phase 4,9,Other|Industry,"September 20, 2018","January 8, 2020","January 8, 2020"
2849,NCT04218552,Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension,"Hypertension,Essential",Drug: AD209|Drug: Amlodipine low|Drug: Amlodipine high|Drug: Telmisartan,Addpharma Inc.,Phase 2,176,Industry,"February 25, 2020","February 25, 2021","February 25, 2021"
2850,NCT04218513,Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection,Drug-drug Interaction,Drug: Compound Edaravone Injection|Drug: Edaravone Injection|Drug: 2-Aminoethanesulfonic Acid Injection,"Nanjing Yoko Biomedical Co., Ltd.",Phase 1,24,Industry,"May 10, 2019","May 31, 2019","May 31, 2019"
2851,NCT04218162,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean,Acute Migraine,Drug: Lasmiditan 50mg|Drug: Lasmiditan 100mg|Drug: Placebo,IlDong Pharmaceutical Co Ltd,Phase 3,294,Industry,"March 24, 2020","October 30, 2020","October 30, 2020"
2852,NCT04218149,Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,Breast Cancer|Postoperative Pain,Drug: Bupivacaine Injection,Sisli Hamidiye Etfal Training and Research Hospital,Phase 4,70,Other,"May 1, 2019","September 29, 2019","October 1, 2019"
2853,NCT04218110,Preoperative Skin Preparation Study to Evaluate the Antimicrobial Capabilities of Four Test Substances,Surgical Site Infection,Drug: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Drug: Prevantics 3.15 % / 70 % Swabstick,"Professional Disposables International, Inc.",Phase 3,329,Industry,"February 11, 2020","March 10, 2020","March 31, 2020"
2854,NCT04217629,Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects,Sepsis,Drug: SY-005,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",Phase 1,96,Industry,"April 26, 2019","October 5, 2019","August 19, 2020"
2855,NCT04217148,The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia,Immune Thrombocytopenia,Drug: Dexamethasone|Drug: ATRA,"Peking University People's Hospital|Beijing Hospital|Navy General Hospital, Beijing|Beijing Aerospace General Hospital|Qilu Hospital of Shandong University|Beijing Tongren Hospital",Phase 2,132,Other,"January 1, 2020","June 30, 2020","June 30, 2020"
2856,NCT04214808,To Evaluate the Pharmacokinetics and Safety of AD-208,Androgenetic Alopecia,Drug: AD-208|Drug: Avodart Soft Capsule 0.5mg,Addpharma Inc.,Phase 1,24,Industry,"January 3, 2020","February 4, 2020","May 4, 2020"
2857,NCT04214691,A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants,Healthy,Drug: Acetaminophen,"Janssen Korea, Ltd., Korea",Phase 1,30,Industry,"December 17, 2019","January 16, 2020","February 7, 2020"
2858,NCT04214652,Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: IDP-126 Gel|Drug: IDP-126 Vehicle Gel,"Bausch Health Americas, Inc.",Phase 3,180,Industry,"January 27, 2020","March 18, 2021","March 18, 2021"
2859,NCT04214639,Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: IDP-126 Gel|Drug: IDP-126 Vehicle Gel,"Bausch Health Americas, Inc.",Phase 3,183,Industry,"January 17, 2020","January 18, 2021","January 18, 2021"
2860,NCT04214301,An Open-Label Preference Evaluation of BLI800,Colonoscopy,Drug: BLI800,Braintree Laboratories,Phase 4,40,Industry,"September 24, 2019","November 21, 2019","November 21, 2019"
2861,NCT04213807,A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation,Atrial Fibrillation,Biological: MAA868 Cohort 1|Biological: MAA868 Cohort 2|Biological: MAA868 Cohort 3|Other: Placebo,"Anthos Therapeutics, Inc.|Covance",Phase 2,28,Industry,"December 11, 2019","December 29, 2020","March 8, 2021"
2862,NCT04213196,"Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers",Healthy Volunteers,Drug: HSK21542,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Second Affiliated Hospital, School of Medicine, Zhejiang University|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,66,Industry|Other,"January 9, 2020","September 6, 2020","December 7, 2020"
2863,NCT04212377,Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients,Endometrial Cancer,Biological: Dendritic Cells for endometrial cancer,Radboud University Medical Center|Stichting Katholieke Universiteit,Phase 2,8,Other,"April 8, 2019","March 9, 2021","March 9, 2021"
2864,NCT04212000,Bioavailability of Levoketoconazole and Ketoconazole Tablets,Healthy,Drug: Levoketoconazole|Drug: Ketoconazole,Cortendo AB,Phase 1,34,Industry,"December 16, 2019","January 18, 2020","January 23, 2020"
2865,NCT04211909,Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: SOF/VEL/VOX,Gilead Sciences,Phase 3,87,Industry,"January 3, 2020","November 12, 2020","November 12, 2020"
2866,NCT04211558,A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects,Healthy Volunteer,Drug: Ozanimod,Celgene,Phase 1,24,Industry,"August 12, 2020","September 26, 2020","October 9, 2020"
2867,NCT04211545,Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects,Healthy Volunteer,Drug: Rabeprazole|Drug: CC-92480,Celgene,Phase 1,24,Industry,"October 21, 2019","December 26, 2019","December 26, 2019"
2868,NCT04211389,Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis,Chronic Plaque Psoriasis,Drug: ARQ-151 0.3% cream|Drug: ARQ-151 vehicle cream,"Arcutis Biotherapeutics, Inc.",Phase 3,442,Industry,"December 17, 2019","November 23, 2020","November 23, 2020"
2869,NCT04211363,Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis,Chronic Plaque Psoriasis,Drug: Roflumilast 0.3% cream|Drug: Vehicle Cream,"Arcutis Biotherapeutics, Inc.",Phase 3,439,Industry,"December 20, 2019","November 16, 2020","November 16, 2020"
2870,NCT04211272,A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants,Healthy,Drug: Macitentan|Drug: Sildenafil|Drug: Riociguat|Drug: Rosuvastatin,Actelion,Phase 1,47,Industry,"January 14, 2020","April 19, 2021","April 19, 2021"
2871,NCT04210765,"Incremental Clomiphene Citrate Doses in Successive Cycles and FSH, LH and Steroid Hormone Levels",Unexplained Infertility|Ovulation Disorder,Drug: Clomiphene Citrate,Bagcilar Training and Research Hospital,Phase 4,50,Other,"August 2, 2019","May 20, 2020","May 25, 2020"
2872,NCT04210752,"Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers",Prevention of Herpes Zoster (HZ),Drug: Treatment 1 (EG-HZ-001)|Drug: Treatment 2 (EG-HZ-002)|Drug: Treatment 3 (EG-HZ-003)|Drug: Treatment 4 (EG-HZ-004)|Drug: Treatment 5,EyeGene Inc.|Novotech (Australia) Pty Limited,Phase 1,40,Other|Industry,"February 24, 2020","December 3, 2020","December 3, 2020"
2873,NCT04210388,A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers,Coronary Artery Disease (CAD),"Drug: AZD5718 tablet, Formulation A|Drug: AZD5718 tablet, Formulation B|Drug: AZD5718 tablet, Formulation C|Drug: AZD5718 tablet, Formulation D|Drug: AZD5718 film-coated tablet, Reference treatment",AstraZeneca|Parexel,Phase 1,12,Industry,"January 14, 2020","March 9, 2020","March 9, 2020"
2874,NCT04210349,Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age,Influenza,Biological: Quadrivalent Influenza Vaccine|Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1|Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,7106,Industry,"January 9, 2020","December 1, 2020","December 1, 2020"
2875,NCT04209933,Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies,Gastric Cancer|Helicobacter Pylori Infection|Bismuth,Drug: Bismuth potassium citrate containing quadruple therapy|Drug: Colloidal pectin bismuth capsules containing quadruple therapy|Drug: Colloidal pectin bismuth particles A quadruple therapy|Drug: Colloidal pectin bismuth particles B quadruple therapy,Xijing Hospital of Digestive Diseases,Phase 4,240,Other,"May 25, 2020","August 1, 2020","August 30, 2020"
2876,NCT04209699,A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers,Healthy Participants,Drug: BMS-986165|Drug: Famotidine,Bristol-Myers Squibb,Phase 1,18,Industry,"December 27, 2019","February 4, 2020","February 11, 2020"
2877,NCT04209439,Analgesic Effect of Erector Spinae Plane Block for Renal Colic Pain,Renal Colic,Drug: 30 ml %0.25 bupivacaine|Drug: Dexketoprofen-trometamol,Ataturk University,Phase 4,40,Other,"January 1, 2019","January 1, 2020","January 28, 2020"
2878,NCT04209049,A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function,Overweight|Obesity,Drug: NNC0174-0833,Novo Nordisk A/S,Phase 1,33,Industry,"January 15, 2020","January 5, 2021","January 5, 2021"
2879,NCT04208750,Clinical Investigation of the Vision-R800 Device.,Myopia|Hyperopia|Astigmatism|Presbyopia,Device: Vision R-800 Phoropter|Device: Standard Phoropter,"Pete Kollbaum, OD, PhD|Indiana University",Phase 4,119,Other,"November 18, 2019","February 1, 2021","February 1, 2021"
2880,NCT04208620,Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus,Type 2 Diabetes,Drug: Placebo|Drug: Cotadutide,AstraZeneca|MedImmune LLC,Phase 1,16,Industry,"January 21, 2020","July 8, 2020","July 8, 2020"
2881,NCT04208412,"A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II",Hereditary Angioedema,Drug: KVD900|Other: Placebo,"KalVista Pharmaceuticals, Ltd.",Phase 2,84,Industry,"July 2, 2019","December 8, 2020","December 8, 2020"
2882,NCT04208399,A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379,Hepatic Impairment,Drug: JNJ-56136379,Janssen Sciences Ireland UC,Phase 1,16,Industry,"January 9, 2020","March 26, 2021","March 26, 2021"
2883,NCT04208386,A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989,Hepatic Impairment,Drug: JNJ-73763989,Janssen Sciences Ireland UC,Phase 1,16,Industry,"January 8, 2020","July 20, 2020","July 20, 2020"
2884,NCT04208373,A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants,Healthy,Drug: JNJ-64417184|Drug: Itraconazole|Drug: Etravirine,"Janssen Research & Development, LLC",Phase 1,32,Industry,"December 20, 2019","March 10, 2020","March 10, 2020"
2885,NCT04208334,The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer,Cancer Cachexia|Head and Neck Cancer|Head and Neck Neoplasms,Dietary Supplement: Curcumin|Other: Placebo,Phramongkutklao College of Medicine and Hospital,Phase 2,20,Other,"February 13, 2020","February 24, 2021","March 31, 2021"
2886,NCT04208152,A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects,Healthy Volunteers,Drug: anle138b|Drug: Placebo,MODAG GmbH|Quotient Sciences|Aptuit,Phase 1,68,Industry,"December 6, 2019","August 4, 2020","August 4, 2020"
2887,NCT04208061,"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants",Healthy,Drug: Dabigatran Etexilate|Drug: DRV/COBI|Drug: Ritonavir|Drug: Darunavir,"Janssen Research & Development, LLC",Phase 1,28,Industry,"December 18, 2019","March 25, 2021","April 1, 2021"
2888,NCT04207957,A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim,Healthy,Drug: Olorofim,F2G Biotech GmbH|Covance,Phase 1,24,Industry,"December 5, 2019","September 15, 2020","September 15, 2020"
2889,NCT04207840,"Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals",Pharmacokinetics|Epinephrine|Albuterol|Asthma|Anaphylaxis,Combination Product: Epinephrine (0.125 mg/inhalation)|Combination Product: Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Combination Product: Albuterol Sulfate (0.09 mg/inhalation),"Amphastar Pharmaceuticals, Inc.",Phase 4,28,Industry,"December 9, 2019","December 20, 2019","December 23, 2019"
2890,NCT04207801,A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis,Chronic Plaque-type Psoriasis,Drug: AUR101|Drug: Matching Placebo,Aurigene Discovery Technologies Limited,Phase 2,90,Industry,"January 21, 2020","March 20, 2021","April 15, 2021"
2891,NCT04207736,The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.,Allergic Conjunctivitis,Drug: Reproxalap Ophthalmic Solution (0.25%)|Drug: Vehicle Ophthalmic Solution,"Aldeyra Therapeutics, Inc.",Phase 3,95,Industry,"December 5, 2019","February 16, 2021","February 16, 2021"
2892,NCT04207684,Generation of Biological Samples Positive to Testosterone for Anti-doping Control,Healthy Volunteers,Drug: Testosterone injection,Parc de Salut Mar,Phase 1,4,Other,"February 4, 2020","February 26, 2020","February 26, 2020"
2893,NCT04206020,Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome,Dry Eye Syndrome,Drug: SkQ1 Vehicle Solution|Drug: SkQ1 Ophthalmic Solution,"Mitotech, SA|ORA, Inc.",Phase 3,610,Industry,"December 20, 2019","October 6, 2020","October 6, 2020"
2894,NCT04205851,Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis,Inflammation|Rheumatic Diseases,Drug: KIN-1901|Drug: Placebo,Kinevant Sciences GmbH,Phase 1,36,Industry,"November 12, 2019","April 7, 2020","April 7, 2020"
2895,NCT04205565,Study on Clinical Effectiveness of L-Oxiracetam Injection,Craniocerebral Injury,Drug: High dose group: L-oxiracetam Injection|Drug: Low dose group: L-oxiracetam Injection|Drug: Control group: Oxiracetam Injection|Drug: Placebo group: Placebo Injection,"Nanjing Yoko Biomedical Co., Ltd.",Phase 2,200,Industry,"November 8, 2017","January 3, 2020","January 3, 2020"
2896,NCT04205201,The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma,To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients,"Drug: Drugs, Investigational",Chittagong Medical College,Phase 2,80,Other,"June 25, 2018","September 24, 2019","October 5, 2019"
2897,NCT04204902,Bioequivalence of 5 Tablets of 100 Milligrams (mg) Versus 2 Tablets of 250 mg Tablet Formulation 3 (TF3) of Tepotinib,Healthy,Drug: Tepotinib 100 mg|Drug: Tepotinib 250 mg,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,18,Industry,"October 17, 2019","December 16, 2019","December 16, 2019"
2898,NCT04204629,Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects,Healthy Volunteer,Drug: HIP1601 40mg,Hanmi Pharmaceutical Company Limited,Phase 1,25,Industry,"January 13, 2020","February 20, 2020","February 20, 2020"
2899,NCT04204603,A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug: CKD-506|Drug: Placebo,Chong Kun Dang Pharmaceutical,Phase 2,122,Industry,"November 30, 2018","September 30, 2019","October 29, 2019"
2900,NCT04204096,Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III),Typhoid,Biological: Vi-DT (Multi-dose formulation)|Biological: Vi-DT (Single dose formulation)|Biological: Control Vaccine,"International Vaccine Institute|SK Bioscience Co., Ltd.|Bill and Melinda Gates Foundation",Phase 3,1800,Other|Industry,"February 4, 2020","September 11, 2020","January 29, 2021"
2901,NCT04204057,Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Tenalisib,Rhizen Pharmaceuticals SA,Phase 2,21,Industry,"November 28, 2019","October 2, 2020","October 2, 2020"
2902,NCT04203862,A Study of NPC-22 in Healthy Adult Males,Healthy Adult Subjects,Drug: NPC-22|Drug: NPC-22 Placebo,Nobelpharma,Phase 1,40,Industry,"November 19, 2019","February 4, 2020","February 4, 2020"
2903,NCT04203836,A Trial to Evaluate the Effect of Food on LEO 152020,Healthy,Drug: LEO 152020 Tablet,LEO Pharma,Phase 1,12,Industry,"January 9, 2020","December 12, 2020","December 12, 2020"
2904,NCT04203342,A Therapeutic Equivalence Study of Ketoconazole Cream 2%,Tinea Pedis,Drug: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Drug: Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.),Douglas Pharmaceuticals America Ltd|Novum Pharmaceutical Research Services|ACM Global Laboratories,Phase 3,682,Industry|Other,"December 11, 2019","May 28, 2020","July 13, 2020"
2905,NCT04203225,Comparison of Two Application Techniques for LET Gel,"Lacerations|Pain, Procedural|LET","Drug: LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel",Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Children's Hospital of Orange County,Phase 4,48,Other,"May 22, 2017","November 12, 2019","November 12, 2019"
2906,NCT04202172,Functional Assessment of the Infart-related Artery With Bioactive and Polymer-free Coronary Stents (The FUNCOMBO Trial),Endothelial Dysfunction|Coronary Microvascular Disease|Myocardial Infarction,Procedure: Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction,Institut d'Investigació Biomèdica de Bellvitge|Spanish Society of Cardiology,Phase 4,60,Other,"November 5, 2018","March 1, 2020","September 1, 2020"
2907,NCT04202133,Neurocognitive Benefits of a Weight Management Program,Overweight and Obesity,Behavioral: WW (formerly Weight Watchers)|Behavioral: Waitlist,University of Pennsylvania|Weight Watchers International,Phase 4,61,Other|Industry,"November 20, 2019","April 2, 2021","July 20, 2021"
2908,NCT04201275,"The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects",Chronic Hepatitis C,Drug: HEC74647PA capsule|Drug: placebo,"Sunshine Lake Pharma Co., Ltd.",Phase 1,28,Industry,"December 18, 2019","January 17, 2020","January 21, 2020"
2909,NCT04200885,Is Therapeutic Elastic Bandage As Effective As Corticosteroids Following Third Molar Surgery?,Third Molar Surgery,Drug: Dexketoprofen Trometamol|Drug: Dexamethasone 21-Phosphate|Device: Therapeutic Elastic Bandage,Tokat Gaziosmanpasa University,Phase 4,52,Other,"May 2, 2019","August 26, 2019","November 21, 2019"
2910,NCT04200235,A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children,Preoperative Sedation,Drug: Dexmedetomidine hydrochloride nasal spray|Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,48,Industry,"January 6, 2020","August 6, 2020","August 7, 2020"
2911,NCT04200092,Staccato® Granisetron Single Dose PK,Healthy,Combination Product: 0.5mg AZ-010|Combination Product: 1mg AZ-010|Combination Product: 3mg AZ-010|Combination Product: AZ-010 1mg|Drug: IV Granisetron 1mg,"Alexza Pharmaceuticals, Inc.|Celerion",Phase 1,36,Industry,"November 4, 2019","January 10, 2020","January 19, 2020"
2912,NCT04198948,Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers,"Diabetes Mellitus, Type 2",Drug: Omeprazole|Drug: Placebo oral tablet|Drug: Gliclazide,University of Sarajevo|General Hospital Prim. Dr. Abdulah Nakas|University of Dundee|Wellcome Trust,Phase 1,15,Other,"March 4, 2019","August 5, 2019","August 5, 2019"
2913,NCT04197778,Food Effect Study of DDO-3055 Tablets in Healthy Subjects,Anemia in Chronic Kidney Disease,Drug: DDO-3055 tablet,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,14,Industry,"January 6, 2020","January 18, 2020","January 18, 2020"
2914,NCT04197661,Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects,Healthy Elderly Subjects,Drug: HSK3486,"Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Hospital of Jilin University|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,32,Industry|Other,"December 25, 2019","January 22, 2020","May 22, 2020"
2915,NCT04197570,Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial,"Opioid Use|Heart; Surgery, Heart, Functional Disturbance as Result|Anesthesia",Drug: Opioid Anesthetics|Drug: Non Opioid Analgesics,Benaroya Research Institute|Virginia Mason Hospital/Medical Center,Phase 3,9,Other,"February 4, 2020","March 14, 2020","March 14, 2020"
2916,NCT04197349,"Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman",Migraine,Biological: ALD1910|Biological: Sumatriptan,"H. Lundbeck A/S|Alder Biopharmaceuticals, Inc.",Phase 1,96,Industry,"September 24, 2019","August 19, 2020","August 19, 2020"
2917,NCT04197115,"Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone in Sepsis",Sepsis|Septic Shock,Drug: Vitamin C|Drug: Hydrocortisone|Drug: Complex B,"IMSS Hospital General de Zona 11, Piedras Negras",Phase 3,19,Other,"September 1, 2019","August 30, 2020","September 30, 2020"
2918,NCT04196309,Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization,Arterial Occlusion,Drug: low molecular weight heparin,AHEPA University Hospital,Phase 4,60,Other,"May 25, 2017","December 31, 2020","December 31, 2020"
2919,NCT04196231,Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND),Type 2 Diabetes,Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus,"University of Campania ""Luigi Vanvitelli""",Phase 4,258,Other,"November 27, 2019","September 30, 2020","October 20, 2020"
2920,NCT04196179,ANG-3070 in Healthy Adult Participants,Healthy Volunteers,Drug: ANG3070|Drug: Placebo oral capsule,Angion Biomedica Corp,Phase 1,97,Industry,"December 17, 2019","November 27, 2020","March 10, 2021"
2921,NCT04196075,The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer,Squamous Cell Carcinoma of Esophagus,Drug: Andrographis Paniculata,Chinese University of Hong Kong,Phase 3,30,Other,"March 1, 2018","February 28, 2021","June 30, 2021"
2922,NCT04195321,Norepinephrine Versus Phenylephrine for Preventing Spinal Anesthesia Induced Hypotension in Elderly,Spinal Induced Hypotension|Elderly,Drug: Norepinephrine|Drug: phenylephrine,Kasr El Aini Hospital,Phase 4,62,Other,"January 1, 2020","March 26, 2020","March 26, 2020"
2923,NCT04194918,Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers,Tobacco Use Disorder,Behavioral: Computer-Assisted Smoking Cessation Intervention|Other: Text Message|Other: Handout|Other: Questionnaire Administration|Other: Quality-of-Life Assessment|Other: Survey Administration,Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|The Safeway Foundation,Phase 1,25,Other|NIH,"May 18, 2020","September 1, 2020","September 1, 2020"
2924,NCT04194905,Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product,Bioequivalence,Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product|Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product,Laboratorios Andromaco S.A.,Phase 1,10,Industry,"November 21, 2020","November 21, 2020","December 15, 2020"
2925,NCT04194645,"A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.",Healthy,Drug: BI 474121|Drug: Placebo,Boehringer Ingelheim,Phase 1,66,Industry,"January 9, 2020","March 25, 2021","March 25, 2021"
2926,NCT04194294,Role of LIDOCAINE IN Pediatric Cochlear Implant Surgery,Anesthesia,Drug: Lidocaine|Other: Na CL 0.9%,Wahba bakhet|Bahteem Specialized Hospital|Ain Shams University,Phase 4,70,Other,"August 18, 2015","June 5, 2019","June 5, 2019"
2927,NCT04194242,"The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects",Nonalcoholic Steatohepatitis (NASH),Drug: HEC96719 tablets|Drug: Placebo tablet,"Sunshine Lake Pharma Co., Ltd.",Phase 1,64,Industry,"January 3, 2020","July 17, 2020","July 17, 2020"
2928,NCT04193852,Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product,Bioequivalence,Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product,Laboratorios Andromaco S.A.,Phase 1,10,Industry,"November 9, 2019","November 12, 2019","November 25, 2019"
2929,NCT04193748,Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial),Oral Lichen Planus,Drug: Topical pomegranate seeds and peel extracts,Cairo University,Phase 4,42,Other,"September 1, 2019","November 20, 2019","December 13, 2019"
2930,NCT04193631,Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain,Musculoskeletal Pain,Drug: Cannabidiol (CBD),Pure Green,Phase 1,16,Industry,"December 7, 2019","December 9, 2019","December 9, 2019"
2931,NCT04193566,Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes,"Nephropathy|Hypoxia|Mitochondrial Alteration|Type 1 Diabetes|Autonomic Neuropathy, Diabetic",Drug: Forxiga,"Steno Diabetes Center Copenhagen|Glostrup University Hospital, Copenhagen|Novo Nordisk A/S",Phase 4,30,Other|Industry,"February 1, 2020","September 1, 2020","January 1, 2021"
2932,NCT04193319,Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects,Advanced Cancer,Drug: Fluzoparib|Drug: Fluconazole,"Jiangsu HengRui Medicine Co., Ltd.|Hunan Cancer Hospital",Phase 1,20,Industry|Other,"July 19, 2019","September 12, 2019","September 12, 2019"
2933,NCT04192500,"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years",Influenza,Biological: OVX836|Biological: Quadrivalent seasonal influenza vaccine (Influvac TetraTM),"Osivax|Centre for vaccinology (CEVAC), University of Ghent",Phase 2,300,Industry|Other,"December 11, 2019","September 7, 2020","September 7, 2020"
2934,NCT04191928,Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy,Pancreas Cancer|DVT|Pulmonary Embolism,Drug: Apixaban,Thomas Jefferson University,Phase 1,4,Other,"March 3, 2020","July 25, 2020","September 1, 2021"
2935,NCT04191148,"Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli",Urinary Tract Infections,Drug: LBP-EC01|Drug: Placebo,Locus Biosciences,Phase 1,36,Industry,"December 30, 2019","November 19, 2020","November 19, 2020"
2936,NCT04190693,IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo,Type 1 Diabetes Mellitus,Drug: IMCY-0098 or placebo,Imcyse SA,Phase 1,30,Industry,"February 14, 2019","October 8, 2019","November 18, 2019"
2937,NCT04190654,Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite,Hepatic Impairment,Drug: KW-6356,"Kyowa Kirin, Inc.",Phase 1,26,Industry,"November 26, 2019","March 20, 2020","March 20, 2020"
2938,NCT04190290,Anorexia Nervosa Inpatient Physiotherapy Adapted Program,Anorexia Nervosa,Other: Physiotherapy Adapted Program|Diagnostic Test: Evaluation and Control,Universidad de Murcia,Phase 4,26,Other,"April 11, 2018","January 15, 2021","May 1, 2022"
2939,NCT04189900,Generation of Biological Samples Positive to Triptorelin for Anti-doping Control,Healthy Volunteers,Drug: Triptorelin,Parc de Salut Mar,Phase 1,2,Other,"April 26, 2019","May 15, 2019","May 15, 2019"
2940,NCT04189848,Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc,"Healthy Volunteers|Diabetes Mellitus, Type 2|Overweight|Obesity",Drug: Semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,Phase 4,104,Industry,"December 3, 2019","January 29, 2020","February 27, 2020"
2941,NCT04189705,A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis,Acute Gastritis|Chronic Gastritis,Drug: MCT-SR|Drug: Mucosta Tab.,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 3,392,Industry,"December 30, 2019","April 23, 2020","April 23, 2020"
2942,NCT04189588,Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine,Oncology Patients Receiving Chemotherapy,Drug: Cetirizine HCl 10 mg/mL|Drug: Diphenhydramine 50 mg/mL|Drug: anti-CD20 such as Rituximab or Paclitaxel,TerSera Therapeutics LLC,Phase 2,34,Industry,"March 25, 2020","November 23, 2020","December 23, 2020"
2943,NCT04189484,Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors,Healthy Subjects|Pharmacokinetics|Pharmacodynamics,Biological: Evolocumab|Biological: Alirocumab|Biological: Placebo,Food and Drug Administration (FDA)|Spaulding Clinical Research LLC,Phase 1,72,U.S. Fed|Other,"January 7, 2020","April 7, 2021","April 7, 2021"
2944,NCT04189198,A Comparison of 4% Articaine Versus 0.5%Bupivacaine for Ambulatory Surgery Under Supraclavicular Block,Upper Limb Surgery|Hand Surgery,Drug: Articaine|Drug: Bupivacaine,Ain Shams University,Phase 1,60,Other,"December 30, 2019","March 22, 2020","March 27, 2020"
2945,NCT04188730,A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution,Normal Healthy Volunteers,Drug: Lofexidine (granules for reconstitution)|Drug: LUCEMYRA (lofexidine) tablets,"USWM, LLC (dba US WorldMeds)|National Institute on Drug Abuse (NIDA)",Phase 1,16,Industry|NIH,"February 16, 2021","March 26, 2021","March 26, 2021"
2946,NCT04188691,A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine,Norwalk Gastroenteritis|Norovirus Infections,Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Biological: Normal saline|Biological: Aluminum adjuvant,"National Vaccine and Serum Institute, China|Lanzhou Institute of Biological Products Co., Ltd|Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.|Zhengzhou University",Phase 1,510,Industry|Other,"November 28, 2019","December 13, 2020","December 13, 2020"
2947,NCT04188223,Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children,Hepatitis B,Biological: Recombinant Hepatitis B (Bio Farma) Vaccine|Biological: Recombinant Hepatitis B (Bio Farma) Vaccine®,PT Bio Farma,Phase 1,100,Industry,"December 3, 2019","July 16, 2020","July 16, 2020"
2948,NCT04188106,Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment,Smoking Cessation|Stress|Sleep Disturbance|Nausea,Drug: Varenicline Pill|Drug: Hydroxyzine Pill,"Rose Research Center, LLC|Foundation for a Smoke Free World INC",Phase 4,26,Industry|Other,"June 17, 2019","December 15, 2019","December 15, 2019"
2949,NCT04188015,Study of ANX007 in Participants With Primary Open-angle Glaucoma,Open Angle Glaucoma,Biological: 2.5mg ANX007|Biological: 5.0mg ANX007|Other: Sham Procedure,"Annexon, Inc.",Phase 1,17,Industry,"July 25, 2018","June 3, 2019","June 3, 2019"
2950,NCT04187755,Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever,"Neutropenia, Febrile|Leukemia|Pediatric Cancer|Antibiotic Reaction",Drug: Ceftazidime Injection|Drug: Cefepime Injection,Indonesia University,Phase 4,72,Other,"March 1, 2019","July 31, 2019","July 31, 2019"
2951,NCT04187560,Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults,Schizophrenia,Drug: LB-102,LB Pharmaceuticals Inc.,Phase 1,64,Industry,"January 22, 2020","July 1, 2020","November 9, 2020"
2952,NCT04187456,A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body,Solid Tumors,Drug: Savolitinib|Drug: Midazolam,AstraZeneca|Parexel,Phase 1,14,Industry,"December 27, 2019","March 6, 2020","March 6, 2020"
2953,NCT04187339,Study of NGM395 in Adult Participants,Obesity|NAFLD,Biological: NGM395|Other: Placebo,"NGM Biopharmaceuticals, Inc",Phase 1,38,Industry,"February 13, 2020","October 20, 2020","April 22, 2021"
2954,NCT04187300,A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity,Overweight|Obesity,Drug: Semaglutide,Novo Nordisk A/S,Phase 1,68,Industry,"December 16, 2019","September 23, 2020","September 23, 2020"
2955,NCT04187222,Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis,Mucositis Oral,Other: Mechanical debridements|Biological: Bifidobacterium animalis subsp. lactis,University of Sao Paulo,Phase 3,38,Other,"July 1, 2018","August 31, 2019","November 15, 2019"
2956,NCT04187014,Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement,"Blood Loss, Surgical",Drug: Aminocaproic Acid 1000Mg Tab|Drug: Tranexamic acid tablets,Carlos A Acosta-Olivo|Universidad Autonoma de Nuevo Leon,Phase 2,90,Other,"February 6, 2020","April 26, 2021","April 26, 2021"
2957,NCT04186936,"A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers",Healthy,Drug: Combination Caplet with Loperamide HCl and Simethicone|Drug: Loperamide HCl|Drug: Simethicone,McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide,Phase 1,48,Industry,"December 5, 2019","December 26, 2019","December 26, 2019"
2958,NCT04186845,Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT),Prostate Cancer,Drug: rhPSMA-7.3 (18F) Injection,Blue Earth Diagnostics|Parexel,Phase 3,391,Industry,"May 5, 2020","April 9, 2021","October 12, 2021"
2959,NCT04186663,Pharmacokinetics of Advantage Arrest in Children,Dental Caries,Drug: Silver Diamine Fluoride,"Advantage Silver Dental Arrest, LLC|University of California, San Francisco",Phase 2,59,Industry|Other,"August 1, 2019","March 31, 2020","March 31, 2020"
2960,NCT04186442,Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder,Overactive Bladder,Drug: Botulinum toxin type A injection|Drug: Botulinum Toxin Type A Injection [Botox],Hugel,Phase 1,38,Industry,"May 12, 2020","April 26, 2021","October 26, 2021"
2961,NCT04186000,Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola,Ebola Virus Disease,Biological: Ad26.ZEBOV vaccine,Universiteit Antwerpen|Johnson & Johnson|Ace Africa|Innovative Medicines Initiative|Coalition for Epidemic Preparedness Innovations|University of Kinshasa,Phase 2,699,Other|Industry,"December 18, 2019","April 25, 2020","October 12, 2022"
2962,NCT04185740,Medication Responsiveness in Parkinson's Disease,Parkinson Disease|Medication Compliance|Tapping Task|Smartphone,Device: CloudUPDRS - Tapping Task,KU Leuven,Phase 2,33,Other,"July 25, 2019","October 20, 2020","October 20, 2020"
2963,NCT04185220,Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome,Adult T-Cell Lymphoma/Leukemia|Sezary Syndrome|Mycosis Fungoides,Drug: Recombinant human Interleukin-15 (rhIL-15)|Biological: Mogamulizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,6,NIH,"February 26, 2020","November 6, 2020","May 18, 2022"
2964,NCT04185051,A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants,Healthy,Drug: JNJ-67953964|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,76,Industry,"December 17, 2019","April 21, 2021","May 5, 2021"
2965,NCT04184999,Effect of Intraoperative Dexamethasone on Post-op Dry Eye,Dry Eye Syndromes,"Drug: dexamethasone intraocular suspension, 9%|Drug: Prednisolone Acetate 1% Oph Susp",SR Cornea Consultants,Phase 4,40,Other,"August 10, 2019","December 1, 2019","December 1, 2019"
2966,NCT04184232,Treatment of Recurrent Bladder Cancer With Dendritic Cells,Bladder Cancer,Biological: Dendritic cells|Other: Standard treatment according to the Clinical protocols,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University,Phase 2,17,Other,"July 1, 2019","December 31, 2020","December 31, 2020"
2967,NCT04184115,Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness,Motion Sickness,Drug: DPI-386 Nasal Gel|Drug: Placebos,"Repurposed Therapeutics, Inc.",Phase 3,102,Industry,"June 9, 2019","June 11, 2019","June 11, 2019"
2968,NCT04184063,Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA),Progressive Supranuclear Palsy|Multiple System Atrophy,Drug: NBMI|Other: Placebo,EmeraMed,Phase 2,20,Industry,"September 16, 2019","July 30, 2020","June 30, 2021"
2969,NCT04183686,"A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects",Healthy,Drug: ACT-1014-6470 (SAD)|Drug: ACT-1014-6470 (MAD)|Drug: Placebo (SAD)|Drug: Placebo (MAD)|Drug: 14C-ACT-1014-6470 microtracer|Drug: 14C-ACT-1014-6470 microtracer placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,88,Industry,"November 25, 2019","March 15, 2020","March 15, 2020"
2970,NCT04183517,A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males,Pharmacokinetics,Drug: PXS-5382A,Pharmaxis,Phase 1,18,Industry,"December 20, 2019","April 4, 2020","June 24, 2020"
2971,NCT04183491,Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products,Healthy Subjects|Pharmacokinetics|Pharmacodynamics,Biological: Interferon beta-1a|Biological: Peginterferon beta-1a|Biological: Placebo,Food and Drug Administration (FDA)|Spaulding Clinical Research LLC,Phase 1,84,U.S. Fed|Other,"February 28, 2020","January 26, 2021","January 26, 2021"
2972,NCT04183283,A Study of LY3526318 in Healthy Women,Healthy,Drug: LY3526318|Drug: Placebo,Eli Lilly and Company,Phase 1,16,Industry,"December 12, 2019","February 28, 2020","March 6, 2020"
2973,NCT04183192,Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists,Healthy Subjects|Pharmacokinetics|Pharmacodynamics,Biological: Mepolizumab|Biological: Reslizumab|Biological: Placebo,Food and Drug Administration (FDA)|Spaulding Clinical Research LLC,Phase 1,72,U.S. Fed|Other,"February 17, 2020","April 4, 2021","April 4, 2021"
2974,NCT04182958,"A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects",Healthy Adult Male,Drug: (14C)-OPC-61815,"Otsuka Pharmaceutical Co., Ltd.",Phase 1,8,Industry,"November 25, 2019","December 19, 2019","December 19, 2019"
2975,NCT04182880,Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain,Abdominoplasty,Drug: CPL-01|Drug: Placebo,Cali Pharmaceuticals LLC,Phase 2,20,Industry,"January 6, 2020","February 28, 2020","February 28, 2020"
2976,NCT04182191,Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam,"Molar, Third|Pain",Drug: Tenoxicam,University of Sao Paulo,Phase 4,89,Other,"March 1, 2018","July 1, 2019","November 1, 2019"
2977,NCT04182100,Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply,Polycythemia Vera (PV),Drug: P1101|Drug: Low-dose aspirin|Procedure: Phlebotomy,PharmaEssentia Japan K.K.,Phase 2,29,Industry,"December 20, 2019","March 8, 2021","March 8, 2021"
2978,NCT04181567,"Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients",Major Depressive Disorder,Other: electroconvulsive therapy|Drug: agomelatine|Drug: Placebo,"Kaohsiung Kai-Suan Psychiatric Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan)|Ministry of Science and Technology, Taiwan",Phase 4,97,Other,"March 3, 2014","October 8, 2019","November 22, 2019"
2979,NCT04181437,Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2,Healthy,Drug: NVP-1203-R1|Drug: NVP-1203-R2|Drug: NVP-1203-R1 and NVP-1203-R2,NVP Healthcare,Phase 1,40,Industry,"May 1, 2020","May 17, 2020","May 29, 2020"
2980,NCT04180943,Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery,"Anesthesia, Local",Drug: interscalene nerve block,Bassett Healthcare,Phase 4,85,Other,"December 13, 2019","March 1, 2021","June 1, 2021"
2981,NCT04179630,Study of Aldafermin (NGM282) in Participants With Impaired Renal Function,Impaired Renal Function,Biological: Aldafermin (NGM282),"NGM Biopharmaceuticals, Inc",Phase 1,48,Industry,"November 8, 2019","December 4, 2019","December 14, 2019"
2982,NCT04179474,"Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine",Migraine,Drug: Ubrogepant|Drug: Erenumab|Drug: Galcanezumab,Allergan,Phase 1,40,Industry,"September 26, 2019","December 23, 2019","December 23, 2019"
2983,NCT04179461,Personalized Treatment Algorithms for Difficult-to-treat Asthma,Asthma in Children,Drug: Cholecalciferol|Drug: antihistamine|Drug: Azithromycin|Drug: emollient cream|Drug: Fluticasone Propionate|Drug: Asthma Controller Medication,"Children's Hospital Medical Center, Cincinnati",Phase 2,21,Other,"March 16, 2018","October 3, 2019","October 3, 2019"
2984,NCT04179071,A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine,Solid Tumours,Drug: Savolitinib|Drug: Famotidine,AstraZeneca|Parexel,Phase 1,16,Industry,"December 13, 2019","March 11, 2020","March 11, 2020"
2985,NCT04178733,A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants,Healthy,Drug: LY3493269 - SC|Drug: Placebo - SC|Drug: LY3493269 - IV,Eli Lilly and Company,Phase 1,33,Industry,"January 10, 2020","May 11, 2020","May 11, 2020"
2986,NCT04178590,Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis,Periodontitis,Drug: SRP + Injectable Platelet-Rich Fibrin|Drug: SRP + placebo,University of Belgrade,Phase 4,32,Other,"October 2, 2019","June 29, 2020","July 9, 2020"
2987,NCT04178577,Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function,Renal Impairment,Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr),Spero Therapeutics,Phase 1,39,Industry,"December 6, 2019","September 6, 2020","September 11, 2020"
2988,NCT04178447,Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function,Renal Impairment,Drug: Glepaglutide,Zealand Pharma,Phase 1,16,Industry,"December 10, 2019","July 14, 2020","July 14, 2020"
2989,NCT04178109,Oral Use of Dexketoprofen/Tramadol for Acute Postoperative Pain in Total Hip Replacement With a Direct Anterior Approach.,"Postoperative Pain|Pain, Acute",Drug: Dexketoprofen/tramadol (27mg/75mg)|Drug: Tramadol hydrochloride|Drug: Paracetamol|Drug: Ropivacaine Hydrochloride 7.5 MG/ML|Drug: Levobupivacaine Hydrochloride,KAT General Hospital,Phase 2,226,Other,"January 10, 2019","November 10, 2019","November 20, 2019"
2990,NCT04177862,Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center,"Pain|Pain, Acute|Anesthesia",Drug: Sublingual Sufentanil|Drug: IV Fentanyl,University of Minnesota,Phase 4,75,Other,"December 11, 2019","January 31, 2020","January 31, 2020"
2991,NCT04177680,Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia,Hypertriglyceridemia,Drug: Omega 3 pentaenoic acid|Drug: icosapent ethyl,"Matinas BioPharma Nanotechnologies, Inc.|Matinas Biopharma, Inc|MB Clinical Research and Consulting LLC",Phase 2,100,Industry|Other,"June 3, 2020","November 27, 2020","January 18, 2021"
2992,NCT04177290,A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients,Advanced or Metastatic NSCLC,Drug: Sintilimab (M1b)|Drug: Sintilimab (approved),Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,48,Industry,"April 2, 2020","February 28, 2021","September 4, 2022"
2993,NCT04176991,Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia,Friedreich Ataxia,Biological: CTI-1601|Biological: Placebo,"Larimar Therapeutics, Inc.|Veristat, Inc.|Metrum Research Group, LLC",Phase 1,28,Industry|Other,"December 11, 2019","October 31, 2020","October 31, 2020"
2994,NCT04176757,A Study of ZN-c5 in Participants With Breast Cancer,Breast Cancer,Drug: ZN-c5,Zeno Alpha Inc.,Phase 1,35,Industry,"January 3, 2020","April 27, 2021","May 25, 2021"
2995,NCT04176536,A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body,Healthy|Chronic Kidney Disease,Drug: BI 764198,Boehringer Ingelheim,Phase 1,28,Industry,"December 10, 2019","November 17, 2020","November 17, 2020"
2996,NCT04176393,A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation,Relapsed or Refractory Acute Myeloid Leukemia,Drug: ivosidenib,CStone Pharmaceuticals,Phase 1,30,Industry,"November 12, 2019","February 18, 2021","January 18, 2023"
2997,NCT04176367,An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants,Pharmacokinetics,Drug: Nicergoline from China|Drug: Nicergoline from Italy,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer,Phase 1,40,Industry,"December 17, 2019","September 29, 2020","September 29, 2020"
2998,NCT04176328,"Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients",Cystic Fibrosis,Drug: Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.,Neupharma Srl|Sintesi Research Srl|Aptuit|Pari Pharma GmbH,Phase 1,12,Industry,"October 25, 2019","September 16, 2020","September 30, 2020"
2999,NCT04176224,Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis,Japanese Patients With ALS,Drug: MT-1186,Mitsubishi Tanabe Pharma Corporation,Phase 1,9,Industry,"April 17, 2019","September 4, 2019","September 4, 2019"
3000,NCT04175808,Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults,QT Intervals Changes|QTc Intervals Changes,Drug: Omecamtiv Mecarbil (OM)|Drug: Placebo|Drug: Moxifloxacin,Cytokinetics,Phase 1,70,Industry,"November 14, 2019","March 4, 2020","March 4, 2020"
3001,NCT04175522,Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:,Autoimmune Encephalitis,Drug: Immunoglobulin G,Green Cross Corporation|GC Biopharma Corp,Phase 2,23,Industry,"November 20, 2019","June 11, 2020","June 11, 2020"
3002,NCT04174937,"PA Tolerability, Safety and Pharmacokinetics in Healthy Volunteers","Infections, Respiratory",Drug: Potentiator of antibiotics (PA)|Other: Placebo PA,"Scientific Center for Anti-infectious Drugs, Kazakhstan|Institute Of Cardiology & Internal Diseases, Kazakhstan|Al-Farabi Kazakh National University (KazNU)",Phase 1,72,Industry|Other,"June 17, 2016","May 15, 2019","September 15, 2019"
3003,NCT04174872,Epidural Anesthesia for Gynecological Surgeries,Epidural Analgesics for Comparison,Drug: Dexmedetomidine|Drug: Midazolam,Cairo University,Phase 4,150,Other,"December 1, 2019","February 1, 2021","June 1, 2021"
3004,NCT04174131,Restylane + Lidocaine and Restylane Lyft for the Treatment of Nasolabial Folds,Wrinkles Such as Nasolabial Folds,Device: Restylane + Lidocaine|Device: Restylane® Lyft,Erevna Innovations Inc.,Phase 3,10,Other,"November 13, 2019","December 12, 2019","February 12, 2020"
3005,NCT04173962,Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects,Healthy Volunteers,Drug: Ketamine|Drug: Midazolam,Icahn School of Medicine at Mount Sinai,Phase 2,24,Other,"August 8, 2019","March 18, 2021","March 18, 2021"
3006,NCT04173429,Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis,Liver Cirrhosis|Portal Vein Thrombosis,"Drug: Nadroparin calcium, warfarin",Qilu Hospital of Shandong University,Phase 4,64,Other,"January 1, 2017","January 31, 2020","January 31, 2020"
3007,NCT04173364,Interscalene Block and Dysfunction Diaphragmatic,Diaphragmatic Paralysis,Drug: Ropivacaine 0.5% Injectable Solution|Drug: Ropivacaine 0.1% Injectable Solution,"University Hospital, Lille",Phase 3,60,Other,"October 29, 2019","September 21, 2020","September 21, 2020"
3008,NCT04172987,A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants,Healthy,Drug: Tirzepatide|Drug: EE/NGM,Eli Lilly and Company,Phase 1,40,Industry,"February 26, 2020","February 9, 2021","February 9, 2021"
3009,NCT04172831,A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia,Fibromyalgia,Drug: TNX-102 SL|Drug: Placebo SL Tablet,"Tonix Pharmaceuticals, Inc.",Phase 3,503,Industry,"December 9, 2019","October 29, 2020","October 29, 2020"
3010,NCT04172792,Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS),Amyotrophic Lateral Sclerosis,Dietary Supplement: high-caloric fatty diet|Dietary Supplement: ultra-high-caloric fatty diet|Dietary Supplement: ultra-high-caloric carbohydrate-rich diet,"Albert Christian Ludolph, Prof.|Nutritia GmbH, 91052 Erlangen, Germany|University of Ulm",Phase 1,64,Other,"November 26, 2019","April 5, 2021","April 5, 2021"
3011,NCT04172727,Subarachnoid Block With Ultrasound-Guided Transversalis Fascia Plane Block for Cesarean Section,"Caesarean Section|Pain, Acute",Drug: Bupivacaine Hcl 0.25% Inj|Drug: saline 0.9%,Ataturk University,Phase 4,60,Other,"January 1, 2019","May 1, 2019","June 1, 2019"
3012,NCT04171791,A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL),CTCL,Drug: ABT-199 (venetoclax),Yale University,Phase 1,4,Other,"January 15, 2020","February 10, 2021","June 22, 2021"
3013,NCT04171752,Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers,Geriatrics|Healthy,Drug: elafibranor,Genfit,Phase 1,21,Industry,"November 22, 2019","March 22, 2020","March 30, 2020"
3014,NCT04171739,Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim,Healthy,Drug: Itraconazole oral solution|Drug: Rifampicin Oral Capsule|Drug: Olorofim,F2G Biotech GmbH|Hammersmith Medicines Research,Phase 1,24,Industry|Other,"November 18, 2019","February 11, 2020","February 11, 2020"
3015,NCT04171687,Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers,Healthy,Drug: Clopidogrel 75mg|Drug: Tegoprazan 50 mg|Drug: RAPA113,HK inno.N Corporation,Phase 1,36,Industry,"October 21, 2019","February 7, 2020","April 9, 2020"
3016,NCT04171414,A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: CT-P17 SC AI (adalimumab),Celltrion|PPD,Phase 3,62,Industry,"September 9, 2019","November 4, 2019","April 24, 2020"
3017,NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,Multiple Sclerosis,Drug: SAR442168,Sanofi,Phase 1,6,Industry,"November 13, 2019","December 30, 2019","December 30, 2019"
3018,NCT04171258,Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia,Cervical Dystonia,Drug: Botulinum toxin type A injection|Drug: Botulinum Toxin Type A Injection [Botox],Hugel,Phase 1,38,Industry,"May 26, 2020","April 26, 2021","October 26, 2021"
3019,NCT04170829,A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002),Middle East Respiratory Syndrome Coronavirus,Biological: ChAdOx1 MERS,King Abdullah International Medical Research Center|University of Oxford,Phase 1,24,Other,"December 17, 2019","November 26, 2020","November 26, 2020"
3020,NCT04170296,Real World CCH Study in Adult Females With Cellulite,Edematous Fibrosclerotic Panniculopathy (EFP)|Cellulite,Drug: EN3835,Endo Pharmaceuticals,Phase 3,153,Industry,"November 1, 2019","October 6, 2020","January 8, 2021"
3021,NCT04169308,Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty,Deformity of Nasal Cartilage,Drug: Restylane-L® Filler injection,DeNova Research|Galderma R&D,Phase 1,10,Other|Industry,"January 1, 2019","July 20, 2020","July 21, 2020"
3022,NCT04169256,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers",Acute Postoperative Pain,Drug: HYR-PB21|Drug: Liposomal bupivacaine|Other: Normal Saline,Fruithy Medical Pty Ltd,Phase 1,32,Industry,"March 3, 2020","July 30, 2020","July 30, 2020"
3023,NCT04169061,Impact of Acthar on Everyday Life of Participants With Severe Keratitis,Keratitis,Drug: Acthar,Mallinckrodt,Phase 4,36,Industry,"November 13, 2019","November 9, 2020","December 7, 2020"
3024,NCT04168333,Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients,Hepatitis B Virus (HBV),Biological: T101 Group|Biological: Placebo Group,"Tasly Tianjin Biopharmaceutical Co., Ltd.",Phase 1,36,Industry,"January 8, 2018","October 14, 2019","October 14, 2019"
3025,NCT04167670,Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection,Helicobacter Pylori Infection,Drug: Vonoprazan|Drug: Amoxicillin|Drug: Clarithromycin|Drug: Lansoprazole,"Phathom Pharmaceuticals, Inc.",Phase 3,1046,Industry,"December 10, 2019","March 10, 2021","March 18, 2021"
3026,NCT04167553,Study for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities,Obese With Comorbidities|Overweight With Comorbidities|Type2 Diabetes,Drug: HM15136|Drug: Placebo,Hanmi Pharmaceutical Company Limited,Phase 1,53,Industry,"August 30, 2019","December 9, 2020","December 9, 2020"
3027,NCT04167475,Effect of B. Longum 1714™ on Sleep Quality,Subjective Sleep Quality|Objective Sleep Quality,Dietary Supplement: Probiotic capsule|Dietary Supplement: Placebo capsule,PrecisionBiotics Group Ltd.|Nottingham Trent University|Atlantia Food Clinical Trials Ltd.,Phase 2,89,Industry|Other,"January 6, 2020","April 3, 2020","June 23, 2020"
3028,NCT04167462,"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea",Psoriasis,Drug: BMS-986165|Other: Placebo,Bristol-Myers Squibb,Phase 3,220,Industry,"November 25, 2019","March 8, 2021","January 7, 2022"
3029,NCT04167449,Effects of Korean Red Ginseng Extract on Electrical Brain Activity in Elderly Subjects,Brain Waves,Dietary Supplement: HRG80 Hydroponic Red Ginseng|Dietary Supplement: Conventional White Ginseng|Dietary Supplement: Placebo,"EuroPharma, Inc.",Phase 4,30,Industry,"November 1, 2019","March 30, 2020","May 1, 2020"
3030,NCT04167280,Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma,Asthma,Drug: Ipratropium Metered Dose Inhaler|Drug: placebo metered dose inhaler,University of Saskatchewan,Phase 4,12,Other,"November 5, 2019","March 13, 2020","March 13, 2020"
3031,NCT04167254,Sit Down and Play India,"Development, Child",Behavioral: Sit Down and Play,University of Illinois at Chicago|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1,59,Other|NIH,"February 7, 2020","August 18, 2020","April 1, 2021"
3032,NCT04166890,Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia,Drug Effect|Tooth Extraction,Drug: Articaine / EPINEPHrine Cartridge,Universidad de Antioquia,Phase 4,179,Other,"September 4, 2018","January 31, 2020","March 30, 2020"
3033,NCT04166786,Steroid Profile: Differentiating Testosterone Administration From (Simultaneous) Ethanol Consumption,Healthy Volunteers,Drug: Testosterone gel|Drug: Ethanol Solution|Drug: Testosterone placebo (vaseline)|Drug: Ethanol placebo (lemon-flavoured water),Parc de Salut Mar,Phase 1,4,Other,"May 6, 2019","September 26, 2019","September 26, 2019"
3034,NCT04166669,A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001,Fungal Infection,Drug: APX001|Drug: Itraconazole|Drug: Rifampin,Pfizer,Phase 1,36,Industry,"November 12, 2019","March 3, 2020","March 3, 2020"
3035,NCT04166253,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,Breast Cancer,Drug: Vitamin D,Damanhour University,Phase 2,100,Other,"September 1, 2019","April 1, 2020","May 1, 2020"
3036,NCT04165850,Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS,Amyotrophic Lateral Sclerosis|ALS,Drug: Fixed dose combination Ciprofloxacin/Celecoxib,NeuroSense Therapeutics Ltd.,Phase 2,16,Industry,"November 25, 2019","January 19, 2021","January 19, 2021"
3037,NCT04164888,Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy,Hypercholesterolemia,Drug: CIVI 007,"Civi Biopharma, Inc.",Phase 2,49,Industry,"November 11, 2019","June 18, 2020","November 17, 2020"
3038,NCT04164719,Dose-Proportionality and Food Effect Study of TNX-102 SL,Healthy Subjects,Drug: TNX-102 SL,"Tonix Pharmaceuticals, Inc.",Phase 1,16,Industry,"October 14, 2019","December 24, 2019","December 24, 2019"
3039,NCT04164290,A Study to Evaluate the Tolerability and Pharmacokinetics of Jiashen Tablets in Healthy Subjects,Healthy,Drug: Jiashen Tablets|Drug: Jiashen Tablets Placebo,"Tasly Pharmaceutical Group Co., Ltd",Phase 1,70,Industry,"June 29, 2020","April 9, 2021","April 9, 2021"
3040,NCT04164121,A Clinical Study Trial of Phenlarmide in China,Parkinson Disease,Drug: Phenlarmide Tablets|Drug: Placebos,Yiling Pharmaceutical Inc.,Phase 1,36,Industry,"December 17, 2019","December 2, 2020","December 2, 2020"
3041,NCT04163263,"Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris",Moderate to Severe Acne Vulgaris,Drug: BOS-356|Drug: Vehicle,Boston Pharmaceuticals,Phase 1,66,Industry,"November 4, 2019","November 11, 2020","November 11, 2020"
3042,NCT04163185,Initiating Early Control of Migraine Pain and Associated Symptoms,Migraine,Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)|Drug: Placebo,"Axsome Therapeutics, Inc.",Phase 3,302,Industry,"October 8, 2019","March 23, 2020","March 23, 2020"
3043,NCT04162899,A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Drug: SHR0302,Reistone Biopharma Company Limited,Phase 2,105,Industry,"November 6, 2019","August 21, 2020","August 31, 2020"
3044,NCT04162834,Effect of Papaverine on Renal Artery Blood Flow Volume,Kidney Cancer,Drug: Papaverine|Drug: Normal saline,Asan Medical Center,Phase 4,96,Other,"November 21, 2019","April 15, 2021","April 15, 2021"
3045,NCT04162821,Study on Pharmacokinetics of Hydronidone,Pharmacokinetics of Hydronidone,Drug: Hydronidone,"Beijing Continent Pharmaceutical Co, Ltd.",Phase 1,48,Industry,"October 30, 2019","November 27, 2019","March 1, 2021"
3046,NCT04162795,A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies,Allergic Rhinitis,"Drug: Loratadine (Claritin, BAY76-2211)",Bayer,Phase 4,468,Industry,"November 12, 2019","November 13, 2019","November 13, 2019"
3047,NCT04162769,A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Etrasimod 1 mg|Drug: Etrasimod 2 mg|Drug: Etrasimod matching placebo,Arena Pharmaceuticals,Phase 2,140,Industry,"October 4, 2019","September 9, 2020","October 11, 2021"
3048,NCT04162743,The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression,Sleep Apnea Syndromes|Cerebral Infarction,Drug: Trazodone|Drug: Placebo oral tablet,Chang Gung Memorial Hospital,Phase 4,22,Other,"February 1, 2019","March 31, 2020","March 31, 2020"
3049,NCT04162379,Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol,Steroid Anlgesia in Cancer Pain,Drug: Oral tablet,Mansoura University,Phase 2,39,Other,"November 15, 2019","March 1, 2020","March 1, 2020"
3050,NCT04162002,Restylane® Lyft Filler Injection for Hand Rejuvenation on First Impressions,Hand Rejuvination,Drug: Restylane® Lyft,DeNova Research|Galderma R&D,Phase 1,10,Other|Industry,"October 10, 2019","November 18, 2019","November 18, 2019"
3051,NCT04161976,A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus,"Diabetes Mellitus, Type 1",Drug: LY900027|Drug: Insulin Lispro,Eli Lilly and Company,Phase 1,20,Industry,"December 27, 2019","July 14, 2020","July 14, 2020"
3052,NCT04161872,Nutraceutical on Hyperuricemia,Hyperuricemia,Drug: Uricemin|Drug: Placebo,University of Pavia,Phase 4,116,Other,"October 1, 2018","November 30, 2019","December 31, 2019"
3053,NCT04161729,Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery,"Analgesia|Pain, Postoperative|Spine Disease",Drug: Magnesium Sulfate|Drug: Isotonic saline 0.9%,Aristotle University Of Thessaloniki,Phase 4,74,Other,"January 28, 2020","May 3, 2020","May 5, 2020"
3054,NCT04161547,Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers,Asthma; Allergic Rhinitis,Drug: CSPCHA115 100 mg; Matching placebo 100 mg|Drug: CSPCHA115 200 mg; Matching placebo 200 mg|Drug: CSPCHA115 400 mg; Matching placebo 400 mg|Drug: CSPCHA115 600 mg; Matching placebo 600 mg,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1,40,Industry,"December 12, 2019","June 1, 2020","June 1, 2020"
3055,NCT04161482,"An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability",Healthy,Drug: Furosemide 80 mg (8 mg/mL),"scPharmaceuticals, Inc.|Clinical Trial Data Services, Inc.|CSSi Life Sciences",Phase 1,39,Industry|Other,"December 2, 2019","June 24, 2020","June 26, 2020"
3056,NCT04161456,Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata,Acne Conglobata,Drug: Apremilast,Dr. Frank Behrens|Dermatology Department University Hospital Frankfurt|Celgene|Fraunhofer Institute for Molecular Biology and Applied Ecology,Phase 2,1,Other|Industry,"October 9, 2019","February 8, 2021","February 8, 2021"
3057,NCT04161144,Enhancing Self Regulation Among Smokers,"Smoking Cessation|Smoking, Cigarette|Nicotine Dependence",Drug: sirolimus|Drug: Placebo,Medical University of South Carolina,Phase 2,22,Other,"October 1, 2018","December 20, 2019","December 20, 2019"
3058,NCT04160689,Influence of the Implant Connection on Facial Tissues Maturation,Bone Loss|Periodontal Bone Loss|Implant Tissue Failure,Biological: implantology,University of Milan,Phase 4,104,Other,"November 1, 2018","November 1, 2019","November 1, 2019"
3059,NCT04160260,Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia,Community-acquired Pneumonia,Drug: Omadacycline,Paratek Pharmaceuticals Inc,Phase 1,18,Industry,"November 28, 2019","March 23, 2020","April 13, 2020"
3060,NCT04160026,Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya,"Malaria in Pregnancy|Adherence, Treatment",Drug: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Drug: Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Drug: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer,"Liverpool School of Tropical Medicine|Kenya Medical Research Institute|Kamuzu University of Health Sciences|National Institute for Medical Research, Tanzania|London School of Hygiene and Tropical Medicine|University of Bergen|Kilimanjaro Christian Medical Centre, Tanzania",Phase 4,1600,Other,"November 11, 2019","July 31, 2020","July 31, 2020"
3061,NCT04159766,A Study With NLY01 in Subjects With Type 2 Diabetes,"Type2 Diabetes|Diabetes Mellitus, Type 2",Drug: NLY01|Drug: Placebo,"Neuraly, Inc.",Phase 2,20,Industry,"October 16, 2019","December 4, 2020","December 4, 2020"
3062,NCT04159532,Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA),Healthy Adults,Dietary Supplement: MAG-EPA/MAG-DHA|Dietary Supplement: TG-EPA/TG-DHA|Dietary Supplement: EE-EPA/EE-DHA,SCF Pharma,Phase 4,36,Industry,"December 18, 2019","February 25, 2021","February 25, 2021"
3063,NCT04158687,A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia,Schizophrenia,Drug: CTP-692|Drug: Placebo,Concert Pharmaceuticals|Cognitive Research Corporation,Phase 2,326,Industry,"November 26, 2019","December 16, 2020","December 22, 2020"
3064,NCT04158453,"Safety, Blood Levels and Effects of AUT00201",Healthy Volunteer,Drug: AUT00201|Drug: Placebo,Autifony Therapeutics Limited,Phase 1,80,Industry,"October 10, 2019","December 14, 2020","December 24, 2020"
3065,NCT04158102,Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects,Healthy Subjects,Drug: Bupivacaine liposome injectable suspension,"Nuance Pharma (shanghai) Co., Ltd",Phase 1,20,Industry,"November 7, 2019","December 17, 2019","December 26, 2019"
3066,NCT04158076,Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine,Hypercholesterolemia|Hypertension,Drug: Ezetimibe/Rosuvastatin|Drug: Telmisartan|Drug: Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET,Addpharma Inc.,Phase 3,131,Industry,"January 23, 2020","January 14, 2021","January 14, 2021"
3067,NCT04157933,Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease,Parkinson's Disease,Drug: 009-A1|Drug: 009-A2|Drug: 009-A3|Drug: 009-A0|Drug: 009-B1 (active --> placebo) crossover|Drug: 009-B2 (placebo --> active) crossover,"Alexza Pharmaceuticals, Inc.",Phase 1,35,Industry,"October 16, 2019","February 28, 2020","March 6, 2020"
3068,NCT04157738,A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus,Diabetes Mellitus|Type 1 Diabetes,Drug: Rapid-Acting Insulin|Drug: Long acting insulin,Emory University,Phase 4,24,Other,"November 27, 2019","December 17, 2020","December 17, 2020"
3069,NCT04156750,A Study of LY3556050 in Healthy Participants,Healthy,Drug: LY3556050|Drug: Placebo|Drug: Iohexol|Drug: Metformin,Eli Lilly and Company,Phase 1,34,Industry,"November 20, 2019","August 3, 2020","August 3, 2020"
3070,NCT04156685,"Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1",Type2 Diabetes Mellitus,"Drug: Part A, Reference (D635 10/500mg, Astrazeneca)|Drug: Part B, Reference (D635 10/500mg, Astrazeneca)",Chong Kun Dang Pharmaceutical,Phase 1,58,Industry,"August 6, 2019","August 30, 2019","October 2, 2019"
3071,NCT04156646,A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers,Autism Spectrum Disorder,Drug: Balovaptan|Drug: Esomeprazole,Hoffmann-La Roche,Phase 1,16,Industry,"November 19, 2019","December 24, 2019","January 6, 2020"
3072,NCT04155918,Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients,Gout Patients,Drug: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|Drug: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO),Arthrosi Therapeutics,Phase 2,30,Industry,"February 3, 2020","September 3, 2020","September 3, 2020"
3073,NCT04155814,Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects,Bioequivalance,Drug: Iron Sucrose Injection|Drug: Venofer Injection,Baxter Healthcare Corporation|Quotient Sciences,Phase 1,196,Industry,"September 19, 2019","December 18, 2019","December 18, 2019"
3074,NCT04155567,"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants",Healthy Volunteers,Drug: TAK-123,Takeda,Phase 1,10,Industry,"November 13, 2019","December 6, 2019","December 6, 2019"
3075,NCT04155515,A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients,Chronic Hepatics C Virus (HCV) Genotype 1|Non-Cirrhotic|Cirrhosis|Treatment naïve,Drug: TG-2349|Drug: DAG181|Drug: Ribavirin,"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.",Phase 3,370,Industry,"June 13, 2019","August 11, 2020","August 11, 2020"
3076,NCT04155047,A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.,Chronic Obstructive Pulmonary Disease (COPD),Combination Product: Glyocopyrrolate Inhalation Solution administered by Magnair|Drug: Placebo administered by Magnair,Sunovion Respiratory Development Inc.,Phase 4,44,Industry,"November 7, 2019","March 31, 2020","March 31, 2020"
3077,NCT04154722,Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children,Typhoid Fever,Drug: Meropenem Injection|Drug: Azithromycin Powder,Ziauddin University,Phase 4,126,Other,"June 20, 2019","December 30, 2020","December 30, 2020"
3078,NCT04154670,Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment,Healthy|Renal Insufficiency,Biological: MGTA-145,"Magenta Therapeutics, Inc.",Phase 1,23,Industry,"November 7, 2019","March 24, 2020","March 24, 2020"
3079,NCT04154501,A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects,Chronic Pain|Nociceptive Pain|Pain,Drug: CNTX-6016|Other: Other: Placebo,Centrexion Therapeutics,Phase 1,68,Industry,"December 4, 2018","August 21, 2019","August 26, 2019"
3080,NCT04153513,Effect of Lanolin and Breastmilk in the Treatment of Sore and Damaged Nipples in Breastfeeding Women,Breastfeeding,Drug: Lanolin|Other: Mother's milk,University of Mostar|Clinical Hospital Centre Zagreb,Phase 2,206,Other,"January 1, 2019","September 30, 2020","September 30, 2020"
3081,NCT04153435,Calcium for Out-of-Hospital Cardiac Arrest,"Heart Arrest, Out-Of-Hospital",Drug: Calcium Chloride|Drug: Sodium chloride 0.9%,Lars Wiuff Andersen|Central Denmark Region|University of Aarhus|Aarhus University Hospital,Phase 2,397,Other,"January 20, 2020","April 15, 2021","April 15, 2022"
3082,NCT04153409,A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine,Acute Migraine,Drug: LAT8881|Drug: Placebo,Lateral Pharma Pty Ltd,Phase 2,21,Industry,"September 24, 2019","February 15, 2020","April 10, 2020"
3083,NCT04153253,Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage,Diabetic Vitreous Hemorrhage,Drug: Aflibercept Injection [Eylea]|Procedure: Vitrectomy,Al Hadi Hospital,Phase 4,34,Other,"March 7, 2018","July 22, 2019","September 29, 2019"
3084,NCT04153188,Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea,Erythematotelangiectatic Rosacea,Device: The Vbeam® Prima System|Drug: Oxymetazoline HCL 1% Cream,Candela Corporation,Phase 4,34,Industry,"January 15, 2019","November 13, 2020","January 5, 2021"
3085,NCT04152915,A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens,"Healthy Volunteers|Diabetes Mellitus, Type 2",Drug: Semaglutide,Novo Nordisk A/S,Phase 1,68,Industry,"November 25, 2019","May 25, 2020","May 25, 2020"
3086,NCT04152759,Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects,Psoriatic Arthritis,Drug: Drug: BAT2506 injection Other Names: Simponi(EU-licensed),Bio-Thera Solutions,Phase 1,182,Industry,"September 9, 2019","December 31, 2020","December 31, 2020"
3087,NCT04152694,Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy,Infection During Renal Replacement Therapy|Critically Ill,Other: Ceftaroline levels in CRRT,"University of Maryland, Baltimore",Phase 4,4,Other,"March 9, 2018","September 1, 2020","September 1, 2020"
3088,NCT04152317,Dose Comparison of Misoprostol for Cervix Ripening Before Operative Hysteroscopy.,Cervix; Open,Drug: Misoprostol 200mcg Tab|Drug: Misoprostol 800mcg Tab,Professor Fernando Figueira Integral Medicine Institute,Phase 3,80,Other,"November 7, 2019","September 11, 2020","September 12, 2020"
3089,NCT04152148,"A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients",Non-Hodgkin's Lymphoma,Biological: 500mg BAT4306F|Biological: 750mg BAT4306F|Biological: 900mg BAT4306F|Biological: 1000mg BAT4306F,Bio-Thera Solutions,Phase 1,16,Industry,"September 4, 2018","January 13, 2021","January 13, 2021"
3090,NCT04152083,A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine,Migraine,Drug: Eptinezumab|Drug: Placebo,"H. Lundbeck A/S|Alder Biopharmaceuticals, Inc.",Phase 3,485,Industry,"November 7, 2019","July 8, 2020","July 8, 2020"
3091,NCT04151212,A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration,Age-related Macular Degeneration,Drug: BAT5906 injection,Bio-Thera Solutions,Phase 1,24,Industry,"October 30, 2018","February 28, 2021","April 30, 2021"
3092,NCT04150861,Rekovelle PK Trial in Chinese Women,Infertility,Drug: Follitropin Delta,Ferring Pharmaceuticals,Phase 1,24,Industry,"June 23, 2019","November 28, 2019","December 16, 2019"
3093,NCT04150341,Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response,Asthma,Drug: TD-8236|Drug: Placebo,Theravance Biopharma,Phase 2,24,Industry,"November 6, 2019","August 28, 2020","September 3, 2020"
3094,NCT04150250,Cholera Anti-Secretory Treatment Trial,Cholera,Drug: iOWH032|Drug: Placebo|Other: V. cholerae Challenge|Drug: Antibiotics,"PATH|University of Maryland, Baltimore|Pharmaron",Phase 2,47,Other,"November 4, 2019","July 27, 2020","July 27, 2020"
3095,NCT04150172,To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers,Healthy Volunteers,Drug: Rebamipide SR 150mg|Drug: Rebamipide IR 100mg,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 1,40,Industry,"April 22, 2019","May 1, 2019","May 10, 2019"
3096,NCT04150146,To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers,Healthy Volunteers,Drug: Rebamipide SR 150mg after high-fat meal|Drug: Rebamipide SR 150mg under fasting condition,"Korea Otsuka Pharmaceutical Co., Ltd.",Phase 1,24,Industry,"July 5, 2019","July 14, 2019","July 24, 2019"
3097,NCT04150107,A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes,Type 1 Diabetes,Drug: ORMD-0801 Treatment A|Drug: ORMD-0801 Treatment B|Other: Placebo,"Oramed, Ltd.|Integrium",Phase 2,30,Industry,"October 17, 2019","February 6, 2020","March 12, 2020"
3098,NCT04149678,Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites,Healthy Volunteers,Drug: Ozanimod|Drug: Cyclosporine,Celgene,Phase 1,40,Industry,"October 4, 2019","November 13, 2019","December 26, 2019"
3099,NCT04149327,Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment,Peri-implantitis|Periodontal Diseases,Drug: amoxicillin 500 mg + metronidazole 500 mg|Procedure: non-surgical periodontal and peri-implant treatment,University Medical Center Groningen,Phase 4,62,Other,"August 1, 2012",Dec-19,Dec-19
3100,NCT04148729,USG Guided ESP Block in Spinal Surgery,Postoperative Pain,Drug: ESP block|Drug: Control Group,Cukurova University,Phase 4,40,Other,"May 20, 2019","November 20, 2020","December 20, 2020"
3101,NCT04148599,Effect of IV Infusion of Lidocaine Compared to IV Infusion of Dexmedetomidine on Proinflammatory Cytokines,Inflammatory Response,Drug: dexmedetomidine infusion|Drug: lidocaine infusion|Drug: Placebos,"Norma Osama Abdalla Zayed|Abdelhamid, Bassant Mohamed, M.D.|National Cancer Institute, Egypt",Phase 3,54,Other,"January 2, 2018","June 10, 2020","June 13, 2020"
3102,NCT04148287,An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris,Candidemia|Invasive Candidiases|Candida Infection,Drug: APX001,Pfizer,Phase 2,9,Industry,"December 13, 2019","November 30, 2020","December 31, 2020"
3103,NCT04148209,Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants,Healthy,Drug: PF-07081532|Drug: Placebo,Pfizer,Phase 1,22,Industry,"November 5, 2019","March 17, 2020","March 17, 2020"
3104,NCT04147910,"Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356",Healthy Male Subjects,Drug: KW-6356,"Kyowa Kirin, Inc.",Phase 1,8,Industry,"August 21, 2019","October 2, 2019","October 2, 2019"
3105,NCT04147715,"Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults",Healthy Volunteer,Drug: S-648414|Drug: Placebo|Drug: Midazolam|Drug: Dolutegravir,Shionogi|Shionogi Inc.,Phase 1,98,Industry,"October 9, 2019","September 22, 2020","September 29, 2020"
3106,NCT04147416,A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation,Sedation,Drug: HSK3486 0.1-0.2 /0.3 mg / kg group|Drug: Propofol 0.5-1.0/1.5 mg/kg group,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 2,39,Industry,"November 22, 2019","May 31, 2020","July 3, 2020"
3107,NCT04147260,Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin,Healthy,Drug: BI 730357|Drug: Placebo to match BI 730357|Drug: Ciprofloxacin,Boehringer Ingelheim,Phase 1,85,Industry,"November 6, 2019","September 9, 2020","September 9, 2020"
3108,NCT04146805,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects",Chronic Liver Disease|NASH - Nonalcoholic Steatohepatitis,Drug: BLD-0409|Drug: Control: Placebo,Blade Therapeutics,Phase 1,80,Industry,"January 10, 2020","December 3, 2020","April 12, 2021"
3109,NCT04146623,"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray",Influenza,Biological: CodaVax-H1N1 influenza vaccine|Biological: Normal Saline Placebo,"Codagenix, Inc",Phase 1,33,Industry,"May 7, 2019","October 11, 2020","November 11, 2020"
3110,NCT04146584,Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow,Skin Laxity|Wrinkle|Brow Lifting,Device: Sofwave Treatments,Sofwave Medical LTD,Phase 2,93,Industry,"November 20, 2019","March 30, 2021","March 30, 2021"
3111,NCT04146220,Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis,Lupus Nephritis,Drug: Prednisolone,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 4,32,Other,"July 16, 2018","September 30, 2019","September 30, 2019"
3112,NCT04146129,A Phase 1 Study of CDX-0159,Healthy Subjects,Drug: CDX-0159|Drug: Normal saline,Celldex Therapeutics,Phase 1,32,Industry,"October 29, 2019","April 6, 2020","June 26, 2020"
3113,NCT04145856,Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico,Irritable Bowel Syndrome,Dietary Supplement: I31 probiotic|Combination Product: I31 probiotic combined to Alverine/Simethicone|Other: Placebo,Hospital Juarez de Mexico,Phase 4,55,Other,"September 3, 2018","May 2, 2019","August 27, 2019"
3114,NCT04145596,Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment,Hepatic Impairment,Drug: HSK3486,"Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Hospital of Jilin University|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,24,Industry|Other,"November 14, 2019","April 20, 2020","July 13, 2020"
3115,NCT04145583,A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets,Anesthesia|Sedation,Drug: HSK3486|Drug: voriconazole +HSK3486,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,16,Industry,"December 14, 2019","January 6, 2020","May 9, 2020"
3116,NCT04145128,A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants,Healthy Volunteers,Drug: AG881,"Agios Pharmaceuticals, Inc.",Phase 1,32,Industry,"October 2, 2019","December 11, 2019","December 18, 2019"
3117,NCT04144582,Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,Drug: Sintilimab Combined With Docetaxel Monotherapy,Yongchang Zhang|Hunan Province Tumor Hospital,Phase 2,30,Other,"January 1, 2019","September 30, 2020","December 31, 2021"
3118,NCT04144179,Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age,Influenza,Biological: Quadrivalent RIV with H3 strain 1|Biological: Quadrivalent RIV with H3 strain 2|Biological: Quadrivalent RIV with H3 strain 3|Biological: Quadrivalent RIV with H3 strain 4|Biological: Quadrivalent RIV with 2018-2019 NH H3 strain,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 1,150,Industry,"November 6, 2019","February 24, 2020","February 24, 2020"
3119,NCT04144049,A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat,Submental Fat,Drug: MT921|Drug: Placebo,Medy-Tox,Phase 2,176,Industry,"September 10, 2019","March 10, 2020","April 23, 2020"
3120,NCT04143945,"A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity","Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Novo Nordisk A/S,Phase 2,104,Industry,"October 28, 2019","January 4, 2020","January 4, 2020"
3121,NCT04143854,Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines,Lateral Canthal Lines,Drug: MBA-P01(Botulinum toxin A)|Drug: Placebo,Medy-Tox,Phase 2,150,Industry,"May 21, 2019","August 19, 2020","August 19, 2020"
3122,NCT04143815,Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines,Glabellar Frown Lines,Drug: MBA-P01 (Botulinum toxin A)|Drug: Placebo,Medy-Tox,Phase 2,200,Industry,"May 20, 2019","September 1, 2020","September 1, 2020"
3123,NCT04143802,A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM),"Diabetes Mellitus, Type 2",Drug: LY3437943|Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,Phase 1,72,Industry,"December 18, 2019","December 28, 2020","December 28, 2020"
3124,NCT04143750,The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man,Healthy Male Adult,Drug: [14C]Vicagrel,"Jiangsu vcare pharmaceutical technology co., LTD",Phase 1,6,Industry,"November 11, 2019","December 29, 2019","January 14, 2020"
3125,NCT04143477,A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects,Healthy Volunteers,Drug: peficitinib,"Astellas Pharma China, Inc.|Astellas Pharma Inc",Phase 1,36,Industry,"December 5, 2019","December 21, 2020","December 21, 2020"
3126,NCT04143282,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,Metastatic Breast Cancer,Drug: Metformin plus chemotherapy|Drug: Chemotherapy,Hager salah el din|Beni-Suef University,Phase 2,250,Other,"October 20, 2019","April 20, 2020","June 30, 2020"
3127,NCT04143165,Ultrasound Guided Epidural Block in Axial SPA,Epidural Block in Axial Spondyloarthritis,Drug: Epidural block with lidocaine and triamcinilone,Sohag University,Phase 4,52,Other,"October 12, 2019","January 12, 2020","February 12, 2020"
3128,NCT04142970,Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions,Chronic Renal Impairment,Drug: HSK3486,"Sichuan Haisco Pharmaceutical Group Co., Ltd|The First Affiliated Hospital of Zhengzhou University|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,24,Industry|Other,"January 5, 2020","August 4, 2020","August 18, 2020"
3129,NCT04142762,"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults",Chronic Hepatitis B,Drug: ABI-H2158|Drug: Itraconazole|Drug: Rifampin|Drug: Midazolam|Drug: Ethinyl Estradiol / Levonorgestrel|Drug: Esomeprazole|Drug: Placebo matching oral contraceptive,Assembly Biosciences,Phase 1,80,Industry,"October 18, 2019","January 12, 2020","January 29, 2020"
3130,NCT04142242,Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49,Meningococcal Infection (Healthy Volunteers),"Biological: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Other: Blood sample","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,471,Industry,"October 4, 2019","April 1, 2020","May 25, 2022"
3131,NCT04141930,Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle,Influenza|Respiratory Viral Infection,Drug: Baloxavir Marboxil,"University of Washington|Genentech, Inc.",Phase 4,481,Other|Industry,"November 1, 2019","April 1, 2020","April 1, 2020"
3132,NCT04140695,Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2),Atopic Dermatitis,Drug: Tradipitant|Drug: Placebo,Vanda Pharmaceuticals,Phase 3,87,Industry,"October 21, 2019","October 14, 2020","October 14, 2020"
3133,NCT04140292,Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses,Actinic Keratosis,Drug: Photodynamic therapy (PDT)|Drug: Vitamin D3,Case Comprehensive Cancer Center,Phase 2,75,Other,"January 13, 2020","November 24, 2020","May 27, 2021"
3134,NCT04139824,The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults,Gout|Hyperuricemia,Drug: Xanthine Oxidase Inhibitor|Drug: nonsteroidal anti-inflammatory drug,LG Chem,Phase 1,24,Industry,"January 22, 2020","February 25, 2020","February 25, 2020"
3135,NCT04139798,Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study),Dry Eye Disease (DED),Drug: NOV03|Drug: Placebo,Bausch & Lomb Incorporated,Phase 3,599,Industry,"July 20, 2020","March 12, 2021","March 12, 2021"
3136,NCT04139512,One-abutment One-time for Immediate Restoration Procedure in the Esthetic Zone,Implant Tissue Failure,Procedure: guided surgery|Procedure: conventionnel implant placement,University of Liege,Phase 4,18,Other,"June 1, 2018","June 1, 2019","August 1, 2019"
3137,NCT04139226,"A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole",Healthy Volunteers,Drug: CC-11050,Amgen,Phase 1,44,Industry,"August 28, 2019","February 27, 2020","February 27, 2020"
3138,NCT04139018,Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia,Hereditary Hemorrhagic Telangiectasia,Drug: Timolol Gel|Drug: Placebo Gel,Washington University School of Medicine,Phase 2,27,Other,"October 20, 2019","May 20, 2020","May 20, 2020"
3139,NCT04138849,"Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male",Healthy Participants,Drug: BBT-877 single dose|Drug: Placebo single dose,"Bridge Biotherapeutics, Inc.|KCRN Research, LLC",Phase 1,24,Industry,"October 1, 2019","October 25, 2019","October 25, 2019"
3140,NCT04138836,"Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects",Healthy Participants,Drug: BBT-877|Drug: Midazolam|Drug: Itraconazole|Drug: Esomeprazole,"Bridge Biotherapeutics, Inc.|KCRN Research, LLC",Phase 1,48,Industry,"September 17, 2019","November 4, 2019","November 4, 2019"
3141,NCT04138056,"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women",Respiratory Syncytial Virus Infections,Biological: RSVPreF3 formulation 3|Biological: RSVPreF3 formulation 2|Biological: Boostrix-ex-US|Biological: Boostrix-US|Drug: Placebo,GlaxoSmithKline,Phase 2,509,Industry,"November 5, 2019","February 25, 2020","November 22, 2021"
3142,NCT04138043,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants",Healthy Volunteers,Drug: Placebo|Drug: GSK2330811,GlaxoSmithKline,Phase 1,9,Industry,"December 5, 2019","May 28, 2020","May 28, 2020"
3143,NCT04137380,A Study of Mirikizumab in Healthy Chinese Participants,Healthy,Drug: Mirikizumab - IV|Drug: Mirikizumab - SC|Drug: Placebo - IV|Drug: Placebo - SC,Eli Lilly and Company,Phase 1,60,Industry,"December 4, 2019","December 11, 2020","December 11, 2020"
3144,NCT04137341,"A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines",Healthy,Drug: GLPG1972 - A|Drug: GLPG1972 - B|Drug: GLPG1972 - C,Galapagos NV,Phase 1,18,Industry,"October 9, 2019","December 13, 2019","December 13, 2019"
3145,NCT04137302,Administration of Hydrocortisone in Young Healthy Male Volunteers,"Anti-doping Campaign, Detection of Hydrocortisone",Drug: Hydrocortisone administration,"Centre Hospitalier Régional d'Orléans|French Anti-Doping Agency (AFLD)|University Hospital, Tours",Phase 4,21,Other,"November 13, 2019","January 31, 2020","January 31, 2020"
3146,NCT04137055,"Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics",Nonalcoholic Steatohepatitis,Drug: ZSP0678-10mg|Drug: ZSP0678-30mg|Drug: ZSP0678-60mg|Drug: ZSP0678-120mg|Drug: ZSP0678-180mg|Drug: ZSP0678-240mg|Drug: ZSP0678-320mg|Drug: ZSP0678|Drug: ZSP0678-Dose 1|Drug: ZSP0678-Dose 2|Drug: ZSP0678-Dose 3|Drug: ZSP0678 Placebo,"Guangdong Raynovent Biotech Co., Ltd",Phase 1,104,Industry,"November 19, 2019","December 9, 2020","December 9, 2020"
3147,NCT04136327,A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection,Healthy,Drug: GLPG1972 film-coated tablets|Drug: [14C]-GLPG1972 solution for infusion|Drug: [14C]-GLPG1972 oral solution,Galapagos NV,Phase 1,6,Industry,"September 13, 2019","October 21, 2019","October 21, 2019"
3148,NCT04136145,Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects,Systemic Lupus Erythematosus,Drug: Belimumab for IV|Drug: Belimumab for SC,GlaxoSmithKline,Phase 1,36,Industry,"October 28, 2019","January 14, 2020","January 14, 2020"
3149,NCT04136067,A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: NNC0268-0965|Drug: insulin glargine,Novo Nordisk A/S,Phase 1,36,Industry,"October 29, 2019","August 23, 2020","August 23, 2020"
3150,NCT04135833,A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711,NSCLC,Drug: BPI-7711|Drug: Itraconazole|Drug: Rifampicin,"Beta Pharma, Inc.",Phase 1,31,Industry,"December 12, 2019","July 22, 2020","July 22, 2020"
3151,NCT04135820,A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711,NSCLC,Drug: BPI-7711,"Beta Pharma, Inc.",Phase 1,16,Industry,"December 17, 2019","March 25, 2020","March 25, 2020"
3152,NCT04135560,"A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants",Dermatitis Atopic,Drug: PF-07038124 and Vehicle|Drug: PF-07038124 or vehicle,Pfizer,Phase 1,34,Industry,"October 29, 2019","April 10, 2020","April 10, 2020"
3153,NCT04134936,Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL,Diffuse Large B-cell Lymphoma,Drug: Tafasitamab|Drug: Tafasitamab plus lenalidomide,MorphoSys AG,Phase 1,66,Industry,"December 11, 2019","February 11, 2021","August 10, 2022"
3154,NCT04134715,A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants,Healthy,Drug: PF-06826647|Drug: Oral Contraceptive (OC),Pfizer,Phase 1,15,Industry,"October 23, 2019","January 9, 2020","January 9, 2020"
3155,NCT04134676,Therapeutic Potential of Stem Cell Conditioned Medium on Chronic Ulcer Wounds,Chronic Ulcer,Drug: Conditioned Media,"Sukma Skin Treatment|Stem Cell and Cancer Institute, Kalbe Farma Tbk|PT Pharma Metric Labs",Phase 1,38,Other|Industry,"June 1, 2019","May 10, 2020","June 10, 2020"
3156,NCT04134416,Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia,Aphasia|Stroke,Drug: Donepezil|Behavioral: Intensive-Language Action Therapy|Device: Transcranial direct current stimulation,University of Malaga,Phase 3,20,Other,"January 8, 2019","October 20, 2020","October 20, 2020"
3157,NCT04134364,The Effect of Lamina-G on Gastrointestinal Symptom After Gastric Biopsy,Gastrointestinal Symptom,Drug: Sodium alginate,Kyungpook National University Hospital,Phase 4,210,Other,"March 27, 2017","August 23, 2019","September 10, 2019"
3158,NCT04134312,A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer,Solid Metastatic Tumor,Biological: MVA-BN-Brachyury,Bavarian Nordic,Phase 1,13,Industry,"January 8, 2020","January 12, 2021","April 6, 2021"
3159,NCT04134273,Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: CLPG Topical Gel 1%|Drug: Clindamycin|Drug: Placebo,Taro Pharmaceuticals USA,Phase 1,1260,Industry,"March 20, 2019","September 17, 2019","October 15, 2019"
3160,NCT04133987,Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan,Dengue,Biological: Tetravalent live attenuated dengue vaccine admixture TV005|Biological: Placebo,"National Taiwan University Hospital|Centers for Disease Control, Taiwan",Phase 2,252,Other,"October 15, 2018","April 30, 2020","September 30, 2022"
3161,NCT04133116,A Study of LY3471851 in Healthy Participants,Healthy,Drug: LY3471851|Drug: Placebo,Eli Lilly and Company|Nektar Therapeutics,Phase 1,36,Industry,"October 29, 2019","March 6, 2020","March 6, 2020"
3162,NCT04133051,Perioperative Analgesic Efficiency of Quadratus Lumborum Block vs Epidural in Radical Cystectomy,"Pain, Postoperative",Drug: Quadratus Lumborum Block Using Bupivacaine 0.2%|Drug: Epidural Analgesia Using Bupivacaine 0.25%,"National Cancer Institute, Egypt",Phase 2,34,Other,"November 15, 2018","September 15, 2020","September 15, 2020"
3163,NCT04132583,Deflox Tablets Bioequivalence (BE) Trial,Healthy,Drug: Deflox®|Drug: Cataflam DD®,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,16,Industry,"September 21, 2019","October 27, 2019","October 27, 2019"
3164,NCT04132570,A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution,Rhinitis,Drug: Budesonide|Other: Placebo,"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 4,206,Industry,"October 22, 2019","January 22, 2020","January 22, 2020"
3165,NCT04132336,Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed,"Pain, Postoperative",Drug: Naproxen sodium/Caffeine (BAY2880376)|Drug: Naproxen sodium (Aleve)|Drug: Caffeine|Drug: Placebo,Bayer,Phase 2,193,Industry,"November 12, 2019","March 2, 2020","March 3, 2020"
3166,NCT04131595,Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects,Equine Encephalitis,Biological: MVA-BN-WEV Dose 1|Biological: MVA-BN-WEV Dose 2|Biological: MVA-BN-WEV Dose 3,Bavarian Nordic|JPM CBRN Medical,Phase 1,45,Industry|Other,"October 7, 2019","July 22, 2020","July 22, 2020"
3167,NCT04130802,OCS-01 in Treating Inflammation and Pain in Post-cataract Patients,"Inflammation Corneal|Pain, Postoperative",Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|Drug: Placebo,Oculis,Phase 2,153,Industry,"September 27, 2019","January 31, 2020","January 31, 2020"
3168,NCT04129944,A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee,"Osteoarthritis, Knee",Drug: UBX0101|Other: Placebo,"Unity Biotechnology, Inc.",Phase 2,183,Industry,"October 30, 2019","May 20, 2020","August 7, 2020"
3169,NCT04129736,Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis,"Multiple Sclerosis, Pharmacokinetics",Drug: Teriflunomide 14 MG,"Jan Lycke|Sahlgrenska University Hospital, Sweden",Phase 4,12,Other,"October 10, 2019","March 31, 2021","June 30, 2021"
3170,NCT04129255,Octreotide LAR in the Induction of Immunologic Response in NENs Patients,Neuroendocrine Tumors,Drug: Octreotide Acetate,"National Cancer Institute, Naples",Phase 2,34,Other,"June 28, 2017","December 1, 2019","December 1, 2019"
3171,NCT04128917,Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT,Helicobacter Pylori Infection,Drug: Tegoprazan|Drug: RAPAE01,HK inno.N Corporation,Phase 3,102,Industry,"January 21, 2020","December 21, 2020","January 29, 2021"
3172,NCT04128787,A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881,Healthy Volunteers,Drug: AG881 Formulation 1|Drug: AG881 Formulation 2|Drug: Omeprazole,"Agios Pharmaceuticals, Inc.",Phase 1,36,Industry,"September 30, 2019","December 18, 2019","December 18, 2019"
3173,NCT04128007,Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis,Plaque Psoriasis,Drug: Roflumilast foam 0.3%|Drug: Vehicle foam,"Arcutis Biotherapeutics, Inc.",Phase 2,304,Industry,"January 13, 2020","September 23, 2020","September 25, 2020"
3174,NCT04127669,Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke,Stroke Sequelae,Drug: OSU 6162|Drug: Placebo oral tablet,Arvid Carlsson Research AB|Gottfries Clinic AB,Phase 2,101,Industry|Other,"March 20, 2017","January 28, 2020","September 30, 2020"
3175,NCT04127058,Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia,Bipolar I Disorder|Schizophrenia,Drug: Iloperidone,Vanda Pharmaceuticals,Phase 1,12,Industry,"October 7, 2019","November 27, 2019","November 27, 2019"
3176,NCT04126733,Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable),Colorectal Cancer,"Drug: Regorafenib (Stivarga, BAY73-4506)|Biological: Nivolumab (Opdivo)",Bayer|Bristol-Myers Squibb,Phase 2,70,Industry,"October 14, 2019","November 11, 2020","March 28, 2022"
3177,NCT04126707,"The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans",Chronic Myeloid Leukemia (CML),Drug: [14C] HQP1351,Ascentage Pharma Group Inc.|HealthQuest Pharma Inc.,Phase 1,6,Industry,"November 19, 2019","January 13, 2020","January 13, 2020"
3178,NCT04126668,A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers,Advanced Malignant Solid Tumors,Drug: CM082 with fed or fasting,AnewPharma,Phase 1,24,Industry,"December 19, 2019","January 16, 2020","January 16, 2020"
3179,NCT04126213,"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants",Respiratory Syncytial Virus Infections,Biological: RSV MAT 60 µg|Biological: RSV MAT 120 µg|Drug: Placebo,GlaxoSmithKline,Phase 2,534,Industry,"November 5, 2019","July 23, 2020","May 14, 2021"
3180,NCT04126083,Lofexidine for Adults Undergoing Lumbar Spine Surgery,Opioid Withdrawal,Drug: Lofexidine Oral Tablet,"Mayo Clinic|USWM, LLC (dba US WorldMeds)",Phase 4,6,Other|Industry,"September 1, 2019","April 15, 2021","April 15, 2021"
3181,NCT04125810,A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychological Stress,"Stress, Psychological|Healthy",Biological: Probiotic|Other: Placebo,Danisco|ICON plc|Daacro|4Pharma Ltd.,Phase 2,190,Industry|Other,"September 2, 2019","February 7, 2020","February 7, 2020"
3182,NCT04125693,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,Cancer,Drug: Rogaratinib (BAY1163877)|Drug: Combination drug,Bayer,Phase 2,1,Industry,"October 30, 2019","February 16, 2021","February 16, 2021"
3183,NCT04124094,A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade,Bioequivalence,Drug: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Drug: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|Other: Activated Charcoal suspension,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,36,Industry,"October 1, 2019","October 25, 2019","June 9, 2020"
3184,NCT04124081,Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects,Hydronidone,Drug: Hydronidone capsules& Entecavir capsules,"Beijing Continent Pharmaceutical Co, Ltd.",Phase 1,12,Industry,"May 15, 2019","June 15, 2019","August 13, 2019"
3185,NCT04124003,A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin,Healthy Participants,Drug: rosuvastatin|Drug: BMS-963272,Bristol-Myers Squibb,Phase 1,28,Industry,"October 8, 2019","January 3, 2020","January 3, 2020"
3186,NCT04123925,Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study,Colon Cancer Stage II/III,Drug: Nivolumab,"National Cancer Institute, Naples",Phase 2,22,Other,"June 12, 2018","June 17, 2019","September 2, 2019"
3187,NCT04123769,Study on PK of Hydronidone in Patients and Special Population,Hepatitis b & Liver Dysfunction,Drug: Hydronidone,"Beijing Continent Pharmaceutical Co, Ltd.",Phase 1,8,Industry,"September 3, 2019","October 9, 2020","January 30, 2021"
3188,NCT04123652,Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain,Chronic Neuropathic Pain and Fibromyalgia,"Drug: Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992",Allevio Pain Management Clinic,Phase 4,162,Other,"November 5, 2017","November 11, 2020","November 11, 2020"
3189,NCT04123587,Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes,Diabetes Mellitus,Drug: discontinuation of Sulfonylureas,Seoul National University Hospital,Phase 4,58,Other,"September 10, 2019","November 30, 2020","November 30, 2020"
3190,NCT04123405,Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis,Rhinosinusitis,Drug: acetylcysteine|Drug: Placebo,Sandoz,Phase 3,944,Industry,"October 22, 2020","April 20, 2021","April 20, 2021"
3191,NCT04123288,A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men,Healthy Subjects,Drug: ACT-709478,Idorsia Pharmaceuticals Ltd.,Phase 1,20,Industry,"December 16, 2019","February 5, 2020","February 5, 2020"
3192,NCT04122560,"Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration",Fluconazole|Candidiasis|Invasive Fungal Infections|Obesity,Drug: Fluconazole 200mg tab|Drug: Fluconazole 2 MG/ML,Radboud University Medical Center|St. Antonius Hospital,Phase 4,25,Other,"November 30, 2019","March 23, 2021","March 23, 2021"
3193,NCT04121910,A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole,Solid Tumour,Drug: Savolitinib|Drug: Itraconazole,AstraZeneca|Parexel,Phase 1,16,Industry,"November 7, 2019","January 12, 2020","January 12, 2020"
3194,NCT04121091,"Pramipexole to Target ""Anhedonic Depression""","Depression, Bipolar|Depression, Unipolar|Dysthymia|Anhedonia",Drug: Pramipexole Pill,Region Skane|Lund University,Phase 2,13,Other,"October 4, 2019","March 18, 2021","March 18, 2021"
3195,NCT04121078,A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants,Healthy Volunteers,Drug: TAK-906|Drug: Rifampin,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,12,Industry,"October 15, 2019","November 4, 2019","November 16, 2019"
3196,NCT04121052,A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets,Healthy,Drug: JNJ-64417184,"Janssen Research & Development, LLC",Phase 1,20,Industry,"October 8, 2019","December 23, 2019","December 23, 2019"
3197,NCT04120194,Phase 3 Pivotal Trial of NanoFlu™ in Older Adults,"Influenza, Human",Biological: NanoFlu|Biological: Fluzone Quadrivalent,Novavax,Phase 3,2654,Industry,"October 14, 2019","October 29, 2020","December 13, 2020"
3198,NCT04120116,FX-322 in Adults With Stable Sensorineural Hearing Loss,Sensorineural Hearing Loss|Noise Induced Hearing Loss|Sudden Sensorineural Hearing Loss,Drug: FX-322 (One Dose)|Drug: FX-322 (Two Doses)|Drug: FX-322 (Four Doses)|Drug: Placebo,Frequency Therapeutics,Phase 2,95,Industry,"October 4, 2019","October 6, 2020","December 17, 2020"
3199,NCT04119947,Single Ascending Oral Doses of SY-009 in Healthy Subjects,Diabetes,Drug: SY-009,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",Phase 1,24,Industry,"March 1, 2019","May 30, 2019","May 30, 2019"
3200,NCT04118842,A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin,Solid Tumors,Drug: Savolitinib|Drug: Rifampicin,AstraZeneca,Phase 1,40,Industry,"October 17, 2019","February 26, 2020","February 26, 2020"
3201,NCT04118127,A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses,Schizophrenia,"Drug: 2mg conventional tablet, once-weekly tablets","Otsuka Pharmaceutical Co., Ltd.",Phase 1,73,Industry,"October 17, 2019","February 16, 2021","March 3, 2021"
3202,NCT04116840,"Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection",Healthy,Drug: MT1002 for injection,Shaanxi Micot Technology Limited Company,Phase 1,30,Industry,"April 29, 2019","August 1, 2019","November 27, 2019"
3203,NCT04116632,A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults,Obese But Otherwise Healthy Participants,Drug: BMS-963272|Drug: Placebo,Bristol-Myers Squibb,Phase 1,36,Industry,"September 30, 2019","February 10, 2020","February 10, 2020"
3204,NCT04116554,Bilateral Transversus Thoracic Muscle Plane Block as Analgesic in Open Heart Surgeries by US.,Analgesia,Drug: 0.25% bupivacaine.|Device: 0.9%saline,Fayoum University,Phase 4,70,Other,"December 27, 2019","January 31, 2021","February 1, 2021"
3205,NCT04116476,"Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function",Mild and Moderate Hepatic Impairment,Drug: MT-7117,Mitsubishi Tanabe Pharma America Inc.,Phase 1,23,Industry,"August 1, 2019","February 16, 2021","February 16, 2021"
3206,NCT04115111,Diadem to Investigate the Activity and Safety of Durvalumab,Pleura Mesothelioma,Drug: Durvalumab,Mario Negri Institute for Pharmacological Research,Phase 2,57,Other,"October 17, 2018","May 16, 2019","May 16, 2019"
3207,NCT04114461,Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers,Healthy Volunteers,Drug: HL-TOF tab. 5mg|Drug: Xeljanz tab. 5mg,"Hanlim Pharm. Co., Ltd.",Phase 1,33,Industry,"November 6, 2019","December 4, 2019","December 4, 2019"
3208,NCT04114188,Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI),Renal Transplant Rejection,Drug: Antithymocyte Immunoglobulin (Rabbit),"Prof. Dr. Petra Reinke|Institut Klinické a Experimentální Medicíny|Charite University, Berlin, Germany",Phase 2,68,Other,"December 15, 2016",Dec-20,"December 31, 2020"
3209,NCT04114097,The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover,Atopic Dermatitis|Atopic Eczema,"Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Drug: Protopic, tacrolimus ointment 0.1%","Jacob Thyssen|LEO Pharma|University Hospital, Gentofte, Copenhagen",Phase 4,36,Other|Industry,"August 22, 2019","March 15, 2021","March 15, 2021"
3210,NCT04114058,A Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine,Femoro Acetabular Impingement,Drug: liposomal bupivicaine|Procedure: Fascia iliaca blockade,Cedars-Sinai Medical Center,Phase 4,37,Other,"October 29, 2019","March 17, 2020","March 17, 2020"
3211,NCT04113954,Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers,Compartment Syndrome of Leg|Healthy,Drug: Mepivacaine Injection,Brigham and Women's Hospital|Massachusetts Institute of Technology,Phase 1,42,Other,"September 29, 2020","April 6, 2021","April 6, 2021"
3212,NCT04113889,"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome",PCOS,"Drug: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|Drug: Metformin, pioglitazone and placebo",Khyber Medical University Peshawar,Phase 2,147,Other,"October 15, 2019","January 30, 2020","January 30, 2020"
3213,NCT04113668,The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants,Healthy Participants,Drug: BMS-986165|Drug: diflunisal,Bristol-Myers Squibb,Phase 1,48,Industry,"October 1, 2019","November 19, 2019","November 25, 2019"
3214,NCT04112446,"Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects",Healthy,Drug: Saroglitazar magnesium,Zydus Therapeutics Inc.,Phase 1,8,Industry,"September 20, 2019","October 29, 2019","October 29, 2019"
3215,NCT04112303,Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Phase 3,37,Industry,"October 16, 2019","March 26, 2021","June 25, 2021"
3216,NCT04112160,Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal,Pain|Urinary Stone|Urinary Calculi,Drug: Ketorolac|Drug: normal saline,University of Texas Southwestern Medical Center,Phase 2,125,Other,"June 28, 2018","June 30, 2019","August 30, 2019"
3217,NCT04111926,Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery,Overall Survival,Drug: Dexmedetomidine|Drug: Placebo,Peking University First Hospital,Phase 4,619,Other,"October 7, 2019","April 1, 2021","April 1, 2021"
3218,NCT04111848,Magnesium and Ketamine in Postoperative Analgesia,Postoperative Analgesia,Drug: Ketamine|Drug: ketamine and magnesium,"National Cancer Institute, Egypt",Phase 4,90,Other,"November 1, 2019","November 1, 2020","December 1, 2020"
3219,NCT04111614,A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.,Healthy,Drug: Tofacitinib tablet|Drug: Tofacitinib Oral Solution,Pfizer,Phase 1,12,Industry,"October 11, 2019","December 12, 2019","December 12, 2019"
3220,NCT04111523,Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects,Cerebral Apoplexy,Drug: SY-007,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",Phase 1,78,Industry,"March 5, 2019","May 26, 2020","May 26, 2020"
3221,NCT04111432,Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines,"Hand, Foot and Mouth Disease",Biological: Concomitant administration of EV71vaccine with EPI vaccines|Biological: Single injection of EPI vaccine|Biological: EV71 Vaccine only,"Sinovac Biotech Co., Ltd|Shaanxi Provincial Center for Disease Control and Prevention",Phase 4,372,Industry|Other,"July 26, 2019","November 25, 2019","March 25, 2020"
3222,NCT04111328,the Effect of Different Drugs and Infusion Ways on Degree of Postoperative Comfort,"Analgesia, Patient-Controlled",Drug: intravenous sufentanil|Drug: subcutaneous sufentanil|Drug: intravenous hydromorphone|Drug: subcutaneous hydromorphone|Drug: intravenous sufentanil and dexmedetomidine|Drug: subcutaneous sufentanil and dexmedetomidine|Drug: intravenous hydromorphone and dexmedetomidine|Drug: subcutaneous hydromorphone and dexmedetomidine,Jun Wang|First Hospital of China Medical University,Phase 4,600,Other,"October 8, 2019","September 30, 2020","October 30, 2020"
3223,NCT04111159,A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy,Sedation or Anesthesia,Drug: HSK3486|Drug: Propofol,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 3,267,Industry,"December 6, 2019","June 19, 2020","July 27, 2020"
3224,NCT04110886,"Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers",Postoperative Pain|Chronic Pain,Drug: HSK21542|Drug: Placebo,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,120,Industry,"July 2, 2020","December 8, 2020","January 5, 2021"
3225,NCT04110587,Hyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy,Temporomandibular Joint Disc Displacement|Temporomandibular Joint Disorders,Biological: Hyaluronic Acid|Procedure: Temporomandibular Joint Arthroscopy|Drug: Antibiotic therapy|Drug: corticosteroid|Drug: Antiinflammatories|Drug: Analgesics|Other: Exercise program,Universidad Complutense de Madrid|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|Zambon SpA,Phase 4,54,Other|Industry,"December 10, 2013","July 9, 2019","July 9, 2019"
3226,NCT04110145,Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation,Functional Constipation,Drug: Linaclotide|Drug: Placebo,"Allergan|Ironwood Pharmaceuticals, Inc.",Phase 2,35,Industry,"October 14, 2019","April 20, 2021","April 20, 2021"
3227,NCT04110119,Effectiveness of Chiropractic Application for Acute Low Back Pain,"Low Back Pain, Mechanical","Drug: diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Other: Chiropractic Treatment",Medipol University,Phase 2,98,Other,"October 1, 2018","November 1, 2019","December 1, 2019"
3228,NCT04110054,Evaluation of S-600918 in Adults With Refractory Chronic Cough,Chronic Cough,Drug: S-600918|Drug: Placebo to S-600918,Shionogi|Shionogi Inc.,Phase 2,406,Industry,"February 13, 2020","December 8, 2020","December 28, 2020"
3229,NCT04109976,A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug: Bimekizumab,UCB Biopharma SRL|UCB Pharma,Phase 3,214,Industry,"August 13, 2019","November 5, 2020","November 13, 2020"
3230,NCT04109508,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets,Healthy Volunteers|Type 2 Diabetes,Drug: Oral semaglutide,Novo Nordisk A/S,Phase 1,278,Industry,"October 2, 2019","December 24, 2020","January 27, 2021"
3231,NCT04109222,"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",Influenza,"Biological: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Biological: Fluzone High-Dose vaccine, 2019-2020 formulation","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 4,90,Industry,"September 30, 2019","December 10, 2019","December 10, 2019"
3232,NCT04108676,Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects,Advanced Solid Tumor,Drug: Fluzoparib|Drug: Omeprazole,"Jiangsu HengRui Medicine Co., Ltd.|The Third Xiangya Hospital of Central South University",Phase 1,16,Industry|Other,"September 7, 2019","September 18, 2019","November 18, 2019"
3233,NCT04107987,"Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients With Fasting Dysglycemia",Dysglycemia,Dietary Supplement: Reglicem|Other: Placebo,University of Pavia,Phase 3,148,Other,"October 1, 2018","August 31, 2019","August 31, 2019"
3234,NCT04107922,Nutraceutical on Hyperglycemia,Dysglycemia,Dietary Supplement: Glicoset|Other: Placebo,University of Pavia,Phase 3,148,Other,"October 1, 2018","August 31, 2019","August 31, 2019"
3235,NCT04107805,A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated,Healthy,Drug: BI 1323495|Drug: Placebo|Drug: Midazolam,Boehringer Ingelheim,Phase 1,87,Industry,"November 4, 2019","March 5, 2021","March 26, 2021"
3236,NCT04107441,"AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects",Healthy,Drug: AX-8 Part 1|Drug: AX-8 Part 2,Axalbion SA,Phase 1,20,Industry,"September 9, 2019","February 25, 2020","March 4, 2020"
3237,NCT04106778,DMT310-003 Topical in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: DMT310|Drug: Placebo,Dermata Therapeutics,Phase 2,181,Industry,"October 10, 2019","May 4, 2020","May 4, 2020"
3238,NCT04106726,Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea,Facial Rosacea,Drug: Soolantra® Ivermectin cream 1%|Drug: Ivermectin cream 1%|Drug: Placebo for Ivermectin cream 1%,"Zydus Worldwide DMCC|Catawba Research, LLC",Phase 3,525,Industry|Other,"October 17, 2019","August 4, 2020","August 4, 2020"
3239,NCT04106557,A Study of OV101 in Individuals With Angelman Syndrome (AS),Primary Disease or Condition Being Studied: Angelman Syndrome (AS),Drug: Gaboxadol|Drug: Placebo,Ovid Therapeutics Inc.,Phase 3,104,Industry,"September 9, 2019","November 2, 2020","November 2, 2020"
3240,NCT04106297,A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970,Healthy|Psoriasis,Drug: GLPG3970 oral solution|Drug: Placebo oral solution|Drug: GLPG3970 capsule,Galapagos NV,Phase 1,100,Industry,"September 10, 2019","March 5, 2021","March 5, 2021"
3241,NCT04106206,A Safety Study of LY3372689 in Healthy Participants,Healthy,Drug: LY3372689|Drug: Placebo,Eli Lilly and Company,Phase 1,54,Industry,"October 23, 2019","February 12, 2020","February 12, 2020"
3242,NCT04105972,"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del",Cystic Fibrosis,Drug: ELX/TEZ/IVA|Drug: TEZ/IVA|Drug: IVA,Vertex Pharmaceuticals Incorporated,Phase 3,176,Industry,"October 3, 2019","July 24, 2020","July 24, 2020"
3243,NCT04105959,A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model,Inflammatory Response,Drug: RIST4721|Drug: Placebo,"Aristea Therapeutics, Inc.",Phase 1,32,Industry,"July 25, 2019","November 19, 2019","December 9, 2019"
3244,NCT04105582,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Breast Cancer|Triple Negative Breast Cancer,Biological: Neo-antigen pulsed Dendritic cell,Universidad Nacional de Colombia|Fundación Salud de los Andes,Phase 1,5,Other,"August 1, 2019","December 1, 2020","February 1, 2022"
3245,NCT04105426,A Study on the Effectiveness of Antioxidant Supplementation in Tinnitus,Tinnitus,Dietary Supplement: Antioxidants|Dietary Supplement: Placebo,National and Kapodistrian University of Athens,Phase 2,70,Other,"January 10, 2019","May 25, 2019","May 25, 2019"
3246,NCT04105205,First-In-Human Study of Apramycin,Healthy Volunteers,Drug: Apramycin injection|Drug: Placebo injection,Juvabis AG|Innovative Medicines Initiative,Phase 1,40,Industry|Other,"September 25, 2019","July 16, 2020","October 16, 2020"
3247,NCT04104997,"A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers",Dry Eye Syndromes,Drug: 5% GLH8NDE|Drug: Placebos,GL Pharm Tech Corporation,Phase 1,39,Industry,"September 26, 2019","February 18, 2020","July 17, 2020"
3248,NCT04104685,"A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.",Acne Vulgaris,Combination Product: FCD105|Drug: 3% Minocycline Foam|Drug: 0.3% Adapalene Foam|Other: Vehicle Foam,Vyne Therapeutics Inc.,Phase 2,446,Industry,"September 18, 2019","February 28, 2020","March 3, 2020"
3249,NCT04104503,A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects,Healthy,Drug: Lu AF11167|Drug: [14C]-Lu AF11167|Drug: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation),H. Lundbeck A/S,Phase 1,33,Industry,"September 17, 2019","April 9, 2020","April 9, 2020"
3250,NCT04103905,A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas,CD20-positive B Cell Non-Hodgkin Lymphoma,Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection,"Beijing Mabworks Biotech Co., Ltd.",Phase 1,27,Industry,"February 10, 2017","May 30, 2019","May 29, 2020"
3251,NCT04103853,"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer",Metastatic Breast Cancer,Drug: Proxalutamide,"Suzhou Kintor Pharmaceutical Inc,|Peking University Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Ruijin Hospital|The First Affiliated Hospital with Nanjing Medical University|Hebei Medical University Fourth Hospital|Hunan Cancer Hospital",Phase 1,63,Industry|Other,"September 6, 2017","May 22, 2019","June 30, 2020"
3252,NCT04103060,"Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo",Vitiligo,Drug: Cerdulatinib 0.37% gel|Drug: Vehicle gel,"Dermavant Sciences GmbH|Dermavant Sciences, Inc.",Phase 2,33,Industry,"September 27, 2019","November 3, 2020","November 3, 2020"
3253,NCT04103034,"A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers",Cerebrovascular Stroke|Large-Artery Atherosclerosis (Embolus/Thrombosis)|Intracranial Arteriosclerosis,Drug: BT200|Drug: Desmopressin|Drug: Placebo,Band Therapeutics,Phase 1,112,Industry,"October 7, 2019","September 14, 2020","September 14, 2020"
3254,NCT04102553,F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence,Prostate Cancer|Prostate Cancer Recurrent,Drug: F-18-PSMA-1007|Drug: F-18-Fluorocholine,ABX advanced biochemical compounds GmbH,Phase 3,200,Industry,"March 6, 2019","October 30, 2020","March 19, 2021"
3255,NCT04102462,A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198,Healthy,Drug: BI 764198|Drug: Matching placebo,Boehringer Ingelheim,Phase 1,52,Industry,"October 29, 2019","October 8, 2020","October 8, 2020"
3256,NCT04102241,Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis,Psoriasis,Drug: 15mg Hemay005|Drug: Placebos,"Tianjin Hemay Pharmaceutical Co., Ltd|Ganzhou Hemay Pharmaceutical Co., Ltd",Phase 2,216,Industry,"May 30, 2019","October 12, 2020","July 21, 2021"
3257,NCT04100642,A Phase I Clinical Study of Hemay808,Safety Issues,Drug: Hemay808|Drug: Placebo,"Tianjin Hemay Pharmaceutical Co., Ltd|Ganzhou Hemay Pharmaceutical Co., Ltd",Phase 1,42,Industry,"April 8, 2019","October 23, 2019","December 22, 2019"
3258,NCT04100447,"A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection",Adhesions|Ileus,Drug: Tranexamic Acid,"Ronald Hurst, MD, FACS|Centinela Hospital Medical Center",Phase 1,11,Other,"November 5, 2018","March 20, 2020","December 1, 2020"
3259,NCT04099927,A Study of SHR4010 in Patients With Hemodialysis,Pruritus,Drug: SHR0410,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,12,Industry,"July 28, 2019","April 20, 2020","June 15, 2020"
3260,NCT04099732,A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood,Healthy,Drug: Rosuvastatin|Drug: BI 1358894|Device: Dabigatran etexilate,Boehringer Ingelheim,Phase 1,26,Industry,"October 7, 2019","December 10, 2019","December 10, 2019"
3261,NCT04099563,"Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants",HEALTHY,Drug: PF-04965842,Pfizer,Phase 1,13,Industry,"October 14, 2019","November 9, 2019","December 9, 2019"
3262,NCT04098692,Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects,Healthy Volunteers,Drug: Derazantinib capsule|Drug: [14C]-Derazantinib solution for infusion|Drug: [14C]-Derazantinib capsule,Basilea Pharmaceutica,Phase 1,12,Industry,"August 8, 2019","November 18, 2019","November 18, 2019"
3263,NCT04098497,Modeling Mood Course to Detect Markers for Effective Adaptive Interventions- Aim 3,Bipolar Disorder|Psychosocial Intervention,Behavioral: Mobile intervention,"University of Wisconsin, Madison|University of Michigan|National Institute of Mental Health (NIMH)",Phase 1,30,Other|NIH,"September 13, 2019","October 21, 2020","October 21, 2020"
3264,NCT04098263,Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers,Campylobacter Jejuni Infection,Biological: LMN-101,"Lumen Bioscience, Inc.",Phase 1,21,Industry,"November 15, 2019","April 15, 2020","June 24, 2020"
3265,NCT04097938,A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667,Healthy,Drug: GLPG3667 oral suspension|Drug: Placebos|Drug: GLPG3667 capsules,Galapagos NV,Phase 1,52,Industry,"September 18, 2019","March 4, 2020","July 6, 2020"
3266,NCT04097925,Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals,HIV-1-infection,Drug: Doravirine|Drug: Descovy,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Institut d'Investigació Biomèdica de Bellvitge|Hospital Universitari de Bellvitge",Phase 2,30,Other,"February 18, 2020","August 24, 2020","August 24, 2020"
3267,NCT04097769,"The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies",Advanced Solid Tumor,Drug: HX009,Waterstone Hanxbio Pty Ltd,Phase 1,21,Industry,"June 12, 2019","March 18, 2021","September 29, 2022"
3268,NCT04097600,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets,Healthy Volunteers|Type 2 Diabetes,Drug: Oral semaglutide,Novo Nordisk A/S,Phase 1,274,Industry,"September 30, 2019","December 16, 2020","January 20, 2021"
3269,NCT04097574,Study of NPO-13 During Colonoscopy,Bowel Disease,Drug: NPO-13: l-menthol,"Nihon Pharmaceutical Co., Ltd",Phase 2,158,Industry,"August 26, 2019","March 26, 2020","March 26, 2020"
3270,NCT04097405,Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers,Healthy Volunteers,Drug: D-0120|Drug: Placebo oral tablet,"InventisBio Co., Ltd",Phase 1,40,Industry,"September 18, 2019","March 30, 2020","November 18, 2020"
3271,NCT04097288,Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects,Stress Urinary Incontinence|Fecal Incontinence,Drug: Citalopram 40mg|Drug: Reboxetine 8 mg|Drug: Placebo oral tablet,University Hospital Bispebjerg and Frederiksberg,Phase 1,24,Other,"September 17, 2019","February 1, 2020","May 1, 2020"
3272,NCT04096950,Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury,Spinal Cord Injury,Biological: MT-3921 Low dose,Mitsubishi Tanabe Pharma America Inc.,Phase 1,3,Industry,"April 19, 2020","January 6, 2021","January 6, 2021"
3273,NCT04096326,AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines,Glabellar Lines,Drug: AGN-151586|Drug: Placebo,Allergan,Phase 2,198,Industry,"September 26, 2019","September 9, 2020","September 9, 2020"
3274,NCT04096287,Safety and Tolerability of PNT001 in Healthy Adults,Healthy,Biological: PNT001|Drug: Placebo,"Pinteon Therapeutics, Inc",Phase 1,49,Industry,"September 17, 2019","February 15, 2021","February 15, 2021"
3275,NCT04096157,A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants,Healthy Subjects,Drug: Isavuconazonium sulfate IV|Drug: Isavuconazonium sulfate capsules,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,17,Industry,"September 24, 2019","January 16, 2020","January 16, 2020"
3276,NCT04096105,Japanese Pharmacokinetic Bridging Study for CC-93538,Healthy Volunteers,Drug: CC-93538,Celgene,Phase 1,48,Industry,"October 14, 2019","January 29, 2020","January 30, 2020"
3277,NCT04096001,Woebot for Substance Use Disorders,Substance Use Disorders,Device: Woebot-SUDs (W-SUDs),Woebot Health|Stanford University,Phase 1,101,Industry|Other,"March 26, 2020","August 31, 2020","August 31, 2020"
3278,NCT04095286,Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants,"Hypertension, Pulmonary",Drug: AMB new formulation (1 mg)|Drug: Reference AMB (5 mg),GlaxoSmithKline,Phase 1,29,Industry,"September 30, 2019","December 17, 2019","December 17, 2019"
3279,NCT04095182,Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult,Partial-onset Seizures With or Without Secondary Generalisation,Drug: Zebinix 400mg|Drug: Placebo for Zebinix 400mg|Drug: Zebinix 800mg|Drug: Placebo for Zebinix 800mg|Drug: Zebinix 1600mg|Drug: Placebo for Zebinix 1600mg,Whanin Pharmaceutical Company,Phase 1,50,Industry,"August 22, 2019","December 16, 2019","December 16, 2019"
3280,NCT04094883,Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine,Neisseria Gonorrhoeae Infection,Biological: Meningococcal Group B Vaccine,"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute",Phase 4,11,Other,"October 9, 2019","September 1, 2020","September 1, 2020"
3281,NCT04094870,A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women,Perinatal Depression|HIV-1-infection,Drug: Sertraline|Behavioral: Interpersonal therapy,"University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)",Phase 4,80,Other|NIH,"October 30, 2019","October 30, 2020","October 30, 2020"
3282,NCT04094727,Malaria High-Risk Populations in Namibia,Malaria,Drug: Presumptive treatment with Artemether-lumefantrine (AL)|Other: Enhanced vector control,"University of California, San Francisco|University of Namibia|Ministry of Health and Social Services, Namibia|University of Texas Southwestern Medical Center|University of Notre Dame|London School of Hygiene and Tropical Medicine",Phase 4,3302,Other,"October 31, 2019","June 30, 2020","June 30, 2020"
3283,NCT04094519,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,Prostate Cancer,Drug: enzalutamide|Drug: enzalutamide Placebo|Drug: digoxin|Drug: rosuvastatin,"Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc",Phase 1,24,Industry,"January 27, 2020","December 27, 2020","December 27, 2020"
3284,NCT04094025,Irritation and Sensitization Study of d-Amphetamine Transdermal System,Cumulative Irritation and Sensitization,Drug: dATS,Noven Therapeutics,Phase 1,229,Industry,"December 2, 2019","May 16, 2020","May 16, 2020"
3285,NCT04093895,"Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis",Periodontitis,Drug: PerioSept(r),Geistlich Pharma AG,Phase 2,12,Industry,"August 26, 2019","June 10, 2020","September 25, 2020"
3286,NCT04093271,Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep,Sleep|Healthy,Dietary Supplement: Rest-ZZZ|Drug: Active Comparator - Diphenhydramine HCl|Other: Placebo,LifeSeasons Inc.|KGK Science Inc.,Phase 1,27,Industry,"September 24, 2019","December 23, 2019","December 23, 2019"
3287,NCT04093050,Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers,Healthy Volunteer Safety Study,Drug: Vasostrict Injectable Product,Endo Pharmaceuticals,Phase 1,41,Industry,"October 10, 2019","April 8, 2021","April 11, 2021"
3288,NCT04092907,A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye,Dry Eye,Drug: HBM9036 0.25% Ophthalmic Solution|Drug: placebo,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 2,100,Industry,"March 22, 2019","July 3, 2019","July 10, 2019"
3289,NCT04092751,Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects,Pharmacokinetics,Drug: PRA|Drug: SCY-078 plus PRA,"Scynexis, Inc.|Clinical Network Services (CNS) Pty Ltd",Phase 1,28,Industry,"November 22, 2019","December 20, 2019","December 20, 2019"
3290,NCT04092725,Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects,Pharmacokinetics,Drug: DAB|Drug: SCY-078 plus DAB,"Scynexis, Inc.|Clinical Network Services (CNS) Pty Ltd",Phase 1,36,Industry,"September 9, 2019","January 3, 2020","January 3, 2020"
3291,NCT04092712,Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers,Healthy Volunteers,Drug: [14C]-CTP-543,Concert Pharmaceuticals|Celerion,Phase 1,6,Industry,"September 5, 2019","September 11, 2019","September 20, 2019"
3292,NCT04092595,A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants,Healthy Volunteers,Drug: PF-06651600|Drug: Rosuvastatin,Pfizer,Phase 1,12,Industry,"September 26, 2019","January 15, 2020","January 15, 2020"
3293,NCT04092387,Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age,Tobacco Use Disorder,Other: Cigarettes with varying nicotine content|Other: E-Cigarettes,University of Vermont|National Institute on Drug Abuse (NIDA)|Food and Drug Administration (FDA)|Johns Hopkins University,Phase 2,246,Other|NIH|U.S. Fed,Jun-15,Oct-20,Jan-23
3294,NCT04092205,"Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation",Beta Thalassemia Major,Drug: Emeramide,EmeraMed,Phase 2,13,Industry,"November 21, 2019","July 30, 2020","August 30, 2020"
3295,NCT04091880,Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine,Enterovirus Infections|Influenza,Biological: EV71 vaccine and influenza vaccine|Biological: EV71 vaccine|Biological: influenza vaccine,"China National Biotec Group Company Limited|Zhejiang Provincial Center for Disease Control and Prevention|Henan Center for Disease Control and Prevention|Guizhou Center for Disease Control and Prevention|Wuhan Institute of Biological Products Co., Ltd|Changchun Institute of Biological Products Co., Ltd.|Peking University|National Institutes for Food and Drug Control, China",Phase 4,1134,Industry|Other,"September 26, 2019","January 6, 2020","August 10, 2021"
3296,NCT04091763,Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal Disease,"Hemorrhoids, Internal",Drug: Polidocanol Injectable Foam|Device: Rubber band ligation,Universidade do Porto,Phase 2,120,Other,"August 1, 2018","July 1, 2020","July 1, 2020"
3297,NCT04091646,Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis,Seborrheic Dermatitis,Drug: ARQ-154 foam 0.3%|Drug: ARQ-154 vehicle foam,"Arcutis Biotherapeutics, Inc.",Phase 2,226,Industry,"December 4, 2019","August 18, 2020","August 21, 2020"
3298,NCT04091581,Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye,Evaporative Dry Eye,Drug: Systane Complete,University of Waterloo,Phase 4,21,Other,"November 21, 2019","February 6, 2020","February 6, 2020"
3299,NCT04091438,A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia,Idiopathic Hypersomnia,Drug: TAK-925|Drug: TAK-925 Placebo,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,28,Industry,"January 26, 2020","November 25, 2020","November 25, 2020"
3300,NCT04091425,Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP),Obstructive Sleep Apnea,Drug: TAK-925|Drug: Placebo,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,25,Industry,"November 21, 2019","April 2, 2020","April 2, 2020"
3301,NCT04091373,A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide,Type 2 Diabetes Mellitus,Combination Product: cotadutide multidose pen injection,MedImmune LLC,Phase 1,36,Industry,"September 27, 2019","March 6, 2020","March 6, 2020"
3302,NCT04091360,A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease,COPD,Drug: Part A: RPL554|Drug: Placebos|Drug: Part B: RPL554,Verona Pharma plc|Iqvia Pty Ltd,Phase 2,40,Industry,"April 29, 2019","December 10, 2020","January 21, 2021"
3303,NCT04091061,"Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects",Hepatic Impairment|Healthy Volunteers,Drug: PF-06865571 100 mg,Pfizer,Phase 1,24,Industry,"October 3, 2019","April 7, 2020","April 7, 2020"
3304,NCT04090775,A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma,Metastatic Prostatic Adenocarcinoma,Drug: Opdivo Injectable Product|Drug: Yervoy Injectable Product|Drug: Cytoxan|Procedure: Cryosurgical freezing (cryosurgery),"Rampart Health, L.L.C.",Phase 2,12,Industry,"June 28, 2019","July 30, 2020","January 31, 2022"
3305,NCT04090658,A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults,Respiratory Syncytial Virus Infections,Biological: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Drug: Placebo,GlaxoSmithKline,Phase 1,40,Industry,"September 25, 2019","January 10, 2020","December 11, 2020"
3306,NCT04090086,A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants,Healthy,Drug: JNJ-53718678|Drug: JNJ-64417184,"Janssen Research & Development, LLC",Phase 1,16,Industry,"September 16, 2019","December 10, 2019","December 10, 2019"
3307,NCT04090047,A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants,Heathy Participants,Drug: PF-06700841|Drug: Itraconazole,Pfizer,Phase 1,12,Industry,"September 24, 2019","December 19, 2019","December 19, 2019"
3308,NCT04089982,Varenicline Light Smoking Pilot,Smoking Cessation|Smoking Behaviors|Smoking,Drug: Varenicline|Drug: Placebo oral tablet,Duke University,Phase 4,11,Other,"November 4, 2019","March 1, 2020","March 1, 2020"
3309,NCT04089735,"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery",Ocular Inflammation and Pain,"Drug: APP13007, 0.05%|Drug: APP13007, 0.1%|Drug: APP13007 Placebo, 0.05%|Drug: APP13007 Placebo, 0.1%","Formosa Pharmaceuticals, Inc.",Phase 2,132,Industry,"August 13, 2019","April 7, 2020","April 7, 2020"
3310,NCT04089722,"Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the ""Bra Strap Fat"" Region",Brassiere Strap Fat (BSF)|Bra Strap Fat (BSF),Drug: Deoxycholic Acid,Juva Skin & Laser Center|Allergan,Phase 4,22,Other|Industry,"July 26, 2019","June 11, 2020","October 22, 2020"
3311,NCT04088929,The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy,Diabetic Neuropathies,Drug: CBD,Pure Green,Phase 2,32,Industry,"September 30, 2019","November 22, 2019","December 1, 2019"
3312,NCT04088617,The Effects of Exogenous Ketones on Glucose Tolerance,Dietary Supplement: Ketone Supplement|Dietary Supplement: Placebo,Dietary Supplement: Ketone monoester|Dietary Supplement: Placebo,University of British Columbia,Phase 1,20,Other,"August 1, 2019","October 30, 2019","January 5, 2020"
3313,NCT04088357,Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants,Wound Healing,Drug: TolaSure Topical Gel|Drug: Topical Vehicle Gel,"BioMendics, LLC|Symbio, LLC",Phase 2,72,Industry,"August 26, 2019","April 22, 2020","April 22, 2020"
3314,NCT04087759,A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants,Healthy,Drug: Bedaquiline (Test formulation)|Drug: Bedaquiline (Reference formulation),"Janssen Research & Development, LLC",Phase 1,36,Industry,"September 16, 2019","January 7, 2020","January 7, 2020"
3315,NCT04087733,Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery,Ocular Infections,Drug: OZODROP,"University of Molise|Azienda Policlinico Umberto I, Roma|Università degli Studi del Molise, Clinica Oculistica|Clinica Mediterranea, Napoli|Ospedale Santa Croce-Carle Cuneo|Centro Medico Oculistico ALSO, Saronno|Fondazione G.B. Bietti, IRCCS , Roma|Ospedale San Carlo di Nancy, Roma|Centro oftalmologico LASERVISTA, Caserta|Casa di cura GEPOS, Telese|Azienda Ospedaliero-Universitaria Consorziale, Bari|Ospedale generale regionale F. Miulli, Acquaviva delle Fonti|Azienda Ospedaliera Universitaria Mater Domini, Catanzaro|Ospedale Policlinico Casilino, Roma|Ospedale G. Panico, Tricase|Studio oculistico Laborante|Studio oculistico Franchini|U.C.O Ospedali Civico di Cristina Benfratelli|A.O.U. Città della Salute e della Scienza - Molinette Hospital",Phase 4,200,Other,"October 1, 2019","June 30, 2020","September 30, 2020"
3316,NCT04087707,"Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects",Healthy Volunteer,Drug: Step 1: TS-142|Drug: Step 2: TS-142|Drug: Step 2: Placebo,"Taisho Pharmaceutical Co., Ltd.",Phase 2,23,Industry,"September 17, 2019","November 30, 2019","November 30, 2019"
3317,NCT04087187,A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718,Coronary Artery Disease,Drug: Treatment A|Drug: Treatment B|Drug: Treatment C,AstraZeneca|Parexel,Phase 1,14,Industry,"September 20, 2019","October 31, 2019","October 31, 2019"
3318,NCT04086823,"A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.",Submental Fat,Drug: RZL-012|Drug: Placebo,Raziel Therapeutics Ltd.,Phase 2,28,Industry,"February 25, 2020","September 16, 2020","September 16, 2020"
3319,NCT04086758,A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,Drug: zolbetuximab,"Astellas Pharma China, Inc.|Astellas Pharma Inc",Phase 1,12,Industry,"October 18, 2019","January 22, 2021","January 22, 2021"
3320,NCT04086719,An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.,Healthy Male Volunteers,Drug: BMS-986165|Drug: Pyrimethamine,Bristol-Myers Squibb,Phase 1,16,Industry,"September 12, 2019","October 29, 2019","October 29, 2019"
3321,NCT04086602,"Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334",Healthy Volunteers|Cryopyrin Associated Periodic Syndrome,Drug: IZD334|Drug: Placebos,Inflazome UK Ltd,Phase 1,64,Industry,"September 13, 2019","February 4, 2020","February 4, 2020"
3322,NCT04086472,Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005),Respiratory Syncytial Viruses,Biological: Clesrovimab|Other: Placebo|Biological: RSV-A Memphis 37b,Merck Sharp & Dohme LLC,Phase 2,80,Industry,"October 28, 2019","March 22, 2020","August 14, 2020"
3323,NCT04086238,Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects,Healthy,Drug: Decitabine,"EpiDestiny, Inc.",Phase 1,46,Industry,"October 8, 2019","November 21, 2019","November 30, 2019"
3324,NCT04085757,Optimal Timing of Dinoprostone Administration Prior to Office Hysteroscopy,Dinoprostone Timing,Drug: long interval dinoprostone|Drug: short interval dinoprostone,Cairo University,Phase 3,180,Other,"September 15, 2019","December 15, 2019","January 1, 2020"
3325,NCT04085666,"Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)",Phenylketonuria,Drug: CDX 6114|Other: Matching Placebo,Société des Produits Nestlé (SPN),Phase 1,18,Industry,"June 1, 2019","June 30, 2020","August 30, 2020"
3326,NCT04085575,Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty,Postoperative Hemorrhage,Drug: Acide Tranexamique,Centre Hospitalier de Montauban,Phase 4,100,Other,"January 1, 2019","December 9, 2019","January 9, 2020"
3327,NCT04085562,Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.,"Hypertension, Renal",Drug: Bisoprolol Fumarate 5-10 mg|Drug: Amlodipine 5-10 mg,Alexandria University|Damanhour University,Phase 4,46,Other,"September 1, 2019","February 1, 2021","February 1, 2021"
3328,NCT04085367,Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face,Actinic Keratoses,Drug: MAL 16.8% cream|Drug: MAL Vehicle Cream,Galderma R&D,Phase 3,557,Industry,"September 30, 2019","March 3, 2021","April 7, 2021"
3329,NCT04085354,"Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation",Premature Ejaculation,Drug: Multi-Vitamin Tablets|Drug: Dapoxetine|Drug: Dapoxetine and folic acid.|Drug: Dapoxetine and vitamin B12,Sohag University,Phase 3,120,Other,"February 10, 2019","June 1, 2019","August 29, 2019"
3330,NCT04085341,A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion,Diabetic Macular Edema|Retina Vein Occlusion,Drug: GB-102,Graybug Vision,Phase 2,21,Industry,"September 11, 2019","June 5, 2020","June 5, 2020"
3331,NCT04085289,A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants,Healthy,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Phase 1,30,Industry,"November 20, 2019","May 21, 2020","May 21, 2020"
3332,NCT04085224,"6x3 Crossover, Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers","Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers",Drug: Somatropin,LG Chem,Phase 1,24,Industry,"September 10, 2019","January 2, 2020","January 2, 2020"
3333,NCT04084769,"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",Meningococcal Infection (Healthy Volunteers),"Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Biological: Meningococcal Group B vaccine (Trumenba®)|Biological: Meningococcal group B vaccine (Bexsero®)","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,570,Industry,"September 3, 2019","September 14, 2020","September 14, 2020"
3334,NCT04084483,"A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease",Dry Eye Disease,Drug: K-161|Other: Placebo (Vehicle),"Kowa Research Institute, Inc.",Phase 2,238,Industry,"August 4, 2019","January 9, 2020","January 9, 2020"
3335,NCT04083872,Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting),Cardiovascular Diseases,Drug: Reference drug|Drug: Test drug,Chong Kun Dang Pharmaceutical,Phase 1,16,Industry,"September 6, 2019","October 21, 2019","November 1, 2019"
3336,NCT04083846,Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed),Cardiovascular Diseases,Drug: Reference drug|Drug: Test drug 1|Drug: Test drug 2,Chong Kun Dang Pharmaceutical,Phase 1,24,Industry,"September 6, 2019","October 21, 2019","October 25, 2019"
3337,NCT04083807,Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis,Adjunct to Hemostasis During Vascular Surgery,Biological: TISSEEL Lyo|Procedure: Manual compression with surgical gauze pads,Baxter Healthcare Corporation,Phase 3,104,Industry,"July 10, 2019","October 22, 2019","October 22, 2019"
3338,NCT04083716,A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults,Chronic Hepatitis B,Drug: ABI-H2158 Reference Formulation|Drug: ABI-H2158 Test Formulation,Assembly Biosciences,Phase 1,15,Industry,"September 6, 2019","October 5, 2019","October 7, 2019"
3339,NCT04083625,the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy,Abdominal Myomectomy,Drug: carbetocin 100 mcg|Drug: placebo,Cairo University,Phase 4,138,Other,"September 10, 2019","February 10, 2020","February 20, 2020"
3340,NCT04083222,"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx",Hypertension,Drug: Placebo|Drug: ISIS 757456,"Ionis Pharmaceuticals, Inc.",Phase 2,26,Industry,"November 13, 2019","July 20, 2020","July 20, 2020"
3341,NCT04082325,Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men,Healthy,Drug: Lu AF88434|Drug: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Drug: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Drug: Placebo,H. Lundbeck A/S,Phase 1,68,Industry,"July 23, 2019","September 24, 2020","September 24, 2020"
3342,NCT04082286,Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia,Acute Myeloblastic Leukemia|Acute Lymphoblastic Leukemia|Juvenile Myelomonocytic Leukemia,Other: Yttrium-90 labelled monoclonal antibody against CD66,Great Ormond Street Hospital for Children NHS Foundation Trust,Phase 1,9,Other,May-16,"May 14, 2020","May 14, 2020"
3343,NCT04081857,A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects,"Health, Subjective",Drug: HGP1810|Drug: HCP1704,Hanmi Pharmaceutical Company Limited,Phase 1,48,Industry,"June 3, 2019","August 5, 2019","August 5, 2019"
3344,NCT04081662,Examining the Efficacy of Acceptance and Commitment Therapy (ACT) Microinterventions for Distressed First-Generation College Students,Psychological Distress|Self-Assessment|Mood Change,Behavioral: compACT Intervention,"University of Wisconsin, Madison",Phase 1,36,Other,"October 18, 2019","November 20, 2020","May 11, 2021"
3345,NCT04081610,Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution,Dry Eye,Drug: lagricel ofteno multidose|Drug: lagricel ofteno single dose,Laboratorios Sophia S.A de C.V.,Phase 1,34,Industry,"September 9, 2019","October 23, 2019","November 13, 2019"
3346,NCT04081376,Generation of Biological Samples Positive to Hydromorphone for Anti-doping Control,Healthy Volunteers,Drug: Hydromorphone Hydrochloride,Parc de Salut Mar,Phase 1,2,Other,"November 20, 2019","December 18, 2019","December 18, 2019"
3347,NCT04081363,"Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)",Attention Deficit Hyperactivity Disorder,Drug: Centanafadine,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2,13,Industry,"October 7, 2019","December 21, 2019","December 21, 2019"
3348,NCT04081324,A Study of Lasmiditan in Healthy Chinese Participants,Healthy,Drug: Lasmiditan|Drug: Placebo,Eli Lilly and Company,Phase 1,36,Industry,"November 13, 2019","June 15, 2020","June 15, 2020"
3349,NCT04080882,Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands,Platysmal Bands,Biological: AbobotulinumtoxinA dose 1|Other: Placebo|Biological: AbobotulinumtoxinA dose 2|Biological: AbobotulinumtoxinA dose 3,Galderma R&D,Phase 2,80,Industry,"September 25, 2019","December 30, 2019","June 4, 2020"
3350,NCT04080869,Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris,Facial Acne Vulgaris,Drug: retinyl palmitate|Drug: Tretinoin,Assiut University,Phase 2,20,Other,"January 6, 2020","August 28, 2020","November 30, 2020"
3351,NCT04080726,Efficacy and Safety of HIP1601 Capsule,Erosive Gastroesophageal Reflux Disease,Drug: HIP1601|Drug: HGP1705|Drug: HIP1601 Placebo|Drug: HGP1705 Placebo,Hanmi Pharmaceutical Company Limited,Phase 3,213,Industry,"October 25, 2018","December 3, 2019","December 3, 2019"
3352,NCT04080713,Cortiment® MMX Pharmacokinetic Study,Healthy,Drug: Budesonide,Ferring Pharmaceuticals,Phase 1,24,Industry,"September 16, 2019","September 25, 2019","September 25, 2019"
3353,NCT04080336,Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Nulliparous Women,IUD Insertion Complication,Drug: Dinoprostone|Drug: Misoprostol|Drug: placebo,Cairo University,Phase 4,129,Other,"September 10, 2019","December 20, 2019","January 20, 2020"
3354,NCT04080323,Single-dose Vaginal Dinoprostone and Hysterectomy,Hysterectomy,Drug: Dinoprostone 3 mg|Drug: placebo,Cairo University,Phase 3,118,Other,"September 25, 2019","May 30, 2020","June 30, 2020"
3355,NCT04080310,Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin,Cardiovascular Diseases,Drug: Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin,Seoul National University Bundang Hospital|Yuhan Corporation,Phase 4,270,Other|Industry,"March 15, 2018","June 15, 2019","September 17, 2019"
3356,NCT04080206,A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis,Plaque Psoriasis,Drug: 188-0551 Spray|Drug: RLD,"Therapeutics, Inc.",Phase 2,55,Industry,"April 7, 2020","January 20, 2021","January 20, 2021"
3357,NCT04079803,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,Alzheimer Disease,Drug: Placebo oral tablet|Drug: Simufilam 100 mg tablet|Drug: Simufilam 50 mg oral tablet,"Cassava Sciences, Inc.|National Institute on Aging (NIA)",Phase 2,64,Industry|NIH,"September 9, 2019","March 31, 2020","March 31, 2020"
3358,NCT04079790,Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects,"Infections, Bacterial",Drug: Gepotidacin|Drug: Placebo,GlaxoSmithKline,Phase 1,34,Industry,"September 4, 2019","November 25, 2019","November 25, 2019"
3359,NCT04079530,A Clinical Pharmacology Study of K-877 Controlled Release Tablet,Dyslipidemias,Drug: K-877 IR 0.2 mg/day|Drug: K-877 CR 0.4 mg/day|Drug: K-877 CR 0.8 mg/day,"Kowa Company, Ltd.",Phase 2,60,Industry,"September 13, 2019","December 24, 2019","March 31, 2020"
3360,NCT04079452,Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals,HIV-1-infection,Drug: Doravirine|Drug: Descovy,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Institut d'Investigació Biomèdica de Bellvitge|Hospital Universitari de Bellvitge",Phase 3,15,Other,"February 18, 2020","August 31, 2020","August 31, 2020"
3361,NCT04079413,Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients,"Diabetes|Diabetes Mellitus, Type 1",Drug: GP40071|Drug: NovoRapid® Penfill®,Geropharm,Phase 3,264,Industry,"June 3, 2019","January 21, 2020","January 21, 2020"
3362,NCT04079140,Vaginal Dinoprostone Administration Prior to Intrauterine Device Insertion,IUD Insertion Pain,Drug: Dinoprostone|Drug: placebo,Cairo University,Phase 4,130,Other,"September 15, 2019","November 30, 2019","December 10, 2019"
3363,NCT04079101,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants",Healthy Volunteers,Drug: BIIB104|Drug: Placebo,Biogen,Phase 1,31,Industry,"October 2, 2019","December 27, 2019","December 27, 2019"
3364,NCT04078126,Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.,Chronic Obstructive Pulmonary Disease (COPD),Combination Product: BFF|Combination Product: Symbicort Turbuhaler,AstraZeneca,Phase 3,35,Industry,"September 10, 2019","December 30, 2020","December 30, 2020"
3365,NCT04077424,Senescent Immunity in Elders and Vaccine Responses (SILVER),Flu Vaccine,Biological: Fluzone-High Dose Quadrivalent|Biological: Fluad|Biological: Flublock,Vanderbilt University Medical Center,Phase 4,10,Other,"October 21, 2019","February 1, 2020","February 1, 2020"
3366,NCT04076943,Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia,Chemotherapy Induced Anemia,Drug: Roxadustat,FibroGen|AstraZeneca|Astellas Pharma Inc,Phase 2,92,Industry,"August 20, 2019","March 26, 2021","April 23, 2021"
3367,NCT04076891,Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease,Dercum Disease|Lipedema,Drug: RZL-012,Raziel Therapeutics Ltd.,Phase 2,12,Industry,"June 28, 2018","May 2, 2019","May 2, 2019"
3368,NCT04076293,"Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects",Pharmacology,Drug: HM15912|Drug: Placebo,Hanmi Pharmaceutical Company Limited,Phase 1,40,Industry,"October 29, 2019","November 10, 2020","November 10, 2020"
3369,NCT04076098,Locally Delivered Minocycline in Advanced Periodontitis,"Periodontitis, Adult",Drug: Minocycline Hydrochloride,Mahsa University,Phase 4,40,Other,"June 25, 2018","December 28, 2020","September 20, 2021"
3370,NCT04075955,Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy,Chemotherapy-induced Nausea and Vomiting,Drug: Zyprexa® (OLANZapine 5MG)|Drug: Emend® (Aprepitant),CR-CSSS Champlain-Charles-Le Moyne,Phase 3,30,Other,"April 29, 2019","December 31, 2019","December 31, 2019"
3371,NCT04075643,Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers,Cardiovascular Diseases,Drug: Reference drug|Drug: Test drug,Chong Kun Dang Pharmaceutical,Phase 1,52,Industry,"September 19, 2019","September 30, 2019","October 30, 2019"
3372,NCT04075409,"A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants",Healthy Japanese Participants,Drug: Padsevonil,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,39,Industry,"September 30, 2019","December 27, 2019","December 27, 2019"
3373,NCT04075175,Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects,Diphtheria,Drug: S315|Drug: 0.9% Sodium Chloride (NaCl),MassBiologics,Phase 1,41,Other,"April 23, 2019","October 7, 2019","October 7, 2019"
3374,NCT04075058,Hypofractionated Radiation Therapy in Patients With Breast Cancer,Breast Cancer,Radiation: Hypofractionated Radiation therapy,Postgraduate Institute of Medical Education and Research,Phase 3,1070,Other,Jun-15,Dec-20,Dec-20
3375,NCT04074928,Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects,Influenza|Human|Virus Diseases,Biological: QIVc|Biological: Comparator QIV,Seqirus,Phase 3,2414,Industry,"September 6, 2019","September 3, 2020","September 3, 2020"
3376,NCT04074551,"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia",Hypertension|Dyslipidemias,Drug: HCP1701|Drug: Losartan|Drug: Amlodipine|Drug: Rosuvastatin and Ezetimibe,Hanmi Pharmaceutical Company Limited,Phase 3,145,Industry,"July 16, 2019","March 17, 2020","March 17, 2020"
3377,NCT04074460,Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study,"Cancer, Breast|Cancer Colorectal|Cancer Prostate|Cancer, Lung|Cancer Melanoma Skin|Cancer, Other","Drug: Propofol|Drug: isoflurane, sevoflurane or desflurane","Peter MacCallum Cancer Centre, Australia|M.D. Anderson Cancer Center|Melbourne Health|The Alfred",Phase 4,169,Other,"August 27, 2017","October 31, 2019","June 30, 2020"
3378,NCT04074317,"Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D","Diabetes Mellitus, Type 1|Insulin-dependent Diabetes Mellitus",Drug: PRAM9|Drug: Regular Insulin + Pramlintide|Drug: Regular Insulin,Xeris Pharmaceuticals,Phase 2,18,Industry,"August 22, 2019","April 2, 2020","April 2, 2020"
3379,NCT04074174,Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant,Overweight|Obesity,Drug: NNC0174-0833|Drug: Oral contraceptive (OC) tablets|Drug: Acetaminophen,Novo Nordisk A/S,Phase 1,31,Industry,"September 12, 2019","March 6, 2020","March 6, 2020"
3380,NCT04074161,Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity,Overweight|Obesity,Drug: Semaglutide|Drug: Placebo (semaglutide)|Drug: Liraglutide|Drug: Placebo (liraglutide),Novo Nordisk A/S,Phase 3,338,Industry,"September 11, 2019","March 27, 2021","May 11, 2021"
3381,NCT04073589,Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects,Healthy Volunteers,Biological: ARGX-113 with rHuPH20,argenx,Phase 1,33,Industry,"July 17, 2019","September 26, 2019","September 26, 2019"
3382,NCT04073069,Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults,"Pain, Postoperative|Post-Craniotomy Headache",Drug: The DR group|Drug: The R group,Beijing Tiantan Hospital,Phase 4,96,Other,"September 3, 2019","August 15, 2020","February 15, 2021"
3383,NCT04073056,Efficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy,Morbid Obesity|High BMI,Drug: Bupivacaine,Icahn School of Medicine at Mount Sinai,Phase 4,41,Other,"August 1, 2018","February 23, 2021","February 23, 2021"
3384,NCT04072861,A Study of RBT-9 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease,Acute Kidney Injury,Drug: RBT-9,"Renibus Therapeutics, Inc.",Phase 1,42,Industry,"March 31, 2019","July 31, 2020","October 31, 2020"
3385,NCT04072718,Simultaneous Integrated Boost With Volumetric Arc Radiotherapy in Patients With Breast Cancer,Breast Cancer,Radiation: Radiotherapy,Postgraduate Institute of Medical Education and Research,Phase 2,27,Other,"August 10, 2017","March 31, 2020","March 31, 2020"
3386,NCT04072679,Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,Drug: Sintilimab+IBI305,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 1,50,Other,"October 11, 2018","March 31, 2020","November 11, 2020"
3387,NCT04072562,A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.,Asthma,Drug: AZD7594,AstraZeneca|Parexel,Phase 1,24,Industry,"September 19, 2019","November 28, 2019","November 28, 2019"
3388,NCT04072328,Propofol vs. Midazolam With Propofol for Sedative Endoscopy in Patients With Previous Paradoxical Reaction to Midazolam,Sedation|Endoscopy,Drug: Propofol|Drug: Midazolam,DongGuk University,Phase 2,30,Other,"October 19, 2018","August 10, 2020","December 20, 2020"
3389,NCT04072237,Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia,Hemophilia A|Hemophilia B|Hemophilia A With Inhibitor|Hemophilia B With Inhibitor|Hemophilia A Without Inhibitor|Hemophilia B Without Inhibitor,Biological: MarzAA (marzeptacog alfa [activated]),Catalyst Biosciences,Phase 1,11,Industry,"September 24, 2019","April 30, 2020","June 17, 2020"
3390,NCT04072211,Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District,Hepatitis B Virus|Health Care Associated Infection,Biological: Engerix-B,Centre for Infectious Disease Research in Zambia|University of Oxford,Phase 4,641,Other,"November 25, 2019","August 30, 2020","August 30, 2020"
3391,NCT04072146,Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline,Healthy Subjects,"Drug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg","Oyster Point Pharma, Inc.",Phase 1,22,Industry,"August 26, 2019","November 15, 2019","November 15, 2019"
3392,NCT04071379,Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B,Immunogenicity|Safety,Biological: Recombinant Hepatitis B + DTP-HB-Hib|Biological: Hep B + Pentabio (registered),PT Bio Farma,Phase 3,220,Industry,"October 13, 2020","April 6, 2021","December 16, 2021"
3393,NCT04071262,A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer,Advanced Cancer,Drug: Abemaciclib|Drug: Abiraterone Acetate|Drug: Prednisolone,Eli Lilly and Company,Phase 1,6,Industry,"December 20, 2019","February 12, 2021","August 30, 2021"
3394,NCT04071158,A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS,Respiratory Tract Infection,Biological: RSV Vaccine|Biological: Tdap|Biological: Placebo,Pfizer,Phase 2,713,Industry,"October 1, 2019","December 11, 2019","December 11, 2019"
3395,NCT04071080,The Study of Oral Fluorescite to Confirm the Authenticity of Point of Care Urine Samples,Urine Sample Authenticity,Drug: fluorescein sodium|Drug: Placebo,UpTru Inc.|Medicor Research Inc.,Phase 1,40,Industry|Other,"August 22, 2019","November 28, 2019","November 28, 2019"
3396,NCT04070846,Mass Balance Study of [14C]LC350189 in Healthy Volunteers,Gout|Hyperuricemia,Drug: [14C] LC350189,LG Chem,Phase 1,6,Industry,"February 26, 2020","March 7, 2020","March 7, 2020"
3397,NCT04070495,A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin,Parkinson's Disease,Drug: KW-6356|Drug: Clarithromycin|Drug: Rifampicin,"Kyowa Kirin Co., Ltd.",Phase 1,20,Industry,"August 27, 2019","November 19, 2019","November 19, 2019"
3398,NCT04069715,The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure,Hyperlipidemias|Hypertension,Dietary Supplement: Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|Other: Placebo,"LongStar HealthPro, Inc. DBA Farlong Pharmaceutical|Yunnan PanLongYunHai Pharmaceuticals, Ltd.|KGK Science Inc.",Phase 2,95,Industry|Other,"July 20, 2016","June 1, 2019","June 1, 2019"
3399,NCT04069689,Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.,Dravet Syndrome,Drug: EPX-100 (Clemizole Hydrochloride)|Drug: Placebos,Epygenix,Phase 1,24,Industry,"August 29, 2019","November 27, 2019","November 27, 2019"
3400,NCT04069130,"Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058",Cardiovascular Diseases,Drug: 400 mg of BIA 5-1058,Bial - Portela C S.A.,Phase 1,7,Industry,"January 22, 2019","May 2, 2019","May 2, 2019"
3401,NCT04069078,Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section,Bradycardia|Spinal Anesthetics Causing Adverse Effects in Therapeutic Use|Cesarean Section Complications,Drug: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Other: Normal saline,Assiut University,Phase 4,173,Other,"October 10, 2019","February 25, 2020","February 25, 2020"
3402,NCT04068532,A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants,Healthy Volunteers,Drug: Placebo|Drug: BIIB104,Biogen,Phase 1,30,Industry,"November 15, 2019","November 11, 2020","November 11, 2020"
3403,NCT04068506,Analgesic Effects of Gabapentin and Paracetamol,Hand Injuries,Drug: Gabapentin 600 mg Tab,Dow University of Health Sciences,Phase 4,68,Other,"September 1, 2019","January 7, 2020","January 21, 2020"
3404,NCT04068051,Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine,Migraine,Drug: AXS-07,"Axsome Therapeutics, Inc.",Phase 3,706,Industry,"July 6, 2019","September 22, 2020","September 22, 2020"
3405,NCT04067947,"Phase 1 Pharmacokinetics, Safety, and Tolerability Study",Pain,Drug: XG005|Drug: Placebos,Xgene Pharmaceutical Group,Phase 1,64,Industry,"July 8, 2019","December 3, 2019","February 10, 2020"
3406,NCT04067791,"A Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-release Melatonin in Healthy Adults",Healthy,Dietary Supplement: Prolonged-Release Melatonin|Dietary Supplement: Immediate-Release Melatonin,Pharmavite LLC|KGK Science Inc.,Phase 1,18,Industry,"August 1, 2019","August 27, 2019","August 27, 2019"
3407,NCT04067518,"A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia",Acute Lymphoblastic Leukemia,Biological: SHP674,"Institut de Recherches Internationales Servier|Kyowa Kirin Co., Ltd.|ADIR, a Servier Group company|Servier",Phase 2,28,Other|Industry,"October 17, 2019","February 12, 2021","February 4, 2022"
3408,NCT04067011,Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study,Anthrax,Drug: Ciprofloxacin 500Mg Tablet|Drug: Doxycycline 100Mg Tablet|Biological: AV7909,Emergent BioSolutions|Biomedical Advanced Research and Development Authority,Phase 2,210,Industry|U.S. Fed,"August 12, 2019","March 5, 2020","March 19, 2020"
3409,NCT04066725,Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma,Melanoma (Skin),Drug: Aspirin 81 mg|Drug: Aspirin 325mg|Drug: Placebo oral tablet,University of Utah,Phase 2,95,Other,"July 25, 2019","March 19, 2021","March 19, 2021"
3410,NCT04066712,Renal PK Study of LC350189,Gout|Hyperuricemia,Drug: LC350189 200 mg,LG Chem,Phase 1,37,Industry,"November 19, 2019","September 12, 2020","September 12, 2020"
3411,NCT04066530,A Study to Evaluate the Efficacy and Safety of AD-203,Acute Gastritis|Chronic Gastritis,Drug: AD-203|Drug: Mucosta tab.,Addpharma Inc.,Phase 3,475,Industry,"September 23, 2019","February 26, 2020","February 26, 2020"
3412,NCT04065932,A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets,Lupus,Drug: BMS-986165-01|Drug: BMS-986165 Tablet|Drug: Famotidine,Bristol-Myers Squibb,Phase 1,33,Industry,"August 22, 2019","December 8, 2019","December 10, 2019"
3413,NCT04065698,Pharmacokinetics and Safety of RV521 Formulations,Respiratory Syncytial Virus Infections,Drug: RV521,Pfizer,Phase 1,9,Industry,"August 13, 2019","September 2, 2019","September 9, 2019"
3414,NCT04065633,"Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation","Dermatitis, Atopic",Drug: P3-Fast|Drug: Comm-Fast|Drug: Vari-Fast|Drug: Comm-Fed,Pfizer,Phase 1,46,Industry,"July 18, 2019","December 14, 2019","December 14, 2019"
3415,NCT04065581,Bioequivalence Study for Acarbose/Metformin FDC,"Diabetes Mellitus, Type 2",Drug: Acarbose/Metformin FDC(BAY81-9783)|Drug: Glucobay|Drug: Glucophage,Bayer,Phase 1,24,Industry,"October 14, 2019","November 25, 2019","March 6, 2020"
3416,NCT04065529,Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO),Diarrhea,Combination Product: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Combination Product: placebo + ORS + Zinc supplementation,Ferrer Internacional S.A.|Axonal-Biostatem,Phase 3,150,Industry,"September 11, 2019","June 11, 2020","June 11, 2020"
3417,NCT04065295,A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225,Healthy,Drug: BI 1356225|Drug: Placebo,Boehringer Ingelheim,Phase 1,65,Industry,"September 9, 2019","December 23, 2019","December 23, 2019"
3418,NCT04065074,Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip,"Osteoarthritis, Hip",Drug: FX006 32 mg,"Flexion Therapeutics, Inc.",Phase 2,16,Industry,"July 30, 2019","October 11, 2019","December 30, 2019"
3419,NCT04064905,"Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",Zika Virus,Biological: mRNA-1893|Other: Placebo,"ModernaTX, Inc.|Biomedical Advanced Research and Development Authority",Phase 1,120,Industry|U.S. Fed,"July 30, 2019","March 22, 2021","March 22, 2021"
3420,NCT04064073,Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study),Healthy,Drug: DWP16001|Drug: Metformin IR|Drug: DWP16001+Metformin IR,Daewoong Pharmaceutical Co. LTD.,Phase 1,34,Industry,"August 14, 2019","November 20, 2019","November 20, 2019"
3421,NCT04062175,Efficacy of Adding Azithromycin to Cephalosporin Before Cesarean Delivery,Wound Sepsis,Drug: cephalosporin|Drug: Azithromycin Tablets,Ain Shams University,Phase 4,144,Other,"March 20, 2019","June 20, 2019","July 18, 2019"
3422,NCT04061564,Vagal Nerve Stimulation for Intestinal Barrier Dysfunction in Healthy Volunteers,Intestinal Barrier Dysfunction,Device: Vagal nerve stimulation,Queen Mary University of London,Phase 1,16,Other,"May 13, 2019","August 15, 2019","September 15, 2019"
3423,NCT04061044,A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert,Open Angle Glaucoma and Ocular Hypertension,Drug: Ophthalmic Insert,"Ocular Therapeutix, Inc.",Phase 3,40,Industry,"July 10, 2018","February 10, 2020","September 22, 2020"
3424,NCT04060979,Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis,Bronchiolitis Acute,Drug: Nitric Oxide|Other: Standard Supportive treatment,Beyond Air Inc.,Phase 2,95,Industry,"November 6, 2019","March 2, 2020","April 2, 2020"
3425,NCT04060719,A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood,Healthy,Drug: BI 894416|Drug: Rifampicin,Boehringer Ingelheim,Phase 1,16,Industry,"September 4, 2019","October 17, 2019","October 17, 2019"
3426,NCT04060654,SUBLOCADE Rapid Initiation Extension Study,"Opioid Use Disorder, Severe|Opioid Use Disorder, Moderate",Drug: Sublocade,Indivior Inc.,Phase 4,17,Industry,"October 21, 2019","May 15, 2020","May 15, 2020"
3427,NCT04060511,A Study of HS-10342 in Patients With Advanced Solid Tumor,Advanced Solid Tumor,Drug: HS-10342,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 1,17,Industry,"June 19, 2019","December 4, 2020","September 15, 2021"
3428,NCT04060264,Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,Biological: BCD-148|Biological: Soliris,Biocad,Phase 3,28,Industry,"April 4, 2019","April 27, 2020","December 30, 2020"
3429,NCT04060173,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671",Hyperuricemia|Gout,Drug: ABP-671|Other: Placebo,"Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.",Phase 1,27,Industry,"September 5, 2019","December 29, 2019","February 7, 2020"
3430,NCT04059523,"MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3",Acne Vulgaris,Drug: S6G5T-3|Drug: Retin-A® 0.1% Cream,"Sol-Gel Technologies, Ltd.",Phase 1,62,Industry,"June 27, 2019","February 6, 2020","February 6, 2020"
3431,NCT04059367,Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People,Healthy Volunteers|Overweight|Obesity,Drug: NNC9204-1177|Drug: Cocktail of 5 already approved drugs,Novo Nordisk A/S,Phase 1,45,Industry,"August 15, 2019","January 2, 2020","January 2, 2020"
3432,NCT04058834,A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels,Healthy Volunteers|Hypercholesterolaemia,Drug: NNC0385-0434|Drug: Placebo (NNC0385-0434),Novo Nordisk A/S,Phase 1,39,Industry,"August 20, 2019","April 23, 2020","April 23, 2020"
3433,NCT04058535,"Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD",Neovascular Age-related Macular Degeneration,Biological: Eylea|Biological: ALT-L9,"Alteogen, Inc.",Phase 1,28,Industry,"February 5, 2020","December 22, 2020","December 22, 2020"
3434,NCT04058353,A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes),Cystic Fibrosis,Drug: ELX/TEZ/IVA|Drug: IVA|Drug: TEZ/IVA,Vertex Pharmaceuticals Incorporated,Phase 3,271,Industry,"August 28, 2019","June 12, 2020","June 12, 2020"
3435,NCT04057937,A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis,Palmoplantaris Pustulosis,Drug: Apremilast|Drug: Placebo,Amgen,Phase 2,90,Industry,"October 16, 2019","January 18, 2021","June 7, 2021"
3436,NCT04057755,Botulinum Toxin A as a Treatment for Provoked Vestibulodynia,Vulvodynia,Drug: botulinum toxin A|Drug: NaCl,Karolinska Institutet,Phase 3,90,Other,"May 15, 2016","June 15, 2019","June 15, 2019"
3437,NCT04057729,IMP4297 Food Effect Trial in Healthy Volunteers,Solid Tumor,Drug: IMP4297,"Impact Therapeutics, Inc.",Phase 1,16,Industry,"July 22, 2019","September 27, 2019","September 27, 2019"
3438,NCT04057573,Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2),Non-segmental Vitiligo,Drug: Ruxolitinib cream|Drug: Vehicle,Incyte Corporation,Phase 3,344,Industry,"October 3, 2019","March 15, 2021","October 1, 2021"
3439,NCT04056689,Study to Evaluate DNL151 in Subjects With Parkinson's Disease,Parkinson's Disease,Drug: DNL151|Drug: Placebo,Biogen,Phase 1,36,Industry,"July 23, 2019","December 2, 2020","December 2, 2020"
3440,NCT04056182,Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment,Opioid-use Disorder,Drug: Lofexidine 0.18 MG,"New York State Psychiatric Institute|USWM, LLC (dba US WorldMeds)",Phase 2,20,Other|Industry,"September 1, 2019","January 29, 2021","January 29, 2021"
3441,NCT04056169,Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome,Acute Coronary Syndrome|Carotid Atherosclerotic Plaque With Inflammation,Drug: high-dose rosuvastatin|Drug: low-dose rosuvastatin plus ezetimibe,Yuhan Corporation,Phase 4,50,Industry,"June 29, 2017","July 23, 2019","July 23, 2019"
3442,NCT04056130,A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects,Atopic Dermatitis (AD),Drug: KBL697,KoBioLabs|Novotech (Australia) Pty Limited,Phase 1,36,Industry,"October 4, 2019","December 23, 2019","January 7, 2020"
3443,NCT04056039,Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.,"Cardiovascular Diseases|Arthritis, Rheumatoid",Drug: Atorvastatin|Drug: Colchicine,"Hospital Central ""Dr. Ignacio Morones Prieto""",Phase 2,60,Other,"August 14, 2018","June 14, 2019","June 30, 2019"
3444,NCT04055506,A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants,Healthy Participants,Drug: BMS-986165|Drug: Ritonavir,Bristol-Myers Squibb,Phase 1,16,Industry,"August 14, 2019","September 21, 2019","September 21, 2019"
3445,NCT04055454,A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001),Lassa Virus Infection,Biological: MV-LASV|Other: Placebo,Themis Bioscience GmbH|Coalition for Epidemic Preparedness Innovations|Harmony Clinical Research|Assign Data Management and Biostatistics GmbH,Phase 1,60,Industry|Other,"September 26, 2019","March 13, 2020","January 15, 2021"
3446,NCT04055090,Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy,"Painful Diabetic Neuropathy|Diabetic Neuropathy, Painful",Genetic: Long-Term Follow-Up of Patients who Received Engensis (VM202)|Drug: Long-Term Follow-Up of Patients who Received Placebo,"Helixmith Co., Ltd.",Phase 3,101,Industry,"February 4, 2019","July 24, 2019","July 24, 2019"
3447,NCT04054986,Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer,Breast Cancer,Diagnostic Test: F-Var3 PET/CT|Other: Blood draw,Memorial Sloan Kettering Cancer Center,Phase 1,6,Other,"August 9, 2019","September 18, 2020","September 18, 2020"
3448,NCT04054921,Safety Study for Beta Thalassemia Subjects on PTG-300,β-thalassemia|Ineffective Erythropoiesis,Drug: PTG-300,"Protagonist Therapeutics, Inc.",Phase 2,34,Industry,"May 10, 2019","July 31, 2020","July 31, 2020"
3449,NCT04054882,Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP,Vaccination,Biological: Sabin-IPV and DTaP|Biological: Sabin-IPV|Biological: DTaP,"China National Biotec Group Company Limited|Chengdu Institute of Biological Products Co.,Ltd.|Beijing Institute of Biological Products Co Ltd.|Jiangsu Province Center for Disease Control and Prevention|Anhui Provincial Center for Disease Control and Prevention|Sichuan Center for Disease Control and Prevention|Peking University|National Institutes for Food and Drug Control, China",Phase 4,702,Industry|Other,"August 16, 2019","March 30, 2020","September 9, 2021"
3450,NCT04054479,Penehyclidine for PONV Prophylaxis After Strabismus Surgery,PONV,Drug: Penehyclidine|Drug: normal saline,The First Affiliated Hospital with Nanjing Medical University,Phase 4,228,Other,"July 20, 2019","July 22, 2019","November 1, 2019"
3451,NCT04054375,Weekly Steroids in Muscular Dystrophy,Limb-girdle Muscular Dystrophy|Becker Muscular Dystrophy,Drug: Prednisone,Northwestern University,Phase 2,20,Other,"July 1, 2019","June 1, 2020","March 1, 2022"
3452,NCT04054206,Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers,Healthy Volunteers,Drug: MN-166,MediciNova,Phase 1,12,Industry,"June 24, 2019","July 17, 2019","May 31, 2020"
3453,NCT04054193,Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045),Chemotherapy-induced Nausea and Vomiting,Drug: Fosaprepitant Dimeglumine|Drug: 5-HT3 antagonist|Drug: Dexamethasone,Merck Sharp & Dohme LLC,Phase 4,103,Industry,"September 9, 2019","February 11, 2021","February 11, 2021"
3454,NCT04053959,Artificial Intelligence Assisted Insulin Titration System,Type 2 Diabetes,Drug: AI assisted insulin system|Drug: Physician based insulin regime,Shanghai Zhongshan Hospital,Phase 4,46,Other,"September 27, 2019","January 22, 2020","April 15, 2020"
3455,NCT04053712,Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes,Type 1 Diabetes|Hypoglycemia,Drug: Glucagon|Device: Closed-loop system,Steno Diabetes Center Copenhagen|Technical University of Denmark|University of Copenhagen|Danish Diabetes Academy,Phase 4,13,Other,"July 16, 2019","March 19, 2021","March 19, 2021"
3456,NCT04053387,Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003),Plaque Psoriasis,"Drug: tapinarof cream, 1%","Dermavant Sciences GmbH|IQVIA Biotech|Dermavant Sciences, Inc.",Phase 3,763,Industry,"August 13, 2019","April 6, 2021","April 6, 2021"
3457,NCT04053023,Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects,Cholestasis,Drug: GSK2330672 (linerixibat)|Drug: Obeticholic acid,GlaxoSmithKline,Phase 1,19,Industry,"August 27, 2019","November 25, 2019","November 25, 2019"
3458,NCT04052620,Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study,Pain,Drug: Diclofenac diethylamine 2.32% gel|Drug: Diclofenac diethylamine 1.16% gel|Other: Placebo,GlaxoSmithKline,Phase 3,313,Industry,"October 24, 2019","November 12, 2020","November 12, 2020"
3459,NCT04052594,A Study of LY3475766 in Healthy Participants,Dyslipidemias,Drug: LY3475766 - IV|Drug: LY3475766 - SC|Drug: Placebo - IV|Drug: Placebo - SC,Eli Lilly and Company,Phase 1,48,Industry,"September 3, 2019","March 31, 2021","March 31, 2021"
3460,NCT04052451,"The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder","Depression, Anxiety",Biological: MET-2,NuBiyota,Phase 1,21,Other,"May 16, 2019","May 1, 2020","May 1, 2020"
3461,NCT04052425,Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1),Non-segmental Vitiligo,Drug: Ruxolitinib cream|Drug: Vehicle,Incyte Corporation,Phase 3,330,Industry,"September 20, 2019","March 18, 2021","October 21, 2021"
3462,NCT04052360,Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects,Healthy Volunteers,Drug: Cenerimod|Drug: Matching Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,20,Industry,"August 7, 2019","October 29, 2019","November 2, 2019"
3463,NCT04051827,Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC),"Carcinoma, Non-Small-Cell Lung|Lung Neoplasms",Drug: Midazolam|Drug: TAK-788,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,26,Industry,"December 23, 2019","December 17, 2020","December 7, 2021"
3464,NCT04051723,Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-Craniotomy Pain in Children,"Pain, Postoperative|Children",Drug: The dexamethasone plus ropivacaine|Drug: The ropivacaine,Beijing Tiantan Hospital|Beijing Children's Hospital,Phase 4,80,Other,"September 2, 2019","June 5, 2020","July 5, 2020"
3465,NCT04051710,Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH,Bronchial Asthma,Drug: Test Product|Drug: Reference Product|Drug: Placebo,Aurobindo Pharma Ltd,Phase 3,1550,Industry,"March 12, 2019","August 29, 2019","December 20, 2019"
3466,NCT04051073,Can Continuous Non-invasive Monitoring Improve Stability of Intraoperative Blood Pressure - A Feasibility Study.,Hip Fractures|Hypotension on Induction|Intraoperative Hypotension|Acute Kidney Injury|Myocardial Ischemia|Wound Infection|Perioperative/Postoperative Complications,Device: Continuous non-invasive blood pressure monitoring,University Hospital Birmingham NHS Foundation Trust|University of Warwick,Phase 3,30,Other,"June 13, 2019","August 5, 2019","August 5, 2019"
3467,NCT04050865,A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis,Allergic Conjunctivitis,"Drug: Dexamethasone, 0.4mg|Device: Placebo plug with no drug","Ocular Therapeutix, Inc.",Phase 3,96,Industry,"August 5, 2019","February 28, 2020","February 28, 2020"
3468,NCT04050722,A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks,Gingivitis,Drug: Sensodyne Repair and Protect|Drug: Colgate Cavity Protection,GlaxoSmithKline,Phase 4,130,Industry,"October 7, 2019","November 13, 2019","November 13, 2019"
3469,NCT04050670,A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes,Healthy,Drug: Tirzepatide,Eli Lilly and Company,Phase 1,54,Industry,"September 13, 2019","April 3, 2020","April 3, 2020"
3470,NCT04049630,Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients,"Onchocerciasis, Ocular|Loiasis","Drug: LEV 1 mg/kg|Drug: LEV 1,5 mg/kg|Drug: LEV 2,5 mg/kg|Drug: Placebo","Programme National de Lutte contre l'Onchocercose, Republic of the Congo",Phase 2,255,Other,"January 16, 2021","April 24, 2021","July 15, 2021"
3471,NCT04049448,Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: ABX464,Abivax S.A.,Phase 2,40,Industry,"October 24, 2019","April 30, 2021","January 23, 2023"
3472,NCT04049409,"Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers",Healthy Volunteers,Drug: CMAB809|Drug: Trastuzumab,"Taizhou Mabtech Pharmaceutical Co.,Ltd",Phase 1,72,Industry,"June 17, 2019","November 20, 2019","November 20, 2019"
3473,NCT04049123,A Study of LY900014 in Healthy Chinese Participants,Healthy,Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,Phase 1,15,Industry,"November 18, 2019","October 23, 2020","October 23, 2020"
3474,NCT04048811,A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients,Induction and Maintenance of General Anesthesia,Drug: HSK3486|Drug: Propofol|Drug: Propofol HSK3486,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 2,46,Industry,"December 9, 2019","May 23, 2020","June 22, 2020"
3475,NCT04048356,Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures,Pelvic Organ Prolapse|Urinary Incontinence|Pelvic Floor Disorders|Gynecologic Disease|Post-Op Infection|Surgical Site Infection|Urinary Tract Infections,"Drug: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.",University of New Mexico,Phase 3,158,Other,"July 15, 2019","February 28, 2021","March 14, 2021"
3476,NCT04048343,Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma,Severe Asthma,Drug: Biological: Experimental: Tezepelumab,AstraZeneca|Amgen,Phase 3,65,Industry,"June 10, 2019","March 18, 2021","March 18, 2021"
3477,NCT04048226,Dexmedetomidine-Ketamine Infusion in Breast Surgeries,Total Intravenous Anesthesia,Drug: Placebos|Drug: Dexmedetomidine +Ketamine,Tanta University,Phase 4,98,Other,"September 1, 2019","August 14, 2020","August 14, 2020"
3478,NCT04048200,The Effect of Opioid Free Anesthesia in Bariatric Surgeries,Adverse Effect of Drugs and Medicaments in Therapeutic Use|Adverse Effects in the Therapeutic Use of Anaesthetics,Drug: Fentanyl|Drug: Dexmedetomidine Ketamine,Tanta University,Phase 4,90,Other,"September 1, 2019","June 15, 2020","June 15, 2020"
3479,NCT04047940,A Study of LY900020 in Healthy Chinese Participants,Healthy,Drug: LY900020|Drug: Metformin XR|Drug: Atorvastatin|Drug: Valsartan,Eli Lilly and Company,Phase 1,32,Industry,"November 29, 2019","February 18, 2020","February 18, 2020"
3480,NCT04047446,Liposomal Bupivacaine vs Dexamethasone ISB,Shoulder Pain,Drug: Exparel 133 MG Per 10 ML Injection|Drug: Dexamethasone,"Hospital for Special Surgery, New York",Phase 4,112,Other,"July 11, 2019","March 15, 2021","March 19, 2021"
3481,NCT04047420,Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVC) Administered Rectally,HIV Infections,Drug: TAF/EVG Insert,National Institute of Allergy and Infectious Diseases (NIAID)|CONRAD,Phase 1,23,NIH|Other,"December 11, 2019","March 3, 2021","April 7, 2021"
3482,NCT04047017,Camrelizumab Combined With Apatinib for Recurrent Resistant GTN,Gestational Trophoblastic Disease,Drug: Apatinib|Drug: Camrelizumab,Peking Union Medical College Hospital,Phase 2,20,Other,"August 8, 2019","March 18, 2021","May 15, 2021"
3483,NCT04046939,Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma,Eosinophilic Asthma|Asthma,Drug: Dexpramipexole|Drug: Placebo,Knopp Biosciences,Phase 2,534,Industry,"August 15, 2019","December 3, 2020","March 2, 2021"
3484,NCT04046302,Vaginal Dinoprostone Administration Prior to an Intrauterine Device Insertion in Multiparous Women.,IUD Insertion,Drug: Dinoprostone|Drug: placebo,Cairo University,Phase 4,160,Other,"August 30, 2019","January 10, 2020","January 30, 2020"
3485,NCT04046250,Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690,Mucositis,Drug: TK-112690|Drug: Placebo TK-112690,"Tosk, Inc.|Crystal Life Sciences",Phase 2,22,Industry|Other,"May 15, 2019","October 10, 2019","March 31, 2020"
3486,NCT04046146,Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport,Rheumatoid Arthritis,Drug: Indocyanine Green|Device: MultiSpectral Imaging System,University of Rochester,Phase 1,2,Other,"December 15, 2019","March 15, 2020","March 15, 2020"
3487,NCT04045782,Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders,Inflammatory Bowel Diseases,Drug: single arm,"Pieter Dewint, MD PhD|Algemeen Ziekenhuis Maria Middelares",Phase 4,130,Other,"August 19, 2019","January 29, 2021","January 29, 2021"
3488,NCT04045769,A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers,Healthy,Drug: Saroglitazar magnesium 4mg|Drug: Placebos|Drug: Moxifloxacin 400mg|Drug: Saroglitazar magnesium 20 mg,Zydus Therapeutics Inc.,Phase 1,52,Industry,"August 19, 2019","November 27, 2019","December 2, 2019"
3489,NCT04045743,The Benefit of Bermekimab in Patients With Systemic Sclerosis,"Scleroderma, Systemic",Drug: MABp1 (Bermekimab) OR Placebo|Drug: MABp1 (Bermekimab),Hellenic Institute for the Study of Sepsis,Phase 2,20,Other,"July 19, 2019","January 7, 2021","July 19, 2021"
3490,NCT04045548,Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery,Intrauterine Device,Drug: Dinoprostone|Drug: Placebo,Cairo University,Phase 4,200,Other,"August 10, 2019","January 1, 2020","January 5, 2020"
3491,NCT04045405,"Clinical Study to Assess Safety, PK and PD Parameters of CDR132L",Heart Failure,Drug: CDR132L,Cardior Pharmaceuticals GmbH,Phase 1,28,Industry,"June 21, 2019","January 31, 2020","June 26, 2020"
3492,NCT04045327,Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock,Hypovolemic Shock,Drug: Normal saline + Standard Treatment|Drug: Centhaquine + Standard Treatment,"Pharmazz, Inc.",Phase 3,105,Industry,"January 31, 2019","September 23, 2019","September 27, 2019"
3493,NCT04044703,Improving Dosing of Vancomycin in Young Infants With Infections,Sepsis|Infection|Bacteremia,Drug: Vancomycin - model-based dosing regimen,Murdoch Childrens Research Institute|Royal Children's Hospital|Royal Hospital For Women|University of Otago|Sydney Children's Hospitals Network|Monash Health,Phase 4,44,Other,"August 30, 2019","December 29, 2020","January 3, 2021"
3494,NCT04044664,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,Aptinyx|Premier Research Group plc|Massachusetts General Hospital,Phase 2,160,Industry|Other,"January 25, 2019","August 5, 2020","August 5, 2020"
3495,NCT04044352,H1N1v Virus Challenge Study in Healthy Subjects,Influenza,Biological: Influenza A/Bethesda/MM2/H1N1 Challenge,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,76,NIH,"October 22, 2019","March 2, 2020","March 2, 2020"
3496,NCT04044339,"Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects",Healthy,Drug: TD-5202|Drug: Placebo,Theravance Biopharma,Phase 1,56,Industry,"August 8, 2019","November 27, 2019","November 27, 2019"
3497,NCT04044131,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,Alzheimer Disease|Parkinson Disease,Drug: Metabolic Cofactor Supplementation|Drug: Sorbitol,"Istanbul Medipol University Hospital|ScandiBio Therapeutics AB|Alanya Alaaddin Keykubat University|Sahlgrenska University Hospital, Sweden|KTH Royal Institute of Technology",Phase 2,120,Other|Industry,"December 2, 2019","March 15, 2021","April 20, 2021"
3498,NCT04044079,Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients,Office Hysteroscopy,Drug: Dinoprostone|Drug: Misoprostol|Drug: Placebo,Cairo University,Phase 4,150,Other,"August 20, 2019","January 10, 2020","February 10, 2020"
3499,NCT04044053,Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants,Healthy Participants,Drug: PF-06865571 400 mg Immediate Release (IR) in Fed State|Drug: PF-06865571 50 mg Modified Release (MR) in Fed State|Drug: PF-06865571 400 mg MR in Fed State|Drug: PF-06865571 400 mg MR in Fasted State,Pfizer,Phase 1,12,Industry,"August 13, 2019","October 31, 2019","October 31, 2019"
3500,NCT04043923,Norketotifen for the Treatment of Uncomplicated Influenza-like Illness,Influenza -Like Illness,Drug: Norketotifen|Drug: Placebo,"Emergo Therapeutics, Inc.",Phase 2,238,Industry,"October 21, 2019","April 5, 2020","April 20, 2020"
3501,NCT04042428,Generation of Biological Samples Positive to Somatropin for Anti-doping Control,Healthy Volunteers,Drug: Somatropin injection,Parc de Salut Mar,Phase 1,6,Other,"October 25, 2019","January 8, 2020","January 8, 2020"
3502,NCT04042103,"Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis",Plaque Psoriasis,"Drug: Tapinarof cream, 1%","Dermavant Sciences GmbH|Dermavant Sciences, Inc.",Phase 2,21,Industry,"July 23, 2019","January 9, 2020","January 9, 2020"
3503,NCT04041648,"Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606",Pulmonary Arterial Hypertension,Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Device: L606 Inhalation System|Other: Placebo Solution,Pharmosa Biopharm Inc.|PPD,Phase 1,52,Industry,"November 9, 2018","September 20, 2019","May 12, 2020"
3504,NCT04041609,LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study),Chronic Sinusitis|Chronic Rhinosinusitis (Diagnosis),Drug: LYR-210|Other: Sham comparator,Lyra Therapeutics,Phase 2,71,Industry,"May 9, 2019","March 25, 2020","February 4, 2021"
3505,NCT04041570,Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults,Ebola Virus,Biological: cAd3-EBO S vaccine,National Institute of Allergy and Infectious Diseases (NIAID)|US Military HIV Research Program,Phase 1,40,NIH|Other,"July 2, 2019","September 7, 2020","September 7, 2020"
3506,NCT04041453,Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients,Trichuris Infection|Helminthiasis,Drug: Ivermectin|Drug: Albendazole,Alejandro Krolewiecki|Brock University|Universidad Nacional del Centro de la Provincia de Buenos Aires|Universidad Nacional Autonoma de Honduras|Universidad Nacional de Salta,Phase 2,176,Other,"October 9, 2019","March 7, 2020","March 7, 2020"
3507,NCT04041440,Speech Recognition Training in Children With Hearing Loss,Hearing Loss,Behavioral: clEAR auditory training,Washington University School of Medicine,Phase 1,34,Other,"September 1, 2019","September 16, 2020","September 16, 2020"
3508,NCT04041219,Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients,Immunosuppression|Stem Cell Transplant|Bone Marrow Transplant,Drug: Tacrolimus,Mayo Clinic,Phase 4,10,Other,"June 17, 2019","October 8, 2019","October 8, 2019"
3509,NCT04041011,A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients,Small Cell Lung Cancer,Drug: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316|Drug: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316|Drug: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,23,Industry,"September 17, 2019","April 23, 2021","April 23, 2021"
3510,NCT04040907,"The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject",Gout,Drug: XNW3009|Drug: Placebo,Evopoint Biosciences Inc.,Phase 1,40,Industry,"November 13, 2019","January 20, 2021","May 30, 2021"
3511,NCT04040816,"Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients",Gout|Hyperuricemia,Drug: SAP-001,"Shanton Pharma Co., Ltd.",Phase 2,40,Industry,"January 1, 2019","August 1, 2020","August 30, 2020"
3512,NCT04040309,PRGF Effectiveness for Myofascial Pain Treatment in Masticatory Muscles,Myofascial Pain,Biological: PRGF injection|Drug: Lidocaine injection,Lithuanian University of Health Sciences,Phase 4,50,Other,"May 10, 2019","August 20, 2019","August 25, 2019"
3513,NCT04039880,"Absorption, Metabolism and Excretion of 14C-olorofim in Man",Invasive Fungal Infections,Drug: Olorofim,F2G Biotech GmbH|PRA Health Sciences,Phase 1,12,Industry,"July 30, 2019","September 30, 2019","September 30, 2019"
3514,NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,Type 2 Diabetes,Drug: Tirzepatide|Drug: Placebo,Eli Lilly and Company,Phase 3,475,Industry,"August 30, 2019","December 22, 2020","January 13, 2021"
3515,NCT04039373,Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil,Healthy Participants,Drug: BMS-986256|Drug: Mycophenolate Mofetil,Bristol-Myers Squibb,Phase 1,15,Industry,"July 22, 2019","September 18, 2019","October 16, 2019"
3516,NCT04039217,Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM,ART|HIV,Drug: Biktarvy,Emory University,Phase 4,20,Other,"September 30, 2019","August 28, 2020","August 28, 2020"
3517,NCT04039022,Open-Label Safety Study of AXS-05 in Subjects With Depression,Major Depressive Disorder|Treatment Resistant Depression|Depression,Drug: AXS-05 (dextromethorphan and bupropion) oral tablets,"Axsome Therapeutics, Inc.",Phase 3,876,Industry,"July 8, 2019","October 23, 2020","October 23, 2020"
3518,NCT04037748,Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form,Healthy,Drug: Puran T4®|Drug: Eutirox®,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,72,Industry,"June 25, 2019","September 11, 2019","September 11, 2019"
3519,NCT04037618,"Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose",Healthy,Drug: [14C]-EYP001a,Enyo Pharma,Phase 1,6,Industry,"July 24, 2019","July 27, 2019","August 6, 2019"
3520,NCT04037345,Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis,Knee Osteoarthritis,Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose),Medipost Co Ltd.,Phase 1,12,Industry,"October 7, 2019","November 12, 2020","November 12, 2020"
3521,NCT04036890,Local Minocycline in Patients Under Supportive Periodontal Therapy,Periodontitis,Drug: 2% minocycline hydrochloride controlled-delivery system (MHS)|Drug: Placebos,"National Dental Centre, Singapore",Phase 4,68,Other,"June 3, 2016","October 18, 2019","October 18, 2019"
3522,NCT04036292,Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease,Dry Eye Disease (DED),Drug: OC-01 (varenicline) nasal spray|Drug: Placebo (vehicle) nasal spray,"Oyster Point Pharma, Inc.",Phase 3,758,Industry,"July 23, 2019","April 10, 2020","February 5, 2021"
3523,NCT04036227,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248",Healthy,Drug: GS-248|Drug: Placebo,Gesynta Pharma AB|CTC Clinical Trial Consultants AB,Phase 1,72,Industry,"July 3, 2019","December 20, 2019","December 20, 2019"
3524,NCT04035759,Positive Affect Promotion to Empower Optimal Adherence to HIV Therapy,HIV/AIDS,Behavioral: APPEAL,State University of New York - Downstate Medical Center|National Institute of Nursing Research (NINR),Phase 1,20,Other|NIH,"October 16, 2019","April 26, 2021","April 26, 2021"
3525,NCT04035733,rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects,Bullous Pemphigoid (BP),Drug: rVA576,AKARI Therapeutics,Phase 2,9,Industry,"September 25, 2018","March 12, 2020","April 29, 2020"
3526,NCT04035564,Early Sodium Intake in Preterm Newborns,Hyponatremia|Premature,Drug: Sodium < 1mEq/kg/day|Drug: Sodium 5mEq/kg/day,"Hospital del Niño ""Dr. Federico Gomez Santos""",Phase 4,52,Other,"March 30, 2018","March 2, 2020","March 20, 2020"
3527,NCT04035239,Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma,Glaucoma|Ocular Hypertension,Device: BGS goggles,Stanford University,Phase 1,11,Other,"July 23, 2019","February 28, 2020","March 28, 2022"
3528,NCT04035200,"Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation",Insomnia,Drug: V117957 tablets|Drug: Placebo,Imbrium Therapeutics,Phase 2,114,Industry,"September 23, 2019","November 6, 2020","November 6, 2020"
3529,NCT04035031,Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug: Forxiga 10mg|Drug: Placebo,"University Hospital Inselspital, Berne",Phase 3,13,Other,"January 9, 2020","November 12, 2020","November 12, 2020"
3530,NCT04034290,"A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac",Healthy Volunteers,Biological: GamFluVac|Other: Placebo,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Main military clinical hospital named after academician N. N. Burdenko",Phase 2,224,Other,"October 18, 2019","June 30, 2020","July 31, 2020"
3531,NCT04033575,Clinical Investigation of a Toothpaste Containing Stannous Fluoride as Compared to Colgate Fluoride Toothpaste,Gingivitis,Drug: Colgate Total SF|Drug: Colgate Cavity Protection toothpaste,Colgate Palmolive,Phase 4,88,Industry,"March 6, 2019","June 6, 2019","July 1, 2019"
3532,NCT04033341,A Study of LY3214996 in Healthy Participants,Healthy,Drug: LY3214996|Drug: [14C]-LY3214996,Eli Lilly and Company,Phase 1,6,Industry,"August 1, 2019","September 9, 2019","September 9, 2019"
3533,NCT04033068,Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001),Zika Virus Infection,Biological: Two MV-ZIKA-RSP vaccinations (high dose)|Biological: Two MV-ZIKA-RSP vaccination (low dose)|Biological: One MV-ZIKA-RSP vaccination (high dose) and one placebo|Other: Two placebo injection,Themis Bioscience GmbH,Phase 1,48,Industry,"August 2, 2019","January 30, 2020","June 10, 2020"
3534,NCT04032821,To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects,NSCLC,Drug: Alkotinib（300mg),"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Phase 1,16,Industry,"November 20, 2019","December 16, 2019","December 16, 2019"
3535,NCT04032782,"A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Healthy Subjects",Pharmacology,Drug: HM15136|Drug: Placebo of HM15136,Hanmi Pharmaceutical Company Limited,Phase 1,40,Industry,"October 2, 2018","August 29, 2019","August 29, 2019"
3536,NCT04032327,Local Anesthetics on Postsurgical Analgesia Following Posterior Colporrhaphy,Postoperative Pain,Drug: Exparel plus plain bupivacaine|Drug: Bupivacaine,Walter Reed National Military Medical Center,Phase 2,120,U.S. Fed,"July 1, 2018","August 25, 2020","August 25, 2020"
3537,NCT04031859,Risk Stratification Procedure for Thromboembolism Prophylaxis,Total Knee Replacement Surgeries,Drug: acetylsalicylic acid,"Ministry of Health, Saudi Arabia|Prince Sultan Military College of Health Sciences|Universiti Sains Malaysia",Phase 2,242,Other,"October 10, 2018","July 14, 2019","July 22, 2019"
3538,NCT04031755,A Proof-of-Concept Study of Minocycline in Autism,Autism Spectrum Disorder|Autism,Drug: Minocycline|Drug: Placebos,"Children's Hospital Medical Center, Cincinnati",Phase 1,53,Other,"April 19, 2019","October 30, 2020","October 30, 2020"
3539,NCT04031131,The Use of Topical Anaesthetic in the Banding of Internal Haemorrhoids,Hemorrhoids,Drug: Instillagel|Other: KY Gel,Julie Dawson|Norfolk and Norwich University Hospitals NHS Foundation Trust,Phase 2,38,Other,"October 17, 2019","January 31, 2020","March 1, 2020"
3540,NCT04030598,A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema,Hereditary Angioedema,Drug: Donidalorsen|Drug: Placebo,"Ionis Pharmaceuticals, Inc.",Phase 2,23,Industry,"January 7, 2020","January 4, 2021","March 1, 2021"
3541,NCT04030533,Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants,Healthy,Drug: Guselkumab (SC): Dose 1|Drug: Guselkumab (SC): Dose 2|Drug: Guselkumab (IV): Dose 1|Drug: Guselkumab (IV): Dose 2|Drug: Ustekinumab 6 mg/mL,"Janssen Research & Development, LLC",Phase 1,60,Industry,"November 29, 2019","December 31, 2020","December 31, 2020"
3542,NCT04030247,Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients,Cardiovascular Risk Factor,Drug: Plant Sterol,"Stanford University|Piper Biosciences, Inc.",Phase 4,50,Other|Industry,"January 6, 2020","March 31, 2021","March 31, 2021"
3543,NCT04030091,Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Drug: 3 hours humulin R 100 IU/mL PIT|Drug: 2 hours humulin R 100 IU/mL PIT,Sciema UG|Innovative Diabetes Treatment Studies LLC.,Phase 4,24,Other,"September 6, 2019","October 19, 2020","December 31, 2020"
3544,NCT04029818,Evaluation of a Probiotic on LDL-cholesterol Levels,Cardiovascular Diseases|LDL-cholesterol,Biological: Bifidobacterium BSL_PS404|Biological: Placebo,Biosearch S.A.,Phase 1,40,Industry,"May 24, 2019","July 31, 2019","July 31, 2019"
3545,NCT04029779,Evaluation of Immediately Placed Dental Implants With Local Application of Injectable PRF in Periodontally Compromised Sites,"Bone Density|Bone Loss, Alveolar",Biological: I-PRF,Krishnadevaraya College of Dental Sciences & Hospital,Phase 2,10,Other,"November 11, 2017","November 30, 2019","November 30, 2019"
3546,NCT04029584,Drug-Drug Interaction Between Rifampin and Fluvastatin,Drug-drug Interaction,Drug: rifampin IV|Drug: Rifadin 300Mg Capsule|Drug: Fluvastatin 20 MG,"University of California, San Francisco",Phase 4,10,Other,"April 25, 2019","April 25, 2020","April 25, 2020"
3547,NCT04029571,Effect and Safety of TCM-FMD in Phlegm-Dampness Type Overweight/Obesity Patients(EASTAR),Obesity,Drug: TCM-FMD|Other: FMD,Guangdong Provincial Hospital of Traditional Chinese Medicine,Phase 2,60,Other,"June 21, 2019","September 30, 2020","March 29, 2021"
3548,NCT04029519,"A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation",Lip Augmentation,Device: PN40082,"Prollenium Medical Technologies Inc.|Symbio, LLC",Phase 3,84,Industry,"December 21, 2018","August 27, 2019","August 27, 2019"
3549,NCT04029012,Penthrox in Rezūm BPH,Pain|BPH,Drug: Methoxyflurane,Dean Elterman|Can-Am HIFU Inc.,Phase 4,10,Other,"September 10, 2019","February 14, 2020","February 14, 2020"
3550,NCT04028349,"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)",Ebola Virus Disease,Drug: Ad26.ZEBOV/MVA-BN-Filo,"MRC/UVRI and LSHTM Uganda Research Unit|Epicentre, Mbarara, Uganda|Janssen Pharmaceutica N.V., Belgium|Coalition for Epidemic Preparedness Innovations|Epicentre, Paris, France.",Phase 2,800,Other|Industry,"August 1, 2019","March 19, 2021","March 19, 2021"
3551,NCT04027829,Pharmacokinetics-pharmacodynamics and Safety of Dexmedetomidine in Children,Intensive Care Unit|Postoperative Care,Drug: Dexmedetomidine Hydrochloride,"Seoul National University Hospital|Ministry of Food and Drug Safety, Korea",Phase 2,13,Other,"August 14, 2019","November 14, 2019","November 14, 2019"
3552,NCT04027517,A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.,Anemia of Chronic Kidney Disease,Drug: JTZ-951|Drug: Darbepoetin Alfa,JW Pharmaceutical,Phase 3,172,Industry,"January 15, 2019","February 23, 2021","February 23, 2021"
3553,NCT04027439,Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler,"Pulmonary Disease, Chronic Obstructive",Drug: Part A: RPL554|Drug: Part B: RPL554|Drug: Placebos,Verona Pharma plc|Iqvia Pty Ltd,Phase 2,37,Industry,"December 10, 2018","May 23, 2019","May 23, 2019"
3554,NCT04027192,"Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.",Endometriosis,Drug: BAY2328065 LSF|Drug: BAY2328065 tablet|Drug: Placebo LSF|Drug: Placebo tablet|Drug: Midazolam,Bayer,Phase 1,50,Industry,"July 31, 2019","September 11, 2020","November 16, 2020"
3555,NCT04026997,A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis,Gastroparesis,Drug: CIN-102 Dose 1|Drug: CIN-102 Dose 2|Drug: CIN-102 Dose 3|Drug: Placebo,"CinDome Pharma, Inc.",Phase 2,73,Industry,"September 11, 2019","December 17, 2020","December 17, 2020"
3556,NCT04026438,Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT),"Complication, Postoperative|Regeneration Liver",Drug: Potassium Phosphate Injection,"Institute of Liver and Biliary Sciences, India",Phase 4,130,Other,"January 21, 2019","February 24, 2021","February 24, 2021"
3557,NCT04026074,Concepts for Analgosedation During Placement of Regional Anaesthesia Before Operations.,"Knee Arthropathy|Hip Arthritis|Fractures, Closed",Drug: Fentanyl|Drug: Remifentanil|Drug: Clonidine|Drug: EMLA Cream|Drug: Placebo iv|Drug: Placebo salve,Medical University of Graz,Phase 4,50,Other,"July 26, 2019","October 16, 2019","October 18, 2019"
3558,NCT04026022,Traumatologic Acute Pain Management With Fentanyl Transdermal Therapeutic System (TTS),Hip Fractures (ICD-10 72.01-72.2),Drug: Fentanyl Transdermal System|Drug: Placebo,Medical University of Graz,Phase 3,145,Other,"June 30, 2019","March 6, 2020","March 6, 2020"
3559,NCT04024891,Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis,Mydriasis|Dilation,Drug: Phentolamine Mesylate Ophthalmic Solution 1%|Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo),"Ocuphire Pharma, Inc.",Phase 2,32,Industry,"August 13, 2019","September 17, 2019","September 17, 2019"
3560,NCT04024813,"A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC",Primary Sclerosing Cholangitis,Drug: Seladelpar|Drug: Placebo to match Seladelpar,"CymaBay Therapeutics, Inc.",Phase 2,1,Industry,"November 12, 2019","January 9, 2020","January 9, 2020"
3561,NCT04024527,High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment,Helicobacter Pylori Infection,Drug: Esomeprazole|Drug: Amoxicillin|Drug: Metronidazole,Shanghai Jiao Tong University School of Medicine,Phase 4,306,Other,"July 25, 2019","April 12, 2021","May 24, 2021"
3562,NCT04024501,A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition,Chronic Kidney Disease,Drug: Verinurad ER8 capsule formulation (fasted)|Drug: Verinurad A-capsule formulation (fasted)|Drug: Verinurad A-capsule formulation (fed)|Drug: Verinurad B-capsule formulation (fasted)|Drug: Verinurad B-capsule formulation (fed),AstraZeneca,Phase 1,25,Industry,"July 20, 2019","September 18, 2019","September 18, 2019"
3563,NCT04024332,"Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects",Renal Insufficiency|Healthy,Drug: ACT-541468,Idorsia Pharmaceuticals Ltd.,Phase 1,16,Industry,"September 24, 2019","August 14, 2020","August 14, 2020"
3564,NCT04024228,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older,Influenza (Healthy Volunteers),"Biological: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Biological: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,1539,Industry,"October 28, 2019","January 9, 2020","June 5, 2020"
3565,NCT04024137,Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A,Influenza A,Drug: ZSP1273 200 mg|Drug: Placebo|Drug: ZSP1273-400 mg|Drug: ZSP1273-600 mg,"Guangdong Raynovent Biotech Co., Ltd",Phase 2,172,Industry,"December 7, 2019","May 18, 2020","May 18, 2020"
3566,NCT04024072,To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Brinzolamide 1% ophthalmic suspension|Drug: Azopt 1% Ophthalmic Suspension,Padagis LLC,Phase 3,495,Industry,"June 24, 2019","February 26, 2020","April 30, 2020"
3567,NCT04023994,"A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",Alzheimers Disease,Drug: RO7126209|Drug: Placebo,Hoffmann-La Roche,Phase 1,36,Industry,"August 3, 2019","July 17, 2020","July 17, 2020"
3568,NCT04023903,A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults,Healthy Subject,Drug: Bardoxolone methyl,"Kyowa Kirin Co., Ltd.",Phase 1,36,Industry,"April 4, 2019","June 14, 2019","June 14, 2019"
3569,NCT04023877,A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants,Dementias With Lewy Bodies,Drug: E2027,Eisai Inc.,Phase 1,8,Industry,"July 18, 2019","October 11, 2019","October 11, 2019"
3570,NCT04023760,Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients,Pharmacokinetics|Kidney Transplant|Lung Transplant,Drug: Apixaban,University of Saskatchewan|Saskatchewan Health Research Foundation|Lung Association of Saskatchewan,Phase 4,14,Other,"June 26, 2019","March 30, 2020","March 30, 2020"
3571,NCT04023461,Isolation of Pulmonary Veins With PVAC GOLD in Elderly Patients,Atrial Fibrillation Paroxysmal|Cardiac Arrythmias,Device: PVAC GOLD catheter ablation,University of Sao Paulo General Hospital|Medtronic,Phase 4,60,Other|Industry,"June 29, 2017","February 20, 2021","June 3, 2022"
3572,NCT04023266,A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI,STEMI,Drug: Intravenous N-Acetylcysteine,University of Alberta,Phase 2,44,Other,"September 20, 2019","November 15, 2020","January 1, 2022"
3573,NCT04022889,In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days,Healthy,Device: INTERCEPT Treated Platelets,Cerus Corporation,Phase 2,37,Industry,"November 5, 2019","April 16, 2021","April 17, 2021"
3574,NCT04022694,Preventing Non-communicable Diseases in Guatemala Through Sugary Drink Reduction,Food Preferences,Behavioral: Exposure to beverage health information|Behavioral: Exposure to beverage calorie information,University of Pennsylvania|Fogarty International Center of the National Institute of Health|Universidad Rafael Landivar,Phase 3,628,Other|NIH,"July 8, 2019","August 30, 2019","August 30, 2019"
3575,NCT04022473,Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers,Multiple Sclerosis,Drug: Bafiertam|Drug: Tecfidera,Banner Life Sciences LLC,Phase 1,210,Industry,"July 7, 2019","October 19, 2019","October 19, 2019"
3576,NCT04022317,Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R,Healthy Volunteer,Biological: Biocon Insulin R|Biological: Humulin®R,Biocon Limited|Profil Institut für Stoffwechselforschung GmbH,Phase 1,42,Industry,"June 18, 2019","September 15, 2019","September 20, 2019"
3577,NCT04022304,Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N,Healthy Volunteer,Biological: Biocon Insulin N|Biological: Humulin® N,Biocon Limited|Profil Institut für Stoffwechselforschung GmbH,Phase 1,90,Industry,"June 15, 2019","December 21, 2019","December 27, 2019"
3578,NCT04022291,Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30,Healthy Volunteer,Biological: Humulin ®70/30|Biological: Biocon Insulin 70/30,Biocon Limited|Profil Institut für Stoffwechselforschung GmbH,Phase 1,78,Industry,"June 15, 2019","January 20, 2020","January 27, 2020"
3579,NCT04021862,A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis|Eczema,Drug: Bermekimab Monoclonal Antibody|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,86,Industry,"October 16, 2019","June 30, 2020","November 19, 2020"
3580,NCT04021563,"The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers",Healthy Volunteers,Drug: SR419|Drug: Placebo,"SIMR (Australia) Biotech Pty Ltd.|Syneos Health|Shanghai SIMR Biotechnology Co., Ltd.",Phase 1,64,Industry|Other,"July 26, 2019","December 10, 2019","December 10, 2019"
3581,NCT04021524,BPO vs Hibiclens Soap for Surgical Preparation,Propionibacterium Acnes,Drug: Benzoyl Peroxide 10% Bar|Drug: Chlorhexidine Gluconate,University of Washington,Phase 4,50,Other,"September 10, 2018","May 31, 2019","April 16, 2021"
3582,NCT04021290,Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA),HIV Infections,Drug: DTG/3TC FDC|Drug: CAR,ViiV Healthcare|GlaxoSmithKline|PPD,Phase 3,493,Industry,"November 11, 2019","April 23, 2021","September 9, 2022"
3583,NCT04020718,Engagement With an Adaptive Mobile Health Smoking Cessation Intervention,Tobacco Use Cessation,Behavioral: Brief telephone advice plus tailored text messages|Drug: Mailed nicotine replacement therapy|Behavioral: Proactive telephone coaching,Massachusetts General Hospital,Phase 4,35,Other,"January 31, 2020","November 30, 2020","November 30, 2020"
3584,NCT04020380,Azithromycin a Treatment for Pulmonary Sarcoidosis,"Sarcoidosis, Pulmonary",Drug: Azithromycin 250Mg Capsule,Hull University Teaching Hospitals NHS Trust,Phase 2,21,Other,"September 6, 2019","June 20, 2020","June 20, 2020"
3585,NCT04019795,Modulated Light Therapy in Participants With Pattern Hair Loss,Androgenetic Alopecia,Device: REVIAN 101|Device: REVIAN 102|Device: REVIAN 103|Device: REVIAN 100,"PhotonMD, Inc",Phase 3,161,Industry,"January 5, 2017","May 25, 2019","May 25, 2019"
3586,NCT04019743,Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers,Hypertension|Dyslipidemias,Drug: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|Drug: CKD-333 16/10/40mg formulation 1 Tab. 1T|Drug: CKD-333 16/10/40mg formulation 2 Tab. 1T,Chong Kun Dang Pharmaceutical,Phase 1,24,Industry,"July 28, 2019","August 30, 2019","September 4, 2019"
3587,NCT04019717,Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection,"Hepatitis C|Hepatitis C, Chronic|Chronic Hepatitis C|Hepatitis C Virus Infection|HCV Infection",Drug: AT-527|Drug: Daclatasvir,"Atea Pharmaceuticals, Inc.",Phase 2,10,Industry,"June 20, 2019","January 29, 2020","March 23, 2020"
3588,NCT04019704,A Trial of AXS-05 in Patients With Major Depressive Disorder,Depression|Major Depressive Disorder,Drug: AXS-05|Drug: Placebo,"Axsome Therapeutics, Inc.",Phase 3,327,Industry,"June 20, 2019","November 26, 2019","December 5, 2019"
3589,NCT04019574,Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects,Healthy,Drug: CR845 0.5 mcg/kg IV|Drug: CR845 3 mcg/kg IV|Drug: Moxifloxacin 400 mg Oral Tablet|Other: Placebo,"Cara Therapeutics, Inc.",Phase 1,57,Industry,"June 20, 2019","October 22, 2019","October 29, 2019"
3590,NCT04019184,Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine,Cardiac Surgery|Acute Kidney Injury,Drug: L-Alanyl/L-Glutamine|Drug: Placebo,"University Hospital Muenster|Fresenius Kabi|IZKF (Interdisciplinary Centre for Clinical Research (IZKF), Muenster)",Phase 3,64,Other|Industry,"July 18, 2019","February 13, 2020","May 13, 2020"
3591,NCT04019041,"A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa",Hidradenitis Suppurativa|Acne Inversa|Suppurative Hidradenitis,Drug: bermekimab|Drug: placebo,"Janssen Research & Development, LLC",Phase 2,144,Industry,"September 16, 2019","May 19, 2020","November 17, 2020"
3592,NCT04018950,Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects,Acinetobacter Baumannii-calcoaceticus Complex Infections,Drug: ETX2514|Drug: 14C-ETX2514,Entasis Therapeutics,Phase 1,8,Industry,"June 21, 2019","July 26, 2019","July 26, 2019"
3593,NCT04018612,A Study of Acetaminophen for Post Surgical Dental Pain,"Pain, Postoperative|Dental Pain",Drug: Acetaminophen|Other: Placebo,"Nevakar, Inc.",Phase 2,110,Industry,"April 25, 2019","July 26, 2019","August 15, 2019"
3594,NCT04018599,Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS,Rheumatoid Arthritis|Polyarticular Juvenile Idiopathic Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Crohn Disease|Ulcerative Colitis|Plaque Psoriasis|Pediatric Plaque Psoriasis|Pediatric Crohns Disease|Hidradenitis Suppurativa|Non-infectious Uveitis,Drug: 40 mg MSB11022,Fresenius Kabi SwissBioSim GmbH|PRA Health Sciences,Phase 1,216,Industry,"July 15, 2019","March 17, 2020","March 17, 2020"
3595,NCT04018482,Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study),Age-related Macular Degeneration|Diabetic Retinopathy|Diabetic Macular Edema,Other: Povidone Iodine|Other: Hypochlorous Acid,California Retina Consultants,Phase 4,50,Other,"July 16, 2019","August 14, 2019","August 14, 2019"
3596,NCT04018339,A Study of RTA 402 in Obese Adults,Obese Adult Male,Drug: Bardoxolone methyl|Drug: Placebo,"Kyowa Kirin Co., Ltd.",Phase 1,22,Industry,"August 20, 2019","May 28, 2020","June 18, 2020"
3597,NCT04018313,"To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects",Healthy,Biological: CT-P39|Biological: EU-approved Xolair|Biological: US-licensed Xolair,Celltrion,Phase 1,176,Industry,"May 28, 2020","March 27, 2021","April 30, 2021"
3598,NCT04018274,Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids,Healthy,Drug: PF-06651600|Drug: Ethinyl estradiol (EE) and levonorgestrel(LN),Pfizer,Phase 1,29,Industry,"August 9, 2019","October 16, 2019","October 16, 2019"
3599,NCT04018170,Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers,Healthy,Drug: Study drug|Drug: Placebo,JW Pharmaceutical,Phase 1,102,Industry,"February 15, 2019","December 15, 2019","December 15, 2019"
3600,NCT04018027,Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis,Pruritus|Atopic Dermatitis,Drug: difelikefalin 0.25 mg|Drug: difelikefalin 0.5 mg|Drug: difelikefalin 1.0 mg|Drug: Placebo,"Cara Therapeutics, Inc.",Phase 2,401,Industry,"June 29, 2019","April 1, 2021","April 1, 2021"
3601,NCT04017741,A Study Investigating the Efficacy of GON Blocks.,"Migraine|Chronic Migraine, Headache",Drug: Combined Depo-Medrone and Lidocaine|Drug: Sodium Chloride 0.9% Inj,Barts & The London NHS Trust,Phase 4,8,Other,"February 14, 2018","December 31, 2019","January 23, 2020"
3602,NCT04017195,A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women,Healthy,Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference)|Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test),"Janssen Research & Development, LLC",Phase 1,68,Industry,"July 12, 2019","December 13, 2019","December 13, 2019"
3603,NCT04016974,A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese,"Healthy Volunteers|Diabetes Mellitus, Type 2",Drug: Oral semaglutide|Drug: Placebo,Novo Nordisk A/S,Phase 1,32,Industry,"October 8, 2019","January 23, 2021","February 26, 2021"
3604,NCT04016779,Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD,Attention-Deficit/Hyperactivity Disorder (ADHD),Drug: Placebo|Drug: SPN-812,"Supernus Pharmaceuticals, Inc.",Phase 3,374,Industry,"November 20, 2019","October 10, 2020","October 10, 2020"
3605,NCT04016753,A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants,Healthy Participants,Drug: BMS-986256|Drug: Loestrin,Bristol-Myers Squibb,Phase 1,32,Industry,"August 5, 2019","February 21, 2020","February 21, 2020"
3606,NCT04016233,Tenofovir Rectal Douche to Prevent HIV Transmission,HIV/AIDS|HIV Prevention,Drug: Tenofovir douche,Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|University of Pittsburgh,Phase 1,9,Other|NIH,"January 10, 2020","April 27, 2021","April 27, 2021"
3607,NCT04016077,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers",Hepatic Impairment|Healthy Participants,Drug: PF-06651600 30 mg,Pfizer,Phase 1,18,Industry,"July 19, 2019","March 5, 2020","March 5, 2020"
3608,NCT04015687,A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults,Healthy Participants,Drug: AG-881|Drug: Lamotrigine,"Agios Pharmaceuticals, Inc.",Phase 1,22,Industry,"July 15, 2019","October 9, 2019","October 9, 2019"
3609,NCT04015518,A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis,Palmoplantar Pustulosis (PPP),Drug: Spesolimab|Drug: Placebo,Boehringer Ingelheim,Phase 2,152,Industry,"July 31, 2019","August 6, 2020","July 28, 2021"
3610,NCT04015492,Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII),Hemophilia A,"Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Biological: Rurioctocog alfa pegol (Adynovi)",Bayer,Phase 1,18,Industry,"August 8, 2019","October 25, 2019","January 29, 2020"
3611,NCT04015375,Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Acne Vulgaris,"Drug: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Drug: ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Other: Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)",Torrent Pharmaceuticals Limited|Catawba Research,Phase 3,1150,Industry|Other,"July 11, 2019","February 3, 2020","February 22, 2020"
3612,NCT04015245,SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy,Hepatocellular Carcinoma,Drug: Stronger Neo-Minophagen C,Chimei Medical Center,Phase 4,60,Other,"April 12, 2018","May 9, 2019","May 28, 2019"
3613,NCT04015076,"Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With Inzomelid",Healthy,Drug: Inzomelid|Drug: Placebo,Inflazome UK Ltd,Phase 1,80,Industry,"July 16, 2019","March 23, 2020","March 23, 2020"
3614,NCT04014855,Lactoferrin Versus Iron Supplement in Irondeficiency Anemia and Weight Loss in Obese Children,"Obesity, Childhood",Drug: Iron Supplement,Ain Shams University,Phase 4,50,Other,"October 1, 2018","July 1, 2019","July 1, 2019"
3615,NCT04014777,Study of NGM621 in Participants With Geographic Atrophy,Geographic Atrophy,Biological: NGM621,"NGM Biopharmaceuticals, Inc",Phase 1,15,Industry,"July 26, 2019","May 27, 2020","May 27, 2020"
3616,NCT04014257,A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies,"Phase 1|Solid Tumor, Adult",Drug: NOV1601(CHC2014),Handok Inc.|CMG Pharmaceutical Co. Ltd,Phase 1,17,Industry,"August 9, 2019","January 22, 2021","January 29, 2021"
3617,NCT04013581,Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen,Type 2 Diabetes Mellitus,Drug: TZD group|Drug: SGLT-2 group,Yonsei University,Phase 4,121,Other,"August 5, 2019","May 13, 2020","May 28, 2020"
3618,NCT04013490,Safety Evaluation and Effect of Food Supplement Containing Dietary Fiber From Cassava on the Alterations of Physiological Parameters in Overweight Female Volunteers,Overweight,Dietary Supplement: Cassava dietary fiber capsule,Khon Kaen University,Phase 1,75,Other,"February 27, 2019","July 31, 2019","August 31, 2019"
3619,NCT04013477,Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults,Healthy,Drug: DA-5207|Drug: Donepezil Hydrochloride,"Dong-A ST Co., Ltd.",Phase 1,40,Industry,"June 18, 2019","December 5, 2019","April 6, 2020"
3620,NCT04013386,Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting,"Nausea and Vomiting, Postoperative",Drug: Aprepitant and Dexamethasone|Drug: Mirtazapine and Dexamethasone|Drug: Dexamethasone,Ain Shams University,Phase 4,90,Other,"July 15, 2019","December 31, 2019","December 31, 2019"
3621,NCT04013191,A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants,Elderly Study Participants|Adult Study Participants,Drug: Padsevonil,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,28,Industry,"July 9, 2019","October 3, 2019","October 3, 2019"
3622,NCT04013048,Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor,Solid Tumor,Drug: [14C]-Fluzoparib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,5,Industry,"July 8, 2019","December 24, 2019","December 24, 2019"
3623,NCT04012307,The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions,Bioequivalence,Drug: Candesartan Cilexetil 32mg|Drug: Atacand® PROTECT,"Pharmtechnology LLC|Altasciences Company, Inc.",Phase 1,40,Industry,"July 11, 2019","August 13, 2019","August 14, 2019"
3624,NCT04011241,A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood,Healthy,Drug: BI 1323495|Drug: Itraconazole,Boehringer Ingelheim,Phase 1,14,Industry,"July 24, 2019","September 6, 2019","September 6, 2019"
3625,NCT04011124,A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib,Healthy Male Subjects,Drug: Fluzoparib|Drug: Rifampicin,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,16,Industry,"July 24, 2019","September 16, 2019","September 16, 2019"
3626,NCT04010799,"A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis",Cystic Fibrosis|Non-Cystic Fibrosis Bronchiectasis,Drug: CHF 6333|Drug: Placebo,Chiesi Farmaceutici S.p.A.,Phase 1,68,Industry,"May 27, 2019","March 8, 2021","March 8, 2021"
3627,NCT04010305,Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia,Agitation|Schizophrenia,Drug: Sublingual film containing BXCL501 (Dexmedetomidine)|Drug: Placebo film,BioXcel Therapeutics Inc|Cognitive Research Corporation,Phase 1,135,Industry,"May 22, 2019","July 31, 2019","July 31, 2019"
3628,NCT04009941,Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,Breast Cancer|Neutropenia,Drug: PEG-rhG-CSF,Peking University,Phase 4,104,Other,"August 1, 2019","January 18, 2020","January 31, 2020"
3629,NCT04009824,"Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine",Mosquito-Borne Infectious Diseases,Biological: AGS-v PLUS Vaccine|Biological: Montanide ISA-51 Adjuvant|Biological: Alhydrogel® Adjuvant|Biological: Saline Placebo,National Institute of Allergy and Infectious Diseases (NIAID)|PepTcell Limited (t/a SEEK),Phase 1,51,NIH|Other,"July 8, 2019","March 3, 2020","February 23, 2021"
3630,NCT04009577,A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia,Insomnia,Drug: LEM 5 mg|Drug: LEM 10 mg,Eisai Inc.,Phase 3,53,Industry,"July 15, 2019","March 17, 2020","June 26, 2020"
3631,NCT04008992,An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants,Healthy Participants,Drug: BMS-986259|Other: Placebo|Diagnostic Test: P-Aminohippurate|Diagnostic Test: Iohexol,Bristol-Myers Squibb,Phase 1,132,Industry,"June 18, 2019","January 4, 2021","January 4, 2021"
3632,NCT04008966,Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles,Assisted Reproduction,Drug: combined oral contaraceptive pills|Drug: recombinant FSH|Drug: Urinaru gonadotropin|Drug: GnRH antagonist|Drug: Human chorionic gonadotropin|Drug: GnRH agonist|Procedure: Ovum pick up|Procedure: Embryo transfer|Drug: natural Progesterone,Cairo University,Phase 4,160,Other,"July 20, 2016","June 2, 2019","July 1, 2019"
3633,NCT04008186,A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone,Healthy Adult Subjects,Drug: Omaveloxolone|Drug: Midazolam oral solution|Drug: Repaglinide 1 MG|Drug: MetFORMIN 500 Mg Oral Tablet|Drug: Rosuvastatin|Drug: Digoxin tablet|Drug: Gemfibrozil Tablets|Drug: Itraconazole capsule|Drug: Verapamil Pill,"Reata Pharmaceuticals, Inc.|Covance",Phase 1,61,Industry,"June 14, 2019","August 18, 2019","August 28, 2019"
3634,NCT04007263,A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers,"Stroke, Ischemic|Pain, Postoperative|Substance Abuse|Subarachnoid Hemorrhage",Drug: Placebo|Drug: NP10679,Neurop Inc.|National Institute of Neurological Disorders and Stroke (NINDS)|Pharmaron,Phase 1,24,Industry|NIH|Other,"April 4, 2019","August 30, 2019","October 10, 2019"
3635,NCT04007120,Open-label Study of Inhaled RVT-1601 in Preterm Infants,Respiratory Morbidities of Prematurity (RMP),Drug: RVT-1601,Respivant Sciences GmbH|Respivant Sciences Inc.,Phase 1,8,Industry,"October 1, 2019","May 29, 2020","May 29, 2020"
3636,NCT04007107,"A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity","Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Novo Nordisk A/S,Phase 2,103,Industry,"June 27, 2019","July 28, 2019","September 4, 2019"
3637,NCT04006873,Gut Imaging for Function & Transit in Cystic Fibrosis Study 2,Cystic Fibrosis,Drug: Tezacaftor/Ivacaftor + Ivacaftor|Drug: Placebo oral tablet,Nottingham University Hospitals NHS Trust|Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation|Cystic Fibrosis Trust|University of Nottingham|Nottingham University Hospitals Charity,Phase 2,12,Other|Industry,"September 3, 2019","October 29, 2020","October 29, 2020"
3638,NCT04006704,"Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets",HIV-1,Drug: D/C/F/TAF FDC placebo,"Janssen Pharmaceutica N.V., Belgium",Phase 1,25,Industry,"October 10, 2019","March 6, 2020","March 6, 2020"
3639,NCT04006353,The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects,Drug Interaction,Drug: ABT|Drug: RIF,Shanghai Public Health Clinical Center,Phase 4,24,Other,"July 11, 2019","September 30, 2019","December 3, 2019"
3640,NCT04006301,First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation,Neoplasms|Advanced Solid Tumors|Non-small Cell Lung Cancer|Colorectal Cancer,Drug: JNJ-74699157,"Janssen Research & Development, LLC",Phase 1,10,Industry,"July 26, 2019","July 13, 2020","July 13, 2020"
3641,NCT04006145,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Albireo,Phase 2,47,Industry,"June 6, 2019","June 26, 2020","July 15, 2020"
3642,NCT04005859,Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane,Colorectal Disorders,Drug: Exparel|Drug: IV Lidocaine,Wake Forest University Health Sciences,Phase 4,61,Other,"February 22, 2018","May 9, 2019","July 20, 2021"
3643,NCT04005807,Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults,Healthy Volunteers,Drug: BPN-14967|Drug: Placebo,"Belite Bio, Inc",Phase 1,40,Industry,"July 19, 2019","December 20, 2019","December 20, 2019"
3644,NCT04005755,Maxigesic® IV Phase 3 Exposure Study,Postoperative Pain,Drug: Maxigesic® IV,"AFT Pharmaceuticals, Ltd.",Phase 3,232,Industry,"July 22, 2019","June 30, 2020","July 7, 2020"
3645,NCT04005170,Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer,Unresectable Esophageal Cancer,Drug: Toripalimab|Drug: Paclitaxel/Cisplatin|Radiation: Intensity-modulated radiotherapy,Mian XI|Sun Yat-sen University,Phase 2,42,Other,"June 25, 2019","December 31, 2020","July 31, 2022"
3646,NCT04004988,A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants,Healthy,Drug: Tirzepatide|Device: Prefilled syringe (PFS)|Device: Auto-injector (AI),Eli Lilly and Company,Phase 1,47,Industry,"August 19, 2019","December 16, 2019","December 16, 2019"
3647,NCT04004663,Bioavailability Study of PF-06651600 Formulations in Healthy Participants,Healthy Volunteers,Drug: PF-06651600,Pfizer,Phase 1,12,Industry,"July 15, 2019","October 11, 2019","October 11, 2019"
3648,NCT04004221,Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer,Locally Advanced or Metastatic Urothelial Bladder Cancer,Drug: Tislelizumab,BeiGene,Phase 2,113,Industry,"June 16, 2017","September 16, 2019","March 11, 2021"
3649,NCT04004208,Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy,Retinopathy of Prematurity (ROP),"Drug: Eylea (Aflibercept, BAY86-5321)|Procedure: Laser photocoagulation",Bayer|Regeneron Pharmaceuticals,Phase 3,113,Industry,"September 25, 2019","February 12, 2021","February 12, 2021"
3650,NCT04004195,"Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status",Pharmacokinetics,Drug: BAY2327949,Bayer,Phase 1,32,Industry,"July 10, 2019","February 7, 2020","June 4, 2020"
3651,NCT04003987,ESP Block VS TAP in Laparoscopic Hysterectomy,Hysterectomy,"Drug: Liposomal bupivacaine|Drug: bupivacaine, 0.125%",Indiana University,Phase 3,78,Other,"May 1, 2019","March 4, 2021","March 4, 2021"
3652,NCT04003974,Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD),Facioscapulohumeral Muscular Dystrophy (FSHD),Drug: Losmapimod|Drug: Placebo oral tablet,Fulcrum Therapeutics,Phase 2,80,Industry,"August 9, 2019","January 28, 2021","January 28, 2021"
3653,NCT04003844,Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease,Kawasaki Disease,Drug: Immunoglobulin G|Drug: Acetylsalicylic acid,Green Cross Corporation|GC Biopharma Corp,Phase 4,45,Industry,"February 1, 2019","November 22, 2019","November 22, 2019"
3654,NCT04003467,A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass,Osteoporosis,Drug: EBP05|Drug: Placebo of EBP05,Entera Bio Ltd.,Phase 2,161,Industry,"June 30, 2019","April 27, 2021","May 11, 2021"
3655,NCT04003402,A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects,Healthy Volunteers,Drug: ASP8062|Drug: Alcohol|Drug: ASP8062 Placebo|Drug: Alcohol Placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,20,Industry,"July 16, 2019","October 16, 2019","October 16, 2019"
3656,NCT04003207,Growth Hormone Treatment in Children With Phelan McDermid Syndrome,Phelan McDermid Syndrome,Drug: Recombinant human Growth hormone,Swathi Sethuram|Icahn School of Medicine at Mount Sinai,Phase 2,6,Other,"September 13, 2019","June 5, 2020","June 5, 2020"
3657,NCT04003155,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause,Hot Flashes,Drug: fezolinetant|Drug: placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 3,527,Industry,"July 11, 2019","October 29, 2020","August 11, 2021"
3658,NCT04003142,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2,Hot Flashes,Drug: Fezolinetant|Drug: placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 3,501,Industry,"July 10, 2019","July 30, 2020","April 23, 2021"
3659,NCT04002895,What the Body Does to Foliglurax in Healthy Volunteers,Healthy,Drug: Foliglurax,H. Lundbeck A/S,Phase 1,6,Industry,"June 27, 2019","August 1, 2019","August 8, 2019"
3660,NCT04002752,A Study of JNJ-73763989 in Healthy Japanese Adult Participants,Healthy,Drug: JNJ-73763989|Drug: Placebo,Janssen Sciences Ireland UC,Phase 1,25,Industry,"July 4, 2019","August 23, 2019","August 23, 2019"
3661,NCT04002687,Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ),Malaria,Drug: ATV-PG 1000-400 mg + AQ 612 mg,Medicines for Malaria Venture|Richmond Pharmacology Limited,Phase 1,44,Other|Industry,"April 4, 2019","October 29, 2019","October 29, 2019"
3662,NCT04002544,Nitroglycerin to Facilitate Radial Arterial Catheter Insertion in Children,Radial Artery Canulation,Drug: NTG patch|Other: gauze cover,Cairo University,Phase 4,40,Other,"September 15, 2019","November 15, 2019","November 30, 2019"
3663,NCT04002427,"Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594",Asthma,Drug: Intravenous Infusion|Drug: Inhaled dose,AstraZeneca|Quotient Sciences,Phase 1,6,Industry,"June 11, 2019","July 5, 2019","July 5, 2019"
3664,NCT04002284,Anlotinib in Metastatic HER2 Negative Breast Cancer,Breast Neoplasm|Antineoplastic Agents|Anlotinib,Drug: Anlotinib Hydrochloride,"Peng Yuan|Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 2,26,Other,"July 12, 2018","January 10, 2020","March 15, 2020"
3665,NCT04002089,"Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy",Bunion,Drug: Exparel Injectable Product|Drug: Bupivacaine,"Pacira Pharmaceuticals, Inc",Phase 1,45,Industry,"July 26, 2019","December 2, 2019","December 2, 2019"
3666,NCT04001894,Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease,Platelet Reactivity,Drug: Ticagrelor 90mg|Drug: Clopidogrel 75mg,First Affiliated Hospital of Harbin Medical University,Phase 4,50,Other,"July 2, 2019","December 9, 2020","December 9, 2020"
3667,NCT04001803,Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US),HIV Infections,Drug: CAB LA+RPV LA,ViiV Healthcare,Phase 3,115,Industry,"July 8, 2019","October 5, 2020","March 18, 2022"
3668,NCT04001712,Effect of Early Use of Caffeine Citrate in Preterm Neonates,Preterm Birth,Drug: Caffeine Citrate,Ain Shams University,Phase 3,54,Other,"April 5, 2019","May 5, 2019","June 10, 2019"
3669,NCT04001517,Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies,Dementia With Lewy Bodies (DLB),Drug: Neflamapimod,EIP Pharma Inc|Worldwide Clinical Trials,Phase 2,91,Industry|Other,"September 30, 2019","June 30, 2020","June 30, 2020"
3670,NCT04001088,The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health,Menopause,Dietary Supplement: Probiotic|Other: Placebo,"Lallemand Health Solutions|Nutrasource Pharmaceutical and Nutraceutical Services, Inc.",Phase 2,144,Industry|Other,"July 29, 2019","November 18, 2020","April 23, 2021"
3671,NCT04000139,Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis,Ulcerative Colitis,Drug: Standardized anthocyanin-rich extract|Drug: Placebo,University of Zurich|Swiss National Science Foundation|The Broad Foundation,Phase 2,48,Other,"April 1, 2019","March 11, 2021","March 11, 2021"
3672,NCT03999684,A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma,Adenoid Cystic Carcinoma,Drug: Tretinoin,Dana-Farber Cancer Institute|The V Foundation|Adenoid Cystic Carcinoma Research Foundation,Phase 2,18,Other,"August 5, 2019","April 15, 2020","April 15, 2020"
3673,NCT03999554,Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines,Influenza A,Biological: LD Sing2016 M2SR H3N2 influenza vaccine|Biological: MD Sing2016 M2SR H3N2 influenza vaccine|Biological: HD Sing2016 M2SR H3N2 influenza vaccine|Biological: LD Bris10 M2SR H3N2 influenza vaccine|Other: Placebo,FluGen Inc,Phase 1,206,Industry,"September 3, 2019","July 1, 2020","July 1, 2020"
3674,NCT03999411,Smartphone Intervention for Smoking Cessation and Adherence to Anti- Retroviral Therapy (ART) Among People Living With Human Immunodeficiency Virus (HIV),Smoking|Smoking Cessation|HIV,"Drug: Nicoderm C-Q Transdermal Product|Behavioral: Adherence to Antiretroviral Therapy Counseling|Behavioral: Behavioral Smoking Cessation Counseling|Behavioral: ""Crave-to-Quit"" app|Behavioral: vDOT ""emocha"" app",University of Miami,Phase 4,39,Other,"September 9, 2019","October 14, 2020","October 14, 2020"
3675,NCT03999372,Evaluation of Sperm Selection Technique Using Hyaluronic Acid Binding in Intra-cytoplasmic Sperm Injection (ICSI),"Infertility, Male",Biological: Hyaluronan binding system|Other: ICSI,ClinAmygate,Phase 4,300,Other,"July 5, 2019","December 2, 2019","January 10, 2020"
3676,NCT03998683,A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis,Psoriasis,Drug: Guselkumab 100 mg|Drug: Placebo,Janssen-Cilag Ltd.,Phase 3,117,Industry,"September 3, 2019","March 2, 2021","November 30, 2021"
3677,NCT03998514,A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver Disease,Drug: CB4211 Dose 1|Drug: CB4211 Dose 2|Drug: CB4211 Dose 3|Drug: CB4211 Dose 4|Drug: CB4211 Dose 5|Drug: CB4211 Dose 6|Drug: CB4211 Dose TBD|Drug: Placebo,"CohBar, Inc.",Phase 1,88,Industry,"July 9, 2018","April 19, 2021","April 19, 2021"
3678,NCT03998163,CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,Uremic Pruritus,Drug: CR845 0.5 mcg/kg,"Cara Therapeutics, Inc.",Phase 3,222,Industry,"May 6, 2019","February 26, 2020","March 6, 2020"
3679,NCT03997838,Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty,"Pain, Postoperative",Drug: VVZ-149 Injections|Drug: Placebo,"Vivozon, Inc.",Phase 3,307,Industry,"May 23, 2019","August 3, 2019","August 21, 2019"
3680,NCT03997812,Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy,"Pain, Postoperative",Drug: VVZ-149 Injections|Drug: Placebo,"Vivozon, Inc.",Phase 2,60,Industry,"May 23, 2019","August 7, 2019","August 21, 2019"
3681,NCT03997734,"Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects",Chronic Low Back Pain,Drug: AB001|Drug: oral capsule|Drug: positive comparative patch|Drug: Placebos,Frontier Biotechnologies Inc.,Phase 1,34,Industry,"June 24, 2019","November 11, 2019","November 11, 2019"
3682,NCT03997006,Is Aminophylline More Effective Than Neostigmine/Atropine Mixture in the Treatment of Post-dural Puncture Headache,Post-Dural Puncture Headache,Drug: IV Aminophylline|Drug: IV Neostigmine Methylsulfate + Atropine Sulphate,Damanhour Teaching Hospital,Phase 4,60,Other,"January 1, 2019","January 1, 2020","January 1, 2020"
3683,NCT03996694,"Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.",Respiratory Depression,Drug: Belbuca 300 µg|Drug: Belbuca 600 µg|Drug: Belbuca 900 µg|Drug: Oxycodone 30 mg|Drug: Oxycodone 60 mg|Drug: Placebo,BioDelivery Sciences International|PRA Health Sciences,Phase 1,19,Industry,"July 23, 2019","October 27, 2019","October 27, 2019"
3684,NCT03996603,Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy,Female Urogenital Diseases|Vaginal Atrophy|Postmenopausal Atrophic Vaginitis|Genitourinary Disease|Postmenopausal Symptoms,Drug: Conjugated Estrogens Cream,University of Alabama at Birmingham,Phase 4,25,Other,"August 1, 2019","January 14, 2021","January 14, 2021"
3685,NCT03996538,Vaccination Efficacy With Metformin in Older Adults,Aging|Age-Related Immunodeficiency|Vaccine Response Impaired,Drug: Metformin Hydrochloride Extended-Release Tablets|Biological: Influenza Vaccine,UConn Health,Phase 1,26,Other,"June 5, 2019","February 4, 2020","February 4, 2020"
3686,NCT03996447,Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI),CNS Lesion|Blood Brain Barrier Defect,Drug: gadopiclenol|Drug: Gadobutrol 1Mmol/mL Solution for Injection Vial,Guerbet,Phase 3,260,Industry,"June 3, 2019","September 11, 2020","September 11, 2020"
3687,NCT03996434,Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS,Ovarian Hyperstimulation Syndrome,Drug: Gonadotropin|Drug: Antagonist,ClinAmygate|Cairo University|Al-Azhar University|Beni-Suef University,Phase 4,300,Other,"July 1, 2019","November 10, 2019","November 20, 2019"
3688,NCT03996226,A Food-Effect Study of E7386 in Healthy Participants,Food Effect in Healthy Participants,Drug: E7386,Eisai Inc.,Phase 1,17,Industry,"June 7, 2019","October 29, 2019","October 29, 2019"
3689,NCT03995888,Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer,Prostate Cancer,Drug: rhPSMA-7.3 (18F) Injection,Blue Earth Diagnostics,Phase 1,16,Industry,"June 11, 2019","April 16, 2020","April 16, 2020"
3690,NCT03995784,Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B,Hemophilia B,Biological: Coagulation Factor IX variant,Catalyst Biosciences,Phase 2,6,Industry,"June 18, 2019","February 28, 2020","April 30, 2020"
3691,NCT03995680,Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm,Hookworm Infections,Drug: Mebendazole,Swiss Tropical & Public Health Institute|Public Health Laboratory Ivo de Carneri,Phase 2,397,Other,"July 12, 2019","October 9, 2019","October 9, 2019"
3692,NCT03994731,Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout,Gout,Biological: Pegloticase|Drug: methotrexate|Drug: placebo|Dietary Supplement: folic acid|Drug: gout flare prophylaxis regimen|Drug: fexofenadine|Drug: acetaminophen|Drug: methylprednisolone,"Horizon Therapeutics Ireland DAC|Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 4,152,Industry,"June 13, 2019","March 17, 2021","April 11, 2022"
3693,NCT03994406,Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel,Contact Lens Discomfort|Contact Lens-induced Corneal Disorder|Contact Lens Acute Red Eye|Contact Lens-induced Corneal Fluorescein Staining,Drug: CLM2 topical gel|Drug: Placebo topical gel,"Glia, LLC",Phase 2,30,Industry,"June 27, 2019","August 30, 2019","October 30, 2019"
3694,NCT03994211,Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer,Solid Tumor,Drug: pamiparib 60 mg|Drug: pamiparib 20 mg|Drug: itraconazole|Drug: rifampin|Drug: pamiparib,BeiGene,Phase 1,25,Industry,"May 29, 2019","October 25, 2019","August 6, 2021"
3695,NCT03993704,Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants,Healthy,Drug: LHF-535,Kineta Inc.|Wellcome Trust,Phase 1,24,Industry|Other,"September 16, 2019","January 9, 2020","June 9, 2020"
3696,NCT03993639,KRN125 for Mobilization of Hematopoietic Stem Cells,Peripheral Blood Stem Cell Transplantation,Drug: Pegfilgrastim,"Kyowa Kirin Co., Ltd.",Phase 2,35,Industry,"May 28, 2019","July 21, 2020","August 28, 2020"
3697,NCT03993392,SUBLOCADE Rapid Initiation Study,Opioid-use Disorder,Drug: TM buprenorphine|Drug: SUBLOCADE,Indivior Inc.,Phase 4,26,Industry,"August 29, 2019","December 26, 2019","December 26, 2019"
3698,NCT03993288,"Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.",Mild and Moderate Iron-deficiency Anaemia,"Drug: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Drug: MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)",Sandoz,Phase 3,267,Industry,"June 27, 2019","June 18, 2020","June 18, 2020"
3699,NCT03992872,Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317),Chikungunya,Biological: Chikungunya,Emergent BioSolutions|Walter Reed Army Institute of Research (WRAIR),Phase 2,60,Industry|U.S. Fed,"November 20, 2019","January 19, 2021","January 19, 2021"
3700,NCT03992365,Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonoscopy,Bowel Preparation,"Drug: Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|Drug: Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl",Universal Integrated Corp.,Phase 3,472,Industry,"June 10, 2019","October 15, 2019","January 15, 2020"
3701,NCT03992261,Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis,Plaque Psoriasis,Drug: Halobetasol Topical Foam,Mayne Pharma International Pty Ltd,Phase 4,23,Industry,"June 14, 2019","December 30, 2019","December 30, 2019"
3702,NCT03992066,"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease",Anemia Associated With Chronic Kidney Disease,Drug: Vadadustat|Drug: Darbepoetin alfa|Drug: Epoetin alfa,Akebia Therapeutics,Phase 1,46,Industry,"May 28, 2019","May 5, 2020","July 15, 2020"
3703,NCT03992014,Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat,Cholestasis,Drug: Linerixibat tablet|Drug: [14C]-linerixibat intravenous infusion|Drug: Linerixibat oral solution,GlaxoSmithKline,Phase 1,6,Industry,"July 8, 2019","August 26, 2019","August 26, 2019"
3704,NCT03992001,Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients,Thalassemia Major,Biological: Blood component A|Biological: Blood component B,Università degli Studi di Ferrara,Phase 4,55,Other,"May 14, 2018","July 31, 2019","July 31, 2019"
3705,NCT03991494,"Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer",Advanced Solid Tumors,Drug: [14C]-pamiparib,BeiGene,Phase 1,4,Industry,"May 29, 2019","October 21, 2019","August 5, 2020"
3706,NCT03991442,BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination,Essential Hypertension,Drug: Fimasartan/Amlodipine,"Boryung Pharmaceutical Co., Ltd",Phase 3,257,Industry,"June 17, 2019","March 2, 2021","March 2, 2021"
3707,NCT03991312,Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants,Healthy Volunteers,Drug: itraconazole|Drug: rifampin|Drug: mitapivat sulfate,"Agios Pharmaceuticals, Inc.",Phase 1,28,Industry,"June 20, 2019","August 14, 2019","September 10, 2019"
3708,NCT03991143,"Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction",ST Elevation Myocardial Infarction,Drug: ATH3G10|Drug: Placebo,Athera Biotechnologies AB,Phase 2,82,Industry,"March 29, 2019","July 6, 2020","April 19, 2021"
3709,NCT03990805,A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis,Degenerative Arthritis|Knee Osteoarthritis,Biological: JOINTSTEM|Drug: saline,R-Bio,Phase 3,260,Industry,"June 11, 2019","December 15, 2020","December 15, 2020"
3710,NCT03990766,Smell Changes & Efficacy of Nasal Theophylline,Olfactory Disorder|Anosmia|Viral Infection|Theophylline Causing Adverse Effects in Therapeutic Use|Smell Disorder,Drug: Theophylline|Drug: Saline Nasal,Washington University School of Medicine,Phase 2,27,Other,"May 15, 2019","January 15, 2021","January 15, 2021"
3711,NCT03990688,A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects,Healthy,Drug: AK3280|Drug: Placebo,Ark Biosciences Inc.,Phase 1,48,Industry,"October 3, 2019","September 9, 2020","September 21, 2020"
3712,NCT03990649,Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS),Complex Regional Pain Syndrome,Drug: Soticlestat|Drug: Placebo,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 2,24,Industry,"July 23, 2019","June 29, 2020","October 28, 2020"
3713,NCT03990519,A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants,Healthy,Drug: JNJ-26366821|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,33,Industry,"June 24, 2019","February 19, 2020","February 19, 2020"
3714,NCT03990090,A Study of TG103 in Chinese Healthy Adult Subjects,Healthy,Drug: TG103|Drug: Placebo,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1,32,Industry,"July 29, 2019","November 11, 2020","November 11, 2020"
3715,NCT03989609,Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock,Septic Shock,Drug: Dexmedetomidine Injection [Precedex]|Drug: Midazolam,Kasr El Aini Hospital,Phase 2,24,Other,"June 20, 2019","February 20, 2020","August 20, 2021"
3716,NCT03989557,Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms,Unruptured Intracranial Aneurysm|Stents|Antiplatelet Drugs,Drug: Aspirin and clopidogrel/Ticagrelor|Device: Light transmittance aggregometry,Beijing Neurosurgical Institute,Phase 4,314,Other,"July 1, 2019","July 20, 2020","August 13, 2020"
3717,NCT03989544,A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects,Asthma,Biological: Tezepelumab,AstraZeneca|Amgen,Phase 1,315,Industry,"June 19, 2019","December 30, 2019","December 30, 2019"
3718,NCT03989232,A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,Phase 3,961,Industry,"June 19, 2019","September 18, 2020","November 9, 2020"
3719,NCT03988907,A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants,Spinal Muscular Atrophy,Drug: Risdiplam|Drug: Midazolam,Hoffmann-La Roche,Phase 1,35,Industry,"June 18, 2019","September 29, 2019","September 29, 2019"
3720,NCT03988803,A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other,Healthy,Drug: BI 425809|Drug: Memantine,Boehringer Ingelheim,Phase 1,16,Industry,"July 17, 2019","October 30, 2019","October 30, 2019"
3721,NCT03988530,Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects,Motion Sickness,Drug: Scopolamine|Other: Placebo Nasal Gel,"Repurposed Therapeutics, Inc.",Phase 3,98,Industry,"June 7, 2019","November 23, 2020","November 23, 2020"
3722,NCT03988413,"Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People",Diabetic Neuropathy Peripheral,Drug: 25mg|Drug: 50mg|Drug: 100mg|Drug: 200mg|Drug: 400mg|Drug: 800mg,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 1,54,Industry,"August 5, 2019","January 14, 2020","January 14, 2020"
3723,NCT03988335,A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP),Palmoplantar Pustulosis,Drug: RIST4721|Drug: Placebo,"Aristea Therapeutics, Inc.",Phase 2,35,Industry,"February 13, 2019","November 5, 2019","November 19, 2019"
3724,NCT03988088,A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine,Migraine,Drug: Lasmiditan,Eli Lilly and Company,Phase 1,18,Industry,"July 22, 2019","January 19, 2020","February 24, 2020"
3725,NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,Type 2 Diabetes,Drug: Tirzepatide|Drug: Semaglutide,Eli Lilly and Company,Phase 3,1879,Industry,"July 30, 2019","January 28, 2021","February 15, 2021"
3726,NCT03987685,Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies,Solid Tumor,Drug: Oratopo,"Athenex, Inc.",Phase 1,10,Industry,"July 19, 2018","January 9, 2021","January 9, 2021"
3727,NCT03987620,Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis,Candida Vulvovaginitis,Drug: Ibrexafungerp|Drug: Placebo,"Scynexis, Inc.",Phase 3,455,Industry,"June 7, 2019","March 29, 2020","April 29, 2020"
3728,NCT03987451,A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage,Non-alcoholic Steatohepatitis,Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,Phase 2,71,Industry,"June 18, 2019","April 22, 2021","June 10, 2021"
3729,NCT03987204,Ivabradine for Rate Control in Permanent Atrial Fibrillation,"Atrial Fibrillation|Atrial Fibrillation, Persistent",Drug: Ivabradine,Yale University,Phase 1,4,Other,"June 15, 2019","September 17, 2019","September 17, 2019"
3730,NCT03987191,Insulin Pump to Multiple Daily Injection Transition Clinical Trial,Type 1 Diabetes,Drug: Multiple daily ijnection using Insulin Degludec and Insulin Aspart,"University of Colorado, Denver",Phase 4,38,Other,"January 10, 2020","October 8, 2020","October 8, 2020"
3731,NCT03987074,"Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)",Nonalcoholic Steatohepatitis,Drug: Semaglutide|Drug: Firsocostat|Drug: Cilofexor,Gilead Sciences|Novo Nordisk A/S,Phase 2,109,Industry,"July 29, 2019","July 13, 2020","July 13, 2020"
3732,NCT03986970,The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention,HIV/AIDS,Drug: Tenofovir,Wits Health Consortium (Pty) Ltd|University of Cape Town|University of Liverpool|Imperial College London|MRC/UVRI Uganda Research Unit|Karolinska Institutet|King's College London|London School of Hygiene and Tropical Medicine,Phase 2,72,Other,"November 11, 2019","February 25, 2021","February 25, 2021"
3733,NCT03986905,The Prevention and Treatment of Nausea Associated With Motion Sickness,Motion Sickness,Drug: Scopolamine Nasal Gel|Other: Placebo,"Repurposed Therapeutics, Inc.",Phase 3,300,Industry,"April 26, 2019","May 19, 2019","June 19, 2019"
3734,NCT03986762,Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid,"Cocaine Dependence, in Remission|Cocaine Abuse, in Remission|Cocaine-Related Disorders",Drug: Clavulanic Acid,Temple University|National Institute on Drug Abuse (NIDA),Phase 1,9,Other|NIH,"March 12, 2019","December 20, 2019","December 20, 2019"
3735,NCT03986138,Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI),Lesion in Body Region,Drug: gadopiclenol|Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution,Guerbet,Phase 3,304,Industry,"August 27, 2019","December 9, 2020","December 9, 2020"
3736,NCT03985982,Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII),Glabellar Frown Lines,Drug: Botulinum Toxin A|Drug: Placebo,Croma-Pharma GmbH,Phase 3,355,Industry,"April 29, 2019","March 15, 2020","December 22, 2020"
3737,NCT03985969,Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin,Drug-drug Interaction,Drug: elafibranor|Drug: CHRONO-INDOCID,Genfit,Phase 1,26,Industry,"September 23, 2019","March 15, 2020","March 31, 2020"
3738,NCT03985410,Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers,Acinetobacter Baumannii-calcoaceticus Complex Infections,Drug: ETX2514|Drug: Placebo|Drug: moxifloxacin,Entasis Therapeutics,Phase 1,32,Industry,"May 23, 2019","July 24, 2019","July 24, 2019"
3739,NCT03985319,Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1),GERD,Drug: YYD601 20mg|Drug: Nexium tab 20mg,"Yooyoung Pharmaceutical Co., Ltd.",Phase 1,28,Industry,"July 8, 2019","February 7, 2020","March 20, 2020"
3740,NCT03985007,CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia,"Acute Myeloid Leukemia, Relapsed, Adult",Drug: CDIAG regimen,The First Affiliated Hospital of Soochow University|Jining Medical University,Phase 2,40,Other,"January 1, 2018","December 31, 2020","March 16, 2021"
3741,NCT03984838,"Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent",HIV Infections,Drug: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet,"ViiV Healthcare|Janssen, LP",Phase 1,16,Industry,"June 17, 2019","August 13, 2019","August 13, 2019"
3742,NCT03984825,Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive,HIV Infections,Drug: GSK3640254|Drug: Portia,ViiV Healthcare,Phase 1,23,Industry,"June 13, 2019","August 16, 2019","August 16, 2019"
3743,NCT03984760,Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis,Hyperphosphatemia|End Stage Renal Disease|ESRD,Drug: Ferric Citrate|Drug: Sevelamer Carbonate,Panion & BF Biotech Inc.|Shandong Weigao Panion Pharmaceutical Co. Ltd.,Phase 3,240,Industry|Other,"June 19, 2019","February 20, 2021","February 20, 2021"
3744,NCT03984526,Atropine or Ephedrine Pretreatment for Preventing Bradycardia in Elderly Patients,"Anesthesia, Spinal|Dexmedetomidine|Bradycardia",Drug: normal saline|Drug: atropine 0.5mg|Drug: ephedrine 8mg,Ajou University School of Medicine,Phase 4,102,Other,"June 25, 2019","September 15, 2020","September 15, 2020"
3745,NCT03984370,Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass,Hyperinsulinemic Hypoglycemia|Postprandial Hypoglycemia,Drug: ZP4207|Other: Placebo (saline),"University Hospital, Gentofte, Copenhagen",Phase 2,10,Other,"September 18, 2019","February 26, 2020","February 26, 2020"
3746,NCT03983980,Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002),Plaque Psoriasis,Drug: Tapinarof|Drug: Vehicle Cream,"Dermavant Sciences GmbH|IQVIA Biotech|Dermavant Sciences, Inc.",Phase 3,515,Industry,"June 6, 2019","May 13, 2020","May 29, 2020"
3747,NCT03983876,"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)",Phase 1,Drug: Adalimumab,Alvotech Swiss AG,Phase 1,207,Industry,"July 1, 2019","December 3, 2019","December 3, 2019"
3748,NCT03983239,Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects,Healthy Volunteers,Drug: Fedratinib|Drug: Rifampin|Drug: Efavirenz,"Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation",Phase 1,32,Industry,"June 21, 2019","November 2, 2019","November 6, 2019"
3749,NCT03982849,Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma,Melasma,Drug: Hydroquinone 4% Cream|Drug: silymarin 0.7% cream,Islamabad Medical and Dental College,Phase 2,92,Other,"July 15, 2019","December 31, 2019","January 15, 2020"
3750,NCT03982368,A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye,Dry Eye Syndrome,Drug: rhNGF 20 μg/ml|Drug: rhNGF 20 μg/ml + vehicle|Other: Vehicle,Dompé Farmaceutici S.p.A,Phase 2,261,Industry,"June 10, 2019","July 15, 2020","July 15, 2020"
3751,NCT03982277,Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy,Tuberculosis,Drug: Rifampin 300 Mg Oral Capsule,Makerere University,Phase 2,130,Other,"April 30, 2019","March 16, 2021","July 23, 2021"
3752,NCT03982238,Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients,Type 2 Diabetes,Drug: Insulin|Drug: Metformin|Drug: Dapagliflozin,"Majianhua|Nanjing First Hospital, Nanjing Medical University",Phase 4,74,Other,"June 15, 2019","November 15, 2019","December 31, 2019"
3753,NCT03982186,A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection,"Hepatitis B, Chronic",Drug: JNJ-73763989|Drug: Placebo for JNJ-73763989|Drug: JNJ-56136379|Drug: Placebo for JNJ-56136379|Drug: Nucleos(t)ide Analog (NA),Janssen Sciences Ireland UC,Phase 2,471,Industry,"August 1, 2019","March 29, 2021","April 26, 2022"
3754,NCT03982069,Immunologic Response to FluMist vs. Flucelvax,"Influenza, Human|Immune Response",Biological: FluMist live attenuated influenza vaccine|Biological: Flucelvax inactivated influenza vaccine,Richard Zimmerman MD|Centers for Disease Control and Prevention|University of Pittsburgh,Phase 4,465,Other|U.S. Fed,"September 20, 2019","December 9, 2020","December 9, 2020"
3755,NCT03981887,"Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin",Healthy,Drug: Nafithromycin|Other: Placebo,"Wockhardt|Clinartis, LLC|Keystone Bioanalytical, Inc.",Phase 1,10,Industry|Other,"June 18, 2019","July 2, 2019","August 7, 2019"
3756,NCT03981822,A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts,"Condylomata Acuminata|Papillomavirus Infections|Skin Diseases, Viral|Skin Diseases, Infectious|Skin Diseases|Sexually Transmitted Diseases, Viral|Sexually Transmitted Diseases|Warts",Combination Product: VP-102 and applicator|Combination Product: Placebo,"Verrica Pharmaceuticals Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|BioClinica, Inc.",Phase 2,105,Industry|Other,"June 25, 2019","May 21, 2020","July 8, 2020"
3757,NCT03981419,A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty,Postoperative Recovery,Biological: GRF6021|Other: Placebo,"Alkahest, Inc.",Phase 2,38,Industry,"July 12, 2019","January 23, 2021","March 4, 2021"
3758,NCT03981094,A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants,Idiopathic Pulmonary Fibrosis (IPF),Drug: BMS-986278|Drug: Pirfenidone,Bristol-Myers Squibb,Phase 1,22,Industry,"May 10, 2019","July 27, 2019","July 30, 2019"
3759,NCT03980821,A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies,Advanced Solid Malignancies,Drug: AZD4635,AstraZeneca,Phase 1,10,Industry,"July 4, 2019","September 7, 2020","September 7, 2020"
3760,NCT03980756,"A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole",Gastritis,Drug: AD-206 20mg|Drug: Esomeprazole 20mg|Drug: AD-206 40mg|Drug: Esomeprazole 40mg,Addpharma Inc.,Phase 1,88,Industry,"June 5, 2019","April 27, 2020","June 18, 2020"
3761,NCT03980704,Preoperative High Protein vs Immunodiet in Surgical Cancer Patients,General Surgery|Cancer of Colon,Drug: IMPACT|Drug: resource protein,Stanley Dudrick's Memorial Hospital,Phase 4,299,Other,"April 1, 2019","December 31, 2020","March 31, 2021"
3762,NCT03980691,Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir,HIV/AIDS,Biological: Chidamide with CAR-T or TCR-T cell therapy,Guangzhou 8th People's Hospital|Sun Yat-sen University,Phase 1,4,Other,"December 1, 2017","May 31, 2020","May 31, 2020"
3763,NCT03980522,A Pilot Study of KPL-914 in Recurrent Pericarditis,Recurrent Pericarditis,Drug: KPL-914,"Kiniksa Pharmaceuticals (UK), Ltd.|Kiniksa Pharmaceuticals, Ltd.",Phase 2,26,Industry,"January 24, 2018","May 17, 2019","May 17, 2019"
3764,NCT03980288,4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3,Advanced Hepatocellular Carcinoma,Drug: CAR-GPC3 T Cells,"Zhejiang University|CARsgen Therapeutics Co., Ltd.",Phase 1,6,Other|Industry,"July 23, 2019","December 30, 2020","December 30, 2020"
3765,NCT03980080,"Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects",Healthy Subjects,Drug: OSE-127|Drug: Placebo,OSE Immunotherapeutics|Servier,Phase 1,63,Industry,"December 19, 2018","November 4, 2019","November 4, 2019"
3766,NCT03980041,Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275),Bladder Cancer|Urothelial Carcinoma|Solid Tumor|Advanced Cancer,Drug: IPI-549 (eganelisib)|Drug: Nivolumab|Drug: Placebos,"Infinity Pharmaceuticals, Inc.|Bristol-Myers Squibb",Phase 2,49,Industry,"September 25, 2019","November 30, 2020","November 15, 2022"
3767,NCT03979469,Opioid Versus Non-opioid Anesthesia for Ambulatory Surgery in Children,Effect of Anesthesia in Postoperative Pain|Effect of Anesthesia in Extubation Time|Effect of Anesthesia in Discharge Time From Postanesthesia Care Unit|Effect of Anesthesia in Postoperative Adverse Events|Effect of Anesthesia in Discharge Time From the Hospital,"Drug: Ketamine, dexmedetomidine|Drug: fentanyl, remifentanil","Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""",Phase 2,100,Other,"August 1, 2018","August 1, 2019","August 1, 2019"
3768,NCT03979274,A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers,Healthy,Drug: Reference Eutirox®|Drug: Test Eutirox®,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,44,Industry,"December 6, 2019","January 13, 2020","January 25, 2020"
3769,NCT03979248,A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants,Healthy,Drug: BMS-986165|Drug: Rabeprazole,Bristol-Myers Squibb,Phase 1,21,Industry,"May 16, 2019","July 7, 2019","July 7, 2019"
3770,NCT03978832,"Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone",Schizophrenia,Drug: PERSERIS|Drug: Risperidone,Indivior Inc.,Phase 4,69,Industry,"June 28, 2019","May 12, 2020","May 12, 2020"
3771,NCT03978403,A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers,Migraine,"Drug: M207 3.8 mg ""Sled"" (two 1.9 mg patches made on a ""Sled"" coater, foil pouches)|Drug: M207 3.8 mg ""MACAP"" (two 1.9 mg patches made on a ""MACAP"" coater, foil cups)|Drug: M207 3.8 mg ""MiniMac"" (two 1.9 mg patches made on a ""MiniMac"" coater, foil cups|Drug: Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose",Zosano Pharma Corporation,Phase 1,24,Industry,"May 29, 2019","June 28, 2019","June 28, 2019"
3772,NCT03978208,Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients,Osteoarthritis,Drug: ATB-346 low dose|Other: Placebo|Drug: ATB-346 mid-dose|Drug: ATB-346 standard dose,"Antibe Therapeutics Inc.|Veristat, Inc.",Phase 2,381,Industry|Other,"March 29, 2019","December 29, 2019","December 29, 2019"
3773,NCT03978143,Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants,Healthy Volunteers,Drug: Treatment A|Drug: Treatment B|Drug: Treatment C|Drug: Treatment D|Drug: Treatment E|Drug: Treatment F|Drug: Treatment G|Drug: Treatment H,Pfizer,Phase 1,25,Industry,"June 12, 2019","October 17, 2019","October 17, 2019"
3774,NCT03977805,Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects,Healthy,Drug: Hetrombopag Olamine,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,6,Industry,"May 25, 2019","June 13, 2019","June 13, 2019"
3775,NCT03977727,FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump,Type 1 Diabetes Mellitus,Drug: Fiasp®|Drug: Novolog®|Device: 670G hybrid closed loop continuous subcutaneous insulin infusion system,"Texas Diabetes & Endocrinology, P.A.",Phase 3,40,Other,"June 11, 2019","March 9, 2020","April 20, 2020"
3776,NCT03977155,"Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)",Diarrhea-predominant Irritable Bowel Syndrome,Drug: BOS-589|Drug: Placebo,Boston Pharmaceuticals,Phase 2,133,Industry,"June 4, 2019","May 6, 2020","May 6, 2020"
3777,NCT03976869,"A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma",Asthma,Drug: AZD7594,AstraZeneca|Parexel,Phase 1,36,Industry,"July 24, 2019","July 9, 2020","July 9, 2020"
3778,NCT03976752,Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens,HIV/AIDS,Drug: Genvoya,Emory University|Centers for Disease Control and Prevention,Phase 1,41,Other|U.S. Fed,"March 13, 2019","September 20, 2019","September 20, 2019"
3779,NCT03976687,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients",NASH - Nonalcoholic Steatohepatitis|Healthy,Drug: EYP001a,Enyo Pharma,Phase 1,16,Industry,"June 11, 2019","May 25, 2020","May 25, 2020"
3780,NCT03976466,Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.,Infection,Device: Antibiotic local prophylaxis with medicated calcium sulfate beads|Procedure: Classical parenteral antibiotic prophylaxis,Hospital Regional Tlalnepantla,Phase 4,87,Other,"May 22, 2019","April 22, 2020","July 15, 2020"
3781,NCT03976401,A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH),NASH - Nonalcoholic Steatohepatitis,Drug: EFX|Drug: Placebo,"Akero Therapeutics, Inc",Phase 2,110,Industry,"May 28, 2019","February 10, 2021","January 10, 2022"
3782,NCT03975166,A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers,Bioequivalence,Drug: Test Product|Drug: Reference Product,Respirent Pharmaceuticals Co Ltd.|Becro Ltd.,Phase 1,34,Industry,"May 21, 2019","June 25, 2019","August 10, 2019"
3783,NCT03974932,Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen,Analgesia,Drug: HTX-011|Drug: Ibuprofen|Drug: Acetaminophen|Drug: Celecoxib|Drug: +/- Bupivacaine HCl|Device: Luer Lock Applicator,Heron Therapeutics,Phase 3,116,Industry,"June 5, 2019","December 7, 2020","January 7, 2021"
3784,NCT03974776,Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants,Healthy,Biological: PF-06946860|Other: Placebo,Pfizer,Phase 1,8,Industry,"July 8, 2019","January 10, 2020","January 10, 2020"
3785,NCT03974594,Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients,Colorectal Cancer,Drug: Trifluridine and Tipiracil Tablets|Drug: TAS-102,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Phase 1,64,Industry,"May 21, 2019","July 16, 2019","July 16, 2019"
3786,NCT03974360,Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache,Post-Traumatic Headache|Mild Traumatic Brain Injury|Post-Concussion Syndrome,Drug: AMG 334,Danish Headache Center|Novartis|Amgen,Phase 2,100,Other|Industry,"April 5, 2019","December 31, 2019","December 31, 2019"
3787,NCT03974035,Does it Worth to Reinforce With Additional Anesthesia to Improve Postoperative Course After Orthognathic Surgery?,Dentofacial Deformities,Drug: Second infiltration pre-extubation with ropivacaine,Servei Central d' Anestesiologia,Phase 2,52,Other,"January 10, 2018","January 20, 2020","January 30, 2020"
3788,NCT03973515,Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus,Type2 Diabetes Mellitus,Drug: glucokinase activator|Drug: Placebo,"PegBio Co., Ltd.",Phase 1,16,Other,"August 27, 2019","December 19, 2019","December 19, 2019"
3789,NCT03973073,Effects of Combination Therapy With Camouflage in the Repigmentation of Vitiligo,Vitiligo,Combination Product: CapulinTM|Other: topical applications and NB-UVB,Peking University People's Hospital,Phase 1,30,Other,"August 1, 2019","November 1, 2019","November 21, 2019"
3790,NCT03973047,Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran,Nausea,Drug: Bremelanotide|Drug: Zofran|Drug: Placebo,"AMAG Pharmaceuticals, Inc.",Phase 1,228,Industry,"June 17, 2019","July 19, 2019","July 20, 2019"
3791,NCT03972501,An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD),Meibomian Gland Dysfunction (MGD)|Contact Lens Discomfort (CLD),Drug: AZR-MD-001 Vehicle|Drug: AZR-MD-001 Active Dose,Azura Ophthalmics|The University of New South Wales,Phase 2,26,Industry|Other,"October 4, 2019","December 11, 2020","December 11, 2020"
3792,NCT03972462,NPC-12G Gel 0.2% Sirolimus PK Bridging Study,Bioavailability Study,Drug: NPC-12G Gel 0.2%|Drug: Rapamune® 2 mg tablet,Nobelpharma,Phase 1,12,Industry,"May 31, 2019","June 17, 2019","June 17, 2019"
3793,NCT03972150,A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer,Neoplasms,Drug: BI 836880|Drug: BI 754091,Boehringer Ingelheim,Phase 1,21,Industry,"June 12, 2019","October 27, 2020","March 28, 2022"
3794,NCT03972137,Heart Rate Variability Biofeedback for Smoking Cessation,Tobacco Smoking,Behavioral: Cognitive-Behavioral Smoking Cessation|Behavioral: Heart Rate Variability Biofeedback (HRVB)|Drug: Transdermal Nicotine patch,"Rutgers, The State University of New Jersey|National Institute on Drug Abuse (NIDA)",Phase 2,10,Other|NIH,"April 24, 2019","February 20, 2020","February 20, 2020"
3795,NCT03971929,Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension,Hypertension,Drug: SHR0532|Drug: SHR placebo|Drug: Hydrochlorothiazide 25 mg,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,36,Industry,"July 31, 2019","September 3, 2020","September 3, 2020"
3796,NCT03971916,"A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers",Healthy Chinese Volunteers,Drug: HBM9161(HL161BKN)|Drug: Placebo,Harbour BioMed (Guangzhou) Co. Ltd.,Phase 1,24,Industry,"June 3, 2019","November 6, 2019","November 6, 2019"
3797,NCT03971695,A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321,Healthy,Drug: BI 706321|Drug: Placebo,Boehringer Ingelheim,Phase 1,61,Industry,"June 18, 2019","December 4, 2020","December 4, 2020"
3798,NCT03971539,Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma,Asthma,Drug: BI 894416|Drug: Placebo,Boehringer Ingelheim,Phase 1,68,Industry,"July 15, 2019","October 26, 2020","October 26, 2020"
3799,NCT03971123,Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production,Alzheimer Disease,Drug: Tricaprilin|Drug: Placebo,Cerecin,Phase 1,32,Industry,"August 30, 2019","April 2, 2020","May 26, 2020"
3800,NCT03970824,To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects,Healthy,Biological: CT-P17|Biological: US-licensed Humira|Biological: EU-approved Humira,Celltrion,Phase 1,312,Industry,"May 31, 2019","November 13, 2019","January 15, 2020"
3801,NCT03970798,"A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin",Parkinson's Disease,Drug: Midazolam|Drug: Caffeine|Drug: Rosuvastatin|Drug: KW-6356,"Kyowa Kirin Co., Ltd.",Phase 1,50,Industry,"May 22, 2019","July 31, 2019","July 31, 2019"
3802,NCT03970733,"Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis",Lyme Borreliosis,Biological: VLA15|Biological: Placebo,Pfizer|Valneva Austria GmbH,Phase 2,246,Industry,"July 1, 2019","April 7, 2020","March 28, 2022"
3803,NCT03970434,Drug Concentration of Metformin According to Sampling Method,Healthy,Other: Venous blood collection|Other: Peripheral blood collection,Chonbuk National University Hospital,Phase 1,20,Other,"May 30, 2019","June 5, 2019","June 5, 2019"
3804,NCT03970122,FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects,Healthy Volunteers,Drug: GFB-887|Drug: Placebo,"Goldfinch Bio, Inc.",Phase 1,70,Industry,"May 29, 2019","March 4, 2020","April 4, 2020"
3805,NCT03969849,"Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants",Healthy Volunteers|Birch Pollen Allergy,Drug: REGN5713-5714-5715|Drug: Matching placebo,Regeneron Pharmaceuticals,Phase 1,96,Industry,"June 3, 2019","March 27, 2020","March 27, 2020"
3806,NCT03969719,A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus,Non-alcoholic Steatohepatitis,Drug: Placebo|Drug: PF-06835919,Pfizer,Phase 2,164,Industry,"July 18, 2019","March 2, 2021","March 30, 2021"
3807,NCT03969108,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Thyroid Cancer|Thyroid Goiter|Graves Disease,Drug: Indocyanine Green,"University Health Network, Toronto",Phase 4,10,Other,"August 6, 2019","November 12, 2019","November 13, 2019"
3808,NCT03968978,Tezepelumab Home Use Study,Asthma,Biological: Tezepelumab (APFS)|Biological: Tezepelumab (AI),AstraZeneca|Amgen,Phase 3,216,Industry,"May 21, 2019","June 5, 2020","June 5, 2020"
3809,NCT03968302,ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION,Helicobacter Pylori Infection,Drug: ARM A Triple therapy for helicobacter pylori|Drug: ARM B Quadruple therapy for helicobacter pylori,Ziauddin University,Phase 2,196,Other,"June 1, 2018","May 15, 2019","May 15, 2019"
3810,NCT03968159,Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment,Adjunctive Treatment of Major Depressive Disorder,Drug: Pimavanserin|Drug: Placebo,ACADIA Pharmaceuticals Inc.,Phase 3,298,Industry,"April 25, 2019","April 30, 2020","May 29, 2020"
3811,NCT03968146,Erector Spinae Plane Block in Scoliotic Adolescents,Scoliosis Idiopathic|Scoliosis; Adolescence|Erector Spinae Plane Block,Procedure: Erector Spinae Plane Block|Drug: Fentanyl|Drug: additional Fentanyl|Drug: Morphine|Drug: rescue Morphine|Drug: pethidine|Drug: Ketorolac|Drug: Acetaminophen,Kasr El Aini Hospital,Phase 2,30,Other,"June 18, 2019","November 5, 2019","December 2, 2019"
3812,NCT03967886,Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients,Non-erosive Reflux Disease,Drug: YYD601 20mg|Drug: Nexium 20mg|Drug: Placebos,"Yooyoung Pharmaceutical Co., Ltd.",Phase 3,170,Industry,"April 10, 2019","December 20, 2019","May 27, 2020"
3813,NCT03967847,Oral Ketorolac for Arthroscopic Rotator Cuff Repair,Rotator Cuff Tear|Postoperative Pain,Drug: Ketorolac,University Hospitals Cleveland Medical Center,Phase 3,44,Other,"February 11, 2019","October 14, 2020","May 17, 2021"
3814,NCT03966742,Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis,Desmoid|Desmoid Fibromatosis of Skin|Desmoid Neoplasm of Chest Wall|Desmoid Tumor Caused by Somatic Mutation|Aggressive Fibromatoses|Fibromatosis Desmoid|Desmoid Fibromatosis,Procedure: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis,Rabin Medical Center,Phase 2,8,Other,"October 11, 2018","December 18, 2020","December 18, 2020"
3815,NCT03966365,Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®,Glaucoma,Drug: PRO-122|Drug: Krytantek Ofteno®,Laboratorios Sophia S.A de C.V.,Phase 1,24,Industry,"May 2, 2019","August 30, 2019","August 30, 2019"
3816,NCT03966079,Thrombolysis Endovascular Treatment of Pulmonary Embolism,Pulmonary Embolism|Acute Pulmonary Embolism,Drug: recombinant tissue plasminogen activator,Beijing Tsinghua Chang Gung Hospital,Phase 3,50,Other,"January 1, 2017","January 31, 2020","January 31, 2020"
3817,NCT03966040,A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults,Staphylococcus Aureus Infection,Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|Biological: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14,Jiangsu Province Centers for Disease Control and Prevention|Chengdu Olymvax Biopharmaceuticals Inc.|PLA Army Medical University,Phase 1,144,Other|Industry,"May 16, 2019","December 16, 2019","May 16, 2020"
3818,NCT03965962,Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults,Rabies (Healthy Volunteers),Biological: VRVg-2|Biological: Purified Inactivated Rabies Vaccine|Biological: Human Diploid Cell Vaccine (HDCV)|Biological: Rabies immune globulin (human),"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,640,Industry,"July 1, 2019","December 22, 2020","July 1, 2021"
3819,NCT03965871,"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression",Bipolar Depression,Drug: Esketamine DPI - low dose|Drug: Esketamine DPI - medium dose|Drug: Esketamine DPI - high dose|Drug: Placebo DPI,"Celon Pharma SA|National Center for Research and Development, Poland",Phase 2,88,Industry|Other,"March 28, 2019","January 3, 2021","February 19, 2021"
3820,NCT03965858,"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression",Major Depressive Disorder,Drug: Esketamine DPI - low dose|Drug: Esketamine DPI - medium dose|Drug: Esketamine DPI - high dose|Drug: Placebo DPI,"Celon Pharma SA|National Center for Research and Development, Poland",Phase 2,88,Industry|Other,"February 25, 2019","March 15, 2020","April 24, 2020"
3821,NCT03965637,Intravenous Ascorbic Acid Administration in Hysterectomy,Abdominal Hysterectomy,Drug: vitamin C,Shahid Beheshti University,Phase 3,80,Other,"August 23, 2019","January 30, 2020","January 30, 2020"
3822,NCT03965533,"Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects",Healthy Volunteers,Drug: GSK2831781|Drug: Placebo,GlaxoSmithKline,Phase 1,36,Industry,"June 10, 2019","December 10, 2019","December 10, 2019"
3823,NCT03965351,TRPV2 Agonists in the Fontan Circulation,Fontan,Drug: Probenecid|Other: Placebo,"Children's Hospital Medical Center, Cincinnati|American Heart Association",Phase 4,8,Other,"March 21, 2017","June 30, 2020","December 31, 2020"
3824,NCT03965117,Effect of Norepinephrine Infusion on Hepatic Blood Flow During Goal-directed Haemodynamic Therapy.,General Anesthesia,Drug: Norepinephrine,"University Hospital, Ghent",Phase 4,49,Other,"May 28, 2019","October 22, 2020","October 14, 2022"
3825,NCT03965052,Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®,Glaucoma,Drug: PRO 179|Drug: Travatan 0.004 % Ophthalmic Solution,Laboratorios Sophia S.A de C.V.,Phase 1,24,Industry,"April 24, 2019","July 2, 2019","August 29, 2019"
3826,NCT03965013,A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes,"Diabetes Mellitus, Type 1|Healthy Volunteers",Drug: NNC0268-0965|Drug: Placebo|Drug: insulin glargine,Novo Nordisk A/S,Phase 1,78,Industry,"June 5, 2019","December 14, 2019","December 14, 2019"
3827,NCT03964493,TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection,Skin and Subcutaneous Tissue Bacterial Infections|Gram-Positive Bacterial Infections,Drug: TNP-2092|Drug: Vancomycin,TenNor Therapeutics Limited|TenNor Therapeutics Inc.,Phase 2,118,Industry,"April 20, 2019","September 28, 2020","September 28, 2020"
3828,NCT03964038,A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects,Healthy Volunteer,Drug: gilteritinib|Drug: gilteritinib mini tablet,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,48,Industry,"May 21, 2019","July 2, 2019","July 16, 2019"
3829,NCT03964012,Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5),Meningococcal Meningitis,Biological: NmCV-5|Biological: Menactra,Serum Institute of India Pvt. Ltd.|PATH,Phase 3,1800,Industry|Other,"August 20, 2019","February 23, 2020","March 4, 2021"
3830,NCT03963895,Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis,End Stage Renal Disease|Thrombosis,Drug: AB002 Dose 1|Drug: AB002 Dose 2|Drug: placebo,"Aronora, Inc.|Celerion",Phase 2,40,Industry,"July 5, 2019","December 29, 2020","December 29, 2020"
3831,NCT03963401,A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug: PF-06700841|Other: Placebo,Pfizer,Phase 2,219,Industry,"June 13, 2019","April 6, 2020","January 15, 2021"
3832,NCT03962907,Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery,Staphylococcus Aureus|Orthopaedic Surgery|Surgical Site Infection|Prevention,"Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|Drug: BACTROBAN® Nasal ong",Lindenhofgruppe AG,Phase 4,1318,Industry,"January 1, 2019","March 30, 2020","June 30, 2020"
3833,NCT03962738,A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine,Migraine,Drug: Lasmiditan|Drug: Placebo,Eli Lilly and Company,Phase 2,846,Industry,"May 31, 2019","June 8, 2020","June 8, 2020"
3834,NCT03962114,Effects of Vitamin B3 in Patients With Ataxia Telangiectasia,Ataxia Telangiectasia|ATM Gene Mutation,Dietary Supplement: Vitamin B3,Radboud University Medical Center|A-T Children's Project|Twan foundation (https://twanfoundation.nl),Phase 2,24,Other,"March 18, 2019","December 1, 2019","March 1, 2020"
3835,NCT03962101,Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake,Congestive Heart Failure,Drug: OPC-61815 injection,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,45,Industry,"June 17, 2019","June 30, 2020","June 30, 2020"
3836,NCT03962049,Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function,Hepatic Impairment|Healthy Participants,Drug: Linzagolix,ObsEva SA,Phase 1,24,Industry,"May 15, 2019","October 23, 2019","November 1, 2019"
3837,NCT03961997,Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants,Adult|Drug Interactions|Healthy Volunteers|Humans,Drug: Lorlatinib 50 mg|Drug: Lorlatinib 75 mg|Drug: Lorlatinib 100 mg,Pfizer,Phase 1,16,Industry,"August 22, 2019","December 9, 2019","December 9, 2019"
3838,NCT03961932,Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function,Renal Impairment|Healthy Participants,Drug: Linzagolix,ObsEva SA,Phase 1,33,Industry,"May 15, 2019","January 22, 2020","January 31, 2020"
3839,NCT03961919,Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Transplant-Related Hematologic Malignancy,Drug: Fludarabine|Drug: ARA-C|Drug: Treosulfan|Procedure: Peripheral Blood Stem Cell Transplant,Ciceri Fabio|IRCCS San Raffaele,Phase 2,15,Other,"February 10, 2009","December 31, 2019","December 31, 2021"
3840,NCT03961529,Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis,Atopic Dermatitis,Drug: 0.3% OPA-15406 ointment|Drug: 1% OPA-15406 ointment,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,366,Industry,"May 14, 2019","November 11, 2020","November 11, 2020"
3841,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),Multiple Sclerosis (MS),Other: Data Collection,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 4,662,Industry,"August 15, 2019","February 27, 2021","May 13, 2021"
3842,NCT03961126,Evaluation of Vulvar Lichen Sclerosus Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma.,Vulvar Lichen Sclerosus,Drug: Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Drug: Corticosteroids (clobetasol 0.05%),Instituto de Investigacion Sanitaria La Fe,Phase 2,20,Other,"September 6, 2017","December 12, 2019","December 12, 2019"
3843,NCT03961100,A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.,Solid Tumor,Drug: Entrectinib 600 mg (T1)|Drug: Entrectinib 600 mg (T2)|Drug: Entrectinib 200 mg (R)|Drug: Entrectinib 200 mg (T),"Genentech, Inc.",Phase 1,31,Industry,"June 6, 2019","August 9, 2019","August 9, 2019"
3844,NCT03961009,"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients",Primary Immunodeficiency Disease,Biological: Kedrion IVIG 10%,Kedrion S.p.A.,Phase 3,47,Industry,"April 30, 2019","December 21, 2020","December 21, 2020"
3845,NCT03960957,Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines,Glabellar Frown Lines,Biological: AbobotulinumtoxinA|Other: Placebo,Galderma R&D,Phase 3,301,Industry,"June 17, 2019","September 27, 2019","April 16, 2020"
3846,NCT03960866,Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma,Open Angle Glaucoma|Ocular Hypertension,Drug: Phentolamine Mesylate Ophthalmic Solution 1%|Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo),"Ocuphire Pharma, Inc.",Phase 2,39,Industry,"May 28, 2019","September 11, 2019","September 11, 2019"
3847,NCT03960801,Assessment of Remifentanil for Rapid Sequence Induction and Intubation in Full Stomach Patient Compared to Muscle Relaxant,Intra-tracheal Intubation,Drug: Remifentanil group|Drug: neuromuscular blockade group,Nantes University Hospital,Phase 3,1150,Other,"October 9, 2019","April 22, 2021","April 22, 2021"
3848,NCT03960502,A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881,Healthy Male Participants,Drug: AG-881|Drug: [13C315N3]AG-881,"Agios Pharmaceuticals, Inc.",Phase 1,5,Industry,"May 16, 2019","September 7, 2019","September 7, 2019"
3849,NCT03960489,A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects,Healthy Adult Subjects,Drug: Roxadustat,"Astellas Pharma Global Development, Inc.|FibroGen|Astellas Pharma Inc",Phase 1,24,Industry,"July 31, 2019","October 14, 2019","October 14, 2019"
3850,NCT03960450,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis",Psoriasis,Drug: BOS-475|Drug: Vehicle,Boston Pharmaceuticals,Phase 1,20,Industry,"April 23, 2019","January 28, 2020","January 28, 2020"
3851,NCT03959514,"AT247, NovoRapid® and Fiasp® in Glucose Clamp Study","Diabetes Mellitus, Type 1",Biological: NovoRapid|Biological: Fiasp|Biological: AT247,Arecor Limited,Phase 1,18,Industry,"April 12, 2019","July 30, 2019","August 8, 2019"
3852,NCT03959501,Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy,Type 2 Diabetes|Ketonemia,Drug: Dapagliflozin 10 mg|Drug: Sitagliptin 100mg,The University of Hong Kong,Phase 4,60,Other,"August 16, 2017","October 16, 2020","October 16, 2020"
3853,NCT03959189,"Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1","Myotonic Dystrophy, Type 1 (DM1)|Myotonic Dystrophy",Drug: ERX-963|Drug: Placebo,"Expansion Therapeutics, Inc.",Phase 1,12,Industry,"June 17, 2019","March 31, 2020","April 30, 2020"
3854,NCT03959176,The Effect of Brimonidine,Intraocular Pressure,Drug: Brimonidine|Drug: Tropicamide|Drug: Phenylephrine Ophthalmic Product,Wake Forest University Health Sciences,Phase 4,13,Other,"July 20, 2019","July 20, 2019","July 20, 2019"
3855,NCT03958864,"A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects",Healthy Volunteer,Drug: CC-90001,Celgene,Phase 1,60,Industry,"April 4, 2019","June 13, 2019","June 13, 2019"
3856,NCT03958799,A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada,Tetanus Immunisation (Healthy Volunteers)|Diphtheria Immunisation (Healthy Volunteers)|Pertussis Immunisation (Healthy Volunteers),Biological: Investigational Tdap vaccine Formulation B|Biological: Investigational Tdap vaccine Formulation C|Biological: Investigational Tdap vaccine Formulation A|Biological: Investigational Tdap vaccine Formulation D|Biological: Licensed Tdap vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 1,71,Industry,"June 26, 2019","April 6, 2021","April 6, 2021"
3857,NCT03958656,T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma,"Myeloma-Multiple|Myeloma, Plasma-Cell",Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rimiducid|Biological: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,13,NIH,"June 13, 2019","October 13, 2020","January 19, 2021"
3858,NCT03958513,To Evaluate the Effect of Wound Infiltration With Bupivacaine for Post-operative Pain Relief After Laparoscopic Cholecystectomy,Post-operative Pain,Drug: Bupivacaine|Drug: 0.9% normal saline,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Phase 2,58,Other,"January 1, 2019","July 31, 2019","July 31, 2019"
3859,NCT03958201,Best Management of Muscle Relaxation- Objective Monitoring,"Residual Paralysis, Post Anesthesia",Combination Product: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex,University of Washington,Phase 4,200,Other,"May 28, 2019","January 31, 2020","March 31, 2020"
3860,NCT03957772,The Efficacy of Extra- Versus Intrafascial Injection for Supraclavicular Brachial Plexus Block,Upper Extremity Problem,Procedure: Extrafascial injection|Procedure: Intrafascial injection,Hôpital du Valais|University of Lausanne Hospitals,Phase 4,50,Other,"January 1, 2020","April 30, 2021","April 30, 2021"
3861,NCT03956953,"Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects",Autoimmune Diseases,Drug: BMS-986165|Other: Placebo,Bristol-Myers Squibb,Phase 1,135,Industry,"April 4, 2019","September 25, 2019","September 25, 2019"
3862,NCT03956862,GB001 in Adult Participants With Chronic Rhinosinusitis,Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Chronic Rhinosinusitis With Nasal Polyps (CRSwNP),Drug: GB001|Drug: Placebo,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.",Phase 2,97,Industry,"May 16, 2019","July 9, 2020","August 5, 2020"
3863,NCT03956524,Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults,Typhoid Fever,Biological: EuTCV|Biological: Typbar-TCV™|Biological: Typhim Vi®,"EuBiologics Co.,Ltd",Phase 1,75,Industry,"March 16, 2019","August 31, 2019","August 31, 2019"
3864,NCT03956355,Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001),Plaque Psoriasis,Drug: Tapinarof|Drug: Vehicle Cream,"Dermavant Sciences GmbH|IQVIA Biotech|Dermavant Sciences, Inc.",Phase 3,510,Industry,"May 21, 2019","May 26, 2020","May 26, 2020"
3865,NCT03955939,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,Metastatic Breast Cancer,Drug: LY3295668 Erbumine|Drug: Endocrine therapy|Drug: Midazolam,Eli Lilly and Company,Phase 1,5,Industry,"August 2, 2019","May 14, 2020","May 14, 2020"
3866,NCT03955770,"Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.",Chronic Obstructive Pulmonary Disease,Combination Product: High-flow oxygen therapy (HFOT)|Combination Product: Low-flow oxygen therapy (LFOT),University of Zurich|National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov,Phase 4,79,Other,"May 20, 2019","August 2, 2019","August 2, 2019"
3867,NCT03955666,"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects",Safety,Biological: PRV-3279 or placebo,"Provention Bio, Inc.",Phase 1,16,Industry,"August 7, 2019","December 11, 2019","December 11, 2019"
3868,NCT03955575,Treatment of Bile Acid Malabsorption With Liraglutide,Bile Acid Malabsorption,Drug: Liraglutide 6 MG/ML|Drug: Colesevelam,"Filip Krag Knop|Herlev and Gentofte Hospital|University Hospital, Gentofte, Copenhagen",Phase 4,52,Other,"March 7, 2019","March 10, 2021","May 31, 2022"
3869,NCT03955549,Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial,Schizophrenia Spectrum and Other Psychotic Disorders,Behavioral: Insight Enhancement Program (IEP)|Behavioral: Metacognitive Training for Psychosis (MCT)|Drug: Treatment As Usual (TAU),Agiad Psychiatry Hospital|University of Pittsburgh,Phase 3,99,Other,"May 1, 2019","January 30, 2021","January 30, 2021"
3870,NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Placebo,Eli Lilly and Company,Phase 3,478,Industry,"June 3, 2019","October 5, 2020","October 28, 2020"
3871,NCT03954743,"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","Infections, Rotavirus",Biological: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|Biological: Lyophilized formulation of GSK's oral live attenuated HRV vaccine,GlaxoSmithKline,Phase 3,1351,Industry,"July 19, 2019","November 30, 2020","November 30, 2020"
3872,NCT03954626,Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD,Age-Related Macular Degeneration|Macular Degeneration|Wet Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases,Biological: brolucuzumab 6 mg IVT,Novartis Pharmaceuticals|Novartis,Phase 3,14,Industry,"June 7, 2019","July 9, 2019","July 31, 2019"
3873,NCT03954600,"A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects",Healthy Volunteers,Drug: NPT520-34 (125 mg)|Drug: Placebos (125 mg),Neuropore Therapies Inc.|Celerion,Phase 1,49,Industry,"May 5, 2019","October 2, 2019","October 9, 2019"
3874,NCT03954444,"A Clinical Endpoint Bioequivalence Study of ""Oxymetazoline Hydrochloride Cream""",Rosacea,"Drug: Oxymetazoline Hydrochloride|Drug: Rhofade Cream, 1%|Drug: Placebo",Actavis Inc.|Teva Pharmaceuticals USA,Phase 3,1105,Industry,"April 15, 2019","January 7, 2020","February 27, 2020"
3875,NCT03954379,IPACK Study in Total Knee Arthroplasty Patients,Knee Replacement Arthroplasty,"Drug: Standard of Care (ACB, SA, peri-op pain management)|Drug: IPACK and multi-modal analgesic regimen|Procedure: Periarticular Local Anesthetic Infiltration|Drug: IV Dexamethasone 8mg at the end of surgery as standard of care","University Health Network, Toronto",Phase 4,78,Other,"October 24, 2019","December 2, 2020","March 31, 2021"
3876,NCT03954366,"Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives",Neoplasms,Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives,"Clovis Oncology, Inc.",Phase 1,36,Industry,"April 25, 2019","December 6, 2019","June 9, 2021"
3877,NCT03954158,Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis,Atopic Dermatitis,Drug: Crisaborole ointment 2%|Drug: Vehicle,Pfizer,Phase 2,81,Industry,"June 15, 2019","December 16, 2019","December 16, 2019"
3878,NCT03953989,Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy,HCM - Hypertrophic Non-Obstructive Cardiomyopathy,Drug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die,IRCCS San Raffaele|Menarini International Operations Luxembourg SA,Phase 2,26,Other|Industry,Oct-16,"February 1, 2020","March 6, 2020"
3879,NCT03953092,"A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699",Diabete Mellitus,Drug: YG1699|Drug: Placebos,"Youngene Therapeutics Inc., Ltd.",Phase 1,64,Industry,"May 1, 2019","November 13, 2019","November 13, 2019"
3880,NCT03953079,A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD,Neovascular Age-Related Macular Degeneration,Drug: Drug: GB-102|Drug: Aflibercept,Graybug Vision,Phase 2,56,Industry,"September 26, 2019","December 15, 2020","June 3, 2021"
3881,NCT03952923,CD19-CAR-T in B-cell Malignancies Patients,B-cell Malignancy,Biological: CD19-CAR-T cells,"Hebei Yanda Ludaopei Hospital|China Immunotech (Beijing) Biotechnology Co., Ltd.|Avalon GloboCare Corp.",Phase 1,11,Other|Industry,"August 1, 2019","January 1, 2021","March 31, 2021"
3882,NCT03952507,A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants,Healthy,Drug: JNJ-64417184 600 (Oral Tablet Formulation)|Drug: JNJ-64417184 (Oral Suspension Formulation),"Janssen Research & Development, LLC",Phase 1,18,Industry,"May 15, 2019","June 22, 2019","June 22, 2019"
3883,NCT03952286,ED-Initiated School-based Asthma Medication Supervision,Asthma|Asthma in Children,Drug: ED-Dispensing home and school supervision,Ashley Lowe|University of Arizona,Phase 4,90,Other,"August 1, 2019","December 30, 2020","January 1, 2021"
3884,NCT03952143,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,Eli Lilly and Company,Phase 3,628,Industry,"May 27, 2019","January 20, 2021","January 20, 2021"
3885,NCT03951805,A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Insulin Glargine,Novo Nordisk A/S,Phase 2,205,Industry,"May 9, 2019","December 12, 2019","January 17, 2020"
3886,NCT03951753,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM),"Diabetes Mellitus, Type 2",Drug: Tirzepatide|Drug: Semaglutide|Drug: Placebo,Eli Lilly and Company,Phase 1,117,Industry,"June 28, 2019","April 8, 2021","April 8, 2021"
3887,NCT03951077,Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome,Polycystic Ovary Syndrome,Drug: Elagolix|Drug: Placebo,AbbVie,Phase 2,118,Industry,"August 12, 2019","February 10, 2021","February 10, 2021"
3888,NCT03951051,The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.,Bioequivalence,Drug: Olmesartan Medoxomil 40 mg|Drug: Olmetec®,"Pharmtechnology LLC|Altasciences Company, Inc.",Phase 1,32,Industry,"May 6, 2019","June 16, 2019","June 16, 2019"
3889,NCT03951025,Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN),Biological Availability,Dietary Supplement: Melatonin oral administration|Dietary Supplement: Melatonin sublingual administration,"Technological Centre of Nutrition and Health, Spain|Fundació Eurecat|Hospital Universitari Sant Joan de Reus|Plantas Medicinales y Complementos Alimenticios (PLAMECA), S.A.|University Rovira i Virgili",Phase 2,13,Other,"June 5, 2019","August 7, 2019","August 7, 2019"
3890,NCT03950960,A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants,Healthy Participants,Drug: BMS-986256|Drug: Itraconazole,Bristol-Myers Squibb,Phase 1,15,Industry,"May 2, 2019","July 31, 2019","August 7, 2019"
3891,NCT03950882,A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD,Nonalcoholic Fatty Liver,Drug: PXL770|Drug: Placebo,Poxel SA,Phase 1,17,Industry,"August 1, 2019","March 29, 2020","March 31, 2020"
3892,NCT03950856,Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),"Pneumococcal Infections|Pneumonia, Pneumococcal",Drug: V114|Drug: Prevnar 13™,Merck Sharp & Dohme LLC,Phase 3,2340,Industry,"June 12, 2019","April 3, 2020","April 3, 2020"
3893,NCT03950700,Bupivacaine in the Treatment of Postoperative Pain of Impacted Third Molar Extraction,"Teeth, Impacted",Drug: Bupivacaine-epinephrine|Drug: Saline Solution,CES University,Phase 4,40,Other,"June 1, 2019","December 31, 2019","January 1, 2020"
3894,NCT03950622,Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),Pneumococcal Infections,Biological: V114|Biological: Prevnar 13®,Merck Sharp & Dohme LLC,Phase 3,1205,Industry,"June 13, 2019","March 30, 2020","March 30, 2020"
3895,NCT03949712,Pediatric Transcranial Static Magnetic Field Stimulation to Improve Motor Learning,Healthy|Pediatrics,Device: Transcranial Static Magnetic Field Stimulation (tSMS)|Device: Sham Transcranial Static Magnetic Field Stimulation (tSMS),University of Calgary,Phase 1,24,Other,"March 30, 2018","June 1, 2019","June 1, 2019"
3896,NCT03949426,"Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects",Systemic Lupus Erythematosus,Drug: KPG-818,"Kangpu Biopharmaceuticals, Ltd.",Phase 1,40,Industry,"May 1, 2019","September 29, 2019","September 29, 2019"
3897,NCT03949244,Nailfold Capillary Blood Flow With Latanoprost Bunod,"Glaucoma, Open-Angle",Drug: Latanoprost 0.005%|Drug: Latanoprost bunod 0.024%|Drug: Normal saline 0.9%|Diagnostic Test: Nailfold capillaroscopy,Icahn School of Medicine at Mount Sinai,Phase 4,47,Other,"August 15, 2019","October 1, 2020","October 1, 2020"
3898,NCT03948451,Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers,Cardiovascular Disease,Drug: [14C]AZD5718 Oral Suspension,AstraZeneca|Quotient Sciences,Phase 1,6,Industry,"April 30, 2019","July 2, 2019","July 2, 2019"
3899,NCT03948386,3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty,"Osteoarthritis, Hip",Drug: isobaric bupivacaine|Drug: hyperbaric bupivacaine|Drug: isobaric mepivacaine,Thomas Jefferson University,Phase 4,159,Other,"May 13, 2019","November 11, 2019","November 11, 2019"
3900,NCT03948243,Licorice Botanical Dietary Supplements - Metabolism and Safety in Women,Food-drug Interaction,Dietary Supplement: Licorice|Drug: Alprazolam 2 MG|Drug: Caffeine 100 MG|Drug: Tolbutamide 250 mg|Drug: Dextromethorphan 30mg,University of Illinois at Chicago|Oregon State University,Phase 1,19,Other,"April 1, 2019","July 31, 2020","April 22, 2022"
3901,NCT03947489,Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions,Healthy,Drug: Sarpogrelate HCL 300mg,Daewoong Pharmaceutical Co. LTD.,Phase 1,38,Industry,"March 4, 2019","May 6, 2019","May 6, 2019"
3902,NCT03946657,Anesthetics and Cerebral Oxygenation in LSG,Morbid Obesity|Bariatric Surgery Candidate|Anesthesia,Drug: Inhalational anesthetic|Drug: Intravenous anesthetic,Ondokuz Mayıs University,Phase 4,60,Other,"January 20, 2019","June 1, 2019","June 1, 2019"
3903,NCT03945981,Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults,HIV Infections,Drug: Dolutegravir + Lamivudine FDC,ViiV Healthcare,Phase 3,131,Industry,"July 2, 2019","April 29, 2020","October 20, 2020"
3904,NCT03945825,Flublok or Fluzone With Advax-CpG55.2 or AF03,Influenza|Influenza Immunisation,Drug: AF03|Biological: Delta Inulin-CpG55.2|Biological: Influenza Virus Quadrivalent Inactivated Vaccine|Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,241,NIH,"June 10, 2019","September 18, 2020","September 18, 2020"
3905,NCT03945604,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,Triple Negative Breast Cancer,Drug: SHR-1210 + Apatinib +Fluzoparib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,32,Industry,"June 4, 2019","February 9, 2021","February 9, 2021"
3906,NCT03945539,A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants,Healthy,Drug: JNJ-56136379|Drug: Itraconazole,Janssen Sciences Ireland UC,Phase 1,16,Industry,"May 15, 2019","October 4, 2019","October 4, 2019"
3907,NCT03945344,Effect of Charcoal on Gastrointestinal Absorption of Tiotropium,Healthy Volunteer Study,Drug: Tiotropium,"Orion Corporation, Orion Pharma",Phase 1,20,Industry,"May 27, 2019","June 19, 2019","June 19, 2019"
3908,NCT03945253,"Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors",Advanced Solid Tumors,Drug: ASP8374,Astellas Pharma Inc,Phase 1,6,Industry,"August 5, 2019","June 12, 2020","June 12, 2020"
3909,NCT03944291,Pudendal Nerve Block for Post-Episiotomy Pain Relief,"Pain, Postoperative",Procedure: Pudendal Nerve Block,Ain Shams University,Phase 3,102,Other,"May 1, 2019","January 1, 2020","January 20, 2020"
3910,NCT03944031,A Study of the Effects of LY3372689 on the Brain in Healthy Participants,Healthy,Drug: LY3372689|Diagnostic Test: [18F]LSN3316612,Eli Lilly and Company,Phase 1,17,Industry,"May 8, 2019","February 19, 2020","February 19, 2020"
3911,NCT03943992,Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD),Erosive Esophagitis,Drug: YYD601 40mg|Drug: Nexium 40mg|Drug: Placebos,"Yooyoung Pharmaceutical Co., Ltd.",Phase 3,170,Industry,"January 29, 2019","January 31, 2020","July 1, 2020"
3912,NCT03943888,Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children,"Anesthesia, General|Neuromuscular Blockade",Drug: Sugammadex Injection 2mg/kg|Drug: Sugammadex Injection 4mg/kg|Drug: Sugammadex Injection 8mg/kg|Drug: Neuromuscular reversal agent injection,"Seoul National University Hospital|Ministry of Food and Drug Safety, Korea",Phase 2,40,Other,"August 12, 2019","February 20, 2020","February 20, 2020"
3913,NCT03943251,"The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects",Healthy,Drug: HEC113995PA•H2O tablet|Drug: Placebo tablet,"Sunshine Lake Pharma Co., Ltd.",Phase 1,69,Industry,"July 4, 2019","December 11, 2019","December 11, 2019"
3914,NCT03943095,Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity,Dentin Hypersensitivity|Dentin Sensitivity,Other: Potassium Nitrate|Other: Stannous Fluoride,GlaxoSmithKline,Phase 2,123,Industry,"May 13, 2019","August 28, 2019","August 28, 2019"
3915,NCT03943056,"A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants",Healthy Volunteer,Drug: BIIB091|Drug: Placebo,Biogen,Phase 1,64,Industry,"May 13, 2019","January 10, 2020","January 10, 2020"
3916,NCT03942666,PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects,Asthma,Drug: Treatment A|Drug: Treatment B|Drug: Treatment C|Drug: Treatment D|Drug: Treatment E|Drug: Treatment F,Chiesi Farmaceutici S.p.A.,Phase 1,30,Industry,"May 10, 2019","November 22, 2019","November 22, 2019"
3917,NCT03942458,Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19,Healthy Subjects|PK/PD,Drug: Vicagrel 6mg|Drug: Clopidogrel 75mg,"Jiangsu vcare pharmaceutical technology co., LTD",Phase 1,50,Industry,"April 3, 2019","June 28, 2019","September 3, 2019"
3918,NCT03942406,"Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults",Pertussis|Whooping Cough,Combination Product: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device,ILiAD Biotechnologies|PPD,Phase 2,300,Industry,"June 15, 2019","February 14, 2020","June 24, 2020"
3919,NCT03942042,A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis,Generalized Pustular Psoriasis|Erythrodermic Psoriasis,Drug: Ixekizumab,Eli Lilly and Company,Phase 4,12,Industry,"July 5, 2019","July 22, 2020","July 22, 2020"
3920,NCT03942029,A Drug Interaction Study of LY3154207 in Healthy Participants,Healthy,Drug: LY3154207 Capsule|Drug: LY3154207 Tablet|Drug: Placebo|Drug: Fluconazole Tablet,Eli Lilly and Company,Phase 1,36,Industry,"June 21, 2019","December 28, 2019","December 28, 2019"
3921,NCT03941548,Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata,Alopecia Areata,Drug: CTP-543|Drug: CTP-543 Matching Placebo,Concert Pharmaceuticals,Phase 2,66,Industry,"May 24, 2019","April 10, 2020","April 10, 2020"
3922,NCT03941340,Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers,Healthy Male Volunteers,Drug: [14]-AST2818,"Allist Pharmaceuticals, Inc.",Phase 1,6,Industry,"April 8, 2019","September 6, 2019","September 6, 2019"
3923,NCT03940742,A Study of Tirzepatide in Participants With Impaired Liver Function,Hepatic Insufficiency,Drug: Tirzepatide,Eli Lilly and Company,Phase 1,32,Industry,"July 22, 2019","September 22, 2020","September 22, 2020"
3924,NCT03940729,PWID; Longitudinal S Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine,"Intravenous Drug Abuse, S Aureus Colonization",Drug: Chlorhexidine Topical,Lund University,Phase 4,61,Other,"December 15, 2016","January 1, 2020","January 1, 2020"
3925,NCT03940326,Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures,"Epilepsy, Idiopathic Generalized",Drug: Levetiracetam|Drug: Valproate,Mazandaran University of Medical Sciences,Phase 4,103,Other,"April 1, 2018","October 1, 2019","December 1, 2019"
3926,NCT03940183,Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Trelagliptin Succinate|Drug: Placebo Oral Tablet,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Phase 3,254,Industry,"July 8, 2019","December 3, 2020","December 28, 2020"
3927,NCT03939975,Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC,"Carcinoma, Hepatocellular",Drug: pembrolizumab or nivolumab or JS001,Sun Yat-sen University,Phase 2,50,Other,"June 1, 2019","July 31, 2019","July 31, 2019"
3928,NCT03939702,Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants,Thrombosis,Drug: BMS-986177,Bristol-Myers Squibb,Phase 1,9,Industry,"May 2, 2019","July 11, 2019","July 11, 2019"
3929,NCT03939429,Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects,Bacterial Infections,Drug: QPX2015|Drug: Placebo oral capsule,"Qpex Biopharma, Inc.|Biomedical Advanced Research and Development Authority",Phase 1,40,Industry|U.S. Fed,"May 20, 2019","October 6, 2019","October 6, 2019"
3930,NCT03939312,Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine,Episodic Migraine,Drug: Atogepant,Allergan,Phase 3,685,Industry,"May 6, 2019","March 31, 2021","March 31, 2021"
3931,NCT03939234,Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.,Chronic Lymphocytic Leukemia,"Combination Product: PD-L1, PD-L2 peptides with Montanide ISA51",Lars Møller Pedersen|IO Biotech|Herlev Hospital,Phase 2,19,Other|Industry,"April 26, 2019","March 15, 2021","March 15, 2021"
3932,NCT03938740,Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec,"Diabetes Mellitus, Type 1",Drug: HDV-Insulin Lispro and Insulin Degludec (-40%)|Drug: HDV-Insulin Lispro and Insulin Degludec (-10%),Diasome Pharmaceuticals,Phase 2,61,Industry,"March 18, 2019","December 6, 2019","March 18, 2020"
3933,NCT03938636,Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging,Rheumatoid Arthritis,Drug: TC99m-tilmanocept,Navidea Biopharmaceuticals,Phase 2,95,Industry,"April 8, 2019","February 8, 2021","June 30, 2021"
3934,NCT03937882,Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3,Dry Eye Syndromes|Dry Eye,Drug: RGN-259|Drug: Placebo,"ReGenTree, LLC",Phase 3,700,Industry,"May 24, 2019","November 8, 2020","October 7, 2021"
3935,NCT03937869,Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV,Bacterial Vaginoses,Drug: Secnidazole,Lupin Research Inc,Phase 4,40,Industry,"November 28, 2018","November 5, 2020","November 5, 2020"
3936,NCT03937596,Adjunctive D-Cycloserine in Major Depressive Disorder,Major Depressive Disorder,Drug: D-cycloserine|Device: Transcranial Magnetic Stimulator|Drug: Placebo oral capsule,University of Calgary,Phase 2,50,Other,"December 1, 2019","December 24, 2020","December 24, 2020"
3937,NCT03937479,Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD,COPD,"Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium",Verona Pharma plc|Iqvia Pty Ltd|LGC Limited,Phase 2,416,Industry,"May 1, 2019","November 15, 2019","November 15, 2019"
3938,NCT03937258,A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants,Healthy,Drug: PF-04965842|Drug: Probenecid,Pfizer,Phase 1,12,Industry,"May 21, 2019","July 26, 2019","July 26, 2019"
3939,NCT03936959,"A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",Advanced Cancer,Drug: LY3434172,Eli Lilly and Company,Phase 1,10,Industry,"May 24, 2019","March 30, 2020","April 29, 2021"
3940,NCT03936907,"Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers",Healthy Subjects,Drug: OWCP Orally Disintegrating Tablet|Drug: Sativex,One World Cannabis Ltd.,Phase 1,16,Industry,"April 15, 2019","July 18, 2019","July 18, 2019"
3941,NCT03936387,Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management: A Pilot Study,"Pain, Postoperative",Drug: Ropivacaine,Boston Children's Hospital,Phase 3,10,Other,"July 1, 2019","September 1, 2019","September 12, 2019"
3942,NCT03936374,A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants,Healthy,Drug: BMS-986205|Drug: omeprazole,Bristol-Myers Squibb,Phase 1,16,Industry,"May 8, 2019","July 20, 2019","July 20, 2019"
3943,NCT03936166,A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers,Healthy Volunteers,Drug: CRN01941 Oral Solution|Drug: CRN01941 Oral Capsule|Drug: Placebo Oral Solution|Drug: Placebo Oral Capsule,Crinetics Pharmaceuticals Inc.,Phase 1,57,Industry,"April 29, 2019","December 16, 2019","December 16, 2019"
3944,NCT03935633,Short-term Clinical Study of CN128 in Thalassemia Patients,Thalassemia,Drug: CN128 Tablets,"Hangzhou Zede Pharma-Tech Co., Ltd.",Phase 1,16,Other,"December 3, 2018","May 6, 2019","December 17, 2019"
3945,NCT03935399,Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin,Chronic Pain,Drug: Oxytocin|Drug: Saline,Wake Forest University Health Sciences,Phase 4,10,Other,"August 8, 2019","March 15, 2020","April 30, 2020"
3946,NCT03935334,"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors",Hemophilia A or B With Inhibitor,"Biological: Biosimilar eptacog alfa, activated (AryoSeven)|Biological: Eptacog alfa, activated (Novoseven)",AryoGen Pharmed Co.,Phase 3,48,Industry,"July 23, 2018","January 31, 2021","February 3, 2021"
3947,NCT03935217,A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis,Trichomonas Infection,Drug: Secnidazole|Drug: Placebo,Lupin Research Inc,Phase 3,147,Industry,"April 23, 2019","March 18, 2020","March 18, 2020"
3948,NCT03935204,"Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)",Condylomata Acuminata|Cervical Cancer,"Biological: HPV Vaccine,270μg/1.0ml|Biological: Placebo","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",Phase 2,627,Other|Industry,"May 13, 2019","October 18, 2019","April 1, 2021"
3949,NCT03935165,Prospective Evaluation of Near-infrared Fluorescence Imaging Use as a Supportive Tool in Deep Infiltrating Endometriosis Surgery,Pelvic Endometriosis|Endometriosis Outside Pelvis,Drug: Indocyanine Green,Catholic University of the Sacred Heart,Phase 2,51,Other,"January 4, 2016","May 19, 2019","May 19, 2019"
3950,NCT03935152,Oral Dydrogesterone in the Management of Preterm Labor,Preterm Labor,Drug: Dydrogesterone|Drug: placebo,Chulalongkorn University,Phase 4,48,Other,"May 11, 2019","May 31, 2020","May 31, 2020"
3951,NCT03934541,"Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants",HIV Infections,Biological: MPER-656 Liposome Vaccine|Biological: Placebo for MPER-656 Liposome Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,24,NIH,"August 26, 2019","February 5, 2021","May 26, 2021"
3952,NCT03934502,Effect of Meal Composition and Timing on Evobrutinib Bioavailability,Healthy,Drug: Evobrutinib,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",Phase 1,20,Industry,"April 15, 2019","June 12, 2019","June 12, 2019"
3953,NCT03934450,Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen,Malaria|Glucose 6 Phosphate Dehydrogenase Deficiency,Drug: RPQ|Drug: SPQ|Drug: Primaquine Phosphate|Drug: Placebo,"University of Mississippi, Oxford",Phase 1,36,Other,"August 17, 2018","May 1, 2019","May 1, 2019"
3954,NCT03934333,A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS),Relative Bioavailability,Drug: BDA MDI 160/180 mcg|Drug: Pulmicort Flexhaler 180 mcg,AstraZeneca,Phase 1,11,Industry,"May 16, 2019","September 10, 2019","September 10, 2019"
3955,NCT03934203,This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study),Healthy,Drug: BI 409306|Drug: Moxifloxacin|Drug: Placebo matching to BI 409306,Boehringer Ingelheim,Phase 1,47,Industry,"May 9, 2019","September 6, 2019","September 6, 2019"
3956,NCT03933943,A Study of LY3361237 in Participants With Systemic Lupus Erythematosus,"Lupus Erythematosus, Systemic",Drug: LY3361237|Drug: Placebo,Eli Lilly and Company,Phase 1,28,Industry,"May 21, 2019","February 15, 2021","February 15, 2021"
3957,NCT03933488,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants",Healthy Participants,Drug: TAK-994|Drug: TAK-994 Placebo,Takeda,Phase 1,121,Industry,"May 1, 2019","March 29, 2020","March 29, 2020"
3958,NCT03933293,A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH,Homozygous Familial Hypercholesterolemia,Drug: AK102|Drug: Statins|Drug: Ezetimibe,"Akeso|AD Pharmaceuticals Co., Ltd.",Phase 2,10,Industry,"May 13, 2019","March 15, 2021","March 15, 2021"
3959,NCT03933280,Conscious Sedation for Cataract Operations Under Topical Anaesthesia,Conscious Sedation,Drug: Nalbuphine|Drug: Propofol|Drug: Dexmedetomidine|Drug: Benoxinate Hydrochloride 0.4% Eye Drops,Menoufia University,Phase 2,100,Other,"July 1, 2019","December 1, 2020","January 1, 2021"
3960,NCT03932916,Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects,AD,Drug: Donepezil Pamoate for Injection 17mg|Drug: Donepezil Pamoate for Injection 34mg|Drug: Donepezil Hydrochloride 5mg,"Shanghai Synergy Pharmaceutical Sciences Co., Ltd.|Zhejiang Huahai Pharmaceutical Co., Ltd.",Phase 1,38,Industry,"July 2, 2019","August 6, 2020","September 11, 2020"
3961,NCT03932864,"Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor",Healthy Volunteers,Biological: MGTA-145|Biological: plerixafor|Biological: Placebo,"Magenta Therapeutics, Inc.",Phase 1,107,Industry,"April 22, 2019","February 25, 2020","February 25, 2020"
3962,NCT03932825,Nitrous Oxide for Major Depressive Disorder,"Depressive Disorder|Major Depressive Disorder|Treatment Resistant Depression|Depressive Disorder, Major|Depression",Drug: Nitrous Oxide|Drug: Placebo,Lingjiang Li|Central South University,Phase 2,44,Other,"April 1, 2019","March 31, 2021","March 31, 2021"
3963,NCT03932669,Effect of Nilotinib in Cerebellar Ataxia Patients,"Ataxia, Cerebellar|Ataxia, Progressive",Drug: Nilotinib,Seoul National University Hospital,Phase 2,70,Other,"November 19, 2018","August 13, 2020","August 13, 2020"
3964,NCT03932578,Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS,Nausea|Vomiting,Drug: Atropine sulfate|Drug: Metoclopramide,Mansoura University,Phase 4,60,Other,"May 5, 2019","August 28, 2019","August 28, 2019"
3965,NCT03932240,In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB),Hemostasis,Drug: Fibrinogen Concentrate (FC)|Drug: Cryoprecipitate,Emory University,Phase 3,36,Other,"August 13, 2019","April 9, 2021","November 16, 2021"
3966,NCT03931915,Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis,Endometriosis,Drug: TAK-385|Drug: Leuprorelin acetate,"ASKA Pharmaceutical Co., Ltd.",Phase 3,335,Industry,"May 8, 2019","June 12, 2020","September 28, 2020"
3967,NCT03931785,A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome,Irritable Bowel Syndrome With Diarrhea (IBS-D),Drug: MD-7246|Drug: Placebo,"Ironwood Pharmaceuticals, Inc.|Allergan Sales, LLC",Phase 2,515,Industry,"May 1, 2019","February 26, 2020","March 11, 2020"
3968,NCT03931590,A Human AME Study for Omaveloxolone,Healthy Male Subjects,Drug: [14C]-Omaveloxolone,"Reata Pharmaceuticals, Inc.",Phase 1,8,Industry,"April 11, 2019","May 31, 2019","May 31, 2019"
3969,NCT03931447,A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants,Healthy,Biological: JNJ-72537634|Biological: Placebo,"Janssen Research & Development, LLC",Phase 1,33,Industry,"April 30, 2019","February 10, 2020","February 10, 2020"
3970,NCT03930940,Remote Ischemic Conditioning for Intracerebral Hemorrhage,Intracerebral Hemorrhage,Device: remote ischemic conditioning|Other: Regular treatment,Capital Medical University|Heze Municipal Hospital|The Sixth People's Hosptial of Hengshui|Weihai Municipal Hospital,Phase 1,40,Other,"July 9, 2019","November 17, 2019","February 10, 2020"
3971,NCT03930641,Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration,Neovascular Age Related Macular Degeneration,Drug: RTH258,Novartis Pharmaceuticals|Novartis,Phase 3,34,Industry,"May 23, 2019","July 2, 2019","July 2, 2019"
3972,NCT03930602,Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165,Healthy,Drug: BMS-986165|Drug: Fluvoxamine,Bristol-Myers Squibb,Phase 1,16,Industry,"May 1, 2019","May 27, 2019","May 27, 2019"
3973,NCT03930472,#WYMarketsMatter: Testing Two Farmers Market Voucher Strategies to Increase Food Security,Food Security|Produce Consumption,Behavioral: Market vouchers,University of Wyoming|Wyoming Food for Thought,Phase 2,30,Other,"July 30, 2019","September 30, 2019","August 30, 2020"
3974,NCT03930264,Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®),Therapeutic Equivalency,Drug: Azathioprine 50Mg Tab|Drug: Azathioprine 10mg/mL oral suspension,Nova Laboratories Limited|Medicines Evaluation Unit Ltd|Syne Qua Non Limited|Alderley Analytical Ltd|Black County Pathology Services|Diamond Pharma Services Regulatory Affairs Consultancy|Boyd Consultants,Phase 1,30,Industry|Other,"April 11, 2019","May 24, 2019","May 31, 2019"
3975,NCT03930186,"A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy",Plaque Psoriasis,Drug: Apremilast|Drug: Topical Therapy,Amgen,Phase 3,152,Industry,"June 17, 2019","May 8, 2020","September 25, 2020"
3976,NCT03929744,A Study of LY3502970 in Healthy Participants,Healthy,Drug: LY3502970|Drug: Placebo|Drug: Atorvastatin|Drug: Simvastatin|Drug: Midazolam,Eli Lilly and Company,Phase 1,133,Industry,"June 12, 2019","November 2, 2020","November 2, 2020"
3977,NCT03929510,"Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.",Healthy Volunteers,Drug: 14C-PF-06651600|Drug: 14C-PF-06651600 IV|Drug: PF-06651600,Pfizer,Phase 1,6,Industry,"April 23, 2019","July 5, 2019","July 5, 2019"
3978,NCT03929367,PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers,Chronic Pain,Drug: Oxytocin,Wake Forest University Health Sciences,Phase 4,11,Other,"May 10, 2019","March 1, 2020","March 1, 2020"
3979,NCT03929224,The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown,Skin Infection,Drug: Medicinal honey|Drug: Bacitracin,Ascension South East Michigan,Phase 4,17,Other,"October 25, 2018","September 1, 2020","September 1, 2020"
3980,NCT03929172,"A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects",Papillomavirus Infections,Biological: AAVLP-HPV|Drug: Placebo,2A Pharma AB|Celerion,Phase 1,20,Industry,"February 28, 2019","May 29, 2020","May 29, 2020"
3981,NCT03929016,Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects,Visceral Leishmaniasis|Cutaneous Leishmaniases,Drug: DNDI-0690|Drug: Placebo of DNDI-0690,Drugs for Neglected Diseases|Wellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable Elimination of Leishmaniasis,Phase 1,64,Other,"April 4, 2019","December 6, 2019","July 2, 2020"
3982,NCT03928821,"Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants",HIV Infections,Biological: PGT121|Biological: PGDM1400|Biological: 10-1074|Biological: VRC07-523LS,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,27,NIH,"July 17, 2019","March 25, 2021","March 25, 2021"
3983,NCT03928522,Antibiotic Elution in Total Knee Arthroplasty,Total Knee Replacement,Drug: hand mixed vancomycin|Drug: hand mixed tobramycin|Device: pre-mixed tobramycin,Washington University School of Medicine,Phase 4,60,Other,"January 28, 2019","September 30, 2019","September 30, 2019"
3984,NCT03928470,Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg,Non-erosive Reflux Disease(NERD),Drug: EsoDuo Tab. 20/800mg,Chong Kun Dang Pharmaceutical,Phase 4,379,Industry,"January 29, 2019","December 20, 2019","December 20, 2019"
3985,NCT03928353,"Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects",Healthy,Drug: PB2452 Infusion|Drug: Placebo - Sodium Chloride|Drug: Ticagrelor Oral Tablet - Pre-Treatment|Drug: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment,PhaseBio Pharmaceuticals Inc.,Phase 2,23,Industry,"April 16, 2019","October 9, 2019","October 9, 2019"
3986,NCT03928340,Effect of Adding Metformin to Insulin Therapy on Pregnancy Outcomes in Women With Uncontrolled Type I Diabetes.,Type1 Diabetes Mellitus,Drug: Metformin|Drug: Insulin,Kasr El Aini Hospital|Amal Kotb Abdallah|Amir Gabr|Mohamed Abdeltawwab Mahmoud,Phase 4,80,Other,"April 29, 2019","March 29, 2020","March 29, 2020"
3987,NCT03928327,A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants,Healthy Volunteers,Drug: TAK-788|Drug: Itraconazole|Drug: Rifampin,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,24,Industry,"May 2, 2019","August 16, 2019","August 16, 2019"
3988,NCT03928262,Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects,Healthy Subjects,Biological: Benralizumab,AstraZeneca,Phase 1,36,Industry,"April 2, 2019","August 12, 2019","August 12, 2019"
3989,NCT03927781,Perioperative Pregabalin in Ureteroscopy: a Pilot,"Nephrolithiasis|Urolithiasis|Perioperative/Postoperative Complications|Pain, Postoperative|Pain, Acute|Anesthesia|Urologic Diseases|Anesthesia Morbidity",Drug: Pregabalin 300mg,University of Missouri-Columbia,Phase 3,10,Other,"April 1, 2019","October 17, 2019","October 17, 2020"
3990,NCT03927716,A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1),Molluscum Contagiosum,Drug: SB206 12%|Drug: Placebo,"Novan, Inc.|Synteract, Inc.",Phase 3,352,Industry,"June 3, 2019","October 28, 2019","January 29, 2020"
3991,NCT03927703,A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC,Molluscum Contagiosum,Drug: SB206 12%|Drug: Placebo,"Novan, Inc.|Synteract, Inc.",Phase 3,355,Industry,"June 13, 2019","November 11, 2019","February 3, 2020"
3992,NCT03927677,The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.,Gout|Hyperuricemia,Drug: Xanthine Oxidase Inhibitor,LG Chem,Phase 1,24,Industry,"November 5, 2019","November 26, 2019","November 26, 2019"
3993,NCT03927508,First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism,Pulmonary Embolism,Drug: r-tPA|Device: The Bashir™ Endovascular Catheter,"Thrombolex, Inc.",Phase 1,9,Industry,"March 14, 2019","December 19, 2019","January 23, 2020"
3994,NCT03927313,"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM",Tuberculosis Meningitis|HIV-1-infection,Drug: Linezolid|Drug: High dose rifampicin|Drug: Aspirin|Drug: Standard of Care anti-tuberculous therapy|Drug: Dexamethasone,University of Cape Town,Phase 2,52,Other,"June 12, 2019","March 30, 2021","March 31, 2021"
3995,NCT03927209,A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.,Healthy,Drug: BI 1467335,Boehringer Ingelheim,Phase 1,10,Industry,"June 6, 2019","November 22, 2019","November 22, 2019"
3996,NCT03927170,Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed),Healthy,Combination Product: Janumet XR tablet 100/1000 mg|Combination Product: GLH1SM tablet 100/1000 mg,GL Pharm Tech Corporation,Phase 1,25,Industry,"May 2, 2019","September 11, 2019","October 23, 2019"
3997,NCT03926780,Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi,Anticoagulants; Increased|Left Ventricular Thrombosis,Drug: Rivaroxaban 20 MG|Drug: Warfarin Sodium,The Young Investigator Group of Cardiovascular Research,Phase 3,79,Other,"December 1, 2018","May 1, 2020","May 1, 2020"
3998,NCT03926611,This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines,Chronic Spontaneous Urticaria,Drug: LOU064 Arm 1|Drug: LOU064 Arm 2|Drug: LOU064 Arm 3|Drug: LOU064 Arm 4|Drug: LOU064 Arm 5|Drug: LOU064 Arm 6|Drug: Placebo arm,Novartis Pharmaceuticals|Novartis,Phase 2,311,Industry,"June 6, 2019","January 14, 2021","April 15, 2021"
3999,NCT03926286,Fecal Microbial Transplant (FMT) for Sjogrens Syndrome,Sjogren's Syndrome,Drug: FMP-30,University of Miami|Sjogrens Syndrome Foundation|Microbiome Health Research Institute,Phase 1,10,Other,"April 15, 2019","June 1, 2020","June 1, 2020"
4000,NCT03926169,A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa,Hidradenitis Suppurativa,Drug: Risankizumab|Drug: Placebo for risankizumab,AbbVie,Phase 2,243,Industry,"June 3, 2019","February 2, 2021","August 2, 2021"
4001,NCT03926117,Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition,Chronic Kidney Diseases|Inflammation,Biological: Ziltivekimab,Novo Nordisk A/S,Phase 2,264,Industry,"June 3, 2019","June 26, 2020","June 26, 2020"
4002,NCT03926026,Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis,Blepharitis,Drug: Fluticasone Propionate|Drug: Placebo,"Nicox Ophthalmics, Inc.",Phase 2,36,Industry,"March 18, 2019","October 21, 2019","October 21, 2019"
4003,NCT03925935,Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation,Hodgkin Lymphoma|Non-hodgkin Lymphoma,Biological: AB-205,Angiocrine Bioscience|California Institute for Regenerative Medicine (CIRM),Phase 1,42,Industry|Other,"May 7, 2019","November 18, 2020","November 8, 2021"
4004,NCT03925857,Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS,Organ Dysfunction Syndrome Sepsis,Biological: Allocetra-OTS,Enlivex Therapeutics Ltd.,Phase 1,10,Industry,"January 27, 2019","December 10, 2019","January 12, 2020"
4005,NCT03925779,Conscious Sedation for Outpatient Colonoscopy,Conscious Sedation,Drug: Dexmedetomidine|Drug: Propofol|Drug: Remifentanil,Menoufia University,Phase 2,80,Other,"June 15, 2019","December 31, 2020","January 5, 2021"
4006,NCT03925727,Tavilermide Ophthalmic Solution for the Treatment of Dry Eye,Keratoconjunctivitis Sicca|Dry Eye,Drug: Tavilermide ophthalmic solution|Other: Placebo,"Mimetogen Pharmaceuticals USA, Inc.",Phase 3,623,Industry,"March 28, 2019","June 11, 2020","June 11, 2020"
4007,NCT03925246,Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas,High Grade Glioma|Brain Cancer,Drug: Nivolumab,Assistance Publique - Hôpitaux de Paris|Bristol-Myers Squibb,Phase 2,43,Other|Industry,"July 30, 2019","December 2, 2020","August 18, 2021"
4008,NCT03925051,Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers,Postmenopausal Osteoporosis,Drug: Prolia®|Drug: CMAB807,"Shanghai Biomabs Pharmaceutical Co., Ltd.",Phase 1,132,Industry,"July 1, 2019","March 21, 2020","June 18, 2020"
4009,NCT03924518,Adjunctive Granisetron Therapy in Patients With Sepsis or Septic Shock,Sepsis,Drug: Granisetron Hydrochloride|Drug: Placebo（Normal saline）,Zhujiang Hospital,Phase 2,154,Other,"April 25, 2019","November 28, 2020","December 28, 2020"
4010,NCT03924427,An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis,Psoriasis,Drug: BMS-986165,Bristol-Myers Squibb,Phase 3,74,Industry,"April 10, 2019","March 24, 2021","March 24, 2021"
4011,NCT03923933,Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial,"Renal Insufficiency, Chronic",Drug: Chlorthalidone|Drug: Bumetanide,Hospital General de México Dr. Eduardo Liceaga,Phase 2,34,Other,"June 18, 2019","October 28, 2019","October 28, 2019"
4012,NCT03923738,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).",Giant Cell Arteritis,Drug: Tocilizumab,Hoffmann-La Roche,Phase 1,24,Industry,"August 5, 2019","November 12, 2020","November 12, 2020"
4013,NCT03922945,A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity,Adolescent Obesity|Obesity in Adolescence|Adolescent Overweight,Drug: VI-0521 oral capsule|Drug: Placebo oral capsule|Behavioral: Lifestyle Modification,VIVUS LLC,Phase 4,223,Industry,"May 2, 2019","April 16, 2021","April 16, 2021"
4014,NCT03922750,A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Insulin glargine U100,Novo Nordisk A/S,Phase 2,154,Industry,"May 9, 2019","December 19, 2019","January 27, 2020"
4015,NCT03922633,A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants,Healthy Male Participants,Drug: E3112|Other: Placebo,"EA Pharma Co., Ltd.|Eisai Inc.",Phase 1,24,Industry,"April 22, 2019","May 20, 2020","October 1, 2020"
4016,NCT03922607,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis",Psoriasis,Drug: ABBV-157|Drug: Placebo for ABBV-157,AbbVie,Phase 1,65,Industry,"June 11, 2019","April 13, 2021","April 13, 2021"
4017,NCT03922464,Efficacy and Safety of Poly-L-lactic Acid,Buttock Contouring|Buttock Lifting,Device: Poly-L-lactic acid (Sculptra® Aesthetic),Erevna Innovations Inc.,Phase 4,30,Other,"April 8, 2019","January 8, 2020","March 8, 2020"
4018,NCT03922321,Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,Drug: RVT-1401,Immunovant Sciences GmbH,Phase 2,7,Industry,"April 22, 2019","February 29, 2020","May 21, 2020"
4019,NCT03922061,"Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant",Polio,Biological: dmLT|Biological: fIPV,University of Vermont,Phase 1,29,Other,"March 19, 2019","July 18, 2019","June 4, 2020"
4020,NCT03921775,A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery,Anesthesia for Elective Surgery Patients,Drug: Remimazolam Tosilate|Drug: Propofol,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,330,Industry,"May 13, 2019","December 30, 2019","December 30, 2019"
4021,NCT03921723,Dolutegravir Pediatric Liquid Formulation Study,HIV Infections,Drug: Dolutegravir dispersible tablet|Drug: Dolutegravir oral suspension|Drug: Dolutegravir oral solution,ViiV Healthcare,Phase 1,22,Industry,"May 7, 2019","July 25, 2019","July 25, 2019"
4022,NCT03921411,A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD),Atopic Dermatitis,Biological: Nemolizumab,Galderma R&D,Phase 2,20,Industry,"April 9, 2019","August 19, 2020","August 19, 2020"
4023,NCT03921268,Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402,Asthma,Drug: AZD1402,AstraZeneca,Phase 1,18,Industry,"March 25, 2019","June 13, 2019","June 13, 2019"
4024,NCT03920865,A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function,"Muscular Atrophy, Spinal",Drug: Risdiplam,Hoffmann-La Roche,Phase 1,26,Industry,"May 16, 2019","January 2, 2020","January 2, 2020"
4025,NCT03920852,A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis,Atopic Dermatitis,Drug: Ruxolitinib cream,Incyte Corporation,Phase 1,41,Industry,"May 30, 2019","December 26, 2019","December 26, 2019"
4026,NCT03920150,Vitamin D 24'000 IU for Oral Intermittent Supplementation,Vitamin D Deficiency,Drug: Vitamin D3|Drug: Vitamin D oily capsules,"University Hospital, Basel, Switzerland",Phase 3,58,Other,"September 30, 2019","May 31, 2020","May 31, 2020"
4027,NCT03919890,"A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers",Venous Thromboembolism,Drug: ONO-7684|Drug: ONO-7684 Placebo,Ono Pharmaceutical Co. Ltd,Phase 1,72,Industry,"January 17, 2019","August 23, 2019","August 23, 2019"
4028,NCT03919448,A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab,Pharmacokinetics|Safety Issues,Biological: Bevacizumab,Laboratorios Richmond S.A.C.I.F.|FP Clinical Pharma S.R.L.|Syngene International Limited,Phase 1,90,Industry|Other,"April 1, 2019","September 11, 2019","September 11, 2019"
4029,NCT03919409,First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants,Healthy Volunteers,Drug: TS-161|Drug: TS-161 Placebo,Taisho Pharmaceutical R&D Inc.,Phase 1,70,Industry,"June 3, 2019","February 11, 2020","February 11, 2020"
4030,NCT03918980,Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064,"Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis",Drug: LOU064|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 1,185,Industry,"August 18, 2016","January 27, 2020","January 27, 2020"
4031,NCT03918967,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants",Healthy,Drug: CT-G11|Drug: CT-G20|Drug: CT-G11 Placebo|Drug: CT-G20 Placebo,Celltrion,Phase 1,72,Industry,"April 8, 2019","June 6, 2020","June 6, 2020"
4032,NCT03918629,Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study,Clostridium Difficile Associated Disease,Biological: Clostridium difficile|Biological: Placebo,Pfizer,Phase 3,1994,Industry,"April 1, 2019","December 22, 2020","December 22, 2020"
4033,NCT03918551,Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions,Bioequivalence,Drug: Febuxostat|Drug: Adenuric,"Pharmtechnology LLC|Altasciences Company, Inc.",Phase 1,50,Industry,"May 3, 2019","June 6, 2019","June 6, 2019"
4034,NCT03918239,A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.,Healthy Volunteers,Drug: SHP643,Shire|Takeda,Phase 1,190,Industry,"May 14, 2019","November 13, 2019","November 13, 2019"
4035,NCT03918187,Intrathecal Nalbuphine Versus Midazolam in Cesarean Section,Cesarean Section Pain,Drug: Bupivacaine|Drug: Nalbuphine|Drug: Midazolam,Zagazig University,Phase 1,90,Other,"April 10, 2019","August 30, 2019","December 1, 2019"
4036,NCT03918135,Comparison of the Efficacy of Intravenous Paracetamol and Ibuprofen in the Treatment of Fever Due to Upper Respiratory Tract Infection,Fever,Drug: Paracetamol|Drug: Ibuprofen,Pamukkale University,Phase 4,200,Other,"January 1, 2019","January 1, 2020","January 1, 2020"
4037,NCT03917940,Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride,Diabetic Patients,Dietary Supplement: Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Drug: Glimepiride,Damanhour University,Phase 4,70,Other,"January 31, 2019","May 1, 2020","May 10, 2020"
4038,NCT03917628,Pharmacokinetics and Safety in Healthy Volunteers,Healthy,Drug: SCT630|Drug: adalimumab-EU source,Sinocelltech Ltd.,Phase 1,146,Industry,"May 29, 2019","November 4, 2019","November 4, 2019"
4039,NCT03917472,Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,Diabetic Macular Edema,Drug: Brolucizumab|Drug: Aflibercept,Novartis Pharmaceuticals|Novartis,Phase 3,517,Industry,"July 17, 2019","March 24, 2021","March 24, 2021"
4040,NCT03917420,Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract,HIV/AIDS,Drug: Tenofovir 300Mg Oral Tablet|Drug: Emtricitabine 200 MG,"University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,10,Other|NIH,"March 26, 2019","September 4, 2019","September 4, 2019"
4041,NCT03917225,A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients,Friedreich Ataxia,Drug: MIN-102|Drug: Placebo,"Minoryx Therapeutics, S.L.",Phase 2,39,Industry,"March 26, 2019","August 13, 2020","September 14, 2020"
4042,NCT03916549,Acupuncture in Low Anterior Resection Syndrome Treatment,Low Anterior Resection Syndrome,Device: Acupuncture,"National Cancer Institute, Lithuania|Vilnius University",Phase 1,10,Other,"November 1, 2018","December 1, 2019","December 31, 2019"
4043,NCT03916406,THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS,Healthy Volunteer,Drug: PF 06835919|Drug: Midazolam,Pfizer,Phase 1,10,Industry,"April 18, 2019","June 25, 2019","June 25, 2019"
4044,NCT03916393,PF-06651600 Taste Study.,Healthy Participants,Drug: PF-06651600 20 mg|Other: Bitrex solution,Pfizer,Phase 1,10,Industry,"April 15, 2019","May 10, 2019","May 10, 2019"
4045,NCT03916094,"Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2",Solid Tumor,Drug: HLX22,Shanghai Henlius Biotech,Phase 1,11,Industry,"July 31, 2019","January 4, 2021","December 27, 2021"
4046,NCT03916081,Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis,Atopic Dermatitis,Drug: Roflumilast Cream 0.05%|Drug: Roflumilast Cream 0.15%|Drug: Vehicle Cream,"Arcutis Biotherapeutics, Inc.",Phase 2,136,Industry,"May 31, 2019","November 4, 2019","November 4, 2019"
4047,NCT03916042,"A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease",Dry Eye,Drug: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Drug: Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID,"Aldeyra Therapeutics, Inc.",Phase 2,206,Industry,"April 23, 2019","November 22, 2019","November 22, 2019"
4048,NCT03915860,Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris,Acne Vulgaris,Drug: Trifarotene,Galderma R&D,Phase 3,47,Industry,"March 27, 2019","December 23, 2019","December 23, 2019"
4049,NCT03915470,Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection,Staphylococcal Infections|Surgical Site Infection,Drug: XF-73|Drug: Placebo,Destiny Pharma Plc,Phase 2,124,Industry,"August 29, 2019","January 4, 2021","March 29, 2021"
4050,NCT03915340,Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions,Bioequivalence,Drug: Propafenone|Drug: Rytmonorm,"Pharmtechnology LLC|Altasciences Company, Inc.",Phase 1,32,Industry,"March 23, 2019","May 8, 2019","May 8, 2019"
4051,NCT03915080,Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A,Hemophilia A,Drug: Oktokog alpha,Lund University,Phase 4,14,Other,Dec-16,"April 9, 2021","April 9, 2021"
4052,NCT03915067,BOTOX® for the Treatment of Platysma Prominence,Platysma Prominence,Drug: BOTOX® purified neurotoxin complex|Drug: Placebo,Allergan,Phase 2,171,Industry,"April 23, 2019","April 16, 2020","April 16, 2020"
4053,NCT03914755,"A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects",Healthy,Drug: Tucatinib,Seagen Inc.,Phase 1,36,Industry,"May 8, 2019","August 4, 2019","August 4, 2019"
4054,NCT03914690,Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage,Premature Infants,Drug: Erythropoietin|Drug: Normal saline,"Zhengzhou University|Zhengzhou Children's Hospital, China|Göteborg University",Phase 2,316,Other,Jul-14,Jul-19,Jul-19
4055,NCT03913260,A Study of Different Injectable Formulations of LY3375880 in Healthy Participants,Healthy,Drug: LY3375880|Drug: Buffer Matrix (No LY3375880)|Device: Autoinjector (AI)|Device: Manual Syringe,Eli Lilly and Company,Phase 1,83,Industry,"May 1, 2019","September 19, 2019","September 19, 2019"
4056,NCT03913091,Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA),Shoulder Pain,Drug: Liposomal Bupivacaine|Drug: 0.5% Bupivacaine HCL,NYU Langone Health,Phase 4,184,Other,"March 1, 2019","January 19, 2021","January 19, 2021"
4057,NCT03913000,"A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease",Renal Impairment,Drug: ID-085,Idorsia Pharmaceuticals Ltd.,Phase 1,32,Industry,"April 29, 2019","August 22, 2019","August 22, 2019"
4058,NCT03912974,Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects,Healthy,Drug: Escitalopram|Drug: Placebo oral capsule,"University Hospital, Basel, Switzerland",Phase 1,27,Other,"July 4, 2019","November 26, 2020","November 26, 2020"
4059,NCT03912805,"ET-01 in Subjects With Lateral Canthal Lines, LCL-209","Lateral Canthal Lines, LCL|Crow's Feet","Biological: botulinum toxin, Type A|Biological: Vehicle",Eirion Therapeutics Inc.,Phase 2,38,Industry,"February 27, 2019","May 6, 2019","October 4, 2019"
4060,NCT03912532,"Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)",NASH - Nonalcoholic Steatohepatitis,Biological: NGM282|Other: Placebo,"NGM Biopharmaceuticals, Inc",Phase 2,171,Industry,"May 16, 2019","March 4, 2021","March 29, 2021"
4061,NCT03912441,First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects,Healthy,Biological: BCD-147,Biocad,Phase 1,15,Industry,"January 30, 2019","September 30, 2019","September 30, 2019"
4062,NCT03912259,Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Dupilumab|Drug: Placebo|Drug: Emollient (moisturizer),Sanofi|Regeneron Pharmaceuticals,Phase 3,165,Industry,"December 19, 2018","February 14, 2020","February 14, 2020"
4063,NCT03912233,A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis,Cystic Fibrosis,Drug: VX-121|Drug: TEZ|Drug: VX-561|Drug: TEZ/IVA|Drug: IVA|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Phase 2,87,Industry,"April 30, 2019","December 10, 2019","December 10, 2019"
4064,NCT03911817,Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients,Septic Shock,Drug: Midodrine,Ain Shams University,Phase 4,60,Other,"November 15, 2017","June 30, 2019","July 30, 2019"
4065,NCT03911713,A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis,Cystic Fibrosis,Drug: VX-561|Drug: IVA|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Phase 2,77,Industry,"April 17, 2019","August 20, 2020","August 20, 2020"
4066,NCT03911401,Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis,Atopic Dermatitis,Drug: 0.3% OPA-15406|Drug: 1% OPA-15406|Drug: Placebos,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,251,Industry,"May 7, 2019","December 13, 2019","December 13, 2019"
4067,NCT03911310,[18F]PSMA-11 PET/CT Phase 3 Clinical Study,Prostate Cancer,Diagnostic Test: [18F]PSMA-11|Diagnostic Test: [68Ga]PSMA-11,"University Hospital, Ghent",Phase 3,96,Other,"April 1, 2019","March 20, 2020","September 20, 2020"
4068,NCT03911102,Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines,Lateral Canthal Lines,Biological: DaxibotulinumtoxinA for injection,"Revance Therapeutics, Inc.",Phase 2,63,Industry,"March 11, 2019","April 23, 2020","April 23, 2020"
4069,NCT03910673,Intravenous Fosfomycin Pharmacokinetics Study,Bacterial Infection|Multiple-drug Resistance|Pathogen Resistance,Drug: Fosfomycin disodium,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,39,NIH,"June 27, 2019","December 17, 2020","December 17, 2020"
4070,NCT03910361,Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases,Type2 Diabetes|Non-Alcoholic Fatty Liver Disease,Drug: Evogliptin|Drug: Pioglitazone,"Dong-A ST Co., Ltd.",Phase 4,51,Industry,"April 12, 2019","July 2, 2020","July 2, 2020"
4071,NCT03910088,Pregabalin Versus Hydrocortisone for Postdural Puncture Headache After Spinal for Cesarean,Post-Dural Puncture Headache,Drug: Pregabalin 100Mg Oral Cap|Drug: Hydrocortisone|Drug: Acetaminophen|Other: oral fluids|Drug: Caffeine|Drug: Diclofenac,Cairo University,Phase 4,30,Other,"April 20, 2019","June 30, 2019","June 30, 2019"
4072,NCT03909607,Nebulized Sub-dissociative Dose Ketamine for Treating Pain,Pain,Drug: Ketamine 0.75 mg/kg|Drug: Ketamine 1.0 mg/kg|Drug: Ketamine 1.5 mg/kg,Antonios Likourezos|Maimonides Medical Center,Phase 4,120,Other,"April 16, 2019","October 30, 2020","June 30, 2021"
4073,NCT03909451,Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects,Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Placebo,Sanofi,Phase 1,24,Industry,"April 28, 2019","August 19, 2019","August 19, 2019"
4074,NCT03909074,Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months,"Hand, Foot and Mouth Disease",Biological: 36-71 months old children-experimental EV71 vaccine.|Biological: 36-71 months old children-control EV71 vaccine.|Biological: 6-35 months old children-experimental EV71 vaccine.,"Sinovac Biotech Co., Ltd",Phase 3,900,Industry,"March 10, 2019","June 17, 2019","November 13, 2019"
4075,NCT03908970,Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome,Atopic Dermatitis,Drug: 1% OPA-15406|Drug: Placebos,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,364,Industry,"March 25, 2019","December 28, 2019","December 28, 2019"
4076,NCT03908957,to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers,Safety Issues,Drug: Ga68-Dolacga Injection,"Institute of Nuclear Energy Research, Taiwan",Phase 1,12,Other,"February 12, 2019","August 9, 2019","August 9, 2019"
4077,NCT03907683,Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity,Cardiovascular Risk Factor,Behavioral: Short Message with Text and Optional Image,Penn State University,Phase 1,82,Other,"April 3, 2019","July 21, 2020","July 21, 2020"
4078,NCT03907540,"Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025",Autoimmune Diseases|Fibrosis,Drug: Belumosudil 200 mg tablet|Drug: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|Drug: [14C]-KD025 200 mg capsule,"Kadmon Corporation, LLC|Quotient Sciences",Phase 1,5,Industry,"April 5, 2019","May 20, 2019","May 20, 2019"
4079,NCT03907280,"A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood",Healthy,Drug: BI 1265162 (T1)|Drug: BI 1265162 (T2)|Drug: BI 1265162 (R)|Drug: BI 1265162 (T3),Boehringer Ingelheim,Phase 1,12,Industry,"April 23, 2019","December 6, 2019","December 6, 2019"
4080,NCT03907241,"CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL",Primary Immunodeficiency,Drug: Octanorm 16.5%,Octapharma,Phase 3,27,Industry,"March 1, 2016","September 5, 2019","September 5, 2019"
4081,NCT03907215,A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects,Healthy,Drug: ACT541468|Drug: ACT541468 placebo|Drug: Citalopram,Idorsia Pharmaceuticals Ltd.,Phase 1,24,Industry,"April 9, 2019","June 26, 2019","June 26, 2019"
4082,NCT03906799,Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF),Atrial Fibrillation,Drug: OMT-28|Drug: Placebo,Omeicos Therapeutics GmbH,Phase 2,136,Industry,"March 19, 2019","November 20, 2019","March 20, 2020"
4083,NCT03906058,Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy,Nasopharyngeal Carcinoma,Drug: Anlotinib,Sun Yat-sen University,Phase 2,39,Other,"April 29, 2019","February 27, 2021","April 30, 2022"
4084,NCT03906045,A Scintigraphy Study of PT010 in COPD Patients,Chronic Obstructive Pulmonary Disease,Drug: BGF-MDI,AstraZeneca|Simbec Research,Phase 1,18,Industry,"April 4, 2019","March 5, 2020","March 5, 2020"
4085,NCT03906006,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects",Gout|Hyperuricemia,Drug: ABP-671|Other: Placebo,"Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.",Phase 1,32,Industry,"October 17, 2018","June 20, 2019","June 20, 2019"
4086,NCT03905850,A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects,Healthy Volunteers|Growth Hormone Deficiency,Drug: somapacitan,Novo Nordisk A/S,Phase 1,33,Industry,"March 29, 2019","July 15, 2019","July 15, 2019"
4087,NCT03905512,A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy,Chronic Gout,Drug: SEL-212|Drug: SEL-037|Drug: SEL-110|Drug: KRYSTEXXA®,"Selecta Biosciences, Inc.",Phase 2,170,Industry,"March 28, 2019","August 3, 2020","August 5, 2020"
4088,NCT03905408,Pleurodesis Using Hypertonic Glucose to Treat Post-operative Air Leaks,Postoperative Air Leak,Drug: 50 mL of 50% Glucose|Drug: 100 mL of 50% Glucose|Drug: 150 mL of 50% Glucose|Drug: 200 mL of 50% Glucose,Lawson Health Research Institute,Phase 1,12,Other,"September 17, 2019","February 1, 2021","February 1, 2021"
4089,NCT03905135,Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,Peripheral T-cell Lymphoma NOS|Mycosis Fungoides|Sezary Syndrome|Anaplastic Large Cell Lymphoma,Drug: rhIL-15|Biological: Avelumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,8,NIH,"June 7, 2019","March 25, 2021","May 17, 2022"
4090,NCT03905096,A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other,Healthy,Drug: BI 425809|Drug: Donepezil,Boehringer Ingelheim,Phase 1,32,Industry,"April 12, 2019","August 30, 2019","August 30, 2019"
4091,NCT03904836,Tobramycin Administered at the Beginning of Dialysis,"Renal Dialysis|Renal Failure, Chronic",Drug: Tobramycin,Maisonneuve-Rosemont Hospital,Phase 1,11,Other,"January 31, 2019","December 31, 2019","December 31, 2019"
4092,NCT03904576,A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms,Healthy,Drug: BI 1358894|Drug: Placebo,Boehringer Ingelheim,Phase 1,20,Industry,"April 18, 2019","August 29, 2019","August 29, 2019"
4093,NCT03904511,"Safety, Tolerability and Behavioural Effects of Souroubea-Platanus in Healthy Volunteers","Anxiety|Stress, Psychological",Other: Souroubea-Platanus Preparation|Other: Placebo,University of Ottawa|Souroubea Botanicals Inc.,Phase 1,45,Other,"May 15, 2019","December 31, 2019","February 1, 2020"
4094,NCT03904446,Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients,Uterine Atony With Hemorrhage,Drug: Methylergonovine|Drug: Normal Saline (placebo),Cynthia Wong|University of Iowa,Phase 4,160,Other,"June 8, 2019","February 15, 2021","February 15, 2021"
4095,NCT03903926,Efficacy Trial of a Commercial EV71 Vaccine,"Hand, Foot and Mouth Disease",Biological: 5000 volunteers (6-35 months)-EV71 vaccine,"Sinovac Biotech Co., Ltd",Phase 4,15500,Industry,"March 26, 2019","June 30, 2020","October 30, 2020"
4096,NCT03903822,"Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis",Atopic Dermatitis,Drug: PF-06700841|Drug: Vehicle (Placebo),Pfizer,Phase 2,292,Industry,"May 13, 2019","May 7, 2020","May 7, 2020"
4097,NCT03903081,The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects,Chronic Hepatitis C,Drug: HEC110114 tablet|Drug: Placebo Oral Tablet,"Sunshine Lake Pharma Co., Ltd.",Phase 1,93,Industry,"March 6, 2019","October 29, 2019","October 29, 2019"
4098,NCT03903016,A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes,Type 1 Diabetes,Drug: Insulin Lispro SAR342434,Sanofi,Phase 1,90,Industry,"March 26, 2019","August 19, 2019","August 19, 2019"
4099,NCT03902691,Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis,Chronic Kidney Diseases,Drug: Pegol-Sihematide|Drug: ESPO,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Phase 3,372,Industry,"May 15, 2019","February 28, 2021","May 30, 2022"
4100,NCT03902613,18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder,Bipolar Depression,Drug: Lurasidone,New York State Psychiatric Institute|Columbia University,Phase 4,1,Other,"February 7, 2019","August 1, 2019","August 1, 2019"
4101,NCT03902574,Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg,Healthy Adult Male,Drug: Brexpiprazole ODT 2mg with water|Drug: Brexpiprazole ODT 2mg without water|Drug: Brexpiprazole conventional tablet 2mg,"Otsuka Pharmaceutical Co., Ltd.",Phase 1,21,Industry,"March 27, 2019","June 18, 2019","June 18, 2019"
4102,NCT03902548,Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers,Alzheimer Disease,Drug: [18F]P16-129,"Five Eleven Pharma, Inc.",Phase 1,14,Industry,"February 21, 2018","November 2, 2019","November 2, 2019"
4103,NCT03902002,A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function,Hepatic Impairment,Drug: Omaveloxolone 50 mg capsules,"Reata Pharmaceuticals, Inc.",Phase 1,48,Industry,"July 19, 2019","January 27, 2020","January 27, 2020"
4104,NCT03901729,A Trial to Study BAY1753011 in Patients With Congestive Heart Failure,Heart Failure (HF),Drug: BAY 1753011|Other: Placebo BAY 1753011|Drug: Furosemide|Other: Placebo Furosemide,Bayer,Phase 2,482,Industry,"May 29, 2019","April 16, 2021","May 21, 2021"
4105,NCT03901482,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine",Migraine|Migraine With Aura|Migraine Without Aura,Drug: Dihydroergotamine|Drug: Placebos,"Satsuma Pharmaceuticals, Inc.",Phase 3,1201,Industry,"June 24, 2019","July 31, 2020","August 13, 2020"
4106,NCT03901352,Study of Mirogabalin for Central Neuropathic Pain,Central Neuropathic Pain,Drug: Placebo|Drug: Mirogabalin,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.",Phase 3,300,Industry,"March 12, 2019","December 28, 2020","December 28, 2020"
4107,NCT03901313,Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers,Healthy Volunteers,Drug: Treatment A - 400 mg Fasting|Drug: Treatment B - 400 mg Fed|Drug: Treatment C - 200 mg Fed,"Daiichi Sankyo, Inc.",Phase 1,24,Industry,"April 1, 2019","May 8, 2019","May 22, 2019"
4108,NCT03901144,A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier,"Dermatitis, Atopic",Drug: 2% urea/20% glycerol cream|Drug: Miniderm® 20% cream|Drug: Diprobase® cream,ACO Hud Nordic AB|The University of Sheffield Medical School,Phase 2,50,Industry|Other,"February 21, 2019","November 29, 2019","December 10, 2019"
4109,NCT03901118,Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer,Ovarian Cancer,Drug: chiauranib|Drug: etoposide|Drug: paclitaxel,"Chipscreen Biosciences, Ltd.",Phase 2,47,Industry,"July 1, 2019","December 18, 2020","December 18, 2020"
4110,NCT03900572,A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine,HPV Infections,Biological: HPV Vaccine|Drug: Placebo,"Shanghai Zerun Biotechnology Co.,Ltd",Phase 1,90,Industry,"March 9, 2019","April 30, 2020","April 30, 2020"
4111,NCT03899909,"A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects",Healthy,Drug: GLPG3121 SAD|Drug: Placebo SAD|Drug: GLPG3121 MAD|Drug: Placebo MAD,Galapagos NV,Phase 1,31,Industry,"March 29, 2019","June 3, 2019","June 3, 2019"
4112,NCT03899480,Adoptive Transfer of Haploidentical NK Cells and N-803,Hiv|HIV Infections|Immune Deficiency,Biological: Haploidentical Natural Killer (NK) Cells,University of Minnesota,Phase 1,9,Other,"May 1, 2019","April 1, 2021","April 1, 2021"
4113,NCT03899246,Sickle Cell Pain: Intervention With Capsaicin Exposure,Neuropathic Pain|Sickle Cell Disease,Drug: Eight Percent Topical Capsaicin,Children's Hospital of Michigan,Phase 1,10,Other,"July 3, 2019","March 30, 2020","March 30, 2020"
4114,NCT03899142,Pharmacokinetics of New HepBQuin,Healthy,Biological: a human hepatitis B immunoglobulin solution for injection for intramuscular administration,Prothya Biosolutions,Phase 1,24,Industry,"March 20, 2019","July 4, 2019","July 4, 2019"
4115,NCT03898791,A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer,Small Cell Lung Cancer,Drug: LY3295668 Erbumine,Eli Lilly and Company,Phase 1,48,Industry,"July 16, 2019","June 2, 2020","March 30, 2021"
4116,NCT03898583,"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.",Psoriasis Vulgaris,Drug: Microarray patch A|Drug: Microarray patch B|Drug: Placebo|Drug: Daivobet,LEO Pharma,Phase 1,15,Industry,"April 15, 2019","October 29, 2019","October 29, 2019"
4117,NCT03898011,A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions,Healthy Adults,Drug: Lamotrigine|Drug: Lamictal,"Pharmtechnology LLC|ClinPharmInvest, LLC",Phase 1,28,Industry|Other,"March 23, 2019","May 4, 2019","May 4, 2019"
4118,NCT03897946,Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC,Hepatitis B,Biological: Birth dose hepatitis B vaccine,"University of North Carolina, Chapel Hill|The American Society of Tropical Medicine and Hygiene|Burroughs Wellcome",Phase 4,569,Other|Industry,"August 20, 2019","February 5, 2021","February 5, 2021"
4119,NCT03897868,A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension,Hypertension,Drug: HCP1803|Drug: Amlodipine|Drug: Losartan|Drug: Placebo,Hanmi Pharmaceutical Company Limited,Phase 2,248,Industry,"March 21, 2019","February 26, 2020","February 26, 2020"
4120,NCT03897348,Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD),Alcohol Use Disorder,Drug: Placebo|Drug: Lacosamide 100 mg|Drug: Lacosamide 200 mg,"University of California, San Francisco|San Francisco VA Health Care System",Phase 2,4,Other|U.S. Fed,"September 17, 2018","June 12, 2019","June 12, 2019"
4121,NCT03897309,Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines,Norovirus Infection,Biological: VXA-G1.1-NN|Biological: VXA-G2.4-NS|Biological: Placebo Tablets,Vaxart,Phase 1,86,Industry,"March 20, 2019","January 15, 2021","April 1, 2021"
4122,NCT03897257,A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis,Tinea Pedis,Drug: UHE-103A1 cream|Drug: UHE-103A2 cream|Drug: UHE-103B cream|Drug: UHE-103A1B cream|Drug: UHE-103A2B cream,"Therapeutics, Inc.",Phase 2,240,Industry,"March 15, 2019","October 21, 2019","May 5, 2020"
4123,NCT03896971,Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia,Aplastic Anemia,Drug: Combination of thrombopoietin mimetic and cyclosporin A,Safaa AA Khaled|Assiut University,Phase 4,66,Other,"November 15, 2019","December 1, 2020","June 1, 2021"
4124,NCT03896477,Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants,"Pneumonia, Pneumococcal",Biological: Pneumosil|Biological: Prevenar 13|Biological: Synflorix,"PATH|Serum Institute of India Pvt. Ltd.|Medical Research Council Unit, The Gambia|University College, London|FHI 360",Phase 3,660,Other|Industry,"July 18, 2019","December 17, 2020","December 17, 2020"
4125,NCT03896152,"Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria",Paroxysmal Nocturnal Hemoglobinuria,Drug: LNP023,Novartis Pharmaceuticals|Novartis,Phase 2,13,Industry,"April 5, 2019","April 7, 2020","February 9, 2022"
4126,NCT03896009,Maximizing Outcomes in Treating Acute Migraine,Migraine,Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)|Drug: Meloxicam|Drug: Rizatriptan|Drug: Placebo,"Axsome Therapeutics, Inc.",Phase 3,1594,Industry,"March 4, 2019","December 10, 2019","December 10, 2019"
4127,NCT03895970,Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors,Liver Neoplasm Malignant Primary|Cholangiocarcinoma|Combinational Immunotherapy|Biomarker,Drug: Lenvatinib plus Pembrolizumab,Peking Union Medical College Hospital,Phase 2,32,Other,"April 20, 2019","April 1, 2021","August 1, 2021"
4128,NCT03895801,Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.,Granulomatosis With Polyangiitis (GPA)|Microscopic Polyangiitis (MPA),Drug: IFX-1|Drug: Placebo-IFX-1|Drug: Glucocorticoid (GC)|Drug: Placebo-Glucocorticoid (Placebo-GC),InflaRx GmbH,Phase 2,57,Industry,"April 3, 2019","April 14, 2021","June 8, 2021"
4129,NCT03895697,A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: dasiglucagon,Zealand Pharma,Phase 3,92,Industry,"March 26, 2019","July 30, 2019","July 30, 2019"
4130,NCT03895684,Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: SP-2577 Seclidemstat,"Salarius Pharmaceuticals, LLC",Phase 1,23,Industry,"June 25, 2019","April 13, 2021","April 13, 2021"
4131,NCT03895385,A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects,Healthy Volunteers,Drug: Bimekizumab,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,56,Industry,"April 2, 2019","October 4, 2019","October 4, 2019"
4132,NCT03895372,A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis,Psoriasis,Drug: PF-06826647 or Placebo|Drug: PF-06826647,Pfizer,Phase 2,179,Industry,"June 27, 2019","May 21, 2020","November 26, 2020"
4133,NCT03894969,Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine,Respiratory Disorders,Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A),GlaxoSmithKline,Phase 2,541,Industry,"April 23, 2019","August 31, 2020","August 13, 2021"
4134,NCT03894904,Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients,Pediatrics|Anesthesia|Vasospasm,"Drug: Papaverine|Drug: Heparin|Drug: Rescue papaverine, as needed","The University of Texas Health Science Center, Houston",Phase 4,100,Other,"April 1, 2019","October 10, 2020","October 10, 2020"
4135,NCT03894813,Probiotics as Adjuvant Treatment for Bacterial Vaginosis,Bacterial Vaginosis,"Drug: ""Probiotics"" and ""Metronidazole""|Drug: Metronidazole Vaginal","Peking University Shenzhen Hospital|BGI, China",Phase 4,126,Other,"March 26, 2019","December 30, 2020","December 30, 2020"
4136,NCT03894800,Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl,Acute Pain|Trauma|Hypovolemia,Drug: Methoxyflurane (M)|Drug: Fentanyl (F1)|Drug: Fentanyl (F2)|Drug: NaCl (C),Oslo University Hospital,Phase 4,12,Other,"April 23, 2019","October 29, 2019","October 29, 2019"
4137,NCT03894579,Autologous Natural Killer Cells in Subjects With Plaque Psoriasis,Plaque Psoriasis,Biological: Study Product: SNK01,"NKGen Biotech, Inc.",Phase 1,9,Industry,"July 18, 2019","December 3, 2019","December 3, 2019"
4138,NCT03894124,Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers,Human Immunodeficiency Virus,Drug: Doravirine,Chelsea and Westminster NHS Foundation Trust|Merck Sharp & Dohme LLC|Imperial College London|University of Liverpool,Phase 1,14,Other|Industry,"June 12, 2019","July 25, 2019","August 6, 2019"
4139,NCT03893799,A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease,Acute Kidney Injury,Drug: RBT-1,"Renibus Therapeutics, Inc.",Phase 1,54,Industry,"August 27, 2019","April 22, 2020","December 31, 2020"
4140,NCT03893747,Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China,"Hand, Foot and Mouth Disease",Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|Biological: The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|Biological: The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor,"Jiangsu Province Centers for Disease Control and Prevention|Wuhan Institute of Biological Products Co., Ltd",Phase 4,3000,Other|Industry,"April 1, 2019","May 1, 2020","May 1, 2020"
4141,NCT03893526,Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes,Type2 Diabetes,Drug: Entresto|Drug: Sitagliptin|Drug: Valsartan|Drug: Placebo,University of Copenhagen|Hvidovre University Hospital,Phase 4,12,Other,"January 25, 2019","March 1, 2021","March 1, 2021"
4142,NCT03893097,Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children,Schistosoma Haematobium|Schistosoma Mansoni,Drug: Praziquantel|Drug: Artesunate + Mefloquine,"Institute of Tropical Medicine, Belgium|Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation (IRESSEF)",Phase 3,726,Other,"October 14, 2019","March 4, 2021","March 4, 2021"
4143,NCT03892902,A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects,Healthy,Drug: ACT-541468|Drug: Zopiclone 7.5 mg|Other: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,56,Industry,"March 25, 2019","October 10, 2019","October 10, 2019"
4144,NCT03892668,Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy.,Myomectomy,Drug: Tranexamic Acid|Drug: oxytocin|Drug: placebo,Cairo University,Phase 4,150,Other,"April 30, 2019","February 1, 2020","March 15, 2020"
4145,NCT03892616,A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood,Healthy,Drug: BI 1358894 (B)|Drug: BI 1358894 (C)|Drug: BI 1358894 (D)|Drug: BI 1358894 (E)|Drug: BI 1358894 (A),Boehringer Ingelheim,Phase 1,24,Industry,"April 8, 2019","July 3, 2019","July 3, 2019"
4146,NCT03892499,"A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers",Healthy,Drug: Olinciguat|Drug: Itraconazole,Cyclerion Therapeutics,Phase 1,24,Industry,"May 3, 2019","June 23, 2019","July 3, 2019"
4147,NCT03891862,Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia,Tardive Dyskinesia (TD),Drug: Valbenazine|Drug: Placebo oral capsule,Neurocrine Biosciences,Phase 4,135,Industry,"March 18, 2019","December 23, 2019","January 30, 2020"
4148,NCT03891758,Confirmatory Study of BK1310 in Healthy Infants,Tetanus|Diphtheria|Pertussis|Poliomyelitis|Bacterial Meningitis,Biological: DPT-IPV-Hib|Biological: Hib vaccine|Biological: DPT-IPV,Mitsubishi Tanabe Pharma Corporation|The Research Foundation for Microbial Diseases of Osaka University,Phase 3,267,Industry|Other,"April 1, 2019","September 18, 2019","August 10, 2020"
4149,NCT03891524,A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery,"Arthroplasty, Replacement, Knee",Drug: JNJ-70033093 25 mg|Drug: JNJ-70033093 50 mg|Drug: JNJ-70033093 100 mg|Drug: JNJ-70033093 200 mg|Drug: Placebo|Drug: Enoxaparin 40 mg,"Janssen Research & Development, LLC|Bristol-Myers Squibb",Phase 2,1242,Industry,"June 17, 2019","April 6, 2021","April 6, 2021"
4150,NCT03891472,Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer,Cancer of Pancreas|Unresectable Pancreatic Cancer|Chemotherapy Effect|SBRT,"Drug: Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.",Medical University of Silesia,Phase 2,40,Other,"January 1, 2017","July 31, 2019","July 31, 2019"
4151,NCT03891225,Efficacy of Amniotic Membrane Over Pancreatic Anastomosis After Pancreaticoduodenenctomy to Preventing Pancreatic Fistula,Post Operative Pancreatic Fistula|Pancreatic Resection|Biological Dressing,Procedure: Amniotic Membrane implantation,Casa di Cura Dott. Pederzoli|Fondazione Banca dei Tessuti di Treviso onlus,Phase 1,20,Other,"March 25, 2019","September 30, 2020","December 20, 2020"
4152,NCT03891108,"A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants",Heart Failure,Drug: BMS-986231 Formulation A|Drug: BMS-986231 Formulation B|Drug: BMS-986231 Formulation C|Drug: BMS-986231 Formulation D,Bristol-Myers Squibb,Phase 1,60,Industry,"February 28, 2019","July 29, 2019","July 29, 2019"
4153,NCT03890887,A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood,Healthy,Drug: BI 1291583|Drug: Itraconazole,Boehringer Ingelheim,Phase 1,14,Industry,"April 12, 2019","July 29, 2019","July 29, 2019"
4154,NCT03890809,An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage,Liver Dysfunction|Healthy Volunteers,Drug: BMS-986165,Bristol-Myers Squibb,Phase 1,32,Industry,"February 26, 2019","November 30, 2019","November 30, 2019"
4155,NCT03890770,A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.,Renal Impairment|Healthy Volunteer,Drug: BMS-986165,Bristol-Myers Squibb,Phase 1,44,Industry,"April 4, 2019","February 7, 2020","February 13, 2020"
4156,NCT03890744,ModraDoc006/r in Patients With Breast Cancer,Metastatic Breast Cancer|Recurrent Breast Cancer,Drug: ModraDoc006/r,Modra Pharmaceuticals,Phase 2,12,Industry,"January 30, 2019","February 13, 2020","November 9, 2020"
4157,NCT03890367,Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers,Meningococcal Infection (Healthy Volunteers),"Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Biological: Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Biological: Meningococcal group C polysaccharide Conjugate vaccine adsorbed","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,707,Industry,"September 12, 2019","October 14, 2020","October 14, 2020"
4158,NCT03890302,"Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A",Rheumatoid Arthritis,Drug: FB704A|Drug: Placebo,"Fountain Biopharma Inc.|Oneness Biotech Co., Ltd.",Phase 1,31,Industry,"March 14, 2019","May 27, 2020","May 27, 2020"
4159,NCT03889886,Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED),Dry Eye,Drug: SDP-4 Ophthalmic Solution (0.1%)|Drug: SDP-4 Ophthalmic Solution (1.0%)|Drug: SDP-4 Ophthalmic Solution (3.0%)|Drug: Vehicle,"Silk Technologies, Ltd.",Phase 2,305,Industry,"April 16, 2019","October 7, 2019","October 11, 2019"
4160,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,Drug: SAR442168|Drug: Placebo|Drug: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI),Sanofi,Phase 2,130,Industry,"March 29, 2019","January 2, 2020","January 2, 2020"
4161,NCT03888716,"A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease",Mitochondrial Diseases|Mitochondrial Respiratory Chain Deficiencies|MELAS Syndrome|Mitochondrial Myopathies,Drug: KL1333|Drug: Placebo Oral Tablet,Abliva AB,Phase 1,72,Industry,"March 18, 2019","March 16, 2021","March 16, 2021"
4162,NCT03888378,Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction,Meibomian Gland Dysfunction|MGD-Meibomian Gland Dysfunction,Drug: 0.3% Topical Minocycline Ointment|Drug: 1% Topical Minocycline Ointment|Other: Topical Vehicle Ointment,Hovione Scientia Limited,Phase 2,270,Industry,"April 2, 2019","September 18, 2020","February 1, 2021"
4163,NCT03887884,Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder),Parkinson's Disease,Drug: CVT-301|Drug: Sinemet,Acorda Therapeutics,Phase 1,23,Industry,"March 5, 2019","June 28, 2019","June 28, 2019"
4164,NCT03887429,Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal,Impulse Control Disorders,Drug: SXC-2023|Drug: Placebos,"Promentis Pharmaceuticals, Inc.|Celerion|Baylor College of Medicine",Phase 2,34,Industry|Other,"March 4, 2019","July 2, 2019","July 9, 2019"
4165,NCT03887299,Antimicrobial Dressing Versus Standard Dressing in Obese Women Undergoing Cesarean Delivery,Cesarean Section Complications|Wound Breakdown|Wound Infection|Satisfaction|Surgical Wound Infection,Combination Product: ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Other: Standard Wound Care,"The University of Texas Medical Branch, Galveston",Phase 4,154,Other,"April 18, 2019","January 18, 2020","February 28, 2020"
4166,NCT03887026,Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis,Allergic Rhinitis|Allergic Rhinoconjunctivitis,Drug: Norketotifen|Drug: Placebo,"Emergo Therapeutics, Inc.",Phase 2,36,Industry,"April 1, 2019","May 18, 2019","May 29, 2019"
4167,NCT03886948,A Study of Injections of LY3074828 in Healthy Participants,Healthy,Drug: LY3074828|Device: PFS|Device: AI,Eli Lilly and Company,Phase 1,66,Industry,"March 27, 2019","October 4, 2019","October 4, 2019"
4168,NCT03886896,Intravenous Lidocaine in Children Undergoing Laparoscopic Appendectomy,Acute Appendicitis|Postoperative Pain|Postoperative Nausea and Vomiting,Drug: Lidocaine,Medical University of Warsaw,Phase 4,74,Other,"March 22, 2019","January 15, 2020","January 17, 2020"
4169,NCT03886701,"Doravirine, Rifapentine and Isoniazid Interaction",Latent Tuberculosis|Human Immunodeficiency Virus|Rifamycins Causing Adverse Effects in Therapeutic Use|Drug Interaction Potentiation,Drug: Doravirine (DOR)|Drug: Rifapentine (RPT)|Drug: Isoniazid (INH),Walter K. Kraft|Merck Sharp & Dohme LLC|Thomas Jefferson University,Phase 1,11,Other|Industry,"April 22, 2019","May 20, 2019","May 20, 2019"
4170,NCT03886688,HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers,Healthy,Drug: HEC53856|Drug: placebo,"Sunshine Lake Pharma Co., Ltd.",Phase 1,116,Industry,"May 14, 2019","January 1, 2020","January 1, 2020"
4171,NCT03886415,Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.,Myelofibrosis,Drug: Jaktinib hydrochloride tablets,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Phase 2,118,Industry,"January 8, 2019","February 2, 2021","February 2, 2021"
4172,NCT03886272,A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood,Healthy,Drug: BI 730357 (Test)|Drug: BI 730357 (Reference),Boehringer Ingelheim,Phase 1,43,Industry,"April 11, 2019","June 21, 2019","June 21, 2019"
4173,NCT03886220,A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women,Uterine Fibroids,Drug: Elagolix|Drug: Placebo,AbbVie,Phase 4,82,Industry,"April 12, 2019","March 31, 2021","April 28, 2021"
4174,NCT03885947,VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies,Hematological Malignancy|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Hodgkin Lymphoma,Biological: Cord blood stem cells|Drug: Valproic Acid|Drug: Fludarabine|Drug: cytoxan|Drug: Thiotepa|Biological: TBI,Alla Keyzner|Icahn School of Medicine at Mount Sinai,Phase 1,7,Other,"February 21, 2019","March 10, 2021","March 10, 2021"
4175,NCT03885934,Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024),Pneumococcal Infections,Biological: V114|Biological: Prevnar 13®,Merck Sharp & Dohme LLC,Phase 3,606,Industry,"June 25, 2019","December 9, 2020","December 9, 2020"
4176,NCT03885882,A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants,Healthy Subjects,Drug: E0302 SR1|Drug: E0302 SR3|Drug: E0302 SR2|Drug: E0302 IR,"Eisai Co., Ltd.|Eisai Inc.",Phase 1,24,Industry,"April 13, 2019","June 26, 2019","June 26, 2019"
4177,NCT03885596,Open-Label CA-008 (Vocacapsaicin) in Bunionectomy,Pain,Drug: CA-008|Drug: Ketorolac|Drug: Acetaminophen IV|Drug: Fentanyl|Drug: Bupivacaine Hydrochloride|Drug: Lidocaine HCl|Drug: Celecoxib|Drug: Acetaminophen Oral|Drug: Lidocaine Hydrochloride|Drug: Exparel,Concentric Analgesics,Phase 2,36,Industry,"March 25, 2019","July 2, 2019","October 22, 2019"
4178,NCT03885011,"A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia",Presbyopia,Drug: CSF-1|Drug: CSF-1 Component #1|Drug: CSF-1 Component #2,Orasis Pharmaceuticals Ltd.,Phase 2,166,Industry,"February 26, 2019","July 11, 2019","July 26, 2019"
4179,NCT03884530,Ticagrelol Versus Aspirin in Ischemic Stroke,Acute Stroke|Ischemic Stroke,Drug: Ticagrelor (Brilique) 90|Drug: Aspirin 75mg,Kafrelsheikh University|Ain Shams University,Phase 3,169,Other,"May 1, 2019","September 30, 2020","September 30, 2020"
4180,NCT03884504,MDT-1118 Japan DT Study,Heart Failure,Device: Ventricular Assist Device System,Medtronic Cardiac Rhythm and Heart Failure,Phase 3,10,Industry,"May 1, 2019","December 30, 2020","October 19, 2022"
4181,NCT03884491,A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects,Healthy,Drug: Vortioxetine IV|Drug: Vortioxetine SLA|Drug: Vortioxetine SLB|Drug: Vortioxetine SLC,H. Lundbeck A/S,Phase 1,16,Industry,"March 18, 2019","June 25, 2019","July 22, 2019"
4182,NCT03883984,Cysteamine for Asthma,Asthma,Drug: Cysteamine Bitartrate|Drug: Placebo Oral Tablet,"Children's Hospital Medical Center, Cincinnati",Phase 1,60,Other,"June 18, 2019","February 10, 2021","February 10, 2021"
4183,NCT03883919,Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy,Pancreatic Cancer|Pancreas Cancer|Cancer of the Pancreas,Drug: 5-FU|Drug: Leucovorin|Drug: Liposomal Irinotecan|Drug: Paricalcitol|Procedure: Serum and plasma blood samples|Procedure: Tumor biopsy,Washington University School of Medicine|Ipsen,Phase 1,20,Other|Industry,"July 11, 2019","March 23, 2021","July 2, 2022"
4184,NCT03883906,Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant,Allogeneic Stem Cell Transplant|Viral Infection,Biological: Viral Specific T-cells (VSTs),"Children's Hospital Medical Center, Cincinnati|Hoxworth Blood Center",Phase 2,30,Other,"March 16, 2019","October 31, 2020","October 1, 2021"
4185,NCT03883776,Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors,Neuroendocrine Tumors,Drug: Al18F-NOTA-octreotide|Device: PET/CT|Other: Venous blood samples,Universitaire Ziekenhuizen KU Leuven,Phase 1,12,Other,"April 11, 2019","October 29, 2019","October 29, 2019"
4186,NCT03883698,Safety of Sofosbuvir in People With Advanced Kidney Failure,"Kidney Failure, Chronic|Hepatitis C",Drug: Sofosbuvir|Drug: Daclatasvir 60 mg,Sanjay Gandhi Postgraduate Institute of Medical Sciences,Phase 3,30,Other,"March 15, 2019","August 1, 2020","August 1, 2020"
4187,NCT03883620,Safety Study of Dengushield in Healthy Adults,Phase 1|Dengue,Biological: Dengushield 1 mg/kg (Cohort 1) intravenous|Biological: Dengushield 3 mg/kg (Cohort 2) intravenous|Biological: Placebo 3 mg/kg (Cohort 2) intravenous|Biological: Dengushield 7 mg/kg (Cohort 3) intravenous|Biological: Placebo 7 mg/kg (Cohort 3) intravenous|Biological: Dengushield 12 mg/kg (Cohort 4) intravenous|Biological: Placebo 12 mg/kg (Cohort 4) intravenous,Serum Institute of India Pvt. Ltd.|PPD,Phase 1,40,Industry,"March 22, 2019","December 23, 2019","December 23, 2019"
4188,NCT03883113,Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model,Influenza,Biological: MVA-NP+M1|Biological: Saline|Biological: H3N2 (A/Belgium/2417/2015),Vaccitech (UK) Limited,Phase 2,145,Industry,"June 3, 2019","December 16, 2019","April 17, 2020"
4189,NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Insulin Degludec,Eli Lilly and Company,Phase 3,1444,Industry,"April 1, 2019","December 11, 2020","January 4, 2021"
4190,NCT03882801,Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039),Obstructive Sleep Apnea (OSA),Drug: Gefapixant|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 1,24,Industry,"April 10, 2019","October 22, 2019","October 22, 2019"
4191,NCT03882281,Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia,"Chronic Myeloid Leukemia, Chronic Phase",Drug: HQP1351,Ascentage Pharma Group Inc.|HealthQuest Pharma Inc.,Phase 1,12,Industry,"March 25, 2019","November 16, 2019","November 16, 2019"
4192,NCT03882255,A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State,Healthy,Drug: Ponesimod dose range (2 - 20 mg)|Drug: Placebo Propranolol|Drug: Propranolol 80 mg,"Janssen Pharmaceutica N.V., Belgium",Phase 1,52,Industry,"March 20, 2019","August 26, 2019","August 26, 2019"
4193,NCT03882112,Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects,Heathy Volunteer,Drug: HIP1601 40mg,Hanmi Pharmaceutical Company Limited,Phase 1,24,Industry,"April 17, 2019","August 28, 2019","August 28, 2019"
4194,NCT03881852,Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT),Narcolepsy|Cataplexy Narcolepsy|Excessive Sleepiness,Drug: AXS-12 (Reboxetine)|Drug: Placebo,"Axsome Therapeutics, Inc.",Phase 2,21,Industry,"January 30, 2019","November 27, 2019","November 27, 2019"
4195,NCT03881163,"A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers",Respiratory Tract Disorders,Drug: N-acetylcysteine (NAC),Zambon SpA,Phase 1,24,Industry,"November 11, 2019","January 18, 2020","January 18, 2020"
4196,NCT03881059,Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA),Active Psoriatic Arthritis,Other: BMS-986165 Placebo|Drug: BMS-986165 Dose A|Drug: BMS-986165 Dose B|Drug: Ustekinumab|Other: Ustekinumab Placebo,Bristol-Myers Squibb,Phase 2,203,Industry,"April 1, 2019","April 27, 2020","January 27, 2021"
4197,NCT03880825,Drug Interaction Study of Levoketoconazole and Metformin,Healthy Subjects,Drug: Metformin 500 mg Oral Tablet|Drug: Levoketoconazole 150 - 600 mg (BID),Cortendo AB,Phase 1,32,Industry,"March 28, 2019","May 3, 2019","May 3, 2019"
4198,NCT03880409,How Successful is Supplemental Intraseptal Anaesthesia in Patients With Mandibular Teeth Extraction or Irreversible Pulpitis,Overcoming the Failure of Anesthesia in the Mandibular Teeth,"Drug: 2% lidocaine with 1:000,000 epinephrine|Drug: 4% articaine with 1:000,000 epinephrine",Taibah University,Phase 1,100,Other,"February 9, 2019","September 3, 2019","September 8, 2019"
4199,NCT03880266,"A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis",Palmar Hyperhidrosis,"Drug: Glycopyrronium cloth, 2.4%|Drug: Vehicle",Journey Medical Corporation,Phase 2,72,Industry,"February 22, 2019","May 24, 2019","May 24, 2019"
4200,NCT03880253,Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers,Healthy,Drug: CTP-692,Concert Pharmaceuticals,Phase 1,30,Industry,"April 10, 2019","May 16, 2019","May 16, 2019"
4201,NCT03879928,"A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers",Healthy Subjects,Drug: Single ascending doses of FM101|Drug: Multiple ascending doses of FM101|Drug: Food effects of FM101,Future Medicine,Phase 1,50,Industry,"January 8, 2019","August 18, 2019","May 1, 2020"
4202,NCT03879889,Smoking Reduction Intervention for Smoking Parents of Paediatric Patients in Hong Kong,"Smoking, Tobacco",Drug: Nicotine patch,Chinese University of Hong Kong,Phase 4,210,Other,"February 1, 2017","July 31, 2019","July 31, 2019"
4203,NCT03879863,"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease",Dry Eye,Drug: Reproxalap Ophthalmic Solution (0.25%) QID|Drug: Vehicle Ophthalmic Solution QID|Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID|Drug: Vehicle Ophthalmic Solution QID to BID,"Aldeyra Therapeutics, Inc.",Phase 3,406,Industry,"April 16, 2019","October 4, 2019","October 4, 2019"
4204,NCT03879603,VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults,Venezuelan Equine Encephalitis|Western Equine Encephalitis|Eastern Equine Encephalitis|Alphavirus Infections,Biological: VRC-WEVVLP073-00-VP|Other: VRC-GENMIX083-AL-VP,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,30,NIH,"April 2, 2019","February 26, 2020","February 26, 2020"
4205,NCT03879408,Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study,Pain,Drug: 440 mg naproxen sodium with 1000 mg acetaminophen|Drug: 220 mg naproxen sodium with 650 mg acetaminophen|Drug: 10 mg hydrocodone + 650 mg acetaminophen|Drug: 440 mg naproxen sodium|Drug: Placebo tablet,"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 2,290,Industry,"May 28, 2019","November 7, 2019","November 13, 2019"
4206,NCT03878888,Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control,"Postoperative Pain|Surgery|Anesthesia, Local",Drug: Exparel 266 MG Per 20 ML Injection,"St. Luke's Hospital, Pennsylvania",Phase 4,52,Other,"January 15, 2019","July 1, 2019","July 1, 2019"
4207,NCT03878277,Evaluation of Coffee Therapy for Improvement of Renal Oxygenation,"Type1diabetes|Type1 Diabetes Mellitus|Diabetic Kidney Disease|Juvenile Diabetes|Diabetic Nephropathies|Diabetes Complications|Diabetes, Autoimmune",Drug: Starbucks® Cold brew - 325ml bottle,"University of Colorado, Denver|Johns Hopkins University",Phase 2,10,Other,"July 1, 2019","January 21, 2020","September 30, 2021"
4208,NCT03878004,Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac,Healthy,Biological: GamTBvac vaccine|Biological: placebo,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|contract research organization Cromos Pharma|contract research organization K-Research",Phase 2,180,Other,"December 1, 2018","December 31, 2019","May 31, 2020"
4209,NCT03877926,VELOCITY: An Anthrax Vaccine Clinical Study,Anthrax,Biological: AV7909|Biological: BioThrax,Emergent BioSolutions|Biomedical Advanced Research and Development Authority,Phase 3,3862,Industry|U.S. Fed,"March 11, 2019","August 6, 2020","August 6, 2020"
4210,NCT03877718,A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain,Migraine|Pain|Nausea|Vomiting|Aura,Drug: Arm 1: CL-H1T|Drug: Arm 2: CL-H1T|Drug: Arm 3: Sumatriptan Succinate 100 mg capsule|Drug: Arm 4: Promethazine HCl 18.75 mg|Drug: Arm 5: Promethazine HCl 37.5 mg|Other: Placebo,"Charleston Laboratories, Inc",Phase 2,475,Industry,"February 1, 2019","August 27, 2019","August 27, 2019"
4211,NCT03877562,The Effect of CORT118335 on Olanzapine-Induced Weight Gain,Antipsychotic-induced Weight Gain,Drug: Olanzapine|Drug: CORT118335|Drug: Placebo,Corcept Therapeutics,Phase 1,96,Industry,"April 1, 2019","March 13, 2020","March 25, 2020"
4212,NCT03877237,DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction,Heart Failure With Reduced Ejection Fraction (HFrEF),Drug: Dapagliflozin|Other: Placebo,AstraZeneca,Phase 3,313,Industry,"April 9, 2019","March 7, 2020","March 7, 2020"
4213,NCT03877224,DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction,Heart Failure With Preserved Ejection Fraction (HFpEF),Drug: Dapagliflozin|Other: Placebo,AstraZeneca,Phase 3,504,Industry,"April 4, 2019","July 9, 2020","July 9, 2020"
4214,NCT03876210,Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs,Arthritis,"Combination Product: PK101|Drug: PK101-001, PK101-002","PMG Pharm Co., Ltd",Phase 1,47,Industry,"July 12, 2019","July 22, 2019","August 5, 2019"
4215,NCT03876106,A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions,EGFR Inhibitor Induced Acneiform Lesions,Drug: LUT014,Lutris Pharma Ltd.,Phase 1,10,Industry,"August 21, 2019","July 9, 2020","November 18, 2020"
4216,NCT03876041,Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome,Systemic Inflammatory Response Syndrome,Drug: solumedrol|Drug: Dexamethasone phosphate,Assiut University,Phase 4,60,Other,"September 1, 2019","September 1, 2020","November 1, 2020"
4217,NCT03875508,A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis,Psoriasis,Drug: Risankizumab|Device: Autoinjector,AbbVie,Phase 3,108,Industry,"June 4, 2019","April 24, 2020","August 25, 2020"
4218,NCT03875482,A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis,Psoriasis,Drug: Risankizumab|Drug: Placebo solution for risankizumab,AbbVie,Phase 3,157,Industry,"May 13, 2019","February 20, 2020","July 15, 2020"
4219,NCT03875001,A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men,Healthy,Drug: BI 1358894|Drug: Placebo,Boehringer Ingelheim,Phase 1,24,Industry,"March 25, 2019","July 20, 2019","July 20, 2019"
4220,NCT03874715,Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Type 1 Diabetes Mellitus,Drug: Insulin Aspart SAR341402|Drug: Insulin Aspart|Drug: Insulin glargine U100,Sanofi,Phase 3,210,Industry,"March 11, 2019","July 8, 2020","July 8, 2020"
4221,NCT03874156,MUscle Side-Effects of Atorvastatin in Coronary Patients,Statin Adverse Reaction,Drug: Atorvastatin 40mg|Drug: Placebo Oral Tablet,Vestre Viken Hospital Trust|The Hospital of Vestfold|Oslo University Hospital|University of Oslo,Phase 4,77,Other,"March 5, 2019","December 12, 2019","December 12, 2019"
4222,NCT03874013,Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency,Growth Hormone Deficiency,Drug: MOD-4023|Drug: Genotropin,"OPKO Health, Inc.",Phase 3,44,Industry,"December 7, 2017","March 6, 2020","March 6, 2020"
4223,NCT03873987,Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients,Acute Bacterial Skin and Skin Structure Infection,Drug: Current Formulation of Oritavancin|Drug: Kimyrsa,"Melinta Therapeutics, Inc.",Phase 1,102,Industry,"July 16, 2019","August 27, 2019","September 4, 2019"
4224,NCT03873415,Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males,Psoriasis,Drug: BMS-986165,Bristol-Myers Squibb,Phase 1,9,Industry,"January 25, 2019","May 1, 2019","May 1, 2019"
4225,NCT03873324,Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers,Healthy Volunteers,Drug: CPL500036 compound|Drug: Placebo,"Celon Pharma SA|National Center for Research and Development, Poland",Phase 1,56,Industry|Other,"December 20, 2018","September 16, 2019","September 16, 2019"
4226,NCT03873246,Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study),Dry Eye Disease,Drug: OC-01 0.1% 0.6 mg/ml|Drug: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|Other: placebo comparator,"Oyster Point Pharma, Inc.",Phase 2,123,Industry,"February 18, 2019","January 7, 2020","January 7, 2020"
4227,NCT03873233,Flow Controlled Ventilation (FCV) With the Evone Ventilator and Tritube Versus Volume Controlled Ventilation (VCV),Pulmonary Ventilation,Device: Aisys Carestation ventilator and normal endotracheal tube|Device: Evone ventilator and Tritube,"University Hospital, Antwerp",Phase 3,8,Other,"March 15, 2019","August 5, 2019","August 5, 2019"
4228,NCT03873116,Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan,"Hereditary Angioedema, HAE",Drug: BCX7353 capsules|Drug: Placebo oral capsule,BioCryst Pharmaceuticals,Phase 3,19,Industry,"February 28, 2019","November 15, 2019","July 8, 2021"
4229,NCT03872843,Opioid Free Management After Ureteroscopy,Kidney Stone,"Drug: Norco 5milligram-325milligram Tablet|Drug: Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED",Wake Forest University Health Sciences,Phase 4,22,Other,"September 19, 2019","February 26, 2020","February 26, 2020"
4230,NCT03872830,A Phase Ⅱ Clinical Study Trial of Felbinac Trometamol Injection in China,Pain,Drug: Felbinac Trometamol Injection|Drug: Placebos,Shijiazhuang Yiling Pharmaceutical Co. Ltd,Phase 2,165,Industry,"March 27, 2019","September 30, 2019","December 5, 2019"
4231,NCT03872596,Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder,Bipolar Disorder|Schizophrenia,Drug: Seroquel IR 300mg|Drug: Seroquel IR 25mg|Drug: Quetiapine Formulation A 300mg|Drug: Quetiapine Formulation B 300mg|Drug: Quetiapine Formulation 25mg,"Otsuka Pharmaceutical Development & Commercialization, Inc.|PRA Health Sciences",Phase 1,58,Industry,"March 27, 2019","October 30, 2019","November 27, 2019"
4232,NCT03872232,Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan,Hypercholesterolemia|Hypertension,Drug: Ezetimibe/Rosuvastatin|Drug: Telmisartan,Addpharma Inc.,Phase 3,180,Industry,"February 26, 2019","August 12, 2020","August 12, 2020"
4233,NCT03871803,β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR),Heart Failure With Normal Ejection Fraction|Chronotropic Incompetence,Drug: Controlled withdrawal of beta-blockers|Diagnostic Test: Cardiopulmonary Exercise Testing,Fundación para la Investigación del Hospital Clínico de Valencia,Phase 4,52,Other,"October 1, 2018","February 27, 2021","February 27, 2021"
4234,NCT03871439,"OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS",Healthy,Drug: PF-05221304 Formulation A|Drug: PF-05221304 Formulation B,Pfizer,Phase 1,10,Industry,"March 13, 2019","May 8, 2019","May 8, 2019"
4235,NCT03870880,Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension,Schizophrenia,Drug: Risperidone ISM 75 mg|Drug: Risperidone ISM 100 mg,Rovi Pharmaceuticals Laboratories,Phase 3,215,Industry,"August 25, 2017","January 8, 2020","January 8, 2020"
4236,NCT03870711,10% Lidocaine Spray for Intrauterine Device Insertion,Contraception|Intrauterine Device,Drug: lidocaine spray|Drug: Placebo,Mahidol University,Phase 4,124,Other,"August 1, 2018","December 17, 2019","December 17, 2019"
4237,NCT03870555,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants",Healthy Volunteers,Drug: TAK-954|Drug: TAK-954 Placebo,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,6,Industry,"March 8, 2019","May 16, 2019","May 16, 2019"
4238,NCT03870100,The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects,Osteoporosis,Drug: SHR-1222|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,50,Industry,"April 15, 2019","October 14, 2019","January 6, 2020"
4239,NCT03869333,Dose Escalating Study of Intramuscular Invaplex[AR-DETOX],Diarrhea,Biological: Invaplex[AR-DETOX]|Other: Placebo,PATH,Phase 1,58,Other,"March 18, 2019","June 12, 2020","June 12, 2020"
4240,NCT03869320,"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects",Healthy,Drug: ACT-1004-1239|Other: Placebo|Drug: ACT-1004-1239 (Food-effect subpart)|Other: Placebo (Food-effect subpart),Idorsia Pharmaceuticals Ltd.,Phase 1,64,Industry,"March 25, 2019","July 11, 2019","July 11, 2019"
4241,NCT03869060,Expansion of a Dengue-1 Live Virus Human Challenge,Dengue,Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC),"State University of New York - Upstate Medical University|Janssen Pharmaceutica N.V., Belgium|U.S. Army Medical Research and Development Command",Phase 1,9,Other|Industry|U.S. Fed,"February 4, 2019","September 20, 2019","September 20, 2019"
4242,NCT03869047,"Dexmedetomidine Added to Bupivacaine Versus Bupivacaine inTransincisionalU/S Guided Quadratus Lumborum Block in Open Renal Surgeries , A New Technique",Anesthesia,Drug: Dexmedetomidine +bupivacaine|Drug: Bupivacaine,Ain Shams University,Phase 4,80,Other,"March 6, 2019","August 1, 2019","August 15, 2019"
4243,NCT03868748,Safety Evaluation of β-arbutin in Healthy Human Subjects,Healthy Volunteers,Dietary Supplement: Beta-arbutin|Other: Placebo,SP Nutraceuticals Inc.|Canadian Glycomics Network (GlycoNet),Phase 1,39,Industry|Other,"October 23, 2019","March 1, 2021","March 1, 2021"
4244,NCT03868436,PENTHROX™ in the Canadian Emergency Department (ED),"Pain, Acute",Drug: Methoxyflurane 3mL,"Purdue Pharma, Canada",Phase 4,99,Industry,"April 8, 2019","March 30, 2020","September 8, 2020"
4245,NCT03868098,Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis,"Dermatitis, Atopic",Drug: Crisaborole 2%|Drug: Placebo ointment,Innovaderm Research Inc.,Phase 4,31,Other,"May 21, 2019","November 25, 2020","November 25, 2020"
4246,NCT03867331,"To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers","Malaria,Falciparum",Biological: 5 microgram VLPM01|Biological: 15 microgram VLPM01|Biological: 30 microgram VLPM01|Other: Plasmodium falciparum challenge,VLP Therapeutics,Phase 1,36,Industry,"March 13, 2019","May 21, 2020","May 21, 2020"
4247,NCT03867253,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,Mild to Moderate Alzheimer's Disease,Drug: ORY-2001 Low dose|Drug: ORY-2001 High dose|Drug: Placebo,Oryzon Genomics S.A.|Alzheimer's Drug Discovery Foundation,Phase 2,24,Industry|Other,"May 16, 2019","November 12, 2020","November 12, 2020"
4248,NCT03867123,A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients,Glioblastoma (GBM),Drug: LAM561|Radiation: RT|Drug: TMZ,Laminar Pharmaceuticals,Phase 1,18,Industry,"December 4, 2018","July 1, 2020","July 1, 2020"
4249,NCT03867097,Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2),Raynaud Phenomenon Secondary to Systemic Sclerosis,"Drug: Placebo IV infusion|Drug: Iloprost Injection, for intravenous use","Eicos Sciences, Inc.",Phase 2,41,Industry,"March 4, 2019","September 30, 2019","September 30, 2019"
4250,NCT03866811,Reducing Teen Pregnancy in the Emergency Department,Reproductive Behavior|Sexual Behavior|Adolescent Behavior|Contraception,Behavioral: Dr. Erica,Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2,146,Other|NIH,"March 3, 2019","July 2, 2020","July 2, 2020"
4251,NCT03866369,Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose,Healthy Subjects,Drug: Moxifloxacin|Drug: Placebo|Drug: Lanifibranor,Inventiva Pharma|Parexel,Phase 1,36,Industry,"January 17, 2019","August 27, 2019","August 27, 2019"
4252,NCT03865953,Oral LAT8881 in Neuropathic Pain,Neuropathic Pain|Diabetic Peripheral Neuropathy (DPN)|Post Herpetic Neuralgia (PHN),Drug: LAT8881|Drug: Placebo,Lateral Pharma Pty Ltd,Phase 2,53,Industry,"April 9, 2019","April 19, 2020","May 3, 2020"
4253,NCT03865732,Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study),PCDH19-Related Epilepsy,Drug: Ganaxolone|Drug: Placebo,Marinus Pharmaceuticals,Phase 2,29,Industry,"May 17, 2019","January 19, 2021","June 20, 2022"
4254,NCT03865680,Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth,White Spot Lesion,Drug: CPP-ACP|Drug: Duraphat,Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,180,Other,"April 28, 2019","March 25, 2020","April 10, 2020"
4255,NCT03865446,Evaluate Severe Hepatic Impairment on Dacomitinib PK,Severe Hepatic Impairment,Drug: Dacomitinib,Pfizer,Phase 1,16,Industry,"April 5, 2019","October 24, 2019","October 24, 2019"
4256,NCT03865238,"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine",Enterovirus 71 Infection,Biological: EV71vac|Biological: Placebo,Medigen Vaccine Biologics Corp.,Phase 3,3061,Industry,"April 23, 2019","April 16, 2021","April 16, 2021"
4257,NCT03865121,Pilot Trial of Transnasal Nicotine in Parkinson Disease,Parkinson Disease,Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY),El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Howard University,Phase 2,6,Other,"March 4, 2019","November 2, 2019","November 2, 2019"
4258,NCT03864601,A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants,Healthy,Drug: 14C-JNJ-56136379,"Janssen Research & Development, LLC",Phase 1,6,Industry,"April 9, 2019","June 14, 2019","June 14, 2019"
4259,NCT03864458,Dose-finding Study of KHK7791 in Hyperphosphatemia Patients,Hyperphosphatemia,Drug: KHK7791|Drug: Placebo,"Kyowa Kirin Co., Ltd.",Phase 2,207,Industry,"April 15, 2019","December 10, 2019","December 31, 2019"
4260,NCT03864445,Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients,Hyperphosphatemia,Drug: KHK7791|Drug: Placebp,"Kyowa Kirin Co., Ltd.",Phase 2,47,Industry,"April 29, 2019","December 3, 2019","December 3, 2019"
4261,NCT03864432,"An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)",Type 2 Diabetes Mellitus,Drug: Gemigliptin 25mg|Drug: Gemigliptin 50mg|Drug: Gemigliptin 100mg|Drug: Gemiglptin 50mg multiple dose,LG Chem,Phase 1,48,Industry,"July 2, 2019","October 3, 2019","February 28, 2020"
4262,NCT03863574,Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis,Non Alcoholic Steatohepatitis,Drug: Saroglitazar Magnesium 2mg|Drug: Saroglitazar Magnesium 4mg|Drug: Placebos,Zydus Therapeutics Inc.,Phase 2,16,Industry,"June 12, 2019","July 2, 2020","October 30, 2020"
4263,NCT03863080,A Study of RVT-1401 in Myasthenia Gravis (MG) Patients,Myasthenia Gravis,Drug: RVT-1401|Drug: Placebo,Immunovant Sciences GmbH,Phase 2,17,Industry,"May 21, 2019","October 7, 2020","December 21, 2020"
4264,NCT03863015,IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest,Heart Arrest|Out-Of-Hospital Cardiac Arrest|Systemic Inflammatory Response Syndrome,Drug: Tocilizumab 20 Mg/mL Intravenous Solution|Drug: isotonic saline,"Christian Hassager|Rigshospitalet, Denmark",Phase 2,80,Other,"March 4, 2019","December 23, 2019","June 30, 2020"
4265,NCT03862807,Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant,"Amyloidosis, Familial|Transthyretin Amyloidosis",Drug: Patisiran,Alnylam Pharmaceuticals,Phase 3,24,Industry,"March 27, 2019","October 6, 2020","October 20, 2020"
4266,NCT03862391,Does Low Flow Anesthesia Reduce Postanaesthetic Emergence Agitation?,"Agitated; State, Acute Reaction to Stress",Drug: Analgesics|Drug: Antiemetics,Sakarya University,Phase 4,60,Other,"June 1, 2018","November 1, 2019","November 1, 2019"
4267,NCT03861936,BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence,Masseter Muscle Prominence,Biological: OnabotulinumtoxinA|Drug: Normal saline,Allergan,Phase 2,150,Industry,"May 16, 2019","April 3, 2020","July 2, 2020"
4268,NCT03861780,Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation,Bacteria Microflora Reduction,Drug: Project X 26ml|Drug: Project X 5.1ml|Drug: Prevantics Maxi Swabstick,"Professional Disposables International, Inc.",Phase 3,152,Industry,"April 2, 2019","June 6, 2019","June 6, 2019"
4269,NCT03861611,"A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain.",Back Pain Without Radiation|Low Back Pain,Drug: Ketorolac|Drug: Ibuprofen|Drug: Diclofenac|Behavioral: Educational Intervention,Montefiore Medical Center,Phase 4,198,Other,"July 12, 2019","February 2, 2021","February 2, 2021"
4270,NCT03861481,"A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy",Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP),Drug: Rozanolixizumab|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 2,34,Industry,"March 26, 2019","March 31, 2021","March 31, 2021"
4271,NCT03861416,"""Unifuzol®"" in Patients With Peripheral Arterial Disease",Peripheral Arterial Disease,Drug: L-arginine 1.4% 500 ml|Drug: L-arginine 1.4% 250 ml + placebo 250 ml|Drug: Placebo solution,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 2,360,Industry,"March 16, 2018","September 13, 2019","October 26, 2019"
4272,NCT03861364,Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.,"Hemodynamics Instability|Anesthesia, General|Anesthesia, Intravenous",Drug: Propofol,Helse Fonna,Phase 4,68,Other,"September 3, 2019","May 19, 2020","May 31, 2020"
4273,NCT03861247,Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients,Maintenance Hemodialysis|Hyperphosphatemia,Drug: Phosphate-binder intervention|Dietary Supplement: Phosphorus-restricted dietary intervention,"Chen Jing|Huadong Hospital|Shanghai Tongji Hospital, Tongji University School of Medicine|Huashan Hospital",Phase 3,123,Other,"November 29, 2019","January 3, 2021","April 15, 2021"
4274,NCT03861143,Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis,Ulcerative Colitis,Drug: BT-11 (500 mg)|Drug: BT-11 (1000 mg)|Drug: Placebo,Landos Biopharma Inc.,Phase 2,198,Industry,"August 14, 2019","December 10, 2020","June 17, 2021"
4275,NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,Type 2 Diabetes,Drug: Tirzepatide|Drug: Dulaglutide,Eli Lilly and Company,Phase 3,636,Industry,"May 7, 2019","March 10, 2021","March 31, 2021"
4276,NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Oral antihyperglycemic medication (OAM),Eli Lilly and Company,Phase 3,443,Industry,"March 30, 2019","January 26, 2021","February 16, 2021"
4277,NCT03860974,Serratus Plane Versus Paravertebral Nerve Blocks for Breast Surgery,Breast Surgery,Drug: Serratus Plane block (single injection)|Drug: Paravertebral block (single injection),"University of California, San Diego",Phase 4,100,Other,"May 9, 2019","February 12, 2021","February 13, 2021"
4278,NCT03860948,A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers,Bioequivalence,Drug: Savolitinib Test Preparation|Drug: Savolitinib Reference Preparation,Hutchison Medipharma Limited|Hutchmed,Phase 1,36,Industry,"April 16, 2019","May 2, 2019","May 14, 2019"
4279,NCT03860896,GB004 in Adult Subjects With Active Ulcerative Colitis,Ulcerative Colitis,Drug: GB004|Drug: Placebo,"GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.",Phase 1,34,Industry,"April 24, 2019","December 17, 2019","December 17, 2019"
4280,NCT03860597,Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia,Schizophrenia|Schizo Affective Disorder|Schizoaffective Disorder|Healthy,Drug: Memantine|Drug: Placebos,"University of California, San Diego",Phase 4,42,Other,"April 1, 2018","March 31, 2021","March 31, 2021"
4281,NCT03859739,"Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)",HIV-1 Infection,Drug: MK-8558,Merck Sharp & Dohme LLC,Phase 1,21,Industry,"April 26, 2019","May 29, 2020","May 29, 2020"
4282,NCT03859414,PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians,Asthma|Chronic Obstructive Pulmonary Disease,Drug: Therapeutic Dose 1|Drug: Therapeutic Dose 2|Drug: Supra-therapeutic Dose|Drug: Placebo,Chiesi Farmaceutici S.p.A.,Phase 1,32,Industry,"March 18, 2019","July 24, 2019","July 24, 2019"
4283,NCT03859323,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants",Healthy Volunteers,Drug: SHP681|Other: Placebo,Shire|Takeda,Phase 1,104,Industry,"March 26, 2019","January 6, 2020","January 6, 2020"
4284,NCT03859219,"A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants",Healthy-volunteers,Drug: Rozanolixizumab|Drug: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,65,Industry,"March 18, 2019","April 28, 2020","April 28, 2020"
4285,NCT03858894,Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6,Primary Open-angle Glaucoma and Ocular Hypertension,Drug: DE-117 Ophthalmic Solution QD|Drug: DE-117 Ophthalmic Solution BID,Santen Inc.,Phase 2,98,Industry,"January 28, 2019","June 20, 2019","June 20, 2019"
4286,NCT03858634,"A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases",Chronic Idiopathic Urticaria|Chronic Idiopathic Pruritus|Lichen Planus|Lichen Simplex Chronicus|Plaque Psoriasis,Drug: KPL-716|Drug: Placebo,"Kiniksa Pharmaceuticals, Ltd.",Phase 2,58,Industry,"May 29, 2019","April 1, 2020","June 8, 2020"
4287,NCT03858075,"Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults",Healthy Volunteers,Drug: BLU-782|Drug: Placebo|Drug: BLU-782 taken with food,Blueprint Medicines Corporation,Phase 1,108,Industry,"February 12, 2019","September 11, 2019","September 11, 2019"
4288,NCT03857646,The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns,Prematurity,"Drug: Intralipid, 20% Intravenous Emulsion|Drug: SMOF lipid","The University of Texas Health Science Center, Houston",Phase 4,66,Other,"March 2, 2019","June 11, 2020","June 11, 2020"
4289,NCT03857568,A Trial of SHR0410 Injection in Hemodialysis Participants.,Pruritus,Drug: SHR0410|Drug: Placebo,Atridia Pty Ltd.,Phase 1,8,Industry,"April 15, 2019","November 8, 2019","November 8, 2019"
4290,NCT03857542,A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia,Presbyopia,Drug: Pilocarpine HCl Ophthalmic Solution|Other: Vehicle,Allergan,Phase 3,427,Industry,"March 1, 2019","September 10, 2020","September 10, 2020"
4291,NCT03857425,Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets,Gastritis|H Pylori Infection|Dyspepsia,Drug: Clostridum Butyricum Capsule|Drug: Bacillus Coagulans Tablets|Drug: Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets,Xijing Hospital of Digestive Diseases,Phase 4,150,Other,"March 1, 2019","August 31, 2019","September 15, 2019"
4292,NCT03857399,Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin,Fungal Infection,Drug: Caspofungin,Cttq,Phase 2,32,Industry,"September 17, 2018","December 31, 2019","December 31, 2019"
4293,NCT03857165,"Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients","Gout, Hyperuricemia",Drug: SAP-001,"Shanton Pharma Co., Ltd.",Phase 1,24,Industry,"September 24, 2018","June 2, 2019","October 31, 2019"
4294,NCT03856996,"A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells",HIV Infections,Biological: Stable CH505TF gp120|Biological: Transient CH505TF gp120|Biological: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE),National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,30,NIH,"May 23, 2019","March 16, 2021","September 7, 2021"
4295,NCT03856970,"Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers",Healthy Volunteers,Drug: Microgestin®|Drug: Levothyroxine|Drug: Glyburide|Drug: Digoxin|Drug: IW-3718,"Ironwood Pharmaceuticals, Inc.",Phase 1,87,Industry,"March 11, 2019","June 25, 2019","July 3, 2019"
4296,NCT03856866,Hydroxychloroquine Administration for Reduction of Pexophagy,Zellweger Syndrome|Peroxisome Biogenesis Disorders,Drug: Hydroxychloroquine|Drug: Placebo,The Hospital for Sick Children,Phase 2,3,Other,"January 11, 2019","May 5, 2020","May 5, 2020"
4297,NCT03856827,A Study of IW-6463 in Healthy Volunteers,Other,Drug: IW-6463|Drug: Matching Placebo,Cyclerion Therapeutics,Phase 1,110,Industry,"February 6, 2019","October 22, 2019","October 22, 2019"
4298,NCT03856788,Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery,Laparoscopic Sleeve Gastrectomy|Subcostal Transversus Abdominis Plane Block,Drug: Saline|Drug: Bupivacaine,Icahn School of Medicine at Mount Sinai,Phase 4,43,Other,"December 10, 2018","March 25, 2021","March 25, 2021"
4299,NCT03856541,A Study of SHR-A1403 in Patients With Advanced Solid Tumor,Advanced Solid Tumor,Drug: SHR-A1403,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,9,Industry,"February 13, 2019","December 30, 2019","May 7, 2020"
4300,NCT03856359,Trial of Rifaximin in Probable Alzheimer's Disease,Alzheimer's Disease,Drug: Rifaximin 550 milligrams (MG),"Duke University|Bausch Health Americas, Inc.",Phase 2,10,Other|Industry,"April 9, 2019","November 19, 2020","November 19, 2020"
4301,NCT03856047,Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.,Overweight|Obesity,Drug: NNC0174-0833|Drug: Placebo (NNC0174-0833)|Drug: Liraglutide 3.0 mg|Drug: Placebo (Liraglutide 3.0 mg),Novo Nordisk A/S,Phase 2,706,Industry,"March 1, 2019","March 2, 2020","March 25, 2021"
4302,NCT03854812,Magnesium Sulphate Versus Fentanyl Sedation During Burr-hole Surgery,Monitored Anesthesia Care,Drug: Magnesium Sulphate|Drug: Fentanyl|Drug: Propofol,Kasr El Aini Hospital,Phase 2,32,Other,"March 1, 2019","October 12, 2019","October 12, 2019"
4303,NCT03854578,A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions,"Depressive Disorder, Major",Drug: BI 1358894|Drug: Placebo matching BI 1358894|Drug: Citalopram,Boehringer Ingelheim,Phase 1,73,Industry,"March 12, 2019","August 27, 2019","September 23, 2019"
4304,NCT03854552,A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.,Healthy,Drug: BI 764198|Drug: Placebo,Boehringer Ingelheim,Phase 1,72,Industry,"March 15, 2019","August 7, 2019","August 7, 2019"
4305,NCT03854305,Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease,Crohn's Disease,Drug: PRV-6527|Drug: Placebo,"Provention Bio, Inc.",Phase 2,93,Industry,"March 20, 2018","August 13, 2019","August 13, 2019"
4306,NCT03853694,Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section,Elective Cesarean Section|Pain Management,Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Drug: 150 mcg Duramorph + multi-modal pain regimen|Drug: Exparel TAP + multi-modal pain regimen,"Pacira Pharmaceuticals, Inc",Phase 4,167,Industry,"March 4, 2019","January 9, 2020","January 16, 2020"
4307,NCT03853551,Osimertinib Study in Indian Patients,Non Small Cell Lung Cancer (NSCLC),Drug: Osimertinib,AstraZeneca,Phase 4,60,Industry,"April 18, 2019","April 15, 2020","April 15, 2020"
4308,NCT03853421,Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin,Safety and Tolerability,Drug: Sevuparin,Modus Therapeutics AB,Phase 1,24,Industry,"February 6, 2019","May 6, 2019","May 6, 2019"
4309,NCT03852901,Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production,Empaglifozin|Physiological Effects of Drugs|Hypoglycemic Agents|Sodium-Glucose Transporter 2 Inhibitors,Drug: empagliflozin (Jardiance) 25 mg,National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),Phase 1,21,NIH,"March 28, 2019","November 12, 2020","December 13, 2021"
4310,NCT03852862,Double Regional Anesthesia in Video Assisted Thoracoscopy,Video Assisted Thoracoscopy|Anesthesia,Drug: Serratus plane block and paravertebral block|Drug: paravertebral block,"University Hospital, Rouen",Phase 4,112,Other,"May 8, 2019","November 10, 2020","November 10, 2020"
4311,NCT03852537,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,Pneumonia,Drug: Methylprednisolone|Other: Usual Care,Mayo Clinic,Phase 2,44,Other,"December 2, 2019","November 17, 2020","November 17, 2020"
4312,NCT03852524,Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention,Postoperative Ileus,Drug: Methylnaltrexone|Other: Placebo,Ohio State University,Phase 2,82,Other,"February 21, 2019","April 4, 2021","May 12, 2021"
4313,NCT03852472,Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA),Hidradenitis Suppurativa|Acne Inversa,Drug: Avacopan|Other: Placebo,ChemoCentryx,Phase 2,435,Industry,"December 28, 2018","July 30, 2020","March 9, 2021"
4314,NCT03851705,A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH),Homozygous Familial Hypercholesterolemia,Drug: Inclisiran Sodium for injection|Drug: Placebo|Drug: Placebos,Novartis Pharmaceuticals|Novartis,Phase 3,56,Industry,"February 6, 2019","March 2, 2020","September 9, 2021"
4315,NCT03850886,Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients,Non Alcoholic Fatty Liver Disease,Dietary Supplement: Niacinamide Oral Tablet|Drug: Antidiabetic,Ain Shams University,Phase 2,61,Other,"January 15, 2019","August 7, 2019","August 7, 2019"
4316,NCT03850587,Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee,"Osteoarthritis, Knee",Drug: Celecoxib 200mg|Drug: Tramadol 37.5Mg+ Celecoxib 200mg|Drug: Tramadol 75mg+ Celecoxib 200mg|Drug: Tramadol 150mg+ Celecoxib 200mg,"Yooyoung Pharmaceutical Co., Ltd.|CliPS Co., Ltd",Phase 2,261,Industry,"August 30, 2018","May 12, 2020","September 7, 2020"
4317,NCT03850483,"Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis",Psoriasis,Drug: PF-06700841|Drug: Vehicle (Placebo),Pfizer,Phase 2,344,Industry,"April 8, 2019","April 20, 2021","April 20, 2021"
4318,NCT03849729,Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery,Obesity|Morbid Obesity|Bariatric Surgery|Non-alcoholic Fatty Liver|Weight Loss,Drug: Phentermine|Other: Placebo,Hospital Juarez de Mexico,Phase 4,92,Other,"March 1, 2018","April 1, 2020","April 1, 2020"
4319,NCT03849508,Phenylephrine Versus Norepinephrine for Maintenance of Hemodynamic During Cesarean Section Under Spinal Anesthesia,Cesarean Section Complications|Spinal Anesthesia,Drug: Norepinephrine|Drug: Phenylephrine,Centre Hospitalier Régional d'Orléans,Phase 4,124,Other,"February 27, 2019","December 2, 2020","December 2, 2020"
4320,NCT03849404,"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis",Plaque Psoriasis,Biological: Adalimumab,Alvotech Swiss AG,Phase 3,413,Industry,"February 20, 2019","December 23, 2019","July 20, 2020"
4321,NCT03849313,"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)",Healthy Volunteers,Drug: Adalimumab,Alvotech Swiss AG,Phase 1,390,Industry,"March 20, 2019","February 17, 2020","February 17, 2020"
4322,NCT03848793,A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.,"Diabetes Mellitus, Type 2",Drug: HS-20004,"Jiangsu HengRui Medicine Co., Ltd.",Phase 2,128,Industry,"March 6, 2019","June 4, 2020","December 14, 2020"
4323,NCT03848507,Impact of Hyperoncotic Albumin to Support Blood Loss Replacement,"Blood Loss, Surgical|Fluid Retention",Drug: albumin 20%,"University Hospital Inselspital, Berne",Phase 4,24,Other,"March 18, 2019","February 12, 2020","February 18, 2020"
4324,NCT03848416,A Study of Ixekizumab in Healthy Participants,Healthy,Biological: Ixekizumab,Eli Lilly and Company,Phase 1,99,Industry,"January 29, 2019","June 7, 2019","June 7, 2019"
4325,NCT03848221,Direct Application of Systane Complete to Contact Lenses,Dry Eye|Contact Lens Complication,Drug: Systane Complete|Drug: Sensitive Eyes Rewetting Drops,University of Alabama at Birmingham|Alcon Research,Phase 4,73,Other|Industry,"May 28, 2019","October 20, 2019","October 20, 2019"
4326,NCT03848208,A Single Dose-escalation Study of Cytisine in Adult Smokers,Smoking Cessation,Drug: cytisine|Drug: placebo,Achieve Life Sciences,Phase 1,74,Industry,"February 28, 2019","September 12, 2019","September 12, 2019"
4327,NCT03848065,"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)",Pneumococcal Infections,Biological: V114|Biological: Pneumococcal 13-valent Conjugate Vaccine (PCV13),Merck Sharp & Dohme LLC,Phase 1,133,Industry,"April 2, 2019","June 24, 2020","June 24, 2020"
4328,NCT03847974,Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003,Hypercholesterolemia,Drug: LIB003,LIB Therapeutics LLC,Phase 2,32,Industry,"February 14, 2019","April 7, 2020","August 31, 2020"
4329,NCT03847506,Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets,"Hypertension, Hyperlipidemia",Drug: Ezetimibe/Rosuvastatin|Drug: Candesartan cilexetil/Amlodipine besylate|Drug: Candesartan cilexetil,HK inno.N Corporation,Phase 4,127,Industry,"July 5, 2018","December 2, 2020","December 2, 2020"
4330,NCT03847207,"A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310",Healthy,Drug: HTL0030310|Drug: Pasireotide|Drug: Placebo,Heptares Therapeutics Limited,Phase 1,42,Industry,"February 13, 2019","April 1, 2020","September 3, 2020"
4331,NCT03846973,Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid,Tranexamic Acid,Drug: Tranexamic Acid|Other: Placebo,Hamad Medical Corporation,Phase 3,220,Industry,"December 2, 2018","January 31, 2021","February 10, 2021"
4332,NCT03846648,CyPep-1 in Cutaneous Warts,Cutaneous Warts,Drug: Cypep-1,"Centre for Human Drug Research, Netherlands",Phase 1,56,Other,"March 11, 2019","December 20, 2019","December 20, 2019"
4333,NCT03846453,A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes,Dry Eye,Biological: HL036 Ophthalmic Solution|Biological: Placebo,"HanAll BioPharma Co., Ltd.|Daewoong Pharmaceutical Co. LTD.",Phase 3,637,Industry,"March 10, 2019","November 22, 2019","November 22, 2019"
4334,NCT03846427,Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma,Marginal Zone Lymphoma,Drug: Zanubrutinib,BeiGene,Phase 2,68,Industry,"February 19, 2019","January 18, 2021","May 4, 2022"
4335,NCT03845387,A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.,Parkinson Disease,Drug: KDT-3594|Drug: Pramipexole,"Kissei Pharmaceutical Co., Ltd.",Phase 2,74,Industry,"February 26, 2019","February 21, 2020","February 21, 2020"
4336,NCT03845231,Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route,Influenza,Biological: Flucelvax(R)|Other: Human Challenge virus,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 2,82,NIH,"April 29, 2019","December 20, 2019","October 28, 2020"
4337,NCT03845153,Metformin Effect on Fracture Healing in Post-Menopausal Women,Bone Fracture,Drug: Metformin Retard 850 mg|Other: Placebo,Damanhour University,Phase 4,40,Other,"January 1, 2019","January 1, 2021","January 1, 2021"
4338,NCT03845075,"48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)",Hypothalamic Injury-induced Obesity (HIO),Drug: Tesofensine|Drug: Placebo,Saniona,Phase 2,21,Industry,"February 20, 2019","October 16, 2020","October 16, 2020"
4339,NCT03845023,Trial of AD036 in Obstructive Sleep Apnea,Obstructive Sleep Apnea,Drug: AD036 Dose 1|Drug: AD036 Dose 2|Drug: AD036 Dose 3|Drug: Placebo,Apnimed,Phase 2,140,Industry,"March 7, 2019","October 23, 2019","October 23, 2019"
4340,NCT03844984,Lidocaine-Ketamine Versus Ketamine for Induction of Anesthesia in Septic Shock Patients,Septic Shock,Drug: ketamine full dose|Drug: Midazolam|Drug: Normal saline|Drug: ketamine half dose|Drug: Lidocaine,Cairo University,Phase 3,43,Other,"February 20, 2019","September 20, 2019","September 20, 2019"
4341,NCT03844945,"Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan",Open Angle Glaucoma|Ocular Hypertension,Drug: Netarsudil Ophthalmic Solution 0.01%|Drug: Netarsudil Ophthalmic Solution 0.02%|Drug: Netarsudil Ophthalmic Solution 0.04%|Other: Netarsudil Ophthalmic Solution Placebo,Aerie Pharmaceuticals,Phase 2,215,Industry,"March 19, 2019","September 19, 2019","September 19, 2019"
4342,NCT03844841,The Deep Sedation for Ablation Study,Atrial Fibrillation|Ablation|Sedation|Propofol|Dexmedetomidine,Drug: Propofol|Drug: Dexmedetomidine,"University Hospital Inselspital, Berne",Phase 4,160,Other,"July 1, 2019","December 31, 2020","December 31, 2020"
4343,NCT03844555,Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients,Renal Impairment|Renal Insufficiency|Kidney Diseases|Pharmacokinetics,Drug: Elafibranor,Genfit,Phase 1,23,Industry,"February 28, 2019","March 15, 2020","March 21, 2020"
4344,NCT03844191,A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4,Coronary Disease,Drug: RUC-4 Compound,CeleCor Therapeutics|Precision For Medicine|CirQuest Labs|CRL,Phase 1,44,Industry|Other,"February 18, 2019","November 1, 2019","December 1, 2019"
4345,NCT03844074,A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD),Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration|Wet Macular Degeneration,Biological: bevacizumab|Biological: ranibizumab,"Outlook Therapeutics, Inc.",Phase 3,61,Industry,"October 1, 2018","July 23, 2020","August 13, 2020"
4346,NCT03843931,Saline Injections vs Education and Exercise in Knee Osteoarthritis,"Osteoarthritis, Knee",Behavioral: GLA:D|Drug: Intra-articular saline injection,Marius Henriksen|Frederiksberg University Hospital,Phase 2,206,Other,"August 5, 2019","December 2, 2020","December 18, 2020"
4347,NCT03843632,Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058),Varicella,Biological: VARIVAX™,Merck Sharp & Dohme LLC,Phase 3,150,Industry,"March 1, 2019","June 19, 2020","June 19, 2020"
4348,NCT03843541,"A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions",Respiratory Tract Diseases|Abnormal Mucus Secretions,Drug: N-acetylcysteine (NAC) 600 mg|Drug: Ambroxol hydrochloride 30 mg|Other: placebo,Zambon SpA,Phase 3,333,Industry,"June 25, 2019","January 23, 2021","February 5, 2021"
4349,NCT03843502,A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics,Pharmacokinetics,Drug: Kava Dietary Supplement,"University of Florida|National Center for Complementary and Integrative Health (NCCIH)|Thorne HealthTech, Inc",Phase 1,10,Other|NIH|Industry,"February 26, 2020","April 21, 2021","July 13, 2021"
4350,NCT03843281,Efficacy of Paracetamol in Addition to Morphine to Improve Analgesia in the Emergency Department,Analgesia,Drug: Paracetamol|Drug: Placebo|Drug: Morphine,Bruno Minotti|Cantonal Hospital of St. Gallen,Phase 4,222,Other,"May 2, 2019","October 15, 2020","October 15, 2020"
4351,NCT03843151,A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood,Healthy,Drug: BI 1358894|Drug: Itraconazole,Boehringer Ingelheim,Phase 1,16,Industry,"March 19, 2019","June 3, 2019","June 3, 2019"
4352,NCT03843112,Modulating the Vaginal Microbiome After Implantation Failure,"Implantation Failure|Infertility, Female|Vaginal Flora Imbalance",Drug: Vivag Plus|Drug: Placebo - Cap,Zealand University Hospital|ARTPred|Bifodan A/S,Phase 4,74,Other,"March 1, 2019","January 5, 2021","February 27, 2021"
4353,NCT03842904,A Study Comparing the Effects of Trimbow to Fostair in COPD,Chronic Obstructive Pulmonary Disease (COPD),Drug: Trimbow pMDI|Drug: Fostair pMDI,Medicines Evaluation Unit Ltd|Chiesi UK,Phase 4,23,Industry,"December 13, 2018","July 30, 2019","August 6, 2019"
4354,NCT03842761,A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems,Healthy|Hepatic Insufficiency,Drug: BI 685509|Drug: Placebo,Boehringer Ingelheim,Phase 1,64,Industry,"March 6, 2019","April 9, 2021","May 20, 2021"
4355,NCT03842436,Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use,"HIV/AIDS|Substance Use Disorders|Adherence, Medication",Device: Digital pill|Drug: Truvada,Brigham and Women's Hospital|Gilead Sciences,Phase 4,16,Other|Industry,"October 1, 2018","April 22, 2020","April 22, 2020"
4356,NCT03842202,A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity,Overweight|Obesity,Drug: Semaglutide|Drug: Placebo,Novo Nordisk A/S,Phase 1,72,Industry,"February 15, 2019","November 4, 2019","November 4, 2019"
4357,NCT03841812,Comparation Analgesia Efficiency With Propofol Combine Sevoflurane vs Propofol,Nociceptive Pain|Analgesic Adverse Reaction|Inhalant Use,Drug: 5mg/kg/h Propofol|Drug: Sevoflurane|Drug: 2 mg/kg/h Propofol,China International Neuroscience Institution,Phase 3,146,Other,"January 20, 2020","June 1, 2020","July 1, 2020"
4358,NCT03841630,A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants,Healthy,Drug: LY3437943|Drug: Placebo,Eli Lilly and Company,Phase 1,45,Industry,"March 13, 2019","July 25, 2019","July 25, 2019"
4359,NCT03841604,Effect of Safinamide on Parkinson's Disease Related Chronic Pain,Idiopathic Parkinson Disease,Drug: Safinamide Methanesulfonate|Other: Safinamide methanesulfonate matching placebo,Zambon SpA,Phase 4,94,Industry,"April 9, 2019","April 30, 2021","May 3, 2021"
4360,NCT03841526,Glucagon Ready-to-Use for the Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D,Hypoglycemia,Drug: Glucagon RTU Injection|Other: Vehicle for Glucagon RTU Injection,Xeris Pharmaceuticals,Phase 2,48,Industry,"February 27, 2019","March 23, 2020","March 23, 2020"
4361,NCT03841331,"Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin",Pruritus,Drug: 5 mg Serlopitant Tablets|Drug: Matching Placebo Tablets,Vyne Therapeutics Inc.,Phase 2,233,Industry,"January 22, 2019","December 10, 2019","January 21, 2020"
4362,NCT03840837,Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease,Parkinson Disease|Parkinson Disease Dementia,Drug: Rivastigmine transdermal patch,"University of Maryland, Baltimore|National Institute on Aging (NIA)",Phase 4,31,Other|NIH,"May 2, 2019","April 1, 2020","April 1, 2020"
4363,NCT03840811,Experimental Human Infection With Neisseria Gonorrhoeae,Gonococcal Infection,Drug: Cefixime|Drug: Ceftriaxone|Drug: Ciprofloxacin|Biological: Neisseria gonorrhoeae strain FA1090 A26|Biological: Neisseria gonorrhoeae strain FA7537,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,27,NIH,"April 23, 2017","November 25, 2019","November 25, 2019"
4364,NCT03840616,Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections,Recurrent Vulvovaginal Candidiasis,Drug: Oteseconazole (VT-1161) 150mg capsule|Drug: Fluconazole 150mg capsule|Drug: Placebo,Mycovia Pharmaceuticals Inc.,Phase 3,219,Industry,"March 13, 2019","December 2, 2020","December 2, 2020"
4365,NCT03840174,Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003),Cytomegalovirus Infections,Biological: V160|Other: Placebo,Merck Sharp & Dohme LLC,Phase 1,18,Industry,"March 8, 2019","November 7, 2019","November 7, 2019"
4366,NCT03839875,Evaluation of Efficacy and Safety of Gynomax® XL Ovule,Trichomonal Vaginitis|Bacterial Vaginosis|Candidal Vulvovaginitis|Mixed Vaginal Infections,Drug: Gynomax® XL Vaginal Ovule,Exeltis Turkey|Monitor CRO,Phase 4,116,Industry,"April 3, 2019","August 9, 2019","August 9, 2019"
4367,NCT03839485,Endodontic Treatment of Primary Teeth With Guedes-Pinto Paste Without Antibiotic,Pulp Disorder,Drug: Endodontic treatment using Guedes-Pinto Paste|Drug: Endodontic using Guedes-Pinto Paste without antibiotic,University of Sao Paulo,Phase 3,98,Other,"June 8, 2018","June 30, 2019","April 10, 2021"
4368,NCT03839251,Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients,Schizophrenia,Drug: abilify maintena,"Chonbuk National University Hospital|Otsuka Pharmaceutical Co., Ltd.",Phase 4,82,Other|Industry,"June 1, 2018","January 22, 2020","September 30, 2020"
4369,NCT03838731,Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge,Cat Allergy|Mild Asthma,Drug: REGN1908-1909|Drug: Placebo,Regeneron Pharmaceuticals,Phase 2,56,Industry,"February 12, 2019","December 21, 2019","April 6, 2020"
4370,NCT03838185,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147",Alzheimer's Disease,Drug: J147|Drug: Placebo,"Abrexa Pharmaceuticals, Inc.|Iqvia Pty Ltd",Phase 1,64,Industry,"January 22, 2019","February 1, 2020","February 1, 2020"
4371,NCT03838133,"A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy",Hallux Valgus,Drug: TLC590|Drug: Naropin®|Drug: Normal Saline|Drug: Bupivacaine,Taiwan Liposome Company,Phase 2,150,Industry,"March 5, 2019","March 31, 2020","March 31, 2020"
4372,NCT03837743,Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis,Plaque Psoriasis,Drug: DUR-928 Topical Solution|Drug: Vehicle Topical Solution,"Durect|Therapeutics, Inc.",Phase 2,25,Industry,"February 21, 2019","November 11, 2019","May 20, 2020"
4373,NCT03837093,Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers,Healthy Volunteers,Drug: ILT101|Drug: Placebo,Assistance Publique - Hôpitaux de Paris|Iltoo Pharma,Phase 1,40,Other|Industry,"June 6, 2019","March 3, 2021","November 6, 2021"
4374,NCT03836703,Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women,Hematologic Pregnancy Complications,Drug: Feroglobin single daily use|Drug: Feroglobin twice daily dose,Ain Shams University,Phase 4,450,Other,"February 1, 2019","July 1, 2020","August 1, 2020"
4375,NCT03836677,A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD,Chronic Obstructive Pulmonary Disease (COPD),Combination Product: BGF|Combination Product: GFF,AstraZeneca,Phase 3,23,Industry,"February 26, 2019","November 11, 2019","November 11, 2019"
4376,NCT03835975,Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination,Pneumococcal Disease,Biological: 13vPnC|Biological: PPSV23|Biological: 20vPnC,Pfizer,Phase 3,875,Industry,"February 12, 2019","February 12, 2020","February 12, 2020"
4377,NCT03835715,Study With Vortioxetine on Emotional Functioning in Patients With Depression,Major Depressive Disorder,Drug: Vortioxetine,H. Lundbeck A/S,Phase 4,150,Industry,"February 5, 2019","February 21, 2020","February 21, 2020"
4378,NCT03834766,Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD,ADHD,"Drug: AMPH ER Tab 5, 10, 15 and 20 mg|Drug: AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg","Tris Pharma, Inc.|Premier Research Group plc",Phase 3,130,Industry,"February 6, 2019","October 19, 2019","October 19, 2019"
4379,NCT03834129,Dexmedetomidine Intra Venous Arthroplasty,Primary Total Knee Arthroplasty,Drug: Dexmedetomidine|Drug: sodium chloride 0.9%,CMC Ambroise Paré,Phase 3,94,Other,"May 13, 2019","January 11, 2020","January 11, 2020"
4380,NCT03833999,"Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea",Motility Disorder of Intestine|Ondansetron|Small Bowel Water,Drug: Ondansetron 8mg|Diagnostic Test: abdominal MRI|Drug: Lactulose|Drug: Placebo oral capsule,University of Nottingham,Phase 4,16,Other,"October 16, 2018","June 27, 2019","June 27, 2019"
4381,NCT03833947,Dexamethasone vs Bicarbonate to Intracuff Lignocaine 2% in General Anaesthesia,Anesthesia|Anesthesia; Adverse Effect|Anesthesia Intubation Complication,Drug: lignocaine+bicarbonate|Drug: lignocaine+dexamethasone,Aligarh Muslim University,Phase 4,100,Other,"March 15, 2019","October 30, 2019","December 30, 2019"
4382,NCT03833661,M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer),Biliary Tract Cancer|Cholangiocarcinoma|Gallbladder Cancer,Drug: M7824,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 2,159,Industry,"March 26, 2019","November 9, 2020","September 30, 2022"
4383,NCT03832738,Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis|Psoriasis|Skin Diseases,Drug: JTE-451 Tablets|Drug: Placebo Tablets,Akros Pharma Inc.,Phase 2,152,Industry,"January 17, 2019","March 13, 2020","March 13, 2020"
4384,NCT03832647,Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne,Acne,Combination Product: Epiduo|Drug: Salicylic Acid|Other: Hydréane légère,Vichy Laboratoires,Phase 4,200,Industry,"February 18, 2019","February 17, 2020","February 17, 2020"
4385,NCT03832465,Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution,Helicobacter Pylori Infection,Drug: Levofloxacin film-coated tablet|Drug: Levofloxacin intravenous solution,Mackay Memorial Hospital,Phase 4,20,Other,"June 14, 2019","July 1, 2020","December 27, 2020"
4386,NCT03832400,Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC),Ulcerative Colitis,Biological: MET-2|Drug: Placebo oral capsule,NuBiyota,Phase 1,11,Other,"February 4, 2019","March 1, 2020","March 1, 2020"
4387,NCT03832192,"Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study",Delirium|Fall Injury,Behavioral: care.coach Avatar (HELP-Protocolized),Victor Wang|National Institute of Nursing Research (NINR)|Pace University|care.coach corporation,Phase 2,351,Industry|NIH|Other,"January 8, 2019","January 7, 2021","January 7, 2021"
4388,NCT03832114,Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted,Glomerulonephritis,Drug: LNP023,Novartis Pharmaceuticals|Novartis,Phase 2,27,Industry,"February 20, 2019","April 23, 2021","April 23, 2021"
4389,NCT03831971,The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers,Opiod Use Disorder,Drug: ANS-6637,National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,26,NIH,"March 1, 2019","August 9, 2019","December 30, 2019"
4390,NCT03831880,Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD,Growth Hormone Deficiency,Drug: Genotropin|Drug: somatrogon,Pfizer,Phase 3,87,Industry,"February 7, 2019","August 28, 2020","August 28, 2020"
4391,NCT03831854,Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine,Reducing Psychological Side Effects of Ketamine,Drug: Lamotrigine 300 MG|Drug: Placebo|Drug: Ketamine,The Cleveland Clinic,Phase 3,46,Other,"January 24, 2019","December 31, 2020","December 31, 2020"
4392,NCT03831607,A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD,Hyperphosphatemia,Drug: KHK7791,"Kyowa Kirin Co., Ltd.",Phase 2,67,Industry,"December 27, 2018","November 26, 2019","November 26, 2019"
4393,NCT03831399,Leucine Supplementation in Sarcopenic Older Individuals,Frail Elderly Syndrome|Sarcopenia,Dietary Supplement: Leucine|Dietary Supplement: Placebo,University of Valencia|Armonea Group - La Saleta|Bonusan BV,Phase 1,59,Other,"February 1, 2019","October 1, 2019","October 14, 2019"
4394,NCT03830905,Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI,Influenza|Acute Respiratory Viral Infections,Drug: XC221|Drug: Placebo,PHARMENTERPRISES LLC|RSV Therapeutics LLC,Phase 2,120,Industry,"January 31, 2019","July 3, 2019","July 3, 2019"
4395,NCT03830762,Xanamem™ in Healthy Elderly Subjects,Safety|Peripheral Neuropathy|Cortisol|Central Nervous System|Cognitive Function|Healthy Ageing|Small Fibre Neuropathy|Cerebrospinal Fluid|Electrocardiography,Drug: Xanamem|Drug: Matching Placebo,Actinogen Medical|ICON plc,Phase 1,42,Industry,"January 21, 2019","December 7, 2019","January 7, 2020"
4396,NCT03830723,Personalized Insemination Treatment Study,Infertility|Intrauterine Insemination|Reproduction,Drug: Follitropin delta,Clinique Ovo,Phase 2,110,Industry,"January 9, 2020","January 20, 2021","September 27, 2021"
4397,NCT03830528,A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects,Parkinson's Disease,Drug: KW-6356 Low Dose|Drug: KW-6356 Middle Dose|Drug: KW-6356 High Dose|Drug: KW-6356 X Dose|Drug: KW-6356 Y Dose|Drug: Placebo,"Kyowa Kirin Co., Ltd.",Phase 1,48,Industry,"February 26, 2019","October 10, 2019","October 10, 2019"
4398,NCT03830489,Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice,Cleansing Quality of the Colon,Drug: polyethylene glycol|Drug: polyethylene glycol plus ascorbic acid,Hospital Universitario de Canarias,Phase 4,260,Other,"February 4, 2019","October 21, 2019","October 30, 2019"
4399,NCT03830333,Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015),Complicated Intra-abdominal Infections,Drug: Ceftolozane/Tazobactam|Drug: Metronidazole|Drug: Meropenem|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 3,268,Industry,"March 20, 2019","October 14, 2020","October 14, 2020"
4400,NCT03830281,A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy,Type 1 Diabetes Mellitus,Drug: Ultra-Rapid Lispro|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,471,Industry,"February 14, 2019","January 6, 2020","January 6, 2020"
4401,NCT03830203,Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate,Rheumatoid Arthritis,Drug: BAT1806|Drug: Actemra(EU-licensed),Bio-Thera Solutions,Phase 3,621,Industry,"December 19, 2018","January 5, 2021","January 5, 2021"
4402,NCT03830125,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects",Idiopathic Pulmonary Fibrosis,"Drug: BBT-877, Single dose|Drug: Placebo group|Drug: BBT-877, Multiple doses","Bridge Biotherapeutics, Inc.|KCRN Research, LLC",Phase 1,88,Industry,"February 13, 2019","November 24, 2019","November 24, 2019"
4403,NCT03829514,Fenofibrate in Type 2 Diabetes,"Diabetes Mellitus, Type II",Drug: Fenofibrate,Medical University of South Carolina,Phase 4,10,Other,"February 4, 2019","March 4, 2020","March 4, 2020"
4404,NCT03829241,Randomized Trial of Adult Participants With Generalized Anxiety Disorder,Generalized Anxiety Disorder,Drug: Troriluzole|Drug: Placebo,"Biohaven Pharmaceuticals, Inc.",Phase 3,881,Industry,"February 19, 2019","January 14, 2020","May 8, 2020"
4405,NCT03828617,Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults,Pneumococcal Disease,Biological: 20vPnC|Biological: 13vPnC,Pfizer,Phase 3,1710,Industry,"February 14, 2019","October 9, 2019","October 9, 2019"
4406,NCT03828539,Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine,Migraine,Biological: Erenumab|Drug: Topiramate|Biological: Erenumab matching placebo|Drug: Topiramate matching placebo,Novartis Pharmaceuticals|Novartis,Phase 4,777,Industry,"February 22, 2019","July 29, 2020","July 29, 2020"
4407,NCT03828474,Sickness Evaluation at Altitude With Acetazolamide at Relative Doses,Acute Mountain Sickness,Drug: Acetazolamide Pill,Stanford University,Phase 1,108,Other,"August 9, 2019","September 29, 2019","September 29, 2019"
4408,NCT03828084,"Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects",Healthy,Drug: Decitabine,"EpiDestiny, Inc.",Phase 1,16,Industry,"April 3, 2019","May 2, 2019","May 3, 2019"
4409,NCT03828058,Envarsus XL Immunosuppression Following Liver Transplantation,Recipients of Liver Transplant,Drug: Envarsus XR|Drug: Prograf,Methodist Healthcare,Phase 2,110,Other,"April 1, 2019","December 31, 2020","December 31, 2020"
4410,NCT03827408,"Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment",Dental Anxiety,Drug: Midazolam group (MDZ)|Drug: Dexmedetomidine group (DEX)|Drug: Combination of Midazolam and Dexmedetomidine (MDZ/DEX),Nourhan M.Aly|Alexandria University|University of Alexandria,Phase 2,72,Other,"November 27, 2017","August 29, 2019","December 22, 2019"
4411,NCT03827395,Safety Study of Hepatitis E Vaccine (HEV239),Hepatitis E|Immunisation,Biological: HEV 239|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,25,NIH,"April 12, 2019","August 28, 2020","August 28, 2020"
4412,NCT03827018,KPL-301 for Subjects With Giant Cell Arteritis,Giant Cell Arteritis,Combination Product: mavrilimumab|Combination Product: placebo|Drug: prednisone,"Kiniksa Pharmaceuticals, Ltd.",Phase 2,70,Industry,"September 20, 2018","August 13, 2020","November 25, 2020"
4413,NCT03826472,Almond Butter and Fasting Glucose,Type2 Diabetes,Other: Almond Butter,Penn State University,Phase 2,10,Other,"March 8, 2019","March 1, 2020","March 1, 2020"
4414,NCT03825887,Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients,Acute Myeloid Leukemia|Stem Cell Leukemia,Drug: Nalbuphine|Drug: Morphine,Children's Cancer Hospital Egypt 57357,Phase 3,80,Other,"February 1, 2018","December 31, 2020","December 31, 2020"
4415,NCT03825380,Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients,Ocular Hypertension|Glaucoma,Drug: Bimatoprost|Drug: Lumigan®,Laboratoires Thea,Phase 3,485,Industry,"November 23, 2018","February 3, 2021","February 24, 2021"
4416,NCT03825315,DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis,Plantar Fasciitis,Biological: DAXI for Injection: LOW Dose|Other: DAXI for Injection: HIGH Dose|Other: Placebo,"Revance Therapeutics, Inc.",Phase 2,155,Industry,"December 31, 2018","June 4, 2020","June 4, 2020"
4417,NCT03825016,Lidocaine Infusion in Hystroscopy,Pain,Drug: Lidocaine Hydrochloride|Drug: Diclofenac Sodium,Ain Shams University,Phase 2,44,Other,"August 1, 2017","January 10, 2020","January 10, 2020"
4418,NCT03824873,Internal Iliac Artery Ligation Before Cesarean Hysterectomy in Morbidly Adherent Placenta,Blood Loss,Procedure: Internal iliac artery ligation|Procedure: cesarean hysterectomy,Ain Shams University,Phase 3,40,Other,"March 1, 2017","January 1, 2020","July 2, 2020"
4419,NCT03824795,"Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD",Clostridium Difficile Infection,Drug: MGB-BP-3,MGB Biopharma Limited|Syneos Health,Phase 2,34,Industry|Other,"February 7, 2019","April 3, 2020","April 3, 2020"
4420,NCT03824678,"Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects",Hepatic Impairment|Healthy Volunteers,Drug: CC-220,Celgene,Phase 1,40,Industry,"February 13, 2019","June 18, 2019","June 18, 2019"
4421,NCT03824665,"Nalbuphine, Fentanyl and no Additive to Local Anaesthetic Mixture","Nalbuphine,Fentanyl and Local Anesthetic Mixture",Drug: Nalbuphine Group|Drug: Fentanyl Group|Drug: Control Group,Cairo University,Phase 4,120,Other,"February 5, 2019","May 10, 2019","May 18, 2019"
4422,NCT03824457,"Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia",Pneumonia,Drug: Rheosorbilact®|Drug: Ringer lactate,Yuria-Pharm,Phase 4,150,Industry,"January 8, 2018","February 17, 2020","February 17, 2020"
4423,NCT03824405,"Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis",Atopic Dermatitis,Drug: BTX 1204|Drug: Vehicle,Botanix Pharmaceuticals,Phase 2,200,Industry,"February 4, 2019","January 27, 2020","March 4, 2020"
4424,NCT03824379,Magnesium Supplementation in Diabetic Nephropathy,Diabetic Nephropathies,Dietary Supplement: Magnesium citrate|Drug: Antidiabetic,Ain Shams University,Phase 2,60,Other,"June 1, 2019","March 1, 2020","March 1, 2020"
4425,NCT03824314,Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section,Cesarean Section Complications,Drug: Midazolam|Drug: Fentanyl,Mohamed Abdelrady Mohamed|Assiut University,Phase 1,80,Other,"May 1, 2019","January 1, 2020","February 1, 2020"
4426,NCT03824080,Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes,Acute Myeloid Leukemia|High-risk Myelodysplastic Syndrome|Low-risk Myelodysplastic Syndrome,Drug: Bemcentinib,"GWT-TUD GmbH|Groupe Francophone des Myelodysplasies|Amsterdam UMC, location VUmc|BerGenBio ASA",Phase 2,45,Other|Industry,"December 20, 2018","July 13, 2020","June 8, 2021"
4427,NCT03823391,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)",Rheumatoid Arthritis (RA),Drug: ABBV-3373|Drug: Placebo for ABBV-3373|Drug: Adalimumab|Drug: Placebo for adalimumab,AbbVie,Phase 2,48,Industry,"March 27, 2019","April 8, 2020","August 26, 2020"
4428,NCT03823352,Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients,"Leukemia, Myeloid, Acute",Drug: Antroquinonol,Golden Biotechnology Corporation,Phase 2,12,Industry,"February 20, 2019","December 31, 2020","December 31, 2020"
4429,NCT03823300,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE),Wet Macular Degeneration,Drug: Faricimab|Drug: Aflibercept|Procedure: Sham Procedure,Hoffmann-La Roche,Phase 3,658,Industry,"March 11, 2019","October 5, 2020","January 7, 2022"
4430,NCT03823287,A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA),Wet Macular Degeneration,Drug: Faricimab|Drug: Aflibercept|Procedure: Sham Procedure,Hoffmann-La Roche,Phase 3,671,Industry,"February 19, 2019","October 26, 2020","January 18, 2022"
4431,NCT03823118,S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer,Small Cell Lung Cancer Recurrent,Drug: S1/Anlotinib,Taizhou Hospital,Phase 2,48,Other,"March 1, 2019","June 28, 2020","April 17, 2021"
4432,NCT03822832,A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated,"Dermatitis, Atopic",Drug: BI 655130|Drug: Placebo,Boehringer Ingelheim,Phase 2,51,Industry,"February 12, 2019","January 17, 2020","July 22, 2020"
4433,NCT03822416,Treating Smokers With Mental Illness,Smoking Cessation|Cigarette Smoking|Schizophrenia|Psychotic Disorders|Major Depressive Disorder|Bipolar Disorder I|Bipolar II Disorder|Mental Illness,Drug: Nicotine patch|Drug: Nicotine lozenge|Behavioral: Therapy|Other: Information,"University of Minnesota|Hennepin County Medical Center, Minneapolis|Brown University",Phase 2,38,Other,"March 1, 2019","May 4, 2020","May 4, 2020"
4434,NCT03822377,Ticagrelor Administered as Standard Tablet or Orodispersible Formulation,ST Elevation Myocardial Infarction|NSTEMI - Non-ST Segment Elevation MI,Drug: Ticagrelor orodispersible tablets|Drug: Ticagrelor standard tablets,Azienda Ospedaliero Universitaria di Sassari|AstraZeneca,Phase 3,130,Other|Industry,"June 27, 2019","August 31, 2020","August 31, 2020"
4435,NCT03822182,Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery,"Rotator Cuff Tear|Pain, Postoperative",Drug: liposomal bupivicaine|Drug: Dexamethasone,Indiana University,Phase 4,78,Other,"October 24, 2018","January 22, 2020","January 22, 2020"
4436,NCT03822091,Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1,Type 1 HEPATO RENAL SYNDROME(HRS),Drug: Terlipressin|Drug: Terlipressin and Noradrenaline,Postgraduate Institute of Medical Education and Research,Phase 3,60,Other,"January 28, 2019","January 30, 2020","January 30, 2020"
4437,NCT03821415,Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome,Dry Eye Syndromes,Drug: RP101,Redwood Pharma AB|Cross Research S.A.,Phase 2,104,Industry,"January 18, 2019","November 18, 2019","November 18, 2019"
4438,NCT03821402,Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity,Upper Limb Spasticity,Biological: DAXI for injection dose LOW DOSE|Biological: DAXI for injection dose MEDIUM DOSE|Biological: DAXI for injection Dose HIGH DOSE|Other: Placebo,"Revance Therapeutics, Inc.",Phase 2,83,Industry,"December 12, 2018","November 23, 2020","November 23, 2020"
4439,NCT03820908,Bisantrene for Relapsed /Refractory AML,Acute Myelogenous Leukemia|Allogeneic Stem Cell Transplantation,Drug: Bisantrene,Sheba Medical Center|Race Oncology Ltd,Phase 2,10,Other|Industry,"July 18, 2019","May 19, 2020","July 22, 2020"
4440,NCT03820414,"Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects",Herpes Zoster|Varicella Zoster,Biological: CRV 101|Biological: Placebo,Curevo Inc|Access to Advanced Health Institute (AAHI)|Mogam Biotechnology Research Institute|Green Cross Corporation,Phase 1,90,Industry|Other,"January 3, 2019","April 4, 2020","April 30, 2020"
4441,NCT03820037,Relative Bioavailability and Bioequivalence of Opicapone,Parkinson Disease,Drug: Ongentys|Drug: BIA 9-1067 (test),Bial - Portela C S.A.,Phase 1,45,Industry,"March 19, 2019","June 9, 2019","June 9, 2019"
4442,NCT03819790,The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians,"Diabetes Mellitus, Type 2",Drug: Basal insulin glargine and lixisenatide|Drug: Basal insulin Basaglar/Lantus + gliclazide MR|Drug: Metformin,LMC Diabetes & Endocrinology Ltd.,Phase 4,119,Other,"October 2, 2018","November 19, 2019","November 19, 2019"
4443,NCT03819647,Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria,Primary Hyperoxaluria,Drug: stiripentol (Diacomit),Biocodex,Phase 2,15,Industry,"May 21, 2019","December 18, 2020","March 8, 2021"
4444,NCT03819270,A Safety Study of LY3372689 Given By Mouth to Healthy Participants,Healthy,Drug: LY3372689|Drug: Placebo,Eli Lilly and Company,Phase 1,23,Industry,"February 5, 2019","June 23, 2019","June 24, 2019"
4445,NCT03819114,Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy,HIV Infections|Tuberculosis,Drug: Levonorgestrel (LNG),AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,122,Other|NIH,"May 6, 2019","November 2, 2020","November 30, 2020"
4446,NCT03819010,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",Breast Cancer,Drug: Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Drug: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib,MedSIR|Pfizer,Phase 2,66,Other|Industry,"May 7, 2019","July 30, 2019","December 31, 2019"
4447,NCT03818828,Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01),Venous Leg Ulcer,Biological: TTAX01|Other: Profore Compression Therapy|Other: Cadexomer Iodine dressing,Tissue Tech Inc.,Phase 2,31,Industry,"February 14, 2019","December 20, 2019","January 28, 2020"
4448,NCT03818815,"A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months",Acute Otitis Media,Combination Product: OP0201|Combination Product: Placebo|Drug: Amoxicillin-clavulanate,"Novus Therapeutics, Inc",Phase 2,103,Industry,"February 21, 2019","March 9, 2020","March 26, 2020"
4449,NCT03817853,"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma",Advanced Follicular Lymphoma,Drug: Obinutuzumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone/Prednisolone/Methylprednisolone|Drug: Vincristine,Hoffmann-La Roche,Phase 4,114,Industry,"February 26, 2019","August 4, 2020","January 25, 2023"
4450,NCT03817788,Randomized Controlled Trail of Polyethylene Glycol vs Sodium Phosphate for Colonic Cleansing of Colonoscopy,Polyethylene Glycol|Sodium Phosphate,Drug: polyethylene glycol|Drug: sodium phosphate,Dong Yang|Xu Hong|Jilin University,Phase 4,586,Other,"April 26, 2019","April 2, 2020","April 12, 2020"
4451,NCT03817619,Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet,Hepatitis C|Deglutition Disorders,Drug: Zepatier whole tablet|Drug: Zepatier crushed tablet,Radboud University Medical Center,Phase 1,11,Other,"March 28, 2019","July 30, 2019","July 30, 2019"
4452,NCT03817580,Comparative Study of Antimicrobial Effectiveness,Bacterial Microflora Reduction,Drug: Project X 26ml|Drug: Project X 5.1ml|Drug: Prevantics Maxi Swabstick,"Professional Disposables International, Inc.",Phase 3,170,Industry,"February 18, 2019","June 4, 2019","June 4, 2019"
4453,NCT03817476,A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood,Healthy,Drug: BI 425809 (Treatment T1)|Drug: BI 425809 (Treatment T2)|Drug: BI 425809 (Treatment R),Boehringer Ingelheim,Phase 1,18,Industry,"February 11, 2019","May 28, 2019","May 28, 2019"
4454,NCT03817424,"A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis",Systemic Lupus Erythematosus|Cutaneous Lupus Erythematosus|Sjogren's Syndrome|Systemic Sclerosis|Polymyositis|Dermatomyositis,Drug: VIB7734|Drug: Placebo,Viela Bio|Viela Bio (acquired by Horizon Therapeutics),Phase 1,31,Industry,"December 13, 2018","July 20, 2020","July 20, 2020"
4455,NCT03816761,Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes,"Diabetes Mellitus, Type 1",Drug: Fast-acting insulin aspart|Device: iLet™,Novo Nordisk A/S,Phase 2,24,Industry,"February 25, 2019","May 31, 2019","June 10, 2019"
4456,NCT03816631,A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment,Hepatic Impairment,Drug: Pimodivir,Janssen-Cilag International NV,Phase 1,42,Industry,"May 28, 2019","April 27, 2020","April 27, 2020"
4457,NCT03816553,"SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer",Recurrent Cervical Carcinoma|Metastatic Cervical Cancer,Drug: SHR-1210|Drug: Apatinib,Sun Yat-sen University,Phase 2,45,Other,"January 19, 2019","April 30, 2020","August 31, 2022"
4458,NCT03815331,Xiaflex® Plus Testosterone Treatment Pilot Study Protocol,Peyronie's Disease (PD),Drug: Xiaflex®|Drug: Aveed,Men's Health Boston,Phase 4,20,Other,"January 14, 2019","December 29, 2020","December 30, 2020"
4459,NCT03815318,Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A,Hemophilia A,Drug: Recombinant Human Coagulation FVIII,"Sinocelltech Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Parexel|Q2 Solutions",Phase 3,73,Industry|Other,"January 21, 2019","January 16, 2020","January 16, 2020"
4460,NCT03815292,Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke,Mild Cognitive Impairment|Ischemic Stroke,Drug: MMH-MAP|Drug: Placebo,Materia Medica Holding,Phase 3,276,Industry,"October 19, 2018","January 27, 2020","January 27, 2020"
4461,NCT03814720,"Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults",Influenza Infection,Biological: VRC-FLUNPF099-00-VP (H1ssF_3928),National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,52,NIH,"April 1, 2019","April 6, 2021","April 6, 2021"
4462,NCT03814642,Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants,Healthy,Drug: Clopidogrel 75 mg|Drug: Tegoprazan 50 mg|Drug: Esomeprazole 20 mg,HK inno.N Corporation,Phase 1,25,Industry,"January 21, 2019","July 22, 2019","July 22, 2019"
4463,NCT03814343,Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis,"Fungal Infection|Onychomycosis|Fungus, Nail",Drug: amphotericin B in 30% DMSO|Drug: 30% DMSO,Mahidol University,Phase 4,19,Other,"January 15, 2019","November 15, 2020","November 30, 2020"
4464,NCT03814005,A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute|Renal Insufficiency|Liver Disease|Neoplasms",Drug: Azacitidine|Drug: Pevonedistat|Drug: Docetaxel|Drug: Paclitaxel|Drug: Carboplatin,Takeda,Phase 1,17,Industry,"July 10, 2019","March 19, 2021","April 19, 2022"
4465,NCT03813992,Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction,Erectile Dysfunction,Drug: MED2005,Futura Medical Developments Ltd.,Phase 3,1005,Industry,"November 1, 2018","July 21, 2019","January 17, 2020"
4466,NCT03813940,"Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)",Condylomata Acuminata|Cervical Cancer,"Biological: HPV Vaccine,135μg/0.5ml|Biological: HPV Vaccine,270μg/1.0ml","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",Phase 1,24,Other|Industry,"January 3, 2019","August 18, 2019","April 1, 2021"
4467,NCT03813199,Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: ABX464 50mg|Drug: Matching Placebo|Drug: ABX464 100mg|Drug: Methotrexate,Abivax S.A.,Phase 2,60,Industry,"July 4, 2019","April 27, 2021","April 27, 2021"
4468,NCT03813186,Effect of Food on Blood Levels of ASTX727,Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia,Drug: ASTX727 + Day 2 Food|Drug: ASTX727 + Day 4 Food,"Astex Pharmaceuticals, Inc.",Phase 1,18,Industry,"November 8, 2018","June 14, 2019","December 16, 2019"
4469,NCT03813160,Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis,Dermatomyositis,Drug: Lenabasum 20 mg|Drug: Lenabasum 5 mg|Drug: Placebo,Corbus Pharmaceuticals Inc.,Phase 3,176,Industry,"December 17, 2018","March 31, 2021","October 5, 2021"
4470,NCT03813069,"Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma",Trachoma,Other: IR3535|Other: Permethrin lower dose|Other: Permethrin higher dose,"London School of Hygiene and Tropical Medicine|Federal Minstry of Health of Ethiopia|Oromia Regional Health Bureau, Ethiopia|The Fred Hollows Foundation, Ethiopia|The Fred Hollows Foundation, UK|The Fred Hollows Foundation, Australia",Phase 2,64,Other,"January 10, 2019","December 23, 2019","December 23, 2019"
4471,NCT03812588,Contact: Developing New Clinical Management Strategies,Major Depressive Disorder,Drug: Escitalopram|Drug: Placebo,New York State Psychiatric Institute|University of Haifa,Phase 4,29,Other,"January 30, 2019","May 27, 2020","August 1, 2021"
4472,NCT03812510,Safety Study of A-101 Topical Solution for the Treatment of Common Warts,Common Wart,Drug: A-101,"Aclaris Therapeutics, Inc.",Phase 3,426,Industry,"February 7, 2019","November 27, 2019","December 20, 2019"
4473,NCT03812328,Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement,Venous Thromboembolism,Drug: SelK2|Biological: Enoxaparin,Tetherex Pharmaceuticals Corporation,Phase 2,207,Industry,"February 20, 2019","October 1, 2019","November 14, 2019"
4474,NCT03812224,A Controlled Trial of Erenumab in Migraine Prevention,Migraine,Drug: Erenumab|Drug: Placebo,Amgen,Phase 3,261,Industry,"April 12, 2019","March 16, 2020","November 25, 2020"
4475,NCT03812198,"A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People",Healthy,"Drug: LEO 32731 modified release tablet|Drug: LEO 32731 blend, hard capsule|Drug: LEO 32731 API, hard capsule|Drug: LEO 32731 soft capsule|Drug: LEO 32731 gastro-resistant capsule|Drug: LEO 32731|Other: Placebo",LEO Pharma,Phase 1,66,Industry,"January 22, 2019","June 13, 2019","June 13, 2019"
4476,NCT03811912,Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata,Alopecia Areata,Drug: CTP-543|Drug: CTP-543 Matching Placebo,Concert Pharmaceuticals,Phase 2,57,Industry,"March 21, 2019","November 21, 2019","November 21, 2019"
4477,NCT03811652,A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors,Non Small Cell Lung Cancer Squamous (NSCLC-Sq)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Small Cell Lung Cancer (SCLC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer (CRC)|Metastatic Castration-resistant Prostate Cancer (mCRPC),Drug: MEDI7247,MedImmune LLC,Phase 1,8,Industry,"December 20, 2018","December 10, 2019","December 10, 2019"
4478,NCT03811574,STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity,Overweight|Obesity,Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,Phase 3,401,Industry,"January 21, 2019","November 20, 2020","November 20, 2020"
4479,NCT03810495,The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers,Opioid Use Disorder,Drug: naltrexone implant,"Go Medical Industries Pty Ltd|National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute|Columbia University|Clinilabs, Inc.",Phase 1,20,Industry|NIH|Other,"April 11, 2019","March 18, 2021","March 22, 2021"
4480,NCT03810235,The OBstetric Lidocaine Patch (OBLido) Trial,"Pain, Postoperative",Drug: Transdermal Lidocaine Patch|Drug: Transdermal Hydrocolloid Placebo Patch,"University of Wisconsin, Madison",Phase 4,66,Other,"February 15, 2019","September 9, 2019","November 30, 2019"
4481,NCT03809949,Opioid Free Versus Opioid Balanced Anesthesia,PONV|Opioid Use,Drug: Fentanyl Opioid anesthesia|Drug: Saline Nonopioid anesthesia,University of Alexandria,Phase 4,60,Other,"January 16, 2019","May 21, 2019","May 22, 2019"
4482,NCT03809910,Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants,Dental Plaque,Device: Reference MTB|Device: Reference PTB|Device: Prototype PTB (Gum line mode)|Device: Prototype PTB (Combined mode),GlaxoSmithKline,Phase 2,40,Industry,"July 8, 2019","August 9, 2019","August 9, 2019"
4483,NCT03809702,Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia,Herpes Zoster,Drug: Pregabalin|Drug: Placebo,B.P. Koirala Institute of Health Sciences|University Grants Commission,Phase 4,82,Other,"July 15, 2018","September 20, 2019","December 30, 2019"
4484,NCT03809611,A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.,Presbyopia,Drug: UNR844-Cl|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,125,Industry,"April 26, 2019","December 16, 2019","December 16, 2019"
4485,NCT03809065,Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension,Tissue Perfusion|Deliberate Hypotension|Sinus Endoscopic Surgery,Drug: Nitroglycerin|Drug: Labetalol,Cairo University,Phase 4,40,Other,"January 19, 2019","May 25, 2019","May 25, 2019"
4486,NCT03809052,"A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects",Safety and Tolerability,Drug: GB1211|Drug: Placebo,Galecto Biotech AB,Phase 1,78,Industry,"January 14, 2019","June 25, 2019","June 25, 2019"
4487,NCT03808844,A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects,Induction of Anesthesia,Drug: HSK3486|Drug: Propofol,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 3,178,Industry,"March 22, 2019","August 14, 2019","September 3, 2019"
4488,NCT03808688,Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Netarsudil Ophthalmic Solution 0.02%,Aerie Pharmaceuticals,Phase 4,261,Industry,"December 27, 2018","July 26, 2019","July 26, 2019"
4489,NCT03808298,Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects,Healthy Volunteers,Drug: Balovaptan therapeutic dose Treatment A|Drug: Balovaptan supra-therapeutic dose Treatment B|Drug: Active control [moxifloxacin] on Day 2 Treatment C|Drug: Active control [Moxifloxacin] on Day 15 Treatment D|Drug: Placebo for Balovaptan Treatment C|Drug: Placebo for Balovaptan Treatment D|Drug: Placebo for Moxifloxacin Treatment A|Drug: Placebo for Moxifloxacin Treatment B|Drug: Moxifloxacin Treatment C|Drug: Placebo for Moxifloxacin Treatment C|Drug: Placebo for Moxifloxacin Treatment D|Drug: Moxifloxacin Treatment D,Hoffmann-La Roche,Phase 1,57,Industry,"February 7, 2019","June 14, 2019","July 13, 2019"
4490,NCT03808259,A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants,Healthy,Drug: (S)-ketamine Oral Thin Film|Drug: (S)-ketamine IV Infusion|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,96,Industry,"December 20, 2018","September 4, 2019","September 4, 2019"
4491,NCT03807921,Anticoagulation for Aortic Bioprosthesis (ANTIPRO),Aortic Valve Stenosis|Aortic Valve Disease|Aortic Valve Insufficiency|Aortic Valve Regurgitation,Drug: Warfarin|Drug: Aspirin,"Instituto Nacional de Cirugia Cardiaca, Uruguay|Universidad de la Republica",Phase 4,140,Other,"January 1, 2019","December 30, 2019","December 31, 2019"
4492,NCT03807882,Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia,Treatment Resistant Schizophrenia,Other: Bilateral M-ECT|Drug: Clozapine,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4,60,Other,"February 1, 2019","May 31, 2020","June 30, 2020"
4493,NCT03807739,A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential,Healthy Volunteers,Drug: GDC-0134 F09 Formulation|Drug: GDC-0134 F15 Formulation|Drug: GDC-0134 F16 Formulation,"Genentech, Inc.",Phase 1,38,Industry,"February 1, 2019","May 30, 2019","May 30, 2019"
4494,NCT03807700,To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive,Denture Retention,Drug: Experimental Denture Adhesive,GlaxoSmithKline,Phase 3,119,Industry,"February 4, 2019","May 4, 2019","May 4, 2019"
4495,NCT03807297,TIVA vs Inhalational Mode of Anaesthesia,Anesthesia Awareness,"Drug: Injection dexmedetomidine|Drug: Injection, Propofol, 10 Mg|Other: sevoflurane|Other: nitrous oxide","Rajiv Gandhi Cancer Institute & Research Center, India",Phase 2,100,Other,"January 10, 2019","November 30, 2019","December 30, 2019"
4496,NCT03807245,Group B Streptococcus Vaccine in Healthy Females,Group B Strep Infection,Biological: GBS-NN/NN2 with Alhydrogel® 25|Biological: Placebo GBS-NN/NN2 with Alhydrogel® 25|Biological: Placebo GBS-NN/NN2 with Alhydrogel® 50|Biological: GBS-NN/NN2 with Alhydrogel® 50,Minervax ApS|Simbec Research,Phase 1,60,Other|Industry,"January 9, 2019","October 14, 2019","May 7, 2020"
4497,NCT03806933,Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines,Moderate to Severe Glabellar Frown Lines,Drug: NT 201,Merz Pharmaceuticals GmbH,Phase 2,241,Industry,"January 23, 2019","September 10, 2020","October 8, 2020"
4498,NCT03806790,Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris,Psoriasis Vulgaris,Drug: LEO 90100 foam|Drug: Dovobet® ointment,LEO Pharma,Phase 3,182,Industry,"January 24, 2019","June 10, 2019","June 10, 2019"
4499,NCT03806595,A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine,Migraine in Children|Posttraumatic Headache,"Drug: Lidocaine 2% Injectable Solution|Drug: Normal Saline Flush, 0.9% Injectable Solution",University of British Columbia,Phase 1,30,Other,"July 3, 2019","December 3, 2020","December 3, 2020"
4500,NCT03806582,Effect of a Higher Blood-pressure on Right Ventricular Function,Blood Pressure|Right Ventricular Dysfunction,Drug: Norepinephrine,Medical Centre Leeuwarden,Phase 4,78,Other,"March 1, 2019","May 15, 2020","May 25, 2020"
4501,NCT03806127,Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome,Irritable Bowel Syndrome,Drug: Vibegron|Drug: Placebo,Urovant Sciences GmbH,Phase 2,222,Industry,"December 31, 2018","September 25, 2020","October 6, 2020"
4502,NCT03805984,"Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers",Lassa Fever,Drug: INO-4500|Drug: Placebo|Device: CELLECTRA® 2000,Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations,Phase 1,60,Industry|Other,"May 9, 2019","October 21, 2020","October 21, 2020"
4503,NCT03805945,Effect of Dexmedetomidine on Parturient Undergoing Elective Cesarean Section.,Cesarean Section,Drug: dexmedetomidine group|Drug: control group,The Affiliated Hospital of Xuzhou Medical University,Phase 4,160,Other,"June 1, 2019","December 2, 2019","December 2, 2019"
4504,NCT03805438,ED90 of 3% Chloroprocaine for Cervical Cerclage,"Cerclage, Cervical",Drug: Chloroprocaine Hcl 3% Inj,Duke University|University of Arkansas,Phase 4,47,Other,"February 7, 2019","October 23, 2020","October 23, 2020"
4505,NCT03805152,Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia,Cervical Dystonia,Drug: Neuronox(R)|Drug: Dysport (R),Rajavithi Hospital,Phase 3,52,Other,"October 25, 2019","January 31, 2021","January 31, 2021"
4506,NCT03804476,Phase 1 Study to Assess AER-271,"Stroke|Stroke, Acute|Stroke, Ischemic",Drug: AER-271|Drug: Placebo,"Aeromics, Inc.|Covance",Phase 1,80,Industry,"June 26, 2018","July 18, 2019","August 28, 2019"
4507,NCT03804268,Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia,Presbyopia,Other: Vehicle|Drug: Pilocarpine HCl Ophthalmic Solution,Allergan,Phase 3,323,Industry,"December 21, 2018","October 31, 2019","October 31, 2019"
4508,NCT03803644,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects",Healthy Volunteer,Drug: CC-92480,Celgene,Phase 1,56,Industry,"December 21, 2018","May 28, 2019","May 28, 2019"
4509,NCT03803605,Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons,HIV-1 Infection,Biological: VRC07-523LS|Drug: Vorinostat (VOR),"University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,15,Other|NIH,"February 12, 2019","January 28, 2021","January 28, 2021"
4510,NCT03803475,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Prostate Cancer,Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI),"Thomas Hope|University of California, San Francisco",Phase 3,485,Other,"October 11, 2018","August 25, 2020","August 25, 2020"
4511,NCT03803371,Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets,Healthy,Drug: Ultracet Tablets|Drug: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer),Pfizer,Phase 4,60,Industry,"March 26, 2019","June 28, 2019","June 28, 2019"
4512,NCT03803241,Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.,Colorectal Cancer,Drug: CD133+ infusion|Other: portal vein embolization,"Hospital San Carlos, Madrid",Phase 2,4,Other,"May 31, 2019","December 31, 2020","June 30, 2021"
4513,NCT03803228,Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders,Fertility Disorders,Drug: DUOSTIM|Drug: Conventional stimuli,Centre Hospitalier Intercommunal Creteil|Laboratoires Genévrier|IBSA Institut Biochimique SA,Phase 3,88,Other|Industry,"September 3, 2018","March 3, 2021","November 24, 2021"
4514,NCT03802916,Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload,Iron Overload Due to Repeated Red Blood Cell Transfusions,Drug: Deferiprone DR tablets 1000 mg (Low dosage)|Drug: Deferiprone DR tablets 1000 mg (High dosage),ApoPharma|Chiesi Canada Corp,Phase 2,30,Industry,"March 6, 2019","December 4, 2019","December 19, 2019"
4515,NCT03802864,Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine,Male Infertility,Drug: Liposomal Bupivacaine|Drug: Standard Bupivacaine,"Weill Medical College of Cornell University|Pacira Pharmaceuticals, Inc",Phase 4,50,Other|Industry,"February 4, 2019","January 30, 2020","January 30, 2020"
4516,NCT03802786,Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects,Hepatic Impairment,Drug: Imeglimin,Poxel SA,Phase 1,14,Industry,"November 6, 2018","July 3, 2019","July 8, 2019"
4517,NCT03802617,A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.,Uremic Pruritus,Drug: MR13A9|Drug: Placebo,"Kissei Pharmaceutical Co., Ltd.|Maruishi Pharmaceutical",Phase 2,247,Industry,"February 1, 2019","October 22, 2019","October 22, 2019"
4518,NCT03802565,Tolperisone in Acute Muscle Spasm of the Back,Back Pain|Acute Pain|Back Spasm Upper Back|Back Strain|Muscle Cramp|Muscle Spasm|Low Back Pain,Drug: Tolperisone|Drug: Placebo,"Neurana Pharmaceuticals, Inc.",Phase 2,415,Industry,"February 1, 2019","June 28, 2019","July 12, 2019"
4519,NCT03802552,Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections,Osteomyelitis|Septic Arthritis|Pyomyositis,Drug: Cefadroxil|Drug: Cephalexin,"University of Colorado, Denver",Phase 1,17,Other,"May 1, 2019","April 30, 2021","April 30, 2021"
4520,NCT03802526,Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2,Healthy,Drug: NVP-1805-R1|Drug: NVP-1805-R2|Drug: NVP-1805-R1 and NVP-1805-R2,NVP Healthcare,Phase 1,37,Industry,"April 3, 2019","July 4, 2019","September 27, 2019"
4521,NCT03802344,"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream",Psoriasis Vulgaris,Drug: MC2-01 cream|Drug: Cal/BDP combination|Drug: Vehicle,MC2 Therapeutics,Phase 3,498,Industry,"December 12, 2018","October 2, 2019","October 2, 2019"
4522,NCT03802292,"First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23",Healthy Volunteers,Biological: YQ23|Biological: Matching Placebo,New Beta Innovation Limited,Phase 1,58,Industry,"January 16, 2019","September 20, 2020","November 20, 2020"
4523,NCT03802201,Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia,β-thalassemia|Ineffective Erythropoiesis|Chronic Anemia,Drug: PTG-300,"Protagonist Therapeutics, Inc.",Phase 2,63,Industry,"December 19, 2018","July 31, 2020","July 31, 2020"
4524,NCT03802162,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355",Alzheimer's Disease (AD),Drug: CKD-355A (D797/Memantine HCl 20mg)|Drug: CKD-355B (D797/Memantine HCl 20mg)|Drug: D797|Drug: D324 (Memantine HCl 10mg),Chong Kun Dang Pharmaceutical,Phase 1,60,Industry,"February 15, 2019","May 10, 2019","August 31, 2019"
4525,NCT03801980,Phase 3 Study of SK-1403,Secondary Hyperparathyroidism,Drug: SK-1403|Drug: Placebo,"Sanwa Kagaku Kenkyusho Co., Ltd.",Phase 3,153,Industry,"January 21, 2019","December 17, 2019","December 21, 2019"
4526,NCT03801967,"A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration",Heart Failure,Drug: AZD9977|Drug: Placebo,AstraZeneca|Parexel,Phase 1,28,Industry,"January 24, 2019","May 2, 2019","May 2, 2019"
4527,NCT03801629,Neuroimmune Effects of Opioid Administration,Drug Effect,Drug: High Morphine Dose|Drug: Low Morphine Dose,Yale University,Phase 1,10,Other,"September 12, 2019","March 10, 2021","March 10, 2021"
4528,NCT03801304,Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,Drug: Atezolizumab|Drug: Vinorelbine,"University Hospital, Brest|Groupe Français de Pneumo-Cancérologie|Roche Farma, S.A|Pierre Fabre Medicament",Phase 2,80,Other|Industry,"January 24, 2019","January 4, 2021","February 23, 2022"
4529,NCT03801265,Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement,Hip Osteoarthritis,Procedure: Lumbar plexus block|Procedure: Quadratus lumborum type 3 block|Drug: Ropivacaine injection,Sharad Khetarpal|University of Pittsburgh,Phase 4,46,Other,"March 19, 2019","May 30, 2020","May 30, 2020"
4530,NCT03800979,Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata,Alopecia Areata,Drug: Tofacitinib,"Institute of Dermatology, Thailand",Phase 4,19,Other,"January 12, 2019","January 30, 2021","January 30, 2021"
4531,NCT03800875,Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting,"Diabetes Mellitus, Type 1",Drug: 27-hour inpatient intervention,McGill University|Diabetes Canada,Phase 2,24,Other,"February 8, 2019","September 19, 2020","September 19, 2020"
4532,NCT03800745,Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy.,Postoperative Passage of Flatus|Postoperative Bowel Movement,Drug: Colace 100Mg Capsule|Drug: Miralax,The Cleveland Clinic|Michael Sprague MD|Pamela Frazzini-Padilla MD|Katherine Smith MD|Jennifer Afton Cooper MD,Phase 4,81,Other,"November 9, 2018","May 5, 2020","May 5, 2020"
4533,NCT03800550,A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants,Healthy,Drug: Bedaquiline|Drug: Clarithromycin,"Janssen Research & Development, LLC",Phase 1,16,Industry,"February 13, 2019","June 4, 2019","June 4, 2019"
4534,NCT03800472,"A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases",Healthy,Drug: GLPG3312 IR|Drug: Placebo|Drug: GLPG3312 MR|Drug: GLPG3312 FE MR,Galapagos NV,Phase 1,95,Industry,"January 15, 2019","March 10, 2020","March 10, 2020"
4535,NCT03800290,Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake,Healthy,Drug: Clenbuterol Hydrochloride|Drug: Placebos,Maastricht University,Phase 2,11,Other,"June 1, 2019","April 23, 2021","April 23, 2021"
4536,NCT03799926,Exploratory Study of ZG-801 for the Treatment of Hyperkalemia,Hyperkalemia,Drug: patiromer|Drug: placebo,Zeria Pharmaceutical,Phase 2,184,Industry,"February 18, 2019","November 6, 2019","February 2, 2021"
4537,NCT03799822,Oral Anticoagulation in Hemodialysis,Atrial Fibrillation,Drug: Rivaroxaban 10 MG Oral Tablet|Dietary Supplement: MK-7 2000µg thrice weekly|Drug: Vitamin K Antagonist - Drug,Onze Lieve Vrouw Hospital,Phase 4,132,Other,"May 1, 2017","September 15, 2020","October 1, 2020"
4538,NCT03799731,Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers,Colorectal Cancer,Drug: GM102|Drug: Trifluridine/Tipiracil|Drug: GM102 expansion,GamaMabs Pharma,Phase 2,65,Industry,"July 11, 2018","January 19, 2021","February 10, 2021"
4539,NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,"Multiple Sclerosis, Chronic Progressive",Biological: NurOwn (MSC-NTF cells),Brainstorm-Cell Therapeutics,Phase 2,23,Industry,"March 13, 2019","March 11, 2021","March 30, 2021"
4540,NCT03799627,Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa,Anemia|Dialysis-dependent Chronic Kidney Disease,Drug: Vadadustat|Drug: Epoetin Alfa|Drug: Vadadustat TIW,Akebia Therapeutics,Phase 2,175,Industry,"January 31, 2019","June 5, 2020","July 15, 2020"
4541,NCT03799510,Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children,Schistosomiasis,Biological: Sm14|Drug: GLA-SE solution,Oswaldo Cruz Foundation|Orygen Biotecnologia SA|Biomedical Research Center EPLS|Access to Advanced Health Institute (AAHI),Phase 2,95,Other,"December 13, 2018","July 1, 2019","August 7, 2019"
4542,NCT03799484,Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment,Forehead Rhytides|Forehead Wrinkles,Drug: Botulinum toxin type A|Drug: 2.5% lidocaine/2.5% prilocaine|Device: petrolatum ointment,"The University of Texas Health Science Center, Houston|Robert Cizik Eye Clinic",Phase 4,14,Other,"January 4, 2019","June 14, 2019","June 14, 2019"
4543,NCT03799198,Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity,Obesity,Other: Weight Management Program (WMP)|Drug: Medication for chronic weight management (Rx),Novo Nordisk A/S,Phase 4,200,Industry,"January 7, 2019","May 22, 2020","May 22, 2020"
4544,NCT03798912,"A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform",Healthy Volunteers,Combination Product: RaniPill capsule containing octreotide,RANI Therapeutics,Phase 1,62,Industry,"July 9, 2019","February 17, 2020","February 17, 2020"
4545,NCT03798561,Study to Evaluate ASN008 Topical Gel (TG),"Dermatitis, Atopic|Pruritus|Dermatitis Eczema",Drug: ASN008 TG|Drug: Placebo TG,Asana BioSciences,Phase 1,24,Industry,"January 14, 2019","March 20, 2020","March 20, 2020"
4546,NCT03798366,A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis,Systemic Sclerosis,Drug: GLPG1690|Drug: Placebo,Galapagos NV,Phase 2,33,Industry,"January 14, 2019","May 21, 2020","June 22, 2020"
4547,NCT03798314,Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma,Recurrent Nervous System Lymphoma|Recurrent Primary Vitreoretinal DLBCL|Refractory Nervous System Lymphoma|Refractory Primary Vitreoretinal DLBCL,Biological: Nivolumab|Drug: Pomalidomide,Mayo Clinic|National Cancer Institute (NCI),Phase 1,3,Other|NIH,"January 30, 2019","December 30, 2020","September 15, 2021"
4548,NCT03798080,Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin,Type 2 Diabetes Mellitus,Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Metformin,Sanofi,Phase 3,426,Industry,"February 19, 2019","December 1, 2020","December 1, 2020"
4549,NCT03798054,Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s),Type 2 Diabetes Mellitus,Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Lixisenatide (AVE0010)|Drug: Metformin|Drug: SGLT2 inhibitor,Sanofi,Phase 3,878,Industry,"February 15, 2019","March 1, 2021","March 1, 2021"
4550,NCT03797872,Psoriatic Oligoarthritis Intervention With Symptomatic thErapy,Psoriatic Arthritis,Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Methylprednisolone|Drug: Triamcinolone,"University of Oxford|National Institute for Health Research, United Kingdom",Phase 4,1,Other,"April 17, 2019","July 16, 2020","July 16, 2020"
4551,NCT03797703,Efficacy of Lidocaine Gel Enema After Endoscopic Hemorrhoid Band Ligation for Relief of Post Procedural Pain,Hemorrhoids,Drug: Lidocaine Hydrochloride 2% gel enema,Advocate Health Care,Phase 1,75,Other,"November 26, 2018","May 29, 2020","June 5, 2020"
4552,NCT03797521,A Study in Patients With Trichotillomania,Trichotillomania,Drug: SXC-2023|Drug: Placebo,"Promentis Pharmaceuticals, Inc.",Phase 2,128,Industry,"December 19, 2018","December 2, 2019","December 16, 2019"
4553,NCT03796910,"A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers",Healthy Volunteers,Drug: SPR720 for SAD|Drug: Placebo for SAD|Drug: SPR720 for MAD|Drug: Placebo for MAD,Spero Therapeutics|Simbec Research,Phase 1,96,Industry,"December 18, 2018","September 24, 2019","September 24, 2019"
4554,NCT03796858,A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy,"Arthritis, Psoriatic",Drug: Guselkumab 100 mg|Drug: Placebo,"Janssen Pharmaceutica N.V., Belgium",Phase 3,285,Industry,"March 22, 2019","November 11, 2020","November 11, 2020"
4555,NCT03796728,A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation,Lip Augmentation,Device: Juvéderm® VOLIFT™ with Lidocaine,Allergan,Phase 4,60,Industry,"December 19, 2018","June 9, 2020","June 9, 2020"
4556,NCT03796676,JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis,Atopic Dermatitis,Drug: Placebo|Drug: PF-04965842|Drug: PF04965842,Pfizer,Phase 3,287,Industry,"February 18, 2019","April 8, 2020","April 8, 2020"
4557,NCT03796637,A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren,Duchenne Muscular Dystrophy,Drug: Ataluren,PTC Therapeutics,Phase 2,6,Industry,"April 11, 2019","June 3, 2019","June 3, 2019"
4558,NCT03796026,A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea,"Sleep Apnea, Obstructive",Drug: Seltorexant 40 mg|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,34,Industry,"January 4, 2019","June 7, 2019","June 14, 2019"
4559,NCT03795922,MT10109L in the Treatment of Glabellar Lines,Glabellar Lines,Drug: MT10109L|Drug: Placebo,Medy-Tox,Phase 3,234,Industry,"December 24, 2018","March 13, 2020","January 25, 2021"
4560,NCT03795441,A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults,Healthy,Biological: Ad26.RSV.preF,Janssen Vaccines & Prevention B.V.,Phase 1,24,Industry,"January 7, 2019","July 28, 2019","July 28, 2019"
4561,NCT03795389,"Study to Assess PK, Safety and Tolerability in Patients With DM and CKD","Chronic Kidney Disease|Chronic Kidney Disease, Stage 3 (Moderate)|Chronic Kidney Disease, Stage 4 (Severe)|Diabetes",Drug: DM199,DiaMedica Therapeutics Inc,Phase 1,33,Industry,"February 12, 2019","July 21, 2019","July 21, 2019"
4562,NCT03795116,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,Fibrosis|Skin Scarring|Skin Wound|Hypertrophic Scar|Scar|Keloid,Device: LED-RL phototherapy|Device: Mock irradiation,State University of New York - Downstate Medical Center,Phase 2,30,Other,"March 18, 2019","October 26, 2020","October 26, 2020"
4563,NCT03794765,Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis,Ulcerative Colitis|Inflammatory Bowel Diseases|Acute Severe Colitis,Drug: Ceftriaxone|Drug: Metronidazole|Other: Placebo infusion,Postgraduate Institute of Medical Education and Research,Phase 2,50,Other,"April 1, 2019","March 4, 2020","April 4, 2020"
4564,NCT03794557,The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD,COPD,Drug: Sterile Water Injection|Drug: PUL-042 Inhalation Solution,"Pulmotect, Inc.|Imperial College Healthcare NHS Trust|VirTus Respiratory Research Ltd|MWB Consulting Ltd|Data Magik Ltd",Phase 2,20,Industry|Other,"January 21, 2019","December 16, 2020","March 23, 2021"
4565,NCT03794544,Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer,Resectable|Early-stage|NSCLC,Drug: Durvalumab|Combination Product: Oleclumab|Combination Product: Monalizumab|Combination Product: Danvatirsen,MedImmune LLC,Phase 2,84,Industry,"March 8, 2019","January 13, 2021","January 13, 2021"
4566,NCT03794336,Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive,Type 2 Diabetes Mellitus,Drug: Alogliptin|Drug: Acarbose|Drug: Metformin|Drug: Aspirin,Sanofi,Phase 4,1293,Industry,"June 29, 2019","December 14, 2020","December 14, 2020"
4567,NCT03794323,A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood,Healthy,Drug: BI 764122|Drug: Placebo,Boehringer Ingelheim,Phase 1,76,Industry,"January 30, 2019","August 12, 2019","August 12, 2019"
4568,NCT03794310,Study of NPF-08 in Patients Who Receive Colonoscopy,Patients Who Receive Colonoscopy,Drug: NPF-08 （1-day treatment）|Drug: NPF-08 （2-day split dose）|Drug: Moviprep（1-day treatment）,"Nihon Pharmaceutical Co., Ltd",Phase 3,632,Industry,"January 5, 2019","June 19, 2019","June 19, 2019"
4569,NCT03794180,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects,Healthy Adult Subjects,Drug: TJ003234|Drug: Placebo,I-Mab Biopharma Co. Ltd.,Phase 1,32,Industry,"March 18, 2019","September 5, 2019","September 5, 2019"
4570,NCT03793751,Effect of Intraoperative Dexmedetomidine on Early Postoperative Cognitive Dysfunction,Cognitive Dysfunction,Drug: Dexmedetomidine Injection,Tata Main Hospital,Phase 4,120,Other,"October 1, 2017","December 1, 2019","December 1, 2019"
4571,NCT03793608,Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy,Peanut Allergy,Drug: Dupilumab,Regeneron Pharmaceuticals|Sanofi,Phase 2,25,Industry,"March 12, 2019","February 19, 2021","May 12, 2021"
4572,NCT03793543,Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer,Prostate Cancer,Drug: 18F-DCFPyL Injection,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 1,23,Other,"March 27, 2019","March 6, 2020","October 15, 2021"
4573,NCT03793439,"Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis","Sarcoidosis, Pulmonary|Sarcoidosis Lung|Sarcoidosis",Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Diagnostic Test: Spirometry|Genetic: RNA Sequencing|Diagnostic Test: Laboratory testing|Drug: Corticosteroid|Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension,Oregon Health and Science University|Pfizer,Phase 1,5,Other|Industry,"May 15, 2019","June 24, 2020","June 24, 2021"
4574,NCT03792997,A Therapeutic Protocol in Previous Failed ART Patients With High Total NK Cells,Unexplained Infertility,Combination Product: combination therapy for high peripheral NK cells,Benha University|Hawaa Fertility Center,Phase 2,100,Other,"January 1, 2019","December 15, 2019","December 10, 2021"
4575,NCT03792672,A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS),Healthy Volunteers,Drug: TAK-653|Drug: Placebo|Drug: Ketamine,Neurocrine Biosciences|Takeda,Phase 1,24,Industry,"February 11, 2019","May 15, 2019","June 18, 2019"
4576,NCT03792555,A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve),Acromegaly,Drug: Paltusotine|Drug: Placebo,Crinetics Pharmaceuticals Inc.,Phase 2,13,Industry,"December 18, 2018","July 15, 2020","August 12, 2020"
4577,NCT03792477,A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males,Hypogonadism,Biological: Test formulation|Biological: Reference formulation,Pfizer,Phase 1,74,Industry,"January 19, 2019","April 2, 2020","April 2, 2020"
4578,NCT03792308,A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers,Healthy Volunteers,Drug: SPR206|Drug: Placebo,Spero Therapeutics|Clinical Network Services (CNS) Pty Ltd,Phase 1,94,Industry,"December 18, 2018","December 23, 2019","December 23, 2019"
4579,NCT03792100,"Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded ""All in One"" for Parenteral Nutrition",Parenteral Nutrition|Surgery,"Drug: SmofKabiven emulsion for infusion|Drug: Hospital compounded ""All in one"" emulsion",Fresenius Kabi|Parexel,Phase 3,273,Industry,"January 3, 2019","January 23, 2020","January 23, 2020"
4580,NCT03791775,Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease,Second-degree Hemorrhoids,Drug: Polidocanol foam (Atossisclerol® 3%),Societa Italiana di Chirurgia ColoRettale|SICCR - Gaetano Gallo,Phase 2,183,Other,"January 2, 2019","June 2, 2019","June 2, 2020"
4581,NCT03791710,Effect of Autologous Fat Grafting on Acute Burn Wound Healing,Burns,Procedure: autologous fat grafting|Drug: Topical Cream|Procedure: split thickness skin grafting,Ahmed Mohamed Abouzaid|Abouqir General Hospital,Phase 3,100,Other,"March 14, 2019","January 31, 2020","January 31, 2020"
4582,NCT03790839,Drug Interaction Study Between Dorzagliatin and Sitagliptin,Patients,Drug: Sitagliptin|Drug: Dorzagliatin,Hua Medicine Limited,Phase 1,15,Industry,"January 31, 2019","August 30, 2019","August 30, 2019"
4583,NCT03790787,Drug Interaction Study Between Dorzagliatin and Empagliflozin,Patients,Drug: Empagliflozin|Drug: Dorzagliatin,Hua Medicine Limited,Phase 1,16,Industry,"April 18, 2019","March 15, 2020","March 15, 2020"
4584,NCT03790488,Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies,Cancer,Drug: JTX-4014,"Jounce Therapeutics, Inc.",Phase 1,18,Industry,"December 6, 2018","July 2, 2019","February 28, 2023"
4585,NCT03790423,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,Breast Cancer|Lung Cancer|Pancreatic Cancer|Ovarian Cancer|Cervix Cancer,Drug: Injection of 18F-ASIS|Other: PET/CT scan,"Rigshospitalet, Denmark",Phase 1,10,Other,"January 3, 2019","November 18, 2019","November 18, 2019"
4586,NCT03790215,Dydrogesterone in the Treatment of Endometrial Polyps,Endometrial Polyp,Drug: Dydrogesterone,Peking Union Medical College Hospital,Phase 4,60,Other,"February 1, 2019","September 30, 2019","December 31, 2019"
4587,NCT03790072,Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML),Acute Myeloid Leukemia,Biological: OmnImmune®,TC Biopharm,Phase 1,10,Industry,"November 27, 2018","March 26, 2021","March 26, 2021"
4588,NCT03790020,"COMPARISON OF TRANSVERSUS ABDOMINIS PLANE BLOCK, LOCAL ANESTHETIC INJECTION TO THE PORT SITES AND INTRAPERITONEAL LOCAL ANESTHESIA APPLICATIONS IN POSTOPERATIVE PAIN MANAGEMENT IN PATIENTS WITH LAPAROSCOPIC APPENDECTOMY",Postoperative Pain,Drug: Bupivacaine,Fatih Sultan Mehmet Training and Research Hospital,Phase 4,3,Other,"November 1, 2018","November 1, 2020","March 1, 2021"
4589,NCT03790007,COMPARISON OF INTRAOPERATIVE LOCAL ANESTHETIC APPLICATIONS IN POSTOPERATIVE PAIN MANAGEMENT IN LAPAROSCOPIC CHOLECYSTECTOMY PATIENTS,Postoperative Pain,Drug: Bupivacaine,Fatih Sultan Mehmet Training and Research Hospital,Phase 4,3,Other,"November 1, 2018","December 1, 2020","March 1, 2021"
4590,NCT03789734,Safety Study of BLS-M22 in Healthy Volunteers,"Muscular Dystrophy, Duchenne",Biological: BLS-M22|Other: Placebo,BioLeaders Corporation,Phase 1,37,Industry,"June 4, 2019","April 23, 2020","November 27, 2020"
4591,NCT03789656,An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge),Acromegaly,Drug: Paltusotine,Crinetics Pharmaceuticals Inc.,Phase 2,47,Industry,"January 15, 2019","August 3, 2020","August 31, 2020"
4592,NCT03789578,A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together,"Diabetes Mellitus, Type 2",Drug: NNC0148-0287sema|Drug: Semaglutide|Drug: NNC0148-0287,Novo Nordisk A/S,Phase 1,30,Industry,"January 17, 2019","October 10, 2019","October 10, 2019"
4593,NCT03789318,Study in Subjects Undergoing Complete Abdominoplasty,Postsurgical Pain,Drug: CA-008 5 mg|Drug: Placebo|Drug: Bupivacaine Hydrochloride|Drug: Hydromorphone|Drug: Fentanyl|Drug: Acetaminophen|Drug: Oxycodone|Drug: CA-008 10 mg|Drug: CA-008 15 mg,Concentric Analgesics,Phase 2,54,Industry,"December 3, 2018","May 16, 2019","June 12, 2019"
4594,NCT03789292,A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Biological: CT-P17 SC|Biological: Humira SC,Celltrion,Phase 3,648,Industry,"November 26, 2018","October 8, 2019","April 24, 2020"
4595,NCT03788967,"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",Complicated Urinary Tract Infection|Acute Pyelonephritis,Drug: TBPM-PI-HBr|Drug: Ertapenem|Drug: Dummy Infusion|Drug: Dummy tablets,Spero Therapeutics,Phase 3,1372,Industry,"June 3, 2019","May 20, 2020","May 27, 2020"
4596,NCT03788616,"Fluoride Release,Compressive Strength and Clinical Performance of a Bioactive Restorative Material in ART",Dental Caries,Drug: Fuji IX EXTRA|Drug: ACTIVA KIDS bioactive restorative material,"Marina F Fahmy, MD|Ain Shams University",Phase 3,110,Other,"November 17, 2018","November 17, 2019","November 17, 2019"
4597,NCT03788395,The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma,Asthma,Device: Symbicort Turbohaler plus Turbo+|Drug: Symbicort Turbohaler without Turbo+,Istituto per la Ricerca e l'Innovazione Biomedica,Phase 4,18,Other,"January 10, 2019","January 23, 2020","January 23, 2020"
4598,NCT03788252,Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease,Chronic Kidney Diseases,Drug: Renamezin,Gumi Cha Medical Center,Phase 4,150,Other,"November 23, 2018","July 14, 2020","July 14, 2020"
4599,NCT03787758,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B",Huntington Disease,Drug: SAGE-718,Sage Therapeutics,Phase 1,6,Industry,"February 28, 2019","October 7, 2019","October 7, 2019"
4600,NCT03787225,"A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity",Obesity|Overweight,Drug: NNC0174-0833|Drug: Placebo (NNC0174-0833),Novo Nordisk A/S,Phase 1,66,Industry,"January 7, 2019","June 4, 2019","June 4, 2019"
4601,NCT03786770,Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis),Frown Lines,Biological: DaxibotulinumtoxinA for injection,"Revance Therapeutics, Inc.",Phase 2,61,Industry,"January 24, 2019","March 9, 2020","March 9, 2020"
4602,NCT03786289,Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection,Healthy Subjects,Biological: Recombinant human serum albumin/erythropoietin fusion protein|Biological: Recombinant erythropoietin injection (CHO cells),Tianjin SinoBiotech Ltd.,Phase 1,34,Industry,"December 3, 2018","July 3, 2019","December 9, 2019"
4603,NCT03785587,A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis,Primary Axillary Hyperhidrosis,"Drug: Sofpironium Bromide Gel, 15%",Botanix Pharmaceuticals,Phase 2,21,Industry,"December 21, 2018","September 6, 2019","September 6, 2019"
4604,NCT03785145,MT10109L in the Treatment of Lateral Canthal Lines,Lateral Canthal Lines,Drug: MT10109L|Drug: Placebo,Medy-Tox,Phase 3,235,Industry,"December 20, 2018","February 27, 2020","January 25, 2021"
4605,NCT03785054,"Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242",Healthy,Drug: HTL0014242|Drug: Placebo oral capsule,Heptares Therapeutics Limited|Covance,Phase 1,71,Industry,"November 14, 2018","March 11, 2021","March 11, 2021"
4606,NCT03784898,Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada,Multiple Sclerosis,Other: Blood draw for future biomarker analysis,"Genzyme, a Sanofi Company|Sanofi",Phase 4,13,Industry,"February 8, 2019","December 11, 2019","December 11, 2019"
4607,NCT03784703,Type 2 Diabetic Patients Maintained on Statin Therapy,Dyslipidemia Associated With Type II Diabetes Mellitus,Drug: Atorvastatin 40 Mg Oral Tablet|Drug: Rosuvastatin 10 Mg Oral Tablet,Damanhour University|Tanta University,Phase 4,160,Other,"January 1, 2018","January 30, 2020","January 31, 2020"
4608,NCT03784378,Continued Access to RXDX-105,Non Small Cell Lung Cancer|Ovarian Cancer|RET Gene Mutation|BRAF Gene Mutation,Drug: RXDX-105,Memorial Sloan Kettering Cancer Center,Phase 1,3,Other,"December 14, 2018","September 30, 2020","September 30, 2020"
4609,NCT03784079,A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults,HIV Infections,Drug: GSK3640254|Drug: Placebo matching GSK3640254 Mesylate salt,ViiV Healthcare,Phase 2,34,Industry,"January 31, 2019","February 6, 2020","February 6, 2020"
4610,NCT03783897,A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects,NASH - Nonalcoholic Steatohepatitis,Drug: EDP-305|Drug: Oral Contraceptive,"Enanta Pharmaceuticals, Inc|Covance",Phase 1,43,Industry,"November 27, 2018","June 4, 2019","June 18, 2019"
4611,NCT03783702,Pain Control Following Sinus Surgery,Sinusitis|Opioid Use|Opioid Abuse|Narcotic Use|Otolaryngologic Disease|Postoperative Pain|Pain,Drug: OxyCODONE 5 Mg (milligram) Oral Tablet|Drug: Ibuprofen 600 Mg (milligram) Oral Tablet|Drug: Acetaminophen 650 MG (milligram) Oral Tablet,Stanford University|Mayo Clinic|Vanderbilt University Medical Center|Albert Einstein College of Medicine|University of British Columbia|NorthShore University HealthSystem,Phase 4,118,Other,"April 4, 2019","July 1, 2020","December 30, 2020"
4612,NCT03783377,"Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)",Hypertriglyceridemia|Familial Chylomicronemia,Drug: ARO-APOC3|Drug: sterile normal saline (0.9% NaCl),Arrowhead Pharmaceuticals,Phase 1,112,Industry,"March 8, 2019","February 11, 2021","February 11, 2021"
4613,NCT03783130,"Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults",Human Immunodeficiency Virus Prevention|Human Immunodeficiency Virus (HIV),Biological: VRC-HIVRGP096-00-VP|Other: Alum Adjuvant,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,16,NIH,"March 7, 2019","June 24, 2020","June 24, 2020"
4614,NCT03782792,Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis,Generalized Pustular Psoriasis,Drug: Spesolimab|Drug: Placebo,Boehringer Ingelheim,Phase 2,53,Industry,"January 31, 2019","September 23, 2020","January 5, 2021"
4615,NCT03782701,The Effect of Lumify™ Eyedrops on Eyelid Position,Eyelid Droop,Drug: Brimonidine tartrate ophthalmic solution 0.025%|Other: Sterile balanced saline solution,University of Miami,Phase 4,43,Other,"June 18, 2019","April 1, 2020","April 1, 2020"
4616,NCT03782467,Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015,Solid Tumor|Neoplasms,Biological: ATOR-1015,Alligator Bioscience AB,Phase 1,33,Industry,"January 30, 2019","March 3, 2021","March 3, 2021"
4617,NCT03782103,"In-vivo Efficacy of Patient Preoperative Prep, ZuraPrep (ZP)",Surgical Skin Preparation,Drug: ZuraPrep Clear Solution|Drug: ChloraPrep|Drug: ZuraPrep Vehicle,"Zurex Pharma, Inc.",Phase 3,156,Industry,"January 25, 2019","May 12, 2019","September 26, 2019"
4618,NCT03781947,A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers,Healthy,Drug: teverelix TFA,Antev Ltd.,Phase 1,48,Industry,"November 19, 2018","March 16, 2020","March 16, 2020"
4619,NCT03781739,MANP in Hypertension and Metabolic Syndrome,Hypertension|Metabolic Syndrome,Drug: MANP,Mayo Clinic|American Heart Association,Phase 1,22,Other,"August 18, 2017","November 14, 2019","December 10, 2019"
4620,NCT03781726,Multi-center Study to Transplant Hepatitis-C Infected Kidneys,Renal Failure Chronic|Hepatitis C,Drug: glecaprevir/pibrentasvir treatment,Raymond Chung|AbbVie|University of Pennsylvania|Johns Hopkins University|University of Cincinnati|Weill Medical College of Cornell University|University of Michigan|Northwestern University|Massachusetts General Hospital,Phase 4,30,Other|Industry,"April 10, 2019","March 20, 2020","December 31, 2021"
4621,NCT03781479,Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients,"Muscular Atrophy, Spinal",Drug: Amifampridine Phosphate|Drug: Placebo Oral Tablet,"Catalyst Pharmaceuticals, Inc.",Phase 2,13,Industry,"January 21, 2019","July 23, 2020","July 23, 2020"
4622,NCT03780621,Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impairment,"Cognitive Impairment, Mild",Dietary Supplement: Andrographis and Withania|Dietary Supplement: Placebo,"EuroPharma, Inc.",Phase 1,16,Industry,"April 1, 2019","June 1, 2019","June 1, 2019"
4623,NCT03780426,tSMS in Essential Tremor,Essential Tremor,Device: tSMS|Device: sham,Fundación de investigación HM,Phase 2,30,Other,"October 1, 2018","December 1, 2019","December 1, 2019"
4624,NCT03780010,Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC,Non Small Cell Lung Cancer,Drug: TRC105,Tracon Pharmaceuticals Inc.|University of Alabama at Birmingham,Phase 1,15,Industry|Other,Sep-15,Jun-19,Jun-19
4625,NCT03779633,Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse,Pelvic Organ Prolapse,Drug: Linoladiol Estradiol|Other: Placebo vaginal cream,Medical University of Vienna,Phase 4,120,Other,"February 2, 2017","August 27, 2020","August 27, 2020"
4626,NCT03779178,Landiolol in Postoperative Atrial Fibrillation,Atrial Fibrillation,Drug: Landiolol|Drug: Placebo,Hospices Civils de Lyon,Phase 3,58,Other,"January 17, 2019","December 4, 2019","December 4, 2019"
4627,NCT03778099,The Effect of Cinnamon on Ovulation Induction in Women With Polycystic Ovary Syndrome,Polycystic Ovary Syndrome|Ovulation,Drug: Cinnamon Cap 500 MG|Drug: Placebo,King Abdulaziz University,Phase 3,33,Other,"September 20, 2018","January 10, 2020","February 3, 2020"
4628,NCT03777488,"Pharmacokinetics of Tranexamic Acid After Oral, Intramuscular or Intravenous Administration: a Prospective, Randomised, Cross-over Trial in Healthy Volunteers.",Healthy Volunteer Study,Drug: Tranexamic Acid 1 gram intravenously|Drug: Tranexamic acid 2 grams oral solution|Drug: Tranexamic acid 1 gram intramuscular,London School of Hygiene and Tropical Medicine,Phase 1,15,Other,"October 30, 2019","October 14, 2020","October 14, 2020"
4629,NCT03777332,Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy,Geographic Atrophy,Drug: PEGCETACOPLAN (APL-2),"Apellis Pharmaceuticals, Inc.",Phase 1,19,Industry,"November 5, 2018","April 1, 2021","April 1, 2021"
4630,NCT03777254,"Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration",Neovascular Age-related Macular Degeneration,Biological: RC28-E,"RemeGen Co., Ltd.",Phase 1,12,Industry,"January 7, 2019","August 20, 2019","August 20, 2019"
4631,NCT03777176,Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism,Congenital Hyperinsulinism,Drug: dasiglucagon|Other: Standard of Care,Zealand Pharma,Phase 3,32,Industry,"March 4, 2019","September 8, 2020","October 5, 2020"
4632,NCT03777059,12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine,Episodic Migraine,Drug: Atogepant|Drug: Placebo,Allergan,Phase 3,910,Industry,"December 14, 2018","June 19, 2020","June 19, 2020"
4633,NCT03776851,Erythropoietin in Hemolytic Uremic Syndrome,Hemolytic-Uremic Syndrome|Anemia,Drug: erythropoietin,Hospital General de Niños Pedro de Elizalde,Phase 4,24,Other,"January 1, 2019","December 30, 2020","December 30, 2020"
4634,NCT03776838,Impact of Nociceptive-Level (NOL) Intraoperative Guided Analgesia During Gynecological Laparoscopic Surgery Under General Anesthesia,Gynecologic Laparoscopic Surgery|Hysterectomy|Oophorectomy,Drug: Intravenous Fentanyl guided by SoC+NOL|Drug: Intravenous Fentanyl guided by SoC,Ciusss de L'Est de l'Île de Montréal|Medasense Biometrics Ltd,Phase 4,70,Other,"November 30, 2018","December 6, 2019","September 15, 2021"
4635,NCT03776786,Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans,Treatment of Acute Yellow Fever Virus Infection,Biological: TY014|Other: 0.9% Saline,Tysana Pte Ltd,Phase 1,37,Industry,"December 6, 2018","July 1, 2019","October 10, 2019"
4636,NCT03776539,A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02,Impaired Renal Function,Drug: ELX-02,"Eloxx Pharmaceuticals, Inc.|Syneos Health",Phase 1,24,Industry|Other,"January 4, 2019","July 30, 2019","August 7, 2019"
4637,NCT03776500,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing","Tuberculosis, Pulmonary",Drug: PBTZ169|Drug: Placebo,Innovative Medicines for Tuberculosis|Bill and Melinda Gates Foundation,Phase 1,32,Other,"February 21, 2019","March 20, 2020","March 20, 2020"
4638,NCT03776344,Virtual Reality for Post Operative Pain,"Pain, Postoperative",Device: Virtual Reality intervention - Oculus Rift HD,Babes-Bolyai University,Phase 2,62,Other,"October 10, 2018","July 31, 2019","September 30, 2019"
4639,NCT03776240,A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects,Healthy Volunteers,Drug: HD201|Drug: EU-Herceptin|Drug: US-Herceptin,Prestige Biopharma Limited,Phase 1,105,Industry,"April 1, 2019","August 19, 2019","August 19, 2019"
4640,NCT03776175,"A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.",Non-Alcoholic Fatty Liver Disease (NAFLD),Drug: PF-05221304 Monotherapy|Drug: PF-06865571 Monotherapy|Drug: Placebo|Drug: PF-05221304 and PF-06865571 Combination,Pfizer,Phase 2,99,Industry,"January 4, 2019","September 9, 2019","October 11, 2019"
4641,NCT03775434,A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis,Eczema|Atopic Dermatitis,Drug: Experimental: B244,AOBiome LLC|Novella Clinical,Phase 1,28,Industry|Other,"December 7, 2018","May 18, 2019","June 10, 2019"
4642,NCT03775278,"A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects",Otherwise Healthy Overweight or Obese,Drug: PHP-303|Other: Placebo,pH Pharma,Phase 1,50,Industry,"December 17, 2018","July 24, 2019","April 7, 2020"
4643,NCT03774875,"A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life",Psoriasis,Drug: Apremilast|Drug: Placebo,Amgen,Phase 4,277,Industry,"March 28, 2019","February 1, 2021","November 3, 2021"
4644,NCT03774459,ANAVEX2-73 Study in Parkinson's Disease Dementia,Parkinsons Disease With Dementia,Drug: High dose ANAVEX2-73|Drug: Mid dose ANAVEX2-73|Drug: Placebo oral capsule,Anavex Life Sciences Corp.|Anavex Germany GmbH,Phase 2,132,Industry,"July 9, 2018","September 30, 2020","September 30, 2020"
4645,NCT03774355,"Study to Compare Safety and Pharmacokinetics of ""CG1801"" and ""CGL1802"" in Healthy Volunteers",Healthy,Drug: CG1801|Drug: CGL1802,"CrystalGenomics, Inc.",Phase 1,36,Industry,"December 17, 2018","May 3, 2019","May 3, 2019"
4646,NCT03774290,Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients,Asthma,Drug: PBF-680|Drug: Placebo oral capsule,Palobiofarma SL|Pivotal S.L.,Phase 2,107,Industry,"June 1, 2018","February 5, 2020","March 16, 2020"
4647,NCT03773796,Nabilone for Non-motor Symptoms in Parkinson's Disease,Parkinson Disease,Drug: Nabilone 0.25 mg,Medical University Innsbruck,Phase 3,22,Other,"August 6, 2018","January 31, 2020","January 31, 2020"
4648,NCT03773666,A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2),Muscle Invasive Bladder Cancer,Drug: Durvalumab|Drug: Oleclumab,Dana-Farber Cancer Institute|AstraZeneca,Phase 1,12,Other|Industry,"February 20, 2019","February 4, 2021","August 2, 2021"
4649,NCT03773211,Renaparin® in Kidney Transplantation,Delayed Graft Function,Drug: Renaparin|Drug: Placebo,Corline Biomedical AB,Phase 1,16,Industry,"February 14, 2019","April 21, 2020","April 21, 2020"
4650,NCT03773068,"A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein",Biological Availability,Drug: BAY1817080 - Formulation A|Drug: BAY1817080 - Formulation B|Drug: [13C715N]-BAY 181708 stable isotope label (SIL),Bayer,Phase 1,30,Industry,"December 13, 2018","June 21, 2019","August 12, 2019"
4651,NCT03772951,The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia,Schizophrenia,Other: Cognitive Remediation Therapy|Drug: Clozapine,Shanghai Mental Health Center,Phase 4,154,Other,"January 10, 2019","March 31, 2021","March 31, 2021"
4652,NCT03772847,Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial,Intravenous Alteplase Thrombolysis|Neurological Improving,Drug: ginkgolide,"Second Affiliated Hospital, School of Medicine, Zhejiang University|Dongyang People's Hospital|Haiyan People's Hospital|The Second Affiliated Hospital of Jiaxing University|Tongxiang Second People's Hospital|Tongxiang First People's Hospital|Changxing People's Hospital|The Central Hospital of Lishui City|The First People's Hospital of Huzhou|Taizhou First People's Hospital",Phase 4,1189,Other,"July 31, 2018","May 1, 2020","December 31, 2021"
4653,NCT03772587,"A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis",Generalized Myasthenia Gravis,Drug: M281|Other: Placebo,"Momenta Pharmaceuticals, Inc.",Phase 2,68,Industry,"April 10, 2019","June 25, 2020","June 25, 2020"
4654,NCT03772340,Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness,Motion Sickness,Drug: Tradipitant|Drug: Placebo,Vanda Pharmaceuticals,Phase 2,150,Industry,"December 20, 2018","June 6, 2019","June 27, 2019"
4655,NCT03772223,A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.,Healthy Volunteers,Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Drug: Treatment B (Budesonide metered dose inhaler)|Drug: Treatment C (Albuterol Sulfate metered dose inhaler),AstraZeneca,Phase 1,91,Industry,"January 21, 2019","May 10, 2019","May 10, 2019"
4656,NCT03772041,Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure,Congestive Heart Failure,Drug: OPC-61815|Drug: Tolvaptan Tab 15 MG,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,294,Industry,"January 16, 2019","July 21, 2020","July 29, 2020"
4657,NCT03771963,Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults,Dengue Fever,Biological: Tetravalent Dengue Vaccine (TDV),Takeda,Phase 3,200,Industry,"March 28, 2019","October 14, 2019","March 13, 2020"
4658,NCT03771638,DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men,"Adherence, Medication|Risk Behavior|Pre-Exposure Prophylaxis|HIV Prevention",Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet|Other: DOT Diary mobile app,"Public Health Foundation Enterprises, Inc.|National Institute of Mental Health (NIMH)|San Francisco Department of Public Health|Emory University|AiCure",Phase 4,100,Other|NIH|Industry,"February 1, 2019","April 21, 2020","April 21, 2020"
4659,NCT03771443,Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease,Gluten Sensitivity,Drug: experimental gluten free toothpaste,Cairo University,Phase 3,20,Other,"July 21, 2019","January 21, 2020","January 21, 2020"
4660,NCT03771170,"Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis",Peritonitis|Intoxication,Drug: Rheosorbilact®|Drug: Ringer lactate,Yuria-Pharm,Phase 4,180,Industry,"January 10, 2018","December 3, 2019","December 3, 2019"
4661,NCT03771040,Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels,Asthma,Drug: Masitinib|Drug: Placebo,AB Science,Phase 3,347,Industry,Dec-16,Sep-20,Sep-20
4662,NCT03770637,Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery,Hyperinsulinemic Hypoglycemia,Drug: Glucagon RTU|Other: Placebo,Xeris Pharmaceuticals,Phase 2,14,Industry,"May 10, 2019","February 26, 2020","February 26, 2020"
4663,NCT03770091,Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis,Arthritis,Drug: Theraworx|Drug: Placebo,John Fowler|University of Pittsburgh,Phase 3,40,Other,"December 21, 2018","July 30, 2020","August 1, 2020"
4664,NCT03769896,Nabilone for Non-motor Symptoms in Parkinson's Disease,Parkinson Disease,Drug: Nabilone 0.25 mg|Drug: Placebo,Medical University Innsbruck,Phase 2,48,Other,"October 3, 2017","July 15, 2019","July 15, 2019"
4665,NCT03769831,The PK/PD Study of SHR2285 Tablets in Healthy Subjects,Thrombosis,Drug: SHR2285|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,28,Industry,"February 25, 2019","July 22, 2019","July 22, 2019"
4666,NCT03769662,Follow on Extension of XT-150-1-0201,"Osteoarthritis, Knee",Biological: XT-150,"Xalud Therapeutics, Inc.",Phase 1,16,Industry,"March 20, 2019","October 30, 2019","December 30, 2019"
4667,NCT03769597,Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population,Cirrhosis Renal,Drug: Iohexol Inj 300 MG/ML,"University Hospital, Limoges",Phase 4,13,Other,"January 2, 2019","August 28, 2019","August 28, 2019"
4668,NCT03769194,"Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.",Lyme Borreliosis,Biological: VLA15|Biological: Placebo,Pfizer,Phase 2,572,Industry,"December 17, 2018","December 18, 2019","October 2, 2020"
4669,NCT03768466,Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment,Low Back Pain,Drug: Brand Name: Targin®,Mundipharma Korea Ltd,Phase 4,123,Industry,"November 21, 2018","February 20, 2020","September 17, 2020"
4670,NCT03768427,Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439),Hypercholesterolemia,Combination Product: EZ 10 mg/Ator 10 mg|Combination Product: EZ 10 mg/Ator 20 mg|Drug: Atorvastatin|Drug: Placebo for FDC EZ/Ator|Drug: Placebo for atorvastatin,Organon and Co,Phase 3,454,Industry,"May 27, 2019","March 17, 2021","April 1, 2021"
4671,NCT03767855,A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects,Symptomatic Obstructive Hypertrophic Cardiomyopathy|Healthy Subjects,Drug: CK-3773274 - Granules in Capsule|Drug: Placebo - Granules in Capsule|Drug: CK-3773274 - Tablets,Cytokinetics,Phase 1,114,Industry,"December 4, 2018","January 3, 2020","January 3, 2020"
4672,NCT03767738,Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe,Chorioretinal Vascular Disease,Drug: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals,Phase 4,65,Industry,"December 19, 2018","August 19, 2020","August 19, 2020"
4673,NCT03767543,Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM),Type 2 Diabetes Mellitus,Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010,Sanofi,Phase 3,265,Industry,"March 11, 2019","October 23, 2020","October 23, 2020"
4674,NCT03766867,Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression,Major Depressive Disorder,Drug: Vortioxetine infusion 25 mg|Drug: Vortioxetine tablets 10 mg/day|Drug: Placebo infusion|Drug: Placebo tablets,H. Lundbeck A/S,Phase 2,80,Industry,"December 3, 2018","July 31, 2019","August 28, 2019"
4675,NCT03766854,A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week,"Diabetes Mellitus, Type 1",Drug: insulin icodec|Drug: Insulin glargine U100,Novo Nordisk A/S,Phase 1,24,Industry,"December 7, 2018","December 9, 2019","December 9, 2019"
4676,NCT03766685,A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO),Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis,Drug: Bimekizumab,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 3,172,Industry,"December 20, 2018","July 14, 2020","September 8, 2020"
4677,NCT03766295,Masitinib Plus Gemcitabine in Pancreatic Cancer,Locally Advanced or Metastatic Pancreatic Cancer,Drug: Masitinib|Drug: Gemcitabine|Drug: Placebo,AB Science,Phase 3,377,Industry,Jul-14,Dec-20,Dec-20
4678,NCT03766217,Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair,Cleft Lip and Palate,Combination Product: Mesenchymal stem cells associated with biomaterials|Combination Product: Iliac crest autogenous bone graft,"Hospital Sirio-Libanes|Ministry of Health, Brazil",Phase 3,62,Other,"April 5, 2019","December 6, 2019","December 15, 2019"
4679,NCT03765762,A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease,Severe Alzheimer Disease,Drug: GRF6019|Other: Placebo,"Alkahest, Inc.",Phase 2,26,Industry,"January 15, 2019","December 17, 2019","December 17, 2019"
4680,NCT03765671,Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients,Hepatic Impairment|Liver Disease|Pharmacokinetics,Drug: Elafibranor,Genfit|Syneos Health|University of Miami,Phase 1,30,Industry|Other,"December 12, 2018","June 7, 2019","June 14, 2019"
4681,NCT03765294,A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea,Obstructive Sleep Apnea,Drug: ACT-541468|Drug: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,28,Industry,"March 14, 2019","November 5, 2019","November 5, 2019"
4682,NCT03764475,Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis,Plaque Psoriasis,Drug: Roflumilast,"Arcutis Biotherapeutics, Inc.",Phase 2,332,Industry,"December 18, 2018","October 8, 2020","October 8, 2020"
4683,NCT03764085,"Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.",Sepsis|Intoxication; Septic,Drug: Rheosorbilact®|Drug: Ringer lactate,Yuria-Pharm,Phase 4,180,Industry,"December 6, 2016","December 11, 2019","December 11, 2019"
4684,NCT03763877,A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD,Nonalcoholic Fatty Liver,Drug: PXL770|Drug: Placebo Oral Capsule,Poxel SA,Phase 2,121,Industry,"March 29, 2019","August 3, 2020","August 10, 2020"
4685,NCT03763760,High-Dose Steroid for Hip Arthroplasty Patients Expected to Have Postoperative Pain,Postoperative Pain|Postoperative Nausea and Vomiting|Hip Osteoarthritis|Perioperative/Postoperative Complications|Surgery|Opioid Use|Catastrophizing Pain|Chronic Pain,Drug: Dexamethasone,"Copenhagen University Hospital, Hvidovre|Sygehus Lillebaelt",Phase 4,160,Other,"January 29, 2019","January 1, 2021","January 1, 2021"
4686,NCT03763734,High-Dose Steroid for Knee Arthroplasty Patients Expected to Have Postoperative Pain,Postoperative Pain|Postoperative Nausea and Vomiting|Knee Osteoarthritis|Perioperative/Postoperative Complications|Surgery|Opioid Use|Catastrophizing Pain|Chronic Pain,Drug: Dexamethasone,"Copenhagen University Hospital, Hvidovre|Sygehus Lillebaelt",Phase 4,88,Other,"January 29, 2019","January 1, 2021","January 1, 2021"
4687,NCT03763227,Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy,Retinal Dystrophies,Drug: Intravitreal ranibizumab (IVR) injection|Drug: Carbonic Anhydrase Inhibitor (CAI) therapy,Sultan Qaboos University,Phase 2,13,Other,"July 24, 2015","August 29, 2019","August 29, 2019"
4688,NCT03763149,"A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas",Advanced Malignancies,Biological: IBI188,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,20,Industry,"February 19, 2019","March 29, 2021","March 29, 2021"
4689,NCT03762343,Ultrasound-guided Greater Occipital Nerve Block in Children Undergoing Posterior Fossa Craniotomy,Posterior Fossa Tumor,Drug: ultrasound guided Greater occipital nerve block|Drug: control group C,Kasr El Aini Hospital,Phase 3,40,Other,"January 1, 2019","December 1, 2020","December 1, 2020"
4690,NCT03762031,A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers,Healthy,Drug: GC4711 30mg|Drug: GC4711 60mg|Drug: GC4711 90mg|Drug: GC4711 120mg|Drug: Placebo|Drug: GC4711 75mg|Drug: GC4711 105mg,"Galera Therapeutics, Inc.",Phase 1,70,Industry,"March 19, 2019","March 4, 2020","March 4, 2020"
4691,NCT03761810,A Study of S6G5T3 in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: S6G5T-3|Drug: S6G5T-8,"Sol-Gel Technologies, Ltd.",Phase 3,434,Industry,"December 14, 2018","October 23, 2019","October 23, 2019"
4692,NCT03761784,A Study of S6G5T-3 in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: S6G5T-3|Drug: S6G5T-8,"Sol-Gel Technologies, Ltd.",Phase 3,424,Industry,"December 21, 2018","December 31, 2019","December 31, 2019"
4693,NCT03761537,Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7,Atopic Dermatitis,Drug: Tralokinumab|Other: Placebo,LEO Pharma,Phase 3,277,Industry,"December 13, 2018","April 21, 2020","September 28, 2020"
4694,NCT03761264,Systemic and Local Antimicrobials in the Management of Dental Abscess in Children,Dentoalveolar Abscess,Drug: Odontopaste®|Drug: Pulpdent|Drug: Amoxicillin,University of Malaya,Phase 2,55,Other,"September 18, 2018","February 13, 2020","February 13, 2020"
4695,NCT03761225,Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer,Metastatic Castrate Resistant Prostate Cancer,Drug: Masitinib|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo,AB Science,Phase 3,714,Industry,Sep-14,"December 15, 2020","December 15, 2020"
4696,NCT03761004,WD-1603 PK Study in Healthy Volunteers,Healthy Volunteers,Drug: carbidopa-levodopa,"Hong Kong WD Pharmaceutical Co., Limited",Phase 1,8,Industry,"January 14, 2019","September 5, 2019","September 5, 2019"
4697,NCT03760991,Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin,Type 2 Diabetes Mellitus,Drug: INSULIN GLARGINE (U300),Sanofi,Phase 4,372,Industry,"December 18, 2018","September 23, 2020","September 23, 2020"
4698,NCT03760640,A Study of LY900014 in a Medtronic Pump,Type1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,Phase 2,42,Industry,"February 18, 2019","October 7, 2019","October 7, 2019"
4699,NCT03760198,Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis,Hyperhidrosis Primary Focal Axilla,Drug: Meditoxin|Other: Placebo,Medy-Tox,Phase 3,220,Industry,"August 3, 2018","July 3, 2019","September 17, 2019"
4700,NCT03760185,Pupil Dilation for Treatment of IFIS,Intraoperative Floppy Iris Syndrome,Drug: Brimonidine Tartrate,Denver Health and Hospital Authority,Phase 2,13,Other,"January 4, 2019","September 25, 2020","September 25, 2020"
4701,NCT03760146,Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults,Pneumococcal Disease,Biological: 20vPnC|Biological: 13vPnC|Biological: PPSV23|Other: Saline,Pfizer,Phase 3,3902,Industry,"December 12, 2018","December 16, 2019","December 16, 2019"
4702,NCT03760133,The Change of Gut Microbiota After Bowel Preparation and the Effect of Probiotics,Gut Microbiota|Bowel Preparation|Colonoscopy,Drug: Duolac,"Kosin University Gospel Hospital|Cell Biotech Co., Ltd.",Phase 2,100,Other|Industry,"December 1, 2018","November 30, 2019","December 31, 2019"
4703,NCT03760081,"A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors",Incurable Platinum Refractory Germ Cell Tumors|Tumors,Drug: ASP1650,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 2,19,Industry,"March 19, 2019","October 16, 2020","October 16, 2020"
4704,NCT03760068,Mylan Insulin Aspart Study,"Diabetes Mellitus, Type 1",Drug: MYL-1601D Product|Drug: FlexPen NovoLog®,Mylan Inc.|Mylan GmbH|Viatris Inc.,Phase 3,478,Industry,"November 7, 2018","December 28, 2019","January 17, 2020"
4705,NCT03760003,Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Drug: ABX464 25mg|Drug: ABX464 50mg|Drug: ABX464 100mg|Drug: Placebo,Abivax S.A.,Phase 2,254,Industry,"September 23, 2019","April 1, 2021","April 16, 2021"
4706,NCT03759964,Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery,"Anemia, Iron Deficiency",Drug: Ferric carboxymaltose|Drug: Placebo,"St Joseph University, Beirut, Lebanon|Vifor Pharma|Saint-Joseph University",Phase 4,194,Other|Industry,"December 15, 2018","December 9, 2020","January 2, 2021"
4707,NCT03759600,"Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer",Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: Niraparib,Takeda,Phase 2,20,Industry,"December 26, 2018","July 1, 2019","December 28, 2022"
4708,NCT03759301,Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders,"Infertility, Female",Drug: Growth Hormones Somatropin Recombinant|Drug: Placebo saline solution,"ClinAmygate|National Research Centre, Egypt",Phase 4,156,Other,"December 20, 2018","May 5, 2019","June 5, 2019"
4709,NCT03759197,A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis,Plaque Psoriasis,Drug: 188-0551 Spray|Drug: Vehicle Spray,"Therapeutics, Inc.",Phase 3,206,Industry,"November 26, 2018","August 27, 2019","August 27, 2019"
4710,NCT03758924,Study of ANAVEX2-73 in Patients With Rett Syndrome,Rett Syndrome,Drug: ANAVEX2-73|Drug: Placebo,Anavex Life Sciences Corp.|International Rett Syndrome Foundation Rettsyndrome.org,Phase 2,31,Industry|Other,"February 28, 2019","October 30, 2020","October 30, 2020"
4711,NCT03758885,Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF,Infertility,Drug: Nolasiban|Drug: Placebo,ObsEva SA,Phase 3,820,Industry,"January 10, 2019","November 21, 2019","November 11, 2020"
4712,NCT03758781,IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors,Metastatic Cancer|Recurrent Cancer|Solid Tumor|Renal Cell Carcinoma|Urothelial Carcinoma|NSCLC|Squamous Cell Carcinoma|Non-Small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck,Drug: IRX 2|Drug: Nivolumab,H. Lee Moffitt Cancer Center and Research Institute,Phase 1,12,Other,"February 13, 2019","February 21, 2021","August 11, 2021"
4713,NCT03758612,"A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults","Tuberculosis|Tuberculosis, Pulmonary","Drug: TBI-223 50mg|Drug: Placebo for TBI-223 50mg|Drug: TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Drug: Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Drug: TBI-223 300 mg capsule|Drug: Placebo for TBI-223 300 mg capsule|Drug: TBI-223 Prototype 1 SR Tablet|Drug: TBI-223 Prototype 2 SR Tablet|Drug: TBI-223 Prototype 3 SR Tablet|Drug: TBI-223 IR Tablet",Global Alliance for TB Drug Development,Phase 1,91,Other,"January 16, 2019","February 22, 2020","March 14, 2020"
4714,NCT03758456,HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human,"Rhinitis, Allergic|Rhinoconjunctivitis, Allergic",Biological: HAL-MRE1,HAL Allergy,Phase 1,45,Industry,"November 21, 2018","May 17, 2019","May 17, 2019"
4715,NCT03757715,Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery,Pain Management,Drug: Bupivacaine|Drug: Dexamethasone,University of Alabama at Birmingham,Phase 4,46,Other,"May 20, 2019","March 12, 2021","April 12, 2021"
4716,NCT03757650,THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY,"Helicobacter Pylori Infection|Obesity, Morbid",Drug: Bismuth Subsalicylate,Fatih Sultan Mehmet Training and Research Hospital,Phase 4,3,Other,"October 1, 2018","November 1, 2020","February 1, 2021"
4717,NCT03757325,Study to Evaluate DNL747 in Subjects With Alzheimer's Disease,Alzheimer Disease,Drug: DNL747|Drug: Placebo,Denali Therapeutics Inc.,Phase 1,16,Industry,"February 13, 2019","December 5, 2019","December 5, 2019"
4718,NCT03757234,IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis,Acute Pyelonephritis,Drug: Omadacycline|Drug: Levofloxacin,Paratek Pharmaceuticals Inc,Phase 2,201,Industry,"November 19, 2018","June 26, 2019","July 24, 2019"
4719,NCT03757143,"Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure",Intravascular-catheter Colonization|Catheter Failure,"Drug: Povidone-Iodine-Alcohol|Drug: Chlorhexidine-Alcohol|Device: Insyte Autoguard BC Winged|Device: Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes",Poitiers University Hospital,Phase 4,1000,Other,"January 7, 2019","September 27, 2019","September 27, 2019"
4720,NCT03757130,Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity,Obesity,Drug: AMG 598|Drug: Placebo|Drug: Liraglutide,Amgen,Phase 1,50,Industry,"November 26, 2018","December 16, 2019","December 16, 2019"
4721,NCT03756974,BX-1 in Spasticity Due to Multiple Sclerosis,Spasticity Due to Multiple Sclerosis,Drug: BX-1|Drug: Placebo,Bionorica SE,Phase 3,397,Industry,"February 18, 2019","March 30, 2021","March 30, 2021"
4722,NCT03756883,Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma,Asthma,Drug: Fluticasone Propionate and Salmeterol Inhalation Powder|Drug: Placebo Inhalation Powder,Actavis Inc.|Teva Pharmaceuticals USA,Phase 3,999,Industry,"December 3, 2018","October 26, 2019","November 10, 2019"
4723,NCT03756220,Ascorbic Acid and Thiamine Effect in Septic Shock,Septic Shock|Sepsis,Drug: Combination therapy of vitamin C and thiamine|Drug: Normal saline solution,Tae Gun Shin|National Research Foundation of Korea|Samsung Medical Center,Phase 2,116,Other,"December 1, 2018","January 13, 2020","April 14, 2020"
4724,NCT03756129,Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression,"Depressive Disorder, Treatment-Resistant",Drug: MIJ821|Drug: Placebo|Drug: Ketamine,Novartis Pharmaceuticals|Novartis,Phase 2,70,Industry,"February 8, 2019","March 23, 2020","March 23, 2020"
4725,NCT03756103,Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients,"Hypertension,Essential",Drug: SPH3127 tablet Dose 1|Drug: SPH3127 tablet Dose 2|Drug: SPH3127 tablet Dose 3|Drug: SPH3127 tablet Placebo,"Shanghai Pharmaceuticals Holding Co., Ltd|R&G Pharma Studies Co.,Ltd.",Phase 2,120,Industry,"January 11, 2019","June 30, 2020","June 30, 2020"
4726,NCT03755947,"Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia",B-Cell Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis),Drug: Ibrutinib|Drug: Obinutuzumab|Drug: Venetoclax,Grupo Cooperativo de Hemopatías Malignas,Phase 2,3,Other,"December 1, 2018","December 31, 2020","February 1, 2021"
4727,NCT03755440,PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.,Gastric Cancer Stage IV|EBV,Drug: PD-1 antibody (SHR-1210),Sun Yat-sen University,Phase 2,6,Other,"December 1, 2018","December 31, 2020","December 31, 2020"
4728,NCT03754959,This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam,Healthy,Drug: BI 1358894|Drug: Placebo|Drug: Midazolam,Boehringer Ingelheim,Phase 1,50,Industry,"December 18, 2018","July 22, 2019","July 22, 2019"
4729,NCT03754634,"A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP",Thrombocytopenia,Drug: Eltrombopag and Diacerein,Shandong University|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Anhui Medical University|The First Affiliated Hospital of Dalian Medical University|Shenzhen Second People's Hospital|Zhejiang Provincial Hospital of TCM,Phase 2,30,Other,"May 1, 2019","June 1, 2020","November 1, 2020"
4730,NCT03754582,A Study of Intravenous Perampanel in Japanese Participants With Epilepsy,Epilepsy|Seizures,Drug: Perampanel,"Eisai Co., Ltd.|Eisai Inc.",Phase 2,21,Industry,"November 27, 2018","December 10, 2019","December 10, 2019"
4731,NCT03754309,A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis,"Dermatitis, Atopic",Drug: KY1005|Drug: Placebo,Kymab Limited,Phase 2,89,Industry,"December 13, 2018","May 12, 2020","October 8, 2020"
4732,NCT03754062,Pharmacological Modulation of Belief Salience,Haloperidol|Placebo|L-DOPA,Drug: Placebo - Cap|Drug: L-dopa|Drug: Haloperidol,King's College London|Medical Research Council,Phase 1,30,Other,"June 1, 2017","September 1, 2019","September 1, 2019"
4733,NCT03753763,Safinamide for Multiple System Atrophy (MSA),Multiple System Atrophy,Drug: Safinamide Methanesulfonate|Drug: Safinamide Methanesulfonate matching placebo,Zambon SpA,Phase 2,49,Industry,"October 29, 2019","January 5, 2021","January 5, 2021"
4734,NCT03753113,Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%,Androgenetic Alopecia,Drug: Topical Herbal Solution|Drug: Topical Minoxidil 5%,Farid Masoud|Tabriz University of Medical Sciences,Phase 3,24,Other,"November 28, 2018","September 2, 2019","September 2, 2019"
4735,NCT03751657,A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Placebo (insulin 287)|Drug: Metformin|Drug: Dipeptidyl peptidase-4 inhibitors|Drug: Insulin glargine|Drug: Placebo (insulin glargine),Novo Nordisk A/S,Phase 2,247,Industry,"November 29, 2018","December 16, 2019","January 17, 2020"
4736,NCT03751488,A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients,Schizo Affective Disorder|Schizophrenia|Schizoaffective Disorder,Drug: LY03010|Drug: Invega Sustenna 156 MG in 1 ML Prefilled Syringe,Luye Pharma Group Ltd.,Phase 1,48,Industry,"December 12, 2018","July 24, 2019","July 24, 2019"
4737,NCT03751280,Study of Efficacy of PEAR-004 in Schizophrenia,Schizophrenia,Device: PEAR-004|Device: Sham,Novartis Pharmaceuticals|Novartis,Phase 2,112,Industry,"December 10, 2018","September 26, 2019","September 26, 2019"
4738,NCT03751124,Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,Uterine Leiomyoma|Uterine Fibroids,Drug: Relugolix|Drug: Estradiol/norethindrone acetate|Drug: Placebo for relugolix|Drug: Placebo for E2/NETA,Myovant Sciences GmbH,Phase 3,229,Industry,"October 16, 2018","February 19, 2021","November 18, 2021"
4739,NCT03749642,Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy,Painful Diabetic Neuropathy,Drug: trazodone/gabapentin 2.5/25 mg|Drug: trazodone/gabapentin 5/50 mg|Drug: trazodone/gabapentin 10/100|Drug: Gabapentin|Drug: Placebo oral capsule,Aziende Chimiche Riunite Angelini Francesco S.p.A|Chiltern International Inc.,Phase 2,240,Industry,"November 22, 2018","June 6, 2020","June 6, 2020"
4740,NCT03749356,Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients,Kidney Transplant,Drug: TacroBell SR cap.,Chong Kun Dang Pharmaceutical,Phase 4,141,Industry,"September 5, 2018","July 30, 2020","December 4, 2020"
4741,NCT03749252,"Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI",Central Nervous System Indication|Pediatric Patients|Body Indication,Drug: P03277,Guerbet,Phase 2,80,Industry,"November 6, 2018","December 18, 2019","August 10, 2020"
4742,NCT03748992,A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection,Nontuberculous Mycobacterium Infection,Drug: gNO,Medical University of South Carolina|Cystic Fibrosis Foundation|Oregon Health and Science University,Phase 2,10,Other,"January 28, 2019","March 26, 2020","March 26, 2020"
4743,NCT03748979,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy",Healthy Participants|Narcolepsy,Drug: TAK-925|Drug: Placebo,Takeda,Phase 1,57,Industry,"November 21, 2018","October 24, 2019","October 24, 2019"
4744,NCT03748940,Study of LY3074828 in Healthy Participants,Healthy,Drug: LY3074828|Drug: Placebo|Drug: LY900021,Eli Lilly and Company,Phase 1,60,Industry,"October 10, 2018","June 18, 2019","June 18, 2019"
4745,NCT03748836,Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety,Healthy Volunteers,Drug: ALPN-101|Drug: Placebo,"Alpine Immune Sciences, Inc.|Clinical Network Services (CNS) Pty Ltd",Phase 1,96,Industry,"January 29, 2019","November 18, 2019","November 18, 2019"
4746,NCT03748706,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,Alzheimer Disease,"Drug: PTI-125, 100 mg tablets","Pain Therapeutics|National Institute on Aging (NIA)|Cassava Sciences, Inc.",Phase 2,13,Industry|NIH,"March 7, 2019","May 8, 2019","May 8, 2019"
4747,NCT03747575,A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: MSTT1041A|Drug: Placebo,"Genentech, Inc.",Phase 2,65,Industry,"February 6, 2019","March 11, 2020","May 5, 2020"
4748,NCT03746522,"Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity",Bardet Biedl Syndrome (BBS)|Alström Syndrome (AS),Drug: Setmelanotide|Drug: Placebos,"Rhythm Pharmaceuticals, Inc.",Phase 3,52,Industry,"December 10, 2018","November 16, 2020","March 8, 2021"
4749,NCT03746483,OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Exocrine Pancreatic Insufficiency (EPI)|Cystic Fibrosis (CF),Drug: MS1819|Drug: Porcine PERT,"First Wave BioPharma, Inc.",Phase 2,41,Industry,"January 10, 2019","July 13, 2019","July 27, 2019"
4750,NCT03746015,Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults,Dengue Fever,Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV),Takeda,Phase 2,179,Industry,"December 28, 2018","March 1, 2021","March 1, 2021"
4751,NCT03745989,Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014),Solid Tumors,Drug: MK-8353|Drug: Selumetinib,Merck Sharp & Dohme LLC,Phase 1,30,Industry,"February 22, 2019","March 19, 2021","March 19, 2021"
4752,NCT03745937,A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,Phase 2,20,Industry,"January 7, 2019","May 28, 2019","May 28, 2019"
4753,NCT03745885,A Study of the Efficacy and Safety of Supaglutide in Healthy Participants,"Diabetes Mellitus, Type 2",Drug: Supaglutide injection|Drug: Placebo,"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",Phase 1,48,Other,"December 4, 2018","June 10, 2019","December 13, 2019"
4754,NCT03745807,An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors,Advanced Cancer,Biological: NKTR-214|Biological: Nivolumab,Bristol-Myers Squibb|Nektar Therapeutics|Ono Pharmaceutical Co. Ltd,Phase 1,3,Industry,"April 9, 2019","December 18, 2019","December 18, 2019"
4755,NCT03745716,APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS),MDS,Drug: APR-246 + azacitidine|Drug: Azacitidine,Aprea Therapeutics,Phase 3,154,Industry,"January 11, 2019","November 27, 2020","January 14, 2022"
4756,NCT03745651,TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis,Atopic Dermatitis,Drug: Ruxolitinib cream|Drug: Vehicle cream,Incyte Corporation,Phase 3,618,Industry,"December 20, 2018","November 18, 2019","November 9, 2020"
4757,NCT03745638,Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis,Atopic Dermatitis,Drug: Ruxolitinib Cream|Drug: Vehicle Cream,Incyte Corporation,Phase 3,631,Industry,"December 20, 2018","December 23, 2019","December 1, 2020"
4758,NCT03745625,A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486,Anesthesia|Sedation,Drug: HSK3486|Drug: Propofol,"Sichuan Haisco Pharmaceutical Group Co., Ltd|Haisco Pharmaceutical Group Co., Ltd.",Phase 1,16,Industry,"January 9, 2019","July 2, 2019","August 27, 2019"
4759,NCT03745001,"To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers",Healthy,Drug: EHP-101 Liquid single dose|Drug: EHP-101 Liquid multiple doses|Drug: Matching placebo,Emerald Health Pharmaceuticals,Phase 1,104,Industry,"September 14, 2018","August 11, 2019","September 13, 2019"
4760,NCT03744637,A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002),Pulmonary Arterial Hypertension,Drug: MK-5475|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 1,25,Industry,"January 18, 2019","December 11, 2020","December 11, 2020"
4761,NCT03744403,A Study of CS1001 in Subjects With Advanced Solid Tumors,Advanced Solid Tumors,Drug: CS1001,CStone Pharmaceuticals,Phase 1,24,Industry,"December 4, 2018","October 31, 2020","July 21, 2021"
4762,NCT03744182,A Study of Multiple Doses of HM15211 in Obese Subjects With NAFLD,NAFLD,Drug: HM15211|Drug: Placebo of HM15211,Hanmi Pharmaceutical Company Limited,Phase 1,66,Industry,"November 1, 2018","March 18, 2020","March 18, 2020"
4763,NCT03743376,The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients,HIV-1 Infection,Biological: UB-421(25 mg/kg) Q2W|Biological: UB-421(25 mg/kg) Q4W,"United BioPharma|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|Taoyuan General Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.",Phase 2,31,Industry|Other,"December 12, 2018","October 15, 2020","December 31, 2021"
4764,NCT03742882,"A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects",Hepatic Impairment,Drug: CC-90001,Celgene,Phase 1,40,Industry,"December 6, 2018","June 10, 2019","June 10, 2019"
4765,NCT03742713,Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer,Cancer|Ovarian Cancer,Drug: CPC634 (CriPec® docetaxel),Cristal Therapeutics,Phase 2,25,Industry,"October 1, 2018","December 1, 2020","December 1, 2020"
4766,NCT03742531,Does Induction Dosage in Latent Phase Affect Active Phase of Labor?,Oxytocin|Induction of Labor,Drug: oxytocin,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,Phase 2,300,Other,"December 15, 2018","June 15, 2019","December 1, 2019"
4767,NCT03742440,GrafixPL PRIME Evaluation Case Study,Diabetic Foot Ulcer,Biological: GrafixPL PRIME,University of Texas Southwestern Medical Center|Osiris Therapeutics,Phase 4,40,Other|Industry,"November 20, 2018","March 1, 2020","March 1, 2020"
4768,NCT03742232,Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.,Colon Polyp|Colon Adenoma|Colon Lesion,Drug: PEG3350|Drug: Macrogol 4000,Istituto Clinico Humanitas,Phase 4,399,Other,"October 31, 2018","March 31, 2020","March 31, 2020"
4769,NCT03740737,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1),Infertility,Drug: Follitropin delta|Other: Placebo,Ferring Pharmaceuticals,Phase 3,579,Industry,"October 26, 2018","November 13, 2020","November 20, 2020"
4770,NCT03740555,"A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.",Healthy,Drug: HNC042 single dose|Drug: Placebo single dose|Drug: HNC042 multiple ascending doses|Drug: Placebo multiple ascending doses,Guangzhou Henovcom Bioscience Co. Ltd.,Phase 1,74,Industry,"November 9, 2018","July 19, 2019","July 19, 2019"
4771,NCT03739866,"Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults",HIV-1 Infection,Drug: Lenacapavir|Drug: Placebo|Drug: B/F/TAF|Drug: TAF,Gilead Sciences,Phase 1,53,Industry,"November 26, 2018","November 14, 2019","June 15, 2020"
4772,NCT03739684,Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer,Prostate Cancer|Prostate Adenocarcinoma|Prostate Cancer Recurrent|Prostate Cancer Metastatic,Drug: 18F-DCFPyL|Diagnostic Test: PET/CT Imaging,"Progenics Pharmaceuticals, Inc.",Phase 3,208,Industry,"November 27, 2018","August 29, 2019","August 29, 2019"
4773,NCT03739632,Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets,Major Depressive Disorder,Drug: Hypidone Hydrochloride tablets|Other: Placebo,"Zhejiang Huahai Pharmaceutical Co., Ltd.",Phase 2,240,Industry,"November 30, 2018","December 18, 2019","December 23, 2019"
4774,NCT03739593,Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO),Macular Edema,Drug: AR-1105-CF1|Drug: AR-1105-CF2,Aerie Pharmaceuticals,Phase 2,49,Industry,"March 13, 2019","May 14, 2020","July 9, 2020"
4775,NCT03739294,Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate,Pharmacokinetics,Drug: Fluticasone Furoate/ Vilanterol Trifenatate,"Bispebjerg Hospital|Rigshospitalet, Denmark",Phase 2,26,Other,"February 8, 2019","December 14, 2020","December 14, 2020"
4776,NCT03739190,A Clinical Investigation to Assess the Performance of Natural Rubber Latex Condoms in Couples,Control of Pregnancy|Prevention of Sexually Transmitted Infections,Device: NRL Condom,Reckitt Benckiser Healthcare (UK) Limited,Phase 4,470,Industry,"July 22, 2019","December 27, 2019","December 27, 2019"
4777,NCT03739125,Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes,Type2 Diabetes,Drug: CKD-501 0.5mg|Drug: Placebo,Chong Kun Dang Pharmaceutical,Phase 3,226,Industry,"November 7, 2017","May 25, 2020","December 2, 2020"
4778,NCT03739112,Efficacy of a Plant-derived Quadrivalent VLP Vaccine in the Elderly,Virus Diseases|RNA Virus Infections|Respiratory Tract Diseases|Respiratory Tract Infections,Biological: Quadrivalent VLP Vaccine|Biological: Quadrivalent Comparator Vaccine,Medicago,Phase 3,12793,Industry,"September 18, 2018","May 17, 2019","June 14, 2019"
4779,NCT03738761,Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine,Hypertension,Drug: Amlessa®|Drug: Co-Amlessa®,KRKA|Clinres Farmacija d.o.o.|University Medical Centre Ljubljana,Phase 4,471,Industry|Other,"February 13, 2018","September 27, 2019","September 27, 2019"
4780,NCT03738618,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2),"Infertility, Female",Drug: Follitropin delta|Drug: Placebo,Ferring Pharmaceuticals,Phase 3,521,Industry,"October 29, 2018","December 21, 2020","December 21, 2020"
4781,NCT03738475,"Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease",Celiac Disease,Drug: TIMP-GLIA|Drug: Placebo,"Takeda|COUR Pharmaceuticals Development Company, Inc.",Phase 2,34,Industry|Other,"November 11, 2018","June 24, 2019","July 22, 2019"
4782,NCT03738397,A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Biological: Upadacitinib|Biological: Dupilumab|Drug: Placebo to dupilumab|Drug: Placebo to upadacitinib,AbbVie,Phase 3,692,Industry,"February 21, 2019","August 27, 2020","December 9, 2020"
4783,NCT03738241,2017 A/H7N9 IIV Revaccination,Avian Influenza|Influenza Immunisation,Biological: A/H7N9|Drug: AS03|Other: Phosphate Buffered Saline (PBS) diluent,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,304,NIH,"December 18, 2018","June 19, 2020","June 19, 2020"
4784,NCT03737851,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis (MS),Drug: elezanumab|Drug: placebo,AbbVie,Phase 2,208,Industry,"December 11, 2018","January 7, 2021","September 9, 2021"
4785,NCT03737812,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,Multiple Sclerosis (MS),Drug: elezanumab|Drug: placebo,AbbVie,Phase 2,123,Industry,"February 27, 2019","January 15, 2021","August 30, 2021"
4786,NCT03737708,A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA),Rheumatoid Arthritis (RA),Drug: tacrolimus|Drug: methotrexate|Biological: adalimumab|Biological: tocilizumab|Biological: abatacept,"Astellas Pharma Korea, Inc.|Astellas Pharma Inc",Phase 4,21,Industry,"February 13, 2019","June 16, 2020","June 16, 2020"
4787,NCT03737656,Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women,Pharmacokinetics,Drug: Progesterone vaginal ring,"Grünenthal GmbH|Grünenthal, S.A.",Phase 1,106,Industry,"November 1, 2018","May 3, 2019","May 9, 2019"
4788,NCT03737474,A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder,Major Depressive Disorder,Drug: Brexpiprazole,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,248,Industry,"October 4, 2018","March 17, 2021","April 13, 2021"
4789,NCT03737344,BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage,Intracerebral Haemorrhage,Drug: IL-1Ra Kineret®|Other: IL-1Ra Placebo,"Adrian Parry-Jones|Northern Care Alliance NHS Foundation Trust|National Institute for Health Research, United Kingdom|Manchester University NHS Foundation Trust|University of Manchester",Phase 2,25,Other,"May 17, 2019","February 19, 2021","April 30, 2021"
4790,NCT03737253,Hormone Evaluation in Artificial Reproductive Technology,Female Infertility,Drug: Follitropin alpha|Drug: Menotropin,Lund University|Ferring Pharmaceuticals,Phase 4,796,Other|Industry,"September 1, 2016","December 31, 2020","December 31, 2020"
4791,NCT03737110,Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis,Recurrent Pericarditis,Drug: Rilonacept|Drug: Placebo,"Kiniksa Pharmaceuticals (UK), Ltd.|Kiniksa Pharmaceuticals, Ltd.",Phase 3,86,Industry,"January 7, 2019","May 29, 2020","June 30, 2022"
4792,NCT03736928,Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines,Glabellar Frown Lines,Biological: AbobotulinumtoxinA dose level 1 or 2|Other: placebo|Biological: AbobotulinumtoxinA dose 3|Biological: AbobotulinumtoxinA dose 4,Galderma R&D,Phase 2,401,Industry,"November 26, 2018","December 9, 2019","August 20, 2020"
4793,NCT03736850,Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors,Locally Advanced or Metastatic Solid Tumors,Drug: CS3006,CStone Pharmaceuticals,Phase 1,17,Industry,"October 19, 2018","May 15, 2020","May 15, 2020"
4794,NCT03736837,Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC,Non Small Cell Lung Cancer,Drug: Anlotinib Plus Icotinib,"Tianjin Medical University Cancer Institute and Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Phase 2,60,Other|Industry,"December 1, 2018","January 1, 2021","January 1, 2021"
4795,NCT03736785,A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug: LY3209590|Drug: Insulin Degludec,Eli Lilly and Company,Phase 2,399,Industry,"November 15, 2018","February 18, 2020","February 18, 2020"
4796,NCT03736473,A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients,Advanced Solid Malignancies,Drug: MEDI9447 (oleclumab),AstraZeneca,Phase 1,6,Industry,"November 7, 2018","June 19, 2019","June 19, 2019"
4797,NCT03736369,Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3),Erosive Esophagitis,Drug: DWP14012 40mg|Drug: DWP14012 40mg placebo|Drug: Esomeprazole 40mg|Drug: Esomeprazole 40mg placebo,Daewoong Pharmaceutical Co. LTD.,Phase 3,263,Industry,"December 13, 2018","August 7, 2019","August 7, 2019"
4798,NCT03736161,Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis,Psoriatic Arthritis,Drug: Group A- Tofacitinib|Drug: Group B- Methotrexate,Globe Pharmaceuticals Limited,Phase 3,61,Other,"September 15, 2017","September 28, 2019","September 28, 2019"
4799,NCT03735966,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,HER2 Positive Breast Cancer,Drug: Pyrotinib plus trastuzumab and docetaxel and carboplatin,Henan Cancer Hospital,Phase 2,75,Other,"November 20, 2018","October 20, 2020","October 20, 2020"
4800,NCT03735849,"Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants",HIV Infections,Biological: VRC07-523LS,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,28,NIH,"January 18, 2019","December 21, 2020","December 21, 2020"
4801,NCT03735836,Effect of Fish Oil Monoglycerides on the Omega-3 Index,Pharmacokinetic in Normal Population,Other: MAG-EPA/MAG-DHA omega-3 oils,Samuel Fortin|SCF Pharma,Phase 4,32,Industry,"August 8, 2018","August 9, 2019","August 9, 2019"
4802,NCT03735810,Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses,Healthy Volunteer,Drug: LBS-008|Drug: Placebos,"RBP4 Pty Ltd|Belite Bio, Inc",Phase 1,71,Industry,"November 15, 2018","September 16, 2019","September 16, 2019"
4803,NCT03735368,Dexmedetomidine and Pregabalin for Conscious Sedation During Cataract Surgery,Conscious Sedation,Drug: Dexmedetomidine Injection|Drug: Placebo oral capsule|Drug: Pregabalin Oral Capsule|Drug: topical anesthesia,Abd-Elazeem Abd-Elhameed Elbakry|Menoufia University,Phase 2,60,Other,"December 10, 2018","October 30, 2019","November 29, 2019"
4804,NCT03735225,"Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration",Hypoglycemia,Drug: Dasiglucagon|Drug: Placebo,Zealand Pharma,Phase 1,60,Industry,"November 7, 2018","June 24, 2019","June 24, 2019"
4805,NCT03735030,Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation,Infertility,Drug: Human hCG 10'000 IU|Drug: Recombinant hCG 6'500 IU,IBSA Institut Biochimique SA,Phase 1,26,Industry,"November 27, 2018","August 2, 2019","August 2, 2019"
4806,NCT03734991,Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303),Candida Vulvovaginitis,Drug: Ibrexafungerp|Drug: Placebo,"Scynexis, Inc.",Phase 3,376,Industry,"January 4, 2019","August 21, 2019","September 4, 2019"
4807,NCT03734601,Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorder|Chronic Lymphocytic Leukemia|B-cell Lymphoma|T-cell Lymphoma|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Chronic Myelomonocytic Leukemia,Radiation: Total body irradiation (TBI)|Drug: Anti-thymocyte globulin (ATG)|Drug: Tacrolimus|Drug: Mycophenolate mofetil (MMF)|Radiation: Total lymphoid irradiation (TLI),Stanford University,Phase 2,22,Other,"November 5, 2018","December 26, 2019","November 17, 2020"
4808,NCT03734354,"The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects",Health,Drug: Brexpiprazole,Otsuka Beijing Research Institute,Phase 1,30,Industry,"April 7, 2019","May 18, 2020","May 18, 2020"
4809,NCT03734302,"The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects",Healthy,Drug: Brexpiprazole,Otsuka Beijing Research Institute,Phase 1,10,Industry,"April 24, 2019","June 10, 2020","June 10, 2020"
4810,NCT03734263,Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.,Pyruvate Dehydrogenase Complex Deficiency,Drug: sodium phenylbutyrate,Fondazione Telethon,Phase 2,1,Other,"October 1, 2018","July 30, 2019","December 30, 2020"
4811,NCT03734159,The Benefit of Local Anesthesia at the Sternum in Patients With Coronary Surgery,Coronary Bypass Graft Stenosis,Drug: Ropivacaine|Drug: sodium chloride 0.9%,CMC Ambroise Paré,Phase 4,35,Other,"December 13, 2018","June 21, 2019","November 7, 2019"
4812,NCT03733587,GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors,Solid Tumor,Drug: GX-I7|Drug: Cyclophosphamide,"Genexine, Inc.",Phase 1,24,Industry,"October 17, 2018","April 2, 2020","May 13, 2020"
4813,NCT03733301,A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Baricitinib|Drug: Topical corticosteroid|Drug: Placebo,Eli Lilly and Company|Incyte Corporation,Phase 3,329,Industry,"November 16, 2018","July 29, 2019","August 22, 2019"
4814,NCT03733210,Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer,Squamous Cell Carcinoma of the Head and Neck|Carcinoma of the Head and Neck,Drug: Panitumumab-IRDye800|Drug: 89-Zirconium (Zr-89) Panitumumab|Device: Pinpoint IR IR9000 fluorescence imaging system (FIS)|Device: SPY-PHI IR9000 fluorescence imaging system (FIS)|Device: Explorer Air camera|Device: PDE-NEO II camera|Device: FIS-00 fluorescence imaging system (FIS)|Device: Da Vinci Firefly Imaging System|Device: IGP-ELVIS-v4 Macroscopic Specimen Imager|Device: Vevo 3100 LAZR-X|Device: Pearl Triology Imaging System|Device: Odyssey CLx Imaging System|Device: Leica fluorescence microscope,Andrei Iagaru|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Stanford University,Phase 1,14,Other|NIH,"January 7, 2019","December 11, 2020","August 9, 2021"
4815,NCT03732833,MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines,Lateral Canthal Lines|Glabellar Lines,Drug: MT10109L|Drug: Placebo,Medy-Tox,Phase 3,424,Industry,"November 5, 2018","March 5, 2020","January 25, 2021"
4816,NCT03732248,Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders,Alcohol Use Disorder|Alcohol Dependence,Drug: Rapamycin|Drug: Placebo,Medical University of South Carolina,Phase 1,21,Other,"July 12, 2018","December 20, 2019","January 20, 2020"
4817,NCT03731182,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)",Pneumococcal Infections,Biological: V114|Biological: Prevnar 13™,Merck Sharp & Dohme LLC,Phase 3,104,Industry,"January 23, 2019","June 8, 2020","June 8, 2020"
4818,NCT03731169,CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels,Aspergillosis Invasive|Fungal Infection,Genetic: Voriconazole genotype-specific dosing|Drug: Standard of Care,"University Health Network, Toronto",Phase 4,30,Other,"January 10, 2018","August 31, 2019","August 28, 2020"
4819,NCT03731091,"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).",Psoriasis Vulgaris,"Drug: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Drug: Enstilar® foam (LEO Pharma Inc.)|Other: Placebo of Calcipotriene/ betamethasone dipropionate topical foam",Glenmark Pharmaceuticals Ltd. India,Phase 3,494,Industry,"October 31, 2018","March 17, 2020","March 17, 2020"
4820,NCT03731052,Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307),Plaque Psoriasis,Drug: 188-0551 Spray|Drug: Vehicle Spray,"Therapeutics, Inc.",Phase 3,217,Industry,"October 16, 2018","December 20, 2019","December 20, 2019"
4821,NCT03730961,An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic,Cardiac Failure|Myocardial Failure|Congestive Heart Failure|Heart Decompensation,Drug: BMS-986231|Drug: Furosemide|Drug: Placebo,Bristol-Myers Squibb,Phase 2,23,Industry,"January 17, 2019","December 11, 2019","January 9, 2020"
4822,NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Insulin Glargine,Eli Lilly and Company,Phase 3,2002,Industry,"November 20, 2018","January 22, 2021","April 22, 2021"
4823,NCT03730363,Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma,Hodgkin Lymphoma|Refractory Hodgkin Lymphoma,Drug: Pentamidine,Reinhold Munker|University of Kentucky,Phase 1,1,Other,"December 19, 2018","May 23, 2019","May 23, 2019"
4824,NCT03730142,A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma,Advanced Cancer,Drug: WXFL10030390,"Shanghai Jiatan Pharmatech Co., Ltd",Phase 1,82,Industry,"October 25, 2018","July 25, 2020","July 25, 2020"
4825,NCT03729375,The Effect Of An Anesthetic Procedure On Post Operative Pain Management In Carpal Tunnel Release,"Pain, Postoperative|Carpal Tunnel Syndrome",Drug: 10cc injection of bupivacaine|Drug: 20cc injection of bupivacaine,University of South Florida,Phase 1,52,Other,"October 4, 2018","October 4, 2020","October 4, 2020"
4826,NCT03729362,PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD,Pompe Disease (Late-onset),Drug: AT2221|Biological: alglucosidase alfa|Biological: ATB200,Amicus Therapeutics,Phase 3,123,Industry,"December 4, 2018","January 15, 2021","January 15, 2021"
4827,NCT03728504,Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema,Chronic Hand Dermatitis,Drug: ASN002|Drug: Placebo Oral Tablet,Asana BioSciences,Phase 2,97,Industry,"January 3, 2019","April 29, 2020","April 29, 2020"
4828,NCT03728153,"Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania","Acute Stroke|Stroke, Ischemic",Drug: Fluoxetine 20 MG Oral Tablet,Massachusetts General Hospital|Muhimbili University of Health and Allied Sciences,Phase 2,34,Other,"November 26, 2019","January 6, 2021","January 6, 2021"
4829,NCT03728023,A Study of AZD4205 in Healthy Adult Subjects,Healthy Volunteers,Drug: AZD4205|Drug: Placebo,Dizal Pharmaceuticals,Phase 1,66,Industry,"November 12, 2018","August 20, 2019","August 20, 2019"
4830,NCT03727750,"Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML",ECG|Pharmacokinetics|Safety,Drug: Gemtuzumab Ozogamicin,Pfizer,Phase 4,51,Industry,"July 3, 2019","April 27, 2021","April 27, 2021"
4831,NCT03727321,FMT and Fiber in Patients With Metabolic Syndrome,Obesity|Metabolic Syndrome,Combination Product: Fecal Microbial Transplant|Dietary Supplement: Fiber|Dietary Supplement: Cellulose,University of Alberta|The Weston A. Price Foundation,Phase 2,68,Other,"July 1, 2018","January 16, 2020","January 16, 2020"
4832,NCT03727074,Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream,Actinic Keratosis (AK),Drug: 5-FU Cream|Drug: Efudex®|Drug: Vehicle,"Sol-Gel Technologies, Ltd.",Phase 3,462,Industry,"December 21, 2018","December 19, 2019","December 19, 2019"
4833,NCT03727022,"A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis",Knee Osteoarthritis,Drug: Placebo|Drug: SM04690,"Biosplice Therapeutics, Inc.",Phase 2,102,Industry,"November 28, 2018","September 18, 2020","August 18, 2021"
4834,NCT03726515,CART-EGFRvIII + Pembrolizumab in GBM,Glioblastoma,Biological: CART-EGFRvIII T cells|Biological: Pembrolizumab,University of Pennsylvania,Phase 1,7,Other,"March 11, 2019","February 27, 2021","February 27, 2021"
4835,NCT03726294,A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer,Malignant Neoplasm,Drug: NBM-BMX softgel capsules,NatureWise Biotech & Medicals Corporation,Phase 1,33,Industry,"October 16, 2018","April 24, 2020","October 25, 2021"
4836,NCT03726125,A Study of LY3374849 in Healthy Participants,Healthy,Drug: LY3374849 - SC|Drug: Insulin Degludec - SC|Drug: LY3374849 - IV|Drug: Insulin Degludec - IV,Eli Lilly and Company,Phase 1,89,Industry,"November 20, 2018","September 27, 2019","September 27, 2019"
4837,NCT03725852,A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Drug: GLPG1205|Drug: Placebo,Galapagos NV,Phase 2,68,Industry,"September 27, 2018","July 21, 2020","August 14, 2020"
4838,NCT03725722,"Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.",Atopic Dermatitis,Drug: Delgocitinib cream|Drug: Delgocitinib cream vehicle,LEO Pharma,Phase 2,251,Industry,"December 28, 2018","May 19, 2020","May 19, 2020"
4839,NCT03725033,Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance,Impaired Glucose Tolerance,Drug: Subetta|Drug: Placebo,Materia Medica Holding,Phase 3,538,Industry,"October 10, 2018","March 23, 2020","March 23, 2020"
4840,NCT03723837,Persistence of IPV Immunity,Poliomyelitis,Biological: Inactivated Polio Vaccine (IPV),"Tribhuvan University Teaching Hospital, Institute Of Medicine.|World Health Organization|Centers for Disease Control and Prevention",Phase 4,502,Other|U.S. Fed,"November 21, 2018","June 30, 2019","July 30, 2019"
4841,NCT03723785,A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems,"Diabetes Mellitus, Type 2",Drug: Insulin icodec,Novo Nordisk A/S,Phase 1,58,Industry,"November 9, 2018","September 6, 2019","September 6, 2019"
4842,NCT03723772,A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week,"Diabetes Mellitus, Type 1",Drug: Insulin icodec|Drug: IGlar U100,Novo Nordisk A/S,Phase 1,66,Industry,"November 29, 2018","June 26, 2020","June 26, 2020"
4843,NCT03723746,A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants,Healthy,Biological: JNJ-67670187|Biological: Placebo,"Janssen Research & Development, LLC",Phase 1,74,Industry,"October 25, 2018","December 16, 2019","December 16, 2019"
4844,NCT03723525,Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals,HIV,Combination Product: Package of HIV care|Combination Product: Standard HIV care,"National Centre for AIDs and STD Control, Nepal|Sukraraj Tropical and Infectious Disease Hospital|National Academy of Medical Sciences, Nepal|Tribhuvan University Teaching Hospital, Institute Of Medicine.|Rapti Sub-regional Hospital|Western Regional Hospital|Seti Zonal Hospital|Tikapur Hospital|Mahakali Zonal Hospital|Bharatpur Eye Hospital|B.P. Koirala Institute of Health Sciences|Expertise France|Karolinska Institutet",Phase 4,1073,Other,"January 22, 2018","December 24, 2019","December 24, 2019"
4845,NCT03723447,Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®),"Pain, Postoperative|Crohn Disease|Inflammatory Bowel Diseases|Colorectal Cancer|Gastrointestinal Cancer|Gastrointestinal Disease|Digestive System Disease|Pain|Pain, Neuropathic|Intestinal Disease",Drug: Liposomal bupivacaine|Drug: Bupivacaine/epinephrine/dexamethasone,Cedars-Sinai Medical Center,Phase 4,102,Other,"October 23, 2018","October 29, 2019","October 29, 2019"
4846,NCT03722927,The Use Of Liposomal Bupivacaine For Pain Control,"Pain, Breast",Drug: Bupivacaine|Drug: Liposomal Bupivacaine,Wake Forest University Health Sciences,Phase 4,3,Other,"June 14, 2018","January 29, 2020","January 29, 2020"
4847,NCT03722823,A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects,Hepatic Impairment,Drug: Tucatinib,Seagen Inc.,Phase 1,37,Industry,"October 10, 2018","May 7, 2019","May 7, 2019"
4848,NCT03722589,Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP,Influenza,Biological: Flublok|Biological: Flucelvax|Biological: Fluarix|Biological: Fluzone|Biological: Fluzone High-Dose,Centers for Disease Control and Prevention|Baylor Scott and White Health|Kaiser Permanente|Abt Associates,Phase 4,864,U.S. Fed|Other|Industry,"September 12, 2018","July 31, 2020","July 31, 2020"
4849,NCT03722576,Vidofludimus Calcium for Primary Sclerosing Cholangitis,Primary Sclerosing Cholangitis,Drug: Vidofludimus calcium,Elizabeth Carey|Arizona State University|Mayo Clinic,Phase 2,18,Other,"June 17, 2019","June 30, 2020","June 30, 2020"
4850,NCT03722472,Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults,Pulmonary TB,Biological: ID93 + GLA-SE,Access to Advanced Health Institute (AAHI)|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,48,Other|NIH,"October 2, 2018","June 15, 2020","June 15, 2020"
4851,NCT03722290,Metformin in Children and Adults With Fragile X Syndrome,Fragile X Syndrome,Drug: Metformin,Université de Sherbrooke|FRAXA Research Foundation,Phase 2,15,Other,"September 1, 2018","October 24, 2019","November 1, 2020"
4852,NCT03722004,Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study,Poliomyelitis,Biological: mOPV1|Biological: bOPV|Biological: fIPV,"Centers for Disease Control and Prevention|International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4,1256,U.S. Fed|Other,"December 18, 2018","December 19, 2019","December 19, 2019"
4853,NCT03721705,Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type,"Alzheimer Disease|Cognitive Dysfunction|Mild Cognitive Impairment|Mild Dementia|Cognitive Decline|Dementia, Alzheimer Type",Device: Renew NCP-5,"Renew Research, LLC|Navitas Clinical Research, Inc|ClinEdge, LLC",Phase 3,190,Other,"November 12, 2018","March 23, 2021","March 23, 2021"
4854,NCT03721328,Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation,Prosthetic Joint Infection,Combination Product: vancomycin hydrochloride and tobramycin sulfate,"Osteal Therapeutics, Inc.",Phase 2,15,Industry,"October 26, 2018","August 25, 2020","August 25, 2020"
4855,NCT03721172,Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy,Psoriasis,Drug: Apremilast|Other: Placebo,Amgen,Phase 3,595,Industry,"March 11, 2019","March 6, 2020","July 24, 2020"
4856,NCT03721107,A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome,Irritable Bowel Syndrome,Biological: Blautix|Other: Placebo,4D pharma plc,Phase 2,366,Industry,"October 11, 2018","May 13, 2020","May 13, 2020"
4857,NCT03721016,MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL),Glabellar Lines|Lateral Canthal Lines,Drug: MT10109L|Drug: Placebo,Medy-Tox,Phase 3,415,Industry,"October 26, 2018","March 5, 2020","January 22, 2021"
4858,NCT03720678,A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies,GastroEsophageal Cancer|Colorectal Cancer,Drug: etrumadenant|Drug: mFOLFOX,"Arcus Biosciences, Inc.",Phase 1,44,Industry,"November 18, 2018","January 27, 2021","June 25, 2021"
4859,NCT03720548,A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD),Alzheimer Disease,Drug: LY3372993|Drug: Placebo,Eli Lilly and Company,Phase 1,36,Industry,"November 5, 2018","May 14, 2019","May 14, 2019"
4860,NCT03720470,Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy,"Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases",Drug: PF-04965842 100 mg|Drug: PF-04965842 200 mg|Drug: Dupilumab|Drug: Oral Placebo|Drug: Injectable Placebo,Pfizer,Phase 3,838,Industry,"October 29, 2018","December 27, 2019","March 6, 2020"
4861,NCT03719885,TrueTear in Sjogren's Disease Patients,Dry Eye Syndromes|Sjogren's Syndrome,Device: TrueTear Intranasal Tear Neurostimulator,University of Pennsylvania|Allergan,Phase 2,55,Other|Industry,"November 1, 2018","July 25, 2019","November 1, 2019"
4862,NCT03719612,DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY,Cardiac Disease,Drug: DEFINITY®,Lantheus Medical Imaging|Syneos Health,Phase 3,160,Industry|Other,"December 28, 2018","January 9, 2020","January 9, 2020"
4863,NCT03719482,Assessment of the Biodistribution and Safety of [18F]MNI-1054,Healthy Volunteers,Drug: [18F]MNI-1054,Invicro,Phase 1,4,Other,"October 5, 2018","May 2, 2019","May 2, 2019"
4864,NCT03719443,First in Human Study to Assess Safety of VIS649 in Healthy Subjects,Immunoglobulin A Nephropathy|IgAN - IgA Nephropathy|IgA Nephropathy,Biological: VIS649|Biological: Placebo,"Visterra, Inc.",Phase 1,41,Industry,"October 9, 2018","August 10, 2019","August 10, 2019"
4865,NCT03719066,Extended Dose Intervals With Oral Cholera Vaccine in Cameroon,Adverse Reaction to Cholera Vaccine|Cholera Vaccination Reaction,Biological: killed whole cell oral cholera vaccine,Johns Hopkins Bloomberg School of Public Health|Bill and Melinda Gates Foundation|Meilleur Accès aux Soins de Santé (M.A. Santé),Phase 2,181,Other,"October 23, 2018","February 27, 2020","October 5, 2021"
4866,NCT03719053,Single Dose Truvada Study,Medication Adherence|HIV Prevention,Drug: Tenofovir,Johns Hopkins University,Phase 1,44,Other,"October 25, 2018","June 30, 2020","June 30, 2020"
4867,NCT03718884,A Study of Mirikizumab in Participants With Plaque Psoriasis,Psoriasis,Drug: Drug Cocktail|Drug: Mirikizumab,Eli Lilly and Company,Phase 1,26,Industry,"October 23, 2018","October 28, 2019","October 28, 2019"
4868,NCT03718754,En-bloc vs Conventional Resection of Primary Bladder Tumor,Bladder Cancer,Device: En-Bloc TURB|Device: Conventional TURB,David D'Andrea|Medical University of Vienna,Phase 3,384,Other,"February 28, 2019","January 20, 2021","January 20, 2021"
4869,NCT03718533,Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function,Poor Graft Function,Drug: Eltrombopag,Novartis Pharmaceuticals|Novartis,Phase 2,10,Industry,"December 17, 2018","November 3, 2020","November 3, 2020"
4870,NCT03718468,A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine,Influenza,Biological: GC FLU Quadrivalent|Biological: Fluarix Tetra,Medigen Vaccine Biologics Corp.,Phase 3,842,Industry,"October 30, 2018","July 3, 2019","July 3, 2019"
4871,NCT03718429,Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies,Coronary Artery Disease|Peripheral Arterial Disease|Atrial Fibrillation,Drug: Rivaroxaban 2.5 mg Tablet,"University of Florida|Janssen Scientific Affairs, LLC",Phase 4,86,Other|Industry,"January 14, 2019","February 13, 2020","August 30, 2020"
4872,NCT03718091,M6620 (VX-970) in Selected Solid Tumors,Solid Tumor|Leiomyosarcoma|Osteosarcoma,Drug: M6620,Massachusetts General Hospital|EMD Serono,Phase 2,30,Other|Industry,"January 8, 2019","June 1, 2020","July 8, 2020"
4873,NCT03717987,The Effect of Botulinum Toxin A In Patients With Excessive Gingival Display With And Without Zinc Supplementation,Excessive Gingival Display,Drug: Botulinum toxin type A|Dietary Supplement: Zinc supplementation,Cairo University,Phase 3,26,Other,"January 3, 2019","September 1, 2019","December 12, 2019"
4874,NCT03717961,Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis,Raynaud Phenomenon Secondary to Systemic Sclerosis,Drug: BOTOX® solution|Drug: Placebo group,Assistance Publique - Hôpitaux de Paris,Phase 3,91,Other,"October 15, 2018","July 31, 2020","July 31, 2020"
4875,NCT03717506,"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris",Acne Vulgaris,Drug: GDC 268 Lotion|Drug: Clindamycin Phosphate Lotion 1%|Drug: GDC Vehicle Lotion,"Gage Development Company, LLC",Phase 3,1236,Industry,"October 10, 2018","February 17, 2020","April 16, 2020"
4876,NCT03717272,Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects,Marijuana Abuse,Drug: AEF0117|Drug: Placebo oral capsule,"Aelis Farma|National Institute on Drug Abuse (NIDA)|Columbia University|New York State Psychiatric Institute|ClinStar, LLC",Phase 2,29,Industry|NIH|Other,"October 23, 2018","July 31, 2020","January 1, 2021"
4877,NCT03717155,Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC,Squamous Non-Small Cell Lung Cancer,Drug: Avelumab|Drug: Cetuximab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin,"Merck KGaA, Darmstadt, Germany",Phase 2,43,Industry,"October 30, 2018","September 30, 2020","May 27, 2021"
4878,NCT03716622,A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication,Helicobacter Pylori,Drug: Furazolidone|Drug: Clarithromycin,Shandong University,Phase 4,350,Other,"July 31, 2018","August 31, 2019","August 31, 2019"
4879,NCT03716583,Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer,Radiation Dermatitis|Radiation Dermatitis Acute|Breast Cancer,Drug: Melatonin|Drug: Dimethyl Sulfoxide|Drug: Placebos,Dennis Bregner Zetner|Herlev Hospital,Phase 2,48,Other,"April 30, 2019","January 31, 2021","January 31, 2021"
4880,NCT03716115,Therapeutic Approaches to Malnutrition Enteropathy,Severe Acute Malnutrition,Dietary Supplement: Colostrum high protein powder (Neovite)|Drug: N-Acetyl Glucosamine (GInNAC)|Drug: Teduglutide|Drug: Budesonide,Queen Mary University of London,Phase 2,125,Other,"May 4, 2020","April 27, 2021","April 27, 2021"
4881,NCT03716076,Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study,Cardiac Arrythmias,Drug: Carbetocin,University of British Columbia,Phase 4,50,Other,"November 1, 2018","June 15, 2019","April 24, 2020"
4882,NCT03715829,A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects,Active Non-segmental Vitiligo,Drug: PF-06651600|Drug: placebo|Drug: PF06700841|Device: narrow-band UVB phototherapy,Pfizer,Phase 2,366,Industry,"November 26, 2018","February 5, 2021","February 5, 2021"
4883,NCT03715504,Study of TP-3654 in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: TP-3654,"Sumitomo Pharma Oncology, Inc.",Phase 1,22,Industry,"April 16, 2019","March 30, 2021","July 8, 2021"
4884,NCT03715348,Trial of PCC Versus FFP in Patients Undergoing Heart Surgery,Bleeding|Surgery|Transfusion,Drug: Prothrombin Complex Concentrate (PCC)|Biological: Fresh Frozen Plasma,Queen Mary University of London|British Heart Foundation,Phase 2,50,Other,"March 1, 2019","January 29, 2020","January 29, 2020"
4885,NCT03715192,A Safety Study of LY3462817 in Healthy Participants,Healthy,Biological: LY3462817 IV|Biological: LY3462817 SC|Drug: Placebo,Eli Lilly and Company,Phase 1,64,Industry,"December 13, 2018","December 11, 2019","December 11, 2019"
4886,NCT03714919,A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients,Adenoid Hypertrophy,Drug: Dextromethorphan|Drug: Acetaminophen|Drug: Dexmedetomidine|Drug: Ketamine,Arlyne Thung|Nationwide Children's Hospital,Phase 2,10,Other,"August 2, 2019","November 10, 2019","November 10, 2019"
4887,NCT03714776,"A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure",Mild Hypertension,Drug: Placebo|Drug: ISIS 757456,"Ionis Pharmaceuticals, Inc.",Phase 2,25,Industry,"January 3, 2019","November 13, 2019","November 13, 2019"
4888,NCT03714685,Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations,Healthy Males,Drug: Firibastat,Quantum Genomics SA|Quotient Sciences,Phase 1,12,Industry,"February 15, 2019","May 15, 2019","June 7, 2019"
4889,NCT03714620,Sub-dissociative Dose Ketamine Dosing Study,Acute Pain,Drug: Ketamine,Loyola University,Phase 4,98,Other,"October 15, 2018","September 17, 2019","September 17, 2019"
4890,NCT03714555,"Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine",Metastatic Pancreatic Cancer,Diagnostic Test: Safety Laboratories|Other: AE Assessment|Other: Physical Exam|Other: Concomitant Medication Review|Diagnostic Test: Tumor Imaging|Drug: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|Drug: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|Drug: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate,HonorHealth Research Institute|Cantex Pharmaceuticals,Phase 2,1,Other|Industry,"October 17, 2019","July 22, 2020","July 29, 2020"
4891,NCT03714529,A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma,Basal Cell Carcinoma,Biological: PD-L1,Herlev and Gentofte Hospital|University of Copenhagen,Phase 2,10,Other,"November 1, 2018","February 5, 2020","February 5, 2020"
4892,NCT03714152,A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B,Chronic Hepatitis B,Drug: ABI-H2158|Drug: Placebo for ABI-H2158,Assembly Biosciences,Phase 1,80,Industry,"November 13, 2018","November 23, 2020","January 7, 2021"
4893,NCT03713957,A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment,Parkinson Disease,Drug: GRF6021|Other: Placebo,"Alkahest, Inc.|Michael J. Fox Foundation for Parkinson's Research",Phase 2,79,Industry|Other,"November 12, 2018","July 20, 2020","July 20, 2020"
4894,NCT03713658,A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities,Schizophrenia,Drug: Risperidone 3 mg|Drug: Paliperidone Palmitate 50 mg eq.|Drug: Paliperidone Palmitate 75 mg eq.|Drug: Paliperidone Palmitate 100 mg eq.|Drug: Paliperidone Palmitate 150 mg eq.|Drug: Paliperidone Palmitate 175 mg eq.|Drug: Paliperidone Palmitate 263 mg eq.|Drug: Paliperidone Palmitate 350 mg eq.|Drug: Paliperidone Palmitate 525 mg eq.,"Janssen Research & Development, LLC",Phase 4,34,Industry,"October 18, 2018","December 2, 2019","December 2, 2019"
4895,NCT03713242,"A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment",Hepatic Impairment,Drug: ACT-541468 25 mg|Drug: ACT-541468 25 mg (or 10 mg depending on interim results),Idorsia Pharmaceuticals Ltd.,Phase 1,32,Industry,"February 26, 2018","February 27, 2020","February 27, 2020"
4896,NCT03713216,Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy,"Pain, Postoperative",Drug: Naldebain|Drug: Morphine,Cathay General Hospital,Phase 4,44,Other,"July 1, 2018","October 1, 2019","January 1, 2020"
4897,NCT03713190,Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).,End Stage Renal Disease,Combination Product: Empagliflozin|Drug: Placebo,University of Pisa,Phase 2,25,Other,"September 10, 2018","February 15, 2020","March 15, 2020"
4898,NCT03712735,Programmed Intermittent Epidural Bolus For Laboring Obstetrical Women,Labor Pain,Drug: Bupivacaine 0.08% - fentanyl 2mcg,University of British Columbia,Phase 4,390,Other,"October 23, 2018","March 2, 2021","March 2, 2021"
4899,NCT03712449,A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment,"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality",Device: JUVÉDERM®|Drug: BOTOX Cosmetic®|Drug: BELKYRA®|Other: SkinMedica,Allergan,Phase 4,59,Industry,"January 22, 2019","July 29, 2020","July 29, 2020"
4900,NCT03712423,PET Study With [89Zr]-Df-CriPec® Docetaxel,Solid Tumor,Drug: Cripec Docetaxel,"Amsterdam UMC, location VUmc|Cristal Therapeutics",Phase 1,7,Other|Industry,"April 1, 2018","March 25, 2020","May 8, 2020"
4901,NCT03712358,PVSRIPO for Patients With Unresectable Melanoma,Melanoma,Biological: PVSRIPO,"Istari Oncology, Inc.|Duke University",Phase 1,12,Industry|Other,"November 26, 2018","March 23, 2021","March 23, 2021"
4902,NCT03712280,MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy),Hepatic Cirrhosis|Hepatic Encephalopathy (HE),Drug: MNK6106|Drug: Rifaximin,Mallinckrodt,Phase 2,50,Industry,"December 1, 2018","July 14, 2020","July 14, 2020"
4903,NCT03712137,Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition,Jawline Definition,Device: VOLUX XC|Other: No-treatment control,Allergan,Phase 3,206,Industry,"November 12, 2018","February 4, 2020","January 26, 2021"
4904,NCT03712124,A Study of CNSA-001 in Women With Diabetic Gastroparesis,Gastroparesis,Drug: CNSA-001|Drug: Placebo,PTC Therapeutics,Phase 2,21,Industry,"February 27, 2019","September 8, 2019","October 8, 2019"
4905,NCT03711578,"Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)",Non Hodgkin Lymphoma,"Drug: Tenalisib,",Rhizen Pharmaceuticals SA,Phase 2,20,Industry,"November 25, 2018","June 16, 2020","October 16, 2020"
4906,NCT03711487,The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection,Colorectal Surgery|Foeniculum|Ileus,Drug: Foeniculum Vulgare Seed Ironing,West China Hospital,Phase 2,300,Other,"October 20, 2018","June 15, 2019","July 15, 2019"
4907,NCT03710889,Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption,"Osteoporosis, Postmenopausal|Osteoporosis|Osteoporosis Vertebral|Osteoporosis Risk|Osteoporosis Fracture|Osteoporosis Localized to Spine|Osteoporosis, Age-Related|Osteoporosis Senile|Osteoporosis of Vertebrae",Drug: Abaloparatide,"Radius Health, Inc.",Phase 3,23,Industry,"September 20, 2018","July 15, 2020","July 15, 2020"
4908,NCT03710707,Study to Evaluate DNL201 in Subjects With Parkinson's Disease,Parkinson Disease,Drug: DNL201|Drug: Placebo,Denali Therapeutics Inc.,Phase 1,29,Industry,"December 4, 2018","December 6, 2019","December 6, 2019"
4909,NCT03710330,Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section,Cesarean Section Complications,Drug: normal saline|Drug: 1gm tranexamic acid|Drug: 0.5 gm tranexamic acid,Aswan University Hospital,Phase 4,360,Other,"November 1, 2018","March 30, 2020","August 1, 2020"
4910,NCT03710187,HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients,Septic Shock,Drug: Hydrocortisone,University of Tennessee Medical Center,Phase 2,84,Other,"November 5, 2018","September 27, 2019","September 27, 2019"
4911,NCT03709654,"A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne",Acne Vulgaris,Biological: NB01|Other: Vehicle Control,"Naked Biome, Inc.|Therapeutics, Inc.",Phase 1,36,Industry,"November 1, 2018","September 30, 2019","September 30, 2019"
4912,NCT03709628,"A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients",Crohn Disease,Drug: EB8018 (First-in-class FimH blocker),Enterome,Phase 1,8,Industry,"March 7, 2018","November 12, 2019","December 4, 2019"
4913,NCT03709420,"A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219",Endometriosis,Drug: Placebo|Drug: FOR-6219,Forendo Pharma Ltd|Richmond Pharmacology Limited,Phase 1,87,Industry,"August 13, 2018","November 11, 2020","November 11, 2020"
4914,NCT03709355,Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs,HIV-1-infection,Drug: Elpida®|Drug: Rifampin|Drug: Rifabutin|Drug: Clarithromycin|Drug: Omeprazole|Drug: Atorvastatin|Drug: Levonorgestrel+Ethinylestradiol,Viriom,Phase 1,56,Industry,"November 14, 2018","September 6, 2019","September 6, 2019"
4915,NCT03708848,Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy,Helicobacter Pylori Infection,Drug: Esomeprazole|Drug: Bismuth Potassium Citrate|Drug: Clarithromycin|Drug: Metronidazole|Drug: Levofloxacin|Drug: Tetracycline,Shanghai Jiao Tong University School of Medicine,Phase 4,112,Other,"December 5, 2018","September 30, 2019","September 30, 2019"
4916,NCT03708718,Prednisolone in Early Diffuse Systemic Sclerosis,Systemic Sclerosis,Drug: Prednisolone 5 mg|Drug: Placebo oral capsule; From August 2020 'no additional treatment',Prof. Ariane herrick|Versus Arthritis|University of Manchester,Phase 2,35,Other,"December 21, 2017","March 4, 2021","May 27, 2021"
4917,NCT03708588,Chewed Versus Integral Pill of Ticagrelor,Percutaneous Coronary Intervention,Drug: Ticagrelor,Aurora Health Care,Phase 4,112,Other,"September 19, 2018","December 31, 2020","July 31, 2021"
4918,NCT03708211,"A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors","Neoplasms, Advanced Solid",Drug: TAK-931 PIC|Drug: TAK-931 Tablet|Drug: Esomeprazole,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,20,Industry,"March 28, 2019","December 3, 2019","December 3, 2019"
4919,NCT03708198,Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks,Thoracic,Drug: Liposomal Bupivacaine,University of Virginia,Phase 4,15,Other,"June 11, 2018","October 11, 2019","August 11, 2020"
4920,NCT03707990,A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese,Obesity and Overweight,Drug: NNC0165-1875|Drug: Placebo (NNC0165-1875)|Drug: Semaglutide,Novo Nordisk A/S,Phase 1,88,Industry,"October 15, 2018","August 13, 2019","August 13, 2019"
4921,NCT03707808,"Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab",Solid Tumor|Metastases to Soft Tissue,Drug: intratumoral injection of autologous CD1c (BDCA-1)+ myDC,Universitair Ziekenhuis Brussel,Phase 1,9,Other,"January 29, 2018","December 24, 2020","December 24, 2020"
4922,NCT03707717,A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants,Healthy Volunteers,Drug: Bimekizumab,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,189,Industry,"October 15, 2018","June 5, 2019","June 5, 2019"
4923,NCT03707587,M7824 in People With Recurrent Respiratory Papillomatosis,"Recurrent Respiratory Papillomatosis|Respiratory Papillomatosis|Laryngeal Papilloma, Recurrent|Human Papilloma Virus",Drug: M7824,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,9,NIH,"December 19, 2018","October 29, 2019","July 6, 2022"
4924,NCT03707535,"To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis",Rheumatoid Arthritis,Biological: CT-P13|Biological: Remicade,Celltrion,Phase 3,270,Industry,"November 12, 2018","March 16, 2020","March 5, 2021"
4925,NCT03707041,"Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model",Malaria,Drug: P218 (1000 mg) Oral Capsules|Drug: Placebo Oral Capsules|Drug: P218 (100 mg) Oral Capsules|Biological: PfSPZ Challenge,"Medicines for Malaria Venture|SGS Life Sciences, a division of SGS Belgium NV|Institute of Tropical Medicine, Belgium|Washington University School of Medicine|Swiss BioQuant A.G., Switzerland|PrimeVigilance Ltd., UK|Biologic LLP, UK|Sanaria Inc.|FGK Representative Service B.V., The Netherlands",Phase 1,32,Other|Industry,"November 16, 2018","May 27, 2019","June 3, 2019"
4926,NCT03706911,"Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects",HIV-1-infection,Drug: VM-1500A-LAI,Viriom,Phase 1,27,Industry,"January 21, 2019","March 27, 2020","May 18, 2020"
4927,NCT03706456,Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease,Complex Perianal Fistulas in Adult Participants With Crohn's Disease,Biological: Darvadstrocel,Takeda,Phase 3,22,Industry,"March 6, 2019","July 20, 2020","February 10, 2023"
4928,NCT03706313,Genicular Nerve Block for Total Knee Arthroplasty,Post-operative Pain,Drug: 15mL 0.25% bupivacaine|Procedure: Genicular nerve block|Drug: Saline,Duke University,Phase 4,40,Other,"January 15, 2019","October 16, 2019","October 22, 2019"
4929,NCT03706209,Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis,Psoriasis,Drug: MP1032|Drug: Placebo,MetrioPharm AG|Bioskin GmbH,Phase 2,153,Industry,"February 27, 2018","June 12, 2019","June 12, 2019"
4930,NCT03706157,Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE,Hepato Cellular Carcinoma,"Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline","University Hospital, Strasbourg, France",Phase 4,10,Other,"November 26, 2018","October 9, 2019","October 9, 2019"
4931,NCT03706040,A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis,Dermatitis,Biological: Placebo|Biological: Risankizumab,AbbVie,Phase 2,172,Industry,"December 27, 2018","October 28, 2020","April 26, 2021"
4932,NCT03705793,Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis,Chronic Rhinosinusitis (Diagnosis)|Allergic Rhinosinusitis|Chronic Eosinophilic Rhinosinusitis,Drug: Mometasone Furoate Nasal Irrigation|Drug: Mometasone Nasal Spray,Washington University School of Medicine,Phase 4,53,Other,"January 1, 2019","February 15, 2020","March 15, 2020"
4933,NCT03704870,Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection,"Lung Cancer|Lung Diseases|Lung Cancer, Nonsmall Cell|Surgery|Lung Adenocarcinoma",Diagnostic Test: Chest Xray|Diagnostic Test: No daily chest xray,"University Health Network, Toronto",Phase 2,50,Other,"January 26, 2018","December 31, 2019","March 31, 2020"
4934,NCT03704740,Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months,Influenza,Biological: NBP607-QIV|Biological: Agrippal,"SK Bioscience Co., Ltd.",Phase 3,676,Industry,"October 25, 2018","July 12, 2019","July 12, 2019"
4935,NCT03704623,Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic,Acute Renal Colic|Ureteric Stone,Drug: Paracetamol|Drug: Parecoxib,Mansoura University|Amiri Hospital,Phase 4,200,Other,"May 1, 2019","August 15, 2020","August 15, 2020"
4936,NCT03704519,Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.,Cerebrovascular Circulation,Drug: Darolutamide (BAY1841788)|Drug: Enzalutamide|Other: Placebo,Bayer,Phase 1,26,Industry,"October 23, 2018","October 1, 2019","November 5, 2019"
4937,NCT03704467,Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer,Ovarian Cancer,Drug: M6620|Drug: Avelumab|Drug: Carboplatin,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 1,3,Industry,"March 4, 2019","November 6, 2019","November 6, 2019"
4938,NCT03704428,"Safety, Tolerability and PK of SHR1314 in axSpA",Axial Spondyloarthritis,Drug: SHR-1314,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,45,Industry,"April 19, 2018","January 14, 2020","January 14, 2020"
4939,NCT03703882,Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy,"Muscular Dystrophy, Duchenne",Drug: Edasalonexent|Drug: Placebo,Catabasis Pharmaceuticals,Phase 3,131,Industry,"October 2, 2018","September 22, 2020","September 22, 2020"
4940,NCT03703570,A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations,Parkinson's Disease,Drug: KW-6356|Drug: Placebo,"Kyowa Kirin Co., Ltd.",Phase 2,502,Industry,"September 29, 2018","April 15, 2020","April 15, 2020"
4941,NCT03703349,Preoperative Oral Magnesium to Prevent Postoperative Atrial Fibrillation Following Coronary Surgery (POMAF-CS),Atrial Fibrillation|Coronary Artery Disease|Surgery--Complications,Drug: Magnesium Sulfate|Drug: Placebo Oral Tablet,"St Joseph University, Beirut, Lebanon",Phase 4,200,Other,"November 24, 2018","October 20, 2019","October 20, 2019"
4942,NCT03703336,Phase III Study of Liquid Formulation of ROTAVIN,Diarrhea|Diarrhea Rotavirus,Biological: ROTAVIN (liquid formulation)|Biological: ROTAVIN-M1 (frozen formulation),"Center for Research and Production of Vaccines and Biologicals, Vietnam|PATH|National Institute of Hygiene and Epidemiology, Vietnam|Children's Hospital Medical Center, Cincinnati",Phase 3,825,Other,"March 16, 2019","January 8, 2020","January 8, 2020"
4943,NCT03703310,"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)",Basal Cell Nevus Syndrome,"Drug: Patidegib Topical Gel, 2%|Drug: Patidegib Topical Gel, Vehicle","PellePharm, Inc.",Phase 3,174,Industry,"February 19, 2019","December 28, 2020","December 28, 2020"
4944,NCT03703206,The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA),"Knee Arthroplasty, Total",Drug: ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK),University of Pennsylvania,Phase 3,130,Other,"July 1, 2018","August 27, 2019","August 27, 2021"
4945,NCT03703102,Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: KHK4083|Drug: Placebo,"Kyowa Kirin, Inc.|Kyowa Kirin Co., Ltd.",Phase 2,274,Industry,"October 22, 2018","February 6, 2020","November 12, 2020"
4946,NCT03702777,A Study of ASP8302 in Participants With Underactive Bladder,Underactive Bladder,Drug: ASP8302|Drug: Placebo,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 2,135,Industry,"November 20, 2018","April 28, 2020","April 28, 2020"
4947,NCT03702621,Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery,Colorectal Surgery,Drug: liposomal Bupivacaine|Drug: Bupivacaine Hydrochloride,Indiana University,Phase 3,90,Other,"August 30, 2018","March 13, 2020","March 13, 2020"
4948,NCT03702400,Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery,Hypotension|Spinal Anesthesia,Drug: Phenylephrine 100 mcg|Drug: Norepinephrine 5 mcg,Hospital dos Servidores do Estado do Rio de Janeiro,Phase 2,72,Other,"October 1, 2018","June 1, 2020","October 1, 2020"
4949,NCT03702374,"Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy",Diabetic Retinopathy,Drug: Combined antioxidant therapy|Other: Placebo,University of Guadalajara|Instituto Mexicano del Seguro Social,Phase 3,132,Other,"September 26, 2018","November 30, 2020","December 31, 2020"
4950,NCT03702361,Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease,Primary Disease,Drug: VPRIV,Shaare Zedek Medical Center,Phase 4,15,Other,"September 4, 2018","September 30, 2019","March 18, 2021"
4951,NCT03701984,The Effect of Intrauterine Lidocaine Infusion and Oral Tramadol on Pain During Diagnostic Office Hysteroscopy,Hysteroscopy,Drug: Lidocaine|Drug: Tramadol|Drug: placebo,Cairo University,Phase 4,156,Other,"October 15, 2018","August 10, 2019","August 15, 2019"
4952,NCT03701555,"A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease",Digestive System Disease,Other: PvP001 placebo|Drug: PvP001 100 mg|Drug: PvP001 300 mg|Drug: PvP001 900 mg|Drug: Maximum Feasible Dose (MFD) of PvP002|Drug: Maximum Tolerated Dose (MTD) of PvP001|Drug: MTD of PvP001 following 7 days of PPI treatment|Other: PvP002 placebo|Drug: PvP001 600 mg|Drug: PvP003 placebo|Drug: PvP003|Drug: PvP003 150 mg,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,139,Industry,"June 19, 2018","January 31, 2021","July 2, 2021"
4953,NCT03700970,Comparing Local Anesthetics for TAP Block During Abdominally-based Free Flap for Breast Reconstruction,Breast Reconstruction|Anesthesia|Transverse Abdominis Plane Block,Drug: Liposomal bupivacaine|Drug: Regular bupivacaine,Vanderbilt University Medical Center,Phase 4,60,Other,"June 13, 2019","March 15, 2021","March 30, 2021"
4954,NCT03700658,A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046,Contraception,Drug: TV-46046|Drug: Depo-subQ 104|Drug: TV-46046 Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.|FHI 360",Phase 1,27,Industry|Other,"January 15, 2019","October 2, 2020","October 2, 2020"
4955,NCT03700320,Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine,Episodic Migraine,Drug: Standard of Care (SOC) Migraine Preventive Medication|Drug: Atogepant,Allergan,Phase 3,744,Industry,"October 8, 2018","May 21, 2020","May 21, 2020"
4956,NCT03699722,A Women-Focused PrEP Intervention,Behavior and Behavior Mechanisms|Information Literacy,Behavioral: Education + Activities|Behavioral: Information,University of Pennsylvania|New York Blood Center,Phase 1,83,Other,"November 3, 2018","October 10, 2019","November 10, 2019"
4957,NCT03699462,The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery,Coronary Artery Occlusive Disease(CAOD),Drug: Plasma solution-A injection|Drug: 5% Albumin,Yonsei University,Phase 4,106,Other,"November 13, 2018","October 17, 2020","October 17, 2020"
4958,NCT03699124,Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial,Smallpox,Biological: FD MVA-BN,Bavarian Nordic|Biomedical Advanced Research and Development Authority,Phase 3,1129,Industry|U.S. Fed,"June 19, 2019","January 6, 2020","June 22, 2020"
4959,NCT03698864,A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica,Necrobiosis Lipoidica,Drug: PCS499,Processa Pharmaceuticals,Phase 2,12,Industry,"November 7, 2018","February 25, 2020","February 25, 2020"
4960,NCT03698695,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers",Cognitive Impairment|Alzheimer Disease,Drug: THN 201|Drug: Donepezil|Drug: Placebo,Theranexus,Phase 1,152,Industry,"September 27, 2018","October 20, 2019","December 20, 2019"
4961,NCT03698682,Short Compared With Standard Duration of Antibiotic Treatment for AECOPD,Chronic Obstructive Pulmonary Disease,Drug: Levofloxacin 500mg,University of Monastir,Phase 2,310,Other,"January 1, 2018","January 31, 2021","January 31, 2021"
4962,NCT03698409,Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.,"Chronic Migraine, Headache",Drug: Preserved saline in reconstitution of Botox,State University of New York - Upstate Medical University,Phase 4,68,Other,"January 1, 2019","August 1, 2019","August 1, 2019"
4963,NCT03698305,A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product,Healthy Subjects,Drug: ASP5354|Drug: Placebo,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,30,Industry,"October 25, 2018","May 20, 2019","May 20, 2019"
4964,NCT03698279,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age,Influenza,"Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Biological: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Biological: Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Biological: FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 2,665,Industry,"October 9, 2018","October 16, 2019","October 16, 2019"
4965,NCT03697798,A Study Exploring Whooping Cough Protection in Children and Adults,Pertussis,Biological: Boostrix®-IPV combination vaccine,University of Oxford|National Institute for Public Health and the Environment (RIVM)|University of Turku,Phase 4,122,Other,"April 18, 2018","January 14, 2020","January 14, 2020"
4966,NCT03697629,A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma,Multiple Myeloma in Relapse,Drug: Daratumumab,Canadian Myeloma Research Group,Phase 2,40,Other,"December 3, 2018","July 21, 2020","December 20, 2021"
4967,NCT03697460,Topical Ruxolitinib Lichen Planus,Lichen Planus,Drug: INCB018424,Aaron R. Mangold|Mayo Clinic,Phase 2,12,Other,"August 30, 2018","June 25, 2020","August 25, 2020"
4968,NCT03697330,Liberal Versus Restrictive Fluid Protocols in Adults,Intraoperative Complications,Drug: Ringer lactate,Assiut University,Phase 2,80,Other,"January 28, 2018","June 30, 2019","June 30, 2019"
4969,NCT03697265,A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD),Premenstrual Dysphoric Disorder,Drug: Sepranolone (UC1010) low dose|Drug: Sepranolone (UC1010) high dose|Drug: Placebo,Asarina Pharma|Ergomed,Phase 2,475,Industry,"April 20, 2018","July 28, 2020","October 23, 2020"
4970,NCT03697252,A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia,Schizophrenia,Drug: Xanomeline and Trospium Chloride Capsules|Drug: Placebo Capsules,Karuna Therapeutics,Phase 2,182,Industry,"September 18, 2018","September 4, 2019","September 4, 2019"
4971,NCT03697226,Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.,"HSIL of Cervix|HSIL, High Grade Squamous Intraepithelial Lesions|High-Grade Cervical Intraepithelial Neoplasia|Human Papilloma Virus|HIV Negative|Cervical Cancer|CIN - Cervical Intraepithelial Neoplasia|Cervical Neoplasm|Cervical Dysplasia",Drug: Topical ABI-1968,Antiva Biosciences,Phase 1,8,Industry,"December 21, 2018","May 26, 2020","June 12, 2020"
4972,NCT03697161,A Study of OV101 in Individuals With Fragile X Syndrome,Fragile X Syndrome (FXS),Drug: OV101 (gaboxadol),Ovid Therapeutics Inc.,Phase 2,23,Industry,"September 17, 2018","February 3, 2020","February 26, 2020"
4973,NCT03696771,Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer,NON-breast HER2+ Malignancies,Drug: NJH395,Novartis Pharmaceuticals|Novartis,Phase 1,18,Industry,"December 27, 2018","October 19, 2020","October 19, 2020"
4974,NCT03696758,Improving Right Ventricular Function in Young Adults Born Preterm,"Infant,Premature",Procedure: Pulmonary Function Testing|Procedure: Electrocardiogram|Procedure: Cardiac Magnetic Resonance Imaging|Drug: Metoprolol|Drug: Sildenafil,"University of Wisconsin, Madison|National Center for Advancing Translational Sciences (NCATS)",Phase 2,10,Other|NIH,"October 30, 2018","February 24, 2020","February 24, 2020"
4975,NCT03696550,A Safety and PK Study of IV Eravacycline,Bacterial Infections,Drug: Eravacycline (TP-434),"Tetraphase Pharmaceuticals, Inc.|La Jolla Pharmaceutical Company",Phase 1,19,Industry,"December 20, 2018","March 14, 2021","March 19, 2021"
4976,NCT03696459,A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants,Healthy,"Drug: JNJ-53718678, 2000 mg|Drug: JNJ-53718678, 3000 mg|Drug: JNJ-53718678, 4500 mg or Dose to be decided|Drug: JNJ-53718678 500 mg|Drug: JNJ-53718678 Placebo|Drug: Moxifloxacin 400 mg|Drug: Moxifloxacin Placebo","Janssen Research & Development, LLC",Phase 1,52,Industry,"October 2, 2018","December 13, 2019","December 13, 2019"
4977,NCT03696355,Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas,Brain and Central Nervous System Tumors,Drug: GDC-0084|Radiation: radiation therapy,St. Jude Children's Research Hospital|Kazia Therapeutics Limited,Phase 1,27,Other|Industry,"November 19, 2018","April 2, 2021","September 4, 2022"
4978,NCT03696108,A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038),Chronic Cough,Drug: Gefapixant|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 3,175,Industry,"October 31, 2018","October 7, 2020","October 7, 2020"
4979,NCT03695562,Stability of Dental Implants Placed in Patients With Vitamin D Deficiency Using Sequential Drilling Versus a New One Single Drilling Design,Implant Stability With Vitamin D Deficiency,Procedure: sequential drilling technique,Cairo University,Phase 4,30,Other,"February 1, 2019","August 20, 2020","February 14, 2021"
4980,NCT03695198,A Study of LY3361237 in Healthy Participants,Healthy,Drug: LY3361237 - SC|Drug: LY3361237 - IV|Drug: Placebo - SC|Drug: Placebo - IV,Eli Lilly and Company,Phase 1,64,Industry,"October 26, 2018","August 29, 2019","August 29, 2019"
4981,NCT03695185,A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy,Ulcerative Colitis (UC),Drug: Ravagalimab 600 mg|Drug: Ravagalimab 300 mg,AbbVie,Phase 2,42,Industry,"March 26, 2019","April 5, 2021","January 10, 2022"
4982,NCT03695094,"A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil",Epilepsy,Drug: Padsevonil|Drug: Oxcarbazepine|Drug: Levetiracetam|Drug: Lamotrigine|Drug: Brivaracetam,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 1,31,Industry,"September 18, 2018","May 18, 2019","May 30, 2019"
4983,NCT03694522,A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer,Gastric Cancer,Biological: Bemarituzumab|Drug: Placebo|Drug: Modified FOLFOX6,"Five Prime Therapeutics, Inc.|Zai Lab (Shanghai) Co., Ltd.",Phase 2,155,Industry,"September 14, 2018","September 23, 2020","May 13, 2022"
4984,NCT03694353,Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU,Phenylketonuria (PKU),Drug: Pegvaliase,BioMarin Pharmaceutical,Phase 3,37,Industry,"September 13, 2018","January 13, 2021","January 13, 2021"
4985,NCT03694275,"A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)",15q Duplication Syndrome|CDKL5 Deficiency Disease,Drug: Soticlestat,Takeda|Ovid Therapeutics Inc.,Phase 2,20,Industry,"September 10, 2018","July 13, 2020","July 31, 2020"
4986,NCT03693989,Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification,Cataract,Drug: Difluprednate 0.05%|Drug: Prednefrin,Laboratorios Sophia S.A de C.V.,Phase 3,178,Industry,"October 4, 2018","August 7, 2019","October 22, 2019"
4987,NCT03693599,Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean,Post Partum Hemorrhage,Drug: carbetocin|Drug: Syntometrine,Cairo University,Phase 4,1200,Other,"October 1, 2018","September 15, 2019","September 30, 2019"
4988,NCT03693560,Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD,"Coronary Artery Disease|Diabetes Mellitus, Type 2",Drug: Vildagliptin 50 mg Oral Tablet|Drug: Metformin 1000 mg Oral Tablet|Drug: Glimepiride upto 4 mg Oral Tablet,Damanhour University|Tanta University,Phase 4,80,Other,"October 8, 2018","September 10, 2019","October 10, 2019"
4989,NCT03693508,A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression,HIV Infections|Severe Immunosuppression,Drug: Genvoya®,Fundacion SEIMC-GESIDA|Merck Sharp & Dohme LLC,Phase 4,50,Other|Industry,"April 13, 2018","May 28, 2020","May 28, 2020"
4990,NCT03693430,Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,Overweight|Obesity,Drug: Semaglutide|Drug: Placebo (Semaglutide),Novo Nordisk A/S,Phase 3,304,Industry,"October 5, 2018","January 29, 2021","March 23, 2021"
4991,NCT03693131,Efficacy of MND-2119 in Participants With Hypertriglyceridemia,Hypertriglyceridemia,Drug: Icosapent (MND-2119)|Drug: Icosapent (EPADEL CAPSULES 300),"Mochida Pharmaceutical Company, Ltd.",Phase 3,580,Industry,"October 27, 2018","June 15, 2019","June 29, 2019"
4992,NCT03692949,A Study of LY3451838 in Healthy Participants,Healthy,Drug: LY3451838|Drug: Placebo,Eli Lilly and Company,Phase 1,53,Industry,"December 11, 2018","February 26, 2020","February 26, 2020"
4993,NCT03692910,A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode,Bipolar Disorder I|Bipolar Disorder II|Major Depressive Episode,Drug: SAGE-217|Drug: Placebo,Sage Therapeutics,Phase 2,35,Industry,"August 23, 2018","May 21, 2019","May 21, 2019"
4994,NCT03692871,A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK),Pneumococcal Infections,Biological: V114|Biological: Prevnar 13™,Merck Sharp & Dohme LLC,Phase 3,2409,Industry,"December 14, 2018","March 26, 2021","March 26, 2021"
4995,NCT03692299,Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis,Systemic Sclerosis|Small Intestinal Bacterial Overgrowth,Drug: Saccharomyces Boulardii Oral Tablet|Drug: Metronidazole,"Coordinación de Investigación en Salud, Mexico",Phase 4,39,Other,Jun-15,"July 26, 2019","July 26, 2019"
4996,NCT03692286,Assessment of Postoperative Pain After Using Various Intracanal Medication in Patients With Necrotic Pulp,Postoperative Pain,Combination Product: Silver nanoparticle/Calcium hydroxide|Drug: Silver Nanoparticles in gel form|Drug: Calcium Hydroxide Intracanal medication,Cairo University,Phase 4,30,Other,"June 1, 2019","August 18, 2020","September 18, 2020"
4997,NCT03691974,Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee,"Osteoarthritis, Knee|Osteoarthritis, Hip",Drug: Fasinumab|Other: Placebo,"Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.",Phase 2,180,Industry,"October 15, 2018","January 30, 2020","January 7, 2021"
4998,NCT03691818,Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis,KNEE OSTEOARTHRITIS,Drug: X0002 Spray|Drug: Ibuprofen Tablet|Drug: Ibuprofen Placebo Tab|Drug: X0002 Placebo Spray,"Tianjin XinChen-Techfields Pharma Co., LTD.",Phase 2,353,Industry,"July 16, 2018","October 21, 2019","October 21, 2019"
4999,NCT03691779,Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age,Cystic Fibrosis,Drug: ELX/TEZ/IVA|Drug: IVA,Vertex Pharmaceuticals Incorporated,Phase 3,71,Industry,"October 2, 2018","August 7, 2020","August 7, 2020"
5000,NCT03691623,A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model,RSV Infection,Drug: EDP-938 Dose 1|Drug: EDP-938 Dose 2|Drug: Placebo|Drug: EDP-938 Dose 3|Drug: EDP-938 Dose 4,"Enanta Pharmaceuticals, Inc|hVIVO Services Limited",Phase 2,179,Industry|Other,"October 15, 2018","September 30, 2019","October 18, 2019"
5001,NCT03691584,"Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers",Healthy Subjects,Drug: TP-6076|Procedure: Bronchoalveolar lavage,"Tetraphase Pharmaceuticals, Inc.|PRA Health Sciences|La Jolla Pharmaceutical Company",Phase 1,8,Industry,"November 26, 2018","June 30, 2019","December 18, 2019"
5002,NCT03691467,the Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant,Immediate Dental Implant,Device: immediate dental implant|Drug: Hyaluronic Acid,Ibrahim Samy Kalboush|Cairo University,Phase 4,24,Other,"September 30, 2019","January 12, 2021","May 30, 2021"
5003,NCT03691337,Fascia Iliaca Blocks for Total Hip Arthroplasty,THA,Drug: Marcaine 0.25 % Injectable Solution|Drug: Sodium chloride,New York School of Regional Anesthesia,Phase 4,75,Other,"May 15, 2018","November 12, 2019","December 4, 2019"
5004,NCT03691090,Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer,Advanced Esophageal Cancer,Drug: SHR-1210|Drug: Placebo|Drug: paclitaxel|Drug: cisplatin,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,596,Industry,"December 3, 2018","October 30, 2020","April 30, 2022"
5005,NCT03690973,Evaluation of Bone Changes After Immediate Implant Placement or Socket Preservation With or Without Surgical Flap in The Aesthetic Zone,Alveolar Socket Preservation,Drug: Alveolar socket preservation with graft and flap surgery|Device: Immediate implant placement with bone using flapless surgery|Device: Immediate implant placement with bone using flap surgery|Drug: Alveolar socket preservation with graft and flapless surgery,Cairo University,Phase 4,32,Other,"September 30, 2018","December 30, 2020","March 30, 2021"
5006,NCT03690141,An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC),Castrate-resistant Prostate Cancer (CRPC),Drug: tomivosertib (eFT508),Effector Therapeutics,Phase 2,16,Industry,"October 12, 2018","April 27, 2020","April 27, 2020"
5007,NCT03689998,Evaluation of Melatonin Application of Immediate Dental Implant,Immediate Dental Implant,Device: immediate implant placement|Drug: Melatonin,Cairo University,Phase 4,24,Other,"September 30, 2019","January 12, 2021","May 30, 2021"
5008,NCT03689374,"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Insulin aspart|Drug: Insulin glargine U100,Novo Nordisk A/S,Phase 3,2274,Industry,"October 1, 2018","February 22, 2021","February 22, 2021"
5009,NCT03689361,Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.,Migraine Aura,Combination Product: MRI|Diagnostic Test: MRI control|Other: telephone consultation,"University Hospital, Toulouse",Phase 4,60,Other,"December 22, 2018","October 11, 2020","December 11, 2020"
5010,NCT03689153,A Study of JNJ-63733657 in Healthy Japanese Participants,Healthy,Drug: JNJ-63733657|Drug: Placebo,Janssen Pharmaceutical K.K.,Phase 1,24,Industry,"September 28, 2018","July 11, 2019","July 11, 2019"
5011,NCT03688802,Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation,Dry Eye Disease,Drug: OC-01 (varenicline) nasal spray|Drug: Placebo (vehicle control) nasal spray,"Oyster Point Pharma, Inc.",Phase 2,18,Industry,"September 25, 2018","September 30, 2019","September 30, 2019"
5012,NCT03688685,A Clinical Study to Evaluate CAD-1883 in Essential Tremor,Essential Tremor,Drug: CAD-1883,Cadent Therapeutics,Phase 2,25,Industry,"January 23, 2019","September 10, 2019","September 24, 2019"
5013,NCT03688555,A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis,Bilateral Nasal Polyposis,Drug: ACT-774312|Drug: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 2,10,Industry,"October 19, 2018","November 24, 2020","December 1, 2020"
5014,NCT03688269,Minimal Effective Concentration (EC90) of Ropivacaine,"Anesthesia, Conduction|Ropivacaine|Dexamethasone|Axillary Brachial Plexus Block",Drug: Intravenous dexamethasone|Drug: Intravenous saline|Drug: Perineural ropivacaine,Centre Hospitalier Universitaire de Besancon,Phase 3,146,Other,"October 5, 2018","November 4, 2019","May 4, 2020"
5015,NCT03688152,A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: INCB053914|Drug: INCB050465,Incyte Corporation,Phase 1,9,Industry,"December 3, 2018","September 1, 2020","September 1, 2020"
5016,NCT03688074,Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE),"Asthma|Bronchial Diseases|Respiratory Tract Diseases|Lung Diseases, Obstructive|Lung Diseases|Respiratory Hypersensitivity|Hypersensitivity, Immediate|Hypersensitivity|Immune System Diseases",Biological: Tezepelumab|Other: Placebo,AstraZeneca|Amgen,Phase 2,116,Industry,"November 2, 2018","November 16, 2020","November 16, 2020"
5017,NCT03688061,Class II Invariant Chain HCV Vaccine Study,Hepatitis C,Biological: ChAd3-hliNSmut|Biological: MVA-hliNSmut,University of Oxford|Oxford University Hospitals NHS Trust|ReiThera Srl|European Commission|GlaxoSmithKline,Phase 1,25,Other|Industry,"December 4, 2017","August 4, 2019","August 4, 2022"
5018,NCT03687827,A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study,"Diabetes Mellitus, Type 2",Drug: Insulin degludec|Drug: Insulin glargine,Novo Nordisk A/S,Phase 4,498,Industry,"October 2, 2018","December 20, 2019","December 27, 2019"
5019,NCT03687736,Subject Satisfaction With AbobutulinumtoxinA Treatment,Glabellar Frown Lines,Biological: AbobotulinumtoxinA,Galderma R&D,Phase 4,120,Industry,"October 2, 2018","November 7, 2019","December 4, 2019"
5020,NCT03687684,Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects,Healthy Volunteers,Drug: TAK-831|Drug: Placebo,Neurocrine Biosciences|Takeda,Phase 1,40,Industry,"October 9, 2018","June 9, 2019","June 19, 2019"
5021,NCT03687632,ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects,Persistent Corneal Epithelial Defect,Biological: ST266,"Noveome Biotherapeutics, formerly Stemnion",Phase 2,13,Industry,"June 10, 2019","August 18, 2020","August 25, 2020"
5022,NCT03687502,The Role of Contrast Enhanced Ultrasound in Appendicitis,Acute Appendicitis,Drug: Sulfur hexafluoride lipid-type A microspheres,Children's Mercy Hospital Kansas City,Phase 2,37,Other,"January 4, 2019","March 26, 2021","July 5, 2022"
5023,NCT03687372,Study of A-101 Topical Solution for the Treatment of Common Warts,Common Wart,Drug: A-101|Other: vehicle,"Aclaris Therapeutics, Inc.",Phase 3,503,Industry,"September 17, 2018","June 20, 2019","September 6, 2019"
5024,NCT03687333,Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment,Glycogen Storage Disease Type II,Drug: ALGLUCOSIDASE ALFA (MYOZYME),"Genzyme, a Sanofi Company|Sanofi",Phase 4,10,Industry,"December 4, 2018","December 30, 2020","December 30, 2020"
5025,NCT03687255,Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections,Urinary Tract Infections,Drug: cefepime/AAI101 combination|Drug: Piperacillin/tazobactam,"Allecra|Medpace, Inc.",Phase 3,1043,Industry,"September 24, 2018","January 30, 2020","February 15, 2020"
5026,NCT03687242,Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia,Congenital Adrenal Hyperplasia|CAH - Congenital Adrenal Hyperplasia|CAH - 21-Hydroxylase Deficiency,Drug: SPR001,Spruce Biosciences,Phase 2,11,Industry,"September 6, 2018","September 17, 2019","September 24, 2019"
5027,NCT03686904,Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds,Wound Infection,Drug: Benzalkonium Gel|Other: standard of care topical gel|Procedure: Debridement|Drug: benzalkonium irrigation|Other: Saline Irrigation (SOC Irrigation),Georgetown University|Next Science TM,Phase 4,11,Other|Industry,"November 19, 2018","February 14, 2020","February 14, 2020"
5028,NCT03686163,Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke,Acute Ischemic Stroke,Drug: Nerve Growth Factors|Drug: normal saline,"Jinling Hospital, China",Phase 4,106,Other,Jan-16,"December 31, 2019","December 31, 2020"
5029,NCT03686059,Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease,Ocular Surface Disease,Drug: Omega 3|Device: punctal plug,Benha University,Phase 4,90,Other,"July 2, 2018","November 15, 2019","November 20, 2019"
5030,NCT03685747,Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis,Peritoneal Dialysis-associated Peritonitis,Drug: Vancomycin,Thomas Jefferson University,Phase 1,4,Other,"November 15, 2018","August 30, 2020","October 1, 2020"
5031,NCT03685708,HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I),Hepatitis|Safety and Tolerability,Biological: HEPLISAV-B,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,78,NIH,"December 7, 2018","December 16, 2020","December 16, 2020"
5032,NCT03685695,"Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Fallopian Tube Endometrioid Tumor|Fallopian Tube Mucinous Neoplasm|Fallopian Tube Serous Neoplasm|Ovarian Clear Cell Tumor|Ovarian Endometrioid Tumor|Ovarian Mucinous Tumor|Ovarian Serous Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Other: Laboratory Biomarker Analysis|Device: Monitoring Device|Other: Physical Activity|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Roswell Park Cancer Institute,Phase 2,9,Other,"June 27, 2017","August 1, 2019","July 30, 2020"
5033,NCT03685682,Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients,Varicella Zoster Vaccine,Biological: recombinant subunit Herpes zoster vaccine,"University Health Network, Toronto",Phase 3,23,Other,"May 25, 2018","September 5, 2019","September 5, 2019"
5034,NCT03685630,A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization,Partial Seizures With or Without Secondary Generalization|Epilepsy,Drug: Brivaracetam,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 3,10,Industry,"January 4, 2019","March 27, 2021","March 27, 2021"
5035,NCT03685604,PVP Iodine vs Chlorhexidine in Alcohol for Disinfection of the Surgical Site,Surgical Site Infections,Drug: CHX disinfection|Drug: PI Disinfection,"University Hospital, Basel, Switzerland|Swiss National Science Foundation",Phase 4,3321,Other,"September 10, 2018","June 30, 2020","June 30, 2020"
5036,NCT03685500,A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c),HIV Infections,Drug: Symtuza® (TAF/FTC/DRV/c)|Drug: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c),"Fundacion SEIMC-GESIDA|Janssen-Cilag, S.A.",Phase 4,78,Other|Industry,"December 4, 2018","June 25, 2020","June 25, 2020"
5037,NCT03684044,Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza,Influenza,Drug: Baloxavir Marboxil|Other: Placebo,Hoffmann-La Roche,Phase 3,363,Industry,"January 8, 2019","March 16, 2020","March 16, 2020"
5038,NCT03683719,"Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema",Chronic Hand Eczema,Drug: Delgocitinib cream|Drug: Delgocitinib cream vehicle,LEO Pharma,Phase 2,258,Industry,"November 28, 2018","March 6, 2020","April 20, 2020"
5039,NCT03683576,GB001 in Adult Subjects With Moderate to Severe Asthma,Asthma,Drug: GB001|Drug: Placebo,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.",Phase 2,481,Industry,"October 22, 2018","July 23, 2020","August 18, 2020"
5040,NCT03682770,Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy),Peanut Allergy,Drug: Dupilumab|Drug: Placebo matching dupilumab|Drug: AR101,"Regeneron Pharmaceuticals|Sanofi|Aimmune Therapeutics, Inc.",Phase 2,149,Industry,"October 3, 2018","October 16, 2020","July 23, 2021"
5041,NCT03682705,A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis,Rheumatoid Arthritis (RA),Drug: Elsubrutinib|Drug: Upadacitinib|Drug: Placebo for elsubrutinib|Drug: Placebo for upadacitinib,AbbVie,Phase 2,242,Industry,"October 8, 2018","March 26, 2020","March 26, 2020"
5042,NCT03682380,A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants,Healthy,Drug: Seltorexant High Dose|Drug: Seltorexant Low Dose,"Janssen Research & Development, LLC",Phase 1,151,Industry,"October 1, 2018","August 23, 2019","August 23, 2019"
5043,NCT03682302,Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL,Postoperative Pain Management,Drug: Exparel|Drug: 0.5% Bupivacaine HCl,"Pacira Pharmaceuticals, Inc",Phase 3,98,Industry,"April 2, 2019","August 30, 2019","September 24, 2019"
5044,NCT03682120,Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza,Avian Influenza|Influenza Immunisation,Biological: A/H7N9|Drug: MF59|Other: Phosphate Buffered Saline (PBS) diluent,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,372,NIH,"November 2, 2018","April 30, 2020","April 30, 2020"
5045,NCT03682107,Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device,Hantavirus Pulmonary Infection|Immunisation,Biological: Andes virus DNA vaccine|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,48,NIH,"February 19, 2019","September 23, 2020","September 23, 2020"
5046,NCT03681457,"Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects",Non-alcoholic Fatty Liver Disease,Drug: LJN452,Novartis Pharmaceuticals|Novartis,Phase 1,42,Industry,"September 24, 2018","September 25, 2019","September 25, 2019"
5047,NCT03681093,Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma,Nasal Polyps,Drug: Fevipiprant 150 mg|Drug: Fevipiprant 450 mg|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,98,Industry,"March 26, 2019","May 29, 2020","June 10, 2020"
5048,NCT03680404,The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction,Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction,Drug: Control (Phenylephrine)|Drug: Phenylephrine + Apocynin|Drug: Phenylephrine + Allopurinol|Drug: Phenylephrine + Tempol,The University of Texas at Arlington,Phase 1,24,Other,"October 1, 2018","February 1, 2020","February 1, 2020"
5049,NCT03679884,Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep,Insomnia Disorder,Drug: Daridorexant 10 mg|Drug: Daridorexant 25 mg|Drug: Daridorexant 50 mg|Drug: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 3,804,Industry,"October 9, 2018","February 22, 2021","February 22, 2021"
5050,NCT03679767,A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203),Metastatic Non-small Cell Lung Cancer|Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer|Unresectable Melanoma|Metastatic Melanoma|Locally Advanced Renal Cell Carcinoma|Metastatic Clear-Cell Renal Cell Carcinoma,Drug: Retifanlimab,Incyte Corporation,Phase 2,121,Industry,"January 9, 2019","April 15, 2021","June 28, 2022"
5051,NCT03679013,Effectiveness of an Opioid Sparing Pain Regimen in Cardiac Surgery,"Pain, Postoperative",Drug: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Drug: Opiate based pain regimen.,Inova Health Care Services,Phase 2,19,Other,"April 19, 2019","July 12, 2019","July 12, 2019"
5052,NCT03677973,A Study to Investigate the Safety of AB680 in Healthy Volunteers,Healthy Volunteers,Drug: AB680|Other: Placebo,"Arcus Biosciences, Inc.",Phase 1,64,Industry,"October 16, 2018","August 19, 2019","August 19, 2019"
5053,NCT03677934,A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration,Neovascular Age-Related Macular Degeneration,Drug: PDS Implant filled with 100 mg/mL Ranibizumab|Drug: Intravitreal Injections of 10 mg/mL Ranibizumab,Hoffmann-La Roche,Phase 3,415,Industry,"September 12, 2018","May 22, 2020","June 9, 2021"
5054,NCT03677531,Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy,Malignant Neoplasm,Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy|Other: Video,OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Oregon Health and Science University,Phase 1,6,Other|NIH,"May 31, 2018","September 25, 2019","September 25, 2019"
5055,NCT03677401,"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis",Pruritus|Prurigo Nodularis,Drug: 5mg Serlopitant Tablets|Drug: Placebo Tablets,Vyne Therapeutics Inc.,Phase 3,295,Industry,"August 29, 2018","January 9, 2020","February 6, 2020"
5056,NCT03677336,Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI,"Infertility, Female|Infertility|Genital Diseases, Male|Genital Diseases, Female|Progesterone|Dydrogesterone|Hormones|Hormones, Hormone Substitutes, and Hormone Antagonists|Physiological Effects of Drugs|Progestins",Drug: Dydrogesterone Oral Tablet|Drug: Micronized progesterone|Drug: Placebo Dydrogesterone oral tablet|Drug: Placebo Micronized progesterone,CRG UZ Brussel|Universitätsklinikum Hamburg-Eppendorf|Abbott|KU Leuven,Phase 4,30,Other|Industry,"May 1, 2019","August 24, 2020","August 24, 2020"
5057,NCT03676751,MORDOR II Burkina Faso: Longitudinal Trial,Child Growth|Diversity of Microbiome|Child Mortality|Resistance Bacterial,Drug: Azithromycin|Drug: Placebo,"University of California, San Francisco|Centre de Recherche en Sante de Nouna, Burkina Faso|Bill and Melinda Gates Foundation",Phase 4,500,Other,"October 10, 2019","July 6, 2020","July 6, 2020"
5058,NCT03676634,Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®,Botulism,Biological: rBV A/B,California Department of Public Health,Phase 2,32,Other,"March 7, 2019","April 25, 2020","July 3, 2020"
5059,NCT03676413,A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma,Asthma,Drug: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|Drug: ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|Drug: Placebo,Respirent Pharmaceuticals Co Ltd.,Phase 3,451,Industry,"October 2, 2018","August 2, 2019","June 30, 2020"
5060,NCT03676335,Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye,Dry Eye,Drug: CsA eye gel|Drug: CsA for eye emulsion|Drug: Hypromellose Eye Drops,Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.,Phase 2,240,Industry,"May 9, 2018","June 30, 2019","December 12, 2019"
5061,NCT03676322,Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants,Healthy,Drug: M5049|Drug: Placebo,"Merck KGaA, Darmstadt, Germany",Phase 1,96,Industry,"September 20, 2018","July 26, 2019","July 26, 2019"
5062,NCT03676296,Effect of Puerarin on Heart Health in Men,Cardiovascular Disease Risk Factors,Drug: Puerarin|Drug: Placebo,The University of Hong Kong|Health and Medical Research Fund,Phase 2,217,Other,"September 5, 2018","April 17, 2021","April 17, 2021"
5063,NCT03676101,Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females,Cervical Cancers|Vulvar Cancer|Vaginal Cancer|CIN1|CIN2|CIN 3|AIS|Invasive Carcinoma|Mild Dysplasia of Vulva|Moderate Dysplasia of Vulva|Vin III|VaIN1|VaIN2|VaIN3|Genital Wart,Biological: 9-valent HPV Recombinant Vaccine|Biological: Placebo,"Shanghai Bovax Biotechnology Co., Ltd.|Chongqing Bovax Biopharmaceutical Co., Ltd.",Phase 1,90,Industry,"October 10, 2018","August 20, 2019","January 10, 2020"
5064,NCT03675581,A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD),"Scleroderma, Systemic",Drug: Microgynon|Drug: Nintedanib,Boehringer Ingelheim,Phase 1,17,Industry,"November 8, 2018","October 9, 2019","October 10, 2019"
5065,NCT03675477,A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.,Ulcerative Colitis,Drug: SHR0302|Drug: Placebo,Reistone Biopharma Company Limited,Phase 2,164,Industry,"April 13, 2019","November 30, 2020","February 3, 2021"
5066,NCT03674476,An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function,NAFLD|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Drug: BMS-986036,Bristol-Myers Squibb,Phase 1,40,Industry,"September 11, 2018","June 24, 2019","June 24, 2019"
5067,NCT03674294,Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy,Gastrointestinal Neoplasms|Chemotherapy-induced Nausea and Vomiting,Drug: Aprepitant|Drug: Palonosetron|Drug: Dexamethasone|Drug: Placebo Oral Tablet,Sun Yat-sen University,Phase 3,248,Other,"August 4, 2015","March 31, 2020","June 1, 2020"
5068,NCT03674125,"Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection",HCV Infection,Biological: GLS-6150,"GeneOne Life Science, Inc.|Inovio Pharmaceuticals",Phase 1,32,Industry,"September 4, 2018","April 7, 2020","May 4, 2020"
5069,NCT03674112,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,HER2-Positive Early Breast Cancer,Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|Drug: Pertuzumab IV|Drug: Trastuzumab IV,Hoffmann-La Roche,Phase 2,160,Industry,"December 19, 2018","February 24, 2020","October 12, 2022"
5070,NCT03673696,The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects,Chronic Hepatitis c,Drug: HEC74647PA Capsule|Drug: placebo,"Sunshine Lake Pharma Co., Ltd.",Phase 1,105,Industry,"September 4, 2018","July 2, 2019","July 5, 2019"
5071,NCT03673345,Development of Childhood Anti-Influenza Immunity,Influenza|Influenza Immunisation,Biological: Influenza Virus Quadrivalent Inactivated Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,125,NIH,"September 25, 2018","December 22, 2020","December 22, 2020"
5072,NCT03673020,Phase 1a Study to Evaluate Immunogenicity of ASV®,"Solid Tumor, Adult",Biological: ASV® AGEN2017 + QS-21 Stimulon® adjuvant,Agenus Inc.,Phase 1,3,Industry,"May 16, 2019","February 3, 2021","February 3, 2021"
5073,NCT03672604,A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects,Safety and Tolerability in Healthy Volunteers,Drug: NLY01,"Neuraly, Inc.",Phase 1,96,Industry,"September 19, 2018","July 30, 2019","July 30, 2019"
5074,NCT03672175,A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder,Major Depressive Disorder,Drug: SAGE-217|Drug: Placebo,Sage Therapeutics,Phase 3,581,Industry,"November 19, 2018","September 24, 2019","March 17, 2020"
5075,NCT03672097,Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI),Acute Coronary Syndrome (ACS),Drug: Prasugrel,"Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company|Daiichi Sankyo, Inc.",Phase 4,204,Industry,"October 16, 2018","August 19, 2020","August 19, 2020"
5076,NCT03672006,t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection,Central Venous Catheter Thrombosis|Central Venous Catheter Associated Bloodstream Infection,Biological: alteplase (recombinant t-PA)|Drug: Heparin,Medical College of Wisconsin,Phase 2,20,Other,"April 22, 2019","December 15, 2019","December 15, 2019"
5077,NCT03671564,Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia,Drug: Milademetan,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.",Phase 1,14,Industry,"August 23, 2018","September 6, 2019","September 6, 2019"
5078,NCT03670810,A Study of Lasmiditan (LY573144) Over Four Migraine Attacks,Migraine,Drug: Lasmiditan|Drug: Placebo,Eli Lilly and Company,Phase 3,1633,Industry,"June 24, 2019","June 12, 2020","July 8, 2021"
5079,NCT03670641,Remission Through Early Monitored Insulin Therapy - Duration Month,Type 2 Diabetes Mellitus,Drug: Glargine|Drug: Lispro|Device: Dexcom G6,Sandra Sobel|University of Pittsburgh,Phase 4,10,Other,"March 26, 2019","July 31, 2020","July 31, 2020"
5080,NCT03670355,Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir,HIV Infections,Drug: Tenofovir (TFV) IVR|Drug: Placebo IVR,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,49,NIH,"December 7, 2018","September 25, 2019","September 25, 2019"
5081,NCT03670160,Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome,Neonatal Abstinence Syndrome,Drug: Phenobarbital|Drug: Clonidine,University of Tennessee Medical Center,Phase 2,25,Other,"October 1, 2018","May 31, 2020","May 31, 2020"
5082,NCT03670043,Tolerance & Responsiveness Improvement for Metformin (TRIM),Type2 Diabetes Mellitus,Drug: Psyllium powder|Drug: Metformin Extended Release Oral Tablet,West Side Institute for Science and Education,Phase 4,29,Other,"March 19, 2019","October 15, 2020","August 15, 2021"
5083,NCT03669861,Safety and Efficacy of Abatacept in IgG4-Related Disease,IgG4-related Disease,Drug: Abatacept,Massachusetts General Hospital|Bristol-Myers Squibb,Phase 2,10,Other|Industry,"November 13, 2018","April 10, 2020","November 10, 2020"
5084,NCT03669588,An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness,Generalized Myasthenia Gravis,Biological: ARGX-113|Biological: Placebo,argenx,Phase 3,167,Industry,"August 22, 2018","April 6, 2020","April 6, 2020"
5085,NCT03669393,A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1),Retinal Telangiectasis|Idiopathic Juxtafoveal Retinal Telangiectasia,Drug: THR-317 8mg,ThromboGenics|Oxurion,Phase 2,8,Industry,"September 18, 2018","November 22, 2019","November 22, 2019"
5086,NCT03669250,CVN058 Effect on Mismatch Negativity in Schizophrenics,Schizophrenia,Drug: CVN058|Drug: Placebos,"Cerevance Alpha, Inc.|Cerevance",Phase 1,20,Industry,"November 9, 2018","March 6, 2020","March 6, 2020"
5087,NCT03669224,Effect of Nano Care Gold on Marginal Integrity of Resin Composite,Caries Class Ii,Other: Nano Care Gold|Other: No intervention|Other: Chlorhexidine,Cairo University,Phase 1,57,Other,"November 1, 2019","March 19, 2021","March 19, 2021"
5088,NCT03668808,Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.,"Diabetes Mellitus, Type 1",Drug: Insulin Degludec|Drug: Insulin Glargine|Device: TRESIBA® FLEXTOUCH®|Device: LANTUS® SOLOSTAR® INSULIN PEN,Sansum Diabetes Research Institute|Novo Nordisk A/S,Phase 4,25,Other|Industry,"November 16, 2018","September 19, 2020","September 19, 2020"
5089,NCT03668470,Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes,Adult Subjects With Type1Diabetes and Insulin Microsecretion,Drug: Dulaglutide|Drug: Placebo,Hospices Civils de Lyon,Phase 2,45,Other,"January 31, 2019","February 3, 2021","February 3, 2021"
5090,NCT03667300,Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency,Type2 Diabetes Mellitus|Albuminuria|Renal Insufficiency,Drug: Evogliptin|Drug: Linagliptin,Samsung Medical Center,Phase 2,209,Other,"March 16, 2017","May 14, 2019","May 14, 2019"
5091,NCT03667053,Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children,Hypoglycemia,Drug: dasiglucagon|Drug: placebo|Drug: GlucaGen HypoKit,Zealand Pharma,Phase 3,42,Industry,"September 28, 2018","June 28, 2019","June 28, 2019"
5092,NCT03667001,Comparing Analgesic Efficacy of Systemic Lidocaine Against Placebo in General Anesthesia in Bariatric Surgery,"Pain, Postoperative",Drug: Lidocaine Hydrochloride|Drug: Saline Solution,"Miodrag Filipovic, Prof. Dr. med.|Cantonal Hospital of St. Gallen",Phase 3,140,Other,"November 16, 2018","April 1, 2021","April 1, 2021"
5093,NCT03666923,A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME),Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,Drug: THR-687 dose level 1|Drug: THR-687 dose level 2|Drug: THR-687 dose level 3,ThromboGenics|Oxurion,Phase 1,12,Industry,"September 17, 2018","November 20, 2019","November 20, 2019"
5094,NCT03666572,Pilot of a Prebiotic and Probiotic Trial in Young Infants With Severe Acute Malnutrition,Severe Acute Malnutrition,Other: Bifidobacterium infantis|Other: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Other: Placebo (Lactose),"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2,87,Other,"September 21, 2018","August 26, 2019","March 18, 2020"
5095,NCT03666442,Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer,Rectal Cancer,Drug: XELOX,West China Hospital,Phase 2,61,Other,"June 1, 2018","January 1, 2020","January 1, 2022"
5096,NCT03666208,Sirolimus Coated Angioplasty Balloon in the Salvage of Thrombosed Arteriovenous Graft,End Stage Renal Failure on Dialysis|Arteriovenous Graft Occlusion,Device: Sirolimus Coated Balloon,Singapore General Hospital,Phase 2,20,Other,"July 1, 2018","September 2, 2019","September 2, 2019"
5097,NCT03665428,Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea,Helicobacter Pylori Infection,Drug: PAMB treatment (modified quadruple therapy)|Drug: PBMT treatment (bismuth-containing quadruple therapy),Chuncheon Sacred Heart Hospital|Hallym University Medical Center,Phase 4,233,Other,"July 16, 2018","August 6, 2019","December 31, 2019"
5098,NCT03665311,Saline Versus Albumin Fluid for Extracorporeal Removal With Slow Low Efficiency Dialysis Feasibility Study,Renal Replacement Therapy|Acute Kidney Injury|Hypotension,Biological: 25% Albumin fluid|Other: Normal Saline,Ottawa Hospital Research Institute,Phase 2,60,Other,"March 25, 2019","January 15, 2020","January 15, 2020"
5099,NCT03665038,A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD),Post Partum Depression,Drug: Brexanolone,Sage Therapeutics,Phase 3,28,Industry,"September 7, 2018","January 8, 2021","January 8, 2021"
5100,NCT03664921,Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy,"Diabetic Neuropathies|Neuropathic Pain|Pain, Chronic",Drug: Omnitram Oral Tablet|Drug: Placebo Oral Tablet,"Syntrix Biosystems, Inc.|DF/Net Research|National Institute on Drug Abuse (NIDA)",Phase 2,55,Industry|Other|NIH,"November 15, 2018","August 17, 2020","August 17, 2020"
5101,NCT03664752,Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: IDP-120 Gel|Drug: IDP-120 Vehicle Gel,"Bausch Health Americas, Inc.",Phase 3,585,Industry,"December 10, 2018","May 7, 2020","May 7, 2020"
5102,NCT03664739,Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris,Acne Vulgaris,Drug: IDP-120 Gel|Drug: IDp-120 Vehicle Gel,"Bausch Health Americas, Inc.",Phase 3,608,Industry,"December 5, 2018","March 23, 2020","March 23, 2020"
5103,NCT03664674,Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease,Meniere Disease,Drug: OTO-104|Drug: Placebo,"Otonomy, Inc.",Phase 3,148,Industry,"August 27, 2018","December 22, 2020","December 22, 2020"
5104,NCT03663855,Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria,Cystinuria,Drug: Tiopronin,NYU Langone Health,Phase 2,10,Other,"November 1, 2018","September 10, 2019","September 10, 2019"
5105,NCT03663751,Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation,Response Rate,Drug: Decitabine,Shanghai Jiao Tong University School of Medicine,Phase 2,14,Other,"July 1, 2018","December 1, 2020","March 1, 2021"
5106,NCT03663673,Effect of Different Skin Creams on TEWL,"Dermatitis, Atopic",Drug: EpiCeram|Drug: Aveeno Daily Moisturising Sheer Hydration Lotion®,Stanford University|End Allergies Together (EAT),Phase 1,17,Other,"September 1, 2018","July 18, 2019","July 18, 2019"
5107,NCT03663582,Study of Teduglutide in Japanese Participants With Short Bowel Syndrome,Short Bowel Syndrome,Drug: Teduglutide|Device: Syringe|Device: Needle|Device: Vial Adapter for Device,Shire|Takeda,Phase 3,7,Industry,"July 6, 2018","August 6, 2019","August 6, 2019"
5108,NCT03663478,Continuous TQL Block for Elective Cesarean Section,"Postoperative Pain|Anesthesia, Local",Drug: Ropivacaine|Drug: Saline,Zealand University Hospital,Phase 4,32,Other,"September 4, 2018","April 8, 2020","April 8, 2020"
5109,NCT03663283,Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty,Arthropathy Shoulder,Drug: Liposomal Bupivacaine|Drug: Bupivacaine Hydrochloride,Mayo Clinic,Phase 4,104,Other,"October 29, 2018","February 14, 2020","February 14, 2020"
5110,NCT03663205,A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC,Non-Small Cell Lung Cancer,"Drug: Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed|Drug: Cisplatin or Carboplatin,Pemetrexed",BeiGene,Phase 3,334,Industry,"July 23, 2018","October 26, 2020","April 26, 2023"
5111,NCT03663101,Dysport in Post-Surgical Neuralgia,Chronic Scar Pain,Drug: Lidocaine|Biological: Botulinum toxin type A|Drug: Placebo,Ipsen,Phase 2,16,Industry,"October 30, 2018","November 8, 2019","November 8, 2019"
5112,NCT03662984,Ciprofibrate and Pre-diabetes,Myocardial Insulin Sensitivity|Impaired Glucose Metabolism|Diastolic Dysfunction,Drug: Ciprofibrate 100Mg Tablet|Drug: Placebo Oral Tablet,Maastricht University Medical Center|Maastricht University,Phase 3,11,Other,"November 1, 2018","November 6, 2020","November 13, 2020"
5113,NCT03662542,A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis,"Colitis, Ulcerative",Drug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Golimumab Dose 1|Drug: Golimumab Dose 2|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,214,Industry,"November 20, 2018","December 1, 2020","November 15, 2021"
5114,NCT03662074,Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer,Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Drug: Gemcitabine|Biological: Nivolumab,Wake Forest University Health Sciences|National Cancer Institute (NCI),Phase 2,14,Other|NIH,"November 7, 2018","October 7, 2020","February 3, 2022"
5115,NCT03661996,"An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA",Knee Osteoarthritis,Drug: CNTX-4975-05|Drug: Lidocaine without epinephrine|Device: ElastoGel|Device: Breg Ice Water Pump,Centrexion Therapeutics,Phase 3,854,Industry,"September 18, 2018","October 22, 2019","October 22, 2019"
5116,NCT03661879,Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity,Metabolism and Nutrition Disorder|Obesity,Drug: NNC9204-1706|Drug: Placebo (NNC9204-1706),Novo Nordisk A/S,Phase 1,60,Industry,"September 12, 2018","September 5, 2019","October 9, 2019"
5117,NCT03661632,An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors,Advanced Cancer,Drug: BMS-986310|Biological: Nivolumab,Bristol-Myers Squibb,Phase 1,27,Industry,"September 11, 2018","November 11, 2019","December 29, 2020"
5118,NCT03661515,Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML,Acute Myeloid Leukemia,Drug: Selinexor|Drug: fludarabine|Drug: idarubicin|Drug: cytarabine|Drug: G-CSF,PETHEMA Foundation,Phase 1,16,Other,"July 17, 2018","July 15, 2019","October 15, 2019"
5119,NCT03661489,Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery,"Anesthesia, Intravenous",Drug: Remimazolam|Drug: Propofol,Paion UK Ltd.|ORION Clinical Services|Simbec Research|Creative Clinical Research GmbH,Phase 3,469,Industry|Other,"July 24, 2018","April 2, 2020","April 2, 2020"
5120,NCT03660943,A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain,"Osteoarthritis, Knee",Drug: Placebo|Drug: CNTX-4975-05,Centrexion Therapeutics,Phase 3,332,Industry,"September 9, 2018","June 11, 2020","June 11, 2020"
5121,NCT03660839,Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria,Plasmodium Falciparum Infection,Drug: Artefenomel (OZ439)|Drug: Ferroquine (SSR97193),Sanofi|Medicines for Malaria Venture,Phase 2,140,Industry|Other,"September 11, 2018","November 6, 2019","November 6, 2019"
5122,NCT03660488,Cefixime for Alternative Syphilis Treatment,Syphilis|Early Syphilis,Drug: Cefixime 400 milligram Oral Capsule [Suprax]|Drug: Benzathine Penicillin G,"University of California, Los Angeles|AIDS Healthcare Foundation",Phase 2,58,Other,"September 3, 2018","January 30, 2021","January 30, 2021"
5123,NCT03660241,A Renal Impairment Study for PF-04965842,Renal Impairment,Drug: PF-04965842,Pfizer,Phase 1,23,Industry,"October 5, 2018","November 5, 2019","November 5, 2019"
5124,NCT03660059,A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX),Rheumatoid Arthritis (RA),Drug: Peficitinib|Drug: Plaebo|Drug: Disease-modifying antirheumatic drugs (DMARDs),"Astellas Pharma China, Inc.|Astellas Pharma Inc",Phase 3,385,Industry,"September 27, 2018","April 1, 2021","November 2, 2021"
5125,NCT03659201,Efficacy and Safety of Neosil on Chronic Effluvium,Chronic Telogen Effluvium,Drug: Neosil complete|Drug: Pantogar|Drug: Neosil,EMS|Luxbiotech,Phase 4,232,Industry|Other,"September 3, 2018","June 4, 2019","March 30, 2020"
5126,NCT03658746,Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection,Helicobacter Pylori Infection,"Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Drug: one proton pump inhibitor, colloidal bismuth pectin|Drug: two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)",Shandong University,Phase 4,420,Other,"January 1, 2019","December 31, 2019","December 31, 2019"
5127,NCT03657966,DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer,Ovarian Cancer Recurrent,Biological: DCVAC/OvCa|Drug: Standard of Care Chemotherapy,SOTIO a.s.|SOTIO Biotech,Phase 2,33,Industry,"November 23, 2017","November 11, 2020","February 25, 2021"
5128,NCT03657797,Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension,"Glaucoma, Open-Angle|Hypertension, Ocular",Drug: NCX 470|Drug: Latanoprost 0.005%,"Nicox Ophthalmics, Inc.",Phase 2,656,Industry,"August 1, 2018","August 23, 2019","August 23, 2019"
5129,NCT03657355,Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users,Healthy Recreational Drug Users,Drug: ACT-541468|Drug: Suvorexant|Drug: Zolpidem|Drug: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,63,Industry,"September 7, 2018","August 8, 2019","August 8, 2019"
5130,NCT03657238,"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers",Healthy,Drug: RD01|Drug: Placebo,Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd,Phase 1,84,Industry,"April 8, 2018","August 2, 2019","August 2, 2019"
5131,NCT03656744,A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM),"Fatty Liver, Nonalcoholic|NAFLD|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Digestive System Diseases|Type 2 Diabetes Mellitus (T2DM)",Drug: HTD1801|Drug: Placebo,HighTide Biopharma Pty Ltd,Phase 2,101,Industry,"November 26, 2018","February 7, 2020","March 9, 2020"
5132,NCT03656484,New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin,Chronic Periodontitis,Drug: Tetracycline-Metronidazole (TM) group|Drug: TM-Melatonin-Hyaluronic acid (TM-MHa) group,Concordia Dent Srl|Carol Davila University of Medicine and Pharmacy|Romanian National Authority for Scientific Research and Innovation (UEFISCIDI)|University Politechnica of Bucharest|TURKEY MEDISEN Ltd,Phase 2,50,Other,"January 15, 2019","December 20, 2019","December 20, 2019"
5133,NCT03656198,Non-specific Effects of Rabies Vaccine,Influenza-like Illness|Upper Respiratory Disease|Diarrhea|Fever,Biological: Rabivax-S|Drug: Sterile Water Injection,Ross University School of Veterinary Medicine|Serum Institute of India Pvt. Ltd.,Phase 4,546,Other|Industry,"August 29, 2018","July 27, 2020","July 27, 2020"
5134,NCT03656068,An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis,"Non-alcoholic Steatohepatitis|Fatty Liver|Fibrosis, Liver|Compensated Cirrhosis",Drug: Nitazoxanide 500mg BID,"Pinnacle Clinical Research, PLLC",Phase 2,21,Other,"December 4, 2018","November 25, 2020","November 25, 2020"
5135,NCT03655964,Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke,"Stroke, Ischemic",Drug: Olmesartan|Drug: Nebivolol|Other: No antihypertensive treatment,Aristotle University Of Thessaloniki,Phase 2,60,Other,"August 20, 2018","August 20, 2019","August 20, 2019"
5136,NCT03655834,Dose Individualization of Pemetrexed - IMPROVE-III,Non Small Cell Lung Cancer|Mesothelioma,Drug: Pemetrexed,Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development,Phase 4,10,Other,"February 1, 2019","September 20, 2020","August 1, 2021"
5137,NCT03655535,Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes,Type2 Diabetes Mellitus,Drug: BTI320|Other: Placebo,Boston Therapeutics|Sugardown Company Limited,Phase 2,66,Industry,"September 19, 2018","August 30, 2019","August 30, 2019"
5138,NCT03654651,Peanuts and Glycemic Control,Type2 Diabetes|Cardiovascular Diseases,Drug: Peanut|Drug: High carbohydrate snack,Penn State University|The Peanut Institute,Phase 2,51,Other,"October 1, 2018","December 20, 2019","December 20, 2019"
5139,NCT03654326,A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034),Endometriosis-related Pain,Drug: Gefapixant|Drug: Placebo|Drug: Naproxen,Merck Sharp & Dohme LLC,Phase 2,187,Industry,"September 11, 2018","June 30, 2020","June 30, 2020"
5140,NCT03654313,Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus,Atherosclerosis|Cardiovascular Disease,Biological: MEDI6570|Biological: Placebo|Biological: Part B Placebo,MedImmune LLC,Phase 1,88,Industry,"September 28, 2018","July 21, 2020","July 21, 2020"
5141,NCT03653416,Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty,Osteo Arthritis Knee,Device: Ipack|Drug: Bupivacaine|Procedure: Peri Articular Infiltration,Icahn School of Medicine at Mount Sinai,Phase 4,99,Other,"March 1, 2018","August 1, 2019","August 1, 2019"
5142,NCT03653403,"Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel",Acne Vulgaris,Drug: IDP-126 Gel|Drug: Control Gel,"Bausch Health Americas, Inc.",Phase 1,61,Industry,"August 8, 2018","June 19, 2019","June 19, 2019"
5143,NCT03653208,"Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers",Healthy,Drug: hzVSF-v13|Drug: Placebo,"ImmuneMed, Inc.",Phase 1,56,Industry,"November 20, 2018","February 29, 2020","February 29, 2020"
5144,NCT03653026,A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis (UC),Drug: Placebo|Drug: Upadacitinib,AbbVie,Phase 3,522,Industry,"December 6, 2018","January 14, 2021","January 14, 2021"
5145,NCT03652779,A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers,Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin,Drug: Tecarfarin 10mg|Drug: Tecarfarin 20mg|Drug: Tecarfarin 30mg|Drug: Tecarfarin 40mg,Lee's Pharmaceutical Limited,Phase 1,40,Industry,"June 22, 2018","October 28, 2019","October 28, 2019"
5146,NCT03652714,The Effect of Ganglion Sphenopalatine Block (GSP-block) Versus Placebo on Postdural Puncture Headache,Postdural Puncture Headache|Sphenopalatine Ganglion Block,Procedure: Ganglion sphenopalatine block with local anesthetic|Procedure: Ganglion sphenopalatine block with placebo,University Hospital Bispebjerg and Frederiksberg,Phase 3,40,Other,"September 19, 2018","September 2, 2019","September 9, 2019"
5147,NCT03652038,Single and Multiple Ascending Dose Study of TD-8236 by Inhalation,Asthma,Drug: TD-8236|Drug: Placebo,Theravance Biopharma,Phase 1,94,Industry,"November 7, 2018","July 13, 2020","July 13, 2020"
5148,NCT03650998,Transmuscular Quadratus Lumborum Block for Total Laparoscopic Hysterectomy.,Postoperative Pain,Drug: Ropivacaine|Drug: Saline,Zealand University Hospital,Phase 4,70,Other,"September 28, 2018","December 1, 2019","December 1, 2019"
5149,NCT03650452,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies",Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome,Drug: TAK-935|Drug: Placebo,Takeda|Ovid Therapeutics Inc.,Phase 2,141,Industry,"August 8, 2018","June 9, 2020","July 20, 2020"
5150,NCT03650075,To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers,Idiopathic Pulmonary Fibrosis (IPF),Drug: MG-S-2525,Metagone Biotech Inc.,Phase 1,81,Industry,"February 25, 2019","December 31, 2019","February 27, 2020"
5151,NCT03650036,Root Canal Treatment in Primary Molars With Necrotic Pulp Using Two Different Pulp Therapies,Dental Pulp Necrosis,Drug: Pulp Therapy CTZ Paste|Drug: Pulp Therapy ZOE Paste,Federal University of Piaui,Phase 2,86,Other,"June 4, 2018","May 21, 2019","March 4, 2022"
5152,NCT03649477,Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome,Prader-Willi Syndrome,Drug: 3.2 mg intranasal carbetocin|Drug: 9.6 mg intranasal carbetocin|Drug: placebo,"Levo Therapeutics, Inc.",Phase 3,130,Industry,"November 20, 2018","May 13, 2020","July 9, 2022"
5153,NCT03649412,A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772,Autoimmune Diseases,Drug: GSK2982772 Modified Release|Drug: GSK2982772 Immediate Release,GlaxoSmithKline|Quotient Sciences,Phase 1,33,Industry,"September 26, 2018","May 7, 2019","May 7, 2019"
5154,NCT03649152,Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan,Focal Segmental Glomerulosclerosis,Drug: Propagermanium|Drug: Placebo,Dimerix Bioscience Pty Ltd|Iqvia Pty Ltd,Phase 2,8,Industry,"November 8, 2018","June 16, 2020","July 13, 2020"
5155,NCT03649113,Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin,Hemangioma Liver,Procedure: sclerotherapy arm,Tehran University of Medical Sciences,Phase 1,25,Other,"September 1, 2018","September 1, 2019","July 1, 2020"
5156,NCT03648879,Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome,Gastric Cancer|Gastric Neoplasms,Device: Endoscope+Cellvizio(R) 100 microscope,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,37,NIH,"February 11, 2019","April 20, 2020","May 5, 2020"
5157,NCT03648827,A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD),Duchenne Muscular Dystrophy,Drug: Ataluren,PTC Therapeutics,Phase 2,20,Industry,"December 21, 2018","October 23, 2020","October 23, 2020"
5158,NCT03647839,"Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer",Colorectal Cancer Metastatic,Drug: Nivolumab 10 MG/ML|Drug: BNC 105|Drug: BBI608,Australasian Gastro-Intestinal Trials Group,Phase 2,90,Other,"September 6, 2018","January 29, 2021","April 9, 2021"
5159,NCT03647488,Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer,"Carcinoma, Non-Small-Cell Lung",Drug: Capmatinib|Drug: Spartalizumab|Drug: Docetaxel,Novartis Pharmaceuticals|Novartis,Phase 2,18,Industry,"December 26, 2018","September 7, 2020","September 7, 2020"
5160,NCT03647267,Effects of Pneumatic Vitreolysis on Vitreomacular Traction,Vitreomacular Traction,Device: Pneumatic Vitreolysis (C3F8 injection)|Other: Observation,Jaeb Center for Health Research|National Institutes of Health (NIH)|National Eye Institute (NEI),Phase 3,46,Other|NIH,"October 16, 2018","August 6, 2020","August 6, 2020"
5161,NCT03647228,"A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis",Healthy Subjects|Cystic Fibrosis,Drug: IONIS-ENaCRx|Drug: Placebo,"Ionis Pharmaceuticals, Inc.",Phase 1,98,Industry,"December 13, 2018","October 13, 2020","October 13, 2020"
5162,NCT03646864,A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Drug: ACT-541468|Other: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 1,28,Industry,"November 15, 2018","September 19, 2019","September 19, 2019"
5163,NCT03646721,"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM","Diabetes Mellitus, Type 2",Drug: DA-1241|Drug: Placebo|Drug: Sitagliptin,"Dong-A ST Co., Ltd.",Phase 1,108,Industry,"August 29, 2018","May 7, 2020","May 7, 2020"
5164,NCT03646162,Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer,Prostate Cancer Metastatic,Drug: Veru-944|Drug: Placebo,Veru Inc.,Phase 2,93,Industry,"September 14, 2018","April 30, 2020","October 15, 2020"
5165,NCT03645746,"Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers",Healthy Volunteer,Drug: REGN5069|Drug: Placebo,Regeneron Pharmaceuticals,Phase 1,56,Industry,"August 23, 2018","September 30, 2019","September 30, 2019"
5166,NCT03645668,Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients,Sepsis,Drug: Meropenem Injection,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 4,80,Other,"January 30, 2018","November 14, 2019","December 14, 2019"
5167,NCT03645499,An Open-Label Study to Assess Safety,Plaque Psoriasis,Drug: Topical TA-102 A|Drug: Topical TA-102 B|Drug: Topical TA-102 C|Drug: Topical TA-102 D|Drug: Topical TA-102 E,Taro Pharmaceuticals USA,Phase 1,88,Industry,"April 4, 2018","October 24, 2019","January 7, 2020"
5168,NCT03645434,"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.",Chronic Obstructive Pulmonary Disease,Drug: AZD8871|Drug: Anoro® Ellipta®,AstraZeneca|Parexel,Phase 2,73,Industry,"October 10, 2018","August 7, 2019","August 7, 2019"
5169,NCT03645148,Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer,Pancreatic Cancer|Pancreatic Carcinoma,Biological: iNeo-Vac-P01|Other: GM-CSF,"Zhejiang Provincial People's Hospital|Hangzhou Neoantigen Therapeutics Co., Ltd.",Phase 1,7,Other|Industry,"October 24, 2017","November 1, 2020","April 1, 2021"
5170,NCT03644264,PA21 Safety and Efficacy in Adult Chinese Subjects,Chronic Kidney Disease Requiring Chronic Dialysis|Hyperphosphatemia,Drug: PA21|Drug: sevelamer carbonate,Vifor Fresenius Medical Care Renal Pharma,Phase 3,286,Industry,"August 31, 2018","August 21, 2020","August 21, 2020"
5171,NCT03643952,"Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)","Bacteremia|Soft Tissue Infections|Skin Diseases, Infectious",Drug: Daptomycin for Injection,Merck Sharp & Dohme LLC,Phase 2,18,Industry,"December 6, 2018","April 7, 2020","April 7, 2020"
5172,NCT03643614,Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula,Rectovaginal Fistula,Procedure: Injection of autologous regenerative cells of adipose tissue,South Ural State Medical University,Phase 1,16,Other,"August 1, 2017","November 15, 2019","January 22, 2020"
5173,NCT03642834,Study of ICP-105 in Solid Tumors Patients,Solid Tumor,Drug: ICP-105,"Beijing InnoCare Pharma Tech Co., Ltd.",Phase 1,21,Industry,"September 21, 2018","December 14, 2020","March 1, 2021"
5174,NCT03642704,HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure,Mother to Child HIV Transmission,Drug: Reinforced preventive ARV therapy,"ANRS, Emerging Infectious Diseases",Phase 4,56,Other,"February 22, 2017","September 17, 2019","September 17, 2019"
5175,NCT03642600,The Gut Microbiome in Women With Polycystic Ovary Syndrome,PCOS|Obesity|Metabolic Syndrome,Dietary Supplement: dietary advice plus myo-inositol and folic acid|Drug: dietary advice plus Liraglutide Pen Injector,Universitaire Ziekenhuizen KU Leuven,Phase 4,21,Other,"February 28, 2019","February 1, 2020","July 3, 2020"
5176,NCT03640390,Dexmedetomidine Versus Magnesium Sulfate Infusion During Spinal Anesthesia,Postoperative Pain,Drug: Dexmedetomidine|Drug: Magnesium Sulphate|Drug: Normal saline,Cairo University,Phase 3,60,Other,"August 30, 2018","August 30, 2019","September 10, 2019"
5177,NCT03640247,Pain Medications Following Thyroidectomy and Parathyroidectomy,Thyroid Disease|Parathyroid Diseases,Drug: Non-narcotic group regimen|Drug: Narcotic group regimen,MetroHealth Medical Center,Phase 1,126,Other,"November 15, 2018","December 1, 2019","December 1, 2019"
5178,NCT03640156,Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin,Autism Spectrum Disorder,Drug: Oxytocin|Other: Placebo,KU Leuven,Phase 3,25,Other,"July 26, 2018","December 19, 2019","December 19, 2019"
5179,NCT03640065,Evaluation of The Effect of Live Probiotic Cultures Present in Fermented Dairy Product (Yogurt) Versus The Effect of Freeze-Dried Probiotic Sachets on Gingival Bleeding of Adolescents,Gingival Inflammation,Drug: freeze-dried probiotic sachets|Dietary Supplement: fermented dairy product ( yogurt),Cairo University,Phase 4,20,Other,"October 20, 2019","March 1, 2020","March 31, 2020"
5180,NCT03639896,Endothelial Injury Mechanism in Elderly Patients Undergoing Major Surgery,Endothelial Dysfunction|Blood Brain Barrier Defect|Postoperative Cognitive Dysfunction,Drug: Dexmedetomidine|Drug: Saline,The First Affiliated Hospital of Anhui Medical University|Hangzhou Cancer Hospital,Phase 4,464,Other,"July 1, 2019","October 30, 2020","October 31, 2020"
5181,NCT03639558,TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting,Psychiatric Emergency|Aggression|Agitation,Drug: Haloperidol + Promethazine + Chlorpromazine|Drug: Haloperidol + Promethazine,Joseph Dib|University of Nottingham|Hopital Psychiatrique De La Croix,Phase 4,100,Other,"August 28, 2018","July 1, 2019","July 7, 2019"
5182,NCT03639311,"Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study",HIV Infections,Drug: CAB LA|Drug: RPV LA|Drug: RPV|Drug: DTG,"ViiV Healthcare|Janssen, LP",Phase 2,97,Industry,"August 20, 2018","December 11, 2019","January 30, 2023"
5183,NCT03639246,Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer,Ovarian Cancer,Drug: AVB-S6-500|Drug: Paclitaxel (Pac)|Drug: Pegylated liposomal doxorubicin (PLD)|Other: Placebo,"Aravive, Inc.",Phase 1,53,Industry,"December 6, 2018","January 8, 2021","December 30, 2022"
5184,NCT03639168,Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC),Adenoid Cystic Carcinomas|Cisplatin,Drug: Chidamide combined with cisplatin,Fudan University,Phase 2,22,Other,"June 6, 2018","June 24, 2020","June 2, 2021"
5185,NCT03638921,35RC17_8826_NEPHROPAIN Phase APRES : Interest of the Equimolar Oxygen Nitride Mixture (MEOPA) in the Treatment of Pain in Patients Presenting to the Emergency Department for Suspected Renal Colic: a Study BEFORE AFTER,Renal Colic,Drug: MEOPA,Rennes University Hospital|Fondation Apicil,Phase 2,60,Other,"October 1, 2018","June 1, 2019","June 1, 2019"
5186,NCT03638258,"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis",Plaque Psoriasis,Drug: Roflumilast Cream 0.3%|Drug: Roflumilast Cream 0.15%|Drug: Vehicle Cream,"Arcutis Biotherapeutics, Inc.",Phase 2,331,Industry,"September 21, 2018","May 29, 2019","May 29, 2019"
5187,NCT03636932,RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine,Chronic Kidney Diseases,Drug: N-acetylcysteine (NAC)|Drug: Placebo|Biological: Blood sample,Assistance Publique Hopitaux De Marseille,Phase 2,40,Other,"April 30, 2019","February 4, 2021","May 23, 2023"
5188,NCT03636893,Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer,Gastric Cancer|Chemotherapy Effect,Drug: FLOT Chemotherapy|Drug: SOX Chemotherapy,Ruijin Hospital,Phase 2,74,Other,"August 24, 2018","March 31, 2020","March 31, 2020"
5189,NCT03636750,A Study of Injection HB002.1T in Subjects With Solid Tumor,Solid Tumor,Drug: HB002.1T,"Huabo Biopharm Co., Ltd.",Phase 1,27,Industry,"June 28, 2018","February 20, 2020","March 21, 2020"
5190,NCT03636542,Evaluation of Diaphragm Movement After an Interscalene Block,Phrenic Nerve Paralysis,Drug: liposomal bupivacaine|Drug: bupivacaine,University of Minnesota,Phase 4,26,Other,"August 1, 2018","June 3, 2020","June 3, 2020"
5191,NCT03636477,A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102,Glioblastoma,Biological: Ad-RTS-hIL-12|Drug: veledimex|Drug: Nivolumab,Alaunos Therapeutics,Phase 1,21,Industry,"June 18, 2018","October 15, 2020","June 30, 2021"
5192,NCT03636451,Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o,"Abortion, Spontaneous|Abortion in First Trimester|Pain Uterus|Abortion Early|Abortion, Missed",Drug: 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Drug: 20cc 1% lidocaine with 2 units of vasopressin paracervical block,"University of California, San Diego|Society of Family Planning|University of California, Los Angeles",Phase 3,114,Other,"October 29, 2018","December 14, 2020","September 27, 2022"
5193,NCT03636269,CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,Uremic Pruritus,Drug: CR845 0.5 mcg/kg|Drug: Placebo,"Cara Therapeutics, Inc.",Phase 3,473,Industry,"July 17, 2018","March 30, 2020","March 30, 2020"
5194,NCT03636204,A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation,Healthy|Frontotemporal Dementia,Biological: AL001|Other: Placebo,Alector Inc.,Phase 1,64,Industry,"September 14, 2018","December 31, 2019","December 31, 2019"
5195,NCT03635957,Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout,Gout,Biological: Pegloticase|Drug: Methotrexate (MTX)|Drug: Standard Gout Flare Prophylaxis|Drug: Infusion Reaction (IR) Prophylaxis|Dietary Supplement: Folic Acid,"Horizon Therapeutics Ireland DAC|Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 4,14,Industry,"September 26, 2018","October 23, 2019","October 26, 2020"
5196,NCT03635905,Gabapentin for Pain Management During Dilation and Evacuation,Pain,Drug: Gabapentin|Drug: Placebo,Medstar Health Research Institute|Society of Family Planning Research Fund,Phase 4,130,Other,"May 26, 2017","May 9, 2019","May 20, 2020"
5197,NCT03635684,Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen,Pain|Fever|Drug Effect|Drug Reaction,Drug: Acetaminophen,Saint-Joseph University,Phase 2,31,Other,"May 17, 2018","June 1, 2020","June 1, 2020"
5198,NCT03635450,Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE,Moderate to Severe Hypoxic-ischemic Encephalopathy,Biological: Infusion of hCT-MSC,"Joanne Kurtzberg, MD|Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA)|Duke University",Phase 1,6,Other,"December 27, 2018","July 28, 2019","December 28, 2020"
5199,NCT03635047,A Phase I Study for Safety and Tolerability of AL002.,Healthy|Alzheimer Disease,Biological: AL002|Other: Saline Solution,Alector Inc.,Phase 1,69,Industry,"November 12, 2018","August 3, 2020","November 25, 2020"
5200,NCT03634995,An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants,Healthy Participants,Drug: BMS-986256|Other: Placebo,Bristol-Myers Squibb,Phase 1,118,Industry,"August 14, 2018","October 9, 2019","October 9, 2019"
5201,NCT03634735,Thiamin Against Robust IBD Fatigue,Fatigue,Drug: Thiamine|Other: Placebo,University of Aarhus,Phase 4,40,Other,"November 27, 2018","April 21, 2020","October 27, 2020"
5202,NCT03634436,The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects,Hypercholesteremia,Drug: SHR-1209|Drug: Placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,32,Industry,"August 30, 2018","May 28, 2019","May 28, 2019"
5203,NCT03633656,Iron Dosing Pilot Study Using Model Predictive Control,"Renal Insufficiency, Chronic|Anemia, Iron Deficiency|Anemia of Chronic Kidney Disease",Device: Model predictive control|Device: Model Predictive Control of Iron Dosing,University of Louisville,Phase 4,10,Other,"February 1, 2019","July 31, 2019","August 30, 2019"
5204,NCT03633396,A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis,Palmoplantar Pustulosis,Biological: Imsidolimab|Drug: Placebo,"AnaptysBio, Inc.",Phase 2,59,Industry,"May 20, 2019","April 23, 2021","April 23, 2021"
5205,NCT03633123,D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection,Abdominal Surgery|Colon Surgery|Post-Op Infection,Drug: D_PLEX|Other: Standard of Care (SoC),PolyPid Ltd.,Phase 2,200,Industry,"October 4, 2018","September 6, 2019","October 6, 2019"
5206,NCT03632525,Intravenous Iron in Adults With Cystic Fibrosis,Cystic Fibrosis|Iron-deficiency,Drug: Ferric carboxymaltose,University of Oxford,Phase 4,20,Other,"February 22, 2019","March 27, 2020","October 26, 2021"
5207,NCT03632291,"Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients",Urticaria Chronic,Biological: UB-221,United BioPharma,Phase 1,15,Industry,"April 9, 2019","January 19, 2021","January 19, 2021"
5208,NCT03631875,Co-induction Ketamine-propofol: Effects on Laryngeal Mask Airway Insertion Conditions in Children,Anesthesia Intubation Complication,Drug: Ketamine,"University Hospital, Mahdia",Phase 4,120,Other,"May 1, 2019","November 30, 2019","November 30, 2019"
5209,NCT03631732,"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",HIV-1 Infection,Drug: B/F/TAF|Drug: NRTIs|Drug: Third Agent,Gilead Sciences,Phase 3,496,Industry,"August 28, 2018","August 12, 2019","August 19, 2020"
5210,NCT03631355,Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA,Anterior Cruciate Ligament Reconstruction,Drug: Tranexamic Acid,NYU Langone Health,Phase 4,110,Other,"June 6, 2018","March 1, 2020","March 1, 2020"
5211,NCT03630627,A Phase I Study of SB26 in Healthy Volunteers,Healthy Volunteers,Drug: SB26|Drug: Placebo,"Samsung Bioepis Co., Ltd.",Phase 1,58,Industry,"August 22, 2018","April 16, 2020","April 16, 2020"
5212,NCT03630549,Village-based vs Clinic-based ART Care - a Cluster Randomized Controlled Trial in Lesotho,HIV/AIDS,Other: Standard of Care|Other: Village-based ART refill,"Niklaus Labhardt|Ministry of Health, Lesotho|SolidarMed|University of Basel|University Hospital, Basel, Switzerland|Swiss Tropical & Public Health Institute",Phase 4,257,Other,"August 16, 2018","December 8, 2020","December 8, 2020"
5213,NCT03630198,Pain Outcomes Following Intralesional Corticosteroid Injections,Keloid|Alopecia Areata|Acne|Hypertrophic Scar|Epidermal Inclusion Cyst|Frontal Fibrosing Alopecia|Lichen Plano-Pilaris|Keratoacanthoma|Plaque Psoriasis|Lichen Simplex Chronicus|Prurigo Nodularis|Nummular Eczema|Granuloma Annulare|Morphea|Lichen Planus,Drug: Corticosteroid with lidocaine|Drug: Corticosteroid with normal saline,Vanderbilt University Medical Center,Phase 4,31,Other,"October 1, 2018","September 1, 2019","September 1, 2019"
5214,NCT03629925,Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC,Squamous NSCLC,Drug: Sintilimab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Placebo|Drug: Carboplatin,Innovent Biologics (Suzhou) Co. Ltd.,Phase 3,357,Industry,"September 28, 2018","March 25, 2020","September 30, 2021"
5215,NCT03629886,"Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study",Cervical Intraepithelial Neoplasia,"Biological: HPV (Types 16, 18) Vaccine, Adsorbed",GlaxoSmithKline,Phase 4,3537,Industry,"August 22, 2018","February 28, 2020","February 28, 2020"
5216,NCT03628924,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)",Hidradenitis Suppurativa,Drug: Guselkumab dose 1|Drug: Guselkumab dose 2|Drug: Guselkumab dose 3|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,184,Industry,"September 4, 2018","May 22, 2020","May 22, 2020"
5217,NCT03628716,CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,Bladder Cancer,Biological: CV301|Biological: Atezolizumab,Bavarian Nordic,Phase 2,43,Industry,"September 18, 2018","November 3, 2020","February 2, 2021"
5218,NCT03628352,Taste-masking Study for Tricaprilin in Sensory Panelists,Taste Profile Assessments,Drug: Tricaprilin,Cerecin,Phase 1,9,Industry,"September 10, 2018","August 22, 2019","August 22, 2019"
5219,NCT03628066,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,Breast Cancer,Drug: Letrozole|Drug: Palbociclib|Drug: Goserelin|Diagnostic Test: Oncotype DX Breast Recurrence Score,"NSABP Foundation Inc|Genomic Health®, Inc.|Pfizer",Phase 2,24,Other|Industry,"October 22, 2018","November 30, 2020","January 30, 2021"
5220,NCT03627897,ESP Block in Pediatric Patients for Postoperative Analgesia,"Opioid Use|Pain, Postoperative|Quality of Life",Drug: Bupivacain|Drug: saline,Cukurova University,Phase 4,40,Other,"August 1, 2019","March 1, 2021","April 1, 2021"
5221,NCT03627767,Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects,"Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases",Drug: PF-04965842 100 mg|Drug: PF-04965842 200 mg|Drug: Placebo,Pfizer,Phase 3,1235,Industry,"June 11, 2018","September 2, 2020","October 7, 2020"
5222,NCT03627715,Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan,Diabetic Kidney Disease,Drug: Propagermanium|Drug: Placebo,Dimerix Bioscience Pty Ltd|Iqvia Pty Ltd,Phase 2,45,Industry,"November 6, 2018","July 23, 2020","August 18, 2020"
5223,NCT03627611,Identification of Non-responders to Levothyroxine Therapy,Hypothyroidism|Biomarkers|Endocrine System Diseases,Drug: Levothyroxin|Drug: Liothyronine,Oslo University Hospital|Hormonlaboratoriet|Spesialistsenteret Pilestredet Park,Phase 2,69,Other,"August 14, 2018","June 22, 2020","June 22, 2020"
5224,NCT03627494,"First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect",Muscular Dystrophies,Drug: GSK3439171A|Drug: Placebo,GlaxoSmithKline,Phase 1,66,Industry,"August 30, 2018","August 26, 2019","August 26, 2019"
5225,NCT03627468,A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis,Primary Axillary Hyperhidrosis,"Drug: Sofpironium Bromide Gel, 5%|Drug: Sofpironium Bromide Gel, 15%",Botanix Pharmaceuticals,Phase 3,300,Industry,"September 5, 2018","January 27, 2020","January 27, 2020"
5226,NCT03627299,Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors,End Stage Renal Disease|Hepatitis C,Drug: 300mg glecaprevir/pibrentasivir 120mg,Johns Hopkins University,Phase 4,11,Other,"September 25, 2018","December 19, 2019","September 20, 2021"
5227,NCT03627065,A Study of INCB050465 in Primary Sjögren's Syndrome,Primary Sjögren's Syndrome,Drug: Parsaclisib,Incyte Corporation,Phase 2,10,Industry,"February 28, 2019","December 7, 2019","January 2, 2020"
5228,NCT03626948,SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,Drug: SK-1403,"Sanwa Kagaku Kenkyusho Co., Ltd.",Phase 3,157,Industry,"September 13, 2018","February 4, 2020","February 5, 2020"
5229,NCT03626545,Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy,Non-Small-Cell Lung,Drug: Canakinumab|Drug: Docetaxel|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,245,Industry,"January 23, 2019","January 8, 2021","December 20, 2021"
5230,NCT03625778,"A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants",Obesity,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,Phase 1,51,Industry,"August 14, 2018","August 25, 2019","August 25, 2019"
5231,NCT03625622,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,Mild to Moderate Alzheimer's Disease,Drug: AR1001|Drug: Placebo,"AriBio Co., Ltd.",Phase 2,210,Industry,"April 1, 2019","December 22, 2020","June 28, 2021"
5232,NCT03625466,"A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",Cystic Fibrosis,Drug: LUM/IVA|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Phase 2,51,Industry,"August 10, 2018","October 9, 2020","October 7, 2021"
5233,NCT03625453,Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder,Tourette Syndrome|Motor Tic Disorder,Drug: ABX-1431|Drug: Placebo,"Abide Therapeutics|FGK Clinical Research GmbH|BASi (Bioanalytical Systems, Inc.)|CogState Ltd.",Phase 2,50,Industry,"October 15, 2018","January 20, 2020","January 20, 2020"
5234,NCT03625050,"Efficacy and Safety of Chuna Manual Treatment as an Adjunctive Therapy After Total Knee Arthroplasty: A Study Protocol for a Single-Center, Randomized, Assessor Blind, Parallel-Group Clinical Trial",Total Knee Replacement|Manipulation,Procedure: Chuna + Usual care(Celecoxib and esomeprazole)|Drug: Usual care(Celecoxib and esomeprazole),Gachon University Gil Oriental Medical Hospital|Catholic Kwandong University,Phase 2,22,Other,"November 1, 2018","December 30, 2020","May 31, 2021"
5235,NCT03624920,Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness,Parkinson Disease,Drug: THN102 Dosage A|Drug: THN102 Dosage B|Drug: THN102 Dosage C,Theranexus,Phase 2,77,Industry,"July 12, 2018","December 20, 2019","February 24, 2020"
5236,NCT03624127,Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis,Psoriasis,Drug: BMS-986165|Other: Placebo|Drug: Apremilast,Bristol-Myers Squibb,Phase 3,666,Industry,"August 7, 2018","September 2, 2020","September 2, 2020"
5237,NCT03623022,"Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)",Healthy,Drug: Clinical Center Reference Endotoxin (CCRE)|Drug: Normal saline,"University of North Carolina, Chapel Hill|Environmental Protection Agency (EPA)|RTI International|United States Department of Defense",Phase 1,15,Other|U.S. Fed,"October 17, 2018","September 17, 2019","September 17, 2019"
5238,NCT03622658,Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis,Axial Spondyloarthritis,Biological: Placebo|Biological: Namilumab,Izana Bioscience Ltd.|Iqvia Pty Ltd|Innovate UK,Phase 2,42,Industry|Other,"September 6, 2018","February 4, 2020","February 4, 2020"
5239,NCT03622593,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema,Diabetic Macular Edema,Drug: Aflibercept|Drug: Faricimab|Procedure: Sham Procedure,Hoffmann-La Roche,Phase 3,951,Industry,"October 9, 2018","October 19, 2020","August 27, 2021"
5240,NCT03622580,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE),Diabetic Macular Edema,Drug: Aflibercept|Drug: Faricimab|Procedure: Sham Procedure,Hoffmann-La Roche,Phase 3,940,Industry,"September 5, 2018","October 20, 2020","September 3, 2021"
5241,NCT03622541,Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD,FLT3-ITD Mutation|AML,Drug: Sorafenib 200mg,The University of Hong Kong,Phase 2,46,Other,"November 15, 2010","December 1, 2019","March 1, 2020"
5242,NCT03622463,A Trial of Antroquinonol in Patients With Atopic Dermatitis,Atopic Dermatitis,Drug: Antroquinonol|Other: Placebo,Golden Biotechnology Corporation,Phase 2,14,Industry,"July 17, 2018","July 9, 2019","July 9, 2019"
5243,NCT03622216,A Dose Escalation Study of Bradanicline in Refractory Chronic Cough,Chronic Cough,Drug: Bradanicline|Drug: Placebo,"Attenua, Inc.",Phase 2,46,Industry,"November 5, 2018","May 7, 2019","May 22, 2019"
5244,NCT03622112,A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects,Asthma,Drug: AZD7594 DPI 55μg/50μg.|Drug: AZD7594 DPI 99 µg/90 µg|Drug: AZD7594 DPI 198 µg/180 µg|Drug: AZD7594 DPI 396 µg/360 µg once daily.|Drug: AZD7594 DPI 792 µg/720 µg|Drug: Placebo for AZD7594 once daily.|Drug: FF 100 µg once daily (open-label),AstraZeneca|Parexel,Phase 2,808,Industry,"January 2, 2019","September 30, 2019","September 30, 2019"
5245,NCT03622060,Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion,Radial Artery Injury at Wrist and Hand Level|Occlusion of Artery|Vasodilation,Drug: Nitroglycerin,Hermina Heart Center Kemayoran|Hermina Hospital Group,Phase 3,600,Other,"June 4, 2018","May 21, 2019","May 22, 2019"
5246,NCT03622021,A Study of AK111 in Healthy Subjects,Psoriasis,Drug: AK111 or Placebo,Akesobio Australia Pty Ltd|Akeso,Phase 1,68,Industry,"August 14, 2018","January 20, 2020","February 20, 2020"
5247,NCT03621657,The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation,Clostridium Difficile Infection|C.Difficile Diarrhea|CDI,Drug: Low Dose FMT Capsule DE|Drug: Single Dose FMT Capsule DE|Drug: Placebo oral capsule,"University of Wisconsin, Madison|Agency for Healthcare Research and Quality (AHRQ)",Phase 2,1,Other|U.S. Fed,"March 21, 2019","February 27, 2020","February 27, 2020"
5248,NCT03621072,Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France,Bioequivalence,Drug: Fluconazole 150mg Capsule Originator|Drug: Fluconazole 150mg Capsule Localized Originator,Pfizer,Phase 1,36,Industry,"June 3, 2019","July 20, 2019","July 20, 2019"
5249,NCT03621046,Use of Low-dose Zolpidem in Parkinson's Disease,Parkinson Disease,Drug: Zolpidem|Other: Placebo,Aston University|University Hospital Birmingham NHS Foundation Trust,Phase 2,28,Other,"August 20, 2018","December 31, 2019","January 24, 2020"
5250,NCT03620890,Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy,"Diabetes Mellitus, Type 2",Drug: Neutral Protamine Hagedorn (NPH)|Drug: Detemir insulin,"The University of Texas Health Science Center, Houston",Phase 4,108,Other,"September 4, 2018","July 29, 2020","July 29, 2020"
5251,NCT03620162,A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION),Pneumococcal Infections,Biological: Prevnar 13™|Biological: V114|Biological: RotaTeq™|Biological: Pentacel™|Biological: RECOMBIVAX HB™|Biological: HIBERIX™|Biological: M-M-R™ II|Biological: VARIVAX™,Merck Sharp & Dohme LLC,Phase 3,900,Industry,"October 18, 2018","December 14, 2020","December 14, 2020"
5252,NCT03620136,Comparison of Two Techniques of Locoregional Analgesia in Total Knee Prosthesis Surgery : Block to the Adductor Channel Versus Peri-articular Local Infiltrations,Analgesic,Drug: locoregional analgesia by a block on the adductor channel|Drug: locoregional analgesia by periarticular local infiltrations,Hospices Civils de Lyon,Phase 3,98,Other,"February 7, 2018","November 27, 2019","November 28, 2019"
5253,NCT03619902,A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis,Generalized Pustular Psoriasis,Biological: Imsidolimab,"AnaptysBio, Inc.",Phase 2,8,Industry,"January 30, 2019","January 20, 2021","January 20, 2021"
5254,NCT03619837,Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant,Hepatitis C|Transplantation Disease Transmission,Drug: Sofosbuvir/Velpatasvir|Drug: Sofosbuvir/Velpatasvir/Voxilaprevir,"University of California, San Francisco",Phase 4,122,Other,"July 15, 2018","December 21, 2019","August 13, 2020"
5255,NCT03619616,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults",Idiopathic Pulmonary Fibrosis(IPF)|Solid Tumor,Drug: ZSP1603 7.5 mg|Drug: ZSP1603 12.5 mg|Drug: Placebo 12.5mg|Drug: ZSP1603 25 mg|Drug: Placebo 25mg|Drug: ZSP1603 50 mg|Drug: Placebo 50mg,"Guangdong Zhongsheng Pharmaceutical Co., Ltd.",Phase 1,40,Industry,"July 16, 2018","June 28, 2019","October 22, 2019"
5256,NCT03619252,Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents,Multiple Myeloma|Pneumococcal Infection|Febrile Neutropenia|Pneumococcal Pneumonia,Biological: Vaccination with pneumococcal conjugate vaccine (PCV13)|Drug: Standard Antibacterial Prophylaxis,"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology|Belarusian State Medical University",Phase 4,36,Other,"July 1, 2018","January 30, 2021","June 30, 2021"
5257,NCT03619239,Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma,Newly Diagnosed Glioblastoma,Drug: GX-I7,"Genexine, Inc.",Phase 1,15,Industry,"June 20, 2018","September 25, 2020","September 25, 2020"
5258,NCT03618355,Trial of eRapa in Prostate Cancer Patients,Prostate Cancer,Drug: eRapa (encapsulated rapamycin),"Rapamycin Holdings, Inc. dba Emtora Biosciences|Cancer Insight, LLC|Rapamycin Holdings Inc.",Phase 1,15,Industry,"August 28, 2018","December 2, 2019","December 2, 2019"
5259,NCT03618264,Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy,"Pain, Postoperative|Post-Craniotomy Headache",Drug: Miscible liquid of dexamethasone and ropivacaine|Drug: Ropivacaine,Beijing Tiantan Hospital,Phase 4,140,Other,"April 4, 2019","August 15, 2019","February 13, 2020"
5260,NCT03618238,Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",Drug: Anlotinib,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 2,20,Other,"July 25, 2018","April 30, 2021","April 30, 2021"
5261,NCT03618225,Duloxetine Role in Reducing Opioid Consumption After Thoracotomy,Post-thoracotomy Pain,Drug: Oral Duloxetine 60mg|Drug: placebo pill,Assiut University,Phase 4,60,Other,"August 15, 2018","January 31, 2020","January 31, 2020"
5262,NCT03618056,Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus,HIV Infections|Systemic Lupus Erythematosus,Biological: AIDSVAX® B/E,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,1,NIH,"December 19, 2018","July 17, 2020","July 17, 2020"
5263,NCT03618030,PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD),ADHD,Drug: PRC-063 oral capsules|Drug: Placebo oral capsules,"Purdue Pharma, Canada",Phase 3,288,Industry,"August 21, 2018","July 5, 2019","July 5, 2019"
5264,NCT03617913,Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer,Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall|Stage II Bladder Cancer AJCC v8|Stage II Renal Pelvis Cancer AJCC v8|Stage II Ureter Cancer AJCC v8|Stage II Urethral Cancer AJCC v8|Stage III Bladder Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8|Stage IIIB Bladder Cancer AJCC v8|Urethral Urothelial Carcinoma,Drug: Avelumab|Drug: Cisplatin|Drug: Fluorouracil|Drug: Mitomycin|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy,Mayo Clinic|National Cancer Institute (NCI),Phase 2,2,Other|NIH,"September 19, 2018","November 14, 2019","July 27, 2020"
5265,NCT03617835,A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body,Healthy,Drug: Spesolimab,Boehringer Ingelheim,Phase 1,48,Industry,"August 16, 2018","June 3, 2019","June 3, 2019"
5266,NCT03617588,68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer,Prostate Cancer,Drug: Gallium-68 THP-PSMA,Theragnostics Ltd,Phase 2,49,Industry,"June 18, 2018","June 12, 2019","June 12, 2019"
5267,NCT03617536,A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus,Chronic Kidney Diseases|Pruritus,Drug: CR845 0.25 mg Oral Tablet|Drug: CR845 0.5 mg Oral Tablet|Drug: CR845 1 mg Oral Tablet|Drug: Placebo Oral Tablet,"Cara Therapeutics, Inc.",Phase 2,271,Industry,"July 5, 2018","October 24, 2019","November 14, 2019"
5268,NCT03617016,Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia,Dyspepsia,Drug: Domperidone|Drug: Placebo,Xian-Janssen Pharmaceutical Ltd.,Phase 4,160,Industry,"August 27, 2018","July 31, 2020","July 31, 2020"
5269,NCT03616899,Safety and Efficacy of KPI-121 in Subjects With DED,Kerato Conjunctivitis Sicca,Drug: KPI-121 Ophthalmic Suspension|Drug: Vehicle,"Kala Pharmaceuticals, Inc.",Phase 3,901,Industry,"July 10, 2018","February 5, 2020","February 5, 2020"
5270,NCT03616834,Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy,Solid Tumors,Drug: Tomivosertib (eFT-508),Effector Therapeutics,Phase 2,39,Industry,"July 25, 2018","January 31, 2021","June 30, 2021"
5271,NCT03616509,"GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition",Prader-Willi Syndrome,Drug: Growth hormone|Drug: Placebo,Corporacion Parc Tauli|Parc de Salut Mar,Phase 4,30,Other,"June 19, 2017","July 26, 2019","July 26, 2019"
5272,NCT03615833,Pilot Study of Vitamin D Screening Use in Peripheral Arterial Disease Patient Over Maximum Distance Walking,Peripheral Arterial Disease,Drug: Cholecalciferol,"University Hospital, Angers",Phase 4,27,Other,"March 11, 2019","September 21, 2020","September 21, 2020"
5273,NCT03615768,A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris,Acne Vulgaris,Combination Product: Adapalene-Clindamycin Combination Gel|Drug: Adapalene Gel|Drug: Clindamycin Gel,Lee's Pharmaceutical Limited|Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.,Phase 3,1617,Industry,"August 14, 2018","February 13, 2020","April 7, 2020"
5274,NCT03615677,Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis,Erosive Esophagitis (EE),Drug: LXI-15028 50mg|Drug: Esomeprazole 40mg,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",Phase 3,261,Industry,"October 24, 2018","October 18, 2019","October 18, 2019"
5275,NCT03615482,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)",Pneumococcal Infections,Biological: V114|Biological: QIV|Biological: Matching Placebo for V114,Merck Sharp & Dohme LLC,Phase 3,1200,Industry,"September 14, 2018","June 24, 2019","June 24, 2019"
5276,NCT03615404,"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma","Glioblastoma|Malignant Glioma|Medulloblastoma Recurrent|Pediatric Glioblastoma Multiforme|Pediatric Brain Tumor, Recurrent|Pediatric Brain Tumor",Biological: CMV-DCs with GM-CSF|Biological: Td (tetanus toxoid),Gary Archer Ph.D.|Duke University,Phase 1,11,Other,"October 5, 2018","November 19, 2019","July 2, 2020"
5277,NCT03615183,A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002),Human Immunodeficiency Virus|AIDS Virus,Drug: MK-8527,Merck Sharp & Dohme LLC,Phase 1,17,Industry,"February 11, 2019","September 26, 2019","September 26, 2019"
5278,NCT03615066,"Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment",Chronic Hepatitis B,Drug: Placebo|Drug: Selgantolimod|Drug: TAF,Gilead Sciences,Phase 2,67,Industry,"August 28, 2018","December 12, 2019","April 12, 2021"
5279,NCT03615040,Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP),COPD Exacerbation,Drug: MSTT1041A|Drug: Placebo,"University of Leicester|Biomedical Research Centre- Respiratory (Glenfield Hospital, Leicester UK)|Genentech, Inc.",Phase 2,81,Other|Industry,"October 11, 2018","May 29, 2020","December 31, 2020"
5280,NCT03614923,Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP),Chronic Rhinosinusitis,Biological: Etokimab|Biological: Placebo|Drug: Mometasone Furoate Nasal Spray,"AnaptysBio, Inc.",Phase 2,105,Industry,"November 29, 2018","September 2, 2020","October 26, 2020"
5281,NCT03614533,"Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso",Typhoid,Biological: Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Biological: Inactivated Poliovirus Vaccine (IPV),"University of Maryland, Baltimore|Bill and Melinda Gates Foundation|Groupe de Recherche Action en Sante",Phase 2,251,Other,"December 3, 2018","August 22, 2019","August 22, 2019"
5282,NCT03613168,Trastuzumab in HER2-positive Biliary Tract Cancer,Cholangiocarcinoma|Biliary Tract Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification,Drug: Trastuzumab,Changhoon Yoo|Asan Medical Center,Phase 2,4,Other,"June 1, 2019","November 1, 2020","January 4, 2021"
5283,NCT03612947,TAP Block in Laparoscopic Cholecystectomy.,Postoperative Pain,Drug: Bupivacaine +magnesium sulphate|Drug: Bupivacaine only,Assiut University,Phase 2,60,Other,"September 3, 2018","December 15, 2019","December 15, 2019"
5284,NCT03612856,Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis,End Stage Renal Disease|Thrombosis,Drug: AB023- Dose 1|Drug: AB023-Dose 2|Drug: placebo,"Aronora, Inc.",Phase 2,27,Industry,"October 29, 2018","July 6, 2019","July 6, 2019"
5285,NCT03611751,An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis,Psoriasis,Drug: BMS-986165|Other: Placebo|Drug: Apremilast,Bristol-Myers Squibb,Phase 3,1020,Industry,"July 26, 2018","November 29, 2020","November 30, 2020"
5286,NCT03611699,Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients,COPD,Drug: Umeclidinium / Vilanterol Dry Powder Inhaler|Drug: Placebo,Gary L. Pierce|University of Iowa,Phase 4,15,Other,"January 24, 2019","April 1, 2020","April 1, 2020"
5287,NCT03611582,Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program,Overweight|Obesity,Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,Phase 3,611,Industry,"August 1, 2018","March 18, 2020","April 28, 2020"
5288,NCT03611478,Examining the Effects of One-Month Probiotic Treatment on Mental Fatigue,Mental Fatigue|Cognitive Function|Mood,Dietary Supplement: Probiotic formulation|Dietary Supplement: Placebo,Swinburne University of Technology|DuPont Nutrition and Health,Phase 2,128,Other|Industry,"August 30, 2018","June 25, 2019","June 25, 2019"
5289,NCT03611075,"A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)",Autism Spectrum Disorder,Other: No Intervention,Hoffmann-La Roche,Phase 1,144,Industry,"August 13, 2018","May 21, 2020","May 21, 2020"
5290,NCT03611010,Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients,Hypercholesterolemia|Dyslipidemias,Drug: Atorvastatin injection,Cumberland Pharmaceuticals,Phase 2,40,Industry,"August 7, 2018","February 17, 2020","February 24, 2020"
5291,NCT03610685,Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma,Asthma,Drug: Prednisolone|Drug: Placebo oral capsule,"NHS Greater Glasgow and Clyde|Queen's University, Belfast",Phase 4,33,Other,"October 19, 2018","January 7, 2020","January 7, 2020"
5292,NCT03610646,Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME),Diabetic Macular Edema,Drug: MYL-1701P|Drug: Eylea,"Mylan Pharmaceuticals Inc|Momenta Pharmaceuticals, Inc.|Viatris Inc.",Phase 3,355,Industry,"August 23, 2018","November 10, 2020","September 10, 2021"
5293,NCT03610412,Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated,"Diabetes Mellitus, Type 2",Other: Cinnamomum Cassia|Other: Placebo (calcined magnesia),"Coordinación de Investigación en Salud, Mexico",Phase 3,28,Other,"August 1, 2019","November 24, 2020","August 18, 2021"
5294,NCT03610334,"A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088",Healthy Volunteers,Drug: IFB-088 (2.5-60.0mg) oral capsule|Drug: Placebo (2.5-60.mg) oral capsule|Drug: IFB-088 (15.0-50.0mg) oral capsule|Drug: Placebo oral (15.0-50.0mg) capsule,InFlectis BioScience|Qualissima|Assistance Publique Hopitaux De Marseille|Stragen France|Eurofins Optimed,Phase 1,72,Industry|Other,"June 21, 2018","June 21, 2019","December 16, 2019"
5295,NCT03609892,Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy,Gastric Ulcer|Chronic Gastritis|Gastric Cancer|Helicobacter Pylori Infection|Gastritis,Drug: Berberine|Drug: Amoxicillin|Drug: Esomeprazole|Drug: Bismuth|Drug: Tetracycline|Drug: Furazolidone,Xijing Hospital of Digestive Diseases,Phase 4,658,Other,"August 1, 2018","August 20, 2019","August 20, 2019"
5296,NCT03608774,Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM,Anal Chlamydia Infection,Drug: Azithromycin|Drug: Doxycycline|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,177,NIH,"July 13, 2018","February 21, 2020","February 21, 2020"
5297,NCT03608436,The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery,Pneumoperitoneum|Neuromuscular Blockade|Surgery,Procedure: Low pressure pneumoperitoneum|Drug: Rocuronium Bromide,Radboud University Medical Center|Merck Sharp & Dohme LLC,Phase 4,178,Other|Industry,"October 24, 2018","March 3, 2021","June 3, 2021"
5298,NCT03608397,Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1),Cervical Dystonia,Biological: DaxibotulinumtoxinA for injection|Biological: Placebo,"Revance Therapeutics, Inc.|Syneos Health",Phase 3,301,Industry|Other,"June 20, 2018","December 3, 2019","June 16, 2020"
5299,NCT03607851,Efficacy and Safety of Rapid Titration Protocols of Lacosamide,Focal Epilepsy,Drug: Lacosamide - conventional titration|Drug: Lacosamide - rapid titration 1|Drug: Lacosamide - rapid titration 2,Seoul National University Hospital|Dongsan Medical Center|Konkuk University,Phase 4,75,Other,"August 3, 2018","June 7, 2019","June 7, 2019"
5300,NCT03607513,"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants",Healthy,Drug: JNJ-64264681|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,105,Industry,"July 31, 2018","August 9, 2019","August 9, 2019"
5301,NCT03607487,A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa,Hidradenitis Suppurativa,Drug: INCB054707|Drug: Placebo,Incyte Corporation,Phase 2,35,Industry,"October 15, 2018","August 13, 2019","August 13, 2019"
5302,NCT03607227,"Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery","Head and Neck Cancer|Pain, Musculoskeletal",Drug: Levobupivacaine|Drug: Saline Solution,Region Skane,Phase 4,24,Other,"September 1, 2018","April 6, 2021","April 7, 2021"
5303,NCT03607149,"Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies",Non-small Cell Lung Cancer,Drug: Pemetrexed,Centre Georges Francois Leclerc,Phase 4,11,Other,"April 6, 2017","February 20, 2020","February 20, 2020"
5304,NCT03607071,Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma,Myocardial Inflammation,Drug: Prednisolone and taper,Khon Kaen University,Phase 2,20,Other,"May 15, 2018","June 30, 2019","June 30, 2019"
5305,NCT03606876,Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects,Rheumatoid Arthritis,Drug: BAT1806 injection,Bio-Thera Solutions,Phase 1,138,Industry,"June 13, 2018","July 17, 2019","July 17, 2019"
5306,NCT03606785,Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery,Colorectal Surgery,Drug: Tranexamic Acid Injection|Drug: placebo injection,Assiut University,Phase 4,46,Other,"August 5, 2018","January 31, 2020","January 31, 2020"
5307,NCT03606460,A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS),Multiple Sclerosis,Drug: Ocrelizumab Dose 1|Drug: Ocrelizumab Dose 2 and Dose 3,"Genentech, Inc.",Phase 3,141,Industry,"September 14, 2018","May 31, 2019","May 31, 2019"
5308,NCT03606395,"Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression",Treatment Resistant Depression,Drug: NV-5138|Drug: Placebos,"Navitor Pharmaceuticals, Inc.",Phase 1,80,Industry,"June 6, 2018","June 9, 2019","July 7, 2019"
5309,NCT03606122,5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities,Actinic Keratoses,Drug: PD P 506 A,photonamic GmbH & Co. KG,Phase 2,22,Industry,"July 12, 2018","July 16, 2019","July 16, 2019"
5310,NCT03605914,Are NSAIDs Effective Enough for Postoperative Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty,Pain Control After Functional Endoscopic Sinus Surgery and Septoplasty,Drug: diclofenac|Drug: Norco,"The University of Texas Health Science Center, Houston",Phase 4,100,Other,"August 1, 2018","July 1, 2020","July 5, 2020"
5311,NCT03605836,"A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder",Attention Deficit Disorder|Attention Deficit Hyperactivity Disorder,Drug: Centanafadine SR|Other: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,590,Industry,"January 16, 2019","May 14, 2020","May 14, 2020"
5312,NCT03605680,"A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder",Attention Deficit Disorder|Attention Deficit Hyperactivity Disorder,Drug: Centanafadine SR|Other: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,604,Industry,"January 16, 2019","April 11, 2020","April 11, 2020"
5313,NCT03605667,Study of BHV-4157 in Alzheimer's Disease,Alzheimer Disease,Drug: troriluzole|Drug: Placebo oral capsule,"Biohaven Pharmaceuticals, Inc.|Alzheimer's Disease Cooperative Study (ADCS)",Phase 2,350,Industry|Other,"July 31, 2018","December 15, 2020","December 23, 2021"
5314,NCT03605251,Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.,Rheumatoid Arthritis,Drug: TAS5315 low dose|Drug: TAS5315 high dose|Drug: Placebos,"Taiho Pharmaceutical Co., Ltd.",Phase 2,91,Industry,"August 30, 2018","November 30, 2019","May 28, 2020"
5315,NCT03604874,High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour in Obese Women,DELAYED LABOUR,Drug: Oxytocin,Assiut University,Phase 4,202,Other,"September 1, 2018","August 31, 2020","October 19, 2021"
5316,NCT03604757,68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks,Prostate Cancer,Drug: 68Ga-PSMA-617 PET/CT|Drug: 68Ga-RM2 PET/CT,"University Hospital, Bordeaux",Phase 2,22,Other,"April 25, 2018","December 19, 2019","December 19, 2019"
5317,NCT03604705,An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia,Candidemia,Drug: APX001,Pfizer,Phase 2,21,Industry,"October 3, 2018","March 31, 2020","July 2, 2020"
5318,NCT03604679,SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors,Advanced Solid Tumor,Drug: SyB C-0501,SymBio Pharmaceuticals,Phase 1,18,Industry,"May 24, 2018","September 11, 2020","September 11, 2020"
5319,NCT03604471,Lipid-lowering Therapy Individualization,Hypercholesterolemia,Drug: Atorvastatin,Université Catholique de Louvain|Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 4,75,Other,"August 8, 2017","August 27, 2019","August 27, 2019"
5320,NCT03604419,Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes,Type 2 Diabetes Mellitus (T2DM),Drug: PB-119 100 μg+ Glucophage®|Drug: PB-119 150 μg+ Glucophage®|Drug: PB-119 200 μg+ Glucophage®|Drug: PB-119 placebo + Glucophage®,"PegBio Co., Ltd.|Covance",Phase 2,214,Other|Industry,"June 13, 2018","July 23, 2019","July 23, 2019"
5321,NCT03604354,Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Surgery,"Osteoarthritis, Knee",Drug: Tapentadol 100 MG Oral Tablet|Drug: Pregabalin 150mg,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4,95,Other,"August 1, 2018","March 24, 2020","May 19, 2020"
5322,NCT03604341,Cannabinoids for Pain Control During Medical Abortion,Medical Abortion|Pain,Drug: Dronabinol 5mg Cap|Other: Placebo,Oregon Health and Science University|Society of Family Planning,Phase 4,72,Other,"November 1, 2018","May 7, 2019","May 28, 2019"
5323,NCT03604328,Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma,Open-angle Glaucoma,Drug: PA5108,PolyActiva Pty Ltd,Phase 1,8,Industry,"July 24, 2018","June 15, 2020","June 15, 2020"
5324,NCT03604159,"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept",Opioid Dependence,"Drug: Buprenorphine Extended Release|Drug: Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)",NYU Langone Health|NYC Health + Hospitals,Phase 4,52,Other,"June 24, 2019","May 4, 2020","May 4, 2020"
5325,NCT03603704,A Study of LY3209590 in Japanese Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: LY3209590|Drug: Placebo,Eli Lilly and Company,Phase 1,31,Industry,"August 17, 2018","May 27, 2019","May 27, 2019"
5326,NCT03603678,Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor,"Sleep Apnea, Obstructive",Drug: BAY2253651|Drug: Placebo,Bayer,Phase 2,34,Industry,"August 13, 2018","May 23, 2019","September 2, 2019"
5327,NCT03603665,A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults,Botulism,Biological: NTM-1633|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,24,NIH,"September 25, 2018","June 11, 2019","June 11, 2019"
5328,NCT03603496,Post-Discharge Smoking Cessation Strategies: Helping HAND 4,Smoking Cessation,Behavioral: Transitional Tobacco Care Management (TTCM)|Behavioral: eReferral to State Tobacco Quitline (QL)|Drug: Nicotine replacement therapy,Massachusetts General Hospital|University of Pittsburgh Medical Center|Vanderbilt University Medical Center,Phase 4,1416,Other,"September 1, 2018","November 17, 2020","November 17, 2020"
5329,NCT03603379,Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas,Glioblastoma,Drug: C225-ILs-dox,"University Hospital, Basel, Switzerland",Phase 1,9,Other,"November 16, 2018","November 1, 2020","November 1, 2020"
5330,NCT03602560,ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA),Primary Biliary Cholangitis,Drug: seladelpar 5-10 mg|Drug: seladelpar 10 mg|Drug: Placebo,"CymaBay Therapeutics, Inc.",Phase 3,265,Industry,"October 1, 2018","February 16, 2020","February 16, 2020"
5331,NCT03602339,Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose,Magnetic Resonance Imaging,"Drug: Gadoterate (Dotarem/Clariscan)|Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)",Bayer,Phase 4,157,Industry,"November 14, 2018","March 13, 2020","May 26, 2020"
5332,NCT03601052,"Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids",Keloid,Drug: Remlarsen|Drug: Placebo,"miRagen Therapeutics, Inc.",Phase 2,14,Industry,"June 11, 2018","June 24, 2020","June 24, 2020"
5333,NCT03600870,Midodrine in Hepatopulmonary Syndrome,Hepatopulmonary Syndrome (HPS),Drug: Midodrine,Mayo Clinic,Phase 1,10,Other,"August 2, 2018","December 1, 2020","December 1, 2020"
5334,NCT03600714,"Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon",Liver Disease|Hepatitis D,Drug: Peg-interferon lambda|Drug: Lonafarnib|Drug: Ritonavir,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 2,26,NIH,"August 1, 2018","February 5, 2020","August 11, 2020"
5335,NCT03600480,A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese,Obesity|Overweight,Drug: NNC0174-0833|Drug: Semaglutide|Drug: Placebo (NNC0174-0833),Novo Nordisk A/S,Phase 1,96,Industry,"July 25, 2018","June 12, 2020","June 12, 2020"
5336,NCT03600428,Safety of LAIV4 in Children With Asthma,Asthma in Children|Vaccine Adverse Reaction|Vaccine Reaction|Asthma|Wheezing|Influenza,Biological: Live Attenuated Influenza Vaccine (LAIV)|Biological: Inactivated Influenza Vaccine (IIV),"Vanderbilt University Medical Center|Centers for Disease Control and Prevention|Duke University|Children's Hospital Medical Center, Cincinnati",Phase 4,152,Other|U.S. Fed,"October 15, 2018","March 20, 2020","March 20, 2020"
5337,NCT03600376,Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS,Exertional Heat Stroke,Drug: Ryanodex and Standard of Care|Other: Standard of Care,"Eagle Pharmaceuticals, Inc.",Phase 3,17,Industry,"August 19, 2018","August 14, 2019","August 14, 2019"
5338,NCT03599791,DYmista NAsal Spray in CHInese Patients,Allergic Rhinitis,Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT|Drug: Fluticasone Propionate 0.05 MG/ACTUAT,MEDA Pharma GmbH & Co. KG|Viatris Inc.,Phase 3,900,Industry,"June 29, 2018","September 24, 2019","September 24, 2019"
5339,NCT03599427,"Added Value of Systemic Lidocaine on Postoperative Pain, Opiate Use and Nausea After Knee Arthroscopy","Surgery|Pain, Postoperative|Nausea, Postoperative|Opioid Use",Drug: systemic lidocaine|Drug: Placebo,Algemeen Ziekenhuis Maria Middelares,Phase 4,60,Other,"September 1, 2018","June 1, 2019","June 30, 2019"
5340,NCT03599284,"The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel",Coronary Artery Disease|Percutaneous Coronary Intervention|Platelet Aggregation Inhibitors,Drug: Vicagrel 5mg|Drug: Vicagrel 6mg|Drug: Vicagrel 7.5mg|Drug: Clopidogrel 75mg,"Jiangsu vcare pharmaceutical technology co., LTD",Phase 2,279,Industry,"August 30, 2018","June 11, 2019","July 28, 2019"
5341,NCT03599063,"Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects",Healthy,Biological: PF-06946860|Other: Placebo,Pfizer,Phase 1,63,Industry,"July 30, 2018","September 18, 2019","September 18, 2019"
5342,NCT03598699,"A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)",Dry Eye,Drug: AXR-159,"AxeroVision, Inc.|ORA, Inc.",Phase 2,102,Industry,"July 9, 2018","January 12, 2021","January 12, 2021"
5343,NCT03597919,A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.,Poliomyelitis,Biological: Sabin IPV,"Centers for Disease Control and Prevention, China|Shandong Province Centers for Disease Control and Prevention|World Health Organization",Phase 4,560,Other,"May 28, 2018","September 30, 2019","January 15, 2020"
5344,NCT03597620,Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis,Psoriasis,Drug: Metaderm,University of Alabama at Birmingham,Phase 4,11,Other,"November 7, 2018","October 31, 2020","December 13, 2022"
5345,NCT03597529,CHOCOlate MeLatonin for AdolescenT MigrainE,Migraine,Drug: Melatonin,"Amy Gelfand|University of California, San Francisco",Phase 2,84,Other,"September 25, 2017","December 1, 2019","December 1, 2019"
5346,NCT03597516,"Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance",Lactose Intolerance,Drug: RP-G28|Drug: Placebos,"Ritter Pharmaceuticals, Inc.",Phase 3,557,Industry,"June 26, 2018","July 2, 2019","July 2, 2019"
5347,NCT03597412,Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM,Atherosclerotic Cardiovascular Disease|Type 2 Diabetes Mellitus,Drug: Rosuvamibe|Drug: Monorova,Yuhan Corporation,Phase 4,236,Industry,"October 17, 2018","August 12, 2020","August 12, 2020"
5348,NCT03597295,A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202),Squamous Cell Carcinoma of Anal Canal,Drug: Retifanlimab,Incyte Corporation,Phase 2,94,Industry,"October 8, 2018","June 8, 2020","November 10, 2021"
5349,NCT03596762,A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms,Menopause|Hot Flashes|Night Waking,Drug: Elinzanetant (BAY3427080)|Drug: Placebo,Bayer|Nerre Therapeutics Ltd.,Phase 2,199,Industry,"November 20, 2018","November 21, 2019","November 21, 2019"
5350,NCT03596697,A Study in Healthy Volunteers,Hepatitis B|Infectious Disease|Liver Diseases,Drug: CRV431|Drug: Placebo|Drug: TDF,"Hepion Pharmaceuticals, Inc.",Phase 1,92,Industry,"July 9, 2019","September 30, 2020","June 4, 2021"
5351,NCT03596372,Study of BAY1834942 in Patients With Solid Tumors,Advanced CEACAM6-expressing Solid Tumors,Drug: BAY1834942,Bayer,Phase 1,30,Industry,"June 19, 2018","November 16, 2020","February 22, 2021"
5352,NCT03596203,TCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy,Diabetic Neuropathies,Device: TransCutaneous Magnetic Stimulator (TCMS),"University of Maryland, Baltimore",Phase 1,17,Other,"November 1, 2018","June 30, 2019","July 30, 2019"
5353,NCT03596177,A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type II|Obesity",Drug: MEDI0382|Drug: Placebo,MedImmune LLC,Phase 2,28,Industry,"September 26, 2018","December 22, 2019","December 22, 2019"
5354,NCT03595644,Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer,Stage IV Non-small Cell Lung Cancer,Radiation: SBRT+TKI|Drug: TKI,"Tongji Hospital|Wuhan Union Hospital, China|Renmin Hospital of Wuhan University|Wuhan University|Hubei Cancer Hospital",Phase 2,74,Other,"February 12, 2017","June 10, 2019","December 10, 2020"
5355,NCT03595618,A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis,Osteoarthritis,Drug: GLPG1972|Drug: Placebo,Galapagos NV|Institut de Recherches Internationales Servier,Phase 2,932,Industry|Other,"August 14, 2018","July 14, 2020","July 14, 2020"
5356,NCT03595488,Dupilumab for Aspirin-exacerbated Respiratory Disease,Aspirin-exacerbated Respiratory Disease,Drug: Dupilumab,Rochester General Hospital,Phase 2,11,Other,"September 5, 2018","December 11, 2019","December 11, 2019"
5357,NCT03595449,Lidocaine Jelly for Pain Control During Mohs Surgery,"Pain|Satisfaction, Consumer",Drug: Lidocaine jelly|Drug: Surgilube,Mayo Clinic,Phase 4,233,Other,"August 13, 2018","August 31, 2020","August 31, 2020"
5358,NCT03594890,Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects,Influenza,Biological: OVX836 (Intramuscular)|Biological: Placebo (Intramuscular)|Biological: OVX836 (Intranasal)|Biological: Placebo (Intranasal),Osivax|Aepodia,Phase 1,72,Industry,"June 12, 2018","August 7, 2019","August 7, 2019"
5359,NCT03594227,"ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis",Alopecia,Drug: ATI-501 400mg BID (Low dose)|Drug: ATI-501 600mg BID (Mid dose)|Drug: ATI-501 800mg BID (High dose)|Drug: Placebo,"Aclaris Therapeutics, Inc.",Phase 2,87,Industry,"June 11, 2018","June 6, 2019","June 18, 2019"
5360,NCT03593785,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.",Hypercholesterolemia,Drug: AZD8233,AstraZeneca|Parexel,Phase 1,73,Industry,"August 3, 2018","December 19, 2020","December 19, 2020"
5361,NCT03593538,Effects of Metformin During Nicotine Withdrawal,Smoking|HIV-1-infection,Drug: Metformin|Drug: Placebo,University of Pennsylvania|Pennsylvania Department of Health,Phase 2,80,Other,"April 1, 2016","March 13, 2020","March 13, 2020"
5362,NCT03593200,"A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH",PNH,Drug: Pegcetacoplan,"Apellis Pharmaceuticals, Inc.",Phase 2,4,Industry,"August 16, 2018","October 22, 2019","October 22, 2019"
5363,NCT03592745,Transcutaneous Vagus Nerve Stimulation (tVNS) and Robotic Training to Improve Arm Function After Stroke,Stroke|Cerebrovascular Accident (CVA)|Hemiparesis,Device: Transcutaneous Vagus Nerve Stimulation (tVNS)|Device: Sham Transcutaneous Vagus Nerve Stimulation (tVNS),Northwell Health,Phase 2,36,Other,"August 9, 2018","June 12, 2020","June 1, 2021"
5364,NCT03592342,Intra-oral Treatment of OLP With Rivelin®-CLO Patches,Oral Lichen Planus,Drug: Clobetasol Propionate,Dermtreat|Proinnovera GmbH|X-act Cologne Clinical Research GmbH,Phase 2,140,Industry,"June 28, 2018","December 20, 2019","December 20, 2019"
5365,NCT03592277,Vitamin C & Thiamine to Treat Sepsis and Septic Shock,Sepsis|Septic Shock,Drug: Vitamin C|Drug: Vitamin B1,Saint Francis Care,Phase 2,120,Other,"September 14, 2018","February 22, 2021","February 22, 2021"
5366,NCT03592069,Concomitant Versus Hybrid Regimen for H. Pylori Eradication,H.Pylori Infection|H.Pylori Gastrointestinal Disease|H. Pylori Associated Phlegmonous Gastritis,Drug: 10 day concomitant regimen|Drug: 14 day hybrid regimen,"Alexandra Hospital, Athens, Greece|Hellenic Society of Gastroenterology",Phase 4,345,Other,"February 21, 2018","October 21, 2020","January 31, 2021"
5367,NCT03591887,A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis,Plaque Psoriasis,Biological: ABY-035|Biological: Placebo,Affibody|TFS Trial Form Support,Phase 2,108,Industry,"March 6, 2018","April 18, 2020","November 29, 2021"
5368,NCT03591718,A Study to Test Different Doses of BI 456906 in Patients With Obesity,Obesity,Drug: BI 456906|Drug: Placebo,Boehringer Ingelheim,Phase 1,131,Industry,"July 26, 2018","April 20, 2020","April 30, 2020"
5369,NCT03591653,"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks",Non-erosive Reflux Disease,Drug: LXI-15028|Drug: Placebo,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",Phase 3,291,Industry,"October 29, 2018","October 30, 2019","November 26, 2019"
5370,NCT03591575,Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children,Beta Thalassemia Major Anemia|Iron Overload,Drug: Deferiprone oral solution|Drug: Placebo,Chiesi Canada Corp,Phase 4,64,Industry,"November 9, 2018","September 29, 2020","September 29, 2020"
5371,NCT03590912,Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion,Otitis Media With Effusion,Drug: Mometasone 50 Mcg/Inh Nasal Spray|Drug: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Drug: Steroid Drug (prednisolone),Lumbini Medical College,Phase 4,160,Other,"September 5, 2018","February 16, 2020","March 18, 2020"
5372,NCT03590769,Arterial Imaging of Inflammation and Resolution After Endovascular Surgery,"Peripheral Arterial Disease|Claudication, Intermittent|Claudication|PAD|SFA - Superficial Femoral Artery Stenosis|Iliac Artery Disease|Vascular Calcification",Drug: 18F-FDG,"University of California, San Francisco",Phase 1,9,Other,"June 1, 2017","September 3, 2019","September 3, 2019"
5373,NCT03590392,Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001),Chikungunya Fever,Biological: ChAdOx1 Chik,University of Oxford,Phase 1,24,Other,"July 31, 2018","September 30, 2019","September 30, 2019"
5374,NCT03590197,"Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy",Generalized Epilepsy,Drug: Melatonin 3 mg|Other: Placebo,"All India Institute of Medical Sciences, Bhubaneswar",Phase 4,104,Other,"August 6, 2018","March 3, 2020","April 12, 2020"
5375,NCT03589885,Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Drug: Placebo 2 mL auto-injector|Drug: Placebo 1 mL prefilled syringe|Drug: Secukinumab 2 mL auto-injector|Drug: Secukinumab 1 mL prefilled syringe,Novartis Pharmaceuticals|Novartis,Phase 3,122,Industry,"December 19, 2018","November 19, 2019","August 5, 2020"
5376,NCT03589807,2013/2017 H7N9 Prime-Boost Interval,Avian Influenza|Influenza Immunisation,"Biological: A/H7N9|Drug: AS03|Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Other: Phosphate Buffered Saline (PBS) diluent",National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,180,NIH,"August 21, 2018","June 14, 2020","June 14, 2020"
5377,NCT03589768,Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants,Clostridium Difficile Immunisation|Diphtheria|Diphtheria Immunisation|Pertussis|Tetanus|Tetanus Immunisation,"Biological: Tetanus and Diphtheria Toxoids Adsorbed|Biological: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide",National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,399,NIH,"January 24, 2019","July 1, 2020","July 1, 2020"
5378,NCT03589469,Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma Refractory|Diffuse Large B-cell Lymphoma Recurrent,Drug: Loncastuximab tesirine,ADC Therapeutics S.A.,Phase 2,145,Industry,"August 1, 2018","May 24, 2020","August 9, 2022"
5379,NCT03589105,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",Multiple Sclerosis,Drug: Ocrelizumab 300 mg|Drug: Ocrelizumab 600 mg,Hoffmann-La Roche,Phase 4,423,Industry,"August 6, 2018","February 15, 2021","February 15, 2021"
5380,NCT03588910,Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription,Surgery,Drug: Acetaminophen|Drug: Ibuprofen 600 mg|Drug: Oxycodone,Montefiore Medical Center,Phase 2,120,Other,"August 8, 2018","July 4, 2019","August 4, 2019"
5381,NCT03588884,"Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Insufficiency|CKD Stage 3|CKD Stage 4,Drug: Calcifediol Oral Capsule|Drug: Calcifediol Oral Product|Drug: Cholecalciferol|Drug: Paricalcitol Oral Capsule,"OPKO Health, Inc.",Phase 4,69,Industry,"June 8, 2018","April 24, 2020","April 24, 2020"
5382,NCT03588026,Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576,Paroxysmal Nocturnal Hemoglobinuria (PNH),Drug: rVA576|Other: Standard of care (SOC),AKARI Therapeutics,Phase 3,9,Industry,"June 7, 2018","September 3, 2020","September 3, 2020"
5383,NCT03587649,Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss,Alzheimer Disease|Parkinson Disease|Healthy Volunteers,Drug: [18F]MNI-1126,Invicro,Phase 1,12,Other,"May 7, 2018","February 26, 2020","February 26, 2020"
5384,NCT03587636,Liposome Bupivacaine Interscalene Total Shoulder,Acute Pain,Drug: liposome bupivacaine|Drug: Bupivacaine,University of Minnesota,Phase 2,77,Other,"September 17, 2018","March 15, 2021","March 17, 2021"
5385,NCT03586973,A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,Drug: Cabozantinib,Takeda,Phase 2,34,Industry,"August 6, 2018","July 17, 2019","June 29, 2021"
5386,NCT03586427,AGN-241751 in the Treatment of Major Depressive Disorder,"Depressive Disorder, Major",Drug: AGN-241751|Drug: Placebo,"Gate Neurosciences, Inc",Phase 2,251,Industry,"June 13, 2018","July 22, 2019","August 21, 2019"
5387,NCT03585803,"A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011",Acute Radiation Syndrome,Drug: KMRC011 5μg or Placebo|Drug: KMRC011 10μg or Placebo|Drug: KMRC011 15μg or Placebo|Drug: KMRC011 20μg or Placebo|Drug: KMRC011 25μg or Placebo,"Intron Biotechnology, Inc.",Phase 1,26,Industry,"June 11, 2018","September 11, 2019","November 28, 2019"
5388,NCT03585712,"Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill",Contraception,Drug: Norgestrel 0.075 mg,HRA Pharma|Health Decisions,Phase 2,52,Industry|Other,"July 24, 2018","April 7, 2020","April 7, 2020"
5389,NCT03585556,AAVCAGsCD59 for the Treatment of Wet AMD,Wet Age-related Macular Degeneration,Drug: Intravitreal anti-VEGF|Biological: Intravitreal AAVCAGsCD59|Drug: Oral prednisolone,"Janssen Research & Development, LLC",Phase 1,25,Industry,"September 13, 2018","January 29, 2020","January 18, 2022"
5390,NCT03585517,Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T),AML,Drug: IM23,"Beijing Immunochina Medical Science & Technology Co., Ltd.",Phase 1,10,Industry,"July 21, 2018","August 1, 2020","October 1, 2020"
5391,NCT03585478,Latiglutenase as a Treatment for Celiac Disease,Celiac Disease,Drug: Latiglutenase|Other: Placebo,"Immunogenics, LLC|National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH)",Phase 2,79,Industry|NIH,"March 1, 2019","January 22, 2021","January 22, 2021"
5392,NCT03585413,Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery,Obesity|Gastric Bypass|NAFLD,Dietary Supplement: Micronutrient-probiotic-combination|Dietary Supplement: Micronutrient-placebo-combination,"Bonn Education Association for Dietetics r.A., Cologne, Germany|St. Franziskus Hospital|University of Bonn|FormMed HealthCare AG",Phase 3,60,Industry|Other,"August 31, 2018","January 17, 2020","January 17, 2020"
5393,NCT03584698,Evening Primrose Oil to Misoprostol During Induction of Second-trimester Missed Miscarriage,Missed Abortion,Drug: Misoprostol 100Mcg Tab|Drug: Evening Primrose Oil 1000 MG,Assiut University,Phase 4,144,Other,"September 1, 2019","January 15, 2021","March 31, 2021"
5394,NCT03584087,Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL,Acute Variceal Haemorrhage,Drug: Normal Saline|Drug: Terlipressin,Postgraduate Institute of Medical Education and Research,Phase 4,74,Other,"May 7, 2018","July 31, 2019","July 31, 2019"
5395,NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",Breast Neoplasms,Drug: Eribulin Mesylate,Eisai Inc.,Phase 4,200,Industry,"March 28, 2018","June 28, 2019","June 28, 2019"
5396,NCT03583905,Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet,Hypertensive Patients With Dyslipidemia,Drug: CKD-330|Drug: Placebo of CKD-330|Drug: D086|Drug: Placebo of D086|Drug: D723|Drug: Placebo of D723,Chong Kun Dang Pharmaceutical,Phase 3,154,Industry,"April 4, 2018","July 17, 2019","July 17, 2019"
5397,NCT03583606,A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z),Ebola Disease|Immunisation,Biological: ChAd3-EBO-Z|Biological: MVA Multi-Filo Ebola Vaccine|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,61,NIH,"November 12, 2018","January 14, 2020","January 14, 2020"
5398,NCT03583372,An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).,Overactive Bladder,Drug: Vibegron|Drug: placebos|Drug: Tolterodine Tartrate ER,Urovant Sciences GmbH,Phase 3,506,Industry,"June 14, 2018","June 13, 2019","July 25, 2019"
5399,NCT03583346,Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA),"Osteoarthritis, Knee",Drug: M6495|Drug: Placebo,"Merck KGaA, Darmstadt, Germany",Phase 1,32,Industry,"August 23, 2018","July 31, 2019","July 31, 2019"
5400,NCT03582761,Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71,"Hand, Foot and Mouth Disease",Biological: EV71 vaccine,"Jiangsu Province Centers for Disease Control and Prevention|Wuhan Institute of Biological Products Co., Ltd|Hubei Provincial Center for Disease Control and Prevention",Phase 4,40000,Other|Industry,"May 1, 2019","May 1, 2020","May 1, 2020"
5401,NCT03581591,"Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets","Hypophosphatemia|Hypophosphatemic Rickets|Pain, Chronic",Biological: Burosumab,Redwood Dermatology Sciences|Ultragenyx Pharmaceutical Inc,Phase 3,1,Other|Industry,"January 31, 2018","December 6, 2019","December 6, 2019"
5402,NCT03581409,Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm,"Aneurysm, Cerebral|Endovascular Procedures",Drug: Aspirin|Drug: Prasugrel|Drug: Clopidogrel|Drug: Cilostazol,Seoul National University Hospital|Seoul National University Bundang Hospital,Phase 4,198,Other,"October 24, 2018","January 22, 2021","January 22, 2021"
5403,NCT03580408,"Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma",Hodgkin Lymphoma|Coexisting Medical Conditions,Drug: Nivolumab|Drug: Vinblastin,The Lymphoma Academic Research Organisation,Phase 2,64,Other,"August 31, 2018","February 19, 2021","August 12, 2021"
5404,NCT03580278,"A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2",Psoriasis,Biological: ABY-035/AFO2,Affibody,Phase 1,33,Industry,"November 13, 2019","September 22, 2020","September 22, 2020"
5405,NCT03580187,Nebulized Morphine in Chest Trauma Patients: A Prospective Study,Blunt Injury of Thorax,Drug: Morphine (+),"University Hospital, Mahdia",Phase 3,75,Other,"June 14, 2018","April 15, 2020","April 15, 2020"
5406,NCT03580031,Booster Dose of HCG for Unruptured Follicle in Non IVF/ICSI Cycles,LUF - Luteinised Unruptured Follicle Syndrome,Drug: hCG|Drug: Saline Solution,Tanta University,Phase 4,110,Other,"August 1, 2018","January 1, 2021","January 1, 2021"
5407,NCT03579693,Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease,Chronic Kidney Disease|Sarcopenia|Frailty,Dietary Supplement: CoQ10|Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo,University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2,26,Other|NIH,"November 14, 2018","April 26, 2021","April 26, 2021"
5408,NCT03579628,AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors,Advanced Cancer,Drug: AsiDNA,Onxeo,Phase 1,33,Industry,"April 5, 2018","February 24, 2021","February 20, 2022"
5409,NCT03579589,The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal,Neuromuscular Blockade,Drug: Sugammadex vs Neostigmine,Ohio State University,Phase 1,40,Other,"August 15, 2018","December 15, 2019","December 15, 2019"
5410,NCT03579459,Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age,Clostridium Difficile Associated Disease,Biological: Clostridium difficile vaccine|Biological: placebo,Pfizer,Phase 3,1317,Industry,"July 31, 2018","August 6, 2019","August 6, 2019"
5411,NCT03579030,Safety and PK/PD of RTA 1701 in Healthy Adults,Healthy,Drug: Placebo oral capsule|Drug: RTA 1701 capsules,"Reata Pharmaceuticals, Inc.",Phase 1,90,Industry,"June 20, 2018","June 28, 2019","June 28, 2019"
5412,NCT03578822,"Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial",Acute Ischaemic Stroke,Drug: Recombinant human urokinase|Drug: Aspirin|Drug: rhPro-UK simulation agent|Drug: Aspirin simulation agent,"Tasly Biopharmaceuticals Co., Ltd.",Phase 3,149,Industry,"August 10, 2018","February 28, 2020","March 1, 2020"
5413,NCT03578809,A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction,ST Elevation Myocardial Infarction,Biological: MEDI6012|Other: Placebo,MedImmune LLC|Thrombolysis in Myocardial Infarction (TIMI) Study Group,Phase 2,593,Industry|Other,"June 5, 2018","January 18, 2021","January 18, 2021"
5414,NCT03578640,Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4,"Hepatitis C, Chronic","Drug: Elbasvir, Grazoprevir 50-100Mg Oral Tablet",King Fahad Medical City,Phase 3,30,Other,"July 1, 2018","June 30, 2020","June 30, 2020"
5415,NCT03578497,Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome,Polycystic Ovary Syndrome,Drug: IL-1 receptor antagonist Anakinra,"University Hospital, Basel, Switzerland",Phase 2,18,Other,"August 31, 2018","July 30, 2020","July 30, 2020"
5416,NCT03578276,Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen,Cataract,Drug: Pred-Gati-Brom|Drug: Prednisolone acetate 1% ophthalmic suspension|Drug: Gatifloxacin Ophthalmic|Drug: Bromfenac 0.075% Oph Solution,"Carolina Eyecare Physicians, LLC|Science in Vision|Imprimis Pharmaceuticals, Inc.",Phase 4,35,Other|Industry,"June 22, 2018","December 4, 2019","December 4, 2019"
5417,NCT03577743,Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,Metastatic Triple Negative Breast Cancer|Safety Issues|Efficacy,Drug: Bevacizumab,Assiut University,Phase 2,54,Other,"July 1, 2018","March 15, 2020","February 15, 2021"
5418,NCT03577171,A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV),Chronic Hepatitis B,Drug: ABI-H0731|Drug: SOC ETV|Drug: Placebo Oral Tablet,Assembly Biosciences,Phase 2,25,Industry,"June 19, 2018","June 21, 2019","June 21, 2019"
5419,NCT03576716,Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation,Chronic Kidney Disease,Drug: D6-25-hydroxyvitamin D3,University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1,19,Other|NIH,"June 1, 2018","July 8, 2019","January 1, 2021"
5420,NCT03576469,A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions,CVI - Common Variable Immunodeficiency,Biological: C1-esterase inhibitor [recombinant] (C1-INH-R),IMMUNOe Research Centers,Phase 4,20,Industry,"June 13, 2018","December 1, 2019","March 1, 2020"
5421,NCT03576313,Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination,Malaria,Drug: dihydroartemisinin-piperaquine (DP)|Drug: ivermectin (IVM)|Other: standard malaria control interventions only,"London School of Hygiene and Tropical Medicine|Institute of Tropical Medicine, Belgium|National Malaria Control Programme, The Gambia|Liverpool School of Tropical Medicine|Radboud University Medical Center|University of Durham|Imperial College London",Phase 3,4939,Other,"August 11, 2018","December 31, 2019","July 31, 2021"
5422,NCT03576066,A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection,Chronic Hepatitis B,Drug: ABI-H0731|Drug: SOC NUC|Drug: Placebo Oral Tablet,Assembly Biosciences,Phase 2,73,Industry,"June 11, 2018","July 5, 2019","July 5, 2019"
5423,NCT03575871,Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis,"Dermatitis, Atopic",Drug: PF-04965842 100 mg|Drug: PF-04965842 200 mg|Drug: Placebo,Pfizer,Phase 3,391,Industry,"June 29, 2018","August 13, 2019","August 13, 2019"
5424,NCT03575806,Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection,Hepatocellular Carcinoma|Malignant Neoplasm,Combination Product: TACE plus autologous Tcm immunotherapy|Procedure: TACE,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Newish Technology (Beijing) Co., Ltd.",Phase 2,52,Other|Industry,"January 9, 2017","October 31, 2019","October 31, 2019"
5425,NCT03575676,Efficacy and Safety of SOM3355 in Huntington's Disease Chorea,Huntington's Chorea,Drug: SOM3355 100mg BID|Drug: SOM3355 200mg BID|Drug: Placebo BID,SOM Innovation Biotech SA,Phase 2,32,Industry,"August 8, 2018","August 22, 2019","August 22, 2019"
5426,NCT03575104,Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep,Insomnia Disorder,Drug: Daridorexant|Other: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 3,924,Industry,"May 29, 2018","April 9, 2020","May 14, 2020"
5427,NCT03575065,Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China,HER2-negative Breast Cancer,Drug: BGB-290,BeiGene,Phase 2,88,Industry,"June 22, 2018","October 9, 2020","April 14, 2021"
5428,NCT03574948,5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores,Crohn Disease|Ulcerative Colitis|Fatigue|Remission,Drug: 5-HTP|Drug: Placebo oral capsule,"University Hospital, Ghent",Phase 2,175,Other,"December 6, 2018","February 23, 2021","March 3, 2021"
5429,NCT03574805,Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma,Asthma,Drug: PRS-060|Drug: Placebo,Pieris Australia Pty Ltd,Phase 1,76,Industry,"June 26, 2018","September 15, 2020","September 15, 2020"
5430,NCT03574753,Lung-MAP S1400K: c-MET Positive,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC V7,Drug: ABBV-399,SWOG Cancer Research Network,Phase 2,28,Other,"March 16, 2018","December 21, 2019","July 30, 2021"
5431,NCT03574584,A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese,Metabolism and Nutrition Disorders|Overweight or Obesity,Drug: NNC0165-1562|Drug: Semaglutide|Drug: Placebo (NNC0165-1562),Novo Nordisk A/S,Phase 1,37,Industry,"June 18, 2018","July 27, 2019","July 27, 2019"
5432,NCT03574363,Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease,Chronic Kidney Diseases|Hypertension,Drug: KBP-5074 0.25 mg tablet|Drug: KBP-5074 0.5 mg tablet,KBP Biosciences|Worldwide Clinical Trials,Phase 2,162,Industry|Other,"April 25, 2018","August 5, 2020","August 5, 2020"
5433,NCT03573999,Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation,Brain Edema|Metabolic Disturbance|Electrolyte and Fluid Balance Conditions,Drug: Mannitol|Drug: NaCl 7.5%,Aristotle University Of Thessaloniki,Phase 4,54,Other,"June 29, 2018","October 31, 2019","December 20, 2019"
5434,NCT03573518,Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris,Acne Vulgaris,Drug: BTX 1503|Drug: Vehicle,Botanix Pharmaceuticals,Phase 2,368,Industry,"June 26, 2018","August 16, 2019","September 5, 2019"
5435,NCT03573323,A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis,Plaque Psoriasis,Drug: Ixekizumab|Drug: Guselkumab|Drug: Placebo,Eli Lilly and Company,Phase 4,1027,Industry,"November 9, 2018","July 15, 2019","January 8, 2020"
5436,NCT03572933,Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder,CDKL5 Deficiency Disorder,Drug: ganaxolone|Drug: Placebo,Marinus Pharmaceuticals,Phase 3,101,Industry,"June 30, 2018","July 31, 2020","May 28, 2021"
5437,NCT03572829,Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC,Vomiting|Nausea Post Chemotherapy|Head Neck Cancer,Drug: Aprepitant,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 2,44,Other,"March 1, 2018","January 9, 2020","July 1, 2020"
5438,NCT03572413,The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.,Pneumoperitoneum|Neuromuscular Blockade|Surgery|Immune Suppression,Procedure: Low pressure pneumoperitoneum|Drug: Rocuronium bromide,Radboud University Medical Center|Merck Sharp & Dohme LLC,Phase 4,100,Other|Industry,"October 24, 2018","August 31, 2020","December 1, 2020"
5439,NCT03571672,DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY,Cardiac Disease,Drug: DEFINITY,Lantheus Medical Imaging|Syneos Health,Phase 3,153,Industry|Other,"October 24, 2018","August 30, 2019","August 30, 2019"
5440,NCT03571620,Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients,Atopic Dermatitis,Drug: Q301 Cream|Drug: Vehicle,"Qurient Co., Ltd.",Phase 2,258,Industry,"June 21, 2018","November 30, 2019","April 21, 2020"
5441,NCT03571516,"Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome",Short Bowel Syndrome,Drug: Teduglutide|Other: Standard Medical Therapy|Device: Syringe|Device: Needle,Shire|Takeda,Phase 3,10,Industry,"August 31, 2018","September 24, 2020","September 24, 2020"
5442,NCT03571490,Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot Assisted Partiel Nephrectomy,Postoperative Pain|Ultrasound Guided Transmuscular Quadratus Lumborum Block,Drug: Ropivacaine|Drug: Saline,Zealand University Hospital,Phase 4,50,Other,"June 26, 2018","June 24, 2019","June 24, 2019"
5443,NCT03571256,A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS),Tourette Syndrome,Drug: TEV-50717|Drug: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.|Nuvelution TS Pharma, Inc.",Phase 3,158,Industry,"May 31, 2018","December 9, 2019","December 9, 2019"
5444,NCT03570697,Imaging of Coronary Plaques in Participants Treated With Evolocumab,Coronary Artery Disease (CAD),Drug: Evolocumab|Drug: Placebo|Drug: Statin therapy,Amgen,Phase 3,164,Industry,"November 19, 2018","December 18, 2020","January 21, 2021"
5445,NCT03570645,Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block,Lung Cancer,Drug: Dexmedetomidine Group|Drug: dexamethasone group|Drug: control group,"China Medical University, China",Phase 4,154,Other,"July 12, 2019","November 11, 2019","November 18, 2019"
5446,NCT03570554,A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale,"Osteoarthritis, Knee","Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Acetaminophen ER|Drug: Celecoxib|Drug: Placebo",Bayer,Phase 2,41,Industry,"June 29, 2018","June 14, 2019","June 14, 2019"
5447,NCT03570541,TQL-block for Laparoscopic Hemicolectomy,Postoperative Pain,Drug: Ropivacaine|Drug: Acetaminophen|Device: Patient controlled analgesia|Drug: Morphine|Drug: Saline|Diagnostic Test: Blood samples|Behavioral: Quality of recovery-15 questionaire|Diagnostic Test: Orthostatic hypotension,Zealand University Hospital,Phase 4,69,Other,"June 28, 2018","December 5, 2020","January 3, 2021"
5448,NCT03570359,A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza,Chronic Obstructive Pulmonary Disease (COPD),Drug: Interferon Beta-1A|Other: Placebo,Synairgen Research Ltd.,Phase 2,122,Industry,"January 29, 2018","May 5, 2020","May 5, 2020"
5449,NCT03569631,A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome,Fragile X Syndrome|FXS|Fra(X) Syndrome,Drug: BPN14770|Drug: Placebo,Tetra Discovery Partners,Phase 2,30,Industry,"July 9, 2018","July 31, 2020","July 31, 2020"
5450,NCT03569475,"Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder",Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Fluoxetine|Drug: Placebo,Allergan,Phase 3,501,Industry,"July 6, 2018","March 1, 2021","March 1, 2021"
5451,NCT03569267,A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects,"Cicatrix, Hypertrophic",Drug: OLX10010|Drug: Placebo,"Olix Pharmaceuticals, Inc.",Phase 1,48,Industry,"May 21, 2018","June 27, 2019","June 27, 2019"
5452,NCT03569098,Dysport in Hallux Abducto Valgus (HAV) Phase IIa,Hallux Abducto Valgus,Biological: Botulinum toxin type A|Drug: Placebo,Ipsen,Phase 2,186,Industry,"June 19, 2018","December 17, 2019","May 22, 2020"
5453,NCT03568838,Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention,Myocardial Infarction,Drug: Enoxaparin,Sheffield Teaching Hospitals NHS Foundation Trust|Medical Research Council,Phase 4,100,Other,"June 28, 2018","May 1, 2020","May 1, 2020"
5454,NCT03568643,Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot),Uncomplicated Severe Acute Malnutrition,Drug: Azithromycin|Drug: Amoxicillin,"University of California, San Francisco|Centre de Recherche en Sante de Nouna, Burkina Faso|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Phase 3,301,Other|NIH,"June 3, 2020","December 25, 2020","December 25, 2020"
5455,NCT03568604,"Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia",Dyspareunia,Drug: Prasterone,San Diego Sexual Medicine,Phase 4,18,Other,"August 7, 2018","January 28, 2020","January 28, 2020"
5456,NCT03568539,IBI308 in Subjects With Advanced/Metastatic Solid Malignancies,Advanced/Metastatic Solid Malignancies,Drug: IBI308,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,39,Industry,"June 27, 2018","November 9, 2020","December 7, 2020"
5457,NCT03568500,"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic",Schizophrenia|Schizoaffective Disorder|First Episode Psychosis,Device: Digital Medicine System|Drug: Aripiprazole|Drug: Olanzapine|Drug: Quetiapine|Drug: Risperidone,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 4,44,Industry,"May 21, 2018","May 21, 2019","September 6, 2019"
5458,NCT03568331,Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE),Atopic Dermatitis,Drug: Tradipitant|Drug: Placebo,Vanda Pharmaceuticals,Phase 3,375,Industry,"June 30, 2018","November 1, 2019","February 1, 2020"
5459,NCT03568162,Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis,Moderate to Severe Atopic Dermatitis,Drug: ISB 830 - Part 1 Group 1|Drug: ISB 830 - Part 1 Group 2|Drug: ISB 830 - Part 1 Group 3|Drug: Placebo - Part 1 Group 4|Drug: ISB 830 - Part 2 Group 5|Drug: Placebo - Part 2 Group 6,Ichnos Sciences SA|Glenmark Pharmaceuticals S.A.,Phase 2,462,Industry,"May 31, 2018","August 11, 2020","August 3, 2021"
5460,NCT03568136,Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis,"Dermatitis, Atopic|Eczema, Atopic|Neurodermatitis, Atopic",Drug: Secukinumab 300 mg|Drug: Placebo,GWT-TUD GmbH|Novartis Pharmaceuticals,Phase 2,22,Other|Industry,"September 18, 2018","May 4, 2020","May 4, 2020"
5461,NCT03567980,A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis,Seborrheic Dermatitis,Drug: Crisaborole,University of Alabama at Birmingham,Phase 4,30,Other,"September 1, 2018","April 30, 2020","May 12, 2021"
5462,NCT03567382,Arresting Vertical Transmission of Hepatitis B Virus,Hepatitis B|Vertical Transmission of Infectious Disease,Drug: Tenofovir Disoproxil Fumarate|Biological: Monovalent HBV vaccine,"University of North Carolina, Chapel Hill|Kinshasa School of Public Health|Ohio State University",Phase 4,179,Other,"September 24, 2018","March 6, 2020","August 15, 2020"
5463,NCT03567057,A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,Multiple Sclerosis|Walking Impairment,"Drug: ADS-5102, 274 mg","Adamas Pharmaceuticals, Inc.",Phase 3,424,Industry,"July 18, 2018","November 17, 2020","April 18, 2021"
5464,NCT03566940,"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule",Healthy,Biological: sIPV|Biological: cIPV,Janssen Vaccines & Prevention B.V.,Phase 2,302,Industry,"July 31, 2018","August 7, 2019","October 17, 2019"
5465,NCT03566238,This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2,PFIC1|PFIC2,Drug: A4250 (odevixibat)|Drug: Placebo,Albireo,Phase 3,62,Industry,"May 16, 2018","July 27, 2020","July 28, 2020"
5466,NCT03566134,A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder,Overactive Bladder,Drug: DA-8010 Placebo|Drug: DA-8010 2.5mg|Drug: DA-8010 5mg|Drug: Solifenacin 5mg|Drug: Solifenacin succinate placebo,"Dong-A ST Co., Ltd.",Phase 2,306,Industry,"July 10, 2018","December 27, 2019","December 27, 2019"
5467,NCT03565354,Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients,"Anemia, Iron-Deficiency|Colorectal Cancer",Drug: iron isomaltoside(Monofer®),"Prince of Wales Hospital, Shatin, Hong Kong",Phase 3,40,Other,"July 1, 2018","June 30, 2020","June 30, 2020"
5468,NCT03565211,Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures,Progesterone Supplementation in Women Undergoing ART,Drug: Progesterone vaginal ring,Ferring Pharmaceuticals,Phase 3,352,Industry,"July 26, 2018","July 29, 2019","July 29, 2019"
5469,NCT03565094,Single Dose of Lu AF28996 to Healthy Young Men,Healthy,Drug: Lu AF28996 solution|Drug: Lu AF28996 capsule,H. Lundbeck A/S,Phase 1,39,Industry,"May 29, 2018","August 17, 2019","August 21, 2019"
5470,NCT03565068,"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)",Schizophrenia,Drug: MK-8189|Drug: Placebo|Drug: Background AAP Therapy,Merck Sharp & Dohme LLC,Phase 1,75,Industry,"June 20, 2018","April 3, 2020","April 3, 2020"
5471,NCT03564886,Hyperosmolar Saline Irrigation Fluid in Arthroscopic Knee Surgery,Arthroscopic Knee Surgery,Drug: Hyperosmolar Saline|Drug: Normal saline,University of Missouri-Columbia,Phase 4,48,Other,"January 1, 2019","September 5, 2019","September 5, 2019"
5472,NCT03564509,A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.,Controlled Ovarian Stimulation,Drug: FE 999302 (dose 1) and follitropin delta|Drug: FE 999302 (dose 2) and follitropin delta|Drug: FE 999302 (dose 3) and follitropin delta|Drug: FE 999302 (dose 4) and follitropin delta|Drug: FE 999302 (dose 5) and follitropin delta|Other: Placebo and follitropin delta,Ferring Pharmaceuticals,Phase 2,616,Industry,"May 14, 2018","October 21, 2019","January 8, 2020"
5473,NCT03564301,Metronidazole as an Adjunct of Non- Surgical Treatment of Peri-implantitis,Peri-Implantitis,Drug: Placebo oral capsule|Drug: Metronidazole 250 MG,Juan Blanco Carrión|Osteology Foundation|University of Santiago de Compostela,Phase 4,20,Other,"March 3, 2018","March 1, 2020","December 22, 2020"
5474,NCT03564132,Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder,Tourette Disorder|Tic Disorders,Drug: Yigansan|Drug: Placebo,China Medical University Hospital,Phase 2,38,Other,"June 16, 2018","August 15, 2020","August 31, 2022"
5475,NCT03564119,A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea,Papulopustular Rosacea,Drug: S5G4T-1|Drug: S5G4T-2,"Sol-Gel Technologies, Ltd.",Phase 3,372,Industry,"June 21, 2018","June 10, 2019","June 10, 2019"
5476,NCT03563599,"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB",Drug: Telacebec (Q203)|Drug: Rifafour e-275,"Qurient Co., Ltd.",Phase 2,60,Industry,"July 23, 2018","September 9, 2019","September 9, 2019"
5477,NCT03563560,A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: Alvocidib|Drug: Cytarabine|Drug: Mitoxantrone|Drug: Daunorubicine,"Sumitomo Pharma Co., Ltd.",Phase 1,10,Industry,"May 15, 2018","March 31, 2020","March 31, 2020"
5478,NCT03562624,A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components,Contraception,"Drug: BAY98-7443|Drug: Levonogestrel (Skyla, BAY86-5028)",Bayer,Phase 2,177,Industry,"June 22, 2018","May 16, 2019","August 1, 2019"
5479,NCT03562481,Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years,"Anesthesia, Local|Pain","Drug: 1% Buffered Lidocaine 1:100,000 Epinephrine|Drug: 2% Unbuffered Lidocaine 1:100,000 Epinephrine","University of North Carolina, Chapel Hill",Phase 4,26,Other,"July 24, 2018","June 30, 2019","June 30, 2019"
5480,NCT03562377,Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5),Atopic Dermatitis,Drug: Tralokinumab|Drug: Placebo|Biological: Tdap vaccine|Biological: Meningococcal vaccine,LEO Pharma,Phase 2,215,Industry,"July 13, 2018","September 17, 2019","November 22, 2019"
5481,NCT03562156,A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection),Recurrent Vulvovaginal Candidiasis,Drug: Oteseconazole (VT-1161)|Drug: Placebo,Mycovia Pharmaceuticals Inc.,Phase 3,438,Industry,"August 16, 2018","October 19, 2020","August 6, 2021"
5482,NCT03562130,"Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients",Short Bowel Syndrome,Drug: Teduglutide,Assistance Publique - Hôpitaux de Paris|Imagine Institute,Phase 4,25,Other,"July 2, 2018","December 11, 2019","July 13, 2020"
5483,NCT03561883,Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs),Gastroesophageal Reflux Disease (GERD),Drug: IW-3718|Drug: placebo|Drug: Standard-dose PPIs QD,"Ironwood Pharmaceuticals, Inc.",Phase 3,609,Industry,"September 6, 2018","July 28, 2020","November 6, 2020"
5484,NCT03561779,Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee,"Osteoarthritis, Knee",Drug: YYD302 2ml|Drug: Active comparator: Synovian Inj.,"Yooyoung Pharmaceutical Co., Ltd.",Phase 3,184,Industry,"February 21, 2018","June 14, 2019","October 4, 2019"
5485,NCT03561753,Pilot Clinical Trial of PRS TB Regimen I - Phase II,Pulmonary Tuberculosis TB in Sputum: (+) Microscopy,"Drug: Group A (the standard 2HRZE/4HR regimen）|Drug: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)","Shanghai Pulmonary Hospital, Shanghai, China|Shanghai Center for Disease Control and Prevention|No.85 Hospital, Changning, Shanghai, China|Shanghai Public Health Clinical Center|Bill and Melinda Gates Foundation|University of California, Los Angeles",Phase 4,97,Other,"December 1, 2017","December 31, 2019","January 31, 2020"
5486,NCT03561701,A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection),Recurrent Vulvovaginal Candidiasis,Drug: Oteseconazole (VT-1161)|Drug: Placebo,Mycovia Pharmaceuticals Inc.,Phase 3,425,Industry,"August 23, 2018","October 13, 2020","August 3, 2021"
5487,NCT03561675,Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years,Acute Mountain Sickness,Drug: ACETAZOLAMIDE oral capsule|Drug: Placebo oral capsule,University of Zurich|National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov,Phase 4,349,Other,"May 15, 2018","August 31, 2019","August 31, 2019"
5488,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,Multiple Sclerosis,Combination Product: ofatumumab with PRF|Combination Product: ofatumumab with AI,Novartis Pharmaceuticals|Novartis,Phase 2,284,Industry,"September 11, 2018","August 26, 2019","May 5, 2020"
5489,NCT03560271,A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Cyclo-Z|Other: Placebo,"NovMetaPharma Co., Ltd.|InClin, Inc.|FGK Clinical Research GmbH",Phase 2,256,Industry|Other,"June 18, 2018","June 25, 2019","July 15, 2019"
5490,NCT03560245,A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine,Alzheimer Disease,Drug: Bryostatin|Other: Placebo,"Neurotrope Bioscience, Inc.|Worldwide Clinical Trials",Phase 2,108,Industry|Other,"June 20, 2018","July 25, 2019","July 25, 2019"
5491,NCT03559699,A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD),"Pyruvate Kinase Deficiency|Anemia, Hemolytic",Drug: AG-348,"Agios Pharmaceuticals, Inc.",Phase 3,27,Industry,"June 26, 2018","November 12, 2020","November 12, 2020"
5492,NCT03559348,Locally Advanced or Metastatic Pancreatic Adenocarcinoma,Pancreatic Adenocarcinoma,"Drug: chemotherapy: TS-1, Leucovorin and Gemcitabine","National Health Research Institutes, Taiwan|National Taiwan University Hospital|China Medical University Hospital|Kaohsiung Medical University|Chang Gung Memorial Hospital|National Cheng-Kung University Hospital",Phase 2,49,Other,"April 3, 2018","April 20, 2020","April 20, 2020"
5493,NCT03559257,A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine,Migraine,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Phase 3,463,Industry,"July 31, 2018","June 19, 2019","September 19, 2019"
5494,NCT03559192,A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression,"Depressive Disorder, Major",Drug: JNJ-67953964|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,181,Industry,"July 16, 2018","May 6, 2020","May 6, 2020"
5495,NCT03559166,First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis,Fibrosis,Drug: BLD-2660,Blade Therapeutics,Phase 1,88,Industry,"July 11, 2018","October 4, 2019","October 4, 2019"
5496,NCT03558997,Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy,Allergic Rhinitis,Drug: Dupilumab|Drug: Timothy Grass SCIT|Drug: Placebo matching dupilumab|Drug: Placebo matching SCIT,Regeneron Pharmaceuticals|Sanofi,Phase 2,103,Industry,"June 7, 2018","May 14, 2019","June 13, 2019"
5497,NCT03558516,Magnesium and Intraoperative Blood Loss in Meningioma Surgery,Meningioma,Drug: Magnesium group|Drug: Normal saline group,Mahidol University,Phase 3,80,Other,"August 1, 2018","February 3, 2020","February 18, 2020"
5498,NCT03558503,A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer,Bladder Cancer|Urothelial Carcinoma|Urothelial Carcinoma Bladder,Drug: UGN-102,UroGen Pharma Ltd.,Phase 2,63,Industry,"October 15, 2018","January 3, 2020","October 21, 2020"
5499,NCT03558139,Trial of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy,Ovarian Cancer,Drug: Magrolimab|Drug: Avelumab,"Gilead Sciences|Merck KGaA, Darmstadt, Germany",Phase 1,34,Industry,"May 23, 2018","December 3, 2020","December 3, 2020"
5500,NCT03557931,A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication,Schizophrenia,Drug: ASP4345|Drug: placebo|Drug: risperidone|Drug: quetiapine|Drug: olanzapine|Drug: ziprasidone|Drug: aripiprazole|Drug: brexpiprazole|Drug: paliperidone|Drug: lurasidone,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 2,233,Industry,"July 13, 2018","October 21, 2019","October 21, 2019"
5501,NCT03557437,High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment,Helicobacter Pylori Infection,"Drug: Esomeprazole|Drug: Amoxicillin, Metronidazole|Drug: Bismuth Potassium Citrate",Shanghai Jiao Tong University School of Medicine,Phase 4,216,Other,"May 25, 2018","June 10, 2019","June 10, 2019"
5502,NCT03557333,Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301),Migraine Headache,Combination Product: INP104,Impel Pharmaceuticals,Phase 3,360,Industry,"July 13, 2018","March 17, 2020","March 17, 2020"
5503,NCT03557307,Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma,Asthma,Biological: Benralizumab,AstraZeneca,Phase 3,598,Industry,"August 1, 2018","April 16, 2021","March 24, 2022"
5504,NCT03556852,CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE,Postpartum Hemorrhage,Drug: Carbetocin|Drug: Misoprostol,Cairo University,Phase 4,150,Other,"July 2, 2018","May 24, 2019","May 30, 2019"
5505,NCT03556761,Furosemide for Accelerated Recovery of Blood Pressure Postpartum,"Hypertension, Pregnancy-Induced",Drug: Oral furosemide|Drug: Placebo Oral Tablet,University of Pennsylvania,Phase 2,384,Other,"June 20, 2018","December 4, 2019","February 5, 2020"
5506,NCT03556592,Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4,Atopic Dermatitis,Drug: Tralokinumab|Drug: Caffeine|Drug: Warfarin|Drug: Omeprazole|Drug: Metoprolol|Drug: Midazolam Hydrochloride,LEO Pharma,Phase 1,40,Industry,"August 13, 2018","March 16, 2020","June 20, 2020"
5507,NCT03556371,Evaluation of N-Acetylcysteine Efficacy to Reduce the Craving and to Prolong Abstinence Time of Coca Paste,Cocaine-Related Disorders,Drug: N-Acetylcysteine|Drug: Placebo oral capsule,"University of Concepcion, Chile|Comisión Nacional de Investigación Científica y Tecnológica",Phase 2,140,Other,"April 9, 2018","August 9, 2019","August 9, 2019"
5508,NCT03556358,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer",Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer,Biological: TX05 (trastuzumab)|Biological: Herceptin®|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide,"Tanvex BioPharma USA, Inc.",Phase 3,809,Industry,"June 28, 2018","November 27, 2020","February 4, 2021"
5509,NCT03556345,A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2,Gastric Cancer|HER2 Overexpressing Gastric Carcinoma,Drug: RC48-ADC,"RemeGen Co., Ltd.",Phase 2,127,Industry,"July 10, 2018","June 1, 2020","August 31, 2020"
5510,NCT03556033,Effect of Dapagliflozin on IAH in T1DM,"Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness",Drug: Dapagliflozin|Drug: Placebo oral capsule,Radboud University Medical Center,Phase 2,15,Other,"November 23, 2018","December 20, 2019","December 20, 2019"
5511,NCT03556007,A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Drug: LY3471851|Drug: Placebo,Eli Lilly and Company|Nektar Therapeutics,Phase 1,48,Industry,"April 18, 2018","August 29, 2019","August 29, 2019"
5512,NCT03555994,A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo|Drug: Liraglutide,MedImmune LLC,Phase 2,49,Industry,"May 31, 2018","April 14, 2021","April 14, 2021"
5513,NCT03555825,Burke-Hocoma Efficiency Study,Hemiparesis|Hemiplegia,Device: Hocoma ArmeoSpring,Burke Medical Research Institute|Hocoma,Phase 3,47,Other,"May 1, 2016","July 1, 2019",Dec-20
5514,NCT03555305,A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants,Healthy,Drug: Insulin Glargine|Drug: Lantus,Eli Lilly and Company,Phase 1,58,Industry,"September 26, 2018","November 4, 2019","November 4, 2019"
5515,NCT03554993,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects",Healthy Volunteer,Drug: CC-99677|Other: Placebo,Celgene,Phase 1,97,Industry,"May 23, 2018","July 3, 2019","July 3, 2019"
5516,NCT03554798,A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine,Poliomyelitis,Biological: nOPV2 (monovalent oral polio vaccine),Fidec Corporation|Bill and Melinda Gates Foundation,Phase 2,1025,Other,"December 4, 2018","February 19, 2020","February 19, 2020"
5517,NCT03554408,First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS,Human Immunodeficiency Virus,Drug: 10-1074-LS|Drug: 3BNC117-LS,Rockefeller University,Phase 1,77,Other,"June 20, 2018","February 4, 2021","February 4, 2021"
5518,NCT03554018,Ibuprofen With or Without Acetaminophen for Low Back Pain,Low Back Pain,Drug: Acetaminophen|Drug: Ibuprofen 600 mg|Behavioral: Educational intervention|Drug: Placebo oral capsule,Montefiore Medical Center,Phase 3,120,Other,"October 16, 2018","September 30, 2019","September 30, 2019"
5519,NCT03553940,H3N2 M2SR in Pediatric Population,Influenza|Influenza Immunisation,Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Other: Placebo|Biological: Quadrivalent MDCK Inactivated Influenza Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,43,NIH,"August 15, 2018","August 27, 2020","August 27, 2020"
5520,NCT03553823,Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab,Chronic Plaque-type Psoriasis,Procedure: Skin biopsies,Novartis Pharmaceuticals|Novartis,Phase 2,40,Industry,"January 14, 2019","January 28, 2020","January 28, 2020"
5521,NCT03553498,IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients,Acute Pain,Drug: IV acetaminophen|Drug: IV placebo|Drug: hydromorphone,Albert Einstein College of Medicine,Phase 3,162,Other,"November 27, 2018","May 15, 2019","May 15, 2019"
5522,NCT03552757,Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity,Obesity|Overweight,Drug: Semaglutide 1.0 mg|Drug: Semaglutide 2.4 mg|Drug: Placebo I (Semaglutide)|Drug: Placebo II (Semaglutide),Novo Nordisk A/S,Phase 3,1210,Industry,"June 4, 2018","March 24, 2020","May 1, 2020"
5523,NCT03552575,The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI,Heart Failure,Drug: sacubitril/valsartan|Drug: Valsartan,NHS Greater Glasgow and Clyde|University of Glasgow,Phase 3,93,Other,"July 1, 2018","July 25, 2020","July 25, 2020"
5524,NCT03552263,Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS),Acute Mountain Sickness (AMS),Drug: T89 capsule|Drug: Placebo capsule,"Tasly Pharmaceuticals, Inc.",Phase 2,132,Industry,"June 7, 2018","October 20, 2019","November 10, 2019"
5525,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,Malignant Melanoma,Drug: Dabrafenib|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Phase 3,556,Industry,"August 29, 2018","October 5, 2020","September 16, 2021"
5526,NCT03550209,Fatty Acid Supplementation in Children With ASD,Autism Spectrum Disorder,Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo,Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital,Phase 2,72,Other|NIH,"June 28, 2018","January 10, 2020","January 10, 2020"
5527,NCT03549598,d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis,Cardiac Sarcoidosis,Drug: 68Ga-DOTATATE PET/CT|Drug: 18FDG PET/CT scan|Drug: 13NH3 PET/CT scan,Mayo Clinic,Phase 4,15,Other,"July 20, 2018","October 2, 2019","October 2, 2019"
5528,NCT03549234,Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery,Breast Surgery,Drug: Erector Spinae (single injection)|Drug: Paravertebral (single injection),"University of California, San Diego",Phase 4,100,Other,"July 12, 2018","May 8, 2019","May 8, 2019"
5529,NCT03548987,Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,Metabolism and Nutrition Disorder|Obesity,Drug: Semaglutide|Drug: Placebo,Novo Nordisk A/S,Phase 3,902,Industry,"June 4, 2018","February 22, 2020","March 20, 2020"
5530,NCT03548935,STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,Metabolism and Nutrition Disorder|Overweight or Obesity,Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,Phase 3,1961,Industry,"June 4, 2018","March 30, 2020","March 5, 2021"
5531,NCT03548714,Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol,Alcohol Dependence|Alcohol Interaction,Drug: PT150|Other: Beverage,"Pop Test Oncology LLC|Pharmacotherapies for Alcohol and Substance Use Disorders Alliance|Congressionally Directed Medical Research Programs|Michael E. DeBakey VA Medical Center|Baylor College of Medicine|University of California, San Diego",Phase 1,10,Industry|Other|U.S. Fed,"September 1, 2018","July 15, 2019","July 15, 2019"
5532,NCT03548415,"Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands",Acromegaly,Drug: IONIS-GHR-LRx|Drug: Placebo,"Ionis Pharmaceuticals, Inc.",Phase 2,43,Industry,"September 13, 2018","February 18, 2021","April 2, 2021"
5533,NCT03548337,"Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India",Vaccines,Biological: 13vPnC,Pfizer,Phase 4,301,Industry,"May 31, 2018","December 20, 2019","December 20, 2019"
5534,NCT03548220,A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD),"Pyruvate Kinase Deficiency|Anemia, Hemolytic",Drug: Placebo|Drug: AG-348,"Agios Pharmaceuticals, Inc.",Phase 3,80,Industry,"August 9, 2018","October 9, 2020","October 9, 2020"
5535,NCT03547804,"A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer",Small-cell Lung Cancer,Drug: Apatinib|Drug: chemotherapy,The First Hospital of Jilin University,Phase 2,31,Other,"May 31, 2018","October 25, 2019","September 1, 2020"
5536,NCT03547583,Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF,Chronic Heart Failure With Preserved Ejection Fraction,"Drug: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Drug: Placebo",Bayer|Merck Sharp & Dohme LLC|Canadian VIGOUR Centre|Duke Clinical Research Institute,Phase 2,789,Industry|Other,"June 15, 2018","October 15, 2019","November 4, 2019"
5537,NCT03547388,Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment,Head and Neck Neoplasms|Recurrence Tumor,Device: Moderate whole body hyperthermia using water-filtered IR-A-radiation,"Charite University, Berlin, Germany|Erwin Braun foundation",Phase 1,10,Other,"July 1, 2018","May 4, 2020","May 4, 2020"
5538,NCT03547245,"A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted",HIV/AIDS,Biological: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|Biological: DPBS Sucrose,International AIDS Vaccine Initiative,Phase 1,46,Other,"June 15, 2018","January 17, 2020","August 13, 2021"
5539,NCT03547167,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",Pneumococcal Infections,Biological: V114|Biological: Prevnar 13™|Biological: PNEUMOVAX™23,Merck Sharp & Dohme LLC,Phase 3,1515,Industry,"July 16, 2018","January 20, 2020","January 20, 2020"
5540,NCT03546907,"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",Chronic Obstructive Pulmonary Disease,Drug: SAR440340|Drug: Placebo|Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Drug: Any short-acting β agonist as prescribed by treating physician as standard of care,Sanofi|Regeneron Pharmaceuticals,Phase 2,343,Industry,"July 16, 2018","October 3, 2019","February 21, 2020"
5541,NCT03546816,"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis",Pruritus|Prurigo Nodularis,Drug: 5mg Serlopitant Tablets|Drug: Placebo Tablets,Vyne Therapeutics Inc.,Phase 3,285,Industry,"May 2, 2018","January 14, 2020","February 14, 2020"
5542,NCT03546790,"Laboratory Smoking of Marijuana ""Blunts""",Cannabis,Drug: Marijuana,Battelle Memorial Institute,Phase 1,8,Other,"April 10, 2019","September 30, 2019","September 30, 2019"
5543,NCT03546634,Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China,Poliomyelitis,Biological: Sabin IPV,"Centers for Disease Control and Prevention, China|Shandong Province Centers for Disease Control and Prevention",Phase 4,280,Other,"May 24, 2018","June 5, 2019","January 15, 2020"
5544,NCT03546465,"Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects",Healthy Volunteers,Drug: ropeginterferon alfa-2b,PharmaEssentia Japan K.K.|PharmaEssentia,Phase 1,36,Industry,"May 7, 2018","July 15, 2019","July 15, 2019"
5545,NCT03545789,Phase 1 Test-retest Evaluation of [18F]MNI-958 PET,Healthy Volunteers|Alzheimer Disease|Progressive Supranuclear Palsy,Drug: [18F]MNI-958,Invicro,Phase 1,16,Other,"March 12, 2018","February 6, 2020","February 6, 2020"
5546,NCT03545503,Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation,Intubation Complication,Drug: Etomidate|Drug: Ketamine,"South East Area Health Education Center, Wilmington, NC|New Hanover Regional Medical Center",Phase 4,428,Other,"January 1, 2018","September 1, 2019","September 1, 2019"
5547,NCT03545373,Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study),Tuberculosis|Respiratory Tract Infections|Pneumonia,Drug: Azithromycin|Drug: Amoxicillin,London School of Hygiene and Tropical Medicine|Kamuzu University of Health Sciences,Phase 3,1583,Other,"February 25, 2019","March 14, 2020","April 14, 2020"
5548,NCT03545347,"Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.",Hip Fractures,Drug: Nandrolone Decanoate|Dietary Supplement: Protein-rich nutritional supplement|Other: Physical therapy|Drug: Sodium Chloride 9mg/ml Injection,"Morten Tange Kristensen PT, PhD|Hvidovre University Hospital",Phase 2,29,Other,"September 3, 2018","May 20, 2020","June 3, 2020"
5549,NCT03545243,PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia,Dysbiosis,Drug: Pantoprazole 40mg|Other: PPI withdrawal,Universitaire Ziekenhuizen KU Leuven,Phase 4,79,Other,"April 23, 2018","March 8, 2020","September 22, 2020"
5550,NCT03545191,Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder,Insomnia Disorder,Drug: Daridorexant 25 mg|Drug: Daridorexant 50 mg|Other: Placebo,Idorsia Pharmaceuticals Ltd.,Phase 3,930,Industry,"June 4, 2018","January 25, 2020","February 25, 2020"
5551,NCT03544606,Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor,Induction of Labor Affected Fetus / Newborn,Drug: isosorbide mononitrate|Drug: Placebos,ahmed nagy shaker ramadan|Cairo University,Phase 3,140,Other,"January 1, 2019","January 1, 2021","February 15, 2021"
5552,NCT03543657,Maintenance Treatment of Renal Anemia in Dialysis Subjects,"Anemia|Renal Insufficiency, Chronic",Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa|Drug: Placebo of Molidustat (BAY85-3934)|Drug: Placebo of Darbepoetin alfa,Bayer,Phase 3,229,Industry,"June 23, 2018","August 7, 2019","December 24, 2019"
5553,NCT03543462,Diaphragmatic Resection And Gynecological Ovarian Neoplasm,Ovarian Cancer,Device: thoracic Drain Tube 24 Fr.,Catholic University of the Sacred Heart,Phase 4,88,Other,"March 20, 2018","November 11, 2019","January 11, 2020"
5554,NCT03543436,Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections,Urinary Tract Infections,Drug: Temocillin|Drug: meropenem or imipenem,Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Paris Saint Joseph|French National Network of Clinical Research in Infectious Diseases (RENARCI),Phase 3,29,Other,"January 4, 2019","October 29, 2020","December 14, 2020"
5555,NCT03543410,A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression,Depressive Episode|Bipolar 1 Depression,Drug: SEP-4199 200 mg|Drug: SEP-4199 400 mg|Drug: Placebo,Sunovion,Phase 2,344,Industry,"June 26, 2018","April 23, 2020","April 23, 2020"
5556,NCT03543358,A Long-Term Study of Rovalpituzumab Tesirine,Cancer,Drug: rovalpituzumab tesirine,AbbVie,Phase 2,3,Industry,"September 10, 2018","November 26, 2019","November 26, 2019"
5557,NCT03543254,"""Follow the Sutures"". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine",Migraine Disorders|Chronic Disease,Drug: BoNT-A,Norwegian University of Science and Technology|St. Olavs Hospital|Mayo Clinic,Phase 2,20,Other,"June 1, 2018","January 1, 2021","January 1, 2021"
5558,NCT03542994,A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis,Psoriasis|Atopic Dermatitis,Other: EDP1066|Drug: Placebo oral capsule,"Evelo Biosciences, Inc.",Phase 1,114,Industry,"April 24, 2019","January 3, 2020","January 3, 2020"
5559,NCT03542877,Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer,Colorectal Cancer,Drug: Oral Tablet: Cabozantinib,"Academic Thoracic Oncology Medical Investigators Consortium|University of Colorado, Denver",Phase 2,44,Industry|Other,"June 1, 2018","October 19, 2020","March 7, 2022"
5560,NCT03542838,Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis,"Osteoarthritis, Knee|Pain, Knee",Drug: Resiniferatoxin|Drug: Saline,"Sorrento Therapeutics, Inc.",Phase 1,94,Industry,"July 12, 2018","April 13, 2020","February 11, 2021"
5561,NCT03542552,Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa,Placenta Previa,Drug: Magnesium Sulfate|Drug: Nifedipine,Assiut University,Phase 3,176,Other,"June 1, 2018","March 30, 2021","April 30, 2021"
5562,NCT03542305,Lorlatinib Renal Impairment Study,Renal Impairment,Drug: Lorlatinib,Pfizer,Phase 1,29,Industry,"August 23, 2018","February 20, 2020","February 20, 2020"
5563,NCT03542214,Calcium Electroporation for the Treatment of Colorectal Cancer,Colorectal Cancer Stage IV,Combination Product: Calcium electroporation,Zealand University Hospital,Phase 1,6,Other,"April 24, 2018","October 1, 2020","January 1, 2021"
5564,NCT03541980,Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?,Sickle Cell Anemia Crisis,Drug: Acetaminophen|Drug: Normal saline,Newark Beth Israel Medical Center,Phase 4,71,Other,"February 20, 2018","February 20, 2020","February 20, 2020"
5565,NCT03541941,Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair,"Analgesia, Postoperative",Drug: Exparel|Drug: Bupivacaine Hcl 0.25% Inj|Drug: Placebo,"The Cleveland Clinic|Pacira Pharmaceuticals, Inc",Phase 4,164,Other|Industry,"July 3, 2018","December 19, 2019","December 19, 2019"
5566,NCT03541668,Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST),Acute Ischaemic Stroke,Drug: Recombinant human urokinase|Drug: Alteplase,"Tasly Biopharmaceuticals Co., Ltd.",Phase 3,674,Industry,"May 18, 2018","April 14, 2020","May 24, 2020"
5567,NCT03541655,Safety and Activity of F14 for Management of Pain Following Total Knee Replacement,Total Knee Replacement|Postoperative Pain,Drug: Bupivacaine HCl|Drug: F14 (celecoxib),Arthritis Innovation Corporation,Phase 2,20,Industry,"May 4, 2018","June 20, 2019","March 30, 2020"
5568,NCT03541603,Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF,"Hypertension Pulmonary Secondary|Heart Failure, Right Sided|Heart Failure With Normal Ejection Fraction",Drug: Levosimendan|Drug: Matching Placebo,"Tenax Therapeutics, Inc.",Phase 2,38,Industry,"November 14, 2018","April 7, 2020","April 7, 2020"
5569,NCT03541499,Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults,Pertussis|Pertussis Immunisation,Biological: BPZE1|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,50,NIH,"October 23, 2018","May 15, 2020","May 15, 2020"
5570,NCT03541356,Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal,Parkinson's Disease,Combination Product: Placebo|Combination Product: L-dopa 35 mg|Combination Product: L-dopa 70mg|Combination Product: L-dopa 140 mg|Combination Product: L-dopa 70mg/carbidopa 7mg,Impel Pharmaceuticals,Phase 2,32,Industry,"May 8, 2018","June 11, 2019","June 11, 2019"
5571,NCT03541200,Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms,Vasomotor Symptoms (VMS),Drug: MT-8554,Mitsubishi Tanabe Pharma America Inc.,Phase 2,190,Industry,"April 18, 2018","November 15, 2019","November 15, 2019"
5572,NCT03541005,Evaluation of Obex® in Overweight and Obesity,Overweight and Obesity,Dietary Supplement: Obex|Dietary Supplement: Placebo,Catalysis SL,Phase 3,160,Industry,"October 1, 2018","September 1, 2019","July 3, 2021"
5573,NCT03540043,Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis,Atopic Dermatitis Eczema,Drug: Administration of Placebo|Drug: Administration of PUR0110 (Thykamine) 0.05%|Drug: Administration of PUR0110 (Thykamine) 0.1%|Drug: Administration of PUR0110 (Thykamine) 0.25%,PurGenesis Technologies Inc.,Phase 2,162,Industry,"October 23, 2017","December 31, 2019","June 3, 2020"
5574,NCT03539952,Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease,Wilson Disease,Drug: Penicillamine (D1-W12)|Drug: TETA 4HCL (W12-60)|Drug: Penicillamine (W12-W60)|Drug: TETA 4HCL (60-<W108),Orphalan,Phase 3,77,Industry,"September 3, 2018","August 19, 2020","January 18, 2022"
5575,NCT03538808,Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence,Medication Adherence,Drug: Varenicline|Other: Placebo,University of Alabama at Birmingham,Phase 4,80,Other,"November 6, 2018","October 29, 2019","October 29, 2019"
5576,NCT03538743,"4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes",Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-06882961,Pfizer,Phase 1,98,Industry,"June 25, 2018","May 23, 2019","June 10, 2019"
5577,NCT03538522,"A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831","Mild Cognitive Impairment|Alzheimer Disease|Alzheimer Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Cognitive Impairment|Tauopathies|Neurodegenerative Diseases|Neurocognitive Disorders|Cognitive Disorder",Drug: N-831(Traneurocin) 10 mg QD|Drug: NA-831 (Traneurocin) 20 mg QD|Drug: NA-831 (Traneurocin) 40 mg QD|Drug: Placebo oral capsule QD,"NeuroActiva, Inc.",Phase 2,126,Industry,"September 15, 2018","September 30, 2019","October 30, 2019"
5578,NCT03538431,Improving Driving in Young People With Autism Spectrum Disorders,Autism Spectrum Disorder,Drug: Buspirone,Massachusetts General Hospital|Massachusetts Institute of Technology,Phase 4,26,Other,"October 31, 2018","December 16, 2019","December 16, 2019"
5579,NCT03538054,Dextromethorphan in Fibromyalgia,Fibromyalgia,Drug: Dextromethorphan|Drug: Placebo,University of Alabama at Birmingham,Phase 2,27,Other,"June 26, 2018","March 18, 2020","March 18, 2020"
5580,NCT03538028,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,Cervical Cancer|Microsatellite Instability (MSI)-High Endometrial Cancer|Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma (Uveal Melanoma Excluded)|Merkel Cell Carcinoma|Mesothelioma|MSI-high Colorectal Cancer|Non-small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Small Cell Lung Cancer (SCLC)|Renal Cell Carcinoma (RCC)|Triple-negative Breast Cancer|Urothelial Carcinoma|Diffuse Large B-cell Lymphoma,Biological: INCAGN02385,Incyte Biosciences International Sàrl|Incyte Corporation,Phase 1,22,Industry,"June 18, 2018","October 7, 2020","October 7, 2020"
5581,NCT03537196,DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C),Hepatitis C|Drug Use|Viral Hepatitis C,Drug: Sofosbuvir 400 mg and Daclatasvir 60 mg|Drug: Sofosbuvir 400 mg and Daclatasvir 90 mg|Drug: Ribavirin|Drug: Sofosbuvir and Daclatasvir for 24 weeks,"ANRS, Emerging Infectious Diseases",Phase 4,979,Other,"November 13, 2018","November 30, 2020","November 30, 2020"
5582,NCT03537014,A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1),Posttraumatic Stress Disorder,Behavioral: Therapy|Drug: MDMA|Drug: Placebo,Multidisciplinary Association for Psychedelic Studies,Phase 3,100,Other,"November 21, 2018","August 11, 2020","August 21, 2020"
5583,NCT03536754,A Study of CCX140-B in Subjects With FSGS,FSGS|Focal Segmental Glomerulosclerosis|Glomerulosclerosis,Other: Placebo|Drug: CCX140-B,"ChemoCentryx|Medpace, Inc.",Phase 2,46,Industry,"May 1, 2018","November 26, 2019","February 19, 2020"
5584,NCT03536117,Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates,Tuberculosis,Biological: MTBVAC|Biological: BCG,"Biofabri, S.L|South African Tuberculosis Vaccine Initiative|Universidad de Zaragoza|TuBerculosis Vaccine Initiative",Phase 2,99,Industry|Other,"February 11, 2019","March 8, 2021","March 7, 2022"
5585,NCT03535961,Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer,Breast Cancer,Drug: apatinib+oral etoposide,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 2,32,Other,"May 1, 2017","May 1, 2019","May 1, 2019"
5586,NCT03535259,Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma,"Hepatocellular Carcinoma, Radiotherapy, Sorafenib","Radiation: concurrent sorafenib and IMRT, followed sorafenib maintenance","Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 2,86,Other,"April 20, 2018","January 31, 2020","June 1, 2021"
5587,NCT03535194,A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2),Psoriasis,Drug: Mirikizumab|Drug: Placebo|Drug: Secukinumab,Eli Lilly and Company,Phase 3,1484,Industry,"June 26, 2018","March 5, 2020","June 3, 2020"
5588,NCT03534492,Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB),Bladder Cancer,Drug: Durvalumab|Drug: Olaparib,Spanish Oncology Genito-Urinary Group|AstraZeneca|Sistemas Genómicos|Apices Soluciones S.L.,Phase 2,29,Other|Industry,"November 16, 2018","March 16, 2020","March 16, 2020"
5589,NCT03534297,Study of Dapansutrile Capsules in Heart Failure,Systolic Heart Failure,Drug: dapansutrile capsules|Drug: Placebo capsules,Olatec Therapeutics LLC,Phase 1,30,Industry,"May 16, 2018","November 21, 2019","November 21, 2019"
5590,NCT03533751,"Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis",Atopic Dermatitis,Biological: Etokimab|Drug: Placebo,"AnaptysBio, Inc.",Phase 2,302,Industry,"June 19, 2018","December 3, 2019","December 3, 2019"
5591,NCT03533257,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,Alzheimer Disease,Drug: AMX0035|Drug: Placebo,Amylyx Pharmaceuticals Inc.|Alzheimer's Drug Discovery Foundation|Alzheimer's Association,Phase 2,95,Industry|Other,"August 27, 2018","April 15, 2021","August 15, 2021"
5592,NCT03533244,A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia,Pterygium,Drug: 0.1% AG-86893 Eye Drops|Drug: 0.3% AG-86893 Eye Drops|Drug: Vehicle Eye Drops,Allgenesis Biotherapeutics Inc.,Phase 2,64,Industry,"October 11, 2018","September 5, 2019","October 25, 2019"
5593,NCT03533179,Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition,Drug Overdose|Overdose of Beta-adrenergic Blocking Drug,Drug: Glucagon|Drug: Esmolol|Drug: Physiologic saline - glucagon dummy|Drug: Physiologic saline - esmolol dummy,University Hospital Bispebjerg and Frederiksberg,Phase 4,10,Other,"June 1, 2018","October 1, 2019","October 1, 2019"
5594,NCT03533114,A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension,Idiopathic Hypersomnia,Drug: JZP-258|Drug: Placebo Oral Solution,Jazz Pharmaceuticals,Phase 3,154,Industry,"November 27, 2018","June 12, 2020","December 18, 2020"
5595,NCT03532802,The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.,Hypertrophic Cardiomyopathy,Drug: Metoprolol Succinate|Drug: Placebo oral capsule,Steen Hvitfeldt Poulsen|Aarhus University Hospital Skejby,Phase 2,30,Other,"May 1, 2018","September 1, 2020","September 1, 2020"
5596,NCT03532451,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,Bladder Cancer,Drug: Nivolumab|Drug: Nivolumab/Lirilumab,"PrECOG, LLC.|Bristol-Myers Squibb",Phase 1,43,Other|Industry,"March 22, 2019","November 27, 2020","October 5, 2022"
5597,NCT03531957,Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT),Atopic Dermatitis,Drug: ASN002|Drug: Placebo Oral Tablet,Asana BioSciences,Phase 2,244,Industry,"July 5, 2018","July 22, 2019","August 14, 2019"
5598,NCT03531905,Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C,"Diabetes|Diabetes Mellitus, Type 2|Cholesterolemia",Drug: Bempedoic acid + Ezetimibe FDC Oral Tablet|Drug: Ezetimibe 10 mg Oral Tablet|Drug: Placebo Oral Tablet|Drug: Placebo oral capsule,"Esperion Therapeutics, Inc.",Phase 2,242,Industry,"May 9, 2018","June 18, 2019","June 18, 2019"
5599,NCT03531840,Olaparib in People With Malignant Mesothelioma,Mesothelioma,Drug: Olaparib|Device: ClinOmics,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,23,NIH,"July 11, 2018","December 4, 2019","October 21, 2020"
5600,NCT03531697,Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery,Inflammation Following Ocular Surgery,Drug: Generic Loteprednol Etabonate|Drug: Reference Listed Drug (RLD),Sandoz,Phase 1,381,Industry,"April 26, 2018","September 7, 2019","October 7, 2019"
5601,NCT03531684,Efficacy and Safety of MMFS in Early AD,Alzheimer Disease,Dietary Supplement: MMFS-205-SR|Dietary Supplement: Placebo,"Neurocentria, Inc.|Ohio State University",Phase 2,10,Industry|Other,"March 20, 2018","April 22, 2020","April 22, 2020"
5602,NCT03531294,Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement,Diabetic Retinopathy,Drug: Aflibercept Injection,Greater Houston Retina Research|Regeneron Pharmaceuticals|The Cleveland Clinic,Phase 2,40,Other|Industry,"May 23, 2018","April 9, 2021","April 9, 2021"
5603,NCT03530917,A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.,Healthy Participants,Drug: RO7020531|Drug: Placebo,Hoffmann-La Roche,Phase 1,70,Industry,"May 15, 2018","May 15, 2019","May 15, 2019"
5604,NCT03530670,Effect of Premedication Type on Preoperative Anxiety in Children,Preoperative Anxiety,Other: oral midazolam|Other: Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|Other: Playing smartphone game,Diskapi Yildirim Beyazit Education and Research Hospital,Phase 4,138,Other,"August 6, 2018","June 30, 2019","June 30, 2019"
5605,NCT03530514,"A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers",Healthy Volunteers,Drug: REGN4461|Drug: Placebo,Regeneron Pharmaceuticals,Phase 1,113,Industry,"April 24, 2018","January 27, 2020","January 27, 2020"
5606,NCT03529955,Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis,"Dermatomyositis, Adult Type",Drug: Apremilast 30mg,Tulane University,Phase 2,8,Other,"June 12, 2018","February 28, 2021","April 7, 2021"
5607,NCT03529942,Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee,"Osteoarthritis, Knee",Drug: FX006 32 mg,"Flexion Therapeutics, Inc.",Phase 3,129,Industry,"April 24, 2018","November 8, 2019","March 9, 2020"
5608,NCT03529773,A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults,Respiratory Tract Infections,Biological: Formulation A|Biological: Formulation B|Biological: Placebo,Pfizer,Phase 2,1235,Industry,"April 18, 2018","November 20, 2019","December 28, 2020"
5609,NCT03529123,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India),Type 2 Diabetes Mellitus,Drug: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|Drug: INSULIN GLARGINE (HOE901)|Drug: Metformin|Drug: Insulin Glulisine (HMR1964),Sanofi,Phase 3,247,Industry,"June 19, 2018","November 25, 2019","November 25, 2019"
5610,NCT03528629,A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,Gastric Cancer|Gastro-esophageal Junction (GEJ) Cancer,Drug: Zolbetuximab,Astellas Pharma Inc,Phase 1,18,Industry,"May 17, 2018","March 3, 2020","March 3, 2020"
5611,NCT03528551,A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A,Congenital Bleeding Disorder|Haemophilia A,Drug: Turoctocog alfa pegol,Novo Nordisk A/S,Phase 3,160,Industry,"April 30, 2018","December 3, 2020","December 3, 2020"
5612,NCT03527238,Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine,Liver Transplant|Kidney Transplant,Other: PPM-based Computation Assisted Drug Dosing|Drug: Tacrolimus,University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2,62,Other|NIH,"September 21, 2018","June 2, 2020","August 31, 2021"
5613,NCT03527173,"A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults","Dysentery, Bacillary",Biological: S.sonnei vaccine|Drug: Placebo|Biological: S. sonnei 53G challenge strain,GlaxoSmithKline,Phase 2,71,Industry,"August 29, 2018","May 8, 2019","November 11, 2019"
5614,NCT03527147,Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study),NHL|DLBCL|Non-hodgkin's Lymphoma|Diffuse Large B Cell Lymphoma,Drug: AZD9150|Drug: Acalabrutinib|Drug: AZD6738|Drug: Hu5F9-G4|Drug: Rituximab|Drug: AZD5153,Acerta Pharma BV|AstraZeneca,Phase 1,30,Industry,"June 19, 2018","March 31, 2021","March 31, 2021"
5615,NCT03526861,Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).,Atopic Dermatitis,Drug: Tralokinumab|Drug: Placebos,LEO Pharma,Phase 3,301,Industry,"June 19, 2018","April 15, 2020","March 16, 2021"
5616,NCT03525886,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia",CAH - Congenital Adrenal Hyperplasia,Drug: NBI-74788,Neurocrine Biosciences,Phase 2,18,Industry,"April 10, 2018","April 7, 2020","April 7, 2020"
5617,NCT03525834,Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.,Renal Angiomyolipoma,Drug: Everolimus,Novartis Pharmaceuticals|Novartis,Phase 4,40,Industry,"November 9, 2018","September 25, 2020","September 25, 2020"
5618,NCT03525821,Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED),"Fractures, Closed",Drug: Ketamine Hydrochloride,Fondation Lenval,Phase 3,9,Other,"July 5, 2018","September 13, 2020","September 13, 2020"
5619,NCT03525795,ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: CPI-1205|Drug: ipilimumab,Constellation Pharmaceuticals,Phase 1,24,Industry,"December 14, 2017","June 12, 2019","June 12, 2019"
5620,NCT03525379,Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure,Congestive Heart Failure Chronic,Drug: Resveratrol|Drug: Placebo,University of Alberta,Phase 2,13,Other,"October 26, 2017","October 8, 2019","October 8, 2019"
5621,NCT03525210,"Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients",Human Papilloma Virus|Hiv|Organ Transplants,Biological: 9-valent HPV vaccine,Universitaire Ziekenhuizen KU Leuven,Phase 3,271,Other,"April 4, 2018","September 1, 2019","July 15, 2020"
5622,NCT03524651,Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia,Iron Deficiency Anemia,Drug: Ferrous Sulfate|Drug: Fe-ASP,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Attikon Hospital|Amalia Fleming Prefecture General Hospital of Melissia|G.Gennimatas General Hospital,Phase 4,60,Industry|Other,"May 2, 2018","January 8, 2021","January 8, 2021"
5623,NCT03524508,Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer,Metastatic Biliary Tract Cancer,Drug: Onivyde|Drug: 5-FU/LV,Changhoon Yoo|Ulsan University Hospital|Chungnam National University Hospital|Kyungpook National University Chilgok Hospital|Inje University|Asan Medical Center,Phase 2,178,Other,"September 4, 2018","September 30, 2020","December 31, 2021"
5624,NCT03523871,A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret,Hepatitis C,Drug: Mavyret,NYU Langone Health,Phase 2,20,Other,"May 12, 2018","September 1, 2020","September 1, 2020"
5625,NCT03523390,Phase I/Ib Multiple Ascending Dose Study in China,Metastatic Solid Tumors,Drug: Avelumab,"Merck KGaA, Darmstadt, Germany",Phase 1,21,Industry,"April 24, 2018","July 29, 2019","February 8, 2021"
5626,NCT03523117,Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA,Iron Deficiency Anemia,Drug: Ferric carboxymaltose|Drug: Ferrous Sulfate,"American Regent, Inc.",Phase 3,79,Industry,"January 31, 2019","December 22, 2020","January 29, 2021"
5627,NCT03522935,Subcutaneous Elafin in Healthy Subjects,Pulmonary Arterial Hypertension,Drug: Elafin|Drug: Placebo,Roham T. Zamanian|Duke University|SRI International|Stanford University,Phase 1,30,Other|Industry,"March 18, 2019","October 25, 2019","November 18, 2020"
5628,NCT03522415,Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis,Moderately to Severely Active Rheumatoid Arthritis,Drug: HLX01|Drug: Methotrexate（MTX）,Shanghai Henlius Biotech,Phase 3,275,Industry,"May 28, 2018","April 5, 2020","September 11, 2020"
5629,NCT03521960,Buspirone for Opioid Tapering,"Opioid-Related Disorders|Dependency (Psychology)|Pain, Chronic|Opiate Withdrawal Syndrome",Drug: Buspirone oral capsule|Drug: Placebo oral capsule,Johns Hopkins University,Phase 1,18,Other,"May 30, 2018","June 30, 2020","June 30, 2020"
5630,NCT03521687,Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA),Central Centrifugal Cicatricial Alopecia,Drug: Apremilast,Icahn School of Medicine at Mount Sinai,Phase 4,20,Other,"November 15, 2018","February 12, 2021","February 12, 2021"
5631,NCT03521635,The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa,Parkinson Disease,Drug: Pramipexole SR|Drug: Pramipexole IR,Boehringer Ingelheim,Phase 4,98,Industry,"July 3, 2018","January 7, 2020","January 7, 2020"
5632,NCT03521505,Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration,Bronchoscopy,Drug: Dexmedetomidine arm|Drug: Propofol arm,Chang Gung Memorial Hospital,Phase 4,50,Other,"May 11, 2018","January 22, 2020","January 22, 2020"
5633,NCT03521037,Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor,Neoplasms,Drug: Rucaparib camsylate,"Clovis Oncology, Inc.",Phase 1,16,Industry,"February 27, 2018","September 27, 2019","February 24, 2021"
5634,NCT03520998,A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease,Alzheimer Disease|Mild to Moderate Alzheimer Disease,Drug: GRF6019,"Alkahest, Inc.",Phase 2,47,Industry,"April 16, 2018","May 24, 2019","May 24, 2019"
5635,NCT03520972,Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects,Type 2 Diabetes Mellitus,Drug: PB-119 75ug|Drug: PB-119 150ug|Drug: PB-119 200ug|Drug: placebo,"PegBio Co., Ltd.|Tigermed Consulting Co., Ltd",Phase 2,251,Other|Industry,"June 5, 2018","July 29, 2019","July 29, 2019"
5636,NCT03520920,BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL),Marginal Zone Lymphoma|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma,Drug: Zanubrutinib|Drug: Rituximab,BeiGene,Phase 2,41,Industry,"January 4, 2018","August 28, 2020","August 28, 2020"
5637,NCT03520231,Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases,Urothelial Carcinoma|Kidney Cancer|Ureter Cancer|Bladder Cancer,Drug: Denosumab|Other: Denosumab Placebo|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D,"University Health Network, Toronto|Amgen",Phase 2,6,Other|Industry,"September 4, 2018","December 1, 2020","December 1, 2020"
5638,NCT03520036,"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria",Erythropoietic Protoporphyria (EPP),Drug: MT-7117 low dose|Drug: MT-7117 high dose|Drug: Placebo,Mitsubishi Tanabe Pharma America Inc.,Phase 2,102,Industry,"July 5, 2018","September 28, 2019","September 28, 2019"
5639,NCT03518684,Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma,"Labor Stage, Second",Drug: Natalis,American University of Beirut Medical Center,Phase 4,160,Other,"April 3, 2018","June 28, 2019","June 30, 2019"
5640,NCT03518138,Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor,Vasomotor Symptoms (VMS),Drug: Q-122|Drug: Placebo,Que Oncology|Syneos Health,Phase 2,132,Industry|Other,"October 24, 2018","July 29, 2020","September 9, 2020"
5641,NCT03518047,Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation,Psoriasis,Drug: risankizumab|Drug: placebo for rizankizumab,AbbVie,Phase 3,50,Industry,"July 19, 2018","February 11, 2020","February 11, 2020"
5642,NCT03518021,Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital,Overdose|Drug Abuse,"Drug: Naloxone, intranasal|Drug: placebo, intranasal|Drug: Naloxone, intramuscular|Drug: placebo, intramuscular",Norwegian University of Science and Technology|St. Olavs Hospital|Oslo University Hospital,Phase 3,286,Other,"May 15, 2018","October 6, 2020","October 6, 2020"
5643,NCT03517956,"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",Advanced or Metastatic Solid Tumor,Drug: Rogaratinib (BAY1163877)|Drug: Copanlisib (BAY80-6946),Bayer,Phase 1,16,Industry,"July 25, 2018","February 1, 2021","February 1, 2021"
5644,NCT03517540,"Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis",Non-alcoholic Steatohepatitis (NASH),Drug: Tropifexor (LJN452)|Drug: Cenicriviroc (CVC),Novartis Pharmaceuticals|Allergan|Novartis,Phase 2,193,Industry,"September 11, 2018","September 15, 2020","October 15, 2020"
5645,NCT03517176,CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer,Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma,Drug: CEND-1|Drug: Nab-paclitaxel|Drug: Gemcitabine,"Lisata Therapeutics, Inc.",Phase 1,30,Industry,"July 31, 2018","June 19, 2020","June 19, 2020"
5646,NCT03516591,A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes,Myelodysplastic Syndrome (MDS),Drug: AMV564 14-Day CIV,"Amphivena Therapeutics, Inc.",Phase 1,14,Industry,"June 22, 2018","July 31, 2020","July 31, 2020"
5647,NCT03516526,Towards Personalized Dosing of Natalizumab in Multiple Sclerosis,Multiple Sclerosis,Drug: Natalizumab,"Amsterdam UMC, location VUmc|Prothya Biosolutions|Erasmus Medical Center|St. Antonius Hospital|OLVG|Rijnstate Hospital",Phase 4,61,Other|Industry,"November 3, 2016","June 21, 2019","July 1, 2019"
5648,NCT03516123,A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors,"Solid Tumor, Adult",Drug: CS3006,CStone Pharmaceuticals,Phase 1,18,Industry,"June 14, 2018","June 18, 2020","June 18, 2020"
5649,NCT03515980,An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function,Liver Dysfunction|Liver Insufficiency|Hepatic Failure|Myocardial Failure|Cardiac Failure|Congestive Heart Failure|Heart Decompensation,Drug: BMS-986231,Bristol-Myers Squibb,Phase 1,76,Industry,"May 25, 2018","August 29, 2019","August 29, 2019"
5650,NCT03515538,Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers,Oral Mucositis,Drug: RRx-001|Drug: Cisplatin for injection|Radiation: Radiation Therapy,"EpicentRx, Inc.|Prothex Pharma, Inc.",Phase 2,48,Industry|Other,"July 12, 2018","October 22, 2019","October 8, 2020"
5651,NCT03515044,Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE),Overt Hepatic Encephalopathy,Drug: 40 mg Rifaximin SSD once daily|Drug: 40 mg Rifaximin SSD twice daily|Drug: 80 mg Rifaximin SSD once daily|Drug: 80 mg Rifaximin SSD twice daily|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 2,71,Industry,"September 13, 2018","March 12, 2020","March 12, 2020"
5652,NCT03514511,Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis,Atopic Dermatitis,Drug: LEO 138559|Drug: LEO 138559 placebo,LEO Pharma,Phase 1,47,Industry,"May 7, 2018","March 2, 2021","March 2, 2021"
5653,NCT03514420,Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL),Familial Partial Lipodystrophy,Drug: AKCEA-ANGPTL3-LRx,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",Phase 2,4,Industry,"June 15, 2018","July 30, 2019","August 21, 2019"
5654,NCT03514381,Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma,Soft Tissue Sarcoma,Drug: Patients starting a treatment with Doxorubicin and Ifosfamide,Institut Claudius Regaud,Phase 4,59,Other,"May 18, 2018","November 23, 2020","November 23, 2020"
5655,NCT03512548,Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites,Healthy,Drug: Relacorilant 350mg|Drug: Itraconazole|Drug: Relacorilant 300mg,Corcept Therapeutics,Phase 1,52,Industry,"April 10, 2018","July 29, 2019","August 23, 2019"
5656,NCT03512340,Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers,Advanced Solid Cancers|Hematologic Cancers,Drug: SRF231,Surface Oncology,Phase 1,148,Industry,"March 13, 2018","September 15, 2020","September 29, 2020"
5657,NCT03512288,Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants,Pneumococcal Infections,Biological: Multivalent|Biological: 13vPnC,Pfizer,Phase 2,460,Industry,"April 16, 2018","February 11, 2020","February 11, 2020"
5658,NCT03512210,"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection",Hepatitis C|HIV-1-infection|Liver Diseases,Drug: Sofosbuvir/Velpatasvir (SOF/VEL)|Other: Minimal Monitoring (MINMON) Strategy,AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,400,Other|NIH,"October 22, 2018","July 30, 2020","February 28, 2021"
5659,NCT03511898,A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME),Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,Drug: THR-149 dose level 1|Drug: THR-149 dose level 2|Drug: THR-149 dose level 3,ThromboGenics|Oxurion,Phase 1,12,Industry,"May 18, 2018","May 22, 2019","May 22, 2019"
5660,NCT03511599,Cycloserine rTMS Plasticity Augmentation in Depression,Major Depressive Disorder,Drug: Cycloserine|Device: Transcranial Magnetic Stimulation|Drug: Placebo Oral Tablet,University of Calgary,Phase 1,12,Other,"September 3, 2018","December 8, 2020","April 21, 2021"
5661,NCT03510910,Multimodal Analgesia With Acetaminophen vs. Narcotics Alone After Hip Arthroscopy,Hip Arthroscopy,Drug: Acetaminophen|Drug: Percocet,NYU Langone Health,Phase 4,100,Other,"April 10, 2018","December 1, 2019","December 1, 2019"
5662,NCT03510884,An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia,Hypercholesterolaemia,Drug: Alirocumab SAR236553 (REGN727)|Drug: Rosuvastatin|Drug: Atorvastatin|Drug: Simvastatin|Drug: Pravastatin|Drug: Lovastatin|Drug: Fluvastatin|Drug: Ezetimibe|Drug: Cholestyramine|Drug: Nicotinic acid|Drug: Fenofibrate|Drug: Omega-3 fatty acids|Drug: Placebo,Sanofi|Regeneron Pharmaceuticals,Phase 3,153,Industry,"May 31, 2018","January 14, 2021","August 5, 2022"
5663,NCT03510741,Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.,Schizophrenia|Schizophreniform Disorders|Schizoaffective Disorder,Drug: Sodium Benzoate|Drug: N-Acetylcysteine|Drug: Placebo|Drug: Sodium Benzoate Plus N-Acetylcysteine,Pakistan Institute of Living and Learning,Phase 2,64,Other,"January 1, 2019","December 30, 2020","March 30, 2021"
5664,NCT03510715,An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia,Hypercholesterolemia,Drug: Alirocumab SAR236553 (REGN727)|Drug: Atorvastatin|Drug: Simvastatin|Drug: Fluvastatin|Drug: Pravastatin|Drug: Lovastatin|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Cholestyramine|Drug: Nicotinic acid|Drug: Fenofibrate|Drug: Omega-3 fatty acids,Sanofi|Regeneron Pharmaceuticals,Phase 3,18,Industry,"August 31, 2018","February 17, 2020","February 17, 2020"
5665,NCT03510624,Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus,Type 2 Diabetes Mellitus,Drug: Rebaudioside A|Drug: Placebo,Universitaire Ziekenhuizen KU Leuven,Phase 1,30,Other,"November 9, 2018","April 1, 2021","April 1, 2021"
5666,NCT03510481,"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali",Malaria,Biological: PfSPZ Vaccine|Drug: Normal Saline|Drug: artemether 20mg/lumefantrine 120mg (AL),"National Institute of Allergy and Infectious Diseases (NIAID)|Sanaria Inc.|Malaria Research and Training Center, Bamako, Mali|National Institutes of Health Clinical Center (CC)",Phase 1,478,NIH|Industry|Other,"May 14, 2018","November 23, 2019","February 13, 2020"
5667,NCT03509922,A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity,"Peripheral Artery Disease, PAD",Drug: Anplag Tab. 100mg bid|Drug: Anplag Tab. 100mg tid,Yuhan Corporation,Phase 4,60,Industry,"October 11, 2018","December 26, 2019","March 5, 2020"
5668,NCT03509636,A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer,Ovarian Cancer,Drug: Fluzoparib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,113,Industry,"April 4, 2018","August 26, 2019","July 23, 2020"
5669,NCT03509350,"Vitamin C, Thiamine, and Steroids in Sepsis",Sepsis,Drug: Vitamin C|Drug: Thiamine|Drug: Hydrocortisone|Drug: Vitamin C Placebo|Drug: Thiamine Placebo|Drug: Hydrocortisone Placebo,Emory University|The Marcus Foundation,Phase 3,501,Other,"August 22, 2018","August 22, 2019","January 29, 2020"
5670,NCT03509025,Follow-up Study for Participants Jointstem Clinical Trial,Knee Osteoarthritis,Drug: Jointstem,R-Bio,Phase 2,11,Industry,"February 8, 2017","December 9, 2020","December 9, 2020"
5671,NCT03508830,Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial,Thoracic Diseases|Postoperative Pain|Opioid Use,Drug: Liposomal bupivacaine|Drug: Bupivacaine Injection,"University of California, San Francisco",Phase 3,91,Other,"December 30, 2018","January 30, 2021","January 30, 2021"
5672,NCT03508700,A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD,PTSD,Drug: TNX-102 SL 5.6 mg,"Tonix Pharmaceuticals, Inc.",Phase 3,93,Industry,"April 19, 2018","September 30, 2019","September 30, 2019"
5673,NCT03508609,Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease,Coronary Microvascular Dysfunction,Biological: CLBS16,"Lisata Therapeutics, Inc.|National Heart, Lung, and Blood Institute (NHLBI)|Cedars-Sinai Medical Center|Mayo Clinic",Phase 2,20,Industry|NIH|Other,"April 19, 2018","December 10, 2019","May 5, 2020"
5674,NCT03508323,Tenelia Elderly CGMS Study(TEDDY),Type 2 Diabetes Mellitus,Drug: Teneligliptin|Drug: Placebo,Handok Inc.,Phase 4,65,Industry,"April 3, 2018","December 12, 2019","December 12, 2019"
5675,NCT03508011,A Study of IMP4297 in Patients With Advanced Solid Tumors,Advanced Solid Tumours|Breast Cancer|Ovarian Cancer|Prostate Cancer,Drug: IMP4297,"Impact Therapeutics, Inc.",Phase 1,57,Industry,"August 23, 2017","December 16, 2020","December 16, 2020"
5676,NCT03507738,"Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants",Healthy,Biological: MT-5625 low dose|Biological: MT-5625 middle dose|Biological: MT-5625 high dose|Biological: Rotarix|Biological: Placebo,Mitsubishi Tanabe Pharma Corporation,Phase 1,110,Industry,"July 3, 2018","June 28, 2019","June 28, 2019"
5677,NCT03507543,The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors,Advanced Solid Tumours|Breast Cancer|Ovarian Cancer|Prostate Cancer|Primary Peritoneal Cancer,Drug: IMP4297,"Impact Therapeutics, Inc.",Phase 1,39,Industry,"February 3, 2017","September 24, 2020","March 17, 2021"
5678,NCT03506841,Cerebrolysin and Neurodevelopment in Preterm Infants,Infant Development|Cerebral Palsy|Preterm Infant,Drug: Cerebrolysin,Mansoura University Children Hospital,Phase 1,60,Other,Jun-16,Jun-19,Jun-19
5679,NCT03506815,Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines,Upper Extremity Deep Vein Thrombosis|Central Venous Catheter Thrombosis|Cancer,Drug: Rivaroxaban 10 MG,Ottawa Hospital Research Institute|Queen Elizabeth II Health Sciences Centre|University of Alberta|Hamilton Health Sciences Corporation,Phase 3,100,Other,"March 15, 2019","May 14, 2020","June 14, 2020"
5680,NCT03506789,Dexamethasone Twice for Pain Treatment of Total Knee Arthroplasty,Postoperative Pain,Drug: Dexamethasone|Drug: Placebos,Naestved Hospital,Phase 4,485,Other,"September 14, 2018","March 11, 2020","June 7, 2020"
5681,NCT03506477,Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color,Plaque Psoriasis|Psoriasis,Drug: Enstilar® foam|Drug: Vehicle foam,Icahn School of Medicine at Mount Sinai,Phase 4,25,Other,"May 21, 2018","September 25, 2019","September 25, 2019"
5682,NCT03506412,Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction,Heart Failure With Preserved Ejection Fraction,Drug: Entresto™ 49Mg-51 mg tablet,Mayo Clinic|National Institute on Aging (NIA),Phase 4,40,Other|NIH,"June 25, 2018","March 23, 2021","March 23, 2021"
5683,NCT03506113,GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial,Ventilator Associated Pneumonia,Drug: Gram stain-guided antibiotic choice|Drug: Guidelines-based antibiotics choice,Osaka General Medical Center|Chukyo Hospital|Ebina General Hospital|Hitachi General Hospital|Kansai Medical University|Kansai Medical University Medical Center|Nagasaki University|Saga University|University of the Ryukyus|Wakayama Medical University|Tajima Emergency and Critical Care Medical Center|Sapporo City General Hospital,Phase 4,206,Other,"April 1, 2018","June 28, 2020","June 28, 2020"
5684,NCT03505996,A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma,Hodgkin Lymphoma,Biological: CS1001,CStone Pharmaceuticals,Phase 2,82,Industry,"May 22, 2018","February 19, 2020","November 1, 2021"
5685,NCT03505528,An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer,Metastatic Breast Cancer,Drug: Nanoparticle albumin-bound paclitaxel|Drug: Phenelzine Sulfate,EpiAxis Therapeutics|The Canberra Hospital|Southern Medical Day Care Centre|Liverpool Cancer Therapy Centre,Phase 1,8,Industry|Other,"August 17, 2017","October 30, 2019","October 30, 2019"
5686,NCT03505190,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.",Healthy Participants,Drug: RO7062931|Drug: Placebo,Hoffmann-La Roche,Phase 1,41,Industry,"May 3, 2018","July 5, 2019","July 5, 2019"
5687,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,"Orion Corporation, Orion Pharma",Phase 3,496,Industry,"June 21, 2018","July 23, 2020","July 23, 2020"
5688,NCT03504852,Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis,Moderate to Severe Chronic Plaque-type Psoriasis,Drug: secukinumab 150 mg,Novartis Pharmaceuticals|Novartis,Phase 3,331,Industry,"June 25, 2018","September 13, 2019","July 15, 2020"
5689,NCT03503318,Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia,Schizophrenia,Drug: TV-46000|Drug: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3,544,Industry,"April 27, 2018","September 30, 2020","December 3, 2020"
5690,NCT03503292,Pharmacogenomics and Post-Operative Nausea and Vomiting,Postoperative Nausea,Drug: Granisetron|Drug: Ondansetron,Mayo Clinic,Phase 4,92,Other,"May 2, 2018","December 30, 2019","December 30, 2019"
5691,NCT03502616,Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS),Ankylosing Spondylitis,Drug: Tofacitinib,Pfizer,Phase 3,270,Industry,"June 7, 2018","December 19, 2019","August 20, 2020"
5692,NCT03502005,"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1",Human Immunodeficiency Virus,Drug: bictegravir/emtricitabine/tenofovir alafenamide,"Midland Research Group, Inc.|Gilead Sciences",Phase 4,100,Other|Industry,"March 1, 2018","December 30, 2019","December 30, 2019"
5693,NCT03501043,Assessment of Gait After Dysport Treatment,Equinovarus; Acquired,Drug: Dysport,Albert Einstein Healthcare Network,Phase 4,11,Other,"June 11, 2018","August 22, 2019","August 22, 2019"
5694,NCT03500549,Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH),Paroxysmal Nocturnal Hemoglobinuria,Drug: Pegcetacoplan|Drug: Soliris,"Apellis Pharmaceuticals, Inc.",Phase 3,80,Industry,"June 14, 2018","November 14, 2019","August 13, 2020"
5695,NCT03500484,Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.,"Obesity, Childhood|Neural Development",Drug: Liraglutide,Yale University,Phase 2,14,Other,"June 6, 2018","June 25, 2020","June 25, 2020"
5696,NCT03500302,Effect of Evolocumab on Coronary Endothelial Function,Human Immunodeficiency Virus|Coronary Artery Disease,Drug: Evolocumab,Johns Hopkins University|American Heart Association,Phase 2,19,Other,"May 4, 2018","November 30, 2019","November 30, 2019"
5697,NCT03500094,"Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)",Fabry Disease,Drug: Migalastat HCl 150 mg,Amicus Therapeutics,Phase 3,22,Industry,"September 27, 2018","February 2, 2021","February 6, 2021"
5698,NCT03499899,"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",Triple-negative Breast Cancer,Drug: LAG525|Drug: PDR001|Drug: Carboplatin,Novartis Pharmaceuticals|Novartis,Phase 2,88,Industry,"July 2, 2018","February 27, 2020","November 24, 2021"
5699,NCT03499834,A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy,Non-small Cell Lung Cancer (NSCLC) Stage IV,Biological: Immune Killer Cells (IKC),"Ivy Life Sciences, Co., Ltd|Taipei Veterans General Hospital, Taiwan|Tri-Service General Hospital",Phase 2,26,Industry|Other,"December 5, 2017","February 16, 2020","February 16, 2020"
5700,NCT03499795,"VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2",Anal Neoplasm,Biological: VGX-3100|Device: CELLECTRA™ 5PSP,Inovio Pharmaceuticals,Phase 2,22,Industry,"May 3, 2018","June 16, 2020","May 25, 2021"
5701,NCT03499483,Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP),HIV Prevention,Drug: bictegravir,Fenway Community Health,Phase 4,52,Other,"January 24, 2019","March 30, 2020","March 31, 2020"
5702,NCT03499444,A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor,Advanced Solid Tumor,Drug: Rucaparib,"Clovis Oncology, Inc.",Phase 1,29,Industry,"February 6, 2018","June 18, 2019","April 13, 2022"
5703,NCT03499223,A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME),Diabetes Mellitus|Diabetic Retinopathy|Macular Edema,Drug: Ranibizumab 0.5mg|Drug: THR-317 8mg|Drug: Sham injection,Oxurion,Phase 2,70,Industry,"April 20, 2018","July 18, 2019","July 18, 2019"
5704,NCT03498703,Azathioprine in Recurrent Implantation Failure,Recurrent Implantation Failure|In Vitro Fertilization|Intracytoplsmic Sperm Injection,Drug: Azathioprine Pill|Drug: Placebo Oral Tablet,Ain Shams University|Capital Birth Center,Phase 2,64,Other,"April 25, 2018","July 1, 2019","July 1, 2019"
5705,NCT03498456,Triple Therapy With Tegoprazan in H. Pylori Positive Patients,Helicobacter Pylori Infection,Drug: Tegoprazan/Amoxicillin/Clarithromycin|Drug: Lansoprazole/Amoxicillin/Clarithromycin,HK inno.N Corporation,Phase 3,284,Industry,"June 28, 2018","December 31, 2019","December 31, 2019"
5706,NCT03498430,Copanlisib Chinese PK Study,"Lymphoma, Non-Hodgkin","Drug: Copanlisib (Aliqopa, BAY80-6946)",Bayer,Phase 1,13,Industry,"April 27, 2018","August 6, 2019","June 2, 2020"
5707,NCT03497845,Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59,"Influenza A Virus, H5N1 Subtype",Biological: VN|Biological: IN|Biological: dk/BANG|Biological: gf/WA|Biological: bhg/QL|Biological: AS03 adjuvant|Biological: MF59 adjuvant,Biomedical Advanced Research and Development Authority,Phase 2,720,U.S. Fed,"March 15, 2018","November 19, 2019","November 19, 2019"
5708,NCT03497806,Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection,Clostridium Difficile Infection|Recurrent Clostridium Difficile Infection|C. Diff|CDI|Recurrent C. Diff|rCDI|C. Difficile|Recurrent CDI|FMT|Fecal Microbiota|Fecal Transplant,Biological: CP101,"Finch Research and Development LLC.|Medpace, Inc.",Phase 2,132,Industry,"May 1, 2018","December 31, 2020","April 1, 2021"
5709,NCT03497429,A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors,Advanced Solid Tumors,Drug: Niraparib,Takeda,Phase 1,9,Industry,"April 5, 2018","February 10, 2020","February 10, 2020"
5710,NCT03497377,Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.,Metastatic Prostate Cancer,Drug: 18F-DCFPyL Injection|Drug: 18F-NaF,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),Phase 1,25,Other|NIH,"May 16, 2016",Apr-20,Apr-20
5711,NCT03497325,Effect of Autologous Platelet-rich Plasma in Uterine Wound Healing,Cesarean Section Complications,Drug: autologus platelet rich plasma|Drug: placebo,Ain Shams University,Phase 2,134,Other,"February 1, 2020","December 15, 2020","December 15, 2020"
5712,NCT03497273,Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects,Acute Graft-versus-host Disease,Drug: Itacitinib|Drug: Corticosteroid,Incyte Corporation,Phase 1,14,Industry,"March 20, 2018","November 30, 2019","February 17, 2020"
5713,NCT03496779,Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine,Refractory Peripheral T-Cell Lymphoma|Relapsed Peripheral T-Cell Lymphoma,Drug: Brentuximab Vedotin - induction|Drug: Gemcitabine|Drug: Brentuximab Vedotin - maintenance|Procedure: autologous or allogeneic stem cell transplantation,The Lymphoma Academic Research Organisation,Phase 2,71,Other,"April 10, 2018","January 31, 2020","October 8, 2022"
5714,NCT03496571,A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis,Eosinophilic Gastritis|Eosinophilic Gastroenteritis,Drug: AK002|Other: Placebo,Allakos Inc.,Phase 2,65,Industry,"July 18, 2018","June 24, 2019","June 24, 2019"
5715,NCT03496233,"Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients",Chronic HCV Hepatitis,Drug: Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier],Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Phase 3,75,Other,"September 19, 2018","May 20, 2020","June 20, 2020"
5716,NCT03496012,Efficacy and Safety of BIIB111 for the Treatment of Choroideremia,Choroideremia,Genetic: BIIB111,"NightstaRx Ltd, a Biogen Company|Biogen",Phase 3,170,Other,"December 11, 2017","December 1, 2020","December 1, 2020"
5717,NCT03495817,A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution,Androgenetic Alopecia,Drug: ATI-50002,"Aclaris Therapeutics, Inc.",Phase 2,31,Industry,"March 22, 2018","October 15, 2019","October 30, 2019"
5718,NCT03495557,Prevalence of Port Site Hernia After Mesh Placement in Laparoscopic Cholecystectomy.,Incisional Hernia,Procedure: Control|Device: Experimental,Hospital de Mataró,Phase 4,200,Other,"January 1, 2018","December 1, 2020","September 1, 2021"
5719,NCT03495323,"A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors",Cancer,Drug: LY3300054|Drug: Prexasertib,Dana-Farber Cancer Institute|Eli Lilly and Company,Phase 1,17,Other|Industry,"May 16, 2018","February 1, 2021","February 1, 2021"
5720,NCT03495167,Study of SyB C-1101 in Patients With Myelodysplastic Syndrome,Myelodysplastic Syndrome,Drug: SyB C-1101,SymBio Pharmaceuticals,Phase 1,10,Industry,"October 6, 2017","May 28, 2019","May 28, 2019"
5721,NCT03495102,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Dulaglutide,Eli Lilly and Company,Phase 3,1842,Industry,"April 5, 2018","May 28, 2019","October 10, 2019"
5722,NCT03494816,Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion,Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Non-metastatic Renal Cell Carcinoma,Drug: Axitinib Oral Tablet,Scottish Clinical Trials Research Unit|Pfizer,Phase 2,24,Other|Industry,"December 15, 2017","March 3, 2020","June 10, 2020"
5723,NCT03494764,Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares,"Colitis, Ulcerative",Other: Hyperbaric Oxygen Therapy,"Dartmouth-Hitchcock Medical Center|Foundation for Clinical Research in IBD|The Eli and Edythe Broad Foundation|University of California, San Diego|Mayo Clinic|University of Pittsburgh Medical Center|Virginia Mason Memorial Hospital|University of Texas Southwestern Medical Center|University of Maryland, College Park|NYU Langone Health",Phase 2,39,Other,"September 7, 2017","March 31, 2020","March 31, 2020"
5724,NCT03494387,VitamIn and oXygen Interventions and Cardiovascular Events,Postoperative Cardiac Complication,Drug: Oxygen|Drug: Antioxidants,University Hospital Bispebjerg and Frederiksberg,Phase 4,600,Other,"April 6, 2018","March 1, 2020","March 24, 2020"
5725,NCT03494270,High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients,ASCVD,Drug: Rosuvamibe|Drug: Monorova,Yuhan Corporation,Phase 4,270,Industry,"March 18, 2018","September 26, 2019","September 26, 2019"
5726,NCT03493607,AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy,Phelan-McDermid Syndrome|Epilepsy,Drug: AMO-01,Alexander Kolevzon|Icahn School of Medicine at Mount Sinai,Phase 2,6,Other,"May 30, 2018","March 31, 2020","March 31, 2020"
5727,NCT03493503,Status Asthmaticus on the PICU; Intravenous Salbutamol,Childhood Asthma With Status Asthmaticus,Drug: Salbutamol|Drug: Sodium Chloride 0.9%,Erasmus Medical Center,Phase 4,58,Other,"April 5, 2017","May 21, 2019","May 21, 2019"
5728,NCT03493490,Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery,"Pain, Postoperative|Analgesic Adverse Reaction|Cruciate Ligament Rupture",Drug: Neodolpasse|Drug: Diclofenac|Drug: Placebo,Medical University of Vienna,Phase 4,72,Other,"March 1, 2018","May 31, 2019","May 31, 2019"
5729,NCT03493451,Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms,"Peripheral T Cell Lymphoma|PTCL|Extranodal NK/T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Extranodal NK T Cell Lymphoma|Extranodal NK T Cell Lymphoma, Nasal|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma Recurrent|Angioimmunoblastic T-Cell Lymphoma Refractory|Peripheral T-cell Lymphoma NOS|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-Cell Lymphoma Refractory|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Large Cell Lymphoma, ALK-negative|ALK-negative Anaplastic Large Cell Lymphoma|ALK-Positive Anaplastic Large Cell Lymphoma|Cutaneous T-cell Lymphoma",Drug: Tislelizumab,BeiGene,Phase 2,77,Industry,"April 13, 2018","April 21, 2021","April 21, 2021"
5730,NCT03493269,A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis,Healthy Volunteers|Psoriasis,Drug: BAY1834845|Other: Matching Placebo|Drug: Midazolam,Bayer,Phase 1,72,Industry,"April 16, 2018","September 16, 2020","February 5, 2021"
5731,NCT03493126,"Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function",Vaginal Atrophy,Drug: Estradiol|Other: Placebo,Ohio State University|International Urogynecological Association,Phase 4,59,Other,"October 15, 2018","September 1, 2020","September 1, 2020"
5732,NCT03493061,A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM,Colo-rectal Cancer|Liver Metastases,Drug: Irinotecan|Drug: Oxaliplatin|Drug: Floxuridine,Sun Yat-sen University,Phase 2,60,Other,"February 1, 2018","December 30, 2020","December 30, 2022"
5733,NCT03493048,Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM,Colorectal Cancer|Liver Metastases,Drug: Irinotecan|Drug: Cetuximab|Drug: 5-fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin,Sun Yat-sen University,Phase 2,140,Other,"January 1, 2018","December 30, 2020","December 30, 2022"
5734,NCT03492996,A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace,Healthy,Drug: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose,"LegoChem Biosciences, Inc",Phase 1,6,Industry,"June 21, 2020","August 3, 2020","September 23, 2020"
5735,NCT03492931,"PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)",Sickle Cell Disease,Drug: Ticagrelor,AstraZeneca,Phase 1,21,Industry,"March 28, 2018","May 7, 2019","May 7, 2019"
5736,NCT03492840,Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease,Lipedema|Dercum Disease,Drug: RZL-012,Raziel Therapeutics Ltd.|University of Arizona,Phase 2,12,Industry|Other,"May 1, 2018","May 6, 2019","May 6, 2019"
5737,NCT03492099,Assessing the Safety of Buprenorphine in People With Sickle Cell Disease,Sickle Cell Disease,Drug: buprenorphine,Johns Hopkins University,Phase 2,47,Other,"August 1, 2018","September 23, 2019","February 28, 2022"
5738,NCT03491904,To Assess the Patients' Ability to Self-Administer Fasinumab,"Osteoarthritis, Knee|Osteoarthritis, Hip",Drug: Fasinumab AI|Drug: Fasinumab PFS,"Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.",Phase 1,100,Industry,"January 23, 2019","January 15, 2020","December 15, 2020"
5739,NCT03491748,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants",Healthy Volunteers,Drug: ETX0282|Drug: Cefpodoxime proxetil|Drug: Placebo,Entasis Therapeutics,Phase 1,99,Industry,"March 16, 2018","September 11, 2019","September 11, 2019"
5740,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,ZevraDenmark,Phase 3,245,Industry,"July 31, 2018","December 18, 2020","December 18, 2020"
5741,NCT03490669,"Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors",Advanced Solid Tumors|Pancreatic Cancer|Non Small Cell Lung Cancer|Ovarian Cancer,Biological: MSC-1,AstraZeneca,Phase 1,41,Industry,"May 21, 2018","September 23, 2019","September 23, 2019"
5742,NCT03490123,Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication,Yaws,Drug: R1-Total community treatment with azithromycin|Drug: R2-Total community treatment with azithromycin|Drug: R3-Total community treatment with azithromycin|Drug: R2-Total targeted treatment with azithromycin|Drug: R3-Total targeted treatment with azithromycin,Lihir Medical Centre|Barcelona Institute for Global Health|National Department of Health of Papua New Guinea|World Health Organization|University of Masarykova|Harvard School of Public Health (HSPH),Phase 4,56000,Other,"April 16, 2018","April 1, 2020","April 1, 2020"
5743,NCT03489850,Ibudilast and Withdrawal-Related Dysphoria,Alcohol Use Disorder,Drug: Ibudilast|Other: Placebo,"University of California, Los Angeles",Phase 2,52,Other,"July 16, 2018","March 31, 2020","March 31, 2020"
5744,NCT03489772,Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement,Healthy Volunteers,Drug: ITI-214|Drug: Placebo,"Intra-Cellular Therapies, Inc.|Laureate Institute for Brain Research, Inc.",Phase 1,26,Industry|Other,"July 10, 2018","August 5, 2019","August 5, 2019"
5745,NCT03489395,A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation,Atrial Fibrillation,Drug: Edoxaban,Raffaele De Caterina|Hippocrates Research|G. d'Annunzio University,Phase 2,25,Other,"January 30, 2018","December 31, 2020","April 30, 2021"
5746,NCT03489369,Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,Metastatic Cancer|Solid Tumor|Lymphoma,Drug: Sym022,Symphogen A/S,Phase 1,15,Industry,"May 8, 2018","January 6, 2020","January 6, 2020"
5747,NCT03489343,Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,Metastatic Cancer|Solid Tumor|Lymphoma,Drug: Sym023,Symphogen A/S,Phase 1,24,Industry,"May 24, 2018","June 3, 2020","June 3, 2020"
5748,NCT03488563,Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine,Migraine,Biological: B244|Biological: Vehicle,"AOBiome LLC|Veristat, Inc.",Phase 2,313,Industry|Other,"March 30, 2018","June 17, 2019","July 16, 2019"
5749,NCT03488524,Open Label Extension Study of AMX0035 in Patients With ALS,Amyotrophic Lateral Sclerosis|ALS,Drug: AMX0035,Amylyx Pharmaceuticals Inc.|Massachusetts General Hospital Neurology Clinical Research Institute,Phase 2,95,Industry|Other,"March 29, 2018","March 1, 2021","November 1, 2021"
5750,NCT03487913,The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease,Autosomal Dominant Polycystic Kidney Disease,Drug: Lixivaptan,Palladio Biosciences,Phase 2,31,Industry,"September 14, 2018","December 2, 2019","February 11, 2020"
5751,NCT03487783,Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome,Tourette Syndrome,Drug: Aripiprazole Oral Solution|Drug: Placebo Oral Solution,Otsuka Beijing Research Institute,Phase 3,121,Industry,"May 2, 2018","February 14, 2020","February 14, 2020"
5752,NCT03487770,Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder,Autistic Disorder,Drug: Aripiprazole Oral Solution|Drug: Placebo Oral Solution,Otsuka Beijing Research Institute,Phase 3,111,Industry,"April 9, 2018","April 21, 2020","April 21, 2020"
5753,NCT03487549,Cantharidin and Occlusion in Verruca Epithelium,"Common Wart|Warts Hand|Warts|Papillomavirus Infections|DNA Virus Infections|Skin Diseases, Viral|Skin Diseases, Infectious|Skin Diseases|Virus Diseases|Tumor Virus Infections|Verruca Vulgaris|Verruca","Combination Product: VP-102 Cantharidin topical film forming solution|Combination Product: VP-102 Cantharidin, topical film forming solution","Verrica Pharmaceuticals Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|BioClinica, Inc.|ALMAC Clinical Services",Phase 2,56,Industry|Other,"March 27, 2018","May 16, 2019","July 15, 2019"
5754,NCT03487276,Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS),Hidradenitis Suppurativa (HS),Drug: IFX-1|Drug: Placebo,"InflaRx GmbH|Quintiles, Inc.",Phase 2,179,Industry,"February 26, 2018","May 27, 2019","January 27, 2020"
5755,NCT03487133,Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma,Relapsed and/or Refractory Cutaneous T-cell Lymphoma,Drug: bortezomib/dexamethasone,Samsung Medical Center,Phase 2,32,Other,"September 19, 2017","September 30, 2020","September 30, 2020"
5756,NCT03486990,"Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease",Celiac Disease,Drug: TIMP-GLIA,"Takeda|COUR Pharmaceutical Development Company, Inc.",Phase 1,23,Industry,"January 23, 2018","May 24, 2019","July 22, 2019"
5757,NCT03486912,A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis,Hepatic Cirrhosis|Liver Fibrosis|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis,Drug: BMS-986036|Other: Placebo,Bristol-Myers Squibb,Phase 2,155,Industry,"June 12, 2018","October 8, 2020","September 14, 2021"
5758,NCT03486899,A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis,Liver Fibrosis|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis,Drug: BMS-986036|Other: Placebo,Bristol-Myers Squibb,Phase 2,197,Industry,"June 19, 2018","September 14, 2020","August 17, 2021"
5759,NCT03486834,V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002),Cytomegalovirus (CMV) Infections,Biological: V160|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 2,2200,Industry,"April 30, 2018","October 30, 2020","June 30, 2021"
5760,NCT03486678,SHR-1210 in Combination With GEMOX in Patients With Advanced BTC,Biliary Tract Cancer|Cholangiocarcinoma,Drug: SHR-1210+GEMOX,"The First Affiliated Hospital with Nanjing Medical University|Jiangsu HengRui Medicine Co., Ltd.",Phase 2,38,Other|Industry,"February 10, 2018","August 1, 2020","November 30, 2020"
5761,NCT03486457,Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis,Psoriatic Arthritis,Drug: Tofacitinib|Other: Placebo,Pfizer,Phase 3,204,Industry,"August 10, 2018","April 28, 2021","April 28, 2021"
5762,NCT03486314,A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors,Advanced Solid Neoplasm,Drug: Pevonedistat|Drug: Rifampin|Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,20,Industry,"August 13, 2018","May 10, 2019","February 28, 2021"
5763,NCT03486080,Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction,Acute Myocardial Infarction|Acute Myocardial Ischemia|STEMI - ST Elevation Myocardial Infarction,Drug: Dutogliptin Tartrate|Drug: Filgrastim Injectable Product|Drug: Placebos,"Recardio, Inc.",Phase 2,49,Industry,"December 7, 2018","February 26, 2021","February 26, 2021"
5764,NCT03485976,Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP),Pityriasis Rubra Pilaris,Drug: Ixekizumab,Oregon Health and Science University|Eli Lilly and Company,Phase 2,12,Other|Industry,"May 23, 2018","October 14, 2019","January 13, 2020"
5765,NCT03485534,Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients,"Hepatitis B, Chronic",Drug: Tenofovir Disoproxil Fumarate|Drug: Tenofovir Disoproxil,"Daewoong Pharmaceutical Co. LTD.|C&R Research, Inc.",Phase 4,189,Industry,"January 23, 2018","November 4, 2019","November 4, 2019"
5766,NCT03485287,Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada),Posttraumatic Stress Disorder,Drug: MDMA|Behavioral: Therapy,Multidisciplinary Association for Psychedelic Studies,Phase 2,4,Other,"March 13, 2018","June 4, 2019","June 4, 2019"
5767,NCT03485222,"Are the ""Cardiac Benefits"" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).",Cardiovascular Diseases,Drug: Empagliflozin|Drug: Placebos,Icahn School of Medicine at Mount Sinai|Boehringer Ingelheim|Eli Lilly and Company,Phase 4,84,Other|Industry,"May 21, 2018","February 13, 2020","February 13, 2020"
5768,NCT03485144,A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan,Dengue,Biological: TV003|Biological: Placebo for TV003,Medigen Vaccine Biologics Corp.,Phase 2,54,Industry,"December 12, 2017","May 10, 2019","May 10, 2019"
5769,NCT03485092,"Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects",Heart Failure|Diabetes Mellitus,Drug: Empagliflozin 10 MG|Drug: Placebo Oral Tablet,NHS Greater Glasgow and Clyde|University of Glasgow,Phase 4,105,Other,"March 16, 2018","March 28, 2020","March 28, 2020"
5770,NCT03483961,"Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults",Chikungunya Virus Infection,Biological: CHIKV VLP/unadjuvanted|Biological: CHIKV VLP/adjuvanted|Biological: Placebo,Emergent BioSolutions,Phase 2,445,Industry,"April 18, 2018","September 14, 2020","September 21, 2020"
5771,NCT03483870,Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section,Pruritus,Drug: Morphine Sulfate|Drug: Placebo|Drug: Granisetron,Assiut University,Phase 2,80,Other,"June 1, 2018","October 1, 2020","October 30, 2020"
5772,NCT03483688,A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects,B-cell Non-Hodgkin Lymphoma,Biological: CD19-directed CAR-T cells,Peking Union Medical College Hospital|Cellular Biomedicine Group Ltd.,Phase 1,6,Other|Industry,"March 6, 2018","December 10, 2019","January 10, 2020"
5773,NCT03483675,Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease,Chronic Graft Versus Host Disease,Biological: Immunosuppressive Therapy|Other: Survey Administration,Fred Hutchinson Cancer Center|National Cancer Institute (NCI),Phase 2,21,Other|NIH,"June 6, 2018","May 14, 2020","March 3, 2021"
5774,NCT03483324,Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia in Remission|Myelodysplastic Syndromes|Other Acute Leukemias,Biological: Unmanipulated Umbilical Cord Blood (UCB)|Biological: AB-110,Angiocrine Bioscience|California Institute for Regenerative Medicine (CIRM),Phase 1,10,Industry|Other,"April 24, 2018","December 21, 2020","January 31, 2022"
5775,NCT03483116,A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine,Rotavirus Infections,Biological: RV3-BB|Biological: Placebo,Murdoch Childrens Research Institute,Phase 2,688,Other,"June 15, 2018","January 27, 2020","January 27, 2020"
5776,NCT03483090,Investigating the Effect of Deep Sea Krill Oil Supplementation in Osteoarthritis of the Knee,"Osteoarthritis, Knee",Dietary Supplement: Swisse High Strength Deep Sea Krill Oil|Other: Placebo,"Swisse Wellness Pty Ltd|Commonwealth Scientific and Industrial Research Organisation, Australia",Phase 2,235,Industry|Other,"February 27, 2018","December 30, 2019","December 30, 2019"
5777,NCT03482973,Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery,Coronary Artery Disease|Sternal Pain,Drug: Bupivacaine Group|Other: Placebo,Beth Israel Deaconess Medical Center,Phase 3,80,Other,"June 21, 2018","November 25, 2019","November 27, 2019"
5778,NCT03482882,Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression,Treatment of Depression in Adults With Parkinson's Disease (PD),Drug: Pimavanserin,ACADIA Pharmaceuticals Inc.,Phase 2,47,Industry,"March 9, 2018","July 9, 2019","July 24, 2019"
5779,NCT03482752,Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis,Autoimmune Pulmonary Alveolar Proteinosis,Drug: Molgramostim,Savara Inc.,Phase 3,62,Industry,"April 16, 2018","January 14, 2021","January 14, 2021"
5780,NCT03482583,Tobacco Use Treatment in Cancer Patients,"Smoking, Cigarette",Drug: Nicotine Replacement Therapy|Other: Referral to AHEC/Quitline,University of Florida,Phase 4,90,Other,"May 14, 2018","December 31, 2019","December 31, 2019"
5781,NCT03482063,The Effects of 12 Weeks Supplementation With a B-vitamin and Herbal Supplement on Neurocognitive Function and Mood,Neurocognitive Function|Mood,Dietary Supplement: Swisse Ultiboost Memory + Focus|Other: Placebo,Swisse Wellness Pty Ltd|Swinburne University of Technology,Phase 2,141,Industry|Other,"June 18, 2018","January 9, 2020","January 9, 2020"
5782,NCT03482024,A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function,Renal Insufficiency|End Stage Renal Disease,Drug: Tirzepatide,Eli Lilly and Company,Phase 1,45,Industry,"March 30, 2018","August 19, 2019","August 19, 2019"
5783,NCT03481816,Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines,Prostatic Neoplasms|Prostatic Cancer,Biological: ETBX-071; adenoviral PSA vaccine|Biological: ETBX-061; adenoviral MUC1 vaccine|Biological: ETBX-051; adenoviral brachyury vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,18,NIH,"July 24, 2018","January 15, 2020","March 9, 2021"
5784,NCT03481660,A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,Diabetic Macular Edema,Drug: Brolucizumab|Drug: Aflibercept,Novartis Pharmaceuticals|Novartis,Phase 3,360,Industry,"July 27, 2018","June 29, 2020","June 8, 2021"
5785,NCT03481634,Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,Diabetic Macular Edema,Drug: Brolucizumab|Drug: Aflibercept,Novartis Pharmaceuticals|Novartis,Phase 3,566,Industry,"July 23, 2018","November 11, 2020","October 18, 2021"
5786,NCT03481517,Wound Infiltration With Local Anesthetic Agent for Laparoscopic Appendectomy in Adult,Appendicitis Acute,Drug: Bupivacaine,National Taiwan University Hospital,Phase 4,47,Other,"April 23, 2018","July 8, 2019","July 31, 2019"
5787,NCT03480802,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",Pneumococcal Infections,Biological: V114|Biological: Prevnar 13™|Biological: PNEUMOVAX™23,Merck Sharp & Dohme LLC,Phase 3,302,Industry,"July 6, 2018","September 16, 2019","January 17, 2020"
5788,NCT03480763,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",Pneumococcal Infections,Biological: V114|Biological: Prevnar 13™|Biological: PNEUMOVAX™23,Merck Sharp & Dohme LLC,Phase 3,652,Industry,"June 22, 2018","December 23, 2019","December 23, 2019"
5789,NCT03480022,"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",Pre Diabetes|Polycystic Ovary Syndrome|Obesity Android,Drug: Liraglutide Pen Injector [Saxenda]|Drug: Placebo Liraglutide Pen Injector,Woman's|Novo Nordisk A/S,Phase 3,88,Other|Industry,"September 26, 2018","February 22, 2021","May 19, 2021"
5790,NCT03480009,Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion,Abortion in First Trimester,Drug: Dextromethorphan Hydrobromide|Drug: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Drug: Oxycodone,Study Investigator-Sponsor|Society of Family Planning|University of Pittsburgh,Phase 3,156,Other,"July 28, 2018","June 30, 2019","June 30, 2019"
5791,NCT03479892,A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity,Metabolism and Nutrition Disorder|Obesity,Drug: NNC0194-0499|Drug: Placebo,Novo Nordisk A/S,Phase 1,57,Industry,"March 13, 2018","June 4, 2019","June 4, 2019"
5792,NCT03478995,Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors,Locally Advanced or Metastatic Solid Tumors,Drug: GX-I7,"Genexine, Inc.",Phase 1,35,Industry,"March 5, 2018","March 16, 2020","March 16, 2020"
5793,NCT03478982,"Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern",Epilepsy,Drug: Staccato Alprazolam|Drug: Placebos,"Engage Therapeutics, Inc.|UCB Pharma",Phase 2,156,Industry,"March 16, 2018","December 22, 2019","January 4, 2020"
5794,NCT03478930,An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps,Nasal Polyps|Chronic Rhinosinusitis,Drug: Omalizumab|Drug: Placebo,Hoffmann-La Roche,Phase 3,249,Industry,"May 9, 2018","March 16, 2020","March 16, 2020"
5795,NCT03478787,Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis,Psoriasis,Drug: risankizumab|Drug: secukinumab,AbbVie,Phase 3,327,Industry,"May 8, 2018","July 8, 2020","July 8, 2020"
5796,NCT03478319,A Study of ACE-2494 in Healthy Subjects,Healthy Volunteers,Drug: ACE-2494 or placebo,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 1,48,Industry,"February 15, 2018","June 13, 2019","June 17, 2019"
5797,NCT03478111,CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: CMAB008|Drug: MTX|Drug: Remicade,"Shanghai Biomabs Pharmaceutical Co., Ltd.",Phase 3,390,Industry,"March 30, 2018","June 23, 2019","August 27, 2019"
5798,NCT03477916,Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.,Obesity|Metabolic Syndrome,Biological: FMT|Biological: Placebo FMT|Dietary Supplement: Prebiotic Fiber|Dietary Supplement: Cellulose,University of Alberta|W. Garfield Weston Foundation,Phase 2,68,Other,"April 9, 2018","June 1, 2020","December 31, 2020"
5799,NCT03477851,Tramadol Simultaneously With Sciatic Nerve Block for Calcaneus Fracture Osteosynthesis,"Foot Fracture|Pain, Acute",Drug: Tramadol Hydrochloride|Drug: Placebo,Medical University of Warsaw,Phase 4,40,Other,"June 15, 2017","June 30, 2020","December 30, 2020"
5800,NCT03477630,"Treatment of Osteoarthrosis of the Knee With Platelet Rich Plasma, Comparative Study With Hyaluronic Acid",Osteoarthritis,Biological: Platelet Rich Plasma|Drug: Hyaluronic Acid,"Karla Andrea Arias Varela|Varela, Karla Andrea Arias, M.D.",Phase 3,28,Other,"February 14, 2019","July 25, 2020","September 16, 2020"
5801,NCT03477487,"Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain","Osteoarthritis, Knee",Biological: XT-150,"Xalud Therapeutics, Inc.",Phase 1,32,Industry,"June 8, 2018","July 19, 2019","September 30, 2019"
5802,NCT03476460,Sodium Chloride and Contrast Nephropathy,"Kidney Failure, Chronic|Kidney Failure, Acute|Heart Failure|Diabetes",Drug: Oral sodium chloride|Drug: Intravenous sodium chloride,Hospital Universitario Ramon y Cajal,Phase 2,269,Other,"March 1, 2014","November 29, 2019","November 29, 2019"
5803,NCT03476317,Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease,Crohn Disease,Drug: Vancomycin|Drug: Neomycin|Drug: Ciprofloxacin|Drug: Polyethylene Glycol 3350|Drug: Fluconazole,Children's Hospital of Philadelphia|University of Pennsylvania|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2,10,Other|NIH,"July 12, 2018","December 31, 2020","December 31, 2020"
5804,NCT03476239,Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL),Acute Lymphoblastic Leukemia,Drug: Blinatumomab|Drug: Dexamthasone,Amgen,Phase 3,121,Industry,"October 18, 2017","August 21, 2019","April 8, 2021"
5805,NCT03475056,cAd3-Marburg Vaccine in Healthy Adults,Marburg Virus Disease,Biological: cAd3-Marburg vaccine,National Institute of Allergy and Infectious Diseases (NIAID)|US Military HIV Research Program,Phase 1,40,NIH|Other,"October 9, 2018","December 19, 2019","December 19, 2019"
5806,NCT03474562,High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension,ASCVD|Impaired Fasting Glucose|Hypertension,Drug: Duowell®|Drug: Monorova® + Amlopin®,Yuhan Corporation,Phase 4,100,Industry,"April 3, 2018","June 7, 2019","June 7, 2019"
5807,NCT03474081,A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"Pulmonary Disease, Chronic Obstructive",Drug: FF/UMEC/VI|Drug: Tiotropium|Drug: Albuterol/salbutamol|Drug: Placebo to match FF/UMEC/VI|Drug: Placebo to match tiotropium|Device: ELLIPTA inhaler|Device: HANDIHALER|Device: MDI,GlaxoSmithKline|Parexel,Phase 4,800,Industry,"March 29, 2018","July 17, 2019","July 17, 2019"
5808,NCT03473561,Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea,"Diarrhea, Infantile",Drug: Racecadotril plus ORS,Abbott,Phase 3,31,Industry,"August 25, 2018","January 8, 2020","January 8, 2020"
5809,NCT03473314,Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection,Non-Tuberculous Mycobacterial Pneumonia,Drug: Nitric Oxide gas at 160ppm,University of British Columbia|Mallinckrodt,Phase 2,1,Other|Industry,"March 9, 2018","July 11, 2020","July 21, 2020"
5810,NCT03473015,Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion,ST Elevation Myocardial Infarction,Device: PICSO,Oxford University Hospitals NHS Trust|Miracor Medical SA,Phase 2,75,Other|Industry,"July 1, 2015","October 31, 2020","October 31, 2020"
5811,NCT03472885,Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab,Paroxysmal Nocturnal Hemoglobinuria (PNH),Drug: Danicopan|Drug: Eculizumab,"Alexion|Achillion, a wholly owned subsidiary of Alexion",Phase 2,12,Industry,"May 8, 2018","September 20, 2019","January 5, 2023"
5812,NCT03472521,Prevention of Persistent Opioid Use in Mothers,Opioid Use|Postpartum Disorder|Chronic Pain Syndrome,Drug: Gabapentin|Drug: Placebo,Stanford University,Phase 4,78,Other,"September 17, 2018","July 2, 2020","April 10, 2021"
5813,NCT03472495,Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial,Atrial Fibrillation and Flutter,Drug: Diltiazem Oral Product|Drug: Diltiazem Injectable Product,Virginia Commonwealth University,Phase 4,19,Other,"June 1, 2018","March 21, 2021","March 21, 2021"
5814,NCT03472469,MAST Trial: Multi-modal Analgesic Strategies in Trauma,Nonspecific Pain Post Traumatic Injury,Drug: Acetaminophen IV/PO|Drug: Acetaminophen PO|Drug: Ketorolac|Drug: Celebrex|Drug: Naproxen|Drug: Tramadol|Drug: Pregabalin|Drug: Gabapentin|Drug: Lidocaine|Drug: Opioids|Drug: Regional anesthesia,"The University of Texas Health Science Center, Houston|National Center for Advancing Translational Sciences (NCATS)",Phase 4,1561,Other|NIH,"April 2, 2018","July 3, 2019","July 3, 2019"
5815,NCT03472365,A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer,Gastric Cancer|GastroEsophageal Cancer,Biological: SHR-1210|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Apatinib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 2,67,Industry,"April 2, 2018","November 25, 2020","November 25, 2020"
5816,NCT03472274,Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO),Bladder Cancer,Drug: Durvalumab|Drug: Tremelimumab|Drug: Cisplatin-based neoadjuvant chemotherapy,Fundacion CRIS de Investigación para Vencer el Cáncer|AstraZeneca|Apices Soluciones S.L.,Phase 2,101,Other|Industry,"October 25, 2018","April 30, 2021","April 12, 2023"
5817,NCT03472261,Integrated Management of Pronation Deformity in Cerebral Palsy,Cerebral Palsy,Drug: Botulinum toxin type A|Other: Upper extremity orthoses|Other: Home exercise program,Kocaeli University,Phase 3,35,Other,"March 26, 2018","March 30, 2020","March 30, 2020"
5818,NCT03472053,A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer Stage IIIB,Drug: BIO-11006 plus standard of care|Drug: Standard of Care,"BioMarck Pharmaceuticals, Ltd.",Phase 2,60,Industry,"February 1, 2018","December 30, 2019","December 30, 2019"
5819,NCT03471988,Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis,Deep Mycosis,Drug: AK1820|Drug: Voriconazole,Asahi Kasei Pharma Corporation,Phase 3,103,Industry,"April 16, 2018","April 21, 2021","April 21, 2021"
5820,NCT03471611,Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis,"Atherosclerosis, Coronary",Drug: Autologous CD34+ Cells|Drug: Granulocyte Colony-Stimulating Factor (G-CSF),Mayo Clinic,Phase 1,21,Other,"June 15, 2018","October 2, 2020","October 2, 2020"
5821,NCT03471078,Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers,Chemotherapy-induced Thrombocytopenia,Drug: Avatrombopag|Drug: Placebo Oral Tablet,"Sobi, Inc.",Phase 3,122,Industry,"October 12, 2018","August 28, 2020","January 31, 2023"
5822,NCT03470545,Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy,Obstructive Hypertrophic Cardiomyopathy,Drug: mavacamten|Drug: Placebo,"MyoKardia, Inc.",Phase 3,251,Industry,"May 29, 2018","March 14, 2020","May 6, 2020"
5823,NCT03470259,Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging,Papillary Thyroid Cancer|Lymph Node Metastases,Drug: IV adminstration of EMI-137|Device: Multispectral Fluorescence Reflectance Imaging|Device: Spectroscopy,University Medical Center Groningen|Erasmus Medical Center,Phase 1,19,Other,"June 20, 2018","December 31, 2019","December 31, 2019"
5824,NCT03470077,Effect of Intravenous Nalbuphine on Emergence Agitation,Postoperative Complications,Drug: IV nalbuphine 0.1 mg/kg with induction of anesthesia.|Drug: IV nalbuphine 0.1 mg/kg at the end of surgery.,Assiut University,Phase 2,80,Other,"July 31, 2019","September 30, 2020","December 1, 2020"
5825,NCT03469349,Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB,Peripheral Arterial Diseases,Drug: Actovegin|Drug: Placebo,Takeda,Phase 3,366,Industry,"May 1, 2018","May 28, 2019","August 28, 2019"
5826,NCT03469310,Minimizing Narcotic Analgesics After Endocrine Surgery,Thyroid Cancer|Thyroid Nodule|Thyroid Neoplasms|Thyroid Goitre|Thyroid Diseases|Parathyroid Diseases|Parathyroid Adenoma|Parathyroid Hyperplasia,Drug: Acetaminophen 500Mg Cap|Drug: Tylenol #3 Oral Tablet|Drug: Tramadol,Minerva A Romero Arenas|DHR Health Institute for Research and Development,Phase 4,126,Other,"March 9, 2018","December 21, 2019","October 2, 2020"
5827,NCT03469271,Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients,Cancer,"Drug: 1,25 (OH)2 D3|Other: Inspiratory isometric resistance training|Drug: Oral Placebo|Other: Sham Inspiratory Isometric Resistance Training|Device: Threshold Inspiratory Muscle Trainer (IMT)",Mayo Clinic|Andersen Foundation,Phase 4,59,Other,"May 25, 2018","May 21, 2020","May 21, 2020"
5828,NCT03469128,Cognitive Processing Therapy vs. Sertraline for the Treatment of PTSD & SUD in Egyptian Patients,Psychologic Manipulation,Behavioral: Cognitive processing therapy|Drug: Sertraline|Other: Placebo Control,British University In Egypt,Phase 1,150,Other,"January 1, 2016","January 1, 2020","January 1, 2020"
5829,NCT03468933,Fibrinolysis Compared to Thoracoscopy for Pleural Infection,Pleural Infection|Empyema|Pleural Diseases|Parapneumonic Effusion,Drug: tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Procedure: Medical Thoracoscopy,Tulane University,Phase 4,32,Other,"November 1, 2017","December 30, 2019","December 30, 2019"
5830,NCT03468855,A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo,Vitiligo,Drug: ATI-50002 topical solution,"Aclaris Therapeutics, Inc.",Phase 2,34,Industry,"March 19, 2018","October 16, 2019","October 16, 2019"
5831,NCT03468790,Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.,"Asthma, Allergic",Drug: CMAB007|Drug: Symbicort|Drug: Seretide|Drug: Ventolin|Drug: placebo,"Shanghai Biomabs Pharmaceutical Co., Ltd.",Phase 3,393,Industry,"May 9, 2018","January 12, 2021","March 9, 2021"
5832,NCT03468478,Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation,Kidney Transplant Infection,Drug: Sirolimus|Drug: Everolimus|Drug: Mycophenolic acid,Hospital do Rim e Hipertensão,Phase 4,1209,Other,"June 18, 2017","March 18, 2021","August 23, 2021"
5833,NCT03467932,A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus,T2DM (Type 2 Diabetes Mellitus),Drug: Cohort A: ORMD-0801|Drug: Placebo oral capsule|Drug: Cohort B: ORMD-0801,"Oramed, Ltd.|Integrium",Phase 2,373,Industry,"May 29, 2018","October 21, 2019","February 18, 2020"
5834,NCT03467763,Trial of an Intervention to Improve Metformin Persistence and Adherence,Metformin Adverse Reaction|Tolerance,Drug: Metformin Extended Release Oral Tablet|Drug: Placebo oral capsule,Weill Medical College of Cornell University|Agency for Healthcare Research and Quality (AHRQ),Phase 4,13,Other|U.S. Fed,"February 9, 2018","February 1, 2020","August 1, 2020"
5835,NCT03467425,INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design,"Pulmonary Disease, Chronic Obstructive",Drug: FF/UMEC/VI|Drug: Inhaled Corticosteroid|Drug: LAMA|Drug: LABA|Drug: COPD rescue medications,GlaxoSmithKline,Phase 4,3109,Industry,"April 11, 2018","October 10, 2019","October 10, 2019"
5836,NCT03467347,PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel,Healthy|Contraception|Contraceptive Usage|Women,Drug: VR: 200 mg DPV + 320 mg LNG,"International Partnership for Microbicides, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Division of AIDS, US National Institute of Allergy and Infectious Diseases|National Institute of Mental Health (NIMH)|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,25,Industry|NIH|Other,"July 17, 2018","August 30, 2019","October 7, 2019"
5837,NCT03467334,Infant Colic Treatment With Probiotics,Infant Colic,Dietary Supplement: B. breve|Dietary Supplement: B. breve plus L. fermentum|Drug: Simethicone 20 MG,"Mónica Olivares Martín; PhD|European Regional Development Fund|Ministerio de Ciencia e Innovación, Spain|Biosearch S.A.",Phase 2,156,Industry|Other,"May 31, 2017","June 15, 2019","June 15, 2019"
5838,NCT03467152,"Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies",Dementia With Lewy Bodies,Drug: Irsenontrine|Drug: Placebo,Eisai Inc.,Phase 2,326,Industry,"May 4, 2018","April 15, 2020","April 15, 2020"
5839,NCT03467113,A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol,Dravet Syndrome|Lennox Gastaut Syndrome,Drug: ZX008 0.2 to 0.8 mg/kg/day|Drug: Cannabidiol,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.|UCB Pharma",Phase 1,9,Industry,"January 19, 2018","June 24, 2020","June 24, 2020"
5840,NCT03466983,A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease,IBD,Drug: Iron Isomaltoside|Drug: Ferric Carboxymaltose,Pharmacosmos A/S,Phase 4,97,Industry,"May 23, 2018","May 25, 2020","May 25, 2020"
5841,NCT03466333,Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia,Cardiovascular Diseases|Pre-Eclampsia Onset Less Than 37 Weeks (Diagnosis),Drug: Enalapril Maleate|Drug: Placebo oral capsule,Manchester University NHS Foundation Trust,Phase 2,118,Other,"September 5, 2018","September 11, 2020","September 11, 2020"
5842,NCT03466203,Safety Study of LLF580 in Obese Volunteers,Obesity,Biological: LLF580|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 1,61,Industry,"February 26, 2018","November 13, 2019","November 13, 2019"
5843,NCT03466099,"Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)",Diabetic Macular Edema,Drug: KVD001 Injection|Other: Sham Procedure,"KalVista Pharmaceuticals, Ltd.",Phase 2,129,Industry,"February 16, 2018","October 10, 2019","October 10, 2019"
5844,NCT03466021,Effects of Liraglutide in Chronic Obstructive Pulmonary Disease,"Pulmonary Disease, Chronic Obstructive",Drug: Liraglutide|Drug: Placebo,Claus Bogh Juhl|Hospital of South West Jutland,Phase 4,40,Other,"January 1, 2018","May 31, 2020","May 31, 2020"
5845,NCT03465878,A Study of LY900014 in Participants With Type 1 Diabetes Mellitus,Type 1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,Phase 1,56,Industry,"March 26, 2018","November 14, 2019","November 14, 2019"
5846,NCT03465722,(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST,GIST,Drug: avapritinib|Drug: regorafenib,Blueprint Medicines Corporation,Phase 3,476,Industry,"March 26, 2018","March 9, 2020","September 15, 2021"
5847,NCT03465410,OPTImization of the Dose of tacroliMUS by Bayesian Prediction,KIDNEY TRANSPLANTATION,Drug: Standard dosage of Tacrolimus|Drug: Bayesian Prediction Tacrolimus dosage,NURIA LLOBERAS BLANCH|Hospital Universitari de Bellvitge,Phase 4,96,Other,"March 21, 2017","September 21, 2020","September 21, 2020"
5848,NCT03464968,mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line,Biliary Cancer Metastatic,"Drug: Oxaliplatin,5FU, leucovorin|Drug: irinotecan,5FU, leucovorin",Seoul National University Bundang Hospital,Phase 2,120,Other,"July 29, 2015","February 10, 2020","July 25, 2020"
5849,NCT03464916,Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients,Relapsed or Refractory Multiple Myeloma,Biological: CAR2 Anti-CD38 A2 CAR-T Cells,"Sorrento Therapeutics, Inc.",Phase 1,10,Industry,"October 15, 2018","August 23, 2020","February 28, 2022"
5850,NCT03464734,Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma,Metastatic Urothelial Carcinoma,Drug: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,70,Other,"January 16, 2019","January 21, 2020","January 21, 2020"
5851,NCT03464552,Celecoxib in Colposcopic Directed Biopsy,Colposcopy,Drug: Celecoxib 200mg|Procedure: Colposcopic guided biopsy|Drug: Placebo oral capsule,Cairo University,Phase 4,170,Other,"April 15, 2018","June 30, 2019","June 30, 2019"
5852,NCT03464383,Anxiety and Depression in Epilepsy: A Treatment Study,Anxiety|Depression|Epilepsy,Drug: Escitalopram 10mg|Other: Referral to Psychiatry|Other: Survey only,Wake Forest University Health Sciences,Phase 4,69,Other,"May 7, 2018","September 20, 2019","September 20, 2019"
5853,NCT03464201,Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study,Ovarian Cancer,Drug: Enzalutamide 40 MG,Grupo Español de Tumores Huérfanos e Infrecuentes|Astellas Pharma Inc|Apices Soluciones S.L.,Phase 2,16,Other|Industry,"April 13, 2018","November 11, 2020","November 11, 2020"
5854,NCT03464136,Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year,Crohn Disease,Biological: Placebo for Ustekinumab|Biological: Placebo for Adalimumab|Biological: Ustekinumab (6 mg/kg)|Biological: Ustekinumab (90 mg)|Biological: Adalimumab (40 mg),"Janssen Scientific Affairs, LLC",Phase 3,386,Industry,"March 29, 2018","December 15, 2020","May 21, 2021"
5855,NCT03463915,Clinical Trial Comparing Two Bladder Instillations for IC/BPS,Interstitial Cystitis|Bladder Pain Syndrome,Drug: Bladder instillation WITH triamcinolone acetonide|Drug: Bladder instillation WITHOUT triamcinolone acetonide,"Olivia Cardenas-Trowers, M.D.|University of Louisville",Phase 3,90,Other,"January 25, 2019","October 23, 2020","October 23, 2020"
5856,NCT03463876,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE),Hepatocellular Carcinoma,Drug: SHR 1210+apatinib,"Jiangsu HengRui Medicine Co., Ltd.",Phase 2,190,Industry,"February 5, 2018","March 10, 2021","March 10, 2021"
5857,NCT03463681,A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma,Metastatic Renal Cell Carcinoma,Drug: Cabometyx,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,49,Other,"June 11, 2018","April 8, 2021","April 8, 2021"
5858,NCT03463525,Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases,Non-small Cell Lung Cancer,Drug: Osimertinib|Drug: [11C]osimertinib,AstraZeneca,Phase 1,4,Industry,"October 24, 2018","March 19, 2020","October 5, 2020"
5859,NCT03463473,A Phase I Study of MSB2311 in Advanced Solid Tumors,Advanced Solid Tumors,Drug: MSB2311 Injection,"Suzhou Transcenta Therapeutics Co., Ltd.",Phase 1,19,Industry,"April 12, 2018","June 1, 2020","June 1, 2020"
5860,NCT03463369,"A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed","Hepatitis B, Chronic",Biological: JNJ-64300535|Biological: Placebo|Drug: Nucleos(t)ide Analogs (NA),Janssen Sciences Ireland UC,Phase 1,30,Industry,"April 18, 2018","March 23, 2021","March 23, 2021"
5861,NCT03463135,A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients,Food Allergy,Drug: Glucopyranosyl Lipid A (GLA)|Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Drug: Placebo for GLA|Drug: Placebo for SLIT PE,Sanofi,Phase 1,27,Industry,"May 7, 2018","May 8, 2019","March 10, 2020"
5862,NCT03462121,A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease,Mild to Moderate Dementia Due to Alzheimer's Disease|With or Without Coexisting Cerebrovascular Disease,Drug: RPh201|Other: Placebo,Regenera Pharma Ltd,Phase 2,83,Industry,"March 1, 2018","December 28, 2019","March 30, 2020"
5863,NCT03461861,Network-Level Mechanisms for Preclinical Alzheimer's Disease Development,APOE 4,Drug: AGB101 220 mg|Other: Placebo,Medical College of Wisconsin|National Institute on Aging (NIA),Phase 2,26,Other|NIH,"April 11, 2019","March 31, 2021","March 31, 2021"
5864,NCT03461718,Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.,Administration and Dosage of Ketamine|Endoscopic Sedation,Drug: Ketamine|Drug: Midazolam injection|Drug: Fentanyl,Brooke Army Medical Center,Phase 2,66,U.S. Fed,"March 5, 2018","October 1, 2019","October 1, 2019"
5865,NCT03461380,Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms,Menopause,Dietary Supplement: Menopause Relief EP-40|Dietary Supplement: Low Dose Black Cohosh|Dietary Supplement: High Dose Black Cohosh|Dietary Supplement: Placebo,"EuroPharma, Inc.|I.Zhordania Institute of Reproductology",Phase 2,220,Industry|Other,"October 1, 2018","September 30, 2019","October 1, 2019"
5866,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1,SMA,Biological: Onasemnogene Abeparvovec-xioi,Novartis Gene Therapies|Novartis,Phase 3,33,Industry,"August 16, 2018","September 11, 2020","September 11, 2020"
5867,NCT03461211,Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,Biological: Teprotumumab,"Horizon Pharma USA, Inc.",Phase 3,51,Industry,"April 16, 2018","June 8, 2020","February 17, 2021"
5868,NCT03461042,The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia,Chronic Insomnia,Drug: Ramelteon 8mg|Drug: Placebo,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science",Phase 4,17,Other,"February 6, 2018","July 31, 2019","March 16, 2020"
5869,NCT03461003,N-of-1 Trials In Children With Hypertension,Pediatric Hypertension,Other: NICHE method|Other: Usual care|Drug: Amlodipine|Drug: Lisinopril|Drug: Hydrochlorothiazide|Drug: Losartan,"The University of Texas Health Science Center, Houston|National Center for Advancing Translational Sciences (NCATS)",Phase 4,49,Other|NIH,"April 2, 2018","November 14, 2020","May 2, 2021"
5870,NCT03460756,A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression,"Depressive Disorder|Depression|Depression, Postpartum|Behavioral Symptoms|Mood Disorders|Mental Disorder|Pregnancy Complications|Postpartum Blues|PPD|Postpartum Disorder",Drug: Ganaxolone|Drug: Placebo,Marinus Pharmaceuticals,Phase 2,84,Industry,"December 28, 2017","July 5, 2019","July 5, 2019"
5871,NCT03460743,Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.,"Influenza, Human",Biological: Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Biological: Control group - quadrivalent inactivated influenza vaccine,Laboratorios Liomont|EPIC Research CRO|ILS Clinical Research|Q Square Solutions,Phase 3,1556,Industry|Other,"March 22, 2018","October 22, 2019","October 22, 2019"
5872,NCT03460652,KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD,ADHD,Drug: KP415 oral capsule,Zevra Therapeutics,Phase 3,282,Industry,"March 13, 2018","June 20, 2019","July 9, 2019"
5873,NCT03460405,"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants",Safety Issues|Immunogenicity,Biological: Vi-DT Vaccine|Biological: Vi Polysaccharide Vaccine|Biological: IPV Vaccine,PT Bio Farma,Phase 2,600,Industry,"July 16, 2018","December 31, 2019","January 30, 2020"
5874,NCT03459040,A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD,Graft-versus-host-disease|GVHD,Drug: Alpha 1-Antitrypsin,John Levine|National Cancer Institute (NCI)|Icahn School of Medicine at Mount Sinai,Phase 2,30,Other|NIH,"August 17, 2018","August 21, 2020","August 21, 2020"
5875,NCT03458247,Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer,Prostate Cancer,Drug: Abiraterone acetate standard dose|Drug: Abiraterone acetate escalated dose,"Assistance Publique - Hôpitaux de Paris|Janssen, LP",Phase 2,94,Other|Industry,"June 22, 2018","April 29, 2021","December 27, 2021"
5876,NCT03457129,Fycompa Titration Intervals and Effects on Retention Rate,Epilepsy,Drug: Perampanel Oral Tablet,University of Arizona|Eisai Inc.,Phase 4,20,Other|Industry,"April 18, 2018","February 24, 2021","December 15, 2021"
5877,NCT03457116,Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty,Rhinoplasty|Non-steroidal Ant Inflammatory Drugs|Opioid Use,Drug: Norco|Drug: NSAID,NYU Langone Health,Phase 4,70,Other,"January 30, 2018","November 2, 2020","November 2, 2020"
5878,NCT03457103,Capnometry-Assisted Breathing Training for COPD,Chronic Obstructive Pulmonary Disease,Device: Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Device: Pulmonary Rehabilitation (PR),NYU Langone Health,Phase 2,31,Other,"June 16, 2015","August 2, 2019","August 2, 2019"
5879,NCT03456908,F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies,Myeloma Before MV-NIS Treatment|Endometrial Cancer Before VSV-hINF-NIS Treatment,Combination Product: 18F-TFB-PET,Mayo Clinic,Phase 1,2,Other,"March 16, 2018","December 31, 2019","December 31, 2019"
5880,NCT03456882,The Effect of RNS60 on ALS Biomarkers,Amyotrophic Lateral Sclerosis,Drug: RNS60,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,Phase 2,147,Other,"May 30, 2017","November 23, 2020","May 30, 2021"
5881,NCT03456830,Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria,Enteric Hyperoxaluria,Drug: ALLN-177|Drug: Placebo,Allena Pharmaceuticals,Phase 3,115,Industry,"May 21, 2018","September 30, 2019","October 28, 2019"
5882,NCT03456752,Perioperative Dexamethasone on Postoperative Outcome in IBD,Inflammatory Bowel Diseases|Dexamethasone|Postoperative Ileus|Postoperative Complications,Drug: Dexamethasone|Drug: Normal saline,"Jinling Hospital, China",Phase 2,302,Other,"June 1, 2018","December 13, 2019","January 13, 2020"
5883,NCT03456687,Effects of Exenatide on Motor Function and the Brain,Parkinson's Disease,Drug: Exenatide,University of Florida|National Institute of Neurological Disorders and Stroke (NINDS),Phase 1,5,Other|NIH,"June 5, 2018","October 16, 2020","August 25, 2021"
5884,NCT03456154,Botox vs Occlusal Splint for Masseter Pain,"Pain, Face",Drug: Botox Injectable Product|Device: Occlusal splint,Federal University of Pelotas,Phase 4,60,Other,"March 15, 2018","January 15, 2021","March 1, 2021"
5885,NCT03455335,Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia,Critical Limb Ischemia,Drug: 20 million hMSCs|Drug: 40 million hMSCs|Drug: 80 million hMSCs,"National University of Ireland, Galway, Ireland|University Hospital of Limerick",Phase 1,12,Other,"March 23, 2015","October 31, 2019","October 31, 2019"
5886,NCT03455322,Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.,Renal Impairment in Hepatorenal Syndrome,Drug: norepinephrine versus midodrine & octreotide,National Hepatology & Tropical Medicine Research Institute,Phase 4,60,Other,"August 15, 2018","April 20, 2020","July 10, 2020"
5887,NCT03455309,Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization,Staphylococcus Aureus,Biological: NDV-3A|Biological: Placebo,"NovaDigm Therapeutics, Inc.|Infectious Diseases Clinical Research Program|Uniformed Services University of the Health Sciences",Phase 2,382,Industry|Other|U.S. Fed,"January 30, 2018","July 19, 2019","October 15, 2019"
5888,NCT03454217,Impact of Tramadol and Oxycodone on Sleep Apnea,Sleep Apnea,Drug: Oxycodone|Drug: Tramadol,Centre Hospitalier Universitaire Vaudois,Phase 4,60,Other,"March 1, 2018","September 30, 2020","September 30, 2020"
5889,NCT03454165,A Study of BNC105P Combined With Ibrutinib,Chronic Lymphocytic Leukemia,Combination Product: BNC105P|Combination Product: Ibrutinib,Dartmouth-Hitchcock Medical Center,Phase 1,6,Other,"March 9, 2018","January 14, 2021","January 14, 2021"
5890,NCT03453723,Pain Prevention During Propofol Infusion in Pediatric: Hypnoanalgesia of the Hand Versus Lidocaine.,Pain,Procedure: Magic glove hypnosis technique|Drug: lidocaine,"University Hospital, Toulouse",Phase 4,100,Other,"April 18, 2018","June 19, 2019","June 19, 2019"
5891,NCT03452982,Sentinel Lymph Node in Early Ovarian Cancer,Ovarian Cancer,Other: sentinel node technique,Instituto de Investigacion Sanitaria La Fe,Phase 2,20,Other,"March 23, 2018","August 21, 2019","August 21, 2019"
5892,NCT03452891,Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients,Periodontal Diseases,Other: Methylcellulose|Drug: Simvastatin-Methylcellulose,University of Nebraska,Phase 4,50,Other,"March 1, 2019","July 31, 2020","December 31, 2020"
5893,NCT03452488,"A Double-blind, Placebo Controlled, Randomized INTerventional Clinical Trial (SARA-INT)",Sarcopenia|Gait Disorders in Old Age|Muscle Weakness,Drug: BIO101|Drug: Placebo oral capsule,Biophytis,Phase 2,233,Industry,"May 24, 2018","December 30, 2020","January 20, 2021"
5894,NCT03452475,Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children,Plasmodium Falciparum,Drug: Arterolane-piperaquine|Drug: Arterolane-piperaquine+mefloquine|Drug: Artemether-lumefantrine,University of Oxford|Mahidol Oxford Tropical Medicine Research Unit,Phase 3,219,Other,"March 7, 2018","June 3, 2019","June 3, 2019"
5895,NCT03452228,Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis,Severe Hypertriglyceridemia (sHTG),Drug: evinacumab|Drug: Placebo,Regeneron Pharmaceuticals,Phase 2,52,Industry,"June 7, 2018","December 17, 2019","July 23, 2020"
5896,NCT03452150,D-0316 First Time in Patients Ascending Dose Study,Advanced Non Small Cell Lung Cancer,Drug: D-0316,"InventisBio Co., Ltd",Phase 1,84,Industry,"January 3, 2018","August 28, 2020","December 31, 2020"
5897,NCT03451695,Effect of Intrathecal Morphine on Chronic Pain After Elective Caesarean Section,Chronic Pain Post-Procedural,Drug: Morphine|Drug: Placebo,B.P. Koirala Institute of Health Sciences,Phase 4,290,Other,"April 1, 2018","December 26, 2020","March 30, 2021"
5898,NCT03451266,Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia,Preeclampsia Severe|Preeclampsia Postpartum,Drug: Vitamin C|Drug: placebo,University Medical Centre Ljubljana,Phase 1,34,Other,"April 7, 2018","June 25, 2019","June 27, 2019"
5899,NCT03451084,A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: ASLAN003,ASLAN Pharmaceuticals,Phase 2,24,Other,"January 5, 2018","September 11, 2019","December 13, 2019"
5900,NCT03451071,Postpartum HPV Vaccination,HPV-Related Malignancy,Drug: Gardasil9,University of Alabama at Birmingham|Merck Sharp & Dohme LLC,Phase 4,195,Other|Industry,"April 29, 2019","June 1, 2020","December 30, 2020"
5901,NCT03451045,Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis,Cystic Fibrosis,Drug: Lenabasum 20 mg|Drug: Lenabasum 5 mg|Other: Placebo,Corbus Pharmaceuticals Inc.|Cystic Fibrosis Foundation,Phase 2,447,Industry|Other,"December 22, 2017","June 17, 2020","June 17, 2020"
5902,NCT03451019,Different Effects of Non-calcium Phosphate Binders on Serum Calcium,Chronic Kidney Disease,Drug: Sevelamer Hydrochloride|Drug: Lanthanum Carbonate,Medical University of Lodz|Shire,Phase 4,34,Other|Industry,"March 1, 2018","December 15, 2020","December 30, 2020"
5903,NCT03450915,A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine,Influenza,Biological: M-001|Biological: Saline,BiondVax Pharmaceuticals ltd.,Phase 3,12460,Industry,"August 1, 2018","July 2, 2020","October 23, 2020"
5904,NCT03450902,Chinese Herbal Therapy Combined With Acupuncture for Female Mixed Urinary Incontinence,Urinary Incontinence,Combination Product: Chinese herb & acupuncture|Combination Product: Chinese herb & sham acupuncture|Combination Product: Placebo & acupuncture|Other: Placebo & sham acupuncture,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Phase 2,136,Other,"March 14, 2018","April 18, 2021","April 18, 2021"
5905,NCT03450629,Evaluation of Safety and Efficacy of PDP-716,Open Angle Glaucoma|Ocular Hypertension,Drug: Brimonidine Tartrate Ophthalmic Suspension|Drug: Brimonidine Tartrate Ophthalmic Solution,Sun Pharma Advanced Research Company Limited,Phase 3,682,Industry,"September 13, 2018","December 1, 2020","December 1, 2020"
5906,NCT03450161,"Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting","Hyperalgesia|Opioid Use|Pain, Postoperative|Pain, Chronic",Drug: Fentanyl dosing schemes,"University Hospital, Ghent|University Hospital, Basel, Switzerland",Phase 4,80,Other,"May 14, 2018","February 1, 2020","January 9, 2021"
5907,NCT03450083,Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis,Chronic Rhinosinusitis (Diagnosis)|Nasal Polyps|Eosinophilia,Drug: Benralizumab|Drug: Placebo,Johns Hopkins University,Phase 2,33,Other,"July 1, 2017","January 1, 2020","February 1, 2020"
5908,NCT03449758,Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: SARILUMAB|Drug: Azathioprine|Drug: Chloroquine|Drug: Hydroxychloroquine|Drug: Leflunomide|Drug: Methotrexate|Drug: Sulfasalazine,Sanofi|Regeneron Pharmaceuticals,Phase 4,84,Industry,"March 5, 2018","July 31, 2019","July 31, 2019"
5909,NCT03449654,Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Liraglutide|Drug: Placebo (for liraglutide),"Steno Diabetes Center Copenhagen|Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark",Phase 4,102,Other,"October 26, 2017","August 16, 2019","August 16, 2019"
5910,NCT03449446,"Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",Nonalcoholic Steatohepatitis,Drug: SEL|Drug: FIR|Drug: CILO|Drug: Placebo to match FIR|Drug: Placebo to match CILO|Drug: Placebo to match SEL,Gilead Sciences,Phase 2,395,Industry,"March 21, 2018","October 30, 2019","November 19, 2019"
5911,NCT03449199,Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria,Diabetic Kidney Disease,Drug: TMX-049|Drug: Placebo,"Teijin America, Inc.",Phase 2,130,Industry,"April 10, 2018","May 7, 2019","June 4, 2019"
5912,NCT03449147,A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030),Chronic Cough,Drug: Placebo|Drug: Gefapixant 15 mg BID|Drug: Gefapixant 45 mg BID,Merck Sharp & Dohme LLC,Phase 3,1317,Industry,"March 15, 2018","August 20, 2020","October 30, 2020"
5913,NCT03449134,A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027),Chronic Cough,Drug: Placebo|Drug: Gefapixant,Merck Sharp & Dohme LLC,Phase 3,732,Industry,"March 14, 2018","June 5, 2020","August 17, 2020"
5914,NCT03448939,A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea,Papulopustular Rosacea,Drug: S5G4T-1|Drug: S5G4T-2,"Sol-Gel Technologies, Ltd.",Phase 3,361,Industry,"June 18, 2018","May 24, 2019","May 24, 2019"
5915,NCT03448731,Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA),Skin Toxicity,Drug: Doxycycline 50Mg Tablet,Fundacion CRIS de Investigación para Vencer el Cáncer|Amgen|Apices Soluciones S.L.,Phase 2,34,Other|Industry,"May 10, 2018","April 6, 2020","April 6, 2020"
5916,NCT03448419,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms,Heart Failure,Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,312,Industry,"March 20, 2018","September 30, 2019","October 7, 2019"
5917,NCT03448406,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.,Heart Failure,Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,315,Industry,"March 20, 2018","October 4, 2019","October 9, 2019"
5918,NCT03448068,Perioperative Ketamine for Pain With Gastric Bypass,Laparoscopic Gastric Bypass Surgery|Ketamine,Drug: Ketamine|Drug: Standard therapy,Mayo Clinic,Phase 2,34,Other,"April 16, 2018","January 9, 2020","January 9, 2020"
5919,NCT03447873,Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual),HIV Infections,Drug: Continue with triple therapy|Drug: Switch to DTG + 3TC|Drug: Switch to DRV/cobicistat + 3TC,Hospitales Universitarios Virgen del Rocío|Instituto de Salud Carlos III,Phase 4,153,Other,"June 1, 2017","September 15, 2020","February 3, 2021"
5920,NCT03447756,Titration Study of ABX-1431,Post Herpetic Neuralgia|Diabetic Peripheral Neuropathy|Small Fiber Neuropathy|Post-Traumatic Neuralgia,Drug: ABX-1431|Drug: Placebo oral capsule,Abide Therapeutics,Phase 1,39,Industry,"October 2, 2017","May 7, 2019","May 7, 2019"
5921,NCT03447314,Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,Neoplasms,Drug: GSK1795091|Drug: GSK3174998|Drug: GSK3359609|Drug: Pembrolizumab,GlaxoSmithKline|Iqvia Pty Ltd,Phase 1,54,Industry,"March 26, 2018","July 1, 2020","March 11, 2022"
5922,NCT03447132,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,Breast Neoplasm Female,Drug: Fulvestrant 500mg|Drug: Palbociclib 125mg|Drug: Goserelin 3.6 MG|Drug: Placebos,"International Cancer Research Group, United Arab Emirates|AstraZeneca|Pfizer|Genomic Health®, Inc.",Phase 3,354,Other|Industry,"December 20, 2017","April 12, 2021","July 20, 2021"
5923,NCT03446846,A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder,Major Depressive Disorder,Drug: MIN-117 5.0 mg|Drug: MIN-117 2.5 mg|Drug: Placebo,Minerva Neurosciences,Phase 2,360,Industry,"March 30, 2018","November 21, 2019","December 13, 2019"
5924,NCT03446573,Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO),HIV Infections,Drug: DTG + 3TC|Drug: TAF based regimen (TBR),ViiV Healthcare|GlaxoSmithKline,Phase 3,743,Industry,"January 18, 2018","May 20, 2019","May 3, 2022"
5925,NCT03446209,Tocilizumab for the Treatment of Familial Mediterranean Fever,Familial Mediterranean Fever,Drug: Tocilizumab Infusion RoAcemtra (EU)|Drug: 0.9% physiological saline,University Hospital Tuebingen,Phase 2,30,Other,"April 23, 2018","October 30, 2020","October 30, 2020"
5926,NCT03445884,68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis,Acute Myocardial Infarction,Drug: 68Ga-NODAGA-E[c(RGDyK)]2,"Rigshospitalet, Denmark",Phase 2,42,Other,"February 20, 2018","July 1, 2020","July 1, 2020"
5927,NCT03445871,Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate,Rheumatoid Arthritis,Biological: Blood sample|Diagnostic Test: CRQ,Centre Hospitalier Universitaire de Saint Etienne,Phase 4,60,Other,"July 2, 2018","May 28, 2020","May 28, 2020"
5928,NCT03445728,China-Administration of Nicorandil Group（CHANGE）,Myocardial Infarction|Percutaneous Coronary Intervention|Nicorandil,Drug: Nicorandil|Other: Placebo,Chinese PLA General Hospital|First People's Hospital of Yulin|Beijing Chao Yang Hospital|Wuhan Asia Heart Hospital|Hainan Hospital of PLA General Hospital|Zunyi Medical College|Guizhou Provincial People's Hospital|Second Affiliated Hospital of Nanchang University|The Second Hospital of Hebei Medical University,Phase 4,238,Other,"February 24, 2018","July 31, 2020","October 1, 2021"
5929,NCT03445650,RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS),Sjogren-Larsson Syndrome,Drug: ADX-102 1% Topical Dermal Cream (reproxalap)|Drug: Vehicle of ADX-102 Topical Dermal Cream,"Aldeyra Therapeutics, Inc.",Phase 3,11,Industry,"July 18, 2018","January 18, 2020","January 18, 2020"
5930,NCT03445338,"To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers",Healthy,Drug: K0706,Sun Pharma Advanced Research Company Limited,Phase 1,18,Industry,"April 15, 2018","December 6, 2019","December 6, 2019"
5931,NCT03444883,Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD,Non-erosive Reflux Disease,Drug: Ilaprazole,"Il-Yang Pharm. Co., Ltd.",Phase 3,277,Industry,"October 31, 2018","February 25, 2020","February 25, 2020"
5932,NCT03444766,Study of Nivolumab for Advanced Cancers in India,Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms,Drug: Nivolumab,Bristol-Myers Squibb,Phase 4,100,Industry,"March 6, 2018","July 17, 2019","July 17, 2019"
5933,NCT03444103,A Pilot Trial of Clazakizumab in Late ABMR,Antibody-mediated Rejection,Drug: Clazakizumab / Clazakizumab|Drug: Placebo / Clazakizumab,"Medical University of Vienna|CSL Behring|University of Alberta|Charite University, Berlin, Germany",Phase 2,20,Other|Industry,"January 16, 2018","June 30, 2020","June 30, 2020"
5934,NCT03444038,Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome,Tourette Syndrome,Drug: Valbenazine,Neurocrine Biosciences,Phase 2,85,Industry,"February 8, 2018","July 12, 2019","July 12, 2019"
5935,NCT03443427,A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine,Respiratory Disorders,Biological: NTHi Mcat investigational vaccine (GSK3277511A)|Biological: Placebo,GlaxoSmithKline,Phase 2,200,Industry,"March 20, 2018","December 31, 2019","September 23, 2020"
5936,NCT03442764,A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM),Non-obstructive Hypertrophic Cardiomyopathy,Drug: mavacamten|Drug: Placebo,"MyoKardia, Inc.",Phase 2,59,Industry,"March 30, 2018","January 7, 2020","January 7, 2020"
5937,NCT03442751,Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus,Progressive Keratoconus,Drug: Paracel 1|Drug: Paracel Placebo|Drug: Paracel 2 R0185|Device: KXL High Power System (2 J)|Device: KXL High Power System (10 J),Glaukos Corporation,Phase 3,279,Industry,"April 6, 2018","November 1, 2019","August 10, 2020"
5938,NCT03441581,Eluxadoline Bile Acid Malabsorption (BAM) Study,Irritable Bowel Syndrome With Diarrhea,Drug: Eluxadoline,Allergan,Phase 4,24,Industry,"February 23, 2018","April 28, 2020","April 28, 2020"
5939,NCT03441555,A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia,Acute Myeloid Leukemia (AML),Drug: Venetoclax|Drug: Alvocidib,"AbbVie|Sumitomo Pharma Oncology, Inc.",Phase 1,36,Industry,"May 30, 2018","January 25, 2021","January 25, 2021"
5940,NCT03441360,"Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)",Relapsed/Refractory Rhabdomyosarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Ewing Sarcoma,Drug: Eribulin mesylate,Eisai Inc.,Phase 2,23,Industry,"April 17, 2018","January 7, 2021","January 21, 2022"
5941,NCT03441269,Adult Oral Ibuprofen Study for ED Pain Patients,"Pain, Acute",Drug: Oral Ibuprofen,Antonios Likourezos|Maimonides Medical Center,Phase 4,225,Other,"November 1, 2018","June 30, 2019","August 31, 2019"
5942,NCT03440814,A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome,Prader-Willi Syndrome,Drug: DCCR|Drug: Placebo for DCCR,"Soleno Therapeutics, Inc.",Phase 3,127,Industry,"May 9, 2018","May 1, 2020","May 1, 2020"
5943,NCT03440034,Study of Pioglitazone in Sporadic Inclusion Body Myositis,Myositis|Inclusion Body Myositis|Muscular Diseases|Musculoskeletal Disease|Neuromuscular Diseases|Nervous System Diseases,Drug: Pioglitazone,Johns Hopkins University,Phase 1,19,Other,"May 22, 2018","December 31, 2020","December 31, 2020"
5944,NCT03439839,"Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH),Drug: LNP023,Novartis Pharmaceuticals|Novartis,Phase 2,16,Industry,"April 9, 2018","April 22, 2020","February 28, 2022"
5945,NCT03439670,A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD),Duchenne Muscular Dystrophy,Drug: Vamorolone|Drug: Prednisone|Other: Placebo,"ReveraGen BioPharma, Inc.|European Union|Cooperative International Neuromuscular Research Group|Newcastle University|University of Pittsburgh",Phase 2,121,Industry|Other,"June 29, 2018","February 23, 2021","August 19, 2021"
5946,NCT03439657,Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older,Herpes Zoster,Biological: HZ/su vaccine GSK1437173A|Biological: Prevenar13,GlaxoSmithKline,Phase 3,913,Industry,"April 12, 2018","May 6, 2019","March 3, 2020"
5947,NCT03439488,"A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B",Chronic Hepatitis B,Drug: JNJ-440|Drug: Placebo,Alios Biopharma Inc.,Phase 1,130,Industry,"March 26, 2018","October 10, 2019","October 10, 2019"
5948,NCT03439124,Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia,Community-acquired Pneumonia (CAP)|Hospital-acquired Pneumonia (HAP),Drug: ceftobiprole medocaril|Drug: IV standard-of-care cephalosporin,Basilea Pharmaceutica,Phase 3,138,Industry,"November 27, 2017","March 16, 2020","March 16, 2020"
5949,NCT03438435,Fluorescence QRH-882260 Peptide Imaging in the Bile Duct,Cholangiocarcinoma,Drug: QRH-882260 Heptapeptide,"D. Kim Turgeon, MD|University of Washington|University of Michigan",Phase 1,1,Other,"April 22, 2019","August 21, 2020","August 21, 2020"
5950,NCT03438396,A Trial of Tisotumab Vedotin in Cervical Cancer,Cervical Cancer,Drug: tisotumab vedotin,Seagen Inc.|Genmab|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Belgian Gynaecological Oncology Group|Gynecologic Oncology Group,Phase 2,102,Industry|Other,"June 12, 2018","February 6, 2020","August 2, 2022"
5951,NCT03438318,Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer,Non Small Cell Lung Cancer,Drug: CMP-001|Drug: Atezolizumab|Radiation: Radiation Therapy,Regeneron Pharmaceuticals|Novella Clinical,Phase 1,29,Industry|Other,"March 15, 2018","December 11, 2019","December 11, 2019"
5952,NCT03438227,Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial,Iron Deficiency Anemia of Pregnancy|Iron Malabsorption,Drug: Iron dextran|Drug: Ferrous sulfate 325mg,Indiana University,Phase 4,52,Other,"April 15, 2018","December 31, 2019","December 31, 2019"
5953,NCT03437278,Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU),Chronic Spontaneous Urticaria,Drug: Ligelizumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,49,Industry,"August 1, 2018","October 23, 2020","February 3, 2021"
5954,NCT03437265,A Pharmacokinetic Study of PLENVU® in Healthy Subjects,Pharmacokinetic,Drug: PLENVU powder for oral solution,Norgine|Quotient Sciences,Phase 1,19,Industry,"September 3, 2020","October 5, 2020","October 5, 2020"
5955,NCT03437044,Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI,"Diabetes Mellitus, Type 2|Coronary Artery Disease",Drug: Ticagrelor|Drug: Clopidogrel,University of Florida|AstraZeneca,Phase 4,40,Other|Industry,"March 14, 2018","June 27, 2019","June 27, 2020"
5956,NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,Diabetic Nephropathy,Drug: Canagliflozin|Drug: Placebo,Mitsubishi Tanabe Pharma Corporation,Phase 3,308,Industry,"February 15, 2018","January 21, 2021","January 21, 2021"
5957,NCT03436316,"A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.",Asthma,Drug: AZD8154,AstraZeneca|Parexel,Phase 1,78,Industry,"July 26, 2018","July 29, 2019","July 29, 2019"
5958,NCT03436199,Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment,Walking Impairment|Multiple Sclerosis,"Drug: ADS-5102, 137 mg|Drug: ADS-5102, 274 mg|Other: Placebo","Adamas Pharmaceuticals, Inc.",Phase 3,558,Industry,"March 29, 2018","December 10, 2019","December 10, 2019"
5959,NCT03435874,"Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania","Malaria,Falciparum",Biological: ChAd63 RH5|Biological: MVA RH5|Biological: Rabies Vaccine,University of Oxford|Ifakara Health Institute|Medical Research Council,Phase 1,63,Other,"April 12, 2018","July 11, 2019","July 11, 2019"
5960,NCT03435081,A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Drug: Baricitinib|Drug: Placebo,Eli Lilly and Company|Incyte Corporation,Phase 3,440,Industry,"February 20, 2018","December 9, 2019","August 16, 2021"
5961,NCT03435055,Network-Level Effects of Nitrous Oxide in the Human Brain,Healthy,Drug: Nitrous Oxide Gas for Inhalation,University of Michigan,Phase 4,21,Other,"July 21, 2017","October 11, 2019","October 11, 2019"
5962,NCT03434704,Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole,"Transplant-Related Hematologic Malignancy|Leukemia, Acute|Myelodysplastic Syndromes|Graft Vs Host Disease|Fungal Infection","Drug: Conditioning treatment ""Thiotepa-Treosulfan-Fludarabine""|Procedure: PBSC graft|Drug: GvHD prophylaxis|Drug: Primary antifungal prophylaxis",Ciceri Fabio|IRCCS San Raffaele,Phase 2,10,Other,"June 18, 2018","October 13, 2019","October 13, 2019"
5963,NCT03434613,Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver Disease|Dyslipidemias,Drug: Rosuvastatin|Drug: Rosuvastatin/ezetimibe combination,Yonsei University,Phase 4,64,Other,"May 14, 2018","September 11, 2019","September 11, 2019"
5964,NCT03434379,A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Drug: Atezolizumab|Drug: Bevacizumab|Drug: Sorafenib,Hoffmann-La Roche,Phase 3,558,Industry,"March 15, 2018","August 31, 2020","November 17, 2022"
5965,NCT03434275,Evaluation of Preoperative N1539 in Total Knee Arthroplasty,"Pain, Postoperative",Drug: N1539|Drug: Placebo,Baudax Bio,Phase 3,194,Industry,"February 19, 2018","May 21, 2019","May 21, 2019"
5966,NCT03434197,Safety and Efficacy of SFPP in Knee Osteoarthritis,Osteoarthritis Knee Pain,Drug: Esflurbiprofen|Drug: Diclofenac diethylamine,"Taisho Pharmaceutical Co., Ltd.",Phase 3,313,Industry,"February 5, 2018","January 11, 2021","January 11, 2021"
5967,NCT03434041,"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","Depressive Disorder, Treatment-Resistant",Drug: Esketamine 56 mg|Drug: Esketamine 84 mg|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral Antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC",Phase 3,252,Industry,"May 25, 2018","April 13, 2021","April 13, 2021"
5968,NCT03433859,Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs),Hyperhidrosis|Residual Limbs,Drug: OnabotulinumtoxinA|Other: Topical Aluminium Chloride (cosmetic product),Direction Centrale du Service de Santé des Armées,Phase 3,54,Other,Mar-16,"September 10, 2020","March 3, 2021"
5969,NCT03433482,A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age,"Meningitis, Meningococcal",Biological: MenACWY liquid|Biological: MenACWY,GlaxoSmithKline,Phase 2,1707,Industry,"August 30, 2018","July 26, 2019","December 17, 2019"
5970,NCT03433235,Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation,Acute Ischemic Stroke,Drug: Edoxaban,Jong Sung Kim|Kyung Hee University Hospital|Soon Chun Hyang University|Dong-A University Hospital|Asan Medical Center,Phase 2,68,Other,"June 19, 2018","April 14, 2020","July 2, 2020"
5971,NCT03432858,Preoperative Antibiotics for Carpal Tunnel Release Surgery,Carpal Tunnel Syndrome,Drug: Vancomycin|Drug: Cefazolin|Drug: Saline Solution,WellSpan Health,Phase 4,184,Other,"May 17, 2018","December 14, 2020","December 14, 2020"
5972,NCT03432650,Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy,Hip Disease,Drug: Bupivacaine + dexamethasone|Device: Ultrasound,"Hospital for Special Surgery, New York",Phase 3,96,Other,"June 1, 2018","December 20, 2020","September 9, 2021"
5973,NCT03432442,Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients,Dengue Hemorrhagic Fever,Drug: Ivermectin,Mahidol University,Phase 2,24,Other,"September 4, 2018","September 22, 2020","September 22, 2020"
5974,NCT03432260,"A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis",Alcoholic Hepatitis,Drug: DUR-928 30 mg|Drug: DUR-928 90 mg|Drug: DUR-928 150 mg,Durect|CTI Clinical Trial and Consulting Services,Phase 2,19,Industry|Other,"April 18, 2018","September 9, 2019","September 9, 2019"
5975,NCT03431974,Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis,Psoriasis,Drug: LD-Aminopterin oral capsule|Drug: Placebo oral capsule,"Syntrix Biosystems, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 2,19,Industry|NIH,"November 1, 2018","January 11, 2021","January 11, 2021"
5976,NCT03431948,Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer,Cancer,Drug: Nivolumab|Drug: Cabiralizumab|Drug: Urelumab|Radiation: Stereotactic Body Radiation Therapy,University of Chicago|Bristol-Myers Squibb,Phase 1,60,Other|Industry,"March 15, 2018","February 29, 2020","April 11, 2022"
5977,NCT03431805,TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery,Postpartum Hemorrhage,Drug: Tranexamic Acid Injectable Solution|Drug: Sodium Chloride 0.9%,"University Hospital, Bordeaux|Ministry of Health, France",Phase 3,4574,Other,"March 3, 2018","January 14, 2020","April 8, 2020"
5978,NCT03431168,A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV,HIV|Pregnancy Malaria|Sexually Transmitted Infection,Drug: Azithromycin/TMPS|Drug: Placebo/TMPS,University of Alabama at Birmingham,Phase 2,308,Other,"March 7, 2018","January 1, 2021","January 1, 2022"
5979,NCT03430895,"Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract",Non-Transitional Cell Carcinoma of the Urothelial Tract|Small Cell of the Bladder|Adenocarcinoma of the Bladder|Squamous Cell Carcinoma of the Bladder|Metastatic Bladder Cancer,Drug: durvalumab and tremelimumab,Memorial Sloan Kettering Cancer Center|AstraZeneca,Phase 2,15,Other|Industry,"January 31, 2018","February 10, 2021","February 10, 2021"
5980,NCT03430843,A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma,Esophageal Squamous Cell Carcinoma (ESCC),Drug: Tislelizumab|Drug: Paclitaxel|Drug: Docetaxel|Drug: Irinotecan,BeiGene,Phase 3,513,Industry,"January 26, 2018","December 1, 2020","December 28, 2022"
5981,NCT03430661,"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects",Healthy,Drug: ACT-246475|Drug: Clopidogrel|Drug: Prasugrel|Drug: Placebo|Drug: Ticagrelor,Idorsia Pharmaceuticals Ltd.,Phase 1,77,Industry,"January 24, 2018","May 20, 2019","May 29, 2019"
5982,NCT03430518,Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,HER2-Negative Metastatic Breast Cancer|Recurrent Ovarian Cancer,Drug: Durvalumab|Drug: Eribulin,Amy Tiersten|AstraZeneca|Eisai Inc.|Icahn School of Medicine at Mount Sinai,Phase 1,9,Other|Industry,"May 17, 2018","February 10, 2020","February 10, 2020"
5983,NCT03430089,Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine,Influenza|Flu,"Biological: Shz QIV 0.25 mL, 2 doses|Biological: Shz QIV 0.5 mL, 2 doses|Biological: Shz QIV 0.5 mL, single dose","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 1,101,Industry,"February 22, 2019","June 6, 2019","June 6, 2019"
5984,NCT03429400,Study of Oral Morphine Sulfate Administration in Pediatric Subjects,"Pain, Postoperative",Drug: Morphine Sulfate,West-Ward Pharmaceutical|Premier Research Group plc,Phase 3,51,Industry,"April 17, 2018","May 29, 2019","May 29, 2019"
5985,NCT03429218,First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: TP-0184,"Sumitomo Pharma Oncology, Inc.",Phase 1,24,Industry,"July 10, 2018","March 8, 2021","March 8, 2021"
5986,NCT03429049,A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain,"Osteoarthritis, Knee",Drug: CNTX-4975-05|Drug: Placebo,Centrexion Therapeutics,Phase 3,332,Industry,"January 24, 2018","November 22, 2019","November 22, 2019"
5987,NCT03428607,Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2],SCLC,Drug: AZD6738|Drug: Olaparib,Samsung Medical Center,Phase 2,26,Other,"October 17, 2018","January 15, 2021","January 15, 2021"
5988,NCT03428360,Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy,Epilepsy,"Drug: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category",Aquestive Therapeutics|Syneos Health|Covance,Phase 3,149,Industry|Other,"January 23, 2018","June 25, 2020","June 25, 2020"
5989,NCT03428334,Roflumilast in Non-CF Bronchiectasis Study,Non-cystic Fibrosis Bronchiectasis,Drug: Oral roflumilast,The University of Hong Kong,Phase 2,20,Other,"May 10, 2018","August 31, 2019","August 31, 2019"
5990,NCT03428230,Intrathecal Paracetamol Before Spinal Anaesthesia With Chloroprocaine HCl 1% for Short Knee Procedures,"Pain, Postoperative","Drug: 30 mg Paracetamol 3% (1 mL)|Drug: 60 mg Paracetamol 3% (2 mL)|Drug: 90 mg Paracetamol 3% (3 mL)|Drug: Placebo, 0.9% saline solution|Drug: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection",Sintetica SA|Cross Research S.A.,Phase 2,60,Industry,"August 6, 2018","October 22, 2019","October 22, 2019"
5991,NCT03428217,CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma,Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma,Drug: CB-839|Drug: Cabozantinib|Drug: Placebo,"Calithera Biosciences, Inc",Phase 2,444,Industry,"April 24, 2018","August 31, 2020","July 16, 2021"
5992,NCT03428100,A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable,Atopic Dermatitis,Drug: Baricitinib|Drug: Placebo|Drug: Topical corticosteroid,Eli Lilly and Company|Incyte Corporation,Phase 3,463,Industry,"May 15, 2018","November 25, 2019","April 20, 2023"
5993,NCT03427879,Effect of Flavonoids on Gut Permeability in Cyclists,"Gut Permeability, Gut Inflammation",Drug: Low flavonoid beverage|Drug: High flavonoid beverage,Utah State University,Phase 1,12,Other,"September 14, 2018","May 15, 2019","July 31, 2019"
5994,NCT03427814,Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer,Advanced or Inoperable Gastric Cancer,Drug: pamiparib|Drug: Placebo,BeiGene,Phase 2,136,Industry,"July 23, 2018","September 16, 2020","January 3, 2023"
5995,NCT03427710,A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level,Hypercholesterolemia,Drug: CiVi007|Other: Placebo,"Civi Biopharma, Inc.",Phase 1,36,Industry,"February 7, 2018","February 14, 2020","August 18, 2020"
5996,NCT03427411,M7824 in Subjects With HPV Associated Malignancies,Human Papilloma Virus|Cervical Cancer|Oropharyngeal Cancer|Anal Cancer|Vaginal or Penile Cancer,Drug: M7824,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,57,NIH,"February 27, 2018","February 2, 2021","December 31, 2022"
5997,NCT03427125,A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis,Hyperphosphatemia,Drug: Tenapanor|Drug: Placebo|Drug: Sevelamer Carbonate,Ardelyx,Phase 3,564,Industry,"January 8, 2018","November 15, 2019","February 27, 2020"
5998,NCT03426722,L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors,Gastrointestinal Stromal Tumors (GISTs),Drug: L-carnitine|Drug: Placebo,Asan Medical Center|Hanmi Pharmaceutical Company Limited,Phase 3,4,Other|Industry,"March 1, 2018","December 24, 2019","December 24, 2019"
5999,NCT03426605,A Study of LAM-003 in Patients With Acute Myeloid Leukemia,Oncology|Acute Myeloid Leukemia,Drug: Open Label LAM-003,"AI Therapeutics, Inc.",Phase 1,13,Industry,"January 16, 2018","February 20, 2020","October 5, 2020"
6000,NCT03426592,Effect of High Dose Vitamin D Supplementation on HIV Latency,Human Immunodeficiency Virus,"Drug: Vitamin D3, 10000 Intl Units Oral Capsule|Drug: Placebo oral capsule",University of Melbourne|Melbourne Health|The Alfred|Melbourne Sexual Health Centre|University of Illinois at Chicago|National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,30,Other|NIH,"January 29, 2018","May 21, 2019","May 21, 2019"
6001,NCT03426267,Evaluation of Efficacy and Safety of SDN-037,Inflammation and Pain Associated With Ocular Surgery,Drug: SDN-037|Drug: Placebo,Sun Pharma Advanced Research Company Limited,Phase 3,325,Industry,"September 28, 2018","March 5, 2020","March 5, 2020"
6002,NCT03425773,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,Stomach Neoplasms,Biological: BVAC-B,"Cellid Co., Ltd.",Phase 1,8,Industry,"February 26, 2018","May 13, 2019","May 13, 2019"
6003,NCT03425747,Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,Drug: Calcium Carbonate|Drug: Calcium Citrate,Campus Bio-Medico University,Phase 4,26,Other,"October 15, 2019","April 1, 2020","April 1, 2020"
6004,NCT03425396,Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis,Uncomplicated Urinary Tract Infection|Cystitis,Drug: Omadacycline tablets|Drug: Nitrofurantoin capsules,Paratek Pharmaceuticals Inc,Phase 2,225,Industry,"January 4, 2018","May 15, 2019","June 5, 2019"
6005,NCT03425253,Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour,Contour,Drug: BELKYRA®|Device: Juvéderm® VOLUMA™ with Lidocaine,Allergan,Phase 4,58,Industry,"February 2, 2018","December 5, 2019","December 5, 2019"
6006,NCT03425084,Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics,Organic Cation Transporter 1|Morphine,Drug: Morphine,University of Southern Denmark|Danish Council for Independent Research|The Faculty of Health Sciences SDU|Region of Southern Denmark,Phase 1,86,Other,"June 1, 2018","February 7, 2020","February 7, 2020"
6007,NCT03424239,Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery,Bariatric Surgery Candidate,Drug: Zoledronic Acid|Dietary Supplement: Calcium citrate + vitamin D|Dietary Supplement: Vitamin D3,Massachusetts General Hospital,Phase 4,6,Other,"August 1, 2018","January 1, 2020","January 1, 2020"
6008,NCT03424044,Three Way Crossover Closed Loop Study With Xeris Glucagon,Type1diabetes,Device: Artificial Pancreas Controller in Dual Hormone Mode|Device: Artificial Pancreas Controller in Single Hormone Mode|Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|Drug: XeriSol glucagon,Oregon Health and Science University|Xeris Pharmaceuticals,Phase 1,23,Other|Industry,"March 29, 2018","May 17, 2019","May 17, 2019"
6009,NCT03423823,Ziv-aflibercept Efficacy in Better Regulating AMD,Wet Macular Degeneration|Wet Age-related Macular Degeneration,Drug: Ziv-Aflibercept 25 MG/ML [Zaltrap]|Drug: Ranibizumab,Kapil Kapoor|Wagner Macula & Retina Center,Phase 2,62,Other,"July 7, 2017","June 26, 2020","June 26, 2020"
6010,NCT03423797,The Caries-arresting Effect of Incorporating fTCP to NaF Varnish Applied Following AgNO3 in Preschool Children,Early Childhood Caries,Drug: 25% AgNO3 solution followed by 5% NaF|Drug: 25% AgNO3 solution followed by 5% NaF with fTCP,The University of Hong Kong,Phase 3,408,Other,"September 1, 2017","May 1, 2020","August 30, 2020"
6011,NCT03422562,Probiotics and Intestinal Microbiome in Preterm Infants,Microbial Colonization,Dietary Supplement: Florababy,Belal Alshaikh|University of Calgary,Phase 3,62,Other,"October 26, 2017","March 30, 2020","April 26, 2021"
6012,NCT03422510,FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS),Primary Focal Segmental Glomerulosclerosis,Drug: CXA-10,"Complexa, Inc.|Kidney Research Network, formerly NephCure Accelerating Cures Institute|Medpace, Inc.|MicroConstants|Arkana Labs|NephCure Kidney International",Phase 2,33,Industry|Other,"April 15, 2018","July 31, 2020","July 31, 2020"
6013,NCT03422172,"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men",HIV Infections,Drug: Oral CAB|Drug: CAB LA,ViiV Healthcare|PPD,Phase 1,48,Industry,"April 10, 2018","April 20, 2020","April 20, 2020"
6014,NCT03422159,"Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.","Sepsis, Severe|Septic Shock",Drug: Ascorbic Acid|Drug: Thiamine|Drug: Hydrocortisone|Drug: Sodium Chloride 0.9%,"Community Medical Center, Toms River, NJ",Phase 2,140,Other,"February 5, 2018","June 5, 2019","August 27, 2019"
6015,NCT03422068,This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.,Idiopathic Pulmonary Fibrosis,Drug: BI 1015550|Drug: Placebo,Boehringer Ingelheim,Phase 1,15,Industry,"March 16, 2018","July 1, 2019","July 10, 2019"
6016,NCT03421743,Pilot Trial of Inhaled Molgramostim in Nontuberculous Mycobacterial (NTM) Infection,"Mycobacterium Infections, Nontuberculous",Drug: Inhaled molgramostim,Savara Inc.,Phase 2,32,Industry,"March 1, 2018","October 15, 2019","January 13, 2020"
6017,NCT03421431,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis",Non-Alcoholic Steatohepatitis,Drug: EDP-305 Dose 1|Drug: EDP-305 Dose 2|Drug: Placebo,"Enanta Pharmaceuticals, Inc|ICON Clinical Research|Triangle Biostatistics",Phase 2,134,Industry|Other,"April 25, 2018","June 14, 2019","July 10, 2019"
6018,NCT03421210,Effects of Smoking Environments on Brain Reactivity,Cigarette Smoking,Drug: Nicotine patch,Duke University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),Phase 4,88,Other|NIH,"March 5, 2018","October 16, 2019","December 23, 2019"
6019,NCT03421197,A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate),Psoriasis,Drug: PPC-06 400 mg QD|Drug: PPC-06 400 mg BID|Drug: PPC-06 600 mg|Drug: Placebo,Dr. Reddy's Laboratories Limited,Phase 2,426,Industry,"January 25, 2018","March 30, 2020","March 30, 2020"
6020,NCT03420742,"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors",Drug: Midazolam|Drug: Brigatinib,Takeda,Phase 1,24,Industry,"June 26, 2019","March 24, 2020","April 29, 2021"
6021,NCT03420300,EBR/GZR for HCV-1b Patients Receiving Hemodialysis,Hepatitis C,Drug: EBR/GZR,National Taiwan University Hospital|Merck Sharp & Dohme LLC,Phase 4,40,Other|Industry,"June 5, 2018","November 2, 2019","February 3, 2020"
6022,NCT03419806,Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease,Parkinson Disease,Drug: Infudopa i.v.|Drug: Infudopa s.c.|Drug: LCIG (Duodopa),Vastra Gotaland Region|The Swedish Research Council|Dizlin Medical Design AB|Göteborg University,Phase 1,25,Other,"February 16, 2018","March 27, 2020","April 20, 2020"
6023,NCT03419676,Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy,Pancreatic Fistula,Device: Hemopatch,Hospital Miguel Servet|Aragon Health Science Institute,Phase 3,64,Other,"May 1, 2018","June 30, 2020","February 10, 2022"
6024,NCT03418935,Remaxol® in Mechanical Jaundice of Non-malignant Origin,"Jaundice, Obstructive",Drug: Remaxol (succinate + methionine + inosine + nicotinamide)|Drug: Ringer's Solution,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 3,342,Industry,"April 3, 2017","March 31, 2020","April 13, 2020"
6025,NCT03418675,Brexpiprazole in Borderline Personality Disorder,Borderline Personality Disorder,Drug: Rexulti|Drug: Placebo,University of Chicago|Otsuka America Pharmaceutical,Phase 2,80,Other|Industry,"November 26, 2018","December 30, 2020","April 14, 2021"
6026,NCT03418623,Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder,Alcohol Use Disorder,Drug: GET73|Other: Placebo,Laboratorio Farmaceutico Ct S.r.l.|Latis S.r.l.,Phase 2,24,Industry,"March 8, 2018","March 13, 2020","March 13, 2020"
6027,NCT03418324,Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy,Prostate Cancer,Drug: TRC105|Drug: Abiraterone|Drug: Enzalutamide,Cedars-Sinai Medical Center,Phase 2,11,Other,"March 5, 2018","November 6, 2019","November 6, 2019"
6028,NCT03418168,A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects,"Anemia|Renal Insufficiency, Chronic",Drug: Molidustat (BAY85-3934),Bayer,Phase 3,51,Industry,"February 22, 2018","July 25, 2019","July 29, 2019"
6029,NCT03418090,Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant,Pulmonary Surgical Procedures,Drug: 129Xe MRI|Drug: 133XE scintigraphy,"Polarean, Inc.",Phase 3,48,Industry,"August 17, 2018","November 4, 2019","November 4, 2019"
6030,NCT03417947,Vitamin D Supplementation in Children With Sickle Cell Disease,Sickle Cell Disease,Dietary Supplement: Vitamin D bolus|Dietary Supplement: Placebo,St. Justine's Hospital|Euro-Pharm,Phase 3,42,Other,"November 30, 2018","September 30, 2019","September 30, 2019"
6031,NCT03417687,Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection,Pulmonary Surgical Procedures,Drug: 129Xe MRI|Drug: 133 Xe scintigraphy,"Polarean, Inc.",Phase 3,38,Industry,"August 17, 2018","October 31, 2019","March 10, 2020"
6032,NCT03417661,An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes,Antimicrobial Effect,Drug: HEXI-PREP By Clinell Wipes|Drug: Chloraprep|Drug: Placebos,Gama Healthcare Ltd.,Phase 3,93,Industry,"June 29, 2018","June 6, 2019","September 18, 2019"
6033,NCT03417245,A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors,Hemophilia A|Hemophilia B,Drug: fitusiran|Drug: factor concentrates,"Genzyme, a Sanofi Company|Sanofi",Phase 3,120,Industry,"March 1, 2018","January 26, 2021","July 14, 2021"
6034,NCT03417141,Valchlor in the Treatment of Lichen Planopilaris,Lichen Planopilaris,Drug: Mechlorethamine 0.016% Top Gel,Mayo Clinic|Actelion,Phase 2,12,Other|Industry,"April 1, 2018","August 30, 2019","August 30, 2019"
6035,NCT03417102,A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors,Hemophilia A|Hemophilia B,Drug: fitusiran|Drug: Bypassing agents,"Genzyme, a Sanofi Company|Sanofi",Phase 3,60,Industry,"February 14, 2018","November 25, 2020","June 23, 2021"
6036,NCT03416751,Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis,Cirrhosis|Alcohol Abuse,Biological: Fecal Microbial Transplant|Other: Placebo,Hunter Holmes Mcguire Veteran Affairs Medical Center|OpenBiome,Phase 1,20,U.S. Fed|Industry,"February 1, 2018","April 10, 2020","April 10, 2020"
6037,NCT03416621,Project Q Pilot: Smoking Cessation for Light Smokers,Tobacco Use Cessation,Behavioral: Cognitive behavioral cessation counseling|Behavioral: Counseling and placebo drug intervention|Drug: Counseling and active drug intervention,Duke University,Phase 3,31,Other,"May 17, 2018","February 29, 2020","February 29, 2020"
6038,NCT03416270,ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure,Type 2 Diabetes Mellitus|Heart Failure,Drug: Ertugliflozin|Drug: Placebo,"University Health Network, Toronto|University Medical Center Groningen|Merck Sharp & Dohme LLC|University of Toronto|Toronto General Hospital",Phase 2,34,Other|Industry,"June 28, 2018","April 14, 2021","April 14, 2021"
6039,NCT03416179,A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia,"Leukemia, Myeloid, Acute",Drug: glasdegib|Drug: daunorubicin + cytarabine|Drug: azacitidine|Drug: Placebo|Drug: cytarabine|Procedure: HSCT,Pfizer,Phase 3,730,Industry,"April 20, 2018","June 5, 2020","January 17, 2022"
6040,NCT03416127,Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2",Drug: Propolis|Drug: Metformin|Drug: Placebo,University of Guadalajara,Phase 2,36,Other,"January 30, 2018","December 20, 2019","December 20, 2019"
6041,NCT03416062,Remaxol® in Malignant Mechanical Jaundice,Jaundice; Malignant,Drug: Remaxol®|Drug: Ringer's Solution,POLYSAN Scientific & Technological Pharmaceutical Company,Phase 3,240,Industry,"April 3, 2017","February 3, 2020","March 4, 2020"
6042,NCT03415750,Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants,"Hypertrophy, Left Ventricular",Drug: Everolimus|Drug: Mycophenolate mofetil|Drug: Tacrolimus,Edoardo Melilli|Hospital Universitari de Bellvitge,Phase 4,20,Other,Nov-16,May-20,May-20
6043,NCT03415503,Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner,Dyslipidemias,Drug: Medox® Anthocyanin capsules,Sun Yat-sen University,Phase 3,169,Other,"October 1, 2018","October 1, 2019","October 1, 2019"
6044,NCT03415399,"Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma","Lymphoma, B-Cell",Biological: ET190L1 ARTEMIS™ T cells,Eureka Therapeutics Inc.|Peking University,Phase 1,4,Industry|Other,"September 9, 2017","December 31, 2020","December 31, 2020"
6045,NCT03415126,A Study of ASN007 in Patients With Advanced Solid Tumors,Cancer|Malignancy|Neoplasia|Neoplasm|Neoplasm Metastasis|Colon Cancer|Colonic Neoplasms|Colon Cancer Liver Metastasis|Metastatic Cancer|Metastatic Melanoma|Metastatic Colon Cancer|Metastatic Lung Cancer|Non Small Cell Lung Cancer Metastatic|Pancreatic Cancer|Pancreas Cancer|Pancreas Adenocarcinoma|Pancreas Neoplasm|Metastatic Nonsmall Cell Lung Cancer|Metastatic Pancreatic Cancer,Drug: ASN007: ascending doses|Drug: ASN007 RD,Asana BioSciences,Phase 1,49,Industry,"January 19, 2018","June 30, 2020","June 30, 2020"
6046,NCT03414931,NMDA Modulation in Major Depressive Disorder in Late- Life,"Depressive Disorder, Major",Drug: NMDA|Drug: Sertraline|Drug: Placebo - Cap,Chang Gung Memorial Hospital,Phase 2,136,Other,Jan-16,Nov-20,Nov-20
6047,NCT03414879,Ketamine Versus Lidocaine Nebulization for Awake Fiberoptic Intubation,Anesthesia,Drug: Ketamine|Drug: Lidocaine,Ain Shams University,Phase 4,60,Other,"January 15, 2018","July 25, 2019","July 25, 2019"
6048,NCT03414294,A Study to Evaluate the Safety of K-755 in Healthy Volunteers,Healthy,Drug: K-755 Part A (SAD)|Drug: Placebo Part A (SAD)|Drug: K-755 Part B (MAD)|Drug: Placebo Part B (MAD)|Drug: K-755 Part C (FE)|Drug: K-755 Part D (FE)|Drug: K-755 Part E (MAD)|Drug: Placebo Part E (MAD),"Kowa Company, Ltd.",Phase 1,121,Industry,"February 27, 2018","November 14, 2019","November 14, 2019"
6049,NCT03414268,Micronized dHACM Injectable for the Treatment of Plantar Fasciitis,"Fasciitis, Plantar",Other: Micronized dHACM|Drug: Saline Injection,"MiMedx Group, Inc.",Phase 3,208,Industry,"January 8, 2018","March 17, 2021","March 17, 2021"
6050,NCT03414255,Micronized dHACM Injectable for the Treatment of Achille Tendonitis,Tendonitis;Achilles,Biological: Micronized DHACM|Drug: Saline Injection,"MiMedx Group, Inc.",Phase 3,146,Industry,"January 9, 2018","March 30, 2021","March 30, 2021"
6051,NCT03414047,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,Ovarian Cancer,Drug: Prexasertib,Eli Lilly and Company,Phase 2,172,Industry,"April 10, 2018","June 3, 2019","October 3, 2020"
6052,NCT03413618,Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis,Deep Vein Thrombosis|Postthrombotic Syndrome,Drug: Rivaroxaban|Drug: Diosmin|Other: compression stockings,Pirogov Russian National Research Medical University,Phase 4,90,Other,"December 20, 2017","July 31, 2019","July 31, 2019"
6053,NCT03413579,Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom,Cervical Cancer,Biological: Nimotuzumab ( h-R3)|Other: Placebo,El Kendi Pharmaceuticals Manufacturing Company,Phase 3,37,Industry,Nov-15,Mar-20,Feb-21
6054,NCT03413319,Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104,Progressive Supranuclear Palsy (PSP),Drug: ABBV-8E12,AbbVie,Phase 1,3,Industry,"April 17, 2018","November 20, 2019","November 20, 2019"
6055,NCT03412890,LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,Heavy Menstrual Bleeding|Uterine Fibroid,Drug: Relugolix|Drug: Estradiol/norethindrone acetate,Myovant Sciences GmbH,Phase 3,477,Industry,"October 19, 2017","January 21, 2020","January 13, 2021"
6056,NCT03412682,To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis,"Colitis, Ulcerative","Drug: Budesonide (6 mg)|Drug: Budesonide (9 mg)|Drug: Mesalazine (3,600 mg)",Ferring Pharmaceuticals,Phase 3,274,Industry,"March 2, 2018","May 11, 2020","May 26, 2020"
6057,NCT03412006,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease",Diabetic Kidney Disease,Drug: Fulacimstat (BAY1142524)|Drug: Placebo,Bayer,Phase 2,152,Industry,"February 2, 2018","October 2, 2019","October 10, 2019"
6058,NCT03411902,Weight Loss With Risedronate for Bone Health,Bariatric Surgery Candidate|Bone Loss|Weight Loss,Drug: Risedronate Sodium 150 MG|Other: Placebo,Wake Forest University Health Sciences|Wake Forest University,Phase 4,24,Other,"June 15, 2018","July 22, 2020","July 22, 2020"
6059,NCT03411798,Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS,Ankylosing Spondylitis,Drug: Yisaipu®,Nanfang Hospital of Southern Medical University,Phase 4,76,Other,"December 15, 2017","July 1, 2019","July 1, 2019"
6060,NCT03410953,Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines,"Hepatitis B|Hepatitis|Hepatitis, Viral, Human|Hepatitis B Immunization","Biological: Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).",Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Instituto de Investigación Biomédica de Salamanca|Spanish Clinical Research Networt (SCReN),Phase 4,67,Other,"April 13, 2018","October 31, 2019","October 31, 2019"
6061,NCT03410914,Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy,Pancreas Cancer|Pancreas Disease|Pancreas Adenocarcinoma|Pancreas; Fistula|Surgery|Surgery--Complications|Surgery Site Fistula,Device: Hemopatch,"Sunnybrook Health Sciences Centre|Baxter Healthcare Corporation|Hamilton Health Sciences Corporation|The Ottawa Hospital|Queen's University|Royal University Hospital Foundation|London Health Sciences Centre|University Health Network, Toronto",Phase 2,52,Other|Industry,"August 13, 2018","October 3, 2020","October 23, 2020"
6062,NCT03410862,Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza,"Influenza, Human",Drug: Elderberry Extract|Drug: Placebos,michael macknin|Pharmacare Laboratories|The Cleveland Clinic,Phase 4,87,Other,"January 29, 2018","June 25, 2019","June 25, 2019"
6063,NCT03410108,Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC),ALK-positive Advanced NSCLC,Drug: Brigatinib,Takeda,Phase 2,104,Industry,"January 29, 2018","September 29, 2020","July 28, 2021"
6064,NCT03409627,Novel INXN-4001 Triple Effector Plasmid in Heart Failure,Heart Failure|Cardiovascular Diseases|Heart-Assist Device,Biological: INXN-4001,"Triple-Gene, LLC|Intrexon Corporation|Precigen, Inc",Phase 1,12,Industry,"April 9, 2018","March 4, 2020","August 12, 2020"
6065,NCT03409276,"Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults",HIV Infections,"Biological: env (A,B,C,A/E)/gag (C) DNA Vaccine|Biological: gp120 (A,B,C,A/E) Protein Vaccine|Biological: Placebo|Biological: GLA-SE adjuvant",National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,60,NIH,"March 16, 2018","May 11, 2020","October 22, 2020"
6066,NCT03409107,Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ),Anaemia,Drug: Daprodustat (GSK1278863)|Drug: Placebo|Drug: Iron therapy,GlaxoSmithKline,Phase 3,614,Industry,"March 5, 2018","October 7, 2020","October 7, 2020"
6067,NCT03408873,CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL),Bipolar Disorder|Medication Adherence|Medication Non Adherence,Drug: Abilify Maintena|Behavioral: Customized Adherence Enhancement (CAE),"Martha Sajatovic|Otsuka Pharmaceutical Development & Commercialization, Inc.|University Hospitals Cleveland Medical Center",Phase 4,30,Other|Industry,"April 1, 2018","May 6, 2020","May 6, 2020"
6068,NCT03408821,CM Delivered PST in LLD Pilot,Late Life Depression,Other: Problem Solving Therapy (PST),Lawson Health Research Institute|Bell Let's Talk Community Fund,Phase 1,29,Other,"February 1, 2018","May 31, 2019","May 31, 2019"
6069,NCT03408730,Lot-to-lot Consistency of Sci-B-Vac™ in Adults,Hepatitis B Vaccines,Biological: Hepatitis B Vaccination,VBI Vaccines Inc.,Phase 3,2838,Industry,"December 14, 2017","October 1, 2019","October 1, 2019"
6070,NCT03408587,CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER),Uveal Melanoma|Liver Metastases,Biological: CVA21|Biological: Ipilimumab,Viralytics,Phase 1,11,Industry,"January 29, 2018","May 22, 2019","May 22, 2019"
6071,NCT03408262,Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women,Human Immunodeficiency Virus,Biological: Ad4-EnvCN54|Biological: MVA-CN54|Biological: CN54gp140/MPLA,Imperial College London,Phase 1,68,Other,"October 6, 2017","February 10, 2020","February 10, 2020"
6072,NCT03407495,The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma,Magnetic Resonance Imaging,Drug: IOP Injection (MPB-1523),MegaPro Biomedical Co. Ltd.,Phase 2,52,Industry,"November 22, 2018","August 30, 2020","October 30, 2020"
6073,NCT03406962,MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT),Inherited Metabolic Disorders (IMD),Drug: MGTA-456,"Magenta Therapeutics, Inc.",Phase 2,8,Industry,"February 9, 2018","February 10, 2020","January 15, 2021"
6074,NCT03406858,Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Prostate Carcinoma Metastatic in the Bone|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7,Biological: HER2Bi-Armed Activated T Cells|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Phase 2,15,Other|NIH,"June 7, 2018","January 20, 2021","November 7, 2022"
6075,NCT03406780,A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy,"Muscular Dystrophies|Muscular Dystrophy, Duchenne|Muscular Disorders, Atrophic|Muscular Diseases|Neuromuscular Diseases|Nervous System Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn",Biological: CAP-1002|Drug: Placebo,Capricor Inc.,Phase 2,18,Industry,"March 4, 2018","March 10, 2020","March 10, 2020"
6076,NCT03406507,A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,Biological: Ravulizumab,Alexion,Phase 3,13,Industry,"February 22, 2018","March 25, 2020","August 25, 2022"
6077,NCT03406364,Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor,Solid Tumor,Drug: MG005,Metagone Biotech Inc.,Phase 1,17,Industry,"June 6, 2018","January 9, 2020","July 24, 2020"
6078,NCT03406078,Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma,Asthma,Biological: Tezepelumab|Other: Placebo,AstraZeneca|Amgen,Phase 3,150,Industry,"March 5, 2018","September 25, 2020","September 25, 2020"
6079,NCT03405922,Perianal Nerval Block in Proctological Interventions,Perianal Fistula|Fissure in Ano|Hemorrhoids,Drug: Placebo 40 mL Saline 0.9%|Drug: 40 mL Ropivacain 0.5%,"University Hospital, Basel, Switzerland",Phase 4,166,Other,"February 1, 2018","July 5, 2019","July 5, 2019"
6080,NCT03405714,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy",Epilepsy,Drug: Brivaracetam,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 2,50,Industry,"June 1, 2018","November 4, 2020","November 4, 2020"
6081,NCT03405142,Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer,Head and Neck Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Head and Neck Cancer,Drug: Panitumumab-IRDye800|Drug: Lymphoseek,Eben Rosenthal|National Cancer Institute (NCI)|Stanford University,Phase 2,3,Other|NIH,"August 1, 2019","December 4, 2019","April 27, 2021"
6082,NCT03404791,A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy,Urinary Bladder Neoplasms,Drug: TAR-200,"Janssen Research & Development, LLC",Phase 1,35,Industry,"November 20, 2017","December 23, 2019","September 15, 2022"
6083,NCT03404648,Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI,Prostate Adenocarcinoma,Drug: C-11 choline PET tracer|Drug: Gadobutrol|Device: PET/MR scanner,Mayo Clinic,Phase 3,19,Other,"November 1, 2017","January 23, 2020","January 23, 2020"
6084,NCT03404544,Impact of Carbetocin Administration on Heart Rate When Given as an Infusion Versus as a Bolus.,Cesarean Section Complications|Hemodynamic Instability,Drug: Carbetocin bolus|Drug: Carbetocin infusion,Ciusss de L'Est de l'Île de Montréal,Phase 4,70,Other,"June 11, 2018","January 28, 2020","January 15, 2021"
6085,NCT03403634,"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver",Metastatic Carcinoma in the Liver|Recurrent Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,Drug: Celecoxib|Other: Laboratory Biomarker Analysis|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,Roswell Park Cancer Institute|National Cancer Institute (NCI),Phase 2,19,Other|NIH,"April 19, 2018","December 23, 2020","August 29, 2021"
6086,NCT03403517,Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period,"Complication, Postoperative",Drug: Methylprednisolone|Drug: Dexamethasone,"Rigshospitalet, Denmark",Phase 4,174,Other,"December 11, 2017","August 28, 2020","September 28, 2020"
6087,NCT03403374,Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia,Homozygous Familial Hypercholesterolemia HoFH,Drug: evolocumab,Amgen,Phase 4,30,Industry,"August 4, 2018","November 27, 2019","November 27, 2019"
6088,NCT03403348,"A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants",Healthy,Drug: JNJ-64417184|Drug: Placebo,"Janssen BioPharma, Inc.",Phase 1,130,Industry,"May 9, 2018","November 24, 2019","November 24, 2019"
6089,NCT03403309,"Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial",Multiple System Atrophy,Drug: 1) Inosine 5'-monophosphate|Drug: Placebo,Yonsei University,Phase 2,43,Other,"May 2, 2018","June 10, 2019","June 10, 2019"
6090,NCT03403049,Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer,Pancreatic Cancer|Cancer,Radiation: Carbon Ion|Drug: Gemcitabine + Cisplatin|Drug: Gemcitabine + Capecitabine|Drug: Gemcitabine + Erlotinib|Drug: Gemcitabine|Radiation: Photon,Albert Einstein College of Medicine|Shanghai Proton and Heavy Ion Center,Phase 1,14,Other,"April 1, 2016","July 9, 2019","July 9, 2019"
6091,NCT03402841,Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients,Non-Germline BRCA Mutated Ovarian Cancer,Drug: Olaparib,"AstraZeneca|Iqvia Pty Ltd|Myriad Genetics, Inc.|Covance|Theradex|Parexel",Phase 3,279,Industry,"January 30, 2018","October 2, 2020","March 10, 2022"
6092,NCT03402659,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease",Alzheimer Disease,Drug: neflamapimod|Other: placebo,"EIP Pharma Inc|Worldwide Clinical Trials|Amsterdam UMC, location VUmc",Phase 2,161,Industry|Other,"December 29, 2017","June 30, 2019","July 31, 2019"
6093,NCT03401229,Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis,Nasal Polyposis,Biological: Benralizumab 30 mg SC + Mometasone Furoate|Biological: Matching placebo SC + Mometasone Furoate,AstraZeneca,Phase 3,413,Industry,"January 15, 2018","July 31, 2020","July 31, 2020"
6094,NCT03401112,A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia),Sickle Cell Disease,Drug: IMR-687|Drug: Placebo,"Imara, Inc.",Phase 2,100,Industry,"January 26, 2018","August 28, 2020","August 28, 2020"
6095,NCT03400878,Comparing Morbidity and Mortality Effects of Two Different Strains of BCG,Heterologous Immunity|Infant Morbidity|Infant Mortality|Trained Immunity|Vaccine Reaction|Vaccine Adverse Reaction,Biological: BCG-Japan|Biological: BCG-Russia,Bandim Health Project|Research Center for Vitamins and Vaccines,Phase 4,17505,Other,"October 14, 2017","June 1, 2020","October 1, 2020"
6096,NCT03400800,Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol,"ASCVD|Risk Factor, Cardiovascular|Elevated Cholesterol",Drug: Inclisiran Sodium|Drug: Placebo,The Medicines Company,Phase 3,1617,Industry,"November 1, 2017","July 31, 2019","August 27, 2019"
6097,NCT03400267,The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor,STEMI|STEMI - ST Elevation Myocardial Infarction,Drug: Paracetamol|Drug: Fentanyl,A.H. Tavenier|Isala,Phase 4,200,Other,"February 16, 2018","October 22, 2019","November 22, 2019"
6098,NCT03400033,Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD),Anaemia,Drug: Daprodustat tablets|Drug: Matching placebo tablets|Drug: Epoetin alfa vials|Drug: Saline vials or bags,GlaxoSmithKline,Phase 3,407,Industry,"September 5, 2018","June 19, 2020","June 19, 2020"
6099,NCT03399786,Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia,Homozygous Familial Hypercholesterolemia,Drug: evinacumab|Drug: Placebo,Regeneron Pharmaceuticals,Phase 3,65,Industry,"January 18, 2018","June 10, 2019","March 17, 2020"
6100,NCT03399604,Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil,Primary Pulmonary Hypertension,Drug: LIQ861 Inhaled Treprostinil,"Liquidia Technologies, Inc.|Nuventra, Inc.",Phase 3,121,Industry|Other,"January 2, 2018","May 6, 2019","November 25, 2019"
6101,NCT03399474,Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia,Limb Deformity,Drug: Lidocaine Hydrochloride 2%|Drug: Dexmedetomidine 0.5 ug/kg|Drug: Dexmedetomidine Injection 0.25 ug/kg,Assiut University,Phase 4,60,Other,"March 1, 2018","July 30, 2020","August 30, 2020"
6102,NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,ASCVD|Elevated Cholesterol,Drug: Inclisiran Sodium|Drug: Placebo,The Medicines Company,Phase 3,1561,Industry,"December 21, 2017","September 10, 2019","September 17, 2019"
6103,NCT03398824,Pilot Study of Metformin for Patients With Fanconi Anemia,Fanconi Anemia,Drug: metformin HCl,Boston Children's Hospital,Phase 2,15,Other,"March 29, 2018","October 9, 2020","October 9, 2020"
6104,NCT03398005,A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1),Hypertriglyceridemia,Drug: CaPre|Drug: Placebo,Acasti Pharma Inc.,Phase 3,256,Industry,"January 23, 2018","July 21, 2019","November 20, 2019"
6105,NCT03397173,TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid,Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Acute Myeloid Leukemia,Drug: Azacitidine|Drug: Ascorbic acid,Case Comprehensive Cancer Center,Phase 2,12,Other,"March 16, 2018","January 3, 2021","January 21, 2021"
6106,NCT03397134,Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia,Negative Symptoms of Schizophrenia,Drug: Placebo Oral Tablet|Drug: Roluperidone 32 mg|Drug: Roluperidone 64 mg,Minerva Neurosciences,Phase 3,515,Industry,"December 15, 2017","May 26, 2020","February 15, 2021"
6107,NCT03397121,Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH),Heterozygous Familial Hypercholesterolemia|Elevated Cholesterol,Drug: Inclisiran|Drug: Placebo,The Medicines Company,Phase 3,482,Industry,"November 28, 2017","August 27, 2019","September 17, 2019"
6108,NCT03396952,Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma,Stage III Cutaneous Melanoma|Stage IIIA Cutaneous Melanoma|Stage IIIB Cutaneous Melanoma|Stage IIIC Cutaneous Melanoma|Stage IV Cutaneous Melanoma,Drug: Aspirin|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,"University of California, San Francisco|Merck Sharp & Dohme LLC",Phase 2,27,Other|Industry,"April 19, 2018","April 30, 2020","June 30, 2022"
6109,NCT03396211,A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer,Cancer,Drug: Apatinib|Drug: Nivolumab,Elevar Therapeutics,Phase 1,30,Industry,"December 22, 2017","October 28, 2020","March 16, 2022"
6110,NCT03396107,Antenatal Corticosteroid in Elective Cesarean Section,Cesarean Section Complications,Drug: Dexamethasone|Drug: Placebo,Assiut University,Phase 3,498,Other,"May 17, 2018","November 25, 2019","May 24, 2020"
6111,NCT03395704,A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis,Hereditary Hemochromatosis,Drug: LJPC-401|Drug: Placebo,La Jolla Pharmaceutical Company|PRA Health Sciences,Phase 2,70,Industry,"November 29, 2017","October 28, 2019","October 28, 2019"
6112,NCT03395223,MEthylene Blue In Patients With Acquired Methemoglobinemia,Acquired Methaemoglobinaemia,Drug: Methylene Blue,Provepharm SAS,Phase 4,7,Industry,"July 6, 2018","August 31, 2020","August 31, 2020"
6113,NCT03395119,Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects,Healthy|Dietary Supplement,Drug: Ozone|Dietary Supplement: Fish Oil|Dietary Supplement: Olive Oil,"University of North Carolina, Chapel Hill|Environmental Protection Agency (EPA)",Phase 1,44,Other|U.S. Fed,"December 18, 2017","December 18, 2020","December 18, 2020"
6114,NCT03395080,A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma,Endometrial Cancer|Uterine Cancer|Ovarian Cancer|Carcinosarcoma,Drug: Paclitaxel|Drug: 300mg DKN-01|Drug: 600mg DKN-01,"Leap Therapeutics, Inc.",Phase 2,111,Industry,"March 5, 2018","September 9, 2020","January 27, 2021"
6115,NCT03395002,Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment,COPD,Drug: Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Drug: Tiotropium 18 mcg Inhalation Powder|Drug: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder,Neutec Ar-Ge San ve Tic A.Ş,Phase 4,58,Industry,"March 22, 2018","April 30, 2020","April 30, 2020"
6116,NCT03394989,BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients,Bronchial Asthma,"Drug: Fluticasone propionate/salmeterol 100/50 µg|Other: Placebo|Drug: Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT",Cipla Ltd.,Phase 3,1366,Industry,"October 17, 2018","December 3, 2019","March 31, 2020"
6117,NCT03394924,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis",Primary Biliary Cholangitis,Drug: EDP-305 1 mg|Drug: EDP-305 2.5 mg|Drug: Placebo,"Enanta Pharmaceuticals, Inc|Pharmaceutical Research Associates|Triangle Biostatistics",Phase 2,68,Industry|Other,"December 27, 2017","December 19, 2019","January 16, 2020"
6118,NCT03394755,Thrombosomes® in Bleeding Thrombocytopenic Patients,Thrombocytopenia|Hematologic Diseases|Bone Marrow Aplasia,Biological: Thrombosomes,"Cellphire Therapeutics, Inc.|Department of Health and Human Services",Phase 1,24,Industry|U.S. Fed,"March 19, 2018","August 1, 2019","September 25, 2019"
6119,NCT03394287,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,Breast Cancer,Drug: SHR-1210|Drug: Apatinib,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2,40,Other,"January 10, 2018","December 30, 2019","September 30, 2020"
6120,NCT03394118,TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy,NSCLC,Drug: Osimertinib,Asan Medical Center|AstraZeneca,Phase 2,63,Other|Industry,"August 11, 2017","March 11, 2021","April 8, 2021"
6121,NCT03394027,ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma,"Triple Negative Breast Cancer|Endometrial Cancer|Hormone Receptor Positive, HER2 Negative Breast Cancer",Drug: ONC201,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,30,NIH,"January 17, 2018","March 18, 2021","October 7, 2021"
6122,NCT03393702,Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin,"Pain, Postoperative|Surgery, Thoracic",Drug: Gabapentin|Drug: Placebo,"National Institute for Tuberculosis and Lung Diseases, Poland",Phase 4,104,Other,"May 9, 2017","December 30, 2019","December 3, 2020"
6123,NCT03393026,A Study of Lurasidone HCl in Subjects With Schizophrenia,Schizophrenia,Drug: Lurasidone,"Standard Chem. & Pharm. Co., Ltd.",Phase 4,54,Industry,"January 3, 2018","September 17, 2019","September 17, 2019"
6124,NCT03392896,Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria,Primary Hyperoxaluria,Drug: DCR-PHXC|Drug: Placebo,"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",Phase 1,43,Industry,"December 6, 2017","November 19, 2019","November 19, 2019"
6125,NCT03392428,A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer,Cancer of the Prostate|Metastatic Cancer,Other: 177Lu-PSMA617|Drug: Cabazitaxel,Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Australian Nuclear Science and Technology Organisation (ANSTO)|Endocyte|Prostate Cancer Foundation of Australia (PCFA)|Australasian Radiopharmaceutical Trials network (ARTnet)|Movember Foundation,Phase 2,201,Other|Industry,"January 29, 2018","December 31, 2019","December 31, 2021"
6126,NCT03392389,"Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults",Human Metapneumovirus and Human Parainfluenza Infection,Biological: mRNA-1653|Other: Placebo,"ModernaTX, Inc.",Phase 1,124,Industry,"December 4, 2017","July 29, 2019","July 29, 2019"
6127,NCT03391804,Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia,Enteric Hyperoxaluria|Primary Hyperoxaluria|Hyperoxalemia,Drug: ALLN-177,Allena Pharmaceuticals,Phase 2,15,Industry,"July 17, 2018","December 13, 2019","December 13, 2019"
6128,NCT03391154,Efficacy of Low Dose Levothyroxine During Pregnancy,Euthyroid Females,Drug: levothyroxin,Ain Shams University,Phase 3,180,Other,"May 1, 2017","August 30, 2020","August 30, 2020"
6129,NCT03389490,Toujeo Versus NPH Self-titration Study,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine 300 UNT/ML|Drug: Neutral protamine hagedorn insulin,Elaine Chow|Sanofi|Chinese University of Hong Kong,Phase 4,50,Other|Industry,"January 1, 2018","December 17, 2019","May 1, 2020"
6130,NCT03389308,Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex,Epidermolysis Bullosa|Epidermolysis Bullosa Simplex,Drug: diacerein 1% ointment,"Castle Creek Pharmaceuticals, LLC",Phase 2,51,Industry,"December 1, 2017","April 17, 2020","April 17, 2020"
6131,NCT03389126,Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment,"Carcinoma, Hepatocellular",Drug: Avelumab,"Seoul National University Hospital|Merck KGaA, Darmstadt, Germany",Phase 2,30,Other|Industry,"December 1, 2017","December 31, 2019","January 31, 2020"
6132,NCT03388866,Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis,Atopic Dermatitis|Effects of Immunotherapy,Drug: Mite extract sublingual immunotherapy (SLIT)|Other: Placebo,Casa Espirita Terra de Ismael|Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4,91,Other,"May 2, 2018","October 30, 2019","June 26, 2020"
6133,NCT03388853,Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.,COPD,Drug: Acetylcysteine/Doxofylline|Other: Placebo,Neutec Ar-Ge San ve Tic A.Ş,Phase 4,68,Industry,"February 20, 2018","December 21, 2019","December 21, 2019"
6134,NCT03388645,Challenge Infection of Healthy Adult Volunteers With RSV A2,Upper Respiratory Tract Infections,Biological: 10^6.3 PFU of RSV A2|Biological: 10^7 PFU of RSV A2,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,19,NIH,"February 20, 2018","November 15, 2019","December 6, 2019"
6135,NCT03388541,Low Dose Dexmedetomidine and Delirium After Cardiac Surgery,Cardiac Surgical Procedures,Drug: Dexmedetomidine|Drug: Placebo,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 4,420,Other,"January 17, 2018","August 12, 2019","August 12, 2019"
6136,NCT03388268,TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment,Clostridium Difficile Infection|Diarrhea,Drug: Oral Vancomycin|Drug: Placebo|Device: Toxin enzyme immunoassay|Device: Nuceleic acid amplification test,Washington University School of Medicine,Phase 4,15,Other,"December 29, 2017","January 31, 2021","January 31, 2021"
6137,NCT03387566,A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration,Neovascular Age-Related Macular Degeneration,Drug: HB002.1M,"Huabo Biopharm Co., Ltd.",Phase 1,21,Industry,"February 8, 2018","February 1, 2020","March 23, 2020"
6138,NCT03387150,"Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults",HIV Infections,Biological: VRC07-523LS|Biological: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,124,NIH,"February 28, 2018","December 7, 2020","December 7, 2020"
6139,NCT03387137,"Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children",RSV Infection,Biological: RSV 6120/∆NS2/1030s|Biological: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,45,NIH,"October 13, 2017","November 22, 2019","May 31, 2021"
6140,NCT03387020,Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors,"CNS Embryonal Tumor, Not Otherwise Specified|Malignant Glioma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Diffuse Intrinsic Pontine Glioma",Drug: Everolimus|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ribociclib,Pediatric Brain Tumor Consortium|National Cancer Institute (NCI),Phase 1,22,Other|NIH,"January 13, 2018","April 1, 2020","April 1, 2020"
6141,NCT03386669,Novel Neuroimage Study in Tauopathies With Parkinsonism,Parkinsonism,Drug: F-18,Chang Gung Memorial Hospital,Phase 2,44,Other,"July 31, 2017","July 31, 2019","July 31, 2019"
6142,NCT03386656,Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery,"Osteoarthritis, Knee",Drug: Amchafibrin|Other: Saline Solution,Fundación Pública Andaluza Progreso y Salud|Andalusian Network for Design and Translation of Advanced Therapies,Phase 3,150,Other,"November 28, 2017","May 1, 2019","May 8, 2019"
6143,NCT03386630,Effects of Analgesics in Cesarean Section Elective,Anesthesia; Functional,Drug: Hyperbaric bupivacaine+Sufentanil|Drug: Hyperbaric bupivacaine+Morphine,Fundación Pública Andaluza Progreso y Salud|Andalusian Network for Design and Translation of Advanced Therapies,Phase 4,66,Other,"March 28, 2018","June 30, 2019","July 28, 2019"
6144,NCT03386149,Clinical Research on the Efficacy of Bosinji on Herniated Intervertebral Disc of Lumbar Spine,Lumbar Disc Herniation,Drug: Bosinji|Drug: Loxonine tab.|Procedure: Acupuncture,Kyunghee University Medical Center|Kyung Hee University Hospital at Gangdong|DongGuk University|Daegu Korean Medicine Hospital of Daegu Haany University,Phase 3,74,Other,"December 28, 2017","December 27, 2019","January 22, 2020"
6145,NCT03386136,Therapeutic Oxygen for Gastrointestinal Atony (TOGA),Ileus|Ogilvie Syndrome|Small Bowel Obstruction,Drug: 100% Oxygen,University of Florida,Phase 1,17,Other,"January 25, 2018","October 17, 2019","October 17, 2019"
6146,NCT03385668,Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies,Pulmonary Fibrosis,Drug: Pirfenidone,Assistance Publique - Hôpitaux de Paris|Roche Pharma AG,Phase 2,7,Other|Industry,"January 31, 2018","July 24, 2020","July 24, 2020"
6147,NCT03385239,Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD),Hypertriglyceridemia|Cardiovascular Diseases,Drug: ISIS 678354|Drug: Placebo,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",Phase 2,114,Industry,"January 30, 2018","November 25, 2019","February 25, 2020"
6148,NCT03384940,DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01),Colorectal Neoplasm,Drug: DS-8201a,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.|AstraZeneca",Phase 2,86,Industry,"February 23, 2018","August 9, 2019","November 10, 2020"
6149,NCT03384745,"A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis",Psoriasis,Drug: M1095 (Sonelokimab)|Drug: Placebo|Drug: Secukinumab,Bond Avillion 2 Development LP|Avillion LLP,Phase 2,313,Industry,"July 31, 2018","June 20, 2019","March 26, 2020"
6150,NCT03384693,Defibrotide TMA Prophylaxis Pilot Trial,Thrombotic Microangiopathies,Drug: Defibrotide,"University of California, San Francisco",Phase 2,25,Other,"May 1, 2018","July 31, 2020","July 31, 2020"
6151,NCT03384329,Efficacy of Resveratrol in Depression,Depression,Drug: Resveratrol Pill|Drug: Placebos,Russian Academy of Medical Sciences|Russian Science Foundation,Phase 4,30,Other,"July 4, 2018","August 27, 2019","September 18, 2019"
6152,NCT03383328,Study for Optimizing Anti-inflammatory Prophylaxis,Postoperative Cystoid Macular Edema|Irvine-Gass Syndrome,"Drug: NSAID + prednisolone, preoperative|Drug: NSAID + prednisolone, postoperative|Drug: NSAID, preoperative|Drug: NSAID, postoperative|Drug: Drop-less surgery","Line Kessel|Rigshospitalet, Denmark",Phase 4,470,Other,"February 1, 2018","December 18, 2019","December 18, 2019"
6153,NCT03382847,HCV Positive Heart Donors,Heart Failure,"Combination Product: Transplant with HCV positive donor, followed by surveillance and treatment of viremia",NYU Langone Health,Phase 4,25,Other,"January 5, 2018","May 6, 2020","May 6, 2020"
6154,NCT03382821,Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach,Cervical Radiculopathy,Procedure: Transforaminal ESI with dexamethasone|Procedure: Transforaminal catheter-targeted ESI with triamcinolone|Drug: Dexamethasone Sodium Phosphate 10 MG/ML|Drug: Lidocaine|Drug: Triamcinolone Acetonide 40mg/mL,University of Utah|Epimed,Phase 4,120,Other,"September 15, 2017","April 15, 2020","August 19, 2020"
6155,NCT03382639,"A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia",Schizophrenia,Drug: Luvadaxistat|Drug: Placebo,Neurocrine Biosciences|Takeda,Phase 2,307,Industry,"January 4, 2018","December 29, 2020","January 12, 2021"
6156,NCT03382418,"Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States",HIV Infections,Biological: gp145 C.6980 Vaccine|Biological: Placebo|Biological: Aluminum Hydroxide Adjuvant,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,45,NIH,"December 27, 2017","September 25, 2019","September 25, 2019"
6157,NCT03382405,"Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults",Cytomegalovirus Infection,Biological: mRNA-1647|Biological: mRNA-1443|Other: Placebo,"ModernaTX, Inc.",Phase 1,181,Industry,"November 13, 2017","October 28, 2020","October 28, 2020"
6158,NCT03381768,Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma,Follicular Lymphoma,Biological: PD-L2 peptide|Biological: PD-L2 and PD-L1 peptide,Lars Møller Pedersen|Herlev Hospital,Phase 1,8,Other,"December 12, 2017","February 12, 2020","February 12, 2020"
6159,NCT03381599,Stem Cells After Peripheral Mobilization and Harvest,Stem Cells|Orthopedic Disorder,Drug: Filgrastim Injection,"Andrews Research & Education Foundation|Auburn University|Arthrex, Inc.",Phase 1,10,Other|Industry,"March 28, 2018","September 4, 2019","September 4, 2019"
6160,NCT03380871,A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Nonsquamous Nonsmall Cell Neoplasm of Lung",Biological: NEO-PV-01|Biological: Pembrolizumab|Other: Adjuvant|Drug: Carboplatin|Drug: Pemetrexed,BioNTech US Inc.|Merck Sharp & Dohme LLC|BioNTech SE,Phase 1,38,Industry,"May 4, 2018","October 31, 2019","February 5, 2021"
6161,NCT03380520,Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy,Heart Failure,Drug: Ferric Carboxymaltose|Drug: Placebo,Hasselt University|Ziekenhuis Oost-Limburg,Phase 4,75,Other,"October 1, 2017","December 31, 2020","August 4, 2021"
6162,NCT03380130,A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC,Hepatocellular Carcinoma,Drug: Nivolumab|Device: SIR-Spheres,"Clinica Universidad de Navarra, Universidad de Navarra|Sirtex Medical|Bristol-Myers Squibb",Phase 2,41,Other|Industry,"September 11, 2017","March 1, 2020","November 4, 2020"
6163,NCT03380026,Mechlorethamine Induced Contact Dermatitis Avoidance Study,Cutaneous T-cell Lymphoma|Cutaneous T-cell Lymphoma Stage I|Mycosis Fungoides|Folliculotropic Mycosis Fungoides|Granulomatous Slack Skin|Syringotropic Mycosis Fungoides|Mycosis Fungoides Variant|Transformed Mycosis Fungoides,Drug: Triamcinolone|Drug: Valchlor 0.016 % Topical Gel,"Rochester Skin Lymphoma Medical Group, PLLC|Rochester General Hospital",Phase 2,28,Other,"December 13, 2017","August 3, 2020","December 13, 2020"
6164,NCT03380000,Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women,Postmenopausal Women,Drug: Beetroot juice|Drug: Beetroot juice placebo,Penn State University,Phase 2,16,Other,"September 12, 2014",Sep-19,Jan-20
6165,NCT03379974,Exercise Versus DDAVP in Patients With Mild Hemophilia A,Hemophilia A,Drug: DDAVP Inhalant Product|Behavioral: Exercise Intervention,Nationwide Children's Hospital|The Hospital for Sick Children,Phase 4,32,Other,"July 31, 2018","August 30, 2019","December 5, 2019"
6166,NCT03379844,HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients,Hepatocellular Carcinoma|Hepatocellular Carcinoma Non-resectable,Device: Holmium-166 radioembolization,UMC Utrecht|Dutch Cancer Society|Erasmus Medical Center|Quirem Medical B.V.,Phase 2,30,Other|Industry,"August 21, 2017","January 1, 2020","August 1, 2021"
6167,NCT03379675,"A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus",Respiratory Syncytial Virus Infections,Drug: JNJ-53718678 500 mg|Drug: JNJ-53718678 80 mg|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,72,Industry,"February 6, 2018","November 27, 2019","December 26, 2019"
6168,NCT03379506,Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079),HCV Infection,Drug: EBR/GZR FDC Tablet|Drug: Placebo|Drug: Grazoprevir Oral Granules|Drug: Elbasvir Oral Granules,Merck Sharp & Dohme LLC,Phase 2,57,Industry,"January 25, 2018","October 28, 2019","July 23, 2020"
6169,NCT03379389,Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis,Urinary Tract Infections,Drug: Methenamine + Methylthioninium|Drug: Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Drug: Antibiotics,Fundação Educacional Serra dos Órgãos,Phase 4,284,Other,"March 31, 2018","May 1, 2019","June 1, 2021"
6170,NCT03379311,"A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis",Atopic Keratoconjunctivitis|Vernal Keratoconjunctivitis|Perennial Allergic Conjunctivitis,Drug: AK002,Allakos Inc.,Phase 1,30,Industry,"February 26, 2018","August 8, 2019","August 8, 2019"
6171,NCT03379181,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Hyperthyroidism,Drug: Propranolol,"University Hospital, Basel, Switzerland",Phase 4,19,Other,"July 18, 2017","February 12, 2020","February 12, 2020"
6172,NCT03378921,Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis,Pouchitis|Ulcerative Colitis,Biological: Fecal microbiota transplantation|Biological: Placebo,Helsinki University Central Hospital,Phase 2,26,Other,"February 27, 2018","September 25, 2019","September 25, 2019"
6173,NCT03378479,Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients,"Aspergillosis; Pulmonary, Invasive (Etiology)",Drug: SOC +Posaconazole 18 MG/ML (milligram/milliliter)|Other: standard of care (SOC),Universitaire Ziekenhuizen KU Leuven|Merck Sharp & Dohme LLC,Phase 4,88,Other|Industry,"December 27, 2017","March 31, 2020","March 30, 2021"
6174,NCT03377699,"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes","Diabetes|Diabetes Mellitus, Type 1",Drug: Insulin degludec|Drug: Insulin Aspart|Drug: Insulin detemir,Novo Nordisk A/S,Phase 3,225,Industry,"November 22, 2017","December 17, 2020","December 17, 2020"
6175,NCT03377556,Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer,ATM Gene Mutation|ATR Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCC Gene Mutation|FANCD2 Gene Mutation|FANCF Gene Mutation|FANCM Gene Mutation|NBN Gene Mutation|PALB2 Gene Mutation|RAD51 Gene Mutation|RAD51B Gene Mutation|RAD54L Gene Mutation|Recurrent Squamous Cell Lung Carcinoma|RPA1 Gene Mutation|Stage IV Squamous Cell Lung Carcinoma AJCC v7,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Talazoparib,SWOG Cancer Research Network|National Cancer Institute (NCI),Phase 2,51,Other|NIH,"March 3, 2017","January 10, 2021","April 16, 2021"
6176,NCT03375697,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",Alzheimer Disease,Drug: JNJ-63733657|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,72,Industry,"December 22, 2017","December 16, 2019","December 16, 2019"
6177,NCT03375671,Rapid Agitation Control With Ketamine in the Emergency Department,Violent Aggressive Behavior|Ketamine,Drug: Ketalar|Drug: Midazolam injection|Drug: Haloperidol,David Barbic|St Paul's Emergency Department Research Fund|Centre for Health Evaluation and Outcome Sciences (CHÉOS)|University of British Columbia,Phase 2,81,Other,"May 29, 2018","March 12, 2020","March 12, 2020"
6178,NCT03375515,PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain,Cancer Pain,Drug: Hydromorphone|Device: PCA pump,Fujian Cancer Hospital,Phase 3,214,Other,"September 29, 2018","December 10, 2019","January 10, 2020"
6179,NCT03375294,Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD),Post Traumatic Stress Disorder,Drug: Nitrous Oxide,Stanford University,Phase 2,3,Other,"April 1, 2018","July 31, 2019","April 5, 2020"
6180,NCT03375255,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)","Muscular Dystrophy, Duchenne",Drug: SRP-5051,"Sarepta Therapeutics, Inc.",Phase 1,15,Industry,"February 5, 2018","August 19, 2019","August 19, 2019"
6181,NCT03374943,A Trial of KB004 in Patients With Glioblastoma,Glioblastoma,Drug: KB004,"Olivia Newton-John Cancer Research Institute|Humanigen, Inc.",Phase 1,12,Other|Industry,"December 5, 2017","January 25, 2021","September 22, 2021"
6182,NCT03374397,"PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy",Ovarian Cyst Benign,Drug: Surgiguard,Seoul National University Hospital,Phase 3,52,Other,"December 6, 2017","August 31, 2019","August 31, 2019"
6183,NCT03374358,Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir,HIV Seropositivity|Metabolic Syndrome|Fatty Liver,Drug: Raltegravir,Helsinki University Central Hospital|Merck Sharp & Dohme LLC,Phase 4,45,Other|Industry,"January 10, 2018","November 2, 2019","November 30, 2019"
6184,NCT03373786,A Study of RG-012 in Subjects With Alport Syndrome,Alport Syndrome,Drug: RG012,"Genzyme, a Sanofi Company|Sanofi",Phase 1,4,Industry,"December 22, 2017","May 20, 2019","May 20, 2019"
6185,NCT03373760,Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Biological: Tremelimumab,SWOG Cancer Research Network|National Cancer Institute (NCI),Phase 2,67,Other|NIH,"October 2, 2017","May 18, 2020","March 29, 2022"
6186,NCT03373669,Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine,Cholera|Vibrio Cholerae Infection,Biological: Oral Cholera Vaccine|Biological: Adjusted Dose Oral Cholera Vaccine,Johns Hopkins Bloomberg School of Public Health,Phase 4,120,Other,"November 16, 2017","October 16, 2019","December 1, 2020"
6187,NCT03373461,Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation,IgA Nephropathy,Drug: LNP023|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,112,Industry,"February 7, 2018","December 29, 2020","June 22, 2021"
6188,NCT03373383,Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy,Drug-resistant Epilepsy|Focal-Onset Seizures,Drug: Padsevonil|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 2,411,Industry,"February 12, 2018","January 30, 2020","January 30, 2020"
6189,NCT03373006,A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer,Prostate Cancer,Drug: Axumin PET/CT,HALO Diagnostics,Phase 2,20,Industry,"February 27, 2018","January 30, 2020","January 30, 2020"
6190,NCT03372954,Retrograde Application of Bone Marrow Aspirate Concentrate,Heart Failure,Drug: BMAC,University Hospital Ostrava,Phase 2,40,Other,"January 1, 2018","December 31, 2020","December 31, 2021"
6191,NCT03372837,Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma,Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL,Drug: Rituximab,SymBio Pharmaceuticals,Phase 3,40,Industry,"January 15, 2018","December 31, 2019","December 31, 2019"
6192,NCT03372083,Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis,Iron Overload,Drug: Deferasirox,Novartis Pharmaceuticals|Novartis,Phase 4,44,Industry,"January 16, 2018","December 5, 2019","December 5, 2019"
6193,NCT03371836,Use of Clobazam for Epilepsy and Anxiety,Epilepsy|Anxiety,Drug: Clobazam,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",Phase 4,20,Other,"October 1, 2017","December 31, 2019","December 31, 2019"
6194,NCT03371810,Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder,Attention-Deficit / Hyperactivity Disorder|Depression|Obesity,Behavioral: Bright light therapy|Behavioral: Physical exercise,Goethe University|Heidelberg University|Radboud University Medical Center|Hospital Vall d'Hebron|King's College London,Phase 2,207,Other,"March 13, 2017","August 31, 2020","August 31, 2020"
6195,NCT03371355,"Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease","NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic",Drug: Placebo|Drug: ISIS 703802 40 mg|Drug: ISIS 703802 80 mg|Drug: ISIS 703802 20 mg,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",Phase 2,105,Industry,"December 21, 2017","November 21, 2019","February 24, 2020"
6196,NCT03371329,Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage,Hemorrhagic Stroke|Intracerebral Hemorrhage,Biological: MSC,Mayo Clinic,Phase 1,9,Other,"December 12, 2017","October 9, 2020","October 9, 2020"
6197,NCT03371082,Gan & Lee Insulin Glargine Target Type (1) Evaluating Research,"Diabetes Mellitus, Type 1",Biological: Gan & Lee Insulin Glargine Injection|Biological: Lantus®,"Gan and Lee Pharmaceuticals, USA",Phase 3,550,Industry,"October 31, 2017","August 19, 2019","August 19, 2019"
6198,NCT03370653,A Study in MPS VI to Assess Safety and Efficacy of Odiparcil,Mucopolysaccharidosis VI,Drug: Odiparcil|Other: Placebo,Inventiva Pharma,Phase 2,20,Industry,"December 30, 2017","September 24, 2019","October 22, 2019"
6199,NCT03369951,Minocycline Pharmacokinetics (ACUMIN),Bacterial Infection,Drug: Minocycline,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,58,NIH,"March 28, 2018","July 20, 2019","July 20, 2019"
6200,NCT03369847,Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge,Asthma|Pediatric ALL,"Drug: budesonide, beclomethasone",New York City Health and Hospitals Corporation,Phase 4,43,Other,"September 10, 2017","May 30, 2019","June 30, 2019"
6201,NCT03369236,A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G),C3 Glomerulopathy|C3 Glomerulonephritis|Dense Deposit Disease,Drug: Danicopan|Drug: Placebo,Alexion,Phase 2,13,Industry,"June 12, 2018","December 11, 2019","December 18, 2020"
6202,NCT03369015,Effect of D-amphetamine on Reward Functioning,Anhedonia,Drug: 10 mg d-amphetamine|Drug: 20mg d-amphetamine|Drug: Placebo,"The University of Texas Health Science Center, Houston|Emory University",Phase 1,68,Other,"January 24, 2018","May 23, 2019","May 23, 2019"
6203,NCT03368235,Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: AZD9567|Drug: Prednisolone,AstraZeneca,Phase 2,21,Industry,"January 18, 2018","November 12, 2019","November 12, 2019"
6204,NCT03368170,Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia,Parkinson Disease,Drug: Mesdopetam (IRL790),Integrative Research Laboratories AB|The Clinical Trial Company,Phase 2,75,Industry,"April 12, 2018","June 12, 2019","June 12, 2019"
6205,NCT03367403,A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ),Alzheimer Disease,Drug: Donanemab|Drug: Placebo|Drug: LY3202626,Eli Lilly and Company,Phase 2,272,Industry,"December 18, 2017","December 4, 2020","September 21, 2021"
6206,NCT03366857,Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients,Supplemental Oxygen|Brain Natriuretic Peptide|Cardiac Risk Patients|Perioperative,Drug: Oxygen 30 %|Drug: Oxygen 80 %,Medical University of Vienna,Phase 4,260,Other,"December 1, 2017","December 31, 2019","May 30, 2020"
6207,NCT03366766,"Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery",Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage II Non-Small Cell Lung Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer,Biological: Nivolumab|Drug: Cisplatin|Drug: Pemetrexed Disodium|Drug: Gemcitabine Hydrochloride,Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University,Phase 2,14,Other|Industry,"December 20, 2017","December 6, 2020","February 8, 2023"
6208,NCT03365999,Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.,Knee Osteoarthritis|Blood Clot|Transfusion Related Complication|Blood Loss,Drug: Oral Tranexamic Acid|Drug: Oral Aminocaproic Acid,Universidad Autonoma de Nuevo Leon,Phase 2,92,Other,"October 15, 2017","July 1, 2019","July 1, 2019"
6209,NCT03365921,A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial),Hepatitis E,"Biological: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.","Xiamen Innovax Biotech Co., Ltd|Jiangsu Province Centers for Disease Control and Prevention",Phase 4,360,Industry|Other,"October 27, 2018","June 16, 2019","June 16, 2019"
6210,NCT03365635,Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C,Hepatitis C|Hemodialysis|Nosocomial Infection,Drug: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier],University of Pennsylvania|Merck Sharp & Dohme LLC,Phase 4,6,Other|Industry,"September 22, 2019","May 1, 2020","September 1, 2020"
6211,NCT03365297,Therapeutics in Active Prostate Cancer Surveillance,Prostate Cancer,Drug: Apalutamide,CCTU- Cancer Theme|Janssen-Cilag Ltd.|Cambridge University Hospitals NHS Foundation Trust,Phase 2,11,Other|Industry,"June 5, 2018","July 25, 2019","July 25, 2019"
6212,NCT03364985,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers",Healthy,Drug: DWP16001|Drug: Placebo|Drug: Dapagliflozin,Daewoong Pharmaceutical Co. LTD.,Phase 1,123,Industry,"December 3, 2017","May 21, 2019","July 30, 2019"
6213,NCT03364348,4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer,HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer,Drug: Utomilumab|Drug: Trastuzumab|Drug: Ado-Trastuzumab Emtansine,George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University,Phase 1,18,Other|NIH,"October 30, 2017","February 15, 2021","February 14, 2022"
6214,NCT03364309,A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis,Plaque Psoriasis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Phase 3,438,Industry,"April 26, 2018","June 4, 2020","June 4, 2020"
6215,NCT03364270,TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study,Carotid Arteries,Drug: PET/CT Imaging with [F-18] RGD-K5,Balaji Tamarappoo|Cedars-Sinai Medical Center,Phase 2,6,Other,"October 10, 2018","February 28, 2020","May 31, 2020"
6216,NCT03364049,Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002),Solid Neoplasms,Drug: MK-7162|Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 1,33,Industry,"December 6, 2017","October 19, 2020","October 19, 2020"
6217,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),Multiple Sclerosis,Drug: Mavenclad®,"Merck KGaA, Darmstadt, Germany",Phase 4,270,Industry,"May 28, 2018","May 5, 2020","February 21, 2022"
6218,NCT03363321,PF-06741086 Long-term Treatment in Severe Hemophilia,Hemophilia A or B,Biological: PF-06741086,Pfizer,Phase 2,20,Industry,"May 30, 2018","August 5, 2020","August 5, 2020"
6219,NCT03363295,Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis,Endophthalmitis|Macula Edema|Cataract,Drug: Moxifloxacin Injection,Universidade Federal de Pernambuco,Phase 4,120,Other,"July 1, 2017","December 30, 2019","December 30, 2019"
6220,NCT03362723,A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors,Solid Tumors,Drug: Idasanutlin,Hoffmann-La Roche,Phase 1,48,Industry,"November 27, 2017","June 11, 2019","June 11, 2019"
6221,NCT03361969,Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.,Prostatic Neoplasm,Drug: Estetrol|Drug: Placebo Oral Tablet,Pantarhei Oncology B.V.,Phase 2,63,Other,"April 16, 2018","May 15, 2020","May 15, 2020"
6222,NCT03361956,"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection",Hepatitis B,Drug: JNJ-56136379|Drug: Placebo|Drug: NA (ETV or TDF),Janssen Sciences Ireland UC,Phase 2,232,Industry,"February 13, 2018","September 5, 2019","August 13, 2020"
6223,NCT03361605,Neuroimaging of Anesthetic Modulation of Human Consciousness,Healthy,Drug: Propofol,University of Michigan,Phase 4,30,Other,"April 12, 2017","July 12, 2019","July 12, 2019"
6224,NCT03361501,A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2),Hypertriglyceridemia,Drug: CaPre|Drug: Placebo,Acasti Pharma Inc.,Phase 3,278,Industry,"February 1, 2018","September 24, 2019","January 9, 2020"
6225,NCT03361384,Alcohol and Implicit Process in Sexual Risk Behavior in MSM,Alcohol Drinking|Sex Behavior|Men,Drug: Alcohol|Other: Placebo (non-alcoholic beverage),Syracuse University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Boston University|University of South Dakota,Phase 1,260,Other|NIH,May-16,"June 30, 2020","June 30, 2020"
6226,NCT03361163,Controlled Human Infection for Vaccination Against Streptococcus Pyogenes,Streptococcus Pyogenes Pharyngitis|Streptococcus Pharyngitis|Strep Throat|Streptococcus Pyogenes Infection|Group A Streptococcus: B Hemolytic Pharyngitis|Group A Streptococcal Infection|Gram-Positive Bacterial Infections|Bacterial Infections,"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)","Andrew Steer|University of Melbourne|Nucleus Network Ltd|National Health and Medical Research Council, Australia|Telethon Kids Institute|The Peter Doherty Institute for Infection and Immunity|Queen Fabiola Children's University Hospital|Griffith University|University of Wollongong|The University of Queensland|University of Auckland, New Zealand|University of Tennessee|Murdoch Childrens Research Institute",Phase 1,25,Other,"July 10, 2018","September 28, 2019","April 21, 2020"
6227,NCT03361098,DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2,Type 2 Diabetes Mellitus|Obesity,Drug: Dapagliflozin 10mg|Drug: Exenatide|Other: placebo exenatide|Other: placebo dapagliflozin,"Amsterdam UMC, location VUmc|AstraZeneca",Phase 4,65,Other|Industry,"September 18, 2017","November 25, 2019","March 25, 2020"
6228,NCT03360734,Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors,"Solid Tumor, Adult","Drug: First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)",Glycotope GmbH,Phase 1,50,Industry,"November 2, 2017","May 4, 2020","September 29, 2020"
6229,NCT03359980,Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer,Fecal Microbiota Transplantation,Drug: fecal microbiota transfer,MaaT Pharma,Phase 2,24,Industry,"August 13, 2018","February 25, 2020","November 26, 2020"
6230,NCT03359850,Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients,Ovarian Neoplasms|Neoplasms|Solid Tumor|Hepatic Impairment,Drug: Niraparib,"Tesaro, Inc.",Phase 1,17,Industry,"February 20, 2018","September 16, 2019","June 24, 2020"
6231,NCT03359837,Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy,Type 2 Diabetes Mellitus,Drug: INSULIN GLARGINE (HOE901)|Drug: Insulin Glulisine|Drug: Biphasic insulin aspart 30|Drug: Repaglinide|Drug: Acarbose|Drug: Metformin,Sanofi,Phase 4,384,Industry,"January 20, 2018","June 29, 2020","June 29, 2020"
6232,NCT03359811,Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway,Peritoneal Cancer,Drug: Local Anesthetic Solution|Drug: Bupivacaine HCl|Drug: Liposomal Bupivacaine,M.D. Anderson Cancer Center,Phase 3,75,Other,"November 27, 2017","November 24, 2020","November 24, 2020"
6233,NCT03359785,"A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia",Schizophrenia,Drug: Luvadaxistat|Drug: Matching Placebo,Neurocrine Biosciences|Takeda,Phase 2,31,Industry,"December 21, 2017","December 21, 2020","December 21, 2020"
6234,NCT03359590,Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients,Pharmacological Action,Drug: Sitagliptin 100 mg|Drug: Placebo,Profil Institut für Stoffwechselforschung GmbH|Merck Sharp & Dohme LLC,Phase 2,20,Industry,"March 21, 2018","July 17, 2019","July 17, 2019"
6235,NCT03359538,Rapamycin Treatment for ALS,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda Cà Granda|Fondazione Salvatore Maugeri|University of Padova",Phase 2,63,Other,"September 19, 2017","December 15, 2020","February 15, 2022"
6236,NCT03359473,Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD),Cachexia,Drug: GSK2881078|Drug: Matching Placebo,GlaxoSmithKline|Parexel,Phase 2,97,Industry,"February 28, 2018","November 19, 2019","November 19, 2019"
6237,NCT03359460,Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome,Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Refractory High Risk Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Therapy-Related Myelodysplastic Syndrome,Drug: Ibrutinib|Drug: Lenalidomide,"Brian Jonas|Pharmacyclics LLC.|Celgene|National Cancer Institute (NCI)|University of California, Davis",Phase 1,4,Other|Industry|NIH,"December 1, 2017","August 29, 2019","November 17, 2019"
6238,NCT03359395,Pre-medication With Alfentanil vs Placebo During ECT,Blood Pressure|Electroconvulsive Therapy,Drug: Alfentanil|Drug: Placebos,Wake Forest University Health Sciences,Phase 4,100,Other,"June 4, 2018","February 17, 2020","February 17, 2020"
6239,NCT03359356,Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD),Alopecia Areata,Drug: Dupilumab|Drug: Placebo,Icahn School of Medicine at Mount Sinai|Rockefeller University|Regeneron Pharmaceuticals|Sanofi,Phase 2,60,Other|Industry,"January 9, 2018","January 14, 2020","December 17, 2020"
6240,NCT03359213,A Study of JR-141 in Patients With Mucopolysaccharidosis II,Mucopolysaccharidosis II,Drug: JR-141,"JCR Pharmaceuticals Co., Ltd.",Phase 2,18,Industry,"July 26, 2018","October 4, 2019","October 4, 2019"
6241,NCT03359018,Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma,Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity,Drug: Apatinib|Drug: SHR-1210,"Peking University People's Hospital|Jiangsu HengRui Medicine Co., Ltd.",Phase 2,43,Other|Industry,"January 1, 2018","October 22, 2019","January 30, 2020"
6242,NCT03358719,"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",Acute Myeloid Leukemia|Blasts 30 Percent or Less of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia|High Risk Myelodysplastic Syndrome|Myelodysplastic Syndrome|Refractory Anemia,Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Drug: Decitabine|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Poly ICLC,Roswell Park Cancer Institute|Celldex Therapeutics,Phase 1,8,Other|Industry,"March 27, 2018","February 27, 2020","August 25, 2021"
6243,NCT03358576,Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI),Intra Abdominal Infections,Drug: Ertapenem|Drug: Sulopenem-Etzadroxil/Probenecid|Drug: Ciprofloxacin|Drug: Metronidazole|Drug: Amoxicillin-Clavulanate|Drug: Sulopenem,"Iterum Therapeutics, International Limited",Phase 3,674,Industry,"September 18, 2018","October 2, 2019","October 2, 2019"
6244,NCT03358030,A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis,End-stage Renal Disease (ESRD),Drug: ISIS 416858|Drug: Placebo,"Ionis Pharmaceuticals, Inc.|Bayer",Phase 2,213,Industry,"December 26, 2017","July 10, 2019","July 10, 2019"
6245,NCT03357731,A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function,Heart Failure|Cardiac Failure|Reduced Ventricular Ejection Fraction,Drug: HNO Donor|Drug: Nitroglycerin (NTG)|Other: Placebo,Bristol-Myers Squibb,Phase 2,49,Industry,"November 30, 2017","May 10, 2019","May 10, 2019"
6246,NCT03357614,Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults,Complicated Urinary Tract Infections,Drug: Sulopenem|Drug: Sulopenem-Etzadroxil/Probenecid|Drug: Ertapenem|Drug: Ciprofloxacin|Drug: Amoxicillin-clavulanate,"Iterum Therapeutics, International Limited",Phase 3,1395,Industry,"September 18, 2018","December 14, 2019","December 14, 2019"
6247,NCT03357380,A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver,Hepatobiliary Disorders|Non-alcoholic Fatty Liver Disease,Drug: Semaglutide|Drug: Placebo,Novo Nordisk A/S,Phase 1,67,Industry,"November 28, 2017","March 20, 2020","March 20, 2020"
6248,NCT03356561,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers",Healthy,Biological: Ad26.ZIKV.001 5*10^10 vp|Biological: Ad26.ZIKV.001 1*10^11 vp|Biological: Placebo,Janssen Vaccines & Prevention B.V.,Phase 1,100,Industry,"November 26, 2017","September 23, 2019","September 23, 2019"
6249,NCT03356145,12 Versus 20 mL PCB for D&E Cervical Prep,Pain,Drug: 12 mL paracervical block|Drug: 20 mL paracervical block,Stanford University,Phase 4,96,Other,"January 1, 2017","October 15, 2020","October 15, 2020"
6250,NCT03355794,A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),Diffuse Intrinsic Pontine Glioma|Malignant Glioma of Brain|High Grade Glioma|Bithalamic High Grade Glioma|Brainstem Glioma|Glioblastoma|Anaplastic Astrocytoma,Drug: ribociclib|Drug: Everolimus,"Children's Hospital Medical Center, Cincinnati|Novartis",Phase 1,19,Other|Industry,"November 14, 2017","July 31, 2020","July 31, 2022"
6251,NCT03355664,Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam,"Malaria, Falciparum",Drug: ACT|Drug: TACT,University of Oxford,Phase 3,310,Other,"March 19, 2018","March 4, 2020","March 4, 2020"
6252,NCT03354884,caBozantinib in cOllectiNg ductS Renal Cell cArcInoma,Collecting Duct Carcinoma (Kidney),Drug: cabozantinib,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,23,Other,"January 12, 2018","November 19, 2020","November 19, 2020"
6253,NCT03354598,Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women,Uncomplicated Urinary Tract Infections,Drug: Sulopenem-Etzadroxil/Probenecid|Drug: Ciprofloxacin,"Iterum Therapeutics, International Limited",Phase 3,1671,Industry,"August 1, 2018","January 16, 2020","January 20, 2020"
6254,NCT03354429,THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death,Acute Ischaemic Stroke|Transient Ischaemic Attack,Drug: Ticagrelor|Drug: Placebo,AstraZeneca,Phase 3,11016,Industry,"January 22, 2018","December 13, 2019","December 13, 2019"
6255,NCT03354117,On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility,Contraception,Drug: Ulipristal Acetate 30 MG Oral Tablet,Stanford University,Phase 1,12,Other,"March 15, 2018","May 31, 2019","May 31, 2019"
6256,NCT03353753,Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies,Gastrointestinal Stromal Tumors,Drug: DCC-2618|Drug: Placebo Oral Tablet,Deciphera Pharmaceuticals LLC,Phase 3,129,Industry,"February 27, 2018","May 31, 2019","May 11, 2022"
6257,NCT03353740,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"Thomas Hope|University of California, San Francisco",Phase 3,346,Other,"September 20, 2017","September 1, 2020","September 1, 2020"
6258,NCT03353675,A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer Metastatic,Biological: TG4010|Drug: Chemotherapy|Drug: Nivolumab,Transgene|Bristol-Myers Squibb,Phase 2,44,Industry,"January 5, 2018","November 20, 2019","February 17, 2021"
6259,NCT03353506,Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection,Enterocolitis|Recurrent Clostridium Difficile Infection,Biological: LFMT|Biological: LSFF,Dina Kao|University of Alberta,Phase 2,11,Other,"February 14, 2018","June 5, 2019","October 10, 2019"
6260,NCT03353350,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise,Type 2 Diabetes Mellitus,Drug: efpeglenatide (SAR439977)|Drug: placebo,Hanmi Pharmaceutical Company Limited|Sanofi,Phase 3,406,Industry,"December 5, 2017","January 29, 2020","September 7, 2020"
6261,NCT03353298,Lowering Uric Acid in Live Kidney Donors,Renal Transplant Donor of Left Kidney|Renal Transplant Donor of Right Kidney,Drug: Allopurinol 300 mg|Drug: Placebo Oral Tablet,Oslo University Hospital|South-Eastern Norway Regional Health Authority|University of Oslo,Phase 2,71,Other,"January 17, 2018","September 25, 2020","September 25, 2020"
6262,NCT03353233,Evaluation of Utility of Ultrasound Guided iPACK Block for Knee Extension After Total Knee Arthroplasty.,Knee Osteoarthritis|Primary Total Knee Arthroplasty|Physical Therapy|Pain|Knee Extension,Drug: Ropivacaine|Procedure: Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|Drug: Saline,Duke University,Phase 4,50,Other,"May 3, 2018","January 22, 2021","January 23, 2021"
6263,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,Melanoma,Drug: Dabrafenib|Drug: Trametinib,"Cambridge University Hospitals NHS Foundation Trust|National Institute for Health Research, United Kingdom|Oxford University Hospitals NHS Trust|University of Oxford",Phase 2,79,Other,"November 3, 2017","March 31, 2020","November 27, 2020"
6264,NCT03352843,Single Low-dose Primaquine Efficacy and Safety.,Malaria,Drug: Primaquine,"Tropical Pesticides Research Institute, Tanzania|European and Developing Countries Clinical Trials Partnership (EDCTP)",Phase 4,157,Other,"June 11, 2019","February 28, 2020","February 28, 2020"
6265,NCT03352076,"Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy",Endometriosis,Drug: Vaginal Danazol|Drug: Oral Danatrol,Viramal Limited,Phase 2,30,Industry,"December 28, 2017","October 24, 2019","May 26, 2020"
6266,NCT03351608,"Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)",Neuromuscular Blockade,Drug: Sugammadex 2 mg/kg|Drug: Sugammadex 4 mg/kg|Drug: Neostigmine + Glycopyrrolate|Drug: Neostigmine + Atropine,Merck Sharp & Dohme LLC,Phase 4,288,Industry,"February 12, 2018","January 28, 2020","January 28, 2020"
6267,NCT03351478,Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin,Type 2 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Empagliflozin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,Phase 3,770,Industry,"November 27, 2017","May 16, 2019","May 16, 2019"
6268,NCT03351322,ENERGI-F701 for Female Hair Loss Treatment,Female Pattern Baldness|Hair Loss|Alopecia,Drug: ENERGI-F701|Drug: Regaine,"Energenesis Biomedical Co., Ltd.|A2 Healthcare Taiwan Corporation",Phase 2,67,Industry,"May 23, 2018","November 29, 2019","December 26, 2019"
6269,NCT03351114,Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea,Morphea,Drug: Crisaborole,Duke University|Pfizer,Phase 2,8,Other|Industry,"September 1, 2018","March 10, 2020","March 10, 2020"
6270,NCT03350815,Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis,Ankylosing Spondylitis,Drug: 150 mg open-label secukinumab|Drug: 150 mg double-blinded secukinumab|Drug: 300 mg double-blinded secukinumab,Novartis Pharmaceuticals|Novartis,Phase 4,322,Industry,"March 13, 2018","March 11, 2021","May 29, 2021"
6271,NCT03350542,A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s),Coronary Artery Disease,Device: SYNERGY 48 mm,Boston Scientific Corporation,Phase 3,100,Industry,"April 12, 2018","January 16, 2020","January 8, 2021"
6272,NCT03350347,A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects,"Anemia|Renal Insufficiency, Chronic",Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa,Bayer,Phase 3,164,Industry,"December 13, 2017","July 5, 2019","November 28, 2019"
6273,NCT03350321,A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects,"Anemia|Renal Insufficiency, Chronic",Drug: Molidustat (BAY85-3934)|Drug: Darbepoetin alfa,Bayer,Phase 3,162,Industry,"December 12, 2017","May 17, 2019","October 11, 2019"
6274,NCT03350035,Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus,Status Epilepticus|Convulsive Status EPILEPTICUS|Non Convulsive Status Epilepticus|Epilepsy,"Drug: IV Ganaxolone active|Drug: IV Placebo, non-active",Marinus Pharmaceuticals,Phase 2,17,Industry,"February 19, 2018","September 18, 2019","September 18, 2019"
6275,NCT03349983,Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury),Safety Issues,Biological: MVA-BN-Brachyury/ FPV-Brachyury,Bavarian Nordic,Phase 1,11,Industry,"January 8, 2018","June 13, 2020","June 13, 2020"
6276,NCT03349710,"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer",Squamous Cell Carcinoma of the Head and Neck,Biological: Nivolumab|Drug: Cetuximab|Drug: Cisplatin|Radiation: Radiotherapy,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 3,74,Industry,"December 15, 2017","October 14, 2019","October 14, 2019"
6277,NCT03349684,Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients,"Diabetes Mellitus, Type 2",Drug: Acarbose|Drug: Metformin|Drug: Placebo,Bayer,Phase 3,287,Industry,"March 5, 2018","August 12, 2019","August 21, 2019"
6278,NCT03349502,MG4101 for Refractory or Relapsed AML,Acute Myeloid Leukemia,Drug: MG4101,Seoul National University Hospital,Phase 2,11,Other,"November 1, 2017","March 30, 2020","April 30, 2020"
6279,NCT03349424,Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy,Pancreatic Fistula,Drug: Somatostatin,Peking Union Medical College Hospital,Phase 4,205,Other,"June 22, 2018","May 24, 2019","May 24, 2019"
6280,NCT03349073,An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors,Advanced Refractory Solid Tumors,Drug: T-1101 (Tosylate),Taivex Therapeutics Corporation,Phase 1,3,Industry,"September 14, 2017","June 24, 2019","June 24, 2019"
6281,NCT03349034,Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps,Head and Neck Cancer|Free Tissue Transfer,Drug: Ropivicaine|Drug: Local Saline Infusion,Icahn School of Medicine at Mount Sinai,Phase 2,24,Other,"September 13, 2017","September 30, 2019","September 30, 2019"
6282,NCT03348527,"A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer",Prostate Cancer,Drug: 2-Hydroxyflutamide Depot,Lidds AB|CMX Research,Phase 2,61,Industry|Other,"May 12, 2017","October 30, 2020","November 30, 2020"
6283,NCT03348514,"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",Advanced Solid Tumors,Drug: CPX-POM - 30 mg/m^2|Drug: CPX-POM - 60 mg/m^2|Drug: CPX-POM - 120 mg/m^2|Drug: CPX-POM - 240 mg/m^2|Drug: CPX-POM - 360 mg/m^2|Drug: CPX-POM - 600 mg/m^2|Drug: CPX-POM - 900 mg/m^2|Drug: CPX-POM - 1200 mg/m^2,CicloMed LLC|Cmed Clinical Services,Phase 1,19,Industry|Other,"January 15, 2018","May 31, 2020","May 31, 2020"
6284,NCT03348462,Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis,Psoriasis Vulgaris,Drug: ethosomal preparation of anthralin|Drug: liposomal preparation of anthralin,Assiut University,Phase 4,20,Other,"November 30, 2017","December 30, 2019","January 15, 2020"
6285,NCT03347890,Reward Mechanisms in Obesity,Obesity,Drug: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo,"Zoltan Pataky|University of Geneva, Switzerland|University Hospital, Geneva",Phase 4,70,Other,"March 5, 2018","March 18, 2020","March 30, 2020"
6286,NCT03347643,The Effectiveness of tDCS on Internet Game Addiction,Addiction|Internet Gaming Disorder,Device: tDCS with real stimulation|Device: tDCS with sham stimulation,Seoul National University Hospital|National Research Foundation of Korea|SMG-SNU Boramae Medical Center,Phase 2,31,Other,"September 22, 2017","September 1, 2019","October 8, 2019"
6287,NCT03347344,Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL),Spinocerebellar Ataxia Type 2,Drug: Riluzole|Drug: Placebo,Assistance Publique - Hôpitaux de Paris,Phase 3,42,Other,"January 17, 2018","December 14, 2020","December 14, 2020"
6288,NCT03347292,Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC,"Carcinoma, Hepatocellular","Drug: Regorafenib(Stivarga, BAY73-4506)|Drug: Pembrolizumab",Bayer|Merck Sharp & Dohme LLC,Phase 1,58,Industry,"June 18, 2018","December 17, 2020","September 6, 2022"
6289,NCT03347279,Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma,Asthma,Biological: Experimental: Tezepelumab|Other: Placebo,AstraZeneca|Amgen,Phase 3,1061,Industry,"November 23, 2017","September 8, 2020","November 12, 2020"
6290,NCT03347188,A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH),Post-Traumatic Headache,Drug: Fremanezumab|Drug: Placebo,"Teva Branded Pharmaceutical Products R&D, Inc.",Phase 2,87,Industry,"December 18, 2017","March 13, 2020","June 3, 2020"
6291,NCT03347110,A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis,Psoriatic Arthritis,Drug: Bimekizumab,UCB Biopharma SRL|UCB Pharma,Phase 2,184,Industry,"November 22, 2017","October 29, 2020","October 29, 2020"
6292,NCT03346200,Karma Intervention Study,Risk Reduction|Mammographic Density Reduction,Drug: Tamoxifen Oral Tablet|Drug: Placebo Oral Tablet,Per Hall|Karolinska Institutet,Phase 2,1440,Other,Nov-16,Oct-19,Dec-19
6293,NCT03346083,Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients,VTE Prophylaxis,Drug: Betrixaban,Portola Pharmaceuticals,Phase 1,21,Industry,"July 18, 2018","October 8, 2019","October 8, 2019"
6294,NCT03346057,Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145),Reversal of Neuromuscular Blockade,Drug: Sugammadex 2 mg/kg|Drug: Sugammadex 4 mg/kg|Drug: Sugammadex 16 mg/kg|Drug: Neostigmine + Glycopyrrolate|Drug: Rocuronium|Drug: Vecuronium,Merck Sharp & Dohme LLC,Phase 4,344,Industry,"December 20, 2017","September 4, 2019","September 4, 2019"
6295,NCT03345992,Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System,Sepsis|Pneumonia|Gram-Negative Bacteria Infection|Multiple Organ Failure|Respiratory Distress Syndrome|Mortality|Biomarkers,Drug: Clarithromycin|Drug: Water for injection,Hellenic Institute for the Study of Sepsis|European Commission,Phase 3,110,Other,"December 15, 2017","September 22, 2019","December 19, 2020"
6296,NCT03345914,Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD),"Dermatitis, Atopic",Drug: Dupilumab|Drug: Matching Placebo|Other: Background Treatment: Topical Corticosteroids|Other: Background Treatment: Moisturizers,Regeneron Pharmaceuticals|Sanofi,Phase 3,367,Industry,"November 17, 2017","June 20, 2019","September 10, 2019"
6297,NCT03345771,Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty,Osteoarthritis,Combination Product: Antimicrobial Barrier Dressing|Device: Negative Pressure Wound Therapy (NPWT),NYU Langone Health,Phase 3,230,Other,"November 13, 2017","April 1, 2021","June 1, 2021"
6298,NCT03345342,A Study of Paliperidone Palmitate 6-Month Formulation,Schizophrenia,Drug: PP6M|Drug: PP3M 350 mg eq.|Drug: PP3M 525 mg eq.|Drug: PP1M|Other: Placebo,"Janssen Research & Development, LLC",Phase 3,841,Industry,"November 20, 2017","May 8, 2020","May 8, 2020"
6299,NCT03345316,Study of FFI-1010 in Pediatric Kidney Disease,Children Under 18 Years Old With Kidney Disease,Drug: FFI-1010,"Fuji Yakuhin Co., Ltd.",Phase 3,60,Industry,"November 1, 2017","November 1, 2019","November 1, 2019"
6300,NCT03345160,Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study,Treatment Efficacy,Drug: Peanut Flour,Johns Hopkins University,Phase 2,7,Other,"April 27, 2018","October 7, 2020","October 7, 2020"
6301,NCT03345082,A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD,Neovascular Age-related Macular Degeneration,Biological: OPT-302|Biological: ranibizumab|Other: sham intravitreal injection,Opthea Limited,Phase 2,366,Industry,"November 6, 2017","May 14, 2019","May 14, 2019"
6302,NCT03345004,Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes,"Diabetes Mellitus, Type 1|Diabetes Mellitus|Autoimmune Diseases|Metabolic Disease|Glucose Metabolism Disorders|Immune System Diseases|Endocrine System Diseases|Juvenile Diabetes|Insulin Dependent Diabetes|Autoimmune Diabetes|Vitamin D|Physiological Effects of Drugs",Biological: Diamyd|Dietary Supplement: Vitamin D|Biological: Placebo for Diamyd|Dietary Supplement: Placebo for Vitamin D,Diamyd Medical AB,Phase 2,109,Industry,"December 20, 2017","July 13, 2020","April 27, 2021"
6303,NCT03344640,"Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy",Tendinopathy,Drug: secukinumab|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,96,Industry,"December 15, 2017","August 2, 2019","October 17, 2019"
6304,NCT03343704,This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding,Hemorrhage,Drug: Idarucizumab,Boehringer Ingelheim,Phase 3,19,Industry,"March 26, 2018","July 2, 2020","July 2, 2020"
6305,NCT03343509,Topical Versus Oral Metronidazole Following Excisional Haemorrhoidectomy,Hemorrhoids|Postoperative Pain,Drug: Metronidazole Oral|Drug: Metronidazole Ointment|Drug: Placebo Oral Tablet|Drug: Placebo Ointment,"University of Auckland, New Zealand",Phase 4,120,Other,"March 11, 2019","February 1, 2020","February 1, 2020"
6306,NCT03342911,"Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Laryngeal Squamous Cell Carcinoma|Stage IV Oral Cavity Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma,Drug: Paclitaxel|Drug: Carboplatin|Biological: Nivolumab,Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University,Phase 2,34,Other|Industry,"November 13, 2017","October 6, 2020","October 6, 2020"
6307,NCT03342833,Blood Flow Restriction Training in Chronic Heart Failure: an Effective Training Strategy?,Chronic Heart Failure,Device: Blood flow restriction,University of Leeds,Phase 2,25,Other,"March 10, 2018","January 1, 2021","April 1, 2021"
6308,NCT03342456,The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers,Duodenal Ulcer Due to Helicobacter Pylori,Drug: Doxycycline Hyclate Enteric-Coated Capsules|Drug: Amoxicillin Capsules|Drug: Ilaprazole Enteric-Coated Tablets|Drug: Furazolidone Tablets|Drug: Potassium Citrate Tablets,"The Third Xiangya Hospital of Central South University|Livzon Pharmaceutical Group Inc.|Yung Shin Pharm. Ind. Co., Ltd.",Phase 4,184,Other|Industry,"December 13, 2017","June 20, 2019","September 20, 2019"
6309,NCT03342404,A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia,Thalassemia,Drug: Luspatercept|Other: Placebo|Other: Best Supportive Care (BSC),"Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2,145,Industry,"February 1, 2018","September 14, 2020","November 28, 2022"
6310,NCT03342053,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)",Huntington's Disease,Drug: RO7234292 (RG6042),Hoffmann-La Roche,Phase 2,46,Industry,"January 2, 2018","October 8, 2019","October 8, 2019"
6311,NCT03342001,Hypothyroidism Treated With Calcitonin,Hypothyroidism,Drug: Calcitonin,"University of Maryland, Baltimore",Phase 4,11,Other,"June 18, 2018","June 30, 2019","August 14, 2019"
6312,NCT03341754,"Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults",Malaria,Biological: D/ChAd63-CA|Biological: D/ChAd63-CAT|Other: Infectivity Control (IC) Group,U.S. Army Medical Research and Development Command|University of Oxford|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID)|Naval Medical Research Center,Phase 1,52,U.S. Fed|Other,"September 15, 2018","October 28, 2019","March 23, 2020"
6313,NCT03341429,Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response,Obesity,Drug: Liraglutide Pen Injector [Saxenda]|Drug: Placebo,"University College, London",Phase 4,70,Other,"August 22, 2018","November 28, 2019","June 11, 2020"
6314,NCT03340922,MANual vs. automatIC Local Activation Time Annotation for Guiding Premature Ventricular Complex Ablation,Ventricular Premature Complexes|Catheter Ablation,Device: Automatic annotation of LAT (WF-method)|Device: Manual annotation of LAT (M-method),Centro Medico Teknon,Phase 4,100,Other,"June 26, 2018","May 31, 2020","August 31, 2020"
6315,NCT03340493,Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2),Ischemic Stroke,Drug: Tenecteplase,Neuroscience Trials Australia|The Florey Institute of Neuroscience and Mental Health,Phase 2,300,Other,"December 6, 2017","July 23, 2019","February 1, 2020"
6316,NCT03339661,Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.,Kidney Transplant Infection,Drug: Group 1_No proph treatment|Drug: Group 2A_Proph treatment and γδ T cell expansion|Drug: Group 2B_Proph treatment and no γδ T cell expansion,"University Hospital, Bordeaux",Phase 2,38,Other,"November 23, 2017","November 23, 2020","November 23, 2020"
6317,NCT03339349,Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma,Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolus,Drug: Enoxaparin,University of Utah,Phase 2,137,Other,"November 15, 2017","June 30, 2019","October 29, 2019"
6318,NCT03339297,An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD),Graft-versus-host Disease|Acute-graft-versus-host Disease,Drug: Defibrotide|Drug: Standard of Care,Jazz Pharmaceuticals,Phase 2,152,Industry,"February 21, 2018","May 12, 2020","May 12, 2020"
6319,NCT03339219,A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma,Advanced Renal Cell Carcinoma,Drug: Cabozantinib,Takeda,Phase 2,35,Industry,"December 13, 2017","August 25, 2020","August 25, 2020"
6320,NCT03338998,"Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).",Hemorrhagic Stroke|Intracerebral Hemorrhage (ICH),Drug: BAF312 solution|Drug: Matching Placebo for BAF312 solution|Drug: BAF312 tablet|Drug: Matching Placebo for BAF312 tablet,Novartis Pharmaceuticals|Novartis,Phase 2,32,Industry,"December 24, 2017","May 13, 2020","May 13, 2020"
6321,NCT03338855,Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.,"Diabetes Mellitus, Type 2|Skeletal Muscle Insulin Sensitivity",Drug: Dapagliflozin,AstraZeneca,Phase 4,26,Industry,"March 5, 2018","November 4, 2019","November 4, 2019"
6322,NCT03338348,Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2,Acute Myeloid Leukemia|Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2),Drug: Vosaroxin|Drug: Azacitidine,University of Ulm|Sunesis Pharmaceuticals,Phase 2,9,Other|Industry,"April 19, 2018","October 31, 2019","October 31, 2019"
6323,NCT03338244,Mortality Reduction After Oral Azithromycin Contingency: Mortality Study,Childhood Mortality,Drug: Azithromycin|Drug: Placebo,"University of California, San Francisco|The Carter Center|Bill and Melinda Gates Foundation",Phase 4,66228,Other,"October 20, 2017","July 31, 2020","July 31, 2020"
6324,NCT03338023,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus,Type 1 Diabetes,Drug: LY2963016|Drug: Lantus®|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,272,Industry,"March 23, 2018","March 5, 2020","March 5, 2020"
6325,NCT03338010,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus,Type 2 Diabetes,Drug: LY2963016|Drug: Lantus®,Eli Lilly and Company,Phase 3,536,Industry,"March 22, 2018","March 18, 2020","March 18, 2020"
6326,NCT03337542,AR101 Real-World Open-Label Extension Study,Peanut Allergy,Biological: AR101,"Aimmune Therapeutics, Inc.",Phase 3,243,Industry,"October 18, 2017","September 20, 2019","September 20, 2019"
6327,NCT03337165,Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis,"Musculoskeletal Diseases|Joint Disease|Arthritis|Arthritis, Rheumatoid|Rheumatic Diseases|Connective Tissue Diseases|Autoimmune Diseases|Immune System Diseases",Biological: tolerogenic dendritic cells,Russian Academy of Medical Sciences,Phase 1,10,Other,Dec-16,May-19,Aug-19
6328,NCT03337113,Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers,Tobacco Use Disorder,Other: Working Memory Training|Other: Sham Working Memory Training|Device: repetitive Transcranial Magnetic Stimulation|Device: Sham repetitive Transcranial Magnetic Stimulation,Kent State University|Brown University|Butler Hospital,Phase 2,50,Other,"March 5, 2018","January 31, 2021","January 31, 2021"
6329,NCT03337035,Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children,Autism Spectrum Disorder,Drug: intranasal oxytocin|Dietary Supplement: oral probiotics|Dietary Supplement: oral placebo,Massachusetts General Hospital,Phase 1,35,Other,"December 1, 2018","October 2, 2019","October 2, 2019"
6330,NCT03336801,The Effect of Propofol or Sevoflurane on Renal Function,Acute Kidney Injury|Anesthesia,Procedure: Back Surgery|Drug: Propofol|Drug: Sevoflurane,Uppsala University|The Swedish Research Council,Phase 4,37,Other,"September 1, 2017","January 10, 2020","January 10, 2020"
6331,NCT03336645,Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan,Nervous System Diseases,Drug: SHP615,Shire|Takeda,Phase 3,25,Industry,"October 23, 2017","August 19, 2019","August 19, 2019"
6332,NCT03336528,Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes,Type 2 Diabetes,Drug: Degludec|Drug: Glargine|Drug: Aspart,Emory University|Novo Nordisk A/S,Phase 4,180,Other|Industry,"January 2, 2018","March 1, 2021","March 1, 2021"
6333,NCT03336450,Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting,Nervous System Diseases,Drug: SHP615|Drug: MHOS/SHP615,"Shire|Takeda Development Center Americas, Inc.|Takeda",Phase 3,3,Industry,"April 23, 2018","October 13, 2020","October 13, 2020"
6334,NCT03336437,Estrogen and the Urogenital Microbiome in GSM,Menopause,Drug: Estradiol vaginal ring|Other: Placebo vaginal ring,Oregon Health and Science University,Phase 4,40,Other,"February 1, 2018","August 23, 2019","August 23, 2019"
6335,NCT03335904,AT1R Blockade and Periodic Breathing During Sleep in Hypoxia,Sleep Disordered Breathing|Hypoxia|Respiration; Sleep Disorder|Chemoreceptor Apnea,Other: Hyperoxic Hypercapnic Ventilatory Response Test|Other: Hypoxic Hypercapnic Ventilatory Response Test|Other: Repeated Hypoxic Apneas|Other: Hypoxic Sleep Study|Drug: Losartan|Drug: Placebo,University of British Columbia,Phase 4,14,Other,"January 1, 2018","August 1, 2019","August 1, 2019"
6336,NCT03335774,Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids,Internal Hemorrhoids,"Drug: Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|Drug: Placebo (Vehicle) Suppository (Nivagen)",Nivagen Pharmaceuticals Inc.,Phase 2,103,Industry,"February 12, 2019","March 5, 2021","March 5, 2021"
6337,NCT03335540,An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment,Advanced Cancer,Biological: Nivolumab|Biological: Relatlimab|Biological: Cabiralizumab|Biological: Ipilimumab|Drug: IDO1 Inhibitor|Radiation: Radiation Therapy,Bristol-Myers Squibb,Phase 1,20,Industry,"May 7, 2018","March 31, 2021","August 25, 2021"
6338,NCT03335527,Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients,Aged|Postoperative Period|Intensive Care Units|Mechanical Ventilation Complication|Sleep Disorders|Dexmedetomidine,Drug: Dexmedetomidine|Drug: Placebo (normal saline),Peking University First Hospital,Phase 4,80,Other,"November 17, 2017","October 31, 2019","November 30, 2019"
6339,NCT03335423,Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions,Metformin|Organic Cation Transporter 1|Codeine,Drug: Oral metformin|Drug: Intravenous metformin|Drug: Oral codeine and oral metformin|Drug: Oral codeine and intravenous metformin,University of Southern Denmark,Phase 1,228,Other,"March 1, 2018","June 13, 2020","June 13, 2020"
6340,NCT03335163,The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users,Migraine|Migraine;Menstrual|Contraception,Drug: Topiramate,"University of Colorado, Denver|Merck Sharp & Dohme LLC",Phase 1,48,Other|Industry,"March 15, 2018","April 22, 2021","April 22, 2021"
6341,NCT03334838,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study,Chagas' Disease,"Drug: Nifurtimox (Lampit, BAYA2502)",Bayer,Phase 1,36,Industry,"June 10, 2019","November 7, 2019","January 29, 2020"
6342,NCT03334747,Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.,Malaria,Drug: KAE609|Drug: Coartem,Novartis Pharmaceuticals|Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z|Novartis,Phase 2,188,Industry|Other,"November 16, 2017","November 23, 2019","November 23, 2019"
6343,NCT03334721,Gabapentin for Bipolar & Cannabis Use Disorders,Bipolar I Disorder|Bipolar II Disorder|Cannabis Use Disorder|Substance Use Disorders,Drug: Gabapentin|Drug: Placebo Oral Capsule,Medical University of South Carolina|National Institute on Drug Abuse (NIDA),Phase 2,23,Other|NIH,"October 1, 2017","July 1, 2019","July 1, 2019"
6344,NCT03334058,"A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus",Pemphigus Vulgaris|Pemphigus Foliaceus,Drug: ARGX-113,argenx,Phase 2,34,Industry,"October 18, 2017","October 28, 2020","October 28, 2020"
6345,NCT03333928,A POC and Dose-Ranging Study of HTD1801 in PSC Patients,Primary Sclerosing Cholangitis (PSC),Drug: HTD1801|Drug: Placebo,HighTide Biopharma Pty Ltd,Phase 2,59,Industry,"February 9, 2018","April 30, 2020","August 14, 2020"
6346,NCT03333278,"The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial","Shock, Septic|Critically Ill|Vasoplegic Syndrome|Sepsis","Drug: Vitamin C|Drug: Thiamine|Drug: Hydrocortisone,","Australian and New Zealand Intensive Care Research Centre|Austin Hospital, Melbourne Australia|Melbourne Health|Barwon Health|Monash Health|The Alfred|Wellington Hospital|Western Health, Australia",Phase 2,216,Other,"May 2, 2018","July 16, 2019","October 6, 2019"
6347,NCT03333109,Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients,Episodic Migraine,Biological: Erenumab|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,900,Industry,"February 8, 2018","January 13, 2020","January 13, 2020"
6348,NCT03332771,Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy,Type 2 Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Glimepiride|Drug: Metformin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,Phase 3,954,Industry,"December 1, 2017","August 6, 2019","September 6, 2019"
6349,NCT03332459,A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection,Respiratory Syncytial Virus Infections,Drug: Lumicitabine|Drug: Placebo,"Janssen Research & Development, LLC",Phase 2,7,Industry,"January 5, 2018","April 13, 2020","April 13, 2020"
6350,NCT03332225,A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis,Sepsis|Macrophage Activation Syndrome,Drug: Anakinra|Drug: Recombinant human interferon-gamma|Drug: Placebo,Hellenic Institute for the Study of Sepsis,Phase 2,36,Other,"December 15, 2017","December 31, 2019","December 31, 2019"
6351,NCT03332212,A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin,Heart Failure,Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,72,Industry,"March 1, 2018","May 21, 2020","May 28, 2020"
6352,NCT03332173,Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM),Waldenström's Macroglobulinemia (WM),Drug: Zanubrutinib,BeiGene,Phase 2,44,Industry,"August 31, 2017","May 8, 2019","January 11, 2021"
6353,NCT03332121,B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma,CD20 Positive B Cell Non-Hodgkin's Lymphoma,Biological: B001,"Shanghai Pharmaceuticals Holding Co., Ltd",Phase 1,30,Industry,"March 22, 2018","November 30, 2020","February 28, 2021"
6354,NCT03331965,Metoclopramide Versus Placebo for GJ Placement,Radiation Exposure|Enteral Nutrition,Drug: Metoclopramide 5 MG/ML Injectable Solution|Drug: Saline,Duke University,Phase 2,110,Other,"April 9, 2018","October 3, 2019","October 3, 2019"
6355,NCT03331627,Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL,Acute Hearing Loss,Drug: STR001-IT and STR001-ER,Strekin AG,Phase 3,165,Industry,"February 24, 2018","February 6, 2020","February 6, 2020"
6356,NCT03331588,Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer,"Lung Neoplasms|Thoracic Surgery|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Carcinoma, Bronchogenic|Thoracic Neoplasm",Procedure: Subxiphoid uniportal VATS|Procedure: Intercostal uniportal VATS,"Shanghai Pulmonary Hospital, Shanghai, China",Phase 3,200,Other,"November 10, 2017","February 28, 2020","February 28, 2020"
6357,NCT03331562,A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer,Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma,Drug: Pembrolizumab|Drug: paricalcitol|Drug: placebo,Translational Genomics Research Institute|Stand Up To Cancer|Merck Sharp & Dohme LLC,Phase 2,24,Other|Industry,"December 27, 2017","June 29, 2020","July 10, 2020"
6358,NCT03330899,Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil,Influenza|H7N9 Influenza,Biological: H7N9 antigen + adjuvant IB160|Biological: H7N9 antigen + adjuvant SE|Biological: H7N9 antigen without adjuvant|Biological: Placebo (PBS),Butantan Institute,Phase 1,432,Other,"September 24, 2018","January 30, 2020","August 25, 2020"
6359,NCT03329937,Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,"Neoplasms, Breast",Drug: Niraparib,"Tesaro, Inc.",Phase 1,21,Industry,"April 12, 2018","January 2, 2020","March 31, 2020"
6360,NCT03329911,A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer,Non-squamous Non-small Cell Lung Cancer,Drug: EU Avastin®|Drug: BAT1706|Drug: Paclitaxel|Drug: carboplatin,Bio-Thera Solutions,Phase 3,651,Industry,"October 20, 2017","November 5, 2019","May 27, 2021"
6361,NCT03329846,"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma",Melanoma|Skin Cancer,Drug: BMS-986205|Biological: Nivolumab|Drug: Placebo,Bristol-Myers Squibb,Phase 3,20,Industry,"November 30, 2017","July 2, 2020","July 2, 2020"
6362,NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],"Neoplasm, Gastrointestinal",Drug: DS-8201a|Drug: Physician's Choice,"Daiichi Sankyo Co., Ltd.|AstraZeneca|Daiichi Sankyo, Inc.",Phase 2,233,Industry,"November 2, 2017","November 8, 2019","December 11, 2020"
6363,NCT03329638,A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE),Myopia,Drug: DE-127 Ophthalmic Solution low dose|Drug: DE-127 Ophthalmic Solution medium dose|Drug: DE-127 Ophthalmic Solution high dose|Drug: Placebo Ophthalmic Solution,"Santen Pharmaceutical Co., Ltd.",Phase 2,99,Industry,"October 27, 2017","September 12, 2019","April 9, 2020"
6364,NCT03329560,Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV,HIV-1-infection,Biological: Oral fecal microbiota transplantation,"The University of Texas Health Science Center, Houston",Phase 1,6,Other,"April 12, 2018","October 8, 2019","October 8, 2019"
6365,NCT03328897,Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria,Chronic Spontaneous Urticaria,Drug: Omalizumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,418,Industry,"April 26, 2017","July 23, 2019","September 24, 2019"
6366,NCT03328845,Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study),Type 1 Diabetes Mellitus,Drug: Toujeo SoloStar|Drug: Tresiba|Drug: Humalog Kwikpen|Drug: NovoRapid|Drug: Apidra,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,Phase 4,300,Other,"January 20, 2017","November 30, 2020","November 20, 2021"
6367,NCT03328676,The Effect of Cannabis on Dementia Related Agitation and Aggression,Agitation Related to Dementia,Drug: Cannabis|Drug: Placebo oil,TO Pharmaceuticals,Phase 2,64,Industry,"December 7, 2017","August 18, 2019","August 18, 2019"
6368,NCT03328507,A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects,Colonoscopy,Drug: BLI4900|Drug: PEG Control,Braintree Laboratories,Phase 2,143,Industry,"November 9, 2017","November 12, 2019","November 12, 2019"
6369,NCT03328494,Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies,Advanced Nonhaematologic Malignancies,Drug: BOS172722|Drug: Paclitaxel,Boston Pharmaceuticals,Phase 1,38,Industry,"October 13, 2017","March 16, 2021","March 16, 2021"
6370,NCT03328325,Age and Response to Flu Vaccines,Influenza|Influenza Immunisation,Biological: Influenza Virus Quadrivalent Inactivated Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,152,NIH,"December 14, 2017","February 9, 2020","April 20, 2020"
6371,NCT03326752,Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC,Advanced Non Small Cell Lung Cancer,Drug: DV281|Device: Breath Actuated Nebulizer|Drug: DV281 (RP2D)|Drug: Approved Anti-PD-1 Inhibitor,Dynavax Technologies Corporation,Phase 1,26,Industry,"September 20, 2017","September 19, 2019","September 19, 2019"
6372,NCT03326583,The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia,ESRD|Hyperkalemia|End Stage Renal Disease,Drug: Patiromer,Dominic Raj|George Washington University,Phase 2,27,Other,"November 1, 2017","December 31, 2020","December 31, 2020"
6373,NCT03326180,Study of Peri-Articular Anaesthetic for Replacement of the Knee,Knee Osteoarthritis,Drug: Liposomal bupivacaine|Drug: Bupivacaine hydrochloride,University of Leeds|University of Oxford,Phase 3,533,Other,"March 29, 2018","February 28, 2021","April 21, 2021"
6374,NCT03325556,Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis,Dementia-related Psychosis,Drug: Placebo|Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg,ACADIA Pharmaceuticals Inc.,Phase 3,392,Industry,"September 27, 2017","July 31, 2019","October 30, 2019"
6375,NCT03325075,"Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects",Chikungunya Virus,Biological: VAL-181388|Other: Placebo,"ModernaTX, Inc.|Defense Advanced Research Projects Agency",Phase 1,60,Industry|U.S. Fed,"August 15, 2017","November 1, 2019","November 1, 2019"
6376,NCT03324776,Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients,Type2 Diabetes,Drug: Afrezza Inhalant Product,Model Clinical Research LLC|Mannkind Corporation,Phase 3,28,Other|Industry,"October 16, 2017","June 10, 2020","June 10, 2020"
6377,NCT03323801,RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia,"Male Infertility, Azoospermia",Drug: 13-cis retinoic acid,University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2,10,Other|NIH,"July 25, 2017","May 16, 2019","May 31, 2019"
6378,NCT03322657,Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular,Neuromuscular Blockade|Anesthesia,Drug: Neostigmine|Drug: Glycopyrrolate|Drug: Sugammadex,The Cleveland Clinic,Phase 4,69,Other,"November 14, 2017","December 31, 2020","February 1, 2021"
6379,NCT03321955,Ziconotide as First-Line IDT,Neuropathic Pain,"Drug: Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Diagnostic Test: Quantitative sensory testing|Diagnostic Test: Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor",Albany Medical College,Phase 4,13,Other,"November 3, 2016","August 30, 2020","December 30, 2020"
6380,NCT03321929,Intraoperative Detection of Residual Cancer in Breast Cancer,Breast Cancer,Combination Product: LUM Imaging System,"Lumicell, Inc.|National Cancer Institute (NCI)",Phase 2,234,Industry|NIH,"February 6, 2018","April 10, 2020","April 10, 2020"
6381,NCT03321617,Glutamate Reducing Interventions in Schizophrenia,Clinical High Risk for Psychosis,Drug: Pomaglumetad methionil,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),Phase 1,16,Other|NIH,"April 17, 2018","March 13, 2020","March 13, 2020"
6382,NCT03321526,"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","Depressive Disorder, Major",Drug: JNJ-42847922|Drug: Placebo Matching to JNJ-42847922|Drug: Quetiapine XR|Drug: Placebo Matching to Quetiapine XR|Drug: Selective Serotonin Reuptake Inhibitor (SSRI)|Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI),"Janssen Research & Development, LLC",Phase 2,107,Industry,"December 12, 2017","June 13, 2019","June 27, 2019"
6383,NCT03321071,Healthy Summer Learners,Overweight and Obesity|Academic Acheivement,Behavioral: Healthy Summer Learners|Behavioral: 21st Century Summer Learning Center,University of South Carolina,Phase 1,180,Other,"May 1, 2018","May 1, 2020","May 1, 2021"
6384,NCT03320850,BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence,Urinary Incontinence|Overactive Bladder With Urinary Incontinence,Drug: OnabotulinumtoxinA and Hydrogel admixture|Drug: Placebo and Hydrogel admixture,Allergan,Phase 2,383,Industry,"October 4, 2017","July 21, 2020","July 21, 2020"
6385,NCT03320707,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants",Healthy,Drug: Daratumumab|Drug: Placebo|Drug: rHuPH20,"Janssen Research & Development, LLC",Phase 1,66,Industry,"October 16, 2017","August 27, 2019","August 27, 2019"
6386,NCT03320486,Non-inferiority Trial of Dapaconazole Versus Ketoconazole,Tinea Pedis,Drug: Dapaconazole|Drug: Ketoconazole,Biolab Sanus Farmaceutica,Phase 3,360,Industry,"November 1, 2017","August 27, 2019","November 12, 2019"
6387,NCT03320057,Medication Abortion Via Pharmacy Dispensing,Pregnancy Related|Abortion Early,Drug: Mifepristone|Other: Training on mifepristone dispensing,"Daniel Grossman|University of California, San Diego|University of California, Davis|University of Washington|Kaiser Permanente|Planned Parenthood of the Great Northwest and the Hawaiian Islands|University of California, San Francisco",Phase 4,326,Other,"June 1, 2018","July 4, 2020","July 4, 2020"
6388,NCT03319953,"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia",Stable Schizophrenia,Drug: TAK-041|Drug: Placebo|Drug: Second Generation Antipsychotics (SGA),Neurocrine Biosciences|Takeda,Phase 2,23,Industry,"December 21, 2017","September 11, 2019","November 6, 2019"
6389,NCT03319732,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,"Multiple Sclerosis|Spasticity, Muscle",Drug: Arbaclofen,"RVL Pharmaceuticals, Inc.|Osmotica Pharmaceutical US LLC",Phase 3,323,Industry,"April 3, 2018","January 27, 2020","June 11, 2020"
6390,NCT03319459,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma,Drug: FATE-NK100|Drug: Cetuximab|Drug: Trastuzumab,Fate Therapeutics,Phase 1,44,Industry,"January 18, 2018","May 29, 2020","December 15, 2020"
6391,NCT03319420,Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome,Dry Eye Due to Sjögren's Syndrome,Drug: LO2A eye drops|Drug: Systane Ultra UD,Ocuwize LTD,Phase 4,60,Industry,"March 29, 2018","January 1, 2021","January 1, 2021"
6392,NCT03318874,Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction,Dry Eye Syndromes|Meibomian Gland Dysfunction,Device: Blephasteam|Device: THERA°PEARL Eye Mask|Drug: Hylo-comod,Oslo University Hospital|Schepens Eye Research Institute|The Norwegian Dry Eye Clinic,Phase 4,70,Other,"October 19, 2017","April 15, 2020","November 17, 2021"
6393,NCT03318445,Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair,"Solid Tumor, Unspecified, Adult",Drug: Rucaparib|Drug: Irinotecan,"Pamela Munster|Clovis Oncology, Inc.|University of California, San Francisco",Phase 1,22,Other|Industry,"January 12, 2018","March 1, 2021","March 1, 2021"
6394,NCT03318315,Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4,Avian Influenza|Influenza|Influenza Immunisation,Drug: AS03|Biological: Inactivated influenza H7N9 vaccine|Biological: Influenza Virus Quadrivalent Inactivated Vaccine|Other: Phosphate Buffered Saline (PBS) diluent,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,149,NIH,"February 20, 2018","July 25, 2019","July 25, 2019"
6395,NCT03318016,Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia,Acute Myeloid Leukemia|Relapsed/Refractory Acute Myeloid Leukemia,Drug: Cyclophosphamide,"University of Colorado, Denver",Phase 1,5,Other,"December 15, 2017","January 15, 2020","January 20, 2021"
6396,NCT03317795,Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids,Heavy Menstrual Bleeding|Menorrhagia|Uterine Fibroids,Drug: Levonorgestrel IUS|Drug: Tranexamic Acid,Shannon K. Laughlin-Tommaso|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Mayo Clinic,Phase 4,18,Other|NIH,"November 14, 2017","December 28, 2020","December 28, 2020"
6397,NCT03317743,Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: NOV140101 (IDX-1197),"Idience Co., Ltd.|IlDong Pharmaceutical Co Ltd|National OncoVenture",Phase 1,32,Industry|Other,"August 29, 2017","December 8, 2020","October 13, 2021"
6398,NCT03317613,Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain,Neuropathic Pain,Drug: Qutenza,Centre Hospitalier Universitaire de Saint Etienne|Institut de Cancérologie de la Loire,Phase 2,84,Other,"November 9, 2017","December 4, 2020","December 20, 2021"
6399,NCT03317093,Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device,Inflamed Meninges|Suspected Meningitis|Ventriculitis,Drug: Ceftobiprole Medocaril|Other: Blood samples and cerebrospinal fluid,Centre Hospitalier Universitaire Dijon,Phase 2,5,Other,"March 29, 2018","October 21, 2019","November 4, 2019"
6400,NCT03317028,CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM),T2DM With Inadequate Glycemic Control,Drug: CS02 tablet and placebo tablet,"Center Laboratories, Inc.",Phase 2,201,Industry,"October 10, 2017","April 21, 2020","April 21, 2020"
6401,NCT03317002,"AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).",Coronary Artery Disease,Drug: AZD5718|Drug: Placebo,AstraZeneca,Phase 2,129,Industry,"October 30, 2017","April 8, 2020","April 8, 2020"
6402,NCT03316599,"Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer",Pancreatic Cancer,Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: Ficlatuzumab,"Dana-Farber Cancer Institute|AVEO Pharmaceuticals, Inc.",Phase 1,26,Other|Industry,"January 17, 2018","October 10, 2020","July 29, 2021"
6403,NCT03316586,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,Breast Cancer,Drug: Nivolumab|Drug: Cabozantinib,Dana-Farber Cancer Institute|Bristol-Myers Squibb|Exelixis,Phase 2,18,Other|Industry,"November 30, 2017","August 30, 2019","August 30, 2019"
6404,NCT03316482,Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty,Central Precocious Puberty,Drug: Leuplin DPS 11.25mg,Jin Soon Hwang|Ajou University School of Medicine,Phase 4,58,Other,"June 11, 2015","August 29, 2019","December 30, 2019"
6405,NCT03316170,"Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors",Smoking Cessation|Social Stress,Behavioral: Social Support|Drug: NRT Sampling,Jessica Burris|Kentucky Lung Cancer Research Program|University of Kentucky,Phase 2,49,Other,"November 6, 2017","March 31, 2020","March 31, 2020"
6406,NCT03315793,A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder,Depressive Disorder,Drug: Duloxetine Hydrochloride|Drug: Placebo,Shionogi|Eli Lilly and Company|Shionogi Inc.,Phase 3,149,Industry,"December 4, 2017","November 8, 2019","November 8, 2019"
6407,NCT03315689,Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT),Alopecia Universalis (AU)|Alopecia Totalis (AT),Drug: Vehicle|Drug: ATI-50002,"Aclaris Therapeutics, Inc.",Phase 2,11,Industry,"December 14, 2017","June 20, 2019","June 20, 2019"
6408,NCT03315507,"A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH",Pulmonary Arterial Hypertension,Drug: PB1046 Subcutaneous Injection,PhaseBio Pharmaceuticals Inc.,Phase 1,3,Industry,"October 20, 2017","August 8, 2019","August 8, 2019"
6409,NCT03315104,Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A,Influenza A H3N2|Influenza A H1N1,Biological: FLU-IGIV|Other: Placebo for FLU-IGIV,Emergent BioSolutions,Phase 2,65,Industry,"November 17, 2017","June 17, 2019","June 17, 2019"
6410,NCT03313557,AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies,Solid Tumors,Drug: Wee-1 kinase inhibitor AZD1775,"AstraZeneca|Quintiles, Inc.",Phase 1,48,Industry,"October 27, 2017","May 17, 2019","May 17, 2019"
6411,NCT03313050,A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age,Pneumococcal Infections,Biological: Multivalent|Biological: Tdap|Biological: polysaccharide,Pfizer,Phase 2,511,Industry,"October 12, 2017","May 24, 2019","May 24, 2019"
6412,NCT03312907,A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE,Systemic Lupus Erythematosus,Drug: Belimumab|Drug: Rituximab|Drug: Rituximab-placebo|Drug: Standard therapy (Including Immunosuppressants)|Drug: Standard therapy (Excluding Immunosuppressants)|Drug: Steroid Taper,GlaxoSmithKline,Phase 3,292,Industry,"March 1, 2018","May 29, 2020","July 7, 2021"
6413,NCT03312855,Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept,Stable Coronary Artery Disease,Drug: Revacept 80 mg|Drug: Revacept 160 mg|Drug: Placebo,Deutsches Herzzentrum Muenchen|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|AdvanceCor GmbH|Technical University of Munich|German Federal Ministry of Education and Research,Phase 2,334,Other|Industry,"November 20, 2017","February 29, 2020","March 26, 2020"
6414,NCT03312738,"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor",Advanced Breast Cancer,Drug: Everolimus|Drug: Exemestane|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,159,Industry,"September 15, 2017","May 19, 2020","April 25, 2022"
6415,NCT03312634,An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.,Fibrodysplasia Ossificans Progressiva,Drug: Palovarotene,Clementia Pharmaceuticals Inc.|Ipsen,Phase 3,107,Industry,"November 30, 2017","January 24, 2020","September 7, 2022"
6416,NCT03312335,Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus,"Lupus Erythematosus, Systemic",Drug: Low-dose Aldesleukin (Proleukin®),"Onur Boyman, MD|University of Zurich",Phase 2,16,Other,"August 8, 2018","December 23, 2019","December 23, 2019"
6417,NCT03312231,Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly,Avian Influenza|Influenza Immunisation,Drug: AS03|Biological: Inactivated influenza H7N9 vaccine|Other: Phosphate Buffered Saline (PBS) diluent,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,720,NIH,"February 14, 2018","September 26, 2019","September 26, 2019"
6418,NCT03312023,Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection,Hepatitis B,Drug: Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|Drug: Sofosbuvir 400 MG [Sovaldi]|Drug: Ledipasvir 90 MG,"University of Maryland, Baltimore|Gilead Sciences",Phase 2,21,Other|Industry,"February 1, 2018","August 10, 2020","June 30, 2021"
6419,NCT03311854,"A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)","Macrophage Activation Syndrome|Lymphohistiocytosis, Hemophagocytic|Arthritis, Juvenile|Adult Onset Still Disease",Drug: Emapalumab,Swedish Orphan Biovitrum,Phase 2,14,Industry,"February 20, 2018","May 19, 2020","May 19, 2020"
6420,NCT03311464,A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan,Pyoderma Gangrenosum,Drug: adalimumab,AbbVie,Phase 3,22,Industry,"October 27, 2017","August 20, 2019","April 21, 2020"
6421,NCT03310970,Pharmacokinetics of Lidocaine in Healthy Adults,Healthy,Drug: Lidocaine 5% patch|Drug: Lidocaine hydrochloride|Drug: Lidoderm 5% patch,Nicole K Brogden|Long Island University|University of Iowa,Phase 4,23,Other,"March 14, 2018","October 9, 2019","October 9, 2019"
6422,NCT03310021,"A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects",Bleeding,Biological: Andexanet alfa|Drug: Apixaban|Drug: Rivaroxaban|Drug: Edoxaban|Drug: Placebo,Portola Pharmaceuticals|Alexion,Phase 2,108,Industry,"August 28, 2017","August 13, 2019","August 13, 2019"
6423,NCT03309943,Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity,Cigarette Smoking,Drug: Propranolol|Drug: Placebo,Duke University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),Phase 4,44,Other|NIH,"January 16, 2018","July 15, 2019","July 15, 2019"
6424,NCT03309605,Phase 1 Study of ELX-02 in Healthy Adult Subjects,Genetic Disease|Nonsense Mutation,Drug: ELX-02|Drug: Placebo,"Eloxx Pharmaceuticals, Inc.|SGS Life Sciences, a division of SGS Belgium NV",Phase 1,62,Industry|Other,"October 11, 2017","June 17, 2019","July 17, 2019"
6425,NCT03309163,Effect of Tramadol in Prevention of Postpartum Depression,Caesarean Section,Drug: Tramadol|Drug: Hydromorphone|Drug: Ropivacaine (Epidural analgesia),Xinqiao Hospital of Chongqing,Phase 4,1230,Other,"October 9, 2017","June 13, 2019","August 13, 2019"
6426,NCT03309007,"A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes",PreDiabetes|Aging,Drug: Metformin|Drug: Placebo Oral Tablet,University of New Mexico,Phase 3,24,Other,"September 1, 2017","August 20, 2020","August 20, 2020"
6427,NCT03308942,Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants,Neoplasms,Drug: Niraparib|Biological: Pembrolizumab|Biological: TSR-042 (Dostarlimab),"Tesaro, Inc.",Phase 2,53,Industry,"September 29, 2017","May 4, 2020","August 31, 2021"
6428,NCT03308721,Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity,Metabolism and Nutrition Disorder|Obesity,Drug: NNC9204-1177 A 1.0 mg/mL|Drug: PLACEBO,Novo Nordisk A/S,Phase 1,99,Industry,"October 16, 2017","January 3, 2020","January 3, 2020"
6429,NCT03308565,Adipose Stem Cells for Traumatic Spinal Cord Injury,Spinal Cord Injuries|Paralysis,"Biological: Autologous, Adipose derived Mesenchymal Stem Cells",Mohamad Bydon|Mayo Clinic,Phase 1,10,Other,"December 5, 2017","October 22, 2019","October 11, 2021"
6430,NCT03308084,Use of Local Intraoperative Steroid in MIS TLIF,Dysphasia,Drug: Methylprednisolone|Drug: Dexamethasone,Rush University Medical Center,Phase 3,105,Other,"November 13, 2015","May 3, 2019","May 3, 2019"
6431,NCT03307629,Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer,Cancer,Drug: NOX66|Radiation: Irradiation Therapy,Noxopharm Limited,Phase 1,26,Industry,"November 1, 2017","December 1, 2019","September 15, 2020"
6432,NCT03307551,Evaluation of Automated Propofol Delivery in Patients Undergoing Thoracic Surgery,Thoracic Diseases|Surgery,Drug: Propofol,Dr Nitin Sethi|Sir Ganga Ram Hospital,Phase 4,30,Other,"October 31, 2017","June 25, 2019","June 25, 2019"
6433,NCT03306394,A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).,Metastatic Colorectal Cancer,Drug: Trifluridine/Tipiracil hydrochloride (S95005),"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 3,907,Other|Industry,"October 18, 2016","November 30, 2020","November 30, 2020"
6434,NCT03306277,Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Novartis Gene Therapies|Novartis,Phase 3,22,Industry,"October 24, 2017","November 12, 2019","November 12, 2019"
6435,NCT03306043,"A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622",Hypereosinophilic Syndrome,Drug: Mepolizumab,GlaxoSmithKline,Phase 3,102,Industry,"November 13, 2017","December 30, 2019","December 30, 2019"
6436,NCT03305809,A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Lewy Body Dementia,Drug: LY3154207|Drug: Placebo,Eli Lilly and Company,Phase 2,344,Industry,"November 9, 2017","July 10, 2020","July 10, 2020"
6437,NCT03305757,Seroma Reduction After Mastectomy,Seroma|Aspiration|Breast Cancer,Drug: Artiss|Procedure: vicryl sutures|Procedure: Conventional,Zuyderland Medisch Centrum,Phase 4,339,Other,"June 1, 2014","August 31, 2019","August 31, 2019"
6438,NCT03305666,Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures,"Drug Effect|Rib Fractures|Rib Trauma|Surgical Procedure, Unspecified|Pain; Catheter (Other)|Nerve Pain|Local Infiltration|Anesthesia, Local|Intercostal Rib|Opioid Dependence|Chest Injury Trauma|Pneumonia",Drug: Liposomal bupivacaine injection|Drug: Bupivacaine indwelling catheter,Denver Health and Hospital Authority,Phase 4,36,Other,"October 5, 2017","July 20, 2020","January 31, 2021"
6439,NCT03305445,Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Ipilimumab|Drug: Nivolumab,Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb,Phase 1,6,Other|Industry,"May 14, 2018","April 1, 2021","April 1, 2021"
6440,NCT03304626,Budesonide for Liver Transplant Immune Suppression,Acute Cellular Graft Rejection|New Onset Diabetes After Transplant,Drug: Budesonide 3Mg Capsule|Drug: Standard of Care Prednisone,University of Cincinnati|American College of Gastroenterology,Phase 2,40,Other,"June 27, 2017","December 31, 2019","December 31, 2019"
6441,NCT03304379,Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip,"Osteoarthritis, Knee|Osteoarthritis, Hip",Drug: Fasinumab|Other: Diclofenac|Other: Celecoxib|Drug: Matching placebo,"Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.",Phase 3,1650,Industry,"October 26, 2017","December 13, 2019","November 9, 2020"
6442,NCT03304210,"PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer","Peritoneal Carcinomatosis|Ovarian Cancer Stage IIIB|Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IV|Breast Cancer Stage IIIB|Breast Cancer Stage IIIc|Breast Cancer Stage IV|Stomach Cancer Stage III|Stomach Cancer Stage IV With Metastases|Pancreas Cancer, Stage III|Pancreas Cancer, Stage IV",Drug: PIPAC with Abraxane,"University Hospital, Ghent|Kom Op Tegen Kanker|University Ghent|Hopital Lariboisière|University Women's Hospital Tübingen|Candiolo Cancer Institute - IRCCS|Centre Hospitalier Universitaire Vaudois",Phase 1,20,Other,"September 16, 2017","May 6, 2020","May 6, 2020"
6443,NCT03304093,Immunotherapy by Nivolumab for HIV+ Patients,Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage IIIB|HIV/AIDS,Drug: Nivolumab Injection,"Intergroupe Francophone de Cancerologie Thoracique|ANRS, Emerging Infectious Diseases",Phase 2,30,Other,"October 19, 2017","February 18, 2021","February 18, 2022"
6444,NCT03304054,Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG,"Myasthenia Gravis, Generalized",Drug: Amifampridine Phosphate|Drug: Placebo Oral Tablet,"Catalyst Pharmaceuticals, Inc.",Phase 3,93,Industry,"April 18, 2018","January 31, 2020","March 15, 2020"
6445,NCT03303989,REduCing Immunogenicity to PegloticasE (RECIPE) Study,Gout Chronic,Drug: Pegloticase 8 MG/ML [Krystexxa]|Drug: MMF|Drug: Placebo,University of Alabama at Birmingham|University of Michigan,Phase 2,35,Other,"June 14, 2018","April 27, 2020","March 31, 2021"
6446,NCT03303105,Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine,Migraine,Drug: TEV-48125,"Otsuka Pharmaceutical Co., Ltd.",Phase 3,50,Industry,"December 7, 2017","June 16, 2020","June 16, 2020"
6447,NCT03302936,Assessing Pyridium for Post-Sling Urinary Retention,Urinary Retention,Drug: Phenazopyridine,Icahn School of Medicine at Mount Sinai,Phase 4,98,Other,"October 24, 2017","July 1, 2019","July 1, 2019"
6448,NCT03302871,Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A,Cerebral Palsy,Drug: Botulinum toxin type A|Device: transcranial direct current stimulation|Other: hybrid training model of CIMT and BIT|Other: usual care,Kocaeli University,Phase 3,40,Other,"January 18, 2016","January 30, 2020","January 30, 2020"
6449,NCT03302741,Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings,Spasticity,Drug: Botulinum neurotoxin (BTX)|Other: Physical Therapy|Device: Standard BTX injection (ultrasound guided)|Device: 3-dimensional innervation zone (3DIZ) guided injection,"The University of Texas Health Science Center, Houston|University of Houston",Phase 4,17,Other,"November 21, 2017","November 18, 2019","November 18, 2019"
6450,NCT03302299,Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT),Tuberculosis|HIV/AIDS|Alcohol Abuse,Drug: Isoniazid 300 Mg ORAL TABLET|Drug: Pyridoxine 25 Mg Oral Tablet,"University of California, San Francisco|Boston University|Boston Medical Center|Mbarara University of Science and Technology",Phase 4,302,Other,"April 7, 2017","April 1, 2021","April 1, 2021"
6451,NCT03302234,Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598),"Carcinoma, Non-Small-Cell Lung",Biological: Pembrolizumab|Biological: Ipilimumab|Other: Placebo,Merck Sharp & Dohme LLC,Phase 3,568,Industry,"December 14, 2017","September 1, 2020","September 7, 2022"
6452,NCT03301467,Controlled Trial Evaluating Avacopan in C3 Glomerulopathy,C3 Glomerulopathy (C3G),Drug: Avacopan|Drug: Avacopan Matching Placebo,"ChemoCentryx|Medpace, Inc.",Phase 2,57,Industry,"September 29, 2017","March 3, 2021","October 27, 2021"
6453,NCT03301350,Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer,Breast Cancer|Triple Negative Breast Cancer,Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pegfilgrastim|Drug: Filgrastim,"University of Wisconsin, Madison",Phase 2,29,Other,"November 7, 2017","March 23, 2020","February 7, 2022"
6454,NCT03301272,Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease,Parkinson Disease,Drug: Onabotulinumtoxin A Injection|Other: Placebo,"University of North Carolina, Chapel Hill",Phase 2,16,Other,"March 22, 2018","August 21, 2019","August 21, 2019"
6455,NCT03301155,Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI,Preventive Medicine,Drug: Anaferon for children|Drug: Placebo,Materia Medica Holding,Phase 4,1036,Industry,"October 3, 2017","May 20, 2019","May 20, 2019"
6456,NCT03300960,Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation,Infertility,Drug: Provera 10 mg.|Drug: Ganirelix (GnRH antagonist),"Instituto Valenciano de Infertilidad, IVI VALENCIA",Phase 3,318,Other,"October 20, 2017","June 25, 2019","June 25, 2019"
6457,NCT03299946,Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),Locally Advanced Hepatocellular Carcinoma,Drug: Cabozantinib|Drug: Nivolumab,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Exelixis|Bristol-Myers Squibb,Phase 1,15,Other|Industry,"May 14, 2018","December 9, 2019","October 1, 2021"
6458,NCT03299868,Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients,Peripherally Inserted Central Catheter|Intravenous Access,Device: peripherally inserted central catheter (PICC),Pusan National University Yangsan Hospital,Phase 2,66,Other,"May 1, 2017","June 30, 2020","June 30, 2020"
6459,NCT03299244,Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT),Secondary Hyperparathyroidism|Chronic Kidney Disease,Drug: Etelcalcetide|Drug: Cinacalcet,Amgen,Phase 3,637,Industry,"May 15, 2018","April 8, 2020","April 8, 2020"
6460,NCT03298984,Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,Acute Myeloid Leukemia,Drug: Alvocidib|Drug: Cytarabine|Drug: Daunorubicin,"Sumitomo Pharma Oncology, Inc.",Phase 1,32,Industry,"September 25, 2017","March 20, 2020","March 20, 2020"
6461,NCT03298672,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017",Alzheimer Disease,Drug: NDX-1017|Drug: Placebo,Athira Pharma|Alzheimer's Drug Discovery Foundation|Biotrial Inc.,Phase 1,88,Industry|Other,"October 9, 2017","September 5, 2019","September 5, 2019"
6462,NCT03298542,"A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes",Pre-Symptomatic Type 1 Diabetes,Drug: Golimumab|Drug: Placebo,"Janssen Research & Development, LLC",Phase 1,8,Industry,"October 16, 2017","December 21, 2020","June 1, 2021"
6463,NCT03298516,A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy,"Leukemia, Myeloid, Acute",Drug: DCLL9718S|Drug: Azacitidine,"Genentech, Inc.",Phase 1,19,Industry,"November 15, 2017","July 16, 2019","July 16, 2019"
6464,NCT03298022,"Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis",Ulcerative Colitis,Biological: AbGn-168H,AltruBio Inc.,Phase 2,24,Industry,"April 10, 2018","April 6, 2020","June 1, 2020"
6465,NCT03297710,"TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery",Rectal Adenocarcinoma|Recurrent Rectal Carcinoma|Stage IV Rectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7,Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102,Mayo Clinic|National Cancer Institute (NCI),Phase 1,7,Other|NIH,"December 11, 2017","March 16, 2020","April 30, 2021"
6466,NCT03297216,Improving Pregnancy Outcomes With Progesterone,Pre-term Birth|HIV-1-infection,Drug: 17P|Other: Placebo,"University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|AMAG Pharmaceuticals, Inc.|Bill and Melinda Gates Foundation",Phase 3,800,Other|NIH|Industry,"February 7, 2018","June 25, 2020","August 6, 2020"
6467,NCT03296787,A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954,Renal Impairment|Healthy Volunteers,Drug: TAK-954,Takeda,Phase 1,32,Industry,"November 21, 2017","August 9, 2019","August 9, 2019"
6468,NCT03296553,"Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.",Kaposi Sarcoma|Human Immunodeficiency Virus|Immune Reconstitution Syndrome,Drug: Valganciclovir|Drug: Antiretroviral Combinations,National Institute of Cancerología|Instituto Nacional de Enfermedades Respiratorias,Phase 2,40,Other,"October 1, 2015","August 26, 2019","August 26, 2019"
6469,NCT03296527,Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women,Controlled Ovarian Simulation,Drug: Follitropin alfa|Drug: Follitropin delta,Ferring Pharmaceuticals,Phase 3,1011,Industry,"December 1, 2017","January 3, 2020","July 26, 2020"
6470,NCT03296423,Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly,Infection|Hospitalization|Mortality,Biological: Vaccination|Biological: Placebo,Hellenic Institute for the Study of Sepsis|Radboud University Medical Center,Phase 4,200,Other,"September 21, 2017","August 31, 2020","November 30, 2020"
6471,NCT03296163,A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer,Drug: MB02 (Bevacizumab Biosimilar Drug)|Drug: EU-approved Avastin®|Drug: Carboplatin|Drug: Paclitaxel,mAbxience Research S.L.,Phase 3,627,Industry,"February 6, 2018","July 3, 2019","February 27, 2020"
6472,NCT03294395,New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea,Gonorrhea,"Drug: Ertapenem 1000 MG|Drug: Fosfomycin Oral Suspension|Drug: Gentamicin Sulfate, Injectable|Drug: Ceftriaxone",Public Health Service of Amsterdam|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 3,346,Other,"September 18, 2017","June 5, 2020","June 5, 2020"
6473,NCT03294304,"BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy",Muscle Invasive Bladder Cancer,Drug: Nivolumab|Drug: Cisplatin|Drug: Gemcitabine,"Masonic Cancer Center, University of Minnesota|Bristol-Myers Squibb",Phase 2,43,Other|Industry,"January 29, 2018","June 5, 2020","July 1, 2021"
6474,NCT03294109,Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy,"Pain, Postoperative|Analgesics, Opioid|Analgesics, Non-Narcotic|Physiological Effects of Drugs|Peripheral Nervous System Agents|Patient Satisfaction|Return to Work|Activity, Sexual",Drug: Abdominal wall block with liposomal bupivicaine,"University of California, Los Angeles",Phase 4,146,Other,"January 1, 2018","June 24, 2020","June 24, 2020"
6475,NCT03293654,A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers,Healthy Volunteers,Drug: MB02|Drug: US licenced Avastin®|Drug: EU approved Avastin®,mAbxience Research S.L.,Phase 1,114,Industry,"December 7, 2017","May 29, 2019","May 29, 2019"
6476,NCT03293368,Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus,Erosive Oral Lichen Planus,Biological: Platelet rich plasma|Drug: Triamcinolone Acetonide,Cairo University,Phase 2,20,Other,"January 1, 2018","January 1, 2021","January 1, 2021"
6477,NCT03293290,Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks,HIV Infections,Drug: PrEP,Yale University,Phase 1,105,Other,"December 11, 2017","May 15, 2020","May 15, 2020"
6478,NCT03293186,"Anti-adhesive Effect and Safety of ""Thermo-sensitive Adhesion Barrier (MEDICLORE)""",Adhesion|Thyroidectomy,Combination Product: MEDICLORE,Seoul National University Hospital,Phase 4,90,Other,"July 1, 2017","December 27, 2020","December 31, 2020"
6479,NCT03292796,RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.,Open Angle Glaucoma and Cataract,Drug: Prostaglandins,Julie Dawson|Norfolk and Norwich University Hospitals NHS Foundation Trust,Phase 2,56,Other,"December 7, 2016","October 21, 2019","July 25, 2020"
6480,NCT03292783,"This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001",Advanced Solid Tumors,Drug: NOV1501 (ABL001),"ABL Bio, Inc.|National OncoVenture",Phase 1,45,Industry|Other,"September 18, 2017","March 2, 2021","March 2, 2021"
6481,NCT03292588,A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children,Asthma,Biological: Mepolizumab|Drug: Placebo,"National Institute of Allergy and Infectious Diseases (NIAID)|Inner-City Asthma Consortium|GlaxoSmithKline|Rho Federal Systems Division, Inc.",Phase 2,335,NIH|Other|Industry,"November 7, 2017","April 20, 2021","April 20, 2021"
6482,NCT03292406,"A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)",Cutaneous T Cell Lymphoma,Drug: Placebo|Drug: CD11301 0.03%|Drug: CD11301 0.06%,Galderma R&D,Phase 2,86,Industry,"December 19, 2017","March 17, 2020","March 17, 2020"
6483,NCT03292315,Once Weekly GLP-1 in Persons With Spinal Cord Injury,Spinal Cord Injuries|Insulin Resistance|Pre Diabetes|Obesity,Drug: Semaglutide 1MG Injection [Ozempic]|Other: No Intervention,James J. Peters Veterans Affairs Medical Center|Kessler Institute for Rehabilitation,Phase 4,5,U.S. Fed|Industry,"October 16, 2018","March 1, 2020","March 1, 2023"
6484,NCT03292250,"Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]",HNSCC|Head and Neck Neoplasms,"Drug: BYL719|Drug: Poziotinib|Drug: Nintedanib|Drug: Abemaciclib|Drug: Durvalumab,Tremelimumab",Seoul National University Hospital|Korean Cancer Study Group|Chungnam National University Hospital,Phase 2,180,Other,"September 10, 2017","March 1, 2020","March 10, 2022"
6485,NCT03291938,IACS-010759 in Advanced Cancers,Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Pancreatic Ductal Adenocarcinoma|Progesterone Receptor Negative|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Lymphoma|Refractory Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Solid Neoplasm,Drug: Oxidative Phosphorylation Inhibitor IACS-010759|Other: Pharmacodynamic Study|Other: Pharmacokinetic Study,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,29,Other|NIH,"November 13, 2017","November 23, 2020","November 23, 2020"
6486,NCT03291054,Epacadostat and Pembrolizumab in Patients With GIST,Gastrointestinal Stromal Tumors,Drug: Pembrolizumab|Drug: Epacadostat,Richard D. Carvajal|Columbia University,Phase 2,1,Other,"February 28, 2018","August 19, 2020","August 19, 2020"
6487,NCT03290625,Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II),Caries of Infancy|Dental Anxiety,Drug: Dexmedetomidine Hydrochloride|Drug: Ketamine Hydrochloride,Universidade Federal de Goias|Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG),Phase 4,12,Other,"November 9, 2017","September 12, 2019","March 5, 2020"
6488,NCT03290560,Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke,Acute Ischemic Stroke,Drug: Recombinant human tissue kallikrein|Other: Placebo,DiaMedica Therapeutics Inc,Phase 2,92,Industry,"January 19, 2018","January 23, 2020","January 23, 2020"
6489,NCT03289819,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,Malignant Neoplasm of Breast,Drug: Pembrolizumab|Drug: nab-paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide,Institut fuer Frauengesundheit|Merck Sharp & Dohme LLC|Celgene Corporation,Phase 2,53,Other|Industry,"March 23, 2018","August 27, 2020","January 22, 2021"
6490,NCT03289650,Extended Release Tacrolimus vs. Twice-Daily Tacrolimus,End Stage Renal Disease|Rejection of Renal Transplant,Drug: Tacrolimus|Drug: Tacrolimus Extended Release Oral Tablet [Envarsus],Lorenzo Gallon|Northwestern University,Phase 3,29,Other,"September 5, 2017","February 23, 2021","February 23, 2021"
6491,NCT03289533,A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100),"Carcinoma, Hepatocellular",Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736),Pfizer,Phase 1,22,Industry,"September 8, 2017","August 27, 2019","October 25, 2019"
6492,NCT03289416,Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis,Knee Osteoarthritis,Combination Product: Pure PRP II|Combination Product: PureBMC,"Andrews Research & Education Foundation|EmCyte Corporation|BioSciences Research Associates, Inc",Phase 4,90,Other|Industry,"December 5, 2013",Feb-20,Feb-20
6493,NCT03289403,The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis,Infertility|Autoimmune Thyroiditis,Drug: Immunomodulatory|Drug: Thyroxine,Aljazeera Hospital,Phase 2,100,Other,"March 7, 2018","September 15, 2019","October 20, 2019"
6494,NCT03289169,Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines,Glabellar Frown Lines,Drug: MEDITOXIN®,Medy-Tox,Phase 4,300,Industry,"December 30, 2016","May 29, 2019","May 29, 2019"
6495,NCT03289026,Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study,Acute Schizophrenia Episode,Drug: Aripiprazole,Peking University,Phase 4,770,Other,"September 1, 2017","January 23, 2020","February 2, 2021"
6496,NCT03288480,A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma,Multiple Myeloma,Drug: PT-112,Promontory Therapeutics Inc.,Phase 1,24,Industry,"December 15, 2017","September 30, 2020","March 1, 2021"
6497,NCT03288454,Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT,Healthy,Drug: Ciraparantag|Drug: Placebo|Drug: Apixaban,"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.|AMAG Pharmaceuticals, Inc.",Phase 2,60,Industry,"August 30, 2017","August 5, 2019","August 5, 2019"
6498,NCT03288129,Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures,Partial Onset Seizures|Secondarily Generalized Seizures|Primary Generalized Tonic-Clonic Seizures,Drug: Perampanel,Eisai Inc.,Phase 4,54,Industry,"August 23, 2017","April 27, 2021","April 27, 2021"
6499,NCT03287960,Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity,Leptin Receptor Deficiency Obesity,Drug: Setmelanotide|Drug: Placebo,"Rhythm Pharmaceuticals, Inc.",Phase 3,15,Industry,"January 30, 2018","September 25, 2020","September 25, 2020"
6500,NCT03287869,A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.,Bipolar I Disorder|Acute Mania,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",Phase 3,381,Industry,"October 24, 2017","July 31, 2019","July 31, 2019"
6501,NCT03287635,Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease,Dry Eye Disease,Drug: Corticotropin 80Unit/Ml Repository Injection,Toyos Clinic|Mallinckrodt,Phase 4,19,Other|Industry,"July 1, 2018","February 1, 2020","March 4, 2020"
6502,NCT03287609,EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS),Acute Coronary Syndrome,Drug: Evolocumab 140 mg/mL|Drug: Placebo,"University Hospital Inselspital, Berne|Amgen|University of Bern",Phase 3,308,Other|Industry,"January 23, 2018","May 20, 2019","August 7, 2019"
6503,NCT03287505,Aripiprazole IM Depot for Chinese Patients With Schizophrenia,Schizophrenia,Drug: Aripiprazole IM Depot,Otsuka Beijing Research Institute,Phase 1,24,Industry,"June 23, 2017","November 8, 2019","November 8, 2019"
6504,NCT03287310,"First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma",Asthma,Drug: GSK3511294|Drug: Placebo|Drug: Salbutamol/albuterol,GlaxoSmithKline,Phase 1,50,Industry,"October 17, 2017","July 31, 2019","July 31, 2019"
6505,NCT03287089,Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery,Catheter-Associated Urinary Tract Infection,Drug: Nitrofurantoin 100 MG|Drug: Placebo Oral Tablet,Wake Forest University Health Sciences,Phase 4,164,Other,"September 29, 2017","May 30, 2019","June 1, 2019"
6506,NCT03285711,Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN),Lupus Membranous Nephropathy,Drug: Filgotinib|Drug: Lanraplenib|Drug: Filgotinib placebo|Drug: Lanraplenib placebo,Gilead Sciences,Phase 2,9,Industry,"October 6, 2017","May 3, 2019","February 3, 2020"
6507,NCT03285594,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents,Type 2 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Insulin glargine (HOE901)|Drug: Placebo|Drug: Oral Antidiabetes Drugs (OADs),Lexicon Pharmaceuticals|Sanofi,Phase 3,571,Industry,"September 15, 2017","September 17, 2019","September 27, 2019"
6508,NCT03285503,PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia,Schizophrenia,Drug: Aripiprazole IM Depot,Otsuka Beijing Research Institute,Phase 1,12,Industry,"August 17, 2018","October 14, 2019","October 14, 2019"
6509,NCT03285178,"A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)",Sickle Cell Disease,Drug: IW-1701|Drug: Placebo,Cyclerion Therapeutics,Phase 2,70,Industry,"December 22, 2017","July 22, 2020","July 22, 2020"
6510,NCT03284853,Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension,Open Angle Glaucoma|Ocular Hypertension,Drug: Netarsudil/Latanoprost 0.02%/0.005%|Drug: GANFORT®,Aerie Pharmaceuticals,Phase 3,436,Industry,"September 5, 2017","November 6, 2020","November 6, 2020"
6511,NCT03284307,UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study,Unconsciousness|Consciousness,Drug: Dexmedetomidine|Drug: Ketamine|Drug: Propofol|Drug: Midazolam,"University of Wisconsin, Madison",Phase 4,35,Other,"August 10, 2017","March 12, 2020","March 12, 2020"
6512,NCT03283670,Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies,"Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant",Drug: Nitrous Oxide 25%|Drug: Nitrous Oxide 50%|Drug: Placebo Gas,Washington University School of Medicine|Brain & Behavior Research Foundation,Phase 2,24,Other,"November 22, 2016","February 18, 2020","February 18, 2020"
6513,NCT03283566,Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT,Chronic Pancreatitis|Insulin Dependent Diabetes,Drug: Hydroxychloroquine|Drug: Placebo,The Cleveland Clinic|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|Stanford University,Phase 2,9,Other,"October 3, 2017","May 31, 2020","May 31, 2020"
6514,NCT03283371,"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","Epilepsy, Focal Seizures, Partial Seizures",Drug: Natalizumab|Other: Placebo,Biogen,Phase 2,67,Industry,"March 20, 2018","January 11, 2020","November 18, 2020"
6515,NCT03283202,Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors,Diffuse B-Cell Lymphoma,Drug: Avadomide (CC-122)|Drug: Rituximab|Drug: Cyclophosphamide 750mg/m2 by IV infusion|Drug: Vincristine|Drug: Prednisone,Celgene,Phase 1,35,Industry,"October 4, 2017","July 30, 2019","December 16, 2020"
6516,NCT03282851,Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456,Healthy,Drug: MSB11456|Drug: US-licensed Actemra|Drug: EU-approved RoActemra,Fresenius Kabi SwissBioSim GmbH,Phase 1,696,Industry,"November 27, 2017","October 1, 2019","October 1, 2019"
6517,NCT03282799,Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women,HIV/AIDS|Contraception,Drug: etonogestrel implant,"Catherine Anne Chappell|Infectious Disease Institute, Kampala, Uganda|University of Nebraska|University of Pittsburgh",Phase 2,72,Other,"February 19, 2019","December 22, 2020","October 25, 2022"
6518,NCT03282227,A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine,Migraine,Drug: M207 Microneedle System,Zosano Pharma Corporation,Phase 3,342,Industry,"November 7, 2017","May 17, 2019","May 17, 2019"
6519,NCT03282123,Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD,PTSD,Drug: MDMA|Behavioral: Therapy,Multidisciplinary Association for Psychedelic Studies,Phase 2,38,Other,"November 16, 2017","August 10, 2019","August 10, 2019"
6520,NCT03282006,Treating Pyelonephritis an Urosepsis With Pivmecillinam,Pyelonephritis|Urinary Tract Infections,Drug: pivmecillinam,Sykehuset i Vestfold HF|University of Oslo,Phase 4,53,Other,"September 29, 2017","April 21, 2020","April 21, 2020"
6521,NCT03281876,A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.,Respiratory Disorders,Biological: NTHi Mcat investigational vaccine (GSK3277511A)|Biological: Placebo,GlaxoSmithKline,Phase 2,606,Industry,"November 27, 2017","March 26, 2020","March 26, 2020"
6522,NCT03281824,"Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients",HER2-positive Breast Cancer,Biological: ALT-P7 (HM2-MMAE),"Alteogen, Inc.",Phase 1,27,Industry,"January 11, 2018","March 12, 2020","January 15, 2021"
6523,NCT03281577,Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants,Diabetic Gastroparesis|Idiopathic Gastroparesis,Drug: TAK-954|Drug: Placebo,Takeda,Phase 2,36,Industry,"January 2, 2018","June 7, 2019","July 12, 2019"
6524,NCT03281538,Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,Uremic Pruritus,Drug: CR845,"Cara Therapeutics, Inc.",Phase 3,288,Industry,"August 14, 2017","February 11, 2020","February 11, 2020"
6525,NCT03281382,Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer,Biological: Ad5-yCD/mutTKSR39rep-hIL12,Henry Ford Health System,Phase 1,12,Other,"July 1, 2017","May 28, 2019","May 28, 2019"
6526,NCT03280927,Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis,Mild to Moderate Onychomycosis Due to Dermatophyte,Drug: Jublia®,"Dong-A ST Co., Ltd.",Phase 4,97,Industry,"November 10, 2017","January 22, 2020","January 22, 2020"
6527,NCT03280745,Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery,Cardiovascular Diseases|Valvular Heart Disease,Drug: Hypertonic saline|Drug: 0.9% saline,"University Hospital Inselspital, Berne",Phase 4,165,Other,"February 27, 2018","May 27, 2019","September 30, 2019"
6528,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),Phase 3,263,Industry|Other,"August 28, 2017","October 30, 2020","October 30, 2020"
6529,NCT03280030,A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML,Acute Myeloid Leukemia,Drug: Midostaurin|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,75,Industry,"April 6, 2018","March 11, 2020","November 14, 2022"
6530,NCT03279744,A Study to Evaluate the Efficacy and Safety of Radion™-Pdt in Patients With Oral Precancerous Lesion,Erythroleukoplakia of Mouth|Verrucous Hyperplasia of Oral Mucosa,Drug: Radion™-pdt,"Pharma Power Biotec Co., Ltd.",Phase 2,25,Industry,"September 6, 2017","September 4, 2019","December 20, 2019"
6531,NCT03279562,Patient Driven Recovery With Nalmefene and Coaching,"Opioid-use Disorder|Harmful; Use, Alcohol",Drug: Nalmefene,"Yale University|First Pavlov State Medical University in St. Petersburg, Russia",Phase 1,10,Other,"September 1, 2017","December 30, 2019","December 30, 2019"
6532,NCT03278600,Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary,Cancer of Unknown Primary Site,Genetic: tissue-of-origin (ORIGIN-PanCA○R) profiling,Fudan University,Phase 3,182,Other,"September 18, 2017","March 18, 2021","March 18, 2021"
6533,NCT03277703,Flu Vaccine Response in Patients on Biologic Therapies,Rheumatologic Disorder|Inflammatory Bowel Diseases|Immune Complex Diseases,Biological: Influenza vaccine,"Stony Brook University|University of North Carolina, Chapel Hill",Phase 2,30,Other,"November 3, 2017","January 1, 2020","January 1, 2020"
6534,NCT03277690,A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.,Endogenous Cushing's Syndrome,Drug: Levoketoconazole|Drug: Placebo,Cortendo AB,Phase 3,84,Industry,"September 26, 2017","June 30, 2020","August 31, 2020"
6535,NCT03277339,Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders,Generalized Anxious Disorders,Drug: Paroxetine|Other: Thermal cure,"Centre Hospitalier Henri Laborit|Association Francaise pour la Recherche Thermale|Les thermes de Saujon|Poitiers University Hospital|Centre National de la Recherche Scientifique (CeRCA, umr 7295), France",Phase 4,52,Other,"January 19, 2017","January 8, 2020","February 5, 2020"
6536,NCT03277261,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ),Relapsing Multiple Sclerosis (RMS),Biological: Ublituximab|Drug: Teriflunomide|Drug: Oral Placebo|Drug: IV Placebo,"TG Therapeutics, Inc.",Phase 3,549,Industry,"September 19, 2017","July 23, 2020","November 6, 2020"
6537,NCT03277248,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS),Relapsing Multiple Sclerosis (RMS),Biological: Ublituximab|Drug: Teriflunomide|Drug: Oral Placebo|Drug: IV Placebo,"TG Therapeutics, Inc.",Phase 3,545,Industry,"August 25, 2017","August 4, 2020","November 12, 2020"
6538,NCT03277066,A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis,Osteoarthritis of the Knee,Drug: Diclofenac Sodium Active Topical Patch 1|Drug: Diclofenac Sodium Active Topical Patch 2|Drug: Placebo patch,"Noven Pharmaceuticals, Inc.|Noven Therapeutics",Phase 2,289,Industry,"September 7, 2017","September 25, 2019","September 25, 2019"
6539,NCT03276975,A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment,Cerebrospinal Fluid Leaks,Drug: TISSEEL,Duke University,Phase 2,15,Other,"December 18, 2017","March 19, 2020","March 19, 2020"
6540,NCT03276962,"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age",Malaria,"Biological: RTS,S/AS01E (Full dose)|Biological: RTS,S/AS01E (1/5th dose)|Biological: Rabies vaccine",GlaxoSmithKline,Phase 2,1498,Industry,"September 28, 2017","November 4, 2019","November 11, 2022"
6541,NCT03276780,Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence,Smoking Cessation,Behavioral: Counseling|Drug: combination NRT,University of Alabama at Birmingham,Phase 4,80,Other,"May 3, 2018","May 31, 2020","October 31, 2020"
6542,NCT03276468,Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas,Follicular Lymphoma|Diffuse Large B Cell Lymphoma|Marginal Zone Lymphoma|Mucosa Associated Lymphoid Tissue,Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Venetoclax,The Lymphoma Academic Research Organisation,Phase 2,136,Other,"February 12, 2018","September 19, 2019","August 24, 2022"
6543,NCT03276013,"Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer",Endometrial Neoplasms,Drug: Pembrolizumab,Vall d'Hebron Institute of Oncology,Phase 2,48,Other,"May 30, 2018","April 30, 2020","August 26, 2021"
6544,NCT03275922,"Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE",Migraine,Drug: Placebo ZNS|Drug: ZNS,"Impax Laboratories, LLC|AstraZeneca",Phase 3,374,Industry,"November 27, 2017","July 2, 2020","September 28, 2020"
6545,NCT03275454,"A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)","Purpura, Thrombocytopenic, Idiopathic",Drug: BIVV009 6.5 grams|Drug: BIVV009 7.5 grams,"Bioverativ, a Sanofi company|Sanofi",Phase 1,12,Industry,"August 14, 2017","February 16, 2021","February 16, 2021"
6546,NCT03275389,"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","Influenza, Human",Biological: D-SUIV cH8/1N1+AS03|Biological: D-SUIV cH5/1N1+AS03|Biological: D-SUIV cH11/1N1+AS03|Biological: D-SUIV cH8/1N1+AS01|Biological: D-SUIV cH5/1N1+AS01|Biological: D-SUIV cH11/1N1+AS01|Biological: D-SUIV cH8/1N1|Biological: D-SUIV cH5/1N1|Biological: D-SUIV cH11/1N1|Biological: Placebo|Biological: Fluarix Quadrivalent,GlaxoSmithKline,Phase 1,470,Industry,"September 8, 2017","March 26, 2020","March 26, 2020"
6547,NCT03275025,A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: YRA-1909 low dose|Drug: YRA-1909 mid dose|Drug: YRA-1909 high dose|Drug: Placebo,"Yungjin Pharm. Co., Ltd.",Phase 2,116,Industry,"April 1, 2017","November 19, 2019","November 19, 2019"
6548,NCT03274856,A Study of GLWL-01 in Patients With Prader-Willi Syndrome,Prader-Willi Syndrome,Drug: GLWL-01|Drug: Placebo,GLWL Research Inc.,Phase 2,19,Other,"February 20, 2018","June 12, 2019","June 12, 2019"
6549,NCT03274804,Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC,Metastatic Colorectal Cancer|MSS,Biological: Pembrolizumab|Drug: Maraviroc,University Hospital Heidelberg|Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Phase 1,20,Other,"April 1, 2018","March 1, 2020","March 1, 2020"
6550,NCT03274752,Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction,Cardiac Remodeling|Myocardial Infarction,Drug: Paroxetine|Drug: Placebo oral capsule,"University Hospital Inselspital, Berne",Phase 2,50,Other,"October 26, 2017","January 1, 2021","March 1, 2022"
6551,NCT03273712,"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)",Neuroendocrine Tumors|Meningioma|Neuroblastoma|Medulloblastoma,Radiation: 90Y-DOTA tyr3-Octreotide|Diagnostic Test: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|Drug: Amino Acids,University of Iowa|National Institutes of Health (NIH)|National Cancer Institute (NCI),Phase 2,39,Other|NIH,"September 29, 2017","May 27, 2020","May 27, 2020"
6552,NCT03272542,PRebiotic to IMprovE Calcium Absorption,Obesity,Dietary Supplement: Prebiotic: soluble corn fiber|Dietary Supplement: Placebo: maltodextrin,"San Francisco Veterans Affairs Medical Center|University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",Phase 2,20,U.S. Fed|Other|NIH,"November 21, 2017","January 31, 2020","January 31, 2020"
6553,NCT03272347,Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011),HIV-1 Infection,Drug: Islatravir|Drug: Placebo to Islatravir|Drug: Doravirine|Drug: Placebo to Doravirine|Drug: Lamivudine|Drug: Placebo to Lamivudine|Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Drug: Doravirine/Islatravir,Merck Sharp & Dohme LLC,Phase 2,123,Industry,"November 27, 2017","March 8, 2021","March 9, 2022"
6554,NCT03272256,Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma,Advanced Solid Tumor,Drug: IM156,"ImmunoMet Therapeutics, Inc.",Phase 1,22,Industry,"October 9, 2017","December 2, 2019","July 28, 2020"
6555,NCT03272165,Single Ascending Dose Study of MEDI1341 in Healthy Volunteers,Parkinson's Disease,Drug: MEDI1341|Drug: Placebo,"AstraZeneca|Covance|MMS Holdings, Inc|Catalent|Takeda",Phase 1,50,Industry|Other,"October 17, 2017","March 31, 2021","March 31, 2021"
6556,NCT03271528,Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers,Alcohol Use Disorder,Drug: Lacosamide|Drug: Placebo oral capsule,Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 1,66,Other|NIH,"April 15, 2018","August 31, 2020","August 31, 2020"
6557,NCT03271151,Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty,"Joint Disease|Pain, Acute|Pain, Chronic",Drug: Cymbalta|Other: Placebo,"Hospital for Special Surgery, New York",Phase 4,160,Other,"September 28, 2017","December 3, 2020","February 10, 2021"
6558,NCT03271047,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,MSS|RAS-mutant Colorectal Cancer,Drug: binimetinib|Drug: nivolumab|Drug: ipilimumab,Pfizer|Bristol-Myers Squibb,Phase 2,75,Industry,"October 18, 2017","October 13, 2020","February 25, 2021"
6559,NCT03270514,Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride,"Coronary Artery Disease|Coronary Artery Stenoses|Valve Regurgitation, Mitral|Valve Regurgitation, Tricuspid",Drug: Exparel Injectable Product|Drug: Bupivacaine Hydrochloride,"Kathirvel Subramaniam|Pacira Pharmaceuticals, Inc|University of Pittsburgh",Phase 3,60,Other|Industry,"November 15, 2018","December 13, 2019","February 25, 2020"
6560,NCT03270462,CNS Study of Patients Switching From Tacrolimus to Envarsus,Renal Transplant Patients,Drug: Envarsus XR,"University of Colorado, Denver",Phase 4,20,Other,"December 1, 2017","May 2, 2020","June 2, 2020"
6561,NCT03270332,Effect of Inhaled Albuterol in Pulmonary Hypertension,Pulmonary Hypertension,Drug: Albuterol|Drug: Placebo,University of Miami,Phase 2,10,Other,"October 5, 2017","July 2, 2020","July 2, 2020"
6562,NCT03270085,Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption,Chronic Diarrhea|Irritable Bowel Syndrome With Diarrhea|Bile Acid Malabsorption,Drug: Colesevelam|Other: Placebo,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2,30,Other|NIH,"December 7, 2017","May 31, 2019","May 31, 2019"
6563,NCT03269760,Multimodal Sleep Pathway for Shoulder Arthroplasty,Sleep Disturbance|Shoulder Arthritis|Arthroplasty Complications|Perioperative/Postoperative Complications,Drug: Zolpidem,"University of California, San Francisco",Phase 1,122,Other,"September 1, 2017","February 1, 2020","February 1, 2020"
6564,NCT03269435,Greater Occipital Nerve Block Versus Metoclopramide,Migraine,Procedure: Greater occipital nerve block with bupivacaine|Drug: Metoclopramide,Montefiore Medical Center,Phase 4,99,Other,"November 1, 2017","March 21, 2020","March 21, 2020"
6565,NCT03269344,Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer,Oropharynx Cancer,Drug: Gabapentin|Drug: Placebo Oral Capsule,Henry Ford Health System,Phase 3,65,Other,"June 5, 2017","December 9, 2020","December 9, 2020"
6566,NCT03268382,"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246",High-grade Serous Ovarian Cancer,Drug: APR-246|Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD),Aprea Therapeutics,Phase 2,36,Industry,"July 31, 2017","July 10, 2019","July 10, 2019"
6567,NCT03267329,Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension,Hypertension|Dyslipidemia,Drug: Duowell®|Drug: Telmisartan,Yuhan Corporation,Phase 4,80,Industry,"September 11, 2017","September 2, 2020","September 2, 2020"
6568,NCT03267121,A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,Head and Neck Squamous Cell Carcinoma,Drug: Apatinib Mesylate Tablets|Drug: Tegafur Gimeracil Oteracil Potassium Capsules,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,Phase 2,38,Other,"October 1, 2017","September 30, 2020","November 1, 2020"
6569,NCT03267030,Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase,Acute Lymphoblastic Leukemia,Drug: GRASPA,Birgitte Klug Albertsen|ERYtech Pharma|Aarhus University Hospital,Phase 2,55,Other|Industry,"August 23, 2017","August 1, 2020","October 22, 2020"
6570,NCT03266965,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,Multiple Sclerosis,Drug: Carbidopa|Dietary Supplement: L-Histidine,University of Miami|United States Department of Defense,Phase 1,18,Other|U.S. Fed,"March 23, 2018","August 7, 2020","August 7, 2020"
6571,NCT03265444,Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy,Multiple System Atrophy,Biological: CS10BR05,"Corestem, Inc.",Phase 1,9,Industry,"April 13, 2018","December 5, 2019","December 5, 2019"
6572,NCT03265145,Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE],"Pulmonary Disease, Chronic Obstructive",Drug: Stiolto Respimat|Drug: ICS (Inhaled Corticosteroid) (Triple therapy)|Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)|Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy),Boehringer Ingelheim|HealthCore-NERI,Phase 4,714,Industry|Other,"September 20, 2017","September 30, 2020","September 30, 2020"
6573,NCT03264066,A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,Solid Tumors,Drug: Cobimetinib|Drug: Atezolizumab|Drug: Atezolizumab Cohort 7,Hoffmann-La Roche,Phase 2,87,Industry,"November 23, 2017","June 25, 2020","June 25, 2020"
6574,NCT03263936,Epigenetic Reprogramming in Relapse/Refractory AML,Acute Myelogenous Leukemia,Drug: Decitabine|Drug: Vorinostat|Drug: Filgrastim (G-CSF)|Drug: Fludarabine|Drug: Cytarabine,Therapeutic Advances in Childhood Leukemia Consortium,Phase 1,37,Other,"July 11, 2017","July 9, 2020","February 10, 2022"
6575,NCT03263780,High Resolution PET-MRI Before Prostate Cancer HIFU,Prostate Cancer,Drug: 18F-Fluciclovine,Timothy J. Daskivich|Blue Earth Diagnostics|Cedars-Sinai Medical Center,Phase 2,21,Other|Industry,"December 7, 2017","January 8, 2020","January 8, 2020"
6576,NCT03263715,A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE),Polymyalgia Rheumatica,Drug: Tocilizumab Prefilled Syringe [Actemra]|Drug: Placebos|Drug: Glucocorticoids,Medical University of Vienna,Phase 3,39,Other,"November 24, 2017","June 2, 2020","June 2, 2020"
6577,NCT03263611,AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain,Degenerative Disc Disease,Drug: Placebo|Drug: AMG0103,"AnGes, Inc.",Phase 1,25,Industry,"February 26, 2018","February 15, 2021","February 15, 2021"
6578,NCT03263494,CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D),Type 1 Diabetes Mellitus,Device: Continuous Glucose Monitor (CGM),Jaeb Center for Health Research|The Leona M. and Harry B. Helmsley Charitable Trust,Phase 3,153,Other,"January 25, 2018","May 8, 2019","November 7, 2019"
6579,NCT03263442,High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation,Hematopoietic Stem Cell Transplantation|Delirium|Thiamine Deficiency,Drug: Thiamine|Drug: Normal saline,UNC Lineberger Comprehensive Cancer Center|Rising Tide Foundation,Phase 2,66,Other,"October 16, 2017","March 2, 2020","August 10, 2020"
6580,NCT03263286,Home Therapy for Stroke Rehabilitation Using the HandSOME Exoskeleton,Stroke,Device: HandSOME,The Catholic University of America|MedStar National Rehabilitation Network,Phase 1,15,Other,"April 15, 2017","October 7, 2019","October 7, 2019"
6581,NCT03262662,EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking,Tobacco Smoking,Drug: Varenicline|Behavioral: Brief smoking cessation counseling,State University of New York at Buffalo|National Cancer Institute (NCI)|Pfizer,Phase 3,320,Other|NIH|Industry,"October 1, 2017","April 5, 2021","July 8, 2021"
6582,NCT03262636,"Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)","Brain Tumor, Primary|Brain Tumor, Recurrent",Drug: Indocyanine Green,University of Pennsylvania,Phase 1,363,Other,Jun-15,"March 10, 2020","March 10, 2020"
6583,NCT03262441,MMF for HIV Reservoir Reduction,Human Immunodeficiency Virus I Infection,Drug: Mycophenolate Mofetil 500Mg Tab,Fred Hutchinson Cancer Center|University of Washington,Phase 2,5,Other,"February 12, 2018","August 31, 2019","August 31, 2019"
6584,NCT03262389,Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma,Multiple Myeloma,Drug: Fludeoxyglucose PET CT|Drug: Sodium Acetate C11 PET CT|Drug: Fludeoxyglucose PET MRI|Drug: Sodium Acetate C11 PET MRI,"Michael C Roarke, MD|Mayo Clinic",Phase 2,10,Other,"September 19, 2017","November 23, 2019","November 23, 2019"
6585,NCT03261947,"A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors","Metastatic Pancreatic Cancer|Colorectal Cancer|Esophageal Neoplasms|Carcinoma, Non-small-cell Lung",Drug: TAK-931,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 2,101,Industry,"October 25, 2017","August 24, 2020","August 24, 2020"
6586,NCT03261401,"First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Subjects",Healthy,Drug: M5717|Drug: Placebo,"Merck KGaA, Darmstadt, Germany",Phase 1,112,Industry,"September 15, 2017","June 14, 2019","June 14, 2019"
6587,NCT03260790,Pneumococcal Vaccines in Patients With Asthma,Asthma,Biological: PCV13|Biological: PPSV23,Mayo Clinic,Phase 4,17,Other,"October 1, 2017","December 21, 2020","December 25, 2020"
6588,NCT03258905,Phone App for Grounding,Substance-Related Disorders,Behavioral: Grounding enhanced app|Behavioral: Grounding text-only app,Treatment Innovations|National Institutes of Health (NIH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2,62,Industry|NIH,"November 1, 2019","September 3, 2020","September 3, 2020"
6589,NCT03257644,A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis,Atopic Dermatitis,Drug: Ruxolitinib phosphate cream,Incyte Corporation,Phase 1,70,Industry,"September 21, 2017","October 7, 2020","October 7, 2020"
6590,NCT03256864,Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient,Liver Transplantation,Drug: Tacrolimus and Everolimus,Chang Gung Memorial Hospital,Phase 4,10,Other,Jan-16,"June 30, 2019","May 30, 2020"
6591,NCT03256344,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,Metastatic Triple Negative Breast Cancer|Metastatic Colorectal Cancer,Biological: Talimogene Laherparepvec|Biological: Atezolizumab,Amgen|Roche-Genentech,Phase 1,36,Industry,"March 19, 2018","May 26, 2020","December 3, 2021"
6592,NCT03256253,Pregabalin as Treatment for Alcohol Use Disorder,Alcohol Use Disorder,Drug: Pregabalin,New York State Psychiatric Institute,Phase 2,18,Other,"February 15, 2018","May 31, 2019","May 31, 2020"
6593,NCT03256136,"Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC",Lung Cancer,Drug: Carboplatin|Drug: Nivolumab|Drug: pemetrexed|Drug: Ipilimumab,Massachusetts General Hospital|Bristol-Myers Squibb,Phase 2,9,Other|Industry,"November 22, 2017","August 19, 2019","August 19, 2019"
6594,NCT03255824,A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation,Anesthesia,"Drug: Dexmedetomidine and Midazolam|Drug: Propofol, Midazolam, and Fentanyl",Montefiore Medical Center,Phase 4,144,Other,"March 20, 2018","August 23, 2019","December 27, 2019"
6595,NCT03255096,"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",Diffuse Large B-cell Lymphoma|High-Grade B-cell Lymphoma,Drug: RO6870810|Drug: Venetoclax|Drug: Rituximab,Hoffmann-La Roche,Phase 1,39,Industry,"August 28, 2017","July 3, 2019","July 3, 2019"
6596,NCT03254849,Empagliflozin and Sympathetic Nerve Traffic,Type 2 Diabetes Mellitus,Drug: Empagliflozin|Drug: Hydrochlorothiazide 25 mg,Profil Institut für Stoffwechselforschung GmbH,Phase 4,75,Industry,"December 8, 2017","April 20, 2020","April 20, 2020"
6597,NCT03254485,A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF),Heart Failure With Preserved Ejection Fraction,Drug: IW-1973|Drug: Placebo Oral Tablet,Akebia Therapeutics|Cyclerion Therapeutics,Phase 2,196,Industry,"November 7, 2017","August 19, 2019","August 19, 2019"
6598,NCT03254277,3BNC117-LS First-in-Human Phase 1 Study,Human Immunodeficiency Virus,Drug: 3BNC117-LS|Drug: Placebo,Rockefeller University,Phase 1,43,Other,"September 13, 2017","December 31, 2020","December 31, 2020"
6599,NCT03253796,Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038),Spondyloarthritis,Biological: Golimumab|Biological: Placebo,Merck Sharp & Dohme LLC,Phase 4,323,Industry,"November 7, 2017","March 17, 2021","March 17, 2021"
6600,NCT03253133,Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC,Colorectal Cancer,Drug: Oxaliplatin|Drug: LV5FU or Folfiri|Drug: Oxycodone,Institut du Cancer de Montpellier - Val d'Aurelle,Phase 1,19,Other,"May 10, 2016","October 28, 2020","April 24, 2023"
6601,NCT03252535,Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease,Huntington Disease,Biological: Cellavita HD lower dose|Biological: Cellavita HD higher dose|Other: Placebo,Azidus Brasil|Cellavita Pesquisa Científica Ltda,Phase 2,35,Industry|Other,"January 15, 2018","March 23, 2021","April 30, 2021"
6602,NCT03252431,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Breast Cancer|Neutropenia,Drug: F-627|Drug: Neulasta,EVIVE Biotechnology,Phase 3,393,Industry,"April 12, 2018","September 25, 2019","March 5, 2020"
6603,NCT03251170,Ketamine Versus Fentanyl for Induction of Anesthesia in Septic Shock,Septic Shock,Drug: Ketamine|Drug: Fentanyl|Drug: Midazolam,Cairo University,Phase 4,42,Other,"January 25, 2018","December 25, 2019","December 30, 2019"
6604,NCT03251131,REVERSE-AKI Randomized Controlled Pilot Trial,Acute Kidney Injury|Critical Illness,Other: Restrictive fluid management,"Helsinki University Central Hospital|Austin Hospital, Melbourne Australia|Guy's and St Thomas' NHS Foundation Trust|University Hospital, Ghent|Medical University Innsbruck|Lausanne University Hospital",Phase 2,100,Other,"November 8, 2017","January 31, 2020","April 30, 2020"
6605,NCT03250273,A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,Metastatic Cholangiocarcinoma|Cholangiocarcinoma|Pancreatic Cancer|Metastatic Pancreatic Cancer|Unresectable Pancreatic Cancer|Unresectable Cholangiocarcinoma,Drug: Entinostat|Drug: Nivolumab,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb|National Cancer Institute (NCI),Phase 2,44,Other|Industry|NIH,"November 6, 2017","November 20, 2020","November 20, 2020"
6606,NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,Relapsing Multiple Sclerosis,Drug: Ofatumumab|Drug: Matching placebo of ofatumumab,Novartis Pharmaceuticals|Novartis,Phase 2,64,Industry,"March 15, 2018","December 26, 2019","July 29, 2020"
6607,NCT03249259,The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes,"Diabetes Mellitus, Type 2",Drug: Choline alfoscerate|Drug: Placebo,Seoul National University Bundang Hospital,Phase 3,36,Other,"March 10, 2016","June 30, 2019","September 30, 2019"
6608,NCT03248856,Triamcinolone Levels in Cochlear Perilymph,Cochlear Hearing Loss,Drug: Triamcinolone Acetonide,Christoph Arnoldner|Medical University of Vienna,Phase 1,40,Other,"October 2, 2017","December 31, 2020","May 31, 2021"
6609,NCT03248843,A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors,Advanced or Metastatic Solid Tumors,Drug: KN035,"3D Medicines (Sichuan) Co., Ltd.|3D Medicines",Phase 1,35,Industry,"September 15, 2017","March 31, 2020","March 31, 2020"
6610,NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,Breast Cancer,Drug: Ribociclib|Drug: Letrozole 2.5mg|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel,SOLTI Breast Cancer Research Group|Novartis,Phase 2,106,Other|Industry,"July 13, 2017","June 10, 2019","July 20, 2019"
6611,NCT03248297,Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries,Postpartum Sepsis|Postpartum Endometritis|Postpartum Fever,Drug: Azithromycin|Drug: Azithromycin and amoxicillin|Drug: Placebo,University of Alabama at Birmingham|Merck Sharp & Dohme LLC,Phase 4,756,Other|Industry,"January 12, 2018","May 15, 2020","October 1, 2020"
6612,NCT03248037,Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation,Fuchs' Endothelial Dystrophy|Bullous Keratopathy,Drug: Netarsudil|Drug: Placebo,Cornea Research Foundation of America,Phase 3,120,Other,"September 5, 2017","July 9, 2019","July 9, 2019"
6613,NCT03246724,Oral Versus Intravenous Sedation for Ocular Procedures,Surgery|Sedation,Drug: Triazolam|Drug: Midazolam|Drug: Microcrystalline Cellulose|Drug: Sodium chloride 0.9%,Boston Medical Center,Phase 4,327,Other,"October 16, 2017","November 30, 2019","November 30, 2019"
6614,NCT03246555,Fimasartan in the Senior Subjects,The Elderly (≥ 70 Years) With Essential Hypertension,Drug: Fimasartan or Fimasartan/Hydrochlorothiazide|Drug: Perindopril or Perindopril/Indapamide,"Boryung Pharmaceutical Co., Ltd",Phase 3,241,Industry,"July 15, 2016","August 19, 2019","December 9, 2019"
6615,NCT03246321,PIPAC for Peritoneal Metastases of Colorectal Cancer,Colorectal Neoplasms|Peritoneal Neoplasms|Appendiceal Neoplasms|Peritoneal Carcinomatosis,Combination Product: repetitive ePIPAC-OX,Koen Rovers|Catharina Ziekenhuis Eindhoven,Phase 2,20,Other,"October 1, 2017","October 1, 2019","October 1, 2019"
6616,NCT03245853,Epi-On Corneal Crosslinking for Keratoconus,"Keratoconus|Keratoconus, Unstable",Drug: Riboflavin 5'-Phosphate,Comprehensive EyeCare of Central Ohio|Glaukos Corporation,Phase 4,20,Other|Industry,"July 18, 2017","September 1, 2019","September 30, 2019"
6617,NCT03245255,Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound,Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure,Drug: Sonazoid,"Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|GE Healthcare",Phase 2,80,Other|NIH|Industry,"December 4, 2017","September 18, 2020","September 18, 2020"
6618,NCT03244644,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3),Clostridium Difficile Infection,Drug: RBX2660|Drug: Placebo,Rebiotix Inc.,Phase 3,267,Industry,"July 31, 2017","April 2, 2020","August 3, 2020"
6619,NCT03244553,Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study,Ineffective Esophageal Motility|Dysphagia,Drug: Prucalopride,University of Calgary,Phase 2,28,Other,"October 20, 2017","December 2, 2019","December 2, 2019"
6620,NCT03244319,Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial),MV(Mitral Valve) Repair,Drug: Edoxaban|Drug: Warfarin|Drug: parenteral anti-coagulant (UFH),Yonsei University,Phase 3,220,Other,"December 1, 2017","September 30, 2019","September 30, 2019"
6621,NCT03244228,"A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878",Healthy,Drug: HTL0016878|Drug: Placebo - Concentrate,Heptares Therapeutics Limited|Allergan,Phase 1,120,Industry,"August 25, 2017","September 23, 2019","September 23, 2019"
6622,NCT03243942,"Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement",Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure,Drug: Definity,Thomas Jefferson University|American Heart Association|Lantheus Medical Imaging,Phase 2,56,Other|Industry,"June 1, 2017","June 26, 2019","June 26, 2019"
6623,NCT03243851,Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma,Glioblastoma,Drug: Temozolomide+Metformin|Drug: Temozolomide+Placebo,"Yong-Kil Hong|Saint Vincent's Hospital, Korea|Incheon St.Mary's Hospital|National Cancer Center, Korea|Konkuk University Hospital|Seoul National University Bundang Hospital|Samsung Medical Center|Seoul National University Hospital|Asan Medical Center|Ajou University School of Medicine|Severance Hospital|Chonnam National University Hospital|Seoul St. Mary's Hospital",Phase 2,81,Other,"November 21, 2016","December 31, 2020","December 31, 2020"
6624,NCT03243656,Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia,Eltrombopag,Drug: Eltrombopag,Assiut University,Phase 4,20,Other,"December 20, 2017","December 29, 2019","January 5, 2020"
6625,NCT03243331,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,Triple Negative Breast Cancer|Metastatic Breast Cancer,Drug: Gedatolisib|Drug: PTK7-ADC,Kathy Miller|Indiana University,Phase 1,18,Other,"January 19, 2018","May 27, 2020","May 27, 2020"
6626,NCT03242993,[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging,Metastatic Cancer Lung|Metastatic Ovarian Cancer,Drug: [18F]-AzaFol|Drug: folarell,"University of Lausanne Hospitals|University Hospital, Zürich|Cantonal Hospital of St. Gallen",Phase 1,15,Other,"April 1, 2017","June 1, 2019","June 1, 2019"
6627,NCT03242928,Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD),Cocaine-related Disorder,Drug: AFQ056|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,68,Industry,"December 4, 2017","December 16, 2019","December 16, 2019"
6628,NCT03242902,To Decrease Fatigue With Light Therapy,Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma,Device: Light therapy intensity 1|Device: Light therapy intensity 2,The Netherlands Cancer Institute|Dutch Cancer Society,Phase 3,166,Other,"September 20, 2017","November 25, 2019","August 11, 2020"
6629,NCT03242824,The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma,Glioma,Drug: Fluorine F 18 Fluorodopa|Radiation: Intensity-Modulated Radiation Therapy|Procedure: Positron Emission Tomography,Mayo Clinic,Phase 2,21,Other,"September 29, 2017","June 16, 2020","June 16, 2021"
6630,NCT03242018,"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control",Type 2 Diabetes Mellitus|Chronic Kidney Disease Stage 4,Drug: Placebo|Drug: Sotagliflozin,Lexicon Pharmaceuticals|Sanofi,Phase 3,277,Industry,"August 16, 2017","May 16, 2019","December 11, 2019"
6631,NCT03241641,Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.,Chronic Hepatitis b,Drug: Tenofovir Alafenamide|Drug: Tenofovir Disoproxil Fumarate,Young-Suk Lim|Samsung Medical Center|Korea University Guro Hospital|Konkuk University Medical Center|Seoul National University Hospital|Asan Medical Center,Phase 4,174,Other,"October 26, 2017","March 25, 2021","March 25, 2021"
6632,NCT03241550,A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients,Hematological Malignancy,Drug: isavuconazonium sulfate - intravenous|Drug: isavuconazonium sulfate - oral,"Astellas Pharma Global Development, Inc.|Basilea Pharmaceutica International Ltd|Astellas Pharma Inc",Phase 1,49,Industry,"October 2, 2017","July 5, 2019","July 5, 2019"
6633,NCT03241485,Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery,Pain,Drug: Intrathecal morphine|Drug: Placebo,University of Chicago,Phase 4,79,Other,"June 19, 2018","September 1, 2020","September 1, 2020"
6634,NCT03240081,Treating Postmenopausal Dyspareunia Where it Hurts,Dyspareunia,Drug: 50mcg estradiol cream|Drug: 100mcg estradiol cream,Oregon Health and Science University,Phase 4,50,Other,"June 20, 2017","November 21, 2019","November 21, 2019"
6635,NCT03239080,Effect of Denosumab in Erosion Healing in RA,Rheumatoid Arthritis,Drug: Denosumab|Other: Placebo,Chinese University of Hong Kong,Phase 2,110,Other,"June 19, 2017","May 24, 2020","May 24, 2020"
6636,NCT03238963,"A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.",Diabetic Retinopathy,Drug: BI 1467335|Drug: Placebo,Boehringer Ingelheim,Phase 2,79,Industry,"September 19, 2017","May 14, 2020","May 14, 2020"
6637,NCT03238859,10 Days of Theta Burst Stimulation as a Tool to Treat Cocaine Dependence,Cocaine Dependence|Alcohol Dependence,Device: Real cTBS|Device: Sham cTBS,Medical University of South Carolina|National Institute on Drug Abuse (NIDA),Phase 2,84,Other|NIH,"August 1, 2016","June 7, 2019","June 7, 2019"
6638,NCT03238742,The Efficacy of Xuebijing Injection on Sepsis,Sepsis,Drug: Xuebijing Injection|Drug: normal saline,"Southeast University, China|National Health and Family Planning Commission, P.R.China",Phase 4,1817,Other,"October 20, 2017","July 28, 2019","January 8, 2020"
6639,NCT03238235,Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy,Becker Muscular Dystrophy,Drug: givinostat|Drug: placebo,Italfarmaco,Phase 2,51,Industry,"December 12, 2017","March 19, 2021","March 19, 2021"
6640,NCT03238027,A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors,Solid Tumor|Metastatic Tumor|Locally Advanced Malignant Neoplasm|Unresectable Malignant Neoplasm,Drug: SNDX-6352|Drug: Durvalumab,Syndax Pharmaceuticals,Phase 1,45,Industry,"September 1, 2017","November 20, 2020","November 20, 2020"
6641,NCT03237728,Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients,Sepsis,"Drug: 0.06mg/kg,KB|Drug: 0.12mg/kg,KB|Drug: 0.24mg/,KB|Drug: Placebos","Tianjin Chasesun Pharmaceutical Co., LTD|Southwest Hospital, China",Phase 1,44,Industry|Other,"July 28, 2017","September 25, 2019","September 25, 2019"
6642,NCT03237325,DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer,Squamous Cell Carcinoma of the Oral Cavity and Oropharynx|Oral Mucositis,Drug: SGX942|Drug: Placebo,Soligenix,Phase 3,266,Industry,"December 4, 2017","June 24, 2020","June 24, 2021"
6643,NCT03236506,A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study,Hepatitis C,Drug: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Behavioral: Psychological intervention|Drug: Sofosbuvir 400 MG,University of Dundee,Phase 2,129,Other,"January 19, 2018","August 31, 2020","October 28, 2020"
6644,NCT03236246,KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial),Chronic Kidney Diseases|Iron Deficiency Anemia,Drug: KRX-0502,Keryx Biopharmaceuticals,Phase 4,206,Industry,"August 15, 2017","August 30, 2019","September 27, 2019"
6645,NCT03235752,Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis,Active Ulcerative Colitis,Drug: TJ301 300mg|Drug: TJ301 600mg|Drug: Placebo,I-Mab Biopharma HongKong Limited,Phase 2,91,Industry,"February 6, 2018","December 21, 2020","December 21, 2020"
6646,NCT03235570,A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102),Solid Tumors,Drug: Pemigatinib,Incyte Corporation,Phase 1,44,Industry,"August 1, 2017","March 4, 2020","March 4, 2020"
6647,NCT03235505,Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers,Smoking Cessation|Electronic Cigarette,Drug: Nicotine|Drug: Varenicline Tartrate|Behavioral: Motivational Interview,University of Oulu|Lapland Central Hospital Rovaniemi Finland,Phase 4,450,Other,"August 1, 2018","March 31, 2021","December 31, 2021"
6648,NCT03235154,A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic,"Hepatitis C, Chronic|Hepatitis C|Opiate Dependence",Drug: sofosbuvir/velpatasvir,Community Research Initiative of New England|Gilead Sciences,Phase 4,11,Other|Industry,"October 11, 2017","September 26, 2019","September 26, 2019"
6649,NCT03234907,Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.,Crohn's Disease,Drug: Vedolizumab IV|Drug: Placebo,Takeda,Phase 3,215,Industry,"August 3, 2017","August 14, 2020","August 14, 2020"
6650,NCT03234712,"A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)",Advanced Solid Tumors Cancer,Drug: ABBV-321,AbbVie,Phase 1,62,Industry,"October 10, 2017","April 14, 2021","April 14, 2021"
6651,NCT03234491,Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy,Post-Prandial Hyperglycemia|Post-Prandial Hypoglycemia,Device: DiAS|Drug: Afrezza low dose|Drug: Afrezza high dose,Yale University,Phase 1,15,Other,"November 22, 2017","July 22, 2019","July 22, 2019"
6652,NCT03234348,MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction,Acute Coronary Syndrome|ST Segment Elevation Myocardial Infarction|Stent,Device: Percutaneous coronary intervention,Hospital Clinic of Barcelona|Spanish Society of Cardiology,Phase 3,151,Other,"July 1, 2017","June 30, 2019","October 31, 2019"
6653,NCT03233776,Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT,Multiple Myeloma,Drug: Anakinra,Radboud University Medical Center,Phase 2,9,Other,"August 21, 2017","May 7, 2019","August 1, 2020"
6654,NCT03233412,Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions,High Grade Intraepithelial Neoplasia|Cervix Cancer,Procedure: Control|Drug: Imiquimod,Barretos Cancer Hospital|Farmoquimica S.A.,Phase 2,90,Other|Industry,"January 1, 2018","January 14, 2020","January 14, 2020"
6655,NCT03233230,Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: M2591 25 mg QD|Drug: M2951 75 mg QD|Drug: M2951 50 mg BID|Drug: Placebo,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 2,390,Industry,"September 18, 2017","September 23, 2019","September 23, 2019"
6656,NCT03233126,A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia,X-linked Hypophosphatemic Rickets/Osteomalacia,Drug: KRN23,"Kyowa Kirin Co., Ltd.",Phase 3,16,Industry,"July 6, 2017","February 17, 2020","February 17, 2020"
6657,NCT03232398,Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus,Acute Myocardial Infarction|Left Ventricular Thrombosis|Anticoagulants and Bleeding Disorders,Drug: Apixaban Oral Tablet [Eliquis]|Drug: Warfarin,Hadassah Medical Organization,Phase 3,40,Other,"January 1, 2018","March 31, 2021","May 31, 2021"
6658,NCT03232281,"Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis",Endometriosis,Drug: Triptorelin Pamoate PR 3-month|Drug: Triptorelin Acetate PR 1-month,Ipsen,Phase 3,300,Industry,"July 28, 2017","May 17, 2019","November 16, 2019"
6659,NCT03232177,Anagre Cap. in Patients With High-Risk Essential Thrombocythemia,Essential Thrombocythemia,Drug: Anagre Cap.,Yuhan Corporation,Phase 4,70,Industry,"June 5, 2017","December 5, 2020","December 5, 2020"
6660,NCT03232112,Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?,"Alcohol Dependence, in Remission|Addiction, Alcohol",Drug: Exenatide 2 MG Injection|Drug: BD PosiFlush (saline),"Anders Fink-Jensen, MD, DMSci|The Novavì outpatient clinics, Copenhagen|Neurobiology Research Unit, Rigshospitalet, Copenhagen|Section of Biostatistics University of Copenhagen, Copenhagen|Psychiatric Centre Rigshospitalet",Phase 2,152,Other,"August 7, 2017","March 15, 2020","October 5, 2020"
6661,NCT03231176,Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine,ASLAN Pharmaceuticals,Phase 2,62,Other,"December 19, 2017","July 5, 2019","April 13, 2020"
6662,NCT03230916,A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020),Suspected or Documented Gram-negative Bacterial Infection,Drug: IMI/REL FDC,Merck Sharp & Dohme LLC,Phase 1,47,Industry,"November 6, 2017","July 28, 2020","August 11, 2020"
6663,NCT03230838,MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034),Complicated Urinary Tract Infection|Pyelonephritis,Drug: Ceftolozane/Tazobactam|Drug: Meropenem,Merck Sharp & Dohme LLC,Phase 2,134,Industry,"April 26, 2018","December 3, 2020","December 3, 2020"
6664,NCT03230071,Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia,Vascular Dementia,Drug: TMBCZG|Other: placebo,"Dongzhimen Hospital, Beijing|Beijing Union pharmaceutical factory II|Beijing Compete Medical Technology Development Co. Ltd.",Phase 2,160,Other,"July 28, 2017","August 22, 2019","February 5, 2021"
6665,NCT03229486,Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium Anesthesia,Emergence Delirium,Drug: Sugammadex Injection [Bridion]|Drug: Neostigmine+Glycopyrronium,Pusan National University Yangsan Hospital,Phase 4,40,Other,"March 1, 2017","July 30, 2019","December 30, 2019"
6666,NCT03229278,Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,Lymphoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Cancer|Recurrent Bladder Carcinoma|Recurrent Classical Hodgkin Lymphoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Renal Cell Carcinoma|Stage III Bladder Cancer|Stage III Lymphoma|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage III Renal Cell Cancer|Stage III Skin Melanoma|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Skin Melanoma|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Bladder Cancer|Stage IV Lymphoma|Stage IV Non-Small Cell Lung Cancer AJCC v7|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Bladder Cancer|Stage IVB Bladder Cancer|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Solid Neoplasm,Drug: Enzyme Inhibitor Therapy|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Pembrolizumab,"Rutgers, The State University of New Jersey|National Cancer Institute (NCI)",Phase 1,14,Other|NIH,"August 17, 2017","January 8, 2020","January 30, 2020"
6667,NCT03229265,Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer,Hyperkalemia|Kidney Transplant,Drug: Patiromer,The Rogosin Institute|Weill Medical College of Cornell University,Phase 4,8,Other,"August 1, 2017","August 7, 2019","August 7, 2019"
6668,NCT03229252,An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis,Cystic Fibrosis,Drug: Placebo Inhalation Solution|Drug: SPX-101,"Spyryx Biosciences, Inc.",Phase 2,91,Industry,"August 1, 2017","June 20, 2019","June 20, 2019"
6669,NCT03228836,Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients,Effect of Drugs,Drug: Sintilimab,Innovent Biologics (Suzhou) Co. Ltd.,Phase 2,28,Industry,"August 23, 2017","February 28, 2020","February 28, 2020"
6670,NCT03228680,Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women,Infertility,Drug: Follitropin delta|Drug: Follitropin beta,Ferring Pharmaceuticals,Phase 3,373,Industry,"July 29, 2017","June 10, 2019","July 8, 2019"
6671,NCT03228498,Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment,Vascular Cognitive Impairment,Drug: Choline alphoscerate|Drug: Placebo,Azienda Ospedaliero-Universitaria Careggi|MDM S.p.A.,Phase 2,62,Other,"May 2, 2017","July 9, 2019","July 9, 2019"
6672,NCT03228394,A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression,"Depression|Depressive Disorder|Depression, Postpartum|Behavioral Symptoms|Mood Disorders|Mental Disorders|Puerperal Disorders|Pregnancy Complications|Postpartum|PPD",Drug: Ganaxolone|Drug: Placebo,Marinus Pharmaceuticals,Phase 2,91,Industry,"June 27, 2017","May 10, 2019","May 10, 2020"
6673,NCT03228030,Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial,Heart Failure|Heart Failure With Reduced Ejection Fraction|Thiamine Deficiency|Congestive Heart Failure,Dietary Supplement: Thiamine|Dietary Supplement: Placebo,Hamilton Health Sciences Corporation|McMaster/St. Peter's Hospital Chair of Aging|McMaster University,Phase 1,24,Other,"April 2, 2018","April 30, 2021","April 30, 2021"
6674,NCT03227926,Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance,Colorectal Cancer,Drug: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Diagnostic Test: Molecular Screening,Fondazione del Piemonte per l'Oncologia,Phase 2,32,Other,"October 11, 2017","November 6, 2019","December 31, 2021"
6675,NCT03227796,"Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain",Healthy Volunteers|Osteoarthritis,Drug: LEVI-04|Drug: Placebo,Levicept|Hammersmith Medicines Research|MAC Clinical Research,Phase 1,56,Industry|Other,"July 28, 2017","March 31, 2021","March 31, 2021"
6676,NCT03227484,Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes,PreDiabetes|Body Weight,Drug: Empagliflozin 25mg|Drug: Placebo Oral Tablet,University Hospital Tuebingen,Phase 2,42,Other,"June 9, 2017","October 25, 2019","November 18, 2019"
6677,NCT03227263,BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).,"Rendu Osler Disease|Telangiectasia, Hereditary Hemorrhagic",Drug: Bevacizumab|Drug: sodium chloride 0.9%,Hospices Civils de Lyon,Phase 3,24,Other,"September 28, 2017","May 15, 2020","May 15, 2020"
6678,NCT03227029,"Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age",Respiratory Syncytial Virus Infections,Biological: RSV ΔNS2/Δ1313/I1314L|Biological: RSV 276|Biological: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,65,NIH,"September 22, 2017","December 19, 2019","October 1, 2020"
6679,NCT03226574,Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain,Intractable Cancer Pain,Drug: Resiniferatoxin,"Sorrento Therapeutics, Inc.",Phase 1,17,Industry,"September 1, 2017","March 18, 2020","June 18, 2020"
6680,NCT03226431,Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0,Lung Transplant,Drug: Ascorbic Acid,Duke University,Phase 1,6,Other,"December 11, 2017","June 25, 2019","June 25, 2019"
6681,NCT03226392,Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma,Asthma,Drug: QAW039|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,704,Industry,"October 31, 2017","July 5, 2019","August 1, 2019"
6682,NCT03226223,Pharmacogenetics of Naltrexone for Stimulant Abuse,Substance Use Disorders|Methamphetamine Abuse,Drug: Intranasal Methamphetamine,New York State Psychiatric Institute,Phase 2,18,Other,"September 15, 2016","July 15, 2019","July 30, 2020"
6683,NCT03225651,Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism,Stem Cell Transplantation,Biological: Stem cell transplantation|Behavioral: Psychological therapy and Rehabilitation,Vinmec Research Institute of Stem Cell and Gene Technology,Phase 2,30,Other,"July 18, 2017","August 30, 2019","August 30, 2019"
6684,NCT03225261,The Effect of Citrus Extract on Gastrointestinal Health,Irritable Bowel Syndrome,Dietary Supplement: Citrus extract|Dietary Supplement: Placebo,Maastricht University Medical Center,Phase 2,29,Other,"November 20, 2017","February 12, 2021","February 13, 2021"
6685,NCT03225105,M3541 in Combination With Radiotherapy in Subjects With Solid Tumors,Solid Tumors,Drug: M3541|Radiation: Palliative Radiotherapy (RT),"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 1,15,Industry,"September 6, 2017","September 2, 2019","April 27, 2020"
6686,NCT03224338,"Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects",HIV II Infection,Drug: Dolutegravir 50 mg,"Blueclinical, Ltd.",Phase 2,30,Other,"April 5, 2017","July 2, 2019","July 2, 2019"
6687,NCT03223831,Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.,Unresectable Malignant Gastric Outlet Obstruction,Other: Partially covered pyloro-duodenal stent|Other: Uncovered pyloro-duodenal stents,"Chinese University of Hong Kong|National University Hospital, Singapore|Singapore General Hospital|Changi General Hospital|Baldota Institute of Digestive Diseases, Mumbai, India.",Phase 3,116,Other,"August 1, 2017","November 1, 2020","November 1, 2020"
6688,NCT03223714,Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion,Macular Edema|Central Retinal Vein Occlusion,Drug: Conbercept Ophthalmic Injection|Drug: sham injection,"Chengdu Kanghong Biotech Co., Ltd.",Phase 3,242,Industry,"May 24, 2016","April 13, 2020","September 28, 2020"
6689,NCT03223649,Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth,Healthy|Obesity|Overweight,Other: Walking Bouts|Other: Sedentary,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC),Phase 2,129,NIH,"July 26, 2017","June 26, 2020","February 23, 2021"
6690,NCT03223350,Topical Capsaicin for Cyclical Vomiting,Cyclical Vomiting,Drug: Capsaicin 0.1% Cream|Drug: Placebos,Henry Ford Health System,Phase 2,30,Other,"December 20, 2017","August 5, 2019","August 5, 2019"
6691,NCT03223298,Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles,"Pain, Head|Pain Syndrome|Temporomandibular Disorder|Myofascial Pain Syndrome|Myofascial Pain",Drug: Botulinum toxin type A|Drug: 0.9% Sodium Chloride Injection,Weill Medical College of Cornell University|New York Presbyterian Hospital|Allergan,Phase 3,75,Other|Industry,"August 31, 2018","March 13, 2020","March 13, 2020"
6692,NCT03223272,Mechanisms of Refractory Hypertension (Reserpine),Refractory Hypertension,Drug: Reserpine,University of Alabama at Birmingham,Phase 2,7,Other,"July 23, 2015","January 31, 2020","January 31, 2020"
6693,NCT03222843,"Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient",Idiopathic Thrombocytopenic Purpura,Drug: Hetrombopag Olamine|Drug: matching placebo,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,424,Industry,"June 30, 2017","November 11, 2019","January 7, 2021"
6694,NCT03222349,Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy,Epilepsy,Drug: Diazepam Buccal Film,Aquestive Therapeutics|Syneos Health|Covance,Phase 2,24,Industry|Other,"August 31, 2017","January 28, 2020","March 11, 2020"
6695,NCT03221179,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers",Healthy Volunteers,Biological: RO7049665|Biological: Placebo,Hoffmann-La Roche,Phase 1,49,Industry,"July 10, 2017","July 5, 2019","July 5, 2019"
6696,NCT03220958,Metoclopramide for Post Traumatic Headache,Post-Traumatic Headache,Drug: Metoclopramide|Drug: Diphenhydramine|Drug: Normal saline,Montefiore Medical Center,Phase 3,160,Other,"August 1, 2017","April 1, 2020","April 1, 2020"
6697,NCT03220854,SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx,Solid Tumor,Radiation: Stereotactic radiotherapy|Other: Biological: humanized anti-PD-1 monoclonal antibody|Other: Biological: humanized anti-PD-L1 monoclonal antibody,Virginia Commonwealth University|National Cancer Institute (NCI),Phase 2,5,Other|NIH,"October 10, 2017","January 27, 2020","September 22, 2021"
6698,NCT03220737,VAXCHORA Pediatric Study to Assess Safety and Immunogenicity,Cholera (Disorder),"Biological: VAXCHORA (Cholera Vaccine, Live, Oral)|Other: Placebo",Emergent BioSolutions,Phase 4,550,Industry,"July 21, 2017","September 10, 2019","March 6, 2020"
6699,NCT03220295,Putative Cognitive Enhancer VU319,Cognitive Impairment,Drug: Single Dose of VU319|Drug: Single Dose Placebo|Other: Fed State|Other: Fasted State|Drug: Dose Escalation of VU319|Drug: Placebo Dose Escalation,Vanderbilt University|Vanderbilt University Medical Center,Phase 1,52,Other,"July 28, 2017","October 30, 2019","October 30, 2019"
6700,NCT03220243,Stem Cell Coated Fistula Plug in Patients With Crohn's RVF,Fistula Vagina|Crohn Disease,Drug: MSC-AFP,Mayo Clinic,Phase 1,5,Other,"October 19, 2017","September 20, 2020","September 20, 2020"
6701,NCT03220217,To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET),Gastro-Enteropancreatic Neuroendocrine Tumor,Drug: Satoreotide trizoxetan 5-20μg|Drug: Satoreotide trizoxetan 30-45μg,Ipsen,Phase 2,29,Industry,"September 26, 2017","July 25, 2019","August 5, 2019"
6702,NCT03219710,"""Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)""",Chemotherapy-induced Nausea and Vomiting,Drug: Ondansetron|Drug: Dexamethasone|Drug: Aprepitant|Drug: Olanzapine,"All India Institute of Medical Sciences, New Delhi",Phase 3,240,Other,"July 1, 2017","July 31, 2019","July 31, 2019"
6703,NCT03219411,Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes,Dysglycemia|Obesity,Dietary Supplement: Cinnamon|Other: placebo,Joslin Diabetes Center|Kyunghee University,Phase 2,12,Other,"August 28, 2017","July 1, 2019","July 30, 2019"
6704,NCT03218995,Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping,Duchenne Muscular Dystrophy,Drug: Eteplirsen,"Sarepta Therapeutics, Inc.",Phase 2,15,Industry,"August 16, 2017","March 10, 2021","March 10, 2021"
6705,NCT03218917,Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis,Non-Cystic Fibrosis Bronchiectasis,Drug: Brensocatib 10 mg|Drug: Brensocatib 25 mg|Drug: Placebo,Insmed Incorporated,Phase 2,256,Industry,"October 31, 2017","December 12, 2019","December 12, 2019"
6706,NCT03217591,A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria,Type 2 Diabetes Mellitus With Diabetic Nephropathy,Drug: IW-1973|Drug: Placebo,Akebia Therapeutics|Cyclerion Therapeutics,Phase 2,156,Industry,"August 1, 2017","August 20, 2019","August 20, 2019"
6707,NCT03217136,MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035),Complicated Intra-Abdominal Infection,Drug: Ceftolozane/Tazobactam|Drug: Metronidazole|Drug: Meropenem|Drug: Placebo for Metronidazole,Merck Sharp & Dohme LLC,Phase 2,94,Industry,"April 3, 2018","March 16, 2020","March 16, 2020"
6708,NCT03216499,HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma,Recurrent Glioblastoma,Drug: HIF-2alpha Inhibitor PT2385|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Peloton Therapeutics, Inc.",Phase 2,24,Other|NIH|Industry,"September 14, 2017","August 31, 2019","June 5, 2020"
6709,NCT03215758,Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma,Asthma,Drug: QAW039|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,675,Industry,"November 1, 2017","July 2, 2019","July 30, 2019"
6710,NCT03215277,A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis,Ankylosing Spondylitis,Drug: Bimekizumab|Drug: Certolizumab pegol|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 2,76,Industry,"October 4, 2017","May 25, 2020","May 25, 2020"
6711,NCT03213964,Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Biological: FATE-NK100|Drug: Interleukin-2,"Masonic Cancer Center, University of Minnesota",Phase 1,10,Other,"October 19, 2017","March 10, 2021","March 10, 2021"
6712,NCT03213834,Fibrinolytic Therapy Versus Medical Thoracoscopy,Pleural Diseases,Procedure: Chest thoracoscopy|Procedure: Chest fibrinolytic therapy|Drug: tPA|Drug: DNase,University of Florida,Phase 4,5,Other,"September 14, 2017","February 4, 2020","February 4, 2020"
6713,NCT03213158,Ixazomib for Desensitization,Kidney Diseases|End Stage Renal Disease,Drug: Ixazomib Oral Capsule,"University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc.",Phase 2,10,Other|Industry,"September 15, 2017","April 16, 2021","April 16, 2021"
6714,NCT03212937,"Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma",Peripheral T-cell Lymphoma,Drug: Selinexor|Drug: ICE Chemotherapy,"National Cancer Centre, Singapore",Phase 1,11,Other,"July 1, 2016",Nov-20,Nov-20
6715,NCT03212651,Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab,Bladder Cancer,Drug: Pembrolizumab,"Gustave Roussy, Cancer Campus, Grand Paris|Merck Sharp & Dohme LLC",Phase 2,41,Other|Industry,"October 17, 2017","July 18, 2019","December 13, 2019"
6716,NCT03212365,Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery,Venous Thromboembolism|Deep Venous Thrombosis|Pulmonary Embolus|Reconstructive Surgery,Drug: Fixed dose|Drug: Variable dose,University of Utah|Stanford University,Phase 2,295,Other,"July 3, 2017","June 2, 2019","October 1, 2019"
6717,NCT03211286,Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients,Hip Fractures|Anemia,Drug: Tranexamic Acid|Drug: Saline Solution,"Alejandro Lizaur-Utrilla, PhD, MD|University of Alicante|Elda University Hospital",Phase 4,129,Other,"January 30, 2018","March 2, 2021","March 8, 2022"
6718,NCT03211234,Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects,Age-Related Macular Degeneration,Drug: 2.0 mg DE-122 Injectable Solution + Lucentis|Drug: 4.0 mg DE-122 Injectable Solution + Lucentis|Drug: Lucentis,Santen Inc.,Phase 2,76,Industry,"July 5, 2017","December 31, 2019","January 31, 2020"
6719,NCT03211156,Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin,Vaginitis Gardnerella,Drug: Amoxicillin|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,97,NIH,"September 11, 2017","August 22, 2019","August 22, 2019"
6720,NCT03209973,A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma,Classical Hodgkin Lymphoma,Drug: Tislelizumab,BeiGene,Phase 2,70,Industry,"April 21, 2017","November 2, 2020","November 2, 2020"
6721,NCT03209856,Vitamin D Supplementation in Vitamin Deficient Women Undergoing IVF Cycles: Does it Affect the Fertility Outcome?,Infertility,Drug: Vitamin D,Cairo University,Phase 4,200,Other,"July 6, 2017","March 20, 2021","April 20, 2021"
6722,NCT03209830,Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage,Aneurysmal Subarachnoid Hemorrhage,Drug: OSU 6162|Drug: Placebo Oral Tablet,"Oslo University Hospital|Göteborg University|Sahlgrenska University Hospital, Sweden",Phase 2,100,Other,"September 5, 2017","September 13, 2019","September 13, 2019"
6723,NCT03209700,Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas,Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula,Drug: MSC-AFP,"William A. Faubion, M.D.|Mayo Clinic",Phase 1,7,Other,"July 20, 2017","December 10, 2019","December 10, 2019"
6724,NCT03209219,Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis,Behçet Disease|Uveitis,Drug: Interferon Alfa-2A|Drug: Cyclosporine Pill,Peking Union Medical College Hospital,Phase 3,28,Other,"June 30, 2017","August 31, 2020","January 31, 2021"
6725,NCT03209193,Effect of Anesthetics on Microcirculation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery,Microcirculation|Anesthetic Complication Spinal,Drug: Sevoflurane|Drug: Desflurane,Seoul National University Hospital,Phase 4,72,Other,"July 4, 2017","November 7, 2019","November 7, 2019"
6726,NCT03208933,Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone,Hoffmann-La Roche,Phase 3,60,Industry,"October 23, 2017","November 13, 2019","November 13, 2019"
6727,NCT03208790,Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.,Premalignant Lesion,Drug: Nigella sativa buccal tablets 10mg|Drug: Nigella sativa buccal tablets 5mg|Drug: Placebo buccal tablets,Cairo University,Phase 2,48,Other,"September 30, 2017","March 12, 2020","March 12, 2020"
6728,NCT03208465,Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease,Diabetes Mellitus|Coronary Disease,Drug: Empagliflozin|Drug: Sitagliptin,"CHEOL WHAN LEE, M.D., Ph.D|Asan Medical Center",Phase 4,100,Other,"August 7, 2017","August 1, 2019","August 1, 2019"
6729,NCT03208179,Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa,Pregnancy|Malaria in Pregnancy|Malaria,Drug: dihydroartemisinin-piperaquine|Drug: sulphadoxine-pyrimethamine|Drug: dihydroartemisinin-piperaquine plus azithromycin,"Liverpool School of Tropical Medicine|Kamuzu University of Health Sciences|Kenya Medical Research Institute|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|National Institute for Medical Research, Tanzania|Kilimanjaro Christian Medical Centre, Tanzania|University of Copenhagen|Centers for Disease Control and Prevention|London School of Hygiene and Tropical Medicine|University College, London|Tampere University|University of Bergen|University of Massachusetts, Worcester|University of Toronto|University of Melbourne|Foundation for Innovative New Diagnostics, Switzerland",Phase 3,4680,Other|U.S. Fed,"March 29, 2018","March 15, 2020","March 15, 2020"
6730,NCT03207724,Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia,Pancreatic Cancer|Cachexia|Weight Loss,Drug: Xilonix plus Onivyde and 5FU,"Andrew Hendifar, MD|Ipsen|Janssen Research & Development, LLC|Cedars-Sinai Medical Center",Phase 1,16,Other|Industry,"October 16, 2017","November 21, 2019","October 27, 2020"
6731,NCT03207191,Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation,Acute Myeloid Leukemia (AML) Relapse,Drug: F16IL2|Drug: BI 836858,Philogen S.p.A.|Boehringer Ingelheim,Phase 1,15,Industry,"December 2, 2016","March 26, 2020","March 26, 2020"
6732,NCT03207165,Milrinone Versus Dobutamine in Critically Ill Patients,Low Cardiac Output Syndrome|Cardiogenic Shock|Acute Coronary Syndrome|Pulmonary Edema,Drug: Milrinone|Drug: Dobutamine,Ottawa Heart Institute Research Corporation,Phase 4,192,Other,"August 30, 2017","June 12, 2020","June 12, 2020"
6733,NCT03207139,Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer,Latent Cancer Prostate,Drug: Ga-68 PSMA ligand,Chang Gung Memorial Hospital,Phase 2,71,Other,"June 22, 2017","June 30, 2019","June 30, 2019"
6734,NCT03205956,Measuring Parkinson's Disease Progression,Parkinson's Disease,Drug: Levodopa,"Kevin J. Black, MD|The Michael J. Fox Foundation for Parkinson's Research|Washington University School of Medicine",Phase 1,31,Other,"October 19, 2017","October 18, 2019","October 19, 2019"
6735,NCT03205917,A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults,HIV Infections,Biological: PGDM1400/Placebo (3mg/kg IV)|Biological: PGDM1400/Placebo (10mg/kg IV)|Biological: PGDM1400/Placebo (30mg/kg IV)|Biological: PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|Biological: PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|Biological: PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|Biological: PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|Biological: PGDM1400 + PGT121 (MTD IV),"International AIDS Vaccine Initiative|Beth Israel Deaconess Medical Center|Ragon Institute of MGH, MIT and Harvard|University of Texas Health, Houston AIDS Research Team (HART)|Orlando Immunology Clinic",Phase 1,29,Other,"October 23, 2017","April 20, 2020","April 20, 2020"
6736,NCT03205488,Nilotinib in Parkinson's Disease,Parkinson Disease,Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|Drug: Placebo,Northwestern University|University of Rochester|University of Iowa|Michael J. Fox Foundation for Parkinson's Research,Phase 2,76,Other,"October 16, 2017","August 26, 2019","September 28, 2019"
6737,NCT03205176,"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas",Malignant Solid Tumors|Lymphoma|Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer,Drug: AZD5153|Drug: Olaparib,AstraZeneca,Phase 1,49,Industry,"June 30, 2017","March 1, 2021","April 8, 2021"
6738,NCT03205150,Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients,Obese Patients With Non-alcoholic Steatohepatitis (NASH),Drug: LIK066|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,107,Industry,"October 4, 2017","November 11, 2019","November 14, 2019"
6739,NCT03204929,Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease,Parkinson Disease,Drug: Cu(II)ATSM,Collaborative Medicinal Development Pty Limited,Phase 1,31,Industry,"August 14, 2017","November 30, 2019","February 29, 2020"
6740,NCT03204812,Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer,Castration-Resistant Prostate Carcinoma|Metastatic Malignant Neoplasm in the Bone|Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,Biological: Durvalumab|Biological: Tremelimumab,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,31,Other|NIH,"July 14, 2017","April 13, 2021","April 13, 2021"
6741,NCT03204617,"Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)",HIV,"Biological: DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Biological: At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|Drug: Placebo",Aelix Therapeutics,Phase 1,45,Industry,"July 7, 2017","July 1, 2020","March 10, 2021"
6742,NCT03204331,SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain,Endometriosis Related Pain,Drug: Relugolix|Drug: Estradiol/norethindrone acetate|Drug: Estradiol/norethindrone acetate placebo|Drug: Relugolix placebo,Myovant Sciences GmbH,Phase 3,623,Industry,"November 1, 2017","April 1, 2020","May 31, 2021"
6743,NCT03204318,SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain,Endometriosis Related Pain,Drug: Relugolix|Drug: Estradiol/norethindrone acetate|Drug: Estradiol/norethindrone acetate placebo|Drug: Relugolix placebo,Myovant Sciences GmbH,Phase 3,638,Industry,"December 7, 2017","June 9, 2020","April 8, 2021"
6744,NCT03204279,PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting,Chemotherapy-induced Nausea and Vomiting (CINV),Drug: Netupitant|Drug: Palonosetron,Helsinn Healthcare SA,Phase 2,67,Industry,"August 31, 2017","September 30, 2019","September 30, 2019"
6745,NCT03203876,A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors,Advanced Cancer,Biological: Lirilumab|Biological: Nivolumab|Biological: Ipilimumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 1,10,Industry,"July 14, 2017","August 6, 2020","August 6, 2020"
6746,NCT03203681,"Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters","Hypogonadism, Male",Drug: Natesto,University of Miami|Acerus Pharmaceuticals Corporation,Phase 4,60,Other|Industry,"October 27, 2017","June 1, 2020","June 1, 2020"
6747,NCT03202719,Duration of IPV Priming and Antibody Decay,Poliomyelitis,"Biological: Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|Biological: Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|Biological: Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|Biological: Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|Biological: Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|Biological: Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age","Centers for Disease Control and Prevention|International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 4,1645,U.S. Fed|Other,"November 5, 2017","October 1, 2019","October 1, 2019"
6748,NCT03202550,Oral Sedation During Cervical Dilator Placement,Oral Sedation and Cervical Dilator Pain,Drug: Oxycodone and Lorazepam (Active Comparator)|Drug: Placebo Comparator,Johns Hopkins University|Society of Family Planning,Phase 4,27,Other,"June 28, 2017","May 28, 2019","May 28, 2019"
6749,NCT03202394,Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS,"Respiratory Distress Syndrome, Adult",Drug: BIO-11006|Drug: Placebo,"BioMarck Pharmaceuticals, Ltd.",Phase 2,38,Industry,"August 5, 2017","March 30, 2020","June 15, 2020"
6750,NCT03202368,An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA),Giant Cell Arteritis,Drug: Tocilizumab,Hoffmann-La Roche,Phase 3,3,Industry,"October 25, 2017","August 21, 2019","August 21, 2019"
6751,NCT03201913,Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,Metastatic ER+ Breast Cancer,Drug: TTC-352,"TTC Oncology, LLC",Phase 1,15,Industry,"December 11, 2017","December 31, 2019","April 30, 2020"
6752,NCT03201796,Prulifloxacin in Chronic Bacterial Prostatitis (CBP),Chronic Bacterial Prostatitis,Drug: Prulifloxacin 600 mg|Drug: Levofloxacin 500mg,Aziende Chimiche Riunite Angelini Francesco S.p.A|Hippocrates Research,Phase 2,168,Industry|Other,"February 2, 2016","May 19, 2020","May 19, 2020"
6753,NCT03201419,"A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",Nocturia,Drug: FE 201836|Drug: Desmopressin|Drug: Placebo oral solution|Drug: Placebo ODT,Ferring Pharmaceuticals,Phase 2,302,Industry,"July 27, 2017","October 31, 2019","October 31, 2019"
6754,NCT03201211,A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults,Respiratory Disorders,"Biological: Blood sampling|Biological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|Biological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|Drug: Placebo",GlaxoSmithKline,Phase 1,81,Industry,"June 22, 2017","March 19, 2020","March 19, 2020"
6755,NCT03200860,Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure,Heart Failure Acute|Heart Failure，Congestive|Heart Failure; With Decompensation,Drug: Empagliflozin 10 MG|Drug: Placebo Oral Tablet,University Medical Center Groningen,Phase 2,80,Other,"December 18, 2017","September 18, 2019","September 18, 2019"
6756,NCT03200704,A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer,Breast Cancer|Lymph Node Mapping|Sentinel Lymph Node Biopsy,Combination Product: IC2000 and SPY-PHI|Combination Product: Tc-99m radioactive colloid and Gamma Probe,"Novadaq Technologies ULC, now a part of Stryker",Phase 3,151,Industry,"January 4, 2019","August 27, 2020","September 28, 2020"
6757,NCT03200587,Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC),Renal Cell Carcinoma,Drug: Avelumab|Drug: Cabozantinib,University of Utah|EMD Serono,Phase 1,12,Other|Industry,"June 21, 2018","April 14, 2020","November 25, 2021"
6758,NCT03199976,Efficacy of Intermittent Tiotropium in Early Childhood Wheezing,Wheezy Bronchitis|Asthmatic Bronchitis|Wheezing|Obstruction Airway,Drug: Tiotropium Bromide|Drug: Fluticasone Propionate|Drug: Salbutamol,Helsinki University Central Hospital,Phase 4,80,Other,"April 20, 2016","November 18, 2020","November 18, 2020"
6759,NCT03199911,Topical Antibiotic Prophylaxis for Eyelids,"Antibiotic Side Effect|Eyelid; Wound|Eyelid Diseases|Surgical Wound Infection|Surgical Wound, Recent|Surgical Incision|Skin Cancer Face|Antibiotic Allergy|Surgical Site Infection",Drug: Topical Antibiotic Product|Drug: Topical Non-Antibiotic Ointment,"University of California, San Francisco",Phase 4,401,Other,"October 2, 2017","November 14, 2019","November 14, 2019"
6760,NCT03199586,Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies,Breast Cancer|Pancreas Cancer|Prostate Cancer|Lung Cancer|Colon Cancer|Esophagus Cancer|Liver Cancer|Ovary Cancer|Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies,Drug: NP-G2-044,"Novita Pharmaceuticals, Inc.|Translational Drug Development",Phase 1,23,Industry|Other,"December 21, 2017","May 7, 2020","May 7, 2020"
6761,NCT03199534,A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction,Pelvic Pain|Dyspareunia|Pelvic Floor Dysfunction,Drug: Botulinum toxin A 50u|Drug: Botulinum toxin A 100u|Drug: Botulinum toxin A 150u,EvergreenHealth|The Cleveland Clinic,Phase 4,20,Other,"May 25, 2017","February 26, 2020","February 26, 2020"
6762,NCT03198949,A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II),Epilepsy and Focal Cortical Dysplasia II,Drug: Afinitor (everolimus),Yonsei University,Phase 2,23,Other,"May 24, 2018","September 11, 2020","September 11, 2020"
6763,NCT03198871,IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population,Abdominal Wall Hernia|Pancreatic Diseases|Bowel Disease|Gastric Disease,"Drug: Acetaminophen Injectable Product|Drug: Sodium Chloride 0.9%, Intravenous",Kathirvel Subramaniam|Mallinckrodt|University of Pittsburgh,Phase 4,180,Other|Industry,"May 24, 2018","July 7, 2019","November 30, 2020"
6764,NCT03198741,Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation,Gastrointestinal Injury|Ischemic Heart Disease,Drug: Aspirin + clopidogrel|Drug: Clopidogrel monotherapy|Drug: Aspirin monotherapy,"Shenyang Northern Hospital|Changhai Hospital|ANKON medical technologies (Shanghai)Co.,LTD",Phase 4,783,Other,"July 13, 2017","August 13, 2020","August 13, 2020"
6765,NCT03198728,Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men,"Hypogonadism, Male",Drug: SOV2012-F1|Drug: AndroGel,Marius Pharmaceuticals|Syneos Health,Phase 3,314,Industry|Other,"July 5, 2017","May 1, 2020","May 1, 2020"
6766,NCT03198585,Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction,Heart Failure With Reduced Ejection Fraction,Drug: Empagliflozin 10 MG|Other: Placebo,Morten Schou|Herlev and Gentofte Hospital,Phase 2,190,Other,"June 29, 2017","December 20, 2019","January 17, 2020"
6767,NCT03198130,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1),Recurrent Squamous Cell Carcinoma of Head|Recurrent Squamous Cell Carcinoma of Neck|Metastatic Squamous Cell Carcinoma of Head|Metastatic Squamous Cell Carcinoma Neck,Drug: REGN2810,Regeneron Pharmaceuticals|Sanofi,Phase 1,33,Industry,"July 3, 2017","June 27, 2019","February 21, 2020"
6768,NCT03197935,A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer,Triple-negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Placebo|Drug: Nab-paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Filgrastim|Drug: Pegfilgrastim",Hoffmann-La Roche,Phase 3,333,Industry,"July 24, 2017","April 3, 2020","September 26, 2022"
6769,NCT03197818,Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD),COPD (Chronic Obstructive Pulmonary Disease),Drug: CHF 5993 100/6/12.5 µg|Drug: 160 µg budesonide + 4.5 µg formoterol fumarate,Chiesi Farmaceutici S.p.A.,Phase 3,990,Industry,"December 14, 2016","May 26, 2020","May 26, 2020"
6770,NCT03197766,A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia,Achondroplasia,Drug: BMN 111|Drug: Placebo,BioMarin Pharmaceutical,Phase 3,121,Industry,"December 12, 2016","October 30, 2019","October 30, 2019"
6771,NCT03197740,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",Alzheimer Disease,Drug: Donepezil patch|Drug: aricept Tab,Icure Pharmaceutical Inc.,Phase 3,399,Industry,"October 12, 2017","July 3, 2020","July 20, 2020"
6772,NCT03197714,Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia,Acute Myeloid Leukemia,Drug: OPB-111077,"Hospital Universitario 12 de Octubre|Otsuka Pharmaceutical Co., Ltd.|Apices Soluciones S.L.|Vivia Biotech",Phase 1,9,Other|Industry,"September 7, 2017","March 31, 2020","March 31, 2020"
6773,NCT03197623,Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids,Osteopenia|Osteoporosis|Osteonecrosis,Drug: LLP2A-ALENDRONATE|Drug: Placebo,"Nancy E. Lane, MD|California Institute for Regenerative Medicine (CIRM)|University of California, Davis",Phase 1,58,Other,"October 14, 2016","March 15, 2021","March 31, 2021"
6774,NCT03197493,"Extension, Carbidopa-levodopa in Neovascular AMD",Macula; Degeneration|Retina,Drug: carbidopa-levodopa 25-100 mg,"Snyder, Robert W., M.D., Ph.D., P.C.|Snyder Biomedical Corporation",Phase 2,32,Other,"August 1, 2017","July 9, 2020","July 9, 2020"
6775,NCT03197064,Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia,Postoperative Nausea,Drug: Fosaprepitant 150 mg,Stanford University,Phase 4,11,Other,"January 1, 2018","January 31, 2020","January 31, 2020"
6776,NCT03196986,mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,Drug: mil60|Drug: Bevacizumab,"Beijing Mabworks Biotech Co., Ltd.|Betta Pharmaceuticals Co., Ltd.",Phase 3,517,Industry,"August 15, 2017","August 1, 2019","July 30, 2021"
6777,NCT03196791,Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient,Gastric Cancer|Obesity,Drug: Sugammadex Sodium,Korea University Anam Hospital,Phase 3,196,Other,"October 10, 2017","August 9, 2020","September 9, 2020"
6778,NCT03196505,The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery,"Bariatric Surgery Candidate|Pain, Postoperative",Drug: Exparel 266 MG Per 20 ML Injection|Drug: Bupivacaine,"University of California, San Francisco",Phase 4,231,Other,"December 4, 2017","July 31, 2019","July 31, 2019"
6779,NCT03196167,Sugammadex and Decreased Time to Extubation,Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery,Drug: Sugammadex|Other: Placebo,Yale University|Merck Sharp & Dohme LLC,Phase 4,90,Other|Industry,"May 13, 2017","October 1, 2020","October 10, 2020"
6780,NCT03196076,Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension,Chronic Kidney Diseases|Cystic Kidney Disease,Drug: Perflutren Lipid microsphere,"University of North Carolina, Chapel Hill|Lantheus Medical Imaging",Phase 2,25,Other|Industry,"August 28, 2017","March 19, 2021","March 19, 2021"
6781,NCT03195452,QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient,Virus-HIV,Drug: Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI),Nantes University Hospital,Phase 2,100,Other,"November 8, 2017","October 30, 2019","May 6, 2020"
6782,NCT03194932,Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage,Acute Myeloid Leukemia,Drug: Venetoclax|Drug: Cytarabine|Drug: Idarubicin|Drug: Intrathecal Triple Therapy|Drug: Azacitidine,St. Jude Children's Research Hospital|Gateway for Cancer Research,Phase 1,62,Other,"July 11, 2017","October 27, 2020","June 22, 2022"
6783,NCT03194321,Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients,End Stage Renal Disease,Drug: Tacrolimus Extended-Release Oral Capsule,Cedars-Sinai Medical Center|Astellas Pharma Inc,Phase 4,20,Other|Industry,"September 11, 2017","October 27, 2020","October 27, 2020"
6784,NCT03194295,Activating Community Support for Substance Users,Substance Use Disorders,Behavioral: Community Support Intervention Group|Behavioral: Substance Use Disorder Educational Group,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 2,49,Other|NIH,"January 10, 2018","March 16, 2020","March 16, 2020"
6785,NCT03194217,BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness,Excessive Daytime Sleepiness|Parkinson Disease,Drug: BEN-2001|Drug: Placebo,BenevolentAI Bio,Phase 2,244,Industry,"November 10, 2017","May 28, 2019","May 28, 2019"
6786,NCT03193918,Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,Esophagogastric Adenocarcinoma,Drug: Crenolanib|Drug: Ramucirumab|Drug: Paclitaxel,"Arog Pharmaceuticals, Inc.",Phase 1,30,Industry,"April 14, 2017","July 15, 2020","July 15, 2020"
6787,NCT03193853,TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,Triple Negative Breast Cancer,Drug: Tak-228 & Tak-117|Drug: Cisplatin & Nab Paclitaxel,Baylor Research Institute|Takeda,Phase 2,12,Other|Industry,"July 18, 2017","March 17, 2020","December 1, 2022"
6788,NCT03192150,2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery,Inflammation and Pain Associated With Cataract Surgery,Drug: ISV-305|Other: Vehicle,Sun Pharmaceutical Industries Limited,Phase 3,246,Industry,"January 3, 2018","November 18, 2019","November 18, 2019"
6789,NCT03191799,A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors,Hemophilia A,Drug: Emicizumab,Hoffmann-La Roche,Phase 3,195,Industry,"September 5, 2017","November 19, 2020","November 19, 2020"
6790,NCT03191578,Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®,High-Risk Non-Muscle-Invasive Bladder Cancer,Drug: RUTI®|Drug: Placebo,Archivel Farma S.L.|Fundació Institut Germans Trias i Pujol,Phase 1,44,Industry|Other,"June 16, 2017","January 14, 2020","December 22, 2022"
6791,NCT03190642,Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery,Post-operative Edema|Steroid Use,Drug: Methylprednisolone,Jean Charles Doucet|Nova Scotia Health Authority,Phase 4,180,Other,"January 1, 2018","July 1, 2019","December 31, 2019"
6792,NCT03190616,Apatinib in Refractory Colorectal Cancer,Colorectal Neoplasms,Drug: apatinib,"The First Affiliated Hospital with Nanjing Medical University|Jiangsu HengRui Medicine Co., Ltd.|Beijing gene plus technology co., LTD",Phase 2,54,Other|Industry,"July 1, 2017","June 30, 2019","December 30, 2019"
6793,NCT03190304,The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure,Heart Failure|Exercise Tolerance|Vasodilation|Body Composition|Muscle Strength,Drug: Neprilysin|Drug: Enalapril,University of Sao Paulo General Hospital,Phase 4,52,Other,"June 14, 2017","September 14, 2020","September 23, 2020"
6794,NCT03189524,A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma,B-cell Lymphoma,Drug: Zanubrutinib,BeiGene,Phase 1,44,Industry,"July 5, 2016","August 26, 2020","August 26, 2020"
6795,NCT03188991,Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms,Pancreatic Mucinous-Cystic Neoplasm,Drug: NanoPac®,"NanOlogy, LLC|US Biotest, Inc.",Phase 2,20,Industry,"September 29, 2017","June 29, 2020","June 29, 2020"
6796,NCT03188705,CES1 Carriers in the PAPI Study,"Heart Diseases|Coronary Disease|Coronary Artery Disease|Cardiovascular Diseases|Myocardial Ischemia|Artery Occlusion|Aspirin Sensitivity|Clopidogrel, Poor Metabolism of|Platelet Dysfunction|Platelet Thrombus",Drug: Clopidogrel|Drug: Aspirin,"University of Maryland, Baltimore",Phase 4,6,Other,"October 14, 2019","January 17, 2020","January 17, 2020"
6797,NCT03188666,"A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva",Fibrodysplasia Ossificans Progressiva,Drug: REGN2477|Drug: Matching placebo,Regeneron Pharmaceuticals,Phase 2,44,Industry,"February 26, 2018","September 16, 2019","September 16, 2021"
6798,NCT03188445,Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.,Iron Deficiency Anemia of Pregnancy,Drug: Iron Isomaltoside 1000|Drug: ferrous fumarate with ascorbic acid,Pharmacosmos A/S,Phase 4,201,Industry,"July 11, 2017","June 26, 2020","August 18, 2020"
6799,NCT03188185,A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD),Major Depressive Disorder,Drug: ALKS 5461|Drug: ALKS 5461 Placebo,"Alkermes, Inc.",Phase 3,278,Industry,"June 12, 2017","February 26, 2020","March 5, 2020"
6800,NCT03187912,Accelerated Corneal Cross-linking With Different Riboflavin Solutions,Keratoconus,Drug: Riboflavin,Medical University of Vienna,Phase 3,60,Other,"September 19, 2016","March 30, 2020","March 30, 2020"
6801,NCT03187379,Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler,Post-operative Pain Management,Drug: Exparel|Drug: Bupivacaine,Matthew Kroh|The Cleveland Clinic,Phase 4,102,Other,"June 1, 2017","January 26, 2021","February 1, 2021"
6802,NCT03187314,Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer,Esophageal Neoplasms|Esophageal Diseases|Esophageal Squamous Cell Carcinoma,Drug: Radiation|Drug: SHR-1210,"Hangzhou Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd.",Phase 2,25,Other|Industry,"June 14, 2017","June 30, 2019","June 30, 2019"
6803,NCT03187262,A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia,Waldenström Macroglobulinemia,Drug: Daratumumab,"Dana-Farber Cancer Institute|Janssen, LP",Phase 2,13,Other|Industry,"November 27, 2017","January 31, 2021","December 31, 2021"
6804,NCT03187223,Bendamustine and Melphalan in Myeloma,Multiple Myeloma,Drug: Melphalan|Drug: Bendamustine,"University Hospital Inselspital, Berne|Mundipharma Medical Company",Phase 2,121,Other|Industry,"July 20, 2017","March 12, 2020","May 28, 2020"
6805,NCT03186781,"Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults",Influenza,Biological: VRC-FLUNPF081-00-VP (HA-F A/Sing)|Biological: VRC-FLUDNA082-00-VP (DNA A/Sing),National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,50,NIH,"October 25, 2017","September 3, 2019","September 3, 2019"
6806,NCT03185130,Intravenous Fluids in Benign Headaches Trail,Headache,Drug: Normal Saline 5mL|Drug: Normal Saline 20mL/kg|Drug: Prochlorperazine 0.15 mg/kg up to 10 mg IV|Drug: Diphenhydramine 1 mg/kg up to 50 mg IV,University Medical Center of Southern Nevada,Phase 4,58,Other,"May 16, 2017","May 15, 2019","May 15, 2019"
6807,NCT03185065,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",Fatigue in Multiple Sclerosis,Drug: Amantadine|Drug: Modafinil|Drug: Methylphenidate|Drug: Placebos,Johns Hopkins University|Patient-Centered Outcomes Research Institute,Phase 3,141,Other,"October 4, 2017","November 21, 2019","November 21, 2019"
6808,NCT03185013,REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL),Cervical Dysplasia|Cervical High Grade Squamous Intraepithelial Lesion|HSIL,Biological: VGX-3100|Biological: Placebo|Device: Electroporation (EP),Inovio Pharmaceuticals,Phase 3,201,Industry,"June 28, 2017","July 8, 2020","April 7, 2021"
6809,NCT03184987,A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma,Asthma,Drug: FF/UMEC/VI 100/62.5/25 mcg|Drug: FF/UMEC/VI 200/62.5/25 mcg|Drug: Salbutamol|Other: ACQ-7,GlaxoSmithKline|York Bioanalytical Solution|BI Medical.Inc|SRL Mediserch.Inc|Parexel International Japan|Q2 Solutions,Phase 3,111,Industry|Other,"June 22, 2017","June 25, 2019","June 25, 2019"
6810,NCT03184467,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,Alzheimer Disease,Drug: Normal Saline 0.9%|Drug: GV1001 0.56 mg|Drug: GV1001 1.12 mg,GemVax & Kael,Phase 2,96,Industry,"September 5, 2017","September 5, 2019","September 19, 2019"
6811,NCT03184090,Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC,Metastatic Breast Cancer,Drug: Palbociclib|Drug: Endocrine therapy (non IMP),MedSIR,Phase 2,33,Other,"June 28, 2017","October 27, 2020","October 27, 2020"
6812,NCT03183778,Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.,Chronic Kidney Diseases|Hyperkalemia,Drug: Patiromer|Dietary Supplement: Research Diet Menu,NYU Langone Health,Phase 4,3,Other,"March 12, 2018","August 1, 2019","August 1, 2019"
6813,NCT03183544,Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit,Prostatic Neoplasm,Combination Product: Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 1,3,Other,"January 24, 2019","February 24, 2020","February 24, 2020"
6814,NCT03183479,The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery,Scoliosis; Adolescence|Bleeding|Surgery,Drug: Fibrinogen Concentrate Human|Drug: Normal saline,Peking Union Medical College Hospital,Phase 4,102,Other,"June 14, 2017","August 31, 2019","August 31, 2019"
6815,NCT03183128,ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection,Clostridium Difficile Infection,Biological: SER-109|Drug: Placebo,"Seres Therapeutics, Inc.",Phase 3,182,Industry,"July 10, 2017","July 3, 2020","September 29, 2020"
6816,NCT03182725,Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome,Postural Orthostatic Tachycardia Syndrome,Drug: Ivabradine|Drug: Placebo,"University of California, San Diego|Amgen",Phase 3,37,Other|Industry,"February 6, 2018","May 8, 2020","May 8, 2020"
6817,NCT03182699,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients,Secondary Hyperparathyroidism|Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy,Diagnostic Test: cardiac MRI|Diagnostic Test: echocardiography with strain|Diagnostic Test: Laboratory tests|Diagnostic Test: Body composition monitoring|Diagnostic Test: lung ultrasound,Rainer Oberbauer|Amgen|Medical University of Vienna,Phase 4,62,Other|Industry,"October 1, 2017","December 20, 2019","December 20, 2019"
6818,NCT03181932,AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis,MRSA|Cystic Fibrosis,Drug: Vancomycin inhalation powder|Drug: Placebo inhalation powder,Savara Inc.,Phase 3,188,Industry,"September 20, 2017","July 28, 2020","January 15, 2021"
6819,NCT03181789,"Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA",HIV Infections,Biological: p24CE1/2 pDNA Vaccine|Biological: p55^gag pDNA Vaccine|Biological: IL-12 pDNA Adjuvant|Biological: Placebo|Device: Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,56,NIH,"October 18, 2017","October 25, 2019","April 29, 2020"
6820,NCT03181763,Evaluation of MDMA on Startle Response,Startle Response,Drug: Placebo|Drug: MDMA|Behavioral: Acoustic startle,Multidisciplinary Association for Psychedelic Studies,Phase 1,34,Other,"March 14, 2017","August 1, 2020","August 1, 2020"
6821,NCT03181529,Effects of Psilocybin in Major Depressive Disorder,Major Depressive Disorder,Drug: Psilocybin,Johns Hopkins University,Phase 2,27,Other,"August 10, 2017","December 2, 2020","December 2, 2020"
6822,NCT03181386,Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants,Atrial Fibrillation|Periodontal Disease|Hemorrhage,Drug: Rivaroxaban|Drug: Dabigatran and Apixaban|Drug: Warfarin,University of Sao Paulo General Hospital,Phase 3,60,Other,"May 3, 2017","November 30, 2020","February 1, 2022"
6823,NCT03181308,Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,"Carcinoma, Non-Small-Cell Lung",Drug: Carotuximab (TRC105)|Drug: OPDIVO,Tracon Pharmaceuticals Inc.,Phase 1,11,Industry,"November 9, 2017","July 22, 2019","July 22, 2019"
6824,NCT03181126,A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma,Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma,Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax,AbbVie,Phase 1,69,Industry,"November 27, 2017","November 11, 2020","November 14, 2020"
6825,NCT03180957,Repurposing Anti-TNF for Treating Dupuytren's Disease,Dupuytren's Disease,Drug: Adalimumab|Drug: Saline,"University of Oxford|Department of Health, United Kingdom|Wellcome Trust|180 Therapeutics LP",Phase 2,209,Other,"March 2, 2016",Nov-20,Dec-20
6826,NCT03180840,"Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks",Fabry Disease,Biological: Pegunigalsidase alfa,Protalix,Phase 3,30,Industry,"July 10, 2017","August 1, 2020","August 1, 2020"
6827,NCT03180684,Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3),Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)|Vulvar Dysplasia|Vulvar Intraepithelial Neoplasia (VIN)|VIN2|VIN3|Pre-cancerous Lesions of the Vulva|Human Papillomavirus (HPV),Biological: VGX-3100|Drug: Imiquimod 5% cream|Device: CELLECTRA™ 2000,Inovio Pharmaceuticals,Phase 2,33,Industry,"June 26, 2017","July 23, 2020","December 18, 2020"
6828,NCT03180528,Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer,Skin Basal Cell Carcinoma,Drug: Remetinostat,Kavita Sarin|Medivir|National Institutes of Health (NIH)|American Skin Association|Stanford University,Phase 2,30,Other|Industry|NIH,"July 7, 2018","July 7, 2020","December 31, 2020"
6829,NCT03180476,Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma,Nasopharyngeal Neoplasms,Drug: Apatinib,"Sichuan Cancer Hospital and Research Institute|Jiangsu HengRui Medicine Co., Ltd.",Phase 2,21,Other|Industry,"April 1, 2017","April 1, 2020","April 1, 2020"
6830,NCT03180307,OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer,Ovarian Cancer,Drug: OTL38|Device: near infrared camera imaging system|Procedure: laparotomy,"On Target Laboratories, LLC|SynteractHCR",Phase 3,140,Industry,"January 26, 2018","April 16, 2020","October 16, 2020"
6831,NCT03180294,Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer,Breast Carcinoma|Cervical Carcinoma|Ovarian Carcinoma|Postmenopausal|Uterine Corpus Cancer|Vaginal Carcinoma|Vulvar Carcinoma,Drug: Bupropion 150 mg XL|Drug: Placebo,NRG Oncology|National Cancer Institute (NCI),Phase 2,230,Other|NIH,"May 31, 2017","February 22, 2021","February 22, 2021"
6832,NCT03179410,PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer,Prostate Cancer,Drug: Avelumab,"Andrew J. Armstrong, MD|Duke University",Phase 2,15,Other,"February 1, 2018","January 9, 2020","December 18, 2020"
6833,NCT03178851,Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma,Malignant Melanoma,Biological: Atezolizumab|Drug: Cobimetinib,Hoffmann-La Roche,Phase 1,155,Industry,"June 20, 2017","May 29, 2019","September 21, 2020"
6834,NCT03178773,TExT-MED + FANS Full Trial,Diabetes,Behavioral: TExT-MED|Behavioral: FANS,University of Southern California,Phase 2,166,Other,"July 18, 2017","December 2, 2019","December 2, 2019"
6835,NCT03178669,The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis,Ulcerative Colitis,Drug: cobitolimod|Drug: Placebo,InDex Pharmaceuticals,Phase 2,213,Industry,"June 21, 2017","August 30, 2019","August 30, 2019"
6836,NCT03178643,Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE),"Malaria,Falciparum",Drug: Proguanil Oral Tablet|Drug: Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Drug: Dihydroartemisinin-Piperaquine (DP),"Duke University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,246,Other|NIH,"January 23, 2018","December 16, 2020","December 16, 2020"
6837,NCT03178032,"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas",Brainstem Glioma|Neoadjuvant Therapy,Biological: DNX-2401,"Clinica Universidad de Navarra, Universidad de Navarra|DNAtrix, Inc.|Alcyone Therapeutics, Inc",Phase 1,12,Other|Industry,"May 26, 2017","January 31, 2021","January 31, 2021"
6838,NCT03177603,A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH),"Hypertension, Pulmonary",Drug: GSK2586881,GlaxoSmithKline,Phase 2,23,Industry,"February 21, 2018","May 7, 2019","May 7, 2019"
6839,NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,Relapsing Remitting Multiple Sclerosis,Drug: peginterferon beta-1a|Drug: interferon beta-1a|Drug: interferon beta-1b,Biogen,Phase 4,80,Industry,"January 30, 2017","October 26, 2020","October 26, 2020"
6840,NCT03176849,A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT,Vitamin D Deficiency|Stem Cell Transplant Complications|Pediatric Cancer|Blood Disorder|Pediatric Acute Myeloid Leukemia|Pediatric Acute Lymphoid Leukemia|Myelodysplastic Syndromes|Sickle Cell Anemia in Children|Aplastic Anemia|Thalassemia in Children,Dietary Supplement: Vitamin D3|Dietary Supplement: Standard Vitamin D3 Supplementation,Phoenix Children's Hospital,Phase 4,49,Other,"November 1, 2017","July 1, 2019","July 1, 2019"
6841,NCT03176784,UW Quitting Using Intensive Treatment Study (QUITS),Tobacco Dependence,Drug: Varenicline|Drug: Nicotine patch|Other: Placebo Patch|Other: Placebo Pill,"University of Wisconsin, Madison|Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,1251,Other|NIH,"November 11, 2017","July 9, 2020","July 9, 2020"
6842,NCT03175731,PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors),"Liver Cirrhosis|Hypertension, Portal",Drug: Proton Pump Inhibitors|Drug: Placebo,Yanjing Gao|Qilu Hospital of Shandong University,Phase 4,106,Other,"May 1, 2017","August 30, 2019","August 30, 2019"
6843,NCT03175549,Medication Development in Alcoholism: Apremilast Versus Placebo,Alcohol Use Disorder,Drug: Apremilast|Drug: Placebo,The Scripps Research Institute|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2,51,Other|NIH,"November 1, 2017","April 1, 2020","April 1, 2020"
6844,NCT03175367,Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia,Hypercholesterolemia,Drug: Evinacumab|Drug: Matching placebo|Other: Background Lipid Modifying Therapy (LMT),Regeneron Pharmaceuticals,Phase 2,272,Industry,"November 10, 2017","May 22, 2020","December 14, 2020"
6845,NCT03175029,Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.,Detrusor Underactivity|Overactive Bladder,Drug: TAC-302|Drug: Placebo,"Taiho Pharmaceutical Co., Ltd.",Phase 2,76,Industry,"August 1, 2017","November 1, 2019","March 27, 2020"
6846,NCT03174613,"A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255",Healthy,Drug: LC51-0255|Drug: Placebo,LG Chem,Phase 1,100,Industry,"May 31, 2017","June 12, 2019","July 11, 2019"
6847,NCT03174405,Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.,Metastatic Colorectal Cancer,Drug: Avelumab,AIO-Studien-gGmbH,Phase 2,43,Other,"July 17, 2017","July 16, 2020","July 16, 2021"
6848,NCT03174353,A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula,Pancreatic Leak|Pancreatic Fistula|Pancreaticoduodenal; Fistula|Pancreatectomy; Hyperglycemia,Drug: Lanreotide Prefilled Syringe,University of Washington,Phase 2,114,Other,"February 20, 2018","February 1, 2021","April 1, 2021"
6849,NCT03174002,Handling Oxygenation Targets in the Intensive Care Unit,Hypoxemic Respiratory Failure|Oxygen Toxicity,Drug: Oxygen,"Aalborg University Hospital|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research",Phase 4,2928,Other,"June 19, 2017","November 3, 2020","August 3, 2021"
6850,NCT03173716,Real-Time Myocardial Perfusion Echocardiography in the ICU,Myocardial Perfusion Imaging,Procedure: Definity,Mayo Clinic|Lantheus Medical Imaging,Phase 4,24,Other|Industry,"September 28, 2017","December 31, 2019","December 31, 2019"
6851,NCT03173456,Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED),Musculoskeletal Pain,Drug: oxycodone/APAP|Drug: hydrocodone/APAP|Drug: codeine/APAP|Drug: 400 ibuprofen/APAP|Drug: 800 ibuprofen/APAP,Albert Einstein College of Medicine,Phase 2,600,Other,"November 28, 2017","November 14, 2019","November 14, 2019"
6852,NCT03173391,Long-term Efficacy and Safety of HMS5552 in T2DM Subjects,"Diabetes Mellitus, Type 2",Drug: HMS5552|Drug: Placebo,"Hua Medicine Limited|Tigermed Consulting Co., Ltd",Phase 3,463,Industry,"July 18, 2017","November 30, 2020","November 30, 2020"
6853,NCT03172910,Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT,Healthy,Drug: Ciraparantag|Drug: Placebo|Drug: Rivaroxaban,"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.|AMAG Pharmaceuticals, Inc.",Phase 2,69,Industry,"May 8, 2017","November 12, 2019","November 12, 2019"
6854,NCT03172884,Study of Copanlisib in Hepatic or Renal Impairment,"Hepatic Insufficiency, Renal Insufficiency","Drug: Copanlisib (ALIQOPA, BAY80-6946)",Bayer,Phase 1,30,Industry,"June 14, 2017","March 13, 2020","May 15, 2020"
6855,NCT03172871,Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia,Schizophrenia,Drug: Aripiprazole IM Depot|Drug: Aripiprazole tablet,Otsuka Beijing Research Institute,Phase 3,436,Industry,"May 15, 2017","July 22, 2019","September 30, 2019"
6856,NCT03172819,Special Combination of OBP-301 and Pembrolizumab,Advanced Solid Tumor,Biological: OBP-301|Drug: Pembrolizumab,Toshihiko Doi|Oncolys BioPharma Inc|Merck Sharp & Dohme LLC|National Cancer Center Hospital East,Phase 1,22,Other|Industry,"October 1, 2017","April 6, 2021","April 6, 2022"
6857,NCT03172702,Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia,Hyperkalemia,Drug: Zirconium Cyclosilicate,AstraZeneca,Phase 3,150,Industry,"September 4, 2017","July 6, 2019","July 6, 2019"
6858,NCT03172494,"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/liraglutide|Drug: Insulin degludec|Drug: Liraglutide,Novo Nordisk A/S,Phase 3,720,Industry,"May 26, 2017","June 14, 2019","July 13, 2019"
6859,NCT03171480,Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia,"Preeclampsia|Labor, Premature",Drug: Monoket Pill|Drug: Placebo,Ohio State University,Phase 4,176,Other,"October 30, 2017","July 1, 2020","July 1, 2020"
6860,NCT03170895,Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD,AML|FLT3-ITD Mutation,Drug: Sorafenib|Drug: Omacetaxine Mepesuccinate Injection,The University of Hong Kong,Phase 2,5,Other,"July 1, 2017","February 1, 2020","March 1, 2020"
6861,NCT03170882,"A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma",Relapsed and/or Refractory Multiple Myeloma,Drug: Ixazomib|Drug: Pomalidomide|Drug: Dexamethasone,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 2,122,Industry,"August 1, 2017","August 1, 2020","November 26, 2021"
6862,NCT03170661,Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions.,Surgical Conditions,Drug: Deep neuromuscular block,Leiden University Medical Center|Merck Sharp & Dohme LLC,Phase 4,98,Other|Industry,"June 14, 2017","April 1, 2020","June 1, 2020"
6863,NCT03170336,A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein,Chronic Kidney Diseases,Drug: Amiloride|Drug: Hydrochlorothiazide,Guangdong Provincial People's Hospital,Phase 4,40,Other,"March 1, 2018","August 1, 2020","August 1, 2020"
6864,NCT03170271,A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.,Asthma,Drug: Benralizumab (Medi-563)|Drug: Placebo,AstraZeneca,Phase 3,660,Industry,"July 7, 2017","September 25, 2019","October 21, 2020"
6865,NCT03169244,Buproprion for Binge Drinking,Alcohol Abuse,Drug: Bupropion|Drug: Placebo Oral Tablet,"University of North Carolina, Chapel Hill|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",Phase 2,42,Other|NIH,"September 4, 2017","August 19, 2019","September 17, 2019"
6866,NCT03168854,"Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites",Plasmodium Falciparum Infection,Biological: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Other: Malaria challenge,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,26,NIH,"July 26, 2017","August 16, 2019","August 16, 2019"
6867,NCT03168711,Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),Amyotrophic Lateral Sclerosis,Drug: Inosine|Drug: Placebo,Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund,Phase 2,48,Other,"October 1, 2017","December 10, 2019","January 7, 2020"
6868,NCT03168581,A Proof of Concept Study to Evaluate CN-105 in ICH Patients,Intracerebral Hemorrhage,Drug: CN-105,"AegisCN LLC|Duke Clinical Research Institute|PharPoint Research, Inc.",Phase 2,38,Industry|Other,"August 28, 2017","September 30, 2019","January 25, 2020"
6869,NCT03168568,Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction,Heart Failure,Drug: Valsartan/Sacubitril or placebo|Drug: Valsartan or placebo,University of Zurich|Novartis Pharmaceuticals,Phase 4,79,Other|Industry,"May 4, 2017","September 5, 2020","September 5, 2020"
6870,NCT03168555,Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy,Bile Acid Malabsorption|Cholelithiasis,Drug: chenodeoxycholic acid,Zealand University Hospital,Phase 4,23,Other,"June 22, 2017","May 15, 2019","May 15, 2019"
6871,NCT03168308,Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients,Neuromuscular Blockade,Drug: Sugammadex|Drug: Neostigmine w/ Glycopyrrolate,University of Texas Southwestern Medical Center|Merck Sharp & Dohme LLC,Phase 4,92,Other|Industry,"September 26, 2017","September 30, 2019","September 30, 2019"
6872,NCT03167645,SUbstition of PERioperative Albumin Deficiency Disorders,Hypoalbuminemia,Drug: Human albumin,Technical University of Munich,Phase 4,600,Other,"June 19, 2017","December 21, 2019","April 21, 2021"
6873,NCT03166735,Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH,Non-alcoholic Fatty Liver Disease,Drug: BI 1467335|Drug: Placebo,Boehringer Ingelheim,Phase 2,114,Industry,"June 6, 2017","June 14, 2019","June 14, 2019"
6874,NCT03166501,NMDA Receptor Modulation for Hyperarousal in PTSD,Depression|Post Traumatic Stress Disorder,Drug: Lanicemine|Drug: Placebo,Baylor College of Medicine|National Institute of Mental Health (NIMH),Phase 1,24,Other|NIH,"September 1, 2018","November 12, 2019","November 14, 2019"
6875,NCT03166111,Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery,Contraception,Drug: lidocaine gel|Drug: placebo gel,Assiut University,Phase 3,216,Other,"September 1, 2017","March 31, 2020","May 31, 2020"
6876,NCT03165617,"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age","Influenza, Human",Biological: QIVc|Biological: Non-influenza Comparator Vaccine,Seqirus,Phase 3,4514,Industry,"May 25, 2017","September 30, 2019","September 30, 2019"
6877,NCT03165240,This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated,Diabetic Nephropathies,Drug: BI 690517|Drug: Eplerenone|Drug: Placebo,Boehringer Ingelheim,Phase 1,62,Industry,"October 5, 2017","April 16, 2020","May 7, 2020"
6878,NCT03165227,This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses),Diabetic Nephropathies,Drug: BI 685509|Drug: Placebo,Boehringer Ingelheim,Phase 1,75,Industry,"October 17, 2017","December 10, 2019","December 10, 2019"
6879,NCT03164512,The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol,Cannabidiol Pharmacokinetics,Drug: Oral or vaporized cannabidiol|Drug: Placebo,Johns Hopkins University,Phase 1,19,Other,"June 1, 2018","August 29, 2019","January 22, 2020"
6880,NCT03164382,"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma",Liver Cancer|Hepatic Carcinoma,Drug: FOLFOX regimen|Drug: Sorafenib 200Mg Tab,Sun Yat-sen University,Phase 3,262,Other,"March 1, 2017","October 31, 2020","November 30, 2020"
6881,NCT03164304,Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia,Severe Preeclampsia,Drug: Magnesium Sulfate,Assiut University,Phase 4,222,Other,"May 30, 2017","January 30, 2020","January 30, 2020"
6882,NCT03163303,Smoking Tobacco and Drinking Study,Smoking|Heavy Episodic Drinking,Behavioral: Tobacco Status Project Intervention|Behavioral: Tobacco Status Project + Alcohol Intervention|Drug: nicotine patch,"University of California, San Francisco|National Institute on Drug Abuse (NIDA)",Phase 4,179,Other|NIH,"December 18, 2017","June 30, 2019","June 30, 2019"
6883,NCT03162874,"Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients",Parkinson Disease,Drug: Placebo oral capsule|Drug: PXT002331 - dose 1|Drug: PXT002331 - dose 2,Prexton Therapeutics,Phase 2,157,Industry,"July 4, 2017","February 19, 2020","March 2, 2020"
6884,NCT03162367,Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn,Burn,Biological: Autologous epidermal cell suspension|Drug: Silver sulfadiazine ointment,"SCARM Institute, Tabriz, Iran",Phase 2,40,Other,"April 10, 2019","March 15, 2020","March 15, 2020"
6885,NCT03162250,"Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics",Bacteremia,Drug: DSTA4637S|Drug: Placebo|Drug: SOC,"Genentech, Inc.",Phase 1,27,Industry,"July 13, 2017","January 15, 2020","January 15, 2020"
6886,NCT03161938,High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase,Hip Dysplasia|Postoperative Complications,Drug: Dexamethasone,"Rigshospitalet, Denmark",Phase 4,64,Other,"April 24, 2017","August 20, 2019","August 20, 2019"
6887,NCT03161483,A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus,"Lupus Erythematosus, Systemic",Drug: CC-220|Other: Placebo,Celgene,Phase 2,289,Industry,"July 6, 2017","January 21, 2020","August 3, 2021"
6888,NCT03161132,"Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin",Advanced Ovarian Cancer,Drug: Olaparib|Drug: Pegylated Liposomal Doxorubicin,Grupo Español de Investigación en Cáncer de Ovario|AstraZeneca,Phase 2,32,Other|Industry,"December 13, 2017","February 7, 2020","December 31, 2022"
6889,NCT03161093,A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip,"Osteoarthritis, Knee|Osteoarthritis, Hip",Drug: Fasinumab|Drug: Naproxen|Drug: Fasinumab-matching placebo|Drug: Naproxen-matching placebo,"Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.",Phase 3,3307,Industry,"August 17, 2017","September 9, 2019","August 27, 2021"
6890,NCT03161054,Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas,Aggressive Non-Hodgkin Lymphoma,Drug: Prednisone|Drug: Vinorelbine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Rituximab,Fondazione Italiana Linfomi - ETS,Phase 2,21,Other,"September 12, 2017","April 22, 2020","June 21, 2021"
6891,NCT03159845,Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies,Stem Cell Transplant Complications,Drug: Zinc Sulfate Oral Product|Drug: Levofloxacin 500Mg Oral Tablet|Drug: Fluconazole 200mg tab|Drug: Acyclovir 400 MG,"Azienda Ospedaliero, Universitaria Pisana",Phase 2,20,Other,"January 1, 2014","September 10, 2019","September 10, 2019"
6892,NCT03159585,To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors,"Liver Cancer Stage IV|Gastric Cancer Stage IV|Esophageal Cancer, Stage IV|Bone and Soft Tissue Tumors|Breast Cancer Stage IV|Bladder Carcinoma Stage IV|Prostate Carcinoma Stage IV|Thyroid Cancer Stage IV|Ovarian Cancer Stage IV|Solid Tumor",Drug: TAEST16001,"Zhujiang Hospital|Xiangxue Life Science Research Center|Guangdong Xiangxue Precision Medical Technology Co., Ltd.|Xiangxue Pharmaceutical",Phase 1,6,Other|Industry,"April 14, 2017","June 4, 2019","June 4, 2019"
6893,NCT03159117,Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,Melanoma,Drug: PF-06688992,Memorial Sloan Kettering Cancer Center|Pfizer,Phase 1,7,Other|Industry,"May 16, 2017","January 10, 2020","January 10, 2020"
6894,NCT03158935,The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial,Advanced Ovarian Cancer|Malignant Melanoma,Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Pembrolizumab|Biological: Tumor-Infiltrating Lymphocytes (TILs)|Biological: Interleukin-2 (IL-2),"University Health Network, Toronto|Merck Sharp & Dohme LLC",Phase 1,8,Other|Industry,"July 7, 2017","August 4, 2020","August 4, 2020"
6895,NCT03158688,"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",Relapsed Multiple Myeloma|Refractory Multiple Myeloma,Drug: Dexamethasone|Drug: Daratumumab|Drug: Carfilzomib,Amgen,Phase 3,466,Industry,"June 13, 2017","July 14, 2019","April 15, 2022"
6896,NCT03158376,Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).,Postoperative Pain|Chronic Pain,Drug: Gabapentin|Drug: Placebo,"University Hospital, Lille|University of Lille Nord de France",Phase 3,201,Other,Sep-15,"May 24, 2019","May 24, 2019"
6897,NCT03158311,Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium,Asthma,Drug: QVM149|Drug: Salmeterol/fluticasone plus tiotropium,Novartis Pharmaceuticals|Novartis,Phase 3,1426,Industry,"February 5, 2018","July 12, 2019","July 19, 2019"
6898,NCT03158272,A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread,Advanced Malignancies,Biological: Cabiralizumab|Biological: Nivolumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 1,19,Industry,"May 25, 2017","October 23, 2019","October 23, 2019"
6899,NCT03158103,A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),Gastrointestinal Stromal Tumor (GIST),Drug: MEK162|Drug: Pexidartinib,Memorial Sloan Kettering Cancer Center|Array BioPharma|Plexxikon,Phase 1,3,Other|Industry,"April 15, 2017","April 28, 2021","April 28, 2021"
6900,NCT03157167,An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS),Kaposi Sarcoma|HIV Infections,Drug: Tc99m-tilmanocept,Navidea Biopharmaceuticals|National Institutes of Health (NIH)|National Cancer Institute (NCI),Phase 1,14,Industry|NIH,"December 1, 2017","November 5, 2019","March 30, 2020"
6901,NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,"Carcinoma, Non-Small-Cell Lung",Drug: Afatinib|Drug: pembrolizumab,Boehringer Ingelheim,Phase 2,24,Industry,"November 2, 2017","January 13, 2020","January 13, 2020"
6902,NCT03157037,Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease,Anti-Glomerular Basement Membrane Antibody Disease,Biological: Imlifidase,Mårten Segelmark|Hansa Biopharma AB|Linkoeping University,Phase 2,15,Other|Industry,"June 16, 2017","July 24, 2020","July 24, 2020"
6903,NCT03156816,COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction,Myocardial Infarction,Drug: Colchicine group (experimental arm)|Drug: Placebo group (control arm),Hospices Civils de Lyon,Phase 2,194,Other,"July 23, 2018","November 8, 2020","August 16, 2021"
6904,NCT03156621,Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH),Homozygous Familial Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 3,69,Industry,"October 3, 2017","September 27, 2019","February 13, 2020"
6905,NCT03156504,"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.",Major Depression|Bipolar I Disorder|Bipolar II Disorder|Unipolar Depression,Drug: Ketamine Hydrochloride,Mayo Clinic|National Network of Depression Centers,Phase 4,75,Other,"June 1, 2017","February 12, 2020","March 12, 2020"
6906,NCT03156452,Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate,Immune Thrombocytopenia,Drug: Mycophenolate Mofetil|Drug: Prednisolone,University Hospitals Bristol and Weston NHS Foundation Trust|Cardiff University,Phase 3,123,Other,"October 25, 2017","March 5, 2020","March 5, 2020"
6907,NCT03156153,A Study of Bumetanide for the Treatment of Autism Spectrum Disorders,Autism Spectrum Disorder,Drug: Bumetanide|Drug: Placebo,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Jiao Tong University School of Medicine",Phase 2,120,Other,"May 24, 2017","July 8, 2019","July 10, 2019"
6908,NCT03156023,Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: Rozibafusp Alfa|Drug: Placebo,Amgen,Phase 1,34,Industry,"August 14, 2017","October 17, 2019","June 12, 2020"
6909,NCT03155425,PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma,"Hodgkin Lymphoma, Adult",Drug: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Phase 2,75,Industry,"June 9, 2017","August 31, 2020","September 30, 2020"
6910,NCT03155009,A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer,"Carcinoma, Non-Small-Cell Lung",Drug: Alectinib,Hoffmann-La Roche,Phase 2,44,Industry,"July 10, 2017","September 26, 2019","September 26, 2019"
6911,NCT03154749,DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer,Triple-Negative Breast Cancer,Drug: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe),"Guangdong Provincial People's Hospital|Shantou Central Hospital|First Affiliated Hospital, Sun Yat-Sen University|Henan Cancer Hospital|Dongguan People's Hospital|Baotou Cancer Hospital",Phase 2,93,Other,"September 1, 2016","December 31, 2019","December 31, 2019"
6912,NCT03154658,Serratus Anterior Plane Block in Patients Undergoing Mastectomy,"Pain, Post-operative",Drug: Ropivacaine 0.35%,University of Texas Southwestern Medical Center,Phase 4,66,Other,"April 1, 2017","March 1, 2020","March 1, 2020"
6913,NCT03154476,Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study,Cirrhosis|Congenital Heart Disease,Drug: Sildenafil|Drug: Placebo,Mayo Clinic,Phase 3,20,Other,"July 5, 2017","June 30, 2019","June 30, 2019"
6914,NCT03154125,Sayana® Press Extension Study,Contraception,Drug: Sayana® Press,FHI 360,Phase 3,750,Other,"September 22, 2017","May 30, 2020","May 30, 2020"
6915,NCT03153150,Start or STop Anticoagulants Randomised Trial (SoSTART),"Intracranial Hemorrhages|Intracranial Hemorrhage, Hypertensive|Subarachnoid Hemorrhage|Subdural Hematoma|Intraventricular Hemorrhage|Atrial Fibrillation|Atrial Flutter|Small Vessel Cerebrovascular Disease|Microhaemorrhage",Drug: Apixaban|Drug: Rivaroxaban|Drug: Edoxaban|Drug: Dabigatran|Drug: Acenocoumarol|Drug: Phenindione|Drug: Warfarin,University of Edinburgh|NHS Lothian,Phase 3,203,Other,"March 28, 2018","March 26, 2021","March 26, 2021"
6916,NCT03153111,A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease,Heart Failure With Preserved Ejection Fraction,Drug: Macitentan|Drug: Placebo,Actelion,Phase 2,143,Industry,"July 11, 2017","March 12, 2021","March 12, 2021"
6917,NCT03152864,Stabilizing Behavioral Rhythms to Improve Mental Health,Depressive Symptoms|Anxiety Symptoms|Sleep Symptoms,Behavioral: Full Package,"HealthRhythms, Inc.|National Institute of Mental Health (NIMH)|University of Utah",Phase 2,128,Industry|NIH|Other,"March 1, 2018","May 31, 2019","July 31, 2020"
6918,NCT03152578,Topical Use of 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin for Pain Caused by Osteoarthritis Of The Knee,Pain,Other: BetaC + Capsaicin Topical Cream|Other: BetaC Topical Cream|Other: Placebo Topical Cream,Panag Pharma Inc.,Phase 2,56,Industry,"July 1, 2017","June 30, 2019","July 31, 2019"
6919,NCT03152149,"INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol",Chronic Obstructive Pulmonary Disease,Drug: Tiotropium & olodaterol|Drug: fluticasone furoate & vilanterol,University of Dundee|Boehringer Ingelheim|NHS Tayside,Phase 4,80,Other|Industry,"June 1, 2017","November 26, 2019","November 26, 2019"
6920,NCT03151603,Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial,Urinary Tract Infections,Drug: Arctuvan|Drug: Fosfomycin|Drug: Placebo to Arctuvan|Drug: Placebo to Fosfomycin,University Medical Center Goettingen,Phase 4,398,Other,"May 3, 2017","May 19, 2019","June 20, 2019"
6921,NCT03151343,"SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk",Type2 Diabetes Mellitus,Drug: Empagliflozin|Drug: Placebo Oral Tablet,"Caroline M Kistorp|Danish Heart Foundation|Herlev and Gentofte Hospital|Rigshospitalet, Denmark",Phase 3,92,Other,"March 29, 2017","May 22, 2020","May 22, 2020"
6922,NCT03150589,A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD),Age-Related Macular Degeneration,Drug: SB11 (Proposed ranibizumab biosimilar)|Drug: Lucentis (ranibizumab),"Samsung Bioepis Co., Ltd.",Phase 3,705,Industry,"March 14, 2018","May 24, 2019","December 9, 2019"
6923,NCT03149640,Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia,"Pneumonia, Ventilator-Associated",Drug: Inhaled amikacin|Drug: Inhaled placebo,"University Hospital, Tours",Phase 3,850,Other,"July 19, 2017","March 9, 2021","June 17, 2021"
6924,NCT03149055,Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT),Hematologic Malignancy|Myeloproliferative Disorder,Drug: Isavuconazole,"Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.",Phase 2,99,Other|Industry,"May 4, 2017","August 20, 2019","November 8, 2021"
6925,NCT03148899,Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep,"Sleep Apnea, Obstructive",Drug: Oxytocin Intranasal Spray|Drug: Placebo Intranasal Spray,George Washington University,Phase 2,32,Other,"July 27, 2016","June 7, 2020","June 7, 2020"
6926,NCT03148860,"Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA",Psoriatic Arthritis,Drug: Methotrexate|Drug: Ustekinumab|Other: Placebo,Dr. Frank Behrens|Janssen-Cilag Ltd.|Fraunhofer Institute for Molecular Biology and Applied Ecology,Phase 3,186,Other|Industry,"December 15, 2016","April 12, 2021","October 21, 2021"
6927,NCT03148795,A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Drug: Talazoparib,"Pfizer|Medivation, Inc.",Phase 2,128,Industry,"July 4, 2017","September 4, 2020","March 31, 2023"
6928,NCT03148574,Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery,Post Partum Hemorrhage,Drug: Misoprostol|Drug: Oxytocin,Assiut University,Phase 3,240,Other,"July 2, 2017","September 15, 2019","December 15, 2019"
6929,NCT03148366,Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP,Helicobacter,Drug: Levofloxacin based sequential therapy|Drug: bismuth quadruple therapy for 10 days (BQ),National Taiwan University Hospital,Phase 3,560,Other,Feb-15,Dec-19,Dec-20
6930,NCT03147599,Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders,"Oncology|Incontinence|Incontinence, Daytime Urinary|Incontinence, Nighttime Urinary|Bladder Cancer|Orthotopic Neobladder",Drug: Coloverin|Drug: Placebo,Mansoura University,Phase 4,110,Other,"May 15, 2017","May 1, 2019","May 1, 2019"
6931,NCT03147404,"Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes","Neuroendocrine Carcinoma, Grade 3",Drug: Avelumab,"Samsung Medical Center|Merck KGaA, Darmstadt, Germany",Phase 2,14,Other|Industry,"December 28, 2017","July 22, 2019","July 22, 2019"
6932,NCT03145064,Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma,Diffuse Large B-cell Lymphoma,Drug: Zanubrutinib,BeiGene,Phase 2,41,Industry,"June 30, 2017","May 24, 2019","September 3, 2020"
6933,NCT03144778,Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer,Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7,Biological: Durvalumab|Biological: Tremelimumab,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,39,Other|NIH,"July 12, 2017","March 15, 2021","March 15, 2021"
6934,NCT03144687,A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis,MPN (Myeloproliferative Neoplasms),Drug: Itacitinib|Drug: Ruxolitinib,Incyte Corporation,Phase 2,23,Industry,"January 26, 2018","March 14, 2020","June 1, 2021"
6935,NCT03144245,Study of AMV564 in Patients With AML,Acute Myeloid Leukemia,Biological: AMV564|Combination Product: AMV564 in combination with pembrolizumab,"Amphivena Therapeutics, Inc.",Phase 1,53,Industry,"March 20, 2017","July 21, 2020","November 5, 2020"
6936,NCT03143751,Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients,Moderate to Severe Traumatic Brain Injury,Drug: NaCl20% (Continuous hyperosmolar therapy),Nantes University Hospital,Phase 3,370,Other,"October 31, 2017","March 5, 2020","March 5, 2020"
6937,NCT03143218,"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)","Malaria,Falciparum|Children, Only","Biological: RABIPUR®|Biological: RTS,S/AS01|Drug: SMC with SP+AQ|Drug: SMC placebo","London School of Hygiene and Tropical Medicine|Malaria Research and Training Center, Bamako, Mali|Institut de Recherche en Sciences de la Sante, Burkina Faso",Phase 3,5920,Other,"April 17, 2017","March 31, 2020","March 31, 2020"
6938,NCT03142516,"FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status",Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Cancer Metastatic|Neoplasm Metastasis,Drug: Panitumumab|Drug: Irinotecan|Drug: Folinic acid|Drug: 5-FU,Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|Pivotal S.L.,Phase 2,20,Other|Industry,"October 31, 2017","January 21, 2021","January 21, 2021"
6939,NCT03141073,Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects,"Diabetes Mellitus, Type 2",Drug: HMS5552|Drug: Placebo,Hua Medicine Limited|Covance,Phase 3,767,Industry,"October 15, 2017","February 28, 2021","February 28, 2021"
6940,NCT03140813,An Initial Study of AZD7325 in Adults With Fragile X Syndrome,Fragile X Syndrome,Drug: AZD7325 (High-Dose)|Drug: AZD7325 (Low-Dose)|Drug: Placebo oral capsule,"Children's Hospital Medical Center, Cincinnati",Phase 1,15,Other,"January 16, 2018","June 18, 2020","June 18, 2020"
6941,NCT03140553,TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer,HER2-Positive Breast Cancer,Drug: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab),Guangdong Provincial People's Hospital,Phase 2,140,Other,"September 1, 2016","November 11, 2019","November 11, 2019"
6942,NCT03140527,"Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis",Healthy Volunteer|Cystic Fibrosis,Drug: PTI-801|Drug: Placebo|Drug: PTI-808,"Proteostasis Therapeutics, Inc.",Phase 1,171,Industry,"April 10, 2017","February 27, 2020","February 27, 2020"
6943,NCT03140280,Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN),Myelodysplastic Syndromes,Drug: Freeze-Dried Black Raspberry Powder,Ehab L Atallah|Medical College of Wisconsin,Phase 2,23,Other,"June 5, 2017","June 1, 2019","May 28, 2021"
6944,NCT03139604,GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease,Graft-versus-host Disease (GVHD),Drug: Itacitinib|Drug: Placebo|Drug: Prednisone|Drug: Methylprednisolone,Incyte Corporation,Phase 3,439,Industry,"July 19, 2017","May 2, 2019","July 13, 2020"
6945,NCT03139331,PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,Sarcoma|Refractory Sarcoma,Drug: Pazopanib|Drug: Irinotecan|Drug: Temozolomide,"University of California, San Francisco|UCSF Benioff Children's Hospital Oakland|Dana-Farber Cancer Institute|Alex's Lemonade Stand Foundation",Phase 1,16,Other|Industry,"June 6, 2017","October 15, 2019","September 30, 2020"
6946,NCT03139045,Impact of VeinViewer® Vision to Guide Peripheral Venipuncture in Geriatrics,Venipuncture|Geriatric,Biological: Venous puncture in elderly patients,"Centre Hospitalier Universitaire, Amiens",Phase 3,200,Other,"September 1, 2018","September 1, 2019","December 1, 2021"
6947,NCT03138811,"A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma",Asthma,Drug: CSJ117|Drug: Placebo Comparator,Novartis Pharmaceuticals|Novartis,Phase 1,28,Industry,"December 18, 2017","July 16, 2019","July 16, 2019"
6948,NCT03138655,Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD),Ulcerative Colitis|Crohn's Disease,Drug: Vedolizumab,"Takeda|Takeda Development Center Americas, Inc.",Phase 2,89,Industry,"November 8, 2017","March 31, 2020","May 26, 2020"
6949,NCT03138577,Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular Block,Surgery of Right Upper Extremity,Diagnostic Test: Ultrasound Imaging|Drug: Supraclavicular Block|Other: Bedside Negative Inspiratory Force Meter,Weill Medical College of Cornell University,Phase 4,24,Other,"February 12, 2018","July 30, 2019","July 30, 2019"
6950,NCT03137381,Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata,Alopecia Areata,Drug: CTP-543|Drug: CTP-543 matching placebo,Concert Pharmaceuticals,Phase 2,149,Industry,"August 9, 2017","July 8, 2019","July 8, 2019"
6951,NCT03137303,Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study),COPD Asthma,Device: Spirometry at initial visit|Drug: Albuterol|Device: Spirometry at 12-month follow-up,University of Illinois at Chicago|Agency for Healthcare Research and Quality (AHRQ),Phase 3,402,Other|U.S. Fed,"July 1, 2017","September 30, 2019","September 30, 2019"
6952,NCT03137069,A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).,Urticaria,Drug: GDC-0853|Drug: Placebo,"Genentech, Inc.",Phase 2,134,Industry,"May 26, 2017","September 27, 2019","October 25, 2019"
6953,NCT03136640,ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer,Castration-resistant Prostate Cancer,Drug: ModraDoc006/r,Modra Pharmaceuticals|The Netherlands Cancer Institute,Phase 1,23,Industry|Other,"April 26, 2017","September 5, 2019","September 5, 2019"
6954,NCT03135769,Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias,Gestational Trophoblastic Neoplasias (GTN),Drug: Avelumab administration at 10mg/kg,Hospices Civils de Lyon,Phase 2,24,Other,"February 21, 2017","December 2, 2020","March 17, 2021"
6955,NCT03135522,Pilot of Zinc Acetate to Improve Chronic Cough,Cough,Drug: Zinc Acetate 50 Mg Oral Capsule|Drug: Placebo oral capsule,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)|American Lung Association",Phase 2,34,Other|NIH,"February 14, 2018","December 11, 2019","December 11, 2019"
6956,NCT03135249,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis (MS),Drug: Alemtuzumab,"University of Texas Southwestern Medical Center|Genzyme, a Sanofi Company",Phase 4,9,Other|Industry,"May 1, 2018","November 4, 2020","November 4, 2020"
6957,NCT03135171,Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,Breast Cancer,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Tocilizumab,University of Michigan Rogel Cancer Center,Phase 1,11,Other,"July 26, 2017","March 16, 2020","March 20, 2020"
6958,NCT03134872,A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Lung Diseases|Respiratory Tract Disease|Neoplasms by Site|Neoplasm, Bronchial|Carcinoma, Bronchogenic",Biological: SHR-1210|Drug: Carboplatin|Drug: Pemetrexed,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,419,Industry,"May 12, 2017","July 27, 2019","August 29, 2019"
6959,NCT03133793,CoQ10 and D-ribose in Patients With Diastolic Heart Failure,"Heart Failure, Diastolic",Drug: CoQ10|Drug: D-Ribose Oral Powder|Other: Placebo pills|Other: Placebo powder,University of Kansas Medical Center|National Institute on Aging (NIA),Phase 2,216,Other|NIH,"February 5, 2018","March 12, 2021","March 12, 2021"
6960,NCT03133780,Sedation During Spinal Anesthesia,Sedation During Spinal Anesthesia,Drug: Ketamine|Drug: Midazolam,Assiut University,Phase 2,80,Other,"July 14, 2018","March 7, 2020","March 7, 2020"
6961,NCT03133676,"A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis","Osteoarthritis, Knee",Drug: KA34|Drug: Placebo,"Calibr, a division of Scripps Research|California Institute for Regenerative Medicine (CIRM)",Phase 1,60,Other,"May 2, 2018","April 28, 2020","April 28, 2020"
6962,NCT03131570,Safety and Efficacy of Secukinumab in Mild Psoriasis,Psoriasis,Drug: Secukinumab|Drug: Placebo followed by Secukinumab,"James G. Krueger, MD, PhD|Novartis|Rockefeller University",Phase 2,23,Other|Industry,"May 23, 2017","January 8, 2020","June 21, 2021"
6963,NCT03131219,Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS),Atypical Hemolytic Uremic Syndrome (aHUS),Biological: Ravulizumab,Alexion,Phase 3,31,Industry,"August 31, 2017","December 3, 2019","December 20, 2022"
6964,NCT03130959,A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies,Various Advanced Cancer,Biological: Nivolumab|Biological: Ipilimumab,Bristol-Myers Squibb,Phase 2,166,Industry,"June 12, 2017","March 10, 2020","January 17, 2022"
6965,NCT03130738,Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis,Otomycosis,Drug: 7-Day Miconazole Oil (Miconazole 2%)|Drug: 14-Day Miconazole Oil (Miconazole 2%)|Drug: 14-Day Placebo - Oil Vehicle,"Hill Dermaceuticals, Inc.|QST Consultations, Ltd.",Phase 2,65,Industry|Other,"April 20, 2017","August 6, 2019","August 6, 2019"
6966,NCT03130634,The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment,Metastatic Colorectal Cancer,Drug: Silymarin,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 4,70,Other,Apr-16,Jun-19,Jan-20
6967,NCT03130426,Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi,Type 2 Diabetes Mellitus,Drug: iGlarLixi|Drug: Insulin Glargine|Drug: Metformin|Behavioral: Lifestyle therapy,Population Health Research Institute|Sanofi,Phase 3,161,Other|Industry,"June 27, 2017","June 30, 2019","September 30, 2020"
6968,NCT03130114,Antibiotics for Children With Severe Diarrhoea,Diarrhea,Drug: Azithromycin|Other: Placebo,"World Health Organization|International Centre for Diarrhoeal Disease Research, Bangladesh|Center for Public Health Kinetics|Kenya Medical Research Institute|University of Washington|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|University of Liverpool|Centre pour le developpement des vaccines, Mali|University of Maryland, College Park|Aga Khan University|Muhimbili University of Health and Allied Sciences|Boston Children's Hospital",Phase 3,8268,Other,"May 13, 2017","January 15, 2020","January 15, 2020"
6969,NCT03129646,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Visceral Leishmaniasis,Drug: Miltefosine|Drug: Paromomycin|Drug: Sodium stibogluconate,"Drugs for Neglected Diseases|The Netherlands Cancer Institute|The Institute of Endemic Diseases (IEND), University of Khartoum|Kenya Medical Research Institute|Makerere University|University of Gondar",Phase 3,439,Other,"January 24, 2018","December 11, 2020","December 11, 2020"
6970,NCT03129542,Midodrine Hydrochloride in Early Sepsis,Sepsis|Blood Pressure,Drug: Midodrine Hydrochloride 10 milligrams|Drug: Placebo capsule,Mayo Clinic|Cleveland Clinic Abu Dhabi,Phase 1,33,Other,"August 30, 2017","April 28, 2020","May 15, 2020"
6971,NCT03129100,A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis,Axial Spondyloarthritis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Phase 3,773,Industry,"May 9, 2017","May 26, 2020","May 27, 2021"
6972,NCT03128528,Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure,Chronic Heart Failure,Drug: Empagliflozin 10mg|Drug: Placebo Oral Tablet,University of Erlangen-Nürnberg Medical School,Phase 2,84,Other,"July 1, 2017","January 31, 2020","April 30, 2020"
6973,NCT03128320,The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure,Diabetic Foot,Drug: BAY1193397|Drug: Placebo,Bayer,Phase 2,23,Industry,"May 25, 2017","September 6, 2019","October 28, 2019"
6974,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,Amylyx Pharmaceuticals Inc.|ALS Finding a Cure|ALS Association|Northeast ALS Consortium|Neurological Clinical Research Institute at Massachusetts General Hospital|Leandro P. Rizzuto Foundation,Phase 2,137,Industry|Other,"June 22, 2017","September 25, 2019","November 24, 2019"
6975,NCT03127137,CESI With Low Dose Lidocaine and Transient Weakness,Cervical Radiculitis|Pain,Drug: Experimental Group 1 triamcinolone and lidocaine|Drug: Experimental Group 2 triamcinolone and saline,Northwestern University,Phase 4,123,Other,"August 1, 2018","June 6, 2019","June 15, 2019"
6976,NCT03126370,Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF),Hepatitis C|HIV Coinfection,Drug: TDF with a boosted protease inhibitor|Drug: TAF with a boosted protease inhibitor|Drug: TAF with a boosted protease inhibitor and LDV/SOF,"University of Colorado, Denver",Phase 4,10,Other,"January 8, 2018","July 12, 2019","October 1, 2019"
6977,NCT03125902,A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC),Triple-Negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Atezolizumab Placebo|Drug: Paclitaxel",Hoffmann-La Roche,Phase 3,653,Industry,"August 25, 2017","November 15, 2019","January 17, 2023"
6978,NCT03125616,Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B,Prematurity|Vaccination|Meningococcal Disease,Biological: 4CMenB Vaccine,"St George's, University of London|GlaxoSmithKline|MeningitisNow|Public Health England",Phase 4,136,Other|Industry,"August 1, 2017","September 2, 2019","August 28, 2020"
6979,NCT03125395,"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Drug: LUM/IVA,Vertex Pharmaceuticals Incorporated,Phase 3,57,Industry,"May 12, 2017","July 17, 2019","July 17, 2019"
6980,NCT03125239,Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,Relapsed Adult Acute Myeloid Leukemia|Refractory Adult Acute Myeloid Leukemia,Drug: Merestinib|Drug: LY2874455,"Jacqueline Garcia, MD|Eli Lilly and Company|Dana-Farber Cancer Institute",Phase 1,16,Other|Industry,"August 10, 2017","June 1, 2020","June 1, 2020"
6981,NCT03125057,A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain,Port-wine Stain,Drug: Hemoporfin PDT,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",Phase 4,24,Industry,"August 2, 2017","May 10, 2020","May 10, 2020"
6982,NCT03124433,Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer,Cancer of the Prostate,Drug: Apalutamide,Singapore General Hospital,Phase 2,30,Other,"June 20, 2017","August 22, 2019","August 22, 2019"
6983,NCT03124121,Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels,Ulcerative Colitis,Drug: Golimumab,Guy's and St Thomas' NHS Foundation Trust|Merck Sharp & Dohme LLC,Phase 4,112,Other|Industry,"September 5, 2017","September 30, 2019","September 30, 2019"
6984,NCT03123939,Phase III B in Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,Biological: CTL019,Novartis Pharmaceuticals|Novartis,Phase 3,69,Industry,"April 24, 2017","October 13, 2020","October 13, 2020"
6985,NCT03123861,Gabapentin for Postop Pain After SSLF,Pelvic Organ Prolapse,Drug: Gabapentin|Drug: Placebo oral capsule,"University of North Carolina, Chapel Hill",Phase 4,45,Other,"June 1, 2017","July 25, 2020","July 25, 2020"
6986,NCT03123627,"Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.",Kidney Transplant Infection,Drug: New profilaxis|Drug: Profilaxis recommended,Maimónides Biomedical Research Institute of Córdoba,Phase 3,150,Other,"August 23, 2016","October 21, 2019","October 21, 2019"
6987,NCT03123120,A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy,"Colitis, Ulcerative",Drug: Spesolimab|Drug: Placebo,Boehringer Ingelheim,Phase 2,22,Industry,"June 7, 2017","March 26, 2020","September 16, 2020"
6988,NCT03123107,Vitamin C in Cardiac Surgery Patients,Coronary Artery Bypass Graft Surgery,Drug: Ascorbic Acid,Geisinger Clinic|Wilkes University,Phase 1,6,Other,"July 6, 2017","May 31, 2019","May 31, 2019"
6989,NCT03123016,Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo,Vitiligo,Drug: Apremilast|Procedure: NB-UVB phototherapy,Icahn School of Medicine at Mount Sinai|Celgene,Phase 2,23,Other|Industry,"April 14, 2017","August 5, 2019","August 5, 2019"
6990,NCT03122691,Differences in Cannabis Impairment and Its Measurement Due to Route of Administration,Behavioral Pharmacology of Cannabis,Drug: cannabis,Johns Hopkins University|RTI International|National Institute of Justice|National Institute on Drug Abuse (NIDA),Phase 1,23,Other|NIH,"May 1, 2018","June 11, 2019","February 1, 2020"
6991,NCT03122509,"A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",Metastatic Colorectal Cancer,Drug: durvalumab|Drug: tremelimumab|Radiation: Radiotherapy (RT)|Procedure: ablation,Memorial Sloan Kettering Cancer Center|MedImmune LLC|AstraZeneca,Phase 2,25,Other|Industry,"April 24, 2017","April 28, 2021","April 28, 2021"
6992,NCT03122431,Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases,Systemic Lupus Erythematosus (SLE)|Juvenile SLE|Cutaneous Lupus,Drug: Thalidomide|Drug: Hydroxychloroquine reduced|Drug: standard dose of HCQ,University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 4,93,Other,"June 5, 2017","December 30, 2020","March 30, 2021"
6993,NCT03122119,Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint,Chronic Low Back Pain|Sacroiliitis|Sacroiliac; Backache|Platelet Rich Plasma|Platelet|Injection Site|Ultrasound Therapy; Complications|Treatment,Drug: Platelet Rich Plasma Joint Injection,Star Spine and Sport,Phase 4,51,Other,"May 1, 2017","March 1, 2020","September 1, 2022"
6994,NCT03121833,Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma,"Soft Tissue Sarcoma, Adult, Stage IIB",Drug: Endostar|Drug: Placebo|Drug: AIM regimen / GT regimen,Tianjin Medical University Cancer Institute and Hospital,Phase 2,52,Other,"May 1, 2017","December 20, 2019","December 20, 2019"
6995,NCT03121716,"A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects",Nasopharyngeal Carcinoma,Biological: SHR-1210|Drug: Gemcitabine|Drug: cis-platinum,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,23,Industry,"April 26, 2017","July 28, 2020","July 31, 2020"
6996,NCT03120936,The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community,Transgender Persons|Pre-Exposure Prophylaxis,Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet|Behavioral: PrEP support,"Public Health Foundation Enterprises, Inc.|San Francisco Department of Public Health|University of California, San Francisco|San Francisco Community Health Center|Tri-City Health Center|California HIV/AIDS Research Program",Phase 4,158,Other,"August 8, 2017","August 27, 2020","December 1, 2020"
6997,NCT03119766,Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients,Dyspepsia,Drug: Kolofort|Drug: Placebo,Materia Medica Holding,Phase 4,370,Industry,"June 28, 2017","January 11, 2020","January 11, 2020"
6998,NCT03118817,"Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers",Solid Tumor,Drug: HM95573,Hanmi Pharmaceutical Company Limited,Phase 1,65,Industry,"May 19, 2017","February 4, 2020","February 4, 2020"
6999,NCT03118570,"A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804","Osteogenesis Imperfecta, Type I|Osteogenesis Imperfecta Type III|Osteogenesis Imperfecta Type IV",Drug: setrusumab|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D|Drug: zoledronic acid (optional),Ultragenyx Pharmaceutical Inc|Mereo BioPharma,Phase 2,112,Industry,"September 11, 2017","October 1, 2019","November 12, 2020"
7000,NCT03118310,Treatment of NAFLD With Two Different Diets,NAFLD,Behavioral: 5:2 diet|Behavioral: LCHF|Behavioral: Placebo diet,Karolinska University Hospital,Phase 2,74,Other,"April 6, 2017","August 31, 2020","August 31, 2020"
7001,NCT03117998,"Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus",Type1 Diabetes Mellitus,Biological: REMD-477|Biological: Placebo Comparator,"REMD Biotherapeutics, Inc.",Phase 2,154,Industry,"September 19, 2017","March 5, 2021","March 5, 2021"
7002,NCT03117920,"A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer",Pancreatic Cancer,Drug: Minnelide,Minneamrita Therapeutics LLC|Barts & The London NHS Trust|Translational Genomics Research Institute|Stand Up To Cancer|Cancer Research UK|Lustgarten Foundation|Queen Mary University of London,Phase 2,19,Industry|Other,"April 10, 2017","July 1, 2019","July 1, 2019"
7003,NCT03117790,Impact of Dexmedetomidine on Sleep Quality,"Elderly|Surgery|Analgesia|Dexmedetomidine|Complication,Postoperative|Sleep Quality",Drug: Dexmedetomidine|Drug: Placebo,Peking University First Hospital,Phase 4,118,Other,"June 26, 2017","January 16, 2020","February 18, 2020"
7004,NCT03117634,An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy,Age Related Macular Degeneration|Polypoidal Choroidal Vasculopathy,Drug: Treat and Extend with Aflibercept 2mg|Drug: Fixed Dosing with Aflibercept 2mg,Singapore National Eye Centre|Bayer,Phase 4,54,Other|Industry,"December 1, 2017","June 30, 2020","January 31, 2021"
7005,NCT03116828,A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures,Epilepsy With Partial On-set Seizures,Drug: Eslicarbazepine acetate|Drug: Eslicarbazepine Acetate,Sunovion,Phase 4,102,Industry,"July 7, 2017","June 6, 2019","June 6, 2019"
7006,NCT03116685,A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria,Primary Hyperoxaluria,Biological: Oxabact OC5 - Oxalobacter formigenes HC-1|Other: Placebo,OxThera,Phase 3,25,Industry,"January 9, 2018","April 15, 2021","April 15, 2021"
7007,NCT03116347,"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects",Primary Immunodeficiency Diseases (PID),Biological: HYQVIA|Biological: KIOVIG|Biological: Cuvitru,"Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Takeda",Phase 4,42,Industry,"May 30, 2017","January 15, 2021","January 15, 2021"
7008,NCT03116152,Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment,Esophageal Squamous Cell Carcinoma,Biological: IBI308|Drug: paclitaxel/ irinotecan,Innovent Biologics (Suzhou) Co. Ltd.,Phase 2,190,Industry,"May 10, 2017","October 2, 2019","October 2, 2019"
7009,NCT03115736,TAF for HIV-HBV With Renal Dysfunction,HIV and Hepatitis B Coinfection,Drug: Tenofovir Alafenamide,"University Hospital Inselspital, Berne",Phase 2,24,Other,"May 23, 2017","December 5, 2019","December 5, 2019"
7010,NCT03115307,Luteal Phase Support in Insemination Cycles,"Infertility, Female",Drug: Triptorelin,Tampere University Hospital,Phase 4,167,Other,Jan-17,Nov-19,Nov-19
7011,NCT03115047,Shivering Treatment After Cesarean Delivery: Meperidine vs. Dexmedetomidine,Cesarean Section Complications,Drug: Dexmedetomidine Injection|Drug: Meperidine Injection,Centre hospitalier de l'Université de Montréal (CHUM),Phase 3,80,Other,"May 7, 2017","August 19, 2020","August 20, 2020"
7012,NCT03115021,Neurophysiological Effects of tPCS and tDCS on Patients With Disorders of Consciousness,Disorders of Consciousness,Device: Active tPCS|Device: Active tDCS|Device: Sham tPCS|Device: Sham tDCS,University of Liege,Phase 1,12,Other,"May 1, 2018","September 30, 2019","October 30, 2019"
7013,NCT03114683,Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma,Relapsed/Refractory Classical Hodgkin's Lymphoma,Drug: PD1,Innovent Biologics (Suzhou) Co. Ltd.,Phase 2,96,Industry,"March 30, 2017","September 12, 2019","November 30, 2019"
7014,NCT03114020,Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency,Emphysema|Alpha 1-Antitrypsin Deficiency,Drug: Hyaluronic Acid Inhalation Solution|Drug: Placebo Inhalation Solution,"Gerard Turino|Turino, Gerard, M.D.",Phase 2,27,Other,"March 22, 2017","November 12, 2019","November 12, 2019"
7015,NCT03113825,"Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery","Primary Invasive Malignant Neoplasm of Female Breast|Carcinoma Breast|Breast Cancer Female|Carcinoma, Ductal, Breast|Stage II Breast Cancer|Stage I Breast Cancer|Stage III Breast Cancer",Device: Investigational Imaging device|Drug: AVB-620,"Avelas Biosciences, Inc.|RRD International, Inc.|Clinipace Worldwide",Phase 2,92,Industry|Other,"July 5, 2017","April 8, 2020","November 18, 2020"
7016,NCT03113786,CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients,Protruded Disk,Other: CLARIX™100|Other: CLARIX CORD 1K,"Amniox Medical, Inc.",Phase 4,32,Industry,"November 2, 2011","April 21, 2020","April 21, 2020"
7017,NCT03113188,"CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",Advanced Solid Tumors,Drug: CBP501,CanBas Co. Ltd.,Phase 1,47,Industry,"October 25, 2017","February 15, 2021","February 15, 2021"
7018,NCT03112681,"Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis",Primary Biliary Cirrhosis,Drug: Saroglitazar magnesium 2 mg|Drug: Saroglitazar magnesium 4 mg|Drug: Placebo Oral Tablet,Zydus Therapeutics Inc.,Phase 2,37,Industry,"August 18, 2017","August 7, 2020","August 7, 2020"
7019,NCT03112603,A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3),Graft-versus-host Disease (GVHD),Drug: Ruxolitinib|Drug: Extracorporeal photopheresis (ECP)|Drug: Low-dose methotrexate (MTX)|Drug: Mycophenolate mofetil (MMF)|Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Drug: Infliximab|Drug: Rituximab|Drug: Pentostatin|Drug: Imatinib|Drug: Ibrutinib,Incyte Corporation,Phase 3,330,Industry,"June 29, 2017","May 8, 2020","December 15, 2022"
7020,NCT03111992,"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",Multiple Myeloma,Drug: PDR001|Drug: CJM112|Drug: LCL161,Novartis Pharmaceuticals|Novartis,Phase 1,26,Industry,"December 18, 2017","March 2, 2020","March 2, 2020"
7021,NCT03111810,Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition,Iatrogenic Cushing's Disease,Drug: AZD4017 and prednisolone|Drug: Placebo Oral Tablet and prednisolone,University of Oxford|AstraZeneca,Phase 2,32,Other|Industry,"May 25, 2017","August 1, 2020","August 1, 2020"
7022,NCT03111732,"Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",Biliary Tract Neoplasms|Cholangiocarcinoma|Bile Duct Cancer|Liver Cancer|Gallbladder Cancer,Biological: Pembrolizumab (MK-3475)|Drug: Oxaliplatin|Drug: Capecitabine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,11,NIH,"June 14, 2017","July 22, 2020","November 8, 2021"
7023,NCT03111628,Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU),Urticaria Chronic,Drug: Omalizumab,Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,18,Other|NIH,"October 6, 2017","May 1, 2020","May 1, 2020"
7024,NCT03111381,Toradol to Reduce Ureteroscopic Symptoms Trial,"Urinary Lithiasis|Kidney Diseases|Kidney Stone|Pain, Postoperative",Drug: Toradol,Yale University,Phase 2,94,Other,"August 1, 2017","June 1, 2020","June 1, 2020"
7025,NCT03111186,Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery,Carpal Tunnel Syndrome|Dupuytren Contracture|Trigger Digit|Ganglion Cysts|De Quervain Disease,Drug: Oxycodone Hcl 5Mg|Drug: Ibuprofen 400 mg|Drug: Acetaminophen 650 mg,University of Southern California,Phase 2,40,Other,"April 24, 2017","May 1, 2019","May 1, 2019"
7026,NCT03110848,Effects of Atorvastatin in Graves' Orbitopathy (GO),Thyroid Associated Ophthalmopathy|Hypercholesterolemia,Drug: Atorvastatin|Drug: Methylprednisolone,University of Pisa,Phase 2,88,Other,"June 1, 2020","April 30, 2021","April 30, 2021"
7027,NCT03110783,Bioseal Dural Sealing Study BIOS-14-001,Benign Tumors|Malignant Tumors|Vascular Malformation,Biological: Bioseal,"Guangzhou Bioseal Biotechnology Co., Ltd.",Phase 3,200,Industry,"September 14, 2017","September 20, 2019","September 20, 2019"
7028,NCT03110770,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,Zika Virus|Zika Virus Infection|Virus Diseases|Flavivirus Infections|Flaviviral Diseases|Flaviviridae Infections|RNA Virus Infections,Biological: VRC-ZKADNA090-00-VP|Other: VRC-PBSPLA043-00-VP,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,2428,NIH,"March 29, 2017","October 4, 2019","October 4, 2019"
7029,NCT03110757,"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults",Schistosomiasis,Biological: GLA-AF|Biological: Hepatitis B Virus Vaccine (Recombinant)|Biological: Sm-TSP-2/Alhydrogel,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,60,NIH,"May 20, 2018","November 14, 2019","November 14, 2019"
7030,NCT03110458,Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy,Acute Unilateral Vestibulopathy (AUV),Drug: SENS-111 100mg|Drug: SENS-111 200mg|Drug: Placebo Oral Tablet,Sensorion,Phase 2,107,Industry,"August 16, 2017","October 15, 2019","October 15, 2019"
7031,NCT03110133,"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff",Clostridium Difficile Infection Recurrence,Drug: Full Spectrum Microbiota|Drug: Placebo,Finch Research and Development LLC.,Phase 2,206,Industry,"May 8, 2017","February 28, 2020","June 18, 2020"
7032,NCT03109886,Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma,Hepatocellular Carcinoma,Drug: Milciclib maleate,Tiziana Life Sciences LTD,Phase 2,31,Industry,"July 12, 2017","May 16, 2019","June 20, 2019"
7033,NCT03109847,Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer,Thyroid,Drug: Metformin Hydrochloride|Other: Radioactive Iodine|Other: Placebo,Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University,Phase 2,13,Other,"January 5, 2017","December 29, 2020","December 7, 2022"
7034,NCT03109379,Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder,Idiopathic Overactive Bladder With Urinary Incontinence,Drug: Trospium-Releasing Intravesical System (TAR-302-5018),Taris Biomedical LLC,Phase 1,43,Industry,"April 4, 2017","September 27, 2019","September 27, 2019"
7035,NCT03109015,Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing,"Carcinoma, Renal Cell",Drug: Sunitinib,Duke University,Phase 2,7,Other,"September 27, 2017","October 8, 2019","October 8, 2019"
7036,NCT03108833,A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism,Acute Pulmonary Embolism,Drug: Recombinant Human Prourokinase|Drug: Alteplase,"Tasly Biopharmaceuticals Co., Ltd.",Phase 2,108,Industry,"June 6, 2017","December 19, 2019","December 19, 2019"
7037,NCT03108625,Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age,"Depressive Disorder, Major",Drug: Vortioxetine,H. Lundbeck A/S,Phase 3,94,Industry,"March 1, 2017","April 16, 2020","April 16, 2020"
7038,NCT03108352,Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion,Branch Retinal Vein Occlusion|Macular Edema,Drug: Conbercept ophthalmic injection|Other: sham/Conbercept ophthalmic injection,"Chengdu Kanghong Biotech Co., Ltd.",Phase 3,255,Industry,"April 13, 2016","April 13, 2020","October 16, 2020"
7039,NCT03107793,Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab,Crohn Disease,Drug: Ustekinumab,Janssen-Cilag Ltd.,Phase 3,500,Industry,"April 19, 2017","April 30, 2020","July 20, 2021"
7040,NCT03107208,Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes,Diabetic Ketoacidosis|Type 1 Diabetes Mellitus,Drug: Glargine|Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro),"University of Colorado, Denver",Phase 4,61,Other,"July 21, 2017","March 13, 2021","March 13, 2021"
7041,NCT03106987,A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.,Epithelial Ovarian Cancer,Drug: Active Comparator: Olaparib tablets|Drug: Placebo,AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT),Phase 3,220,Industry|Other,"June 8, 2017","February 15, 2021","February 17, 2022"
7042,NCT03106428,A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,Acute Myeloid Leukemia|Multiple Myeloma|Diffuse Large B-cell Lymphoma,Drug: MEDI7247,MedImmune LLC,Phase 1,67,Industry,"March 29, 2017","January 3, 2020","January 3, 2020"
7043,NCT03106077,Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|Folate Receptor Alpha Positive|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma,Biological: Mirvetuximab Soravtansine,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,96,Other|NIH,"June 5, 2017","October 1, 2019","October 1, 2019"
7044,NCT03105193,Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections,Laparoscopic Colon Resection|Perioperative Analgesia,Drug: IV Saline bolus and infusion|Drug: IP Saline bolus and infusion|Drug: IV lignocaine bolus and infusion|Drug: IP Lignocaine bolus and infusion,"University of Auckland, New Zealand",Phase 4,60,Other,"August 17, 2018","December 1, 2019","December 30, 2019"
7045,NCT03105128,A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease,Crohn's Disease,Drug: placebo for risankizumab|Drug: risankizumab IV|Drug: risankizumab SC,AbbVie,Phase 3,931,Industry,"May 10, 2017","November 9, 2020","April 14, 2021"
7046,NCT03104413,A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment,Crohn's Disease,Drug: placebo for risankizumab IV|Drug: risankizumab SC|Drug: risankizumab IV,AbbVie,Phase 3,618,Industry,"December 18, 2017","November 30, 2020","May 19, 2021"
7047,NCT03104283,Apatinib for the Elderly Advanced Gastric Cancer,Gastric Cancer,Drug: Apatinib,Affiliated Hospital of Qinghai University,Phase 2,48,Other,"June 5, 2017","December 1, 2019","June 2, 2020"
7048,NCT03104075,Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines,Pneumonia|Aging,Biological: Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|Biological: Pneumococcal Vaccine Polyvalent,The Jackson Laboratory|UConn Health|University of Alabama at Birmingham,Phase 4,40,Other,"April 17, 2017","December 5, 2019","August 29, 2020"
7049,NCT03104036,Faecal Bacteriotherapy for Ulcerative Colitis,Ulcerative Colitis,Other: Faecal bacterial transplantation|Drug: Mesalazine 4G Enema,Institute for Clinical and Experimental Medicine|Institute of Animal Physiology and Genetics Academy of Science Czech Republic,Phase 2,61,Other,"June 19, 2017","January 30, 2021","June 30, 2021"
7050,NCT03103724,A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.,Carcinoma Prostate,Drug: Xtandi,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,68,Other,"March 16, 2017","April 23, 2021","April 23, 2021"
7051,NCT03103542,Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies,Hemophilia A,Biological: Recombinant coagulation factor (rFVIIIFc),Swedish Orphan Biovitrum|Bioverativ Therapeutics Inc.,Phase 4,16,Industry,"August 29, 2017","September 4, 2019","August 31, 2020"
7052,NCT03103321,Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer,Stage II Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage I Prostate Cancer|PSA Level Five to Ten|PSA Level Less Than Five|PSA Level Ten to Fifty,Other: Internet-Based Intervention|Other: Best Practice|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Survey Administration|Other: Laboratory Biomarker Analysis,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Phase 3,158,Other|NIH,"July 14, 2017","December 5, 2019","November 25, 2020"
7053,NCT03103100,"Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation",Labor Pain,Drug: 1% Lidocaine|Drug: 0.25% Bupivacaine|Drug: Bupivacaine plus Lidocaine,University of Alabama at Birmingham,Phase 3,75,Other,"October 8, 2015","July 1, 2019","September 9, 2019"
7054,NCT03103087,LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,Heavy Menstrual Bleeding|Uterine Fibroid,Drug: Relugolix|Drug: Estradiol/norethindrone acetate|Drug: Relugolix placebo|Drug: Estradiol/norethindrone acetate placebo,Myovant Sciences GmbH,Phase 3,382,Industry,"June 14, 2017","July 10, 2019","September 16, 2020"
7055,NCT03102736,Ketamine and Nitroprusside for Depression,Depression,Drug: Placebos|Drug: Ketamine|Drug: Nitroprusside,Icahn School of Medicine at Mount Sinai,Phase 2,40,Other,"February 14, 2017","June 12, 2019","June 12, 2019"
7056,NCT03102450,"Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age",Contraception,Drug: Benzalkonium Chloride Spermicide Cream,Laboratoire Innotech International|ITEC Services,Phase 4,151,Industry|Other,"December 26, 2017","October 17, 2019","October 17, 2019"
7057,NCT03102320,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,Neoplasms,Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine (BAY94-9343),"Bayer|ImmunoGen, Inc.|MorphoSys AG",Phase 1,173,Industry,"May 26, 2017","September 16, 2020","July 26, 2021"
7058,NCT03102242,Atezolizumab Immunotherapy in Patients With Advanced NSCLC,"Carcinoma, Non-Small-Cell Lung",Drug: Atezolizumab,"Alliance Foundation Trials, LLC.",Phase 2,64,Other,"November 1, 2017","June 1, 2020","October 1, 2022"
7059,NCT03102047,Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer,Rectal Cancer,Drug: durvalumab,NSABP Foundation Inc,Phase 2,45,Other,"May 14, 2018","February 22, 2021","December 30, 2021"
7060,NCT03101644,Optimization of Darunavir Therapy and Dosage Recommendations,Human Immunodeficiency Virus I Infection,Drug: Darunavir,Université Catholique de Louvain|Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 4,127,Other,"March 23, 2017","June 12, 2019","June 12, 2019"
7061,NCT03101566,Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,Biliary Tract Neoplasms,Drug: Gemcitabine|Drug: Cisplatin|Drug: Ipilimumab|Drug: Nivolumab,University of Michigan Rogel Cancer Center,Phase 2,75,Other,"September 8, 2017","December 3, 2019","June 7, 2021"
7062,NCT03101514,Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study,Head and Neck Cancer|Radiotherapy,Drug: Kanglaite|Drug: chemotherapy,First Affiliated Hospital of Harbin Medical University,Phase 2,53,Other,"January 1, 2017","February 1, 2021","February 1, 2021"
7063,NCT03101488,Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors,Solid Tumors,Drug: KN035,"3D Medicines (Sichuan) Co., Ltd.|3D Medicines",Phase 1,287,Industry,"March 21, 2017","September 2, 2019","August 25, 2020"
7064,NCT03101475,Synergism of Immunomodulation and Tumor Ablation,Colorectal Cancer|Liver Metastases,Drug: Durvalumab (MEDI4736)|Drug: Tremelimumab|Radiation: Sterotactic body radiation therapy (SBRT)|Other: Radiofrequency ablation (RFA),European Organisation for Research and Treatment of Cancer - EORTC,Phase 2,22,Other,"November 23, 2018","March 3, 2021","February 23, 2022"
7065,NCT03101280,A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,Gynecologic Neoplasms,Drug: Atezolizumab|Drug: Rucaparib,Hoffmann-La Roche,Phase 1,29,Industry,"April 27, 2017","August 11, 2020","August 11, 2020"
7066,NCT03100864,This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients,"Colitis, Ulcerative",Drug: Spesolimab,Boehringer Ingelheim,Phase 2,8,Industry,"May 22, 2017","August 5, 2019","October 24, 2019"
7067,NCT03099863,Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection,Urinary Tract Infections,Drug: Cystoscopic Fluid containing Neosporin G. U. Irrigant|Procedure: Cystoscopy|Drug: Cystoscopic Fluid/Placebo,MetroHealth Medical Center,Phase 4,242,Other,Apr-16,Jun-20,Jun-20
7068,NCT03099824,A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers,Healthy Volunteers,Drug: GC4711 Oral Capsule G-101|Drug: IV GC4419|Drug: GC4711 Oral Capsule G-111|Drug: GC4711 Oral Capsule G-112|Drug: GC4711 Oral Capsule G-119|Drug: GC4711 Oral Capsule G-125|Drug: IV GC4711,"Galera Therapeutics, Inc.",Phase 1,56,Industry,"October 16, 2018","January 27, 2020","January 27, 2020"
7069,NCT03099785,Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D,Diarrhea-predominant Irritable Bowel Syndrome,Drug: Rifamycin SV 600mg t.i.d.|Drug: Rifamycin SV b.i.d. + Placebo|Drug: Placebo t.i.d.,Cosmo Technologies Ltd|Cosmo Pharmaceuticals NV,Phase 2,279,Industry,"December 18, 2017","September 11, 2020","December 14, 2020"
7070,NCT03099616,Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Bariatric Surgery,Anesthesia; Bariatric Surgery,Drug: Propofol|Drug: Desflurane,Dr Nitin Sethi|Sir Ganga Ram Hospital,Phase 4,40,Other,"April 4, 2017","December 2, 2019","December 2, 2019"
7071,NCT03099590,Alkontrol-herbal Effects on Alcohol Drinking,Alcohol Drinking|Alcohol Use Disorder|Alcohol Abstinence,"Dietary Supplement: kudzu extract, puerarin|Dietary Supplement: Placebo control",Mclean Hospital,Phase 2,28,Other,"January 1, 2018","March 1, 2020","July 1, 2020"
7072,NCT03099538,Ixekizumab in the Treatment of Bullous Pemphigoid,Bullous Pemphigoid|Pemphigoid,Drug: Ixekizumab,Mayo Clinic|Eli Lilly and Company,Phase 2,4,Other|Industry,"August 15, 2017","June 6, 2019","June 6, 2019"
7073,NCT03099408,Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis,Bacterial Vaginosis|Recurrence,"Drug: Metronidazole Oral|Drug: ""Metronidazole"" and ""Lactobacillus""",Peking University Shenzhen Hospital,Phase 4,66,Other,"July 1, 2017","December 30, 2020","December 30, 2020"
7074,NCT03099382,Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer,Esophageal Carcinoma,Biological: camrelizumab|Drug: Docetaxel|Drug: Irinotecan,"Jiangsu HengRui Medicine Co., Ltd.",Phase 3,457,Industry,"May 5, 2017","May 6, 2019","May 6, 2019"
7075,NCT03099239,hCT-MSCs for Children With Autism Spectrum Disorder (ASD),Autism|Autism Spectrum Disorder|ASD,Biological: hCT-MSC infusion,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",Phase 1,12,Other,"June 6, 2017","June 10, 2019","June 10, 2019"
7076,NCT03099122,A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant,End-stage Renal Disease,Biological: Rabbit Anti-thymocyte Immunoglobulin|Drug: Tacrolimus|Drug: Methylprednisolone|Drug: Mycophenolate mofetil|Drug: Mycophenolate Na|Drug: prednisone,Sanofi,Phase 4,115,Industry,"August 16, 2017","November 12, 2019","November 12, 2019"
7077,NCT03098823,A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE,"Lupus Erythematosus, Systemic|Lupus Erythematosus|Fatigue",Drug: RAYOS|Drug: Prednisone,"Ampel BioSolutions, LLC",Phase 4,62,Industry,"September 12, 2017","May 28, 2019","June 15, 2020"
7078,NCT03097900,Does Caffeine Enhance Bowel Recovery After Colorectal Surgery?,Postoperative Ileus,Drug: Caffeine Citrate|Other: Water,Hadassah Medical Organization,Phase 2,70,Other,"November 2, 2017","December 31, 2019","December 31, 2019"
7079,NCT03097588,Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant,Malignant Neoplasm,Drug: Netupitant|Drug: Palonosetron Hydrochloride|Other: Questionnaire Administration,"OHSU Knight Cancer Institute|Helsinn Therapeutics (U.S.), Inc|Oregon Health and Science University",Phase 2,43,Other|Industry,"April 27, 2017","February 20, 2020","March 20, 2020"
7080,NCT03096795,"Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants",Part I (SAD) - Healthy Participants|Part II (MAD) - Chronic Obstructive Pulmonary Disease|Part III (J-SD) - Healthy Japanese Participants,Drug: MEDI3506|Drug: Placebo,MedImmune LLC,Phase 1,88,Industry,"May 15, 2017","September 30, 2019","September 30, 2019"
7081,NCT03096288,Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity,Atherosclerotic Cardiovascular Disease,Drug: Evolocumab|Other: Placebo,University of Florida|Amgen,Phase 4,259,Other|Industry,"October 3, 2017","November 2, 2020","November 2, 2020"
7082,NCT03096080,"A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)","Polycystic Kidney, Autosomal Recessive",Drug: Tesevatinib,"Kadmon Corporation, LLC",Phase 1,10,Industry,"August 24, 2017","September 30, 2019","September 30, 2019"
7083,NCT03095274,Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin,Neuroendocrine Tumors|Neuroendocrine Neoplasm of Lung,Drug: Durvalumab|Drug: Tremelimumab,Grupo Espanol de Tumores Neuroendocrinos,Phase 2,123,Other,"April 11, 2017","November 30, 2019","May 23, 2022"
7084,NCT03095118,Daratumumab in Treatment of PGNMID and C3 GN,Membranoproliferative Glomerulonephritis,Drug: Daratumumab,Fernando Fervenza|Mayo Clinic,Phase 2,12,Other,"September 7, 2017","October 14, 2019","May 12, 2020"
7085,NCT03094546,Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline,Subjective Cognitive Decline (SCD),Dietary Supplement: Polyamine|Dietary Supplement: Placebo,"Charite University, Berlin, Germany|Freie Universität, Institute of Biology/Genetic, Berlin, Germany|Karl-Franzens-Universität, Institute of Molecular Biosciences, Graz, Austria",Phase 2,100,Other,Jan-17,May-20,Oct-20
7086,NCT03094416,Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors,Hypothyroidism;Postablative,Drug: levothyroxine sodium capsule|Drug: Proton pump inhibitor (PPI)|Drug: Levothyroxine Sodium (LT4) Tablets,IBSA Institut Biochimique SA,Phase 4,66,Industry,"July 30, 2018","June 15, 2020","June 15, 2020"
7087,NCT03093974,Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.,Non Cystic Fibrosis Bronchiectasis,Drug: Colistimethate Sodium|Drug: Saline Solution,Zambon SpA,Phase 3,377,Industry,"June 6, 2017","April 9, 2021","April 9, 2021"
7088,NCT03093480,A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study),Hemophilia A With Inhibitors,Biological: rFVIIIFc,"Bioverativ, a Sanofi company|Swedish Orphan Biovitrum|Sanofi",Phase 4,16,Industry,"December 8, 2017","May 4, 2020","February 16, 2021"
7089,NCT03093454,"Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood","Pain, Postoperative",Drug: Lavender Essential Oil,"Scott Hollenbeck, MD|dōTERRA International|Duke University",Phase 3,58,Other|Industry,"October 27, 2017","January 31, 2020","January 31, 2020"
7090,NCT03093415,Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care,"Hepatitis C|Substance Use Disorders|Substance Abuse, Intravenous",Drug: elbasvir-grazoprevir (50 mg/100 mg),Oregon Health and Science University,Phase 4,100,Other,"May 30, 2017","June 6, 2019","June 6, 2019"
7091,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,Relapsing Remitting Multiple Sclerosis,Drug: ALKS 8700|Drug: Dimethyl Fumarate,"Biogen|Alkermes, Inc.",Phase 3,506,Industry,"March 15, 2017","June 27, 2019","June 27, 2019"
7092,NCT03092895,A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC,Advanced Primary Liver Cancer|Advanced Biliary Tract Carcinoma,Biological: SHR-1210|Drug: Apatinib|Drug: FOLFOX4|Drug: GEMOX,"Jiangsu HengRui Medicine Co., Ltd.",Phase 2,157,Industry,"April 27, 2017","March 31, 2021","March 31, 2021"
7093,NCT03092089,Sonothrombolysis in Patients With STEMI,ST-segment Elevation Myocardial Infarction,"Drug: Definity, (Lipid Microspheres) Intravenous Suspension|Device: Myocardial Contrast Echocardiography|Procedure: Repurfusion therapy with PPCI",Harald Becher|Alberta Health services|University of Alberta,Phase 2,15,Other,"August 15, 2017","October 3, 2019","October 3, 2019"
7094,NCT03090737,Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer,Non-Small Cell Lung Cancer,Biological: Nivolumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 2,129,Industry,"June 2, 2017","February 16, 2021","March 14, 2022"
7095,NCT03090620,Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome,Anticholinergics Toxicity,Drug: Physostigmine|Drug: Lorazepam,"University of Colorado, Denver|American Academy of Clinical Toxicology",Phase 4,19,Other,"March 30, 2017","July 31, 2020","August 31, 2020"
7096,NCT03090152,Minimal Opioid Use After Total Hip Replacement (THR),"Osteoarthritis, Hip",Procedure: Periarticular injection (Deep injection)|Procedure: Periarticular injection (Superficial injection)|Drug: Bupivacaine|Drug: Placebo,"Hospital for Special Surgery, New York",Phase 4,180,Other,"March 8, 2017","June 28, 2019","September 27, 2019"
7097,NCT03089944,A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis,Hepatitis C Virus (HCV),Drug: Glecaprevir/Pibrentasvir,AbbVie,Phase 3,343,Industry,"April 28, 2017","July 31, 2019","November 8, 2019"
7098,NCT03089645,"MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.",Advanced Solid Tumors,Biological: MEDI5083 monotherapy|Biological: MEID5083 with Durvalumab or Tremelimumab|Biological: Medi5083 with Durvalumab and Docetaxel,MedImmune LLC,Phase 1,39,Industry,"March 21, 2017","June 23, 2020","June 23, 2020"
7099,NCT03088930,Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,"Lung Cancer, Nonsmall Cell",Drug: Crizotinib,"University of Colorado, Denver|Pfizer",Phase 2,3,Other|Industry,"December 13, 2017","January 13, 2021","January 13, 2021"
7100,NCT03088826,Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet),Pain Management,Drug: Morphine Sulfate|Drug: Oxycodone|Drug: Acetaminophen,Antonios Likourezos|Maimonides Medical Center,Phase 2,80,Other,"August 18, 2017","December 22, 2020","December 22, 2020"
7101,NCT03088800,IBUPAP Study for Pain Management in Children,Pain Management,Drug: Ibuprofen|Drug: APAP,Antonios Likourezos|Maimonides Medical Center,Phase 2,90,Other,"April 30, 2018","October 31, 2019","July 30, 2020"
7102,NCT03088527,"Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer",Hormone Receptor Positive Malignant Neoplasm of Breast,Drug: RAD140,"Stemline Therapeutics, Inc.",Phase 1,20,Other,"October 23, 2017","August 28, 2020","September 24, 2020"
7103,NCT03087890,Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria,HIV-1-infection|Pneumocystis Pneumonia|Opportunistic Infections|Preventive Therapy|Antibiotic Side Effect,Drug: Cotrimoxazole|Drug: Placebo,University of Bergen|Haukeland University Hospital|Muhimbili University of Health and Allied Sciences|Helse Vest,Phase 4,537,Other,"March 30, 2017","July 25, 2019","July 25, 2019"
7104,NCT03087864,PDL-1 Targeting in Resectable Oesophageal Cancer,"Esophageal Cancer, Stage II|Esophageal Cancer Stage III",Drug: Atezolizumab|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiotherapy 23 x 1.8 Gy,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|UMC Utrecht,Phase 2,40,Other,"June 28, 2017","July 1, 2019","July 1, 2019"
7105,NCT03087851,Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis,Osteoporosis,Drug: Zoledronic Acid,Aarhus University Hospital|University of Aarhus|Amgen,Phase 4,61,Other|Industry,"March 13, 2017","August 1, 2020","August 1, 2020"
7106,NCT03087591,"APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",Metastatic Malignant Neoplasm in the Brain|Metastatic Solid Neoplasm|Recurrent Colorectal Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Solid Neoplasm|Stage IV Colorectal Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer|Unresectable Solid Neoplasm,Other: Laboratory Biomarker Analysis|Biological: siRNA-transfected Peripheral Blood Mononuclear Cells APN401,Wake Forest University Health Sciences|National Cancer Institute (NCI),Phase 1,11,Other|NIH,"April 28, 2017","July 31, 2019","December 8, 2020"
7107,NCT03087513,A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo,Posterior Cervical Decompression and Fusion,Drug: Sugammadex Injection [Bridion]|Drug: Placebo,"University Health Network, Toronto|Merck Sharp & Dohme LLC",Phase 4,40,Other|Industry,"February 5, 2018","December 30, 2019","April 30, 2020"
7108,NCT03087201,CANNAbinoids in the Treatment of TICS (CANNA-TICS),Tourette Syndrome|Tic Disorders,Drug: nabiximols|Drug: placebo,Hannover Medical School|German Research Foundation,Phase 3,98,Other,"April 5, 2018","November 20, 2020","November 20, 2020"
7109,NCT03087110,Stem Cells in Umbilical Blood Infusion for CP,Cerebral Palsy,Biological: Matched sibling donor cord blood cell infusion,Murdoch Childrens Research Institute|The Royal Children's Hospital|Children's Health Queensland|Monash Health|Sydney Children's Hospitals Network|Cerebral Palsy Alliance,Phase 1,12,Other,Mar-16,Sep-19,Dec-20
7110,NCT03087019,Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,Adenoid Cystic Carcinoma,Radiation: Radiation|Drug: Pembrolizumab,Dana-Farber Cancer Institute|Merck Sharp & Dohme LLC,Phase 2,21,Other|Industry,"April 25, 2017","August 4, 2020","August 4, 2020"
7111,NCT03086733,Phase II Lung Metcore - Preoperative Metformin for Lung Cancer,Non Small Cell Lung Cancer|Lung Cancer,Drug: Metformin,"University Health Network, Toronto",Phase 2,28,Other,"December 5, 2016",Jul-20,Aug-20
7112,NCT03086538,Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy,Colo-rectal Cancer,Drug: Pemetrexed|Drug: Tarceva 100Mg Tablet,Samsung Medical Center,Phase 2,29,Other,"May 30, 2017","January 30, 2020","May 25, 2020"
7113,NCT03085797,Effect of Mepolizumab in Severe Bilateral Nasal Polyps,Nasal Polyps,Drug: Mepolizumab|Drug: Placebo|Drug: Mometasone furoate,GlaxoSmithKline|CRF health|Bristol-Myers Squibb,Phase 3,414,Industry|Other,"May 25, 2017","December 11, 2019","December 11, 2019"
7114,NCT03085758,Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB,Septic Shock,Biological: Adrecizumab|Biological: Placebo,Adrenomed AG,Phase 2,301,Industry,"December 12, 2017","December 20, 2019","December 20, 2019"
7115,NCT03085225,Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.,Ovarian Carcinoma|Soft Tissue Sarcoma,Drug: Combination of trabectedin with durvalumab,Institut Bergonié|AstraZeneca|PharmaMar,Phase 1,40,Other|Industry,"May 5, 2017","November 19, 2020","January 4, 2022"
7116,NCT03085095,A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer,Prostate Cancer,Drug: Relugolix|Drug: Leuprolide Acetate,Myovant Sciences GmbH,Phase 3,1134,Industry,"April 18, 2017","October 25, 2019","November 26, 2021"
7117,NCT03084549,Study of the Analgesic Effect of the Perineal Infiltration of Ropivacaine 0.75% Versus Placebo in Post-episiotomy Perineal Pain,Episiotomy,Drug: Administration of Ropivacaïne|Drug: Administration of placebo,Centre Hospitalier Departemental Vendee,Phase 3,272,Other,"October 24, 2017","November 4, 2020","November 4, 2020"
7118,NCT03084536,PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery,Breast Cancer|Breast Cancer Female|Cancer of Breast,Drug: Bupivacaine|Drug: Gabapentin|Drug: Celecoxib|Drug: Acetaminophen|Drug: Midazolam|Drug: Fentanyl,Washington University School of Medicine,Phase 2,134,Other,"June 7, 2017","February 25, 2021","February 25, 2021"
7119,NCT03084471,"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.",Advanced Solid Malignancies,Biological: MEDI4736 (Durvalumab)|Biological: MEDI4736 (Durvalumab) + Tremelimumab,AstraZeneca,Phase 3,867,Industry,"June 5, 2017","March 31, 2020","December 16, 2022"
7120,NCT03084289,A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration,Malaria,Biological: ChAd63-METRAP|Biological: MVA ME-TRAP,University of Oxford,Phase 1,26,Other,"March 28, 2017","July 6, 2020","July 6, 2020"
7121,NCT03083847,Dose Escalation PfSPZ-CVac,Malaria,Drug: Chloroquine Phosphate|Drug: Pyrimethamine|Biological: Sanaria PfSPZ Challenge,National Institute of Allergy and Infectious Diseases (NIAID)|Sanaria Inc.|National Institutes of Health Clinical Center (CC),Phase 1,55,NIH|Industry,"June 5, 2017","June 26, 2019","June 26, 2019"
7122,NCT03083522,Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet,Cold Hypersensitivity,Drug: Ojeok-San|Drug: Placebo,Chan-Yong Jeon|Kyunghee University Medical Center|Kyung Hee University Hospital at Gangdong|Semyung University Affiliated Oriental Medical Hospital|Gachon University Gil Oriental Medical Hospital,Phase 3,60,Other,"March 30, 2017","August 14, 2019","November 30, 2019"
7123,NCT03083132,Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD),Parkinson Disease,Drug: modafinil 50mg|Drug: Placebo oral capsule,University of Arkansas,Phase 2,21,Other,"June 13, 2017","November 12, 2019","November 12, 2019"
7124,NCT03082690,ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study,HIV Prevention,Drug: DuoGel,"Johns Hopkins University|ImQuest Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Phase 1,10,Other|Industry|NIH,"November 1, 2017","May 30, 2019","June 2, 2019"
7125,NCT03082196,Efficacy Of A PVP-I Fluoride Varnish,Dental Caries,Drug: Test varnish|Drug: Standard varnish,"Advantage Dental Services, LLC",Phase 2,284,Industry,"March 30, 2017","May 7, 2019","May 7, 2019"
7126,NCT03082092,Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery,"Osteoarthritis, Knee",Drug: Methylprednisolone Sodium Succinate|Drug: Placebos,"Queen Elizabeth Hospital, Hong Kong",Phase 4,60,Other,"June 1, 2017","June 1, 2019","June 1, 2019"
7127,NCT03081949,Peripartum Cardiomyopathy in Nigeria Registry,Peripartum Cardiomyopathy,Drug: Oral Sodium Selenite 200 µg/day for 3 months,Aminu Kano Teaching Hospital|Nigerian Cardiac Society,Phase 4,100,Other,"June 12, 2017","June 30, 2019","December 31, 2019"
7128,NCT03081884,Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease,Cancer,Drug: FACBC PET-CT Imaging,Emory University|National Cancer Institute (NCI),Phase 2,61,Other|NIH,"March 1, 2017","December 31, 2019","December 31, 2019"
7129,NCT03081780,Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML,Refractory Acute Myelogenous Leukemia|Relapsed Acute Myelogenous Leukemia,Biological: FATE-NK100,"Masonic Cancer Center, University of Minnesota",Phase 1,6,Other,"April 27, 2017","August 1, 2020","December 1, 2020"
7130,NCT03081494,Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: spartalizumab (PDR001)|Drug: regorafenib,Novartis Pharmaceuticals|Novartis,Phase 1,10,Industry,"June 9, 2017","May 7, 2019","May 7, 2019"
7131,NCT03081052,Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes,Heart Transplant Surgery|Lung Transplant Surgery,Drug: iNO|Drug: iEPO,Duke University,Phase 4,519,Other,"May 4, 2017","October 5, 2020","September 5, 2021"
7132,NCT03080311,A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,Small Cell Lung Cancer|Solid Tumor,Drug: APG-1252,Ascentage Pharma Group Inc.,Phase 1,50,Industry,"February 12, 2017","June 22, 2020","July 17, 2020"
7133,NCT03080142,TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery,Colorectal Surgery|TAP Blocks,Drug: Exparel|Drug: Ropivacaine,"University of California, Davis",Phase 4,86,Other,"March 1, 2017","May 29, 2019","May 29, 2019"
7134,NCT03079869,Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients,Hyperphosphatemia,Drug: Ferric Citrate,Kaiser Permanente|Keryx Biopharmaceuticals,Phase 4,55,Other|Industry,"May 1, 2017","September 14, 2019","September 14, 2019"
7135,NCT03079440,TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors,Neuroendocrine Tumors|Neuroendocrine Carcinoma|Temozolomide|Capecitabine,Drug: TEMCAP,Asan Medical Center,Phase 2,31,Other,"May 15, 2017","November 15, 2020","November 15, 2022"
7136,NCT03079219,Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients,Breast Cancer,Drug: Experimental drug: Aprepitant|Drug: Experimental drug: Ondansetron|Drug: Experimental drug: Dexamethasone|Drug: Experimental drug: Olanzapine|Drug: Standard: Aprepitant|Drug: Standard: Ondansetron|Drug: Standard: Dexamethasone,CCTU|Chinese University of Hong Kong,Phase 3,120,Other,"March 23, 2017","March 1, 2021","March 1, 2021"
7137,NCT03079063,"Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency",Factor VII Deficiency,"Biological: Eptacog alfa, biosimilar|Biological: Novoseven",AryoGen Pharmed Co.,Phase 3,24,Industry,"March 1, 2017","November 30, 2020","January 28, 2021"
7138,NCT03078907,Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.,Pulmonary Arterial Hypertension,Drug: Selexipag|Drug: Placebo,Actelion,Phase 4,108,Industry,"November 8, 2017","February 10, 2020","February 10, 2020"
7139,NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,Breast Cancer,Drug: Ribociclib|Drug: Adjuvant endocrine therapy|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,54,Industry,"June 20, 2017","March 9, 2020","March 9, 2020"
7140,NCT03078322,AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression,Major Depressive Disorder,Drug: AV-101|Drug: Placebo,"VistaGen Therapeutics, Inc.",Phase 2,180,Industry,"March 5, 2018","October 1, 2019","October 1, 2019"
7141,NCT03078192,Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging,Pulmonary Vascular Disease,"Drug: GE-141, Hyperpolarized 129Xenon gas|Device: MRI","Bastiaan Driehuys|National Heart, Lung, and Blood Institute (NHLBI)|Duke University",Phase 2,62,Other|NIH,"May 3, 2017","October 22, 2020","October 22, 2020"
7142,NCT03078101,EMPRA (EMPagliflozin and RAs in Kidney Disease),"Diabetic Kidney Disease|Diabetes Mellitus, Type 2|Chronic Kidney Disease stage3|Chronic Kidney Disease stage4",Drug: Empagliflozin 10 MG [Jardiance]|Drug: Placebo Oral Tablet,Medical University of Vienna|Attoquant Diagnostics,Phase 2,51,Other,"April 15, 2017","June 18, 2019","August 7, 2019"
7143,NCT03078075,Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder,Methamphetamine Use Disorder,Drug: Naltrexone: Vivitrol®|Drug: Placebo (PLB) Injectable|Drug: Bupropion: Wellbutrin XL®|Drug: Placebo (PLB) Oral,"University of Texas Southwestern Medical Center|National Institute on Drug Abuse (NIDA)|The Emmes Company, LLC",Phase 3,403,Other|NIH|Industry,"May 5, 2017","July 3, 2019","July 25, 2019"
7144,NCT03077711,Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs,"Urinary Tract Infections, Recurrent",Drug: Trimethoprim|Drug: Methenamine hippurate,NorthShore University HealthSystem,Phase 4,92,Other,Jun-16,"June 21, 2019","June 21, 2019"
7145,NCT03077412,Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease,Fistulizing Crohn's Disease,Drug: Filgotinib|Drug: Placebo to match filgotinib,Gilead Sciences|Galapagos NV,Phase 2,57,Industry,"April 6, 2017","January 20, 2021","February 17, 2021"
7146,NCT03077217,Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy,Covert Hepatic Encephalopathy,Drug: Rifaximin,Shanghai Changzheng Hospital,Phase 4,40,Other,"May 1, 2017","May 31, 2020","May 31, 2020"
7147,NCT03077204,BIO4 Clinical Case Study: Cervical Spine,Degenerative Disc Disease|Trauma (Including Fractures)|Spondylolisthesis,Biological: 1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|Device: Aviator Anterior Cervical Plating System,Seton Healthcare Family,Phase 4,20,Other,"April 6, 2017","January 30, 2020","January 30, 2020"
7148,NCT03077165,Dose-response Relationship Study of S42909 on Leg Ulcer Healing,Venous Leg Ulcer,Drug: S42909 100 mg|Drug: S42909 200 mg|Drug: S42909 400 mg|Drug: S42909 800 mg|Drug: S42909 1200 mg|Drug: Placebo Oral Tablet,Ilkos Therapeutic Inc.,Phase 2,121,Industry,"September 12, 2017","December 12, 2019","January 22, 2020"
7149,NCT03076203,Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad),Prostate Carcinoma Metastatic to the Bone|Stage IV Prostate Adenocarcinoma|Hormone-refractory Prostate Cancer,Drug: Niraparib|Radiation: Radium Ra 223 Dichloride,"Sidney Kimmel Cancer Center at Thomas Jefferson University|Janssen, LP|Prostate Cancer Clinical Trials Consortium|Bayer|Thomas Jefferson University",Phase 1,14,Other|Industry,"September 22, 2017","January 13, 2020","November 7, 2022"
7150,NCT03076151,Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation,Transplantation|Kidney|Pharmacokinetic,Drug: Tacrolimus monohydrate (ADOPORT®),"University Hospital, Limoges",Phase 4,30,Other,"February 12, 2018","July 31, 2019","July 31, 2019"
7151,NCT03075826,A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,Myeloproliferative Neoplasms,Drug: SGI-110,"Weill Medical College of Cornell University|Astex Pharmaceuticals, Inc.",Phase 2,22,Other|Industry,"March 15, 2016","March 31, 2021","March 31, 2021"
7152,NCT03075501,Interactions Between Drug Effects and Environments II,Substance-Related Disorders,Behavioral: Paired|Drug: Stimulant or sedative|Drug: Placebo,University of Illinois at Chicago|National Institute on Drug Abuse (NIDA),Phase 4,133,Other|NIH,Nov-15,Jul-20,Jul-20
7153,NCT03075241,Z-Drugs for Sleep Disorders in Alzheimer's Disease,Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease,Drug: Zolpidem|Drug: Zoplicone|Drug: Placebo,Brasilia University Hospital,Phase 3,62,Other,Oct-16,Apr-20,Apr-20
7154,NCT03074695,DPE Technique in Labor Epidural for Morbidly Obese Women,Morbid Obesity|Labor Pain,Procedure: Dural puncture epidural (DPE)|Procedure: Standard Epidural (EPL)|Drug: Dural puncture epidural (DPE)|Drug: Standard Epidural (EPL),Duke University,Phase 4,141,Other,"April 1, 2017","November 6, 2020","November 6, 2020"
7155,NCT03074006,Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS,Myelodysplastic Syndromes,Drug: TEW-7197,"MedPacto, Inc.",Phase 1,9,Industry,"January 4, 2018","December 31, 2019","December 31, 2019"
7156,NCT03073980,Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Control for Oocyte Retrieval,"Infertility, Female|Pain, Postoperative",Drug: IV Acetaminophen|Drug: PO Acetaminophen|Other: Placebo IV Acetaminophen|Other: Placebo PO Acetaminophen,Massachusetts General Hospital,Phase 4,161,Other,"September 1, 2019","November 1, 2020","December 1, 2020"
7157,NCT03073733,Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa,Retinitis Pigmentosa,Biological: human retinal progenitor cells|Other: Mock injection,"jCyte, Inc|California Institute for Regenerative Medicine (CIRM)",Phase 2,84,Industry|Other,"March 1, 2017","November 13, 2020","November 13, 2020"
7158,NCT03073525,A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers,Advanced Gynecological Cancers|Ovarian Cancer|Cervical Cancer|Uterine Cancer,Biological: Vigil|Drug: Atezolizumab,"Gradalis, Inc.|Roche-Genentech",Phase 2,25,Industry,"May 31, 2017","May 22, 2019","May 18, 2022"
7159,NCT03073213,A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris,Psoriasis,Drug: Ixekizumab,Eli Lilly and Company,Phase 1,32,Industry,"April 13, 2017","May 14, 2019","May 14, 2019"
7160,NCT03073070,RBC Lifespan Measurement in Diabetic Children,Diabetes|Red Blood Cell Survival,Drug: biotin labeled RBCs,Guohua An|University of Iowa,Phase 1,6,Other,"November 15, 2017","September 15, 2019","September 15, 2019"
7161,NCT03072381,PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis,Chronic Lateral Epicondylosis,Biological: Platelet Rich Plasma - Group 1|Drug: Corticosteroid Control - Group 2,"University of Wisconsin, Madison|DePuy Synthes",Phase 2,50,Other|Industry,Jan-17,"October 28, 2020","October 28, 2020"
7162,NCT03072160,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),Drug: Pembrolizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,17,NIH,"June 16, 2017","November 22, 2019","November 22, 2019"
7163,NCT03072134,Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma,"Glioma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma Multiforme|Astrocytoma, Grade III|Astrocytoma, Grade IV|Brain Cancer",Biological: Neural stem cells loaded with an oncolytic adenovirus,Northwestern University|National Cancer Institute (NCI),Phase 1,12,Other|NIH,"April 24, 2017","April 6, 2020","July 1, 2021"
7164,NCT03072030,International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi,Ebola Virus Disease|Prevention,Biological: GamEvac-Combi (vaccine)|Biological: Placebo,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|CREMS (Centre de Recherche Epidémiologie, Microbiologie et Soins médicaux )",Phase 4,2000,Other,"August 3, 2017","December 31, 2019","July 31, 2020"
7165,NCT03071861,Mild Encephalopathy in the Newborn Treated With Darbepoetin,Neonatal Encephalopathy|Hypoxic-Ischemic Encephalopathy Mild,Drug: Darbepoetin Alfa|Drug: Normal Saline,University of New Mexico|University of Utah,Phase 2,28,Other,"December 1, 2017","December 1, 2019","September 1, 2022"
7166,NCT03071055,Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF,Exudative Age Related Macular Degeneration,Drug: Ranibizumab Injection [Lucentis],"Southeast Clinical Research Associates, LLC|Genentech, Inc.",Phase 2,20,Other|Industry,"October 1, 2017","June 3, 2019","June 3, 2019"
7167,NCT03070951,Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids,Uterine Fibroids|Heavy Menstrual Bleeding,Drug: OBE2109|Drug: Placebo to match OBE2109|Drug: Placebo to match Add-back|Drug: Add-back,ObsEva SA,Phase 3,511,Industry,"May 23, 2017","September 16, 2019","October 4, 2020"
7168,NCT03070899,Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids,Uterine Fibroids|Heavy Menstrual Bleeding,Drug: OBE2109|Drug: Placebo to match OBE2109|Drug: Placebo to match Add-back|Drug: Add-back,ObsEva SA,Phase 3,526,Industry,"April 20, 2017","April 14, 2020","April 12, 2021"
7169,NCT03070600,PrEP Implementation for Mothers in Antenatal Care,HIV Infections|Pregnancy Related,Other: Universal PrEP Counseling|Other: Targeted PrEP Counseling,University of Washington|Kenyatta National Hospital|National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,4447,Other|NIH,"January 15, 2018","January 15, 2021","January 15, 2021"
7170,NCT03069703,Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy,Invasive Pneumococcal Infection,Biological: PCV13|Biological: PPV23|Drug: Rituximab,Assistance Publique - Hôpitaux de Paris|EUCLID Clinical Trial Platform|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|CIC 1417 Cochin-Pasteur|Groupe Français d'Etude des Vascularites (GFEV),Phase 2,96,Other,"February 5, 2018","November 24, 2020","November 21, 2021"
7171,NCT03068949,Comparison of Three Licensed Influenza Vaccines,Influenza,Biological: FluBlok|Biological: Fluzone|Biological: FluCelVax|Biological: Fluzone HD,University of Rochester|National Institutes of Health (NIH),Phase 4,413,Other|NIH,"October 28, 2015","June 30, 2020","June 30, 2021"
7172,NCT03068780,Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa,Epidermolysis Bullosa,Drug: Oleogel-S10|Drug: Control gel,Amryt Research Limited|Amryt Pharma,Phase 3,223,Industry,"March 29, 2017","June 11, 2020","May 27, 2022"
7173,NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,Melanoma,Biological: nivolumab|Biological: ipilimumab,Bristol-Myers Squibb,Phase 3,1844,Industry,"April 11, 2017","June 12, 2020","February 2, 2021"
7174,NCT03068429,Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.,Obsessive-Compulsive Disorder,Drug: Sertraline Hydrochloride,University of Sao Paulo,Phase 4,69,Other,"December 1, 2016","December 20, 2019","July 31, 2020"
7175,NCT03068351,Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,Multiple Myeloma,Drug: RO6870810|Biological: daratumumab,Hoffmann-La Roche,Phase 1,24,Industry,"June 26, 2017","August 1, 2019","August 1, 2019"
7176,NCT03067714,A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy,Immunity,Other: Infant formula with added synbiotics|Other: Standard infant formula,Nutricia Research,Phase 3,855,Industry,"March 30, 2017","March 25, 2020","March 25, 2020"
7177,NCT03067610,Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer,"Head and Neck Cancer|Carcinoma, Squamous Cell|Neoplasms, Oral|Neoplasms, Pharyngeal",Radiation: Intensity Modulated Radiation Therapy|Drug: chemotherapy,University of Texas Southwestern Medical Center,Phase 2,72,Other,"January 20, 2017","December 21, 2020","March 9, 2021"
7178,NCT03067441,Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE),Hypercholesterolemia|Atherosclerotic Cardiovascular Disease,Drug: bempedoic acid,"Esperion Therapeutics, Inc.",Phase 3,1462,Industry,"February 3, 2017","November 5, 2019","November 5, 2019"
7179,NCT03066804,"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients",Heart Failure With Preserved Ejection Fraction,Drug: sacubitril/valsartan|Drug: Enalapril|Drug: Valsartan|Drug: Placebo to match sacubitril/valsartan|Drug: Placebo to match enalapril|Drug: Placebo to match valsartan,Novartis Pharmaceuticals|Novartis,Phase 3,2572,Industry,"August 22, 2017","October 28, 2019","October 28, 2019"
7180,NCT03066778,A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),Small Cell Lung Cancer (SCLC),Biological: Pembrolizumab|Drug: Normal saline solution|Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide,Merck Sharp & Dohme LLC,Phase 3,453,Industry,"May 2, 2017","December 2, 2019","September 21, 2021"
7181,NCT03066427,Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.,Clear Cell Renal Carcinoma,Drug: Sunitinib,Spanish Oncology Genito-Urinary Group|Pfizer|Apices Soluciones S.L.,Phase 2,23,Other|Industry,"May 10, 2017","September 22, 2020","September 22, 2020"
7182,NCT03065660,Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage,Missed Miscarriage,"Drug: Mifepristone, Oral, 200 Mg|Drug: Placebo Oral Tablet","University of Birmingham|Birmingham Women's NHS Foundation Trust|Royal Infirmary of Edinburgh|Royal Victoria Infirmary|City Hospitals Sunderland NHS Foundation Trust|Liverpool Women's NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|Barts & The London NHS Trust|Queen's Medical Center|Heart of England NHS Trust|University Hospitals Coventry and Warwickshire NHS Trust|Oxford University Hospitals NHS Trust|St Mary's Hospital, London|University College London Hospitals|University Hospital Southampton NHS Foundation Trust|King's College Hospital NHS Trust|University of Edinburgh|University of Nottingham|Queen Mary University of London|University of Warwick|University of Southampton",Phase 3,711,Other,"September 20, 2017","January 9, 2020","January 9, 2020"
7183,NCT03065400,PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,Chronic Phase Myelofibrosis|Primary Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis|Polycythemia Vera,Drug: Pembrolizumab,John Mascarenhas|Massachusetts General Hospital|Montefiore Medical Center|Icahn School of Medicine at Mount Sinai,Phase 2,10,Other,"June 14, 2017","May 28, 2020","May 28, 2020"
7184,NCT03065244,KIDCARE (Kawasaki Disease Comparative Effectiveness Trial),Mucocutaneous Lymph Node Syndrome,Drug: IVIG|Drug: Infliximab,"University of California, San Diego|Patient-Centered Outcomes Research Institute",Phase 3,105,Other,"February 17, 2017","August 31, 2020","November 2, 2020"
7185,NCT03065179,SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients,"Kidney Cancer Metastatic|Kidney Cancer|Kidney Cancer, Stage IV",Drug: Nivolumab/Ipilimumab|Radiation: SBRT,University of Texas Southwestern Medical Center,Phase 2,29,Other,"March 1, 2017","February 20, 2020","November 17, 2020"
7186,NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,Unresectable Stage IIIB-IV Malignant Melanoma,Drug: Talimogene laherparepvec,Amgen,Phase 1,18,Industry,"March 7, 2017","August 3, 2020","January 12, 2023"
7187,NCT03063788,Imaging the HIV Reservoir,HIV,Drug: 3BNC117-Copper-64,Bayside Health|The Peter Doherty Institute for Infection and Immunity|Monash University|Monash Health|Rockefeller University|Austin Health,Phase 1,17,Other,"September 18, 2018","February 1, 2020","April 1, 2020"
7188,NCT03063255,Comparison of Obturator Nerve Blockade and Neuromuscular Blockade,Cancer of Bladder,Drug: Obturator block|Drug: Neuromuscular block,University of Florida|US Department of Veterans Affairs,Phase 4,60,Other|U.S. Fed,"April 25, 2017","September 19, 2019","September 19, 2019"
7189,NCT03062254,Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy,Prostate Cancer,Drug: radium-223 dichloride,Sir Mortimer B. Davis - Jewish General Hospital,Phase 2,14,Other,"March 22, 2018","July 15, 2020","July 15, 2021"
7190,NCT03061812,Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE),Small Cell Lung Cancer,Drug: Rovalpituzumab tesirine|Drug: Topotecan|Drug: Dexamethasone,AbbVie,Phase 3,444,Industry,"April 11, 2017","February 12, 2020","February 12, 2020"
7191,NCT03061721,Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis,Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Drug: Saroglitazar magnesium 1 mg|Drug: Saroglitazar magnesium 2 mg|Drug: Saroglitazar magnesium 4 mg|Drug: Placebos,Zydus Therapeutics Inc.,Phase 2,106,Industry,"April 6, 2017","October 30, 2020","December 15, 2020"
7192,NCT03061006,Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation,Dementia|Cognition Disorders|Cerebral Ischemic Events,Drug: Dabigatran Etexilate|Drug: Warfarin,"Intermountain Health Care, Inc.|Boehringer Ingelheim",Phase 4,101,Other|Industry,"April 3, 2017","March 15, 2021","March 15, 2021"
7193,NCT03060538,A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease,"Diabetes Mellitus, Type 2|Non-Alcoholic Fatty Liver Disease",Drug: BFKB8488A|Other: Placebo,"Genentech, Inc.",Phase 1,154,Industry,"March 5, 2017","December 13, 2019","December 13, 2019"
7194,NCT03060447,Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers,HIV-1 Infection,Drug: Vesatolimod|Drug: Placebo|Drug: ART,Gilead Sciences,Phase 1,25,Industry,"May 9, 2017","February 13, 2020","February 13, 2020"
7195,NCT03058783,Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects,Atopic Dermatitis,Drug: IDP-124 Lotion|Drug: IDP-124 Vehicle Lotion,"Bausch Health Americas, Inc.",Phase 3,328,Industry,"August 14, 2018","May 12, 2020","May 12, 2020"
7196,NCT03058757,The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation,Bladder Cancer,Drug: intravesical mitomycin-C 40mg/20ml instillation,"National Cancer Center, Korea",Phase 2,71,Other,"February 1, 2017","February 18, 2021","December 31, 2022"
7197,NCT03057977,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced),Heart Failure,Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,3730,Industry,"March 6, 2017","May 1, 2020","May 28, 2020"
7198,NCT03057951,EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved),Heart Failure,Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,5988,Industry,"March 2, 2017","April 26, 2021","April 26, 2021"
7199,NCT03057613,The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck,Squamous Cell Carcinoma of the Head and Neck,Drug: Pembrolizumab|Radiation: IMRT 60-66Gy,Case Comprehensive Cancer Center,Phase 2,18,Other,"May 10, 2017","June 26, 2020","September 9, 2020"
7200,NCT03057600,Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC),Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer,Drug: Paclitaxel|Drug: CB-839,"Calithera Biosciences, Inc",Phase 2,52,Industry,"May 1, 2017","November 25, 2019","November 25, 2019"
7201,NCT03057145,Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,Solid Tumor,Drug: Prexasertib|Drug: Olaparib,"Geoffrey Shapiro, MD, PhD|Eli Lilly and Company|AstraZeneca|Dana-Farber Cancer Institute",Phase 1,29,Other|Industry,"March 10, 2017","February 25, 2020","June 9, 2021"
7202,NCT03056833,Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma,Drug: ribociclib|Drug: Paclitaxel|Drug: Carboplatin,Ronald Buckanovich|University of Pittsburgh,Phase 1,35,Other,"June 10, 2017","June 1, 2020","August 1, 2022"
7203,NCT03056729,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease,Alzheimer's Disease|Healthy Volunteer,Drug: BIIB076|Drug: Placebo,Biogen,Phase 1,46,Industry,"February 17, 2017","March 3, 2020","March 3, 2020"
7204,NCT03056482,Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC),Cannabis Use Disorder,Drug: Ondansetron 8mg|Drug: Haloperidol 0.05mg/kg|Drug: Haloperidol 0.1mg/kg,Queen's University,Phase 4,33,Other,"May 21, 2017","June 30, 2019","July 7, 2019"
7205,NCT03055845,A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain,Low Back Pain,Drug: STA363|Drug: Placebo,Stayble Therapeutics,Phase 1,15,Industry,"March 27, 2017","August 29, 2019","August 29, 2019"
7206,NCT03054610,Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.,"Plantar Fascitis|Botulinum Toxins, Type A","Drug: Betamethason Sodium Phosphate|Drug: Ropivacaine|Drug: Botulinum Toxins, Type A",Universidad Autonoma de Nuevo Leon,Phase 1,60,Other,Jan-15,Mar-20,Apr-20
7207,NCT03053947,Pain Free Laceration Repairs Using Intra-nasal Ketamine,Laceration,Drug: Intranasal Ketamine,Evelyne D.Trottier|St. Justine's Hospital,Phase 2,42,Other,"February 16, 2017","November 27, 2019","November 27, 2019"
7208,NCT03053544,Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer,Rectal Neoplasm Carcinoma in Situ Adenocarcinoma,Drug: Metformin,Sunnybrook Health Sciences Centre|Sunnybrook Research Institute|University of Toronto,Phase 2,15,Other,"December 8, 2016","June 26, 2019","June 26, 2019"
7209,NCT03052660,Impact of Preoperative Midazolam on Outcome of Elderly Patients,Preanesthetic Medication,Drug: Midazolam|Drug: Placebo oral capsule,RWTH Aachen University,Phase 4,782,Other,"October 12, 2017","June 24, 2019","June 24, 2019"
7210,NCT03052478,Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression,Stomach Neoplasms,Drug: Vismodegib 150 mg,Samsung Medical Center,Phase 2,10,Other,"February 10, 2017","December 31, 2019","September 10, 2020"
7211,NCT03052205,A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,Refractory Solid Tumors|Melanoma,Drug: IMO-2125,"Idera Pharmaceuticals, Inc.",Phase 1,54,Industry,"June 9, 2017","July 24, 2019","October 4, 2019"
7212,NCT03052010,The Partners Scale-Up Project,HIV-1-infection,Other: Integrated PrEP as a bridge to ART HIV-1 prevention strategy|Drug: PrEP|Drug: ART,University of Washington|Kenya Medical Research Institute|Kenya National AIDS & STI Control Programme|National Institute of Mental Health (NIMH)|Bill and Melinda Gates Foundation,Phase 4,4898,Other|NIH,"February 6, 2017","December 15, 2020","April 30, 2021"
7213,NCT03051477,Trial of Mistletoe Extract in Patients With Advanced Solid Tumors,Solid Tumor,Drug: Helixor® M,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Believe Big,Phase 1,21,Other,"March 1, 2017","January 29, 2021","August 5, 2022"
7214,NCT03051256,"Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD","Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant",Drug: REL-1017|Drug: Placebo,"Relmada Therapeutics, Inc.|Syneos Health",Phase 2,62,Industry|Other,"May 11, 2018","July 30, 2019","September 30, 2019"
7215,NCT03050879,Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection,Stomach Neoplasms|Indocyanine Green,Drug: Indocyanine Green Tracer,Fujian Medical University,Phase 2,266,Other,"October 15, 2017","July 13, 2019","July 13, 2019"
7216,NCT03050307,Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection,Gastric Ulcer,Drug: TAK-438|Drug: Lansoprazole|Drug: TAK-438 Placebo|Drug: Lansoprazole Placebo|Drug: Bismuth-Containing Quadruple Therapy,Takeda,Phase 3,234,Industry,"April 17, 2017","February 19, 2020","May 26, 2020"
7217,NCT03050216,QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,Acute Myeloid Leukemia,Biological: ALT-803,"Masonic Cancer Center, University of Minnesota",Phase 2,8,Other,"May 16, 2017","December 15, 2019","December 15, 2019"
7218,NCT03049488,"Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults",Respiratory Syncytial Virus,Biological: VRC-RSVRGP084-00-VP|Other: Aluminum Hydroxide Suspension,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,95,NIH,"February 22, 2017","October 3, 2019","October 3, 2019"
7219,NCT03048578,Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery,Obesity,Drug: Saxenda|Drug: Placebo,NYU Langone Health|Novo Nordisk A/S,Phase 4,132,Other|Industry,"May 22, 2017","March 2, 2021","March 2, 2021"
7220,NCT03048422,Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants,HIV Infections,Drug: Dolutegravir|Drug: Emtricitabine/tenofovir alafenamide|Drug: Emtricitabine/tenofovir disoproxil fumarate|Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate,National Institute of Allergy and Infectious Diseases (NIAID),Phase 3,643,NIH,"January 19, 2018","October 3, 2020","October 3, 2020"
7221,NCT03046953,Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma,T-Cell Lymphoma Relapsed|T-Cell Lymphoma Refractory,Drug: Avelumab,University of Birmingham|Bloodwise|Pfizer,Phase 2,34,Other|Industry,"November 14, 2017","July 31, 2020","July 27, 2021"
7222,NCT03046836,"Oxytocin, Alcohol Craving, and Intimate Partner Aggression",Alcohol Use,Drug: Oxytocin|Drug: Placebo,Medical University of South Carolina,Phase 2,200,Other,"July 1, 2017","April 11, 2021","April 11, 2021"
7223,NCT03046056,Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD),Small Bowel Crohn's Disease,Drug: Filgotinib|Drug: Placebo to match filgotinib,Gilead Sciences|Galapagos NV,Phase 2,78,Industry,"April 11, 2017","July 20, 2020","July 20, 2020"
7224,NCT03045328,Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Venetoclax,Steven E. Coutre|Stanford University,Phase 2,22,Other,"September 26, 2017","May 19, 2020","August 5, 2021"
7225,NCT03045016,Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder,Acute Stress Disorder,"Drug: Prazosin, ALPRESS® LP 2,5 et 5 mg",Hospices Civils de Lyon,Phase 2,15,Other,"April 21, 2017","March 30, 2020","March 30, 2020"
7226,NCT03044626,Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC,Carcinoma，Non-Small-Cell Lung|Metastatic Lung Cancer|Nonsmall Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic,Drug: Radiotherapy|Drug: Nivolumab,AIO-Studien-gGmbH|Bristol-Myers Squibb,Phase 2,101,Other|Industry,"February 10, 2017","December 31, 2020","December 31, 2020"
7227,NCT03043742,Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease,Chronic Ischemic Heart Disease,Drug: Bone Marrow Derived Autologous CD133+ Selected Cell Product,Michael Sekela|University of Kentucky,Phase 1,8,Other,"July 12, 2016","November 12, 2020","November 12, 2020"
7228,NCT03043729,mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer,Rectal Cancer|Rectosigmoid Cancer,Drug: Oxaliplatin|Drug: 5-FU|Drug: Leucovorin|Biological: Aflibercept,AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi,Phase 2,119,Other|Industry,"March 6, 2017","January 11, 2021","June 1, 2022"
7229,NCT03043560,Study to Treat Major Depressive Disorder With a New Medication,Depressive Disorder|Anhedonia,Drug: Ezogabine|Drug: Placebos,James Murrough|National Institute of Mental Health (NIMH)|Baylor College of Medicine|Icahn School of Medicine at Mount Sinai,Phase 2,45,Other|NIH,"September 25, 2017","August 30, 2019","August 30, 2019"
7230,NCT03043365,Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults,Lipoprotein Metabolism|PCSK9|Proteomics,Drug: control fish oil|Drug: LCMUFA-rich saury oil,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,37,NIH,"June 15, 2017","May 29, 2019","November 21, 2019"
7231,NCT03042819,Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,Soft Tissue Sarcoma,Drug: Selinexor|Drug: Doxorubicin,"University Health Network, Toronto|Karyopharm Therapeutics Inc",Phase 1,25,Other|Industry,"May 16, 2017","November 30, 2019","June 30, 2021"
7232,NCT03042793,Vaccination With PD-L1 Peptide Against Multiple Myeloma,Multiple Myeloma,Biological: PD-L1 peptide vaccine,Lene Meldgaard Knudsen|Herlev Hospital,Phase 1,10,Other,"February 1, 2017","May 14, 2020","May 14, 2020"
7233,NCT03042767,Anti-LPS Antibody Treatment for Pediatric NAFLD,Nonalcoholic Fatty Liver Disease (NAFLD),Biological: IMM-124E|Other: Placebo,"Miriam Vos, MD|Advanced MR Analytics AB|Immuron Ltd.|Emory University",Phase 2,40,Other|Industry,"February 1, 2017","October 23, 2019","October 23, 2019"
7234,NCT03042416,18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety,Congenital Hyperinsulinism|Neuroblastoma|Neuroendocrine Tumors|Parkinson Disease|Brain Glioma,Drug: 18F-DOPA,University of Alberta|Alberta Health services,Phase 3,400,Other,"June 29, 2017","March 5, 2021","June 2, 2021"
7235,NCT03042273,High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection,Urinary Tract Infection,Dietary Supplement: High Strength Cranberry|Dietary Supplement: Placebo,"Swisse Wellness Pty Ltd|Commonwealth Scientific and Industrial Research Organisation, Australia",Phase 2,150,Industry|Other,"May 15, 2017","December 31, 2019","December 31, 2019"
7236,NCT03041740,Fluid Filled Lung Oxygenation Assistance Trial,Bronchopulmonary Dysplasia,Drug: Perfluorooctyl Bromide,Children's Hospital of Philadelphia|Auto Dealers Caring for Kids Foundation,Phase 1,16,Other,"June 27, 2017","June 10, 2019","June 10, 2019"
7237,NCT03041636,Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Untreated Chronic Lymphocytic Leukemia,Drug: Ruxolitinib|Drug: Ruxolitinib Phosphate,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,1,Other|NIH,"March 8, 2017","April 29, 2020","April 29, 2020"
7238,NCT03041038,The Efficacy and Safety of Secukinumab in Patients With Ichthyoses,Ichthyosis|Autosomal Recessive Congenital Ichthyosis|Lamellar Ichthyosis|Congenital Ichthyosiform Erythroderma|Epidermolytic Ichthyosis|Netherton Syndrome,Drug: Secukinumab|Drug: Placebo,Northwestern University|Icahn School of Medicine at Mount Sinai,Phase 2,20,Other,Dec-16,"August 31, 2020","August 31, 2020"
7239,NCT03041025,Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis,"Scleroderma, Systemic",Drug: GSK2330811|Drug: Placebo,GlaxoSmithKline,Phase 2,35,Industry,"June 5, 2017","July 7, 2020","July 7, 2020"
7240,NCT03039699,Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children,Viral Intestinal Infection,Drug: Ergoferon|Drug: Placebo,Materia Medica Holding,Phase 4,259,Industry,"June 23, 2016","June 1, 2019","June 1, 2019"
7241,NCT03039205,Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor,Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy,Drug: Clopidogrel|Drug: Ticagrelor,University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo,Phase 2,90,Other,"November 7, 2017","December 19, 2019","December 19, 2019"
7242,NCT03039114,Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),Lymphoma,Drug: Parsaclisib|Drug: Hexal|Drug: Gazyvaro,Incyte Corporation,Phase 1,26,Industry,"February 15, 2017","March 30, 2021","March 30, 2021"
7243,NCT03038620,Impact of Liraglutide 3.0 on Body Fat Distribution,"Obesity, Visceral|Cardiovascular Diseases|Fat Disorder",Drug: Liraglutide|Drug: Placebo,University of Texas Southwestern Medical Center|Novo Nordisk A/S,Phase 4,235,Other|Industry,Jan-17,"October 13, 2020","October 13, 2020"
7244,NCT03038516,'Palliative-D' Vitamin D to Palliative Cancer Patients,Vitamin D Deficiency,Drug: Cholecalciferol|Device: Placebo,Region Stockholm,Phase 2,244,Other,"November 1, 2017","June 9, 2020","June 9, 2020"
7245,NCT03038399,Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD),Duchenne Muscular Dystrophy,Drug: Vamorolone 0.25 mg/day/day|Drug: Vamorolone 0.75 mg/day/day|Drug: Vamorolone 2.0 mg/day/day|Drug: Vamorolone 6.0 mg/day/day,"ReveraGen BioPharma, Inc.|University of Pittsburgh|Cooperative International Neuromuscular Research Group",Phase 2,46,Industry|Other,"February 2, 2017","April 30, 2020","April 30, 2020"
7246,NCT03038178,Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease,"Mycobacterium Infections, Nontuberculous|Mycobacteria, Atypical",Drug: LAI plus multi-drug regimen,Kevin Winthrop|Insmed Incorporated|The University of Texas Health Science Center at Tyler|Oregon Health and Science University,Phase 2,30,Other|Industry,Oct-16,"October 31, 2019","December 31, 2019"
7247,NCT03038152,Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery,Breast Carcinoma Metastatic in Lymph Node|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7,Procedure: Axillary Lymph Node Dissection|Procedure: Localization|Device: Medical Device,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 4,54,Other|NIH,"April 11, 2017","March 1, 2021","March 1, 2021"
7248,NCT03038113,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B",Chronic Hepatitis B,Drug: RO7062931|Drug: Placebo|Drug: Immune Modulator,Hoffmann-La Roche,Phase 1,119,Industry,"February 6, 2017","October 18, 2019","October 18, 2019"
7249,NCT03036813,Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE),Sickle Cell Disease,Drug: voxelotor|Other: Placebo,Global Blood Therapeutics,Phase 3,449,Industry,Dec-16,"October 8, 2019","October 8, 2019"
7250,NCT03036150,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease,Chronic Kidney Disease,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca,Phase 3,4304,Industry,"February 2, 2017","June 12, 2020","June 12, 2020"
7251,NCT03036124,Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure,Chronic Heart Failure With Reduced Ejection Fraction (HFrEF),Drug: Dapagliflozin|Drug: Placebo,AstraZeneca,Phase 3,4744,Industry,"February 8, 2017","July 17, 2019","July 17, 2019"
7252,NCT03036059,Twice Yearly Treatment for the Control of LF,Lymphatic Filariasis|Helminth Infection,Drug: 400 μg/kg Ivermectin + 400 mg Albendazole,Noguchi Memorial Institute for Medical Research|Ghana Health Services,Phase 4,1462,Other,"May 19, 2017","December 8, 2019","December 8, 2019"
7253,NCT03035812,Alkalinization by Urologists & Nephrologists,Metabolic Acidosis|Nephrolithiasis|Extracellular Alteration|Blood Pressure|Body Weight,Drug: Alkali,Jean-Philippe Bertocchio|Club des Jeunes Néphrologues,Phase 4,156,Other,"February 1, 2017","February 21, 2020","February 21, 2020"
7254,NCT03035188,Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma,Basal Cell Carcinoma,Drug: Vismodegib,SRH Wald-Klinikum Gera GmbH,Phase 2,40,Other,Jan-17,Jan-20,Jan-21
7255,NCT03035032,A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients,Prostate Cancer,Drug: Leuprolide,Astellas Pharma Singapore Pte. Ltd.|Astellas Pharma Inc,Phase 4,107,Industry,"June 23, 2017","November 19, 2019","November 19, 2019"
7256,NCT03034018,Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia,Insomnia,Drug: suvorexant|Drug: placebo,Brigham and Women's Hospital,Phase 4,60,Other,"May 25, 2017","April 3, 2020","April 3, 2020"
7257,NCT03033836,Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women,HIV Infections,Drug: ARV treatment,Fundación Huésped|ViiV Healthcare,Phase 4,60,Other|Industry,Dec-15,"June 28, 2019","June 28, 2019"
7258,NCT03033823,MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA),Alcohol Withdrawal Syndrome,Drug: Magnesium|Drug: Placebo Oral Tablet,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 3,105,Other,"November 16, 2017","October 23, 2020","October 23, 2020"
7259,NCT03033732,A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse,Opioid Use Disorder,Drug: Methadone|Drug: Buprenorphine-Naloxone,Didier Jutras Aswad|Canadian Institutes of Health Research (CIHR)|Canadian Research Initiative in Substance Misuse,Phase 4,272,Other,"October 2, 2017","March 31, 2020","December 31, 2020"
7260,NCT03033498,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease",Parkinson's Disease (PD),Drug: ABBV-951,AbbVie,Phase 1,29,Industry,"May 17, 2017","June 8, 2019","June 8, 2019"
7261,NCT03031938,Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies,Osteoarthritis|Cancer Pain|Recurrent Low Back Pain,Drug: Investigational medical product (IMP) administered in parent study,Pfizer|Eli Lilly and Company,Phase 3,4,Industry,"November 3, 2017","June 4, 2020","June 4, 2020"
7262,NCT03031782,Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA),Juvenile Psoriatic Arthritis|Enthesitis-related Arthritis,Drug: secukinumab|Other: placebo,Novartis Pharmaceuticals|Novartis,Phase 3,86,Industry,"May 23, 2017","October 7, 2020","November 9, 2020"
7263,NCT03031184,Study of Mirtazapine for Agitation in Dementia,Dementia,Drug: Mirtazapine|Other: Placebo,"University of Sussex|Norwich Clinical Trials Unit|University of East Anglia|University of Cambridge|University College, London|London School of Economics and Political Science|University of Manchester|University of Newcastle Upon-Tyne|Birmingham and Solihull Mental Health NHS Foundation Trust|Alzheimer's Society|The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT",Phase 3,207,Other,Jan-17,Jun-20,Mar-21
7264,NCT03030287,"A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer","Cancer Ovaries|Cancer Peritoneal|Cancer, Fallopian Tube",Drug: OMP-305B83|Drug: Paclitaxel,"OncoMed Pharmaceuticals, Inc.|Mereo BioPharma",Phase 1,44,Industry,Dec-16,Apr-20,Apr-20
7265,NCT03030248,Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients,Clostridium Difficile Infection|Hematologic Diseases|Bone Marrow Transplant|Oncologic Disorders,Drug: Vancomycin Oral Capsule|Drug: Placebo Oral Capsule,Medical College of Wisconsin,Phase 2,9,Other,"June 1, 2018","June 30, 2020","June 30, 2020"
7266,NCT03030222,Empagliflozin Impact on Hemodynamics in Patients With Heart Failure,Heart Failure,Drug: Empagliflozin 10 mg Tab|Drug: Placebo Oral Tablet,Saint Luke's Health System,Phase 4,65,Other,"July 5, 2017","March 10, 2020","March 10, 2020"
7267,NCT03029689,Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY,HIV,Drug: Raltegravir|Drug: Placebo|Drug: Current ART,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Merck Sharp & Dohme LLC",Phase 3,60,Other|Industry,"July 28, 2017","April 30, 2020","April 30, 2020"
7268,NCT03029338,CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma,Lymphomas Non-Hodgkin's B-Cell|Relapse,Biological: CD19 CAR T cells,Institute of Hematology & Blood Diseases Hospital|Juventas Cell Therapy Ltd.,Phase 1,20,Other|Industry,"June 8, 2017","May 22, 2019","June 22, 2021"
7269,NCT03029247,Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP),Anaemia,Drug: Daprodustat|Drug: Epoetin alfa,"GlaxoSmithKline|ERT: Clinical Trial Technology Solutions|Q2 Solutions|Quintiles, Inc.|HemoCue",Phase 2,105,Industry|Other,"July 27, 2017","July 9, 2020","July 9, 2020"
7270,NCT03029208,Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID),Anaemia,Drug: Daprodustat|Drug: Darbepoetin alfa|Drug: Iron therapy,GlaxoSmithKline,Phase 3,312,Industry,"May 11, 2017","September 24, 2020","September 24, 2020"
7271,NCT03029143,Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis,"Colitis, Ulcerative",Drug: Vedolizumab IV,Takeda,Phase 4,278,Industry,"March 29, 2017","October 16, 2020","October 16, 2020"
7272,NCT03029091,An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE),Eosinophilic Esophagitis,Drug: Losartan Potassium,"Children's Hospital Medical Center, Cincinnati|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)",Phase 2,15,Other|NIH,"May 23, 2017","July 22, 2019","August 22, 2019"
7273,NCT03029078,"FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria?",Microbial Colonization|Bacterial Peritonitis|Faeces Smearing,Drug: fecal microbiota transplant,Centre d'Investigation Clinique et Technologique 805,Phase 4,50,Other,"November 1, 2014","December 1, 2020","December 1, 2020"
7274,NCT03028766,WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer,Hypopharynx Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Larynx Cancer,Drug: AZD1775|Drug: Cisplatin|Radiation: Radiotherapy,University of Birmingham|AstraZeneca|Cancer Research UK,Phase 1,9,Other|Industry,"June 22, 2017","October 31, 2019","February 3, 2021"
7275,NCT03028103,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Epizyme, Inc.",Phase 1,32,Industry,"March 27, 2017","October 31, 2019","November 29, 2019"
7276,NCT03027960,Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects,Heart Failure|Type II; Diabetes,Drug: Empagliflozin|Drug: Placebo Oral Capsule,Yale University|Boehringer Ingelheim,Phase 1,21,Other|Industry,"June 27, 2017","May 14, 2019","June 1, 2019"
7277,NCT03027284,A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer,Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkin's Lymphoma,Drug: Merestinib|Drug: Cisplatin|Drug: Gemcitabine,Eli Lilly and Company,Phase 1,19,Industry,"February 3, 2017","June 20, 2019","March 17, 2020"
7278,NCT03027193,A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers,Crohn Disease|Mycobacterium Avium Subspecies Paratuberculosis,Biological: ChAdOx2 HAV|Biological: MVA HAV,University of Oxford,Phase 1,28,Other,"March 15, 2017","January 16, 2020","January 16, 2020"
7279,NCT03026504,Baricitinib in Relapsing Giant Cell Arteritis,"Arteritis, Giant Cell",Drug: Baricitinib,Matthew J Koster|Eli Lilly and Company|Mayo Clinic,Phase 2,15,Other|Industry,"March 9, 2017","April 12, 2021","April 12, 2021"
7280,NCT03025880,Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC,Advanced Breast Cancer,Drug: Pembrolizumab|Drug: Gemcitabine,Spanish Breast Cancer Research Group|Merck Sharp & Dohme LLC,Phase 2,36,Other|Industry,"June 28, 2017","June 3, 2019","July 22, 2021"
7281,NCT03025828,Adrenocorticotropic Hormone in Membranous Nephropathy,Membranous Nephropathy,Drug: ACTHar,Icahn School of Medicine at Mount Sinai,Phase 4,5,Other,"March 19, 2018","December 16, 2020","December 16, 2020"
7282,NCT03025789,Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage,"Trypanosomiasis, African|Sleeping Sickness|Trypanosomiasis; Gambian",Drug: Fexinidazole,Drugs for Neglected Diseases|Sanofi,Phase 3,174,Other|Industry,"November 17, 2016","February 1, 2021","February 1, 2021"
7283,NCT03025113,Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment,Musculoskeletal Pain,Drug: ketoprofen and cyclobenzaprine association|Drug: Cyclobenzaprine,EMS,Phase 3,416,Industry,"March 8, 2018","November 29, 2019","March 27, 2020"
7284,NCT03024216,Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,Prostate Cancer Metastatic,Drug: Atezolizumab1200 mg IV|Drug: Sipuleucel-T,"University of Hawaii|Genentech, Inc.|Dendreon",Phase 1,37,Other|Industry,"February 6, 2017","December 31, 2020","December 31, 2020"
7285,NCT03023722,Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer,Pancreatic Cancer,Drug: anetumab ravtansine,Yale University|Bayer,Phase 2,18,Other|Industry,"May 11, 2017","August 6, 2019","December 11, 2019"
7286,NCT03023111,Miltefosine and GM-CSF in Cutaneous Leishmaniasis,Cutaneous Leishmaniasis,Drug: Sbv|Drug: Miltefosine plus placebo|Drug: Miltefosine plus GM-CSF,Hospital Universitário Professor Edgard Santos|Oswaldo Cruz Foundation,Phase 3,300,Other,"June 30, 2017","August 9, 2019","February 14, 2020"
7287,NCT03023059,Dose Ranging Study of Carbidopa-levodopa,Age-related Macular Degeneration,"Drug: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet","Snyder, Robert W., M.D., Ph.D., P.C.",Phase 2,35,Other,"May 2, 2017","March 18, 2020","May 4, 2020"
7288,NCT03022981,Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Phase 2,216,Industry,"January 26, 2017","November 19, 2019","February 26, 2020"
7289,NCT03022968,Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD),Alzheimer Disease|Benson's Disease,Drug: [18F]T807 PET,"University Hospital, Tours",Phase 2,17,Other,"January 10, 2017","August 27, 2019","November 25, 2019"
7290,NCT03022617,An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis,Psoriatic Nail|Psoriasis Vulgaris|Psoriasis,Drug: Apremilast,University of Alabama at Birmingham|Celgene,Phase 4,12,Other|Industry,Jan-17,"September 1, 2020","September 29, 2022"
7291,NCT03022409,A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).,Head and Neck Squamous Cell Carcinoma,Drug: Ceralasertib|Drug: Olaparib,AstraZeneca,Phase 1,21,Industry,"September 18, 2017","January 20, 2021","January 20, 2021"
7292,NCT03022318,Carbidopa-levodopa in Neovascular AMD,Age-related Macular Degeneration,Drug: carbidopa-levodopa 25-100 mg tablets,"Snyder, Robert W., M.D., Ph.D., P.C.",Phase 2,21,Other,"May 2, 2017","December 26, 2019","May 4, 2020"
7293,NCT03022292,The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy,Wet Macular Degeneration,Drug: Aflibercept Ophthalmic|Device: optovue angiovue,"University of California, Los Angeles|Regeneron Pharmaceuticals",Phase 4,26,Other|Industry,"March 30, 2017","June 25, 2020","August 31, 2020"
7294,NCT03022240,Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children,Cognitive Change|Behavior,Drug: Propofol|Drug: Sevoflurane|Drug: Ametop|Drug: Ondansetron,University of Calgary,Phase 3,50,Other,Jan-17,Sep-19,Sep-19
7295,NCT03021499,Aurinia Renal Response in Active Lupus With Voclosporin,Lupus Nephritis,Drug: Voclosporin|Drug: Placebo Oral Capsule,Aurinia Pharmaceuticals Inc.,Phase 3,358,Industry,"May 17, 2017","September 24, 2019","October 10, 2019"
7296,NCT03020992,A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU,Axial Spondyloarthritis (axSpA)|Anterior Uveitis (AU),Drug: Certolizumab Pegol,UCB Biopharma SRL|UCB Pharma,Phase 4,89,Industry,"December 21, 2016","December 4, 2019","January 23, 2020"
7297,NCT03020966,IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty,"Pain, Postoperative|Opioid Use",Drug: Acetaminophen,"Hospital for Special Surgery, New York|Mallinckrodt",Phase 4,154,Other|Industry,"February 16, 2017","June 16, 2019","June 16, 2019"
7298,NCT03020615,Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies,Sickle Cell Anemia,Drug: Hydroxyurea,"St. Jude Children's Research Hospital|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,58,Other|NIH,"May 12, 2017","June 8, 2020","June 8, 2020"
7299,NCT03019939,Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia,Acute Myeloid Leukemia|Myelodysplastic Syndrome|Neutropenia,Drug: Isavuconazole,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,65,Other|NIH,"March 28, 2017","August 10, 2020","August 10, 2020"
7300,NCT03019575,Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043),Hypogonadotropic Hypogonadism,Drug: Corifollitropin alfa|Drug: hCG,Organon and Co,Phase 3,17,Industry,"February 2, 2017","May 5, 2020","May 5, 2020"
7301,NCT03019536,A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease,Alzheimer Disease,Drug: LY3303560 - IV|Drug: Placebo - IV|Drug: Florbetapir F 18|Drug: Flortaucipir F18,Eli Lilly and Company,Phase 1,24,Industry,"January 31, 2017","June 5, 2019","June 5, 2019"
7302,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),ALS,Drug: Perampanel|Drug: placebo,Tokyo Medical University,Phase 2,66,Other,"April 24, 2017","December 23, 2020","December 23, 2020"
7303,NCT03019055,Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell,"Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma",Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg),"Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin",Phase 1,26,Other,"October 16, 2017","October 1, 2019","August 24, 2021"
7304,NCT03018730,Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa),Fabry Disease,Biological: PRX-102 (pegunigalsidase alfa),Protalix,Phase 3,22,Industry,"May 17, 2017","December 17, 2019","January 9, 2020"
7305,NCT03018652,Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1,Chronic Obstructive Pulmonary Disease (COPD),Drug: Intravenous immunoglobulin|Drug: Normal Saline,Ottawa Hospital Research Institute,Phase 2,22,Other,"March 11, 2018","November 20, 2019","November 20, 2019"
7306,NCT03017521,"K-BASKET, TAS-117, PI3K/AKT Gene Aberration","Solid Tumor, Adult",Drug: TAS-117,Yonsei University,Phase 2,13,Other,"November 21, 2017","December 31, 2019","December 31, 2019"
7307,NCT03017430,Pregabalin for Opiate Withdrawal Syndrome,Opioid Withdrawal,"Drug: Pregabalin|Drug: Clonidine|Drug: Doxylamin|Drug: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)",St. Petersburg Bekhterev Research Psychoneurological Institute,Phase 4,100,Other,Jan-14,Dec-19,Dec-19
7308,NCT03017352,Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases,"Diabetes Mellitus, Type 1",Drug: Exenatide|Drug: Placebos,"Filip Krag Knop|Steno Diabetes Center Copenhagen|University Hospital, Gentofte, Copenhagen",Phase 2,108,Other,Dec-16,Jun-19,Jun-19
7309,NCT03016598,Stimulant Oxytocin Study,Stimulant Use & Co-occuring Opioid Use Disorders,Drug: Intranasal oxytocin|Drug: Intranasal placebo,VA Office of Research and Development,Phase 2,42,U.S. Fed,"January 26, 2018","February 14, 2020","February 14, 2020"
7310,NCT03016325,Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure,Heart Failure,Drug: HNO Donor|Drug: Placebo,Bristol-Myers Squibb,Phase 2,329,Industry,"January 13, 2017","June 23, 2019","November 12, 2019"
7311,NCT03015818,Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD),Aortic Bioprosthesis Structural Valve Dysfunction,Other: 18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT,Nantes University Hospital,Phase 4,25,Other,"January 30, 2017","May 3, 2019","May 3, 2019"
7312,NCT03015324,Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors,Solid Tumor,Drug: Hydroxychloroquine,"Peng Wang, MD PhD|University of Kentucky",Phase 1,38,Other,"August 8, 2017","February 3, 2020","February 2, 2021"
7313,NCT03014258,A Systems Biology Approach to Malaria Immunity,Plasmodium Falciparum Infection,Biological: NF54 P. falciparum malaria challenge,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,27,NIH,"June 7, 2017","July 19, 2019","July 19, 2019"
7314,NCT03014089,"Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",Zika Virus,Biological: mRNA-1325|Other: Placebo,"ModernaTX, Inc.|Biomedical Advanced Research and Development Authority",Phase 1,90,Industry|U.S. Fed,"December 21, 2016",Jul-19,Jul-19
7315,NCT03013400,Ebselen as an add-on Treatment in Hypo/Mania,"Bipolar Disorder|Bipolar Disorder, Manic",Drug: Ebselen|Drug: Placebo oral capsule,"University of Oxford|Stanley Medical Research Institute|Sound Pharmaceuticals, Incorporated",Phase 2,60,Other|Industry,"October 1, 2017","July 9, 2019","July 9, 2019"
7316,NCT03012815,Gabapentin for Alcohol Withdrawal Syndrome,Alcohol Withdrawal Syndrome,Drug: Gabapentin|Drug: Benzodiazepines|Drug: Divalproex Sodium,Mayo Clinic,Phase 4,88,Other,"February 1, 2017","March 1, 2021","March 1, 2021"
7317,NCT03012672,"Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm",Acute Leukemia of Ambiguous Lineage|Acute Myeloid Leukemia|Myeloid Neoplasm,Drug: Cladribine|Drug: Cytarabine|Biological: Granulocyte Colony-Stimulating Factor|Drug: Mitoxantrone Hydrochloride|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,University of Washington|National Cancer Institute (NCI),Phase 2,50,Other|NIH,"December 30, 2016","December 10, 2020","February 26, 2021"
7318,NCT03012477,CISPLATIN + AZD-1775 In Breast Cancer,Triple-negative Metastatic Breast Cancer,Drug: Cisplatin|Drug: AZD1775,Dana-Farber Cancer Institute|AstraZeneca,Phase 2,34,Other|Industry,"January 18, 2017","May 7, 2019","November 30, 2020"
7319,NCT03011632,Response of the Airway in Sinusitis and Asthma,Sinusitis|Asthma,Drug: Mometasone Nasal|Drug: placebo mometasone,Medical University of Lodz,Phase 4,150,Other,Jan-17,Aug-19,Aug-19
7320,NCT03011450,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment,Severe Hypertriglyceridemia,Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877),"Kowa Research Institute, Inc.",Phase 3,471,Industry,"November 26, 2016","July 5, 2019","July 5, 2019"
7321,NCT03009682,"Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations",Small Cell Lung Cancer,Drug: Olaparib,Samsung Medical Center,Phase 2,15,Other,Aug-16,Jan-21,Jan-21
7322,NCT03009461,Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis,HepatoCellular Carcinoma|Portal Vein Thrombosis,Procedure: HAIC|Drug: Sorafenib,Peking University,Phase 2,64,Other,"June 1, 2017","June 15, 2020","December 28, 2020"
7323,NCT03009214,A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours,Malignant Solid Tumor,Drug: AMC303,amcure GmbH,Phase 1,55,Industry,Dec-16,"July 28, 2020","May 7, 2021"
7324,NCT03008889,A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder,Autism Spectrum Disorder,Drug: N-acetylcysteine|Drug: Placebo,Emory University,Phase 2,8,Other,"July 5, 2018","September 12, 2019","September 12, 2019"
7325,NCT03008590,Low Dose Naltrexone for Chronic Pain From Arthritis,"Osteoarthritis|Arthritis, Rheumatoid|Arthritis, Psoriatic",Drug: Naltrexone|Drug: Placebo,VA Office of Research and Development,Phase 2,29,U.S. Fed,"May 1, 2018","December 31, 2019","December 31, 2019"
7326,NCT03008460,"Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy",Digestive System Disease,Drug: Eziclen®/Izinova®|Drug: Klean-Prep®,Ipsen,Phase 3,250,Industry,"October 15, 2017","February 24, 2020","June 29, 2020"
7327,NCT03008369,Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Metastatic Adrenal Gland Pheochromocytoma,Other: Laboratory Biomarker Analysis|Drug: Lenvatinib|Other: Quality-of-Life Assessment,Mayo Clinic|National Cancer Institute (NCI),Phase 2,3,Other|NIH,"May 31, 2017","December 1, 2020","September 28, 2022"
7328,NCT03008070,Phase 2b Study in NASH to Assess IVA337,Non-Alcoholic Steatohepatitis (NASH),Drug: IVA337|Drug: Placebo,Inventiva Pharma,Phase 2,247,Industry,"February 7, 2017","February 20, 2020","March 16, 2020"
7329,NCT03008018,"Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours","Solid Tumor, Adult",Drug: KA2507,Karus Therapeutics Limited,Phase 1,20,Industry,"August 7, 2017","June 10, 2020","June 10, 2020"
7330,NCT03008005,Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study,PostTraumatic Stress Disorder,Drug: Placebo Oral Capsule|Drug: Dronabinol Cap 5 milligrams (MG)|Drug: Dronabinol Cap 10 milligrams (MG),Wayne State University,Phase 4,46,Other,"June 1, 2017","December 31, 2019","December 31, 2019"
7331,NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast,Drug: Palbociclib|Drug: Letrozole|Drug: Fulvestrant|Procedure: Optional research biopsy|Drug: Goserelin|Procedure: Research blood draw|Procedure: Circulating tumor cell blood draw|Procedure: Tumor biopsy (optional),Washington University School of Medicine|Pfizer,Phase 2,55,Other|Industry,"June 15, 2017","March 13, 2020","March 31, 2023"
7332,NCT03007576,Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem),"Osteoarthritis,Knee",Biological: RegStem,EMO Biomedicine Corporation|Far Eastern Memorial Hospital,Phase 1,12,Industry|Other,"August 1, 2017","August 31, 2019","August 31, 2019"
7333,NCT03007394,Lorcaserin in the Treatment of Cocaine Use Disorder,Cocaine-Related Disorders,Drug: Lorcaserin|Drug: Placebo Oral Capsule,National Institute on Drug Abuse (NIDA),Phase 2,272,NIH,"December 19, 2017","December 1, 2019","December 1, 2019"
7334,NCT03007329,Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.,"Steatosis, Liver|Type2 Diabetes",Drug: Exenatide|Drug: Exenatide matching Placebo|Drug: Dapagliflozin,Medical University of Vienna|AstraZeneca,Phase 4,34,Other|Industry,"March 8, 2017","November 26, 2019","January 16, 2020"
7335,NCT03007004,Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis,Systemic Sclerosis Patients With Digital Ulcers,Drug: Botulinum toxin type B (2500 units / vial)|Drug: Physiological saline,Gunma University,Phase 2,10,Other,"December 12, 2016","May 14, 2019","May 14, 2019"
7336,NCT03006926,A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma,Hepatocellular Carcinoma,Drug: lenvatinib|Drug: pembrolizumab (200 mg),"Eisai Co., Ltd.|Merck Sharp & Dohme LLC|Eisai Inc.",Phase 1,104,Industry,"February 13, 2017","October 31, 2019","November 22, 2022"
7337,NCT03006887,Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors,Solid Tumors,Drug: lenvatinib|Drug: pembrolizumab,"Eisai Co., Ltd.|Merck Sharp & Dohme LLC|Eisai Inc.",Phase 1,6,Industry,"January 12, 2017","April 15, 2020","April 15, 2020"
7338,NCT03006809,Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis,Ulcerative Colitis,"Biological: Fecal Microbiota Transplantation (FMT), OpenBiome|Other: pretreatment antibiotics","Najwa Elnachef|University of California, San Francisco",Phase 1,30,Other,"March 2, 2017","May 4, 2020","April 4, 2021"
7339,NCT03006419,Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients,Kidney Transplant Rejection|Kidney Transplant; Complications,Drug: Basiliximab|Drug: Thymoglobulin,"Coordinación de Investigación en Salud, Mexico",Phase 4,100,Other,"December 1, 2016","July 30, 2019","July 30, 2019"
7340,NCT03006393,Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression,Depression,Drug: Infliximab|Other: Placebo,Emory University|National Institute of Mental Health (NIMH),Phase 4,42,Other|NIH,Aug-16,"September 26, 2020","September 26, 2020"
7341,NCT03006029,Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms,Solid Tumors,Drug: TAB08,Theramab LLC,Phase 1,12,Industry,"February 8, 2017","May 14, 2019","August 13, 2019"
7342,NCT03005678,Denosumab Versus Bisphosphonates (Alendronate) in GIOP,Osteoporosis,Drug: Denosumab|Drug: Alendronate,Tuen Mun Hospital,Phase 4,140,Other,"April 1, 2017","November 1, 2019","February 1, 2020"
7343,NCT03005106,StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements,"Burn, Thermal",Biological: StrataGraft Skin Tissue|Procedure: Autograft,"Stratatech, a Mallinckrodt Company|Mallinckrodt",Phase 3,71,Industry,"May 30, 2017","July 31, 2019","March 27, 2020"
7344,NCT03005002,Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,Metastatic Carcinoma in the Liver|MLH1 Gene Mutation|MSH6 Gene Mutation|PMS2 Gene Mutation|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Biological: Tremelimumab,City of Hope Medical Center|National Cancer Institute (NCI),Phase 1,9,Other|NIH,"June 28, 2017","November 26, 2019","November 26, 2019"
7345,NCT03004976,Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke,"Stroke|Stroke, Acute|Brain Injury, Acute",Biological: Umbilical Cord Blood|Other: Placebo,"Joanne Kurtzberg, MD|The Marcus Foundation|Emory University|M.D. Anderson Cancer Center|Duke University",Phase 2,79,Other,"March 14, 2017","July 17, 2020","March 27, 2021"
7346,NCT03004703,ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial,Coronary Disease|Myocardial Infarction,Drug: Tocilizumab|Drug: Sodium chloride 0.9%,Oslo University Hospital|St. Olavs Hospital|South-Eastern Norway Regional Health Authority|University of Oslo|Norwegian University of Science and Technology,Phase 2,200,Other,"March 16, 2017","February 19, 2020","February 10, 2021"
7347,NCT03004612,Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes,Prediabetic State|Insulin Resistance,Combination Product: Linagliptin + metformin|Drug: Metformin,Universidad de Guanajuato|Hospital Regional de Alta Especialidad del Bajio,Phase 4,144,Other,Jan-16,May-19,Jun-19
7348,NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",Advanced or Unresectable Melanoma Progressing After PD1 Blockade,Biological: ONCOS-102|Drug: Cyclophosphamide|Drug: Pembrolizumab,Targovax Oy|Targovax ASA,Phase 1,21,Industry,Dec-16,Jul-20,Oct-20
7349,NCT03003039,A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma,B-Cell Lymphoma,Biological: GB241|Biological: Rituximab,"Nanjing Yoko Biomedical Co., Ltd.",Phase 1,85,Industry,"June 5, 2017","May 20, 2019","May 20, 2019"
7350,NCT03002649,Study of Tofacitinib in Refractory Dermatomyositis,Dermatomyositis,Drug: Tofacitinib,Johns Hopkins University|Pfizer,Phase 1,10,Other|Industry,Jan-17,"September 30, 2020","September 30, 2020"
7351,NCT03002571,Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301),Atopic Dermatitis,Drug: IDP-124 Lotion|Drug: IDP-124 Vehicle Lotion,"Bausch Health Americas, Inc.",Phase 3,338,Industry,"July 24, 2018","April 14, 2020","April 14, 2020"
7352,NCT03002220,Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status,Prostate Cancer,Drug: radium-223,MedSIR|Bayer,Phase 2,52,Other|Industry,Nov-16,"May 6, 2020",
7353,NCT03001817,Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function,Severe Hypertriglyceridemia,Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877)|Drug: Placebo (for Fenofibrate),"Kowa Research Institute, Inc.",Phase 3,551,Industry,"November 28, 2016","June 24, 2019","June 24, 2019"
7354,NCT03001661,An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt,Induction of Labor Affected Fetus / Newborn,Device: Dilapan-S|Drug: Dinoprostone,Birmingham Women's NHS Foundation Trust|University of Birmingham|Medicem International CR s.r.o.,Phase 3,674,Other|Industry,"December 19, 2017","February 6, 2021","February 6, 2021"
7355,NCT03001089,Impact of the Administration of Fludrocortisone in Very Premature Infants,Partial Mineralocorticoid Deficiency,Drug: Oral Fludrocortisone (enteral)|Drug: Placebo Oral Tablet,Assistance Publique - Hôpitaux de Paris,Phase 2,66,Other,"June 1, 2017","September 8, 2020","September 8, 2020"
7356,NCT03001011,Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China,Hyperphosphatemia,Drug: Placebo|Drug: Sevelamer Carbonate (GZ419831),Sanofi,Phase 3,202,Industry,"June 7, 2017","August 16, 2019","August 16, 2019"
7357,NCT03000946,Prevention of Postoperative Pancreatic Fistula by Somatostatin,Pancreatic Surgery,Drug: Somatostatin|Drug: Octreotide,Assistance Publique - Hôpitaux de Paris,Phase 3,655,Other,"May 15, 2017","February 9, 2021","February 9, 2021"
7358,NCT03000374,Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery,Rectal Cancer,Drug: Panitumumab|Drug: 5Fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin,Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen,Phase 2,34,Other|Industry,"May 30, 2017","October 31, 2020","December 15, 2021"
7359,NCT02999399,Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism,Smoking,Other: Brussel Sprouts|Drug: Deuterated Phenanthrene,"Masonic Cancer Center, University of Minnesota",Phase 1,39,Other,"December 1, 2016","March 22, 2021","March 22, 2021"
7360,NCT02999373,Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates,Bronchopulmonary Dysplasia|Premature|Neonatal Death,Other: Autologous Umbilical Cord Blood Mononuclear Cells Therapy,Guangdong Women and Children Hospital,Phase 2,62,Other,"July 1, 2018","January 1, 2020","January 1, 2020"
7361,NCT02999269,ECT Pulse Amplitude and Medial Temporal Lobe Engagement,Major Depressive Disorder,Device: MECTA Spectrum 5000Q Amplitude,University of New Mexico|The Mind Research Network|University of Texas|National Institute of Mental Health (NIMH),Phase 4,62,Other|NIH,Oct-16,"March 23, 2020","March 23, 2020"
7362,NCT02999204,Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients,"Renal Insufficiency, Chronic|Vascular Stiffness|Bone Diseases, Metabolic",Drug: Vitamin D3,Jewish General Hospital,Phase 4,57,Other,Jan-15,"September 23, 2020","October 1, 2020"
7363,NCT02998905,NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH,Atrial Fibrillation|Intracerebral Hemorrhage,Drug: NOAC|Drug: Acetylsalicylic Acid,Population Health Research Institute,Phase 2,30,Other,"April 26, 2017","October 31, 2019","February 18, 2020"
7364,NCT02998879,Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis,Alpha-Mannosidosis,Drug: Velmanase Alfa (e.g. Lamazym),Chiesi Farmaceutici S.p.A.|Cromsource,Phase 2,5,Industry,Dec-16,Jul-20,Jul-20
7365,NCT02998645,Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia,Severe Aplastic Anemia,Drug: eltrombopag|Drug: Cyclosporine,Novartis Pharmaceuticals|Novartis,Phase 2,54,Industry,"May 11, 2017","November 3, 2020","May 2, 2022"
7366,NCT02997995,Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure,Breast Cancer|Estrogen Receptor Positive Tumor|Menopause|Hormone Antagonist,Drug: Immune-attractant|Drug: Durvalumab|Procedure: Biopsy,UNICANCER|Breast International Group,Phase 2,61,Other,"February 15, 2017","July 15, 2019","August 28, 2020"
7367,NCT02997982,Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease,Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex,Drug: Valaciclovir 500Mg Tablet,Hugo Lovheim|Umeå University,Phase 2,33,Other,Dec-16,"March 4, 2020","March 4, 2020"
7368,NCT02997176,An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800),Advanced Solid Tumors,Drug: Talazoparib,"Pfizer|Medivation, Inc.",Phase 1,38,Industry,"September 30, 2016","February 12, 2020","February 12, 2020"
7369,NCT02996461,"VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults",Prevention of Zika Infection|Zika-Specific Immune Response,Biological: VRC-ZKADNA090-00-VP,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,45,NIH,"December 12, 2016","September 3, 2019","September 3, 2019"
7370,NCT02996409,High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy,Tendinopathy|Achilles Tendon Pain|Injection Site Fibrosis,Drug: HVIGI|Drug: LVIGI|Other: Progressive exercise program,Erasmus Medical Center|Dutch Arthritis Association|The Anna Foundation,Phase 4,80,Other|Industry,Dec-16,Jul-19,Jul-19
7371,NCT02995915,Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking,Smoking Cessation|Alcohol Drinking,Other: Nicotine Replacement Therapy|Drug: Bupropion|Behavioral: Cognitive Behavioral Treatment|Behavioral: Mobile Contingency Management|Behavioral: Mobile Monitoring,Duke University,Phase 4,45,Other,Nov-16,"March 2, 2020","March 2, 2020"
7372,NCT02995733,Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief,Asthma,Drug: PARTICS using QVAR,Brigham and Women's Hospital|Patient-Centered Outcomes Research Institute|American Academy of Family Physicians,Phase 4,1220,Other,"November 27, 2017","April 30, 2021","April 30, 2021"
7373,NCT02995291,Reversing the Effects of 0.5% Bupivacaine,"Anesthesia, Local",Drug: OraVerse|Drug: Saline Water (Control),Dalhousie University,Phase 4,44,Other,"February 10, 2017","May 15, 2019","September 15, 2019"
7374,NCT02994940,Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen,Tonsillectomy|Adenoidectomy,Drug: Acetaminophen,"University of California, Davis",Phase 4,74,Other,"August 28, 2017","July 3, 2019","July 3, 2019"
7375,NCT02994927,A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis,ANCA-Associated Vasculitis,Drug: Avacopan|Drug: Prednisone|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Azathioprine,ChemoCentryx,Phase 3,331,Industry,"March 15, 2017","September 7, 2019","November 1, 2019"
7376,NCT02994173,Dose-response of Ketamine in Patient Controlled Analgesia in Orthopaedic Surgery Patients,"Pain, Postoperative",Drug: Oxycodone|Drug: S-Ketamine 0.25|Drug: S-Ketamine 0.5|Drug: S-Ketamine 0.75,Turku University Hospital|University of Turku|University of Helsinki,Phase 4,100,Other,"February 1, 2017","November 3, 2019","December 5, 2019"
7377,NCT02993757,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®,Dengue Fever|Dengue Hemorrhagic Fever|Human Papillomavirus Disease,"Biological: CYD Dengue Vaccine|Biological: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,528,Industry,"December 1, 2016","May 27, 2019","May 27, 2019"
7378,NCT02993731,A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma,"Carcinoma, Pancreatic Ductal",Drug: Napabucasin|Drug: Nab-paclitaxel|Drug: Gemcitabine,"Sumitomo Pharma Oncology, Inc.",Phase 3,1134,Industry,Dec-16,Mar-20,Mar-20
7379,NCT02993705,Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS),"Carcinosarcoma, Ovarian|Carcinosarcomas Uterine",Drug: Trabectedin,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Phase 2,45,Other,"February 22, 2017","November 13, 2019","November 13, 2019"
7380,NCT02993224,"Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet",Transfusion-dependent Thalassemia|Non-transfusion-dependent Thalassemia,Drug: Deferasirox dispersable tablet (DT)|Drug: Deferasirox film coated tablet (FCT),Novartis Pharmaceuticals|Novartis,Phase 2,148,Industry,"July 27, 2017","January 29, 2020","March 11, 2021"
7381,NCT02993107,PALISADE Follow-on Study (ARC004),Peanut Allergy,Biological: AR101,"Aimmune Therapeutics, Inc.",Phase 3,388,Industry,"December 29, 2016","May 31, 2019","May 31, 2019"
7382,NCT02992899,Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder,PostTraumatic Stress Disorder,Device: GammaCore/electroCore non-invasive VNS device|Device: Sham gammaCore/electroCore|Drug: O-15 water,Emory University|Georgia Institute of Technology,Phase 3,56,Other,"April 19, 2017","September 21, 2019","September 21, 2019"
7383,NCT02992483,"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma",Drug: MIK665,Novartis Pharmaceuticals|Novartis,Phase 1,31,Industry,"July 12, 2017","June 7, 2019","June 7, 2019"
7384,NCT02991937,Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children,Appendicitis,Drug: Piperacillin/Tazobactam|Procedure: Surgical Treatment,NYU Langone Health,Phase 4,39,Other,Dec-16,"December 1, 2020","December 1, 2020"
7385,NCT02991911,A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,Metastatic Castration Resistant Prostate Cancer,Biological: MEDI3726 Post-Chemo|Biological: MEDI3726 Pre-Chemo|Biological: MEDI3726 & Enzalutamide Combo,MedImmune LLC,Phase 1,33,Industry,"January 6, 2017","September 30, 2019","September 30, 2019"
7386,NCT02990806,A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE),Rheumatoid Arthritis,Drug: NI-071|Drug: Remicade,"Nichi-Iko Pharmaceutical Co., Ltd.",Phase 3,683,Industry,"January 19, 2017","May 20, 2019","May 20, 2019"
7387,NCT02990481,A Study of TRK-950 in Patients With Advanced Solid Tumors,Locally Advanced or Metastatic Solid Carcinomas|Colon Cancer|Cholangiocarcinoma,Biological: TRK-950,"Toray Industries, Inc",Phase 1,38,Industry,"March 6, 2017","September 16, 2019","September 16, 2019"
7388,NCT02990455,Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder,Alcohol Drinking|Cigarette Smoking Toxicity,Drug: Reduced nicotine cigarettes,Battelle Memorial Institute,Phase 1,47,Other,"November 14, 2017","April 21, 2021","April 21, 2021"
7389,NCT02990286,Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases,"Lung Disease, Interstitial",Drug: Rituximab|Drug: Placebo of Rituximab|Drug: Mycophenolate Mofetil,"University Hospital, Tours",Phase 3,122,Other,"January 20, 2017","July 24, 2019","February 17, 2020"
7390,NCT02989558,A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI,Aortic Valve Stenosis,Drug: Ticagrelor plus ASA|Drug: Clopidogrel plus ASA,University of Athens,Phase 3,90,Other,Dec-16,"February 1, 2020","February 1, 2021"
7391,NCT02989493,Testing Doxazosin to Treat Stress Mechanisms in Alcoholism,Alcoholism,Drug: Doxazosin|Other: Placebo,"University of Wisconsin, Madison|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",Phase 2,61,Other|NIH,"April 12, 2017","March 13, 2020","March 13, 2020"
7392,NCT02989402,"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.",Alzheimer's Disease,Drug: Rivastigmine,Novartis Pharmaceuticals|Novartis,Phase 4,102,Industry,"December 31, 2018","December 31, 2020","December 7, 2022"
7393,NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",Urothelial Carcinoma|Head and Neck Cancer|Melanoma|Bladder Urothelial Carcinoma,Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells,Adaptimmune,Phase 1,10,Industry,Oct-16,"December 18, 2019","June 4, 2020"
7394,NCT02988973,A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia,Chronic Kidney Disease,Drug: roxadustat|Drug: DA,Astellas Pharma Inc|FibroGen,Phase 3,334,Industry,"January 12, 2017","September 13, 2019","March 26, 2020"
7395,NCT02988440,Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,Hepatocellular Carcinoma,Drug: PDR001|Drug: Sorafenib,Novartis Pharmaceuticals|Novartis,Phase 1,20,Industry,"April 20, 2017","February 27, 2020","February 27, 2020"
7396,NCT02988232,Evaluation of the Efficacy and Safety of Herbal Medicine for Treating Work-related Chronic Low Back Pain,Low Back Pain|Workplace,Drug: Sogyeonghwalhyeol-tang|Drug: Placebo,"Gachon University Gil Oriental Medical Hospital|Sangji University Oriental Medical Center, Korea|Semyung University Korean Medicine Hospital in Chungju, Korea|Daejeon University",Phase 4,72,Other,"July 1, 2016","December 30, 2020","December 30, 2020"
7397,NCT02987985,Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy,"Anesthesia|General Anesthesia|Analgesics, Opioid|Postoperative Complications|Pathologic Processes|Physiologic Effects of Drugs|Narcotics|Analgesics|Sleep Disordered Breathing|Obstructive Sleep Apnea of Child|Tonsillectomy|Respiratory Depression|Dexmedetomidine|Ketamine|Lidocaine|Gabapentin|Pulse Oximetry","Drug: Acetaminophen, gabapentin|Drug: Acetaminophen|Drug: Ketamine , Lidocaine , Dexmedetomidine|Drug: Fentanyl, Dexmedetomidine|Drug: Dexamethasone , Ondansetron|Drug: Sevoflurane|Drug: Sevoflurane, Fentanyl",University of Saskatchewan,Phase 3,50,Other,"October 15, 2017","September 20, 2019","December 20, 2020"
7398,NCT02987543,Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),Metastatic Castration-resistant Prostate Cancer,Drug: olaparib|Drug: enzalutamide|Drug: abiraterone acetate,"AstraZeneca|Merck Sharp & Dohme LLC|Foundation Medicine, Inc.|Myriad Genetics, Inc.",Phase 3,387,Industry|Other,"February 6, 2017","June 4, 2019","February 15, 2023"
7399,NCT02987530,National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection,HIV-1 Infection,Drug: Dolutegravir|Drug: Darunavir-cobicistat|Drug: Emtricitabine-Tenofovir,"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",Phase 3,101,Other,"April 11, 2017","July 30, 2019","January 31, 2020"
7400,NCT02987166,HDCRT Plus Pembrolizumab in Advanced Malignancies,Solid Tumor,Radiation: High-Dose Conformal Radiation Therapy|Drug: Pembrolizumab,"James Larner, MD|University of Virginia",Phase 1,21,Other,"March 21, 2017","January 13, 2020","February 10, 2020"
7401,NCT02985983,A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA),Axial Spondyloarthritis,Drug: KHK4827|Drug: Placebo,"Kyowa Kirin Co., Ltd.",Phase 3,159,Industry,"March 7, 2017","September 23, 2019","September 23, 2019"
7402,NCT02984397,Chronic Widespread Pain and White Blood Cell Activation,Widespread Chronic Pain,Drug: Ketotifen Fumarate|Drug: Placebo|Other: Standard of Care,McGill University Health Centre/Research Institute of the McGill University Health Centre|The Louise And Alan Edwards Foundation,Phase 3,44,Other,Dec-16,Jan-20,Jan-20
7403,NCT02984228,Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis,Osteoarthritis|Shoulder Pain,Biological: PRP|Drug: Hyaluronic Acid|Device: Ultrasound,"Hospital for Special Surgery, New York",Phase 4,70,Other,Dec-14,Nov-20,Nov-20
7404,NCT02984072,Menthol for PDT Pain Relief,Actinic Keratosis,Drug: Menthol|Drug: Aqueous Cream,University of Dundee,Phase 4,10,Other,"October 23, 2018","October 10, 2019","October 10, 2019"
7405,NCT02983799,Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",Drug: OLAPARIB,AstraZeneca,Phase 2,272,Industry,"December 22, 2016","December 3, 2020","December 3, 2020"
7406,NCT02983227,A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350,Rheumatoid Arthritis,Drug: GDC-0853,"Genentech, Inc.",Phase 2,496,Industry,"November 30, 2016","July 17, 2019","July 17, 2019"
7407,NCT02983214,Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?,"Ischemic Stroke|Peripheral Artery Disease|Diabetes Mellitus, Type 2",Drug: Clopidogrel|Drug: Cilostazol,University of Ioannina|LIBYTEC Pharmaceutical S.A.,Phase 4,826,Other,Nov-16,Oct-19,Oct-19
7408,NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,Melanoma,Biological: DS-8273a|Biological: Nivolumab,"NYU Langone Health|Bristol-Myers Squibb|Daiichi Sankyo, Inc.",Phase 1,12,Other|Industry,Oct-16,"December 23, 2019","January 1, 2021"
7409,NCT02982954,A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer,Renal Cell Carcinoma,Drug: Nivolumab|Drug: Ipilimumab,Bristol-Myers Squibb,Phase 4,211,Industry,"January 16, 2017","May 11, 2020","October 6, 2021"
7410,NCT02982941,Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,Neuroblastoma|Rhabdomyosarcoma|Osteosarcoma|Ewing Sarcoma|Wilms Tumor|Desmoplastic Small Round Cell Tumor,Drug: Enoblituzumab,MacroGenics,Phase 1,25,Industry,Dec-16,"May 22, 2019","May 22, 2019"
7411,NCT02982850,Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease,Atrial Fibrillation|Valve Heart Disease,Drug: Dabigatran|Drug: Acetylsalicylic acid|Drug: Warfarin,Asan Medical Center|Boehringer Ingelheim,Phase 4,120,Other|Industry,Dec-16,Oct-20,Oct-20
7412,NCT02982057,Non Culprit Lesion Study,STEMI,Device: the ABSORB:bioresorbable vascular scaffold|Drug: O.M.T,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Phase 3,50,Other,Jan-15,"November 1, 2019","November 1, 2019"
7413,NCT02981602,"Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection",Hepatitis B|Chronic Hepatitis B Atypical,Drug: IONIS-HBVRx|Drug: Placebo,"GlaxoSmithKline|Ionis Pharmaceuticals, Inc.",Phase 2,31,Industry,"February 24, 2017","December 18, 2019","December 26, 2019"
7414,NCT02981316,Treatment of Recurrent Clostridium Difficile Infection With RBX7455,Clostridium Difficile Infection,Biological: RBX7455,Mayo Clinic|Rebiotix Inc.,Phase 1,30,Other|Industry,Nov-16,"July 22, 2020","July 22, 2020"
7415,NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,Advanced Melanoma|Triple-Negative Breast Cancer,Biological: Imprime PGG|Drug: Pembrolizumab,"HiberCell, Inc.|Merck Sharp & Dohme LLC",Phase 2,64,Industry,"February 22, 2017","December 31, 2020","December 31, 2020"
7416,NCT02980666,Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support,Short Bowel Syndrome,Drug: Teduglutide,Shire|Takeda,Phase 3,10,Industry,"January 13, 2017","January 21, 2020","January 21, 2020"
7417,NCT02980016,Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals,Tuberculosis|HIV,Drug: rifapentine + isoniazid|Drug: Isoniazid,The Aurum Institute NPC|Aurum Institute|London School of Hygiene and Tropical Medicine|Johns Hopkins University,Phase 3,4027,Other,Nov-16,"October 18, 2019","October 18, 2019"
7418,NCT02980003,PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization,Acute Kidney Injury|Contrast Media Reaction,Drug: isotonic saline|Drug: i.v. sodium bicarbonate|Drug: oral sodium bicarbonate,G. d'Annunzio University,Phase 3,240,Other,Mar-15,"October 30, 2020","May 1, 2021"
7419,NCT02979366,Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome,Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndrome (MDS),Drug: S64315 once a week|Drug: S64315 twice a week,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 1,38,Other|Industry,"March 15, 2017","May 11, 2020","May 11, 2020"
7420,NCT02979288,Treatment of the Intermediate Vaginal Microbiota With Vaginal Lactobacillus Casei Rhamnosus to Improve Pregnancy Outcome,Lactobacillus Infection,Drug: Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Other: NO Intervention,Medical University of Vienna,Phase 3,120,Other,"May 2, 2017","November 1, 2020","December 30, 2020"
7421,NCT02978755,"First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers","Neoplasm, Gynecologic",Drug: GM102|Drug: GM102 escalating doses,GamaMabs Pharma,Phase 1,78,Industry,Jun-16,"June 10, 2020","June 10, 2020"
7422,NCT02978495,Neoadjuvant Carboplatin in Triple Negative Breast Cancer,BRCA1 Hereditary Breast and Ovarian Cancer Syndrome,Drug: Doxorubicin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Cyclophosphamide,Barretos Cancer Hospital,Phase 2,154,Other,"May 17, 2017","December 2, 2019","October 22, 2021"
7423,NCT02978417,Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings,Opioid-Related Disorders,Drug: Naltrexone for extended-release injectable suspension|Drug: Oral naltrexone,"Duke University|Laura and John Arnold Foundation|Alkermes, Inc.|FHR (Fellowship Health Resources, Inc.)|Drug Treatment Court (Wake County, NC)",Phase 4,14,Other|Industry,"September 21, 2017","June 30, 2019","June 30, 2019"
7424,NCT02978040,"Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.",Coronary Artery Disease|STEMI - ST Elevation Myocardial Infarction,Drug: Cangrelor|Drug: Tirofiban|Drug: Prasugrel,"University Hospital Inselspital, Berne",Phase 4,122,Other,"July 4, 2017","August 26, 2019","December 27, 2019"
7425,NCT02976896,Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment,Esophageal Squamous Cell Carcinoma,Drug: Apatinib Mesylate,Yuhong Li|Sun Yat-sen University,Phase 2,43,Other,Aug-16,Dec-19,Dec-22
7426,NCT02976805,Multi-centre Failed Bowel Prep RCT,Colonoscopy|Bowel Preparation,Drug: 4L PegLyte + 15 mg bisacodyl|Drug: 6L PegLyte + 15 mg bisacodyl,"Lawson Health Research Institute|Academic Medical Organization of Southwestern Ontario|Pendopharm|University of Alberta|Université de Montréal|McGill University|University of Western Ontario, Canada",Phase 3,196,Other,"February 13, 2017","February 19, 2020","February 19, 2020"
7427,NCT02976246,Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients,Vitamin K Supplementation|Endstage Renal Disease|Cardiovascular Disease|Bone Disease,Dietary Supplement: Vitamin K2 (MK7)|Other: Placebo,Zealand University Hospital,Phase 4,123,Other,Nov-16,"June 26, 2020",
7428,NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,NSCLC,Drug: Fruquintinib|Drug: Gefitinib,Hutchison Medipharma Limited|Hutchmed,Phase 2,50,Industry,Dec-16,"June 28, 2019","June 28, 2019"
7429,NCT02974959,Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury,Traumatic Brain Injury|Acute Brain Injuries,Device: gammaCore active device|Device: gammaCore sham device,CentraCare|ElectroCore INC,Phase 1,14,Other|Industry,Oct-16,Jun-20,Nov-20
7430,NCT02974868,Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata,Alopecia Areata,Drug: PF-06651600|Drug: PF-06700841|Drug: Placebo,Pfizer,Phase 2,142,Industry,"December 15, 2016","May 15, 2019","May 15, 2019"
7431,NCT02974660,Protamine Sulfate During Transcatheter Aortic Valve Implantation,Aortic Valve Stenosis,Drug: Protamine sulfate|Drug: 0.9% NaCl,Medical University of Warsaw,Phase 4,100,Other,Dec-16,Jul-20,Sep-20
7432,NCT02973477,Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D),Type2 Diabetes|Cardiovascular Diseases,Drug: Dapagliflozin|Drug: Glimepiride,University of Michigan|AstraZeneca,Phase 4,45,Other|Industry,"January 12, 2017","August 22, 2019","August 22, 2019"
7433,NCT02973113,"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",NonHodgkin Lymphoma|Lymphoproliferative Disorders|EBV Related Lymphoma|EBV-Related PTLD|Hodgkin Lymphoma|EBV Related Non-Hodgkin's Lymphoma|EBV Related Hodgkin's Lymphoma,Biological: EBVST Cells|Biological: Nivolumab,"Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",Phase 1,8,Other,"February 16, 2016","September 5, 2019","July 11, 2020"
7434,NCT02973087,rVWF IN PROPHYLAXIS,Von Willebrand Disease,Biological: von Willebrand factor (Recombinant)|Biological: Antihemophilic Factor (Recombinant),"Takeda|Baxalta Innovations GmbH, now part of Shire",Phase 3,29,Industry,"November 16, 2017","July 6, 2020","July 6, 2020"
7435,NCT02973035,Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension,Hypertension,Drug: Amlodipine|Drug: Valsartan,Asan Medical Center|Yuhan Corporation,Phase 4,104,Other|Industry,Dec-16,"January 6, 2020","January 6, 2020"
7436,NCT02972983,Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia,Methicillin Susceptible Staphylococcus Aureus Septicemia|Bacteremia,Drug: Daptomycin|Other: Placebo,McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 4,102,Other,"December 1, 2016",Jul-19,Sep-19
7437,NCT02972476,Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial,Chronic Obstructive Pulmonary Disease,Drug: Budesonide & formoterol fumarate and Aclidinium bromide|Drug: Fluticasone 500 & salmeterol and Aclidinium bromide|Drug: Fluticasone 250 & salmeterol and Aclidinium bromide|Drug: Aclidinium bromide & formoterol fumarate,University of Dundee|AstraZeneca|NHS Tayside,Phase 4,158,Other|Industry,Dec-16,"July 22, 2019","July 22, 2019"
7438,NCT02972424,PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial,Osteoporotic Fractures,Drug: Teriparatide Prefilled Syringe|Drug: Placebo,"Hospital for Special Surgery, New York|Weill Medical College of Cornell University",Phase 2,35,Other,"May 1, 2017","March 8, 2021","July 8, 2021"
7439,NCT02970942,Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.,Hepatobiliary Disorders|Non-alcoholic Steatohepatitis,Drug: Semaglutide|Drug: Placebo,Novo Nordisk A/S,Phase 2,320,Industry,"November 30, 2016","February 13, 2020","March 19, 2020"
7440,NCT02970305,Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE),Schizophrenia,Drug: Pimavanserin|Drug: Placebo,ACADIA Pharmaceuticals Inc.,Phase 2,403,Industry,"November 4, 2016","October 16, 2019","October 28, 2019"
7441,NCT02970292,Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1),Schizophrenia,Drug: Pimavanserin|Drug: Placebo,ACADIA Pharmaceuticals Inc.,Phase 3,396,Industry,"October 26, 2016","May 28, 2019","June 25, 2019"
7442,NCT02970019,Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease,Parkinson Disease,Drug: K0706|Drug: Placebo,Sun Pharma Advanced Research Company Limited,Phase 1,60,Industry,"March 30, 2017","May 28, 2019","May 28, 2019"
7443,NCT02969369,"A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis",Parkinson Disease Psychosis,Drug: SEP-363856|Drug: Placebo capsule,Sunovion,Phase 2,39,Industry,"December 31, 2016","April 20, 2020","April 20, 2020"
7444,NCT02968940,Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,Glioblastoma,Biological: Avelumab|Radiation: Hypofractionated radiation therapy (HFRT),NYU Langone Health|EMD Serono,Phase 2,6,Other|Industry,"March 17, 2017","August 29, 2019","August 29, 2019"
7445,NCT02968602,Minocycline and Tobacco Craving in Smokers With Schizophrenia,Schizophrenia|Tobacco Use,Drug: Minocycline|Other: Placebo,"University of Maryland, Baltimore|National Institute on Drug Abuse (NIDA)",Phase 4,32,Other|NIH,"March 31, 2017","July 23, 2019","July 23, 2019"
7446,NCT02968563,Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug: Tirabrutinib|Drug: Idelalisib|Drug: Obinutuzumab,Gilead Sciences|German CLL Study Group,Phase 2,35,Industry|Other,"December 13, 2016","June 17, 2019","January 14, 2021"
7447,NCT02968433,The Stanford Parkinson's Disease Plasma Study,Parkinson Disease(PD),Drug: Infusions of young plasma,Stanford University,Phase 1,16,Other,Nov-16,Dec-19,Dec-19
7448,NCT02968420,Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine,Human Papillomavirus,"Biological: Human Papillomavirus 9-valent Vaccine, Recombinant",University of British Columbia|Merck Canada Inc.,Phase 4,18,Other|Industry,"September 11, 2017","May 15, 2019","May 15, 2019"
7449,NCT02967653,Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus,"Lithium Use, Nephrogenic Diabetes Insipidus",Drug: Atorvastatin,Lady Davis Institute,Phase 2,60,Other,"July 13, 2017","July 1, 2019","July 1, 2019"
7450,NCT02967432,Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU,Staphylococcus,Drug: Mupirocin Topical Ointment|Drug: Petroleum Jelly,"Crouse Hospital|Jana Shaw, MD|Steven Gross, MD|David Martin, RN|Dale Franz, RPh|Rachel Carey",Phase 2,216,Other,Oct-16,Dec-19,Dec-19
7451,NCT02966834,Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis,Cholestasis,Drug: Placebo|Drug: GSK2330672,GlaxoSmithKline,Phase 2,147,Industry,"January 11, 2017","April 15, 2020","April 15, 2020"
7452,NCT02966314,Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy,Idiopathic Angioedema,Drug: Omalizumab|Drug: Placebos,"University of Wisconsin, Madison|Novartis Pharmaceuticals",Phase 4,12,Other|Industry,"March 30, 2017","January 6, 2020","January 6, 2020"
7453,NCT02966301,Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide,Chronic Graft-Versus-Host Disease|Immune System Diseases,Drug: Arsenic Trioxide Injectable Solution,Medsenic,Phase 2,21,Industry,Dec-16,Jun-20,Jun-20
7454,NCT02966093,A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China,Differentiated Thyroid Cancer (DTC),Drug: Lenvatinib|Drug: Placebo,"Eisai Co., Ltd.|Eisai Inc.",Phase 3,151,Industry,"January 11, 2017","July 31, 2019","December 29, 2021"
7455,NCT02966028,Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD),"Cardiovascular Diseases|Cardiovascular Abnormalities|Calcifications, Vascular|Endstage Renal Disease|ESRD|Coronary Artery Calcification",Drug: SNF472|Drug: Placebo,Sanifit Therapeutics S. A.|Clinipace Worldwide,Phase 2,274,Other|Industry,Nov-16,Aug-19,Sep-19
7456,NCT02965885,A Study of TAS-116 in Patients With Solid Tumors,Advanced Solid Tumors,Drug: TAS-116,"Taiho Oncology, Inc.",Phase 1,31,Industry,"July 10, 2017","May 3, 2019","May 3, 2019"
7457,NCT02964650,Optimising Pacemaker Therapy for Contractility,Chronic Heart Failure,Device: Personalised rate-response settings,University of Leeds,Phase 2,83,Other,"June 20, 2017","September 30, 2019","October 31, 2019"
7458,NCT02964585,Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug: Canagliflozin|Drug: Placebo,"George Washington University|Janssen Scientific Affairs, LLC",Phase 4,34,Other|Industry,Nov-16,Jan-20,Sep-20
7459,NCT02964507,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer,Neoplasms,Drug: GSK525762|Drug: Placebo|Drug: Fulvestrant,GlaxoSmithKline,Phase 1,124,Industry,"February 2, 2017","September 29, 2020","July 19, 2021"
7460,NCT02964455,Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma,Esophageal Squamous Cell Carcinoma,Drug: Docetaxel|Drug: Nedaplatin|Radiation: chest radiation,Sun Yat-sen University,Phase 1,12,Other,Nov-16,Dec-19,May-20
7461,NCT02964091,Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World,Chronic Hepatitis C,Drug: sofosbuvir/ledipasvir,Partners in Health,Phase 4,300,Other,Oct-16,"August 28, 2020","August 28, 2020"
7462,NCT02963493,A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma,Multiple Myeloma,Drug: Melphalan flufenamide (Melflufen)|Drug: Dexamethasone,Oncopeptides AB|Precision For Medicine,Phase 2,157,Industry,"December 28, 2016","October 22, 2020","November 16, 2021"
7463,NCT02962895,Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS),Primary Sjogren Syndrome,Biological: VAY736|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,192,Industry,"June 27, 2017","June 30, 2020","September 23, 2021"
7464,NCT02962739,The Cellular Pharmacology of F-TAF in Dried Blood Spots,Healthy Volunteers,Drug: emtricitabine 200 mg/tenofovir alafenamide 25mg,"University of Colorado, Denver",Phase 1,38,Other,Mar-16,"May 22, 2019","May 22, 2019"
7465,NCT02962583,The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants,Obesity,Other: Weight loss|Drug: Probiotic Formula|Drug: Placebos,Laval University|Lallemand Health Solutions,Phase 2,152,Other|Industry,Jan-17,"June 6, 2019","June 6, 2019"
7466,NCT02962102,Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury,Critically Ill|Acute Kidney Injury,Drug: Calcifediol|Drug: Calcitriol|Drug: Placebos,David Leaf|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Brigham and Women's Hospital,Phase 2,150,Other|NIH,"April 3, 2017","July 16, 2020","August 6, 2020"
7467,NCT02961374,Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,Attenuated Familial Adenomatous Polyposis|Familial Adenomatous Polyposis,Drug: Erlotinib|Drug: Erlotinib Hydrochloride,National Cancer Institute (NCI),Phase 2,46,NIH,"October 27, 2017","February 23, 2020","September 27, 2021"
7468,NCT02961218,"Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia",Sickle Cell Anemia,Drug: ACZ885|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2,49,Industry,"April 5, 2017","June 27, 2019","April 27, 2020"
7469,NCT02960906,A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer,Clear Cell Metastatic Renal Cell Carcinoma,Drug: Nivolumab|Drug: Ipilimumab|Drug: Pazopanib|Drug: Sunitinib,Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie,Phase 2,200,Other,"May 31, 2017","February 15, 2021","February 15, 2021"
7470,NCT02960763,Optimizing Outcomes of Treatment-Resistant Depression in Older Adults,Treatment Resistant Depression|Major Depressive Disorder|Treatment-Refractory Depression|Late Life Depression|Geriatric Depression,Drug: Aripiprazole Augmentation|Drug: Bupropion Augmentation|Drug: Switch to bupropion|Drug: Lithium Augmentation|Drug: Switch to nortriptyline,Washington University School of Medicine|Patient-Centered Outcomes Research Institute|National Institute of Mental Health (NIMH),Phase 4,742,Other|NIH,"February 24, 2017","September 28, 2020","September 1, 2021"
7471,NCT02960711,Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome,Metabolic Syndrome,"Drug: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|Drug: Ludipress, mg stereate, micronized hydrated silica, talcum","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 3,1600,Other,Feb-14,Jul-19,Jul-19
7472,NCT02960581,"Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults",HIV Infection,Biological: PGT121 3mg/kg IV|Biological: PGT121 10mg/kg IV|Biological: PGT121 30mg/kg IV|Biological: PGT121 3mg/kg SC|Biological: Placebo (0.9% Sodium Chloride Injection USP (Saline)),"International AIDS Vaccine Initiative|Beth Israel Deaconess Medical Center, Boston MA|Ragon Institute of MGH, MIT and Harvard, Boston MA|University of Texas Health, Houston AIDS Research Team (HART), Houston TX|Mills Clinical Research, Los Angeles CA|Orlando Immunology Clinic, Orlando FL",Phase 1,48,Other,Nov-16,"July 8, 2019","July 8, 2019"
7473,NCT02959957,Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections,Urinary Tract Infections,Drug: Temocillin|Drug: Cefotaxime,Håkan Hanberger|Public Health Agency of Sweden,Phase 4,157,Other,"May 20, 2016",Aug-19,Aug-19
7474,NCT02959944,Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD),Chronic Graft Versus Host Disease,Drug: ibrutinib|Drug: Placebo|Drug: Prednisone,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Phase 3,193,Industry,"May 11, 2017","March 27, 2020","July 12, 2021"
7475,NCT02959905,Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes),Solid Cancer,Biological: TSA-CTL|Drug: Cyclophosphamide|Drug: Fludarabine,"BGI, China|Sun Yat-sen University",Phase 1,11,Other,"December 22, 2016","September 1, 2020","May 20, 2022"
7476,NCT02959658,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,Primary Progressive Multiple Sclerosis,Drug: Dimethyl fumarate|Drug: Placebo,"Rigshospitalet, Denmark|Biogen",Phase 2,54,Other|Industry,Dec-16,"December 21, 2019","December 9, 2020"
7477,NCT02959190,A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine,Migraine,Drug: Galcanezumab,Eli Lilly and Company,Phase 3,311,Industry,"February 7, 2017","August 10, 2019","August 10, 2019"
7478,NCT02958969,Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma,Venous Thromboembolism|Multiple Myeloma,Drug: Apixaban,Gregory Piazza|Bristol-Myers Squibb|Dana-Farber Cancer Institute,Phase 4,50,Other|Industry,"February 28, 2018","June 30, 2019","November 19, 2019"
7479,NCT02957786,Cytisine Versus Varenicline for Smoking Cessation,Smoking Cessation,Drug: Cytisine|Behavioral: Behavioural support|Drug: Varenicline,"University of Auckland, New Zealand|Lakes District Health Board|Brunel University",Phase 3,679,Other,"September 18, 2017","October 10, 2019","October 10, 2019"
7480,NCT02957682,Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo,Hypercholesterolemia,Drug: Praluent (Alirocumab)|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 4,2176,Industry,"November 2, 2016","March 5, 2020","March 5, 2020"
7481,NCT02957305,Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage,Miscarriage in First Trimester,Drug: Misoprostol 400mcg Tab|Drug: Misoprostol 200mcg Tab,Hospital de Clinicas de Porto Alegre,Phase 4,211,Other,"December 21, 2016","October 19, 2019","June 30, 2020"
7482,NCT02957292,A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).,Contraception,"Drug: Levonorgestrel (13,5 mg) intrauterine device|Device: Cooper (380mm2) intrauterine device",Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Bayer,Phase 4,108,Other|Industry,"June 1, 2016","September 15, 2020","September 15, 2020"
7483,NCT02956512,Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions,Healthy Volunteers,Drug: Dexibuprofen,Apsen Farmaceutica S.A.,Phase 1,52,Industry,"March 18, 2019","July 12, 2019","September 6, 2019"
7484,NCT02955823,A Phase II Study of the FIL on Elderly Frail Patients With DLBCL,Diffuse Large B-cells Non-Hodgkin Lymphoma,Drug: Rituximab-Dexamethasone-Lenalidomide,Fondazione Italiana Linfomi - ETS,Phase 2,68,Other,Sep-16,"September 22, 2020","November 24, 2022"
7485,NCT02955329,Vaping THC From Electronic Cigarettes,Marijuana Dependence,Drug: Nicotine|Drug: Cannabis|Device: PAX Loose Leaf Vaporizer,"University of California, San Francisco|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)",Phase 3,8,Other|NIH,"March 20, 2019","November 30, 2019","November 30, 2019"
7486,NCT02955251,"A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors",Advanced Solid Tumors Cancer,Drug: ABBV-428|Drug: Nivolumab,AbbVie,Phase 1,61,Industry,"November 18, 2016","October 29, 2019","October 29, 2019"
7487,NCT02955212,A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs),Rheumatoid Arthritis (RA),Drug: Upadacitinib|Drug: Placebo,AbbVie,Phase 3,338,Industry,"January 3, 2018","August 14, 2019","September 3, 2020"
7488,NCT02954887,Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7),Infantile Spasms,Drug: GWP42003-P,Jazz Pharmaceuticals,Phase 3,9,Industry,"May 12, 2017","June 13, 2019","June 13, 2019"
7489,NCT02954835,Negative Pressure Therapy for Groin Wounds,Wound Infection,Device: Prevena|Device: Traditional Dressing,Englewood Hospital and Medical Center,Phase 4,2,Other,Dec-16,"September 3, 2019","September 3, 2019"
7490,NCT02954458,Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS),Short Bowel Syndrome,Drug: TED|Other: SOC|Device: Syringe|Device: Needle,Shire|Takeda,Phase 3,61,Industry,"January 9, 2017","November 5, 2020","November 5, 2020"
7491,NCT02953860,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,Breast Cancer,Drug: Fulvestrant with Enzalutamide,"University of Colorado, Denver|United States Department of Defense",Phase 2,32,Other|U.S. Fed,"July 6, 2017","November 21, 2019","April 10, 2020"
7492,NCT02953821,Acthar Gel for Active Systemic Lupus Erythematosus (SLE),"Lupus Erythematosus, Systemic",Drug: Acthar Gel|Drug: Placebo Gel,Mallinckrodt,Phase 4,172,Industry,"December 16, 2016","July 31, 2019","October 25, 2019"
7493,NCT02953639,A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics,Schizophrenia,Drug: Basmisanil|Drug: Placebo,Hoffmann-La Roche,Phase 2,214,Industry,"November 30, 2016","December 12, 2019","December 12, 2019"
7494,NCT02953587,Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery,Obesity,Procedure: Oral Glucose Tolerance Test (OGTT)|Drug: Human Ghrelin|Drug: Saline,Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1,70,Other|NIH,Sep-16,"August 21, 2019","January 30, 2023"
7495,NCT02952885,Strict IGF-1 Control in Acromegaly,Acromegaly,Drug: Pegvisomant,Unity Health Toronto,Phase 3,10,Other,"July 27, 2017","May 7, 2020","May 7, 2020"
7496,NCT02951429,"Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension",Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo|Drug: Sildenafil,Hoffmann-La Roche,Phase 2,177,Industry,"December 31, 2016","September 26, 2019","August 22, 2020"
7497,NCT02950558,Anesthesia for Pain After Ankle Fracture Surgery,Chronic Pain|Ankle Fracture Surgery|Regional Anesthesia,Drug: Ropivacaine|Procedure: Nerve block,University of Cincinnati,Phase 4,14,Other,"May 29, 2018","November 14, 2019","June 19, 2020"
7498,NCT02950467,Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors,Distress|Depression|Grief,Drug: Psilocybin|Behavioral: Modified brief Supportive Expressive Group Therapy,"Joshua Woolley|Heffter Research Institute|River Styx Foundation|Usona Institute|Stupski Foundation|University of California, San Francisco",Phase 1,30,Other,"January 5, 2018","December 31, 2019","December 31, 2019"
7499,NCT02949934,"Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control",Alcohol Use Disorder,Drug: Tolcapone|Drug: Placebo,Medical University of South Carolina|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2,90,Other|NIH,"May 1, 2016","April 13, 2021","April 13, 2021"
7500,NCT02949752,Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile,Antipsychotics Weight Gain,Drug: Aripiprazole,"Institute of Mental Health, Singapore",Phase 4,67,Other,Aug-16,"October 1, 2019","January 1, 2020"
7501,NCT02949362,Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study,Short Bowel Syndrome,Drug: Teduglutide|Other: SOC,Shire|Takeda,Phase 3,29,Industry,"December 9, 2016","July 14, 2020","July 14, 2020"
7502,NCT02948959,Evaluation of Dupilumab in Children With Uncontrolled Asthma,Asthma,Drug: Dupilumab|Drug: Placebo|Drug: Asthma Controller Therapies|Drug: Asthma Reliever Therapies,Sanofi|Regeneron Pharmaceuticals,Phase 3,408,Industry,"April 21, 2017","August 26, 2020","August 26, 2020"
7503,NCT02948660,A Promising Tool for Predicting Consciousness Evolution in Prolonged Disorders of Consciousness,Disorder of Consciousness,Drug: Zolpidem Tartrate Tablets,Xijing Hospital|Guangzhou University of Chinese Medicine|University of Melbourne|Tianjin University,Phase 2,36,Other,"December 1, 2017","June 30, 2019","June 30, 2019"
7504,NCT02947373,Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors,Pediatric Brain Tumors,Drug: Hyperpolarized Pyruvate,"University of California, San Francisco",Phase 1,10,Other,"January 25, 2017","April 30, 2020","July 31, 2020"
7505,NCT02947269,Prucalopride in Postoperative Ileus,Postoperative Ileus|Colorectal Surgery|Postoperative Complications,Drug: Prucalopride|Drug: Placebo Oral Capsule,"University of Auckland, New Zealand",Phase 3,150,Other,"October 25, 2017","August 30, 2020","August 30, 2020"
7506,NCT02947126,Multilevel Models of Therapeutic Response in the Lungs,Cystic Fibrosis,Drug: Hypertonic Saline|Drug: Isotonic Saline|Drug: Indium-DTPA|Drug: Technetium Sulfur Colloid,"Tim Corcoran|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",Phase 1,56,Other|NIH,Jan-17,Feb-20,Dec-22
7507,NCT02946892,Effect of Carvedilol on Exercise Performance in Fontan Patients,Single Ventricle|Fontan,Drug: Carvedilol|Drug: Placebo,University of Texas Southwestern Medical Center|American Heart Association,Phase 4,26,Other,Nov-16,Dec-19,Jan-20
7508,NCT02946671,Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients,Gastric Cancer|Esophageal Cancer|Lung Cancer|Renal Cancer|Oral Cancer,Biological: Mogamulizumab|Biological: Nivolumab,"Osaka University|Kyowa Kirin Co., Ltd.|Ono Pharmaceutical Co. Ltd|Clinical Study Support, Inc.|Fiverings Co., Ltd.",Phase 1,16,Other|Industry,Mar-16,Mar-20,Mar-20
7509,NCT02946554,Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF,Acute-On-Chronic Liver Failure,Biological: HepaStem,Promethera Therapeutics,Phase 2,24,Industry,Dec-16,Jul-19,Jul-20
7510,NCT02946034,Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C,Chronic Kidney Disease|Chronic Hepatitis C,Drug: Viekira Pak ± ribavirin|Drug: Mavyret,Massachusetts General Hospital|AbbVie,Phase 4,10,Other|Industry,"February 1, 2017","September 16, 2020","September 16, 2020"
7511,NCT02945969,Sodium Lowering and Urinary Protein Reduction Trial,Chronic Kidney Disease|Albuminuria,Behavioral: Low Sodium Diet,Tulane University School of Public Health and Tropical Medicine|Tulane University,Phase 3,151,Other,Nov-16,Jan-21,Jan-21
7512,NCT02945163,Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy,HIV Infections,Drug: Tenofovir|Drug: Lamivudine|Drug: Efavirenz,Shanghai Public Health Clinical Center|The Second Hospital of Nanjing Medical University|Yunnan Provincial Infectious Disease Hospital,Phase 4,184,Other,"March 5, 2018","June 5, 2019","August 31, 2019"
7513,NCT02945150,Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant,Renal Failure,Drug: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination),Massachusetts General Hospital|Merck Sharp & Dohme LLC,Phase 4,8,Other|Industry,"February 1, 2017","August 20, 2019","March 5, 2020"
7514,NCT02945007,A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation,Healthy,Drug: JNJ-53718678,"Janssen Research & Development, LLC",Phase 1,82,Industry,"November 8, 2016","January 16, 2020","January 16, 2020"
7515,NCT02944552,"The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI",Drug-Induced Acute Liver Injury,Drug: bicyclol tablet 25mg|Drug: bicyclol tablet 50mg|Drug: polyene phosphatidylcholine capsule 456mg,Drug Induced Liver Disease Study Group|Beijing Union Pharmaceutical Factory,Phase 2,244,Other,"August 18, 2017","June 10, 2019","July 31, 2019"
7516,NCT02944526,The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial,Adhesive Capsulitis|Frozen Shoulder|Nerve Block,Drug: Ropivacaine Monohydrochloride|Drug: Placebo - Concentrate,"Clinique Saint-Jean, Bruxelles|University Hospital St Luc, Brussels",Phase 4,36,Other,Nov-16,"September 16, 2020","September 30, 2020"
7517,NCT02944396,Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Drug: pemetrexed|Drug: nivolumab|Drug: paclitaxel|Drug: veliparib|Drug: carboplatin,AbbVie,Phase 1,25,Industry,"December 23, 2016","October 2, 2019","October 2, 2019"
7518,NCT02944123,Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR),Acute Coronary Syndrome,Drug: Clopidogrel 75 mg|Drug: Prasugrel 5 mg|Drug: Ticagrelor 45 mg,Dong-A University,Phase 3,120,Other,Sep-16,Feb-20,Jun-20
7519,NCT02943850,CNS10-NPC-GDNF for the Treatment of ALS,Amyotrophic Lateral Sclerosis,Biological: Stem cell (HPC) implantation|Device: Stereotactic surgical device,Cedars-Sinai Medical Center|California Institute for Regenerative Medicine (CIRM),Phase 1,18,Other,"April 1, 2017","October 18, 2019","October 18, 2019"
7520,NCT02943785,Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF),Atrial Fibrillation,Drug: Edoxaban-based Regimen|Drug: VKA-based Regimen,"Daiichi Sankyo, Inc.|Chiltern International Inc.",Phase 3,1426,Industry,"March 21, 2017","February 28, 2021","February 28, 2021"
7521,NCT02943655,Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause,Improve Quality of Life|Heavy Menstrual Bleeding,Drug: combined contraceptive pills (microcept)|Drug: medroxyprogesterone acetate (progest)|Drug: mefenamic acid (ponstan forte),Assiut University,Phase 3,240,Other,"November 1, 2017","October 10, 2020","February 10, 2021"
7522,NCT02943135,Lidocaine In-situ Gel Before Intrauterine Device Insertion,Pain Relief,Drug: lidocaine in-situ gel|Drug: placebo in-situ gel,Assiut University,Phase 3,120,Other,"October 1, 2017","December 31, 2019","March 30, 2020"
7523,NCT02942407,Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation,Atrial Fibrillation|End Stage Renal Disease,Drug: apixaban|Drug: warfarin,"Christopher Granger, MD|Bristol-Myers Squibb|Duke University",Phase 4,154,Other|Industry,Dec-16,"July 27, 2019","August 12, 2019"
7524,NCT02942277,"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali",Malaria,Biological: Pfs25M-EPA|Biological: Pfs230D1M-EPA|Other: AS01|Biological: Engerix-B|Biological: Menactra|Other: Normal Saline|Drug: Coartem,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 1,301,NIH,"October 21, 2016","July 15, 2020","July 15, 2020"
7525,NCT02941926,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,Breast Cancer,Drug: Ribociclib|Drug: Letrozole|Drug: Goserelin|Drug: Leuprolide,Novartis Pharmaceuticals|Novartis,Phase 3,3246,Industry,"November 30, 2016","November 8, 2019","November 9, 2022"
7526,NCT02939547,Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1),"Niemann-Pick Disease, Type C1",Drug: Hydroxypropyl-beta-cyclodextrin,"Cyclo Therapeutics, Inc.",Phase 1,13,Industry,"October 11, 2017","February 10, 2020","February 10, 2020"
7527,NCT02938273,Bioimmunoradiotherapy (Cetuximab/RT/Avelumab),"Carcinoma, Squamous Cell of Head and Neck",Drug: avelumab|Radiation: radiotherapy|Drug: cetuximab,"The Netherlands Cancer Institute|Merck KGaA, Darmstadt, Germany",Phase 1,10,Other|Industry,"February 1, 2017","June 26, 2019","September 30, 2019"
7528,NCT02938013,deLIVER: Direct Acting Antiviral Effects on the Liver,HCV Coinfection|Liver Disease|HIV,Drug: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|Drug: Sofosbuvir/Velpatasvir (SOF/VEL),Johns Hopkins University,Phase 4,15,Other,Jan-17,"September 30, 2019","September 30, 2020"
7529,NCT02937454,Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency,Iron Deficiency|Heart Failure,Drug: ferric carboxymaltose|Other: Normal saline 0.9%,Vifor (International) Inc.|Worldwide Clinical Trials|Cytel Inc.|Vifor Pharma,Phase 4,1132,Industry|Other,"April 3, 2017","July 21, 2020","July 21, 2020"
7530,NCT02937350,Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease,Chronic Kidney Disease,Drug: D6-25-hydroxyvitamin D3,University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 1,88,Other|NIH,"March 1, 2017","July 8, 2019","January 1, 2021"
7531,NCT02937285,"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis",Multiple Sclerosis,Drug: Interferon beta 1a|Drug: Mitoxantrone,Rennes University Hospital,Phase 3,35,Other,"December 6, 2010","May 28, 2020","May 28, 2020"
7532,NCT02937116,First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors,"Cancer, Solid Tumor",Drug: IBI308|Drug: IBI308\Cisplatinum\Pemetrexed|Drug: IBI308\cisplatin\gemcitabine|Drug: IBI308\oxaliplatin\capecitabine|Drug: IBI308\etoposide\cisplatin|Drug: IBI308\irinotecan\5-FU,Innovent Biologics (Suzhou) Co. Ltd.,Phase 1,233,Industry,"October 19, 2016","September 30, 2020","September 30, 2020"
7533,NCT02935907,APG-115 in Patients With Advanced Solid Tumors or Lymphomas,Patients With Advanced Solid Tumor or Lymphoma,Drug: APG-115,Ascentage Pharma Group Inc.,Phase 1,50,Industry,Oct-16,"June 28, 2019","June 28, 2019"
7534,NCT02935374,Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children,Acute Otitis Media,Drug: Amoxicillin|Drug: Amoxicillin-Potassium Clavulanate|Drug: Macrolide,University of Oulu|Oulu University Hospital,Phase 4,73,Other,Nov-16,Mar-20,Mar-20
7535,NCT02935309,Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,Rectal Cancer|Rectal Adenocarcinoma,Drug: Lenvatinib|Drug: Capecitabine|Radiation: External Radiation Therapy (XRT),H. Lee Moffitt Cancer Center and Research Institute,Phase 1,20,Other,"October 14, 2016","October 11, 2019","May 14, 2020"
7536,NCT02935075,Optimization of Antiretroviral Therapy,HIV Infections,Drug: Tenofovir disoproxil fumarate|Drug: Lamivudine|Drug: Efavirenz,Shanghai Public Health Clinical Center|Yunnan Provincial Infectious Disease Hospital|The Second Hospital of Nanjing Medical University,Phase 4,184,Other,"March 5, 2018","June 5, 2019","August 31, 2019"
7537,NCT02934555,Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest,Cardiac Arrest,Drug: Ubiquinol|Dietary Supplement: Ensure,Beth Israel Deaconess Medical Center|Kaneka Medical America LLC,Phase 2,48,Other|Industry,Mar-16,"May 25, 2019","June 2, 2019"
7538,NCT02933372,Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3,Parkinson's Disease,Drug: Varenicline,University of Michigan,Phase 2,25,Other,"October 5, 2015","June 26, 2019","June 26, 2019"
7539,NCT02932566,The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction,Cardiac Failure,Drug: Pirfenidone|Drug: Placebo,"Manchester University NHS Foundation Trust|National Institute for Health Research, United Kingdom|University of Manchester|University of Liverpool|Hoffmann-La Roche",Phase 2,129,Other|Industry,"March 2, 2017","November 29, 2019","April 29, 2020"
7540,NCT02932436,Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics,"Diabetes Mellitus, Type 2|Diastolic Dysfunction",Drug: Empagliflozin|Drug: Placebo,Johannes Gutenberg University Mainz|Boehringer Ingelheim,Phase 4,144,Other|Industry,"October 10, 2016","June 15, 2020","August 31, 2020"
7541,NCT02931539,"Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir",Cytomegalovirus (CMV),Drug: Maribavir|Drug: Ganciclovir|Drug: Valganciclovir|Drug: Foscarnet|Drug: Cidofovir,Shire|Takeda,Phase 3,352,Industry,"December 22, 2016","August 17, 2020","August 17, 2020"
7542,NCT02930018,Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke,"Stroke, Acute","Drug: Nerinetide (NA-1), 2.6 mg/kg|Drug: Placebo",NoNO Inc.|University of Calgary,Phase 3,1105,Industry|Other,"March 1, 2017","November 20, 2019","November 20, 2019"
7543,NCT02929563,Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial,Gastrointestinal Hemorrhage,Drug: Pantoprazole|Drug: Placebo (for pantoprazole),McMaster University|Canadian Institutes of Health Research (CIHR),Phase 3,116,Other,"January 9, 2017",Jan-20,Jan-20
7544,NCT02929329,Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction,Heart Failure,Drug: Omecamtiv Mecarbil|Drug: Placebo|Drug: Standard of Care,Cytokinetics,Phase 3,8256,Industry,"January 6, 2017","September 14, 2020","September 14, 2020"
7545,NCT02929134,A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka,Lymphedema|Lymphatic Filariasis|Filariasis,Drug: Doxycycline|Drug: Placebo,The Task Force for Global Health|United States Agency for International Development (USAID),Phase 3,219,Other|U.S. Fed,"February 16, 2018","June 15, 2020","June 15, 2020"
7546,NCT02927925,"A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type",Lymphoma,Drug: Daratumumab,"Janssen Research & Development, LLC",Phase 2,32,Industry,"February 14, 2017","January 2, 2020","January 7, 2020"
7547,NCT02927496,"A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali",Lymphedema|Lymphatic Filariasis|Filariasis,Drug: Doxycycline|Drug: Placebo,The Task Force for Global Health|United States Agency for International Development (USAID),Phase 3,220,Other|U.S. Fed,"June 19, 2018","December 19, 2020","December 19, 2020"
7548,NCT02927314,A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease,Non-alcoholic Steatohepatitis (NASH),Drug: CF102|Drug: Placebo,Can-Fite BioPharma,Phase 2,60,Industry,"November 27, 2017","March 1, 2020","March 1, 2020"
7549,NCT02926768,Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Adenocarcinoma",Drug: CK-101,"Checkpoint Therapeutics, Inc.",Phase 1,136,Industry,Sep-16,Sep-20,Jun-22
7550,NCT02926027,Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy,Hypertriglyceridemia,Drug: Vascepa|Drug: placebo,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Intermountain Research and Medical Foundation,Phase 4,80,Other,"March 28, 2017","May 15, 2020","August 15, 2020"
7551,NCT02924766,A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),Prostatic Neoplasms,Drug: Niraparib|Drug: Apalutamide|Drug: Abiraterone Acetate|Drug: Prednisone,"Janssen Research & Development, LLC",Phase 1,34,Industry,"October 3, 2016","July 18, 2019","July 19, 2019"
7552,NCT02924727,Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI,Acute Myocardial Infarction,Drug: LCZ696 (sacubitril/valsartan)|Drug: Ramipril|Drug: Placebo of LCZ696|Drug: Placebo of ramipril|Drug: Valsartan|Drug: Placebo of valsartan,Novartis Pharmaceuticals|Novartis,Phase 3,5670,Industry,"December 9, 2016","February 26, 2021","February 26, 2021"
7553,NCT02924285,Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease,Heart Diseases|Cardiomyopathies|Ventricular Premature Complexes,Procedure: Procedure (Radiofrequency catheter ablation)|Drug: Amiodarone,University of Leipzig|Leipzig Heart Institute GmbH|Abbott Medical Devices|Zentrum für Klinische Studien Leipzig,Phase 3,80,Other|Industry,"November 1, 2017","December 30, 2020","March 4, 2021"
7554,NCT02923921,Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer,Pancreatic Cancer,Biological: Pegilodecakin|Drug: FOLFOX,Eli Lilly and Company|ARMO BioSciences,Phase 3,567,Industry,"March 1, 2017","September 9, 2019","March 5, 2020"
7555,NCT02923128,Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction,Postoperative Cognitive Dysfunction|Postoperative Delirium,Drug: Dexmedetomidine|Drug: Sufentanyl|Drug: Saline,Zhejiang Cancer Hospital,Phase 4,240,Other,Nov-16,Oct-20,Oct-20
7556,NCT02922127,Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation,Contraception,Drug: Ulipristal Acetate|Drug: Combined Oral Contraceptive Pill,Columbia University|Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center,Phase 1,29,Other,"December 16, 2016","October 21, 2019","October 21, 2019"
7557,NCT02921789,Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients,Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS),Drug: Bleselumab|Drug: Basiliximab|Drug: Mycophenolate Mofetil (MMF)|Drug: Tacrolimus Capsules|Drug: Methylprednisone|Drug: Prednisone,"Astellas Pharma Global Development, Inc.|Kyowa Kirin Co., Ltd.|Astellas Pharma Inc",Phase 2,67,Industry,"May 22, 2017","December 11, 2020","May 18, 2021"
7558,NCT02921269,"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Recurrent Cervical Carcinoma|Stage IV Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7|Stage IVB Cervical Cancer AJCC v6 and v7",Drug: Atezolizumab|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis,National Cancer Institute (NCI),Phase 2,11,NIH,"March 10, 2017","October 1, 2020","January 13, 2021"
7559,NCT02920008,"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",Acute Myeloid Leukemia,Drug: guadecitabine|Drug: Treatment Choice (TC),"Astex Pharmaceuticals, Inc.",Phase 3,302,Industry,"March 16, 2017","January 20, 2020","June 1, 2020"
7560,NCT02919436,Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery,Post-operative Urinary Retention,Drug: Tamsulosin|Drug: Placebo,"Anand Rughani, MD|MaineHealth",Phase 4,610,Other,Mar-16,Jan-20,Nov-20
7561,NCT02918968,Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer,Prostate Cancer,Drug: Enzalutamide|Drug: Flutamide|Other: Androgen deprivation therapy,Astellas Pharma Inc|Pfizer,Phase 4,206,Industry,"November 2, 2016","March 27, 2020","March 27, 2020"
7562,NCT02918851,VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?,Healthy,Biological: Transfusion of 7-day stored red blood cells|Biological: Transfusion of 28-day stored red blood cells|Biological: Transfusion of 42-day stored red blood cells,Stony Brook University,Phase 4,42,Other,Jan-17,"August 9, 2019","November 20, 2019"
7563,NCT02918409,IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy,Cystic Fibrosis,Drug: Colistin|Drug: Tobramycin,National Jewish Health,Phase 4,51,Other,"August 26, 2016","September 10, 2020","November 22, 2021"
7564,NCT02918318,"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression",Depression,Drug: Placebo|Drug: Intranasal esketamine (28 mg)|Drug: Intranasal esketamine (56 mg)|Drug: Intranasal esketamine (84 mg),Janssen Pharmaceutical K.K.,Phase 2,202,Industry,"December 12, 2016","August 19, 2019","December 13, 2019"
7565,NCT02918305,Renal Denervation on Quality of 24-hr BP Control by Ultrasound In Resistant Hypertension,Hypertension|Vascular Diseases,Device: PRDS-001 Renal Denervation Ultrasound System|Procedure: Sham Procedure,"JIMRO Co., Ltd.",Phase 3,140,Industry,Jan-17,Jul-20,Oct-21
7566,NCT02917941,A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma,Relapsed and/or Refractory Multiple Myeloma,Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone,Takeda,Phase 2,34,Industry,"November 1, 2016","August 31, 2019","August 31, 2019"
7567,NCT02917031,Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure,Type 2 Diabetes Mellitus|Heart Failure,Drug: Saxagliptin|Drug: Sitagliptin|Drug: Placebo to match saxagliptin|Drug: Placebo to match sitagliptin,AstraZeneca,Phase 4,348,Industry,"January 10, 2017","August 23, 2019","August 23, 2019"
7568,NCT02916940,Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers.,Sprain,Drug: Diprophos,Brugmann University Hospital,Phase 2,60,Other,"November 16, 2016","February 11, 2020","February 11, 2020"
7569,NCT02916160,Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study,Chronic Heart Failure|Sleep Apnea Syndrome,"Drug: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)","University Hospital, Montpellier",Phase 4,124,Other,"September 22, 2016","February 27, 2020","February 27, 2020"
7570,NCT02916095,Kanitinib in Treating Patients With Advanced Solid Tumors,Solid Tumors,Drug: Kanitinib,"Beijing Konruns Pharmaceutical Co., Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 1,9,Industry|Other,Nov-16,Jan-20,Jul-20
7571,NCT02915744,"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine",Metastasis|Breast Cancer,Drug: NKTR-102|Drug: Eribulin|Drug: Ixabepilone|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Docetaxel|Drug: Nab-paclitaxel,Nektar Therapeutics,Phase 3,178,Industry,Nov-16,Jul-20,Jul-20
7572,NCT02914522,Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis,Ulcerative Colitis,Drug: Filgotinib|Drug: PTM filgotinib,Gilead Sciences|Galapagos NV,Phase 3,1351,Industry,"November 14, 2016","March 31, 2020","March 31, 2020"
7573,NCT02914171,Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly,Ebstein Anomaly,Biological: Autologous Bone Marrow-derived Mononuclear Cells|Device: Insertable cardiac monitor,Timothy J. Nelson|Mayo Clinic,Phase 1,10,Other,Sep-16,"March 18, 2021","March 18, 2021"
7574,NCT02913924,Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients,Cannabis Use Disorder,Drug: Clonazepam|Drug: Placebo,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),Phase 2,68,Other|NIH,Dec-16,Jun-20,Jun-20
7575,NCT02913612,"Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)",Infantile Hemangioma,Drug: 0.25% Timolol Maleate Gel Forming Solution|Drug: 0.5% Timolol Maleate Gel Forming Solution,"Kanecia Obie Zimmerman|The Emmes Company, LLC|National Institutes of Health (NIH)|Duke University",Phase 2,105,Other|Industry|NIH,"May 5, 2017","October 20, 2020","October 20, 2020"
7576,NCT02913261,Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation,Corticosteroid Refractory Acute Graft vs Host Disease,Drug: Ruxolitinib (RUX)|Drug: Best Available Therapy (BAT),Novartis Pharmaceuticals|Novartis,Phase 3,310,Industry,"March 10, 2017","June 24, 2019","April 23, 2021"
7577,NCT02912845,Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies,Rabies,Drug: KamRAB - HRIG,"Kamada, Ltd.|Kedrion S.p.A.",Phase 3,30,Industry,"August 1, 2016","November 13, 2019","November 13, 2019"
7578,NCT02912663,Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.,Ischemic Stroke,Drug: Verapamil and Magnesium Sulfate|Other: Placebo,Justin Fraser|University of Kentucky,Phase 1,10,Other,"October 11, 2017","January 14, 2020","January 14, 2020"
7579,NCT02911285,NAC for Treating Comorbid PTSD and SUD,Posttraumatic Stress Disorder (PTSD)|Alcohol Use Disorder (AUD)|Substance Use Disorder (SUD),Drug: N-acetylcysteine|Drug: Placebo|Behavioral: Cognitive behavioral therapy,Medical University of South Carolina|United States Department of Defense|Institute for Translational Neuroscience,Phase 2,90,Other|U.S. Fed,Oct-16,"August 5, 2019","November 4, 2019"
7580,NCT02911116,Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study),Uveitis,Drug: Ustekinumab,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),Phase 2,8,NIH,"March 30, 2017","March 5, 2020","May 28, 2020"
7581,NCT02910466,A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism,Chronic Hypoparathyroidism|Hypoparathyroidism,Drug: rhPTH(1-84),Shire|Takeda,Phase 4,39,Industry,"October 27, 2016","December 20, 2019","December 20, 2019"
7582,NCT02910219,Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients,Breast Cancer,Drug: Crofelemer,"Sandra Swain|Lombardi Comprehensive Cancer Center|Medstar Health Research Institute|Genentech, Inc.|Napo Pharmaceuticals, Inc.|Georgetown University",Phase 2,53,Other|Industry,"January 31, 2017","November 23, 2020","November 23, 2020"
7583,NCT02909959,Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder,"Autism Spectrum Disorder|Autistic Disorder|Neurodevelopmental Disorder|Childhood Developmental Disorders, Pervasive",Drug: Sulforaphane|Drug: Placebo,"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute",Phase 2,48,Other,"March 1, 2017","May 30, 2019","May 30, 2019"
7584,NCT02909712,Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania,Malaria|Pregnancy Malaria|Cardiotoxicity|Cardiac Safety|Parasitemia,Drug: sulfadoxine-pyrimethamine (SP)|Drug: dihydroartemisinin-piperaquine (DHA-PQP),"London School of Hygiene and Tropical Medicine|Kilimanjaro Christian Medical Centre, Tanzania|National Institute for Medical Research, Tanzania",Phase 2,201,Other,Sep-16,Jan-20,Feb-20
7585,NCT02909478,Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer,Chemotherapy-induced Nausea and Vomiting|Colorectal Cancer,Drug: Aprepitant+Tropisetron|Drug: Dexamethasone+Tropisetron,Sun Yat-sen University,Phase 3,315,Other,"September 1, 2017","October 23, 2019","December 31, 2019"
7586,NCT02909452,Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,"Neoplasms|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Digestive System Neoplasms|Endocrine Gland Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Breast Diseases|Renal Neoplasm|Solid Tumors",Drug: Entinostat|Drug: Pembrolizumab,Syndax Pharmaceuticals|Merck Sharp & Dohme LLC,Phase 1,30,Industry,"September 20, 2016","July 17, 2019","February 9, 2021"
7587,NCT02908217,Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE,Polymyalgia Rheumatica,Drug: Tocilizumab|Drug: Placebo,"University Hospital, Brest|Roche Chugai",Phase 3,113,Other|Industry,"February 15, 2017","November 12, 2020","November 12, 2020"
7588,NCT02908100,A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Drug: GDC-0853|Drug: Placebo,"Genentech, Inc.",Phase 2,260,Industry,"January 19, 2017","May 28, 2019","July 16, 2019"
7589,NCT02907749,Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis,Cirrhosis|Portal Hypertension,Drug: Spironolactone and carvedilol|Drug: Carvedilol,"Changqing Yang|Shanghai Tongji Hospital, Tongji University School of Medicine",Phase 4,96,Other,"January 1, 2018","January 1, 2020","July 31, 2020"
7590,NCT02907359,Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic",Drug: Guadecitabine|Other: Treatment Choice,"Astex Pharmaceuticals, Inc.",Phase 3,417,Industry,"January 13, 2017","March 31, 2020","November 30, 2020"
7591,NCT02906371,Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,"Lymphoblastic Leukemia, Acute, Childhood",Drug: Tocilizumab|Biological: CART 19,University of Pennsylvania|Children's Hospital of Philadelphia,Phase 1,80,Other,Aug-16,"March 11, 2020","June 30, 2021"
7592,NCT02906059,"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",Metastatic Colorectal Cancer,Drug: AZD1775|Drug: Irinotecan,NYU Langone Health|AstraZeneca,Phase 1,7,Other|Industry,Sep-16,"March 12, 2020","March 12, 2020"
7593,NCT02905890,The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis,Bacterial Vaginosis|HIV,Drug: Norethisterone enantate|Device: Condoms,London School of Hygiene and Tropical Medicine|Imperial College London|University of Liverpool|MRC/UVRI and LSHTM Uganda Research Unit,Phase 4,250,Other,"October 2, 2017","December 20, 2019","December 20, 2019"
7594,NCT02905734,Nicotine Replacement Therapy in Nicotine-dependent Arrestees,Nicotine Dependence,Drug: Nicotine patch|Other: placebo patch,Assistance Publique - Hôpitaux de Paris,Phase 4,800,Other,"January 3, 2017","November 25, 2020","May 30, 2021"
7595,NCT02905565,NBP in Adult Patients With Acute Ischemic Stroke (AIS),AIS,Drug: NBP Softgel Capsules|Drug: Placebo,"CSPC-NBP Pharmaceutical Co., Ltd.",Phase 2,177,Industry,"February 28, 2018","August 7, 2020","August 7, 2020"
7596,NCT02905539,A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer,"Anemia, Iron-Deficiency",Drug: Iron Isomaltoside 1000|Drug: Ferric Carboxymaltose,Universität des Saarlandes,Phase 4,26,Other,Jul-16,Jun-20,Jun-20
7597,NCT02904954,"Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",Drug: Durvalumab|Other: Durvalumab plus SBRT,Weill Medical College of Cornell University|AstraZeneca,Phase 2,60,Other|Industry,"December 2, 2016","September 16, 2020","October 4, 2022"
7598,NCT02904330,K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,Drug: K1-70 intramuscular or K1-70 intravenous,AV7 Limited,Phase 1,18,Industry,Aug-16,Apr-21,Apr-21
7599,NCT02903966,GSK2982772 Study in Subjects With Ulcerative Colitis,"Colitis, Ulcerative",Drug: GSK2982772|Drug: Placebo,GlaxoSmithKline,Phase 2,36,Industry,"November 15, 2016","June 17, 2019","June 17, 2019"
7600,NCT02903771,"Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.",Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms,Drug: Part A: Dose Escalation of Cantrixil|Drug: Part B: Expansion Cohort of Cantrixil,Kazia Therapeutics Limited,Phase 1,28,Industry,Nov-16,"March 24, 2020","March 24, 2020"
7601,NCT02903511,Feasibility Study of Metformin Therapy in ADPKD,"Polycystic Kidney, Autosomal Dominant",Drug: Metformin|Drug: Placebo,"University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",Phase 2,56,Other|NIH,Nov-16,"August 17, 2020","August 17, 2020"
7602,NCT02903446,Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions,Gout,Drug: Denosumab,"University of Alabama at Birmingham|University of Auckland, New Zealand",Phase 2,20,Other,"February 1, 2017","March 1, 2020","March 1, 2020"
7603,NCT02903121,Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users,Bleeding|Implants|Breakthrough Bleeding,Drug: Tamoxifen|Drug: Placebo|Drug: Tamoxifen (open label),Oregon Health and Science University|Merck Women's Health Investigator Initiated Studies Program,Phase 4,109,Other,"January 20, 2017","June 5, 2019","June 5, 2019"
7604,NCT02903069,Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer,Glioblastoma|Malignant Glioma,Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune,Celgene|Triphase,Phase 1,66,Industry|Other,"August 17, 2016","January 25, 2021","January 25, 2021"
7605,NCT02902237,tTF-NGR Phase I Study,Malignant Solid Tumors|Lymphomas,Biological: tTF-NGR,"University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)",Phase 1,24,Other,"March 1, 2017","November 5, 2019","November 5, 2019"
7606,NCT02901275,Enhancing Medication-based Analgesia in Humans,"Pain|Cannabis|Opioid Use, Unspecified",Drug: Within-subject test of blinded study medications,Johns Hopkins University,Phase 2,29,Other,Dec-16,"March 23, 2020","March 23, 2020"
7607,NCT02900716,"Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",Chronic Lymphocytic Leukemia|B-Cell Lymphoma,Drug: DTRMWXHS-12|Drug: DTRM-505|Drug: DTRM-555,Zhejiang DTRM Biopharma,Phase 1,48,Industry,Sep-16,"November 23, 2020","November 23, 2020"
7608,NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",Biological: PDR001|Biological: ACZ885|Biological: CJM112|Drug: TMT212|Drug: EGF816,Novartis Pharmaceuticals|Novartis,Phase 1,283,Industry,"August 23, 2016","March 17, 2021","March 17, 2021"
7609,NCT02900352,Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action,Alcohol Use Disorder,Drug: Zonisamide|Drug: Placebo,Virginia Commonwealth University|University of Connecticut|Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|VA Connecticut Healthcare System,Phase 3,156,Other|NIH|U.S. Fed,Oct-16,"April 22, 2021","April 22, 2021"
7610,NCT02900157,Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,Advanced Solid Tumors,Biological: MEDI9090|Biological: Durvalumab,MedImmune LLC,Phase 1,42,Industry,"August 9, 2016","January 23, 2020","January 23, 2020"
7611,NCT02899962,LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris,Psoriasis Vulgaris,Drug: LEO 90100 aerosol foam|Drug: LEO 90100 aerosol foam vehicle,LEO Pharma,Phase 3,722,Industry,"February 15, 2017","June 26, 2019","June 26, 2019"
7612,NCT02898207,"Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",Metastatic High Grade Fallopian Tube Serous Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Primary Peritoneal Serous Adenocarcinoma|Metastatic Triple-Negative Breast Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Breast Carcinoma|Recurrent High Grade Fallopian Tube Serous Adenocarcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Triple-Negative Breast Carcinoma|Refractory Fallopian Tube Serous Adenocarcinoma|Refractory Ovarian Serous Adenocarcinoma|Refractory Primary Peritoneal Serous Adenocarcinoma|Refractory Triple-Negative Breast Carcinoma|Unresectable High Grade Fallopian Tube Serous Adenocarcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Primary Peritoneal Serous Adenocarcinoma,Drug: Olaparib|Drug: Onalespib,National Cancer Institute (NCI),Phase 1,28,NIH,"May 19, 2017","July 29, 2020","January 14, 2022"
7613,NCT02898077,A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer,Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma,Drug: Ramucirumab|Drug: Paclitaxel|Drug: Placebo,Eli Lilly and Company,Phase 3,440,Industry,"March 2, 2017","June 30, 2020","April 12, 2021"
7614,NCT02897076,Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth,Neonatal Complications,Drug: betamethasone 24 mg|Drug: 12mg betamethasone +placebo,Assistance Publique - Hôpitaux de Paris,Phase 3,3250,Other,Jan-17,"January 5, 2020","January 5, 2020"
7615,NCT02896400,Optimizing Tobacco Dependence Treatment in the Emergency Department,Tobacco Use Disorder,Behavioral: Brief Negotiated Interview (BNI)|Drug: Nicotine replacement therapy (NRT)|Other: CT Smokers Quitline (QL)|Other: SmokefreeText (Text),Yale University|National Cancer Institute (NCI)|National Institutes of Health (NIH),Phase 3,1056,Other|NIH,"February 13, 2017","August 14, 2019","August 14, 2019"
7616,NCT02896231,First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001,Non-Small Cell Lung Cancer,Drug: PLB1001,Beijing Pearl Biotechnology Limited Liability Company,Phase 1,37,Industry,Apr-16,Oct-19,Oct-19
7617,NCT02894710,Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO),"Carcinologic Ear, Nose, and Throat (ENT) Surgery",Drug: Lidocaine 20mg/ml|Drug: Glucose 5% (placebo),Hospices Civils de Lyon,Phase 3,143,Other,Dec-16,Jun-19,Dec-19
7618,NCT02894008,A Study of a New Leishmania Vaccine Candidate ChAd63-KH,"Leishmaniasis, Cutaneous",Drug: ChAd63-KH,University of York|University of Khartoum,Phase 2,24,Other,Nov-16,"September 30, 2019","December 31, 2019"
7619,NCT02893228,Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?,Phrenic Nerve Palsy,Procedure: Saline|Drug: Levobupivacaine,"The Adelaide and Meath Hospital, incorporating The National Children's Hospital",Phase 4,36,Other,Oct-16,Sep-19,Nov-19
7620,NCT02893137,Enhancing Optune Therapy With Targeted Craniectomy,Glioblastoma,Device: Optune|Procedure: Craniectomy,Aarhus University Hospital|NovoCure Ltd.|University of Aarhus,Phase 1,15,Other|Industry,"October 1, 2016","May 31, 2019","May 31, 2019"
7621,NCT02892916,Ketamine and Postoperative Cognitive Dysfunction,Post Operative Cognitive Dysfunction,Drug: Ketamine|Drug: Placebo,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 3,307,Other,"March 20, 2017","August 31, 2019","August 31, 2019"
7622,NCT02892422,"Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia",Schizophrenia,Drug: Lu AF35700,H. Lundbeck A/S,Phase 3,528,Industry,Aug-16,"October 10, 2019","October 10, 2019"
7623,NCT02892318,A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia,Drug: Atezolizumab|Drug: Guadecitabine,Hoffmann-La Roche,Phase 1,40,Industry,"October 31, 2016","December 12, 2019","December 12, 2019"
7624,NCT02892149,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD),Anemia|Dialysis-Dependent Chronic Kidney Disease,Drug: Vadadustat|Drug: Darbepoetin alfa,Akebia Therapeutics,Phase 3,3554,Industry,Aug-16,"January 16, 2020","March 30, 2020"
7625,NCT02892019,Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma,Asthma,Drug: Indacaterol acetate 75 μg|Drug: Indacaterol acetate 150 μg,Novartis Pharmaceuticals|Novartis,Phase 2,79,Industry,"April 18, 2017","June 19, 2019","July 17, 2019"
7626,NCT02891915,Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children,Pneumonia,Drug: Amoxicillin|Drug: Amoxicillin-clavulanate|Drug: Cefdinir|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,385,NIH,"December 2, 2016","December 16, 2019","December 16, 2019"
7627,NCT02891850,Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy,Pulmonary Arterial Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Sildenafil|Drug: Tadalafil",Bayer,Phase 4,225,Industry,"January 11, 2017","January 29, 2020","March 3, 2020"
7628,NCT02891837,L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects,Acute Lung Injury,Drug: L-citrulline|Other: Placebo,"Asklepion Pharmaceuticals, LLC",Phase 3,189,Industry,Aug-16,Jun-19,Jul-19
7629,NCT02891408,Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function,Nonalcoholic Steatohepatitis (NASH),Drug: Firsocostat|Drug: Fenofibrate,Gilead Sciences,Phase 1,74,Industry,"September 23, 2016","May 5, 2019","May 13, 2019"
7630,NCT02891278,Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML,Acute Myeloid Leukemia,Drug: Sertraline|Drug: Cytosine arabinoside|Procedure: allogeneic stem cell transplantation,Columbia University|The Leukemia and Lymphoma Society,Phase 1,6,Other,"August 11, 2016","November 17, 2020","November 17, 2020"
7631,NCT02890745,The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Empagliflozin|Drug: Placebo,"Henrik Enghusen Poulsen|University Hospital, Gentofte, Copenhagen|University of Copenhagen|Rigshospitalet, Denmark",Phase 2,31,Other,Nov-16,"January 22, 2020","January 22, 2020"
7632,NCT02889900,Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer,Recurrent Platinum Resistant Ovarian Cancer,Drug: cediranib and olaparib,"AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme LLC",Phase 2,62,Industry,"January 17, 2017","August 27, 2019","March 16, 2021"
7633,NCT02889809,"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year",Asthma,Drug: Fluticasone furoate|Drug: Placebo|Drug: Montelukast|Drug: Short Acting Beta 2 Agonist,GlaxoSmithKline,Phase 4,477,Industry,"October 20, 2016","April 9, 2021","June 4, 2021"
7634,NCT02889510,Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes,Drug: liraglutide|Drug: placebo,"Lecube, Albert, M.D.|Dynamic Solutions|Novo Nordisk A/S",Phase 3,76,Other|Industry,"October 4, 2016","November 18, 2019","December 16, 2019"
7635,NCT02889393,Teduglutide for Enterocutaneous Fistula (ECF),Postoperative Fistula,Drug: Teduglutide|Other: Standard of Care,Daniel Dante Yeh|Takeda|University of Miami,Phase 2,6,Other|Industry,"January 31, 2019","July 15, 2020","July 15, 2021"
7636,NCT02888106,Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent,Chronic Viral Hepatitis B With Delta-agent,Drug: Myrcludex B|Drug: PEG IFN alfa-2a|Drug: Tenofovir,Hepatera Ltd.,Phase 2,90,Industry,Apr-16,"November 22, 2019","October 30, 2020"
7637,NCT02887469,Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients,Hyponatremia Symptomatic,Drug: 3% hypertonic saline,Seoul National University Hospital|National Research Foundation of Korea,Phase 4,178,Other,Aug-16,"September 30, 2019","September 30, 2019"
7638,NCT02885610,Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE),Systemic Lupus Erythematosus,Biological: Placebo plus standard therapy|Biological: RC18 80 mg plus standard therapy|Biological: RC18 160 mg plus standard therapy|Biological: RC18 240 mg plus standard therapy,"RemeGen Co., Ltd.",Phase 2,249,Industry,Dec-15,"June 11, 2019","July 9, 2019"
7639,NCT02884440,Transverse Abdominis Plane Block for Anterior Approach Spine Surgery,Spine Surgery|Low Back Pain|Spondylolisthesis,Drug: TAP block ropivacaine|Drug: TAP block placebo|Drug: General anesthesia,Rennes University Hospital,Phase 2,43,Other,"November 7, 2016","May 25, 2019","May 25, 2019"
7640,NCT02884297,"HexafluOride, a Contrast Agent for Placenta Echo-angiography",Pregnancy,Drug: Contrast agent: SonoVue®.,Centre Hospitalier Régional Metz-Thionville,Phase 3,55,Other,"October 12, 2016","September 30, 2019","September 30, 2019"
7641,NCT02882308,Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.,Squamous Cell Carcinoma of the Head and Neck,Drug: Olaparib|Drug: Cisplatin|Drug: Durvalumab,Hellenic Cooperative Oncology Group|AstraZeneca,Phase 2,41,Other|Industry,"October 20, 2016",Dec-19,"January 10, 2020"
7642,NCT02881190,Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors,Solid Tumors,Drug: RC48-ADC,"RemeGen Co., Ltd.",Phase 1,57,Industry,"December 14, 2015","June 27, 2019","November 8, 2019"
7643,NCT02881138,A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors,Solid Tumors,Drug: RC48-ADC,"RemeGen Co., Ltd.",Phase 1,24,Industry,"March 1, 2016","April 30, 2020","July 15, 2020"
7644,NCT02880956,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease,Alzheimer's Disease,Drug: ABBV-8E12|Drug: placebo for ABBV-8E12,AbbVie,Phase 2,453,Industry,"January 26, 2017","March 30, 2021","July 28, 2021"
7645,NCT02880462,A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia,Schizophrenia,Dietary Supplement: sulforaphane|Other: placebo,Central South University|Stanley Medical Research Institute,Phase 2,172,Other,"December 26, 2016","May 20, 2019","May 20, 2019"
7646,NCT02879305,Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D),"Anaemia|Aspergillosis, Allergic Bronchopulmonary",Drug: Daprodustat|Drug: rhEPO|Drug: Placebo|Drug: Iron therapy,GlaxoSmithKline,Phase 3,2964,Industry,"September 28, 2016","November 9, 2020","November 9, 2020"
7647,NCT02878603,Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES),Acquired Thrombotic Thrombocytopenic Purpura,Biological: Caplacizumab|Other: Standard of Care,Sanofi,Phase 3,104,Industry,"October 6, 2016","October 23, 2020","October 23, 2020"
7648,NCT02878057,Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006),Breast Cancer,Drug: Apatinib,Peking University Cancer Hospital & Institute|Hebei Medical University Fourth Hospital|Peking University First Hospital|Peking University Third Hospital|Shanxi Province Cancer Hospital,Phase 2,30,Other,May-16,"September 2, 2020","September 2, 2020"
7649,NCT02877550,Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients,Follicular Lymphoma,Drug: Obinutuzumab|Drug: Venetoclax,Swiss Group for Clinical Cancer Research,Phase 1,25,Other,"February 15, 2017","April 28, 2020","May 4, 2022"
7650,NCT02877485,The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation,Nasal Obstruction,Drug: Triamcinolone Acetonide|Drug: Ayr saline nasal mist,Stanford University,Phase 4,42,Other,Aug-16,"August 15, 2019","August 15, 2019"
7651,NCT02877381,Tranexamic Acid in Revision Total Joint Arthroplasty,Revision Total Knee Arthroplasty|Revision Total Hip Arthroplasty|Acute Blood Loss Anemia,Procedure: Revision Total Knee Arthroplasty (TKA)|Procedure: Revision Total Hip Arthroplasty (THA),Rush University Medical Center|Mayo Clinic,Phase 4,175,Other,Apr-16,"August 1, 2019","August 1, 2019"
7652,NCT02877134,Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease,Crohn Disease,Drug: JNJ-64304500|Drug: Placebo|Drug: Ustekinumab,"Janssen Research & Development, LLC",Phase 2,388,Industry,"August 25, 2016","December 10, 2020","January 24, 2022"
7653,NCT02876835,Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND),Anaemia,Drug: Daprodustat|Drug: Darbepoetin alfa|Drug: Placebo|Drug: Iron Therapy,GlaxoSmithKline,Phase 3,3872,Industry,"September 27, 2016","April 19, 2021","April 19, 2021"
7654,NCT02876679,Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT,Graft vs Host Disease,Drug: Cyclophosphamide|Drug: Anti-Thymocyte Globulin|Drug: Conditioning regimen,Assistance Publique - Hôpitaux de Paris,Phase 2,94,Other,"April 6, 2017","October 12, 2020","October 12, 2020"
7655,NCT02876224,Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,Colorectal Cancer,Drug: Atezolizumab|Drug: Bevacizumab|Drug: Cobimetinib,Hoffmann-La Roche,Phase 1,51,Industry,"September 30, 2016","June 25, 2019","June 25, 2019"
7656,NCT02875873,Balanced Solution Versus Saline in Intensive Care Study,Critical Illness|Acute Kidney Injury,Drug: Plasma-Lyte|Drug: Saline 0.9%|Other: Slow infusion speed|Other: Fast Infusion Speed,Hospital do Coracao,Phase 3,11075,Other,"May 27, 2017","March 2, 2020","February 28, 2021"
7657,NCT02875860,'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial,"Hernia|Hernia, Diaphragmatic|Hernia, DIaphragmatic, Congenital|Pathological Conditions, Anatomical|Congenital Abnormalities|Congenital Diaphragmatic Hernia|Fetal Anomaly|Fetal Surgery|Pulmonary Hypoplasia",Device: GoldBal2 detachable balloon|Device: Baltaccidbpe100 Delivery Catheter|Other: Standardized postnatal care,Michael A Belfort|Baylor College of Medicine|Universitaire Ziekenhuizen KU Leuven,Phase 2,5,Other,Jan-17,Oct-19,Oct-19
7658,NCT02874989,Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial,Idiopathic Pulmonary Fibrosis (IPF),Drug: Dasatinib + Quercetin|Drug: Placebo,Wake Forest University Health Sciences|Mayo Clinic|The University of Texas Health Science Center at San Antonio,Phase 1,26,Other,"December 16, 2016","June 3, 2019","June 3, 2019"
7659,NCT02874404,TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: PI3K-delta Inhibitor TGR-1202,"Matthew Lunning, DO|National Cancer Institute (NCI)|University of Nebraska",Phase 2,13,Other|NIH,Oct-16,"July 1, 2019","July 1, 2019"
7660,NCT02874313,CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea,Diabetic Retinopathy|Sleep Apnea,Device: Continuous positive airway pressure|Drug: Pharmacological treatment|Other: Conventional anti-diabetic diet recommendations,Hospital Universitario La Paz,Phase 4,82,Other,Aug-16,Mar-21,Mar-21
7661,NCT02874144,Anti-Inflammatory Agent in Sinusitis,Nasal Polyps,Drug: AZ compound|Other: Collection of Biological Specimens|Drug: Intranasal corticosteroid|Drug: Placebo,Northwestern University,Phase 2,43,Other,"June 20, 2016","January 7, 2020","August 10, 2020"
7662,NCT02873975,A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,Advanced Cancers,Drug: LY2606368,Dana-Farber Cancer Institute,Phase 2,27,Other,"October 12, 2016","September 30, 2020","July 1, 2021"
7663,NCT02873806,Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents,Open-angle Glaucoma,Procedure: Implantation of two iStent inject micro-bypass stents|Drug: Topical travoprost|Device: Two iStent inject micro-bypass stents|Drug: Tobramycin|Drug: Dexamethasone,Glaukos Corporation,Phase 4,53,Industry,Mar-13,"November 8, 2019","November 8, 2019"
7664,NCT02873598,A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer,Pancreatic Cancer,Drug: FOLFIRINOX or gemcitabine/abraxane|Radiation: SBRT,"University of Colorado, Denver",Phase 1,14,Other,"November 17, 2016","June 7, 2019","November 28, 2022"
7665,NCT02873338,Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: CX-01|Drug: Idarubicin|Drug: Cytarabine,Chimerix,Phase 2,75,Industry,Aug-16,Jun-19,Jun-19
7666,NCT02873208,"A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia",Schizophrenia,Drug: ALKS 3831,"Alkermes, Inc.",Phase 3,266,Industry,"August 7, 2016","October 17, 2019","October 17, 2019"
7667,NCT02873026,Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study,Eye Injury Trauma,Drug: Triamcinolone Acetonide,Moorfields Eye Hospital NHS Foundation Trust,Phase 3,300,Other,Oct-14,"March 31, 2020","January 31, 2021"
7668,NCT02872155,Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients With Renal Insufficiency (RI) Grade III Under Study Conducting Computed Tomography (CT),Renal Insufficiency,Other: Oral hydratation|Drug: Bicarbonate endovenous hydratation|Drug: Saline endovenous hydratation,David Garcia Cinca|Fundacion Clinic per a la Recerca Biomédica|Hospital Clinic of Barcelona,Phase 3,264,Other,"July 4, 2017","July 15, 2019","July 15, 2019"
7669,NCT02872142,Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis,Biological: Albutein 5%|Procedure: Plasma Exchange,"Grifols Therapeutics LLC|Grifols Biologicals, LLC",Phase 2,12,Industry,"August 29, 2016","August 15, 2019","August 15, 2019"
7670,NCT02871843,RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas,Glioblastoma|Oligodendroglioma|Anaplastic Oligodendroglioma,Drug: RRx-001 dose escalation with TMZ + RT|Radiation: Radiation|Drug: Fixed dose Temozolomide (75 mg/m2)|Drug: TMZ Maintenance,"EpicentRx, Inc.",Phase 1,19,Industry,"February 14, 2017","October 11, 2019","September 19, 2021"
7671,NCT02871687,Effect of Statin Use on Aldosterone Secretion,Healthy Subjects,Drug: Simvastatin|Drug: Pravastatin|Other: Placebo,Brigham and Women's Hospital,Phase 1,103,Other,Apr-16,Mar-21,Mar-21
7672,NCT02871648,The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production,Healthy Volunteers,Drug: Placebo|Drug: Fludrocortisone|Drug: Eplerenone,Brigham and Women's Hospital,Phase 1,23,Other,Jan-16,Oct-19,Dec-19
7673,NCT02871401,A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis,Drug: Valganciclovir|Drug: Placebo,"Vanderbilt University Medical Center|Genentech, Inc.",Phase 1,31,Other|Industry,"January 3, 2018","January 31, 2020","January 31, 2020"
7674,NCT02870634,Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: Cu(II)ATSM,Collaborative Medicinal Development Pty Limited,Phase 1,50,Industry,"November 16, 2016","October 30, 2019","January 30, 2020"
7675,NCT02870582,Donafenib for Previously Treated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: Donafenib|Drug: Placebo,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Phase 3,536,Industry,"December 28, 2016","April 30, 2020","April 30, 2020"
7676,NCT02870478,The Effects of Low Concentration Atropine on Pupil Size and Accommodation,Myopia,Drug: Atropine,"University of California, Berkeley",Phase 3,32,Other,Jul-16,"November 20, 2019","November 20, 2019"
7677,NCT02869971,Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Device: Embosphere® (Prostatic Arteries Embolization)|Drug: Drug therapy,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 3,90,Other,Aug-16,"December 3, 2020","March 25, 2022"
7678,NCT02869035,Treatment Outcome in Major Depressive Disorder,Major Depressive Disorder,Drug: Escitalopram|Drug: Duloxetine,"Rigshospitalet, Denmark|Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak|Psychiatric Centre Copenhagen|Central Visitation, Region Hovedstaden",Phase 1,100,Other,Aug-16,Jul-19,Jul-19
7679,NCT02869022,Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation,Heart Failure,Drug: Custodiol-N|Drug: Custodiol|Procedure: organ perfusion for heart transplantation,Dr. F. Köhler Chemie GmbH,Phase 3,105,Industry,Jul-16,"September 2, 2019","September 2, 2019"
7680,NCT02868281,Asthma Control Test Guided Treatment in Chinese Subjects,Asthma,Drug: ACT guided Routine Treatment|Drug: Routine Treatment,GlaxoSmithKline|MacroStat,Phase 4,530,Industry|Other,"August 26, 2016","August 9, 2019","August 9, 2019"
7681,NCT02868190,Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication,Open Angle Glaucoma,Device: Two trabecular micro-bypass stents (iStent inject),Glaukos Corporation,Phase 4,57,Industry,Mar-13,"November 8, 2019","November 8, 2019"
7682,NCT02867852,Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers,Salivary Glands Tumors,Drug: Abiraterone acetate,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,24,Other,Mar-15,Nov-19,May-20
7683,NCT02867566,A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients,"Diffuse, Large B-Cell, Lymphoma",Drug: IBI301 plus CHOP|Drug: Rituximab plus CHOP,Innovent Biologics (Suzhou) Co. Ltd.,Phase 3,420,Industry,"August 22, 2016","September 5, 2019","December 26, 2019"
7684,NCT02867358,A Clinical Trial of KT07 Capsule in the U.S.A,"Influenza, Human",Drug: KT07 Capsule|Other: Placebo,Yiling Pharmaceutical Inc.,Phase 2,391,Industry,Sep-16,"July 31, 2020","July 31, 2020"
7685,NCT02867267,The Efficacy and Safety of Ta1 for Sepsis,Sepsis,Drug: Thymosin alpha 1|Other: Placebo,Sun Yat-sen University|SciClone Pharmaceuticals,Phase 3,1106,Other|Industry,"September 6, 2016","January 22, 2021","March 23, 2021"
7686,NCT02867020,Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels,Prostate Cancer,Drug: Apalutamide|Drug: Abiraterone|Drug: ADT|Drug: Prednisone,Latin American Cooperative Oncology Group|Janssen Pharmaceuticals,Phase 2,128,Other|Industry,"October 11, 2017","October 9, 2019","June 30, 2021"
7687,NCT02867007,KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors,Solid Tumor|Cancer|Carcinoma,Drug: KHK2455|Drug: Mogamulizumab,"Kyowa Kirin, Inc.",Phase 1,36,Industry,Aug-16,"December 15, 2019","December 15, 2019"
7688,NCT02866721,Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis,Cystic Fibrosis,Biological: Mesenchymal Stem Cells,University Hospitals Cleveland Medical Center|Case Western Reserve University|Cystic Fibrosis Foundation,Phase 1,14,Other,Aug-16,Aug-20,Aug-20
7689,NCT02866643,Labor and Delivery Implant Insertion: A Randomized Controlled Trial,Postpartum Contraception|Family Planning,Drug: Etonogestrel-Immediate|Drug: Etonogestrel-Delayed,Stanford University,Phase 3,95,Other,"October 28, 2016","September 6, 2019","July 31, 2021"
7690,NCT02866175,Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention,Atrial Fibrillation,Drug: Edoxaban|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor|Drug: Vitamin K antagonist,"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company|Daiichi Sankyo, Inc.",Phase 3,1506,Industry,"February 24, 2017","June 6, 2019","June 6, 2019"
7691,NCT02866032,Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO),Distal Subungual Onychomycosis,Drug: MOB015B|Drug: Ciclopirox 80 mg/g,Moberg Pharma AB,Phase 3,452,Industry,Sep-16,"June 10, 2020","June 10, 2020"
7692,NCT02865850,Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD),Anemia|Dialysis-Dependent Chronic Kidney Disease,Drug: Vadadustat|Drug: Darbepoetin alfa,Akebia Therapeutics,Phase 3,369,Industry,Jul-16,"January 31, 2020","March 30, 2020"
7693,NCT02865811,"Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Pembrolizumab|Drug: Pegylated Liposomal Doxorubicin (PLD),Dana-Farber Cancer Institute|Merck Sharp & Dohme LLC,Phase 2,26,Other|Industry,"September 15, 2016",Aug-20,Mar-22
7694,NCT02865616,MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI),Clostridium Difficile Infection,Drug: MET-2|Drug: Vancomycin,NuBiyota,Phase 1,19,Other,"October 27, 2017","March 17, 2020","March 17, 2020"
7695,NCT02865460,Coenzyme Q10 Phase III Trial in Gulf War Illness,Gulf War Illness|Chronic Fatigue|Ubiquinol|Coenzyme Q10,Drug: Ubiquinol|Drug: Placebo,VA Office of Research and Development,Phase 3,100,U.S. Fed,"July 24, 2017","October 7, 2020","December 31, 2020"
7696,NCT02864927,Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea,Meningitis|Meningococcal Meningitis|Meningococcal Infections,"Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 4,1311,Industry,"July 21, 2016","June 12, 2019","June 12, 2019"
7697,NCT02864849,Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer,Rectal Cancer,Drug: Oxaliplatin|Drug: Capecitabine|Radiation: Intensity modulated radiotherapy|Procedure: Total mesorectal excision,Peking University Cancer Hospital & Institute,Phase 2,81,Other,Aug-16,Jun-19,Jun-19
7698,NCT02864394,Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033),"Carcinoma, Non-Small-Cell Lung",Biological: Pembrolizumab|Drug: Docetaxel,Merck Sharp & Dohme LLC,Phase 3,425,Industry,"September 7, 2016","September 9, 2019","October 14, 2022"
7699,NCT02863354,Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy,Proliferative Diabetic Retinopathy,Drug: Aflibercept,"Charles C Wykoff, PhD, MD|Regeneron Pharmaceuticals|Greater Houston Retina Research",Phase 2,43,Other|Industry,Aug-16,May-19,May-19
7700,NCT02863185,Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease,Chronic Kidney Disease,Drug: Pitavastatin|Drug: Atorvastatin,Dong-A University,Phase 4,45,Other,"May 1, 2016","December 31, 2020","December 31, 2020"
7701,NCT02863120,Liposomal Bupivacaine vs Adductor Canal Block in Total Knee Arthroplasty,Knee Osteoarthritis,Drug: liposomal bupivacaine|Drug: bupivacaine HCl|Drug: Ropivacaine|Drug: Saline,"Texas Orthopaedics, Sports and Rehabilitation Associates",Phase 4,63,Other,Jul-16,Dec-19,Dec-19
7702,NCT02862977,Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment,Musculoskeletal Pain,Drug: ketoprofen and cyclobenzaprine association with caffeine|Drug: Cyclobenzaprine with caffeine,EMS,Phase 3,414,Industry,"November 10, 2017","June 5, 2019","December 20, 2019"
7703,NCT02862912,Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal),Adverse Reaction to Spinal Anesthetic|Maternal Care for Cervical Incompetence,Drug: Chloroprocaine|Drug: Bupivacaine|Drug: Fentanyl|Drug: Saline,Columbia University,Phase 4,43,Other,"November 8, 2016","January 31, 2020","January 31, 2020"
7704,NCT02862457,Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434),"Neoplasms|Carcinoma, Non-Small-Cell Lung",Drug: Epacadostat 25 mg|Drug: Epacadostat 100 mg|Biological: pembrolizumab 200 mg|Drug: Cisplatin 75 mg/m^2|Drug: Carboplatin Area Under the Curve (AUC) 5|Drug: Pemetrexed 500 mg/m^2|Drug: Paclitaxel 200 mg/m^2|Drug: Carboplatin AUC 6,Merck Sharp & Dohme LLC,Phase 1,34,Industry,"August 23, 2016","November 20, 2020","November 20, 2020"
7705,NCT02862314,PROcalcitonin Pneumonia / Pneumonitis Associated With ASPIration,Inhalation Pneumonia,Biological: Blood sample,Centre Hospitalier Universitaire de Besancon,Phase 4,167,Other,"February 24, 2015","November 28, 2019","November 28, 2019"
7706,NCT02861859,Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study,Breast Cancer,Drug: Olanzapine|Drug: Olanzapine Placebo,Ottawa Hospital Research Institute,Phase 3,221,Other,Dec-16,"December 23, 2019","December 23, 2019"
7707,NCT02861534,A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001),Heart Failure|Chronic Heart Failure With Reduced Ejection Fraction,Drug: Vericiguat|Drug: Placebo for vericiguat,Merck Sharp & Dohme LLC|Bayer|Canadian VIGOUR Centre|Duke Clinical Research Institute,Phase 3,5050,Industry|Other,"September 20, 2016","June 18, 2019","September 2, 2019"
7708,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),"Multiple Sclerosis, Relapsing-Remitting",Biological: Ocrelizumab,Hoffmann-La Roche,Phase 3,681,Industry,"September 9, 2016","October 25, 2019","December 15, 2020"
7709,NCT02860936,Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14,Adenoid Cystic Carcinomas of the Salivary Glands,Drug: Lenvatinib,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,26,Other,Jun-15,Jun-19,Jun-19
7710,NCT02860819,"Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer",Testicular Cancer,Drug: Veliparib|Drug: Gemcitabine|Drug: Carboplatin,"National Cancer Institute, Slovakia",Phase 2,15,Other,"August 1, 2016","November 30, 2020","February 15, 2021"
7711,NCT02859857,Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors,Neoplasms,Drug: BXQ-350,"Bexion Pharmaceuticals, Inc.|CTI Clinical Trial and Consulting Services",Phase 1,86,Industry|Other,"September 1, 2016","June 17, 2019","June 15, 2020"
7712,NCT02859519,"A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)",Distal Subungual Onychomycosis,Drug: MOB015B|Drug: MOB015B Vehicle,Moberg Pharma AB,Phase 3,365,Industry,Oct-16,"November 13, 2019","November 13, 2019"
7713,NCT02859142,Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation,Smoking Cessation|Alcohol Drinking,Drug: Chantix|Behavioral: Behavioral Counseling Sessions|Drug: NicodermCQ|Drug: Placebo,University of Chicago|Pfizer,Phase 4,122,Other|Industry,"March 29, 2018","September 30, 2020","October 15, 2020"
7714,NCT02859103,Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment,Depression|Anhedonia,Drug: Desvenlafaxine,Unity Health Toronto,Phase 4,56,Other,"June 1, 2017","November 4, 2019","November 4, 2019"
7715,NCT02858895,Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma,Glioblastoma|Grade IV Astrocytoma|Glioblastoma Multiforme|Grade IV Glioma,Drug: MDNA55,"Medicenna Therapeutics, Inc.",Phase 2,47,Industry,"April 11, 2017","September 12, 2019","October 31, 2019"
7716,NCT02858011,The Effect of a Cash Transfer Program and Preventive Nutrition Packages on Household Welfare and Child Nutritional Status in Mali,Poverty|Child Malnutrition,"Other: Cash distribution during first 36 months|Behavioral: Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Dietary Supplement: Preventive Nutrition Packages during last 12 months|Other: Cash distribution during the last 12 months|Behavioral: Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months","International Food Policy Research Institute|Institut de Recherche pour le Developpement|Implementation management committee of the Jigisemejiri program (Ministry of Economics and Finance, Government of Mali)",Phase 4,4320,Other,Sep-14,"August 10, 2019","August 10, 2019"
7717,NCT02857426,A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL),Lymphoma,Drug: Nivolumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Phase 2,66,Industry,"October 21, 2016","June 11, 2019","November 24, 2020"
7718,NCT02857270,A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,Advanced Cancer|Metastatic Melanoma|Metastatic Non-small Cell Lung Cancer|Colorectal Cancer,Drug: LY3214996|Drug: Midazolam|Drug: Abemaciclib|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Encorafenib|Drug: Cetuximab,Eli Lilly and Company,Phase 1,210,Industry,"September 29, 2016","February 10, 2021","October 24, 2022"
7719,NCT02855944,"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Chemotherapy|Drug: Rucaparib,"Clovis Oncology, Inc.|Foundation Medicine",Phase 3,349,Industry,"March 1, 2017","December 3, 2020","September 16, 2022"
7720,NCT02854163,Effect of Secukinumab in the Treatment of Psoriatic Arthritis,Psoriatic Arthritis,Drug: Secukinumab,University of Liverpool|Novartis,Phase 2,30,Other|Industry,"October 15, 2016","September 18, 2019","September 18, 2019"
7721,NCT02853370,Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma,Marginal Zone B-cell Lymphoma,Drug: Bendamustine and Rituximab,International Extranodal Lymphoma Study Group (IELSG),Phase 2,78,Other,Jul-12,Dec-20,Dec-20
7722,NCT02853344,Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),Renal Cell Carcinoma,Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 2,275,Industry,"September 30, 2016","February 5, 2021","April 1, 2022"
7723,NCT02853318,"Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma,Biological: Bevacizumab|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,Roswell Park Cancer Institute,Phase 2,40,Other,"September 1, 2016","June 27, 2019","June 30, 2021"
7724,NCT02853305,Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),"Urothelial Carcinoma Associated 1 RNA, Human",Biological: Pembrolizumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine,Merck Sharp & Dohme LLC,Phase 3,1010,Industry,"September 15, 2016","April 29, 2020","September 15, 2022"
7725,NCT02853045,Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients,Hypertension,Drug: period with drug (trade name) then period with generic|Drug: period with generic then period with drug (trade name),Centre Hospitalier Universitaire de Saint Etienne,Phase 4,50,Other,"June 11, 2015","March 10, 2021","March 10, 2021"
7726,NCT02852837,Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy,Multiple Myeloma,Drug: Daratumumab,"Janssen Research & Development, LLC",Phase 1,50,Industry,"September 26, 2016","December 13, 2019","December 13, 2019"
7727,NCT02852239,Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment,Renal Impairment,Drug: dabrafenib,Novartis Pharmaceuticals|Novartis,Phase 1,22,Industry,"December 19, 2016","September 27, 2019","September 27, 2019"
7728,NCT02851745,Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry,"Diabetes Mellitus, Type 2|Left Ventricular Systolic Dysfunction",Drug: Linagliptin|Drug: Placebo,Heart Care Foundation|Fondazione dell'Associazione Medici Diabetologi,Phase 3,188,Other,Jul-15,"July 2, 2019","July 2, 2019"
7729,NCT02851407,Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients,Veno-occlusive Disease,Drug: Defibrotide|Other: Best Supportive Care,Jazz Pharmaceuticals,Phase 3,372,Industry,"September 1, 2016","October 20, 2020","October 20, 2020"
7730,NCT02851173,Cognitive Enhancement Through Transcranial Laser Therapy,Healthy Participants|Mild Cognitive Impairment,Device: LLLT|Device: Placebo,University of Texas at Austin,Phase 2,99,Other,"February 21, 2016","April 30, 2020","April 30, 2020"
7731,NCT02850601,Dexamethasone Solution for the Treatment of Oral Lichen Planus,Lichen Planus,Drug: Dexamethasone,Brigham and Women's Hospital,Phase 2,24,Other,"February 7, 2017","December 19, 2019","December 20, 2019"
7732,NCT02850016,Romidepsin Plus 3BNC117 Phase 2a Study,Human Immunodeficiency Virus (HIV),Drug: 3BNC117|Drug: Romidepsin,Rockefeller University|University Hospital of Cologne|Aarhus University Hospital,Phase 2,48,Other,"January 6, 2017","December 31, 2020","December 31, 2020"
7733,NCT02849743,Intranasal Oxytocin in Hypothalamic Obesity,Craniopharyngioma|Hypothalamic Obesity,Drug: Syntocinon|Drug: Placebo (for Syntocinon),"Shana McCormack, MD|Children's Hospital of Philadelphia",Phase 2,18,Other,Oct-16,Apr-21,May-22
7734,NCT02848651,A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Drug: Atezolizumab,"Genentech, Inc.",Phase 2,153,Industry,"September 23, 2016","May 14, 2019","May 14, 2019"
7735,NCT02848482,Anti-infective Effect of Non-surgical Treatment With and Without Photodynamic Therapy on Initial Peri-implantitis,Peri-implantitis,Device: Photodynamic therapy|Procedure: Mechanical debridement|Drug: Irrigation,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University,Phase 3,40,Other,"May 1, 2017","May 1, 2019","May 1, 2019"
7736,NCT02848443,Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Nivolumab,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 1,78,Other|Industry,May-16,"August 1, 2019","April 9, 2020"
7737,NCT02848027,Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment,"Osteoarthritis, Knee",Biological: Regenexx SD® procedure,"Regenexx, LLC",Phase 3,400,Industry,"September 8, 2015","June 30, 2020","August 19, 2021"
7738,NCT02847598,Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus|Active Cutaneous Lupus Erythematosus,Drug: BIIB059 (litifilimab)|Drug: Placebo,Biogen,Phase 2,264,Industry,"October 20, 2016","August 28, 2019","November 18, 2019"
7739,NCT02847247,Systemic Inflammatory Response to CCRE,Healthy,Drug: CCRE,"University of North Carolina, Chapel Hill|Environmental Protection Agency (EPA)",Phase 1,25,Other|U.S. Fed,"December 11, 2017","August 6, 2019","August 6, 2019"
7740,NCT02846831,Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes,Type 1 Diabetes,Other: 12-day intervention with sensor-augmented pump therapy|Other: 12-day intervention with single-hormone closed-loop strategy|Device: Insulin pump|Device: Continuous glucose monitoring system|Drug: Insulin,Institut de Recherches Cliniques de Montreal,Phase 2,36,Other,"January 24, 2019","January 27, 2020","January 27, 2020"
7741,NCT02846545,A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes,"Diabetes Mellitus, Type 1",Biological: Golimumab|Biological: Placebo,"Janssen Research & Development, LLC",Phase 2,84,Industry,"August 26, 2016","May 21, 2019","January 5, 2021"
7742,NCT02846532,"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure",Thrombosis,Drug: Rivaroxaban|Drug: Acetylsalicylic Acid,"Janssen Research & Development, LLC|Bayer",Phase 3,112,Industry,"November 16, 2016","July 16, 2020","July 16, 2020"
7743,NCT02845479,The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I,Lung Neoplasms|Esophageal Neoplasms|Stomach Neoplasms,Other: Integrative Care,The Canadian College of Naturopathic Medicine|Ottawa Hospital Research Institute|Lotte & John Hecht Memorial Foundation,Phase 3,22,Other,"December 7, 2018","December 1, 2020","December 7, 2020"
7744,NCT02845453,Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation,Substance Use Disorders|Bipolar Disorder|Mood Disorders,Drug: Quetiapine|Other: Placebo,Boston Medical Center|National Institute on Drug Abuse (NIDA),Phase 4,24,Other|NIH,"January 20, 2017","April 7, 2021","April 7, 2021"
7745,NCT02844439,Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma,Glioblastoma|Recurrent Glioblastoma|Brain Tumor,Drug: Tesevatinib,"Kadmon Corporation, LLC",Phase 2,40,Industry,Jun-16,"April 30, 2020","April 30, 2020"
7746,NCT02843386,Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma,Uveal Melanoma,Drug: Adjuvant chemotherapy by Fotemustin|Other: Intensive surveillance,Institut Curie|Servier|UNICANCER,Phase 3,302,Other|Industry,"June 23, 2009","June 12, 2020","June 12, 2020"
7747,NCT02841280,Chlorthalidone in Chronic Kidney Disease,"Renal Insufficiency, Chronic|Hypertension",Drug: Chlorthalidone|Drug: Placebo,Indiana University,Phase 2,160,Other,Jul-16,Apr-21,Apr-21
7748,NCT02840994,A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer (NSCLC),Biological: CV301|Biological: Pembrolizumab|Biological: Nivolumab,Bavarian Nordic,Phase 1,24,Industry,Dec-16,Jan-20,Jan-20
7749,NCT02840539,"Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma",Mantle Cell Lymphoma,"Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim",Seoul National University Hospital|Consortium for Improving Survival of Lymphoma,Phase 2,19,Other,"October 11, 2016","March 31, 2021","December 31, 2022"
7750,NCT02840474,"Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults",HIV-1,Biological: VRC-HIVMAB080-00-AB|Biological: VRC-HIVMAB075-00-AB,National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group|National Institutes of Health Clinical Center (CC),Phase 1,16,NIH|Other,"April 24, 2017","January 15, 2020","January 15, 2020"
7751,NCT02840175,Treatment Tapering in JIA With Inactive Disease,Juvenile Idiopathic Arthritis,Drug: etanercept|Drug: adalimumab|Drug: Abatacept|Drug: Tocilizumab,Assistance Publique - Hôpitaux de Paris,Phase 3,62,Other,"May 18, 2017","October 29, 2019","October 1, 2020"
7752,NCT02840097,Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study,Brain Injuries|Wounds and Injuries|Hemorrhage,Drug: Tranexamic Acid|Drug: Placebo,"Daniel Nishijima, MD, MAS|Pediatric Emergency Care Applied Research Network|University of California, Davis",Phase 2,31,Other,"March 4, 2019","October 3, 2020","October 3, 2020"
7753,NCT02839668,The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC),Breast Cancer,Drug: Lidocaine|Drug: Sevoflurane|Drug: TIVA-TCI|Drug: Acetaminophen|Drug: Tramadol|Drug: Neostigmine|Drug: Atropine|Device: BIS,Iuliu Hatieganu University of Medicine and Pharmacy|Prof. Dr. I. Chiricuta Institute of Oncology,Phase 2,120,Other,Aug-16,Sep-19,Sep-19
7754,NCT02838797,RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease,Parkinson's Disease|Gastroparesis|Constipation,Drug: RQ-00000010|Drug: Placebo,Virginia Commonwealth University|Michael J. Fox Foundation for Parkinson's Research|RaQualia Pharma Inc.,Phase 1,51,Other|Industry,Jun-16,"August 20, 2019","August 20, 2019"
7755,NCT02838342,Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors,Neuroendocrine Tumors,Drug: Metronomic cyclophosphamide|Drug: Interferon-alpha,Centre Hospitalier Universitaire de Besancon,Phase 2,28,Other,"May 19, 2015",Apr-20,"June 29, 2021"
7756,NCT02837094,Enhanced Epidermal Antigen Specific Immunotherapy Trial -1,Type 1 Diabetes,Drug: C19-A3 GNP,Cardiff University,Phase 1,6,Other,"September 29, 2016","December 31, 2019","December 31, 2019"
7757,NCT02837029,Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres,Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI),Phase 1,27,Other|Industry|NIH,Jul-16,"July 17, 2019","November 1, 2020"
7758,NCT02836925,Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection,Indolent B-cell Lymphoma|Hepatitis C,Drug: Ledipasvir+Sofosbuvir|Drug: Sofosbuvir+Velpatasvir,Fondazione Italiana Linfomi - ETS,Phase 2,40,Other,Mar-16,Feb-20,Nov-22
7759,NCT02836496,Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES),Hypereosinophilic Syndrome,Drug: Mepolizumab 300 mg|Drug: Placebo matching mepolizumab|Drug: Active OCS capsules (5 mg prednisolone or prednisone)|Drug: Placebo matching OCS capsules,GlaxoSmithKline,Phase 3,108,Industry,"March 7, 2017","August 8, 2019","August 8, 2019"
7760,NCT02836483,"A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK",Pulmonary Tuberculosis,"Drug: LCB01-0371 800mg, QD|Drug: LCB01-0371 400mg, BID|Drug: LCB01-0371 800mg, BID|Drug: Tubes 3~5Tablet, QD|Drug: Zyvox 600mg, BID|Drug: LCB01-0371 1200mg, QD","LegoChem Biosciences, Inc",Phase 2,79,Industry,"December 10, 2016","July 1, 2019","July 1, 2019"
7761,NCT02835729,A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: Idarubicin|Drug: Cytarabine|Drug: Indoximod Freebase|Drug: Indoximod HCL F1|Drug: Indoximod HCL F2,NewLink Genetics Corporation|Lumos Pharma,Phase 1,54,Industry,Jul-16,"October 25, 2019","December 27, 2019"
7762,NCT02835534,The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI,Acute ST Elevation Myocardial Infarction,Drug: rhTNK-tPA|Drug: alteplase,"Guangzhou Recomgen Biotech Co., Ltd.|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking University",Phase 4,818,Industry|Other,May-16,Oct-19,Jan-20
7763,NCT02835339,Magnesium Sulfate in Obese Preeclamptics,Preeclampsia,"Drug: Magnesium sulfate 4g loading dose, 1g/hr infusion|Drug: Magnesium sulfate 6g loading dose, 2g/hr infusion",Oregon Health and Science University,Phase 4,66,Other,"July 12, 2016","June 30, 2019","June 30, 2019"
7764,NCT02835079,Treatment Effect of Tamoxifen on Patients With DMD,Duchenne Muscular Dystrophy,Drug: Tamoxifen,Hadassah Medical Organization,Phase 1,19,Other,Nov-16,Nov-20,Nov-20
7765,NCT02834559,Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.,Rhegmatogenous Retinal Detachment|High-risk for Proliferative Vitreoretinopathy (PVR),Drug: 5-fluorouracil and low molecular weight heparin|Drug: Placebo,"Universitätsklinikum Köln|German Research Foundation|The Clinical Trials Centre Cologne|Pharmacy of the University Hospital Erlangen|Institute of Medical Statistics, Informatics and Epidemiology (IMSIE)",Phase 3,326,Other,"October 27, 2016","June 15, 2020","June 15, 2020"
7766,NCT02834416,ADT Exercise Trial and Economic Analysis,Prostate Cancer,Behavioral: Supervised Group Exercise|Behavioral: Home Based Exercise,"University Health Network, Toronto|Tom Baker Cancer Centre|Southlake Regional Health Centre|Scarborough Rouge Hospital",Phase 3,38,Other,Aug-16,"March 31, 2020","March 31, 2020"
7767,NCT02833844,"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia","Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection",Drug: Evolocumab|Drug: Placebo,Amgen,Phase 3,467,Industry,"May 22, 2017","July 9, 2019","January 27, 2020"
7768,NCT02832648,Selenium for Musculoskeletal Health,Osteoporosis,Dietary Supplement: selenase (selenium),"Sheffield Teaching Hospitals NHS Foundation Trust|National Institute for Health Research, United Kingdom|University of Sheffield",Phase 3,123,Other,Jan-17,"January 31, 2020","January 31, 2020"
7769,NCT02832167,An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread,Cancer,Biological: Nivolumab,Bristol-Myers Squibb,Phase 2,239,Industry,"February 22, 2016","October 20, 2019","June 24, 2021"
7770,NCT02832115,Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention,Radial Artery Spasm|Angina|Coronary Artery Disease,Drug: Topical Nitroglycerine|Drug: Topical Lidocaine,Aultman Health Foundation,Phase 4,100,Other,Sep-16,"May 2, 2019","May 2, 2019"
7771,NCT02832037,Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia,Schizophrenia,Drug: BI 425809 dose 1|Drug: BI 425809 dose 2|Drug: BI 425809 dose 3|Drug: BI 425809 dose 4|Drug: Placebo,Boehringer Ingelheim,Phase 2,509,Industry,"July 25, 2016","December 27, 2019","January 29, 2020"
7772,NCT02831686,"A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",Multiple Myeloma|Relapsed and/or Refractory Multiple Myeloma,Drug: Selinexor|Drug: Ixazomib|Drug: Dexamethasone,"Memorial Sloan Kettering Cancer Center|Karyopharm Therapeutics Inc|Millennium Pharmaceuticals, Inc.",Phase 1,18,Other|Industry,Jul-16,"November 19, 2020","November 19, 2020"
7773,NCT02831608,Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis,"Myocardial Infarction|Influenza, Human|Influenza Vaccines|Heart Failure|Stroke",Biological: Influenza vaccine|Biological: Placebo,"Ole Frobert, MD, PhD|Swedish Heart Lung Foundation|Sanofi Pasteur, a Sanofi Company|Uppsala University|Lytics|Region Örebro County",Phase 4,2571,Other|Industry,Oct-16,Apr-21,Aug-21
7774,NCT02831257,AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,Neurofibromatosis 2|Meningioma,Drug: AZD2014,Massachusetts General Hospital|AstraZeneca|United States Department of Defense,Phase 2,18,Other|Industry|U.S. Fed,"August 31, 2016","May 31, 2019","October 1, 2020"
7775,NCT02831166,Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention,"Myocardial Infarction|Complications; Device, Vascular|Injury of Radial Artery|Injury; Blood Vessel, Femoral, Artery",Procedure: Transradial primary percutaneous coronary intervention|Procedure: Transfemoral primary percutaneous coronary intervention,Irmandade Santa Casa Misericórdia Marília,Phase 4,250,Other,Jan-16,Oct-19,Nov-19
7776,NCT02830919,Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL),Osteoarthritis of Knee,Drug: Glucosamine and chondroitin sulfate combination (Eurofarma)|Drug: Glucosamine and chondroitin sulfate combination (Zodic),Eurofarma Laboratorios S.A.,Phase 3,627,Industry,"December 5, 2016","May 10, 2019","May 10, 2019"
7777,NCT02830139,Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer,Malignant Neoplasm of Colorectum,"Procedure: Hyperthermic intraperitoneal chemotherapy (HIPEC)|Procedure: Radical colorectal resection|Drug: Oxaliplatin , Capecitabine|Drug: Normal saline , Cisplatin , 5-Fu",Wuhan University,Phase 2,100,Other,Jul-16,"March 15, 2020","March 15, 2020"
7778,NCT02828384,Comparing the Effectiveness of Two Dietary Interventions for Fecal Incontinence,Fecal Incontinence,Other: low fodmap diet|Dietary Supplement: Psyllium,University of Michigan|The Rome Foundation,Phase 2,40,Other,"October 2, 2014",Jun-19,Jun-19
7779,NCT02827968,Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,Solid Tumors,Drug: KN035,"3D Medicines (Sichuan) Co., Ltd.|3D Medicines",Phase 1,28,Industry,"January 13, 2017",Aug-20,Dec-20
7780,NCT02827526,Methadone and Ketamine for Spinal Surgery,Pain,Drug: Ketamine|Drug: Control,NorthShore University HealthSystem,Phase 4,130,Other,Jul-16,Feb-21,Feb-21
7781,NCT02826772,"Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer",Metastatic Castrate Resistant Prostate Cancer (mCRPC),Drug: GT0918,"Suzhou Kintor Pharmaceutical Inc,",Phase 1,40,Industry,"February 10, 2016","May 15, 2019","February 15, 2020"
7782,NCT02826525,AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.,T2DM With NAFLD,Drug: AZD4076|Drug: Placebo,AstraZeneca,Phase 1,14,Industry,"July 18, 2016","October 11, 2019","October 11, 2019"
7783,NCT02825940,"A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors",Neoplasms,Drug: Atezolizumab|Drug: Gemcitabine|Drug: Cisplatin,Hoffmann-La Roche,Phase 1,120,Industry,"August 4, 2016","January 14, 2020","November 4, 2022"
7784,NCT02824718,Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,Drug: Teriparatide|Drug: Thiazide|Drug: Potassium sparing diuretic|Drug: Alfacalcidol,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 2,16,Other,"June 6, 2017","May 28, 2020","May 28, 2020"
7785,NCT02823990,TG4010 and Nivolumab in Patients With Lung Cancer,Recurrent Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Biological: TG4010|Biological: Nivolumab,"Karen Kelly|National Cancer Institute (NCI)|Transgene|Bristol-Myers Squibb|University of California, Davis",Phase 2,13,Other|NIH|Industry,"December 14, 2016","February 24, 2021","February 24, 2021"
7786,NCT02822625,Efficacity of a Standardized Hypnotic Message During the Application of a Qutenza (Capsaicin) 8% Patch,Pain,Drug: QUTENZA®|Other: hypnotic message|Other: music therapy,Institut de Cancérologie de Lorraine,Phase 3,69,Other,"August 30, 2016","July 10, 2019","July 13, 2019"
7787,NCT02822599,Human Fibrinogen Concentrate in Pediatric Cardiac Surgery,Hypofibrinogenemia|Afibrinogenemia|Bleeding Disorders,Drug: RiaStAP|Drug: Saline,Nicklaus Children's Hospital f/k/a Miami Children's Hospital,Phase 4,30,Other,"June 1, 2017","August 26, 2019","December 24, 2020"
7788,NCT02822144,General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke,Stroke,Drug: Etomidate|Drug: Succinylcholine|Drug: Propofol|Drug: Remifentanil|Drug: Lidocaine,Rennes University Hospital,Phase 3,351,Other,"September 29, 2016",Aug-20,Aug-20
7789,NCT02821754,A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),Biliary Tract Neoplasms|Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma|Bile Duct Cancer,Drug: Durvalumab|Drug: Tremelimumab|Procedure: Trans-arterial Catheter Chemoembolization (TACE)|Procedure: Radiofrequency Ablation (RFA)|Procedure: Cryoablation,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,54,NIH,"July 5, 2016","February 17, 2021","December 31, 2022"
7790,NCT02821520,Initial Versus Delayed PDT Combination With Conbercept in PCV,Polypoidal Choroidal Vasculopathy,Drug: conbercept|Procedure: Initial PDT|Procedure: Delayed PDT,The Eye Hospital of Wenzhou Medical University,Phase 4,80,Other,Jan-17,Jun-19,Jun-19
7791,NCT02821494,Hespecta Vaccination in HPV+ Tumors or Malignant Lesions,Tumors or Premalignant Lesions,Biological: Hespecta,Leiden University|ISA Pharmaceuticals|Dutch Cancer Society|Top Institute Pharma|Leiden University Medical Center,Phase 1,25,Other|Industry,Mar-15,Mar-20,Mar-20
7792,NCT02821416,"Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics",Asthma,Biological: Benralizumab|Other: Placebo,AstraZeneca,Phase 3,46,Industry,"October 11, 2016","October 22, 2019","October 22, 2019"
7793,NCT02821169,Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain,Pain,Drug: ropivacaine|Drug: saline solution 0.9%,"University Hospital, Lille",Phase 3,184,Other,Apr-15,Jun-19,Jun-19
7794,NCT02820610,Intraperitoneal Analgesia in Pediatric Laparoscopy,Analgesia,Drug: Dexmedetomidine|Drug: Magnesium Sulfate|Drug: Normal saline 0.9 %,Assiut University,Phase 2,97,Other,Aug-16,Sep-19,Sep-19
7795,NCT02820350,A Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI).,Acute Kidney Injury,Device: SCD-F40,"CytoPherx, Inc|Innovative BioTherapies (IBT)|Children's Hospital Medical Center, Cincinnati",Phase 2,30,Industry|Other,"December 4, 2016","March 31, 2020","March 31, 2020"
7796,NCT02819479,Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI),Radiation Necrosis,Drug: 25% Mannitol|Drug: Low-dose Intra-arterial Bevacizumab,Norton Healthcare|University of Kentucky,Phase 2,10,Other,"November 23, 2016","June 6, 2019","June 6, 2019"
7797,NCT02819440,PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction,Healthy|Obese,Drug: Tadalafil|Drug: Placebo,Vanderbilt University Medical Center,Phase 2,141,Other,Jul-16,Jun-20,Jun-20
7798,NCT02818738,Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children,First Manifestation of Steroid Sensitive Nephrotic Syndrome,Drug: Levamisole Hydrochloride|Other: Placebo,Assistance Publique - Hôpitaux de Paris,Phase 3,86,Other,"September 6, 2017","February 7, 2021","February 11, 2021"
7799,NCT02818582,"GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen",Ebola,Drug: GS-5734|Other: Placebo Comparator,National Institute of Allergy and Infectious Diseases (NIAID)|Gilead Sciences|National Institutes of Health Clinical Center (CC),Phase 2,38,NIH|Industry,"July 1, 2016","August 31, 2020","August 31, 2020"
7800,NCT02816762,CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea,Diabetic Nephropathy|Sleep Apnea,Device: Continuous positive airway pressure|Drug: Pharmacological treatment|Other: Diet,Hospital Universitario La Paz,Phase 4,180,Other,Jun-16,Dec-20,Dec-20
7801,NCT02816736,EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study),Heart Failure,Drug: LCZ696|Drug: valsartan|Drug: LCZ696 placebo|Drug: valsartan placebo,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,365,Other|NIH,"March 2, 2017","September 15, 2020","September 29, 2020"
7802,NCT02816476,Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis,Amyloidosis,Drug: Daratumumab,"University Hospital, Limoges",Phase 2,40,Other,Sep-16,"October 5, 2019",Oct-20
7803,NCT02816112,Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia,Early Stage Breast Cancer,Drug: Ciprofloxacin|Drug: Neupogen,Ottawa Hospital Research Institute,Phase 4,458,Other,Sep-16,Mar-20,Apr-20
7804,NCT02815670,Reversal Dabigatran Anticoagulant Effect With Idarucizumab,Hemorrhage,Drug: Idarucizumab,Boehringer Ingelheim,Phase 3,1,Industry,"September 7, 2016","October 19, 2019","October 19, 2019"
7805,NCT02815566,Bone Health in Aging HIV Infected Women,Osteoporosis|HIV|Menopause,Drug: tenofovir-alafenamide-emtricitabine|Drug: tenofovir-emtricitabine,"University Health Network, Toronto|University of Modena and Reggio Emilia|San Raffaele University Hospital, Italy|Gilead Sciences|CIHR Canadian HIV Trials Network",Phase 4,34,Other|Industry,"September 12, 2017","February 25, 2021","February 25, 2021"
7806,NCT02815033,Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide,Prostate Cancer Metastatic,Drug: Enzalutamide|Procedure: 11C or 18F-Choline PET/CT|Procedure: Whole body MRI|Procedure: Bone scan,"The European Uro-Oncology Group|Centre for Human Drug Research, Netherlands",Phase 2,66,Other,Jul-15,Jun-20,Dec-20
7807,NCT02814968,PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide,Prostate Cancer Metastatic,Drug: Enzalutamide|Device: 18-FDG PET/CT|Device: Whole body MRI|Device: Bone scan,"The European Uro-Oncology Group|Centre for Human Drug Research, Netherlands",Phase 2,66,Other,Feb-15,Jun-20,Dec-20
7808,NCT02814838,"A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes","Diabetes Mellitus, Insulin-Dependent",Drug: Ladarixin|Drug: Placebo,Dompé Farmaceutici S.p.A,Phase 2,76,Industry,Aug-16,"May 15, 2019","May 15, 2019"
7809,NCT02814708,Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults,Toxic Shock Syndrome,Biological: rTSST-1v,Biomedizinische Forschungs gmbH|Medical University of Vienna,Phase 2,140,Industry|Other,May-16,May-20,Jan-21
7810,NCT02814669,Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,Castrate-Resistant Prostate Cancer,Drug: Atezolizumab|Drug: Radium-223 Dichloride,Hoffmann-La Roche,Phase 1,45,Industry,"September 23, 2016","July 31, 2019","July 31, 2019"
7811,NCT02814175,A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL),Psoriatic Arthritis,Drug: methotrexate (MTX)|Biological: adalimumab (ADA),AbbVie,Phase 4,246,Industry,"August 5, 2016","September 23, 2019","March 19, 2020"
7812,NCT02813967,S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer,Esophageal Cancer|Chemoradiation,Radiation: Radiotherapy 54 Gy|Radiation: Radiotherapy 60 Gy|Drug: S-1,Zhejiang Cancer Hospital,Phase 3,298,Other,Jun-16,Aug-20,Aug-20
7813,NCT02813785,A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy,"Carcinoma, Non-Small-Cell Lung","Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Docetaxel",Hoffmann-La Roche,Phase 3,565,Industry,"July 1, 2016","August 1, 2019","December 27, 2022"
7814,NCT02812992,Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients,Adenocarcinoma Pancreas,Drug: Nab-paclitaxel|Drug: Gemcitabine|Other: Best Supportive Care,AIO-Studien-gGmbH,Phase 4,32,Other,Jun-16,Feb-20,Feb-21
7815,NCT02812940,Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT,Graft-versus-Host Disease,Drug: Everolimus,University of Cologne,Phase 2,19,Other,Apr-16,Jul-19,Dec-20
7816,NCT02812875,"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",Advanced Solid Tumors or Lymphomas,Drug: CA-170,"Curis, Inc.",Phase 1,71,Industry,May-16,"May 7, 2020","May 7, 2020"
7817,NCT02812043,"Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis",Non-dermatophyte Onychomycosis,"Device: 1,064nm Long-pulsed Nd:YAG|Drug: Amorolfine",Mahidol University,Phase 4,60,Other,Aug-16,Jun-19,Dec-19
7818,NCT02810990,Bosutinib in Elderly Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,Drug: Bosutinib,Gruppo Italiano Malattie EMatologiche dell'Adulto,Phase 2,65,Other,"November 17, 2016","April 30, 2020","June 22, 2022"
7819,NCT02810964,Sulforaphane to Reduce Symptoms of Schizophrenia,Schizophrenia|Schizoaffective Disorder,Drug: Sulforaphane Nutraceutical|Drug: Identical-appearing Placebo,Sheppard Pratt Health System,Phase 2,64,Other,"February 22, 2017","November 11, 2019","November 11, 2019"
7820,NCT02810444,"Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID",Primary Immunodeficiency Disease,Biological: IgG Next Generation (BT595),Biotest|Syneos Health,Phase 3,81,Industry|Other,"October 4, 2016","April 1, 2020","April 1, 2020"
7821,NCT02810392,Intranasal Insulin and Post-stroke Cognition: A Pilot Study,Stroke,Drug: Intranasal Insulin|Drug: Intranasal saline,Wake Forest University Health Sciences,Phase 2,20,Other,Apr-16,"March 4, 2020","March 4, 2020"
7822,NCT02809131,Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.,Sick Sinus Syndrome|Complete Heart Block|Syncope|Chronic Systolic Heart Failure,"Drug: polymixin/bacitracin|Drug: cephalexin, or levofloxacin, or clindamycin|Drug: Saline",Vanderbilt University Medical Center|Thomas Jefferson University|The Cooper Health System|Valley Health System|Medtronic,Phase 3,1010,Other|Industry,"April 1, 2016","March 31, 2021","September 30, 2021"
7823,NCT02809053,"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma","Lymphoma, Follicular",Biological: SAIT101|Biological: MabThera®,Archigen Biotech Limited,Phase 3,315,Industry,"January 18, 2017","July 17, 2019","January 10, 2020"
7824,NCT02808975,Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically,Hidradenitis Suppurativa (HS),Drug: Placebo|Drug: Adalimumab,AbbVie,Phase 4,206,Industry,"July 18, 2016","May 16, 2019","October 16, 2019"
7825,NCT02808871,Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1),Rheumatoid Arthritis Interstitial Lung Disease,Drug: Pirfenidone|Drug: Placebo,Brigham and Women's Hospital,Phase 2,123,Other,"April 7, 2017","April 7, 2021","April 7, 2021"
7826,NCT02808819,A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist,Asthma,Biological: Benralizumab,AstraZeneca,Phase 3,447,Industry,"June 30, 2016","June 18, 2020","June 18, 2020"
7827,NCT02808650,Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,Childhood Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prexasertib,Children's Oncology Group|National Cancer Institute (NCI),Phase 1,30,Other|NIH,"February 27, 2017","December 31, 2019","March 31, 2021"
7828,NCT02808442,Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia,Refractory B-cell Acute Lymphoblastic Leukemia|Relapsed B-cell Acute Lymphoblastic Leukemia,Biological: UCART19,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 1,13,Other|Industry,"June 3, 2016","September 17, 2020","November 4, 2020"
7829,NCT02808000,BIP Foley in Prevention of CAUTI at Rehab Station,"Complications; Catheter, Urinary Infection or Inflammation",Device: BIP Foley (latex) or BIP Foley -silicone|Device: Standard catheter,Bactiguard AB|Rehab Station Stockholm,Phase 4,14,Industry|Other,"April 21, 2016","March 9, 2020","March 9, 2020"
7830,NCT02807870,Early Interventions in Children With Attention Deficit/Hyperactivity Disorder,Attention Deficit Disorder With Hyperactivity|Preschool Child,Drug: Methylphenidate|Behavioral: Parental training|Other: Psychoeducational groups for parents|Drug: Placebo pill,University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico,Phase 4,153,Other,Jun-16,Dec-19,"June 30, 2020"
7831,NCT02807337,Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments,Cancer,"Drug: Caphosol|Drug: 0,9% NaCl",Tampere University Hospital|Turku University Hospital|Kuopio University Hospital,Phase 2,47,Other,"August 1, 2016","December 31, 2019","December 31, 2019"
7832,NCT02807272,"Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia","Leukemia, Myelomonocytic, Chronic",Drug: Tipifarnib,"Kura Oncology, Inc.",Phase 2,45,Industry,Oct-16,"December 14, 2020","December 14, 2020"
7833,NCT02807103,Rituximab in Eosinophilic Granulomatosis With Polyangiitis,Eosinophilic Granulomatosis With Polyangiitis (EGPA),Drug: Rituximab|Drug: Placebo-rituximab|Drug: Cyclophosphamide|Drug: Placebo-cyclophosphamide,Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group,Phase 3,107,Other,"December 5, 2016","October 21, 2020","October 21, 2020"
7834,NCT02806986,"Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency",Primary Immunodeficiency,Biological: IGSC 20%,Grifols Therapeutics LLC,Phase 3,61,Industry,Jun-16,"May 15, 2019","May 15, 2019"
7835,NCT02806908,Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy,Narcolepsy|Excessive Sleepiness,Drug: JZP-110|Drug: Placebo,Jazz Pharmaceuticals,Phase 2,24,Industry,Jun-16,"May 19, 2019","May 19, 2019"
7836,NCT02806895,Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA,Obstructive Sleep Apnea|Excessive Sleepiness,Drug: JZP-110|Drug: Placebo,Jazz Pharmaceuticals,Phase 2,34,Industry,"July 5, 2016","May 28, 2019","May 28, 2019"
7837,NCT02805946,Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections,Allogeneic Stem Cell Transplant|Acute Graft Versus Host Disease|Acute Myeloid Leucaemia|Myelo Dysplastic Syndrome,Drug: posaconazole,Radboud University Medical Center|Universitaire Ziekenhuizen KU Leuven,Phase 4,21,Other,"April 28, 2017","July 26, 2019","September 7, 2019"
7838,NCT02805257,Ahmed Glaucoma Valve Surgery With Mitomycin-C,Glaucoma|Primary Open Angle Glaucoma|Secondary Glaucoma|Neovascular Glaucoma,Drug: Mitomycin-C|Other: Balanced Salt Solution|Procedure: Ahmed Glaucoma Valve Implant,"University of California, San Francisco|Bascom Palmer Eye Institute|University of North Carolina|University of Colorado, Denver|University of Maryland|Zhongshan Ophthalmic Center, Sun Yat-sen University|Asociación para Evitar la Ceguera en México|Hospital Central Militar|Shri Ganesh Vinayak Eye Hospital",Phase 2,119,Other,Jun-16,Mar-20,Mar-20
7839,NCT02805179,A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma,Glioma,Radiation: High Dose Radiation|Drug: Temozolomide,University of Michigan Rogel Cancer Center,Phase 2,26,Other,"September 22, 2016","February 6, 2020","November 18, 2020"
7840,NCT02804945,Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies,Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome,Biological: Mesenchymal Stem Cells (MSCs),M.D. Anderson Cancer Center|Katz Foundation,Phase 1,20,Other,"February 24, 2017","June 13, 2019","June 13, 2019"
7841,NCT02804191,Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis,Conjunctivochalasis,Drug: LO2A|Drug: Saline,Ocuwize LTD,Phase 2,62,Industry,Jul-16,Jun-19,Jun-19
7842,NCT02803918,"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)",Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Basal Insulin|Drug: Metformin,Sanofi,Phase 1,23,Industry,"May 17, 2017","January 27, 2020","January 27, 2020"
7843,NCT02803177,Cell Therapy by Autologous BMC for Large Bone Defect Repair,Humerus Fracture Displaced Proximal,Biological: BMC2012|Device: beta-TCP Chronos® Synthes,Goethe University|LOEWE CGT,Phase 2,55,Other,"July 2, 2016","December 31, 2019","December 31, 2019"
7844,NCT02802501,Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria,"Malaria, Vivax",Drug: Tafenoquine|Drug: Matched-Placebo for Tafenoquine|Drug: Primaquine|Drug: Matched-Placebo for Primaquine|Drug: Dihydroartemisinin-piperaquine (DHA-PQP)|Drug: ACT plus PQ (Rescue medication)|Drug: PQ (End of study treatment),GlaxoSmithKline|Medicines for Malaria Venture,Phase 3,150,Industry|Other,"April 8, 2018","August 19, 2019","August 19, 2019"
7845,NCT02802059,E. Coli Nissle 1917 - Suspension for Infection Prophylaxis,Infections,Drug: EcN-Suspension|Drug: Placebo,Ardeypharm GmbH|ICON plc|Clinscience Sp. z o.o.,Phase 3,567,Industry|Other,"October 7, 2015","October 12, 2020","October 12, 2020"
7846,NCT02801669,Study of DU-176b Aged 80 Years or Older,Atrial Fibrillation,Drug: Du-176b|Drug: placebo,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.",Phase 3,984,Industry,"August 5, 2016","December 27, 2019","December 27, 2019"
7847,NCT02801448,Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes,"Diabetes Mellitus, Non-Insulin-Dependent",Drug: sulforaphane|Drug: Placebo,"Anders Rosengren, MD PhD|Region Skane",Phase 2,103,Other,Sep-15,Jun-20,Jun-20
7848,NCT02800642,Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO,Central Retinal Vein Occlusion,"Drug: Aflibercept (Eylea, BAY86-5321)",Bayer,Phase 4,162,Industry,"June 10, 2016","July 31, 2019","July 31, 2019"
7849,NCT02799745,A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance,Prostate Cancer,Drug: Enzalutamide|Other: Active Surveillance,"Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc",Phase 2,227,Industry,"June 9, 2016","August 28, 2020","August 28, 2020"
7850,NCT02799381,A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER),Parkinson's Disease (PD),Drug: Optimized antiparkinsonian treatment|Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)|Device: CADD-Legacy ambulatory infusion pump|Device: Percutaneous endoscopic gastrostomy tube|Device: Jejunal extension tube,AbbVie,Phase 3,63,Industry,"February 9, 2017","September 19, 2019","September 19, 2019"
7851,NCT02799368,Balanced Salt Solution Versus 0.9% Saline Infusion for Prevention of Contrast-induced Acute Kidney Injury (BASIC Trial),"Acute Kidney Injury|Renal Insufficiency, Chronic|Contrast Media Reaction",Drug: CJ Plasma Solution A Injection|Drug: CJ 0.9% Normal Saline Injection,"Seoul National University Hospital|Kyungpook National University Hospital|National Medical Center, Seoul|National Health Insurance Service Ilsan Hospital|Seoul National University Bundang Hospital|Bundang CHA Hospital|Seoul St. Mary's Hospital|Seoul National University Boramae Hospital|Severance Hospital|Ewha Womans University Mokdong Hospital|Incheon St.Mary's Hospital|Gachon University Gil Medical Center",Phase 3,493,Other,Nov-16,May-19,Mar-20
7852,NCT02799238,Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma,Glioblastoma,Biological: ALECSAT|Radiation: Radiotherapy|Drug: Temozolomide,CytoVac A/S,Phase 2,62,Industry,Mar-16,"November 14, 2019","February 24, 2020"
7853,NCT02798744,SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.,"Diabetes Mellitus, Type 2",Drug: Empagliflozin|Behavioral: Diet|Drug: Placebo,"University of Leicester|Loughborough University|University Hospitals, Leicester",Phase 4,68,Other,Dec-16,"July 30, 2019","July 30, 2019"
7854,NCT02798627,Trial Of NS2359 For The Treatment of Cocaine Dependence,Cocaine Use Disorder,Drug: NS2359|Drug: placebo,University of Pennsylvania|Saniona|The Dana Foundation,Phase 2,55,Other|Industry,May-16,Mar-20,Oct-20
7855,NCT02798406,Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects,"Brain Cancer|Brain Neoplasm|Glioma|Glioblastoma|Gliosarcoma|Malignant Brain Tumor|Neoplasm, Neuroepithelial|Neuroectodermal Tumors|Neoplasm by Histologic Type|Neoplasm, Nerve Tissue|Nervous System Diseases",Biological: DNX-2401|Biological: pembrolizumab,"DNAtrix, Inc.|Merck Sharp & Dohme LLC",Phase 2,49,Industry,"October 6, 2016","March 17, 2021","June 30, 2021"
7856,NCT02797951,A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache,Episodic Cluster Headache|Chronic Cluster Headache,Drug: Galcanezumab,Eli Lilly and Company,Phase 3,165,Industry,"July 13, 2016","January 21, 2021","January 21, 2021"
7857,NCT02797171,"Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults",HIV Infections,Biological: VRC01|Biological: VRC01LS,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,80,NIH,"March 1, 2017","June 5, 2019","June 5, 2019"
7858,NCT02797067,Rectal Indomethacin to Prevent Post ESWL-pancreatitis,Pancreatitis,Drug: indomethacin suppository|Drug: Glycerin Suppository,Changhai Hospital,Phase 4,1370,Other,"May 31, 2016",Jul-19,Aug-21
7859,NCT02796833,Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients,Home Parenteral Nutrition,Drug: SMOFlipid20%,"Johane Allard|University Health Network, Toronto",Phase 4,50,Other,Mar-16,Dec-19,Dec-19
7860,NCT02796755,Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation,Inflammation|Fatigue,Drug: Riluzole|Drug: Placebo,Emory University,Phase 4,30,Other,Apr-16,"October 24, 2019","October 24, 2019"
7861,NCT02796170,Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes,Type 2 Diabetes|Hypertension,Drug: Dapagliflozin|Drug: Placebo,Tulane University School of Medicine|AstraZeneca|Tulane University,Phase 4,11,Other|Industry,Mar-16,Aug-19,Aug-20
7862,NCT02795949,Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae,Enterobacteriaceae Infections,Drug: Antipseudomonal beta-lactam antibiotic|Drug: De-escalation(short-spectrum antibiotic),Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases,Phase 3,344,Other,Oct-16,Jan-20,Jan-20
7863,NCT02795182,Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies,Lymphoma|Leukemia,Drug: Zanubrutinib|Drug: Tislelizumab,BeiGene,Phase 1,75,Industry,"June 29, 2016","December 18, 2020","December 18, 2020"
7864,NCT02794168,Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury,Traumatic Brain Injury,Drug: VAS203|Drug: Saline,Vasopharm GmbH|ICON plc,Phase 3,224,Industry,Jun-16,"June 30, 2020","June 30, 2020"
7865,NCT02793960,Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa,Epidermolysis Bullosa,Drug: topical BPM31510 3.0% Cream,"Shasa Hu|Berg, LLC|University of Miami",Phase 1,11,Other|Industry,"August 10, 2016","August 26, 2019","August 26, 2019"
7866,NCT02793544,HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL),"Drug: Fludarabine|Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|Radiation: Total Body Irradiation (TBI) 200cGy on Day -1|Procedure: Infusion of non-T-cell depleted bone marrow on Day 0|Drug: Busulfan|Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1|Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4|Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|Drug: Sirolimus|Drug: Mycophenolate mofetil|Drug: G-CSF|Drug: Pre-HCT Mesna on Days -6 and -5|Drug: Pre-HCT Mesna on Days -2 and -1|Drug: Pre-HCT Mesna on Days -5 and -4|Drug: Post-HCT Mesna",Center for International Blood and Marrow Transplant Research|National Marrow Donor Program,Phase 2,80,Other,Dec-16,Mar-20,Mar-20
7867,NCT02793011,Dexamethasone and Post-tonsillectomy Pain in Children,Pediatric Post-tonsillectomy Pain,Drug: Dexamethasone|Drug: Placebo,Nationwide Children's Hospital|National Institute of General Medical Sciences (NIGMS),Phase 4,137,Other|NIH,Jun-16,"June 27, 2019","June 27, 2019"
7868,NCT02792231,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.,Relapsing Multiple Scelrosis,Drug: Ofatumumab subcutaneous injection|Drug: Teriflunomide-matching placebo capsules|Drug: Teriflunomide capsule|Drug: Matching placebo of ofatumumab subcutaneous injections,Novartis Pharmaceuticals|Novartis,Phase 3,955,Industry,"August 26, 2016","July 10, 2019","October 22, 2020"
7869,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,Drug: Ofatumumab subcutaneous injection|Drug: Teriflunomide-matching placebo capsules|Drug: Teriflunomide capsule|Drug: Matching placebo of ofatumumab subcutaneous injections,Novartis Pharmaceuticals|Novartis,Phase 3,930,Industry,"September 20, 2016","July 5, 2019","July 20, 2020"
7870,NCT02792088,Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues,Chronic Hepatitis B,Drug: Besifovir 150mg|Drug: Tenofovir 300mg,IlDong Pharmaceutical Co Ltd,Phase 3,146,Industry,Jul-15,Feb-20,Feb-20
7871,NCT02792036,Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma,Retinoblastoma,Drug: Carboplatin|Drug: Maxitrol®|Procedure: Focal Therapy|Procedure: Plaque Radiotherapy,St. Jude Children's Research Hospital,Phase 1,8,Other,"November 1, 2016","October 4, 2019","October 4, 2019"
7872,NCT02791438,A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension,Pediatric Hypertension,Drug: Azilsartan|Drug: Placebo,Takeda,Phase 3,27,Industry,"August 18, 2016","June 4, 2019","June 4, 2019"
7873,NCT02790138,A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis,Pouchitis,Drug: Vedolizumab Placebo|Drug: Ciprofloxacin|Drug: Vedolizumab,Takeda,Phase 4,102,Industry,"October 12, 2016","June 11, 2020","February 2, 2021"
7874,NCT02789982,Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study,Post-traumatic Stress Disorder,Drug: β-adrenergic blocker propranolol|Behavioral: Treatment as usual,Assistance Publique - Hôpitaux de Paris|MSD France,Phase 3,364,Other|Industry,"May 27, 2016","December 30, 2019","December 30, 2019"
7875,NCT02789917,APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF,Acute Coronary Syndrome|Atrial Fibrillation|Coronary Artery Disease,Other: Dual Therapy|Other: Triple Therapy,LMU Klinikum|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|Technical University of Munich|Helmholtz Zentrum München|University of Göttingen|University of München|University Medicine Greifswald,Phase 4,403,Other|Industry,Jun-16,Aug-20,Aug-20
7876,NCT02789657,Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,Breast Cancer,Drug: paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: carboplatin|Procedure: Breast surgery|Drug: AC,Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital,Phase 2,32,Other,"November 21, 2016","November 14, 2019","March 27, 2020"
7877,NCT02789605,Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis,Aphthous Stomatitis,Drug: Bacilor|Drug: Placebo,Centre Hospitalier Universitaire de Nice,Phase 2,20,Other,"January 4, 2018","November 25, 2019","July 15, 2020"
7878,NCT02788552,Optimum Thiamine Intervention (OpTIn) Trial,Wernicke-Korsakoff Syndrome,Drug: Thiamine Hydrochloride,Menzies School of Health Research,Phase 4,334,Other,Sep-14,"May 30, 2019","August 1, 2019"
7879,NCT02788513,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,Alzheimer Disease,Drug: BI 425809 dose 1|Drug: BI 425809 dose 2|Drug: BI 425809 dose 3|Drug: BI 425809 dose 4|Drug: Placebo,Boehringer Ingelheim,Phase 2,611,Industry,"August 11, 2016","September 12, 2019","October 11, 2019"
7880,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms,Drug: 75 approved agents|Other: COXEN,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,8,NIH,"March 27, 2017","October 23, 2019","October 23, 2019"
7881,NCT02787590,Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease,Parkinson Disease,Drug: Simvastatin|Drug: Matched Placebo (for Simvastatin),University Hospital Plymouth NHS Trust|University of Plymouth,Phase 2,235,Other,"March 8, 2016","November 1, 2019","December 31, 2020"
7882,NCT02787044,INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure,Heart Failure|Myocardial Infarction,Biological: High Dose Trivalent Influenza Vaccine|Biological: Standard Dose Quadrivalent Influenza Vaccine,"Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|University of Wisconsin, Madison|University of Toronto|Boston VA Research Institute, Inc.|Patient-Centered Outcomes Research Institute|University of Minnesota",Phase 4,5388,Other|NIH,"August 1, 2016","May 31, 2020","May 31, 2020"
7883,NCT02786537,Study of Oral Treatments for Hepatitis C,Chronic Hepatitis C,Drug: SOF/LDV (sofosbuvir/ledipasvir)|Drug: PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Drug: EBR/GZR (elbasvir/grazoprevir)|Drug: Ribavirin,University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme LLC|AbbVie,Phase 4,1275,Other|Industry,Jun-16,"June 13, 2019","September 2, 2020"
7884,NCT02786498,Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing,Fracture,Drug: Vitamin D3|Other: Placebo,"University of Maryland, Baltimore|McMaster University",Phase 2,102,Other,"November 21, 2016",Aug-19,"December 1, 2021"
7885,NCT02785549,Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics,Acute Diverticulitis,Drug: Ibuprofen|Drug: Acetaminophen|Drug: Amoxicillin/clavulanic acid,Corporacion Parc Tauli,Phase 4,480,Other,Nov-16,"January 12, 2020","April 1, 2020"
7886,NCT02784821,"Antibiotic ""Dysbiosis"" in Preterm Infants","Enterocolitis, Necrotizing|Bacteremia|Bronchopulmonary Dysplasia|Intraventricular Hemorrhage|Periventricular Leukomalacia|Chronic Lung Disease|Ileal Perforation",Drug: Antibiotic|Other: Gastric fluid|Other: Breast milk|Other: Stool samples|Drug: Antibiotics - pre-emptive,University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Society for Pediatric Dermatology,Phase 2,186,Other|NIH,"January 16, 2017","September 11, 2019","September 11, 2019"
7887,NCT02784444,"A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH",Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis|NASH - Nonalcoholic Steatohepatitis,Drug: MSDC-0602K|Drug: Placebo,"Cirius Therapeutics, Inc.|Chiltern International Inc.",Phase 2,392,Industry,"September 14, 2016",Jun-19,Jun-19
7888,NCT02783937,Filgrastim for Premature Ovarian Insufficiency,Premature Ovarian Failure,Biological: Filgrastim|Drug: Saline,South Valley University,Phase 4,10,Other,Nov-16,Dec-20,Jun-21
7889,NCT02783482,Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency,Immunologic Deficiency Syndromes,Biological: GC5107,Green Cross Corporation|Parexel|Atlantic Research Group|GC Biopharma Corp,Phase 3,49,Industry|Other,Oct-16,Jul-19,Jul-19
7890,NCT02783066,Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study,Diabetic Foot Ulcer|Offloading,Device: Offloading boot: PulseFlow,Baylor College of Medicine|The Diabetic Boot Company,Phase 2,16,Other,Jan-16,"June 30, 2019","October 30, 2019"
7891,NCT02781610,Standardized Treatment of Pulmonary Exacerbations II,Pulmonary Cystic Fibrosis,Drug: Standard of care IV antibiotic(s),Chris Goss|Cystic Fibrosis Foundation|CF Therapeutics Development Network Coordinating Center|Medical University of South Carolina|University of Washington|Seattle Children's Hospital,Phase 4,982,Other,Jun-16,"March 6, 2020","March 6, 2020"
7892,NCT02781584,"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Fatty Liver Disease (NAFLD),Drug: SEL|Drug: FIR|Drug: CILO|Drug: FENO|Drug: VAS,Gilead Sciences,Phase 2,220,Industry,"June 13, 2016","December 17, 2020","December 17, 2020"
7893,NCT02781064,STATIN: Web-based Investigation of Side Effects,Cardiovascular Disease,Drug: Atorvastatin 20mg|Drug: Placebo,"London School of Hygiene and Tropical Medicine|National Institute for Health Research, United Kingdom",Phase 4,200,Other,"September 1, 2016","August 8, 2019","August 8, 2019"
7894,NCT02780427,ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study,Patients for Transthoracic Echocardiography|Unknown Diagnosis,Drug: intranasal dexmedetomidine,Guangzhou Women and Children's Medical Center,Phase 4,320,Other,"August 10, 2019","January 1, 2021","May 20, 2022"
7895,NCT02778906,Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia,Arthralgia|Arthritis,Drug: Abatacept|Drug: Placebo,University of Erlangen-Nürnberg Medical School|Bristol-Myers Squibb,Phase 3,98,Other|Industry,Nov-14,Dec-19,Dec-19
7896,NCT02778204,Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection,HIV Infections,Drug: Maraviroc,National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|ViiV Healthcare|GlaxoSmithKline,Phase 1,47,NIH|Industry,"June 5, 2017","September 6, 2019","November 20, 2019"
7897,NCT02777710,Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers,Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer,Drug: Pexidartinib|Drug: Durvalumab,Centre Leon Berard|AstraZeneca|Plexxikon,Phase 1,48,Other|Industry,Jun-16,Nov-19,Dec-19
7898,NCT02776813,Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma,Lymphoma,Biological: ACTR087|Biological: rituximab,"Cogent Biosciences, Inc.",Phase 1,34,Industry,Aug-16,"February 12, 2020","February 12, 2020"
7899,NCT02776514,"Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis","Osteoarthritis, Knee",Drug: Triamcort|Drug: Platelet-rich-plasma|Drug: Suplasyn1|Drug: Placebo,Balgrist University Hospital|Stiftung für Rheumaforschung Zurich|Stiftung Marie-Lou Ringgenberg Bern,Phase 2,120,Other,Feb-16,Nov-20,Nov-20
7900,NCT02776059,Pegfilgrastim in Patients With Alcoholic Hepatitis,Alcoholic Hepatitis,Drug: Standard of care + pegfiltrastim|Drug: Standard of care,"Timothy Morgan, MD|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Southern California Institute for Research and Education",Phase 2,34,Other|NIH,"January 21, 2017","March 31, 2020","March 31, 2021"
7901,NCT02774590,Timolol for the Treatment of Acne and Rosacea,Acne Vulgaris|Rosacea,Drug: Timolol,Johns Hopkins University,Phase 1,8,Other,Mar-16,Mar-21,Mar-21
7902,NCT02774005,Study to Assess the Efficacy and Safety of Raxone in LHON Patients,Leber's Hereditary Optic Neuropathy (LHON),Drug: Idebenone,Santhera Pharmaceuticals,Phase 4,199,Industry,May-16,"March 29, 2021","March 29, 2021"
7903,NCT02773641,Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia,Vulvodynia,Drug: Botulinum Toxin Type A|Drug: Sterile Saline Solution,Karolinska Institutet,Phase 3,90,Other,May-16,Jun-19,Jun-19
7904,NCT02773329,Using Game-based Exercise to Improve Balance in Cancer Patients,Chemotherapy Induced Peripheral Neuropathy|Cancer,Other: sensor-based interactive exercise (game-based exercise)|Other: Intervention without game-based exercise,Baylor College of Medicine|National Institutes of Health (NIH),Phase 2,35,Other|NIH,May-16,May-19,May-19
7905,NCT02771860,RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints,Hand Osteoarthritis,Drug: denosumab|Drug: Placebo|Dietary Supplement: Calcium/Vit D supplementation,"University Hospital, Ghent|Amgen",Phase 2,100,Other|Industry,Mar-16,"June 26, 2019","April 28, 2021"
7906,NCT02771210,Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site,Psoriatic Arthritis|Axial Spondyloarthritis|Enthesitis,Biological: Secukinumab|Drug: Secukinumab Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,204,Industry,"August 30, 2016","December 11, 2019","December 11, 2019"
7907,NCT02770885,Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study),Primary Polydipsia,Drug: Dulaglutide|Drug: Placebo,"University Hospital, Basel, Switzerland",Phase 2,50,Other,Mar-16,"May 17, 2019","October 7, 2019"
7908,NCT02770807,EDS in Ataxia Telangiectasia Patients,Nervous System Disease|Genetic Syndrome,Drug: EDS-EP dose range of ~5-10 mg DSP/infusion|Drug: EDS-EP dose range of ~14-22 mg DSP/infusion|Drug: Placebo,Erydel,Phase 3,175,Industry,"March 2, 2017","January 15, 2021","June 24, 2021"
7909,NCT02770794,Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug: Infliximab,Chiba University,Phase 4,211,Other,"April 1, 2016","August 14, 2020","August 14, 2020"
7910,NCT02770716,Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1,Hepatorenal Syndrome,Drug: Terlipressin|Other: Placebo,Mallinckrodt,Phase 3,300,Industry,"July 13, 2016","July 24, 2019","July 24, 2019"
7911,NCT02770391,Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer,Prostate Cancer,Drug: Leuprolide acetate|Drug: Apalutamide|Procedure: Radical prostatectomy,Case Comprehensive Cancer Center,Phase 2,54,Other,"October 17, 2016","April 29, 2020","April 29, 2020"
7912,NCT02770170,"Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis",Lupus Nephritis,Drug: BI 655064 dose 1|Drug: BI 655064 dose 2|Drug: BI 655064 dose 3|Drug: Placebo,Boehringer Ingelheim,Phase 2,121,Industry,"May 16, 2016","June 23, 2020","August 18, 2020"
7913,NCT02770157,Efficacy and Safety of DA-3002 in Short Children Borns SGA.,"Infant, Small for Gestational Age",Drug: DA-3002|Drug: Genotropin®,"Dong-A ST Co., Ltd.",Phase 3,75,Industry,"February 26, 2016","August 28, 2019","August 28, 2019"
7914,NCT02769572,Moxibustion in Osteoarthritis of the Knee,Knee Osteoarthritis,Other: real moxibustion|Drug: placebo gel|Drug: diclofenac sodium gel|Other: sham moxibustion,Chengdu University of Traditional Chinese Medicine,Phase 3,144,Other,May-16,Jun-19,Jun-19
7915,NCT02769481,Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo for Bexagliflozin|Drug: Glimepiride|Drug: Placebo for Glimepiride,Theracos,Phase 3,426,Industry,"August 15, 2016","June 14, 2019","June 14, 2019"
7916,NCT02768727,A Test of Neural Inertia in Humans With Xenon,Neurocognitive Dysfunction,Drug: Xenon,University of Pennsylvania,Phase 2,21,Other,Apr-16,"December 1, 2019","December 1, 2021"
7917,NCT02768298,Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.,Chronic Heart Failure With Reduced Ejection Fraction,Drug: LCZ696|Drug: Enalapril|Drug: Placebo matching enalapril|Drug: Placebo matching LCZ696,Novartis Pharmaceuticals|Novartis,Phase 4,201,Industry,"July 12, 2016","November 25, 2019","November 25, 2019"
7918,NCT02767193,Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients,HIV Infection,Biological: DCV3|Biological: DCV3 with PEG-INF|Biological: Placebo|Biological: Placebo with PEG-INF,Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica,Phase 1,36,Other,May-16,"May 22, 2019","May 22, 2019"
7919,NCT02765633,Cangrelor Neonatal PK/PD and Safety Study,Partial Obstruction of Systemic to Pulmonary Artery Shunt|Complete Obstruction of Systemic to Pulmonary Artery Shunt,Drug: Cangrelor,Chiesi Farmaceutici S.p.A.,Phase 1,22,Industry,"January 3, 2017","August 31, 2019","December 23, 2019"
7920,NCT02765217,Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children,Antibiotic Associated Diarrhea,Drug: Lactobacillus reuteri DSM 17938|Drug: Placebo|Drug: Amoxicillin-Clavulanic Acid,Eskisehir Osmangazi University|Hacettepe University|Acıbadem University School of Medicine|Umraniye Education and Research Hospital|Sisli Hamidiye Etfal Training and Research Hospital|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Ege University Medical School|Yuzuncu Yıl University|Goztepe Training and Research Hospital|Erzurum Regional Training & Research Hospital|Namik Kemal University,Phase 4,1325,Other,"June 1, 2017","July 1, 2020","December 1, 2020"
7921,NCT02764762,Triple Combination Therapy in High Risk Crohn's Disease (CD),Crohn Disease,Drug: Vedolizumab|Drug: Adalimumab|Drug: Methotrexate,Takeda,Phase 4,55,Industry,"April 18, 2017","September 22, 2020","July 5, 2022"
7922,NCT02764333,TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,Ovarian Cancer,Biological: TPIV200|Biological: Durvalumab,"Memorial Sloan Kettering Cancer Center|AstraZeneca|Marker Therapeutics, Inc.",Phase 2,29,Other|Industry,"May 6, 2016","January 20, 2021","January 20, 2021"
7923,NCT02763475,NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents,Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia,Drug: cyclophosphamide|Drug: Fludarabine|Procedure: NK cell infusion|Drug: IL-2,"Instituto de Investigación Hospital Universitario La Paz|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Fundación Mutua Madrileña",Phase 2,7,Other,May-16,Aug-20,Aug-20
7924,NCT02763046,Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis,Ankylosing Spondylitis,Drug: Secukinumab (AIN457) 150 mg s.c.|Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.,Novartis Pharmaceuticals|Novartis,Phase 4,211,Industry,"May 31, 2016","September 24, 2019","September 24, 2019"
7925,NCT02762513,Expansion Trial for Axitinib In Head And Neck Cancer,Squamous Cell Carcinoma of the Head and Neck,Drug: Axitinib,University of Michigan Rogel Cancer Center|National Comprehensive Cancer Network,Phase 2,29,Other,"August 30, 2016","April 9, 2020","April 9, 2020"
7926,NCT02762006,Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,Renal Cell Carcinoma|Kidney Cancer,Drug: Durvalumab|Drug: Tremelimumab,Moshe Ornstein|Case Comprehensive Cancer Center,Phase 1,29,Other,"December 20, 2016","November 6, 2020","November 6, 2020"
7927,NCT02761915,A Phase I Trial of Anti-GD2 T-cells (1RG-CART),Relapsed or Refractory Neuroblastoma,Other: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: 1RG-CART,Cancer Research UK,Phase 1,17,Other,"February 29, 2016","December 16, 2020","December 16, 2020"
7928,NCT02761161,Treatment of Sleep Disturbances in Trauma-affected Refugees,Post Traumatic Stress Disorder|Depression,Drug: Mianserin|Behavioral: Imagery Rehearsal Therapy,"Mental Health Services in the Capital Region, Denmark|Danish Center for Sleep Medicine",Phase 4,241,Other,Mar-16,"June 1, 2019","June 1, 2019"
7929,NCT02760433,"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease",Rheumatoid Arthritis,Drug: Olokizumab|Drug: Placebo,"R-Pharm International, LLC|Quintiles, Inc.|OCT Clinical Trials|Mene Research|R-Pharm",Phase 3,368,Industry|Other,"January 9, 2017","September 12, 2019","October 1, 2019"
7930,NCT02760407,"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease",Rheumatoid Arthritis,Drug: Olokizumab 64mg q4w|Drug: Olokizumab 64mg q2w|Drug: Adalimumab 40mg q2w|Drug: Placebo q2w,"R-Pharm International, LLC|Quintiles, Inc.|OCT Clinical Trials|R-Pharm",Phase 3,1648,Industry|Other,"May 24, 2016","August 2, 2019","November 5, 2019"
7931,NCT02760251,Immunomodulation With Romiplostim in Young Adults With ITP,Immune Thrombocytopenia,Drug: romiplostim,"University Hospital, Basel, Switzerland|University Children's Hospital Basel",Phase 4,15,Other,Apr-16,Jul-19,Mar-20
7932,NCT02759991,Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.,Hepatitis E Infection,Drug: Hecolin|Drug: Hepa-B,"Norwegian Institute of Public Health|International Centre for Diarrhoeal Disease Research, Bangladesh|Sykehuset Innlandet HF",Phase 4,19460,Other,"October 2, 2017","September 30, 2019","September 30, 2019"
7933,NCT02759861,Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics,Genotype 1 Hepatitis C Virus,Drug: harvoni,University of Nebraska,Phase 4,16,Other,Aug-16,Aug-20,Oct-20
7934,NCT02759016,"Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib","Leukemia, Lymphocytic, Chronic, B-Cell",Drug: BI 836826|Drug: Ibrutinib,Boehringer Ingelheim,Phase 1,7,Industry,"June 23, 2016","June 3, 2019","July 9, 2019"
7935,NCT02758912,Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers,"Stroke, Not Specified as Hemorrhage or Infarction|Angina Pectoris","Drug: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg",Burnasyan Federal Medical Biophysical Center,Phase 4,32,Other,Nov-16,"September 25, 2019","October 25, 2019"
7936,NCT02758782,NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis,Ankylosing Spondylitis,Biological: Golimumab|Drug: Celecoxib,"Charite University, Berlin, Germany",Phase 4,156,Other,Sep-16,Jan-21,Jan-21
7937,NCT02758626,Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome,Epilepsy,Drug: ataluren|Drug: Placebo,NYU Langone Health|PTC Therapeutics,Phase 2,15,Other|Industry,Nov-16,"February 27, 2021","February 27, 2021"
7938,NCT02757443,Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients,Cardiac Surgical Procedures|Heart Valve Prosthesis Implantation,Drug: Phosphocreatine sodium tetrahydrate after anaesthesia induction|Drug: 5% Glucose after anaesthesia induction|Drug: Phosphocreatine sodium tetrahydrate added to cardioplegia|Drug: 5% Glucose|Drug: Phosphocreatine sodium tetrahydrate after heart recovery|Drug: 5% Glucose after heart recovery|Drug: Phosphocreatine sodium tetrahydrate after ICU admission|Drug: 5% Glucose after ICU admission,Meshalkin Research Institute of Pathology of Circulation,Phase 3,120,Other,Jun-16,Apr-21,May-21
7939,NCT02756858,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,Alzheimer's Disease,Drug: ANAVEX2-73,Anavex Life Sciences Corp.,Phase 2,21,Industry,Mar-16,Nov-20,Nov-20
7940,NCT02756572,Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms,Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia-2|High Grade Malignant Neoplasm|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2|Myeloid Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia,Drug: Cladribine|Drug: Cyclosporine|Drug: Cytarabine|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mitoxantrone Hydrochloride|Drug: Mycophenolate Mofetil|Other: Questionnaire Administration|Drug: Sirolimus|Radiation: Total-Body Irradiation|Drug: Melphalan Hydrochloride,University of Washington|National Cancer Institute (NCI),Phase 2,30,Other|NIH,"September 22, 2016","March 1, 2020","July 1, 2020"
7941,NCT02756364,Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,Breast Neoplasms,Drug: Fulvestrant|Drug: Sapanisertib,"Calithera Biosciences, Inc",Phase 2,141,Industry,"July 28, 2016","November 25, 2019","November 25, 2019"
7942,NCT02755597,A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,Relapsed/Refractory Multiple Myeloma,Drug: Placebo|Drug: Bortezomib|Drug: Dexamethasone|Drug: Venetoclax,"AbbVie|Genentech, Inc.",Phase 3,291,Industry,"July 11, 2016","March 15, 2021","August 15, 2022"
7943,NCT02755116,Olanzapine for Nausea After Surgery,Postoperative Nausea and Vomiting,Drug: Olanzapine|Drug: Placebo,Jaime B Hyman|Icahn School of Medicine at Mount Sinai,Phase 2,180,Other,Apr-16,"September 5, 2019","September 5, 2019"
7944,NCT02754609,Hookworm Therapy for Coeliac Disease,Celiac Disease,Other: Gluten micro-challenge|Other: Inadvertent gluten challenge|Other: Moderate gluten challenge|Other: Liberal diet|Other: Necator americanus-hookworm larvae L3-10|Other: Tabasco® Sauce|Other: Necator americanus-hookworm larvae L3-20|Other: Gluten free diet,"James Cook University, Queensland, Australia|Townsville Hospital|The Prince Charles Hospital|Christchurch Hospital|Logan Hospital, Queensland|Australian Institute of Tropical Health and Medicine|QIMR Berghofer Medical Research Institute|National Health and Medical Research Council, Australia",Phase 1,54,Other,Sep-16,Oct-19,Oct-19
7945,NCT02754284,Clinical Study of Regeneration on Larynx Soft Tissue Guided by Functional Collagen Scaffold,Vocal Cord Dysfunction,Biological: Autologous fat transplantation|Biological: Functional collagen scaffold transplantation,Chinese Academy of Sciences|Peking Union Medical College,Phase 1,20,Other,Dec-15,Jun-20,Jun-20
7946,NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,Liver Cancer,Drug: whole liver lobe cTACE doxorubicin|Drug: superselective cTACE doxorubicin,Yale University,Phase 1,30,Other,Nov-15,Dec-19,Dec-19
7947,NCT02753530,Study of Arimoclomol in Inclusion Body Myositis (IBM),Inclusion Body Myositis,Drug: Arimoclomol|Other: Placebo,"ZevraDenmark|University of Kansas Medical Center|University College, London",Phase 2,152,Industry|Other,"August 16, 2017","January 11, 2021","January 11, 2021"
7948,NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer,Colorectal Cancer,Drug: Napabucasin|Drug: Fluorouracil|Drug: Leucovorin|Drug: Irinotecan|Drug: Bevacizumab,"Sumitomo Pharma Oncology, Inc.",Phase 3,1253,Industry,Jun-16,"April 28, 2020","May 12, 2021"
7949,NCT02751996,"A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV","Hepatitis B|Hepatitis, Viral",Drug: SB 9200|Drug: Placebo|Drug: Tenofovir,"F-star Therapeutics, Inc.",Phase 2,80,Industry,May-16,"February 10, 2020","February 10, 2020"
7950,NCT02751918,Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer,Ovarian Neoplasms,Drug: Anetumab ravtansine (BAY94-9343)|Drug: Pegylated Liposomal Doxorubicin,Bayer,Phase 1,65,Industry,"June 8, 2016","August 23, 2019","October 31, 2019"
7951,NCT02751411,Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months,Chronic Functional Constipation,Device: micro-enema with Promelaxin|Drug: Macrogol 4000,Aboca Spa Societa' Agricola|Eclisse - Euromed Clinical Supply Services Srl|Ceinge - Biotecnologie Avanzate s.c. a r.l.|Latis S.r.l.|PhAST Consulting Srl,Phase 4,158,Industry|Other,"April 18, 2016","December 31, 2019","March 17, 2020"
7952,NCT02751398,Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10mg|Drug: Placebo 10mg,Yonsei University,Phase 4,60,Other,"August 18, 2016","June 15, 2020","June 15, 2020"
7953,NCT02750670,Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,"Lymphoma, Non-Hodgkin's",Drug: Obinutuzumab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin,"University Health Network, Toronto|Hoffmann-La Roche|Ozmosis Research Inc.",Phase 2,30,Other|Industry,"March 15, 2017","September 9, 2020","February 9, 2021"
7954,NCT02750540,Optimization of a Tenofovir Enema for HIV Prevention,HIV Prevention,Drug: Tenofovir enema|Other: Saline enema,"Johns Hopkins University|University of California, Los Angeles|University of Pittsburgh",Phase 1,21,Other,Oct-16,May-19,May-19
7955,NCT02750462,Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation,Out-of-hospital Cardiac Arrest,Other: Immediate coronary angiography|Other: Delayed/selective coronary angiography,University Hospital Schleswig-Holstein|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK),Phase 4,558,Other,Nov-16,Sep-19,Sep-19
7956,NCT02749968,Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma,Blunt Chest Wall Trauma|Rib Fracture|Sternal Fracture,Drug: Liposomal bupivacaine|Drug: 0.9% sodium chloride,University of Cincinnati|United States Air Force,Phase 2,100,Other|U.S. Fed,"March 9, 2018","January 1, 2021","January 1, 2021"
7957,NCT02749630,"A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)",Ulcerative Colitis|Crohn's Disease,Drug: Placebo|Drug: UTTR1147A,"Genentech, Inc.",Phase 1,70,Industry,"April 11, 2016","February 19, 2020","February 19, 2020"
7958,NCT02749136,Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer,Pancreatic Adenocarcinoma,Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine,Asan Medical Center,Phase 2,44,Other,May-16,Sep-19,Nov-19
7959,NCT02748837,A Study of ERY974 in Patient With Advanced Solid Tumors,Solid Tumors,Drug: ERY974,Chugai Pharmaceutical,Phase 1,29,Industry,Aug-16,Aug-19,Aug-19
7960,NCT02748694,"Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",Healthy Volunteers|Schizophrenia,Drug: TAK-041|Drug: TAK-041 Placebo,Neurocrine Biosciences|Takeda,Phase 1,114,Industry,"May 9, 2016","September 22, 2019","September 22, 2019"
7961,NCT02748616,C. Difficile and Ursodiol,Diarrhea,Drug: Ursodiol,NYU Langone Health,Phase 4,9,Other,"March 1, 2017","November 1, 2019","January 31, 2020"
7962,NCT02748200,External Beam Radiotherapy for Muscle Invasive Bladder Cancer,Toxicity,Radiation: external beam radiotherapy (EBRT),"University Hospital, Ghent",Phase 1,77,Other,Aug-14,Oct-20,Oct-20
7963,NCT02748135,A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,"Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)",Drug: TB-403 20mg/kg|Drug: TB-403 50mg/kg|Drug: TB-403 100mg/kg|Drug: TB-403 175mg/kg,Oncurious NV|Beat Childhood Cancer,Phase 1,18,Industry|Other,May-16,"October 6, 2020","October 6, 2020"
7964,NCT02747940,Neurologic Signatures of Chronic Pain Disorders,Chronic Pain|Chronic Migraine|Fibromyalgia,Drug: flunarizine and/or pregabalin,"Taipei Veterans General Hospital, Taiwan|Ministry of Science and Technology, R.O.C.",Phase 4,200,Other,Dec-15,Dec-19,
7965,NCT02747342,A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer,Neoplasm|Prostate Cancer,Drug: SHR3680; SHR3162,Atridia Pty Ltd.,Phase 1,33,Industry,Sep-16,"June 28, 2019","June 28, 2020"
7966,NCT02747043,Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab,"Lymphoma, Non-Hodgkin",Biological: ABP 798|Biological: Rituximab,Amgen,Phase 3,256,Industry,"May 25, 2016","June 28, 2019","June 28, 2019"
7967,NCT02746991,Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis,Posterior Uveitis|Intermediate Uveitis|Panuveitis,Drug: Sham Injection|Drug: FAI Insert,"EyePoint Pharmaceuticals, Inc.",Phase 3,153,Industry,"June 2, 2015","October 4, 2019","October 4, 2019"
7968,NCT02746952,Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia,B-cell Acute Lymphoblastic Leukemia,Biological: UCART19,"Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",Phase 1,25,Other|Industry,"August 1, 2016","July 28, 2020","July 28, 2020"
7969,NCT02745080,Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis,Psoriatic Arthritis,Biological: Secukinumab|Biological: Adalimumab,Novartis Pharmaceuticals|Novartis,Phase 3,853,Industry,"April 3, 2017","December 30, 2019","December 30, 2019"
7970,NCT02744976,Coronary Artery Disease Progression in Patients With Prediabetes,Coronary Artery Disease|Atherosclerosis|Prediabetic State,Drug: Metformin|Behavioral: Lifestyle recommendations,Pauls Stradins Clinical University Hospital,Phase 4,70,Other,Feb-16,"July 31, 2019",Sep-21
7971,NCT02744430,Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain,Ureteral Obstruction|Flank Pain,Drug: Mirabegron|Other: Placebo,Baylor College of Medicine,Phase 2,33,Other,"July 22, 2017","October 31, 2019","October 31, 2019"
7972,NCT02744339,Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction,"Hypertension, Pulmonary|Heart Failure With Normal Ejection Fraction",Drug: Riociguat|Drug: Placebo,Medical University of Vienna,Phase 2,118,Other,Mar-16,Aug-20,Sep-20
7973,NCT02743871,"Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis",Healthy|Chronic Rhinosinusitis With Nasal Polyps|Atopic Dermatitis,Biological: PF-06817024|Other: Placebo for PF-06817024,Pfizer,Phase 1,97,Industry,"April 27, 2016","March 9, 2021","March 9, 2021"
7974,NCT02743637,A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors,Advanced Malignancy|Advanced Solid Tumors|Neoplasm|Metastasis,Drug: SDX-7320,"SynDevRx, Inc.",Phase 1,32,Industry,Feb-16,"December 16, 2019","December 16, 2019"
7975,NCT02743364,"Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis",Acute Pancreatitis,Other: Laboratory Biomarker Analysis|Other: Placebo Administration|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Simvastatin,National Cancer Institute (NCI),Phase 2,8,NIH,"September 19, 2016","October 14, 2019","May 11, 2022"
7976,NCT02742935,A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects,Solid Tumor|Breast Cancer|Gastrointestinal Cancer,Biological: camrelizumab,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,99,Industry,"April 27, 2016","May 6, 2019","May 6, 2019"
7977,NCT02742857,"Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury",Brain Death,Biological: BQ-A Peptide Extract|Biological: Mesenchymal Stem Cells|Device: Transcranial Laser Therapy|Device: Median Nerve Stimulator,Bioquark Inc.|Revita Life Sciences|Anupam Hospital,Phase 1,20,Industry|Other,Jul-16,Aug-20,Aug-20
7978,NCT02742532,Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress,"Alcohol Use Disorder|Stress Disorders, Post-Traumatic|Anxiety Disorders|Substance Use Disorders",Drug: Oxytocin|Drug: Placebo,"Jennifer Mitchell|United States Naval Medical Center, San Diego|United States Department of Defense|Congressionally Directed Medical Research Programs|Eisenhower Army Medical Center|University of California, San Francisco",Phase 2,63,Other|U.S. Fed,"April 20, 2017","July 1, 2019","July 1, 2019"
7979,NCT02742051,"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer",Breast Cancer,Drug: Everolimus|Drug: Letrozole|Drug: Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Phase 2,40,Other,Jun-16,"March 14, 2020","March 14, 2020"
7980,NCT02741791,A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder,Treatment Resistant Major Depressive Disorder,Drug: AXS-05|Drug: Bupropion,"Axsome Therapeutics, Inc.",Phase 3,312,Industry,Mar-16,"March 20, 2020","March 20, 2020"
7981,NCT02741596,Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Hereditary Angioedema (HAE),Drug: DX-2930,Shire|Takeda,Phase 3,212,Industry,"May 26, 2016","October 31, 2019","October 31, 2019"
7982,NCT02740985,A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies,Advanced Solid Malignancies|Non-Small Cell Lung Cancer (NSCLC)|Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)|Colorectal Carcinoma (CRC),Drug: AZD4635|Drug: Durvalumab|Drug: Abiraterone Acetate|Drug: Enzalutamide|Drug: Oleclumab|Drug: Docetaxel,AstraZeneca,Phase 1,313,Industry,"June 17, 2016","December 31, 2020","March 31, 2023"
7983,NCT02740582,Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users,Alcohol Abuse|Impulsive Behavior,Drug: Tolcapone|Drug: Placebo,"Jennifer Mitchell|University of California, San Francisco",Phase 2,62,Other,"October 1, 2016","September 1, 2019","November 1, 2019"
7984,NCT02740543,Biomarkers of Irritant-Induced and Allergic Asthma,Asthma,Drug: Fluticasone propionate HFA 220,NYU Langone Health,Phase 2,18,Other,Dec-13,"October 23, 2019","October 23, 2019"
7985,NCT02740270,Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,Solid Tumors|Lymphomas,Drug: GWN323|Drug: PDR001,Novartis Pharmaceuticals|Novartis,Phase 1,92,Industry,"July 22, 2016","March 3, 2020","March 3, 2020"
7986,NCT02740127,Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis,Malignant Neoplasms of Male Genital Organs,Procedure: Caudal Nerve Block (CNB)|Drug: Ropivacaine|Drug: Epinephrine|Drug: Decadron|Drug: Clonidine|Drug: Propofol|Behavioral: Phone Call,M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC,Phase 3,52,Other|Industry,Jun-16,"May 10, 2020","May 10, 2020"
7987,NCT02739568,Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA,Excessive Daytime Sleepiness|Obstructive Sleep Apnea,Drug: Pitolisant (BF2.649)|Drug: Placebo,Bioprojet,Phase 3,389,Other,Apr-16,Apr-20,Apr-20
7988,NCT02739542,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),Multiple Sclerosis (MS),Drug: Tecfidera|Drug: Placebo,University of Texas Southwestern Medical Center|Biogen,Phase 4,87,Other|Industry,"March 19, 2016","March 31, 2021","March 31, 2021"
7989,NCT02738736,Clarifying Optimal Sodium Intake Project,Blood Pressure|Hypertension|Kidney Disease|Cardiovascular Disease,Behavioral: Sodium Reduction,"University College Hospital Galway|European Research Council|National University of Ireland, Galway, Ireland",Phase 2,269,Other,Apr-16,Aug-20,Aug-20
7990,NCT02738502,Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors,Maternal-fetal Infection Transmission,Drug: darunavir monotherapy,"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",Phase 2,91,Other,"July 6, 2016","July 16, 2019","July 16, 2020"
7991,NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma,Advanced Melanoma,Biological: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,36,Industry,"April 13, 2016","January 8, 2020","January 8, 2020"
7992,NCT02738450,"Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome",Down Syndrome,Biological: ACI-24 low dose|Biological: ACI-24 high dose|Biological: Placebo,AC Immune SA|National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)|LuMind IDSC Foundation,Phase 1,20,Industry|NIH|Other,Mar-16,Jun-20,Jun-20
7993,NCT02737501,ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants,Non-small Cell Lung Cancer|Lung Cancer|Advanced Malignancies|Carcinoma,Drug: Brigatinib|Drug: Crizotinib,Ariad Pharmaceuticals|Takeda,Phase 3,275,Industry,"May 26, 2016","July 28, 2020","January 29, 2021"
7994,NCT02737358,N-acetylcysteine for Tobacco Use Disorder,Nicotine Dependence|Smoking,Drug: N-acetylcysteine (NAC)|Other: Placebo,Medical University of South Carolina|National Institute on Drug Abuse (NIDA),Phase 2,114,Other|NIH,"August 30, 2016","August 1, 2019","October 10, 2019"
7995,NCT02736968,Auranofin for Giardia Protozoa,Amoebic Dysentery|Giardiasis,Drug: Auranofin|Other: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,93,NIH,"November 6, 2016","March 10, 2021","March 10, 2021"
7996,NCT02736812,Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO),Shock Hemorrhagic,Biological: French Lyophilized Plasma|Biological: Normale Saline Solution,"French Defence Health Service|Bataillon des marins pompiers de Marseille, France|Military Hospital Laveran,Marseille, France|Samu of Marseille, France|Samu of Lyon, France|Lyon-South Hospital, France|Hôpital Edouard Herriot|Fire Brigade Of Paris Emergency Medicine Dept|CH Annecy Genevois|Institut de Recherche Biomedicale des Armees|Marseille North Hospital, France|Samu of Necker, Paris, France|Samu of Annecy, France|Military Hospital Percy , Clamart, France|Military Hospital Begin, Saint-Mandé, France|Centre de transfusion sanguine des Armées, Clamart, France|Henri Mondor University Hospital|Samu of Beaujon, Clichy-La-Garenne, France|Samu of Lariboisière, Paris, France|Samu of Henri Mondor, Créteil, France|Samu of Brest, Brest , France|Samu of Pau , Pau , France",Phase 3,140,Other,"April 1, 2016","October 31, 2019","November 30, 2019"
7997,NCT02736422,"Assessment of New Magnetic Resonance Imaging (MRI) Pulse Sequences for Imaging Hyperpolarised Xenon in Lung, Heart and Brain in Volunteers",Healthy Volunteers,Other: Hyperpolarised Xenon,Sheffield Teaching Hospitals NHS Foundation Trust,Phase 1,40,Other,Jul-11,"December 31, 2020","December 31, 2020"
7998,NCT02736409,An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE),Eosinophilic Esophagitis (EoE),Drug: Oral Budesonide Suspension (OBS)|Drug: Placebo,Shire|Takeda,Phase 3,219,Industry,"April 1, 2016","November 12, 2019","November 12, 2019"
7999,NCT02736305,Use of Regorafenib in Recurrent Epithelial Ovarian Cancer,Ovarian Neoplasms,Drug: Regorafenib,"National Cancer Centre, Singapore",Phase 2,21,Other,"February 3, 2016","November 18, 2019","November 18, 2019"
8000,NCT02735577,Neural Mechanisms of Disulfiram Effects,Alcohol Use Disorder,Drug: Disulfiram,New York State Psychiatric Institute,Phase 4,7,Other,Mar-16,"October 31, 2019","October 16, 2020"
8001,NCT02734862,CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension,Candidemia|Mycoses|Fungal Infection|Fungemia|Invasive Candidiasis,Drug: CD101|Drug: Caspofungin|Drug: Fluconazole|Drug: intravenous placebo|Drug: oral placebo,Cidara Therapeutics Inc.,Phase 2,207,Industry,"July 26, 2016",Jun-19,Jul-19
8002,NCT02733068,A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.,Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Cervical Intraepithelial Neoplasia,Biological: HPV-16/18 vaccine|Biological: HPV-16/18 placebo,"Shanghai Zerun Biotechnology Co.,Ltd|Guangxi Center for Disease Control and Prevention",Phase 3,12000,Industry|Other,"November 2, 2014","July 30, 2019","January 16, 2020"
8003,NCT02731352,Study of Apatinib in Patients With Differentiated Thyroid Cancer,Thyroid Cancer,Drug: Apatinib,Peking Union Medical College Hospital,Phase 2,20,Other,"March 11, 2016","February 27, 2020","February 28, 2021"
8004,NCT02730975,Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer,Prostate Cancer,Drug: AA Reduced dose-normal diet (A)|Drug: AA reduced dose-fat diet (B)|Drug: AA normal dose-fasting conditions (C),Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Phase 1,42,Other,"May 12, 2014","October 10, 2020","October 10, 2020"
8005,NCT02730507,"Surgical Treatment of Spinal Deformity With Sagittal Imbalance Using Patient-specific Rods: A Multicenter, Controlled, Double- Blind Randomized Trial: The PROFILE Study",Spinal Deformity With Sagittal Imbalance,Device: Surgery with patient-specific rod|Device: Conventional straight rod,Hospices Civils de Lyon,Phase 3,73,Other,Oct-16,"February 1, 2021","March 1, 2022"
8006,NCT02730481,"A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies",Solid Tumor,Drug: Oraxol,"Athenex, Inc.",Phase 1,38,Industry,Mar-16,Mar-21,May-21
8007,NCT02730429,Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer,Endometrial Cancer,Drug: Palbociclib/placebo|Drug: Letrozole,Nordic Society of Gynaecological Oncology - Clinical Trials Unit|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Cancer Intergroup (GCIG)|North Eastern German Society of Gynaecological Oncology|Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO)|Grupo Español de Investigación en Cáncer de Ovario,Phase 2,78,Other,"February 15, 2017","December 15, 2020","December 15, 2021"
8008,NCT02730377,Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: alpha-glucosidase inhibitors|Drug: DPP-4 inhibitors|Drug: meglitinides|Drug: SGLT-2 inhibitors|Drug: sulphonylurea|Drug: thiazolidinediones,Novo Nordisk A/S,Phase 4,1991,Industry,"March 28, 2016","August 5, 2019","August 12, 2019"
8009,NCT02730247,Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer,Drug: ramucirumab|Drug: nab-paclitaxel,"Liza Villaruz, MD|University of Pittsburgh",Phase 2,7,Other,"July 5, 2017","September 8, 2019","September 8, 2019"
8010,NCT02728843,Study of Parkinson's Early Stage With Deferiprone,Parkinson's Disease,Drug: Deferiprone|Drug: Placebo,ApoPharma,Phase 2,140,Industry,"October 12, 2016","August 2, 2019","September 4, 2019"
8011,NCT02728752,Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy),Dermatomyositis,Drug: Octagam 10%|Other: Placebo,Octapharma,Phase 3,95,Industry,"February 27, 2017","November 5, 2019","November 5, 2019"
8012,NCT02728726,Sugammadex vs Placebo to Prevent Residual Neuromuscular Block,General Surgery,Drug: Sugammadex|Drug: Placebo,"Mayo Clinic|Merck Sharp & Dohme LLC|University of Texas|Respiratory Motion, Inc.",Phase 4,260,Other|Industry,Jun-16,Dec-19,Dec-19
8013,NCT02728102,Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401),Multiple Myeloma,Procedure: Tumor Cell Collection|Procedure: Autologous Stem Cell Transplant|Drug: Melphalan|Procedure: Leukapheresis|Biological: Myeloma vaccine|Drug: GM-CSF|Drug: Lenalidomide,"National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program",Phase 2,203,NIH|Other,Jul-16,"June 30, 2020","December 9, 2022"
8014,NCT02726503,Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,Drug: Lenvatinib,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Phase 2,39,Other,"April 4, 2016","February 25, 2020","March 20, 2020"
8015,NCT02726009,A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer,Prostate Cancer,Drug: Degarelix,Ferring Pharmaceuticals,Phase 4,230,Industry,May-16,"May 15, 2020","May 15, 2020"
8016,NCT02725593,Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Dapagliflozin placebo,"AstraZeneca|Parexel|Q2 Solutions|PRA Health Sciences|Covance Laboratories, Inc",Phase 3,72,Industry|Other,"June 22, 2016","April 6, 2020","April 6, 2020"
8017,NCT02725489,Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers,Breast Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Uterine Cancer|Cervical Cancer|Endometrial Cancer,Biological: Vigil|Drug: Durvalumab,"Mary Crowley Medical Research Center|Gradalis, Inc.|AstraZeneca",Phase 2,13,Other|Industry,"June 3, 2016","December 30, 2019","December 2, 2020"
8018,NCT02725411,Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain,Low Back Pain,Drug: Celecoxib|Biological: Tanezumab 5 mg|Biological: Tanezumab 10 mg|Drug: Placebo for celecoxib|Biological: Placebo for tanezumab,Pfizer,Phase 3,277,Industry,"May 26, 2016","June 11, 2019","June 11, 2019"
8019,NCT02725268,"A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer",Endometrial Neoplasms,Drug: Paclitaxel|Drug: Sapanisertib|Drug: MLN1117,"Millennium Pharmaceuticals, Inc.|European Network of Translational Research in Ovarian Cancer - EUTROC|European Network of Individualized Treatment in Endometrial Cancer - ENITEC|Takeda",Phase 2,241,Industry|Other,"April 1, 2016","July 2, 2019","October 30, 2020"
8020,NCT02724020,MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,Clear-cell Metastatic Renal Cell Carcinoma,Drug: Everolimus|Drug: MLN0128|Drug: MLN1117,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 2,96,Industry,"June 30, 2016","February 3, 2020","October 13, 2020"
8021,NCT02723864,"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",Neoplasms,Drug: Veliparib + VX-970 + Cisplatin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,53,NIH,"August 9, 2017","December 15, 2020","December 31, 2021"
8022,NCT02723591,To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients,Kidney Transplantation,Drug: Tacrolimus|Drug: Tacrolimus immediate release,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 4,599,Industry,"September 9, 2016","June 14, 2019","June 14, 2019"
8023,NCT02723448,Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy,"Vasculopathy, Retinal, With Cerebral Leukodystrophy|Cerebroretinal Vasculopathy, Hereditary",Drug: aclarubicin,Washington University School of Medicine,Phase 1,4,Other,"December 5, 2016","July 23, 2020","July 23, 2020"
8024,NCT02723383,Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU,Alcoholism,Drug: BACLOFEN|Drug: PLACEBO,Nantes University Hospital,Phase 3,314,Other,"June 27, 2016","August 14, 2019","August 14, 2019"
8025,NCT02723344,"Biological Signatures, Probiotic Among Those With mTBI and PTSD",Mild Traumatic Brain Injury|Post Traumatic Stress Disorder,Dietary Supplement: of Lactobacillus reuteri (L. reuteri; DSM 17938)|Other: Sunflower and medium chain triglyceride oils,VA Office of Research and Development,Phase 1,75,U.S. Fed,"August 1, 2016","May 31, 2019","June 1, 2019"
8026,NCT02723240,NUC-3373 in Advanced Solid Tumours,Cancer,Drug: NUC-3373,University of Oxford,Phase 1,62,Other,Jan-16,"February 24, 2020","February 24, 2021"
8027,NCT02723162,Translational Neuropsychopharmacology Research of Nicotine Addiction,"Nicotine Dependence, Cigarettes",Drug: Varenicline (VRN)|Drug: N-Acetylcysteine (NAC)|Drug: Placebo,Medical University of South Carolina,Phase 2,67,Other,"May 4, 2016","March 9, 2020","March 9, 2020"
8028,NCT02722941,Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT),Multiple Myeloma,Drug: Panobinostat,H. Lee Moffitt Cancer Center and Research Institute|Novartis Pharmaceuticals,Phase 2,30,Other|Industry,"June 10, 2016","June 7, 2020","January 18, 2021"
8029,NCT02722538,Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer,Urinary Bladder Cancer,Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200,Taris Biomedical LLC,Phase 1,22,Industry,"May 31, 2016","May 2, 2019","May 2, 2019"
8030,NCT02722421,Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women,HIV|Contraception,Drug: Levonorgestrel|Drug: Efavirenz,"University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Infectious Diseases Institute, Uganda|University of Liverpool|Northwestern University Feinberg School of Medicine",Phase 2,28,Other|NIH,"April 6, 2017","December 5, 2019","March 30, 2020"
8031,NCT02721966,Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement,Axial Psoratic Arthritis,Biological: Secukinumab|Drug: Secukinumab and Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,503,Industry,"October 3, 2016","June 26, 2019","June 26, 2019"
8032,NCT02721654,Plasma-Lyte 148® versUs Saline Study,Hypovolemia,Drug: Plasma-Lyte 148®|Drug: 0.9% sodium chloride,The George Institute|Australian and New Zealand Intensive Care Society Clinical Trials Group|Baxter Healthcare Corporation,Phase 4,5037,Other|Industry,"September 1, 2017","March 30, 2021","June 30, 2021"
8033,NCT02721589,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects,Advanced Solid Tumors,Biological: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,126,Industry,"April 6, 2016","November 17, 2019","November 17, 2019"
8034,NCT02721433,4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases,Breast Cancer|Prostate Cancer|Metastasis,Drug: Pamidronate|Drug: Denosumab|Drug: Zoledronate,Ottawa Hospital Research Institute,Phase 4,263,Other,Aug-16,Sep-19,Apr-20
8035,NCT02721082,Changing the Default for Tobacco Treatment,Tobacco Use Cessation,Behavioral: Opt Out Treatment Program|Drug: Nicotine Replacement Therapy|Behavioral: Opt In Treatment Program,"University of Kansas Medical Center|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,1000,Other|NIH,"September 1, 2016","July 27, 2020","December 9, 2020"
8036,NCT02721069,Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects,Acute Repetitive Seizures|Breakthrough Seizures,Drug: NRL-1,"Neurelis, Inc.",Phase 3,175,Industry,"April 11, 2016","June 17, 2020","July 23, 2020"
8037,NCT02721043,Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies,Solid Tumors,Biological: Peptides|Drug: Poly-ICLC|Drug: Lenalidomide,Nina Bhardwaj|Icahn School of Medicine at Mount Sinai,Phase 1,13,Other,Apr-16,"November 12, 2019","June 8, 2020"
8038,NCT02720822,Breathlessness Exertion and Morphine Sulphate,Chronic Obstructive Pulmonary Disease|Dyspnea,Drug: Placebo|Drug: Morphine Sulfate|Drug: Plus laxative (Docusate with senna)|Drug: Plus placebo laxative|Device: FitBit charge HR (Accelerometer),Flinders University,Phase 3,171,Other,"August 8, 2016","December 20, 2019","December 20, 2019"
8039,NCT02720744,Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy,Excessive Daytime Sleepiness|Cataplexy|Narcolepsy,Drug: FT218|Drug: Placebo,Avadel,Phase 3,212,Industry,"November 17, 2016","March 25, 2020","March 25, 2020"
8040,NCT02720536,Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation,Chronic Iron Overload,Drug: Deferasirox,Novartis Pharmaceuticals|Novartis,Phase 3,53,Industry,"August 16, 2016","July 23, 2019","July 23, 2019"
8041,NCT02719977,A Phase I Study of CX5461,Cancer,Drug: CX5461,"Canadian Cancer Trials Group|Senhwa Biosciences, Inc.|Stand Up To Cancer",Phase 1,41,Other|Industry,"May 16, 2016","January 30, 2020","January 18, 2023"
8042,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,Metastatic Breast Cancer|Solid Tumors,Drug: Alisertib|Drug: MLN0128,"University of Colorado, Denver",Phase 1,47,Other,"May 13, 2016","March 18, 2020","March 18, 2020"
8043,NCT02718300,A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,MPN (Myeloproliferative Neoplasms),Drug: Parsaclisib|Drug: Ruxolitinib,Incyte Corporation,Phase 2,74,Industry,"February 8, 2017","January 28, 2021","April 29, 2022"
8044,NCT02717871,Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis,Keratitis; Infectious Disease (Manifestation),Device: PACK-CXL|Drug: Cefazolin in combination with either tobramycin or gentamicin|Drug: Cycloplegic agents (cyclopentolate 1% eye drops)|Drug: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Drug: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops),"University Hospital, Geneva",Phase 3,35,Other,Mar-16,Oct-20,Oct-20
8045,NCT02717338,"Blood Donor Competence, Autonomy and Relatedness Enhancement",Blood Donors,Behavioral: Competence|Behavioral: Autonomy|Behavioral: Relatedness,"Ohio University|New York Blood Center|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,2580,Other|NIH,"May 27, 2016","December 31, 2020","December 31, 2020"
8046,NCT02716675,Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men,HIV Infections,Biological: VRC01|Biological: Placebo for VRC01,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,2699,NIH,"April 6, 2016","December 1, 2020","December 1, 2020"
8047,NCT02716142,Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy,Bleeding During Myomectomy,Drug: rectal misoprostol|Drug: sublingual misoprostol,Assiut University,Phase 4,80,Other,"March 1, 2017","December 31, 2019","April 30, 2020"
8048,NCT02715635,Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation,Cardiovascular Diseases,Biological: Typhoid vaccine|Dietary Supplement: Concentrate beetroot Juice|Dietary Supplement: Concentrate beetroot Juice (Placebo),Queen Mary University of London,Phase 1,78,Other,Apr-16,Dec-20,"August 1, 2021"
8049,NCT02715011,"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","Leukemia, Myeloid, Acute",Drug: JNJ-63709178,"Janssen Research & Development, LLC",Phase 1,62,Industry,"June 1, 2016","March 26, 2021","March 26, 2021"
8050,NCT02713867,"A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks",Lung Cancer,Biological: Nivolumab,Bristol-Myers Squibb,Phase 3,363,Industry,"May 24, 2016","July 15, 2019","January 18, 2022"
8051,NCT02713776,Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment,Enterostomy,Drug: Pasireotide|Drug: Placebo,Hospices Civils de Lyon,Phase 2,57,Other,"December 13, 2016","January 8, 2021","January 8, 2021"
8052,NCT02713763,Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib,Pancreatic Neuroendocrine Tumour Metastatic,Drug: Sunitinib,Grupo Espanol de Tumores Neuroendocrinos|Pfizer|Apices Soluciones S.L.,Phase 2,11,Other|Industry,"February 14, 2017","October 23, 2019","October 23, 2019"
8053,NCT02712996,Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children,Traumatic Brain Injury|Attention Deficit Disorder,Drug: Lisdexamfetamine|Drug: Placebo,Vanderbilt University|Shire|Vanderbilt University Medical Center,Phase 4,20,Other|Industry,"February 6, 2017","July 1, 2019","July 1, 2019"
8054,NCT02712424,DAR-901 TB Booster Vaccine to Prevent TB in Adolescents,Tuberculosis,Biological: DAR-901|Biological: Sterile saline placebo,Dartmouth-Hitchcock Medical Center|Muhimbili University of Health and Allied Sciences,Phase 2,625,Other,Mar-16,"February 1, 2020","February 1, 2020"
8055,NCT02712346,The Role of Endothelin-1 in Sickle Cell Disease,Sickle Cell Anemia,Drug: Ambrisentan|Drug: Placebo,"Augusta University|Gilead Sciences|National Heart, Lung, and Blood Institute (NHLBI)",Phase 1,26,Other|Industry|NIH,Sep-15,"May 30, 2019","November 30, 2019"
8056,NCT02712112,A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs,Gastrointestinal Stromal Tumors (GISTs),Drug: Imatinib Mesylate,Asan Medical Center,Phase 2,51,Other,"March 16, 2016","June 15, 2019","June 15, 2019"
8057,NCT02711852,"A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)",Hematologic Malignancy,Drug: Duvelisib,SecuraBio,Phase 2,19,Industry,Apr-16,"May 4, 2020","May 4, 2020"
8058,NCT02710500,rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies,Dysferlinopathy,Drug: rAAVrh74.MHCK7.DYSF.DV,"Sarepta Therapeutics, Inc.",Phase 1,2,Industry,Mar-16,Jul-19,Jul-19
8059,NCT02710084,Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome,Phelan-McDermid Syndrome,Drug: Oxytocin|Drug: Saline,Alexander Kolevzon|Icahn School of Medicine at Mount Sinai,Phase 2,18,Other,"April 29, 2016","July 29, 2020","July 29, 2020"
8060,NCT02709746,Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD),"Depressive Disorder, Major",Drug: Vortioxetine 10 mg/day|Drug: Vortioxetine 20 mg/day|Drug: Fluoxetine 20 mg/day|Other: Placebo,H. Lundbeck A/S|Takeda,Phase 3,784,Industry,May-16,"July 2, 2019","July 30, 2019"
8061,NCT02709564,Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy,Blood Loss in Myomectomy,Drug: Misoprostol 400 sublingual|Drug: placebo 400 sublingual,Assiut University,Phase 3,80,Other,Dec-16,Dec-19,Feb-20
8062,NCT02709278,Aerosol BCG Challenge Trial in Healthy UK Adults,Tuberculosis,Biological: BCG|Other: Saline placebo,University of Oxford|University of Birmingham,Phase 1,46,Other,"March 7, 2016","May 9, 2019","May 9, 2019"
8063,NCT02709148,State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS),Parkinson's Disease,Device: Activa PC+S,University of Minnesota,Phase 1,1,Other,"July 20, 2017","July 31, 2019","July 31, 2020"
8064,NCT02708641,A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML,Acute Myeloid Leukemia,Drug: pembrolizumab,Michael Boyiadzis|Merck Sharp & Dohme LLC|University of Pittsburgh,Phase 2,12,Other|Industry,"October 4, 2016","June 11, 2020",Dec-20
8065,NCT02707809,Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient,Kidney Disease,Drug: Dexmedetomidine,National Taiwan University Hospital,Phase 4,60,Other,Aug-16,May-19,Jul-19
8066,NCT02706977,The Effect of Dopamine on Diabetic Retinopathy,Diabetes,Drug: Low Dose Sinemet CR|Drug: High Dose Sinemet CR|Device: RETeval Electroretinogram (ERG) Testing|Other: Contrast Sensitivity Testing|Other: Visual Acuity Testing,Emory University,Phase 1,60,Other,Jan-16,"August 15, 2019","August 15, 2019"
8067,NCT02706249,Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients,Venous Thormboembolism,Drug: Enoxaparin,"Dana-Farber Cancer Institute|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,50,Other|NIH,Apr-16,"December 7, 2020","June 7, 2021"
8068,NCT02705963,A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors,Solid Tumors,"Drug: Trametinib|Drug: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)",Novartis Pharmaceuticals|Novartis,Phase 1,19,Industry,"October 20, 2016","August 29, 2019","August 29, 2019"
8069,NCT02705482,A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,Select Advanced Solid Tumors,Biological: MEDI0562|Biological: Tremelimumab|Biological: Durvalumab,MedImmune LLC,Phase 1,58,Industry,"March 30, 2016","August 7, 2019","August 7, 2019"
8070,NCT02704754,Suvorexant and Trauma Related Insomnia,Insomnia|Posttraumatic Stress Disorder,Drug: suvorexant|Other: placebo,Howard University|Merck Sharp & Dohme LLC,Phase 4,41,Other|Industry,"May 1, 2016","April 30, 2021","April 30, 2021"
8071,NCT02704429,A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris,Pemphigus Vulgaris,Drug: PRN1008,"Principia Biopharma, a Sanofi Company|Principia Biopharma Australia Pty Ltd.|Sanofi",Phase 2,42,Industry|Other,"January 22, 2016","December 18, 2019","January 10, 2020"
8072,NCT02704390,Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD,Attention Deficit Hyperactivity Disorder,Drug: ORADUR®-Methylphenidate,"Orient Pharma Co., Ltd.|Durect",Phase 3,64,Industry,Jan-16,Aug-19,Aug-19
8073,NCT02704169,Quantitative Endoscopy of H&N,Head and Neck Cancer,Other: Spatially registered endoscopy,"University Health Network, Toronto|Princess Margaret Hospital, Canada",Phase 2,15,Other,Jul-13,"August 12, 2019","August 12, 2019"
8074,NCT02704156,SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer,Pancreatic Cancer,Device: Cyberknife plus Pembrolizumab and Trametinib|Device: Cyberknife plus Gemcitabine,Changhai Hospital,Phase 2,170,Other,Oct-16,Dec-20,Dec-20
8075,NCT02703779,Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),Multiple Myeloma,Drug: Bortezomib|Drug: Granulocyte colony-stimulating factor (G-CSF)|Drug: Mozobil,Siddhartha Ganguly|University of Kansas Medical Center,Phase 2,101,Other,Mar-16,"October 4, 2019","April 8, 2020"
8076,NCT02703714,Pembrolizumab and GM-CSF in Biliary Cancer,Biliary Cancer,Drug: Pembrolizumab|Drug: Sargramostim,"Robin Kate Kelley|American Society of Clinical Oncology|Merck Sharp & Dohme LLC|National Cancer Institute (NCI)|University of California, San Francisco",Phase 2,42,Other|Industry|NIH,"May 6, 2016","December 31, 2020","December 31, 2020"
8077,NCT02703649,Administration of Single High Dose Letrozole for Ovulation Induction,Anovulation,Drug: Letrozole,"Mount Sinai Hospital, Canada",Phase 4,36,Other,Mar-16,"July 31, 2020","July 31, 2020"
8078,NCT02703389,Improving Knowledge Translation Upon Emergency Department Discharge,Otitis Media,Behavioral: Video|Behavioral: Pamphlet,Hamilton Health Sciences Corporation,Phase 3,136,Other,Jan-17,Mar-20,Jun-20
8079,NCT02702388,"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",Thyroid Cancer,Drug: Lenvatinib|Drug: Lenvatinib matching placebo,Eisai Inc.|Merck Sharp & Dohme LLC,Phase 2,241,Industry,"June 8, 2017","December 12, 2019","September 10, 2020"
8080,NCT02702102,Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies,Diffuse Lewy Body Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia,Drug: 11C-PBR28,William Charles Kreisl|National Institute on Aging (NIA)|Columbia University,Phase 2,5,Other|NIH,Dec-15,"September 4, 2019","September 4, 2019"
8081,NCT02701400,Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,Recurrent Small Cell Lung Carcinoma,Biological: Durvalumab|Radiation: Hypofractionated Radiation Therapy|Radiation: Stereotactic Body Radiation Therapy|Biological: Tremelimumab,Emory University|AstraZeneca,Phase 2,18,Other|Industry,"April 14, 2016","August 7, 2020","August 7, 2020"
8082,NCT02700854,Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2,Hypoxic-Ischaemic Encephalopathy|Perinatal Asphyxia|Hypocapnia,Other: 5% carbon-dioxide inhalation,Semmelweis University,Phase 1,10,Other,Feb-16,Sep-19,Nov-19
8083,NCT02700685,Effect of Pycnogenol® on ADHD,ADHD,Dietary Supplement: Pycnogenol|Drug: Methylphenidate|Other: Placebo,Nina Hermans|Universiteit Antwerpen,Phase 3,88,Other,"September 1, 2017","November 20, 2020","November 20, 2020"
8084,NCT02700412,University of Alabama at Birmingham (UAB) Adult CBD Program,Epilepsy|Seizures,Drug: Epidiolex,University of Alabama at Birmingham,Phase 1,80,Other,Apr-15,"August 8, 2019","August 8, 2019"
8085,NCT02699749,A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors,"Nonhematologic Neoplasms, Advanced",Drug: TAK-931,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 1,80,Industry,"March 24, 2016","December 21, 2019","December 21, 2019"
8086,NCT02699086,A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD),Attention-Deficit Hyperactivity Disorder (ADHD),Drug: PDC-1421 Capsule,"BioLite, Inc.",Phase 2,6,Industry,"December 1, 2019","July 15, 2020","July 15, 2020"
8087,NCT02698891,Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer,Early Stage Breast Cancer,Drug: Paclitaxel|Drug: Neulasta,Dana-Farber Cancer Institute,Phase 2,127,Other,"April 7, 2016",Dec-20,Nov-21
8088,NCT02698631,Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging,Atrial Fibrillation,Procedure: Conventional AF ablation|Procedure: LGE-MRI guided AF ablation,Hospital Clinic of Barcelona|Institut d'Investigacions Biomèdiques August Pi i Sunyer|University of Barcelona,Phase 4,154,Other,Jan-16,Jun-19,Sep-20
8089,NCT02698501,Effects of Anti-TSLP in Patients With Asthma,Asthma,Drug: MEDI9929|Drug: Placebo,"Celeste Porsbjerg|Lund University|University of Newcastle, Australia|University of Copenhagen|University Hospital Bispebjerg and Frederiksberg",Phase 2,40,Other,Aug-16,"August 7, 2019","October 7, 2019"
8090,NCT02698215,Combining Varenicline and Naltrexone for Smoking Cessation,Nicotine Dependence|Alcohol Use Disorder,Drug: Varenicline|Drug: Varenicline plus Naltrexone,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",Phase 2,165,Other|NIH,May-16,Dec-19,Dec-19
8091,NCT02697734,Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease,Cushing's Disease,Drug: osilodrostat|Drug: osilodrostat Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,73,Industry,"October 3, 2016","June 19, 2019","December 31, 2020"
8092,NCT02697617,Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease,Polycystic Kidney Disease,Drug: Pioglitazone|Drug: Placebo,Indiana University,Phase 2,18,Other,"January 26, 2016",Oct-19,Jan-20
8093,NCT02697032,FDHT PET and Bicalutamide in Metastatic Breast Cancer,Breast Cancer,Drug: Bicalutamide|Procedure: FDHT PET,University Medical Center Groningen,Phase 2,22,Other,Feb-16,"November 25, 2019","November 25, 2019"
8094,NCT02696902,Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects,Pseudomonas Aeruginosa,Drug: MEDI3902|Other: Placebo,MedImmune LLC|INNOVATIVE MEDICINES INITIATIVE and COMBACTE-MAGNET|Antibacterial Resistance Leadership Group|National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,188,Industry|Other|NIH,"March 25, 2016","December 4, 2019","December 4, 2019"
8095,NCT02696707,An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer,Breast Cancer,Procedure: LVEF 3 month|Procedure: LVEF 4 month,Ottawa Hospital Research Institute,Phase 4,200,Other,Jun-16,May-20,Jul-20
8096,NCT02696564,Losartan Effects on Emphysema Progression,Emphysema,Drug: Losartan|Drug: Placebo,JHSPH Center for Clinical Trials|University of Pittsburgh,Phase 4,220,Other,"May 23, 2017","March 31, 2021","June 30, 2021"
8097,NCT02696408,Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation,Hematologic Malignancy,Device: Laser treatment|Device: Placebo,Institut de Cancérologie de la Loire|Hospices Civils de Lyon|Centre Leon Berard|Société Biophoton,Phase 3,234,Other,"June 27, 2016","November 7, 2019","December 9, 2019"
8098,NCT02696096,Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence,Opioid Addiction,Other: FMRI|Drug: Suboxone,Butler Hospital,Phase 3,21,Other,Aug-16,Feb-20,Feb-20
8099,NCT02696031,Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis,Non-radiographic Spondyloarthritis,Drug: Secukinumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,555,Industry,"April 29, 2016","July 1, 2019","March 11, 2021"
8100,NCT02693119,"A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy",Leber's Hereditary Optic Neuropathy,Drug: elamipretide (MTP-131) 1% topical ophthalmic solution|Drug: Vehicle topical ophthalmic solution,Stealth BioTherapeutics Inc.,Phase 2,12,Industry,Mar-16,Sep-19,Dec-19
8101,NCT02692391,A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis,Acute Pancreatitis,Drug: Indomethacin|Drug: Placebo,University of Pittsburgh,Phase 3,42,Other,Jul-13,"July 19, 2019","December 30, 2019"
8102,NCT02691793,"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors",Refractory Solid Tumors,Drug: Sunitinib,Samsung Medical Center,Phase 4,1,Other,"November 20, 2017","August 30, 2019","November 19, 2019"
8103,NCT02691390,Deep Repetitive Transcranial Magnetic Stimulation for Alcohol Use Disorder,Alcohol Abuse,Device: Active dTMS|Device: Sham dTMS,Soroka University Medical Center,Phase 1,51,Other,"July 1, 2016","December 31, 2019","December 1, 2020"
8104,NCT02691182,Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4),Attention Deficit Hyperactivity Disorder (ADHD),Drug: SPN-810,"Supernus Pharmaceuticals, Inc.",Phase 3,491,Industry,Mar-16,Apr-20,Apr-20
8105,NCT02691065,Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection,HIV,Drug: Integrase Inhibitor,McGill University Health Centre/Research Institute of the McGill University Health Centre|Merck Sharp & Dohme LLC,Phase 4,6,Other|Industry,"January 20, 2017","March 31, 2021","March 31, 2021"
8106,NCT02690883,Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy,Diabetic Nephropathies,Drug: Exenatide|Drug: Lispro,Nanfang Hospital of Southern Medical University,Phase 4,92,Other,"April 8, 2016","December 13, 2019","December 30, 2019"
8107,NCT02690038,Ig PRx in AECOPD: Pilot Study,Chronic Obstructive Pulmonary Disease,Drug: Intravenous immunoglobulin (IVIG)|Drug: Normal Saline,"Ottawa Hospital Research Institute|CSL Behring|Grifols Biologicals, LLC",Phase 2,48,Other|Industry,Sep-16,"November 20, 2019","November 20, 2019"
8108,NCT02689778,Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy,Diabetic Nephropathy|Albuminuria,Drug: Pirfenidone|Drug: Placebo,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Grupo Medifarma, S. A. de C. V.",Phase 3,62,Other|Industry,Mar-16,Dec-19,Dec-19
8109,NCT02689518,EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection,Macular Degeneration|Wet Macular Degeneration,Drug: Intravitreal aflibercept injection,"University of California, San Diego|Regeneron Pharmaceuticals",Phase 4,50,Other|Industry,Apr-14,"November 12, 2019","November 12, 2019"
8110,NCT02689505,Weekly BI 836880 in Patients With Advanced Solid Tumors,Neoplasms,Drug: BI 836880,Boehringer Ingelheim,Phase 1,24,Industry,"April 4, 2016","July 31, 2019","July 31, 2019"
8111,NCT02689089,Taima TB: 3HP Study,Tuberculosis,Drug: 3HP,Ottawa Hospital Research Institute|Government of Nunavut|Government of Canada,Phase 4,182,Other,"November 28, 2016","August 15, 2019","August 15, 2019"
8112,NCT02688881,"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors",Refractory Solid Tumors,Drug: sirolimus,Samsung Medical Center,Phase 4,6,Other,"February 5, 2017","December 30, 2020","February 24, 2021"
8113,NCT02688647,"A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis",Idiopathic Pulmonary Fibrosis,Drug: Belumosudil|Other: BSC,"Kadmon Corporation, LLC",Phase 2,76,Industry,"May 26, 2016","April 13, 2021","April 13, 2021"
8114,NCT02688608,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer,Drug: Pembrolizumab,Saad A Khan|Merck Sharp & Dohme LLC|Stanford University,Phase 2,6,Other|Industry,Oct-16,Oct-20,Oct-21
8115,NCT02687971,Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨,Cutaneous Leishmaniasis,Drug: Miltefosine,Drugs for Neglected Diseases,Phase 2,130,Other,Dec-16,"August 10, 2019","September 10, 2019"
8116,NCT02687490,Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer,Metastatic Breast Cancer,Drug: Abraxane,Fudan University,Phase 2,81,Other,"February 24, 2017","December 1, 2020","December 15, 2020"
8117,NCT02686944,A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors,Gastrointestinal Stromal Tumor,Biological: Intuvax (ilixadencel),Mendus,Phase 1,6,Industry,"June 1, 2016","May 10, 2019","May 10, 2019"
8118,NCT02686021,Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction,"Pain, Postoperative",Drug: Metamizole and Ibuprofen|Drug: Metamizole and Placebo|Drug: Ibuprofen and Placebo,"University Hospital, Basel, Switzerland",Phase 4,36,Other,"February 15, 2016","April 28, 2021","April 28, 2021"
8119,NCT02685852,Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia,Hyperinsulinemic Hypoglycemia,Drug: Exenatide|Drug: Acarbose|Drug: Exenatide Placebo|Drug: Acarbose Placebo,University of Minnesota,Phase 1,11,Other,Feb-16,"July 22, 2019","July 22, 2019"
8120,NCT02685709,Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly,Acromegaly,Drug: Octreotide capsules,"Chiasma, Inc.",Phase 3,146,Industry,Feb-16,Oct-20,Aug-21
8121,NCT02684279,Dasotraline Binge Eating Disorder Extension Study,Binge Eating Disorder,Drug: Dasotraline,Sunovion,Phase 3,533,Industry,"February 29, 2016","June 24, 2019","June 24, 2019"
8122,NCT02684266,A Study of SHR6390 in Advanced Solid Tumor Patients,Neoplasm,Drug: SHR6390,"Jiangsu HengRui Medicine Co., Ltd.",Phase 1,40,Industry,"March 3, 2016","June 28, 2019","June 28, 2019"
8123,NCT02684253,"Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",Head and Neck Squamous Cell Carcinoma (HNSCC),Drug: Nivolumab|Radiation: Stereotactic Body Radiation Therapy (SBRT),Memorial Sloan Kettering Cancer Center,Phase 2,65,Other,"February 11, 2016","January 22, 2021","January 22, 2021"
8124,NCT02683239,Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip,Osteoarthritis of the Knee or Hip,Drug: Fasinumab|Drug: Placebo,"Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.",Phase 3,5331,Industry,"February 17, 2016","December 1, 2020","June 15, 2021"
8125,NCT02683213,Efficacy of Fluoxetine - a Trial in Stroke,Stroke,Drug: Fluoxetine|Drug: Placebo,Karolinska Institutet|The Swedish Research Council|Swedish Heart Lung Foundation|Stroke-Riksförbundet|Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse|Hjärnfonden (The Swedish Brain foundation)|The Swedish Medical Association,Phase 3,1500,Other,"October 20, 2014",Jun-20,Jun-20
8126,NCT02683005,Study of Hepatitis C Treatment During Pregnancy,Hepatitis C|Pregnancy,Drug: ledipasvir/sofosbuvir,Catherine Chappell|Gilead Sciences|University of Nebraska|University of Pittsburgh,Phase 1,9,Other|Industry,Sep-16,"February 3, 2020","February 3, 2020"
8127,NCT02682927,A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome,Dravet Syndrome|Seizure Disorder,Drug: ZX008 (Fenfluramine Hydrochloride)|Drug: Matching Placebo,"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.|UCB Pharma",Phase 3,262,Industry,"January 15, 2016","July 29, 2020","July 29, 2020"
8128,NCT02682862,Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics,Asthma,"Drug: olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Drug: olodaterol 2.5 mcg",University of Dundee,Phase 4,17,Other,"July 11, 2016","May 22, 2019","May 22, 2019"
8129,NCT02682784,Neural Substrates of Emotion: Impact of Cocaine Dependence,Cocaine Use Disorder,Drug: Oxytocin|Drug: Placebo,Medical University of South Carolina,Phase 2,138,Other,Jul-15,"July 27, 2020","July 27, 2020"
8130,NCT02682693,Denosumab as an add-on Neoadjuvant Treatment (GeparX),Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III,Drug: Denosumab|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab,German Breast Group|Amgen|Celgene Corporation,Phase 2,780,Other|Industry,"February 13, 2017","December 31, 2019","December 31, 2020"
8131,NCT02682186,Pectoral Nerve Block for Analgesia After Breast Augmentation,Ambulatory Plastic Surgery|Esthetic Prosthetic Breast Expansion,Drug: Ropivacaine after dilution with sodium chloride 0.9%,"University Hospital, Montpellier",Phase 3,74,Other,"February 1, 2016","October 3, 2019","July 1, 2020"
8132,NCT02681796,Epidural Analgesia Use in Pancreatic Resections,Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer|Pancreas Neoplasms|Pancreatic Cancer,Drug: Bupivacaine,Washington University School of Medicine,Phase 1,23,Other,"June 7, 2016","February 7, 2020","February 7, 2020"
8133,NCT02681029,The Clinical Outcomes Following Transfer of Blastocysts Cultured From Thawed Cleavage Stage Embryos,Infertility,Procedure: Blastocyte Transferring|Procedure: Embryo Transferring,Royan Institute,Phase 3,220,Other,Nov-15,Jul-20,"September 27, 2020"
8134,NCT02680795,"Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",Solid Tumors|Hematological Malignancies,Drug: Belinostat IV,Acrotech Biopharma Inc.|Axis Clinicals Limited,Phase 1,17,Industry,"April 27, 2016","July 21, 2020","July 21, 2020"
8135,NCT02680574,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Anemia|Non-Dialysis-Dependent Chronic Kidney Disease,Drug: Vadadustat|Drug: Darbepoetin alfa,Akebia Therapeutics,Phase 3,1725,Industry,Feb-16,"June 18, 2020","July 31, 2020"
8136,NCT02679755,"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",Breast Cancer,Drug: Palbociclib|Drug: Letrozole,Pfizer,Phase 4,252,Industry,"March 9, 2016","July 25, 2019","July 25, 2019"
8137,NCT02679261,Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve,Bicuspid Aortic Valve,Drug: Atorvastatin|Drug: Placebo,Hospital Universitari Vall d'Hebron Research Institute,Phase 3,220,Other,Jun-16,Feb-21,Feb-21
8138,NCT02678117,"Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain",Postoperative Pain,Drug: Pregabalin & Placebo|Drug: Magnesium sulphate & Placebo|Drug: Pregabalin & Magnesium sulphate|Drug: Placebo,"National Cancer Institute, Egypt",Phase 3,120,Other,Jul-15,Dec-19,Dec-19
8139,NCT02677701,Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF),Cystic Fibrosis,Drug: azithromycin|Drug: placebo (for azithromycin)|Drug: inhaled tobramycin,"Seattle Children's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|Cystic Fibrosis Foundation|CF Therapeutics Development Network Coordinating Center",Phase 4,119,Other|NIH,"October 21, 2016","February 13, 2020","February 13, 2020"
8140,NCT02677324,Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia,Waldenstrom Macroglobulinemia,Drug: ABT199,Dana-Farber Cancer Institute|AbbVie,Phase 2,33,Other|Industry,"May 9, 2016","February 14, 2020","February 7, 2022"
8141,NCT02677181,Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT,aGVHD,Drug: ATG|Drug: CsA|Drug: mycophenolate mofetil|Drug: Methotrexate,"Chinese PLA General Hospital|309th Hospital of Chinese People's Liberation Army|Beijing Naval General Hospital|Space Center Hospital, Peking University",Phase 4,100,Other,Jan-16,Jan-20,Apr-22
8142,NCT02677155,Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma,Follicular Lymphoma,Radiation: Radiotherapy|Biological: Rituximab|Biological: Autologous dendritic cells|Biological: GM-CSF|Biological: Pembrolizumab,Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme LLC,Phase 2,10,Other|Industry,Jan-16,Feb-21,Feb-21
8143,NCT02676869,Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma,Stage IV Melanoma|Stage III Melanoma,Drug: IMP321 (eftilagimod alpha)|Drug: Pembrolizumab,Immutep Australia Pty. Ltd.,Phase 1,24,Industry,Apr-16,Aug-19,Dec-19
8144,NCT02675790,Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa,Sickle Cell Disease|Sickle Cell Anemia|Stroke,Drug: Moderate Dose Hydroxyurea|Drug: Low Dose Hydroxyurea,Vanderbilt University Medical Center|Aminu Kano Teaching Hospital|Murtala Muhammed Specialist Hospital,Phase 3,120,Other,Jan-17,"March 31, 2020","March 31, 2020"
8145,NCT02675205,Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm,Cerebral Aneurysm,Drug: Clopidogrel|Drug: Ticagrelor|Drug: aspirin,Fondation Ophtalmologique Adolphe de Rothschild,Phase 3,100,Other,Dec-15,Jul-20,Dec-20
8146,NCT02674763,Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia,Acute Myeloid Leukemia,Drug: IMGN779,"ImmunoGen, Inc.",Phase 1,62,Industry,Mar-16,Jun-19,Jul-19
8147,NCT02674750,"Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations",Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations,Drug: CUDC-907,"Curis, Inc.",Phase 2,70,Industry,Jul-16,"May 28, 2019","May 28, 2019"
8148,NCT02674386,"Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",Osteoarthritis,Drug: Investigational Medical Product (IMP) administered in parent study,Pfizer|Eli Lilly and Company,Phase 3,154,Industry,"August 23, 2016","July 15, 2019","July 15, 2019"
8149,NCT02674243,Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion,Malignant Pleural Effusion,Drug: Iodopovidone solution|Drug: Talc,Chiang Mai University,Phase 3,60,Other,Nov-15,Dec-19,Dec-19
8150,NCT02674061,Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),Ovarian Neoplasms,Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 2,376,Industry,"February 25, 2016","September 18, 2019","March 18, 2021"
8151,NCT02673398,Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer,HER2 Positive Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7,Other: Comprehensive Geriatric Assessment|Other: Laboratory Biomarker Analysis|Drug: Neratinib|Other: Pharmacological Study,City of Hope Medical Center|National Cancer Institute (NCI),Phase 2,25,Other|NIH,"December 2, 2016","March 12, 2020","September 22, 2022"
8152,NCT02673255,Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program,Healthy,Biological: Tetanus and Diphtheria (Td) Vaccine,"Biomat USA, Inc.|Hammond Clinical Trial Consulting, LLC|Axio Research. LLC",Phase 1,300,Industry|Other,"August 22, 2016","July 29, 2019","July 29, 2019"
8153,NCT02673164,Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease,Heart Failure,Biological: CSCC_ASC,"JKastrup|European Union|Rigshospitalet, Denmark",Phase 2,133,Other,Jan-17,Dec-20,Dec-20
8154,NCT02672566,Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction,Fetal Growth Retardation,Drug: Enoxaparin|Other: Usual care,Centre Hospitalier Universitaire de Saint Etienne,Phase 3,82,Other,"July 22, 2016","September 5, 2019","January 22, 2020"
8155,NCT02672436,ENERGI-F703 for Diabetic Foot Ulcers Phase II Study,Diabetic Foot|Foot Ulcer|Diabetes Mellitus|Wounds,Drug: ENERGI-F703|Drug: ENERGI-F703 matched vehicle,"Energenesis Biomedical Co., Ltd.|A2 Healthcare Taiwan Corporation",Phase 2,141,Industry,"March 15, 2017","October 3, 2019","December 26, 2019"
8156,NCT02670616,Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma,Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma,Drug: Ibrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: vincristine|Drug: Prednisolone,Samsung Medical Center,Phase 2,24,Other,"May 1, 2016",Jun-20,Oct-20
8157,NCT02670252,BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT,Allogeneic Hematopoietic Stem Cell Transplantation|Busulfan|Total Body Irradiation|Acute Lymphocytic Leukemia,Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Radiation: Total Body Irradiation (TBI),"Nanfang Hospital of Southern Medical University|Guangzhou First People's Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University|Xiangya Hospital of Central South University|The Seventh Affiliated Hospital of Sun Yat-sen University|The First Affiliated Hospital of Guangzhou Medical University|Guangdong Second Provincial General Hospital|The Affiliated Hospital of Qingdao University|First People's Hospital of Chenzhou|Guangzhou Panyu Central Hospital",Phase 3,550,Other,Jan-16,Feb-20,Feb-22
8158,NCT02670044,A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,"Leukemia, Myeloid, Acute",Drug: Cobimetinib|Drug: Idasanutlin|Drug: Venetoclax,Hoffmann-La Roche,Phase 1,88,Industry,"March 9, 2016","December 10, 2020","December 10, 2020"
8159,NCT02668978,SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial Using HEMOPATCH,LUNG DISEASES,Device: Hemopatch™ Sealing Hemostat|Procedure: Standard surgical technique,Quirón Madrid University Hospital|Baxter BioScience,Phase 4,170,Other|Industry,Mar-16,"August 31, 2019","August 31, 2019"
8160,NCT02668393,Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma,"Carcinoma, Non-Small-Cell Lung",Drug: Docetaxel|Drug: Nintedanib,Boehringer Ingelheim,Phase 1,14,Industry,"March 7, 2016","November 27, 2019","November 27, 2019"
8161,NCT02667574,Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC),Basal Cell Carcinoma,Drug: ERIVEDGE,"University Hospital, Lille|Hoffmann-La Roche",Phase 2,55,Other|Industry,"November 18, 2014","July 15, 2020","July 15, 2020"
8162,NCT02667392,Biofeedback to Increase Propulsion During Walking After Stroke,Stroke,Procedure: Gait Training with Biofeedback|Procedure: Gait Training with Verbal Feedback,VA Office of Research and Development,Phase 1,11,U.S. Fed,"October 2, 2017","September 16, 2019","September 30, 2019"
8163,NCT02666742,DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation,Ventricular Tachycardia|Premature Ventricular Contraction|Stroke,Drug: DOAC|Drug: Aspirin,Kansas City Heart Rhythm Institute|Kansas City Heart Rhythm Research Foundation,Phase 4,246,Other,"February 16, 2017","May 1, 2020","April 30, 2021"
8164,NCT02665754,"Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis",Allergic Rhinitis,Biological: ILIT with extract of causal allergen|Biological: ILIT with normal saline|Drug: Rescue medication for allergic rhinitis,Gachon University Gil Medical Center|Korea Research Foundation,Phase 1,32,Other,Jul-16,Dec-19,Jan-20
8165,NCT02665416,"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors",Advanced/Metastatic Solid Tumors,Drug: Selicrelumab|Drug: Vanucizumab|Drug: Bevacizumab,Hoffmann-La Roche,Phase 1,94,Industry,"January 25, 2016","October 30, 2019","October 30, 2019"
8166,NCT02665143,A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,Relapsed/Refractory Acute Myeloid Leukemia,Drug: Nintedanib and AML induction,Yale University|Vanderbilt University,Phase 2,25,Other,"July 21, 2016","March 8, 2021","March 30, 2021"
8167,NCT02664909,Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty,Femoral Neck Fractures,Drug: Tranexamic Acid|Drug: Placebo (saline),UConn Health|Orthopaedic Research and Education Foundation,Phase 4,36,Other,"January 1, 2016","June 30, 2019","June 30, 2019"
8168,NCT02664857,Vitamin D Supplementations and Postoperative Pain,Postoperative Pain,Drug: Vitamin D|Drug: Placebo,Cukurova University,Phase 4,50,Other,Jul-16,Dec-20,Dec-20
8169,NCT02664649,Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis,Symptomatic Aortic Stenosis|Eligible for Transcatheter Aortic Valve Replacement,Drug: Apixaban|Drug: Standard of care,Assistance Publique - Hôpitaux de Paris|Action Research Group|Bristol-Meyers Squibb & Pfizer,Phase 3,1510,Other,"August 26, 2016","October 15, 2020","October 15, 2020"
8170,NCT02664441,Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity,Hypothalamic Obesity,Drug: Exenatide|Drug: placebo,Seattle Children's Hospital|Children's Hospitals and Clinics of Minnesota|Vanderbilt University,Phase 3,42,Other,Mar-16,"March 16, 2020","July 31, 2020"
8171,NCT02663895,Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis,Systemic Sclerosis|Calcinosis,Drug: Oral treprostinil,Stanford University|United Therapeutics,Phase 2,12,Other|Industry,Oct-16,"May 13, 2020","May 13, 2020"
8172,NCT02663622,"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)",Graft Versus Host Disease|Hematopoietic Stem Cell Transplantation|Leukemia,Drug: Efprezimod alfa|Drug: Methotrexate|Drug: Tacrolimus|Drug: Placebo,"OncoImmune, Inc.|Ohio State University|University of Michigan Rogel Cancer Center|Indiana University School of Medicine|Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)",Phase 2,44,Industry|Other|NIH,"September 19, 2016","June 8, 2020","May 18, 2021"
8173,NCT02662985,Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA),Psoriatic Arthritis,Drug: AIN457 (secukinumab)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,166,Industry,"August 22, 2016","November 10, 2020","November 10, 2020"
8174,NCT02661685,Safety Study of Adoptive Transfer of Autologous IKDC-like Cells,Neoplasm Metastasis,Biological: autologous IKDC-like cells,"National Defense Medical Center, Taiwan|Ministry of Science and Technology, Taiwan|Academia Sinica, Taiwan",Phase 1,6,Other,May-16,Oct-19,Oct-19
8175,NCT02660944,A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus,Drug: RSLV-132|Drug: Placebo,Resolve Therapeutics,Phase 2,64,Industry,"January 3, 2016","May 28, 2020","August 10, 2020"
8176,NCT02660281,URMC Related Haplo-identical Donor BMT,Hematological Disease|Immune Deficiencies|Solid Tumors|Myelofibrosis|Multiple Myeloma|Lymphoma,Radiation: Total Body Irradiation 1200 cGy|Drug: Fludarabine|Drug: Pre-Stem Cell Infusion Cyclophosphamide|Drug: Pre-Stem Cell Infusion Mesna|Drug: Busulfan|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: Post-Stem Cell Infusion Cyclophosphamide|Drug: Post-Stem Cell Infusion Mesna|Drug: Thiotepa,University of Rochester,Phase 1,74,Other,Oct-15,"October 28, 2019","January 7, 2021"
8177,NCT02660034,"The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors",Solid Tumors,Biological: Tislelizumab|Drug: Pamiparib,"BeiGene|Myriad Genetic Laboratories, Inc.",Phase 1,229,Industry,"February 2, 2016","September 9, 2020","September 9, 2020"
8178,NCT02659891,IVIg to Treat BK Viremia in Kidney Transplant Recipients,Kidney Transplantation|BK Virus|Isoantibodies,Biological: IVIg|Other: Placebo,Massachusetts General Hospital,Phase 1,16,Other,May-16,"December 10, 2020","March 31, 2021"
8179,NCT02659540,Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma,Melanoma,Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiotherapy,Ludwig Institute for Cancer Research|Bristol-Myers Squibb|Conquer Cancer Foundation,Phase 1,20,Other|Industry,"October 13, 2016","May 9, 2019","July 27, 2020"
8180,NCT02659514,Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer,Breast Cancer,Drug: Poziotinib,"Spectrum Pharmaceuticals, Inc",Phase 2,67,Industry,"February 22, 2016","March 11, 2020","March 11, 2020"
8181,NCT02659098,A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy,Visual Acuity|Geographic Atrophy|Macular Degeneration,Drug: CNTO 2476 3.0 x 10^5 cells|Device: Subretinal Delivery System,"Janssen Research & Development, LLC",Phase 2,21,Industry,"December 4, 2015","June 5, 2019","June 5, 2019"
8182,NCT02658929,Study of bb2121 in Multiple Myeloma,Multiple Myeloma,Biological: bb2121,Celgene|bluebird bio,Phase 1,67,Industry,"December 22, 2015","July 22, 2019","September 22, 2022"
8183,NCT02658734,A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane,"HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",Drug: Trastuzumab emtansine,Hoffmann-La Roche,Phase 4,70,Industry,"November 1, 2016","December 14, 2019","December 14, 2019"
8184,NCT02658214,Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,"Small Cell Lung Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Stomach Neoplasms|Triple Negative Breast Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Esophagogastric Junction Neoplasms|Carcinoma, Pancreatic Ductal|Esophageal Squamous Cell Carcinoma",Drug: paclitaxel + carboplatin|Drug: carboplatin + etoposide|Drug: gemcitabine + carboplatin|Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin|Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|Biological: durvalumab|Biological: tremelimumab|Drug: nab-paclitaxel (paclitaxel-albumin) + gemcitabine|Drug: cisplatin + 5-fluorouracil (5FU),AstraZeneca,Phase 1,32,Industry,"April 28, 2016","November 14, 2019","November 14, 2019"
8185,NCT02658175,The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome,Familial Chylomicronemia Syndrome|Lipoprotein Lipase Deficiency|Hyperlipoproteinemia Type 1,Drug: Volanesorsen,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",Phase 3,68,Industry,"December 23, 2015","January 15, 2020","January 15, 2020"
8186,NCT02658019,Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,Hepatocellular Carcinoma,Drug: Pembrolizumab,"Lynn Feun, MD|Merck Sharp & Dohme LLC|University of Miami",Phase 2,29,Other|Industry,"May 6, 2016","November 10, 2019","December 17, 2019"
8187,NCT02657876,ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers,Diabetes|Diabetic Foot Ulcer|Non-healing Wound,Biological: ExpressGraft-C9T1 Skin Tissue,"Stratatech, a Mallinckrodt Company|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Mallinckrodt",Phase 1,5,Industry|NIH,"January 31, 2018","May 28, 2019","May 28, 2019"
8188,NCT02657434,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),Non-Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Pemetrexed,Hoffmann-La Roche,Phase 3,578,Industry,"April 30, 2016","July 18, 2019","December 13, 2022"
8189,NCT02656498,"[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease",Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: [18F]THK-5351,Jae Seung Kim|Korea Health Industry Development Institute|Samsung Medical Center|Asan Medical Center,Phase 2,135,Other,"January 11, 2016","December 31, 2019","December 31, 2019"
8190,NCT02656017,Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease,"Polycystic Kidney, Autosomal Dominant",Drug: Metformin|Other: Placebo,"Kyongtae Ty Bae, M.D., Ph.D.|Tufts Medical Center|University of Maryland, Baltimore|University of Southern California|United States Department of Defense|University of Pittsburgh",Phase 2,97,Other|U.S. Fed,"June 27, 2016","December 7, 2020","December 7, 2020"
8191,NCT02655965,Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption,Locoregional Analgesia in Breast Surgery,Drug: Ropivacaine|Drug: Clonidine|Drug: Sodium Chloride,Jules Bordet Institute,Phase 3,54,Other,May-16,Nov-19,"January 20, 2021"
8192,NCT02655770,Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients,Diabetes Mellitus Type 2|Diastolic Dysfunction|Cardiac MRI|Myocardial Perfusion,Drug: Liraglutide|Drug: Placebo,"Rigshospitalet, Denmark|Slagelse Hospital|Novo Nordisk A/S",Phase 4,40,Other|Industry,Feb-16,Dec-19,Dec-19
8193,NCT02655692,CAP-Ketamine for Antidepressant Resistant PTSD,PTSD|Posttraumatic Stress Disorder,Drug: Ketamine|Drug: Placebo/Saline,VA Office of Research and Development|The University of Texas Health Science Center at San Antonio|Brooke Army Medical Center|Minneapolis Veterans Affairs Medical Center,Phase 2,163,U.S. Fed|Other,"April 18, 2016","July 1, 2020","July 1, 2020"
8194,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,"Genentech, Inc.",Phase 1,54,Industry,"May 31, 2016","March 16, 2020","March 16, 2020"
8195,NCT02655315,Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease,Parkinson Disease,Drug: Deferiprone|Drug: Placebo,"University Hospital, Lille|European Commission|ApoPharma",Phase 2,372,Other|Industry,"February 9, 2016","September 22, 2020","September 22, 2020"
8196,NCT02654977,CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy,Familial Partial Lipodystrophy|Nonalcoholic Steatohepatitis|NAFLD,Drug: Metreleptin,University of Michigan,Phase 2,11,Other,"September 29, 2015","November 14, 2019","November 14, 2019"
8197,NCT02654912,Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration,Malaria,Drug: Reactive Focal Drug Administration,"PATH|Ministry of Health, Zambia|AKROS Global Health",Phase 4,8682,Other,Feb-16,Jun-20,Jul-20
8198,NCT02653976,A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),Peripheral T-Cell Lymphoma,Drug: SP-02L (darinaparsin for injection),Solasia Pharma K.K.,Phase 2,67,Industry,"March 25, 2016","October 11, 2020","June 17, 2021"
8199,NCT02653482,Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure,Chronic Heart Failure With Reduced Systolic Function,Drug: Dapagliflozin|Drug: Dapagliflozin matching placebo,Saint Luke's Health System,Phase 4,263,Other,"March 3, 2016","June 28, 2019","June 28, 2019"
8200,NCT02653300,A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH),Non-Alcoholic Steatohepatitis (NASH)|Type2 Diabetes Mellitus,Biological: Oral Insulin,"Oramed, Ltd.|Hadassah Medical Organization",Phase 2,10,Industry|Other,"September 20, 2018","March 1, 2020","April 1, 2020"
8201,NCT02653209,"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.",Type 2 Diabetes,Drug: Sitagliptin - DPP4i|Drug: Canagliflozin - SGLT2i|Drug: Pioglitazone - TZD,Royal Devon and Exeter NHS Foundation Trust|University of Exeter|NHS Tayside|University of Dundee|University of Glasgow|Newcastle University|King's College London,Phase 4,525,Other,"November 1, 2016",Jan-21,Jan-21
8202,NCT02652871,"LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",Leukemia,Drug: LY2510924|Drug: Idarubicin|Drug: Cytarabine,M.D. Anderson Cancer Center|Eli Lilly and Company|High Impact Clinical Research Support Program,Phase 1,36,Other|Industry,"May 9, 2016","July 16, 2019","July 16, 2019"
8203,NCT02651987,Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg,Pancreatic Tumours|Midgut Neuroendocrine Tumours,Drug: Lanreotide autogel 120 mg,Ipsen,Phase 2,99,Industry,"December 15, 2015","October 16, 2019","October 24, 2019"
8204,NCT02651454,"A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -",Metabolic Syndrome|Obesity,Drug: Daesiho-tang|Drug: Chowiseungcheng-tang|Drug: Placebo,"Gachon University Gil Oriental Medical Hospital|Sangji University Oriental Medical Hospital, Korea|DongGuk University",Phase 4,120,Other,"December 31, 2015","May 2, 2020","December 2, 2020"
8205,NCT02650804,BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients,Pancreatic Cancer,Drug: BPM31510 Nanosuspension Injection|Drug: Gemcitabine,"Berg, LLC",Phase 2,49,Industry,"July 6, 2016","June 11, 2019","June 11, 2019"
8206,NCT02650791,Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study,Hematologic Neoplasms,Drug: Tranexamic Acid,Ottawa Hospital Research Institute,Phase 3,100,Other,Oct-16,Jun-19,Dec-19
8207,NCT02650752,Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,Metastatic Breast Cancer|Central Nervous System (CNS) Metastases,Drug: Lapatinib in Tandem With Capecitabine,Memorial Sloan Kettering Cancer Center|Queens Cancer Center of Queens Hospital|University of Michigan,Phase 1,11,Other,"January 6, 2016","January 22, 2021","January 22, 2021"
8208,NCT02650713,"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",Solid Tumors,Drug: Atezolizumab|Drug: RO6958688,Hoffmann-La Roche,Phase 1,228,Industry,"January 7, 2016","January 13, 2020","January 13, 2020"
8209,NCT02650206,Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type II|Diabetes Mellitus, Adult-Onset|Inflammation",Drug: Victoza (liraglutide) with dietician monitoring|Other: Placebo with dietician monitoring,Stanford University,Phase 1,56,Other,Jan-15,"September 27, 2019","September 27, 2019"
8210,NCT02649465,SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD,Non-alcoholic Fatty Liver Disease,Drug: Tofogliflozin|Drug: Glimepiride,"Kanazawa University|Kowa Company, Ltd.",Phase 4,40,Other|Industry,"November 11, 2015","December 28, 2020","June 30, 2021"
8211,NCT02649231,Ketamine for Reduction of Alcoholic Relapse,Primary Alcohol Use Disorder,Drug: Ketamine|Drug: Placebo|Behavioral: Psychological Therapy|Behavioral: Alcohol Education,"University College, London",Phase 2,96,Other,Oct-16,Feb-20,Feb-20
8212,NCT02649218,A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients,Chronic Spontaneous Urticaria,Biological: Ligelizumab,Novartis Pharmaceuticals|Novartis,Phase 2,226,Industry,"May 24, 2016","May 2, 2019","May 2, 2019"
8213,NCT02648581,"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease",Behçet Disease,Drug: Subcutaneous Ustekinumab,Assistance Publique - Hôpitaux de Paris,Phase 2,16,Other,"June 14, 2017","May 7, 2019","November 19, 2019"
8214,NCT02648490,"An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",Solid Tumour,Drug: HLX07|Drug: Acetaminophen|Drug: dexamethasone|Drug: diphenhydramine|Drug: 5-HT3 inhibitor,"Henlix, Inc",Phase 1,19,Industry,Sep-16,"June 28, 2019","June 28, 2019"
8215,NCT02648464,Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial,Myocardial Infarction|Acute Coronary Syndrome|Inflammation|Hydroxychloroquine|Antirheumatic Agents|Cardiovascular Diseases,Drug: Hydroxychloroquine|Drug: Placebo,"Helsinki University Central Hospital|Finnish Foundation for Cardiovascular Research|Orion Corporation, Orion Pharma|Aarne Koskelo Foundation|Finnish Cultural Foundation",Phase 4,125,Other|Industry,"February 1, 2016","December 31, 2019","December 31, 2019"
8216,NCT02648347,Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease,Anemia|Non-Dialysis-Dependent Chronic Kidney Disease,Drug: Vadadustat|Drug: Darbepoetin alfa,Akebia Therapeutics,Phase 3,1751,Industry,Dec-15,"June 4, 2020","July 31, 2020"
8217,NCT02647671,Aquamin and Prevention of Colon Cancer,Colonic Cancer,Drug: Aquamin®|Drug: Calcium Carbonate|Drug: Placebo,James Varani|University of Michigan,Phase 1,36,Other,Apr-16,Mar-21,Mar-21
8218,NCT02647359,Study of Ataluren in Participants With Nonsense Mutation Aniridia,Aniridia,Drug: Ataluren|Drug: Placebo,PTC Therapeutics,Phase 2,39,Industry,"January 31, 2016","January 22, 2021","January 22, 2021"
8219,NCT02646982,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Mild Cognitive Impairment,Drug: Placebo|Drug: Candesartan,Emory University|National Institute on Aging (NIA),Phase 2,77,Other|NIH,"June 30, 2016","August 17, 2020","August 17, 2020"
8220,NCT02646748,Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,Colorectal Cancer (CRC)|Endometrial Cancer|Melanoma|Head and Neck Cancer|Lung Cancer|MMR-deficient Tumors|Breast Cancer|Pancreatic Cancer|Renal Cell Carcinoma (RCC)|Solid Tumors|UC (Urothelial Cancer),Drug: Pembrolizumab|Drug: itacitinib|Drug: INCB050465,Incyte Corporation,Phase 1,159,Industry,"January 25, 2016","November 7, 2019","November 20, 2020"
8221,NCT02646657,An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis,"Colitis, Ulcerative",Drug: Vedolizumab 300 mg,Geert D'Haens|Takeda|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Phase 4,120,Other|Industry,Jul-15,Aug-20,Aug-20
8222,NCT02646020,Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment,Non-small Cell Lung Cancer,Drug: Aprepitant|Drug: Desloratadine|Drug: Placebo of aprepitant|Drug: Placebo of desloratadine,Sun Yat-sen University,Phase 2,138,Other,Dec-15,"October 1, 2020","December 1, 2020"
8223,NCT02644967,A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma,Metastatic Melanoma,Drug: IMO-2125|Drug: Ipilimumab,"Idera Pharmaceuticals, Inc.",Phase 2,53,Industry,Dec-15,Feb-20,May-21
8224,NCT02644629,Intra-nasal vs. Intra-venous Ketamine Administration,Major Depressive Disorder,Drug: Placebo|Drug: Ketamine (1st phase)|Drug: Ketamine (2st phase),Shalvata Mental Health Center,Phase 4,45,Other,Apr-16,May-20,May-20
8225,NCT02644408,Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy,Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma,Drug: Megestrol（Yining）|Radiation: radiotherapy|Other: chemotherapy,The First Affiliated Hospital of Henan University of Science and Technology,Phase 3,184,Other,"October 1, 2014","December 1, 2019","December 1, 2020"
8226,NCT02643797,Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings,Type 2 Diabetes Mellitus (T2DM),Behavioral: Medical Assistant Health Coaching,Scripps Whittier Diabetes Institute|San Diego State University,Phase 3,602,Other,"March 7, 2016","April 19, 2020","April 19, 2020"
8227,NCT02643381,Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial,Cardiopulmonary Arrest|Respiratory Arrest,Drug: Etomidate|Drug: Ketamine|Procedure: Emergency Endotracheal Intubation|Device: Mechanical Ventilation,University of Texas Southwestern Medical Center,Phase 4,801,Other,"June 6, 2016","December 1, 2020","December 1, 2020"
8228,NCT02642913,Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,Hepatocellular Carcinoma,Drug: Enzalutamide|Drug: Enzalutamide with Sorafenib,"Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.|Mayo Clinic|University of California, San Francisco|University of Southern California|Washington University School of Medicine|Roswell Park Cancer Institute|National Comprehensive Cancer Network",Phase 1,28,Other|Industry,Dec-15,"March 1, 2021","March 1, 2021"
8229,NCT02642809,Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers,Esophageal Neoplasms|Esophageal Cancer|Cancer of the Esophagus,Drug: Pembrolizumab|Radiation: Brachytherapy|Procedure: Endoscopic biopsy|Procedure: Computed tomography-guided biopsy|Procedure: Peripheral blood collection,Washington University School of Medicine|Merck Sharp & Dohme LLC,Phase 1,16,Other|Industry,"June 8, 2016","September 24, 2020","August 3, 2021"
8230,NCT02642393,"Study of Urate Elevation in Parkinson's Disease, Phase 3",Parkinson's Disease,Drug: Inosine|Drug: Placebo,Michael Alan Schwarzschild|The Parkinson Study Group|Michael J. Fox Foundation for Parkinson's Research|University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital,Phase 3,298,Other|NIH,Jun-16,Jun-19,Jun-19
8231,NCT02641808,Does Follicular Flushing Improve the Outcome in Monofollicular IVF Therapy?,Infertility,Other: follicular flushing|Other: no follicular flushing,"University Hospital Inselspital, Berne|University of Bern",Phase 3,164,Other,"August 1, 2016","July 17, 2020","July 17, 2020"
8232,NCT02641691,Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum,"Cancer of Rectum|Cancer of the Rectum|Neoplasm, Rectum|Rectal Cancer|Rectum Cancer|Rectum Neoplasms|Adenocarcinoma of the Rectum",Radiation: Radiation|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil,Washington University School of Medicine,Phase 2,20,Other,"May 27, 2016","February 4, 2020","March 29, 2020"
8233,NCT02640092,Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants,Alzheimer's Disease,Drug: [18F]GTP1,"Genentech, Inc.",Phase 1,72,Industry,"December 23, 2015","June 11, 2019","June 11, 2019"
8234,NCT02639741,Preoperative Melatonin or Vitamin C Administration on Postoperative Analgesia,Postoperative Pain,Drug: Melatonin|Drug: Vitamin C|Other: Placebo,Cukurova University,Phase 4,55,Other,Nov-14,"January 1, 2020","December 30, 2020"
8235,NCT02639286,"Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension",Lipodystrophy,Drug: ISIS 304801|Drug: Placebo,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 2,5,NIH,"December 23, 2015","September 26, 2019","September 26, 2019"
8236,NCT02639182,A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Carcinoma,Drug: AGS-16C3F|Drug: Axitinib,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 2,133,Industry,"May 3, 2016","October 2, 2020","October 2, 2020"
8237,NCT02639065,A Study of Durvalumab (MEDI4736) in Esophageal Cancer,Esophageal Cancer,Drug: Durvalumab,"Shadia Jalal, MD|MedImmune LLC|AstraZeneca|Big Ten Cancer Research Consortium",Phase 2,39,Other|Industry,"April 27, 2016","December 9, 2020","June 9, 2021"
8238,NCT02638207,Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy,Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy,Drug: NewGam,Octapharma,Phase 3,142,Industry,"September 27, 2017","September 5, 2019","September 5, 2019"
8239,NCT02637895,Vortioxetine for Posttraumatic Stress Disorder,Post-Traumatic Stress Disorder,Drug: Placebo|Drug: Vortioxetine,University of Miami|Takeda|Emory University,Phase 4,41,Other|Industry,Dec-16,"January 22, 2020","February 6, 2020"
8240,NCT02637856,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),"Multiple Sclerosis, Relapsing-Remitting",Drug: Ocrelizumab,"Genentech, Inc.",Phase 3,608,Industry,"February 11, 2016","May 3, 2019","May 3, 2019"
8241,NCT02637427,Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures,Blood Coagulation Disorders|Hemorrhage,Biological: Fresh frozen plasma transfusion,"Rutgers, The State University of New Jersey|University of Pittsburgh|Johns Hopkins University|University of Washington|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,57,Other|NIH,"February 26, 2016","June 28, 2019",Nov-20
8242,NCT02637076,Xyrem and Brain Dopamine in Narcolepsy,Narcolepsy With Cataplexy|Healthy Controls,Drug: Xyrem,Centre for Addiction and Mental Health,Phase 4,17,Other,Jan-16,"January 23, 2020","January 23, 2020"
8243,NCT02636946,A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension,Glaucoma|Open-Angle Ocular Hypertension,Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty,Allergan,Phase 3,144,Industry,"February 24, 2016","January 26, 2021","January 26, 2021"
8244,NCT02635945,"A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.",Asthma,Drug: PBF-680|Drug: Placebo,Palobiofarma SL|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital de Sant Pau,Phase 2,8,Industry|Other,Apr-16,"September 30, 2019","November 30, 2019"
8245,NCT02635893,Lower Limb Function After Spinal Cord Injury,Spinal Cord Injury,Drug: D-Cycloserine|Drug: Placebo|Other: Training|Other: Stimulation|Other: Placebo Stimulation,Shirley Ryan AbilityLab|The Craig H. Neilsen Foundation,Phase 4,257,Other,"June 21, 2019","March 9, 2021","April 11, 2021"
8246,NCT02635386,"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)",Polycystic Ovary Syndrome|Obesity,Drug: Exenatide once weekly (EQW )|Drug: Dapagliflozin (DAPA)|Drug: EQW plus DAPA|Drug: Dapagliflozin plus Glucophage (MET ER)|Drug: Phentermine /Topiramate (PHEN/ TPM) ER,Woman's|AstraZeneca,Phase 3,119,Other|Industry,"March 22, 2016","July 22, 2020","October 9, 2020"
8247,NCT02634684,Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.,Schizophrenia,Drug: Dextroamphetamine|Drug: Placebo,"University of California, San Diego",Phase 2,82,Other,"July 1, 2014",Aug-20,Aug-20
8248,NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,Diabetic Retinopathy|Diabetic Macular Edema,Procedure: Prompt Sham|Drug: Prompt aflibercept|Procedure: Deferred laser|Drug: Deferred aflibercept,Jaeb Center for Health Research|Regeneron Pharmaceuticals|Juvenile Diabetes Research Foundation|National Eye Institute (NEI)|National Institutes of Health (NIH),Phase 3,399,Other|Industry|NIH,Jan-16,May-20,"May 11, 2022"
8249,NCT02634008,Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P,"Hepatitis C, Acute",Drug: Paritaprevir/ritonavir/ombitasvir|Drug: Dasabuvir|Drug: Ribavirin|Drug: Glecaprevir/pibrentasvir,Kirby Institute|AbbVie,Phase 3,83,Other|Industry,Jun-16,"April 30, 2021","April 30, 2021"
8250,NCT02633046,Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria,Idiopathic Focal Segmental Glomerulosclerosis,Drug: Acthar Gel,Mallinckrodt ARD LLC|Mallinckrodt,Phase 4,63,Industry,"October 10, 2016","August 27, 2020","August 27, 2020"
8251,NCT02632916,Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study,Osteoporosis,Drug: Zoledronic Acid|Drug: Denosumab,Children's Hospital of Eastern Ontario,Phase 2,10,Other,Aug-16,"February 3, 2020","February 3, 2020"
8252,NCT02632266,Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants,Complication of Prematurity,Dietary Supplement: Powder HMF|Dietary Supplement: Liquid HMF,University of Kansas Medical Center,Phase 4,40,Other,Jul-15,May-19,May-19
8253,NCT02632071,ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer,Metastatic Breast Cancer|Breast Carcinoma,Drug: ACY-1215|Drug: Nab-paclitaxel,Columbia University|Acetylon Pharmaceuticals Incorporated|National Cancer Institute (NCI),Phase 1,17,Other|Industry|NIH,"March 1, 2016","September 30, 2020","September 30, 2020"
8254,NCT02631759,Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage,Acute intraCerebral Haemorrhage,Drug: Lévétiracetam|Drug: Placebo,Hospices Civils de Lyon,Phase 3,50,Other,Oct-16,"April 9, 2021","June 7, 2021"
8255,NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,Drug: Cisplatin|Drug: Gemcitabine|Drug: Copanlisib,H. Lee Moffitt Cancer Center and Research Institute|Bayer,Phase 2,24,Other|Industry,"July 5, 2016","October 25, 2019","March 5, 2021"
8256,NCT02631538,Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome,Sjogren's Syndrome,Drug: Belimumab|Drug: Rituximab|Drug: Placebo belimumab|Drug: Placebo rituximab,GlaxoSmithKline,Phase 2,86,Industry,"February 17, 2016","June 23, 2020","June 23, 2020"
8257,NCT02631070,"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",Myelodysplastic Syndromes,Drug: Luspatercept|Other: Placebo,"Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 3,229,Industry,"February 9, 2016","June 18, 2019","November 26, 2020"
8258,NCT02630199,"Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer",Refractory Cancer,Drug: AZD6738|Drug: Paclitaxel,Samsung Medical Center,Phase 1,65,Other,Dec-15,Dec-20,"April 19, 2021"
8259,NCT02628860,Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy,Pancreatic Cancer|Anemia,Drug: Ferinject (Ferric Carboxymaltose),"National Cancer Center, Korea|JW Pharmaceutical",Phase 2,40,Other|Industry,Jan-14,"April 27, 2020","April 27, 2020"
8260,NCT02628574,"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab",Solid Tumors,Drug: TRX518 monotherapy|Drug: TRX518 with gemcitabine|Drug: TRX518 with pembrolizumab|Drug: TRX518 with nivolumab,"Leap Therapeutics, Inc.",Phase 1,109,Industry,Jan-16,"July 14, 2020","July 14, 2020"
8261,NCT02628444,Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age,Dengue Fever|Dengue Hemorrhagic Fever,Biological: CYD Dengue Vaccine|Biological: Placebo (Sodium chloride 0.9%),"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 2,1050,Industry,"May 2, 2016","April 29, 2020","April 29, 2020"
8262,NCT02626884,Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL),Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Drug: Ibrutinib,University of Cologne,Phase 2,14,Other,Aug-16,Aug-20,Aug-20
8263,NCT02626481,Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma,Multiple Myeloma,Drug: Daratumumab|Drug: Dexamethasone,"University Hospital, Lille|Janssen, LP|Intergroupe Francophone du Myelome",Phase 2,64,Other|Industry,"December 28, 2015","March 9, 2020","March 9, 2020"
8264,NCT02626364,Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,Recurrent/Refractory Glioblastoma,Drug: crenolanib,"Arog Pharmaceuticals, Inc.",Phase 2,11,Industry,Apr-16,Jul-20,Jul-20
8265,NCT02626299,Assessment of DHA On Reducing Early Preterm Birth,Preterm Birth,Drug: Docosahexaenoic acid - 800mg/day|Drug: Docosahexaenoic acid - 200mg/day|Other: Placebo,University of Kansas Medical Center|University of Cincinnati|Ohio State University|Nationwide Children's Hospital,Phase 3,1100,Other,"June 8, 2016","October 5, 2020","October 5, 2020"
8266,NCT02626156,Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence,Venous Hypertension Ulcers|Venous Stasis Ulcer|Venous Ulcer|Venous Insufficiency|Leg Ulcer|Foot Ulcer|Varicose Ulcer|Diabetic Foot,Device: Cooling gel pack|Device: Cooling cotton pack,Medical University of South Carolina,Phase 2,140,Other,"June 1, 2015","March 31, 2020","March 31, 2020"
8267,NCT02625909,Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.,Hepatitis C,Drug: SOF/VEL for 6 weeks|Drug: SOF/VEL for 12 weeks,Kirby Institute,Phase 3,222,Other,"March 9, 2017","March 23, 2020","March 23, 2020"
8268,NCT02625701,Perioperative Fluid Management: Goal-directed Versus Restrictive Strategy,"Complication, Postoperative",Procedure: Goal-directed therapy|Procedure: Restrictive fluid therapy,"University Hospital, Geneva",Phase 3,400,Other,Jan-12,Sep-19,Sep-19
8269,NCT02625610,Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100),"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction",Drug: Avelumab|Drug: Oxaliplatin|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Capecitabine|Other: Best supportive care,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 3,499,Industry,"December 24, 2015","September 13, 2019","June 3, 2021"
8270,NCT02625246,Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis,Bronchiectasis,Biological: hMSCs,Marilyn Glassberg|University of Miami,Phase 1,6,Other,"February 4, 2016","May 15, 2019","May 15, 2019"
8271,NCT02624778,A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD,Alzheimer Disease,Biological: LY3002813|Drug: Placebo,Eli Lilly and Company,Phase 1,61,Industry,"December 22, 2015","August 28, 2019","August 28, 2019"
8272,NCT02624375,Immune Response to Shingles Vaccination,Shingles,Drug: Zoster Vaccine Live,University of Washington|Merck Sharp & Dohme LLC,Phase 4,10,Other|Industry,Feb-16,Nov-19,Nov-19
8273,NCT02624180,Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV,Coronary Artery Disease|Human Immunodeficiency Virus,Drug: Colchicine|Drug: Placebo,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,81,Other|NIH,Nov-15,"August 1, 2020","September 1, 2020"
8274,NCT02623751,Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,Breast Cancer,Drug: KHK2375|Drug: Exemestane,"Kyowa Kirin Co., Ltd.",Phase 1,15,Industry,Nov-15,Oct-20,Oct-20
8275,NCT02623309,Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients,Hematologic Neoplasms,Biological: Allogeneic (Allo) hematopoietic stem cell transplantation,Institut Paoli-Calmettes,Phase 3,108,Other,"February 23, 2016","February 2, 2021","March 12, 2021"
8276,NCT02623205,Advancing Personalized Antidepressant Treatment Using PET/MRI,Depression,Drug: Escitalopram|Drug: Placebo,Stony Brook University,Phase 4,85,Other,May-15,Mar-20,Mar-20
8277,NCT02622984,Remote Brief Intervention and Referrals to Treatment Service for Alcohol,"Alcohol Abuse, Alcohol Dependence",Behavioral: RBIRT|Behavioral: SBIRT,"Polaris Health Directions|University of Massachusetts, Worcester",Phase 2,330,Industry|Other,"March 22, 2017","August 31, 2020","August 31, 2020"
8278,NCT02622386,The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis,Psoriasis,Drug: Riboflavin|Other: Placebo,University of Michigan,Phase 2,23,Other,"August 11, 2016","April 6, 2020","April 6, 2020"
8279,NCT02620306,"A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan",Chronic Kidney Disease,Drug: Fimsartan 60mg~120mg|Drug: Losartan 50mg~100mg,"Boryung Pharmaceutical Co., Ltd",Phase 3,351,Industry,"February 11, 2016","December 23, 2019","May 11, 2022"
8280,NCT02618720,Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery,Elective Colorectal Surgery,Drug: ornidazole|Drug: Placebo,"University Hospital, Clermont-Ferrand",Phase 3,920,Other,"May 25, 2016","November 26, 2019","June 30, 2020"
8281,NCT02618434,Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2),Attention Deficit Hyperactivity Disorder (ADHD),Drug: SPN-810|Drug: Placebo,"Supernus Pharmaceuticals, Inc.",Phase 3,297,Industry,Mar-15,Nov-19,Nov-19
8282,NCT02618408,Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1),Attention Deficit Hyperactivity Disorder (ADHD),Drug: SPN-810 (18 mg)|Drug: SPN-810 (36 mg)|Drug: Placebo,"Supernus Pharmaceuticals, Inc.",Phase 3,333,Industry,"January 25, 2016","September 4, 2019","October 24, 2019"
8283,NCT02617654,Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo for liraglutide,Per-Ola Carlsson|Uppsala University Hospital,Phase 2,18,Other,Nov-15,Sep-20,Sep-20
8284,NCT02617290,Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting,Coronary Artery Disease|Myocardial Ischemia|Myocardial Infarction|Stent Thrombosis|Cardiovascular Diseases,Drug: Ticagrelor|Drug: Clopidogrel,Assistance Publique - Hôpitaux de Paris|Action Research Group|AstraZeneca,Phase 3,1900,Other|Industry,"January 9, 2017","May 29, 2020","September 15, 2020"
8285,NCT02615249,Clinical Evaluation of Metal Panel Allergens: Dose Response Study,"Dermatitis, Eczematous",Biological: Metal Allergen Epicutaneous Patch,Allerderm,Phase 2,122,Industry,"December 5, 2016","July 15, 2019","July 15, 2019"
8286,NCT02615002,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),Alzheimer's Disease,Drug: Piromelatine|Drug: Placebo,Neurim Pharmaceuticals Ltd.,Phase 2,500,Industry,Nov-15,Jun-19,"November 19, 2019"
8287,NCT02614859,Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,Cancer of Prostate,Drug: Observation and Bicalutamide|Drug: Metformin and Bicalutamide,Fox Chase Cancer Center,Phase 2,29,Other,"December 1, 2015","January 24, 2020","January 24, 2020"
8288,NCT02614833,IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma,Adenocarcinoma Breast Stage IV,Biological: IMP321 (eftilagimod alpha)|Drug: Placebo|Drug: Paclitaxel,Immutep S.A.S.,Phase 2,242,Industry,Dec-15,Mar-20,May-21
8289,NCT02614794,A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer,HER2 Positive Breast Cancer,Drug: tucatinib|Drug: capecitabine|Drug: trastuzumab|Drug: placebo,Seagen Inc.,Phase 2,612,Industry,"January 28, 2016","September 4, 2019","August 11, 2022"
8290,NCT02614742,SFX-01 After Subarachnoid Haemorrhage,"Subarachnoid Hemorrhage, Spontaneous",Drug: SFX-01|Drug: Placebo,Evgen Pharma,Phase 2,90,Industry,Apr-16,Sep-19,Nov-19
8291,NCT02614456,Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,Advanced Solid Tumors,Drug: interferon-gamma and nivolumab,"Fox Chase Cancer Center|Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 1,26,Other|Industry,"December 11, 2015","June 12, 2019","June 12, 2019"
8292,NCT02614326,MemFlex to Prevent Depressive Relapse,Major Depressive Disorder,Behavioral: Autobiographical Memory Flexibility (MemFlex) training|Behavioral: Psychoeducation,Medical Research Council Cognition and Brain Sciences Unit,Phase 2,70,Other,Jan-16,Aug-20,Dec-20
8293,NCT02613884,"Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis",Vitamin D Deficiency,Drug: Treatment,Johns Hopkins All Children's Hospital,Phase 2,26,Other,Nov-16,"November 25, 2019","November 25, 2019"
8294,NCT02613169,Infant TB Infection Prevention Study,Tuberculosis,Drug: Isoniazid,University of Washington|Thrasher Research Fund,Phase 2,300,Other,Aug-16,Oct-19,Dec-20
8295,NCT02612779,A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.,Multiple Myeloma,Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Nivolumab,Bristol-Myers Squibb,Phase 2,74,Industry,"February 9, 2016","July 29, 2019","June 12, 2020"
8296,NCT02612558,A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA),Warm Antibody Autoimmune Hemolytic Anemia,Drug: Fostamatinib 150 mg bid,Rigel Pharmaceuticals,Phase 2,26,Industry,Jul-16,Dec-19,Dec-19
8297,NCT02612155,A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy,Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns,Biological: Infusion of autologous cord blood|Biological: Placebo,Michael Cotten|The Robertson Foundation|Duke University,Phase 2,35,Other,"March 30, 2017","August 5, 2019","August 5, 2019"
8298,NCT02611960,Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122),Nasopharyngeal Neoplasms,Biological: Pembrolizumab|Drug: Capecitabine|Drug: Gemcitabine|Drug: Docetaxel,Merck Sharp & Dohme LLC,Phase 3,233,Industry,"April 18, 2016","November 30, 2020","September 30, 2022"
8299,NCT02611817,Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD),Crohn's Disease,Drug: Vedolizumab SC 108 mg|Drug: Placebo|Drug: Vedolizumab IV 300 mg,Takeda,Phase 3,644,Industry,"January 4, 2016","May 6, 2019","August 6, 2019"
8300,NCT02611336,Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy,Acromegaly Cardiomyopathy,Drug: Tadalafil,Andrea M. Isidori|University of Roma La Sapienza,Phase 2,15,Other,Jul-16,Jan-21,Jun-21
8301,NCT02611258,Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs,Cushing's Syndrome Cardiomyopathy,Drug: Tadalafil,Andrea M. Isidori|University of Roma La Sapienza,Phase 2,18,Other,Jul-16,Jan-21,Jun-21
8302,NCT02611167,Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease,Parkinson's Disease,Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg),"The University of Texas Health Science Center, Houston",Phase 1,20,Other,"November 1, 2017","September 18, 2019","September 18, 2019"
8303,NCT02611063,Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant,Hematological Malignancies,Drug: fostamatinib,"Stefanie Sarantopoulos, MD, PhD.|Duke University",Phase 1,22,Other,Jan-16,Feb-21,"February 22, 2022"
8304,NCT02610777,"An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute",Drug: Azacitidine|Drug: Pevonedistat,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 2,120,Industry,"April 14, 2016","September 4, 2019","July 23, 2021"
8305,NCT02609828,Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy,Bone Metastasis|Cancer Pain,Drug: Tanezumab,Pfizer|Eli Lilly and Company,Phase 3,156,Industry,"October 28, 2015","September 17, 2020","June 25, 2021"
8306,NCT02609230,A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma,Advanced Solid Tumors|Multiple Myeloma,Drug: ONC-201,Fox Chase Cancer Center,Phase 1,33,Other,"November 5, 2015",Mar-20,"March 26, 2020"
8307,NCT02608684,A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,Ovarian Cancer,Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin,Cedars-Sinai Medical Center|Merck Sharp & Dohme LLC,Phase 2,21,Other|Industry,"February 8, 2016","May 17, 2019","March 7, 2022"
8308,NCT02607904,An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy,Epilepsy,Drug: GWP42003-P,Jazz Pharmaceuticals,Phase 2,30,Industry,"December 15, 2016","May 27, 2019","May 27, 2019"
8309,NCT02607449,FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis,"Tuberculosis, MDR",Drug: FS-1|Drug: Placebo,"Scientific Center for Anti-infectious Drugs, Kazakhstan|Phthisiopulmonology Center of Almaty, Kazakhstan|National Scientific Center of Phthisiopulmonology, Kazakhstan|Karaganda Medical University|West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan|Semey State Medical University|National Center of Phthisiatry, Bishkek, Kyrgyzstan|Invivo laboratory, Kazakhstan",Phase 3,344,Industry|Other,Dec-13,Aug-20,Oct-20
8310,NCT02606916,Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.,Esophageal Squamous Cell Carcinoma,Radiation: SMART|Drug: DDP|Drug: S-1,Sun Yat-sen University,Phase 2,42,Other,Jul-15,Aug-20,Aug-20
8311,NCT02606032,Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis,Ulcerative Colitis,Drug: Metronidazole|Drug: Doxycycline|Drug: Terbinafine|Drug: Placebo,Hamilton Health Sciences Corporation|Hamilton Academic Health Sciences Organization,Phase 2,75,Other,May-16,Jan-21,"January 27, 2021"
8312,NCT02605967,Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,Nasopharyngeal Carcinoma,Drug: Spartalizumab|Drug: Investigator choice of chemotherapy,Novartis Pharmaceuticals|Novartis,Phase 2,122,Industry,"April 20, 2016","November 5, 2019","February 19, 2021"
8313,NCT02605915,Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer,HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer,Drug: Atezolizumab|Drug: Carboplatin|Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Trastuzumab emtansine|Drug: Doxorubicin|Drug: Cyclophosphamide,Hoffmann-La Roche,Phase 1,98,Industry,"December 31, 2015","November 13, 2019","November 13, 2019"
8314,NCT02605447,EVOLVE Short DAPT Study,Coronary Artery Disease,Drug: 3 months of dual antiplatelet therapy (DAPT)|Device: SYNERGY Stent System,Boston Scientific Corporation,Phase 4,2009,Industry,"February 16, 2016","July 17, 2019","July 17, 2019"
8315,NCT02604433,An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia,Erythrocyte Transfusion|Beta-Thalassemia,Drug: Luspatercept|Other: Placebo,"Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 3,336,Industry,"May 2, 2016","January 5, 2021","January 5, 2021"
8316,NCT02604225,Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B,Cancer,Drug: Methoxyflurane|Drug: Placebo,University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group,Phase 3,420,Other,Dec-15,"December 5, 2019","December 30, 2019"
8317,NCT02603406,Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits,Angiogenesis|Ischemic Stroke,Drug: erythropoietin,"Ajou University School of Medicine|Dong-A Pharmaceutical Co., Ltd.",Phase 2,44,Other|Industry,"July 15, 2016","July 16, 2019","December 31, 2019"
8318,NCT02603003,"the""Fuzheng"" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs",Non-small Cell Lung Cancer(NSCLC),Drug: JinFuKang|Drug: Cisplatin|Drug: Pemetrexed,Shanghai University of Traditional Chinese Medicine,Phase 1,218,Other,Jun-15,"September 1, 2019","September 1, 2019"
8319,NCT02601833,Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques,Caries,Device: Silver Diamine Fluoride|Procedure: Conventional Caries Management,University of Michigan|Mott Children's Health Center,Phase 3,98,Other,Jan-16,"September 18, 2020","September 18, 2020"
8320,NCT02601027,Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA,Breast - Female,Procedure: Transversus Abdominis Plane (TAP) block|Device: Nimbus Infusion Pump IV Administration|Drug: Bupivacaine infusion|Drug: Acetominophen|Drug: Hydromorphone|Drug: Oxycodone|Drug: Ondansetron,Stanford University,Phase 3,120,Other,Nov-15,"September 7, 2019",Jun-21
8321,NCT02601014,Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,Prostate Cancer|Recurrent Prostate Carcinoma|Stage IV Prostate Adenocarcinoma,Biological: Ipilimumab|Biological: Nivolumab|Drug: Enzalutamide,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb,Phase 2,32,Other|Industry,"March 15, 2016","December 3, 2020","October 6, 2021"
8322,NCT02600923,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,Advanced Breast Cancer Female,Drug: Palbociclib|Drug: Letrozole,Pfizer,Phase 3,131,Industry,"April 15, 2016","May 28, 2019","May 28, 2019"
8323,NCT02600507,Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression,Bipolar Depression,Drug: Lumateperone (ITI-007)|Drug: Placebo,"Intra-Cellular Therapies, Inc.",Phase 3,529,Industry,"March 7, 2016","July 2, 2020","July 2, 2020"
8324,NCT02600130,Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease,Alzheimer's Disease,Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo,Longeveron Inc.,Phase 1,33,Industry,"October 10, 2016",Sep-20,Sep-21
8325,NCT02599532,Pharmacokinetics of Apixaban in Nephrotic Syndrome,Nephrotic Syndrome|Proteinuria,Drug: apixaban,"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute",Phase 1,21,Other,"April 30, 2017","June 28, 2019","June 28, 2019"
8326,NCT02599493,EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin,Osteoarticular Infection,Drug: Rifampicin,Rennes University Hospital,Phase 4,544,Other,Jan-16,Dec-20,Dec-20
8327,NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,Melanoma,Drug: Nivolumab|Drug: Ipilimumab,Bristol-Myers Squibb,Phase 3,533,Industry,"December 20, 2015","February 10, 2020","February 10, 2020"
8328,NCT02598596,Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect,Gout,Biological: Pegloticase|Drug: Azathioprine,"Ampel BioSolutions, LLC|IND 2 Results LLC",Phase 2,132,Industry,Dec-15,"April 13, 2020","April 27, 2020"
8329,NCT02597361,Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE),"Ehlers-Danlos Syndrome, Vascular Type",Drug: Irbesartan|Drug: Placebo,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 3,61,Other,Jan-16,"February 19, 2020","February 19, 2020"
8330,NCT02597101,Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes,Type 2 Diabetes Mellitus|Insulin Resistance,Drug: Metformin|Drug: saxagliptin|Drug: AZD9668|Drug: placebo,"Nick Giannoukakis, PhD|National Institutes of Health (NIH)|University of Pittsburgh|University of South Florida|AstraZeneca|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",Phase 2,14,Other|NIH|Industry,Nov-15,"June 10, 2019","June 15, 2019"
8331,NCT02597062,High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma,Multiple Myeloma,Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone,Canadian Cancer Trials Group|Amgen|Canadian Myeloma Research Group,Phase 2,76,Other|Industry,"March 29, 2016","June 19, 2019","February 1, 2022"
8332,NCT02596828,"Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma",Pineoblastoma,Drug: Temozolomide|Drug: Irinotecan|Drug: Dasatinib|Drug: Rapamycin,University of Regensburg,Phase 2,4,Other,Apr-16,Apr-21,Apr-21
8333,NCT02595749,Effects of Intranasal Oxytocin on Cigarette Smoking,Nicotine Dependence|Tobacco Smoking,Drug: Oxytocin|Drug: Placebo,University of Southern California,Phase 4,83,Other,Jul-16,Jul-19,Jul-19
8334,NCT02595489,A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy,X-linked Adrenoleukodystrophy,Dietary Supplement: vitamin D3,"Stanford University|National Institute of Neurological Disorders and Stroke (NINDS)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|ALD Connect, Inc.",Phase 1,21,Other|NIH|Industry,"November 21, 2016","June 30, 2020","June 30, 2020"
8335,NCT02595372,Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy,Cancer of the Breast,Drug: Omeprazole,Kathy Miller|Indiana University,Phase 2,42,Other,"November 12, 2015","November 21, 2019","March 1, 2021"
8336,NCT02594371,"Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer",Metastatic Breast Cancer,Drug: Oraxol|Drug: IV paclitaxel,"Athenex, Inc.",Phase 3,402,Industry,"December 2, 2015","July 25, 2019","June 30, 2022"
8337,NCT02594111,Colchicine in Percutaneous Coronary Intervention,Coronary Artery Disease|Acute Coronary Syndrome,Drug: Colchicine vs Placebo,VA Office of Research and Development|NYU Langone Health,Phase 4,714,U.S. Fed|Other,"May 30, 2013","August 30, 2019","December 31, 2021"
8338,NCT02593682,The Role of Orexin in Human Panic Disorder,Panic Disorder,Drug: suvorexant|Drug: placebo,"University of California, San Francisco",Phase 4,3,Other,May-16,"March 13, 2020","March 13, 2020"
8339,NCT02593539,"Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI",Activated PI3K-delta Syndrome,Drug: Nemiralisib,GlaxoSmithKline,Phase 2,5,Industry,"July 22, 2016","June 4, 2020","June 4, 2020"
8340,NCT02593097,Metformin for the Prevention of Episodic Migraine (MPEM),Migraine,Drug: Metformin|Drug: Matching Placebo,Mayo Clinic,Phase 3,34,Other,Feb-16,Jun-19,Jun-19
8341,NCT02593045,Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL),Cutaneous T-Cell Lymphoma,Biological: IPH4102,Innate Pharma,Phase 1,44,Industry,Oct-15,Apr-20,Apr-20
8342,NCT02592824,Glutamate for Metabolic Intervention in Coronary Surgery II,Coronary Artery Bypass Surgery|Postoperative Complications|Heart Failure,Drug: glutamate infusion|Drug: saline infusion,"University Hospital, Linkoeping|Region Örebro County|University Hospital, Umeå|Sahlgrenska University Hospital, Sweden|Blekinge County Council Hospital|Uppsala University Hospital, Sweden",Phase 3,321,Other,"November 15, 2015","October 30, 2020","October 30, 2020"
8343,NCT02592798,Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD),Nephrotic Syndrome|Focal Segmental Glomerulosclerosis|Minimal Change Disease,Drug: Abatacept|Other: Normal Saline|Other: D5W,Bristol-Myers Squibb,Phase 2,36,Industry,"March 9, 2016","January 28, 2020","January 28, 2020"
8344,NCT02592577,MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC,Non-Small Cell Lung Cancer|Carcinoma,"Biological: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T",Adaptimmune,Phase 1,28,Industry,Nov-15,"March 11, 2020","March 17, 2021"
8345,NCT02592551,MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,Mesothelioma,Drug: MEDI4736|Drug: Tremelimumab|Other: no other name,Baylor College of Medicine,Phase 2,24,Other,"May 11, 2016","August 6, 2019","September 1, 2022"
8346,NCT02592434,Efficacy Study Of Tofacitinib In Pediatric JIA Population,Juvenile Idiopathic Arthritis,"Drug: CP-690,550 (tofacitinib)|Other: placebo",Pfizer,Phase 3,225,Industry,"June 10, 2016","May 16, 2019","May 16, 2019"
8347,NCT02591901,Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods),UTI|Neurogenic Bladder|Antibiotic Resistance,Drug: Uro vaxom|Other: Placebo comparator,"Buckinghamshire Healthcare NHS Trust|National Institute for Health Research, United Kingdom|Oxford Clinical Trials Research Unit",Phase 2,48,Other,"April 6, 2018","August 2, 2019","September 21, 2019"
8348,NCT02591420,Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection,HIV Infections,Biological: VRC01|Biological: Placebo for VRC01|Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient),National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,24,NIH,Apr-16,"March 15, 2021","March 15, 2021"
8349,NCT02590653,"Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI",Myocardial Infarction,Drug: Atorvastatin,Penza State University,Phase 4,200,Other,Oct-14,Dec-19,Feb-20
8350,NCT02589977,"Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF","Heart Failure, Diastolic|Diastolic Heart Failure|Hypertension",Drug: regadenoson,"Marvin W. Kronenberg, M.D.|Astellas Pharma US, Inc.|Vanderbilt University Medical Center",Phase 4,55,Other|Industry,Nov-15,"January 21, 2020","January 21, 2020"
8351,NCT02589821,Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors,Neuroendocrine Tumors,Drug: Surufatinib|Other: Placebo,Hutchison Medipharma Limited|Hutchmed,Phase 3,195,Industry,"December 7, 2015","November 11, 2019","July 7, 2022"
8352,NCT02589119,Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP),Perianal Fistula|Cryptoglandular Perianal Fistula,Drug: MSC-AFP,Mayo Clinic,Phase 1,15,Other,Jan-16,Sep-19,Sep-19
8353,NCT02588833,"Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.",Paroxysmal Nocturnal Hemoglobinuria,Drug: Pegcetacoplan,"Apellis Pharmaceuticals, Inc.",Phase 1,23,Industry,"December 1, 2015","August 26, 2019","August 26, 2019"
8354,NCT02588612,Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC),Neoplasms,Drug: letetresgene autoleucel (GSK3377794)|Drug: Cyclophosphamide|Drug: Fludarabine,GlaxoSmithKline,Phase 1,10,Industry,"February 1, 2016","August 10, 2020","August 10, 2020"
8355,NCT02588326,Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays,Hypersensitivity,Drug: Mometasone furoate drug formulation (MFF) 1|Drug: Mometasone furoate drug formulation (MFF) 2,University of Florida|Food and Drug Administration (FDA)|GlaxoSmithKline,Phase 1,80,Other|U.S. Fed|Industry,"September 21, 2018","July 8, 2020","April 16, 2021"
8356,NCT02588105,Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,Advanced Solid Tumours,Drug: AZD0156|Drug: Olaparib|Drug: irinotecan|Drug: Fluorouracil|Drug: Folinic Acid,AstraZeneca|Syneos Health,Phase 1,84,Industry|Other,"November 10, 2015","September 13, 2019","July 26, 2022"
8357,NCT02587195,A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period,Multiple Sclerosis,Drug: Teriflunomide,Centre Hospitalier Universitaire de Nice,Phase 3,5,Other,"December 18, 2015","August 31, 2020","August 31, 2021"
8358,NCT02586649,24hr Effects of Tiotropium Bromide in Tetraplegia,Spinal Cord Injury,Drug: Tiotropium Bromide|Drug: Placebo,James J. Peters Veterans Affairs Medical Center,Phase 2,10,U.S. Fed,Jul-14,Dec-19,Dec-19
8359,NCT02586155,Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD,"Diabetes Mellitus, Type 2|Coronary Artery Disease",Drug: Apabetalone|Drug: Placebo|Drug: Atorvastatin|Drug: Rosuvastatin,Resverlogix Corp|PPD|ICON plc|Medidata Solutions,Phase 3,2425,Industry,Nov-15,"November 30, 2020","June 21, 2021"
8360,NCT02585973,Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,"Carcinoma, Squamous Cell of Head and Neck",Drug: AZD1775|Drug: Cisplatin|Radiation: Intensity Modulated Radiotherapy Treatments,UNC Lineberger Comprehensive Cancer Center|AstraZeneca,Phase 1,12,Other|Industry,"October 26, 2015","June 14, 2019","June 23, 2021"
8361,NCT02585258,The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study,RheumatoId Arthritis,Drug: Prednisolone|Other: Placebo,"Amsterdam UMC, location VUmc|European Commission",Phase 4,451,Other,"June 30, 2016","December 31, 2020","December 31, 2020"
8362,NCT02584608,Use of ACTIMMUNE in Patients With ADO2,Autosomal Dominant Osteopetrosis Type 2,Drug: ACTIMMUNE,"Indiana University|Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 2,12,Other|Industry,"January 1, 2016","November 12, 2019","November 12, 2019"
8363,NCT02584283,Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation,Liver Failure|End Stage Liver Disease|Biliary Tract Diseases,Procedure: Dual hypothermic oxygenated perfusion|Device: Liver Assist®|Procedure: Perfusion fluid|Drug: Glutathione,"Robert J. Porte|Erasmus Medical Center|Leiden University Medical Center|Universitaire Ziekenhuizen KU Leuven|University Hospital, Ghent|King's College Hospital NHS Trust|University Medical Center Groningen",Phase 3,157,Other,Jan-16,Jan-20,Jan-20
8364,NCT02584140,Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women,HIV Prevention,Behavioral: Text Messaging|Behavioral: Adherence Counseling|Drug: Daily Oral PrEP,"University of California, Los Angeles|University of California, San Diego|California HIV/AIDS Research Program|Los Angeles County Department of Public Health|AIDS Project Los Angeles",Phase 4,136,Other,May-16,"May 15, 2019","June 14, 2019"
8365,NCT02583932,Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer,Advanced Cancer,Drug: Meaning-Making intervention (MMi)|Behavioral: Empathic Visitor,Jewish General Hospital|McGill University Health Centre/Research Institute of the McGill University Health Centre,Phase 3,179,Other,Oct-15,Aug-20,Aug-20
8366,NCT02583516,Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma,Melanoma,Drug: vemurafenib and cobimetinib,"Grupo Español Multidisciplinar de Melanoma|Roche Farma, S.A|Pivotal S.L.",Phase 2,70,Other|Industry,"June 30, 2015","September 30, 2019","September 30, 2019"
8367,NCT02583399,Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients,Pain|Fever,Drug: Ibuprofen,Cumberland Pharmaceuticals,Phase 4,30,Industry,"August 8, 2017","July 2, 2019","July 2, 2019"
8368,NCT02582866,A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994,Epilepsy,Drug: Lacosamide,UCB Biopharma S.P.R.L.|Parexel|UCB Pharma,Phase 3,106,Industry,Jan-16,Jan-20,Jan-20
8369,NCT02582177,Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis,Tinea,Drug: Candicort®|Drug: Nizoral®|Drug: Baycuten N®|Drug: Canesten®,Ache Laboratorios Farmaceuticos S.A.,Phase 3,125,Industry,"June 11, 2019","January 20, 2020","March 24, 2020"
8370,NCT02582125,ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer,Advanced Non-small Cell Lung Cancer,Drug: ONO-4538,Ono Pharmaceutical Co. Ltd,Phase 2,53,Industry,"January 27, 2016","January 4, 2021","December 31, 2021"
8371,NCT02581878,Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma,"Lymphoma, Non-Hodgkin",Drug: BAY1862864,Bayer,Phase 1,21,Industry,"November 20, 2015","November 11, 2019","November 26, 2019"
8372,NCT02581007,Reduced Intensity Conditioning Transplant Using Haploidentical Donors,Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelofibrosis|CMML|Multiple Myeloma,Drug: Fludarabine|Drug: Melphalan|Drug: Cyclophosphamide|Procedure: peripheral blood stem cell transplant,"Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia",Phase 2,25,Other,"October 26, 2015","November 5, 2019","December 28, 2020"
8373,NCT02580630,Achilles Tendinopathy Treated With Training and Injections,Achilles Tendinopathy,Behavioral: Reduction in running and jumping|Other: Training|Drug: Ultrasound guided injection with Glucocorticosteroid|Drug: Ultrasound guided injection with local anaestethic,Bispebjerg Hospital|The Danish Rheumatism Association,Phase 4,100,Other,Apr-16,"December 20, 2020","December 20, 2020"
8374,NCT02580552,"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL","Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides (MF)|Chronic Lymphocytic Leukemia (CLL)|Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype|Adult T-Cell Leukemia/Lymphoma (ATLL)",Drug: Cobomarsen,"miRagen Therapeutics, Inc.",Phase 1,66,Industry,"February 9, 2016","October 6, 2020","October 6, 2020"
8375,NCT02580305,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,Alzheimer's Disease,Drug: SUVN-502|Drug: Placebo|Drug: Donepezil|Drug: Memantine,Suven Life Sciences Limited,Phase 2,564,Industry,Sep-15,"November 5, 2019","November 7, 2019"
8376,NCT02579642,Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy,Depressive Disorder,Drug: Ketamine|Drug: Placebo,University of Alberta|Alberta Health services,Phase 4,48,Other,Oct-15,May-19,May-19
8377,NCT02579629,Use of On-Q Pump for Pain Post C-Section,Pain,Drug: Ropivacaine 0.1%|Drug: Ropivacaine 0.2%|Drug: Normal saline|Device: On-Q ® elastomeric pump,Emory University,Phase 4,64,Other,Jul-15,"July 25, 2019","July 25, 2019"
8378,NCT02579252,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease,Alzheimer's Disease,Biological: AADvac1|Drug: Placebo,Axon Neuroscience SE,Phase 2,208,Industry,Mar-16,Jun-19,Jun-19
8379,NCT02579226,"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.",Advanced Solid Tumours,Drug: AZD2811,AstraZeneca,Phase 1,72,Industry,"October 28, 2015","February 7, 2020","April 3, 2020"
8380,NCT02579096,CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat,Gout|Chronic Kidney Diseases,"Drug: allopurinol capsule, 100-800 mg by mouth once daily|Drug: febuxostat tablet 40-120 mg by mouth once daily|Drug: Placebo, vehicle control (febuxostat-shaped)|Drug: Placebo, vehicle control (allopurinol-shaped)",VA Office of Research and Development,Phase 4,950,U.S. Fed,"March 6, 2017","February 1, 2021","April 15, 2021"
8381,NCT02578901,American Trial Using Tranexamic Acid in Thrombocytopenia,Thrombocytopenia,Drug: Tranexamic Acid|Drug: Placebo,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,330,Other|NIH,Jun-16,Mar-20,"June 11, 2020"
8382,NCT02578732,FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Locally Advanced Pancreatic Cancer|Pancreatic Cancer,Drug: FOLFOXA,Brown University|Rhode Island Hospital,Phase 2,28,Other,"July 12, 2016","December 18, 2019","March 16, 2022"
8383,NCT02577861,Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency,Limbal Stem Cells Deficiency,Procedure: Biopsy from donor eye|Procedure: Implant of Holoclar|Procedure: Ophtalmologic examination|Procedure: Blood sample collection|Procedure: Digital pictures|Procedure: ECG|Behavioral: Questionnaires|Procedure: Physical examination and vital signs,Holostem Terapie Avanzate s.r.l.,Phase 4,70,Industry,Oct-15,Dec-20,"March 11, 2022"
8384,NCT02577614,FEIBA and Use of Blood Products in Cardiac Surgery,Cardiovascular Disease,Drug: FEIBA|Drug: Normal Saline,Oregon Health and Science University,Phase 1,12,Other,Feb-16,Dec-19,Mar-20
8385,NCT02577341,Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer,Non-small-cell Lung Cancer,Drug: Nimotuzumab|Drug: docetaxel and cisplatin|Radiation: daily RT to the chest,Sun Yat-sen University,Phase 2,122,Other,Aug-15,Jun-20,Oct-20
8386,NCT02576990,Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170),Mediastinal Large B-cell Lymphoma|Richter Syndrome,Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 2,80,Industry,"December 2, 2015","May 28, 2019","October 23, 2020"
8387,NCT02575222,Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Drug: Nivolumab,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb,Phase 1,17,Other|Industry,Feb-16,"June 9, 2020","June 9, 2020"
8388,NCT02575183,Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation,Nicotine Dependence,Drug: Varinecline (Chantix)|Drug: Placebo (for Varenicline)|Behavioral: Behavioral Therapy,American University of Beirut Medical Center|Pfizer,Phase 4,152,Other|Industry,"August 31, 2016","March 1, 2021","March 1, 2021"
8389,NCT02574741,Combination Treatment for Augmenting Language in Children With ASD,Autism Spectrum Disorder,Behavioral: Behavioral Therapy|Drug: Aripiprazole|Drug: Placebo,"University of California, Los Angeles",Phase 2,58,Other,Jun-12,Dec-19,Dec-19
8390,NCT02574598,MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients,"Carcinoma, Non-Small-Cell Lung",Drug: MK-3475|Drug: Docetaxel,Instituto Nacional de Cancerologia de Mexico,Phase 2,78,Other,Jun-16,Oct-19,"November 19, 2020"
8391,NCT02574455,Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC),Breast Cancer,Drug: Sacituzumab govitecan|Drug: Eribulin|Drug: Capecitabine|Drug: Gemcitabine|Drug: Vinorelbine,Gilead Sciences,Phase 3,529,Industry,"November 7, 2017","March 30, 2020","December 8, 2020"
8392,NCT02574403,Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS,Atypical Hemolytic Uremic Syndrome,Drug: eculizumab,Nantes University Hospital,Phase 4,58,Other,Nov-15,"December 3, 2019","December 3, 2019"
8393,NCT02574286,Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease,Gaucher Disease,Drug: Velaglucerase alfa|Dietary Supplement: Vitamin D,Shire|Takeda,Phase 4,21,Industry,"June 29, 2016","November 12, 2020","November 30, 2020"
8394,NCT02574026,Tapfinger Psychomotor Target,Functional Brain Mapping,Behavioral: Psychomotor tasks,"University Hospital, Grenoble|Commissariat A L'energie Atomique",Phase 1,37,Other,Aug-10,"July 31, 2020","July 31, 2020"
8395,NCT02573883,Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus,Vulvar Lichen Sclerosus,Device: Fractionated Carbon Dioxide Laser|Drug: Clobetasol Propionate 0.05% ointment,Medstar Health Research Institute,Phase 3,52,Other,Oct-15,Sep-19,Sep-19
8396,NCT02573506,Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer,Non-small Cell Lung Cancer,Radiation: split-course radiotherapy|Drug: Concurrent chemotherapy,Sun Yat-sen University,Phase 2,99,Other,Aug-15,Mar-20,Mar-20
8397,NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",Part 1|MELANOMA|SCCHN|OVCA|SARCOMA|OTHER SOLID TUMORS|Part 1 and 2|NSCLC|UROTHELIAL CARCINOMA,Drug: PF-06801591,Pfizer,Phase 1,147,Industry,"February 10, 2016","November 19, 2020","November 19, 2020"
8398,NCT02571777,Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma,Asthma,Drug: QVM149 150/50/160|Drug: QVM149 150/50/80|Drug: QMF149 150/320|Drug: QMF149 150/160|Drug: salmeterol/fluticasone,Novartis Pharmaceuticals|Novartis,Phase 3,3092,Industry,"December 8, 2015","June 14, 2019","June 14, 2019"
8399,NCT02571179,Intranasal Fentanyl in Treatment of Labour Pain,Labor Pain,Drug: intranasal fentanyl 50 microg dose up to 250 microg,Kuopio University Hospital|Admescope Ltd,Phase 4,20,Other|Industry,Jan-11,Mar-21,Mar-21
8400,NCT02570854,A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients,"Anemia, Iron-Deficiency",Biological: CSJ137|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 1,40,Industry,"September 22, 2015","May 13, 2020","May 13, 2020"
8401,NCT02569476,BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies,B-cell Lymphoid Malignancies,Drug: Zanubrutinib|Drug: Obinutuzumab,BeiGene,Phase 1,119,Industry,"January 13, 2016","September 2, 2020","September 2, 2020"
8402,NCT02569320,HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,Recurrent Plasma Cell Myeloma,Drug: Dexamethasone|Drug: HDAC Inhibitor AR-42|Other: Laboratory Biomarker Analysis|Drug: Pomalidomide,Ohio State University Comprehensive Cancer Center|Celgene,Phase 1,9,Other|Industry,"May 20, 2016","November 14, 2020","March 10, 2021"
8403,NCT02569242,Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,Esophageal Cancer,Drug: Nivolumab|Drug: Docetaxel/Paclitaxel,Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb,Phase 3,419,Industry,"December 14, 2015","October 23, 2020","October 23, 2020"
8404,NCT02568215,Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women,HIV Infections,Biological: VRC01|Biological: Placebo for VRC01,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,1924,NIH,May-16,"March 3, 2021","March 3, 2021"
8405,NCT02567253,Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer,Ovarian Cancer|Primary Peritoneal Cancer,Procedure: Cytoreductive surgery|Drug: IPEC with Cisplatin (75mg/m²)|Drug: IPEC with Cisplatin (100mg/m²)|Drug: Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Drug: HIPEC with Cisplatin (100mg/m²),"University Hospital, Ghent",Phase 2,54,Other,Mar-16,"December 31, 2020","August 25, 2021"
8406,NCT02566993,Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer,Small-cell Lung Cancer,Drug: Lurbinectedin (PM01183)|Drug: Doxorubicin (DOX)|Drug: Cyclophosphamide (CTX)|Drug: Vincristine (VCR)|Drug: Topotecan,PharmaMar,Phase 3,613,Industry,"August 30, 2016","February 24, 2020","February 24, 2020"
8407,NCT02565992,Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA),Melanoma,Biological: CAVATAK|Drug: Pembrolizumab,Viralytics,Phase 1,36,Industry,"December 17, 2015","November 4, 2019","November 4, 2019"
8408,NCT02565914,A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation,Cystic Fibrosis,Drug: TEZ/IVA|Drug: IVA,Vertex Pharmaceuticals Incorporated,Phase 3,1044,Industry,Aug-15,May-19,"December 5, 2022"
8409,NCT02565719,REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection,Chronic Hepatitis B,Drug: REP 2139-Mg|Drug: Pegasys|Drug: Viread|Drug: REP 2165-Mg,Replicor Inc.,Phase 2,40,Industry,Mar-16,May-19,May-19
8410,NCT02565693,Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation,Cerebral Hemorrhage|Atrial Fibrillation,Drug: Apixaban|Drug: Aspirin|Drug: Carbasalate calcium|Drug: Clopidogrel|Drug: Dipyridamole|Other: No antithrombotic treatment,UMC Utrecht|Dutch Heart Foundation|ZonMw: The Netherlands Organisation for Health Research and Development,Phase 2,101,Other,Sep-14,"January 31, 2021","January 31, 2021"
8411,NCT02565186,"An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine",Migraine Disorders,Drug: Lasmiditan,Eli Lilly and Company|CoLucid Pharmaceuticals,Phase 3,2171,Industry,"October 7, 2015","August 20, 2019","August 20, 2019"
8412,NCT02564744,Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL,Diffuse Large B-Cell Lymphoma|B-cell Non-Hodgkin's Lymphoma,Drug: Debio 1562|Drug: Rituximab,Debiopharm International SA,Phase 2,100,Industry,"June 15, 2016","January 13, 2021","June 25, 2021"
8413,NCT02564315,The Long-Term Quitting (Smoking Cessation) Study,Smoking Cessation,Drug: Nicotine Mini-Lozenge for 11 Months|Behavioral: Preparation Phase Behavioral Reduction Counseling|Behavioral: Preparation Phase Recycling Counseling|Behavioral: Preparation Phase Control Treatment|Behavioral: Cessation Phase Supportive Counseling|Behavioral: Cessation Phase Skill Training Counseling|Behavioral: Cessation Phase Brief Information|Drug: Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge,"University of Wisconsin, Madison|Penn State University|University of Illinois at Chicago",Phase 4,1154,Other,"October 30, 2015","November 5, 2019","November 5, 2019"
8414,NCT02564198,A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,Pediatric Solid Tumor|Refractory Tumor|Recurrent Tumor|CNS Malignancies,Drug: Ramucirumab,Eli Lilly and Company|Children's Oncology Group,Phase 1,29,Industry|Other,"December 11, 2015","July 16, 2019","July 16, 2019"
8415,NCT02563535,Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia,Peripheral Artery Disease,Device: DEB|Device: PTA,Ospedale San Donato,Phase 4,105,Other,Sep-15,Jan-20,Jan-20
8416,NCT02563496,"A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria","Malaria, Vivax",Drug: Tafenoquine|Drug: Chloroquine,GlaxoSmithKline|Medicines for Malaria Venture,Phase 2,60,Industry|Other,"February 6, 2017","December 15, 2019","February 17, 2020"
8417,NCT02563067,Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.,Asthma,Drug: QAW039|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,877,Industry,"December 3, 2015","July 4, 2019","August 2, 2019"
8418,NCT02562781,Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?,Vascular Disease,Drug: Oxygen|Other: Air,"Örebro University, Sweden",Phase 3,184,Other,Nov-14,Dec-20,Jan-21
8419,NCT02562755,Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,Hepatocellular Carcinoma (HCC),Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Sorafenib,"SillaJen, Inc.",Phase 3,459,Industry,Oct-15,Jul-20,Jul-20
8420,NCT02562716,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma,Drug: Fluorouracil|Drug: Gemcitabine Hydrochloride|Drug: Irinotecan Hydrochloride|Drug: Oxaliplatin|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Procedure: Pancreatectomy,SWOG Cancer Research Network|National Cancer Institute (NCI),Phase 2,147,Other|NIH,"January 6, 2016","May 31, 2020","September 26, 2022"
8421,NCT02562066,Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes,"Myasthenic Syndromes, Congenital",Drug: amifampridine phosphate|Drug: Placebo,"Catalyst Pharmaceuticals, Inc.",Phase 3,20,Industry,Jan-16,Aug-19,Oct-19
8422,NCT02561000,Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention,Arterial Occlusive Diseases|Coronary Artery Disease|Coronary Disease|Arteriosclerosis|Heart Diseases|Myocardial Ischemia|Vascular Diseases|Acute Coronary Syndrome,Drug: PZ-128|Drug: Placebo,"Tufts Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|RTI International|Inova Fairfax Hospital|University of Massachusetts, Worcester",Phase 2,100,Other|NIH,"May 27, 2016","September 17, 2019","September 17, 2019"
8423,NCT02560935,Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II,Sickle Cell Disease|Stroke,Drug: Hydroxyurea (Moderate Dose)|Drug: Hydroxyurea (Low Dose),Vanderbilt University Medical Center|Aminu Kano Teaching Hospital|Murtala Muhammed Specialist Hospital|National Institute of Neurological Disorders and Stroke (NINDS)|Barau Dikko Teaching Hospital/Kaduna State University,Phase 3,440,Other|NIH,"July 19, 2016","March 3, 2020","March 3, 2020"
8424,NCT02560558,Bela 8 Week Dosing,Kidney Transplantation,Drug: Belatacept,Emory University,Phase 4,166,Other,Sep-15,"August 29, 2019","August 29, 2019"
8425,NCT02560519,Albumin in Cardiac Surgery,C.Surgical Procedure; Cardiac,Drug: Albumin solution|Drug: Ringers acetate solution,Helsinki University Central Hospital,Phase 4,1386,Other,"March 21, 2017","April 13, 2020","November 4, 2020"
8426,NCT02559180,Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab,Diabetic Retinopathy|Macular Edema,Drug: aflibercept,Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic,Phase 4,20,Other|Industry,Oct-15,Dec-20,Dec-20
8427,NCT02559167,Cannabidiol and Cocaine Craving/Dependence,Substance Use Disorder|Cocaine Dependence|Withdrawal From Addictive Substance; Detoxification,Drug: Cannabidiol,Centre hospitalier de l'Université de Montréal (CHUM),Phase 2,79,Other,"July 1, 2016","August 16, 2019","August 16, 2019"
8428,NCT02559115,68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer,Prostate Cancer,Radiation: 68Ga-RM2 (RM2)|Device: PET/CT Scan,Memorial Sloan Kettering Cancer Center,Phase 2,19,Other,"September 21, 2015","June 18, 2020","June 18, 2020"
8429,NCT02559102,Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants,Neurodevelopmental Disorder|Bilateral Inguinal Hernia,Drug: Dexmedetomidine sedation|Drug: General sevoflurane anaesthesia|Procedure: Caudal anaesthesia|Procedure: Inguinal hernia surgery,KK Women's and Children's Hospital|Singhealth Foundation|Singapore Institute for Clinical Sciences|Duke-NUS Graduate Medical School,Phase 3,104,Other,Jul-15,"July 20, 2020","January 31, 2021"
8430,NCT02558504,Radiofrequency in the Treatment of Barrett's Oesophagus,Esophageal Neoplasm,Procedure: Oesophagectomy|Device: Radiofrequency ablation,Hospices Civils de Lyon,Phase 4,87,Other,"January 7, 2013","January 18, 2021","January 18, 2021"
8431,NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Drug: Macitentan|Drug: Tadalafil|Drug: Selexipag,Actelion,Phase 3,247,Industry,"May 1, 2016","August 29, 2019","April 20, 2020"
8432,NCT02556931,"Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myeloproliferative Disorders|Multiple Myeloma|Plasma Cell Neoplasm|Plasma Cell Dyscrasia|Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia|Plasma Cell Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate mofetil,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),Phase 2,117,Other|NIH,Dec-15,Apr-21,Apr-21
8433,NCT02556606,Ketamine for Treatment Resistant Late-Life Depression,Treatment Resistant Depressive Disorder,Drug: Ketamine|Drug: Midazolam,VA Office of Research and Development,Phase 3,33,U.S. Fed,"October 1, 2015","March 31, 2020","March 31, 2020"
8434,NCT02556424,Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema,Inflammatory Macular Edema,Drug: Dexamethasone|Drug: Triamcinolone,Nantes University Hospital,Phase 3,114,Other,Jan-16,"February 15, 2021","February 15, 2021"
8435,NCT02556229,Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).,Inflammatory Choroidal Neovascularization,Drug: Aflibercept,Hospices Civils de Lyon,Phase 2,20,Other,Jun-16,Sep-19,Sep-19
8436,NCT02555748,Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma,Metastatic Renal Cell Cancer,Drug: Pazopanib|Drug: Sunitinib,"Institut Claudius Regaud|University Hospital, Bordeaux",Phase 4,47,Other,"November 17, 2015","January 16, 2020","January 16, 2020"
8437,NCT02555683,Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.,Asthma,Drug: QAW039|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,894,Industry,"December 11, 2015","October 21, 2019","November 4, 2019"
8438,NCT02555371,Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients,Asthma,Biological: Mepolizumab 100mg|Drug: Placebo,GlaxoSmithKline,Phase 3,306,Industry,"January 7, 2016","July 24, 2019","July 24, 2019"
8439,NCT02555111,Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.,Deep Vein Thrombosis|Chronic Portal Vein Thrombosis,Drug: Xarelto,Assistance Publique - Hôpitaux de Paris,Phase 3,112,Other,Sep-15,Feb-20,Feb-20
8440,NCT02554903,Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation,Pulmonary Hypertension,Drug: Macitentan 10mg|Drug: Placebo sugar pill,Actelion,Phase 2,57,Industry,"March 28, 2016","March 13, 2020","March 13, 2020"
8441,NCT02554253,"The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction",Cognitive Disorders|Delirium|Acute Kidney Injury,Drug: Ketamine|Drug: Propofol,Mayo Clinic,Phase 2,52,Other,Sep-15,Dec-20,Dec-20
8442,NCT02553941,Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Refractory Anemia With Excess Blasts in Transformation|Secondary Myelodysplastic Syndrome,Drug: Azacitidine|Drug: Ibrutinib,"Brian Jonas|Pharmacyclics LLC.|University of California, Davis",Phase 1,21,Other|Industry,"May 17, 2016","May 25, 2019","November 7, 2019"
8443,NCT02553785,Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy,Heart Failure,Device: Revivent TC,BioVentrix|Ohio State University,Phase 1,89,Industry|Other,Jun-15,Dec-19,Dec-19
8444,NCT02553473,Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis,"Neuroborreliosis, Borrelia Burgdorferi",Drug: Doxycycline|Drug: Placebo,Sorlandet Hospital HF,Phase 3,121,Other,Oct-15,Jan-20,Feb-21
8445,NCT02553265,Carbidopa for the Treatment of Excessive Blood Pressure Variability,"Dysautonomia, Familial|Baroreflex Failure Syndrome",Drug: Carbidopa Low-Dose|Other: Placebo|Drug: Carbidopa High-Dose,NYU Langone Health,Phase 2,22,Other,Sep-15,"May 10, 2019","May 10, 2019"
8446,NCT02553226,Continued Versus Discontinued Oxytocin Stimulation of Labour,Adverse Reaction to Oxytocin,Drug: Oxytocin|Drug: Placebo,"University of Aarhus|Randers Regional Hospital|Aarhus University Hospital|Kolding Sygehus|Aalborg University Hospital|Herning Hospital|Rigshospitalet, Denmark|University of Amsterdam|Hillerod Hospital, Denmark|Odense University Hospital|Hvidovre University Hospital",Phase 4,1200,Other,Apr-16,"July 1, 2020","July 1, 2020"
8447,NCT02552394,J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts,Prostate Cancer,Drug: huJ591,Weill Medical College of Cornell University,Phase 1,10,Other,Jul-15,"November 14, 2019","January 3, 2021"
8448,NCT02551991,"Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma",Pancreatic Cancer,Drug: nal-IRI|Drug: 5 fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin,Ipsen,Phase 2,56,Industry,"October 19, 2015","February 15, 2021","February 15, 2021"
8449,NCT02551237,Neoadjuvant Treatment for Advanced Rectal Carcinoma,Rectal Carcinoma,Radiation: 50 Gy|Drug: Capecitabine|Radiation: 25 Gy,UNICANCER,Phase 3,103,Other,"January 7, 2016","August 29, 2020",Jun-22
8450,NCT02551185,ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: ACY-241,Celgene,Phase 1,20,Industry,"December 22, 2015","September 30, 2019","October 4, 2019"
8451,NCT02551159,Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer,Squamous Cell Carcinoma of the Head and Neck,Biological: MEDI4736|Biological: Tremelimumab|Biological: MEDI4736+Tremelimumab|Biological: Cetuximab|Drug: 5-fluorouracil (5FU)|Drug: Cisplatin|Drug: Carboplatin,AstraZeneca,Phase 3,823,Industry,"October 15, 2015","July 6, 2020","May 21, 2021"
8452,NCT02551094,Colchicine Cardiovascular Outcomes Trial (COLCOT),Coronary Artery Disease|Myocardial Infarction,Drug: colchicine|Drug: colchicine placebo,Montreal Heart Institute,Phase 3,4745,Other,"December 4, 2015","July 17, 2019","July 17, 2019"
8453,NCT02549677,"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer",Breast Neoplasms,Drug: Epirubicin|Drug: Docetaxel|Drug: cyclophosphamide,Ruijin Hospital,Phase 4,294,Other,Oct-15,Mar-20,Mar-20
8454,NCT02549625,Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells,Congenital Heart Disease,Biological: Autologous Bone Marrow-derived Mononuclear Cells,"Timothy J Nelson, MD, PhD|Mayo Clinic|ReGen Theranostics, Inc.",Phase 1,10,Other,Aug-15,Nov-20,Nov-20
8455,NCT02549586,Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance,"Complication of Transplanted Organ, Nos",Drug: Autologous Hematopoietic Stem Cell Transplant,"Gary A Levy, O. Ont. MD. FRCP AGAF|Ottawa Hospital Research Institute|University of Toronto",Phase 2,5,Other,Dec-15,"April 30, 2020","April 30, 2020"
8456,NCT02549209,Pembro/Carbo/Taxol in Endometrial Cancer,Endometrial Cancer|Endometrial Adenocarcinoma,Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Carboplatin,"Daniela Matei, MD|Merck Sharp & Dohme LLC|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium",Phase 2,46,Other|Industry,"August 22, 2017","December 12, 2019","February 10, 2022"
8457,NCT02549092,A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD),Advanced Parkinson's Disease,Drug: Optimized Medical Treatment|Drug: Levodopa-Carbidopa Intestinal Gel|Device: Nasojejunal (NJ) tube|Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube,AbbVie,Phase 3,89,Industry,"October 26, 2015","May 14, 2020","November 18, 2022"
8458,NCT02548832,Bezafibrate Plus Berberine in Mixed Dyslipidemia,Mixed Dyslipidemia,Drug: Berberine|Drug: Bezafibrate|Drug: Berberine plus Bezafibrate,University of Guadalajara,Phase 3,36,Other,Apr-13,"April 1, 2020","April 1, 2020"
8459,NCT02547922,Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis,Lupus Nephritis,Biological: Anifrolumab|Drug: Placebo,AstraZeneca|Parexel,Phase 2,147,Industry,"November 4, 2015","November 26, 2019","January 18, 2021"
8460,NCT02547818,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,Alzheimer's Disease,Drug: ALZT-OP1a|Drug: ALZT-OP1b|Other: Placebo ALZT-OP1a|Other: Placebo ALZT-OP1b,"AZTherapies, Inc.|PharmaConsulting Group|KCAS Bio|APCER Life Sciences",Phase 3,620,Industry|Other,"September 15, 2015","November 13, 2020","November 18, 2020"
8461,NCT02546934,ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC),Breast Cancer,"Drug: ABX, cisplatin|Drug: Gemcitabine, Cisplatin",Fudan University,Phase 3,254,Other,Mar-16,Apr-20,Apr-20
8462,NCT02546674,Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.,Chronic Myeloid Leukemia,Drug: Nilotinib,Novartis Pharmaceuticals|Novartis,Phase 4,171,Industry,"February 18, 2016","February 23, 2021","March 25, 2021"
8463,NCT02546284,Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML),Chronic Myelomonocytic Leukemia (CMML),Drug: lenzilumab,"Humanigen, Inc.",Phase 1,15,Industry,Jul-16,Feb-20,Feb-20
8464,NCT02546167,CART-BCMA Cells for Multiple Myeloma,Multiple Myeloma,Biological: CART-BCMA,University of Pennsylvania,Phase 1,25,Other,"September 3, 2015","August 21, 2019","July 27, 2020"
8465,NCT02545933,Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor,Myocardial Infarction,Drug: Prasugrel|Drug: Vorapaxar|Drug: Aspirin|Drug: Ticagrelor,University of Florida|Merck Sharp & Dohme LLC,Phase 4,130,Other|Industry,Feb-16,May-19,Jan-20
8466,NCT02545504,Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,Gastric Adenocarcinoma,Drug: Andecaliximab|Drug: Placebo|Drug: Leucovorin|Drug: 5-fluorouracil|Drug: Oxaliplatin,Gilead Sciences,Phase 3,432,Industry,"October 13, 2015","May 15, 2019","May 15, 2019"
8467,NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Diabetic Kidney Disease,Drug: Finerenone (BAY94-8862)|Drug: Placebo,Bayer,Phase 3,7352,Industry,"September 17, 2015","February 2, 2021","February 2, 2021"
8468,NCT02544997,"A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway",Metastatic Breast Cancer,Drug: Poziotinib,Samsung Medical Center,Phase 2,5,Other,Sep-15,Feb-20,Feb-20
8469,NCT02544880,PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC,Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer,Drug: Tadalafil|Biological: Anti-MUC1 Vaccine|Biological: Anti-Influenza Vaccine|Other: Tadalafil Placebo|Other: Anti-MUC1 Vaccine Placebo|Other: Standard of Care Treatment|Other: Anti-Influenza Vaccine Placebo,"Donald T. Weed, MD, FACS|University of Miami",Phase 1,16,Other,"April 25, 2016","June 2, 2019","June 8, 2021"
8470,NCT02544321,Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes,Type 1 Diabetes,Drug: Bromocriptine|Other: Placebo,"University of Colorado, Denver|Juvenile Diabetes Research Foundation",Phase 2,108,Other,Sep-15,Jun-19,Jun-19
8471,NCT02543827,Evaluation of the Efficacy and Safety of MV140,Urinary Tract Infection Bacterial,Biological: MV140|Biological: Placebo,Inmunotek S.L.,Phase 3,240,Industry,Nov-15,"November 4, 2020",Dec-20
8472,NCT02542319,Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease,Chronic Kidney Disease|Vascular Calcification|Uremic Osteodystrophy,Dietary Supplement: Mablet 360 mg|Dietary Supplement: Placebo,Nordsjaellands Hospital|Herlev Hospital,Phase 2,148,Other,Nov-15,Nov-20,Jul-21
8473,NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Chronic Kidney Disease,Drug: Finerenone (BAY94-8862)|Drug: Placebo,Bayer,Phase 3,5734,Industry,"September 17, 2015","April 14, 2020","April 14, 2020"
8474,NCT02540954,Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD),Macular Degeneration,"Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)",Bayer,Phase 3,336,Industry,"September 29, 2015","December 24, 2019","June 4, 2020"
8475,NCT02540707,"Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes",Overactive Bladder Syndrome,Drug: solifenacin|Drug: mirabegron,National Taiwan University Hospital,Phase 4,113,Other,"September 8, 2015","August 26, 2020","August 26, 2020"
8476,NCT02540655,Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia,Cerebellar Ataxia,Biological: Stemchymal®|Procedure: Excipients,Steminent Biotherapeutics Inc.,Phase 2,56,Industry,Sep-15,"February 26, 2021","February 26, 2021"
8477,NCT02540161,Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,Malignant Glioma,Drug: Sym004 - 18 mg/kg|Drug: Sym004 - 24 mg/kg,Annick Desjardins|Symphogen A/S|Duke University,Phase 2,43,Other|Industry,"February 1, 2016","July 10, 2019","April 27, 2020"
8478,NCT02539160,Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease,Coronary Artery Disease|Diabetes Mellitus,Drug: ticagrelor,University of Florida,Phase 4,101,Other,Feb-16,"November 14, 2019","June 17, 2020"
8479,NCT02538341,Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial),Rheumatoid Arthritis|Inflammatory Arthritis|Arthritis|Psoriatic Arthritis|Psoriasis|Ankylosing Spondylitis|Enteropathic Arthritis|Crohn's Disease,Biological: Herpes Zoster (HZ) Vaccine|Drug: Placebo,University of Alabama at Birmingham|Oregon Health and Science University,Phase 2,617,Other,May-16,Dec-19,Dec-20
8480,NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,Malignant Melanoma,Drug: Cobimetinib + Vemurafenib combination treatment,Center Eugene Marquis,Phase 2,43,Other,Dec-15,"November 6, 2019","November 6, 2019"
8481,NCT02536846,The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals,Healthy,Drug: Olanzapine,Dost Ongur|Mclean Hospital,Phase 4,35,Other,"November 17, 2017","November 8, 2019","November 8, 2019"
8482,NCT02536794,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer,Biological: Anti-B7H1 Monoclonal Antibody MEDI4736|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Tremelimumab,Northwestern University|MedImmune LLC|Avon Breast Cancer Foundation|National Cancer Institute (NCI),Phase 2,30,Other|Industry|NIH,"January 14, 2016","February 6, 2020","January 22, 2021"
8483,NCT02536417,Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients,Delirium,Drug: Melatonin|Drug: Sugar pill,Fraser Health,Phase 3,19,Other,"June 29, 2016",Sep-20,Sep-20
8484,NCT02536339,A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,Metastatic Breast Cancer,Drug: Pertuzumab|Drug: Trastuzumab,"Genentech, Inc.",Phase 2,40,Industry,"December 16, 2015","May 1, 2019","December 29, 2020"
8485,NCT02536170,Arginine Therapy for Sickle Cell Disease Pain,Sickle Cell Disease|Vaso-occlusive Pain Episode,Drug: L-arginine|Drug: L-arginine Loading Dose|Other: Placebo,Emory University|Children's Healthcare of Atlanta|National Center for Complementary and Integrative Health (NCCIH),Phase 2,108,Other|NIH,Feb-16,"February 21, 2021","February 21, 2021"
8486,NCT02535325,"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer",Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Adenocarcinoma AJCC v7|Stage III Lung Large Cell Carcinoma AJCC v7|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Adenocarcinoma AJCC v7|Stage IIIA Lung Large Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Adenocarcinoma AJCC v7|Stage IIIB Lung Large Cell Carcinoma AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Adenocarcinoma AJCC v7|Stage IV Lung Large Cell Carcinoma AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7,Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Drug: Methoxyamine|Drug: Methoxyamine Hydrochloride|Drug: Pemetrexed|Drug: Pemetrexed Disodium,National Cancer Institute (NCI),Phase 1,17,NIH,"September 30, 2015","February 27, 2020","June 14, 2022"
8487,NCT02535091,Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures,Partial Epilepsy,Drug: YKP3089,"SK Life Science, Inc.",Phase 3,1345,Industry,"August 3, 2016","March 31, 2021","February 7, 2022"
8488,NCT02533934,Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant,HIV|Hepatitis C|Cirrhosis,Drug: Harvoni,"University of California, San Francisco|National Institute of Allergy and Infectious Diseases (NIAID)|Icahn School of Medicine at Mount Sinai|Columbia University|University of Pennsylvania|University of Maryland, College Park|Georgetown University|Johns Hopkins University|National Institutes of Health Clinical Center (CC)",Phase 4,68,Other|NIH,Aug-16,"December 31, 2019","December 31, 2019"
8489,NCT02533674,"Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors",Solid Tumors,Drug: Gemcitabine plus PM060184,PharmaMar,Phase 1,57,Industry,"December 12, 2014","July 11, 2019","July 11, 2019"
8490,NCT02533180,Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation,Liver Transplant|Liver Transplantation,Biological: Immunosuppression withdrawal,"National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.",Phase 2,100,NIH|Other|Industry,"December 15, 2015","February 10, 2020","July 8, 2022"
8491,NCT02531737,Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer,Lung Neoplasms,Drug: vargatef®|Drug: Docetaxel,"University Hospital, Limoges|Boehringer Ingelheim",Phase 2,59,Other|Industry,Sep-15,"September 26, 2020","September 26, 2020"
8492,NCT02531724,Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery,"Acute Kidney Injury|Renal Insufficiency, Acute",Drug: Levosimendan|Drug: Placebo,"Sahlgrenska University Hospital, Sweden",Phase 4,30,Other,Sep-15,Dec-20,Dec-20
8493,NCT02531685,Phase 1 Study of dmLT ID Vaccination in Healthy Adults,Gastroenteritis Escherichia Coli,Other: Placebo|Biological: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,100,NIH,"June 2, 2016","May 4, 2020","May 4, 2020"
8494,NCT02531581,Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive,Pulmonary Embolism,Drug: Furosemide|Drug: NaCl 9% isotonic,Centre Hospitalier Universitaire de Nice,Phase 4,60,Other,"December 23, 2015","April 9, 2020","April 9, 2020"
8495,NCT02531113,Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease,Crohn's Disease,Drug: RPC1063,Celgene,Phase 2,69,Industry,"October 9, 2015","September 12, 2019","November 28, 2019"
8496,NCT02530424,"""Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment """,Breast Neoplasms,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Palbociclib|Drug: Fulvestrant,Fondazione Michelangelo,Phase 2,102,Other,May-15,Sep-19,Nov-19
8497,NCT02530320,"Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved",Oligodendroglioma|Oligoastrocytoma,Drug: Palbociclib,Grupo Español de Investigación en Neurooncología|Pfizer,Phase 2,40,Other|Industry,"October 25, 2015",Dec-19,Mar-20
8498,NCT02530047,Mesenchymal Stem Cells (MSC) for Ovarian Cancer,Ovarian Cancer,Genetic: MSC-INFβ|Behavioral: Questionnaires,M.D. Anderson Cancer Center,Phase 1,5,Other,"May 16, 2016","June 13, 2019","June 13, 2019"
8499,NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),Neoplasms,Drug: GSK3174998|Drug: Pembrolizumab,GlaxoSmithKline|Merck Sharp & Dohme LLC,Phase 1,141,Industry,"September 11, 2015","April 29, 2020","April 29, 2020"
8500,NCT02528110,Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer,Malignant Neoplasm of Stomach,Procedure: Hyperthermic intraperitoneal chemotherapy (HIPEC)|Procedure: D2 radical gastrectomy|Other: SOX postoperative chemotherapy|Other: XELOX postoperative chemotherapy,Wuhan University,Phase 2,100,Other,Aug-15,"March 10, 2020","March 10, 2020"
8501,NCT02527798,Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD),Bronchopulmonary Dysplasia,Drug: Furosemide Cohort 1|Drug: Furosemide Cohort 2|Drug: Furosemide Cohort 3|Other: Placebo,"University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC",Phase 2,82,Other|NIH|Industry,"November 27, 2015","October 15, 2019","October 15, 2019"
8502,NCT02527564,Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder,Insomnia|Bipolar Disorder,Drug: Suvorexant|Drug: Placebo,Stanford University|Merck Sharp & Dohme LLC,Phase 4,61,Other|Industry,Sep-15,"March 1, 2021","March 1, 2021"
8503,NCT02527265,Afrezza Safety and Pharmacokinetics Study in Pediatric Patients,Type 1 Diabetes Mellitus,Biological: Afrezza,Mannkind Corporation,Phase 2,30,Industry,"September 28, 2017","March 17, 2020","June 25, 2020"
8504,NCT02527200,Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,56,Industry,"November 9, 2015","November 4, 2020","November 19, 2020"
8505,NCT02527083,Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain,"Acute Pain|Chronic Pain|Hernia|Anesthesia, Intravenous|Anesthesia, Intratracheal",Drug: Propofol|Drug: Sevoflurane|Drug: Remifentanil|Drug: Ketamine,VA Pittsburgh Healthcare System,Phase 4,10,U.S. Fed,Jan-15,Jun-19,Jun-19
8506,NCT02526212,Buprenorphine Group Medical Visits in Primary Care,Opioid-Related Disorders,Behavioral: G-BMT|Behavioral: Treatment as usual|Drug: Buprenorphine,Montefiore Medical Center|National Institute on Drug Abuse (NIDA),Phase 3,18,Other|NIH,"January 1, 2017",May-19,May-19
8507,NCT02526017,Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers,Advanced Solid Tumors|Head and Neck Cancer|Pancreatic Cancer|Ovarian Cancer|Renal Cell Carcinoma|Malignant Glioma|Non-small Cell Lung Cancer,Biological: Cabiralizumab|Biological: Nivolumab,"Five Prime Therapeutics, Inc.|Bristol-Myers Squibb",Phase 1,313,Industry,"September 8, 2015","November 18, 2019","November 18, 2019"
8508,NCT02525991,Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting,Agitation,Device: Staccato® Delivery System Loxapine (ADASUVE®),Ferrer Internacional S.A.,Phase 4,323,Industry,"September 8, 2016","December 31, 2019","December 31, 2019"
8509,NCT02525861,"GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study",Alpha1-antitrypsin Deficiency,Biological: GLASSIA,Baxalta now part of Shire|Takeda,Phase 3,34,Industry,"March 8, 2016","July 29, 2020","July 29, 2020"
8510,NCT02525653,Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers,Lung Cancer|Untreated Stage IV or Recurrent Squamous Cell Lung Cancers,Drug: albumin-bound paclitaxel|Drug: gemcitabine,Memorial Sloan Kettering Cancer Center|Celgene Corporation|Miami Cancer Institute,Phase 2,40,Other|Industry,Aug-15,May-19,May-19
8511,NCT02524626,Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve,Postoperative Ileus,Procedure: Sham stimulation|Procedure: Vagus stimulation,KU Leuven|Universitaire Ziekenhuizen KU Leuven,Phase 3,130,Other,"July 1, 2017","December 31, 2019","December 31, 2019"
8512,NCT02523274,Resveratrol and Exercise to Treat Functional Limitations in Late Life,Aging,Drug: Resveratrol|Drug: Placebo|Behavioral: Exercise,University of Florida|National Institute on Aging (NIA)|University of Alabama at Birmingham,Phase 2,60,Other|NIH,Jun-16,May-19,"July 17, 2019"
8513,NCT02519777,Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND),HIV Infections,Drug: Placebo for maraviroc (MVC)|Drug: Placebo for dolutegravir (DTG)|Drug: Dolutegravir (DTG)|Drug: Maraviroc (MVC),National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,191,NIH,"April 21, 2016","December 2, 2019","January 5, 2021"
8514,NCT02519543,Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder,Bipolar Disorder,Drug: Placebo|Drug: Metformin,Cynthia Calkin|Stanley Medical Research Institute|Nova Scotia Health Authority,Phase 3,50,Other,Sep-15,Sep-20,Sep-20
8515,NCT02518191,Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity,Breast Cancer,Drug: GnRHa,Xiangyun Zong|Zhejiang Cancer Hospital|Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Phase 3,345,Other,"September 1, 2015","January 12, 2021","January 12, 2021"
8516,NCT02517489,Community-Acquired Pneumonia : Evaluation of Corticosteroids,Community Acquired Pneumonia,Drug: Hydrocortisone|Drug: Placebo,"University Hospital, Tours",Phase 3,952,Other,"October 28, 2015","July 19, 2020","August 28, 2020"
8517,NCT02516813,"Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",Advanced Solid Tumors,Drug: MSC2490484A (M3814)|Radiation: Fractionated RT|Drug: Cisplatin,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 1,52,Industry,"September 15, 2015","March 26, 2021","November 19, 2021"
8518,NCT02515838,Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD,Sickle-Cell Disease,Drug: Sevuparin|Other: Placebo,Modus Therapeutics AB|Ergomed,Phase 2,147,Industry,Jul-15,May-19,May-19
8519,NCT02514070,Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults,Lipoprotein Metabolism|PCSK9|Proteomics,Drug: EPA-rich fish oil|Drug: DHA-rich fish oil,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,44,NIH,"October 30, 2015","July 23, 2019","July 23, 2019"
8520,NCT02513485,Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa,Depression,Drug: Levodopa+carbidopa|Drug: Placebo,Emory University|National Institute of Mental Health (NIMH),Phase 4,57,Other|NIH,"October 9, 2015","February 21, 2020","August 1, 2020"
8521,NCT02513459,"A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease",Crohn Disease,Drug: Risankizumab 600 mg IV|Drug: Risankizumab 180 mg SC,AbbVie|Boehringer Ingelheim,Phase 2,65,Industry,"September 16, 2015","June 19, 2019","June 19, 2019"
8522,NCT02513329,Stellate Ganglion Block (SGB) For Women for Breast Cancer,Hot Flushes|Hot Flashes,Drug: Bupivicaine|Drug: Saline,Northwestern University|University of Illinois at Chicago,Phase 2,36,Other,Jul-15,Jan-20,Jan-20
8523,NCT02512458,Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer,Bone Metastatic Prostate Cancer,Drug: Cabazitaxel,Hellenic Cooperative Oncology Group|Sanofi,Phase 2,60,Other|Industry,"October 29, 2015",Dec-19,"December 27, 2019"
8524,NCT02511639,Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients,Breast Cancer Metastatic,Drug: Everolimus|Drug: Aromatase Inhibitors,Istituto Oncologico Veneto IRCCS|University of Padova,Phase 3,110,Other,"July 30, 2014","February 28, 2020","July 31, 2020"
8525,NCT02511236,Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention,Smoking Cessation,Behavioral: Group Cognitive Behavioral Therapy|Behavioral: General Health Education|Drug: Transdermal Nicotine Patch,University of Miami|H. Lee Moffitt Cancer Center and Research Institute|James & Esther King Florida Biomedical Research Program,Phase 4,356,Other,Aug-15,"October 23, 2019","October 23, 2019"
8526,NCT02511223,Efficacy and Safety of PARPi to Treat Pancreatic Cancer,Pancreatic Cancer,Drug: OLAPARIB,Sheba Medical Center,Phase 2,24,Other,Jul-16,"April 18, 2021","April 18, 2021"
8527,NCT02510404,Multivirus-specific Cytotoxic T Lymphocytes (mCTL),Refractory Viral Infections,Biological: mCTLs,Catherine Bollard|Children's National Research Institute,Phase 1,1,Other,Apr-14,"May 8, 2019","June 8, 2019"
8528,NCT02509494,Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo,Ebola Virus Disease,Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo|Biological: MenACWY|Biological: Placebo,"Janssen Vaccines & Prevention B.V.|London School of Hygiene and Tropical Medicine|Ministry of Health and Sanitation of Sierra Leone|College of Medicine and Allied Health Sciences (COMAHS)|University of Oxford|Institut National de la Santé Et de la Recherche Médicale, France|Grameen Foundation|World Vision of Ireland",Phase 3,1023,Industry|Other,"September 30, 2015","June 28, 2019","July 3, 2019"
8529,NCT02509156,Stem Cell Injection in Cancer Survivors,Cardiomyopathy Due to Anthracyclines,Biological: Allo-MSCs|Biological: Placebo,"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",Phase 1,46,Other|NIH,Aug-16,Nov-19,"April 20, 2020"
8530,NCT02509026,Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA,"Spondylitis, Ankylosing",Biological: Etanercept,Pfizer,Phase 4,210,Industry,"September 24, 2015","May 28, 2019","September 6, 2019"
8531,NCT02508870,A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes,Myelodysplastic Syndromes,Drug: Atezolizumab|Drug: Azacitidine,Hoffmann-La Roche,Phase 1,46,Industry,"September 30, 2015","June 10, 2019","June 10, 2019"
8532,NCT02508532,(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,Gastrointestinal Stromal Tumors (GIST)|Other Relapsed or Refractory Solid Tumors,Drug: Avapritinib,Blueprint Medicines Corporation,Phase 1,250,Industry,Aug-15,"March 6, 2020","June 3, 2021"
8533,NCT02508155,A Study of MEDI7352 in Painful Osteoarthritis of the Knee,Chronic Pain,Biological: MEDI7352 for IV infusion|Biological: Placebo for IV infusion|Biological: MEDI7352 for Subcutaneous Injection|Biological: Placebo for Subcutaneous Injection,AstraZeneca,Phase 1,132,Industry,"November 17, 2015","December 23, 2020","December 23, 2020"
8534,NCT02505971,Nadolol Versus Propranolol in Children With Infantile Hemangiomas,Infantile Hemangioma,Drug: Nadolol|Drug: Propranolol,The Hospital for Sick Children,Phase 3,74,Other,Sep-15,Apr-20,"June 30, 2020"
8535,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,Hodgkin Lymphoma,Drug: Brentuximab Vedotin|Drug: Adriamycin|Drug: Dacarbazine,Massachusetts General Hospital|Seagen Inc.,Phase 2,34,Other|Industry,"August 7, 2015",Jun-19,Jun-19
8536,NCT02504489,Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC,Non-Small Cell Lung Cancer,Drug: Docetaxel + Plinabulin (DP)|Drug: Docetaxel (D),BeyondSpring Pharmaceuticals Inc.,Phase 3,559,Industry,Dec-15,"March 23, 2021","May 23, 2021"
8537,NCT02504359,Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma,Plasma Cell Leukemia|Recurrent Plasma Cell Myeloma,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Drug: Ixazomib Citrate|Drug: Melphalan|Drug: Methotrexate|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Quality-of-Life Assessment|Drug: Tacrolimus,OHSU Knight Cancer Institute|Oregon Health and Science University,Phase 1,11,Other,"July 20, 2015","September 9, 2020","September 9, 2020"
8538,NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,Peripheral Artery Disease,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Rivaroxaban-Placebo","Bayer|Janssen Research & Development, LLC|Colorado Prevention Center",Phase 3,6564,Industry|Other,"August 18, 2015","November 27, 2019","January 9, 2020"
8539,NCT02503839,Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic,Tuberculosis,Drug: etoricoxib|Biological: H56:IC31,Anne Margarita Dyrhol Riise|University of Oslo|Statens Serum Institut|Haukeland University Hospital|Oslo University Hospital,Phase 1,39,Other,Nov-15,Sep-19,"March 23, 2020"
8540,NCT02503657,Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF),Idiopathic Pulmonary Fibrosis|IPF,Drug: tipelukast|Drug: Placebo,MediciNova,Phase 2,15,Industry,"March 9, 2016","December 7, 2020","March 15, 2022"
8541,NCT02503358,Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7,Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Study|Drug: Selumetinib,OHSU Knight Cancer Institute|Oregon Health and Science University|AstraZeneca,Phase 1,23,Other|Industry,"July 21, 2016","July 16, 2020","July 16, 2020"
8542,NCT02502903,"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders",Bullous Pemphigoid (BP)|Cold Agglutinin Disease (CAD)|Warm Autoimmune Hemolytic Anemia (WAIHA)|End-stage Renal Disease (ESRD),Drug: BIV009|Other: Placebo,"Bioverativ, a Sanofi company|Celerion Clinical Research GmbH|Assign Data Management and Biostatistics GmbH|ABF Pharmaceutical Services GmbH|Quest Diagnostics-Nichols Insitute|Covance Laboratories - Chantilly|PPD Laboratories - Virginia|Softworld Inc. - Cambridge, MA|Sanofi",Phase 1,122,Industry|Other,"July 13, 2015","March 31, 2021","March 31, 2021"
8543,NCT02502708,"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors",Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor,Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation|Drug: Cyclophosphamide|Drug: Etoposide,NewLink Genetics Corporation|Lumos Pharma,Phase 1,81,Industry,Oct-15,"December 12, 2019","February 28, 2020"
8544,NCT02501928,Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.,"Urinary Bladder, Neurogenic",Drug: Fesoterodine PR 4 mg|Drug: Fesoterodine PR 8 mg|Drug: Fesoterodine BIC 2 mg|Drug: Fesoterodine BIC 4 mg,Pfizer,Phase 3,12,Industry,"June 5, 2015","April 1, 2020","April 1, 2020"
8545,NCT02501811,Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure,Ischemic Cardiomyopathy,Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A),"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,125,Other|NIH,Oct-15,"June 25, 2020","July 22, 2020"
8546,NCT02501265,Adaptive Pharmacotherapy for Smoking Cessation,Nicotine Dependence,Behavioral: Varenicline Standard Protocol|Behavioral: Nicotine Patch Standard Protocol|Drug: Varenicline Adaptive Protocol|Drug: Nicotine Adaptive Protocol,Duke University|National Institute on Drug Abuse (NIDA)|Pfizer,Phase 2,188,Other|NIH|Industry,"June 6, 2017","July 30, 2020","May 12, 2021"
8547,NCT02500602,CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders,Posttraumatic Stress Disorder|Alcohol Use Disorders,Drug: doxazosin|Drug: placebo,VA Office of Research and Development|Medical University of South Carolina,Phase 2,144,U.S. Fed|Other,"June 1, 2016","December 16, 2019","December 16, 2019"
8548,NCT02500121,Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer,Urothelial Carcinoma|Bladder Cancer,Other: Placebo|Drug: Pembrolizumab,Matthew Galsky|Hoosier Cancer Research Network|Merck Sharp & Dohme LLC,Phase 2,108,Other|Industry,"November 11, 2015","July 1, 2019","January 1, 2021"
8549,NCT02499822,REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial,Hypertension|High Blood Pressure Variability,Drug: Nifedipine GITS|Drug: Ramipril,Istituto Auxologico Italiano|Bayer,Phase 4,168,Other|Industry,Oct-15,"July 3, 2020","November 1, 2020"
8550,NCT02499562,A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis,"Hepatitis B, Chronic",Drug: Hydronidone|Drug: Placebo|Drug: Entecavir,"Shanghai Genomics, Inc.",Phase 2,168,Industry,"June 25, 2015","November 20, 2020","November 20, 2020"
8551,NCT02499497,A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer,Prostate Cancer,Drug: LY2452473|Drug: Placebo,Dana-Farber Cancer Institute|National Institute of Nursing Research (NINR),Phase 2,114,Other|NIH,"February 29, 2016","October 31, 2020","October 31, 2020"
8552,NCT02497690,Effectiveness of Therapy Via Telemedicine Following Cochlear Implants,Congenital Sensorineural Deafness,Behavioral: Telemedicine|Behavioral: In-person ART,"University of Colorado, Denver|National Institute on Deafness and Other Communication Disorders (NIDCD)|University of Colorado, Boulder",Phase 2,77,Other|NIH,Sep-13,"December 9, 2019","December 9, 2019"
8553,NCT02497404,Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR,"Leukemia, Erythroblastic, Acute|Myelodysplastic Syndromes",Drug: 5-Azacytidine|Drug: Fludarabine|Drug: Melphalan|Drug: Alemtuzumab|Radiation: Total Body Irradiation,Weill Medical College of Cornell University,Phase 2,40,Other,"February 13, 2015","June 17, 2020","June 17, 2021"
8554,NCT02497157,Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: Oxaliplatin (L-OHP)|Drug: Irinotecan hydrochloride hydrate (CPT-11)|Drug: Continuous intravenous infusion of fluorouracil (CIV 5-FU)|Drug: Levofolinate calcium (l-LV)|Drug: Bevacizumab (Bmab),"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Hiroshima Prefectural Hospital|National Hospital Organization Shikoku Cancer Center",Phase 2,45,Other,"May 21, 2015",Jun-19,Jun-19
8555,NCT02497131,Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients,Lymphatic Diseases,Drug: Brentuximab Vedotin,Fondazione Italiana Linfomi - ETS,Phase 2,25,Other,"September 21, 2015","September 24, 2019",Mar-22
8556,NCT02496611,Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity,Severe Obesity,Drug: Weight loss with pharmacotherapy|Drug: Weight loss without pharmacotherapy,University of Minnesota,Phase 2,100,Other,Dec-15,"August 14, 2020","August 14, 2020"
8557,NCT02496117,Renal Nerves Stimulation Study,Hypertension|Renal Denervation,"Procedure: Electrical mapping, nerve stimulation checked renal denervation procedure|Procedure: Electrial mapping, nerve stimulation guided renal denervation procedure",Diagram B.V.,Phase 2,56,Other,"March 14, 2014","July 4, 2019","July 4, 2019"
8558,NCT02494141,Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD,"Polycystic Kidney, Autosomal Dominant",Drug: Curcumin|Other: Placebo,"University of Colorado, Denver",Phase 4,68,Other,"November 12, 2015","February 1, 2021","February 1, 2021"
8559,NCT02493426,Single Dose Intranasal Oxytocin and Cognitive Effects in Autism,Autism Spectrum Disorders,Drug: Intranasal Oxytocin|Drug: Placebo,University of Minnesota,Phase 2,27,Other,May-14,"March 31, 2021","March 31, 2021"
8560,NCT02493257,Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis,Nonallergic Irritant Rhinitis,Drug: Capsaicin|Drug: Placebo,"The University of Texas Health Science Center, Houston|American Academy of Otolaryngic Allergy",Phase 2,22,Other,Oct-14,"August 2, 2019","August 2, 2019"
8561,NCT02492750,Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma,Indolent Plasma Cell Myeloma|Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma,Biological: Anakinra|Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Placebo,Mayo Clinic|National Cancer Institute (NCI),Phase 1,14,Other|NIH,Apr-16,"June 5, 2019","September 13, 2019"
8562,NCT02491983,"Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer",Metastatic Breast Cancer,Drug: Palbociclib|Drug: Fulvestrant|Drug: Letrozole,MedSIR,Phase 2,486,Other,Aug-15,Jan-20,Jan-20
8563,NCT02491788,Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers,"Sleep Disorder, Shift-Work",Drug: Suvorexant|Drug: Placebo,VA Palo Alto Health Care System|Merck Sharp & Dohme LLC|Stanford University,Phase 4,19,U.S. Fed|Industry|Other,"February 1, 2016","August 1, 2019","August 1, 2019"
8564,NCT02491671,"Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection",Prolonged Air Leak|Lung Resection,Device: Hemopatch|Procedure: standard preventive measures,Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Instituto de Investigación Biomédica de Salamanca|Baxter Healthcare Corporation,Phase 3,260,Other|Industry,"November 24, 2015","June 30, 2019","June 30, 2019"
8565,NCT02491320,The Clinical Trial of Acupuncture Pre-treatment on PCOS,Polycystic Ovary Syndrome,Other: Pre-treatment acupuncture|Drug: Letrozole,The First Affiliated Hospital of Guangzhou Medical University|The University of Hong Kong|Karolinska Institutet|Xuzhou Maternity and Child Health Care Hospital|Hexian Memorial Affiliated Hospital of Southern Medical University,Phase 3,384,Other,Aug-15,Oct-19,Oct-19
8566,NCT02491268,A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID),Mild Cognitive Impairment,Drug: Cilostazol|Drug: Placebo,National Cerebral and Cardiovascular Center,Phase 2,166,Other,"May 1, 2015","August 14, 2020","December 1, 2020"
8567,NCT02489695,Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,Drug: Axitinib,Centre Leon Berard,Phase 2,44,Other,Oct-15,Jul-19,Jul-19
8568,NCT02487797,Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation,Dystocia,Drug: Oxytocin|Other: Sodium Chloride 0.9%,Northwestern University,Phase 4,1003,Other,"September 28, 2015","September 1, 2020","September 28, 2020"
8569,NCT02487485,Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects,Depression,Drug: Ketamine|Drug: sirolimus|Drug: Placebo,Yale University,Phase 2,23,Other,Mar-16,Jan-20,Jan-20
8570,NCT02487160,Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens,Cataracts|Presbyopia,Device: SBL-3 multifocal intraocular lens|Device: Control monofocal intraocular lens,Lenstec Incorporated,Phase 3,499,Industry,Aug-15,Aug-19,Aug-19
8571,NCT02486042,Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity,Retinopathy of Prematurity,Drug: Omegaven|Dietary Supplement: Standard lipids (primarily omega-6 fatty acids),"University of California, San Diego|The Hartwell Foundation",Phase 2,48,Other,Mar-14,Dec-19,Dec-19
8572,NCT02485639,Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination,Influenza|Influenza Immunisation,Biological: Influenza Virus Vaccine Inactivated,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,27,NIH,"December 23, 2015","December 31, 2020","December 31, 2020"
8573,NCT02484833,Erbitux MEtastatic Colorectal Cancer Strategy Study,Antineoplastic Agents,Drug: Cetuximab|Drug: FOLFIRI,Armando Orlandi|Catholic University of the Sacred Heart,Phase 3,607,Other,Feb-15,Dec-19,Mar-20
8574,NCT02483364,A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure),Pseudoarthrosis,Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment),Salvat,Phase 2,12,Industry,"November 10, 2015","May 18, 2020","October 20, 2020"
8575,NCT02483247,A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,Cancer,Drug: BBI503|Drug: Capecitabine|Drug: Doxorubicin|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Sunitinib,"Sumitomo Pharma Oncology, Inc.",Phase 1,165,Industry,Sep-15,May-19,May-19
8576,NCT02482532,"Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma",Melanoma,Biological: tvs-CTL Vaccine,Gary Doolittle|University of Kansas Medical Center,Phase 1,7,Other,"October 6, 2016","October 10, 2019","September 13, 2021"
8577,NCT02482207,Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk,Hypertension,Drug: Rosuvastatin|Behavioral: Life style modification,"Asan Medical Center|Dong-A ST Co., Ltd.",Phase 4,96,Other|Industry,Nov-15,"November 26, 2019","November 26, 2019"
8578,NCT02481986,Asthma Action at Erie Trial,Asthma|Children,Behavioral: Community Health Worker|Behavioral: Certified asthma educator,"University of Illinois at Chicago|Erie Family Health Center|Rush University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,223,Other|NIH,"April 1, 2015","March 31, 2020","March 31, 2021"
8579,NCT02481674,"A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi",Huntington's Disease,Drug: VX15/2503|Drug: Placebo,Vaccinex Inc.|Huntington Study Group,Phase 2,301,Industry|Other,Jul-15,Aug-20,Aug-20
8580,NCT02481297,"Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",Leukemia|Chronic Lymphocytic Leukemia|Lymphocytic Leukemia,Drug: Lirilumab|Drug: Rituximab,M.D. Anderson Cancer Center|Bristol-Myers Squibb,Phase 2,7,Other|Industry,"June 23, 2015","August 15, 2019","August 15, 2019"
8581,NCT02480114,Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy,Malignant Head and Neck Neoplasm|Mucositis|Radiation-Induced Disorder,Other: Educational Intervention|Drug: Gabapentin|Other: Pain Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Oxycodone/Acetaminophen|Drug: Hydrocodone/Acetaminophen|Drug: Fentanyl|Drug: Ibuprofen|Drug: Magic Mouthwash,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),Phase 3,79,Other|NIH,Jul-15,Sep-19,Jan-20
8582,NCT02479230,Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients,Breast Cancer|Metastatic Breast Cancer,Biological: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Drug: gemcitabine hydrochloride,"Joseph Baar, MD, PhD|Case Comprehensive Cancer Center",Phase 1,18,Other,"July 17, 2015","October 30, 2019","July 1, 2022"
8583,NCT02478489,Alcohol Disorder hOsPital Treatment Trial,Heavy Drinking|Alcohol Dependence|Alcohol Use Disorder,Drug: Oral naltrexone (PO-NTX)|Drug: Extended-release injectable naltrexone (XR-NTX),Boston University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 4,248,Other|NIH,Jun-16,Jul-20,Oct-20
8584,NCT02478463,Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers,"Infection, Human Immunodeficiency Virus|HIV Infections",Drug: Cabotegravir tablet 30 mg once daily for 28 days.|Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.,ViiV Healthcare,Phase 1,19,Industry,"February 27, 2017","July 25, 2019","July 25, 2019"
8585,NCT02478268,Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Drug: Hyperpolarized 129-Xenon gas|Device: MRI,"Bastiaan Driehuys|University of Wisconsin, Madison|National Heart, Lung, and Blood Institute (NHLBI)|Duke University",Phase 1,64,Other|NIH,May-15,"September 26, 2020","September 26, 2020"
8586,NCT02477839,Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures,Epilepsy With Partial-onset Seizures,Drug: Lacosamide|Other: Placebo,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 3,255,Industry,"June 5, 2015","May 28, 2020","May 28, 2020"
8587,NCT02476968,To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer,BRCA or HRR+ Mutated Ovarian Cancer Patients,Drug: Olaparib,AstraZeneca,Phase 4,181,Industry,"September 28, 2015","April 17, 2020","December 17, 2021"
8588,NCT02475850,Strategies to Reduce Injuries and Develop Confidence in Elders,Accidental Falls|Wounds and Injuries,Other: Evidence-based tailored fall prevention|Other: Usual care,"Brigham and Women's Hospital|Yale University|University of California, Los Angeles|Healthcare Partners|The University of Texas Medical Branch, Galveston|University of Pittsburgh Medical Center|Johns Hopkins University|Mt Sinai Health System|Reliant Medical Group|Partners HealthCare|University of Michigan|University of Iowa Health Alliance|Essentia Health|Wake Forest University|National Institute on Aging (NIA)|Patient-Centered Outcomes Research Institute|National Institutes of Health (NIH)",Phase 3,5451,Other|NIH,Aug-15,Dec-19,Jan-20
8589,NCT02474927,Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation,Lung Transplant Rejection,Drug: Carfilzomib,"John F. McDyer, MD|University of Pittsburgh",Phase 2,22,Other,"November 1, 2015","November 9, 2020","July 26, 2021"
8590,NCT02473406,Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis,"Pancreatitis, Acute Necrotizing",Drug: Thymosin Alpha 1|Drug: normal saline,"Weiqin Li|The First Affiliated Hospital of Nanchang University|The Affiliated Hospital of Qingdao University|Zunyi Medical College|the Affiliated Nanhua Hospital, University of South China|Second Affiliated Hospital of Nantong University|Yijishan Hospital of Wannan Medical College|the 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force|Jiangsu Province Hospital of Traditional Chinese Medicine|Zhejiang Provincial People's Hospital|Luoyang Central Hospital|The Affiliated Hospital of Henan University of Science and Technology|Clinical Medical College of Yangzhou University|The First People's Hospital of Shangqiu|Qilu Hospital of Shandong University|The First Affiliated Hospital of Anhui Medical University|Nanjing University School of Medicine",Phase 4,508,Other,"March 27, 2018","December 24, 2020","March 24, 2021"
8591,NCT02473250,Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging,Bipolar Disorder,Drug: Fluoxetine|Drug: Citalopram,New York State Psychiatric Institute,Phase 4,40,Other,Jan-15,Dec-19,Dec-19
8592,NCT02472691,"Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic",Drug: Lenalidomide|Drug: Azacitidine|Biological: Donor Lymphocyte Infusions,"Heinrich-Heine University, Duesseldorf|Celgene Corporation",Phase 2,50,Other|Industry,May-15,"April 23, 2020","April 23, 2020"
8593,NCT02472275,"PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",Stage I Prostate Adenocarcinoma|Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma,Drug: Antiandrogen Therapy|Other: Laboratory Biomarker Analysis|Drug: Multitargeted Tyrosine Kinase Inhibitor PLX3397|Radiation: Radiation Therapy,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Phase 1,8,Other|NIH,Jun-15,"August 5, 2019","August 5, 2019"
8594,NCT02472249,Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC,Hepatocellular Carcinoma,Radiation: CT perfusion|Drug: Norepinephrine intra-arteriel/hepatic,"University Health Network, Toronto",Phase 4,10,Other,Jan-16,"December 1, 2020","December 1, 2020"
8595,NCT02471911,KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma,Drug: KPT-330|Drug: Rituximab|Drug: Etoposide|Drug: Carboplatin|Drug: Ifosfamide|Drug: Dexamethasone,Weill Medical College of Cornell University|Karyopharm Therapeutics Inc|The Leukemia and Lymphoma Society|FDA Office of Orphan Products Development,Phase 1,22,Other|Industry|U.S. Fed,"December 11, 2015","October 31, 2019","October 14, 2021"
8596,NCT02471846,A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,Solid Tumor,Drug: Atezolizumab|Drug: GDC-0919,"Genentech, Inc.",Phase 1,158,Industry,"July 28, 2015","October 2, 2019","October 2, 2019"
8597,NCT02471339,"Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain",Neurofibromatosis Type 1|Plexiform Neurofibromas,Behavioral: Acceptance and Commitment Therapy (ACT),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 3,66,NIH,"July 7, 2015","December 23, 2020","December 23, 2020"
8598,NCT02471118,"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","Osteoarthritis, Knee",Drug: Adalimumab 40 mg|Drug: Placebo,Canadian Research & Education in Arthritis|AbbVie,Phase 2,62,Industry,Mar-15,Mar-21,Mar-21
8599,NCT02469857,Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections,Necrotizing Soft Tissue Infections|Necrotizing Fasciitis|Fournier's Gangrene,Drug: AB103 0.5 mg/kg|Other: NaCl 0.9%,Atox Bio Ltd|Biomedical Advanced Research and Development Authority,Phase 3,290,Industry|U.S. Fed,"December 1, 2015","August 18, 2019","October 18, 2019"
8600,NCT02469480,Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.,Metastatic Colorectal Cancer,Drug: FerInject|Drug: Ferro sanol,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,Phase 2,64,Other,Mar-15,May-20,Aug-20
8601,NCT02467361,A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,Cancer,Drug: BBI608|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab,"Sumitomo Pharma Oncology, Inc.",Phase 1,104,Industry,Aug-15,"January 29, 2021","January 29, 2021"
8602,NCT02466386,"Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder",Attention Deficit Hyperactivity Disorder (ADHD),Drug: SPD489,Shire|Takeda,Phase 3,113,Industry,"August 21, 2015","January 3, 2020","January 3, 2020"
8603,NCT02466009,Regorafenib in Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: Regorafenib,University of Rochester|Bayer,Phase 2,27,Other|Industry,Mar-15,Jul-19,"March 9, 2022"
8604,NCT02465567,Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos),COPD,Drug: BGF MDI 320/14.4/9.6 μg|Drug: GFF MDI 14.4/9.6 μg|Drug: BGF MDI 160/14.4/9.6 μg|Drug: BFF MDI 320/9.6 μg,"Pearl Therapeutics, Inc.",Phase 3,8588,Industry,"June 30, 2015","July 26, 2019","July 26, 2019"
8605,NCT02464228,Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.,Relapsed or Refractory Peripheral T-Cell Lymphoma,Drug: Tipifarnib,"Kura Oncology, Inc.",Phase 2,65,Industry,"October 8, 2015","March 24, 2021","March 24, 2021"
8606,NCT02464059,Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD,"Pulmonary Disease, Chronic Obstructive",Drug: Vitamin D3,"University of North Carolina, Chapel Hill|Johns Hopkins University",Phase 2,23,Other,"November 10, 2015","April 15, 2020","April 15, 2020"
8607,NCT02463799,Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,Prostate Cancer,Drug: Radium-223|Biological: Sipuleucel-T,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Dendreon|Bayer,Phase 2,36,Other|Industry,"February 22, 2016","December 12, 2019","December 12, 2019"
8608,NCT02463448,Autologous Muscle Derived Cells for Underactive Bladder,Urinary Retention|Urinary Incontinence,Biological: Autologous Muscle Derived Cells,Jason Gilleran|William Beaumont Hospitals,Phase 1,23,Other,"November 16, 2016",Dec-19,Nov-20
8609,NCT02462317,Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment,Muscle Spasticity,Drug: botulinum A toxin|Drug: Baclofen|Drug: Placebo toxin|Drug: placebo baclofen,"University Hospital, Toulouse|Merz Pharmaceuticals GmbH",Phase 4,184,Other|Industry,Apr-15,"December 9, 2019","December 9, 2020"
8610,NCT02462252,"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",Aplastic Anemia|Hypoplastic Myelodysplastic Syndrome,Drug: BL-8040|Drug: horse anti-thymocyte globulin (hATG)|Drug: Methylprednisolone|Drug: Cyclosporine,"BioLineRx, Ltd.",Phase 2,11,Industry,Oct-15,Nov-20,Nov-20
8611,NCT02460900,Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke,Smoking|HIV,Drug: Varenicline|Behavioral: Positively Smoke Free|Drug: Placebo|Behavioral: Standard of Care,"University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,184,Other|NIH,Jul-16,Apr-21,Apr-21
8612,NCT02460692,Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain,Cannabis|Low Back Pain|Neuropathic Pain,Drug: Placebos|Drug: dronabinol|Drug: Vaporized Cannabis 3.7% THC/5.6% CBD,"University of California, San Diego|National Institute on Drug Abuse (NIDA)",Phase 2,131,Other|NIH,Dec-16,"March 25, 2020","March 25, 2020"
8613,NCT02460575,Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months,Healthy,Biological: Lactobacillus reuteri 17938|Biological: Placebo,Tulane University School of Medicine|Johns Hopkins Bloomberg School of Public Health|Asociacion Benefica Prisma|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Virginia|Tulane University,Phase 1,60,Other|NIH,"January 9, 2019","December 29, 2019","December 29, 2019"
8614,NCT02460419,Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma,Nasopharyngeal Carcinoma,Drug: capecitabine|Other: Best supportive care (BSC),Sun Yat-sen University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Affiliated Cancer Hospital of Shantou University Medical College,Phase 3,104,Other,Apr-15,May-20,May-20
8615,NCT02460276,"A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma",Relapsed/Refractory Mantle Cell Lymphoma,Drug: Lenalidomide|Drug: Ibrutinib|Drug: Rituximab,"Lund University Hospital|Celgene|Janssen, LP|Nordic Lymphoma Group",Phase 2,50,Other|Industry,Apr-15,"December 31, 2019","December 31, 2019"
8616,NCT02460198,Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),Colorectal Carcinoma,Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 2,124,Industry,"August 25, 2015","September 9, 2019","February 19, 2021"
8617,NCT02459964,Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain,Advanced Cancers|Pain,Drug: Fentanyl Nasal Spray|Drug: Hydromorphone Hydrochloride|Behavioral: Phone Call,M.D. Anderson Cancer Center,Phase 4,84,Other,"September 14, 2015","June 21, 2020","June 21, 2020"
8618,NCT02459457,A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer,Stage III Esophageal Squamous Cell Carcinoma,Drug: Paclitaxel and Cisplatin|Drug: Paclitaxel and Fluorouracil|Drug: Paclitaxel and Carboplatin|Radiation: Radiotherapy,Fudan University|Huadong Hospital|Wuxi No. 4 People's Hospital|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Xiamen University|Jiangxi Provincial Cancer Hospital|Shanxi Province Cancer Hospital|Gansu Cancer Hospital,Phase 3,321,Other,"July 1, 2015","July 1, 2020",Feb-22
8619,NCT02458716,"Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer",Metastatic Prostate Carcinoma|Metastatic Prostatic Adenocarcinoma|Prostate Carcinoma Metastatic to the Bone,Procedure: Robotic Assisted Radical Prostatectomy|Procedure: Conventional open retropubic radical prostectomy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide),"Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey",Phase 1,26,Other|NIH,"March 6, 2015","January 14, 2020","January 14, 2020"
8620,NCT02458690,eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients,Depression|Major Depressive Disorder|Dysthymic Disorder|Depressive Symptoms|Cardiovascular Diseases|Heart Diseases|Coronary Artery Disease|Stroke,Behavioral: Beating the Blues (BtB)|Behavioral: Problem Solving Treatment in Primary Care (PST-PC)|Drug: Antidepressant Medications|Other: Usual Care,"Indiana University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,216,Other|NIH,Jul-15,Aug-19,Mar-21
8621,NCT02458248,Sodium Intake in Chronic Kidney Disease (STICK),"Kidney Diseases|Renal Insufficiency, Chronic|Renal Insufficiency",Behavioral: Sodium Reduction,"University College Hospital Galway|Health Research Board, Ireland|National University of Ireland, Galway, Ireland",Phase 2,105,Other,Mar-16,Aug-20,Aug-20
8622,NCT02457559,Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies,Relapsed/Refractory B-cell Malignancies,Drug: Tirabrutinib,Gilead Sciences,Phase 1,29,Industry,"September 10, 2015","December 30, 2020","December 30, 2020"
8623,NCT02456948,Adjunct Minocyline in Treatment-resistant Depression,Major Depressive Disorder,Drug: Minocycline|Drug: Placebo,"Charite University, Berlin, Germany",Phase 2,168,Other,Jan-15,"August 7, 2020","August 7, 2020"
8624,NCT02456012,Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients,Peptic Ulcer Hemorrhage,Drug: oral esomeprazole 20 mg twice daily|Drug: oral esomeprazole 20 mg once daily,Hsiu-Chi Cheng|National Cheng-Kung University Hospital,Phase 4,268,Other,Apr-15,"December 31, 2020","December 31, 2020"
8625,NCT02454972,Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,Advanced Solid Tumors,Drug: lurbinectedin (PM01183),PharmaMar,Phase 2,345,Industry,"August 25, 2015","September 18, 2020","September 18, 2020"
8626,NCT02454881,Dose Response Study of Dexmedetomidine in Orthopaedic Spine Surgery Patients,"Pain, Postoperative",Drug: Dexmedetomidine|Drug: Oxycodone,Turku University Hospital|University of Helsinki,Phase 4,107,Other,Jun-15,"October 31, 2019","March 1, 2020"
8627,NCT02453087,A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Drug: DCDS0780A|Drug: Rituximab|Drug: Obinutuzumab,Hoffmann-La Roche,Phase 1,66,Industry,"August 4, 2015","July 12, 2019","July 12, 2019"
8628,NCT02453061,"A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease",Huntington Disease,Drug: Triheptanoin oil|Drug: Placebo,"Institut National de la Santé Et de la Recherche Médicale, France|Ultragenyx Pharmaceutical Inc",Phase 2,100,Other|Industry,"June 29, 2015","December 3, 2019","December 3, 2019"
8629,NCT02451956,"Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy",Advanced Gastric Cancer,Drug: AZD5363|Drug: paclitaxel,Samsung Medical Center,Phase 2,21,Other,"January 7, 2015","May 24, 2019","May 24, 2019"
8630,NCT02450331,A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection,"Carcinoma, Transitional Cell",Drug: Atezolizumab,Hoffmann-La Roche,Phase 3,809,Industry,"October 5, 2015","November 30, 2019","June 14, 2022"
8631,NCT02449551,Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment,Advanced Gastric Adenocarcinoma,Drug: Volitinib,Samsung Medical Center,Phase 2,16,Other,"February 10, 2016","December 30, 2020","August 27, 2021"
8632,NCT02448381,FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides),Cutaneous T-Cell Lymphoma,Drug: SGX301 (synthetic hypericin)|Drug: Placebo,Soligenix,Phase 3,169,Industry,Dec-15,Jun-20,Nov-20
8633,NCT02448329,"Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy",Advanced Gastric Adenocarcinoma,Drug: AZD1775|Drug: paclitaxel,Samsung Medical Center,Phase 2,26,Other,"January 14, 2015",Dec-19,"April 19, 2021"
8634,NCT02447900,Marker Guided Breathhold Radiotherapy in NSCLC,Non-Small Cell Lung Cancer,Device: BioXmark,"Steen Riisgaard Mortensen|Rigshospitalet, Denmark",Phase 1,15,Other,Jul-14,Jun-20,Jun-20
8635,NCT02447419,"Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors",Solid Tumor,Drug: Gefitinib,Samsung Medical Center,Phase 2,16,Other,"December 3, 2014",Jun-20,"December 1, 2020"
8636,NCT02444572,Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®,Gastrointestinal Neoplasms|Thromboembolic Event,Drug: Enoxaparin 4000 IU,Les Laboratoires des Médicaments Stériles,Phase 4,168,Industry,Oct-15,Jul-20,"July 10, 2020"
8637,NCT02444091,Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS),Chronic Fatigue Syndrome (CFS)|Myalgic Encephalomyelitis (ME),Drug: Cyclophosphamide,Haukeland University Hospital|The Kavli Foundation|Oslo University Hospital,Phase 2,40,Other,Mar-15,"December 6, 2019","December 6, 2019"
8638,NCT02443961,Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies,Bronchopulmonary Dysplasia,Biological: Mesenchymal Stem Cell (MSC) therapy,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Instituto de Salud Carlos III|Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar,Phase 1,10,Other,"April 2, 2019","April 2, 2020","July 7, 2022"
8639,NCT02443116,Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH),Nonalcoholic Steatohepatitis (NASH),Biological: NGM282|Other: Placebo,"NGM Biopharmaceuticals, Inc|NGM Biopharmaceuticals Australia Pty Ltd",Phase 2,254,Industry,"July 31, 2015","December 6, 2019","January 17, 2020"
8640,NCT02442778,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",Agitation in Participants With Dementia of the Alzheimer's Type,Drug: AVP-786-18|Drug: Placebo|Drug: AVP-786-28|Drug: AVP-786-42.63,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,522,Industry,"November 11, 2015","August 14, 2019","September 9, 2019"
8641,NCT02442414,A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: KBP-5209,"Sihuan Pharmaceutical Holdings Group Ltd.|Covance|XuanZhu Pharma Co., Ltd.",Phase 1,35,Industry|Other,"April 7, 2015","November 26, 2019","November 26, 2019"
8642,NCT02441062,Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors,Neuroendocrine Tumors|Carcinoid Tumors|Neuroblastoma|Medulloblastoma,Drug: 68Ga-DOTATOC PET/CT,Sue O'Dorisio|University of Iowa,Phase 2,122,Other,Sep-15,"January 20, 2020","January 20, 2020"
8643,NCT02440828,Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia,Ventilator Associated Pneumonia (VAP),Drug: tobramycin inhalation|Drug: placebo,Erasmus Medical Center|Chiesi Farmaceutici S.p.A.,Phase 4,80,Other|Industry,Mar-15,"March 1, 2020","July 1, 2020"
8644,NCT02440464,Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),Multiple Myeloma,Procedure: Allogeneic HSCT|Drug: Fludarabine|Drug: Melphalan|Drug: Bortezomib|Drug: Ixazomib|Drug: Placebo,"National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program",Phase 2,57,NIH|Other,Aug-15,"October 1, 2020","October 1, 2020"
8645,NCT02440425,Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,Ovarian Cancer,Drug: Pembrolizumab|Drug: Paclitaxel,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme LLC,Phase 2,42,Other|Industry,"October 20, 2015",Apr-20,"May 27, 2021"
8646,NCT02439385,Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis,Colorectal Cancer,Drug: Avastin/FOLFIRI|Dietary Supplement: Curcumin,Gachon University Gil Medical Center|Aju Pharm,Phase 2,44,Other,"August 24, 2015","August 1, 2019","August 1, 2019"
8647,NCT02437708,"Regenerative Endodontic Procedure of Immature Permanent Teeth With L-PRF: a Pilot Controlled, Clinical Trial",Endodontic Inflammation,Procedure: REP with L-PRF|Procedure: REP|Biological: stem and progenitor cells,Universitaire Ziekenhuizen KU Leuven,Phase 3,29,Other,Sep-14,Aug-19,Oct-20
8648,NCT02437370,Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Recurrent Bladder Carcinoma|Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter|Regional Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage III Bladder Urothelial Carcinoma|Stage III Urethral Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Urethral Cancer|Urethral Urothelial Carcinoma,Drug: Pembrolizumab|Drug: Docetaxel|Drug: Gemcitabine Hydrochloride,"University of California, Davis|Merck Sharp & Dohme LLC",Phase 1,32,Other|Industry,"September 1, 2015","August 7, 2019","March 10, 2020"
8649,NCT02437084,"Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling",Hyperlipidemia|Insulin Resistance|Type 2 Diabetes,Drug: Atorvastatin,Stanford University|Doris Duke Charitable Foundation,Phase 4,115,Other,May-15,Feb-20,Apr-20
8650,NCT02437045,Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response,Bloodstream Infections,Drug: Meropenem|Drug: Piperacillin-tazobactam combination product,The University of Queensland,Phase 4,100,Other,Apr-15,"December 31, 2020","December 31, 2020"
8651,NCT02436408,VISmodegib for ORbital and Periocular Basal Cell Carcinoma,"Carcinoma, Basal Cell",Drug: Vismodegib,University of Michigan Rogel Cancer Center,Phase 4,35,Other,"July 15, 2015",Sep-20,Sep-20
8652,NCT02435992,Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Drug: RPC1063|Drug: Placebo,Celgene,Phase 3,1012,Industry,"June 17, 2015","March 27, 2020","June 17, 2020"
8653,NCT02435849,Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,B-cell Acute Lymphoblastic Leukemia,Biological: CTL019,Novartis Pharmaceuticals|Novartis,Phase 2,97,Industry,"April 8, 2015","January 21, 2020","November 17, 2022"
8654,NCT02435680,Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),Advanced Triple Negative Breast Cancer (TNBC) With High TAMs,Drug: MCS110|Drug: carboplatin|Drug: gemcitabine,Novartis Pharmaceuticals|Novartis,Phase 2,50,Industry,"August 10, 2015","January 4, 2020","March 23, 2020"
8655,NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,Malignant Melanoma,Drug: pembrolizumab,Abramson Cancer Center at Penn Medicine,Phase 1,33,Other,Apr-15,Jul-19,"September 29, 2021"
8656,NCT02434081,NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma,Non-small Cell Lung Cancer Stage III,Drug: Nivolumab,"ETOP IBCSG Partners Foundation|Bristol-Myers Squibb|Frontier Science Foundation, Hellas",Phase 2,94,Other|Industry,"November 25, 2015","February 29, 2020","March 31, 2020"
8657,NCT02433977,The Effects of NOx and Conjugated Linoleic Acid on Asthmatics,Asthma,Dietary Supplement: Conjugated Linolenic Acid|Drug: Sodium Nitrite|Drug: Sodium Nitrate,"Gladwin, Mark, MD|University of Pittsburgh",Phase 2,6,Other,Sep-15,Nov-19,Nov-19
8658,NCT02433795,Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL),Marginal Zone B-cell Lymphoma,Drug: bendamustine plus rituximab,Seoul National University Hospital|Gyeongsang National University Hospital|Korea Cancer Center Hospital|Seoul National University Boramae Hospital|Hallym University Medical Center|Inje University|Gangnam Severance Hospital|Chonbuk National University Hospital|Chungnam National University|The Catholic University of Korea|Wonju Severance Christian Hospital|Gachon University Gil Medical Center|Seoul National University Bundang Hospital,Phase 2,27,Other,May-15,Oct-19,Oct-19
8659,NCT02433730,Testosterone Therapy in Hypogonadal Men Treated With Opioids,Hypogonadism,Drug: Testosterone|Drug: placebo,Marianne Andersen|Odense University Hospital,Phase 4,40,Other,"May 1, 2015","September 1, 2019","September 1, 2019"
8660,NCT02432846,Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC),"Renal Cell Carcinoma, Metastatic",Biological: Intuvax (INN: ilixadencel)|Drug: Sunitinib,Mendus|TFS Trial Form Support|Accelovance,Phase 2,88,Industry,Apr-15,"January 31, 2021","January 31, 2021"
8661,NCT02432326,A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,Cancer|Advanced Solid Tumors,Drug: BBI608|Drug: BBI503,"Sumitomo Pharma Oncology, Inc.",Phase 1,147,Industry,Apr-15,Dec-19,Apr-20
8662,NCT02432235,Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma,Hodgkin Lymphoma|Non-Hodgkin Lymphoma,Drug: Camidanlumab tesirine,ADC Therapeutics S.A.,Phase 1,133,Industry,"October 5, 2015","October 24, 2019","October 24, 2019"
8663,NCT02432209,Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility,"Infertility, Female",Other: Caloric Restriction|Drug: Orlistat|Other: Moderate physical activity,"Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Penn State University|Augusta University|University of California, San Francisco|University of North Carolina|University of Oklahoma|University of Pennsylvania",Phase 3,379,Other|NIH,Aug-15,"November 30, 2019",May-20
8664,NCT02431988,Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation,Diffuse Large B-Cell Lymphoma,Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells,"University College, London",Phase 1,10,Other,Jun-16,"February 2, 2020","March 21, 2022"
8665,NCT02431975,Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial,HIV,Drug: Nevirapine|Drug: Zidovudine|Drug: Lamivudine|Drug: LPV/r,"Columbia University|National Institutes of Health (NIH)|University of Witwatersrand, South Africa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Phase 4,73,Other|NIH,Aug-15,"April 30, 2020","April 30, 2020"
8666,NCT02431806,Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder,Major Depressive Disorder,Drug: Placebo|Drug: Levomilnacipran|Drug: Fluoxetine,Forest Laboratories,Phase 3,552,Industry,"June 23, 2015","August 19, 2019","August 19, 2019"
8667,NCT02431702,A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform,Schizophrenia|Psychotic Disorders,Drug: Aripiprazole|Drug: Haloperidol|Drug: Olanzapine|Drug: Oral Paliperidone ER|Drug: Perphenazine|Drug: Quetiapine|Drug: Oral Risperidone|Drug: Paliperidone Palmitate Injection (PP1M)|Drug: Paliperidone Palmitate Injection (PP3M),"Janssen Scientific Affairs, LLC",Phase 3,337,Industry,"July 8, 2015","November 12, 2019","November 12, 2019"
8668,NCT02431325,A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV,HIV,Drug: Teduglutide|Drug: Placebo,"Massachusetts General Hospital|Ragon Institute of MGH, MIT and Harvard|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health (NIH)",Phase 2,32,Other|NIH,Dec-15,"January 21, 2020","January 21, 2021"
8669,NCT02431208,A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM),Multiple Myeloma,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Daratumumab|Drug: Lenalidomide|Drug: Pomalidomide|Drug: Dexamethasone",Hoffmann-La Roche,Phase 1,85,Industry,"July 22, 2015","March 19, 2021","March 19, 2021"
8670,NCT02429414,Video Double-Lumen Tube Prospective Randomized Study,Other Surgical Procedures,Device: Non-Video Double Lumen Tube (DLT)|Procedure: Fiberoptic Bronchoscopy (FOB)|Device: Video Double Lumen Tube (VDLT),M.D. Anderson Cancer Center|E.T. View Medical Ltd,Phase 3,83,Other,Sep-15,"December 18, 2020","December 18, 2020"
8671,NCT02429193,Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA,Castration-resistant Prostate Cancer,Drug: Abiraterone + prednisone|Drug: Enzalutamide,"University Health Network, Toronto",Phase 2,16,Other,Mar-16,"September 1, 2019","September 1, 2019"
8672,NCT02427126,Apixaban for Treatment of Embolic Stroke of Undetermined Source,Embolic Stroke of Undetermined Source,Drug: Apixaban|Drug: Aspirin,University Hospital Tuebingen|Bristol-Myers Squibb|Medtronic|ZKS and IKEaB Tübingen,Phase 3,352,Other|Industry,Dec-15,Aug-20,Sep-21
8673,NCT02426944,Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation,Atrial Fibrillation,Drug: NOAC|Device: Left atrial appendage closure,"Charles University, Czech Republic|Ministry of Health, Czech Republic",Phase 4,400,Other,"October 13, 2015","July 20, 2019","July 20, 2019"
8674,NCT02426034,A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer,Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,Drug: ApatinibTablets,"Jiangsu HengRui Medicine Co., Ltd.",Phase 4,2004,Industry,"May 15, 2015","May 29, 2020","September 3, 2020"
8675,NCT02425891,A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130),Triple Negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Nab-Paclitaxel|Drug: Placebo",Hoffmann-La Roche,Phase 3,902,Industry,"June 23, 2015","April 14, 2020","August 31, 2021"
8676,NCT02425644,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,Multiple Sclerosis,Drug: ponesimod|Drug: teriflunomide,Actelion,Phase 3,1133,Industry,"June 4, 2015","May 16, 2019","May 16, 2019"
8677,NCT02425579,Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS),Acute Respiratory Distress Syndrome (ARDS),Drug: Inhaled Carbon Monoxide at 100ppm (4 participants)|Drug: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Drug: Inhaled Carbon Monoxide at 200ppm (4 participants)|Drug: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants),Brigham and Women's Hospital|Weill Medical College of Cornell University|Massachusetts General Hospital|Duke University,Phase 1,12,Other,Apr-15,Aug-19,Aug-19
8678,NCT02424968,CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma,Acute Myeloid Leukemia|B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Hodgkin Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|T-Cell Non-Hodgkin Lymphoma,Biological: Anti-Thymocyte Globulin|Drug: Cyclosporine|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Biological: Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Radiation: Total Nodal Irradiation,Robert Lowsky|National Cancer Institute (NCI)|Stanford University,Phase 2,18,Other|NIH,Jun-15,"July 3, 2020",Apr-21
8679,NCT02424851,Optimising Renal Outcome in Myeloma Renal Failure,Multiple Myeloma|Chronic Kidney Disease,Drug: Bortezomib|Drug: Thalidomide|Drug: Bendamustine|Drug: Dexamethasone,Oxford University Hospitals NHS Trust|Janssen-Cilag Ltd.|Bloodwise|University of Warwick|University of Birmingham,Phase 2,31,Other|Industry,Nov-14,"April 20, 2020","April 20, 2020"
8680,NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis,Drug: IL2|Drug: Placebo,Assistance Publique - Hôpitaux de Paris|Fondation ARSEP/AFM,Phase 2,30,Other,"June 13, 2016","October 11, 2019","June 15, 2020"
8681,NCT02424019,Phase 4 IOP Signals Associated With ILUVIEN®,Diabetic Macular Edema (DME),Drug: ILUVIEN 0.19 MG,Alimera Sciences,Phase 4,153,Industry,"May 6, 2015","July 29, 2020","July 31, 2020"
8682,NCT02423928,Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer,Prostate Cancer,Biological: Dendritic cell based cryoimmunotherapy|Drug: Cyclophosphamide|Drug: ipilimumab,Alden Cancer Therapy II|Haukeland University Hospital|Norwegian Radium Hospital,Phase 1,18,Industry|Other,May-15,"August 16, 2019","August 16, 2019"
8683,NCT02423915,Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,Leukemia|Lymphoma,Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Radiation|Procedure: Fucosylated Regulatory T Cells|Procedure: Cord Blood Infusions|Drug: Mycophenolate mofetil|Drug: Sirolimus|Procedure: Bone Marrow Aspiration|Drug: G-CSF|Procedure: Non-Fucosylated Regulatory T Cells,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cancer Prevention Research Institute of Texas,Phase 1,5,Other|NIH,"July 30, 2015","October 6, 2020","October 6, 2020"
8684,NCT02423863,"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®",Melanoma|Head and Neck Cancer|Sarcoma|Non-Melanoma Skin Cancers,Biological: Hiltonol,"Oncovir, Inc.|National Institutes of Health (NIH)|Icahn School of Medicine at Mount Sinai|Bay Hematology Oncology|National Cancer Institute (NCI)|University of Missouri-Columbia|Chevy Chase Regional Cancer Care Associates LLC|Dermatologic Surgery Center of Washington LLC and Skin Cancer Treatment Center",Phase 2,26,Industry|NIH|Other,Mar-15,"August 31, 2020","August 31, 2020"
8685,NCT02423525,Safety Study of Afatinib for Brain Cancer,Brain Cancer,Drug: Afatinib,Santosh Kesari|Boehringer Ingelheim|Saint John's Cancer Institute,Phase 1,24,Other|Industry,Dec-16,Aug-20,Aug-21
8686,NCT02422485,"A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy",Progressive Supranuclear Palsy,Drug: Salsalate,"Adam Boxer|University of California, San Francisco",Phase 1,10,Other,Apr-15,Dec-19,Dec-19
8687,NCT02421263,The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals,Religious or Spiritual Problem,Drug: Psilocybin,NYU Langone Health,Phase 1,12,Other,Apr-15,"June 5, 2020","June 5, 2020"
8688,NCT02420821,A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC),Renal Cell Carcinoma,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Bevacizumab|Drug: Sunitinib",Hoffmann-La Roche,Phase 3,915,Industry,"May 20, 2015","February 14, 2020","December 13, 2021"
8689,NCT02420691,Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin,Advanced Digestive System Neuroendocrine Neoplasm|Duodenal Neuroendocrine Tumor G1|Functional Pancreatic Neuroendocrine Tumor|Gastric Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Nonfunctional Pancreatic Neuroendocrine Tumor|Thymus Neoplasm,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ribociclib,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Novartis,Phase 2,21,Other|NIH|Industry,"August 25, 2015","June 5, 2019","June 5, 2019"
8690,NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,"Multiple Sclerosis, Relapsing-Remitting",Drug: Alemtuzumab,"University Hospital Muenster|Genzyme, a Sanofi Company",Phase 4,15,Other|Industry,Jun-15,Jul-20,Nov-20
8691,NCT02418195,"miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome",Major Depressive Disorder,Drug: ketamine,University of Alabama at Birmingham|National Institute of Mental Health (NIMH),Phase 2,247,Other|NIH,"April 20, 2015","December 30, 2020","December 30, 2020"
8692,NCT02417701,Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer,Recurrent Lung Squamous Cell Carcinoma|Stage IV Lung Squamous Cell Carcinoma AJCC v7,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib,National Cancer Institute (NCI),Phase 2,34,NIH,"October 6, 2016","December 28, 2020","December 28, 2020"
8693,NCT02417688,PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis,Carotid Atherosclerosis,Device: Cu[64]-25%-CANF-Comb PET-MR,Washington University School of Medicine,Phase 1,44,Other,"April 5, 2015","April 30, 2021","April 30, 2021"
8694,NCT02417467,Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial,Smoking Cessation,Other: Nicotine E-Cigarette|Other: Non-Nicotine E-Cigarette|Behavioral: Counseling,McGill University|Sir Mortimer B. Davis - Jewish General Hospital,Phase 3,376,Other,Nov-16,Dec-19,"October 1, 2020"
8695,NCT02417142,Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia,Schizophrenia|Schizoaffective Disorder,Drug: Exenatide|Drug: Placebo,"University of Massachusetts, Worcester|Stanley Medical Research Institute",Phase 4,70,Other,Sep-14,Jul-19,Jul-20
8696,NCT02416206,High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma,Multiple Myeloma,Drug: BeEAM,"Northside Hospital, Inc.|Teva Pharmaceuticals USA",Phase 2,65,Other|Industry,"April 27, 2015","March 26, 2020","April 21, 2021"
8697,NCT02415985,Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly,HIV|Tuberculosis,Drug: Lopinavir/r will be supplied by NHSO/GPO|Drug: Rifabutin,The HIV Netherlands Australia Thailand Research Collaboration|Bamrasnaradura Infectious Diseases Institute|Chulalongkorn University,Phase 2,40,Other,Jun-15,Dec-19,Dec-19
8698,NCT02415881,Panitumumab IRDye800 Optical Imaging Study,Head and Neck Cancer,Drug: Panitumumab IRDye 800|Device: da Vinci Firefly|Device: IMAGE1 + ICG Hopkins telescope and/or VITOM,Eben Rosenthal|Stanford University,Phase 1,64,Other,Aug-16,"November 23, 2019","September 21, 2021"
8699,NCT02415556,Memory Aid by Intranasal Insulin in Diabetes (MemAID),Type 2 Diabetes Mellitus,Drug: Regular Human Insulin|Drug: Placebo,Beth Israel Deaconess Medical Center|Novo Nordisk A/S|Medtronic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 2,289,Other|Industry|NIH,"October 6, 2015","May 31, 2020","May 31, 2020"
8700,NCT02415153,"Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",Neurofibromatosis Type 1|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Visual Pathway Glioma|Recurrent Primary Central Nervous System Neoplasm|Refractory Primary Central Nervous System Neoplasm,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Pomalidomide,National Cancer Institute (NCI),Phase 1,29,NIH,"July 14, 2015","July 1, 2019","May 27, 2020"
8701,NCT02414685,First Line TIP in Poor Prognosis TGCTs.,Germ Cell Tumor,Drug: Paclitaxel|Drug: Ifosfamide|Drug: Cisplatin,"National Cancer Institute, Slovakia",Phase 2,19,Other,Apr-15,Jun-20,Jun-20
8702,NCT02414399,Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children,Pneumonia|Diarrhea|Malaria|Co-infection|Death|Malnutrition,Drug: Azithromycin|Drug: Placebo,University of Washington|Kenya Medical Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 4,1400,Other|NIH,"June 28, 2016","May 4, 2020","May 4, 2020"
8703,NCT02414009,"Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients",Metastatic Colorectal Cancer,Drug: Capecitabine|Drug: Temozolomide|Drug: Irinotecan|Drug: Fluorouracil|Drug: Leucovorin,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Phase 2,82,Other,Sep-14,"July 30, 2019","July 30, 2019"
8704,NCT02412735,Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain,Degenerative Disc Disease,Drug: Rexlemestrocel-L|Drug: Rexlemestrocel-L + HA Mixture|Drug: Placebo,"Mesoblast, Ltd.|Quintiles, Inc.",Phase 3,404,Industry,"March 6, 2015","May 15, 2020","June 15, 2021"
8705,NCT02411786,A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,Prostate Cancer,Biological: pTVG-AR|Biological: gm-csf,"University of Wisconsin, Madison|Madison Vaccines Incorporated",Phase 1,40,Other,"August 24, 2015","May 1, 2019","November 28, 2020"
8706,NCT02410772,TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens,Tuberculosis,Drug: rifapentine|Drug: rifapentine and moxifloxacin|Drug: control,Centers for Disease Control and Prevention|AIDS Clinical Trials Group,Phase 3,2516,U.S. Fed|Other,"January 25, 2016",Jul-20,May-21
8707,NCT02410512,A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors,Neoplasms,"Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Drug: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody","Genentech, Inc.",Phase 1,610,Industry,"April 24, 2015","November 22, 2019","November 22, 2019"
8708,NCT02409342,A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110],"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed",Hoffmann-La Roche,Phase 3,572,Industry,"July 20, 2015","February 4, 2020","March 8, 2022"
8709,NCT02408484,"Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency",Congenital Fibrinogen Deficiency,Biological: Octafibrin,Octapharma,Phase 3,15,Industry,Dec-15,"June 11, 2019","June 11, 2019"
8710,NCT02408120,Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Insulin aspart|Drug: Supplemental insulin aspart,Emory University,Phase 4,226,Other,Oct-15,"December 11, 2019","December 11, 2019"
8711,NCT02407990,"Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors",Advanced Cancer,Biological: BGB-A317,BeiGene,Phase 1,451,Industry,"June 2, 2015","August 12, 2020","August 12, 2020"
8712,NCT02407899,Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes,"Diabetes Mellitus, Type 1",Drug: Saxagliptin|Drug: Vitamin D3|Drug: Insulin|Drug: Metformin,Second Xiangya Hospital of Central South University|Beijing Hospital|The First Affiliated Hospital with Nanjing Medical University|First Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Henan University of Science and Technology,Phase 4,300,Other,Mar-15,"December 30, 2020","December 31, 2020"
8713,NCT02406885,Apixaban Pharmacokinetics in Bariatric Patients (APB),Bariatric Surgery|Obesity,Drug: Apixaban,Johns Hopkins University,Phase 4,33,Other,"July 19, 2017","February 1, 2020","February 1, 2020"
8714,NCT02405520,Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine,Condylomata Acuminata,Biological: low dosage HPV Vaccine|Biological: medium dosage HPV Vaccine|Biological: high dosage HPV Vaccine|Biological: Aluminium Adjuvant,"Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University",Phase 1,145,Other|Industry,"March 26, 2015","June 5, 2019","May 20, 2022"
8715,NCT02404935,Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC),Metastatic Colorectal Cancer,Drug: Cetuximab|Drug: FOLFIRI and cetuximab,UNICANCER,Phase 2,139,Other,"November 22, 2013","November 1, 2020","October 25, 2021"
8716,NCT02404870,"Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers",Healthy Volunteers,Drug: Placebo|Drug: Canagliflozin,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 1,67,NIH,"September 16, 2014","May 1, 2019","September 3, 2019"
8717,NCT02404376,COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial,ST Elevation Acute Myocardial Infarction,Drug: Exenatide|Other: Remote Ischemic Conditioning (RIC)|Drug: Placebo,Hospital Universitari Vall d'Hebron Research Institute,Phase 3,378,Other,Mar-16,Aug-19,Jun-20
8718,NCT02401347,Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors,Advanced Breast Cancer|HER2/Neu Negative|Triple-Negative Breast Cancer,Drug: Talazoparib Tosylate,Melinda Telli|BioMarin Pharmaceutical|Pfizer|Stanford University,Phase 2,21,Other|Industry,Aug-15,"December 23, 2019",Dec-22
8719,NCT02400632,MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions,Coronary Artery Disease,Device: MAGIC-TOUCH Drug-eluting Balloon,Scitech Produtos Medicos Ltda,Phase 3,60,Industry,Jun-15,"July 30, 2019","December 30, 2019"
8720,NCT02400476,An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,Early Stage HER2+ Breast Cancer,Drug: Neratinib|Drug: Loperamide|Drug: Colestipol|Drug: Budesonide,"Puma Biotechnology, Inc.",Phase 2,563,Industry,Feb-15,"April 22, 2021","April 22, 2021"
8721,NCT02400463,A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome,Hemophagocytic Syndrome (HPS),Drug: Ruxolitinib,University of Michigan Rogel Cancer Center,Phase 2,6,Other,"February 5, 2016","October 10, 2019","January 7, 2020"
8722,NCT02400437,"Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia",Waldenstrom's Macroglobulinemia,Drug: Ixazomib|Drug: Dexamethasone|Drug: Rituximab,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Phase 2,26,Other|Industry,Apr-15,Nov-19,Nov-19
8723,NCT02400047,"Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP",Postoperative Nausea and Vomiting,Drug: Dexamethasone 0.2 mg/kg|Drug: Dexamethasone 0.4 mg/kg|Drug: Ketoprofen 1 mg/kg,Rennes University Hospital,Phase 3,580,Other,"June 3, 2015","July 18, 2019","July 18, 2019"
8724,NCT02399592,Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer,Ovarian Cancer,Drug: Bevacizumab|Drug: Tocotrinol,Vejle Hospital,Phase 2,23,Other,Mar-15,Jul-19,Jul-19
8725,NCT02399215,Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors,Carcinoid Tumor|Metastatic Carcinoid Tumor|Neuroendocrine Neoplasm,Other: Laboratory Biomarker Analysis|Drug: Nintedanib|Other: Pharmacological Study|Other: Quality-of-Life Assessment,Roswell Park Cancer Institute|National Comprehensive Cancer Network,Phase 2,32,Other,"May 15, 2015","September 1, 2019","August 31, 2022"
8726,NCT02398929,BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study),Hypertension,Drug: Bisoprolol 2.5 mg|Drug: Placebo,Chinese University of Hong Kong,Phase 4,100,Other,Jan-13,"January 5, 2021","January 5, 2021"
8727,NCT02398058,Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS),Soft Tissue Sarcoma|Bone Tumor,Drug: trabectedin|Drug: olaparib,Italian Sarcoma Group|PharmaMar|AstraZeneca|Istituto Di Ricerche Farmacologiche Mario Negri,Phase 1,50,Other|Industry,"July 20, 2014","December 1, 2019","December 1, 2019"
8728,NCT02395640,The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer,Gastric Cancer,Drug: Epirubicin|Drug: Oxaliplatin|Drug: Capecitabine,Fudan University,Phase 3,438,Other,Mar-15,"February 23, 2021","February 23, 2021"
8729,NCT02394652,The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial,"Uterine Cervical Neoplasms|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Adenosquamous",Drug: Metformin|Drug: Cisplatin|Drug: FAZA,"University Health Network, Toronto",Phase 2,16,Other,"May 21, 2015","January 12, 2021","January 12, 2021"
8730,NCT02393859,Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL),"Leukemia, Acute Lymphoblastic",Drug: Blinatumomab|Drug: Dexamethasone|Drug: Vincrisitne|Drug: Daunorubicin|Drug: Methotrexate|Drug: Ifosfamide|Drug: PEG-asparaginase|Drug: Erwinia-asparaginase,Amgen,Phase 3,111,Industry,"November 10, 2015","July 17, 2019","December 5, 2022"
8731,NCT02392637,"Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers",Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma,Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Nab-paclitaxel,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,62,Other|NIH,"April 2, 2015","August 13, 2020","August 13, 2020"
8732,NCT02392559,"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders",Heterozygous Familial Hypercholesterolemia,Drug: Evolocumab|Drug: Placebo,Amgen,Phase 3,158,Industry,"March 24, 2016","November 25, 2019","November 25, 2019"
8733,NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Acute Myeloid Leukemia (AML)|Multiple Myeloma|Prostate Cancer|Small Cell Lung Cancer|Non-Hodgkins Lymphoma,Drug: ABBV-075|Drug: Venetoclax,AbbVie,Phase 1,128,Industry,"April 14, 2015","July 5, 2019","July 5, 2019"
8734,NCT02390843,Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors,Retinoblastoma|Clear Cell Sarcoma|Renal Cell Carcinoma|Rhabdoid Tumor|Wilms Tumor|Hepatoblastoma|Neuroblastoma|Germ Cell Tumors|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Osteosarcoma|Rhabdomyosarcoma,Drug: Simvastatin|Drug: Cyclophosphamide|Drug: Topotecan|Drug: Myeloid growth factor,Emory University|Children's Healthcare of Atlanta,Phase 1,13,Other,Feb-15,"September 22, 2019","September 22, 2019"
8735,NCT02390531,Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity,Retinopathy of Prematurity,Drug: Bevacizumab,Jaeb Center for Health Research|Pediatric Eye Disease Investigator Group|National Eye Institute (NEI),Phase 1,120,Other|NIH,"April 28, 2015","June 4, 2019","May 11, 2021"
8736,NCT02389959,Intranasal Bevacizumab for HHT-Related Epistaxis,HHT|Hereditary Hemorrhagic Telangiectasia|Epistaxis|Nose Bleeds|Nasal Bleeding,Drug: Bevacizumab|Drug: Placebo (Saline),Stanford University,Phase 4,40,Other,"August 4, 2014","January 23, 2020","January 23, 2020"
8737,NCT02389751,"Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer",Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7,Drug: Carboplatin|Drug: Ganetespib|Drug: Paclitaxel|Radiation: Radiation Therapy,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,3,Other|NIH,"April 10, 2015","July 16, 2019","July 16, 2019"
8738,NCT02389218,A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF,Atrial Fibrillation,"Device: single ablation (CryoBalloonAblation (CBA)|Drug: sequential drug adjustment (propafenone, sotalol or flecainide)","University Hospital, Ghent",Phase 4,13,Other,"March 3, 2015","May 14, 2020","May 14, 2020"
8739,NCT02386319,Anxiolytic and Analgesic Effects of Melatonin,Anxiety,Drug: Melatonin|Drug: Placebo,Herlev Hospital,Phase 3,36,Other,Aug-16,Mar-21,Apr-21
8740,NCT02385123,Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers,Influenza|Influenza Immunisation,Biological: Influenza Virus Vaccine Inactivated,National Institute of Allergy and Infectious Diseases (NIAID),Phase 4,60,NIH,"April 1, 2015","December 6, 2019","December 31, 2020"
8741,NCT02384889,DFMO in Children With Type 1 Diabetes,Type 1 Diabetes,Drug: Difluoromethylornithine|Drug: Placebo,Indiana University,Phase 1,41,Other,Apr-15,"October 7, 2019","January 6, 2020"
8742,NCT02384876,Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age.,"Intraoperative Arterial Hypotension|Infant, Newborn","Drug: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Drug: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.",Hospices Civils de Lyon,Phase 2,120,Other,Jun-15,"September 5, 2020","September 5, 2020"
8743,NCT02384382,A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),Prostate Carcinoma Metastatic to the Bone|Castration Resistant Prostate Cancer,Drug: Enzalutamide,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Phase 2,23,Industry,"November 30, 2015","May 3, 2019","May 3, 2019"
8744,NCT02384239,A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,Metastatic Breast Cancer|Hormone Receptor Positive,Drug: Palbociclib|Drug: Tamoxifen|Drug: Fulvestrant,"University of California, San Francisco|Translational Breast Cancer Research Consortium|Dana-Farber Cancer Institute",Phase 2,70,Other,"October 19, 2015","January 31, 2021","January 31, 2021"
8745,NCT02383927,Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations,Thyroid Cancer|Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)|HRAS Mutant Tumor|Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor,Drug: Tipifarnib,"Kura Oncology, Inc.",Phase 2,63,Industry,Mar-15,"November 30, 2020","November 30, 2020"
8746,NCT02383251,Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer,Ovarian Cancer,Drug: Pazopanib|Drug: Paclitaxel,ARCAGY/ GINECO GROUP|Novartis,Phase 2,118,Other|Industry,"June 15, 2015",Aug-19,"December 31, 2020"
8747,NCT02383212,Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,Advanced Cancer|Advanced Malignancies,Drug: Cemiplimab|Radiation: Hypofractionated radiotherapy|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Carboplatin|Drug: GM-CSF|Drug: Paclitaxel|Drug: Pemetrexed,Regeneron Pharmaceuticals|Sanofi,Phase 1,398,Industry,"February 2, 2015","November 18, 2019","November 18, 2019"
8748,NCT02382796,A Rollover Protocol of Dacomitinib For Patients In Japan,NSCLC,Drug: Dacomitinib,Pfizer,Phase 2,7,Industry,"July 10, 2015","May 30, 2019","May 30, 2019"
8749,NCT02381470,Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers,Pulmonary Tuberculosis,Drug: Faropenem|Drug: Amoxicillin/clavulanic acid|Drug: Cefadroxil|Drug: Rifampicin,"National University Hospital, Singapore",Phase 2,58,Other,"February 11, 2019","September 28, 2019","October 2, 2019"
8750,NCT02380352,Short-course Antimicrobial Therapy for Paediatric Respiratory Infections,Community-acquired Pneumonia,Drug: Amoxicillin|Drug: Placebo,Hamilton Health Sciences Corporation|Children's Hospital of Eastern Ontario,Phase 4,281,Other,Sep-16,Dec-19,Apr-20
8751,NCT02379806,The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study,Venous Thromboembolism,Drug: Enoxaparin|Drug: Placebo,"University Hospital, Brest",Phase 3,2560,Other,"September 3, 2015",Dec-20,"December 29, 2020"
8752,NCT02378714,Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers,Nicotine Dependence|Major Depressive Disorder,Drug: Varenicline|Behavioral: BASC|Behavioral: Standard treatment,Northwestern University|National Cancer Institute (NCI),Phase 4,300,Other|NIH,"July 24, 2015","March 13, 2020","March 13, 2020"
8753,NCT02377388,DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function,Platelet Aggregation During Acute Myocardial Infarction,Drug: sitagliptin OR saxagliptin|Drug: placebo,University of Sao Paulo General Hospital|InCor Heart Institute,Phase 3,74,Other,"February 7, 2017","February 28, 2020","February 28, 2020"
8754,NCT02375672,Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,Colorectal Cancer,Drug: Pembrolizumab|Drug: mFOLFOX6,Hoosier Cancer Research Network|Merck Sharp & Dohme LLC,Phase 2,30,Other|Industry,"May 28, 2015","October 8, 2020","October 8, 2020"
8755,NCT02373813,Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission,Rheumatoid Arthritis,Drug: etanercept pre-filled syringe subcutaneous injection|Drug: Oral methotrexate|Drug: Placebo for etanercept subcutaneous injection|Drug: Placebo for methotrexate|Dietary Supplement: Folic acid (non-investigational product),Amgen,Phase 3,371,Industry,"February 20, 2015","December 6, 2019","December 6, 2019"
8756,NCT02372175,Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain,Dengue,Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC),U.S. Army Medical Research and Development Command|State University of New York - Upstate Medical University,Phase 1,27,U.S. Fed|Other,Oct-15,"June 28, 2019","June 28, 2019"
8757,NCT02371889,"A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers",Alcoholism|Alcohol Use Disorder (AUD),Drug: Topiramate|Behavioral: Medical Management|Drug: Inactive Placebo,University of Pennsylvania|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health (NIH)|Department of Health and Human Services|Corporal Michael J. Crescenz VA Medical Center,Phase 2,320,Other|NIH|U.S. Fed,"December 18, 2014",Feb-20,Feb-20
8758,NCT02370706,Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis,Myelofibrosis,Drug: PIM447|Drug: Ruxolitinib|Drug: LEE011,Novartis Pharmaceuticals|Novartis,Phase 1,15,Industry,"May 21, 2015","November 9, 2020","November 9, 2020"
8759,NCT02370693,Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis,"Lung Diseases, Interstitial|Systemic Sclerosis|Scleroderma",Drug: Bortezomib|Drug: Placebo|Drug: Mycophenolate mofetil,"Northwestern University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,9,Other|NIH,Mar-16,"December 16, 2019","January 1, 2020"
8760,NCT02370069,The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13,Chronic Kidney Diseases,Biological: Prevnar 13,Lakehead University,Phase 4,138,Other,Jun-15,Aug-20,Aug-20
8761,NCT02369549,Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease,Chronic Kidney Disease,Drug: Micro-particle Curcumin|Drug: Placebo,Lawson Health Research Institute|The Kidney Foundation of Canada|Canadian Institutes of Health Research (CIHR),Phase 3,518,Other,Sep-15,Nov-19,"May 15, 2020"
8762,NCT02369159,"Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza",Influenza,Drug: Peramivir|Drug: Oseltamivir,BioCryst Pharmaceuticals,Phase 3,137,Industry,"March 11, 2015","October 28, 2019","May 14, 2020"
8763,NCT02368860,"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",Pancreatic Cancer,"Drug: oxaliplatin, irinotecan, capecitabine","National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore",Phase 1,33,Other,"September 17, 2013","May 21, 2020","May 21, 2020"
8764,NCT02367456,"A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients",Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia,Drug: PF-04449913 (Glasdegib)|Drug: Azacitidine,Pfizer,Phase 1,73,Industry,"April 28, 2015","January 29, 2020","March 7, 2022"
8765,NCT02367196,"A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers",Hematologic Neoplasms,Drug: CC-90002|Drug: Rituximab,Celgene,Phase 1,60,Industry,"March 12, 2015","December 24, 2020","December 24, 2020"
8766,NCT02367105,Lifestyle Intervention and Testosterone Replacement in Obese Seniors,Obesity and Hypogonadism,Drug: Testosterone|Other: Lifestyle Therapy|Drug: Placebo,VA Office of Research and Development|Michael E. DeBakey VA Medical Center|Baylor College of Medicine|Biomedical Research Institute of New Mexico,Phase 3,83,U.S. Fed|Other,"February 1, 2015","July 31, 2019","December 31, 2019"
8767,NCT02366871,Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy,Gynecologic Cancer|Venous Thromboembolism,Drug: Oral apixaban|Drug: Subcutaneous enoxaparin,"University of Colorado, Denver|Bristol-Myers Squibb",Phase 2,400,Other|Industry,"April 28, 2015",Jun-19,Jun-19
8768,NCT02366728,DC Migration Study for Newly-Diagnosed GBM,"Glioblastoma|Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme",Biological: Unpulsed DCs|Biological: Td|Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Biological: 111In-labeled DCs|Drug: Temozolomide|Drug: Saline|Drug: Basiliximab,Gary Archer Ph.D.|Duke University,Phase 2,64,Other,"October 12, 2015","October 31, 2020","October 31, 2020"
8769,NCT02366312,"A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors",Keratocystic Odontogenic Tumor,Drug: vismodegib,"NYU College of Dentistry|Genentech, Inc.",Phase 2,2,Other|Industry,"October 27, 2015",Aug-19,Aug-19
8770,NCT02366143,A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"Carcinoma, Non-Small-Cell Lung","Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Bevacizumab|Drug: Carboplatin|Drug: Paclitaxel",Hoffmann-La Roche,Phase 3,1202,Industry,"March 31, 2015","September 13, 2019","December 7, 2020"
8771,NCT02366130,Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer,Breast Cancer,Drug: Ra-223 dichloride|Drug: Denosumab|Drug: Hormone Therapy,M.D. Anderson Cancer Center|Bayer,Phase 2,45,Other|Industry,"February 11, 2015","December 16, 2020","December 16, 2020"
8772,NCT02366091,Inflammation and Coronary Endothelial Function,Coronary Artery Disease,Drug: Methotrexate|Drug: Colchicine|Drug: Placebo,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,111,Other|NIH,Jan-15,"August 1, 2020","September 1, 2020"
8773,NCT02364492,A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse,Breast Neoplasms,Drug: MAG-TN3 + AS15,Institut Pasteur,Phase 1,20,Industry,Feb-15,Oct-19,"November 11, 2021"
8774,NCT02363829,A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA),Uterine Cervix Cancer,Drug: Nelfinavir|Biological: Cisplatin,Abramson Cancer Center at Penn Medicine,Phase 1,6,Other,Feb-15,"February 17, 2020","February 17, 2020"
8775,NCT02363751,Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24),Collecting Duct Carcinoma (Kidney),Drug: Bevacizumab,UNICANCER,Phase 2,36,Other,Dec-14,Mar-20,Aug-20
8776,NCT02362958,A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer,HER2 Positive Breast Cancer,Drug: lapatinib and capecitabine or vinorelbine,Sun Yat-sen University,Phase 2,159,Other,"January 9, 2015","May 31, 2020","May 31, 2020"
8777,NCT02361723,Phase 1a/1b BGB-290 for Advanced Solid Tumors.,For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment,Drug: BGB-290,BeiGene,Phase 1,101,Industry,"July 3, 2014","September 3, 2019","September 3, 2019"
8778,NCT02360371,A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans,Opioid Sensitivity|Individual Difference|Abuse Opioids,Drug: Within-subject test of blinded study medication,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Phase 2,100,Other|NIH,Apr-15,May-20,May-21
8779,NCT02360345,Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly,Solid Tumours,Drug: ONX-0801,"Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom|Onyx Therapeutics, Inc.",Phase 1,111,Other|Industry,Sep-13,Jan-20,Mar-21
8780,NCT02359929,BMT Autologous MSCs for GvHD,Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease,Biological: Autologous mesenchymal stromal cells (MSCs),Emory University|CURE Foundation,Phase 1,11,Other,Jan-15,"June 15, 2020","January 11, 2021"
8781,NCT02358681,Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children,Migraine,"Drug: Ketorolac, intranasal|Drug: Ketorolac, intravenous|Drug: Placebo, intravenous|Drug: Placebo, intranasal",Columbia University|Migraine Research Foundation,Phase 3,59,Other,"June 16, 2015","March 31, 2021","March 31, 2021"
8782,NCT02358226,HIV & Drug Abuse Prevention for South African Men,Substance-Related Disorders|Human Immunodeficiency Virus|Alcoholism,Behavioral: Soccer League (SL)|Behavioral: Soccer League/Vocational Training (SL-V),"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",Phase 3,1211,Other|NIH,May-16,Jan-20,Jan-20
8783,NCT02357368,Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk,HIV|Contraception,Drug: Depot medroxyprogesterone acetate (DMPA)|Device: Etonogestrel implant (Eng-Implant)|Device: Levonorgestrel intrauterine device (Lng-IUD)|Device: ParaGard® T 380A Intrauterine Copper Contraceptive,Lisa Haddad|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Emory University,Phase 4,59,Other|NIH,Feb-15,"October 23, 2019","October 23, 2019"
8784,NCT02355535,Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1,Solid Tumor|Pancreatic Neuroendocrine Tumor|Neuroendocrine Tumors,Drug: PAC-1,"Vanquish Oncology, Inc.|University of Illinois at Chicago",Phase 1,48,Industry|Other,Feb-15,"May 18, 2020","May 18, 2020"
8785,NCT02354703,Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder,Alcohol Use Disorder,Drug: Ondansetron|Drug: Placebo,"University of Maryland, Baltimore|University of Pennsylvania",Phase 2,293,Other,Aug-15,"March 31, 2020","March 31, 2020"
8786,NCT02354625,The Safety of ahSC in Chronic SCI With Rehabilitation,Spinal Cord Injury|Paraplegia|Quadriplegia|Tetraplegia,Biological: Autologous human Schwann cells,W. Dalton Dietrich|The Miami Project to Cure Paralysis|University of Miami,Phase 1,8,Other,Jan-15,"August 12, 2019","August 12, 2019"
8787,NCT02353728,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,Chronic Myeloid Leukemia,Drug: Nilotinib,Weill Medical College of Cornell University|Novartis Pharmaceuticals,Phase 2,16,Other|Industry,Jan-15,Feb-21,Feb-21
8788,NCT02352974,GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1),"Diabetes Mellitus, Type 1",Drug: GAD-Alum|Drug: Vitamin D,"Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University",Phase 1,12,Other|Industry,Jan-15,Oct-19,Oct-19
8789,NCT02351856,A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy,LMNA-Related Dilated Cardiomyopathy,"Drug: ARRY-371797, p38 inhibitor, oral",Pfizer,Phase 2,8,Industry,"February 2, 2015","December 21, 2020","December 21, 2020"
8790,NCT02350673,A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors,Solid Tumors,Drug: Atezolizumab|Drug: Cergutuzumab Amunaleukin,Hoffmann-La Roche,Phase 1,70,Industry,"June 29, 2015","December 16, 2019","December 16, 2019"
8791,NCT02350517,Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer,Esophageal Squamous Cell Carcinoma,Drug: Paclitaxel+Nedaplatin+Endostar,Yuhong Li|Sun Yat-sen University,Phase 2,52,Other,Jan-15,Dec-19,Dec-22
8792,NCT02349867,Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer,Pancreatic Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Recurrent Pancreatic Carcinoma,Drug: Gemcitabine|Drug: Sorafenib|Drug: Vorinostat|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy|Other: RosetteSep|Other: DEPfff,Virginia Commonwealth University|National Cancer Institute (NCI),Phase 1,23,Other|NIH,"January 29, 2015","May 13, 2020","May 13, 2022"
8793,NCT02348320,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,Triple Negative Breast Cancer|Triple-Negative Breast Cancer|Triple Negative Breast Neoplasms,Biological: Personalized polyepitope DNA vaccine,Washington University School of Medicine|Susan G. Komen Breast Cancer Foundation,Phase 1,18,Other,"June 17, 2015","March 12, 2020","March 12, 2020"
8794,NCT02347904,Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer,Esophageal Cancer,Drug: S-1 and Oxaliplatin,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Celgene Corporation,Phase 1,40,Other|Industry,Dec-14,Nov-19,Nov-19
8795,NCT02346526,A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer,Prostate Cancer|Castration-resistant Prostate Cancer|Castration-resistant Prostate Cancer Metastatic to Bone,Procedure: Blood Tests|Procedure: CT scan|Procedure: FACBC PET/MRI in a subset of participants|Drug: Radium-223 dichloride|Procedure: bone scan,Massachusetts General Hospital|Bayer,Phase 2,22,Other|Industry,Apr-15,Oct-19,Dec-20
8796,NCT02346487,Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study),HIV,Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC,Drugs for Neglected Diseases|UNITAID|French Development Agency,Phase 3,1003,Other,Sep-15,"May 14, 2019","May 14, 2019"
8797,NCT02346201,Apathy in Dementia Methylphenidate Trial 2,Apathy|Alzheimer's Disease,Drug: Methylphenidate|Drug: Placebo,Johns Hopkins Bloomberg School of Public Health|National Institute on Aging (NIA),Phase 3,200,Other|NIH,Jan-16,"July 15, 2020","July 15, 2020"
8798,NCT02345850,Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301),Acute Leukemia|Myelodysplasia,Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft|Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Methotrexate,"National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)",Phase 3,346,NIH|Other,Aug-15,"October 5, 2020","October 5, 2020"
8799,NCT02345408,Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma,Pancreatic Cancer,Drug: CCX872-B,ChemoCentryx,Phase 1,54,Industry,Feb-15,"May 6, 2020","May 6, 2020"
8800,NCT02343536,"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular",Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone,Celgene,Phase 1,59,Industry,"April 29, 2015","January 29, 2020","January 29, 2020"
8801,NCT02343406,Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas,Glioblastoma,Drug: Depatuxizumab mafodotin|Drug: Temozolomide|Drug: Lomustine,AbbVie|European Organisation for Research and Treatment of Cancer - EORTC,Phase 2,266,Industry|Other,"February 17, 2015","June 24, 2019","June 24, 2019"
8802,NCT02343224,Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas,Juvenile Pilocytic Astrocytomas|Optic Pathway Gliomas,Drug: Pegylated interferon alpha-2b,"Emory University|CURE Childhood Cancer, Inc.",Phase 2,9,Other,Nov-14,"November 11, 2020","November 11, 2020"
8803,NCT02343172,Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,Liposarcoma,Drug: HDM201|Drug: LEE011,Novartis Pharmaceuticals|Novartis,Phase 1,74,Industry,"March 13, 2015","October 16, 2019","October 16, 2019"
8804,NCT02341729,"Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome",Acute Coronary Syndrome,Drug: ticagrelor,"University Hospital, Ghent|AstraZeneca",Phase 4,40,Other|Industry,Mar-15,Dec-19,Dec-19
8805,NCT02340949,Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer,Rectal Cancer,Drug: Aflibercept|Drug: 5-Fluoruracil|Drug: Oxaliplatin|Drug: Leucovorin,Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.,Phase 2,180,Other|Industry,Jan-15,"July 15, 2019","February 4, 2020"
8806,NCT02340728,Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies,Pancreatic Cancer|Unresectable Biliary-pancreatic Malignancies,Device: ERCP with SEMS plus radiofrequency ablation|Device: ERCP with SEMS alone (standard of care),Memorial Sloan Kettering Cancer Center,Phase 3,24,Other,Jan-15,Nov-19,Nov-19
8807,NCT02340169,"Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis",Plaque Psoriasis,"Drug: Topicort® (desoximetasone) Topical Spray, 0.25%",Taro Pharmaceuticals USA,Phase 4,129,Industry,"January 23, 2015","November 22, 2019","November 22, 2021"
8808,NCT02339844,Pan European Collaboration on Antipsychotic Naïve Schizophrenia II,Schizophrenia,Drug: Aripiprazole,University of Copenhagen,Phase 4,130,Other,Jan-14,Jan-21,Jan-21
8809,NCT02339324,Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,Melanoma,Drug: Pembrolizumab and high dose interferon alfa-2b (HDI),Yana Najjar|Merck Sharp & Dohme LLC|University of Pittsburgh,Phase 1,31,Other|Industry,"March 6, 2015","September 1, 2019","November 2, 2019"
8810,NCT02338349,"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer","Advanced ER+, HER2-Negative Breast Cancer",Drug: Elacestrant,"Stemline Therapeutics, Inc.",Phase 1,57,Other,Jan-15,Sep-19,Apr-20
8811,NCT02336815,Selinexor Treatment of Refractory Myeloma,Multiple Myeloma,Drug: Selinexor|Drug: Dexamethasone,Karyopharm Therapeutics Inc,Phase 2,202,Industry,"May 26, 2015","July 26, 2019","July 26, 2019"
8812,NCT02335983,Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma,Multiple Myeloma,Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone,Amgen,Phase 1,107,Industry,"April 30, 2015","October 28, 2019","October 28, 2019"
8813,NCT02335268,VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA,Myelodysplastic Syndromes,Drug: N-Plate / romiplostim,Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH,Phase 2,75,Other,"June 1, 2015","August 30, 2020","May 20, 2021"
8814,NCT02335242,Sildenafil for the Treatment of Lymphatic Malformations,Lymphatic Malformations|Lymphatic Diseases,Drug: Sildenafil 20 mg tablets|Other: Placebo tablets (resembling Revatio),Stanford University|Ann & Robert H Lurie Children's Hospital of Chicago,Phase 2,22,Other,"May 23, 2015","March 30, 2021","March 30, 2021"
8815,NCT02335151,CTC Pancreatic Adenocarcinoma,Adenocarcinoma|Circulating Tumor Cells|Pancreatic Neoplasms,Drug: Desflurane,University of Zurich|Kantonsspital Winterthur KSW|Triemli Hospital|Cantonal Hospital of St. Gallen,Phase 4,86,Other,Oct-16,Sep-19,Oct-19
8816,NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,Melanoma,Biological: DC Vaccine|Biological: Montanide Vaccine|Biological: Poly-ICLC,"Nina Bhardwaj|NYU Langone Health|Memorial Sloan Kettering Cancer Center|Ludwig Institute for Cancer Research|Melanoma Research Alliance|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai",Phase 2,36,Other|Industry,"July 1, 2015","July 15, 2020","July 15, 2020"
8817,NCT02334722,1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients,Brain Neoplasms|Brain Cancer|Brain Tumors|Cancer of the Brain|Cancer of Brain|Seizure,Drug: Levetiracetam,University of Florida,Phase 4,81,Other,"August 5, 2015","October 7, 2020","October 7, 2020"
8818,NCT02334631,High Volume Simethicone VCE Clinical Trial,Small Bowel Diseases,Drug: High Volume Simethicone|Drug: Standard Volume Simethicone,Lawson Health Research Institute,Phase 4,159,Other,Jan-17,Aug-19,Oct-19
8819,NCT02334488,Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function,Chronic Kidney Disease,Drug: Everolimus|Drug: Tacrolimus|Drug: Mycophenolate sodium,Poitiers University Hospital,Phase 3,329,Other,"December 11, 2014","May 31, 2019","July 3, 2020"
8820,NCT02332291,Connectivity Affecting the Antidepressant REsponse Study,Major Depressive Disorder,Drug: Escitalopram|Drug: Bupropion XL,Vanderbilt University Medical Center,Phase 4,95,Other,Apr-15,Aug-20,Aug-20
8821,NCT02330419,Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM,Binge Drinking|HIV,Drug: Placebo|Drug: Naltrexone,"University of California, San Francisco|San Francisco Department of Public Health|National Institutes of Health (NIH)",Phase 2,120,Other|NIH,Apr-15,Jan-21,Jan-21
8822,NCT02329327,A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study),Bleeding,Biological: Andexanet,"Alexion|Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)|Population Health Research Institute",Phase 3,479,Industry|Other,"April 10, 2015","September 24, 2020","September 24, 2020"
8823,NCT02327403,Belatacept Conversion in Proteinuric Kidney Transplant Recipients,Proteinuria,Drug: Belatacept,Brigham and Women's Hospital|Bristol-Myers Squibb,Phase 2,15,Other|Industry,Oct-15,Sep-20,"October 1, 2020"
8824,NCT02325414,Prevention of Bone Loss After Acute SCI by Zoledronic Acid,Spinal Cord Injury|Acute Spinal Cord Injury|Bone Loss|Osteoporosis,Drug: Zoledronic acid|Drug: Placebo,Northwestern University|United States Department of Defense,Phase 2,60,Other|U.S. Fed,Feb-15,"August 25, 2020","August 25, 2020"
8825,NCT02324998,Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy,Prostate Cancer,Drug: Olaparib|Drug: Degarelix,Cambridge University Hospitals NHS Foundation Trust|AstraZeneca,Phase 1,20,Other|Industry,Dec-16,May-19,May-19
8826,NCT02324439,Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: Omega Nutrition cold-milled flaxseeds,Southern Illinois University,Phase 1,15,Other,Mar-15,Mar-20,Mar-21
8827,NCT02324257,A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors,Solid Tumors,Drug: RO6958688|Drug: Obinutuzumab|Drug: Tocilizumab,Hoffmann-La Roche,Phase 1,149,Industry,"December 30, 2014","September 3, 2019","September 3, 2019"
8828,NCT02324153,Ramelteon in the Prevention of Post-operative Delirium,"Delirium|Delirium, Dementia, Amnestic, Cognitive Disorders|Delayed Emergence From Anesthesia|Cognitive Disorders",Drug: Ramelteon|Drug: Microcrystalline Cellulose|Drug: Riboflavin 100 mg,Johns Hopkins University|National Institute on Aging (NIA),Phase 2,80,Other|NIH,"March 24, 2017","June 26, 2019","June 26, 2019"
8829,NCT02323191,A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors,Solid Cancers,Drug: Atezolizumab|Drug: Emactuzumab,Hoffmann-La Roche,Phase 1,221,Industry,"January 19, 2015","August 21, 2020","August 21, 2020"
8830,NCT02322320,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",Multiple Myeloma,Drug: Lenalidomide,"National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program",Phase 3,273,NIH|Other,Mar-15,"June 7, 2019","June 7, 2019"
8831,NCT02321592,"GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma",Hodgkin Lymphoma,Drug: AFM13,University of Cologne|Affimed GmbH|The Leukemia and Lymphoma Society,Phase 2,23,Other|Industry,May-15,Nov-19,Jul-20
8832,NCT02320058,"An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",Melanoma,Drug: Ipilimumab|Drug: Nivolumab,Bristol-Myers Squibb,Phase 2,119,Industry,"March 5, 2015","September 8, 2020","September 8, 2020"
8833,NCT02317393,Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy,Non-seminomatous Germ Cell Tumors|Metastasis,Other: K5-RGD PET|Other: FDG,Centre Francois Baclesse,Phase 2,16,Other,Dec-14,Mar-20,Mar-20
8834,NCT02316509,A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,Breast Cancer,Drug: GDC-0927,"Genentech, Inc.|Seragon Pharmaceuticals",Phase 1,43,Industry|Other,"March 17, 2015","January 10, 2020","January 10, 2020"
8835,NCT02315066,Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,Neoplasms,Drug: PF-04518600|Drug: PF-04518600 plus PF-05082566,Pfizer,Phase 1,174,Industry,"April 23, 2015","November 12, 2020","November 12, 2020"
8836,NCT02314559,A Psychomotor Recuperation Study After Deep Sedation for Colonoscopy Between Target Controlled and Manual Titration of Propofol,Colonoscopy (Ambulatory Patients),Drug: Manual titration of propofol|Drug: Target controlled infusion of propofol,Brugmann University Hospital,Phase 4,164,Other,Feb-15,"July 7, 2020","July 7, 2020"
8837,NCT02314403,Renal Allograft Tolerance Through Mixed Chimerism (Belatacept),"Kidney Failure, Chronic|Renal Insufficiency",Drug: Belatacept|Drug: ATG|Drug: Rituximab|Radiation: Total Body Irradiation|Radiation: Thymic Irradiation|Procedure: Combined Bone Marrow/Kidney Transplantation,Massachusetts General Hospital,Phase 1,2,Other,Feb-15,Mar-21,Jul-21
8838,NCT02312986,FMT for Multidrug Resistant Organism Reversal,Infection With Multi-drug Resistant Organisms,Biological: Fecal microbiota transplantation (FMT),Washington University School of Medicine,Phase 1,1,Other,Aug-15,"July 31, 2020","July 31, 2020"
8839,NCT02312258,A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT),Multiple Myeloma,Drug: Placebo|Drug: Ixazomib,Takeda,Phase 3,706,Industry,"April 9, 2015","August 12, 2019","August 26, 2022"
8840,NCT02311049,Hypofractionated Radiotherapy for Prostate Cancer,Prostate Cancer,Radiation: Hypofractionation,"University Hospital, Ghent",Phase 2,346,Other,"June 1, 2013","June 14, 2020","June 14, 2020"
8841,NCT02310672,REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension,Pulmonary Arterial Hypertension,Drug: Macitentan,Actelion,Phase 4,89,Industry,"June 1, 2015","September 10, 2019","September 10, 2019"
8842,NCT02310464,"Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer,Drug: OBI-833/OBI-821,"OBI Pharma, Inc",Phase 1,25,Industry,"December 22, 2015","December 22, 2020","February 2, 2021"
8843,NCT02309892,A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC,Non-Small Cell Lung Cancer,Drug: L-DOS47,Helix BioPharma Corporation|Theradex,Phase 1,14,Industry,Apr-14,Aug-19,Sep-19
8844,NCT02308137,Domperidone in Secondary Progressive Multiple Sclerosis (SPMS),"Multiple Sclerosis, Secondary Progressive",Drug: Domperidone,University of Calgary|Alberta Innovates Health Solutions,Phase 2,64,Other,Feb-15,"January 3, 2020","January 3, 2020"
8845,NCT02307916,Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations,Tympanic Membrane Perforation,Drug: FGF-2|Other: Placebo,Dr. Bradley Welling|United States Department of Defense|Massachusetts Eye and Ear Infirmary,Phase 2,57,Other|U.S. Fed,Oct-16,Jul-19,Mar-20
8846,NCT02307565,"Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury",Spinal Cord Injury,Drug: Midodrine|Drug: Placebo,James J. Peters Veterans Affairs Medical Center|Kessler Foundation,Phase 3,60,U.S. Fed|Other,Mar-14,Dec-19,Dec-19
8847,NCT02307240,"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",Triple-Negative Breast Cancer|High-grade Serous Ovarian Cancer|Solid Tumors|NUT Midline Carcinoma,Drug: CUDC-907,"Curis, Inc.",Phase 1,43,Industry,Nov-14,"May 31, 2019","May 31, 2019"
8848,NCT02307149,Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI),Melanoma,Biological: CAVATAK|Drug: Ipilimumab,Viralytics|Providence Health & Services,Phase 1,50,Industry|Other,"May 5, 2015","November 5, 2019","November 5, 2019"
8849,NCT02305927,"Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health",HIV,Dietary Supplement: Vitamin D3 (cholecalciferol)|Other: Placebo,Wafaie Fawzi|Management and Development for Health (MDH)|Harvard School of Public Health (HSPH),Phase 3,2300,Other,"June 15, 2015","September 18, 2019","September 18, 2019"
8850,NCT02304991,FARE Peanut SLIT and Early Tolerance Induction,Peanut Hypersensitivity|Food Allergy|Food Hypersensitivity|Peanut Allergy,Drug: Liquid Peanut Extract|Drug: Placebo Glycerin SLIT,"University of North Carolina, Chapel Hill|Food Allergy Research & Education|National Center for Complementary and Integrative Health (NCCIH)|University of Texas Southwestern Medical Center",Phase 2,50,Other|NIH,Jan-15,"December 31, 2020","December 31, 2020"
8851,NCT02304393,A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors,Solid Tumors,Drug: Atezolizumab|Drug: Selicrelumab,Hoffmann-La Roche,Phase 1,140,Industry,"December 12, 2014","November 7, 2019","November 7, 2019"
8852,NCT02304302,Down Syndrome Memantine Follow-up Study,Down Syndrome|Intellectual Disability,Drug: Memantine|Drug: Placebo,University Hospitals Cleveland Medical Center|Alana USA Foundation,Phase 2,160,Other,Oct-14,"July 22, 2020","July 22, 2020"
8853,NCT02303977,Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy,Patients With Stage IV or Recurrent Adenocarcinoma of the Lung,Drug: Abraxane|Drug: Gemcitabine,Abramson Cancer Center at Penn Medicine,Phase 2,37,Other,"June 26, 2015","April 30, 2020","April 30, 2020"
8854,NCT02303795,RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial,Valvular Heart Disease,Drug: Rivaroxaban|Drug: Warfarin,Hospital do Coracao,Phase 2,1005,Other,Aug-15,Aug-20,Aug-20
8855,NCT02302599,Mesenchymal Stem Cells to Treat Type 2 Diabetes,Type 2 Diabetes|Mesenchymal Stem Cells,Biological: Umbilical cord mesenchymal stem cells|Biological: Controlled suspension liquid,Chinese PLA General Hospital,Phase 2,103,Other,Jan-13,Dec-20,Dec-20
8856,NCT02301702,Maternal Tdap Immunization in Guatemala,Pertussis|Whooping Cough,Biological: Tdap|Biological: Td,"Emory University|Universidad del Valle, Guatemala",Phase 2,286,Other,Jul-16,"August 13, 2019","August 13, 2019"
8857,NCT02301156,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia,Drug: Ublituximab|Drug: Ibrutinib,"TG Therapeutics, Inc.",Phase 3,126,Industry,"January 27, 2015","April 1, 2020","April 1, 2020"
8858,NCT02301117,A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,Advanced Solid Tumors,Drug: TAS-102,"Taiho Oncology, Inc.",Phase 1,43,Industry,Jan-15,"June 19, 2019","June 19, 2019"
8859,NCT02301039,SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,Soft Tissue Sarcoma|Bone Sarcoma,Drug: Pembrolizumab,Sarcoma Alliance for Research through Collaboration|Merck Sharp & Dohme LLC,Phase 2,144,Other|Industry,Mar-15,"July 1, 2020","July 1, 2020"
8860,NCT02300545,Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy,"Sarcoma, Soft Tissue|Soft Tissue Sarcoma",Drug: Pazopanib,Washington University School of Medicine|Novartis Pharmaceuticals,Phase 2,56,Other|Industry,"April 8, 2015","May 31, 2019","July 11, 2020"
8861,NCT02299011,Comparison of Biomatrix and Orsiro Drug Eluting Stent,Coronary Artery Disease|Myocardial Ischemia,Device: Orsiro drug eluting stent|Drug: Biomatrix drug eluting stent,Seoul National University Bundang Hospital|Wonju Severance Christian Hospital|Korea University Guro Hospital|Gangnam Severance Hospital|Chungnam National University Hospital|The Catholic University of Korea|Korea University Anam Hospital|Kosin University Gospel Hospital|KangWon National University Hospital|Gachon University Gil Medical Center,Phase 4,2341,Other,Jul-14,Jun-19,Sep-19
8862,NCT02298491,CNS Sarcoidosis and Acthar Gel,CNS Sarcoidosis,Drug: H.P. Acthar Gel,"University of Maryland, Baltimore|Mallinckrodt",Phase 4,4,Other|Industry,May-16,Nov-20,Nov-20
8863,NCT02298283,Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Oncovin|Drug: Bleomycin|Drug: Etoposide|Drug: Procarbazine|Drug: Prednisone|Drug: G-CSF|Radiation: 30 Grays,The Lymphoma Academic Research Organisation,Phase 2,40,Other,Apr-15,"July 9, 2020","July 9, 2020"
8864,NCT02297945,Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome,Cushing's Syndrome,Drug: metyrapone,HRA Pharma,Phase 3,50,Industry,Apr-15,Nov-19,"April 29, 2020"
8865,NCT02293837,Tocilizumab (TCZ) in New-onset Type 1 Diabetes,Type 1 Diabetes Mellitus|New-onset Type 1 Diabetes Mellitus|T1DM|T1D,Drug: Tocilizumab (TCZ)|Drug: Placebo|Other: Standard of Care,"National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.",Phase 2,136,NIH|Other|Industry,"March 12, 2015","July 10, 2019","August 31, 2020"
8866,NCT02293655,The Effects of ADHD Medication (TEAM) Study,ADHD,Drug: OROS-Methylphenidate (MPH),"Children's Hospital Medical Center, Cincinnati|Seattle Children's Hospital",Phase 4,204,Other,"January 12, 2015","June 30, 2020","June 30, 2021"
8867,NCT02292784,Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies,"Obstetric Labour, Premature",Drug: Retosiban|Drug: Atosiban|Drug: Placebo,GlaxoSmithKline|PPD,Phase 3,98,Industry,"June 1, 2015","September 2, 2019","September 2, 2019"
8868,NCT02292238,Benfotiamine in Alzheimer's Disease: A Pilot Study,Alzheimer's Disease,Drug: Benfotiamine,Burke Medical Research Institute|Burke Rehabilitation Hospital|Columbia University|National Institute on Aging (NIA)|Alzheimer's Drug Discovery Foundation|Montefiore Medical Center,Phase 2,71,Other|NIH,"February 15, 2015","July 20, 2020","September 8, 2020"
8869,NCT02291666,Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects,Type 2 Diabetes,Drug: CRCHUM-MT cocktail,Centre hospitalier de l'Université de Montréal (CHUM)|Canadian Institutes of Health Research (CIHR),Phase 4,73,Other,Apr-15,Jul-19,Jul-19
8870,NCT02291289,A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC),Colorectal Cancer,Drug: Cetuximab|Drug: FOLFOX induction regimen|Drug: Fluoropyrimidine (5-FU/LV or capecitabine)|Drug: Atezolizumab|Drug: Vemurafenib|Drug: Bevacizumab|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Cobimetinib|Drug: 5-FU/LV,Hoffmann-La Roche,Phase 2,609,Industry,"April 17, 2015","May 31, 2019","March 24, 2021"
8871,NCT02289950,A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer,Platinum-Sensitive Ovarian Cancer in First Relapse,Drug: Farletuzumab|Drug: Placebo,Eisai Inc.,Phase 2,332,Industry,"March 19, 2015","May 31, 2019","August 13, 2020"
8872,NCT02288936,Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer,Hormone-refractory Prostate Cancer,Drug: Enzalutamide,Spanish Oncology Genito-Urinary Group|Astellas Pharma Inc|Apices Soluciones S.L.,Phase 2,98,Other|Industry,"February 5, 2015","July 22, 2019","July 22, 2019"
8873,NCT02287558,Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study,Hereditary Hemorrhagic Telangiectasia|Idiopathic Vascular Ectasia,Drug: Pomalidomide,The Cleveland Clinic,Phase 1,9,Other,"January 27, 2015","June 1, 2019","June 1, 2019"
8874,NCT02286986,Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy,Epilepsy,Drug: Cannabidiol,University of Utah,Phase 1,26,Other,"September 18, 2014","June 13, 2019","June 13, 2019"
8875,NCT02286726,"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia",Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia,Other: Laboratory Biomarker Analysis|Drug: Liposome-encapsulated Daunorubicin-Cytarabine,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,56,Other|NIH,"May 4, 2015","January 22, 2020","January 22, 2020"
8876,NCT02285985,Effects of Saxagliptin on Adipose Tissue Inflammation in Humans,Type 2 Diabetes Mellitus (T2DM),Drug: Saxagliptin|Drug: Placebo,Phoenix VA Health Care System|Bristol-Myers Squibb,Phase 4,103,U.S. Fed|Industry,Feb-13,"October 12, 2019","October 12, 2019"
8877,NCT02284464,Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients,Other Complication of Kidney Transplant|Renal Transplant Rejection,Drug: Prednisone withdrawal|Drug: Prednisone continuation,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Sociedad Andaluza de Trasplantes de Organos y Tejidos,Phase 4,230,Other,Feb-15,Jul-19,Dec-19
8878,NCT02283671,Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B,Multiple Sclerosis|Neuromyelitis Optica,Biological: Tolerogenic Dendritic cells loaded with myelin peptides,Sara Varea|Fundacion Clinic per a la Recerca Biomédica,Phase 1,20,Other,Sep-15,"July 10, 2019","July 10, 2019"
8879,NCT02283294,Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation,Transient Ischemic Attack|Stroke|Atrial Fibrillation,Drug: Apixaban|Drug: Warfarin,University of South Florida|Bristol-Myers Squibb,Phase 3,91,Other|Industry,Apr-15,Jun-19,Jun-19
8880,NCT02283177,A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,Newly Diagnosed AML With FLT3 Activating Mutations,Drug: crenolanib|Drug: cytarabine|Drug: daunorubicin|Drug: idarubicin,"Arog Pharmaceuticals, Inc.",Phase 2,44,Industry,Jan-15,Dec-19,Dec-19
8881,NCT02282319,Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery,Surgery Ambulatory,Drug: spinal dexmedetomidine 0.5 mcg|Other: spinal chloroprocaine 40 mg|Drug: IV dexmedetomidine 0.5 mcg/kg,"University Hospital, Antwerp",Phase 4,150,Other,Oct-14,Dec-20,Dec-20
8882,NCT02282098,Colchicine in Atrial Fibrillation to Prevent Stroke,Atrial Fibrillation|Stroke,Drug: Colchicine|Drug: Placebo,Population Health Research Institute,Phase 3,80,Other,Nov-14,"November 17, 2020","November 17, 2020"
8883,NCT02281929,Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone,Alcoholic Hepatitis|Alcoholic Liver Disease,Drug: Amoxicillin|Drug: Placebo|Drug: Prednisolone,"University Hospital, Lille|Ministry of Health, France",Phase 3,297,Other,"June 13, 2015","November 19, 2019","November 19, 2019"
8884,NCT02279745,Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Drug: Ralinepag,United Therapeutics,Phase 2,45,Industry,"July 8, 2015","March 29, 2021","March 29, 2021"
8885,NCT02278367,Clinical Evaluation of Flortaucipir F 18,Alzheimer's Disease|Traumatic Brain Injury|Depression,Drug: Flortaucipir F18|Procedure: Brain PET scan,Avid Radiopharmaceuticals,Phase 2,179,Industry,Dec-14,"June 26, 2019","June 26, 2019"
8886,NCT02278315,Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma,Multiple Myeloma,Drug: I-131-CLR1404|Drug: dexamethasone,"Cellectar Biosciences, Inc.",Phase 1,31,Industry,Feb-15,"December 9, 2020","August 10, 2022"
8887,NCT02278198,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Differentiated Thyroid Cancer,Drug: rhTSH,"University of Colorado, Denver",Phase 1,5,Other,"November 30, 2012","September 20, 2019","September 20, 2019"
8888,NCT02276755,Vitamin D Supplementation in TB Prevention,Latent Tuberculosis,Dietary Supplement: Cholecalciferol (vitamin D3)|Other: Placebo,Harvard School of Public Health (HSPH),Phase 3,8851,Other,Sep-15,Jun-19,Jun-20
8889,NCT02276716,The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia,Familial Dysautonomia,Dietary Supplement: Phosphatidylserine,NYU Langone Health,Phase 2,26,Other,Nov-11,"August 1, 2019","August 1, 2019"
8890,NCT02276027,"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma,Drug: BYL719|Drug: INC280|Drug: LDK378|Drug: MEK162,Novartis Pharmaceuticals|Novartis,Phase 2,66,Industry,"January 20, 2015","October 15, 2019","October 15, 2019"
8891,NCT02274051,"The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia",Familial Dysautonomia,Dietary Supplement: Kinetin,NYU Langone Health,Phase 1,15,Other,Nov-09,"May 4, 2019","May 4, 2019"
8892,NCT02273661,Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).,Allergic Bronchopulmonary Aspergillosis,Drug: Liposomal amphotericin B (Ambisome®)|Drug: placebo,Poitiers University Hospital,Phase 2,174,Other,"November 19, 2014","June 28, 2019","June 28, 2019"
8893,NCT02272946,Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk,HIV|Cardiovascular Disease,Drug: Canakinumab|Drug: Placebo,"Priscilla Hsue, MD|Massachusetts General Hospital|University of California, San Francisco",Phase 2,43,Other,Sep-15,Feb-21,Dec-21
8894,NCT02271711,Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors,Recurrent Childhood Medulloblastoma|Recurrent Ependymoma|Recurrent Medulloblastoma,Other: Laboratory Biomarker Analysis|Biological: Natural Killer Cell Therapy,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,12,Other|NIH,"March 17, 2015","August 28, 2020","August 28, 2020"
8895,NCT02271230,Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure,Heart Failure,Drug: Vitamin D and fish oil|Dietary Supplement: Fish oil (EPA/DHA) alone|Drug: Vitamin D alone|Other: Placebo,Brigham and Women's Hospital,Phase 3,25871,Other,Aug-14,Dec-19,Dec-19
8896,NCT02270242,Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention,Cardiovascular Disease|Interventional Cardiology,Drug: Aspirin|Drug: Placebo|Drug: ticagrelor,Icahn School of Medicine at Mount Sinai|AstraZeneca,Phase 4,9006,Other|Industry,Jul-15,"July 10, 2019","July 10, 2019"
8897,NCT02270034,Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma,Glioblastoma Multiforme (Grade IV) of Cerebellum,Drug: Crizotinib,Grupo Español de Investigación en Neurooncología|Pfizer,Phase 1,38,Other|Industry,"August 13, 2014","October 26, 2020","October 26, 2020"
8898,NCT02269293,"Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",Ovarian Cancer|Endometrial Cancer,Drug: Paclitaxel|Drug: Carboplatin|Drug: Selinexor,Memorial Sloan Kettering Cancer Center,Phase 1,23,Other,"October 13, 2014","April 20, 2021","April 20, 2021"
8899,NCT02269267,The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study),"Leukemia, Myeloid, Chronic",Drug: Imatinib (Stopping their TKI)|Drug: Dasatinib (Stopping their TKI)|Drug: Nilotinib (Stopping their TKI)|Drug: Bosutinib (Stopping their TKI),"Medical College of Wisconsin|University of Chicago|University of California, San Francisco|University of Utah|Dana-Farber Cancer Institute|Emory University|Barbara Ann Karmanos Cancer Institute|Duke Cancer Institute|Fred Hutchinson Cancer Center|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|H. Lee Moffitt Cancer Center and Research Institute",Phase 2,173,Other,"December 18, 2014","April 6, 2021","April 6, 2022"
8900,NCT02268409,ACE-536 Extension Study - Beta Thalassemia,Beta-Thalassemia,Drug: ACE-536,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2,51,Industry,Nov-14,"June 18, 2020","June 18, 2020"
8901,NCT02268383,ACE-536 Extension Study - Myelodysplastic Syndromes,Myelodysplastic Syndromes,Drug: ACE-536,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",Phase 2,75,Industry,Oct-14,"May 18, 2020","May 18, 2020"
8902,NCT02266888,B Cell Induction in Pediatric Lung Transplantation,Lung Transplant,Biological: Rituximab (Rituxan®)|Biological: Placebo,"National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation in Children|Rho Federal Systems Division, Inc.",Phase 2,45,NIH|Other|Industry,"January 22, 2015","June 30, 2019","June 30, 2019"
8903,NCT02266394,Hypoxia and Inflammatory Injury in Human Renovascular Hypertension,Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease,Drug: Mesenchymal stem cell|Procedure: Mesenchymal stem cell delivery with stent placement,Mayo Clinic|University of Mississippi Medical Center|University of Alabama at Birmingham,Phase 1,42,Other,"October 21, 2014","September 25, 2020","September 25, 2020"
8904,NCT02265406,PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone,Early Ventilation Acquired Pneumonia in Brain Injured Patients,Drug: Anti-Infective Agents|Drug: Placebo,Poitiers University Hospital,Phase 3,354,Other,Oct-15,"July 25, 2020","July 25, 2020"
8905,NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers,Non-squamous Non-small Cell Lung Cancer,Drug: Paclitaxel|Drug: Carboplatin|Drug: Cisplatin|Drug: Veliparib|Drug: Pemetrexed,AbbVie,Phase 3,595,Industry,"September 30, 2014","November 14, 2019","February 21, 2020"
8906,NCT02264548,A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy,Renal Cell Carcinoma,Radiation: Radio-Ablation,Lawson Health Research Institute,Phase 1,14,Other,Jul-09,"August 4, 2020","August 4, 2020"
8907,NCT02264418,Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours,Solid Tumours,Drug: ODM 203,"Orion Corporation, Orion Pharma",Phase 1,84,Industry,"September 18, 2014",May-19,May-19
8908,NCT02263417,A Randomized Controlled Trail Comparing Subthalamic and Pallidal Deep Brain Stimulation for Dystonia,Dystonia,Device: Deep Brain Stimulation (DBS) of Gpi|Device: Deep Brain Stimulation (DBS) of STN,"Beijing Pins Medical Co., Ltd|Peking Union Medical College Hospital",Phase 4,70,Industry|Other,Jul-15,Dec-19,Jun-20
8909,NCT02263079,A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase,Pediatric Immuno-Tolerant Chronic Hepatitis B,Drug: Entecavir|Drug: Lamivudine|Drug: Pegylated Interferon Alfa-2A,Hoffmann-La Roche,Phase 3,62,Industry,"June 16, 2014","January 29, 2020","January 29, 2020"
8910,NCT02261220,A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,Advanced Solid Tumors,Biological: MEDI4736|Biological: tremelimumab,MedImmune LLC,Phase 1,380,Industry,"October 13, 2014","January 27, 2020","January 27, 2020"
8911,NCT02260258,Neuromuscular Blockade for Post-Cardiac Arrest Care,Cardiac Arrest,Drug: Rocuronium|Drug: Normal Saline,Beth Israel Deaconess Medical Center|University of Pittsburgh Medical Center|Brigham and Women's Hospital|University of Alabama at Birmingham|Beaumont Hospital,Phase 2,83,Other,Oct-14,"May 29, 2019","May 29, 2019"
8912,NCT02259725,Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,Gastrinoma|Glucagonoma|Insulinoma|Metastatic Gastrointestinal Carcinoid Tumor|Pancreatic Polypeptide Tumor|Pulmonary Carcinoid Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma,Drug: regorafenib|Other: laboratory biomarker analysis,University of Southern California|National Cancer Institute (NCI),Phase 2,3,Other|NIH,"August 16, 2016","August 20, 2020","August 20, 2020"
8913,NCT02258451,Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer,Breast Neoplasms,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo (saline)|Drug: Exemestane|Drug: Everolimus",Bayer,Phase 2,283,Industry,"June 4, 2015","January 22, 2020","October 28, 2022"
8914,NCT02258295,Hyaluronate Injection for Lateral Epicondylitis,Tennis Elbow,Drug: Intragel|Drug: Saline,Shaare Zedek Medical Center,Phase 3,35,Other,"January 18, 2017","September 1, 2019","September 1, 2019"
8915,NCT02257580,The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO,E-Aminocaproic Acid|Bilateral Varus Rotational Osteotomy,Drug: E-Aminocaproic acid,"Hospital for Special Surgery, New York",Phase 4,28,Other,"April 1, 2015","October 26, 2020","October 26, 2020"
8916,NCT02257502,Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients,Idiopathic Choroidal Neovascularization,Drug: aflibercept,Hospices Civils de Lyon,Phase 2,20,Other,"July 6, 2015","July 11, 2019","July 11, 2019"
8917,NCT02257242,"Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma","Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone",Drug: Rituximab|Drug: Bendamustine|Drug: Vincristine sulfate liposome injection,"Brown University|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital",Phase 1,11,Other|Industry,"May 10, 2017","August 22, 2020","November 18, 2020"
8918,NCT02256631,"Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants",HIV Infections,Biological: VRC01|Biological: VRC01LS|Biological: VRC07-523LS,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,83,NIH,"June 30, 2015","June 17, 2020","December 16, 2021"
8919,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,Relapsing Remitting Multiple Sclerosis,Drug: alemtuzumab GZ402673,"Genzyme, a Sanofi Company|Sanofi",Phase 4,1062,Industry,"January 7, 2015","July 15, 2020","July 15, 2020"
8920,NCT02255552,Study of Eteplirsen in DMD Patients,Duchenne Muscular Dystrophy (DMD),Drug: eteplirsen,"Sarepta Therapeutics, Inc.",Phase 3,109,Industry,"November 17, 2014","June 14, 2019","June 14, 2019"
8921,NCT02252588,The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Disease,Drug: Chlorhexidine|Other: Placebo,University of Minnesota|Veterans Medical Research Foundation|Flight Attendant Medical Research Institute,Phase 2,44,Other,"September 1, 2014","December 15, 2019","January 1, 2020"
8922,NCT02252107,"10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1",Acute Myeloid Leukemia (AML),Drug: decitabine,Radboud University Medical Center,Phase 2,46,Other,Oct-14,May-19,May-19
8923,NCT02252081,Metformin in Kidney Disease,Chronic Kidney Disease|Cardiovascular Disease|Metabolic Syndrome,Drug: metformin|Drug: Placebo,VA Office of Research and Development,Phase 2,125,U.S. Fed,"October 1, 2014","December 31, 2019","December 31, 2019"
8924,NCT02251431,Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome,Type 2 Diabetes Mellitus|Chronic Kidney Disease|Left Ventricular Diastolic Dysfunction,Drug: BYDUREON|Drug: Placebo,Baylor Research Institute,Phase 3,57,Other,Nov-15,Dec-19,Dec-19
8925,NCT02250157,"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",Solid Tumor,Drug: Oratecan,"Athenex, Inc.",Phase 1,35,Industry,"September 5, 2014","March 4, 2020","March 4, 2020"
8926,NCT02249650,"To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.",Metastatic Colorectal Cancer,Drug: TSB-9-W1,"Taiwan Sunpan Biotechnology Development Co., Ltd.|Virginia Contract Research Organization Co., Ltd.",Phase 1,21,Other,"July 10, 2017","February 12, 2020","August 25, 2020"
8927,NCT02249039,Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study,Mechanical Ventilation Complication,Drug: intermittent IV CLON,Johns Hopkins University,Phase 1,14,Other,Sep-15,Dec-19,Dec-19
8928,NCT02249013,Short-course HIPEC in Advanced Epithelial Ovarian Cancer,Ovarian Cancer,Procedure: Cytoreductive Surgery (CRS)|Procedure: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Drug: Neoadjuvant Chemotherapy (NACT)|Drug: Adjuvant Chemotherapy|Procedure: Fast-track recovery strategy,Professor Fernando Figueira Integral Medicine Institute|Hospital de Câncer de Pernambuco (Recife/PE)|AC Camargo Cancer Center (São Paulo/SP)|Instituto Brasileiro de Controle do Câncer (São Paulo/SP)|Hospital de Cancer de Barretos - Fundacao Pio XII (Barretos/SP)|Hospital Sao Jose (Criciuma/SC)|Hospital de Base do Distrito Federal (Brasilia/DF),Phase 2,15,Other,Feb-15,"February 23, 2021","February 23, 2021"
8929,NCT02247128,Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation,Aortic Valve Disease|Myocardial Infarction|Stroke|Bleeding,Drug: Aspirin + clopidogrel|Drug: Aspirin monotherapy|Drug: OAC + clopicogrel|Drug: OAC monotherapy,St. Antonius Hospital,Phase 4,1016,Other,Jan-14,Mar-20,Apr-20
8930,NCT02246127,Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET),Neuroendocrine Tumors,Drug: Drug: Everolimus|Drug: STZ-5FU,Grupo Espanol de Tumores Neuroendocrinos|European Neuroendocrine Tumor Society|Kantar Health|Novartis Pharmaceuticals,Phase 3,141,Other|Industry,"October 27, 2014","November 18, 2020","July 12, 2021"
8931,NCT02241967,Dose Dependent Effects of tDCS on Post-Operative Pain,Total Knee Arthroplasty (Postoperative Pain)|Total Hip Arthroplasty(Postoperative Pain),Device: 4 Real sessions of Transcranial Direct Current Stimulation|Device: 2 Real Sessions of Transcranial Direct Current Stimulation|Device: 1 Real Session of Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation,VA Office of Research and Development,Phase 1,119,U.S. Fed,"January 7, 2016","July 2, 2020","July 2, 2020"
8932,NCT02241603,Insulin Resistance and Reward,Obesity,Behavioral: Weight loss,VA Office of Research and Development|Washington University School of Medicine,Phase 2,59,U.S. Fed|Other,"November 17, 2014","July 1, 2020","July 1, 2020"
8933,NCT02241499,Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.,Adenocarcinoma of the Esophagus or Esophagogastric Junction,Radiation: Radiation therapy|Drug: Oxaliplatin and fluorouracil.,Lund University Hospital,Phase 2,29,Other,Oct-14,May-19,May-19
8934,NCT02240459,A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment,Overactive Bladder|Mild Cognitive Impairment,Drug: fesoterodine 4mg|Drug: Oxybutynin|Drug: placebo|Drug: fesoterodine 8mg,University of Alberta|Pfizer,Phase 2,47,Other|Industry,Aug-16,"January 31, 2020","January 31, 2020"
8935,NCT02239913,Topiramate-Phentermine Combinations for Cocaine Dependence,Cocaine Use Disorder,Drug: Cocaine|Drug: Placebo|Drug: Phentermine|Drug: Topiramate,University of Kentucky|National Institute on Drug Abuse (NIDA),Phase 1,38,Other|NIH,Sep-14,Sep-19,Sep-19
8936,NCT02239900,Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,Liver Cancer|Lung Cancer,Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT),M.D. Anderson Cancer Center|Bristol-Myers Squibb,Phase 1,143,Other|Industry,"August 26, 2014","October 25, 2019","October 25, 2019"
8937,NCT02239393,Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study,Multiple Sclerosis,Biological: Mesenchymal Stem Cells,Ottawa Hospital Research Institute,Phase 2,31,Other,Jun-15,Dec-19,Dec-19
8938,NCT02237898,Harnessing the Power of Technology: MOMBA for Postpartum Smoking,Smoking Cessation,Behavioral: MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|Behavioral: Office contingency management|Device: Sensordrone™ carbon-monoxide sensor|Device: MoMba Live Long Smartphone application,Yale University|National Cancer Institute (NCI),Phase 1,26,Other|NIH,"February 10, 2017","May 13, 2019","May 13, 2019"
8939,NCT02237638,Phase I Study on VEGF Vaccination in Metastatic Solid Tumors,Metastatic Cancer,Biological: hVEGF26-104/RFASE,"Amsterdam UMC, location VUmc|Immunovo B.V.",Phase 1,30,Other,Apr-14,Jan-20,"January 1, 2020"
8940,NCT02236078,Brief Bactericidal Activity of Anti-Tuberculosis Drugs,Tuberculosis|Drug-resistant Tuberculosis|Isoniazid Resistant Tuberculosis (Disorder),Drug: High dose isoniazid,Centers for Disease Control and Prevention|Kenya Medical Research Institute,Phase 1,18,U.S. Fed|Other,Nov-15,"September 30, 2020","September 30, 2020"
8941,NCT02235909,An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension,Hypertension,Drug: Azilsartan Medoxomil Low-dose|Drug: Losartan|Drug: Placebo for Azilsartan Medoxomil|Drug: Placebo for Losartan|Drug: antihypertension medication - Add-on Therapy|Drug: Azilsartan Medoxomil Medium-dose|Drug: Azilsartan Medoxomil High-dose,"Arbor Pharmaceuticals, Inc.",Phase 3,215,Industry,"December 19, 2014","November 27, 2019","September 27, 2020"
8942,NCT02235792,High Frequency Oscillations in Neurologic Disease,Parkinson|Epilepsy,Device: Activa PC+S,Mayo Clinic,Phase 1,7,Other,Jul-14,"November 20, 2020","November 20, 2020"
8943,NCT02235298,Dapagliflozin Effects on Epicardial Fat,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Metformin|Drug: Placebo,University of Miami|AstraZeneca,Phase 4,100,Other|Industry,Sep-15,"September 10, 2020","September 10, 2020"
8944,NCT02234596,Nintedanib in Patients With Advanced Esophagogastric Cancer,Esophagogastric Adenocarcinoma,Drug: Nintedanib,Memorial Sloan Kettering Cancer Center,Phase 2,34,Other,"September 4, 2014","April 22, 2020","April 22, 2020"
8945,NCT02234323,An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A,Hemophilia A,Biological: rFVIIIFc,"Bioverativ, a Sanofi company|Swedish Orphan Biovitrum|Sanofi",Phase 3,108,Industry,"January 12, 2015","September 23, 2019","September 23, 2019"
8946,NCT02234310,Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B,Hemophilia B,Biological: rFIXFc,"Bioverativ, a Sanofi company|Swedish Orphan Biovitrum|Sanofi",Phase 3,33,Industry,"November 13, 2014","August 20, 2019","August 20, 2019"
8947,NCT02232139,Measurement of Psychomotor Recovery After Anesthesia Using 4CRT,Delayed Recovery From Anaesthesia,Drug: Midazolam,"University Medicine Greifswald|Department of Anesthesiology, Hospital Dresden-Friedrichstadt, Dresden, Germany",Phase 2,124,Other,Mar-16,"June 25, 2019","June 25, 2019"
8948,NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",Multiple Sclerosis,Drug: Fingolimod,Novartis Pharmaceuticals|Novartis,Phase 4,6,Industry,"September 29, 2014","January 24, 2020","January 24, 2020"
8949,NCT02231723,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug: BBI608|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Irinotecan|Drug: Fluorouracil|Drug: MM-398,"Sumitomo Pharma Oncology, Inc.",Phase 1,139,Industry,Aug-14,Jun-20,Jun-20
8950,NCT02230891,Biomarker Guided Therapies in Stage A/B Heart Failure,Hypertension|Diabetes|Cardiovascular Disease,Drug: Carvedilol|Drug: Spironolactone|Other: Usual care,VA Office of Research and Development|Baylor College of Medicine,Phase 2,58,U.S. Fed|Other,"October 1, 2014","December 15, 2020","December 15, 2020"
8951,NCT02230800,PPALM-Palm Oil and Pentoxifylline Against Late Morbidity,Long-term Adverse Effects of Radiotherapy for Pelvic Cancer,Drug: Tocovid SupraBio plus pentoxifylline|Drug: Matching placebos,Royal Marsden NHS Foundation Trust|Malaysia Palm Oil Board,Phase 2,62,Other,"November 25, 2014","December 20, 2019","December 20, 2019"
8952,NCT02230189,Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics,Asthma,Biological: Segmental airway allergen challenge|Procedure: Bronchoscopy|Diagnostic Test: Methacholine challenge test|Diagnostic Test: Spirometry|Diagnostic Test: Allergen skin prick test,"Prescott Woodruff|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, San Francisco",Phase 2,28,Other|NIH,Mar-15,Jan-20,Jan-20
8953,NCT02228525,Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes,Myelodysplastic Syndromes,Drug: selinexor (KPT-330),Memorial Sloan Kettering Cancer Center|M.D. Anderson Cancer Center|Columbia University|Karyopharm Therapeutics Inc,Phase 2,25,Other|Industry,"August 27, 2014","April 6, 2021","April 6, 2021"
8954,NCT02228408,Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD,Chronic Hemodialysis (ESRD),Drug: Hydralazine/Isorsorbide Dinitrate|Drug: Placebo,Brigham and Women's Hospital,Phase 4,17,Other,"August 28, 2017","May 7, 2019","May 7, 2019"
8955,NCT02227667,Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,Advanced Colorectal Cancer,Drug: MEDI4736,Memorial Sloan Kettering Cancer Center|MedImmune LLC|AstraZeneca,Phase 2,16,Other|Industry,"December 2, 2014","June 29, 2020","June 29, 2020"
8956,NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,Locally Advanced Malignant Neoplasm|Inflammatory Breast Carcinoma|Triple-Negative Invasive Breast Carcinoma,Radiation: radiotherapy|Drug: olaparib,The Netherlands Cancer Institute,Phase 1,7,Other,"October 21, 2013",Sep-19,Aug-20
8957,NCT02224573,An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes,Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome,Drug: GWP42003-P,Jazz Pharmaceuticals,Phase 3,681,Industry,"June 11, 2015","September 24, 2020","September 24, 2020"
8958,NCT02224456,Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis,"Hepatitis B, Chronic",Drug: Tenofovir disoproxil fumarate,GlaxoSmithKline,Phase 4,197,Industry,"March 25, 2015","December 4, 2020","December 4, 2020"
8959,NCT02222922,A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,Neoplasms,Drug: PF-06647020 Q3W|Drug: fluconazole|Drug: PF-06647020 Q2W|Drug: PF-06647020 combined with Avelumab,Pfizer,Phase 1,138,Industry,"October 17, 2014","November 5, 2019","November 5, 2019"
8960,NCT02222545,Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies,Thrombotic Microangiopathies,Biological: OMS721,Omeros Corporation,Phase 2,58,Industry,"November 2, 2014","January 30, 2020","August 11, 2020"
8961,NCT02220842,A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,Lymphoma,Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Tazemetostat,Hoffmann-La Roche,Phase 1,96,Industry,"December 18, 2014","January 21, 2020","January 21, 2020"
8962,NCT02220348,A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically,Breast Feeding|Constipation|Irritable Bowel Syndrome,Drug: linaclotide,Forest Laboratories,Phase 1,7,Industry,"July 31, 2014","May 31, 2019","May 31, 2019"
8963,NCT02219178,Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug: lenalidomide|Drug: Subcutaneous bortezomib|Drug: Dexamethasone,Cancer Trials Ireland,Phase 2,42,Other,Nov-14,"October 31, 2019",Apr-20
8964,NCT02218047,AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.,Polycythemia Vera,Drug: Pegylated-Proline-interferon alpha-2b|Drug: Best available therapy (BAT),AOP Orphan Pharmaceuticals AG|PharmaEssentia Corporation (for the U.S.),Phase 3,170,Industry|Other,Nov-14,"April 29, 2021","April 29, 2021"
8965,NCT02217709,Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer,Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer,Drug: phenelzine sulfate|Other: laboratory biomarker analysis|Other: questionnaire administration,University of Southern California|National Cancer Institute (NCI),Phase 2,26,Other|NIH,"September 8, 2014","June 29, 2020","June 29, 2020"
8966,NCT02217501,Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities,Peripheral Arterial Disease,Drug: Clopidogrel|Drug: Acetylsalicylic acid (ASA),University of Texas Southwestern Medical Center,Phase 3,159,Other,Nov-15,"January 30, 2020","January 30, 2020"
8967,NCT02217163,"Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma",Multiple Myeloma,"Drug: Carfilzomib, , Cyclophosphamide, Dexamethasone",Singapore General Hospital,Phase 2,30,Other,Oct-14,Oct-20,Oct-20
8968,NCT02216643,EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke,Stroke|Ischemic Stroke,Procedure: Thrombectomy|Device: Stentriever Solitaire FR® or Penumbra System®,"Hospital de Clinicas de Porto Alegre|Ministry of Health, Brazil|Medtronic|Penumbra Inc.|iSchemaView, Inc|Brainomix Limited",Phase 3,221,Other|Industry,"February 8, 2017","June 30, 2019","June 30, 2019"
8969,NCT02216578,Ph II CABOGIST in GIST,Metastatic Gastrointestinal Stromal Tumor,Drug: cabozantinib,European Organisation for Research and Treatment of Cancer - EORTC,Phase 2,51,Other,"February 2, 2017","May 20, 2019","February 23, 2021"
8970,NCT02215096,Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,Neoplasms,Drug: GSK2636771|Drug: Enzalutamide,GlaxoSmithKline,Phase 1,37,Industry,"November 13, 2014","October 3, 2019","October 3, 2019"
8971,NCT02214550,Chronic Pain Risk Associated With Menstrual Period Pain,"Cystitis, Interstitial|Dysmenorrhea|Migraine Disorders|Pelvic Pain|Endometriosis|Visceral Pain|Chronic Pain",Drug: microgestin 1/20,NorthShore University HealthSystem|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Phase 4,379,Other|NIH,Jul-14,Nov-20,Jan-21
8972,NCT02214160,Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies,Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency|Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency|Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency|Trifunctional Protein (TFP) Deficiency|Carnitine-acylcarnitine Translocase (CACT) Deficiency,Drug: UX007,Ultragenyx Pharmaceutical Inc,Phase 2,94,Industry,"December 9, 2014","December 3, 2020","December 3, 2020"
8973,NCT02213289,PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,Adenocarcinoma,Drug: Trastuzumab|Drug: ABT-806|Drug: Bemarituzumab|Drug: Ramucirumab|Drug: Nivolumab|Drug: Standard cytotherapy,University of Chicago|AbbVie,Phase 2,80,Other|Industry,"January 20, 2015","February 1, 2020","August 20, 2020"
8974,NCT02213068,Belatacept 3 Month Post Transplant Conversion Study,"Transplant; Failure, Kidney|EBV",Drug: belatacept|Drug: Tacrolimus|Drug: MPA,Lorenzo Gallon|Bristol-Myers Squibb|Northwestern University,Phase 4,28,Other|Industry,Jul-14,Sep-20,Sep-20
8975,NCT02211066,TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization,Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion),Drug: Clopidogrel|Drug: Ticagrelor,Hospital Clinic of Barcelona|AstraZeneca,Phase 4,59,Other|Industry,Oct-14,Jun-19,"June 12, 2019"
8976,NCT02210065,Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation,Leukemia|Lymphoma,Biological: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs),M.D. Anderson Cancer Center|Miltenyi Biotec B.V. & Co. KG,Phase 2,6,Other|Industry,"March 3, 2015","May 13, 2019","May 13, 2019"
8977,NCT02209948,Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.,Glioblastoma,Drug: Temozolomide,Grupo Español de Investigación en Neurooncología,Phase 2,166,Other,"August 22, 2014",Jun-19,"June 14, 2019"
8978,NCT02209636,Phosphate Lowering in CKD Trial,Chronic Kidney Disease|Cardiovascular Disease,Drug: Lanthanum carbonate|Drug: placebo|Drug: Ascorbic Acid|Drug: Nitroglycerin|Procedure: Flow-mediated dilation measurement|Procedure: Aortic pulse-wave velocity|Procedure: Endothelial cell collection,VA Office of Research and Development,Phase 4,66,U.S. Fed,"September 15, 2014","June 28, 2019","December 20, 2019"
8979,NCT02208466,Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients,Stroke|Motor Function,Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Drug: Fluoxetine|Device: Sham repetitive transcranial magnetic stimulation (rTMS)|Drug: Placebo Fluoxetine,Spaulding Rehabilitation Hospital,Phase 2,44,Other,Sep-14,"June 25, 2019","June 25, 2019"
8980,NCT02206685,A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery,Thoracolumbar Scoliosis,Drug: Methadone|Drug: Normal Saline,Baylor College of Medicine,Phase 4,74,Other,May-14,"January 27, 2020","January 27, 2020"
8981,NCT02205879,Pregabalin for Alcohol Dependence,Alcoholism,Drug: Pregabalin|Drug: Placebo,"St. Petersburg Bekhterev Research Psychoneurological Institute|St.-Petersburg Bekhterev Research Psychoneurological Institute, Russian Federation",Phase 4,100,Other,Jan-13,Dec-19,Dec-19
8982,NCT02203799,Peanut Oral Immunotherapy in Children With Peanut Allergy,Peanut Allergic Subjects,Biological: Peanut Oral Immunotherapy (POIT),Baylor College of Medicine,Phase 1,27,Other,"July 31, 2014","February 11, 2020","February 11, 2020"
8983,NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,Recurrent Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma,Biological: aldesleukin|Biological: ipilimumab|Other: laboratory biomarker analysis,"Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey",Phase 2,9,Other|NIH,"November 26, 2014","January 27, 2020","January 27, 2020"
8984,NCT02201576,Bortezomib in Rejection of Kidney Transplants,Chronic Antibody-mediated Transplant Rejection,Drug: Bortezomib|Drug: Plasma exchanges and intravenous immunoglobulins,Assistance Publique - Hôpitaux de Paris|Fondation Centaure,Phase 2,60,Other,"February 11, 2015","July 16, 2020","July 16, 2020"
8985,NCT02201251,A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy,Epilepsy,Drug: Topiramate|Drug: Levetiracetam,"Janssen Research & Development, LLC",Phase 3,63,Industry,"October 6, 2014","April 30, 2020","April 30, 2020"
8986,NCT02201212,Everolimus for Cancer With TSC1 or TSC2 Mutation,TSC1|TSC2|Tuberous Sclerosis Complex|MTOR,Drug: Everolimus,Dana-Farber Cancer Institute|Novartis Pharmaceuticals,Phase 2,30,Other|Industry,Sep-14,Jun-19,Jun-19
8987,NCT02200445,Low Dose IL-2 for Ulcerative Colitis,Ulcerative Colitis,Drug: Interleukin-2 (aldesleukin).,"Scott B. Snapper, MD PHD|Boston Children's Hospital",Phase 1,26,Other,Feb-15,"October 1, 2020",Mar-21
8988,NCT02198794,Reducing Involuntary Movements in Participants With Tardive Dyskinesia,Tardive Dyskinesia,Drug: SD-809|Drug: Placebo,"Auspex Pharmaceuticals, Inc.|Teva Branded Pharmaceutical Products R&D, Inc.",Phase 3,343,Industry,"October 20, 2014","December 6, 2019","December 14, 2020"
8989,NCT02198495,Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients,Anemia of Chronic Kidney Disease,Drug: Supplementation of ferric carboxymaltose|Drug: Supplementation of iron sucrose,Medical University of Vienna,Phase 4,143,Other,Sep-14,May-19,May-19
8990,NCT02197637,Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma,Low-Grade Glioma,Drug: ORAL VINORELBINE,"Centre Oscar Lambret|National Cancer Institute, France|Pierre Fabre Laboratories",Phase 2,39,Other|Industry,May-14,Aug-19,Oct-20
8991,NCT02197416,Safety of Dabigatran Etexilate in Blood Clot Prevention in Children,Venous Thromboembolism|Secondary Prevention,Drug: dabigatran etexilate,Boehringer Ingelheim,Phase 3,214,Industry,"September 29, 2014","October 16, 2019","November 19, 2019"
8992,NCT02194985,Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease,Fabry Disease,Drug: migalastat HCl 150 mg,Amicus Therapeutics,Phase 3,84,Industry,"March 14, 2015","October 23, 2019","October 23, 2019"
8993,NCT02194231,ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM),Malignant Pleural Mesothelioma,Drug: Trabectedin,Mario Negri Institute for Pharmacological Research|PharmaMar,Phase 2,145,Other|Industry,Jul-13,"December 12, 2019","December 12, 2019"
8994,NCT02193022,Miltefosine for Children With PKDL,Post Kala Azar Dermal Leishmaniasis,Drug: Miltefosine,"International Centre for Diarrhoeal Disease Research, Bangladesh|Thrasher Research Fund",Phase 3,80,Other,Jul-14,"June 30, 2019","June 30, 2019"
8995,NCT02192970,Bevacizumab Against Recurrent Retinal Detachment,Retinal Detachment|Proliferative Vitreoretinopathy,Drug: Bevacizumab,"University of Wisconsin, Madison",Phase 2,101,Other,"January 21, 2015","November 11, 2019","November 11, 2019"
8996,NCT02192775,UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,Multiple Myeloma,Drug: MV-NIS,University of Arkansas,Phase 2,2,Other,Mar-15,"August 20, 2019","August 20, 2019"
8997,NCT02192424,Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial),Type 2 Diabetes,Drug: Metformin alone|Drug: Metformin + Intermittent Insulin Therapy,"Mount Sinai Hospital, Canada|Canadian Institutes of Health Research (CIHR)",Phase 3,109,Other,Jul-14,Aug-20,Sep-20
8998,NCT02191098,Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People,HIV|Stable ART,Drug: ALT-803,University of Minnesota,Phase 1,10,Other,Jun-15,"September 9, 2019","September 9, 2019"
8999,NCT02190084,Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia,Apathy|Alzheimer's Dementia,Device: Neurostar repetitive transcranial magnetic stimulator,Central Arkansas Veterans Healthcare System,Phase 4,20,U.S. Fed,May-14,May-19,Jul-19
9000,NCT02188459,Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women,Smoking|Nicotine Dependence,Drug: Bupropion,Henry Kranzler|University of Pennsylvania,Phase 2,129,Other,"October 30, 2014","January 22, 2020","January 22, 2020"
9001,NCT02188121,Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients,Serious Mental Illness|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Cardiovascular Disease|Major Depressive Disorder|Psychosis NOS,Drug: Simvastatin|Drug: Losartan,"Mclean Hospital|Michael J. Gill Mental Health Clinic|The Massachusetts Mental Health Center|Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital|The Edinburg Center, Bedford MA",Phase 4,227,Other,Feb-15,Oct-20,Oct-21
9002,NCT02187133,Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,"Lymphoma, Non-Hodgkin|Lymphoma",Drug: Carfilzomib|Drug: Bendamustine|Drug: Rituximab,"University of California, San Francisco|National Comprehensive Cancer Network",Phase 1,10,Other,"May 5, 2015","March 31, 2021","March 31, 2021"
9003,NCT02187003,Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease,"Anemia, Sickle Cell",Drug: Rivipansel|Other: Placebo,GlycoMimetics Incorporated,Phase 3,345,Industry,"June 17, 2015","May 3, 2019","June 25, 2019"
9004,NCT02186275,The Vitamin D in Pediatric Crohn's Disease,Crohn's Disease,"Drug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|Drug: Vitamin D3 800 UI/day then 800 UI/day",St. Justine's Hospital|Canadian Institutes of Health Research (CIHR),Phase 3,25,Other,Feb-16,"December 20, 2019","December 20, 2019"
9005,NCT02185690,"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",Lungcancer,Drug: Binimetinib|Drug: Pemetrexed|Drug: Carboplatin,"University Health Network, Toronto|Novartis Pharmaceuticals",Phase 1,13,Other|Industry,"January 11, 2018","July 4, 2019","July 4, 2019"
9006,NCT02184741,A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage,Recurrent Miscarriage,Drug: GB-0998|Drug: Placebo,Japan Blood Products Organization,Phase 3,99,Industry,"June 3, 2014",May-20,Sep-20
9007,NCT02181829,Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases,Synovial Sarcoma|Single or Multiple Lung Metastases,Radiation: Whole Lung IMRT,Memorial Sloan Kettering Cancer Center,Phase 2,10,Other,Jul-14,"June 24, 2020","June 24, 2020"
9008,NCT02180672,Steroids for Pediatric Apnea Research in Kids,Obstructive Sleep Apnea Syndrome,Drug: Nasal Fluticasone|Drug: Placebo,"Children's Hospital of Philadelphia|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,211,Other|NIH,Sep-14,"December 30, 2019","October 30, 2021"
9009,NCT02179749,Mifepristone Treatment of Alcohol Use Disorder,Alcohol Dependence|Alcohol Use Disorders|Alcohol Abuse|Alcoholism,Drug: Mifepristone 1200 mg daily|Behavioral: Standardized behavioral therapy|Drug: Placebo,The Scripps Research Institute|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2,103,Other|NIH,Sep-14,Nov-19,"November 6, 2019"
9010,NCT02178644,Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,Rectal Cancer,Drug: Chemo with concomitant Capecitabine and KD018,Yale University,Phase 1,29,Other,Jul-14,"September 20, 2019","September 20, 2019"
9011,NCT02178072,"Window Trial 5-aza in HNSCC, T-tare",Head and Neck Squamous Cell Carcinoma,Drug: 5-Azacitadine,Yale University,Phase 1,18,Other,"February 19, 2015","October 23, 2019","October 23, 2019"
9012,NCT02177695,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",Bladder Cancer,Drug: Gemcitabine|Drug: Cisplatin|Drug: Methotrexate|Drug: Vinblastine|Drug: Doxorubicin|Drug: Filgrastim,SWOG Cancer Research Network|National Cancer Institute (NCI),Phase 2,237,Other|NIH,"August 28, 2014",Feb-20,"December 1, 2022"
9013,NCT02176382,Denosumab and Teriparatide Study (DATA-HD and DATA-EX),Postmenopausal Osteoporosis,Drug: denosumab|Drug: teriparatide|Drug: Zoledronic acid,Massachusetts General Hospital,Phase 4,76,Other,Aug-14,Feb-20,Feb-20
9014,NCT02176213,"Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma","Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Drug: Pomalidomide|Drug: Cyclophosphamide|Drug: Dexamethasone,Ajai Chari|Celgene Corporation|Icahn School of Medicine at Mount Sinai,Phase 2,35,Other|Industry,Jun-14,"May 7, 2019","May 7, 2019"
9015,NCT02175433,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies",Relapsed Lymphoid Malignancy|Refractory Lymphoid Malignancy,Drug: AGS67E,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 1,71,Industry,"October 14, 2014","October 29, 2019","October 29, 2019"
9016,NCT02175030,RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC,Contraception,Drug: Copper IUD|Drug: Levonorgestrel IUD,University of Utah,Phase 4,711,Other,Aug-16,Feb-20,Dec-20
9017,NCT02175004,Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP),FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Drug: Inotersen,"Ionis Pharmaceuticals, Inc.",Phase 3,135,Industry,"June 26, 2014","September 11, 2020","January 7, 2021"
9018,NCT02174614,The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT),Cocaine Use Disorder,Behavioral: Treatment As Usual (TAU)|Behavioral: TAU plus Rapid Abstinence Initiation (RAI)|Behavioral: TAU plus RAI plus Cognitive Control Training (CCT),Yale University|National Institute on Drug Abuse (NIDA),Phase 1,99,Other|NIH,Apr-15,"August 31, 2020","August 31, 2020"
9019,NCT02174172,A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors,Solid Cancers,Drug: Atezolizumab|Drug: Bevacizumab|Drug: Interferon alfa-2b|Drug: Ipilimumab|Drug: Obinutuzumab|Drug: PEG-interferon alfa-2a,Hoffmann-La Roche,Phase 1,158,Industry,"August 18, 2014","November 25, 2019","November 25, 2019"
9020,NCT02172950,An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A,Hemophilia A|Severe Hemophilia A,Biological: rVIII-SingleChain,CSL Behring,Phase 3,246,Industry,"October 13, 2014","January 19, 2021","January 19, 2021"
9021,NCT02171429,A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab Placebo,Hoffmann-La Roche,Phase 3,358,Industry,"November 14, 2014","March 2, 2020","May 25, 2020"
9022,NCT02169791,Nonmyeloablative Haploidentical Transplant Followed by MLN9708,Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphomas|Multiple Myeloma,Drug: MLN9708,"Northside Hospital, Inc.|Millennium Pharmaceuticals, Inc.",Phase 2,29,Other|Industry,"July 15, 2014","July 28, 2020","July 28, 2020"
9023,NCT02167958,"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",Leukemia|MDS|Myelofibrosis|Lymphoma,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation|Other: Hematopoietic stem cell infusion|Drug: Tacrolimus|Drug: Mycophenolate|Drug: G-CSF,"Rafic Farah, MD|University of Pittsburgh",Phase 1,28,Other,"February 11, 2015","September 21, 2019","September 21, 2019"
9024,NCT02166242,Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers,"Carcinoma, Non-small Cell Lung",Drug: ethaselen,Hunan Province Tumor Hospital,Phase 1,40,Other,"June 1, 2014","December 1, 2020","December 1, 2021"
9025,NCT02165449,Biomarkers of Fast Acting Therapies in Major Depression,Major Depressive Disorder,Drug: Ketamine,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",Phase 1,60,Other|NIH,Jun-14,Aug-19,Aug-19
9026,NCT02165397,Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia,Waldenström's Macroglobulinemia,Drug: Ibrutinib|Drug: Placebo|Drug: Rituximab,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Phase 3,181,Industry,"July 7, 2014","November 7, 2019","November 7, 2019"
9027,NCT02165215,A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors,"Colitis, Ulcerative",Drug: Etrolizumab|Drug: Placebo,Hoffmann-La Roche,Phase 3,359,Industry,"August 12, 2014","April 6, 2020","April 6, 2020"
9028,NCT02164643,Longitudinal Study of Brain Amyloid imaGing in MEMENTO,Alzheimer's Disease (AD) and Related Disorders,Drug: Flutemetamol (18F)|Drug: Florbetapir (18F),"University Hospital, Bordeaux|Fondation Plan Alzheimer|GE Healthcare|Avid Radiopharmaceuticals",Phase 3,448,Other|Industry,"June 10, 2014","October 9, 2019","October 9, 2019"
9029,NCT02164500,JAK-inhibition in Recurrent Classical Hodgkin Lymphoma,Recurrent Classical Hodgkin Lymphoma,Drug: Ruxolitinib,University of Cologne,Phase 2,12,Other,Oct-15,"May 17, 2019","May 17, 2019"
9030,NCT02164422,Does Guanfacine Attenuate Stress-Induced Drinking?,Alcohol Drinking,Drug: Guanfacine 3mg/day|Drug: Guanfacine 1.5mg/day|Drug: Placebo,Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Phase 2,70,Other|NIH,Jun-14,"March 31, 2020","March 31, 2020"
9031,NCT02163759,A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab Placebo,Hoffmann-La Roche,Phase 3,358,Industry,"November 4, 2014","February 19, 2020","March 19, 2020"
9032,NCT02163434,Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum,Hyperemesis Gravidarum,Drug: Gabapentin|Drug: Metoclopramide,State University of New York at Buffalo|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 2,31,Other|NIH,Jun-14,Oct-19,Nov-19
9033,NCT02162836,A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer,"Prostatic Neoplasms, Castration-Resistant",Drug: JNJ-56021927,Janssen Pharmaceutical K.K.,Phase 1,6,Industry,"June 27, 2014","May 27, 2019","May 27, 2019"
9034,NCT02160782,Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS),Alagille Syndrome,Drug: LUM001 (Maralixibat)|Drug: Placebo,"Mirum Pharmaceuticals, Inc.",Phase 2,31,Industry,"October 28, 2014","May 28, 2020","May 28, 2020"
9035,NCT02160353,Neo-adjuvant Abiraterone Prostate Study,High Risk Localised Prostate Carcinoma,"Drug: Abiraterone acetate, Prednisolone","Cancer Trials Ireland|Janssen, LP",Phase 2,45,Other|Industry,"July 9, 2015","January 19, 2021","January 19, 2021"
9036,NCT02159872,Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,Leukemia,Drug: Omacetaxine,M.D. Anderson Cancer Center|Teva Pharmaceuticals USA,Phase 2,48,Other|Industry,"May 18, 2015","April 14, 2020","April 14, 2020"
9037,NCT02158988,Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis,Malignant Neoplasm of Stomach|Secondary Malignant Neoplasm of Peritoneum|Secondary Malignant Neoplasm of Other and Unspecified Sites,Procedure: HIPEC,"Charite University, Berlin, Germany|German Cancer Aid",Phase 3,105,Other,"March 1, 2014","October 1, 2020","June 9, 2021"
9038,NCT02157792,M6620 First in Human Study,Advanced Solid Tumor,Drug: M6620|Drug: Gemcitabine|Drug: Cisplatin|Drug: Etoposide|Drug: Carboplatin|Drug: Irinotecan,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 1,200,Industry,"December 10, 2012","March 11, 2020","March 11, 2020"
9039,NCT02154737,Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,Pancreatic Cancer,Drug: Gemcitabine|Drug: Erlotinib,"Tony Reid, M.D., Ph.D.|Genentech, Inc.|University of California, San Diego",Phase 1,24,Other|Industry,Jul-13,"September 3, 2020","September 3, 2020"
9040,NCT02154269,Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy,Chronic Chagasic Myocarditis,Drug: Treatment with G-CSF (Granulocyte colony stimulating factor)|Drug: Placebo saline,Hospital Sao Rafael,Phase 2,70,Other,Sep-15,Oct-19,Jun-20
9041,NCT02152943,"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",Advanced Malignant Solid Neoplasm|Estrogen Receptor Positive|HER2/Neu Positive|Postmenopausal|Premenopausal|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Refractory Breast Carcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7,Drug: Everolimus|Other: Laboratory Biomarker Analysis|Drug: Letrozole|Biological: Trastuzumab,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,37,Other|NIH,"July 17, 2014","December 14, 2020","December 14, 2020"
9042,NCT02152696,Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location,Persistent Pregnancy of Unknown Location|Ectopic Pregnancy,Drug: Methotrexate|Procedure: Uterine Evacuation|Other: Expectant Management,"Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Augusta University|Penn State University|University of California, San Francisco|University of North Carolina|University of Oklahoma|University of Pennsylvania",Phase 3,255,Other|NIH,"July 25, 2014",Aug-19,"August 19, 2019"
9043,NCT02151760,"Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer",Metastatic Prostate Cancer,Drug: 18F-DCFPyL,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),Phase 1,37,Other|NIH,May-14,Apr-20,Apr-20
9044,NCT02151604,Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy,Non-small Cell Lung Cancer,Drug: Inhalation of hyperpolarized xenon gas,"Oxford University Hospitals NHS Trust|National Institute for Health Research, United Kingdom",Phase 2,22,Other,"April 23, 2014","December 31, 2020","December 31, 2020"
9045,NCT02150967,"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",Advanced Cholangiocarcinoma|FGFR2 Gene Mutation,Drug: BGJ398 (infigratinib),"QED Therapeutics, Inc.|Helsinn Healthcare SA",Phase 2,143,Industry,"July 23, 2014","March 1, 2021","February 7, 2022"
9046,NCT02150551,Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease,Inflammatory Bowel Diseases,Biological: Allogeneic bone marrow-derived mesenchymal stromal cells,Catherine Bollard|Children's National Research Institute,Phase 1,1,Other,"June 7, 2018","September 27, 2019","September 27, 2019"
9047,NCT02149329,Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO,Febrile Neutropenia|Hematological Malignancy,Drug: Discontinuation of imipenem-cilastatin or meropenem,"Amsterdam UMC, location VUmc|ZonMw: The Netherlands Organisation for Health Research and Development|FondsNutsOhra",Phase 4,276,Other,Dec-14,"August 5, 2019","August 5, 2019"
9048,NCT02146547,European Long-acting Antipsychotics in Schizophrenia Trial,Schizophrenia,Drug: Aripiprazole|Drug: Aripiprazole depot|Drug: Paliperidone|Drug: Paliperidone palmitate,UMC Utrecht,Phase 4,536,Other,Feb-15,"August 26, 2020","August 26, 2020"
9049,NCT02145819,Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?,Supervision of Pregnancy Resulting From In-vitro Fertilization,Drug: hCG|Other: LH peak,Universitair Ziekenhuis Brussel,Phase 4,240,Other,Jan-14,Sep-19,Sep-19
9050,NCT02145767,Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial,Miscarriage|Preterm Birth,Drug: Progesterone|Drug: Placebo,Sir Mortimer B. Davis - Jewish General Hospital|Canadian Institutes of Health Research (CIHR),Phase 2,850,Other,Dec-14,Feb-21,Feb-21
9051,NCT02145130,Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects,Burn Injury|Soft Tissue Injury|Skin Necrosis|Scars|Congenital Giant Nevus|Skin Tumors,Biological: denovoDerm|Biological: denovoSkin,"University of Zurich|University Hospital, Zürich",Phase 1,12,Other,May-14,Mar-21,Mar-21
9052,NCT02145091,"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",Healthy,Drug: Moderately-high dose of psilocybin|Drug: Moderately-low dose of psilocybin|Drug: Very-low dose of psilocybin|Drug: Placebo,Johns Hopkins University,Phase 1,40,Other,May-14,"December 26, 2019","December 26, 2019"
9053,NCT02143219,Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer,Pancreatic Metastatic Cancer|Toxicity,Drug: Oxaliplatine|Drug: Folinic acid|Drug: Irinotecan|Drug: 5-FU,Institut Cancerologie de l'Ouest,Phase 2,72,Other,"July 31, 2014","November 25, 2020","November 25, 2020"
9054,NCT02142634,Budesonide for Induction of Remission in Incomplete Microscopic Colitis,Incomplete Microscopic Colitis,Drug: Budesonide granules 9 mg|Drug: Placebo granules,Dr. Falk Pharma GmbH,Phase 3,44,Industry,May-14,Feb-20,Feb-20
9055,NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,Metastatic Melanoma,Drug: Tremelimumab|Drug: MEDI3617,"F. Stephen Hodi, MD|MedImmune LLC|Dana-Farber Cancer Institute",Phase 1,15,Other|Industry,May-14,"September 23, 2020","September 23, 2020"
9056,NCT02141204,"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants",Rotavirus,Biological: HRV Liquid|Biological: HRV Lyophilized,GlaxoSmithKline,Phase 3,451,Industry,"February 20, 2019","December 28, 2019","December 28, 2019"
9057,NCT02139904,Vinorelbine in Mesothelioma,Mesothelioma,Drug: Vinorelbine|Other: Active Symptom Control,Wales Cancer Trials Unit|Pierre Fabre Laboratories,Phase 2,154,Other|Industry,"March 1, 2016","March 17, 2021","March 17, 2021"
9058,NCT02139280,Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy,Hematologic Malignancies,Drug: Cyclophosphamide,Dartmouth-Hitchcock Medical Center,Phase 2,58,Other,Dec-13,Jul-19,Sep-20
9059,NCT02138929,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,Esophageal Cancer,Drug: Everolimus|Drug: LDE 225,M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI),Phase 1,25,Other|Industry|NIH,"November 10, 2014","June 8, 2020","June 8, 2020"
9060,NCT02138214,Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer,Stage I Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage III Papillary Thyroid Cancer,Procedure: Thyroidectomy|Procedure: entral lymph node dissection (CLND)|Other: Quality-of-life assessment,"University of Wisconsin, Madison|National Cancer Institute (NCI)",Phase 2,117,Other|NIH,"June 6, 2014","October 30, 2019","October 26, 2020"
9061,NCT02137369,The ISLAND Study: InSuLa Assessed Needs for Depression,Depression,Drug: Selective serotonin re-uptake inhibitor|Behavioral: Cognitive Behavioral Therapy|Other: Combination treatment (SSRI + CBT),Emory University|National Institute of Mental Health (NIMH),Phase 4,77,Other|NIH,Sep-14,"October 24, 2019","October 24, 2019"
9062,NCT02137239,Regimen Optimization Study,Kidney Transplantation,Drug: Thymoglobulin|Drug: Belatacept|Drug: mycophenolate mofetil(MMF)|Drug: Corticosteroids|Drug: Everolimus(EVL)|Drug: Tacrolimus(TAC),Bristol-Myers Squibb,Phase 2,58,Industry,"December 31, 2015","May 2, 2019","May 2, 2019"
9063,NCT02136069,A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug: Etrolizumab|Drug: Infliximab|Other: Placebo (IV)|Other: Placebo (Injection),Hoffmann-La Roche,Phase 3,397,Industry,"December 24, 2014","June 23, 2020","June 23, 2020"
9064,NCT02134028,Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE),Asthma,Drug: Dupilumab,Sanofi|Regeneron Pharmaceuticals,Phase 3,2282,Industry,"August 5, 2014","October 11, 2019","October 11, 2019"
9065,NCT02133924,Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease,Acute Graft Versus Host Disease,Drug: natalizumab|Drug: steroids,John Levine|Biogen|Icahn School of Medicine at Mount Sinai,Phase 2,76,Other|Industry,Aug-16,"December 10, 2020","November 21, 2021"
9066,NCT02133846,Safety Study of TPI-287 to Treat CBS and PSP,Primary Four Repeat Tauopathies (4RT)|Corticobasal Syndrome (CBS)|Progressive Supranuclear Palsy (PSP)|Corticobasal Degeneration (CBD),Drug: TPI 287 2 mg/m2|Drug: TPI-287 20 mg/m2|Drug: Placebo|Drug: TPI-287 6.3 mg/m2,"University of California, San Francisco|CBD Solutions|Tau Consortium",Phase 1,44,Other,May-14,Sep-19,Sep-19
9067,NCT02132754,Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),Solid Tumor,Biological: MK-4166|Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 1,116,Industry,"June 27, 2014","July 31, 2019","July 31, 2019"
9068,NCT02132026,Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.,Calcific Aortic Stenosis,Drug: Denosumab|Drug: Alendronic Acid|Drug: Denosumab Placebo|Drug: Alendronic Acid Placebo,University of Edinburgh|British Heart Foundation|NHS Lothian,Phase 2,152,Other,"November 12, 2014","November 28, 2019","November 28, 2019"
9069,NCT02129699,Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy,Lung Cancer Non-small Cell Stage IV,"Drug: Denosumab|Other: None, standard chemotherapy only",ETOP IBCSG Partners Foundation|European Organisation for Research and Treatment of Cancer - EORTC|Amgen,Phase 3,514,Other|Industry,"January 6, 2015","February 29, 2020","February 29, 2020"
9070,NCT02129348,Treatment of Psychosis and Agitation in Alzheimer's Disease,Alzheimer's Disease|Psychosis|Agitation,Drug: Lithium|Drug: Placebo,New York State Psychiatric Institute|National Institute on Aging (NIA),Phase 2,77,Other|NIH,Jun-14,Jan-20,Jan-20
9071,NCT02128243,Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer,"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction|Gastric Neoplasm|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma|Gastric Adenocarcinoma|Esophageal Neoplasms",Drug: S-1 de-escalation|Drug: Chemotherapy by Investigator's choice,"AIO-Studien-gGmbH|Taiho Pharmaceutical Co., Ltd.|Nordic Pharma SAS",Phase 2,242,Other|Industry,Sep-14,"October 8, 2020","October 8, 2020"
9072,NCT02128191,No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants,Bronchopulmonary Dysplasia (BPD),Drug: Oral ibuprofen|Drug: Normal saline,Samsung Medical Center,Phase 2,142,Other,Jul-14,Aug-19,Aug-19
9073,NCT02127437,Lanreotide In Polycystic Kidney Disease Study,Autosomal Dominant Polycystic Kidney Disease (ADPKD,Drug: Lanreotide|Drug: saline,"Assistance Publique - Hôpitaux de Paris|IPSEN pharmaceutical company, Boulogne-Billancourt, France",Phase 3,159,Other,"September 19, 2014","July 31, 2019","July 31, 2019"
9074,NCT02126124,Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.,Smoking Cessation,Device: Sham Treatment|Device: Active dTMS Treatment,Brainsway,Phase 3,224,Industry,"August 20, 2014","November 14, 2019","November 14, 2019"
9075,NCT02125890,Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms,Abdominal Aortic Aneurysms,Drug: Tranexamic Acid,Saskatchewan Health Authority - Regina Area,Phase 3,9,Other,Jul-14,"February 12, 2020","February 12, 2020"
9076,NCT02125357,Sequencing Abiraterone and Enzalutamide in mCRPC,Metastatic Castration-Resistant Prostate Cancer,Drug: Abiraterone acetate|Drug: Enzalutamide,British Columbia Cancer Agency,Phase 2,202,Other,Sep-14,"February 4, 2020","February 4, 2020"
9077,NCT02124707,"Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck,Drug: Cetuximab|Drug: Paclitaxel|Drug: Carboplatin,UNC Lineberger Comprehensive Cancer Center,Phase 2,14,Other,"June 16, 2014","October 1, 2019","October 1, 2019"
9078,NCT02124512,Blood Lipopolysaccharide (LPS) Rifaximin Study,Obese|Insulin Resistance|Metabolic Syndrome,Drug: Rifaximin SSD|Other: Placebo,Philip Kern|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky,Phase 2,12,Other|NIH,Mar-15,"May 31, 2019","May 31, 2019"
9079,NCT02124148,A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer,Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer,Drug: Prexasertib|Drug: Cisplatin|Drug: Cetuximab|Drug: G-CSF|Drug: Pemetrexed|Drug: Fluorouracil|Drug: LY3023414|Drug: Leucovorin,Eli Lilly and Company,Phase 1,167,Industry,"June 18, 2014","February 13, 2020","February 13, 2020"
9080,NCT02123121,Resveratrol to Enhance Vitality and Vigor in Elders,Mitochondrial Function|Physical Function,Drug: Resveratrol 1000 mg/day|Drug: Resveratrol 1500 mg/day|Other: Vegetable cellulose|Other: All groups,University of Florida|National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),Phase 2,59,Other|NIH,Sep-15,"May 2, 2019","May 2, 2019"
9081,NCT02122718,"XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke",Ischaemic Stroke,Drug: Allopurinol|Drug: Placebo,NHS Greater Glasgow and Clyde|University of Glasgow,Phase 4,464,Other,May-14,Feb-21,Feb-21
9082,NCT02122458,Blast Exposed Veterans With Auditory Complaints,Hearing Impairment|Hearing Aid Fitting,Device: mild-gain hearing aids,VA Office of Research and Development,Phase 1,356,U.S. Fed,"August 1, 2015","November 30, 2020","December 31, 2020"
9083,NCT02122380,The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome,Drug: Sitagliptin|Drug: Placebo,"Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center",Phase 4,23,Other|NIH,Feb-16,"August 1, 2019","August 1, 2019"
9084,NCT02121990,"Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,"Drug: Paclitaxel,|Drug: Bevacizumab|Drug: Cisplatin|Drug: Olaparib","Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc.",Phase 1,17,Other|Industry,"April 21, 2014","August 19, 2020","August 19, 2020"
9085,NCT02121262,A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema,Macular Edema,Drug: Dexamethasone|Procedure: Laser Photocoagulation,"Allergan|Tigermed Consulting Co., Ltd",Phase 3,284,Industry,"January 8, 2016","November 1, 2019","November 1, 2019"
9086,NCT02117713,An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome,Alagille Syndrome,Drug: LUM001 (Maralixibat),"Mirum Pharmaceuticals, Inc.|Lumena Pharmaceuticals, Inc.|Childhood Liver Disease Research and Education Network",Phase 2,34,Industry|Other,"March 16, 2015","June 1, 2020","June 1, 2020"
9087,NCT02117453,"Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides",ANCA-associated Primary Necrotizing Vasculitides,Drug: Rosuvastatin|Drug: Placebo,Assistance Publique - Hôpitaux de Paris,Phase 3,121,Other,"October 27, 2014","November 7, 2019","November 7, 2019"
9088,NCT02116608,Treatment of Tracheostomy Granulomas,Granuloma|Tracheostomy,"Drug: Betadine|Drug: Silver Nitrate|Drug: Hydrocortisone Butyrate Cream, 1.0%","University of Colorado, Denver",Phase 4,26,Other,Sep-14,"September 5, 2019","September 5, 2019"
9089,NCT02114359,Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer,Gastric Cancer,Drug: Capecitabine/cisplatin|Drug: S-1/cisplatin|Drug: Capecitabine/oxaliplatin|Drug: 5-fluorouracil/oxaliplatin|Drug: Capecitabine|Drug: S-1|Drug: 5-fluorouracil,"Seoul National University Hospital|Ministry of Health & Welfare, Korea|Korean Cancer Study Group",Phase 3,111,Other,Feb-14,Feb-20,Feb-20
9090,NCT02113878,Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,"Carcinoma, Squamous Cell of Head and Neck|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Hypopharyngeal Cancer|Early Invasive Cervical Squamous Cell Carcinoma|Carcinoma of Larynx|Cancer of Nasopharynx",Drug: BKM120|Drug: Cisplatin|Radiation: Intensity-modulated radiotherapy (IMRT),Dana-Farber Cancer Institute|Novartis Pharmaceuticals,Phase 1,23,Other|Industry,"September 29, 2014","December 6, 2019","January 1, 2022"
9091,NCT02113800,Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study,"Poorly Differentiated Malignant Neuroendocrine Carcinoma|Neuroendocrine Carcinoma, Grade 3|Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3|Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3|Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)",Drug: Everolimus (Afinitor®),AIO-Studien-gGmbH|Assign Data Management and Biostatistics GmbH|Novartis Pharmaceuticals,Phase 2,40,Other|Industry,Aug-15,Apr-20,Apr-20
9092,NCT02112175,Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM,Multiple Myeloma,Drug: Lenalidomide,Celgene,Phase 3,46,Industry,"April 30, 2014","October 12, 2020","October 12, 2020"
9093,NCT02111577,Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,Metastatic Castration-resistant Prostate Cancer,Biological: DCVAC/PCa|Biological: Placebo,SOTIO a.s.|SOTIO Biotech,Phase 3,1182,Industry,"May 26, 2014","January 28, 2020","January 28, 2020"
9094,NCT02110654,Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery,Sinusitis|Nasal Polyps|Asthma,Drug: Montelukast|Drug: mometasone furoate nasal spray,"First Affiliated Hospital, Sun Yat-Sen University",Phase 4,50,Other,Jun-14,"November 1, 2020","November 1, 2020"
9095,NCT02107937,Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma,Ovarian Neoplasms|Ovarian Epithelial Cancer,Biological: DCVAC/OvCa with Standard of Care|Biological: DCVAC/OvCa sequentially chemotherapy|Drug: Standard of Care,SOTIO a.s.|SOTIO Biotech,Phase 2,136,Industry,Nov-13,Nov-20,Nov-21
9096,NCT02107261,Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand,Dystonia,Drug: incobotulinumtoxin A|Drug: Placebo,"Icahn School of Medicine at Mount Sinai|Merz North America, Inc.",Phase 2,21,Other|Industry,Mar-14,"January 27, 2020","January 27, 2020"
9097,NCT02104817,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD),Drug: Epanova® (omega-3 carboxylic acids)|Drug: corn oil control,AstraZeneca|The Cleveland Clinic|IQVIA RDS Inc.,Phase 3,13078,Industry|Other,"October 30, 2014","May 27, 2020","May 27, 2020"
9098,NCT02100696,A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors,Ulcerative Colitis,Drug: Etrozulimab|Drug: Placebo,Hoffmann-La Roche,Phase 3,609,Industry,"May 21, 2014","April 16, 2020","April 16, 2020"
9099,NCT02099747,hATG+CsA vs hATG+CsA+Eltrombopag for SAA,Severe Aplastic Anemia,Drug: hATG|Drug: CsA|Drug: Eltrombopag,European Society for Blood and Marrow Transplantation|Novartis|Pfizer,Phase 3,202,Other|Industry,Jul-15,Dec-20,Dec-20
9100,NCT02099591,Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients,"Constipation, Signs and Symptoms, Digestive",Drug: Naloxegol,Kyowa Kirin Pharmaceutical Development Ltd,Phase 1,61,Industry,Nov-14,Apr-21,Apr-21
9101,NCT02099383,BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.,Stroke|Dehydration,Other: normal saline,Chang Gung Memorial Hospital,Phase 3,244,Other,Apr-14,Jul-20,Jul-20
9102,NCT02097810,"Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.",Locally Advanced Solid Tumors|Metastatic Solid Tumors,Drug: Entrectinib,Hoffmann-La Roche,Phase 1,84,Industry,"July 28, 2014","June 2, 2020","June 2, 2020"
9103,NCT02096614,Investigator Initiated Phase 1 Study of TBI-1201,Solid Tumors,Drug: TBI-1201|Drug: Cyclophosphamide|Drug: Fludarabine,"Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd.",Phase 1,18,Other|Industry,Apr-14,Mar-21,Mar-21
9104,NCT02096055,Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,Untreated Adult Acute Myeloid Leukemia,Drug: Cladribine|Drug: Guadecitabine|Drug: Idarubicin,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,44,Other|NIH,"April 4, 2014","November 24, 2020","November 24, 2020"
9105,NCT02095834,"Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Drug: Bendamustine Hydrochloride|Drug: Carfilzomib|Drug: Dexamethasone|Other: Laboratory Biomarker Analysis,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,18,Other|NIH,"April 24, 2014","January 7, 2021","January 7, 2021"
9106,NCT02095054,Regorafenib and Cetuximab in Patients With Advanced Malignancy,Advanced Cancers,Drug: Regorafenib|Drug: Cetuximab|Behavioral: Questionnaire,M.D. Anderson Cancer Center,Phase 1,39,Other,"March 19, 2014","March 27, 2020","March 27, 2020"
9107,NCT02094625,NAC to Prevent Cisplatin-induced Hearing Loss,"Neuroectodermal Tumors, Primitive|Liver Neoplasms|Osteosarcoma|Other Childhood Cancers Using Cisplatin-based Regimens",Drug: N-Acetylcysteine,Children's Hospital Los Angeles,Phase 1,52,Other,Mar-16,Sep-20,Aug-21
9108,NCT02092467,Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis,"Arthritis, Rheumatoid",Drug: tofacitinib|Biological: adalimumab|Biological: etanercept,Pfizer,Phase 4,4372,Industry,"March 14, 2014","July 22, 2020","July 22, 2020"
9109,NCT02092324,Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Neutrophilic Leukemia",Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Ruxolitinib Phosphate,OHSU Knight Cancer Institute,Phase 2,51,Other,"July 8, 2014","November 22, 2019","January 24, 2020"
9110,NCT02092298,Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer,Gastrointestinal Cancer,Drug: Mitomycin C|Drug: Cisplatin|Drug: Sodium Thiosulfate,M.D. Anderson Cancer Center,Phase 2,21,Other,"May 8, 2014","May 12, 2020","May 12, 2020"
9111,NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).,"Carcinoma, Non-Small-Cell Lung",Drug: Gefitinib|Drug: MEDI4736,MedImmune LLC|AstraZeneca,Phase 1,56,Industry,"March 24, 2014","March 9, 2021","March 9, 2021"
9112,NCT02086500,Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial),Traumatic Hemorrhage,Drug: Tranexamic Acid|Other: Saline control,Jason Sperry|University of Arizona|The University of Texas at San Antonio|University of Utah|University of Pittsburgh,Phase 3,903,Other,Jul-15,Nov-19,Nov-19
9113,NCT02086175,A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma,Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas,Drug: Imprime PGG|Drug: Rituximab,"Dana-Farber Cancer Institute|HiberCell, Inc.",Phase 2,25,Other|Industry,Dec-14,"July 11, 2019","February 1, 2021"
9114,NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,Melanoma|Non-Small Cell Lung Cancer|Brain Metastases,Drug: MK-3475,Yale University,Phase 2,65,Other,Mar-14,"February 27, 2020","February 27, 2020"
9115,NCT02084732,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Thyroid Cancer,Drug: Sorafenib,"Instituto Nacional de Cancerologia, Columbia",Phase 2,35,Other,"October 1, 2013","November 1, 2019","November 1, 2019"
9116,NCT02082249,"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications",Advanced Parkinson's Disease,Drug: ABT-SLV187,AbbVie,Phase 3,30,Industry,"March 10, 2014","October 31, 2019","October 31, 2019"
9117,NCT02081638,Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study,Human Immunodeficiency Virus,Drug: Aspirin|Drug: Atorvastatin,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 2,53,NIH,"April 18, 2014","October 16, 2019","October 16, 2019"
9118,NCT02081469,Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy,"Hepatitis B, Chronic|Tumor",Other: TDF,Chang Gung Memorial Hospital|Gilead Sciences,Phase 4,100,Other|Industry,"March 17, 2014","August 5, 2019","August 5, 2019"
9119,NCT02080221,BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Metastatic Pancreatic Cancer,Drug: FOLFOXA,Brown University|Lifespan|SouthCoast Medical Group|Memorial hospital,Phase 2,50,Other,Aug-14,"January 9, 2020","March 16, 2022"
9120,NCT02078349,Phase I Study of KPT330 in Asian Patients,Solid Tumors,Drug: KPT-330,"National University Hospital, Singapore|Karyopharm Therapeutics Inc",Phase 1,120,Other|Industry,Feb-14,"March 20, 2020","March 20, 2020"
9121,NCT02077920,Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP),Ventilator-associated Pneumonia,Drug: Chlorhexidine|Drug: 0.9% sodium chloride injection|Device: Endotracheal tube|Device: Fiber bronchoscope,General Hospital of Shenyang Military Region,Phase 2,192,Other,Mar-14,Jun-19,Aug-19
9122,NCT02077751,BioRBC Survival in Adults With Prior Antibody Response to BioRBCs,Anemia,Drug: biotin labelled RBCs,"John A Widness|National Heart, Lung, and Blood Institute (NHLBI)|University of Iowa",Phase 1,3,Other|NIH,May-13,Jun-19,Dec-19
9123,NCT02077192,Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Immune Thrombocytopenic Purpura,Drug: Fostamatinib Disodium,Rigel Pharmaceuticals,Phase 3,124,Industry,Jul-14,"June 1, 2020","June 1, 2020"
9124,NCT02076672,Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population,Asbestos Exposure,Drug: Artichoke WPC,Ontario Clinical Oncology Group (OCOG)|Aboca Spa Societa' Agricola,Phase 2,3,Other|Industry,"November 5, 2019","April 28, 2020","April 28, 2020"
9125,NCT02075970,Optimized Erythropoietin (EPO) Treatment,Neonatal Anemia,Drug: Epoetin Alpha|Drug: Biotinylated Red Blood Cells,"John A Widness|Department of Health and Human Services|National Heart, Lung, and Blood Institute (NHLBI)|Janssen Scientific Affairs, LLC|University of Iowa",Phase 2,62,Other|U.S. Fed|NIH|Industry,Jun-14,Jun-19,Dec-19
9126,NCT02075671,Photodynamic Therapy for Papulopustular Rosacea,Rosacea|Papulopustular Rosacea,Drug: Aminolevulinic acid topical solution 20%|Device: Blu-U Light Therapy|Other: Placebo vehicle only,"George Washington University|DUSA Pharmaceuticals, Inc.",Phase 4,30,Other|Industry,"April 24, 2014","August 15, 2019","August 15, 2019"
9127,NCT02075112,Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck,Cancer of Head and Neck,Drug: Soy isoflavone|Radiation: Radiation|Drug: Cisplatin,Emory University|Radiation Therapy Oncology Group,Phase 1,24,Other,Nov-13,Sep-19,Sep-19
9128,NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,Malignant Melanoma,Drug: PLX3397,The Christie NHS Foundation Trust|Cancer Research UK|Christie Charitable Funds,Phase 2,7,Other,Oct-15,"March 2, 2021","March 2, 2021"
9129,NCT02071394,Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth,Hypoxic Ischaemic Encephalopathy,Drug: Xenon gas|Other: Whole body cooling,University Hospitals Bristol and Weston NHS Foundation Trust|University of Bristol,Phase 2,50,Other,Mar-14,"October 7, 2019","April 15, 2020"
9130,NCT02069158,Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor,Breast Cancer|NSCLC|Ovary Cancer|Endometrial Cancer|Small Cell Lung Cancer (SCLC)|Head and Neck (HNSCC),Drug: PF-05212384|Drug: Paclitaxel|Drug: Carboplatin,Cristiana Sessa|Oncology Institute of Southern Switzerland,Phase 1,17,Other,Apr-14,May-19,May-19
9131,NCT02068365,An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy,Chronic Hepaititis B,Drug: Pegyinterferon-alfa-2a,Chinese University of Hong Kong,Phase 4,41,Other,Jun-13,Jun-19,Jun-19
9132,NCT02067988,Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study,Neuroendocrine Tumors,Device: Holmium-166 microspheres hepatic radioembolization.,UMC Utrecht,Phase 2,34,Other,Feb-14,"September 1, 2019","September 1, 2019"
9133,NCT02067182,Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation,Atrial Fibrillation|Cardioembolic Events|Oral Anticoagulation,Drug: Dabigatran,"Georg Nickenig|Boehringer Ingelheim|University Hospital, Bonn",Phase 4,200,Other|Industry,Aug-15,"September 15, 2020","September 15, 2020"
9134,NCT02066662,Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification,"Atrial Fibrillation or Pulmonary Embolism|Need of Long Term Oral Anticoagulation Therapy (OAT)|Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",Drug: Rivaroxaban or Marcumar,RWTH Aachen University|Bayer,Phase 4,192,Other|Industry,Jul-13,Mar-20,Mar-20
9135,NCT02066285,Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma,Solitary Fibrous Tumor|Extraskeletal Myxoid Chondrosarcoma,Drug: Pazopanib,Grupo Espanol de Investigacion en Sarcomas,Phase 2,96,Other,Jun-14,Dec-19,"March 24, 2023"
9136,NCT02065882,"Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency",Congenital Afibrinogenemia|Congenital Hypofibrinogenemia,Biological: BT524 (fibrinogen concentrate from human plasma),Biotest|ICON plc|SYNLAB Analytics and Services Germany GmbH|Phoenix Clinical Research|Accovion GmbH|Pharmetheus AB,Phase 3,36,Industry|Other,Mar-13,"May 18, 2020","November 18, 2020"
9137,NCT02065622,Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis,Ulcerative Colitis (UC),Drug: Adalimumab|Other: Placebo,AbbVie,Phase 3,952,Industry,"March 27, 2014","September 5, 2019","November 11, 2019"
9138,NCT02065570,Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease,Crohn's Disease,Drug: Adalimumab|Drug: Placebo,AbbVie,Phase 3,514,Industry,"May 1, 2014","January 30, 2020","January 30, 2020"
9139,NCT02065557,Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis,Ulcerative Colitis,Biological: Adalimumab|Biological: Placebo,AbbVie,Phase 3,101,Industry,"October 13, 2014","February 7, 2020","February 7, 2020"
9140,NCT02064049,Surveillance and Treatment of Prisoners With Hepatitis C,Hepatitis C,Drug: Sofosbuvir/velpatasvir,Kirby Institute,Phase 4,3692,Other,Oct-14,Nov-19,Nov-19
9141,NCT02064036,Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,Adenocarcinoma of the Prostate,Radiation: Stereotactic Radiosurgical Boost|Drug: Casodex|Drug: Leuprolide,"University of California, Davis",Phase 1,17,Other,"June 6, 2013","December 3, 2020","October 29, 2021"
9142,NCT02063529,FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: FOLFOXIRI + Cetuximab|Drug: FOLFOXIRI,Sun Yat-sen University,Phase 2,101,Other,Feb-14,Dec-19,Dec-19
9143,NCT02058901,"Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.",Solid Tumors,Drug: Sunitinib,"Amsterdam UMC, location VUmc",Phase 1,101,Other,Jul-13,Jun-19,Jun-19
9144,NCT02058706,LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer,Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer,Drug: enzalutamide|Drug: bicalutamide|Procedure: orchiectomy|Drug: leuprolide acetate|Drug: goserelin acetate|Other: laboratory biomarker analysis,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Phase 2,71,Other|NIH,May-14,"March 1, 2021","March 1, 2021"
9145,NCT02057718,Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis,Progressive Familial Intrahepatic Cholestasis (PFIC),Drug: LUM001 (Maralixibat),"Mirum Pharmaceuticals, Inc.",Phase 2,33,Industry,"March 1, 2014","May 8, 2020","May 8, 2020"
9146,NCT02055053,Effects of Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair,Post Operative Pain (Post Laparoscopic Hernia Repair),Drug: 0.5% Bupivicaine,Lahey Clinic,Phase 4,70,Other,Aug-13,"October 16, 2019","October 16, 2019"
9147,NCT02054806,Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28),Solid Tumor,Biological: Pembrolizumab,Merck Sharp & Dohme LLC,Phase 1,477,Industry,"February 17, 2014","April 30, 2021","April 30, 2021"
9148,NCT02053909,Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis,Saphenous Vein Graft Disease,Drug: Aspirin|Drug: Ticagrelor,Boca Raton Regional Hospital|AstraZeneca|Ottawa Heart Institute Research Corporation,Phase 4,250,Other|Industry,Sep-14,Aug-20,Aug-21
9149,NCT02052908,Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome,Lynch Syndrome,Other: Laboratory Biomarker Analysis|Drug: Naproxen|Other: Placebo Administration,National Cancer Institute (NCI),Phase 1,81,NIH,"January 27, 2014","October 25, 2019","January 5, 2021"
9150,NCT02051608,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,Alzheimer's Disease,Drug: Placebo|Drug: Gantenerumab,Hoffmann-La Roche,Phase 3,389,Industry,"March 27, 2014","April 16, 2021","April 16, 2021"
9151,NCT02051309,Guanfacine Clinical Trial for Smoking Cessation,Smoking Cessation,Drug: Guanfacine|Drug: Placebo,Yale University|National Institute on Drug Abuse (NIDA),Phase 2,121,Other|NIH,Mar-14,Nov-20,Nov-20
9152,NCT02049866,Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP,Adult Idiopathic Generalized Osteoporosis,Drug: Denosumab,Elizabeth Shane|Creighton University|Columbia University,Phase 2,33,Other,"November 19, 2014","March 31, 2020","December 23, 2021"
9153,NCT02049593,PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,Metastatic Cancer|Unspecified Adult Solid Tumor,Drug: PARP inhibitor BMN-673|Drug: temozolomide|Drug: irinotecan hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis,"Jonsson Comprehensive Cancer Center|Translational Research in Oncology|BioMarin Pharmaceutical|Medivation, Inc.",Phase 1,44,Other|Industry,"June 12, 2014","October 7, 2019","October 7, 2019"
9154,NCT02049515,A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: IPI-145|Drug: Ofatumumab,SecuraBio,Phase 3,99,Industry,Dec-13,"June 12, 2020","June 12, 2020"
9155,NCT02048917,Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies,Lung Cancer|Head and Neck Cancer,Drug: High Intensity Counseling + Long Acting NRT + PRN NRT|Drug: High Intensity Counseling + bupropion + PRN NRT|Drug: High Intensity Counseling + varenicline + PRN NRT|Drug: High Intensity Counseling + Long Acting NRT|Drug: High Intensity Counseling + bupropion|Drug: High Intensity Counseling + varenicline|Drug: Low Intensity Counseling + Long Acting NRT + PRN NRT|Drug: Low Intensity Counseling + bupropion + PRN NRT|Drug: Low Intensity Counseling + varenicline + PRN NRT|Drug: Low Intensity Counseling + Long Acting NRT|Drug: Low Intensity Counseling + bupropion|Drug: Low Intensity Counseling + varenicline,University of Kentucky|Kentucky Lung Cancer Research Program,Phase 1,93,Other,"July 22, 2014","May 15, 2019","May 15, 2019"
9156,NCT02048722,"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,Drug: regorafenib,Northwestern University|Bayer|National Cancer Institute (NCI),Phase 2,31,Other|Industry|NIH,"June 13, 2014","October 14, 2019","October 12, 2021"
9157,NCT02048007,Mortality Reduction After Oral Azithromycin: Morbidity Study,Childhood Mortality,Drug: Azithromycin|Drug: Placebo,"University of California, San Francisco|Bill and Melinda Gates Foundation|Johns Hopkins University|London School of Hygiene and Tropical Medicine",Phase 4,72000,Other,Nov-14,"August 27, 2020","August 27, 2020"
9158,NCT02047773,Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations,Bronchiectasis,Other: Duration|Drug: Colomycin|Drug: Meropenem,University of Edinburgh|NHS Lothian,Phase 4,90,Other,Jan-14,"February 1, 2020","February 1, 2020"
9159,NCT02047513,Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer,Resectable Pancreatic Cancer|Ductal Adenocarcinoma of the Pancreas,Drug: perioperative nab-paclitaxel/gemcitabine|Drug: adjuvant nab-paclitaxel/gemcitabine,AIO-Studien-gGmbH|Celgene|ClinAssess GmbH,Phase 2,127,Other|Industry,Jul-15,Apr-21,Oct-22
9160,NCT02047318,An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS),Alagille Syndrome,Drug: LUM001 (Maralixibat),"Mirum Pharmaceuticals, Inc.",Phase 2,19,Industry,"December 20, 2013","June 17, 2020","June 17, 2020"
9161,NCT02046460,Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD,Cervical Artery Dissection,Drug: Acetylsalicylic acid|Drug: Vitamin K antagonist,"Stefan Engelter|University Hospital, Basel, Switzerland",Phase 4,194,Other,Sep-13,Jun-19,Jun-19
9162,NCT02046434,Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain,Parkinson's Disease,Drug: Glycerol Phenylbutyrate,"University of Colorado, Denver",Phase 1,38,Other,Jan-14,Sep-19,Sep-19
9163,NCT02046395,Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus,Type 2 Diabetes|Hypertension,"Drug: amlodipine, hydralazine, terazosin or hydrochlorothiazide",Tulane University School of Medicine|Tulane University,Phase 4,33,Other,Jan-12,Dec-19,Dec-19
9164,NCT02046291,Safety of Romiplostim (Nplate®) Following UCBT,Hematologic Malignancies,Drug: Romiplostim,"Masonic Cancer Center, University of Minnesota",Phase 1,21,Other,"April 10, 2015","December 12, 2020","June 1, 2021"
9165,NCT02045602,Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors,Locally Advanced Solid Tumors|Metastatic Solid Tumors|Pancreatic Adenocarcinoma,Genetic: VCN-01|Drug: Gemcitabine|Drug: Abraxane®,Theriva Biologics SL,Phase 1,42,Industry,Jan-14,May-19,Jan-20
9166,NCT02044250,Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM),Coronary Heart Disease,Drug: Clopidogrel|Drug: Aspirin,"Seoul National University Hospital|Chong Kun Dang Pharmaceutical|Samjin Pharmaceutical Co., Ltd.|Daewoong Pharmaceutical Co. LTD.|Hanmi Pharmaceutical co., ltd.",Phase 4,5530,Other|Industry,Feb-14,Aug-20,Mar-21
9167,NCT02044120,"ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma",Ewing Sarcoma,Drug: niraparib|Drug: Temozolomide|Drug: Irinotecan,Sarcoma Alliance for Research through Collaboration,Phase 1,34,Other,May-14,Jan-21,Jan-21
9168,NCT02043665,CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200),Non-small Cell Lung Cancer|Bladder Cancer,Biological: CVA21/pembrolizumab,Viralytics|Merck Sharp & Dohme LLC,Phase 1,85,Industry,"December 18, 2013","January 10, 2020","January 10, 2020"
9169,NCT02043548,Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis,Dermatomyositis|Polymyositis,Drug: tocilizumab|Drug: placebo,"Chester Oddis|Genentech, Inc.|University of Pittsburgh",Phase 2,36,Other|Industry,"October 1, 2014","July 30, 2019","July 31, 2019"
9170,NCT02043288,Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer,Pancreatic Neoplasms,Drug: NC-6004|Drug: Gemcitabine,"Orient Europharma Co., Ltd.|NanoCarrier Co., Ltd.",Phase 3,310,Industry,Jan-14,Dec-19,Dec-19
9171,NCT02042989,MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,Advanced Cancers,Drug: MLN9708|Drug: Vorinostat,"M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.",Phase 1,68,Other|Industry,"June 27, 2014","January 22, 2020","January 22, 2020"
9172,NCT02042287,Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis,Bacterial Vaginosis,Device: Vaginal lactic acid and glycogen gel|Drug: Metronidazole,"University Hospital Inselspital, Berne|Tentan AG",Phase 4,32,Other,Jun-14,"March 19, 2020","March 19, 2020"
9173,NCT02041234,Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment,Type II Diabetes in Subjects BMI 27 to 32,Procedure: Roux-en-Y Gastric Bypass (RYGB)|Drug: Incretin analogues|Drug: Xenical|Drug: SGLT2 inhibitors|Drug: DPP-4 Inhibitors,Khoo Teck Puat Hospital,Phase 4,40,Other,Feb-14,Dec-20,Jun-22
9174,NCT02040142,"Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C",Peritoneal Carcinomatosis|Colorectal Cancer|Appendiceal Cancer|Peritoneal Mesothelioma|Pseudomyxoma Peritonei|Gastric Cancer,Procedure: HIPEC|Drug: Mitomycin C,Albert Einstein College of Medicine,Phase 2,51,Other,Nov-11,"October 31, 2020","November 9, 2020"
9175,NCT02036853,An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome,Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS),Drug: Triheptanoin,Adrian Lacy|Ultragenyx Pharmaceutical Inc|Cook Children's Health Care System,Phase 2,20,Other|Industry,"February 20, 2014","June 30, 2019","June 30, 2019"
9176,NCT02036489,Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia,Acute Lymphobkastic Leukemia,Drug: Vincristine|Drug: Daunorubicin|Drug: Prednisone|Drug: L-asparaginase|Drug: Ciclophosphamide|Drug: Metotrexate|Drug: ARA-C|Drug: Hidrocortisone|Drug: Mercaptopurine|Drug: VP-16|Drug: Dexametasone,PETHEMA Foundation,Phase 4,107,Other,Jan-08,"December 1, 2019","December 1, 2019"
9177,NCT02036060,Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.,Metastatic Prostate Cancer,Drug: docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Drug: docetaxel 75 mg/m2 + prednisone 10 mg/d,"Spanish Oncology Genito-Urinary Group|Janssen, LP|Apices Soluciones S.L.",Phase 2,119,Other|Industry,"February 7, 2014",Jun-20,Oct-20
9178,NCT02035137,131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat,Neuroblastoma,Radiation: 131I-MIBG|Drug: Vincristine|Drug: Irinotecan|Drug: Vorinostat,New Approaches to Neuroblastoma Therapy Consortium,Phase 2,114,Other,Jul-14,"February 26, 2021","February 26, 2021"
9179,NCT02034435,Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism,Metabolic Syndrome,Other: Low Salt diet plus Placebo tablet|Other: Low Sodium diet plus Salt tablet|Drug: Epleronone|Drug: Amlodipine,Vanderbilt University Medical Center,Phase 4,44,Other,Oct-13,Dec-19,Dec-19
9180,NCT02033629,Low Remifentanil Target Controlled Infusions for Cardiac Surgery,Cardiac Surgery,Drug: Ce 1 ng/ml|Drug: Ce 2 ng/ml|Drug: Ce 3 ng/ml,Imam Abdulrahman Bin Faisal University,Phase 3,75,Other,May-14,"May 1, 2019","May 15, 2019"
9181,NCT02032797,Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.,Cryopreservation|Embryo Implantation|Progesteron,Drug: Progesterone,Universitair Ziekenhuis Brussel,Phase 4,300,Other,Nov-12,Sep-19,Sep-19
9182,NCT02032004,Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.,Chronic Heart Failure,Biological: Allogeneic Mesenchymal Precursor Cells (MPCs)|Other: Sham Comparator,"Mesoblast, Inc.|Mesoblast, Ltd.",Phase 3,566,Industry,"February 14, 2014","May 29, 2020","May 29, 2020"
9183,NCT02030834,Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas,"Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas",Biological: CART-19,University of Pennsylvania,Phase 2,63,Other,"February 5, 2014","September 16, 2019","September 1, 2020"
9184,NCT02029950,Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia-2|High Risk Myelodysplastic Syndrome|Myeloproliferative Neoplasm,Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Etoposide|Drug: Idarubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Pomalidomide,National Cancer Institute (NCI),Phase 1,50,NIH,"December 16, 2013","May 13, 2020","May 13, 2020"
9185,NCT02028806,mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer,Drug: mFOLFIRINOX,Yuhong Li|Sun Yat-sen University,Phase 2,40,Other,Feb-13,Dec-20,Dec-20
9186,NCT02028117,Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients,Recurrent Platinum Resistant Ovarian Cancer,Biological: Enadenotucirev,Akamis Bio,Phase 1,38,Industry,Jun-14,"November 19, 2019","November 19, 2019"
9187,NCT02026271,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma,Glioblastoma Multiforme|Anaplastic Oligoastrocytoma,Biological: Ad-RTS-hIL-12|Drug: veledimex,Alaunos Therapeutics,Phase 1,40,Industry,Jun-15,Aug-19,Aug-19
9188,NCT02023593,FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma,Advanced Esophageal Carcinoma,Drug: FOLFIRI,Yuhong Li|Sun Yat-sen University,Phase 2,35,Other,Mar-12,Dec-19,Dec-22
9189,NCT02022917,Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer,Epithelial Ovarian Cancer,Drug: Bevacizumab,Chang Gung Memorial Hospital|Hoffmann-La Roche|Asian Gynecologic Oncology Group|Taiwanese Gynecolgic Oncology Group,Phase 2,22,Other|Industry,Mar-14,Jan-21,Jan-21
9190,NCT02022592,Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care,Sedation in Intensive Care Unit Patients,Drug: Lormetazepam|Drug: Midazolam,"Claudia Spies|Charite University, Berlin, Germany",Phase 4,84,Other,"July 17, 2014","December 12, 2019","March 12, 2020"
9191,NCT02022033,BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial,Pancreatic Cancer,Drug: FOLFOXA,Brown University,Phase 2,25,Other,"February 1, 2014","July 23, 2019","March 17, 2022"
9192,NCT02019940,A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD),PTSD,Drug: Riluzole,Yale University|National Center for PTSD,Phase 1,18,Other|U.S. Fed,Jan-14,Jan-20,Jan-20
9193,NCT02019576,Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib,Clear Cell Metastatic Renal Cell Carcinoma,Radiation: Stereotactic radiotherapy,Sunnybrook Health Sciences Centre|Pfizer,Phase 2,38,Other|Industry,May-14,"February 16, 2021","March 4, 2021"
9194,NCT02018055,TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI,Acute Myocardial Infarction,Drug: Aspirin+Ticagrelor|Drug: Aspirin+Clopidogrel,The Catholic University of Korea|Chonnam National University Hospital,Phase 4,2590,Other,"February 14, 2014","January 21, 2021","January 21, 2021"
9195,NCT02017561,Metformin in the Diastolic Dysfunction of Metabolic Syndrome,Metabolic Syndrome X|Diastolic Dysfunction|Insulin Resistance,Behavioral: Lifestyle Counseling|Drug: Metformin,Universidade do Porto|Centro Hospitalar de Vila Nova de Gaia/Espinho|Merck Serono International SA,Phase 2,54,Other|Industry,Jan-14,Dec-19,Dec-19
9196,NCT02017457,Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Biological: Donor lymphocyte infusion|Drug: Azacytidine,"Carlos Graux, MD, PhD|Celgene Corporation|Belgian Hematological Society|University Hospital of Mont-Godinne",Phase 2,50,Other|Industry,Dec-13,Nov-19,Nov-19
9197,NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,Diabetic Nephropathies|Coronary Artery Disease,Drug: Allopurinol|Drug: Placebo,"Alessandro Doria|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|Joslin Diabetes Center|University of Minnesota|University of Colorado, Denver|University of Michigan|University of Toronto|Northwestern University Feinberg School of Medicine|Albert Einstein College of Medicine|Steno Diabetes Center Copenhagen|Washington University School of Medicine|University of Washington|Emory University|University of Calgary|University of Alberta|University of Texas Southwestern Medical Center|BCDiabetes.Ca",Phase 3,530,Other|NIH,Feb-14,"July 15, 2019","August 31, 2019"
9198,NCT02014883,Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS,Glut1 Deficiency Syndrome,Drug: GLUT1 DS,"Institut National de la Santé Et de la Recherche Médicale, France|Ultragenyx Pharmaceutical Inc",Phase 2,20,Other|Industry,"December 4, 2013","July 4, 2019","July 4, 2019"
9199,NCT02014623,Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis,Allergic Rhinitis,Other: Grass pollen sublingual immunotherapy tablet|Drug: Control,Bayside Health,Phase 4,51,Other,Feb-14,"November 15, 2019",
9200,NCT02013219,A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer,Drug: Alectinib|Drug: Atezolizumab|Drug: Erlotinib,Hoffmann-La Roche,Phase 1,52,Industry,"April 3, 2014","February 5, 2020","February 5, 2020"
9201,NCT02013154,A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab,Esophageal Neoplasms|Adenocarcinoma of the Gastroesophageal Junction|Gastroesophageal Cancer|Squamous Cell Carcinoma|Gastric Adenocarcinoma,Drug: DKN-01|Drug: Paclitaxel|Drug: Pembrolizumab,"Leap Therapeutics, Inc.|Merck Sharp & Dohme LLC",Phase 1,151,Industry,"May 5, 2014","July 19, 2019","January 11, 2021"
9202,NCT02013037,The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation,Antibody-mediated Rejection|Hyperacute Rejection of Cardiac Transplant|Left Ventricular Dysfunction|Cardiac Allograft Vasculopathy|Heart Graft Dysfunction,Drug: Eculizumab,Cedars-Sinai Medical Center|Alexion,Phase 3,36,Other|Industry,Nov-12,"December 30, 2019","April 30, 2020"
9203,NCT02009462,Artefill for the Treatment of HIV-associated Facial Lipoatrophy,HIV-facial Lipoatrophy,Drug: Artefill dermal filler,"Gerald Pierone, Jr. M.D.|Suneva Medical, Inc.|AIDS Research and Treatment Center of the Treasure Coast",Phase 1,31,Other|Industry,Dec-13,Nov-19,Nov-19
9204,NCT02006485,Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies,Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma,Drug: Ublituximab + TGR-1202|Drug: Ublituximab + TGR-1202 + ibrutinib|Drug: Ublituximab + TGR-1202 + bendamustine,"TG Therapeutics, Inc.",Phase 1,160,Industry,"December 13, 2013",Oct-19,Oct-19
9205,NCT02002819,Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability,Alzheimer's Disease,Drug: levetiracetam,University of Minnesota,Phase 2,34,Other,"October 16, 2014","July 21, 2020","July 21, 2020"
9206,NCT02001272,EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer,Ovarian Cancer,Drug: Paclitaxel + Carboplatin every 3 weeks|Drug: Carboplatin monotherapy every 3 weeks|Drug: Weekly Paclitaxel and Carboplatin,Hospices Civils de Lyon,Phase 2,120,Other,Dec-13,Feb-20,Feb-20
9207,NCT02000947,A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,NSCLC|Non-small Cell Lung Cancer|Lung Cancer,Drug: MEDI4736|Drug: Tremelimumab|Drug: tremelimumab,MedImmune LLC,Phase 1,459,Industry,"October 25, 2013","September 17, 2019","September 17, 2019"
9208,NCT02000219,Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis,Primary Hyperoxaluria,Biological: Oxalobacter formigenes,OxThera|FP7-SME-2013 Research for the benefit of SMEs program,Phase 2,12,Industry|Other,"May 19, 2014","January 29, 2020","January 29, 2020"
9209,NCT01999946,Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry,Heroin Dependence|Opioid-Related Disorders,Drug: Extended-Release Naltrexone,"NYU Langone Health|National Institute on Drug Abuse (NIDA)|Friends Research Institute, Inc.|University of California, Los Angeles",Phase 4,217,Other|NIH,"June 27, 2014","May 28, 2019","December 24, 2020"
9210,NCT01999309,Simvastatin Addition for Patients With Recent-onset Schizophrenia,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychosis NOS,Drug: Simvastatin|Drug: Placebo,Iris Sommer|Stanley Medical Research Institute|UMC Utrecht,Phase 3,121,Other,Oct-13,"December 19, 2019","December 19, 2019"
9211,NCT01997515,"Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study",Pain|Obesity|Hypoxia,Drug: Ketamine|Drug: placebo,Northwestern University,Phase 4,80,Other,Nov-13,"July 26, 2019","August 22, 2019"
9212,NCT01997112,PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study,Blood Pressure,Drug: Paracetamol|Drug: Placebo oral capsule,"University of Edinburgh|British Heart Foundation|National Health Service, United Kingdom",Phase 4,100,Other,Jan-14,"June 4, 2019",Oct-19
9213,NCT01996449,The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension,Hypertension,Drug: Eplerenone|Drug: Amlodipine|Procedure: Microneurography|Procedure: Rhythmic handgrip exercise|Procedure: Sustained hand grip|Procedure: Forearm blood flow|Procedure: Arm cycling exercise|Procedure: Cold Pressor test,University of Texas Southwestern Medical Center,Phase 2,14,Other,Jul-13,Apr-21,Apr-21
9214,NCT01994265,Cognitive Impairment Related to Atrial Fibrillation Prevention Trial,Atrial Fibrillation,Drug: Warfarin|Drug: Dabigatran,University of Sao Paulo|Federal University of Minas Gerais|Boehringer Ingelheim,Phase 4,200,Other|Industry,"November 7, 2014","March 9, 2021","March 9, 2021"
9215,NCT01991457,Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia,Adult Lymphoblastic Lymphoma,Drug: Fludarabine|Procedure: Total Body Irradiation,University of Alabama at Birmingham,Phase 2,19,Other,"August 27, 2013","January 30, 2020","August 23, 2022"
9216,NCT01989598,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Trametinib|Drug: Uprosertib,National Cancer Institute (NCI),Phase 2,25,NIH,"October 30, 2013","August 31, 2019","September 28, 2020"
9217,NCT01988896,Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors,Solid Tumors,Drug: Atezolizumab|Drug: Cobimetinib,Hoffmann-La Roche,Phase 1,153,Industry,"December 27, 2013","November 4, 2019","November 4, 2019"
9218,NCT01988571,Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT),Breast Cancer|Lymphoma,Drug: Atorvastatin|Drug: Placebo,"Wake Forest University Health Sciences|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,279,Other|NIH,"February 1, 2014","September 24, 2020","September 24, 2020"
9219,NCT01988506,Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases,Rheumatoid Arthritis|Ankylosing Spondylitis|Systemic Lupus Erythematosus|Psoriasis|Behcet's Disease|Wegener's Granulomatosis|Takayasu's Disease|Crohn's Disease|Ulcerative Colitis|Autoimmune Hepatitis|Sclerosing Cholangitis|Gougerot-sjögren|Idiopathic Thrombocytopenic Purpura|Systemic Sclerosis,Drug: Interleukin 2,Assistance Publique - Hôpitaux de Paris|Iltoo Pharma,Phase 2,81,Other|Industry,"January 6, 2014","October 16, 2019","April 1, 2021"
9220,NCT01986881,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",Type 2 Diabetes Mellitus,Drug: Ertugliflozin|Drug: Placebo|Drug: Glycemic Rescue,Merck Sharp & Dohme LLC|Pfizer,Phase 3,8246,Industry,"November 4, 2013","December 27, 2019","December 27, 2019"
9221,NCT01985360,ISCHEMIA-Chronic Kidney Disease Trial,Cardiovascular Diseases|Coronary Artery Disease|Heart Diseases|Myocardial Ischemia|Kidney Disease|End Stage Renal Failure on Dialysis,Procedure: Cardiac Catheterization|Procedure: Coronary Artery Bypass Graft Surgery|Procedure: Percutaneous Coronary Intervention|Behavioral: Lifestyle|Drug: Medication,"NYU Langone Health|New York University|National Heart, Lung, and Blood Institute (NHLBI)|Duke University|Stanford University|Columbia University",Phase 4,777,Other|NIH,Jan-14,Jun-19,Jul-20
9222,NCT01984827,Effect of Glucose on QTc Interval in Type 1 Diabetes,Diabetes,Drug: Moxifloxacin|Other: hyper-glycaemic clamp,Richmond Research Institute|Richmond Pharmacology Limited,Phase 1,24,Industry,"February 10, 2019","December 31, 2020","December 31, 2020"
9223,NCT01984073,Effects of Niacin On Fatty Acid Trapping,Dyslipidemia,Drug: ER Niacin Oral Fat Challenge|Drug: IR Niacin Oral Fat Challenge|Other: Placebo Oral Fat Challenge,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Arizona Pharmaceuticals Inc.",Phase 1,26,Other|NIH|Industry,Dec-12,Dec-19,Dec-19
9224,NCT01981850,A Phase 2 Study of RO7490677 In Participants With Myelofibrosis,Primary Myelofibrosis|Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis,Biological: RO7490677|Drug: Ruxolitinib,Hoffmann-La Roche,Phase 2,125,Industry,"October 1, 2013","July 10, 2020","July 10, 2020"
9225,NCT01981330,Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring,Improved Healing of Scarred Vocal Folds|Improved Vocal Fold Status|Improved Vocal Fold Function,Biological: aMSC|Biological: aMSC+hyaluronan gel,Karolinska University Hospital|The Swedish Research Council|Laryngfonden|Karolinska Institutet,Phase 1,16,Other,Jan-12,"February 24, 2020","February 24, 2020"
9226,NCT01980680,The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients,Infertility,Drug: hCG|Drug: Progesterone and Estradiol,"Peter Humaidan|Regionshospitalet Viborg, Skive",Phase 4,50,Other,Dec-14,Sep-19,May-20
9227,NCT01977638,Phase 1 Trial of CXD101 in Patients With Advanced Cancer,Advanced Cancer,Drug: CXD101,"Oxford University Hospitals NHS Trust|University of Oxford|National Institute for Health Research, United Kingdom|Cancer Research UK",Phase 1,51,Other,"February 14, 2014","October 8, 2019","October 14, 2022"
9228,NCT01976364,Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis,"Arthritis, Psoriatic",Drug: Tofacitinib|Drug: Methotrexate|Drug: Placebo Methotrexate,Pfizer,Phase 3,686,Industry,"February 17, 2014","May 20, 2019","May 20, 2019"
9229,NCT01975831,A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,Breast Cancer|Ovarian Cancer|Colorectal Cancer|Cervical Cancer|Renal Cell Carcinoma,Drug: Durvalumab|Drug: Tremelimumab,"Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City",Phase 1,104,Other|Industry,"December 19, 2013",Dec-19,"July 2, 2021"
9230,NCT01975480,Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities,Generalized Anxiety Disorder,Drug: Desvenlafaxine,START Clinic for Mood and Anxiety Disorders,Phase 4,29,Other,Jan-13,"April 15, 2020","May 1, 2020"
9231,NCT01973543,Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease,Parkinson's Disease,Biological: VY-AADC01,"Neurocrine Biosciences|University of California, San Francisco|Veristat, Inc.|Feinstein Institute for Medical Research|Oregon Health and Science University|Voyager Therapeutics",Phase 1,15,Industry|Other,Oct-13,"January 24, 2020","January 24, 2020"
9232,NCT01973283,Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults,"Major Depressive Disorder|Dysthymic Disorder|Depressive Disorder, NOS",Drug: Antidepressant Medication,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),Phase 4,100,Other|NIH,"February 19, 2014","December 5, 2019","December 5, 2020"
9233,NCT01972035,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,Transplantation Infection|Epstein-Barr Virus Infections|Cytomegalovirus Infections,Drug: Valacyclovir|Drug: Valganciclovir,University of Minnesota,Phase 2,137,Other,"August 1, 2014","February 28, 2021","February 28, 2021"
9234,NCT01970410,MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV,Multiple Sclerosis,Drug: teriflunomide,Providence Health & Services|Multiple Sclerosis Center of Northeastern New York,Phase 4,55,Other,Oct-13,"April 30, 2021","February 14, 2022"
9235,NCT01969695,An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Drug: ABT-199,"AbbVie|Genentech, Inc.",Phase 1,11,Industry,"December 20, 2013","December 16, 2019","December 16, 2019"
9236,NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,Melanoma|Meningioma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer,Biological: Anti-NY ESO-1 mTCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,11,NIH,"October 24, 2013","April 6, 2020","April 6, 2020"
9237,NCT01967329,CANHelp Working Group Treatment Trials,Helicobacter Pylori Infection,Drug: Standard Triple|Drug: Sequential|Drug: Quadruple,University of Alberta|Alberta Innovates Health Solutions|ArcticNet|Canadian Institutes of Health Research (CIHR),Phase 4,338,Other,Nov-08,May-19,May-19
9238,NCT01966666,"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease",Alzheimer's Disease,Drug: TPI-287 2 mg/m2|Drug: TPI-287 6.3 mg/m2|Drug: TPI-287 20 mg/m2|Drug: Placebo,"University of California, San Francisco",Phase 1,29,Other,Nov-13,Sep-19,Sep-19
9239,NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,Breast Cancer,Drug: Trastuzumab Emtansine|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Paclitaxel|Drug: Epirubicin|Drug: Doxorubicin|Drug: Docetaxel|Drug: Cyclophosphamide|Drug: 5-Fluorouracil,Hoffmann-La Roche,Phase 3,1846,Industry,"January 31, 2014","November 27, 2019","June 4, 2021"
9240,NCT01966302,Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH),Pulmonary Arterial Hypertension,Drug: BPS-314d-MR,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Lung Biotechnology PBC,Phase 2,1,Other|Industry,Nov-13,"June 2, 2019","June 2, 2019"
9241,NCT01966289,SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),Metastatic Colorectal Cancer,Drug: CY|Biological: GVAX|Drug: SGI-110,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Therapeutics, Ltd|Susan Cohan Colon Cancer Foundation",Phase 1,18,Other,"April 14, 2014","June 6, 2020","June 6, 2020"
9242,NCT01965704,Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women,Narcotic Addiction|Neonatal Abstinence Syndrome,Drug: Ondansetron|Drug: Placebo,Stanford University|Santa Clara Valley Medical Center|Thomas Jefferson University,Phase 2,196,Other,"September 9, 2014","September 3, 2020","September 16, 2020"
9243,NCT01963182,Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer,First Line Metastatic Colorectal Cancer,Drug: Irinotecan,Centre Jean Perrin,Phase 2,47,Other,Oct-13,Dec-19,"December 9, 2019"
9244,NCT01963052,ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer,Metastatic Urothelial Cancer,Drug: AGS15E,"Astellas Pharma Global Development, Inc.|Seagen Inc.|Astellas Pharma Inc",Phase 1,93,Industry,"November 14, 2013","July 8, 2019","July 8, 2019"
9245,NCT01959204,Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects,Pain,Drug: Oxycodone,"VistaPharm, Inc.",Phase 4,97,Industry,"October 14, 2013","August 21, 2019","August 21, 2019"
9246,NCT01956669,Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,Solid Tumours,Drug: Pazopanib,Novartis Pharmaceuticals|Children's Oncology Group|Novartis,Phase 2,57,Industry|Other,"October 8, 2014","November 5, 2019","November 5, 2019"
9247,NCT01955187,Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy,MEMBRANOUS NEPHROPATHY,Drug: TACROLIMUS|Drug: RITUXIMAB|Drug: METHYLPREDNISOLONE|Drug: CYCLOPHOSPHAMIDE,"Hospital Universitario 12 de Octubre|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Universitario Fundación Alcorcón|Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre|Biobanco REDinREN|ERA-EDTA|REDinREN|Spanish Society of Nephrology|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|University Hospital, Aachen",Phase 3,86,Other,Jan-14,"June 26, 2019","June 26, 2019"
9248,NCT01953692,A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013),Myelodysplastic Syndrome|Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Primary Mediastinal B-Cell Lymphoma,Biological: Pembrolizumab|Drug: Lenalidomide 20 mg|Drug: Lenalidomide 25 mg,Merck Sharp & Dohme LLC,Phase 1,197,Industry,"November 22, 2013","June 26, 2020","June 26, 2020"
9249,NCT01953120,Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309),Renal Transplant Rejection,Drug: Belatacept,"University of California, Los Angeles|Bristol-Myers Squibb",Phase 4,20,Other|Industry,Oct-13,Apr-21,"April 21, 2021"
9250,NCT01951885,"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention",Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Biphenotypic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Hodgkins Disease|Chronic Lymphocytic Leukemia|Multiple Myeloma,Drug: tacrolimus|Drug: methotrexate|Drug: Mycophenolate mofetil|Drug: Methotrexate (low dose),Case Comprehensive Cancer Center,Phase 3,101,Other,"July 7, 2014","October 9, 2020","August 11, 2021"
9251,NCT01951118,Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly,"Alzheimer Disease|Mild Cognitive Impairment|Delirium, Dementia, Amnestic, Cognitive Disorders",Drug: Donepezil,New York State Psychiatric Institute|National Institutes of Health (NIH)|National Institute on Aging (NIA),Phase 4,121,Other|NIH,Oct-13,May-19,May-19
9252,NCT01950689,NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab),Head and Neck Squamous Cell Carcinoma,Drug: Nimorazole|Radiation: Radiotherapy,The Christie NHS Foundation Trust,Phase 3,338,Other,"September 11, 2014","January 7, 2021","January 7, 2021"
9253,NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,Breast Cancer,Drug: Endocrine therapy combined with trastuzumab|Drug: Chemotherapy combined with trastuzumab,Sun Yat-sen University,Phase 3,392,Other,"September 16, 2013","May 31, 2020","May 31, 2020"
9254,NCT01945567,Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor,Parkinson's Disease|Tremor,"Device: Up to 3 mA, 60 us, 130 Hz deep brain stimulation|Device: Empirical unblinded deep brain stimulation programming",The University of Western Australia,Phase 2,39,Other,Aug-12,"August 30, 2019","August 30, 2020"
9255,NCT01944852,Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.,Renal Insufficiency,Drug: Icodextrin,Pr Eric Goffin|Université Catholique de Louvain,Phase 4,117,Other,Mar-13,"February 28, 2020","February 28, 2020"
9256,NCT01944800,"Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome",Acute Coronary Syndrome (ACS),Drug: Ticagrelor|Drug: Prasugrel,Deutsches Herzzentrum Muenchen|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK),Phase 4,4018,Other,"September 15, 2013",Jul-19,Sep-21
9257,NCT01943851,"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",Neoplasms,Drug: GSK525762,GlaxoSmithKline,Phase 2,111,Industry,"May 14, 2014","April 30, 2020","April 30, 2020"
9258,NCT01943409,Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils,Obstruction|Cancer|Ileus|Malnutrition|Surgery,Drug: Intralipid|Drug: ClinOleic,"Johane Allard|University Health Network, Toronto",Phase 4,303,Other,Jul-13,Dec-19,Dec-19
9259,NCT01941589,Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis,Ulcerative Colitis,Drug: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|Drug: corticosteroids only,Sheba Medical Center,Phase 4,149,Other,Sep-13,Apr-21,Apr-21
9260,NCT01940276,Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,Prostate Cancer,Drug: Abiraterone acetate|Drug: Prednisone,Duke University,Phase 2,100,Other,Oct-13,"October 8, 2019","October 8, 2019"
9261,NCT01939158,"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","Infections, Meningococcal",Biological: Meningococcal vaccine GSK134612|Biological: Prevenar 13™,Pfizer,Phase 3,803,Industry,"October 2, 2013","December 5, 2019","December 5, 2019"
9262,NCT01938729,Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma,Intrahepatic Cholangiocarcinoma|Peripheral Cholangiocarcinoma|Cholangiolar Carcinoma|Cholangiocellular Carcinoma) (ICC),Procedure: Liver resection and placement of hepatic artery infusion pump|Drug: FLOXURIDINE|Drug: DEXAMETHASONE|Drug: GEMCITABINE,Memorial Sloan Kettering Cancer Center|Ohio State University|University of Texas Southwestern Medical Center|Washington University School of Medicine,Phase 1,8,Other,"September 5, 2013","September 10, 2020","September 10, 2020"
9263,NCT01935700,Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma,Hepatocellular Carcinoma|Metastasis|Invasion,Drug: Colchicine,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 2,15,Other,"June 6, 2013","May 31, 2019","May 31, 2019"
9264,NCT01935128,Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction,Renal Transplant,Drug: Arm 1 Everolimus/Reduced dose tacrolimus,University of Toledo Health Science Campus|Novartis Pharmaceuticals|University of Toledo,Phase 4,55,Other|Industry,"July 3, 2013",Jul-20,Jul-20
9265,NCT01931098,Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab,Glioblastoma|Glioblastoma Multiforme|Gliosarcoma|Brain Neoplasms|Central Nervous System Neoplasms,Drug: topotecan|Drug: pazopanib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,35,NIH,"December 10, 2015","September 12, 2019","September 12, 2019"
9266,NCT01928199,Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant,Posttransplant Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo,Washington University School of Medicine|Merck Sharp & Dohme LLC,Phase 4,61,Other|Industry,Sep-13,Jun-20,Oct-20
9267,NCT01927315,Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes,Diabetes|Diabetic Retinopathy,Drug: Fenofibrate 145 mg|Drug: Placebo,University of Padova|Azienda Ospedaliera di Padova,Phase 4,41,Other,Aug-13,Oct-19,Dec-19
9268,NCT01926496,"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%",Actinic Keratosis (AK),"Drug: Ingenol Mebutate Gel, 0.015%|Drug: Imiquimod Cream, 5%",LEO Pharma,Phase 4,485,Industry,"September 11, 2013","July 11, 2019","July 11, 2019"
9269,NCT01923766,Cytotoxic T Cells to Prevent Virus Infections,CMV|EBV|Adenovirus Infections,Drug: Cytotoxic T lymphocytes (CTLs).,Children's National Research Institute|M.D. Anderson Cancer Center,Phase 1,10,Other,Sep-13,"March 25, 2020","March 25, 2020"
9270,NCT01922076,Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,"Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant|Glioblastoma|Gliosarcoma",Drug: Adavosertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Radiation Therapy,National Cancer Institute (NCI),Phase 1,46,NIH,"September 3, 2013","December 31, 2020","September 30, 2022"
9271,NCT01921803,Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer,Prostate Cancer,Radiation: hypofractionation,"University Hospital, Ghent",Phase 2,346,Other,"August 1, 2013","July 14, 2020","July 14, 2020"
9272,NCT01921218,Belatacept Therapy for the Failing Renal Allograft,Failing Renal Allograft,Drug: Belatacept|Drug: Calcineurin inhibitor therapy|Drug: Mycophenolate mofetil|Drug: prednisone,Andrew B Adams|Bristol-Myers Squibb|Emory University,Phase 3,13,Other|Industry,Aug-13,"December 12, 2019","December 12, 2019"
9273,NCT01920711,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",Heart Failure With Preserved Ejection Fraction,Drug: LCZ696|Drug: Valsartan,Novartis Pharmaceuticals|Novartis,Phase 3,4822,Industry,"July 18, 2014","June 7, 2019","June 7, 2019"
9274,NCT01920061,A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC),Neoplasm,Drug: PF-05212384 (gedatolisib)|Drug: Docetaxel|Drug: Cisplatin|Drug: Dacomitinib,Pfizer,Phase 1,110,Industry,"September 10, 2013","January 8, 2020","January 8, 2020"
9275,NCT01919489,Liraglutide Hospital Discharge Trial,Type 2 Diabetes,Drug: Liraglutide + OADs|Drug: Glargine + OADs,Emory University|Novo Nordisk A/S,Phase 4,273,Other|Industry,Mar-14,"August 30, 2020","August 30, 2020"
9276,NCT01918644,Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer,Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer,Radiation: stereotactic body radiation therapy|Drug: capecitabine|Procedure: therapeutic conventional surgery|Procedure: magnetic resonance imaging|Other: laboratory biomarker analysis,"University of Wisconsin, Madison",Phase 1,21,Other,"April 8, 2014","December 4, 2019","April 26, 2022"
9277,NCT01917708,Bone Marrow Transplant With Abatacept for Non-Malignant Diseases,Hurler Syndrome|Fanconi Anemia|Glanzmann Thrombasthenia|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Severe Congenital Neutropenia|Leukocyte Adhesion Deficiency|Shwachman-Diamond Syndrome|Diamond-Blackfan Anemia|Dyskeratosis-congenita|Chediak-Higashi Syndrome|Severe Aplastic Anemia|Thalassemia Major|Hemophagocytic Lymphohistiocytosis|Sickle Cell Disease,Drug: Abatacept,Emory University,Phase 1,10,Other,Jan-14,"September 19, 2019","September 19, 2019"
9278,NCT01916135,"PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative",Carcinoma|Sarcoma|Myeloma|Lymphoma|Melanoma,Radiation: [18F]-SKI-249380|Procedure: PET/CT scan|Other: Blood draws,Memorial Sloan Kettering Cancer Center,Phase 1,11,Other,Jul-13,"April 23, 2020","April 23, 2020"
9279,NCT01915927,Stem Cell Fistula Plug in Perianal Crohn's Disease,Perianal Crohn's Disease,Drug: MSC-AFP,"William A. Faubion, M.D.|Mayo Clinic",Phase 1,20,Other,Jul-13,Dec-19,Dec-19
9280,NCT01913652,Ph II Cabazitaxel DD Liposarcoma,Dedifferentiated Liposarcoma,Drug: Cabazitaxel,European Organisation for Research and Treatment of Cancer - EORTC|Sanofi,Phase 2,42,Other|Industry,Oct-14,Dec-20,Dec-20
9281,NCT01913639,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,Esophageal Cancer|Gastric Cancer,Drug: Regorafenib|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin,Memorial Sloan Kettering Cancer Center|Bayer,Phase 2,39,Other|Industry,Jul-13,Jun-19,Jun-19
9282,NCT01912612,Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain,Pain,Drug: Duloxetine,"University of Michigan Rogel Cancer Center|American Cancer Society, Inc.",Phase 2,82,Other,"October 30, 2013","June 28, 2019","June 28, 2019"
9283,NCT01912534,Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM,Hypertrophic Cardiomyopathy,Drug: Valsartan|Drug: Placebo,"HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,211,Other|NIH,Mar-14,Jul-19,Jul-19
9284,NCT01911507,INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer,Drug: INC280|Drug: erlotinib hydrochloride,"University of California, Davis|Novartis Pharmaceuticals|National Cancer Institute (NCI)",Phase 1,35,Other|Industry|NIH,"August 27, 2013","August 26, 2020","August 26, 2020"
9285,NCT01908101,Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer,Recurrent Breast Carcinoma|Stage IV Breast Cancer,Drug: Eribulin Mesylate|Other: Laboratory Biomarker Analysis,University of Washington|National Cancer Institute (NCI),Phase 2,86,Other|NIH,"January 8, 2014","May 4, 2019","May 4, 2019"
9286,NCT01906944,Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain,Abdominal Pain,Drug: Bupivacaine 0.25%|Drug: Triamcinolone,Mayo Clinic,Phase 2,62,Other,Jan-12,"August 18, 2019","August 18, 2019"
9287,NCT01905228,A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm,Solid Tumors|Glioblastoma,Drug: CBL0137,Incuron,Phase 1,83,Industry,Jul-13,May-19,Jun-19
9288,NCT01905150,"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer",Pancreatic Cancer,Drug: G-FLIP|Drug: G-FLIP-DM|Dietary Supplement: Vitamin C,Bruckner Oncology,Phase 2,34,Other,Jul-14,Jan-20,Jan-20
9289,NCT01904903,Cardiac Safety Study in Patients With HER2 + Breast Cancer,HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Ado Trastuzumab Emtansine,"Medstar Health Research Institute|Genentech, Inc.",Phase 2,31,Other|Industry,Oct-13,Jun-19,Jun-20
9290,NCT01904682,Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs,Myelodysplastic Syndromes,Drug: Oral rigosertib,"Onconova Therapeutics, Inc.",Phase 2,45,Industry,Jul-13,Dec-20,May-21
9291,NCT01900743,Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma,Sarcoma,Drug: Regorafenib|Drug: Placebo,Centre Oscar Lambret|Bayer,Phase 2,219,Other|Industry,"June 5, 2013","September 16, 2020","September 16, 2020"
9292,NCT01900002,Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Recurrent Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma,Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Sorafenib|Drug: Sorafenib Tosylate|Radiation: Yttrium Y 90 Glass Microspheres,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,40,Other|NIH,"September 13, 2013","December 10, 2020","December 10, 2020"
9293,NCT01898923,Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers,Diabetic Foot,Drug: ON101 Cream|Other: Aquacel® Hydrofiber® dressing,"Oneness Biotech Co., Ltd.",Phase 3,236,Industry,"November 23, 2012","May 11, 2020","May 11, 2020"
9294,NCT01898585,An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma,Malignant Melanoma,Drug: Zelboraf,Hoffmann-La Roche,Phase 4,60,Industry,"October 17, 2013","May 22, 2019","May 22, 2019"
9295,NCT01896869,FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer,Metastatic Pancreatic Adenocarcinoma,Drug: Ipilimumab|Biological: Vaccine|Drug: FOLFIRINOX,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 2,83,Other,Nov-13,"May 3, 2019","May 3, 2019"
9296,NCT01896271,High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer,Metastatic Clear Cell Renal Cell Carcinoma,Drug: IL-2|Radiation: Stereotactic Ablative Body Radiation Therapy,University of Texas Southwestern Medical Center|Prometheus Laboratories,Phase 2,30,Other|Industry,"October 2, 2013","August 25, 2020","April 20, 2021"
9297,NCT01895777,Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE),Venous Thromboembolism,Drug: dabigatran etexilate|Drug: standard of care,Boehringer Ingelheim,Phase 3,267,Industry,"September 25, 2013","October 16, 2019","November 14, 2019"
9298,NCT01894061,NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor,Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment,Case Comprehensive Cancer Center|NovoCure Ltd.|National Cancer Institute (NCI),Phase 2,25,Other|Industry|NIH,"June 12, 2013","July 28, 2019","July 28, 2019"
9299,NCT01893775,Antibody Treatment for Advanced Celiac Disease,Celiac Disease|Celiac Sprue|Gluten Enteropathy|Gluten-Sensitive Enteropathy,Biological: Hu-Mik- Beta-1,National Cancer Institute (NCI)|Mayo Clinic|National Institutes of Health Clinical Center (CC),Phase 1,5,NIH|Other,"June 12, 2013","December 20, 2019","December 20, 2019"
9300,NCT01893138,Autologous Muscle Derived Cells for Female Urinary Sphincter Repair,Stress Urinary Incontinence,Other: Placebo|Biological: Iltamiocel,Cook MyoSite,Phase 3,311,Industry,"November 21, 2013","November 1, 2019","November 10, 2020"
9301,NCT01891344,"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Oral rucaparib,"Clovis Oncology, Inc.|Foundation Medicine|Myriad Genetics, Inc.",Phase 2,491,Industry,"October 30, 2013","November 5, 2019","September 28, 2021"
9302,NCT01889186,A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion,Chronic Lymphocytic Leukemia|17p Deletion|Cancer of the Blood and Bone Marrow,Drug: ABT-199 (Main Cohort)|Drug: ABT-199 (Safety Expansion Cohort),"AbbVie|Genentech, Inc.",Phase 2,158,Industry,"June 27, 2013","October 28, 2020","December 15, 2020"
9303,NCT01889069,"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)",Lymphoma,Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone|Drug: Bendamustine,Hoffmann-La Roche,Phase 3,159,Industry,"July 31, 2013","May 28, 2019","May 28, 2019"
9304,NCT01888484,Study of Octanorm Subcutaneous IG in Patients With PID,Primary Immune Deficiency Disorder,Biological: octanorm 16.5%,Octapharma,Phase 3,75,Industry,Mar-14,"June 9, 2020","June 9, 2020"
9305,NCT01886859,Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Lenalidomide,National Cancer Institute (NCI),Phase 1,27,NIH,"April 26, 2013","November 15, 2020","September 21, 2022"
9306,NCT01885390,Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension,"Hypertension|Blood Pressure, High|Blood Pressure, Resistant|Blood Pressure, Uncontrolled",Device: ROX COUPLER,"ROX Medical, Inc.",Phase 3,83,Industry,"March 1, 2014","May 5, 2019","May 5, 2019"
9307,NCT01885078,An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: Baricitinib|Drug: Placebo,Eli Lilly and Company,Phase 3,2877,Industry,"June 27, 2013","November 12, 2020","November 12, 2020"
9308,NCT01884259,Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN,Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Squamous Cell Carcinoma of the Larynx Stage III|Squamous Cell Carcinoma of the Larynx Stage IV|Squamous Cell Carcinoma of the Oropharynx Stage III|Squamous Cell Carcinoma of the Oropharynx Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV,Drug: Docetaxel|Drug: Cisplatin|Drug: 5-fluorouracil|Biological: Cetuximab Induction|Biological: Cetuximab Radioimmunotherapy|Radiation: Boost irradiation,Arbeitsgemeinschaft medikamentoese Tumortherapie,Phase 2,100,Other,May-13,"January 28, 2021","January 13, 2022"
9309,NCT01883076,Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome,Hypoplastic Left Heart Syndrome,Biological: autologous cell-based delivery,"Timothy J Nelson, MD, PhD|University of Oklahoma|Children's Hospital of Philadelphia|Children's Hospitals and Clinics of Minnesota|Children's Hospital Los Angeles|Children's Hospital Colorado|Mayo Clinic|ReGen Theranostics, Inc.",Phase 1,30,Other,"May 15, 2013","April 28, 2021","April 28, 2021"
9310,NCT01881308,Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,Rheumatoid Arthritis,Drug: TNF inhibitors|Drug: Synthetic DMARD(s)|Drug: Co-medication: Synthetic DMARDs,Diakonhjemmet Hospital|The Research Council of Norway|South-Eastern Norway Regional Health Authority,Phase 4,320,Other,"June 17, 2013",Jan-20,Jan-22
9311,NCT01877382,A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas,Advanced Solid Tumor|Lymphoma,Drug: Milademetan,"Daiichi Sankyo, Inc.",Phase 1,108,Industry,Jul-13,"October 8, 2020","December 3, 2020"
9312,NCT01877187,Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer,Liver Cancer,Drug: Lipiodol,Yale University|Guerbet,Phase 2,39,Other|Industry,Apr-13,Feb-20,Feb-20
9313,NCT01876511,"Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)",MSI Positive Colorectal Cancer|MSI Negative Colorectal Cancer|MSI Positive Non-Colorectal Cancers,Drug: MK-3475,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme LLC,Phase 2,113,Other|Industry,Sep-13,Aug-19,Aug-19
9314,NCT01875250,Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,Prostate Cancer,Biological: PROSTVAC-F (Fowlpox)/TRICOM|Biological: PROSTVAC-V (Vaccinia)/TRICOM|Drug: Enzalutamide (Xtandi),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,38,NIH,"July 22, 2013","September 1, 2019","February 28, 2020"
9315,NCT01874587,Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma,Oropharynx Cancer,Radiation: adaptative radiotherapy,Center Eugene Marquis,Phase 3,132,Other,Jul-13,"December 10, 2019","December 8, 2020"
9316,NCT01872598,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,Alzheimer Disease,Drug: Masitinib|Drug: Placebo|Drug: Standard of care,AB Science,Phase 3,721,Industry,Jan-12,Dec-20,Dec-20
9317,NCT01871753,The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria,Asymptomatic Bacteriuria|Bacteriuria|Urinary Tract Infections|Kidney Transplantation,Other: Anti-Infective Agents,"Erasme University Hospital|University Hospital, Lille|Universitair Ziekenhuis Brussel|Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP, France|Centre Hospitalier Universitaire Brugmann|Centre Hospitalier Universitaire de Charleroi|University Ghent|Centre Hospitalier Epicura, Belgium|University of Liege|Nantes University Hospital",Phase 4,198,Other,Apr-14,Jul-19,Jul-19
9318,NCT01866111,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures",Partial Epilepsy,Drug: YKP3089|Drug: Placebo,"SK Life Science, Inc.",Phase 2,437,Industry,"July 31, 2013","April 5, 2021","October 31, 2021"
9319,NCT01865162,Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study,Glioblastoma Multiforme,Other: ketogenic diet,"Mid-Atlantic Epilepsy and Sleep Center, LLC|University of Pittsburgh Medical Center",Phase 1,6,Other,Jan-13,Jan-21,Jan-21
9320,NCT01864850,Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC,Head and Neck Squamous Cell Carcinoma,Radiation: Standard RT|Radiation: Hypofractionated RT,"Groupe Oncologie Radiotherapie Tete et Cou|Gustave Roussy, Cancer Campus, Grand Paris",Phase 3,202,Other,"October 18, 2013",Jun-20,"June 5, 2020"
9321,NCT01864772,"Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC",Metastatic or Recurrent Head and Neck Squamous Cell Cancer,"Drug: Carbo, 5FU, Cetuximab","Groupe Oncologie Radiotherapie Tete et Cou|Gustave Roussy, Cancer Campus, Grand Paris",Phase 2,85,Other,Sep-13,Apr-20,"May 26, 2020"
9322,NCT01864265,Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain,Rheumatoid Arthritis,Drug: Certolizumab Pegol|Drug: Placebo,University of Erlangen-Nürnberg Medical School,Phase 3,156,Other,Jul-13,"June 30, 2019","January 10, 2020"
9323,NCT01862536,Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease,Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease (COPD),Drug: Tadalafil|Drug: placebo,VA Office of Research and Development,Phase 2,44,U.S. Fed,"October 1, 2013","August 31, 2019","August 31, 2019"
9324,NCT01862003,Phase I/II Trial of Antagonism of HER in GI Cancer,Metastatic Colorectal Cancer|Recurrent Colorectal Cancer,Drug: AZD8931|Drug: Irinotecan|Drug: Folinic Acid|Drug: Fluorouracil,"University College, London|Cancer Research UK|AstraZeneca|National Institute for Health Research, United Kingdom",Phase 2,24,Other|Industry,May-14,"August 2, 2019","August 2, 2019"
9325,NCT01861535,Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia,Vulvar Intraepithelial Neoplasia,Drug: Imiquimod|Procedure: Surgery,Medical University of Graz|Austrian Science Fund (FWF),Phase 3,110,Other,Jun-13,Feb-21,Feb-21
9326,NCT01859923,"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)",Multidrug Resistant Tuberculosis,Drug: Delamanid|Drug: Delamanid Pediatric Formulation (DPF)|Drug: Optimized Background Regimen (OBR),"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 2,37,Industry,"July 20, 2013","January 13, 2020","January 13, 2020"
9327,NCT01859819,Treatment for Advanced B-Cell Lymphoma,Diffuse Large Cell Lymphoma|Burkitt's Lymphoma|High Grade B-cell Lymphoma,Drug: Rituximab|Drug: IT Cytarabine,New York Medical College,Phase 2,45,Other,Jan-13,Jun-20,Jun-21
9328,NCT01859026,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,Lung Cancer|Non-Small Cell Lung Cancer,Drug: MEK162|Drug: Erlotinib,H. Lee Moffitt Cancer Center and Research Institute|Array BioPharma,Phase 1,43,Other|Industry,"December 30, 2013","August 22, 2019","August 22, 2019"
9329,NCT01858649,Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.,Metastatic Colorectal Cancer,Procedure: Metastases resection|Drug: Bevacizumab|Drug: 5 FU|Drug: Oxaliplatin|Drug: Irinotecan,Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Grand Hôpital de Charleroi,Phase 2,60,Other,May-13,May-19,May-19
9330,NCT01858558,Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma,Multiple Myeloma,Biological: aMIL|Drug: No aMIL,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The Leukemia and Lymphoma Society,Phase 2,102,Other,Sep-13,"June 19, 2019","June 19, 2019"
9331,NCT01856283,Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells,"Leukemia, Myeloid, Chronic-Phase",Drug: Nilotinib 300mg BID,Niguarda Hospital,Phase 2,87,Other,Mar-13,Jul-20,Jan-21
9332,NCT01856114,Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea,Advanced Cancers,Drug: Fentanyl Buccal Tablet|Other: Placebo Buccal Tablet|Behavioral: Questionnaires,M.D. Anderson Cancer Center|Teva Pharmaceuticals USA,Phase 2,36,Other|Industry,"May 27, 2014","December 4, 2019","December 4, 2019"
9333,NCT01853111,Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants,Vascularized Composite Allotransplantation,Biological: Interleukin-2,Brigham and Women's Hospital|Beth Israel Deaconess Medical Center,Phase 1,1,Other,"March 1, 2014","December 20, 2019","March 10, 2020"
9334,NCT01852942,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,HIV Infection|HIV Infections,Drug: Losartan|Drug: Placebo,University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|Merck Sharp & Dohme LLC,Phase 2,52,Other|NIH|Industry,Sep-14,"July 16, 2019","July 16, 2019"
9335,NCT01851083,Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury,Traumatic Brain Injury,Biological: autologous bone marrow mononuclear cells|Other: Placebo Infusion,"The University of Texas Health Science Center, Houston|National Institute of Neurological Disorders and Stroke (NINDS)",Phase 2,47,Other|NIH,Aug-13,"September 16, 2020","October 12, 2020"
9336,NCT01850524,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug: Ixazomib|Drug: Placebo|Drug: Dexamethasone|Drug: Lenalidomide,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 3,705,Industry,"May 17, 2013","December 2, 2019","June 24, 2022"
9337,NCT01849783,Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma,Drug: dexamethasone|Drug: cisplatin|Drug: doxorubicin|Drug: cyclophosphamide|Drug: etoposide|Drug: bortezomib|Drug: thalidomide|Drug: melphalan|Procedure: autologous stem cell transplant,Margarida Magalhaes-Silverman|National Cancer Institute (NCI)|University of Iowa,Phase 2,41,Other|NIH,"April 4, 2013","September 30, 2020","September 30, 2020"
9338,NCT01846091,Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer,Estrogen Receptor Negative|Estrogen Receptor Positive|Head and Neck Squamous Cell Carcinoma|HER2/Neu Negative|HER2/Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Head and Neck Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma,Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter,Mayo Clinic|National Cancer Institute (NCI),Phase 1,12,Other|NIH,"April 9, 2013","September 18, 2019","November 26, 2019"
9339,NCT01845805,Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine),Pancreatic Cancer,Drug: oral azacitidine|Other: Observation,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 2,49,Other,"January 10, 2014","April 9, 2021","April 9, 2021"
9340,NCT01845337,Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine,Gastrointestinal Cancer|Cancer of Unknown Primary Site|Pancreatic Cancer|Bile Duct Neoplasms,Drug: Teysuno|Drug: Capecitabine,University of Edinburgh|NHS Lothian,Phase 2,59,Other,"February 5, 2014","March 18, 2020","October 8, 2020"
9341,NCT01845116,Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury,Total Parenteral Nutrition-induced Cholestasis,Drug: Omegaven®,Wake Forest University Health Sciences,Phase 2,11,Other,Jul-10,Jul-20,Jul-20
9342,NCT01841333,PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,Adult Acute Myeloid Leukemia in Remission|Recurrent Adult Acute Myeloid Leukemia,Drug: PF-04449913,"University of Colorado, Denver|The Leukemia and Lymphoma Society",Phase 2,31,Other,"April 29, 2013","May 8, 2019","February 4, 2020"
9343,NCT01841242,Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation,Heart Failure|Arrhythmia,Drug: alcoholic povidone iodine|Drug: alcoholic chlorhexidine,"Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France|CareFusion",Phase 4,2276,Other|Industry,"April 23, 2013","January 31, 2021","January 31, 2021"
9344,NCT01841177,Evaluating Precision of Therapy - Milrinone,Congenital Heart Disease,Drug: Milrinone,The Hospital for Sick Children,Phase 2,52,Other,Apr-13,Aug-20,Aug-20
9345,NCT01840579,Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011),Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer,Biological: Pembrolizumab 2 mg/kg|Biological: Pembrolizumab 10 mg/kg|Biological: Pembrolizumab 200 mg|Drug: Cisplatin 75 mg/m^2|Drug: Pemetrexed 500 mg/m^2|Drug: Carboplatin AUC 5 mg/mL/min|Drug: Carboplatin AUC 6 mg/mL/min|Drug: Paclitaxel 200 mg/m^2|Drug: Nab-paclitaxel 100 mg/m^2|Biological: Ipilimumab 1 mg/kg|Drug: Etoposide 100 mg/m^2|Drug: G-CSF (pegfilgrastim) 3.6 mg,Merck Sharp & Dohme LLC,Phase 1,57,Industry,"April 26, 2013","February 28, 2020","February 28, 2020"
9346,NCT01839240,"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia",Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia,Drug: azacitidine|Drug: cytarabine|Drug: mitoxantrone hydrochloride|Other: laboratory biomarker analysis,University of Chicago|National Cancer Institute (NCI),Phase 1,50,Other|NIH,"June 6, 2012","August 16, 2019","August 16, 2019"
9347,NCT01837251,Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer,Recurrent Platinum-sensitive Ovarian Cancer,Drug: Carboplatin|Drug: PLD|Biological: Bevacizumab,AGO Research GmbH|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|ARCAGY/ GINECO GROUP|Australia New Zealand Gynaecological Oncology Group|Scottish Gynaecological Cancer Study Group,Phase 3,682,Industry|Other,May-13,Jan-21,Jan-21
9348,NCT01835626,Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,Locally Advanced Basal Cell Carcinoma|Skin Cancer|Cutaneous Malignancy,Drug: Vismodegib|Radiation: Radiation therapy,"Sue Yom|Genentech, Inc.|University of California, San Francisco",Phase 2,24,Other|Industry,May-13,"September 10, 2019","September 10, 2019"
9349,NCT01833143,Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,Non-Small Cell Lung Cancer,Drug: Bortezomib|Drug: Acyclovir,"Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.",Phase 2,17,Other|Industry,"April 11, 2013","August 28, 2019","August 28, 2019"
9350,NCT01832467,Cetuximab Rechallenge Study,Metastatic Colorectal Cancer,Drug: cetuximab-containing chemotherapy,Chinese University of Hong Kong,Phase 2,17,Other,"April 24, 2013","April 7, 2020","April 7, 2020"
9351,NCT01832402,Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea,Advanced Cancers,Drug: Fentanyl Pectin Nasal Spray|Drug: Placebo Nasal Spray|Other: Walk Test|Behavioral: Questionnaires|Behavioral: Mental Ability Tests,M.D. Anderson Cancer Center|Depomed,Phase 2,35,Other|Industry,"June 11, 2013","November 25, 2019","November 25, 2019"
9352,NCT01832038,"Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures",Epilepsy|Partial-onset Seizures,Drug: Lacosamide,UCB Pharma SA|UCB Japan Co. Ltd.|UCB Pharma,Phase 3,473,Industry,"March 26, 2013","July 31, 2019","July 31, 2019"
9353,NCT01830361,Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML,Acute Myeloid Leukemia,Drug: midostaurin (PKC412),Technische Universität Dresden|Novartis Pharmaceuticals,Phase 2,18,Other|Industry,"March 13, 2013","October 30, 2019","October 30, 2019"
9354,NCT01827111,Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,Melanoma,Drug: ABI-007|Drug: Ipilimumab|Behavioral: Phone Call,M.D. Anderson Cancer Center|Celgene,Phase 2,21,Other|Industry,"April 25, 2013","September 21, 2020","September 21, 2020"
9355,NCT01825356,Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus,Hallux Rigidus,Procedure: Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|Procedure: Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation,"OrthoCarolina Research Institute, Inc.",Phase 4,60,Other,"April 8, 2013",Sep-19,"November 10, 2020"
9356,NCT01824082,Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study,Phantom Limb Pain,Drug: Perineural infusion [continuous peripheral nerve block(s)],"University of California, San Diego|United States Department of Defense",Phase 4,144,Other|U.S. Fed,"December 1, 2013",Nov-19,Oct-20
9357,NCT01822522,Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,Advanced Malignant Solid Neoplasm|HIV Infection|Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Unresectable Solid Neoplasm,Drug: Cabozantinib S-malate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study,National Cancer Institute (NCI),Phase 1,36,NIH,"June 21, 2013","May 22, 2019","May 12, 2021"
9358,NCT01820572,A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based,Kidney Transplantation,Drug: Belatacept|Drug: Tacrolimus|Drug: Cyclosporine,Bristol-Myers Squibb,Phase 3,446,Industry,"March 27, 2013","October 24, 2019","October 24, 2019"
9359,NCT01818986,Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),Metastatic Castrate-resistant Prostate Cancer|mCRPC,Drug: Sipuleucel-T|Radiation: Stereotactic Ablative Body Radiation,University of Texas Southwestern Medical Center,Phase 2,20,Other,"July 10, 2013","December 20, 2019","May 25, 2021"
9360,NCT01817426,Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission,Crohn Disease,Drug: Infliximab|Other: Placebo,Copenhagen University Hospital at Herlev,Phase 4,115,Other,Jan-13,May-20,May-20
9361,NCT01815580,HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women,HIV,Drug: Atripla or Stribild,"Fred Hutchinson Cancer Center|Asociación Civil Impacta Salud y Educación, Peru|Asociación Civil Via Libre, Peru|Epicentro, Peru|National Institute on Drug Abuse (NIDA)",Phase 4,225,Other|NIH,Jul-13,"November 30, 2020","June 30, 2021"
9362,NCT01813305,CSTC1 for Diabetic Foot Ulcers Phase II Study,Diabetic Foot Ulcer|Diabetes Mellitus|Wounds,Drug: CSTC1|Drug: CSTC1 Matched vehicle,Charsire Biotechnology Corp.|ASKLEP Inc.,Phase 2,124,Industry,"July 9, 2014","January 7, 2020","January 7, 2020"
9363,NCT01810393,A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years,Breast Cancer,Drug: Trastuzumab,Hoffmann-La Roche,Phase 3,114,Industry,"June 11, 2013","July 17, 2019","July 17, 2019"
9364,NCT01807897,Oxygen Versus PAP for Sleep Apnea in Heart Failure,Heart Failure|Sleep Apnea Syndromes,Device: Continuous positive airway pressure|Device: Nocturnal supplemental oxygen|Behavioral: Healthy Lifestyle and Sleep Education,VA Office of Research and Development,Phase 4,74,U.S. Fed,"June 23, 2014","June 30, 2020","June 30, 2020"
9365,NCT01804465,Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer,Prostate Cancer,Drug: SipT Treatment|Drug: Ipilimumab,"University of California, San Francisco|M.D. Anderson Cancer Center|Bristol-Myers Squibb|Dendreon",Phase 2,50,Other|Industry,"April 22, 2014","February 27, 2020","August 31, 2020"
9366,NCT01804166,A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL),Hepatosplenic T-Cell Lymphoma,Drug: Infliximab|Drug: Golimumab,"Janssen Scientific Affairs, LLC",Phase 4,1,Industry,"March 21, 2013","February 28, 2020","February 28, 2020"
9367,NCT01803438,Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation,Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases,Device: cryoballoon ablation system|Drug: Antiarrhythmic Drugs,Medtronic Cardiac Rhythm and Heart Failure|Medtronic Atrial Fibrillation Solutions,Phase 4,220,Industry,Jun-14,"October 16, 2019","January 20, 2020"
9368,NCT01796002,Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma,Peripheral T-cell Lymphoma,Drug: Romidepsin + CHOP|Drug: CHOP,The Lymphoma Academic Research Organisation,Phase 3,421,Other,Jan-13,"December 13, 2019","December 13, 2022"
9369,NCT01795573,Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease,Graft Versus Host Disease,Biological: Cultured Treg cells,H. Lee Moffitt Cancer Center and Research Institute,Phase 1,38,Other,"October 29, 2014","August 14, 2020","August 14, 2020"
9370,NCT01795248,The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes,Gestational Diabetes Mellitus,Drug: Liraglutide|Drug: Placebo,"Tina Vilsboll|Novo Nordisk A/S|Rigshospitalet, Denmark|Hvidovre University Hospital|Herlev Hospital|Hillerod Hospital, Denmark|University of Copenhagen|The Novo Nordisk Foundation Center for Basic Metabolic Research|Aarhus University Hospital|University Hospital, Gentofte, Copenhagen",Phase 4,105,Other|Industry,Jul-12,Sep-19,Sep-20
9371,NCT01794507,A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,Relapsed/Refractory Multiple Myeloma,Drug: ABT-199|Drug: bortezomib|Drug: dexamethasone,"AbbVie|Genentech, Inc.",Phase 1,66,Industry,"November 19, 2012","July 16, 2019","July 16, 2019"
9372,NCT01794143,A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes,Type 2 Diabetes|Comparative Effectiveness of Glycemia-lowering Medications,Drug: Sulfonylurea (glimepiride)|Drug: DPP-4 inhibitor (sitagliptin)|Drug: GLP-1 receptor agonist (liraglutide)|Drug: Insulin (glargine),"GRADE Study Group|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|Becton, Dickinson and Company|Bristol-Myers Squibb|Merck Sharp & Dohme LLC|Novo Nordisk A/S|Roche Diagnostics|Sanofi|Centers for Disease Control and Prevention",Phase 3,5047,Other|NIH|Industry|U.S. Fed,May-13,"April 30, 2021",
9373,NCT01793051,Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma,Myeloma,Drug: Minocycline|Other: Placebo|Behavioral: Questionnaires,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,88,Other|NIH,"March 22, 2013","September 18, 2020","September 18, 2020"
9374,NCT01792804,Staphylococcus Aureus Bacteremia Antibiotic Treatment Options,Staphylococcus Aureus Infection,Drug: Trimethoprim-Sulfamethoxazole|Drug: Clindamycin|Drug: Linezolid|Drug: Flucloxacillin|Drug: Cloxacillin|Drug: Vancomycin|Drug: Daptomycin|Drug: Cefazolin,"Heinrich-Heine University, Duesseldorf|German Research Foundation",Phase 3,215,Other,Dec-13,"March 26, 2020","March 26, 2020"
9375,NCT01792115,Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E,Fatty Liver,Drug: Vitamin E 200 IU/d|Drug: Vitamin E 400 IU/d|Drug: Vitamin E 800 IU/d|Behavioral: Diet and Exercise,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 2,22,NIH,"May 1, 2013","August 30, 2019","August 30, 2019"
9376,NCT01791595,A Phase I Trial of AZD3965 in Patients With Advanced Cancer,Adult Solid Tumor|Diffuse Large B Cell Lymphoma|Burkitt Lymphoma,Drug: AZD3965,Cancer Research UK|AstraZeneca,Phase 1,53,Other|Industry,"April 23, 2013","November 17, 2020","November 17, 2020"
9377,NCT01791101,Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.,Thrombocytopenia,Drug: Eltrombopag,Gruppo Italiano Malattie EMatologiche dell'Adulto,Phase 2,10,Other,"September 16, 2013","June 26, 2020","June 26, 2020"
9378,NCT01789281,Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,Neoplasms,Drug: Everolimus|Drug: Sandostatin LAR Depot,Novartis Pharmaceuticals|Novartis,Phase 4,34,Industry,"May 14, 2013","August 28, 2020","August 28, 2020"
9379,NCT01788982,Nintedanib(BIBF1120) in Thyroid Cancer,Medullary Thyroid Cancer (MTC)|Differentiated Thyroid Cancer (DTC),Drug: Nintedanib|Drug: Placebo,European Organisation for Research and Treatment of Cancer - EORTC,Phase 2,100,Other,May-14,"August 28, 2019","August 28, 2019"
9380,NCT01786343,Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML),Leukemia,Drug: Decitabine,M.D. Anderson Cancer Center,Phase 2,74,Other,"February 5, 2013","May 6, 2019","May 6, 2019"
9381,NCT01782131,A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069),Fungal Infections|Invasive Pulmonary Aspergillosis,Drug: Posaconazole|Drug: Voriconazole|Drug: Placebo,Merck Sharp & Dohme LLC,Phase 3,585,Industry,"September 25, 2013","July 10, 2019","September 10, 2019"
9382,NCT01781468,Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma,Fatigue,Drug: armodafinil 150 mg|Other: Placebo|Drug: armodafinil 250 mg,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Phase 3,328,Other|NIH,Jun-13,May-19,"December 15, 2019"
9383,NCT01781455,A Study of BBI503 in Adult Patients With Advanced Solid Tumors,"Cancer, Advanced Solid Tumors",Drug: BBI503,"Sumitomo Pharma Oncology, Inc.",Phase 1,311,Industry,Feb-12,Jun-20,Jun-20
9384,NCT01781390,Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction,Acute Myocardial Infarction,Other: Placebo|Biological: Mesenchymal Precursor Cells (MPC) 12.5 M|Biological: Mesenchymal Precursor Cells (MPC) 25 M,"Mesoblast, Inc.|Mesoblast, Ltd.",Phase 2,106,Industry,"March 11, 2013","April 6, 2021","April 6, 2021"
9385,NCT01779557,Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate,"Kidney Failure,Chronic",Drug: Huaren Peritoneal Dialysate|Drug: Baxter Peritoneal Dialysate,Chinese PLA General Hospital,Phase 4,750,Other,Feb-13,Oct-19,Sep-21
9386,NCT01775475,Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma,AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma,Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: lomustine|Drug: etoposide|Drug: procarbazine hydrochloride|Other: laboratory biomarker analysis,"AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas",Phase 2,7,Other|NIH|Industry,"September 15, 2016","April 1, 2021","July 15, 2021"
9387,NCT01774630,Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2),"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",Drug: Nilotinib,"University Hospital, Bordeaux",Phase 2,31,Other,"April 10, 2013","December 21, 2020","December 21, 2020"
9388,NCT01772420,Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome,Adult Myelodysplastic Syndrome|Anemia|Chronic Myelomonocytic Leukemia,Drug: Eltrombopag Olamine|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide,Albert Einstein College of Medicine|National Cancer Institute (NCI),Phase 2,54,Other|NIH,Oct-12,"July 9, 2020","July 9, 2020"
9389,NCT01772004,Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),Solid Tumors,Drug: Avelumab,"EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono",Phase 1,1756,Industry,"January 31, 2013","December 16, 2019","December 16, 2019"
9390,NCT01760525,A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,Solid Tumor With p53 Wild Type Status,Drug: CGM097,Novartis Pharmaceuticals|Novartis,Phase 1,51,Industry,"March 20, 2013","July 24, 2020","July 24, 2020"
9391,NCT01760447,A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289),Type 2 Diabetes Mellitus,Drug: Sitagliptin plus metformin|Drug: Placebo to metformin|Drug: Metformin|Drug: Placebo to sitagliptin plus metformin|Drug: Sitagliptin plus metformin XR|Drug: Placebo to metformin XR|Drug: Insulin|Drug: Placebo to sitagliptin plus metformin XR|Drug: Metformin XR,Merck Sharp & Dohme LLC,Phase 3,223,Industry,"December 7, 2011","September 17, 2019","September 17, 2019"
9392,NCT01756833,Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial,Aneurysm,Drug: Doxycycline|Drug: Placebo,"University of Maryland, Baltimore|National Institute on Aging (NIA)",Phase 2,261,Other|NIH,May-13,"July 23, 2019","July 23, 2019"
9393,NCT01753297,A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.,Prostate Cancer,Drug: Triptorelin 11.25 mg,Ipsen,Phase 4,226,Industry,"December 11, 2012","September 9, 2019","September 9, 2019"
9394,NCT01751451,"3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",Prostate Cancer,Drug: Abiraterone acetate|Drug: Abiraterone acetate plus degarelix|Drug: Degarelix,"Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|OHSU Knight Cancer Institute|Rutgers Cancer Institute of New Jersey|NorthShore University HealthSystem|Duke University|Northwestern University Feinberg School of Medicine|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|University of North Carolina|Wayne State University|Perlmutter New York University Cancer Center|Weill Medical College of Cornell University|Ferring Pharmaceuticals|GU Research Network, LLC|University of California, Los Angeles",Phase 2,124,Other|Industry,"December 18, 2012","September 28, 2020","September 28, 2020"
9395,NCT01749215,A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD,Alcohol Dependence|Posttraumatic Stress Disorder (PTSD),Drug: Topiramate|Drug: placebo|Behavioral: Medical Management,"University of California, San Francisco|United States Department of Defense|San Francisco Veterans Affairs Medical Center|Northern California Institute of Research and Education",Phase 4,151,Other|U.S. Fed,Feb-13,Jul-19,Jul-19
9396,NCT01748825,AZD1775 for Advanced Solid Tumors,Solid Tumors,Drug: MK-1775 (AZD1775),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,67,NIH,"December 19, 2012","May 19, 2020","May 19, 2020"
9397,NCT01748500,Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer,Prostate Cancer,Drug: Pantoprazole,"University Health Network, Toronto",Phase 2,21,Other,Jan-13,Mar-21,Mar-21
9398,NCT01743989,A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.,Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP),Drug: Nilotinib,Novartis Pharmaceuticals|Novartis,Phase 3,620,Industry,"April 15, 2013","July 8, 2020","July 8, 2020"
9399,NCT01743365,Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer,Gastric Cancer|Gastroesophageal Junction Cancer,Drug: Cisplatin-5FU-Afatinib,Hellenic Cooperative Oncology Group|Boehringer Ingelheim,Phase 2,55,Other|Industry,"February 11, 2013","June 15, 2019","July 29, 2019"
9400,NCT01742988,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",Lymphoma|Relapsed Lymphoma|Refractory Lymphoma|Relapsed and/or Refractory Lymphoma|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Double-hit Lymphoma (DHL)|Triple-hit Lymphoma (THL)|Double-expressor Lymphoma (DEL)|High-grade B-cell Lymphoma (HGBL),Drug: fimepinostat|Drug: Rituximab|Drug: venetoclax,"Curis, Inc.|The Leukemia and Lymphoma Society",Phase 1,106,Industry|Other,Dec-12,"October 9, 2020","October 9, 2020"
9401,NCT01742117,Tailored Antiplatelet Therapy Following PCI,Coronary Artery Disease|Acute Coronary Syndrome|Stenosis,Drug: Clopidogrel|Drug: Ticagrelor,"Mayo Clinic|Spartan Bioscience Inc.|Applied Health Research Centre|National Heart, Lung, and Blood Institute (NHLBI)",Phase 4,5276,Other|Industry|NIH,May-13,"October 31, 2020","October 31, 2020"
9402,NCT01740258,Bevacizumab Beyond Progression (BBP),Malignant Glioma|Grade 4 Malignant Glioma|Glioblastoma|Gliosarcoma,Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab,"Duke University|Genentech, Inc.",Phase 2,68,Other|Industry,Jan-13,"November 14, 2019","November 14, 2019"
9403,NCT01739933,"The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure",Sepsis|Delirium|Impaired Cognition,Drug: Dexmedetomidine|Drug: Propofol,Vanderbilt University Medical Center,Phase 3,438,Other,"May 15, 2013",Jul-19,Jul-19
9404,NCT01739764,An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol,Neoplasms,Drug: Vemurafenib,Hoffmann-La Roche,Phase 4,215,Industry,"February 19, 2013","February 17, 2020","February 17, 2020"
9405,NCT01736943,Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,Acute Myelogenous Leukemia,Drug: Bortezomib|Drug: Doxil,"Joseph Tuscano|Millennium Pharmaceuticals, Inc.|University of California, Davis",Phase 2,25,Other|Industry,"December 19, 2012","May 20, 2019","May 20, 2019"
9406,NCT01735006,Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine,Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection,Biological: HPV Vaccine|Biological: HEV vaccine,"Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Ministry of Science and Technology of the People´s Republic of China",Phase 3,7372,Other|Industry,"November 22, 2012","August 1, 2019","October 18, 2019"
9407,NCT01734382,A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab),Juvenile Idiopathic Arthritis,Drug: Tocilizumab,Hoffmann-La Roche,Phase 4,35,Industry,"June 10, 2013","October 9, 2019","October 9, 2019"
9408,NCT01730118,Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,Breast Neoplasms|Breast Cancer|Adenocarcinomas|Metastatic Solid Tumors Characterized by HER2/Neu Expression,Biological: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,33,NIH,"March 4, 2013","December 3, 2019","December 3, 2019"
9409,NCT01728779,Stereotactic Body Radiation With Nelfinavir for Oligometastases,Oligometastases,Drug: Nelfinavir|Radiation: Stereotactic Body Radiation (SBRT),Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 2,38,Other,"January 8, 2014",Mar-20,Dec-20
9410,NCT01728194,Emotional and Cognitive Control in Late-Onset Depression,Depression,Drug: Escitalopram|Other: Magnetic Resonance Imaging,Weill Medical College of Cornell University|National Institute of Mental Health (NIMH),Phase 4,121,Other|NIH,Jul-12,"July 31, 2019","July 31, 2019"
9411,NCT01725490,The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study,Familial Adenomatous Polyposis,Drug: Metformin|Drug: Placebo,Yonsei University,Phase 2,34,Other,"February 15, 2013","August 30, 2020","August 30, 2020"
9412,NCT01720407,Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face,Lentigo Maligna Melanoma (Head or Neck),Drug: Imiquimod cream + surgery|Drug: Placebo + surgery,Nantes University Hospital|MEDA Pharma GmbH & Co. KG,Phase 3,259,Other|Industry,Dec-12,Oct-19,"November 10, 2022"
9413,NCT01720225,Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,Leukemia,Drug: Decitabine|Drug: Azacitidine,M.D. Anderson Cancer Center,Phase 2,113,Other,"November 6, 2012","January 8, 2020","January 8, 2020"
9414,NCT01716208,Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Drug: Ofatumumab + Fresh Frozen Plasma,"Joseph Tuscano|GlaxoSmithKline|University of California, Davis",Phase 2,12,Other|Industry,"January 14, 2013","October 1, 2019","October 1, 2020"
9415,NCT01712789,Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma,Multiple Myeloma,Drug: Pomalidomide|Drug: Dexamethasone,Celgene,Phase 3,682,Industry,"November 6, 2012","December 11, 2019","December 11, 2019"
9416,NCT01711242,Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma,Gastric Cancer,Drug: Capecitabine|Drug: Oxaliplatin|Radiation: Radiotherapy,xie congying|Wenzhou Medical University,Phase 2,208,Other,Jan-12,Jan-20,Jan-21
9417,NCT01709981,Anti-inflammatory Effects of Colchicine in PCI,Coronary Artery Disease,Drug: Colchicine|Drug: Placebo,NYU Langone Health|Takeda,Phase 4,280,Other|Industry,"May 30, 2013","August 30, 2019","December 13, 2021"
9418,NCT01707394,Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder,Thromboembolism,Drug: Apixaban,Bristol-Myers Squibb|Pfizer,Phase 1,49,Industry,"January 10, 2013","June 30, 2020","June 30, 2020"
9419,NCT01703117,Riluzole in Mild Alzheimer's Disease,Alzheimer's Disease,Drug: Riluzole|Drug: Placebo,Icahn School of Medicine at Mount Sinai|Rockefeller University,Phase 2,50,Other,Nov-13,"May 26, 2020","May 26, 2020"
9420,NCT01702636,STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial,Intracerebral Haemorrhage|Stroke,Drug: Tranexamic Acid|Drug: Placebo,Neuroscience Trials Australia,Phase 2,100,Other,Dec-12,"August 14, 2019",Dec-19
9421,NCT01702571,A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,Breast Cancer,Drug: Trastuzumab Emtansine,Hoffmann-La Roche,Phase 3,2185,Industry,"November 27, 2012","July 31, 2020","July 31, 2020"
9422,NCT01700673,Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Azacitidine|Biological: Sargramostim,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),Phase 2,25,Other|NIH,Jun-13,Jun-20,Jun-20
9423,NCT01698307,Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy,Crohn's Disease,Other: Enhanced Treatment Algorithm|Other: Conventional Step-care Algorithm,Alimentiv Inc.,Phase 4,1095,Other,"March 28, 2014","April 16, 2020","April 16, 2020"
9424,NCT01698138,Prevention of Bladder Dysfunction in Acute Spinal Cord Injury,"Spinal Cord Injuries|Urinary Bladder, Overactive",Drug: Onabotulinumtoxin A|Drug: Placebo,Oslo University Hospital|Sunnaas Rehabilitation Hospital,Phase 4,20,Other,Sep-12,"December 20, 2020","December 20, 2020"
9425,NCT01694277,Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib,Gastrointestinal Stromal Tumors,Drug: Masitinib|Drug: Sunitinib,AB Science,Phase 3,258,Industry,Apr-12,Dec-20,Dec-20
9426,NCT01693783,Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer,Cervical Adenocarcinoma|Cervical Squamous Cell Carcinoma|Human Papillomavirus Infection|Recurrent Cervical Carcinoma|Stage IVA Cervical Cancer AJCC v6 and v7|Stage IVB Cervical Cancer AJCC v6 and v7,Biological: Ipilimumab|Other: Laboratory Biomarker Analysis,National Cancer Institute (NCI),Phase 2,42,NIH,"December 3, 2012","March 18, 2021","November 24, 2021"
9427,NCT01692418,Preoperative Intravenous Iron to Treat Anaemia in Major Surgery,Anaemia,Drug: Ferric carboxymaltose|Drug: Normal saline,"University College, London",Phase 3,487,Other,Jan-14,May-19,May-19
9428,NCT01682226,Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies,Leukemia|Myelodysplastic Syndrome|Lymphoma,Device: CliniMACS Fractionation system (Arm A)|Device: CliniMACS Fractionation system (Arm B)|Biological: Haploidentical donor CD34+ cells,Memorial Sloan Kettering Cancer Center,Phase 2,84,Other,"September 5, 2012","January 8, 2021","January 8, 2021"
9429,NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,Melanoma,Drug: Dabrafenib,Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Novartis,Phase 2,23,Other|Industry,Sep-12,May-19,May-19
9430,NCT01681823,Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA,Prostatic Neoplasms,Dietary Supplement: PectaSol-C Modified Citrus Pectin (MCP),EcoNugenics,Phase 2,60,Industry,Jun-13,Jan-20,Jan-20
9431,NCT01676818,Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer,Recurrent Cervical Cancer|Stage IIIA Cervical Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer,Drug: eribulin mesylate,University of Southern California|National Cancer Institute (NCI),Phase 2,32,Other|NIH,"August 9, 2012","February 21, 2021","August 9, 2021"
9432,NCT01676753,Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,Advanced or Metastatic Breast Cancer|Triple Negative Breast Cancer,Drug: Dinaciclib|Drug: Pembrolizumab,"Jo Chien|Merck Sharp & Dohme LLC|University of California, San Francisco",Phase 1,32,Other|Industry,"December 28, 2016","June 30, 2020","February 28, 2022"
9433,NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,Breast Neoplasms,Drug: Neratinib|Drug: Fulvestrant|Drug: Trastuzumab|Procedure: Tumor biopsy|Procedure: Research blood sample,"Washington University School of Medicine|Puma Biotechnology, Inc.|United States Department of Defense",Phase 2,56,Other|Industry|U.S. Fed,"December 11, 2012","February 11, 2021","March 11, 2021"
9434,NCT01670097,Dexamethasone Dyspnea Study,Advanced Cancers|Hematologic Disorder|Solid Tumors,Drug: Dexamethasone|Drug: Placebo|Behavioral: Questionnaires|Device: Spirometer|Other: Phone Calls,M.D. Anderson Cancer Center,Phase 2,52,Other,Jan-13,Aug-20,"January 26, 2021"
9435,NCT01666756,Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Advanced Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma,Dietary Supplement: Chinese herbal formulation PHY906|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study,City of Hope Medical Center|National Cancer Institute (NCI),Phase 1,18,Other|NIH,"June 11, 2014","May 29, 2020","May 29, 2020"
9436,NCT01664182,"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",Advanced Renal Cell Carcinoma|Advanced Sarcomatoid Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7,Biological: Bevacizumab|Drug: Pazopanib Hydrochloride|Drug: Sorafenib Tosylate|Drug: Sunitinib Malate|Biological: Trebananib,National Cancer Institute (NCI),Phase 2,41,NIH,"August 1, 2012","December 7, 2020","December 7, 2020"
9437,NCT01658995,Management of Etonogestrel Subdermal Implant-related Bleeding,ESI-related Bleeding,Drug: Doxycycline|Drug: Placebo,Petra M. Casey|Mayo Clinic,Phase 3,82,Other,"September 13, 2012","December 30, 2019","December 30, 2019"
9438,NCT01658124,Haemorrhage Alleviation With Tranexamic Acid- Intestinal System,Gastrointestinal Bleeding,Drug: Tranexamic Acid|Drug: Placebo,London School of Hygiene and Tropical Medicine|Rawalpindi Medical College|University of Ibadan,Phase 3,12009,Other,Jul-13,"July 19, 2019","July 19, 2019"
9439,NCT01656642,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,Malignant Melanoma,Drug: Atezolizumab|Drug: Cobimetinib|Drug: Vemurafenib,"Genentech, Inc.",Phase 1,67,Industry,"August 13, 2012","March 25, 2020","March 25, 2020"
9440,NCT01654016,Study of Antiinflammatory Effects of Detralex (Daflon),Chronic Venous Insufficiency,Drug: Detralex,University Hospital Dubrava|Servier,Phase 4,84,Other|Industry,Aug-12,May-19,Sep-19
9441,NCT01649869,Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss,Cytomegalovirus Infection,Other: Placebo|Drug: Valganciclovir,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,54,NIH,"February 24, 2015","December 24, 2019","December 24, 2019"
9442,NCT01647932,Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure,Heart Failure,Drug: hydrochlorothiazide|Drug: Placebo,Spanish Society of Internal Medicine,Phase 3,232,Other,Oct-14,"December 15, 2019","December 15, 2019"
9443,NCT01646645,Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation,Cytomegalovirus,Biological: CMV-pp65 CTLs,Memorial Sloan Kettering Cancer Center|Atara Biotherapeutics,Phase 2,58,Other|Industry,"July 13, 2012","December 11, 2019","December 11, 2019"
9444,NCT01646437,The International Polycap Study 3 (TIPS-3),Cardiovascular Disease|Fractures|Cancers,Drug: Polycap|Drug: Aspirin|Drug: Vitamin D|Drug: Matching Placebo,Population Health Research Institute|Cadila Pharnmaceuticals|Wellcome Trust|Canadian Institutes of Health Research (CIHR)|Heart and Stroke Foundation of Ontario,Phase 3,7793,Other|Industry,Jun-12,"June 30, 2020","August 30, 2021"
9445,NCT01642134,Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI,Aortic Valve Stenosis|Stroke,Drug: aspirin+clopidogrel (Duoplavin),"Andres Iñiguez Romo, MD, PhD|Hospital de Meixoeiro",Phase 4,124,Other,Apr-13,"June 30, 2019","June 30, 2019"
9446,NCT01641107,Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.,Philadelphia Positive|BCR-ABL Positive|Acute Lymphoblastic Leukemia,Drug: Ponatinib,Incyte Corporation,Phase 2,44,Industry,"December 4, 2014","April 24, 2020","September 30, 2021"
9447,NCT01639339,Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis,Lupus Nephritis,Biological: Placebo plus standard therapy|Biological: Belimumab 10 mg/kg plus standard therapy|Drug: Standard therapy,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline",Phase 3,448,Industry,"July 12, 2012","July 25, 2019","March 12, 2020"
9448,NCT01638013,A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K,"Arthritis, Rheumatoid",Drug: Peficitinib,Astellas Pharma Inc,Phase 3,843,Industry,"June 13, 2012","September 30, 2019","September 30, 2019"
9449,NCT01636934,Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy,Lung Cancer,Drug: Minocycline|Other: Placebo|Behavioral: Questionnaires,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,51,Other|NIH,Jul-12,"September 23, 2019","September 23, 2019"
9450,NCT01636622,"Study of Vemurafenib, Carboplatin, and Paclitaxel",Advanced Cancers,Drug: Vemurafenib|Drug: Carboplatin|Drug: Paclitaxel,M.D. Anderson Cancer Center,Phase 1,21,Other,"July 9, 2012","April 21, 2020","April 21, 2020"
9451,NCT01635270,Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma,Non-small Cell Lung Cancer|Radiation Therapy|Locally Advanced Disease|Non-metastatic Disease|Non-resectable Disease,Radiation: mid-position radiation strategy|Radiation: ITV,Centre Leon Berard|CREATIS Laboratory,Phase 2,54,Other,"September 12, 2012",Aug-20,Aug-20
9452,NCT01633970,A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors,Cancer,Drug: 5-FU|Drug: Atezolizumab|Drug: Bevacizumab|Drug: Carboplatin|Drug: Leucovorin|Drug: Nab-paclitaxel|Drug: Oxaliplatin|Drug: Paclitaxel|Drug: Pemetrexed,"Genentech, Inc.",Phase 1,240,Industry,"July 11, 2012","February 26, 2020","February 26, 2020"
9453,NCT01630889,Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease,Chronic Kidney Disease|End Stage Renal Disease|Anemia,Drug: Roxadustat,FibroGen|AstraZeneca|Astellas Pharma Inc,Phase 2,15,Industry,"May 18, 2012","December 12, 2019","December 12, 2019"
9454,NCT01630590,Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,Prostate Cancer,Drug: Cabozantinib|Drug: Androgen Ablation Therapy,M.D. Anderson Cancer Center|Exelixis|High Impact Clinical Research Support Program,Phase 2,62,Other|Industry,"January 8, 2014","April 6, 2021","April 6, 2021"
9455,NCT01630278,Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI),Patent Ductus Arteriosus,Drug: Ibuprofen|Drug: Placebo,Nantes University Hospital,Phase 3,363,Other,Mar-12,Jun-19,Jun-19
9456,NCT01625351,A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,Ewing Sarcoma|Gastrointestinal Tumor|Germ Cell Tumor|Hepatic Tumor|Lymphoma|Wilms Tumor|Rhabdoid Tumor|Clear Cell Carcinoma|Renal Cell Carcinoma|Melanoma|Neuroblastoma|Rhabdomyosarcoma|Non-rhabdomyosarcoma,Drug: alemtuzumab|Drug: fludarabine|Drug: sirolimus|Drug: Busulfan|Drug: melphalan|Biological: stem cells|Device: CliniMACS,"St. Jude Children's Research Hospital|CURE Childhood Cancer, Inc.",Phase 1,23,Other,"August 20, 2012","February 10, 2020","February 10, 2020"
9457,NCT01624766,Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers,Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm,Biological: Anakinra|Biological: Denosumab|Drug: Everolimus,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,57,Other|NIH,"June 19, 2012","February 24, 2021","February 24, 2021"
9458,NCT01623349,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,Ovarian Cancer|Breast Cancer,Drug: BKM120 and Olaparib|Drug: BYL719 and Olaparib,Dana-Farber Cancer Institute|Novartis|AstraZeneca,Phase 1,118,Other|Industry,Sep-12,May-19,Dec-20
9459,NCT01622946,The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach,Total Hip Arthroplasty|Postoperative Blood Loss,Drug: Tranexamic Acid|Drug: placebo,Universitaire Ziekenhuizen KU Leuven,Phase 4,80,Other,Apr-12,Apr-20,Apr-20
9460,NCT01622868,Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,HER2-Positive Breast Carcinoma|Invasive Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7,Other: Laboratory Biomarker Analysis|Drug: Lapatinib Ditosylate|Radiation: Stereotactic Radiosurgery|Radiation: Whole-Brain Radiotherapy,National Cancer Institute (NCI)|NRG Oncology,Phase 2,143,NIH|Other,"July 26, 2012","December 30, 2019","May 20, 2022"
9461,NCT01621217,"Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0",Locally Advanced Cancer in the Anal Region,Drug: Cetuximab|Drug: Mitomycin C|Drug: 5-Fluoruracil|Radiation: Radiotherapy,Lund University Hospital|Merck Sharp & Dohme LLC,Phase 1,21,Other|Industry,Jun-12,Jan-20,Jan-20
9462,NCT01621204,A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients,Immune Thrombocytopenic Purpura,Drug: Eltrombopag|Drug: IVIG infusion,McMaster University|GlaxoSmithKline|Hamilton Health Sciences Corporation|Novartis,Phase 3,74,Other|Industry,Oct-12,Jun-19,Aug-19
9463,NCT01614990,Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia,Cancer Cachexia,Drug: Macimorelin|Drug: Placebo,"Garcia, Jose M., MD, PhD|VA Office of Research and Development|Baylor College of Medicine|AEterna Zentaris",Phase 2,8,Other|U.S. Fed|Industry,May-12,Jul-20,Dec-21
9464,NCT01614665,"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time",Heart Transplantation|Kidney Transplantation|Liver Transplantation,Drug: Tacrolimus|Drug: Tacrolimus prolonged release,Astellas Pharma Europe Ltd.|Astellas Pharma Inc,Phase 2,44,Industry,"April 3, 2012","April 21, 2021","April 21, 2021"
9465,NCT01614197,A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,"Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma",Drug: Temsirolimus|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Hydrocortisone|Drug: Cytarabine,Therapeutic Advances in Childhood Leukemia Consortium|Pfizer,Phase 1,16,Other|Industry,Mar-15,"December 15, 2019","May 31, 2020"
9466,NCT01603407,Finding the Optimum Regimen for Duchenne Muscular Dystrophy,Duchenne Muscular Dystrophy,Drug: Prednisone|Drug: Deflazacort,University of Rochester|Newcastle University|University Medical Center Freiburg|National Institute of Neurological Disorders and Stroke (NINDS),Phase 3,196,Other|NIH,Jan-13,Nov-19,Nov-19
9467,NCT01602861,The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity,Disorder Related to Renal Transplantation,Drug: Spironolactone|Drug: placebo,Odense University Hospital|Fredericia Hosptial,Phase 4,188,Other,Feb-13,Apr-21,Apr-21
9468,NCT01597973,Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME),Pneumonia|Blood Stream Infection,Drug: colistin and meropenem|Drug: colistin and placebo,University of Michigan,Phase 3,467,Other,"October 6, 2012","August 9, 2020","August 9, 2020"
9469,NCT01597778,Double Cord Versus Haploidentical (BMT CTN 1101),Acute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Burkitt's Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma,Biological: Haploidentical Bone Marrow Transplant|Biological: Double Umbilical Cord Blood Transplant,"Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program",Phase 3,368,Other|NIH,Jun-12,"September 11, 2020","September 11, 2020"
9470,NCT01596140,Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,Advanced Cancer|Solid Tumor,Drug: Vemurafenib|Drug: Everolimus|Drug: Temsirolimus,M.D. Anderson Cancer Center,Phase 1,27,Other,"December 18, 2012","June 1, 2020","June 1, 2020"
9471,NCT01595529,"The SCOUT Study: ""Short Course Therapy for Urinary Tract Infections in Children""",Urinary Tract Infection,Drug: Cefixime|Drug: Cephalexin|Other: Placebo|Drug: Trimethoprim/Sulfamethoxazole,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,717,NIH,"May 18, 2012","June 30, 2019","August 12, 2019"
9472,NCT01594229,A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma,Non-Hodgkin's Lymphoma,Drug: ABT-199|Drug: Rituximab|Drug: Bendamustine,"AbbVie|Genentech, Inc.",Phase 1,60,Industry,"May 21, 2012","July 14, 2020","July 14, 2020"
9473,NCT01593020,Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2,Breast Cancer,Drug: Paclitaxel|Drug: Eribulin|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Doxorubicin,M.D. Anderson Cancer Center|Eisai Inc.,Phase 2,54,Other|Industry,"August 3, 2012","November 4, 2020","November 4, 2020"
9474,NCT01589263,Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS,Benign Prostatic Hyperplasia|Lower Urinary Track Symptoms,Drug: onaBoNT-A + placebo|Drug: Tamsulosin + placebo,VA Office of Research and Development,Phase 2,63,U.S. Fed,"June 1, 2012","September 30, 2019","September 30, 2019"
9475,NCT01588184,An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study,Neoplasms,Drug: Bevacizumab,Hoffmann-La Roche,Phase 4,95,Industry,"July 13, 2012","September 27, 2019","September 27, 2019"
9476,NCT01587196,CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery,Prescription Opiate/Medication Dependence,Drug: Vivitrol,University of Pennsylvania,Phase 2,72,Other,Jan-12,"January 1, 2021","January 1, 2021"
9477,NCT01586624,A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1),Cancer|Non Small Cell Lung Cancer,"Drug: Vandetanib, Selumetinib",Cancer Research UK|AstraZeneca,Phase 1,61,Other|Industry,"January 10, 2012","June 11, 2020","June 11, 2020"
9478,NCT01586455,Human Placental-Derived Stem Cell Transplantation,Mucopolysaccharidosis I|Mucopolysaccharidosis VI|Adrenoleukodystrophy|Niemann-Pick Disease|Metachromatic Leukodystrophy|Wolman Disease|Krabbe's Disease|Gaucher's Disease|Fucosidosis|Batten Disease|Severe Aplastic Anemia|Diamond-Blackfan Anemia|Amegakaryocytic Thrombocytopenia|Myelodysplastic Syndrome|Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia,Drug: Human Placental Derived Stem Cell,New York Medical College,Phase 1,43,Other,Apr-13,Jun-20,Sep-22
9479,NCT01584076,Treatment of Residual Amblyopia With Donepezil,Amblyopia,Drug: Donepezil|Other: Patching,Boston Children's Hospital,Phase 1,18,Other,Aug-12,Jan-21,Jan-21
9480,NCT01583283,"Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma",Multiple Myeloma,Drug: ACY-1215|Drug: lenalidomide|Drug: Dexamethasone,Celgene,Phase 1,38,Industry,"July 12, 2012","March 15, 2021","March 24, 2021"
9481,NCT01579994,Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,Advanced Lung Cancer,Drug: Ganetespib (STA-9090) and crizotinib,Memorial Sloan Kettering Cancer Center,Phase 1,13,Other,"April 16, 2012","December 28, 2020","December 28, 2020"
9482,NCT01576172,Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer,Castration-Resistant Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7,Drug: Abiraterone Acetate|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Drug: Veliparib,National Cancer Institute (NCI),Phase 2,159,NIH,"March 30, 2012","October 23, 2019","April 23, 2020"
9483,NCT01573572,Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium,Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema,Drug: pegaptanib sodium injection,Bausch & Lomb Incorporated,Phase 4,131,Industry,"April 22, 2010","November 14, 2019","November 14, 2019"
9484,NCT01573429,Bisphenol A Controlled Exposure Study,Healthy Volunteers,Other: deuterated-Bisphenol A (d-BPA),National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC),Phase 1,38,NIH,"July 18, 2012","June 16, 2020","June 16, 2020"
9485,NCT01572493,Continuous Infusion of rhIL-15 for Adults With Advanced Cancer,Lymphoma|Carcinoma,Biological: rh IL-15 (10 DAYS)|Biological: rh IL-15 (5 DAYS),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,38,NIH,"April 4, 2012","June 20, 2019","July 2, 2019"
9486,NCT01572038,A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer,Breast Neoplasms,Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Trastuzumab,Hoffmann-La Roche,Phase 3,1436,Industry,"June 1, 2012","September 20, 2019","September 20, 2019"
9487,NCT01569295,Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ),Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Placebo to match idelalisib,Gilead Sciences,Phase 3,416,Industry,"June 15, 2012","June 10, 2019","June 10, 2019"
9488,NCT01569178,BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction,Myocardial Infarction|Death,Procedure: Bone Marrow aspiration and intracoronary reinfusion,Queen Mary University of London,Phase 3,375,Other,Sep-13,"November 27, 2019","November 27, 2019"
9489,NCT01568255,Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms,Myopathic Symptoms,Drug: Ergocalciferol|Drug: Placebo,Cedars-Sinai Medical Center,Phase 4,11,Other,Mar-12,Jun-19,Jun-19
9490,NCT01566747,"Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5",Renal Cell Carcinoma,Drug: Pazopanib,Cancer Trials Ireland|Novartis,Phase 2,43,Other|Industry,Mar-11,"April 7, 2020","July 15, 2020"
9491,NCT01563731,Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives,Stroke|Transient Ischemic Attack|Hypertension,Drug: all approved antihypertensive drugs; all approved statins,Istituto Auxologico Italiano|European Society of Hypertension|Chinese Hypertension League,Phase 4,200,Other,Apr-13,"December 31, 2020","March 31, 2021"
9492,NCT01563354,3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial,Neuroendocrine Carcinoma of the Lung and Thymus,Drug: Pasireotide LAR|Drug: Everolimus|Drug: Pasireotide LAR and Everolimus Combination,Novartis Pharmaceuticals|Novartis,Phase 2,124,Industry,"August 16, 2013","February 10, 2020","February 10, 2020"
9493,NCT01562210,Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC,NSCLC,Drug: Olaparib|Drug: Cisplatin|Radiation: Radiation,The Netherlands Cancer Institute|AstraZeneca,Phase 1,28,Other|Industry,Apr-12,May-19,"March 13, 2020"
9494,NCT01557374,TOward the Lowest Effective DOse of Abatacept or Tocilizumab,Rheumatoid Arthritis,"Drug: Tocilizumab, Abatacept|Drug: Decrease Tocilizumab, Abatacept","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Phase 4,232,Other,Apr-12,"November 8, 2019","November 8, 2019"
9495,NCT01557244,A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition,"Urinary Bladder, Neurogenic",Drug: Fesoterodine PR 4 mg|Drug: Fesoterodine PR 8 mg|Drug: Oxybutynin|Drug: Fesoterodine PR|Drug: Fesoterodine BIC 2 mg|Drug: Fesoterodine BIC 4 mg,Pfizer,Phase 3,181,Industry,"July 2, 2012","November 7, 2019","February 13, 2020"
9496,NCT01554618,Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes,Children and Adolescent With Type 2 Diabetes,Drug: Exenatide Once Weekly|Drug: Placebo,AstraZeneca,Phase 3,84,Industry,"December 2, 2011","May 6, 2020","May 5, 2021"
9497,NCT01554514,Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura,Thrombotic Thrombocytopenic Purpura,Biological: rituximab,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,19,Other|NIH,Aug-12,"February 14, 2020","February 14, 2020"
9498,NCT01554410,Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma,Cervical Carcinoma,Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin|Drug: Gemcitabine,"University of California, San Diego",Phase 1,35,Other,Aug-10,"July 16, 2019","August 1, 2020"
9499,NCT01551030,Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium,Metastatic Transitional Cell Carcinoma of the Urothelium,Drug: Buparlisib,Memorial Sloan Kettering Cancer Center|Novartis,Phase 2,19,Other|Industry,Mar-12,"September 2, 2020","September 2, 2020"
9500,NCT01548768,RHYTHM (Formerly Escape II Myocardium),Rheumatoid Arthritis,Drug: TNF inhibitors|Drug: DMARDs,Columbia University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Phase 4,149,Other|NIH,"October 10, 2011",Sep-19,Sep-19
9501,NCT01543490,Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects,"Active, Symptomatic Blepharitis",Drug: ISV-305|Other: Vehicle,Sun Pharmaceutical Industries Limited,Phase 3,558,Industry,"March 30, 2018","February 4, 2020","February 4, 2020"
9502,NCT01542736,Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET),Metastatic Medulloblastoma|High Risk Supratentorial PNET|Metastatic PNET,Drug: Carboplatin|Drug: Vincristine|Radiation: 24 Gy,"University of Colorado, Denver",Phase 2,8,Other,May-07,Sep-20,Sep-20
9503,NCT01540058,Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP,"Neoplasms, Unknown Primary",Other: Cancer Type ID test|Other: No test Empiric strategy,"Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France",Phase 3,243,Other,"March 22, 2012","August 27, 2019","August 27, 2019"
9504,NCT01536743,A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,Ovarian Epithelial Carcinoma,Drug: PD0332991,Jonsson Comprehensive Cancer Center,Phase 2,26,Other,"December 15, 2011","February 24, 2020","February 24, 2020"
9505,NCT01536392,"Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation",Cancer of the Cervix,Drug: Granisetron|Drug: Ondansetron|Behavioral: Questionnaires|Behavioral: Study Drug Diary,M.D. Anderson Cancer Center|Sancuso,Phase 3,76,Other,Mar-12,"October 3, 2019","October 3, 2019"
9506,NCT01535885,"Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV",Epstein-Barr Virus Infections|Adenovirus|Cytomegalovirus Infections,Biological: Cytotoxic T Lymphocytes,Medical College of Wisconsin,Phase 1,25,Other,Feb-12,Oct-19,Oct-19
9507,NCT01534598,FdCyd and THU for Advanced Solid Tumors,Neoplasms,Drug: FdCyd + THU,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 1,59,NIH,"March 5, 2012","October 7, 2019","February 19, 2020"
9508,NCT01532687,Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma,Adult Alveolar Soft Part Sarcoma|Adult Angiosarcoma|Adult Desmoplastic Small Round Cell Tumor|Adult Epithelioid Hemangioendothelioma|Adult Epithelioid Sarcoma|Adult Extraskeletal Myxoid Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Peripheral Nerve Sheath Tumor|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Adult Undifferentiated Pleomorphic Sarcoma|Malignant Adult Hemangiopericytoma|Recurrent Adult Soft Tissue Sarcoma|Sarcoma|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7,Drug: Gemcitabine|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Pazopanib|Drug: Pazopanib Hydrochloride|Other: Placebo Administration,OHSU Knight Cancer Institute|Novartis Pharmaceuticals|Oregon Health and Science University,Phase 2,54,Other|Industry,"March 13, 2012","October 31, 2019","October 31, 2019"
9509,NCT01531959,Midodrine for the Treatment of Refractory Hypotension,Hypotension|Critical Illness,Drug: Midodrine|Drug: Placebo,Massachusetts General Hospital|Sir Charles Gairdner Hospital,Phase 3,139,Other,Apr-12,Jun-19,Jun-19
9510,NCT01531361,Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations,Advanced Malignant Neoplasm|BRAF Gene Mutation|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm,Drug: Crizotinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sorafenib Tosylate|Drug: Vemurafenib,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,46,Other|NIH,"February 6, 2012","January 13, 2021","January 13, 2021"
9511,NCT01531348,Intravitreal Injection of MSCs in Retinitis Pigmentosa,Retinitis Pigmentosa,Other: BM-MSC,"Mahidol University|Ministry of Health, Thailand",Phase 1,14,Other,Apr-12,Jul-20,Jul-20
9512,NCT01530659,Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa,Retinitis Pigmentosa|Usher Syndrome Type 2|Usher Syndrome Type 3,Drug: NT-501|Procedure: Sham,"Neurotech Pharmaceuticals|University of California, San Francisco",Phase 2,22,Industry|Other,Jan-12,"July 1, 2019","July 1, 2019"
9513,NCT01528800,Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients,End-stage Kidney Disease,Drug: Vitamin K1|Drug: Microcrystalline Methylcellulose,Dr. Rachel Holden|Clinical Evaluation Research Unit at Kingston General Hospital,Phase 2,85,Other,Nov-12,Dec-19,Dec-19
9514,NCT01528085,Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia,Drug: Nilotinib,Goethe University,Phase 2,79,Other,Jan-12,"March 10, 2020","March 10, 2020"
9515,NCT01528046,Metformin in Children With Relapsed or Refractory Solid Tumors,Solid Tumors|Primary Brain Tumors,Drug: Vincristine|Drug: Irinotecan|Drug: Temozolomide|Drug: Metformin,H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation,Phase 1,26,Other,"September 24, 2012","September 26, 2019","February 3, 2020"
9516,NCT01524536,Steroid Treatment for Hypereosinophilic Syndrome,Eosinophilia|Hypereosinophilic Syndrome|Leukocyte Disorder|Hematologic Diseases,Drug: prednisone,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Phase 4,26,NIH,"February 16, 2012","December 10, 2020","December 10, 2020"
9517,NCT01519869,"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",Primary Peritoneal Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma,Drug: neoadjuvant chemotherapy,Rachel Miller|University of Kentucky,Phase 2,28,Other,Mar-12,"October 11, 2019","October 11, 2019"
9518,NCT01517802,A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,Metastatic Castration-resistant Prostate Cancer|Metastatic Breast Cancer,Drug: Abiraterone acetate|Drug: Prednisone,"Janssen Research & Development, LLC",Phase 3,32,Industry,"March 28, 2012","April 22, 2021","April 22, 2021"
9519,NCT01516216,Study of Vitamin D in Untreated Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,Drug: FOLFOX + bevacizumab|Dietary Supplement: Vitamin D,Dana-Farber Cancer Institute,Phase 2,139,Other,"April 13, 2012","November 9, 2019","November 9, 2019"
9520,NCT01510340,Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management,HIV,Behavioral: VIH-TAVIE,Centre hospitalier de l'Université de Montréal (CHUM)|Fonds de la Recherche en Santé du Québec,Phase 3,217,Other,Jan-12,Dec-19,Jun-20
9521,NCT01509612,Additive Homeopathy in Cancer Patients,Malignant Tumors,Drug: Additive classical homeopathy|Drug: Homeopathic Placebo globules,Medical University of Vienna,Phase 3,150,Other,"February 1, 2012","July 31, 2019","July 31, 2019"
9522,NCT01503606,Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane,Preterm Premature Rupture of Membrane,Drug: Cefazolin|Drug: Clarithromycin,Samsung Medical Center,Phase 3,151,Other,Oct-11,Dec-20,Dec-21
9523,NCT01503515,"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant",Fungal Infection|Hematopoietic and Lymphoid Cell Neoplasm,Drug: Caspofungin Acetate|Drug: Fluconazole|Other: Laboratory Biomarker Analysis|Drug: Voriconazole,Children's Oncology Group|National Cancer Institute (NCI),Phase 3,292,Other|NIH,"March 21, 2013","December 31, 2019","September 30, 2021"
9524,NCT01503229,Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Adenocarcinoma,Drug: Abiraterone Acetate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prednisone,University of Washington|National Cancer Institute (NCI),Phase 2,32,Other|NIH,Dec-12,"March 12, 2020","March 12, 2020"
9525,NCT01502072,Respiratory Syncytial Virus - RSV Protocol,Bone Marrow Transplant Infection|Infection in Marrow Transplant Recipients|Respiratory Syncytial Virus Infections|Respiratory Syncytial Virus Pneumonia|Cancer|Acute Leukemia,Drug: Ribavirin,M.D. Anderson Cancer Center,Phase 2,48,Other,"December 28, 2011","February 1, 2020","February 1, 2020"
9526,NCT01501760,Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea,Corneal Newvessels,Drug: bevacizumab|Drug: NaCl,"University Hospital, Limoges",Phase 3,38,Other,"May 13, 2012",Oct-19,Oct-19
9527,NCT01498484,Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,EBV-induced Lymphomas|EBV-associated Malignancies|Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma,Biological: EBV-specific T cells (EBV-CTLs),Atara Biotherapeutics|Memorial Sloan Kettering Cancer Center,Phase 2,87,Industry|Other,Dec-11,Jul-19,Jul-19
9528,NCT01497496,Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide,H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation,Phase 2,29,Other|Industry,"January 26, 2012","September 25, 2019","March 20, 2020"
9529,NCT01497184,Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood,Leukemia|Lymphoma,Procedure: HSCT|Genetic: DLI,M.D. Anderson Cancer Center|Ziopharm Oncology,Phase 1,95,Other,Dec-11,"March 8, 2021","March 8, 2021"
9530,NCT01497093,"Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",Multiple Myeloma,Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone,Celgene|Multiple Myeloma Research Consortium,Phase 1,34,Industry|Other,"February 15, 2012","July 23, 2019","July 23, 2019"
9531,NCT01492608,Magnesium Sulphate for Preterm Birth (MASP Study),Cerebral Palsy,Drug: Magnesium sulphate,Hvidovre University Hospital,Phase 3,560,Other,"December 16, 2011","August 12, 2019","August 12, 2019"
9532,NCT01485744,"LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",Pancreatic Cancer,Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan,Massachusetts General Hospital|Dana-Farber Cancer Institute,Phase 1,39,Other,Dec-11,Nov-19,Nov-19
9533,NCT01485614,Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083),Diabetes Mellitus|Type 2 Diabetes,Drug: Sitagliptin|Drug: Metformin|Drug: Placebo to sitagliptin|Drug: Placebo to metformin|Drug: Glycemic Rescue 1|Biological: Glycemic Rescue 2,Merck Sharp & Dohme LLC,Phase 3,200,Industry,"February 10, 2012","October 9, 2019","October 9, 2019"
9534,NCT01479283,Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY),Infection|Bone Neoplasms,Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen|Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen,McMaster University|Orthopedic Research and Education Foundation|The Physicians' Services Incorporated Foundation|Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR),Phase 3,602,Other,Jan-13,Mar-21,Mar-21
9535,NCT01477606,Protocol in Acute Myeloid Leukemia With FLT3-ITD,Acute Myeloid Leukemia,Drug: Midostaurin|Drug: Cytarabine|Drug: Daunorubicin,University of Ulm|Novartis Pharmaceuticals,Phase 2,451,Other|Industry,May-12,"February 26, 2020","February 26, 2020"
9536,NCT01471444,Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS),Disorder Related to Bone Marrow Transplantation|Leukemia|Transplantation Infection,Drug: Fludarabine|Drug: Clofarabine|Drug: Busulfan|Drug: Thymoglobulin|Procedure: Stem Cell Infusion|Drug: Tacrolimus|Drug: Methotrexate,M.D. Anderson Cancer Center|Sanofi,Phase 3,256,Other|Industry,"November 2, 2011","December 14, 2020","December 14, 2020"
9537,NCT01470612,"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",Ulcerative Colitis,"Drug: CP-690,550",Pfizer,Phase 3,944,Industry,"October 1, 2012","August 6, 2020","August 6, 2020"
9538,NCT01467986,Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma,Neuroblastoma Recurrent,Drug: Dasatinib|Drug: Rapamycin|Drug: Irinotecan|Drug: Temozolomide,University of Regensburg,Phase 2,130,Other,Aug-13,"September 30, 2020","September 30, 2020"
9539,NCT01463670,Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance,Multiple Myeloma,Drug: lenalidomide,Memorial Sloan Kettering Cancer Center|Montefiore Medical Center|State University of New York - Downstate Medical Center|University of Rochester|Weill Medical College of Cornell University|Stamford Hospital|Columbia University|State University of New York - Upstate Medical University,Phase 2,11,Other,"October 28, 2011","March 19, 2021","March 19, 2021"
9540,NCT01463306,A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures,"Epilepsy, Partial Seizures|Epilepsy, Primary Generalized Tonic-Clonic Seizures",Drug: Pregabalin,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer,Phase 3,605,Industry,"February 21, 2012","August 22, 2019","August 22, 2019"
9541,NCT01462890,Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer,"Genital Diseases, Female|Ovarian Diseases|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms",Biological: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin|Other: specialized pathology review (Germany only),AGO Study Group|ARCAGY/ GINECO GROUP|Nordic Society of Gynaecological Oncology - Clinical Trials Unit,Phase 3,927,Other,Nov-11,"December 31, 2020",Dec-21
9542,NCT01460498,Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML),Leukemia,Drug: Azacitidine (AZA)|Drug: Tyrosine kinase inhibitor (TKI)|Drug: Azacitidine,M.D. Anderson Cancer Center|Celgene Corporation,Phase 1,3,Other|Industry,"August 8, 2012","August 7, 2019","August 7, 2019"
9543,NCT01456689,A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,Multiple Myeloma,Drug: LGH447|Drug: midazolam,Novartis Pharmaceuticals|Novartis,Phase 1,79,Industry,"April 25, 2012","June 5, 2019","June 5, 2019"
9544,NCT01455831,Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer,Adenocarcinoma of the Colon,Drug: Tinzaparin,Ottawa Hospital Research Institute,Phase 3,616,Other,Sep-11,"December 31, 2020","February 1, 2021"
9545,NCT01453218,Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction,Renal Insufficiency,Drug: ATeGe-Fresenius,Hospital Vall d'Hebron|Hospital Universitari Vall d'Hebron Research Institute,Phase 3,30,Other,Oct-11,Feb-20,Feb-20
9546,NCT01453101,Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,Multiple Myeloma,"Drug: Fludarabine monophosphate, melphalan, Bortezomib",Hackensack Meridian Health,Phase 2,54,Other,"June 9, 2010","June 11, 2020","June 11, 2020"
9547,NCT01449162,Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids,Asthma,Drug: Masitinib|Drug: Placebo,AB Science,Phase 3,420,Industry,Jan-11,Nov-19,Nov-19
9548,NCT01448096,Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma,Large B Cell Diffuse Lymphoma,Drug: Rituximab|Procedure: Prophylactic intrathecal chemotherapy,Chonbuk National University Hospital|Consortium for Improving Survival of Lymphoma,Phase 2,33,Other,Aug-11,"July 10, 2019","July 10, 2019"
9549,NCT01446159,Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer,"Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer",Drug: MEDI-573|Drug: Aromatase Inhibitor,MedImmune LLC,Phase 2,188,Industry,"June 13, 2011","June 28, 2019","June 28, 2019"
9550,NCT01444716,Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Biological: Ofatumumab,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,34,Other|NIH,"December 15, 2011","June 11, 2020","June 11, 2020"
9551,NCT01433497,Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis,"Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Relapse Free",Drug: Masitinib|Drug: Placebo,AB Science,Phase 3,656,Industry,Aug-11,Sep-19,Feb-20
9552,NCT01433445,"Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis",Idiopathic Myelofibrosis|Post Essential Thrombocythemia Myelofibrosis|Post Polycythemia-Vera Myelofibrosis,Drug: panobinostat|Drug: ruxolitinib,Novartis Pharmaceuticals|Novartis,Phase 1,61,Industry,"November 1, 2011","June 22, 2020","June 22, 2020"
9553,NCT01431209,Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,Other: Laboratory Biomarker Analysis|Drug: Ruxolitinib Phosphate,University of Nebraska|National Cancer Institute (NCI),Phase 2,71,Other|NIH,Aug-11,"October 28, 2020","May 26, 2021"
9554,NCT01430416,Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,Uveal Melanoma,Drug: AEB071,Novartis Pharmaceuticals|Novartis,Phase 1,153,Industry,"December 20, 2011","May 22, 2019","May 22, 2019"
9555,NCT01429415,Magnesium Nebulization Utilization in Management of Pediatric Asthma,Acute Asthma,"Drug: Magnesium Sulfate Sandoz|Drug: Sodium Chloride , USP PPC",The Hospital for Sick Children|Canadian Institutes of Health Research (CIHR)|Alberta Children's Hospital|St. Justine's Hospital|Children's Hospital of Eastern Ontario|Stollery Children's Hospital|The Children's Hospital of Winnipeg|Provincial Health Services Authority,Phase 2,818,Other,"September 26, 2011","November 19, 2019","November 22, 2019"
9556,NCT01429337,PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function,Hepatic Impairment,Drug: Midostaurin,Novartis Pharmaceuticals|Novartis,Phase 1,43,Industry,"March 7, 2011","April 13, 2020","May 9, 2020"
9557,NCT01427478,Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck,Head and Neck Squamous Cell Carcinoma,Drug: AFATINIB|Drug: Placebo of AFATINIB,Centre Leon Berard|Boehringer Ingelheim,Phase 3,134,Other|Industry,Sep-11,Nov-20,May-21
9558,NCT01421069,Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis,Juvenile Idiopahtic Arthritis,Drug: etanercept,Pfizer,Phase 3,109,Industry,"October 10, 2011","February 4, 2021","February 4, 2021"
9559,NCT01420874,Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),Colorectal Cancer|Cancer of Pancreas|Pancreatic Neoplasm|Malignant Neoplasm of Large Intestine|Malignant Tumor of Colon|Colon Carcinoma|Cancer of Colon|Pancreatic Cancer,Drug: FOLFOX6|Biological: EGFRBi armed ATC Infusions,Barbara Ann Karmanos Cancer Institute,Phase 1,15,Other,"August 17, 2011","October 19, 2020","October 19, 2020"
9560,NCT01420341,Co-trimoxazole as Maintenance Therapy for Melioidosis,Melioidosis,Drug: Co-trimoxazole 12|Drug: Co-trimoxazole 20,Khon Kaen University,Phase 4,667,Other,Aug-11,"June 21, 2019","June 21, 2019"
9561,NCT01417286,Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer,Inflammatory Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma|Mucinous Ductal Breast Carcinoma|Papillary Ductal Breast Carcinoma|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Tubular Ductal Breast Carcinoma,Radiation: External beam radiation therapy,"Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey",Phase 2,69,Other|NIH,"December 21, 2010","February 20, 2020","February 20, 2020"
9562,NCT01414738,Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases,"Brain Neoplasms, Adult, Malignant",Radiation: Radiotherapy,University of Texas Southwestern Medical Center,Phase 2,50,Other,"October 18, 2011","December 16, 2019","December 16, 2019"
9563,NCT01410890,Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease,Pompe Disease|Glycogen Storage Disease Type II (GSD II),Biological: alglucosidase alfa,"Genzyme, a Sanofi Company|Sanofi",Phase 4,21,Industry,"November 3, 2014","November 20, 2020","November 20, 2020"
9564,NCT01409915,Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease,Alzheimer's Disease,Drug: Sagramostim|Drug: Saline -- placebo comparator,"University of Colorado, Denver|The Dana Foundation",Phase 2,44,Other,Mar-11,"December 9, 2019","December 9, 2019"
9565,NCT01407809,Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy,Idiopathic Intracranial Hypertension (IIH),Device: Venous Sinus Stenting,Weill Medical College of Cornell University,Phase 1,20,Other,Jan-12,"June 1, 2020","June 1, 2020"
9566,NCT01406769,"Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy",Lymphedema|Perioperative/Postoperative Complications|Stage IA Vulvar Cancer AJCC v7|Stage IB Vulvar Cancer AJCC v7|Stage II Vulvar Cancer AJCC v7|Stage IIIA Vulvar Cancer AJCC v7|Stage IIIB Vulvar Cancer AJCC v7|Stage IIIC Vulvar Cancer AJCC v7|Stage IVA Vulvar Cancer AJCC v7|Stage IVB Vulvar Cancer AJCC v6 and v7,Procedure: Bioelectric Impedance Analysis|Procedure: Lymphadenectomy|Procedure: Therapeutic Conventional Surgery,Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation,Phase 2,120,Other|NIH,"July 16, 2012","April 10, 2020","April 10, 2020"
9567,NCT01404949,Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy,Acute Promyelocytic Leukemia,Drug: Tretinoin and Arsenic Trioxide,"Memorial Sloan Kettering Cancer Center|Northwestern University|New York Presbyterian Hospital|University of Southern California|Princess Margaret Hospital, Canada|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,17,Other|NIH,Jul-11,"February 1, 2021","February 1, 2021"
9568,NCT01402882,Clinical Randomisation of an Antifibrinolytic in Significant Head Injury,Traumatic Brain Injury,Drug: Tranexamic Acid,London School of Hygiene and Tropical Medicine,Phase 3,12737,Other,Jul-12,Oct-19,Oct-19
9569,NCT01399918,Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),Renal Cell Carcinoma,Drug: everolimus and bevacizumab,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals,Phase 2,57,Other|Industry,Jul-11,"December 28, 2020","December 28, 2020"
9570,NCT01399372,"Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma",Chemotherapeutic Agent Toxicity|Cognitive/Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity,Biological: Rituximab|Drug: Cytarabine|Drug: Methotrexate|Drug: Procarbazine|Drug: Vincristine|Radiation: low-dose whole-brain radiation therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology,Phase 2,91,Other|NIH,Sep-11,"March 19, 2020","May 20, 2022"
9571,NCT01392209,Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,Brain Cancer|MALIGNANT GLIOMA|Glioblastoma|Anaplastic Astrocytoma (AA)|Anaplastic Oligodendroglioma (AO)|Anaplastic Oligo-astrocytoma (AOA)|Anaplastic Mixed Gliomas|Malignant Glioma NOS,Other: Bevacizumab & Stereotactic Radiotherapy,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University|University of California, San Francisco",Phase 1,15,Other|Industry,"July 8, 2011","November 15, 2019","November 15, 2019"
9572,NCT01392183,Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),Kidney Cancer,Drug: Pazopanib|Drug: Temsirolimus|Behavioral: Quality of Life Assessment|Drug: Benadryl,M.D. Anderson Cancer Center|Novartis,Phase 2,69,Other|Industry,"October 24, 2012","September 8, 2019","September 8, 2019"
9573,NCT01387763,A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms,Polycythemia Vera|Essential Thrombocythemia|Primary Myelofibrosis,Drug: PegIntron|Drug: Pegasys|Drug: Hydrea,Thomas Stauffer Larsen|Odense University Hospital,Phase 3,202,Other,Jan-12,Jun-20,Jun-20
9574,NCT01384513,A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies,"Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aplastic Anemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Mastocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia",Drug: Fludarabine|Drug: Busulfan|Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Device: Allogeneic hematopoietic stem cell transplantation|Procedure: Peripheral blood stem cell transplantation (PBSCT),Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University,Phase 2,40,Other,"August 4, 2011","November 13, 2020","November 16, 2022"
9575,NCT01380938,Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE),Chronic Hepatitis,Drug: Peginterferon alpha-2a + Ribavirin,"Casa Sollievo della Sofferenza IRCCS|Casa di Cura Mater Dei|IRCCS L. Spallanzani|Ospedale Francesco Ferrari|Azienda Ospedaliero Universitaria di Sassari|IRCCS Policlinico S. Matteo|Arcispedale S. Anna, Ferrara|Azienda Ospedaliero-Universitaria, Catania|Ospedale di Venosa|Ospedale Monsignor R. Dimiccoli, Barletta|IRCCS De Bellis, Castellana|USL Napoli 1|Ospedale San Giuseppe Moscati, Avellino|Cardarelli Hospital|Ospedale Civile Vittorio Emanuele II, Bisceglie|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera V. Cervello|Ospedale Civile Spirito Santo|Ospedale di Canosa di Puglia|University of Palermo|San Camillo Hospital, Rome|Campus Bio-Medico University|Ospedale Sandro Pertini, Roma|Ospedali Riuniti di Foggia|Ospedale SS. Annunziata, Taranto|Ospedale di Mottola|Ospedale Santa Caterina Novella, Galatina|University of Florence|Ospedale Valduce, Como|University of Bari|Azienda Ospedaliera, Siracusa|Azienda Ospedaliera, Lucca",Phase 3,1150,Other,"December 1, 2018","November 30, 2019","November 30, 2019"
9576,NCT01379989,"INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer",Ovarian Cancer,Drug: Carboplatin|Drug: Pegylated Lipoxomal Doxorubicin (PLD)|Drug: Trabectedin,Mario Negri Institute for Pharmacological Research|PharmaMar|Averion International Corporation,Phase 3,617,Other|Industry,Jun-11,"December 17, 2020","December 17, 2020"
9577,NCT01379573,Preventive Approach to Congenital Heart Block With Hydroxychloroquine,Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block,Drug: Hydroxychloroquine,NYU Langone Health,Phase 2,74,Other,"January 1, 2011","July 16, 2020","July 16, 2020"
9578,NCT01376778,A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV),Congenital Cytomegalovirus Infection|Maternal Cytomegalovirus Infection,Drug: CMV hyperimmune globulin|Other: Placebo,The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3,399,Other|NIH,Apr-12,Oct-19,"June 30, 2021"
9579,NCT01373684,PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients,Chronic Hepatitis B,Drug: Peginterferon alfa-2a|Drug: Nucleos(t)ide analogue,Foundation for Liver Research|Hoffmann-La Roche,Phase 4,90,Other|Industry,"May 25, 2012","October 28, 2019","October 28, 2019"
9580,NCT01372540,Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia,Plasma Cell Leukemia|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Drug: Carfilzomib|Drug: Filanesib|Other: Laboratory Biomarker Analysis,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,76,Other|NIH,"February 24, 2012","May 16, 2019","May 16, 2019"
9581,NCT01370512,Droxidopa / Pyridostigmine in Orthostatic Hypotension,Orthostatic Hypotension,Drug: Droxidopa|Drug: Pyridostigmine|Other: Placebo|Other: Placebo 2,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS),Phase 2,23,Other|NIH,Nov-11,"January 19, 2021","January 19, 2021"
9582,NCT01369212,Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B,Hepatitis B,Drug: Tenofovir|Drug: Peginterferon-alfa 2a and tenofovir,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh|National Center for Research Resources (NCRR),Phase 3,201,NIH|Other,Nov-12,"March 8, 2021","March 8, 2021"
9583,NCT01365156,Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix,Cervical Squamous Cell Carcinoma|Adenosquamous Carcinoma|Adenocarcinoma|Locally Advanced Malignant Neoplasm|Cervical Cancer,Procedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Radiation: Chemoradiation,M.D. Anderson Cancer Center,Phase 3,28,Other,Aug-11,"January 24, 2020","January 24, 2020"
9584,NCT01363128,Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|Burkitt Leukemia|Burkitt Lymphoma|CD20 Positive|Childhood Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma,Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Biological: Ofatumumab|Drug: Vincristine Sulfate,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,72,Other|NIH,"July 12, 2011","April 8, 2020","April 8, 2020"
9585,NCT01362374,"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors",Neoplasms,Drug: 5-FU|Drug: Docetaxel|Drug: Enzalutamide|Drug: Ipatasertib|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Paclitaxel,"Genentech, Inc.",Phase 1,122,Industry,"July 11, 2011","October 16, 2020","October 16, 2020"
9586,NCT01360320,Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-,Colorectal Serrated Adenomas|Colorectal Tubular Adenomas|Colorectal Villous Adenomas|Colorectal Tubulovillous Adenomas,Dietary Supplement: Green tea extract of Camellia Sinensis|Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo,"Martin-Luther-Universität Halle-Wittenberg|University of Ulm|KKS Netzwerk|Deutsche Krebshilfe e.V., Bonn (Germany)",Phase 2,1001,Other,Nov-11,May-19,Jul-19
9587,NCT01356680,HD17 for Intermediate Stage Hodgkin Lymphoma,Hodgkin Lymphoma,"Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|Radiation: 30Gy IF-RT (Involved-Field Radiotherapy)|Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)",University of Cologne,Phase 3,1100,Other,"January 13, 2012","March 21, 2020","March 23, 2020"
9588,NCT01353625,"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",Glioblastoma Multiforme|Squamous Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis,Drug: CC-115,Celgene,Phase 1,118,Industry,"April 25, 2011","March 12, 2021","March 12, 2021"
9589,NCT01353391,Metformin in Women With Type 2 Diabetes in Pregnancy Trial,Type 2 Diabetes,Drug: Metformin|Drug: Placebo Comparator,"Mount Sinai Hospital, Canada|University Health Network, Toronto|Sunnybrook Research Institute|Canadian Institutes of Health Research (CIHR)",Phase 3,500,Other,"May 25, 2011","June 5, 2019","June 5, 2019"
9590,NCT01343043,A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma,Neoplasms,Drug: NY-ESO-1(c259)T Cells|Drug: Fludarabine|Drug: Cyclophosphamide,GlaxoSmithKline,Phase 1,50,Industry,"September 27, 2012","June 18, 2019","June 18, 2019"
9591,NCT01341652,Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer,Prostate Cancer,Biological: pTVG-HP|Biological: rhGM-CSF,"University of Wisconsin, Madison",Phase 2,99,Other,"May 23, 2011","June 30, 2020","June 30, 2020"
9592,NCT01335399,"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma",Multiple Myeloma,Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608; HuLuc63),Bristol-Myers Squibb|AbbVie,Phase 3,748,Industry,"August 4, 2011","October 1, 2019","September 3, 2021"
9593,NCT01331239,Safety and Efficacy of LCI699 in Cushing's Disease Patients,Cushings Disease|Cushing Disease,Drug: LCI699,Novartis Pharmaceuticals|Novartis,Phase 2,31,Industry,"March 23, 2011","October 22, 2019","October 22, 2019"
9594,NCT01329900,Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas,Lymphoma,Drug: Ofatumumab|Drug: Ifosfamide|Drug: Etoposide|Drug: Mesna|Drug: G-CSF|Procedure: Stem Cell Collection,M.D. Anderson Cancer Center|Novartis,Phase 2,50,Other|Industry,"August 22, 2011","July 21, 2019","July 21, 2019"
9595,NCT01328626,A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,Drug: ABT-199,"AbbVie|Genentech, Inc.",Phase 1,222,Industry,"May 23, 2011","May 8, 2020","May 8, 2020"
9596,NCT01327612,Open Label Extension Study of Conatumumab and Ganitumab (AMG 479),Advanced Solid Tumors|Carcinoid|Colorectal Cancer|Locally Advanced|Lymphoma|Metastatic Cancer|Non-Small Cell Lung Cancer|Sarcoma|Solid Tumors,Drug: Modified FOLFOX6|Biological: Conatumumab|Biological: Ganitumab|Biological: Bevacizumab,Amgen,Phase 2,12,Industry,"March 3, 2011","February 5, 2020","February 5, 2020"
9597,NCT01326715,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,Multiple Sclerosis,Drug: Mangafodipir (Teslascan),National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Phase 1,17,NIH,"October 17, 2013","September 18, 2019","September 13, 2022"
9598,NCT01320592,PD0332991/Paclitaxel in Advanced Breast Cancer,Breast Cancer,Drug: PD0332991|Drug: Paclitaxel,Abramson Cancer Center at Penn Medicine,Phase 1,28,Other,Mar-11,May-19,May-19
9599,NCT01319981,Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,Leukemia,Drug: Rituximab|Drug: Imatinib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Mesna|Drug: VSLI|Drug: Solu-Medrol|Drug: Methotrexate|Drug: Ara-C|Drug: G-CSF|Drug: Pegfilgrastim|Drug: Dexamethasone,"M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc",Phase 2,31,Other|Industry,"March 5, 2013","November 11, 2020","November 11, 2020"
9600,NCT01317875,"Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)",Myelofibrosis,Drug: Ruxolitinib,Incyte Corporation|Novartis,Phase 1,69,Industry,"March 31, 2011","December 31, 2019","December 31, 2019"
9601,NCT01311648,BAY81-8973 Pediatric Safety and Efficacy Trial,Haemophilia A,"Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)",Bayer,Phase 3,94,Industry,"June 9, 2011","September 9, 2019","October 27, 2020"
9602,NCT01300728,Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment,Mild Cognitive Impairment,Drug: NewGam 10% IVIG|Other: Placebo,Sutter Health,Phase 2,52,Other,"January 1, 2011","March 12, 2020","March 12, 2020"
9603,NCT01295944,Carboplatin and Bevacizumab for Recurrent Ependymoma,Ependymoma|Anaplastic Ependymoma,Drug: Carboplatin|Drug: Bevacizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,35,NIH,"April 27, 2011","September 23, 2020","May 14, 2021"
9604,NCT01288352,Early Treatment of Atrial Fibrillation for Stroke Prevention Trial,Atrial Fibrillation|Stroke,Other: early standardised rhythm control,Atrial Fibrillation Network|Sanofi|Abbott|Deutsche Herzstiftung e.V.|European Heart Rhythm Association (EHRA)|BMBF (German Ministry for Science)|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK),Phase 4,2789,Other|Industry,"July 1, 2011","March 6, 2020","May 31, 2020"
9605,NCT01285765,"Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients",DLBCL,Drug: RCHOP21,The Lymphoma Academic Research Organisation|CHU de Nancy,Phase 3,650,Other,Dec-10,"May 23, 2020","May 23, 2020"
9606,NCT01279135,Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix,Cancer Cervix,Radiation: Conventional Radiation|Radiation: Tomotherapy based IGRT,Tata Memorial Hospital,Phase 3,300,Other,"January 1, 2011","December 30, 2019","January 31, 2020"
9607,NCT01276041,"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",Breast Cancer,Drug: pertuzumab in combination with trastuzumab and paclitaxel,"Memorial Sloan Kettering Cancer Center|Genentech, Inc.|University of Pennsylvania",Phase 2,70,Other|Industry,"January 5, 2011","August 7, 2019","August 7, 2019"
9608,NCT01274351,Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP),Chronic Myelogenous Leukemia,Drug: Nilotinib,Novartis Pharmaceuticals|Novartis,Phase 2,112,Industry,"January 25, 2011","August 1, 2019","August 1, 2019"
9609,NCT01273207,Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans,"Bronchiolitis Obliterans|Constructive Bronchiolitis|Graft Versus Host Disease|Bronchiolitis, Exudative|Bronchiolitis, Proliferative|Graft-Versus-Host Disease",Drug: Cyclosporine Inhalation Solution (CIS),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,7,NIH,"March 2, 2012","May 10, 2019","May 23, 2019"
9610,NCT01270724,"Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)",CNS Germ Cell Tumor,"Drug: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).",Nationwide Children's Hospital,Phase 2,10,Other,Aug-10,"October 23, 2019","December 9, 2019"
9611,NCT01270074,Prevention of Bronchiectasis in Infants With Cystic Fibrosis,Cystic Fibrosis|Bronchiectasis,Drug: Azithromycin|Drug: Placebo control,The University of Queensland|Telethon Kids Institute,Phase 3,130,Other,Apr-12,Mar-20,Mar-21
9612,NCT01269424,BG & TMZ Therapy of Glioblastoma Multiforme,Glioblastoma Multiforme,Biological: MGMTP140K-encoding retroviral vector|Drug: O6-benzylguanine|Drug: temozolomide|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: radiation therapy,Stanton Gerson MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center,Phase 1,10,Other|NIH,"November 22, 2011","December 7, 2020","September 26, 2022"
9613,NCT01267812,Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation,Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma,Drug: bortezomib|Biological: rituximab|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: DNA analysis|Other: pharmacological study|Other: pharmacogenomic studies|Other: Questionnaire Administration,City of Hope Medical Center|National Cancer Institute (NCI),Phase 2,23,Other|NIH,"October 3, 2011","November 2, 2020","November 2, 2020"
9614,NCT01266902,A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1,HIV-1 Infection,Drug: Rilpivirine,Janssen R&D Ireland,Phase 3,482,Industry,Feb-11,Feb-20,Feb-20
9615,NCT01266057,Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,Advanced Cancers,Drug: Hydroxychloroquine|Drug: Sirolimus|Drug: Vorinostat,M.D. Anderson Cancer Center,Phase 1,143,Other,"April 28, 2011","February 11, 2021","February 11, 2021"
9616,NCT01265849,"Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity",Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate,Biological: LI|Drug: Cyclophosphamide|Drug: Indomethacin|Dietary Supplement: Zinc|Procedure: Surgery|Drug: Cisplatin|Radiation: Radiotherapy,"CEL-SCI Corporation|Teva Branded Pharmaceutical Products R&D, Inc.|Orient Europharma Co., Ltd.",Phase 3,928,Industry,Dec-10,"May 15, 2020","December 4, 2020"
9617,NCT01258075,Colesevelam for Children With Type 2 Diabetes,Type 2 Diabetes Mellitus,Drug: High-dose colesevelam|Drug: Low-dose colesevelam,"Daiichi Sankyo, Inc.",Phase 4,236,Industry,"February 24, 2011","November 1, 2019","April 21, 2020"
9618,NCT01252914,A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent,Subject With Primary Open-angle Glaucoma (POAG),Device: iStent Supra Stent,Glaukos Corporation,Phase 4,80,Industry,Dec-10,"December 16, 2019","December 16, 2019"
9619,NCT01248247,BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,Drug: Erlotinib|Drug: AZD6244|Drug: MK-2206|Drug: Sorafenib,M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC|National Cancer Institute (NCI)|GlaxoSmithKline|Novartis,Phase 2,334,Other|Industry|NIH,"June 2, 2011","November 30, 2020","November 30, 2020"
9620,NCT01246986,A Study of LY2157299 in Participants With Hepatocellular Carcinoma,"Carcinoma, Hepatocellular",Drug: LY2157299|Drug: Sorafenib|Drug: Ramucirumab,Eli Lilly and Company,Phase 2,204,Industry,"March 30, 2011","June 6, 2019","December 24, 2019"
9621,NCT01238120,The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients,Cancer-related Cognitive Difficulties,Drug: Ibuprofen|Behavioral: Home-Based Exercise|Drug: Placebo,University of Rochester|National Institutes of Health (NIH)|National Cancer Institute (NCI),Phase 2,110,Other|NIH,Nov-10,Dec-19,Dec-20
9622,NCT01237093,Developing Biomarkers of Dietary Intake,Diet Therapy|Healthy Volunteers,"Other: 1. Meat, no fish or soda|Other: 2. Meat and soda, no fish|Other: 3. Meat and fish, no soda|Other: 4. Meat and fish and soda|Other: 5. Fish, no meat or soda|Other: 6. Fish and soda, no meat|Other: 7. No meat, fish or soda|Other: 8. Soda, no meat or fish",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 1,59,NIH,"October 24, 2010","March 31, 2020","March 31, 2020"
9623,NCT01236547,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,Radiation: Intensity-Modulated Radiation Therapy|Drug: Paclitaxel|Drug: Pazopanib Hydrochloride|Other: Placebo Administration,National Cancer Institute (NCI)|NRG Oncology,Phase 2,123,NIH|Other,"October 28, 2010","March 9, 2020","May 20, 2022"
9624,NCT01235494,Development of New MRI Pulse Sequences for Probing Lung Function in Volunteers With Hyperpolarised 3He Gas,Healthy Volunteers,Other: polarised 3 helium,Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield,Phase 1,36,Other,Jul-10,"December 31, 2020","December 31, 2020"
9625,NCT01234766,Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma,"Lymphoma, Follicular",Drug: Bendamustine|Drug: Rituximab|Radiation: Y-90 ibritumomab,"Dartmouth-Hitchcock Medical Center|Cephalon|Spectrum Pharmaceuticals, Inc",Phase 2,39,Other|Industry,Oct-10,Jan-21,"April 1, 2021"
9626,NCT01224392,Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer,Rectal Cancer,Other: Chemoradiotherapy|Radiation: Radiotherapy with boost,Universitair Ziekenhuis Brussel|Vrije Universiteit Brussel,Phase 3,156,Other,Jan-10,"November 30, 2020","November 30, 2020"
9627,NCT01224106,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,Alzheimer's Disease,Drug: Gantenerumab|Drug: Placebo,Hoffmann-La Roche,Phase 3,799,Industry,"November 30, 2010","September 10, 2020","September 10, 2020"
9628,NCT01220752,Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12),Sinonasal Malignancies|Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal Sinuses,Radiation: carbon ion boost,Heidelberg University,Phase 2,36,Other,"June 17, 2011","August 29, 2019","December 19, 2021"
9629,NCT01218555,Study of Everolimus (RAD001) in Combination With Lenalidomide,Solid Organ Malignancies|Adenoidcystic Carcinoma|Neuroendocrine Tumors,Drug: Lenalidomide|Drug: Everolimus,Emory University|Celgene|Novartis,Phase 1,44,Other|Industry,"September 9, 2010","November 5, 2020","November 5, 2020"
9630,NCT01217372,Nephrolithiasis Prevention by Lemon Juice,Nephrolithiasis,Dietary Supplement: Lemon supplementation,Mario Negri Institute for Pharmacological Research,Phase 2,203,Other,Jan-09,"February 16, 2021","February 16, 2021"
9631,NCT01216683,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",Lymphoma,Biological: rituximab|Drug: Bendamustin|Drug: bortezomib|Drug: lenalidomide,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Phase 2,289,Other|NIH,"December 13, 2010","December 2, 2019","December 2, 2019"
9632,NCT01198028,Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma,Metastatic Skin Squamous Cell Carcinoma|Recurrent Skin Squamous Cell Carcinoma,Drug: Erlotinib,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,42,Other|NIH,"March 10, 2011","May 1, 2019","May 1, 2019"
9633,NCT01197170,Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance,Solid Tumors|Advanced Cancer,Drug: Anastrozole|Drug: Bevacizumab|Drug: Everolimus|Drug: Sorafenib|Drug: Erlotinib,M.D. Anderson Cancer Center,Phase 1,277,Other,"September 7, 2010","January 13, 2021","January 13, 2021"
9634,NCT01188096,A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,Brain Tumors,Drug: Poly ICLC,Wake Forest University Health Sciences|Emory University,Phase 2,23,Other,Aug-10,Jul-19,Jul-19
9635,NCT01180595,Roentgen Stereophotogrammetric Analysis (RSA) Trial Comparing Trabecular Metal Monoblock and Modular Tibial Components,Osteoarthritis,Device: Trabecular Metal Modular Tibial Total Knee Component|Device: Trabecular Metal Monoblock Tibial Total Knee Component,Dalhousie University|Zimmer Biomet,Phase 4,50,Other|Industry,Feb-11,Sep-19,Sep-19
9636,NCT01180179,PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers,Peptic Ulcer,Drug: Lansoprazole|Drug: Famotidine,Chinese University of Hong Kong,Phase 4,228,Other,Jun-10,May-19,May-19
9637,NCT01173692,Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.,Oropharynx Cancer,Drug: Minocycline|Drug: Placebo,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,47,Other|NIH,"July 22, 2010","July 7, 2020","July 7, 2020"
9638,NCT01164228,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,Kidney Cancer,Drug: Gemcitabine|Drug: Sunitinib,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Phase 2,87,Other|NIH,"June 17, 2010","March 30, 2020","November 3, 2021"
9639,NCT01146652,Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND),Rheumatoid Arthritis,Drug: SAR153191 (REGN88),Sanofi|Regeneron Pharmaceuticals,Phase 3,2023,Industry,"June 21, 2010","December 31, 2020","December 31, 2020"
9640,NCT01141023,"Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression",Parkinson Disease,Drug: DaTscan,"Ken Marek, MD|Institute for Neurodegenerative Disorders|Michael J. Fox Foundation for Parkinson's Research",Phase 2,1100,Other,Jun-10,"June 30, 2020","June 30, 2020"
9641,NCT01137123,Improve the Treatment of Thoracic Esophageal Cancer,Thoracic Esophageal Squamous Cell Carcinoma,Drug: adjuvant chemotherapy|Procedure: standard two field Lymphadenectomy|Procedure: Total two field Lymphadenectomy|Procedure: three field Lymphadenectomy,Sun Yat-sen University,Phase 3,301,Other,Apr-10,Dec-20,Dec-20
9642,NCT01136395,Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation,Kidney Transplantation|Rituximab (RTx)|Living Donors|Immunology|Virus,Drug: Rituximab|Procedure: living donor transplantation|Procedure: deceased donor transplantation,"University of Giessen|Heidelberg University|German Cancer Research Center|Astellas Pharma US, Inc.|Novartis",Phase 2,85,Other|Industry,Jan-10,"June 18, 2019","June 18, 2019"
9643,NCT01131169,"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions",Multiple Myeloma,"Drug: busulfan, melphalan and fludarabine",Memorial Sloan Kettering Cancer Center|Otsuka America Pharmaceutical|Ludwig Institute for Cancer Research,Phase 2,66,Other|Industry,May-10,"May 15, 2020","May 15, 2020"
9644,NCT01126463,188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas,Hepatocellular Carcinomas,Drug: 188Re-SSS Lipiodol,Center Eugene Marquis|Rennes University Hospital,Phase 1,16,Other,"May 26, 2010","August 6, 2019","August 6, 2019"
9645,NCT01119066,"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies",Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Multiple Myeloma,Radiation: total body irradiation|Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine|Drug: Clofarabine|Procedure: (CliniMACS) T-cell depleted PBSC Transplant,Memorial Sloan Kettering Cancer Center,Phase 2,422,Other,"May 3, 2010","March 30, 2021","March 30, 2021"
9646,NCT01118026,Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma,Lymphoma,Drug: ABVD|Drug: BEACOPP|Radiation: radiation therapy,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Phase 2,101,Other|NIH,Sep-10,"September 30, 2020","September 29, 2021"
9647,NCT01116804,Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC),Primary Liver Cancer,Procedure: MRI of the liver before start of treatment|Procedure: MRI after treatment|Procedure: PET-scan before treatment start|Procedure: PET scan after treatment,"University Hospital, Ghent|University Ghent",Phase 1,36,Other,"June 16, 2010","January 20, 2020","January 20, 2020"
9648,NCT01112826,Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer,Breast Cancer,Drug: Capecitabine,Sun Yat-sen University,Phase 3,443,Other,"April 23, 2010","December 31, 2019","December 31, 2019"
9649,NCT01102088,Simultaneous Integrated Boost (SIB) in Esophageal Cancer,Esophageal Cancer,Radiation: Radiation Therapy,M.D. Anderson Cancer Center,Phase 1,61,Other,Apr-10,"June 8, 2019","June 8, 2019"
9650,NCT01097642,Neo-Adjuvant Study in Triple Negative Breast Cancer Patients,Breast Cancer,Drug: Cetuximab|Drug: Ixabepilone,The Methodist Hospital Research Institute|Bristol-Myers Squibb,Phase 2,40,Other|Industry,"October 10, 2008",Dec-19,Dec-19
9651,NCT01094405,Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy,Nasopharyngeal Cancer|Epstein-Barr Virus Infections,Biological: Recombinant Epstein-Barr Virus (EBV) Vaccine,Chinese University of Hong Kong,Phase 2,25,Other,"March 31, 2010","August 27, 2020","August 27, 2020"
9652,NCT01092182,Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma,"Burkitt Lymphoma|Diffuse Large B-cell Lymphoma, c-MYC Positive|Plasmablastic Lymphoma",Drug: EPOCH-R|Drug: EPOCH-RR,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,194,NIH,"March 25, 2010","September 30, 2020","February 16, 2023"
9653,NCT01090089,Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma,Multiple Myeloma,"Drug: Lenalidomide, Dexamethasone|Drug: Lenalidomide, Dexamethasone, PBSCT",Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|ClinAssess GmbH,Phase 3,348,Other|Industry,"March 1, 2010","January 31, 2020","January 31, 2020"
9654,NCT01088802,Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx,Squamous Cell Carcinoma of Oropharynx,Radiation: IMRT|Drug: Cisplatin|Drug: Carboplatin,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Phase 2,60,Other,Mar-10,Oct-19,Oct-19
9655,NCT01079780,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,Colorectal Cancer,Biological: cetuximab|Biological: ramucirumab|Drug: irinotecan hydrochloride,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Phase 2,136,Other|NIH,"October 8, 2010","February 22, 2021","August 17, 2021"
9656,NCT01076387,Randomized Trial Comparing Robotic and Open Radical Cystectomy,Bladder Cancer,Procedure: open radical cystectomy|Procedure: robotic-assisted radical cystectomy,Memorial Sloan Kettering Cancer Center,Phase 3,124,Other,Feb-10,"March 12, 2020","March 12, 2020"
9657,NCT01068444,The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis,Hepatitis,Drug: Pioglitazone|Drug: placebo,Kaohsiung Medical University Chung-Ho Memorial Hospital,Phase 2,90,Other,Apr-09,Jul-20,Jul-20
9658,NCT01066234,Adjuvant CCRT vs CT in Minimal N2 NSCLC,Non-small Cell Lung Cancer,Radiation: concurrent chemoradiotherapy|Drug: chemotherapy only,Samsung Medical Center,Phase 2,17,Other,"October 23, 2017","January 18, 2021","January 18, 2021"
9659,NCT01064479,Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck,Metastatic Squamous Cell Carcinoma of the Hypopharynx|Metastatic Squamous Cell Carcinoma of the Larynx|Metastatic Squamous Cell Carcinoma of the Oral Cavity|Metastatic Squamous Cell Carcinoma of the Oropharynx|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7,Drug: Carboplatin|Drug: Cisplatin|Drug: Docetaxel|Drug: Erlotinib Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo|Other: Quality-of-Life Assessment,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,123,Other|NIH,"February 5, 2010","November 3, 2020","November 3, 2020"
9660,NCT01054144,Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma,Multiple Myeloma,Drug: Lenalidomide|Drug: Prednisone|Drug: Dexamethasone,H. Lee Moffitt Cancer Center and Research Institute|Celgene,Phase 2,27,Other|Industry,"January 14, 2010",Aug-20,"November 24, 2020"
9661,NCT01037790,Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer,Adult Solid Tumor|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Adult Central Nervous System Germ Cell Tumor|Adult Teratoma|Benign Teratoma|Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Familial Testicular Germ Cell Tumor|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Monodermal and Highly Specialized Teratoma|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Extragonadal Germ Cell Tumor|Recurrent Extragonadal Non-seminomatous Germ Cell Tumor|Recurrent Extragonadal Seminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Melanoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Rectal Cancer|Stage III Extragonadal Non-seminomatous Germ Cell Tumor|Stage III Extragonadal Seminoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Extragonadal Non-seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Melanoma|Stage IV Ovarian Germ Cell Tumor|Stage IV Rectal Cancer|Testicular Immature Teratoma|Testicular Mature Teratoma,Drug: PD-0332991,Abramson Cancer Center at Penn Medicine,Phase 2,304,Other,Oct-09,Oct-19,Oct-19
9662,NCT01035099,RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,Breast Cancer|Infertility,Drug: Letrozole,Weill Medical College of Cornell University,Phase 4,41,Other,Nov-09,"July 23, 2019","September 30, 2022"
9663,NCT01027949,An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Drug: Oral Treprostinil,United Therapeutics,Phase 3,894,Industry,"January 16, 2007","February 12, 2020","February 12, 2020"
9664,NCT00999401,A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,Advanced Solid Tumors,Drug: sapacitabine and seliciclib,"Cyclacel Pharmaceuticals, Inc.",Phase 1,103,Industry,Apr-09,"July 16, 2019","August 13, 2019"
9665,NCT00995202,Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer,Colorectal Cancer,Procedure: Standard Monitoring CEA|Procedure: Intensive Monitoring CEA|Procedure: Standard Monitoring Imagery|Procedure: Intensive Monitoring Imagery,Federation Francophone de Cancerologie Digestive,Phase 3,1997,Other,Sep-09,Dec-19,Jun-21
9666,NCT00982072,Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease,Minimal Change Disease,Drug: tacrolimus|Drug: prednisolone,Imperial College Healthcare NHS Trust,Phase 4,52,Other,Dec-09,"October 10, 2019","October 10, 2019"
9667,NCT00968760,CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies,Lymphoma|B-cell Lymphoma,Procedure: Leukapheresis|Procedure: Stem Cell Transplant|Procedure: CD19-specific T Cell Infusion|Drug: IL-2|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan,M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Alaunos Therapeutics|Intrexon Corporation,Phase 1,34,Other|NIH|Industry,"June 20, 2011","April 23, 2020","April 23, 2020"
9668,NCT00960752,Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,Melanoma,Drug: gp100|Drug: R848 gel|Drug: MAGE-3,M.D. Anderson Cancer Center,Phase 2,47,Other,"May 20, 2010","July 20, 2020","July 20, 2020"
9669,NCT00958633,Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.,Bipolar I Disorder,Drug: Escitalopram|Drug: Wellbutrin XL,University of British Columbia|Canadian Institutes of Health Research (CIHR)|GlaxoSmithKline|Lundbeck Canada Inc.,Phase 3,176,Other|Industry,Nov-10,"March 31, 2020","May 20, 2020"
9670,NCT00946192,Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes,Exercise-related Amenorrhea,"Drug: Transdermal 17Beta-estradiol, progesterone|Drug: Ethinyl Estradiol + Desogestrel|Dietary Supplement: Sham Comparator",Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 3,121,Other|NIH,May-09,Feb-20,Apr-21
9671,NCT00943618,Combining Varenicline and Bupropion for Smoking Cessation,Smoking Cessation,Drug: Varenicline|Drug: Bupropion|Other: Placebo|Behavioral: Counseling/Phone Calls,M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)|Pfizer,Phase 3,641,Other|NIH|Industry,"May 17, 2010","May 31, 2020","September 9, 2021"
9672,NCT00936858,RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,Thyroid Cancer,Drug: RAD001,Dana-Farber Cancer Institute|Massachusetts General Hospital|M.D. Anderson Cancer Center|MOUNT SINAI HOSPITAL|Novartis,Phase 2,50,Other|Industry,Jul-09,"February 27, 2020","February 27, 2020"
9673,NCT00935012,Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy,ATTR-CM|TTR-CM,Drug: tafamidis,Pfizer,Phase 3,31,Industry,"September 30, 2009","November 20, 2019","November 20, 2019"
9674,NCT00925002,Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis,ATTR-PN,Drug: Tafamidis,Pfizer,Phase 3,93,Industry,"August 5, 2009","July 8, 2020","July 8, 2020"
9675,NCT00919503,Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders,Non-Neoplastic Hematologic and Lymphocytic Disorder,Procedure: Allogeneic Bone Marrow Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Drug: Treosulfan|Procedure: Umbilical Cord Blood Transplantation,"Fred Hutchinson Cancer Center|medac GmbH|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)",Phase 2,98,Other|Industry|NIH,"July 31, 2009","June 10, 2020","June 10, 2020"
9676,NCT00915005,"Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence",Non-Small-Cell Lung Carcinoma,Radiation: Photon Therapy|Radiation: Proton Therapy|Drug: Paclitaxel|Drug: Carboplatin,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,275,Other|NIH,Jun-09,"February 24, 2020","February 24, 2020"
9677,NCT00914615,Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3),Liver Metastasis,Radiation: Stereotactic Body Radiation,"University Health Network, Toronto",Phase 2,35,Other,Aug-07,"August 16, 2019","August 7, 2020"
9678,NCT00914355,Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2),Hepatocellular Carcinoma,Radiation: Stereotactic Body Radiation,"University Health Network, Toronto|Princess Margaret Hospital, Canada",Phase 2,92,Other,Aug-07,Aug-20,"December 8, 2020"
9679,NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,Metastatic Melanoma,Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|Drug: non-myeloablative conditioning chemotherapy,Jonsson Comprehensive Cancer Center|California Institute of Technology|University of Southern California|University of Connecticut|National Cancer Institute (NCI),Phase 2,14,Other|NIH,"October 13, 2009","May 30, 2019","May 30, 2019"
9680,NCT00910429,BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension,Pulmonary Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)",Bayer,Phase 3,237,Industry,"July 1, 2009","August 19, 2019","August 19, 2019"
9681,NCT00903266,Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia,Aphasia|Stroke|Cerebrovascular Accident|Apoplexy|Cerebral Infarction,Behavioral: Melodic Intonation Therapy|Behavioral: Speech-Repetition-Therapy,Beth Israel Deaconess Medical Center|National Institute on Deafness and Other Communication Disorders (NIDCD),Phase 3,30,Other|NIH,Feb-08,May-20,Jun-20
9682,NCT00896181,Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC),Stage II Lymphoepithelioma of the Nasopharynx|Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx,Drug: docetaxel|Drug: cisplatin|Drug: carboplatin|Drug: fluorouracil|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy,Stanford University,Phase 2,26,Other,"December 10, 2008","January 3, 2020",Dec-20
9683,NCT00892658,Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP),Hepatocellular Carcinoma,Drug: Sorafenib,"University Health Network, Toronto",Phase 1,24,Other,Jan-09,Nov-19,"December 16, 2020"
9684,NCT00890617,Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis,Lung Cancer|Metastatic Cancer,Procedure: Cryotherapy (PTC)|Drug: Prednisone,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Phase 1,9,Other|NIH,Mar-09,"July 27, 2019",May-21
9685,NCT00880971,Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer,Thoracic Neoplasms|Non-small Cell Lung Cancer,Radiation: Postoperative 3D-CRT or IMRT,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Phase 3,394,Other,"February 18, 2009","December 31, 2019","February 29, 2020"
9686,NCT00880815,"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",CD20 Positive|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Bendamustine|Biological: Filgrastim|Drug: Fludarabine|Drug: Methotrexate|Biological: Rituximab|Drug: Tacrolimus,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 1,60,Other|NIH,"February 17, 2009","May 28, 2019","May 28, 2019"
9687,NCT00871923,Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer|Brain Cancer,Drug: Tarceva (Erlotinib hydrochloride)|Radiation: Radiation Therapy,M.D. Anderson Cancer Center|OSI Pharmaceuticals,Phase 2,44,Other|Industry,"March 26, 2009","December 4, 2019","December 4, 2019"
9688,NCT00867178,Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System,"Medulloblastoma|Pineoblastoma|Supratentorial Embryonal Tumor, Not Otherwise Specified",Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Thiotepa|Drug: Vincristine Sulfate|Drug: Vorinostat,National Cancer Institute (NCI),Phase 1,33,NIH,"February 25, 2009","April 9, 2020","December 22, 2021"
9689,NCT00864318,Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis,Germ Cell Tumors,Drug: Paclitaxel|Drug: Ifosfamide|Drug: Carboplatine|Drug: Etoposide|Procedure: cytapheresis + transfusion of autologous peripheral blood stem cells,Institut Claudius Regaud,Phase 2,101,Other,"March 13, 2009","October 5, 2020","October 5, 2020"
9690,NCT00863681,BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension,"Hypertension, Pulmonary",Drug: Riociguat (BAY63-2521),Bayer,Phase 3,396,Industry,"March 12, 2009","August 19, 2019","August 19, 2019"
9691,NCT00862446,Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease,Parenteral Nutrition Associated Liver Disease,Drug: Omegaven,Vanderbilt University Medical Center,Phase 4,48,Other,Mar-09,Oct-19,Oct-19
9692,NCT00855803,Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis,"Metastatic Cancer|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Radiation: radiation,University of Texas Southwestern Medical Center,Phase 2,35,Other,Feb-09,"January 20, 2021","January 20, 2021"
9693,NCT00843726,Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer,Lung Cancer,Radiation: Arm 1 stereotactic body radiation therapy|Radiation: Arm II stereotactic body radiation therapy,Roswell Park Cancer Institute,Phase 2,98,Other,"September 12, 2008","May 6, 2020","May 6, 2020"
9694,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Relapsing-Remitting Multiple Sclerosis,Drug: dimethyl fumarate|Drug: Placebo,Biogen,Phase 3,1736,Industry,"February 3, 2009","November 8, 2019","November 8, 2019"
9695,NCT00813228,Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals,Diabetes Mellitus Type 1|Diabetes Mellitus Type 2,Drug: Sitagliptin (Januvia),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 1,76,NIH,"January 6, 2009","November 26, 2019","November 26, 2019"
9696,NCT00812669,"CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7",Leukemia,Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Other: flow cytometry|Other: laboratory biomarker analysis,Cancer Trials Ireland,Phase 2,52,Other,"August 18, 2008","November 21, 2019","November 21, 2019"
9697,NCT00812383,Carotid With Bivalirudin Angioplasty,Carotid Artery Disease,Device: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System,Medstar Health Research Institute,Phase 2,299,Other,Aug-03,Jul-19,Dec-19
9698,NCT00811785,"Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency",Menkes Disease|Occipital Horn Syndrome|Unexplained Copper Deficiency,Drug: Copper Histidine,"Cyprium Therapeutics, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH)",Phase 3,93,Industry|NIH,"February 27, 2009","August 28, 2020","August 28, 2020"
9699,NCT00810797,Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer,Breast Cancer,Drug: exemestane|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Other: immunohistochemistry staining method,City of Hope Medical Center|National Cancer Institute (NCI),Phase 2,36,Other|NIH,"December 2, 2008","June 26, 2019","June 26, 2019"
9700,NCT00792077,A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue,Leukemia|CLL,Drug: Lenalidomide,M.D. Anderson Cancer Center,Phase 2,6,Other,Nov-08,"August 3, 2020","August 3, 2020"
9701,NCT00777920,Study of Ambrisentan in Participants With Pulmonary Hypertension,Pulmonary Hypertension,Drug: Ambrisentan,Gilead Sciences,Phase 3,140,Industry,"November 17, 2008","September 11, 2019","September 11, 2019"
9702,NCT00774436,Study of Focal Cryoablation in Low-Risk Prostate Cancer,Prostate Cancer,Procedure: focal cryotherapy,Memorial Sloan Kettering Cancer Center,Phase 2,12,Other,"October 14, 2008","July 23, 2019","July 23, 2019"
9703,NCT00774345,A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy,B-cell Chronic Lymphocytic Leukemia,Drug: Lenalidomide|Drug: Placebo,Celgene,Phase 3,317,Industry,"January 27, 2009","October 27, 2020","October 27, 2020"
9704,NCT00759798,Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL),Chronic Lymphocytic Leukemia|Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,M.D. Anderson Cancer Center,Phase 2,289,Other,"August 13, 2008","July 22, 2020","July 22, 2020"
9705,NCT00749892,Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer,Recurrent Bladder Urothelial Carcinoma|Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Ureter Urothelial Carcinoma|Recurrent Urethral Urothelial Carcinoma|Stage 0a Bladder Cancer AJCC v8|Stage 0a Renal Pelvis Cancer AJCC v8|Stage 0a Ureter Cancer AJCC v8|Stage 0a Urethral Cancer AJCC v8|Stage 0is Bladder Cancer AJCC v8|Stage 0is Renal Pelvis Cancer AJCC v8|Stage 0is Ureter Cancer AJCC v8|Stage 0is Urethral Cancer AJCC v8|Stage II Bladder Cancer AJCC v8|Stage II Renal Pelvis Cancer AJCC v8|Stage II Ureter Cancer AJCC v8|Stage II Urethral Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8,Drug: Erlotinib Hydrochloride,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,34,Other|NIH,"June 10, 2008","June 30, 2019","November 26, 2019"
9706,NCT00748059,The Pathophysiology of Orthostatic Hypotension,Autonomic Nervous System Diseases|Orthostatic Hypotension|Dopamine Beta-Hydroxylase Deficiency|Orthostatic Intolerance,"Procedure: Standing or upright tilt|Procedure: Microneurography|Procedure: QSweat|Device: neck cuff stimulation|Drug: phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|Drug: clonidine,yohimbine,metoclopramide,alpha-methyldopa|Procedure: BodPod|Procedure: Eye exam|Procedure: Sleep study|Procedure: Pain response testing|Procedure: Metabolic chamber|Procedure: Brain function studies|Procedure: Bicycle Exercise Test",Vanderbilt University Medical Center,Phase 1,10,Other,Dec-96,Dec-20,Dec-20
9707,NCT00737893,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy,Prostate Cancer|Erectile Dysfunction,Drug: Placebo|Drug: Erythropoietin (EPO),Johns Hopkins University,Phase 2,56,Other,"July 1, 2017","December 31, 2019","December 31, 2019"
9708,NCT00729118,Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma,Multiple Myeloma|Plasma Cell Neoplasm,Drug: lenalidomide|Drug: vorinostat,Ohio State University Comprehensive Cancer Center|Merck Sharp & Dohme LLC,Phase 1,19,Other|Industry,"September 26, 2008","December 26, 2019","May 4, 2020"
9709,NCT00720785,Natural Killer Cells and Bortezomib to Treat Cancer,"Chronic Myeloid Leukemia (CML)|Pancreatic Ca|Colon/Rectal Ca|Multiple Myeloma|Carcinoma, Non-Small -Cell Lung",Drug: Bortezomib|Biological: NK cells,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 1,35,NIH,"August 1, 2008","April 6, 2021","April 6, 2021"
9710,NCT00712582,"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma",Non-Hodgkin's Lymphoma,"Drug: Etoposide, carboplatin, ifosfamide|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University",Phase 2,96,Other|Industry,"July 1, 2008","March 12, 2021","March 12, 2021"
9711,NCT00702481,Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer,Head and Neck Cancer,Drug: Nimotuzumab|Drug: Cisplatin|Radiation: Radiation,"National Cancer Centre, Singapore|Innogene Kalbiotech Pte. Ltd",Phase 2,32,Other|Industry,"April 28, 2008","September 3, 2019","September 3, 2019"
9712,NCT00695786,Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma,Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma,Drug: Lenalidomide|Biological: Rituximab,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,156,Other|NIH,"June 10, 2008","July 11, 2020","July 11, 2020"
9713,NCT00687882,Evaluation of the Duration of Therapy for Thrombosis in Children,Venous Thrombosis,Other: Shortened duration (6 weeks) of anticoagulant therapy|Other: Conventional duration (3 months) of anticoagulant therapy|Other: No Intervention,"Johns Hopkins All Children's Hospital|National Heart, Lung, and Blood Institute (NHLBI)",Phase 3,608,Other|NIH,Mar-08,"January 5, 2021","February 15, 2022"
9714,NCT00667823,Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,Drug: Macitentan,Actelion,Phase 3,550,Industry,"October 17, 2008","December 7, 2020","December 7, 2020"
9715,NCT00666237,Primary Tube Versus Trabeculectomy Study,Glaucoma,Procedure: Tube shunt surgery|Procedure: Trabeculectomy|Drug: Mitomycin C,University of Miami|Abbott Medical Optics|Research to Prevent Blindness|National Eye Institute (NEI),Phase 4,242,Other|Industry|NIH,"April 1, 2008","April 1, 2021","April 1, 2021"
9716,NCT00657059,Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN),IgA Nephropathy,Drug: irbesartan|Drug: methylprednisolone (MP) or prednisone (pred)|Drug: mycophenolate mofetil (MMF),Sun Yat-sen University,Phase 3,151,Other,Sep-07,May-19,May-19
9717,NCT00631852,A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer,Breast Cancer,Drug: American Ginseng root,Southern Illinois University,Phase 2,16,Other,Feb-08,"June 30, 2019","June 30, 2019"
9718,NCT00629798,"Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)",Acute Myeloid Leukemia|Advanced Myelodysplastic Syndromes,"Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant",Memorial Sloan Kettering Cancer Center,Phase 2,64,Other,"February 12, 2008","October 20, 2020","October 20, 2020"
9719,NCT00620633,Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,Leukemia|Myelodysplastic Syndrome,Biological: WT1-sensitized T cells,Memorial Sloan Kettering Cancer Center|Atara Biotherapeutics,Phase 1,22,Other|Industry,"February 8, 2008","February 26, 2021","February 26, 2021"
9720,NCT00612716,"Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Drug: busulfan|Drug: cyclophosphamide|Biological: Stem cell infusion|Radiation: Total body irradiation,"Masonic Cancer Center, University of Minnesota",Phase 2,6,Other,"October 6, 1999","November 15, 2019","December 15, 2019"
9721,NCT00608933,Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine,"Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",Other: educational intervention|Other: questionnaire administration,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 3,1356,Other|NIH,Jun-08,"December 7, 2020","December 7, 2020"
9722,NCT00606723,"Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML",Acute Myeloid Leukemia (AML),Biological: Hematopoietic stem cells from bone marrow or peripheral blood,Hannover Medical School,Phase 3,154,Other,Apr-10,"February 24, 2021","February 24, 2021"
9723,NCT00603616,Induction of Clinical Response Using Rifaximin in Crohn's Disease,Crohn's Disease,Drug: Placebo Comparator|Drug: Rifaximin,"Scott Lee|Bausch Health Americas, Inc.|University of Washington",Phase 2,36,Other|Industry,Nov-08,"November 3, 2020","November 3, 2020"
9724,NCT00601003,Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma,Neuroblastoma|Medulloblastoma,Drug: Nifurtimox|Drug: Cyclophosphamide|Drug: Topotecan,Wake Forest University Health Sciences|Bayer,Phase 2,112,Other|Industry,"January 14, 2008","April 28, 2020","October 28, 2022"
9725,NCT00599170,Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma,"Diffuse, Large B-Cell, Lymphoma",Drug: Rituximab,University of Southern California,Phase 2,52,Other,"January 10, 2008","January 10, 2020","January 10, 2021"
9726,NCT00594217,Determining How Quickly Progesterone Slows LH Pulse Frequency,Normal|PCOS,Drug: oral micronized progesterone suspension|Other: Placebo,University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1,87,Other|NIH,"November 29, 2007","January 18, 2020","January 18, 2020"
9727,NCT00591630,Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation,Diffuse Large Cell Lymphoma|Lymphoma,Drug: Zevalin|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Drug: Rituximab|Procedure: Stem Cell Transplant,M.D. Anderson Cancer Center,Phase 2,30,Other,"November 14, 2007","March 5, 2020","March 5, 2020"
9728,NCT00590954,Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas,Malignant Gliomas|CNS|Brain Cancer|Cancer,Drug: Perifosine,"Memorial Sloan Kettering Cancer Center|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Online Collaborative Oncology Group|University of Wisconsin, Madison|Columbia University",Phase 2,32,Other|Industry,May-06,"November 11, 2019","November 11, 2019"
9729,NCT00588120,Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria,Enteric Hyperoxaluria|Hyperoxaluria,Drug: C-13 labeled oxalate,Mayo Clinic|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Oxalosis and Hyperoxaluria Foundation (OHF),Phase 1,114,Other|NIH,Dec-98,Jan-20,Jan-20
9730,NCT00585195,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",Non-Small Cell Lung Cancer ALK-positive|Non-Small Cell Lung Cancer c-Met Dependent|Non-Small Cell Lung Cancer ROS Marker Positive|Systemic Anaplastic Large-Cell Lymphoma|Advanced Malignancies Except Leukemia,Drug: PF-02341066|Drug: Rifampin|Drug: Itraconazole,Pfizer,Phase 1,596,Industry,"April 19, 2006","July 30, 2020","January 19, 2022"
9731,NCT00583752,Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21,Recurrent Prostate Cancer,Biological: Adenovirus/PSA Vaccine,David M Lubaroff|United States Department of Defense|University of Iowa,Phase 2,50,Other|U.S. Fed,Dec-07,"December 31, 2020","January 31, 2023"
9732,NCT00583024,Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer,Hormone Refractory Prostate Cancer,Biological: ADENOVIRUS/PSA VACCINE,David M Lubaroff|United States Department of Defense|University of Iowa,Phase 2,32,Other|U.S. Fed,Dec-07,"December 31, 2020","January 31, 2023"
9733,NCT00573651,Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis,Arthritis,Other: Blood Draws for Serum Titers,University Hospitals Cleveland Medical Center|Merck Sharp & Dohme LLC,Phase 4,43,Other|Industry,Nov-07,"December 11, 2020","December 11, 2020"
9734,NCT00569985,Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma,Lymphoma,Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation,City of Hope Medical Center|National Cancer Institute (NCI),Phase 1,5,Other|NIH,Jun-07,"November 12, 2019","November 12, 2019"
9735,NCT00549848,Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,"Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib","St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Enzon Pharmaceuticals, Inc.|National Institute of General Medical Sciences (NIGMS)",Phase 3,600,Other|NIH|Industry,"October 29, 2007","September 26, 2020","March 26, 2022"
9736,NCT00543504,Bevacizumab in Multiple Phase I Combinations,Advanced Cancer,Drug: Bevacizumab|Drug: Sorafenib|Drug: Erlotinib|Drug: Trastuzumab|Drug: Lapatinib|Drug: Sunitinib|Drug: Cetuximab,M.D. Anderson Cancer Center,Phase 1,343,Other,"October 10, 2007","April 29, 2020","April 29, 2020"
9737,NCT00515554,HD18 for Advanced Stages in Hodgkins Lymphoma,Hodgkins Lymphoma,Drug: Rituximab|Drug: BEACOPP escalated,University of Cologne,Phase 3,1500,Other,May-08,Jul-19,Jul-20
9738,NCT00503035,Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers,Familial Adenomatous Polyposis,Drug: Celecoxib|Procedure: Colonoscopy Biopsy,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Phase 2,51,Other|NIH,"August 20, 2003","April 2, 2021","April 2, 2021"
9739,NCT00483106,Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD),Attention Deficit Hyperactivity Disorder,Drug: Ritalin|Drug: Placebo,McGill University,Phase 4,885,Other,Nov-99,"March 31, 2020","March 31, 2020"
9740,NCT00436332,S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma,Lung Cancer,Biological: bevacizumab|Drug: erlotinib hydrochloride,SWOG Cancer Research Network|National Cancer Institute (NCI),Phase 2,84,Other|NIH,Jul-07,"July 20, 2019","August 20, 2019"
9741,NCT00433589,Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes,Breast Cancer,Drug: anthracycline-based|Drug: docetaxel and capecitabine|Drug: tamoxifen|Drug: Letrozole,European Organisation for Research and Treatment of Cancer - EORTC|Agendia|Breast International Group|Roche Pharma AG|Novartis|Sanofi,Phase 3,6600,Other|Industry,Feb-07,Mar-20,Mar-20
9742,NCT00432094,Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors,Childhood Germ Cell Tumor|Ovarian Cancer|Teratoma,Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Drug: thiotepa|Procedure: autologous hematopoietic stem cell transplantation|Drug: Mesna|Biological: filgrastim,"Masonic Cancer Center, University of Minnesota",Phase 2,23,Other,"December 19, 2006",Mar-21,Mar-21
9743,NCT00392756,Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS),Kallmann Syndrome|Hypogonadotropic Hypogonadism|GnRH Deficiency,Drug: gonadotropin releasing hormone (GnRH),Massachusetts General Hospital,Phase 1,624,Other,Apr-89,"May 16, 2019","May 16, 2019"
9744,NCT00391170,Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease,Graft vs Host Disease,Drug: Topical Dexamethasone|Drug: Placebo,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Phase 2,62,NIH,"November 24, 2006","February 1, 2021","February 1, 2021"
9745,NCT00383994,"Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation","Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation",Drug: GM-CSF|Drug: Rituximab|Biological: NK Cell Infusion,"M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Phase 1,6,Other|Industry,Sep-06,"July 22, 2019","July 22, 2019"
9746,NCT00351611,Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo,"Epilepsies, Partial",Drug: Lyrica (pregabalin)|Drug: placebo,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer,Phase 4,187,Industry,"July 26, 2006","February 4, 2020","February 4, 2020"
9747,NCT00345865,Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma,Lymphoma,Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: irradiation therapy|Biological: G-CSF|Drug: Cytarabine,"Masonic Cancer Center, University of Minnesota",Phase 2,473,Other,"August 24, 2005","June 28, 2019","June 28, 2019"
9748,NCT00339625,Polyp Prevention Trial,Diet|Polyps|Adenoma,"Other: low fat, high fiber, high fruit and vegetable eating plan",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 3,2079,NIH,"June 19, 1991","May 11, 2020","May 11, 2020"
9749,NCT00336674,Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes,Type 1 Diabetes,Biological: Intranasal insulin|Other: Placebo,Melbourne Health,Phase 2,110,Other,Dec-06,"November 13, 2019","November 13, 2019"
9750,NCT00309842,Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases,Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|MDS|Refractory Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Non-Hodgkin's Lymphoma|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes,Biological: filgrastim|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation,"Masonic Cancer Center, University of Minnesota",Phase 2,213,Other,"July 28, 2005","July 29, 2019","November 22, 2019"
9751,NCT00305682,Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes,Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: Fludarabine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation|Drug: Sirolimus,"Masonic Cancer Center, University of Minnesota",Phase 2,295,Other,Jun-05,"December 12, 2019","December 12, 2019"
9752,NCT00290511,"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma",Lymphoma,Drug: Fludarabine|Drug: Mitoxantrone|Drug: Rituximab|Drug: Zevalin|Drug: Dexamethasone,"M.D. Anderson Cancer Center|Genentech, Inc.|Biogen",Phase 2,49,Other|Industry,"June 29, 2004","February 12, 2021","February 12, 2021"
9753,NCT00267904,Reference Values for Plasma Catechols,Healthy Volunteers|Normal Physiology,Other: Coffee|Other: Banana|Other: Olives|Other: Temp. manip.,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Phase 1,46,NIH,"March 8, 2006","February 20, 2020","March 18, 2022"
9754,NCT00267865,Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,AIDS-Related-Primary Central Nervous System Lymphoma,Drug: Methotrexate|Drug: Rituximab|Drug: Leucovorin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Phase 2,12,NIH,"September 14, 2006","September 18, 2019","September 19, 2019"
9755,NCT00258427,Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia,Fanconi Anemia,Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Biological: Hematopoietic stem cell transplantation,"Masonic Cancer Center, University of Minnesota",Phase 2,14,Other,"March 26, 2002","October 10, 2020","October 10, 2020"
9756,NCT00175916,Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy,Epilepsy,Drug: Brivaracetam (ucb 34714),UCB Pharma,Phase 3,853,Industry,Sep-05,May-19,May-19
9757,NCT00158678,IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC,Oral Cancer|Oropharynx Cancer|Hypopharynx Cancer,Procedure: IMRT 75 Gy|Procedure: Conventional radiotherapy 70 Gy|Drug: concomitant cisplatin,Groupe Oncologie Radiotherapie Tete et Cou,Phase 3,310,Other,"September 27, 2005","March 22, 2020","March 22, 2020"
9758,NCT00151216,Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis,Batten Disease|Late Infantile Neuronal Ceroid Lipofuscinosis,Biological: AAV2CUhCLN2 (3x10^12 particle units),Weill Medical College of Cornell University|Nathan's Battle Foundation,Phase 1,10,Other,Jun-04,Jun-19,Jun-19
9759,NCT00142233,EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis,Pancreatitis,Dietary Supplement: ANTOX (vers.)1.2|Drug: Magnesium|Other: Placebo ANTOX (vers)1.2|Other: Placebo Magnesiocard (2.5 mmol),University Medicine Greifswald,Phase 3,295,Other,"June 6, 2005",Sep-19,Sep-19
9760,NCT00116142,Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer,Prostate Cancer,Drug: Docetaxel|Drug: Androgen Hormonal Suppression and Radiation|Drug: Androgen Suppression Therapy and Radiation Therapy,Dana-Farber Cancer Institute|Sanofi,Phase 3,350,Other|Industry,Jun-05,"June 29, 2020","June 29, 2020"
9761,NCT00077519,Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer,Pancreatic Cancer,Drug: tipifarnib|Radiation: radiation therapy,Abramson Cancer Center at Penn Medicine|National Cancer Institute (NCI),Phase 1,18,Other|NIH,Jan-04,"December 31, 2019","December 31, 2019"
9762,NCT00072358,Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma,Neuroblastoma,Biological: anti-GD2 murine IgG3 monoclonal antibody 3F8,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),Phase 2,291,Other|NIH,Jul-03,"January 15, 2021","January 15, 2021"
9763,NCT00058422,Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma,Lymphoma,Biological: darbepoetin alfa|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),Phase 2,65,Other|NIH,"February 10, 2003","November 14, 2019","November 14, 2019"
9764,NCT00001277,Studies of Elevated Parathyroid Activity,Hyperparathyroidism|Hypercalcemia|Parathyroid Neoplasm|Multiple Endocrine Neoplasia|MEN1,Drug: 68Ga-Dotatate|Drug: 18F-DOPA,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),Phase 2,1553,NIH,"December 15, 1993","March 11, 2020","December 23, 2020"
9765,NCT00001259,A Treatment Study for Premenstrual Syndrome (PMS),Premenstrual Syndrome|Menstruation Disturbances,Drug: Leuprolide|Drug: Estradiol Patches|Drug: Progesterone|Drug: Placebo patch|Drug: Placebo injection|Drug: Placebo suppository,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),Phase 1,60,NIH,"August 11, 1992","February 6, 2020","February 6, 2020"
